PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wehling, M; Cai, BY; Tidball, JG				Wehling, M; Cai, BY; Tidball, JG			Modulation of myostatin expression during modified muscle use	FASEB JOURNAL			English	Article						atrophy; myotendinous junction; plantaris muscle; rat; unloading	GROWTH-FACTOR-BETA; RAT SOLEUS MUSCLE; HINDLIMB SUSPENSION; EXTRACELLULAR-MATRIX; FACTOR-BETA-1; ACTIVATION; CATTLE; GENE; RNA; MECHANISMS	Previous findings have provided strong evidence that myostatin functions as a negative regulator of muscle mass during development and growth. In the present study , we test the hypothesis that myostatin may serve a similar function in fully differentiated muscle experiencing modified loading. Our findings show that the myostatin expression can be modulated in fully differentiated, non-pathologicalskeletal muscle in a manner that is inversely related to changes in muscle mass. Atrophy of rat hind limb muscles induce by 10 days of unloading resulted in in a 165 decrease in plantaris mass, a 110% increase in myostatin mRNA, and a 37% increase in myostatin protein. Immunohistochemical observations showed that a detectable increase in myostatin concentration at myotendinous junctions during muscle unloading. The concentration of myostatin mRNA and protein returned to values not significantly different from ambulatory controls after 4 days of reloading, during which time plantaris mass also returned to control values. However the results also show that of 30min of daily muscle loading during the unloading period were sufficient to prevent significant losses of muscle mass caused by muscle unloading, although muscle mass loos during unloading is accompanied by increases in myostatin.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tidball, JG (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Young Dr S, Los Angeles, CA 90095 USA.	jtidball@physci.ucla.edu	Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040343] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40343] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe M, 1998, J CELL PHYSIOL, V174, P186, DOI 10.1002/(SICI)1097-4652(199802)174:2<186::AID-JCP6>3.0.CO;2-K; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; CASTILLODEMARUENDA E, 1978, TISSUE CELL, V10, P749, DOI 10.1016/0040-8166(78)90061-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARR KC, 1989, J APPL PHYSIOL, V67, P1827, DOI 10.1152/jappl.1989.67.5.1827; DAUNNO DS, 1992, J APPL PHYSIOL, V72, P428, DOI 10.1152/jappl.1992.72.2.428; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; GIBSON MC, 1982, ANAT REC, V202, P329, DOI 10.1002/ar.1092020305; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; HAUSCHKA EO, 1988, J APPL PHYSIOL, V65, P1231, DOI 10.1152/jappl.1988.65.3.1231; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; KERR LD, 1988, J BIOL CHEM, V263, P16999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MOREYHOLTON E, 1981, PHYSIOLOGIST S, V24, pS45; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Nakashima M, 1999, MECH DEVELOP, V80, P185, DOI 10.1016/S0925-4773(98)00205-6; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; SHAW SR, 1987, J BIOMECH, V20, P225, DOI 10.1016/0021-9290(87)90289-2; Spencer MJ, 1997, J CELL BIOCHEM, V64, P55, DOI 10.1002/(SICI)1097-4644(199701)64:1<55::AID-JCB9>3.0.CO;2-Z; STPIERRE BA, 1994, J APPL PHYSIOL, V77, P290, DOI 10.1152/jappl.1994.77.1.290; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TIDBALL JG, 1991, J BIOMECH, V24, P43, DOI 10.1016/0021-9290(91)90376-X; TISCHLER ME, 1990, METABOLISM, V39, P756, DOI 10.1016/0026-0495(90)90113-Q	33	171	191	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					103	110		10.1096/fasebj.14.1.103	http://dx.doi.org/10.1096/fasebj.14.1.103			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627285				2022-12-28	WOS:000084784700013
J	Pederson, T				Pederson, T			Movement and localization of RNA in the cell nucleus	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		FLUORESCENCE CORRELATION SPECTROSCOPY; LIVING CELLS; MESSENGER-RNA; NUCLEOLUS; ACTIN; CYTOCHEMISTRY; HYBRIDIZATION; FIBROBLASTS; ELEMENTS; U3	The movement of various RNAs from their sites of chromosomal synthesis to their functional locations in the cell is an important step in eukaryotic gene readout, though one less well understood than the transcription, RNA processing; and various functions of RNA. The segregation of the many classes of RNA out into to their appropriate sites in the cell is, from a physical chemical point of view, a remarkable phenomenon. This paper summarizes investigations my colleagues and I have undertaken over the past 7 years to describe the intracellular traffic and localization of RNA in living cells. One approach we have developed is to glass-needle microinject similar to 0.01 pl of fluorescent RNA solutions into the nucleus or cytoplasm of cultured mammalian cells. This 'fluorescent RNA cytochemistry' approach has resolved intranuclear sites ('speckles') for which premessenger RNAs (pre-mRNA) have high affinity and has revealed very rapid movements of certain other RNAs from their nucleoplasmic injection sites to the nucleoli. One of these rapidly trafficking nucleolar RNAs is the signal recognition particle (SRP) RNA, and further results indicate that the nucleolus is a site of SRP RNA processing or ribonucleoprotein assembly prior to export to the cytoplasm, In these fluorescent RNA microinjection studies, rye have also used mutant RNA molecules to identify specific nucleotide sequences that function as targeting elements for the localization of RNAs at their respective intranuclear sites. In a second approach, we have used fluorescent correlation spectroscopy (FCS), a classical biophysical method for measuring molecular motion in vitro, coupled with confocal fluorescence microscopy to measure the. movement of poly(A) RNA in the nucleus, with the interesting finding that these RNAs appear to move about inside the nucleus at rates comparable to diffusion in aqueous solution. Parallel experiments using the method of fluorescence recovery after photobleaching (FRAP) revealed a diffusion coefficient for intranuclear poly(A) RNA close to that measured by FCS, These results bear on the structure of the nucleoplasmic ground substance-an extremely controversial and unsolved problem in cell biology (29), The methods we have developed and these initial results represent the first major step toward a comprehensive understanding of RNA traffic in the cell nucleus.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, 377 Plantat St, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu			NIAMS NIH HHS [AR-08361] Funding Source: Medline; NIGMS NIH HHS [GM-21595] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; Jacobson MR, 1998, NUCLEIC ACIDS RES, V26, P756, DOI 10.1093/nar/26.3.756; Jacobson MR, 1997, J CELL SCI, V110, P829; Jacobson MR, 1995, J CELL BIOL, V131, P1649, DOI 10.1083/jcb.131.6.1649; Jacobson MR, 1997, ANAL MRNA FORMATION, P341; JACOBSON MR, 1998, CELL BIOL LAB HDB, V4, P1; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; Kish V M, 1978, Methods Cell Biol, V17, P377, DOI 10.1016/S0091-679X(08)61155-3; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; Lange TS, 1998, MOL BIOL CELL, V9, P2973, DOI 10.1091/mbc.9.10.2973; Lange TS, 1998, EMBO J, V17, P3176, DOI 10.1093/emboj/17.11.3176; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; PEDERSON T, 1974, J MOL BIOL, V83, P163, DOI 10.1016/0022-2836(74)90386-6; PEDERSON T, 1983, J CELL BIOL, V97, P1321, DOI 10.1083/jcb.97.5.1321; Politz JC, 1995, NUCLEIC ACIDS RES, V23, P4946, DOI 10.1093/nar/23.24.4946; Politz JC, 1998, MOL BIOL CELL, V9, p190A; Politz JC, 1998, P NATL ACAD SCI USA, V95, P6043, DOI 10.1073/pnas.95.11.6043; RIGLER R, 1995, J BIOTECHNOL, V41, P177, DOI 10.1016/0168-1656(95)00054-T; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TAYLOR DL, 1978, P NATL ACAD SCI USA, V75, P857, DOI 10.1073/pnas.75.2.857; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WANG Y, 1982, P NATL ACAD SCI-BIOL, V79, P4660, DOI 10.1073/pnas.79.15.4660; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WANG YL, 1984, J CELL BIOL, V99, P1478, DOI 10.1083/jcb.99.4.1478	30	22	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S238	S242		10.1096/fasebj.13.9002.S238	http://dx.doi.org/10.1096/fasebj.13.9002.S238			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619135				2022-12-28	WOS:000084390200013
J	Hashemi, BB; Penkala, JE; Vens, C; Huls, H; Cubbage, M; Sams, CF				Hashemi, BB; Penkala, JE; Vens, C; Huls, H; Cubbage, M; Sams, CF			T cell activation responses are differentially regulated during clinorotation and in spaceflight	FASEB JOURNAL			English	Article						microgravity culture; clinostat; DNA synthesis; CD69; CD25	PROTEIN-KINASE-C; ANTIGEN-RECEPTOR COMPLEX; LYMPHOCYTES-T; SIGNAL-TRANSDUCTION; INTERLEUKIN-2 PRODUCTION; MESSENGER-RNA; MICROGRAVITY; STIMULATION; EXPRESSION; INDUCTION	Studies of T lymphocyte activation with mitogenic lectins during spaceflight have shown a dramatic inhibition of activation as measured by DNA synthesis at 72 h, but the mechanism of this inhibition is unknown. We have investigated the progression of cellular events during the first 24 h of activation using both spaceflight microgravity culture and a groundbased model system that relies on the low shear culture environment of a rotating clinostat (clinorotation). Stimulation of human peripheral blood mononuclear cells (PBMCs) with soluble anti-CD3 (Leu4) in clinorotation and in microgravity culture shows a dramatic reduction in surface expression of the receptor for IL-2 (CD25) and CD69. An absence of bulk RNA synthesis in clinorotation indicates that stimulation with soluble Leu4 does not induce transition of T cells from G0 to the G1 stage of the cell cycle. However, internalization of the TCR by T cells and normal levels of IL-1 synthesis by monocytes indicate that intercellular interactions that are required for activation occur during clinorotation. Complementation of TCR-mediated signaling by phorbol ester restores the ability of PBMCs to express CD25 in clinorotation, indicating that a PKC associated pathway may be compromised under these conditions. Bypassing the TCR by direct activation of intracellular pathways with a combination of phorbol ester and calcium ionophore in clinorotation resulted in full expression of CD25; however, only partial expression of CD25 occurred in microgravity culture. Though stimulation of purified T cells with Bead-Leu4 in microgravity culture resulted in the engagement and internalization of the TCR, the cells still failed to express CD25. When T cells were stimulated with Bead-Leu4 in microgravity culture, they were able to partially express CD69, a receptor that is constitutively stored in intracellular pools and can be expressed in the absence of new gene expression. Our results suggest that the inhibition of T cell proliferative response in microgravity culture is a result of alterations in signaling events within the first few hours of activation, which are required for the expression of important regulatory molecules.-Hashemi, B. B., Penkala, J. E., Vens, C., Huls, H., Cubbage, M., Sams, C. F. T cell activation responses are differentially regulated during clinorotation and in spaceflight.	NASA, Lyndon B Johnson Space Ctr, Life Sci Res Labs, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER	Sams, CF (corresponding author), NASA, Lyndon B Johnson Space Ctr, Life Sci Res Labs, SD3, Houston, TX 77058 USA.							BERRY N, 1989, J IMMUNOL, V143, P1407; CEUPPENS JL, 1989, CELL IMMUNOL, V118, P136, DOI 10.1016/0008-8749(89)90363-8; COGOLI A, 1993, J LEUKOCYTE BIOL, V54, P259, DOI 10.1002/jlb.54.3.259; Cogoli A, 1997, Gravit Space Biol Bull, V10, P5; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; COGOLI A, 1988, ESA; CogoliGreuter M, 1996, J BIOTECHNOL, V47, P279, DOI 10.1016/0168-1656(96)01380-6; Cooper D, 1998, J LEUKOCYTE BIOL, V63, P550, DOI 10.1002/jlb.63.5.550; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Darzynkiewicz Z, 1990, Methods Cell Biol, V33, P285; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; DEGROOT RP, 1990, J CELL SCI, V97, P33; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; GIARRUSSO PC, 1988, TISSUE ANTIGENS, V31, P59, DOI 10.1111/j.1399-0039.1988.tb02064.x; GMUNDER FK, 1990, BIOL CELL, V70, P33, DOI 10.1016/0248-4900(90)90358-A; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; GREGORIO CC, 1992, P NATL ACAD SCI USA, V89, P4947, DOI 10.1073/pnas.89.11.4947; Hashemi BB, 1996, J IMMUNOL, V156, P3660; HASHEMI BB, 1994, APPL ENG PHYSICS CHE, P145; HASHEMI BB, 1999, ESA SP, V1222; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LAI KN, 1991, PATHOLOGY, V23, P224, DOI 10.3109/00313029109063570; LANDIS RC, 1991, J IMMUNOL, V146, P128; LEDBETTER JA, 1981, J EXP MED, V153, P310, DOI 10.1084/jem.153.2.310; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MANGER B, 1987, J IMMUNOL, V139, P2755; MANIE S, 1990, AM SOC GRAVITATIONAL, V4, P43; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; RIJKEN PJ, 1993, EXP CELL RES, V204, P373, DOI 10.1006/excr.1993.1045; RISSO A, 1991, J IMMUNOL, V146, P4105; RYSER JE, 1982, J IMMUNOL, V128, P1159; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; STEFAN MC, 1983, SCIENCE, V222, P1239; TESTI R, 1989, J IMMUNOL, V142, P1854; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; TODD P, 1993, PHYSICAL FORCES MAMM; TSCHOPP A, 1984, J BIOTECHNOL, V1, P287, DOI 10.1016/0168-1656(84)90020-8; Unsworth BR, 1998, NAT MED, V4, P901, DOI 10.1038/nm0898-901; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Vens C, 1996, J BIOTECHNOL, V47, P203, DOI 10.1016/0168-1656(96)01355-7; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	50	84	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2071	2082		10.1096/fasebj.13.14.2071	http://dx.doi.org/10.1096/fasebj.13.14.2071			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544190				2022-12-28	WOS:000083660700019
J	Didier, C; Emonet-Piccardi, N; Beani, JC; Cadet, J; Richard, MJ				Didier, C; Emonet-Piccardi, N; Beani, JC; Cadet, J; Richard, MJ			L-arginine increases UVA cytotoxicity in irradiated human keratinocyte cell line: potential role of nitric oxide	FASEB JOURNAL			English	Article						DNA damage; NO; metalloenzymes; SNAP	HUMAN SKIN FIBROBLASTS; ADP-RIBOSE SYNTHETASE; HYDROGEN-PEROXIDE; DNA-DAMAGE; PEROXYNITRITE; SUPEROXIDE; APOPTOSIS; INJURY; POLY(ADP-RIBOSE); TOXICITY	Human fibroblasts and keratinocytes possess nitric oxide synthases (NOS), which metabolize L-arginine (L-Arg) for producing nitric oxide (NO.), This report delineates the relations between NO. and UVA in the human keratinocyte cell line HaCaT. NOS activity was stimulated by exposure of cells to L-Arg just after irradiation. L-Arg (5 mM) supply led to an increase in UVA (25.3 J/cm(2)) cytotoxicity (% of viability 18 +/- 3%) whereas neither L-Arg itself nor UVA irradiation induced cell death at the doses used in this study. Cells were also treated either with L-thiocitrulline (L-Thio), an irreversible inhibitor of NOS, or with exogenous superoxide dismutase (SOD) and catalase, L-Thio and SOD prevented L-Arg-mediated deleterious effects in irradiated cells, whereas catalase was ineffective. Intracellular antioxidant enzyme activities were also determined. UVA/L-Arg stress altered catalase (66% decrease) and glutathione peroxidase (83% decrease). DNA damage was evaluated using the 'comet assay' and quantified using the 'tail moment'. UVA alone was genotoxic (mean tail moment: 25.43 +/- 1.23, P < 0.001 compared control cells), The addition of L-Arg potentiated DNA damage (mean tail moment: 41.05+/-3.9) whereas L-Thio prevented them (mean tail moment 9.86 +/- 0.98). We attempted to assess the effect of poly(ADP-ribose) polymerase (PARP) inhibition on cell death. Using the PARP inhibitor 3-aminobenzamide, we established that PARP determines both cell lysis and DNA damage induced by UVA and/or L-Arg, Our findings demonstrated that L-Arg was able to increase UVA-mediated deleterious effects in keratinocytes (both DNA damage age and cytotoxicity) and that the ratio NO./O-2(.-) plays a key role in these processes.	Univ Grenoble 1, LCR7 8, LBSO, F-38043 Grenoble 03, France; CEA, Serv Chim Inorgan & Biol, Dept Rech Fondamentale Mat Condensee, F-38054 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Richard, MJ (corresponding author), CHU Albert Michallon, Lab Biochim C, LBSO, F-38043 Grenoble 03, France.		DIDIER, Christine O/P-2785-2014; Cadet, Jean/M-2971-2018	DIDIER, Christine O/0000-0003-3979-0743; Cadet, Jean/0000-0003-2594-9485				ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Baudouin JE, 1996, J INVEST DERMATOL, V106, P428, DOI 10.1111/1523-1747.ep12343523; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEERS RF, 1952, J BIOL CHEM, V195, P133; BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bruch-Gerharz D, 1998, J INVEST DERMATOL, V110, P1, DOI 10.1046/j.1523-1747.1998.00084.x; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Emonet-Piccardi N, 1998, FREE RADICAL RES, V29, P307, DOI 10.1080/10715769800300341; Filep JG, 1997, BIOCHEM J, V321, P897, DOI 10.1042/bj3210897; Gutierrez HH, 1996, FREE RADICAL BIO MED, V21, P43, DOI 10.1016/0891-5849(95)02226-0; INADA C, 1995, LIFE SCI, V56, P1467, DOI 10.1016/0024-3205(95)00109-J; Ioannidis I, 1996, BIOCHEM J, V318, P789, DOI 10.1042/bj3180789; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Kim Y M, 1995, Adv Pharmacol, V34, P277; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; LECCIA MT, 1993, PHOTOCHEM PHOTOBIOL, V58, P548, DOI 10.1111/j.1751-1097.1993.tb04930.x; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MEBMER UK, 1996, FEBS LETT, V384, P162; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; PARAT MO, 1995, FREE RADICAL RES, V23, P339, DOI 10.3109/10715769509065255; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VILLIOTOU V, 1995, ANTICANCER RES, V15, P931; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Wang RJ, 1996, J INVEST DERMATOL, V106, P419, DOI 10.1111/1523-1747.ep12343428; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	33	21	22	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1817	1824		10.1096/fasebj.13.13.1817	http://dx.doi.org/10.1096/fasebj.13.13.1817			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506585				2022-12-28	WOS:000083063400017
J	Stumm, G; Schlegel, J; Schafer, T; Wurz, C; Mennel, HD; Krieg, JC; Vedder, H				Stumm, G; Schlegel, J; Schafer, T; Wurz, C; Mennel, HD; Krieg, JC; Vedder, H			Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons	FASEB JOURNAL			English	Article						drug abuse; neurotoxicity; bcl gene family	DISMUTASE TRANSGENIC MICE; MDMA ECSTASY; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; METHAMPHETAMINE; CELLS; ABUSE; BRAIN; TRANSCRIPTION; DEATH; JUN	Amphetamine analogs have emerged as popular recreational drugs of abuse. The number of reports of these substances producing severe acute toxicity and death is increasing, In 'Ecstasy'-associated deaths, focal necrosis in the liver and individual myocytic necrosis has been reported. Furthermore, serotonergic and dopaminergic neuronal cell damage has been observed in experimental amphetamine intoxication in laboratory animals, Here we demonstrate that subchronic exposure to D-amphetamine, methamphetamine, methylenedioxyamphetamine, and methylenedioxymethamphetamine ('Ecstasy') results in significant neurotoxicity in rat neocortical neurons in vitro, This neuronal cell death is accompanied by endonucleosomal DNA cleavage and differential expression of anti- and proapoptotic bcl-x(L/S) splice variants. In addition, we observed pronounced induction of cell stress-associated transcription factor c-jun and translation initiation inhibitor p97 after amphetamine treatment. These data support that the neurotoxic effects of different amphetamines are extended to rat neocortical neurons and that apoptotic pathways are involved in amphetamine-induced neurotoxicity.	Univ Marburg, Dept Neuropathol, Marburg, Germany; Univ Marburg, Inst Forens Med, Marburg, Germany; Univ Marburg, Dept Psychiat, Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Stumm, G (corresponding author), Univ Hosp Marburg, Dept Psychiat, Rudolf-Bultmann Str 8, D-35039 Marburg, Germany.	stumm@mailer.uni-marburg.de		Schlegel, Jurgen/0000-0002-5544-2717				BELL DS, 1973, ARCH GEN PSYCHIAT, V29, P35; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; Cadet JL, 1997, SYNAPSE, V25, P176; CERRUTI C, 1995, CLIN EXP PHARMACOL P, V22, P381, DOI 10.1111/j.1440-1681.1995.tb02025.x; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Hirata H, 1997, BRAIN RES, V768, P345, DOI 10.1016/S0006-8993(97)00798-1; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; Huang NK, 1997, LIFE SCI, V61, P2219, DOI 10.1016/S0024-3205(97)00924-7; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCGUIRE PK, 1994, BRIT J PSYCHIAT, V165, P391, DOI 10.1192/bjp.165.3.391; Milroy CM, 1996, J CLIN PATHOL, V49, P149, DOI 10.1136/jcp.49.2.149; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; RICAURTE G, 1985, SCIENCE, V229, P986, DOI 10.1126/science.4023719; RICAURTE GA, 1992, ANN NY ACAD SCI, V648, P371; Robinson TE, 1997, J NEUROSCI, V17, P8491; SCHIFANO F, 1991, LANCET, V338, P1335, DOI 10.1016/0140-6736(91)92633-D; Seiden L S, 1996, NIDA Res Monogr, V163, P251; Simantov R, 1997, FASEB J, V11, P141, DOI 10.1096/fasebj.11.2.9039956; STEELE TD, 1994, ADDICTION, V89, P539, DOI 10.1111/j.1360-0443.1994.tb03330.x; Stewart JL, 1997, J ANAL TOXICOL, V21, P515, DOI 10.1093/jat/21.6.515; TAKEMOTO O, 1995, STROKE, V26, P1639, DOI 10.1161/01.STR.26.9.1639; VEDDER H, 1993, BRAIN RES, V605, P18, DOI 10.1016/0006-8993(93)91351-R; WAGNER GC, 1985, RES COMMUN CHEM PATH, V47, P221; Yamamoto H, 1996, ANN NY ACAD SCI, V801, P327, DOI 10.1111/j.1749-6632.1996.tb17453.x; ZIMMERMAN EF, 1991, PEDIATR ANN, V20, P541, DOI 10.3928/0090-4481-19911001-05	31	138	146	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					1065	1072		10.1096/fasebj.13.9.1065	http://dx.doi.org/10.1096/fasebj.13.9.1065			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336889				2022-12-28	WOS:000080547700011
J	DeFife, KM; Jenney, CR; Colton, E; Anderson, JM				DeFife, KM; Jenney, CR; Colton, E; Anderson, JM			Disruption of filamentous actin inhibits human macrophage fusion	FASEB JOURNAL			English	Article						microfilaments; foreign body giant cells; cytochalasins; macrophage mannose receptor	GIANT-CELL FORMATION; MANNOSE RECEPTOR ACTIVITY; HUMAN-MONOCYTES; BINDING-SITES; INTERLEUKIN-4; PHAGOCYTOSIS; EXPRESSION; ADHESION; RECOGNITION; CYTOCHALASINS	The foreign body reaction to implanted biomaterials, characterized by the presence of macrophages and foreign body giant cells (FBGC), can result in structural and functional failure of the implant. Recently, we have shown that interleukin-4 and interleukin-13 can independently induce human macrophage fusion to form FBGC via a macrophage mannose receptor (MR) -mediated pathway. The MR is believed to mediate both endocytosis of glycoproteins and phagocytosis of microorganisms, which bear terminal mannose, fucose, N-acetylglucosamine, or glucose residues. Polarization of microfilaments to closely apposed macrophage membranes as observed with fluorescence confocal microscopy led us to ask whether MR-mediated fusion occurred via a filamentous actin-dependent pathway. Cytochalasins B and D and latrunculin-A, agents that disrupt microfilaments, inhibited macrophage fusion in a concentration-dependent manner. The concentrations of cytochalasins D and B that inhibited fusion did not significantly decrease macrophage adhesion, spreading, or motility but did inhibit internalization of Candida albicans during interleukin-13-enhanced, MR-mediated phagocytosis, Very low concentrations of cytochalasin B (< 2 mu M) induced a slight enhancement of macrophage fusion, Taken together, the results of this study suggest that cytokine-induced, MR-mediated macrophage fusion requires an intact F-actin cytoskeleton and that the mechanism of fusion is similar to phagocytosis.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Anderson, JM (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.				NHLBI NIH HHS [HL 55714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; ANDERSON JM, 1993, CARDIOVASC PATHOL, V2, pS33; CHAMBERS TJ, 1982, IMMUNOBIOLOGY, V161, P283, DOI 10.1016/S0171-2985(82)80084-3; COLLIER TO, 1998, 71 SCI SESS AM HEART; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DARNELL J, 1990, MOL CELL BIOL, P554; DeFife KM, 1997, J IMMUNOL, V158, P3385; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; GIAIMIS J, 1992, J IMMUNOL METHODS, V154, P185, DOI 10.1016/0022-1759(92)90191-U; Greenberg Steven, 1993, P941; GREISLER HP, 1996, HUMAN BIOMATERIALS A; HASSAN NF, 1989, J IMMUNOL, V143, P2179; HE YW, 1995, J IMMUNOL, V155, P9; HEALY KE, 1994, BIOTECHNOL BIOENG, V43, P792, DOI 10.1002/bit.260430814; HENSON PM, 1988, INFLAMMATION BASIC P, P363; Jenney CR, 1998, J BIOMED MATER RES, V41, P171, DOI 10.1002/(SICI)1097-4636(199808)41:2<171::AID-JBM1>3.0.CO;2-F; KAO WYJ, 1995, J BIOMED MATER RES, V29, P1267, DOI 10.1002/jbm.820291014; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KURACHI T, 1994, J BONE MINER RES, V9, pS179; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LEHTO VP, 1982, LAB INVEST, V47, P391; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MAHONEY EM, 1977, P NATL ACAD SCI USA, V74, P4895, DOI 10.1073/pnas.74.11.4895; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; McNally AK, 1996, AM J PATHOL, V149, P975; MCNALLY AK, 1995, AM J PATHOL, V147, P1487; MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119; MURCH AR, 1982, J PATHOL, V137, P177, DOI 10.1002/path.1711370302; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NEWMAN SL, 1991, J IMMUNOL, V146, P967; NORTON JM, 1980, J IMMUNOL, V125, P252; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; ONO M, 1993, BIOL CELL, V77, P219, DOI 10.1016/S0248-4900(05)80191-1; RAMPAL AL, 1980, BIOCHEMISTRY-US, V19, P679, DOI 10.1021/bi00545a011; REAVEN EP, 1973, J CELL BIOL, V59, P12, DOI 10.1083/jcb.59.1.12; SCHREIBER S, 1990, CELL REGUL, V1, P403, DOI 10.1091/mbc.1.5.403; SHEPHERD VL, 1982, J RETICULOENDOTH SOC, V32, P423; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Smetana K, 1996, BIOMATERIALS, V17, P741, DOI 10.1016/0142-9612(96)86745-7; SOZZANI P, 1995, J BIOL CHEM, V270, P5084, DOI 10.1074/jbc.270.10.5084; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; STOKES K, 1995, J BIOMATER APPL, V9, P321, DOI 10.1177/088532829500900402; SUTTON JS, 1966, J CELL BIOL, V28, P303, DOI 10.1083/jcb.28.2.303; Tapper H, 1996, J LEUKOCYTE BIOL, V59, P613, DOI 10.1002/jlb.59.5.613; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WOODHOUSE KA, 1994, J COLLOID INTERF SCI, V164, P40, DOI 10.1006/jcis.1994.1141; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69; YIN HL, 1988, J CELL SCI, P169; ZHAO Q, 1991, J BIOMED MATER RES, V25, P177, DOI 10.1002/jbm.820250205	53	53	54	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					823	832		10.1096/fasebj.13.8.823	http://dx.doi.org/10.1096/fasebj.13.8.823			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224226				2022-12-28	WOS:000080372500006
J	Bassell, GJ; Oleynikov, Y; Singer, RH				Bassell, GJ; Oleynikov, Y; Singer, RH			The travels of mRNAs through all cells large and small	FASEB JOURNAL			English	Review							ACTIN MESSENGER-RNA; INTRACELLULAR-LOCALIZATION; SUBCELLULAR-LOCALIZATION; 3'-UNTRANSLATED REGION; UNCONVENTIONAL MYOSIN; NEURONAL POLARITY; PROTEIN-SYNTHESIS; BINDING PROTEIN; XENOPUS OOCYTES; BC1 RNA		Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Bassell, GJ (corresponding author), Albert Einstein Coll Med, Dept Neurosci, 1300 Morris Pk, Bronx, NY 10461 USA.	bassell@aecom.yu.edu						Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Arn EA, 1998, CELL, V95, P151, DOI 10.1016/S0092-8674(00)81745-6; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bassell GJ, 1998, J NEUROSCI, V18, P251; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; BASSELL GJ, 1997, CURR OPIN CELL BIOL; BEHAR L, 1995, INT J DEV NEUROSCI, V13, P113, DOI 10.1016/0736-5748(95)00001-W; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Gazzaley AH, 1997, J NEUROSCI, V17, P2006; HAARER BK, 1994, J CELL SCI, V107, P1055; HANNAN AJ, 1995, MOL CELL NEUROSCI, V6, P397, DOI 10.1006/mcne.1995.1030; Hannan AJ, 1998, MOL CELL NEUROSCI, V11, P289, DOI 10.1006/mcne.1998.0693; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; Hazelrigg T, 1998, CELL, V95, P451, DOI 10.1016/S0092-8674(00)81613-X; HILL MA, 1994, J CELL BIOL, V126, P1221, DOI 10.1083/jcb.126.5.1221; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; Knowles RB, 1997, P NATL ACAD SCI USA, V94, P14804, DOI 10.1073/pnas.94.26.14804; Knowles RB, 1996, J NEUROSCI, V16, P7812; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734; Litman P, 1996, DEV BIOL, V176, P86, DOI 10.1006/dbio.1996.9992; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Martone ME, 1996, J NEUROSCI, V16, P7437; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; Muslimov IA, 1998, J CELL BIOL, V141, P1601, DOI 10.1083/jcb.141.7.1601; Muslimov IA, 1997, J NEUROSCI, V17, P4722; NIXON RA, 1987, AXONAL TRANSPORT, P175; Oleynikov Y, 1998, TRENDS CELL BIOL, V8, P381, DOI 10.1016/S0962-8924(98)01348-8; OlinkCoux M, 1996, J NEUROSCI, V16, P1346; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Racca C, 1997, J NEUROSCI, V17, P1691; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Steward O, 1996, J NEUROCYTOL, V25, P717, DOI 10.1007/BF02284837; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TAKEDA S, 1995, NEURON, V14, P1257, DOI 10.1016/0896-6273(95)90272-4; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Theurkauf WE, 1998, DEVELOPMENT, V125, P3655; THOMAS KL, 1994, NEURON, V13, P737, DOI 10.1016/0896-6273(94)90040-X; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; Wallace CS, 1998, J NEUROSCI, V18, P26; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Wiseman JW, 1997, CELL BIOL INT, V21, P243, DOI 10.1006/cbir.1997.0140; Wiseman JW, 1997, INT J BIOCHEM CELL B, V29, P1013, DOI 10.1016/S1357-2725(97)00034-4; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZHANG HL, 1997, ASCB ABSTR, P1239	79	133	134	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					447	454		10.1096/fasebj.13.3.447	http://dx.doi.org/10.1096/fasebj.13.3.447			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064611				2022-12-28	WOS:000079016000004
J	Mowry, KL; Cote, CA				Mowry, KL; Cote, CA			RNA sorting in Xenopus oocytes and embryos	FASEB JOURNAL			English	Review						RNA localization; A-V axis; polarity; oogenesis; RNA binding protein	MATERNAL MESSENGER-RNA; TRACT-BINDING PROTEIN; AMPHIBIAN EARLY DEVELOPMENT; BOX TRANSCRIPTION FACTOR; VEGETAL CORTEX; GERM PLASM; BETA-ACTIN; VG1 PROTEIN; TGF-BETA; INTRACELLULAR-LOCALIZATION	Cytoplasmic localization of mRNA molecules has emerged as a powerful mechanism for generating spatially restricted gene expression. This process is an important contributor to cell polarity in both somatic cells and oocytes, and can provide the basis for patterning during embryonic development. In vertebrates, this phenomenon is perhaps best documented in the frog, Xenopus laevis, where polarity along the animal-vegetal axis coincides with the localization of numerous mRNA molecules. Research over the last several years has made exciting progress toward understanding the molecular mechanisms underlying cytoplasmic mRNA localization.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Brown University	Mowry, KL (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, 69 Brown St, Providence, RI 02912 USA.	kimberly_mowry@brown.edu		Mowry, Kimberly/0000-0002-4126-2889	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030699] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD30699, R01 HD030699] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMUKHTAR KA, 1971, J EMBRYOL EXP MORPH, V26, P195; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLACKLER AW, 1958, J EMBRYOL EXP MORPH, V6, P491; CARPENTER CD, 1982, DEV BIOL, V91, P43, DOI 10.1016/0012-1606(82)90006-9; CHENG H, 1989, J MOL BIOL, V210, P541, DOI 10.1016/0022-2836(89)90130-7; COGGINS LW, 1973, J CELL SCI, V12, P71; CZOLOWSKA R, 1969, J EMBRYOL EXP MORPH, V22, P229; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DANILCHIK MV, 1987, DEV BIOL, V122, P101, DOI 10.1016/0012-1606(87)90336-8; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELINSON RP, 1993, DEV BIOL, V160, P554, DOI 10.1006/dbio.1993.1329; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GARD DL, 1995, CURR TOP DEV BIOL, V30, P215; Gautreau D, 1997, DEVELOPMENT, V124, P5013; Gavis ER, 1997, TRENDS CELL BIOL, V7, P485, DOI 10.1016/S0962-8924(97)01162-8; GERHART J, 1986, BIOSCIENCE, V36, P541, DOI 10.2307/1310156; GERHART J, 1989, DEVELOPMENT, V107, P37; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; Heasman J, 1997, DEVELOPMENT, V124, P4179; Henry GL, 1996, DEVELOPMENT, V122, P1007; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; HOEK KS, 1998, BIOCHEMISTRY-US, V37, P1243; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; Horb ME, 1997, DEVELOPMENT, V124, P1689; Houston DW, 1998, DEVELOPMENT, V125, P171; Hudson C., 1998, MECH DEVELOP, V73, P190; Hudson JW, 1996, DEV GENET, V19, P190, DOI 10.1002/(SICI)1520-6408(1996)19:3<190::AID-DVG2>3.0.CO;2-4; Joseph EM, 1998, DEVELOPMENT, V125, P2677; KALT MR, 1973, Z ZELLFORSCH MIK ANA, V138, P41, DOI 10.1007/BF00307077; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KING ML, 1985, DEV BIOL, V112, P203, DOI 10.1016/0012-1606(85)90134-4; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Kloc M, 1996, DEV BIOL, V180, P119, DOI 10.1006/dbio.1996.0289; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KLOC M, 1991, MOL REPROD DEV, V28, P341, DOI 10.1002/mrd.1080280405; Kloc M, 1998, MECH DEVELOP, V75, P81, DOI 10.1016/S0925-4773(98)00086-0; Kloc M, 1998, MECH DEVELOP, V73, P95, DOI 10.1016/S0925-4773(98)00041-0; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; KLYMKOWSKY MW, 1994, DEV BIOL, V165, P372, DOI 10.1006/dbio.1994.1260; KU M, 1993, DEVELOPMENT, V119, P1161; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; Lustig KD, 1996, DEVELOPMENT, V122, P4001; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; Mowry KL, 1996, P NATL ACAD SCI USA, V93, P14608, DOI 10.1073/pnas.93.25.14608; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERRYOKEEFE H, 1990, IN SITU HYBRIDISATIO, P115; PHILLIPS CR, 1982, J EXP ZOOL, V223, P265, DOI 10.1002/jez.1402230308; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; RESSOM RE, 1988, DEVELOPMENT, V103, P507; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SAGATA N, 1981, DEV GROWTH DIFFER, V23, P23; SAVAGE RM, 1993, DEV BIOL, V157, P371, DOI 10.1006/dbio.1993.1142; Schroeder KE, 1996, DEV GENET, V19, P268, DOI 10.1002/(SICI)1520-6408(1996)19:3<268::AID-DVG10>3.0.CO;2-W; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; SPOHR G, 1981, J MOL BIOL, V151, P573, DOI 10.1016/0022-2836(81)90424-1; Stennard F, 1996, DEVELOPMENT, V122, P4179; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; VINCENT JP, 1987, DEV BIOL, V123, P526, DOI 10.1016/0012-1606(87)90411-8; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1987, P NATL ACAD SCI USA, V84, P2798, DOI 10.1073/pnas.84.9.2798; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; Wyatt J. R., 1993, RNA WORLD, P465; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5; Zhang J, 1996, DEVELOPMENT, V122, P4119; Zhou Y, 1996, DEVELOPMENT, V122, P2947; Zhou Y, 1996, DEV BIOL, V179, P173, DOI 10.1006/dbio.1996.0249	98	94	96	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					435	445		10.1096/fasebj.13.3.435	http://dx.doi.org/10.1096/fasebj.13.3.435			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064610				2022-12-28	WOS:000079016000003
J	Zocchi, E; Usai, C; Guida, L; Franco, L; Bruzzone, S; Passalacqua, M; De Flora, A				Zocchi, E; Usai, C; Guida, L; Franco, L; Bruzzone, S; Passalacqua, M; De Flora, A			Ligand-induced internalization of CD38 results in intracellular Ca2+ mobilization: role of NAD(+) transport across cell membranes	FASEB JOURNAL			English	Article						pyridine nucleotides; cyclic ADP-ribose; intracellular calcium homeostasis; NAD(+) transporter	CYCLIC-ADP-RIBOSE; SEA-URCHIN EGGS; ANTIGEN CD38; SURFACE; PROTEIN; NAD+; GLYCOHYDROLASE; IDENTIFICATION; GLYCOPROTEIN; ERYTHROCYTES	CD38, a transmembrane glycoprotein widely expressed in vertebrate cells, is a bifunctional ectoenzyme catalyzing the synthesis and hydrolysis of cyclic ADP-ribose (cADPR). cADPR is a universal second messenger that releases calcium from intracellular stores. Since cADPR is generated by CD38 at the outer surface of many cells, where it acts intracellularly, increasing attention is paid to addressing this topological paradox. Recently, we demonstrated that CD38 is a catalytically active, unidirectional transmembrane transporter of cADPR, which then reaches its receptor-operated intracellular calcium stores. Moreover, CD38 was reported to undergo a selective and extensive internalization through non clathrin-coated endocytotic vesicles upon incubating CD38(+) cells with either NAD(+) or thiol compounds: these endocytotic vesicles can convert cytosolic NAD into cADPR despite an asymmetric unfavorable orientation that makes the active site of CD38 intravesicular. Here we demonstrate that the cADPR-generating activity of the endocytotic vesicles results in remarkable and sustained increases of intracellular free calcium concentration in different cells exposed to either NAD(+), or GSH, or N-acetylcysteine. This effect of CD38-internalizing Ligands on intracellular calcium levels was found to involve a two-step mechanism: 1) influx of cytosolic NAD(+) into the endocytotic vesicles, mediated by a hitherto unrecognized dinucleotide transport system that is saturable, bidirectional, inhibitable by 8-N-3-NAD(+), and characterized by poor dinucleotide specificity, low affinity, and high efficiency; 2) intravesicular CD38-catalyzed conversion of NAD+ to cADPR, followed by out-pumping of the cyclic nucleotide into the cytosol and subsequent release of calcium from thapsigargin-sensitive stores. This unknown intracellular trafficking of NAD(+) and cADPR based on two distinctive and specific transmembrane carriers for either nucleotide can affect the intracellular calcium homeostasis in CD38(+) cells.	Univ Genoa, Inst Biochem, I-16132 Genoa, Italy; CNR, Inst Cybernet & Biophys, I-16149 Genoa, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)	De Flora, A (corresponding author), Univ Genoa, Inst Biochem, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Passalacqua, Mario/W-1973-2019; Bruzzone, Santina/A-4264-2015	Passalacqua, Mario/0000-0003-2779-6259; Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Beutler E., 1984, GLUTATHIONE RED CELL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 1998, FEBS LETT, V433, P275, DOI 10.1016/S0014-5793(98)00929-6; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Franco L, 1998, FASEB J, V12, P1507; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KONTANI K, 1993, J BIOL CHEM, V268, P16895; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1991, J BIOL CHEM, V266, P2276; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Meldolesi J, 1998, NATURE, V392, P863, DOI 10.1038/31804; NEUBURGER M, 1983, BIOCHEM J, V216, P443, DOI 10.1042/bj2160443; Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	43	85	95	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					273	283		10.1096/fasebj.13.2.273	http://dx.doi.org/10.1096/fasebj.13.2.273			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973315				2022-12-28	WOS:000078615200007
J	Hatton, JP; Gaubert, F; Lewis, ML; Darsel, Y; Ohlmann, P; Cazenave, JP; Schmitt, D				Hatton, JP; Gaubert, F; Lewis, ML; Darsel, Y; Ohlmann, P; Cazenave, JP; Schmitt, D			The kinetics of translocation and cellular quantity of protein kinase C in human leukocytes are modified during spaceflight	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	microgravity; translocation	SIGNAL-TRANSDUCTION; PHORBOL ESTERS; MICROGRAVITY; ACTIVATION; LYMPHOCYTES; CELLS; MICROASSAY; RECEPTORS; RESPONSES; GRAVITY	Protein kinase C (PKC) is a family of serine/threonine kinases that play an important role in mediating intracellular signal transduction in eukaryotes, U937 cells were exposed to microgravity during a space shuttle flight and stimulated with a radiolabeled phorbol ester ([H-3]PDBu) to both specifically label and activate translocation of PKC from the cytosol to the particulate fraction of the cell. Although significant translocation of PKC occurred at all g levels, the kinetics of translocation in flight were significantly different from those on the ground. In addition, the total quantity of [H-3]PDBu binding PKC was increased in flight compared to cells at 1 g on the ground, whereas the quantity in hypergravity (1.4 g) was decreased with respect to 1 g, Similarly, in purified human peripheral blood T cells the quantity of PKC delta varied in inverse proportion to the g level for some experimental treatments, In addition to these novel findings, the results confirm earlier studies which showed that PKC is sensitive to changes in gravitational acceleration. The mechanisms of cellular gravisensitivity are poorly understood but the demonstrated sensitivity of PKC to this stimulus provides us with a useful means of measuring the effect of altered gravity levels on early cell activation events.	Etablissement Tranfus Sanguine, INSERM, U311, F-67065 Strasbourg, France; CHU Rangueil, INSERM, U151, F-31054 Toulouse, France; Univ Alabama, Huntsville, AL 35899 USA; CHU Rangueil, Immunol Lab, F-31054 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Alabama System; University of Alabama Huntsville; CHU de Toulouse	Hatton, JP (corresponding author), Etablissement Tranfus Sanguine, INSERM, U311, F-67065 Strasbourg, France.	jason.hatton@etss.u-strasbg.fr	Cazenave, Jean-Pierre/AAE-2935-2019					ALBRECHTBUEHLER G, 1997, FRONTIERS BIOL SCI S, P54; Banerjee A, 1996, ANN NY ACAD SCI, V793, P226, DOI 10.1111/j.1749-6632.1996.tb33517.x; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cogoli A, 1991, Adv Space Biol Med, V1, P183; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; GAUBERT F, 1998, THESIS U P SABATIER; GENZEL P, 1988, ESA, P21; GMUNDER FK, 1990, BIOL CELL, V70, P33, DOI 10.1016/0248-4900(90)90358-A; Hashemi BB, 1998, FASEB J, V12, pA626; Hatton JP, 1998, J CELL BIOCHEM, V70, P252, DOI 10.1002/(SICI)1097-4644(19980801)70:2<252::AID-JCB11>3.0.CO;2-P; HATTON JP, 1997, FRONTIERS BIOL SCI S, P82; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Keenan C, 1997, IMMUNOLOGY, V90, P557, DOI 10.1046/j.1365-2567.1997.00198.x; Kiang JG, 1996, THYROID, V6, P475, DOI 10.1089/thy.1996.6.475; KILEY SC, 1995, J CELL SCI, V108, P1003; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Moore D, 1996, BIOL MED RES SPACE, P1; PARKER PJ, 1994, PROTEIN KINASE C, P3; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; TABONY J, 1990, NATURE, V346, P448, DOI 10.1038/346448a0; TABONY J, 1996, NANOBIOLOGY, V4, P117; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; Wang Y, 1997, J CLIN INVEST, V99, P2890, DOI 10.1172/JCI119483; WOODS KM, 1994, EXP CELL RES, V211, P171, DOI 10.1006/excr.1994.1074	36	48	50	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S23	S33		10.1096/fasebj.13.9001.s23	http://dx.doi.org/10.1096/fasebj.13.9001.s23			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352142				2022-12-28	WOS:000080403800004
J	Neufeld, G; Cohen, T; Gengrinovitch, S; Poltorak, Z				Neufeld, G; Cohen, T; Gengrinovitch, S; Poltorak, Z			Vascular endothelial growth factor (VEGF) and its receptors	FASEB JOURNAL			English	Review						hypoxia; angiogenesis; oncogene; heparan-sulfate proteoglycan; cytokine	FACTOR GENE-EXPRESSION; ANGIOGENESIS IN-VIVO; HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR GENE; EXON 7-ENCODED DOMAIN; HUMAN-MELANOMA CELLS; FACTOR MESSENGER-RNA; WILD-TYPE P53; PERMEABILITY FACTOR; TYROSINE KINASE	Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular endothelial cells. Five VEGF isoforms are generated as a result of alternative splicing from a single VEGF gene. These isoforms differ in their molecular mass and in biological properties such as their ability to bind to cell-surface heparan-sulfate proteoglycans, The expression of VEGF is potentiated in response to hypoxia, by activated oncogenes, and by a variety of cytokines, VEGF induces endothelial cell proliferation, promotes cell migration, and inhibits apoptosis. In vivo VEGF induces angiogenesis as well as permeabilization of blood vessels, and plays a central role in the regulation of vasculogenesis. Deregulated VEGF expression contributes to the development of solid tumors by promoting tumor angiogenesis and to the etiology of several additional diseases that are characterized by abnormal angiogenesis, Consequently, inhibition of VEGF signaling abrogates the development of a wide variety of tumors. The various VEGF forms bind to two tyrosine-kinase receptors, VEGFR-1 (flt-1) and VEGFR-2 (KDR/flk-1), which are expressed almost exclusively in endothelial cells. Endothelial cells express in addition the neuropilin- and neuropilin-2 coreceptors, which bind selectively to the 165 amino acid form of VEGF (VEGF(165)). This review focuses on recent developments that have widened considerably our understanding of the mechanisms that control VEGF production and VEGF signal transduction and on recent studies that have shed light on the mechanisms by which VEGF regulates angiogenesis.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Neufeld, G (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	gera@tx.technion.ac.il	Neufeld, Gera/F-1524-2019					ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Agani F, 1997, CANCER RES, V57, P4474; Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; BACIC M, 1995, GROWTH FACTORS, V12, P11, DOI 10.3109/08977199509003209; Barleon B, 1997, CANCER RES, V57, P5421; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Barleon B, 1997, J BIOL CHEM, V272, P10382; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; Brown L F, 1997, EXS, V79, P233; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHARNOCKJONES DS, 1994, BIOL REPROD, V51, P524, DOI 10.1095/biolreprod51.3.524; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CHENG SY, 1997, P NATL ACAD SCI USA, V94, P12808; CHEUNG CY, 1995, AM J OBSTET GYNECOL, V173, P753, DOI 10.1016/0002-9378(95)90335-6; CHIANG MK, 1995, GROWTH FACTORS, V12, P1, DOI 10.3109/08977199509003208; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Damert A, 1997, CANCER RES, V57, P3860; Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DembinskaKiec A, 1997, NAT MED, V3, P1177, DOI 10.1038/nm1197-1177a; Deroanne CF, 1997, CANCER RES, V57, P5590; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P110; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; Folkman J, 1998, ENDOCRINOLOGY, V139, P441, DOI 10.1210/en.139.2.441; Folkman J, 1997, EXS, V79, P1; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fournier E, 1997, B CANCER, V84, P397; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Isner JM, 1996, HUM GENE THER, V7, P959, DOI 10.1089/hum.1996.7.8-959; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jiang BH, 1997, CANCER RES, V57, P5328; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Jussila L, 1998, CANCER RES, V58, P1599; KATOH O, 1995, CANCER RES, V55, P5687; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIESER A, 1994, ONCOGENE, V9, P963; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; Kourembanas S, 1997, KIDNEY INT, V51, P438, DOI 10.1038/ki.1997.58; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Magovern CJ, 1997, HUM GENE THER, V8, P215, DOI 10.1089/hum.1997.8.2-215; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Matsumoto K, 1997, NEPHRON, V77, P212, DOI 10.1159/000190275; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUHLHAUSER J, 1995, CIRC RES, V77, P1077, DOI 10.1161/01.RES.77.6.1077; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Okamoto N, 1997, AM J PATHOL, V151, P281; Omura T, 1997, J BIOL CHEM, V272, P23317, DOI 10.1074/jbc.272.37.23317; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PEER J, 1995, LAB INVEST, V72, P638; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Presta LG, 1997, CANCER RES, V57, P4593; RAK J, 1995, CANCER RES, V55, P4575; Ramakrishnan S, 1996, CANCER RES, V56, P1324; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Roberts WG, 1997, CANCER RES, V57, P765; Rockwell Patricia, 1995, Molecular and Cellular Differentiation, V3, P91; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Saleh M, 1996, CANCER RES, V56, P393; Schiffenbauer YS, 1997, P NATL ACAD SCI USA, V94, P13203, DOI 10.1073/pnas.94.24.13203; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Siemeister G, 1996, BIOCHEM BIOPH RES CO, V222, P249, DOI 10.1006/bbrc.1996.0730; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Siemeister G, 1996, CANCER RES, V56, P2299; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Strawn LM, 1996, CANCER RES, V56, P3540; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tsurumi Y, 1997, CIRCULATION, V96, P382; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Walder CE, 1996, J CARDIOVASC PHARM, V27, P91, DOI 10.1097/00005344-199601000-00015; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; Wen Y, 1998, J BIOL CHEM, V273, P2090, DOI 10.1074/jbc.273.4.2090; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wilting J, 1996, DEV BIOL, V176, P76, DOI 10.1006/dbio.1996.9993; Yang XJ, 1996, J NEUROSCI, V16, P6089; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	182	2907	3170	3	357	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					9	22		10.1096/fasebj.13.1.9	http://dx.doi.org/10.1096/fasebj.13.1.9			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872925				2022-12-28	WOS:000078029500002
J	Mazzocchi, G; Rossi, GP; Neri, G; Malendowicz, LK; Albertin, G; Nussdorfer, GG				Mazzocchi, G; Rossi, GP; Neri, G; Malendowicz, LK; Albertin, G; Nussdorfer, GG			11 beta-Hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex	FASEB JOURNAL			English	Article						steroidogenesis; cortisone; 11-dehydrocorticosterone; ACTH; angiotensin II; aminoglutethimide; cyanoketone; metyrapone	APPARENT MINERALOCORTICOID EXCESS; MESSENGER-RIBONUCLEIC-ACID; GENE-EXPRESSION; RAT; CELLS; LOCALIZATION; SECRETION; PROTEINS; ENZYMES; TISSUES	Although oxidation of cortisol or corticosterone by 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) represents the physiological mechanism conferring specificity for aldosterone on the mineralocorticoid receptor in mineralocorticoid target tissues, little attention has been paid until now to the expression and activity of this enzyme in human adrenals. We have shown that human adrenal cortex expresses 11 beta-HSD type 2 (11 beta-HSD2) gene, and found a marked 11 beta-HSD2 activity in microsomal preparations obtained from slices of decapsulated normal human adrenal cortices. Under basal conditions, adrenal slices secreted, in addition to cortisol and corticosterone (B), sizeable amounts of cortisone and 11-dehydrocorticosterone (DH-B), the inactive forms to which the former glucocorticoids are converted by 11 beta-HSD. Addition of the 11 beta-HSD inhibitor glycyrrhetinic acid elicited a moderate rise in the production of cortisol and B and suppressed that of cortisone and DH-B. ACTH and angiotensin II evoked a marked rise in the secretion of cortisol and B, but unexpectedly depressed the release of cortisone and DH-B. ACTH also lowered the capacity of adrenal slices to convert [H-3]cortisol to [H-3]cortisone. This last effect of ACTH was concentration-dependently abolished by both aminoglutethimide and cyanoketone, which blocks early steps of steroid synthesis, but not by metyrapone, an inhibitor of 11 beta-hydroxylase. Collectively, these findings indicate that the human adrenal cortex possesses an active 11 beta-HSD2 engaged in the inactivation of newly formed gluco corticoids. The activity of this enzyme is negatively modulated by the main agonists of glucocorticoid secretion through an indirect mechanism, probably involving the rise in the intra-adrenal concentration of non-11 beta-hydroxylated steroid hormones.	Univ Padua, Dept Anat, I-35121 Padua, Italy; Univ Padua, Dept Clin & Expt Med, I-35121 Padua, Italy; Sch Med, Dept Histol & Embryol, PL-60781 Poznan, Poland	University of Padua; University of Padua	Nussdorfer, GG (corresponding author), Univ Padua, Dept Anat, Via Gabelli 65, I-35121 Padua, Italy.	ggnanat@ipdunidx.unipd.it						BAYLEY E, 1969, ACTA ENDOCRINOL-COP, V62, P339; DAZORD A, 1972, J CLIN ENDOCR METAB, V35, P24, DOI 10.1210/jcem-35-1-24; Diederich S, 1996, EUR J ENDOCRINOL, V134, P301, DOI 10.1530/eje.0.1340301; FARESE RV, 1991, NEW ENGL J MED, V325, P1225; Funder JW, 1996, EUR J ENDOCRINOL, V134, P267, DOI 10.1530/eje.0.1340267; Funder JW, 1995, TRENDS ENDOCRIN MET, V6, P248, DOI 10.1016/1043-2760(95)95219-U; HANUKOGLU I, 1992, J STEROID BIOCHEM, V43, P779, DOI 10.1016/0960-0760(92)90307-5; Latif SA, 1997, STEROIDS, V62, P230, DOI 10.1016/S0039-128X(96)00208-5; LATIF SA, 1994, STEROIDS, V59, P352, DOI 10.1016/0039-128X(94)90001-9; LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V78, P1212, DOI 10.1210/jc.78.5.1212; Li KXZ, 1996, MOL CELL ENDOCRINOL, V120, P67, DOI 10.1016/0303-7207(96)03822-1; MACKINNON M, 1977, J LAB CLIN MED, V90, P1096; MCNICOL AM, 1992, ADRENAL GLAND, P1; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MONDER C, 1991, BIOCHIM BIOPHYS ACTA, V1115, P23, DOI 10.1016/0304-4165(91)90006-3; Musajo F, 1996, LIFE SCI, V59, P1401, DOI 10.1016/0024-3205(96)00467-5; Neri G, 1996, J CLIN ENDOCR METAB, V81, P169, DOI 10.1210/jc.81.1.169; Roland BL, 1996, ENDOCRINOLOGY, V137, P1123, DOI 10.1210/en.137.3.1123; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; Shimojo M, 1996, J MOL ENDOCRINOL, V17, P121, DOI 10.1677/jme.0.0170121; Shimojo M, 1997, ENDOCRINOLOGY, V138, P1305, DOI 10.1210/en.138.3.1305; Smith RE, 1997, ENDOCRINOLOGY, V138, P540, DOI 10.1210/en.138.2.540; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SZALAY KS, 1981, ACTA PHYSIOL HUNG, V57, P225; TRAPNELL BC, 1993, AM J PHYSIOL, V264, pL199, DOI 10.1152/ajplung.1993.264.3.L199; WALKER BR, 1992, CLIN ENDOCRINOL, V37, P483, DOI 10.1111/j.1365-2265.1992.tb01478.x; WALKER BR, 1994, J ENDOCRINOL, V141, P467, DOI 10.1677/joe.0.1410467; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P529, DOI 10.1210/jc.80.2.529; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Whorwood C. B., 1995, Journal of Endocrinology, V144, pP183; WHORWOOD CB, 1993, ENDOCRINOLOGY, V132, P2287, DOI 10.1210/en.132.6.2287; WILLIAMS AC, 1992, J ENDOCRINOLOGY S, V132, P111; YANG K, 1994, J ENDOCRINOL, V143, P121, DOI 10.1677/joe.0.1430121; YANG K, 1995, MOL CELL ENDOCRINOL, V111, pR19, DOI 10.1016/0303-7207(95)03574-Q; ZHOU MY, 1995, ENDOCRINOLOGY, V136, P3729, DOI 10.1210/en.136.9.3729	36	86	86	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1533	1539		10.1096/fasebj.12.14.1533	http://dx.doi.org/10.1096/fasebj.12.14.1533			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806762				2022-12-28	WOS:000076749500012
J	Maiorino, M; Wissing, JB; Brigelius-Flohe, R; Calabrese, F; Roveri, A; Steinert, P; Ursini, F; Flohe, L				Maiorino, M; Wissing, JB; Brigelius-Flohe, R; Calabrese, F; Roveri, A; Steinert, P; Ursini, F; Flohe, L			Testosterone mediates expression of the selenoprotein PHGPx by induction of spermatogenesis and not by direct transcriptional gene activation	FASEB JOURNAL			English	Article						glutathione peroxidases; selenium	HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; I IODOTHYRONINE DEIODINASE; SELENIUM DEFICIENCY; SCHISTOSOMA-MANSONI; RAT TESTIS; IDENTIFICATION; SELENOCYSTEINE; CDNA; SELENOENZYME; TISSUES	Selenium deficiency is known to be associated with male infertility, and the selenoprotein PHGPx has been shown to increase in rat testis after puberty and to depend on gonadotropin stimulation in hypophysectomized rats [Roveri et al. (1992) J. Biol. Chem. 267, 6142-6146]. Exposure of decapsulated whole testis, however, failed to reveal any transcriptional activation or inhibition of the PHGPx gene by testosterone, human chorionic gonadotropin, or forskolin. Nevertheless, it was verified that the specific activity of PHGPx in testis, but not of cGPx, correlated with sexual maturation. Leydig cell destruction in vivo by ethane dimethane sulfonate (EDS) resulted in a delayed decrease in PHGPx activity and mRNA that could be completely prevented by testosterone substitution. cGPx transiently increased upon EDS treatment, probably as a result of reactive macrophage augmentation. In situ mRNA hybridization studies demonstrated an uncharacteristic low level of cGPx transcription in testis, whereas PHGPx mRNA was abundantly and preferentially expressed in round spermatids. The data show that the age or gonadotropinciependent expression of PHGPx in testis does not result from direct transcriptional gene activation by testosterone, but is due to differentiation stage-specific expression in late spermatids, which are under the control of Leydig cell-derived testosterone. The striking burst of PHGPx expression at the transition of round to elongated spermatids suggests an involvement of this selenoprotein in sperm maturation.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Ist Anat Patol, I-35121 Padua, Italy; DIFE, D-14558 Bergholz Rehbrucke, Germany; Tech Univ Braunschweig, Dept Physiol Chem, D-38124 Braunschweig, Germany	University of Padua; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Braunschweig University of Technology	Maiorino, M (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	mmaior@civ.bio.unipd.it	Roveri, Antonella/AAF-3669-2019	Roveri, Antonella/0000-0002-3252-0559				BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; Behne D, 1997, BIOMED ENVIRON SCI, V10, P340; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BEHNE D, 1994, BIOL TRACE ELEM RES, V43-5, P287, DOI 10.1007/BF02917327; BEHNE D, 1982, J NUTR, V112, P1682, DOI 10.1093/jn/112.9.1682; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BESADOUN A, 1976, ANAL BIOCHEM, V70, P241; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BRIGELIUSFLOHE R, 1997, IN PRESS BIOCH J; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Chu FF, 1997, BIOMED ENVIRON SCI, V10, P156; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; CUSAN L, 1982, J ANDROL, V3, P124; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe Leopold, 1997, P415; FOLLMANN H, 1996, BIOFACTORS, V5, P147; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; JACKSON CM, 1984, J REPROD FERTIL, V71, P393; KERR JB, 1989, CELL TISSUE RES, V257, P163; Lei X. G., 1997, FASEB Journal, V11, pA235; LEI XG, 1995, J NUTR, V125, P1438; Maiorino M, 1996, EUR J BIOCHEM, V238, P838, DOI 10.1111/j.1432-1033.1996.0838w.x; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Maiorino M, 1997, BIOMED ENVIRON SCI, V10, P209; Marcocci L, 1997, BIOFACTORS, V6, P351, DOI 10.1002/biof.5520060305; MEYER EHH, 1974, ENDOCRINOLOGY, V95, P1737, DOI 10.1210/endo-95-6-1737; Peltola V, 1996, ENDOCRINOLOGY, V137, P105, DOI 10.1210/en.137.1.105; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schnurr K, 1996, J BIOL CHEM, V271, P4653; SHARPE RM, 1990, AM J ANAT, V188, P3, DOI 10.1002/aja.1001880103; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; STEINERT P, 1998, IN PRESS BIOL CHEM; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wallace E, 1987, SELENIUM BIOL MED A, P181; WEITZEL F, 1990, BIOCHIM BIOPHYS ACTA, V1036, P88, DOI 10.1016/0304-4165(90)90018-R; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; WU ASH, 1979, BIOL REPROD, V20, P793, DOI 10.1095/biolreprod20.4.793; WU ASH, 1973, BIOL REPROD, V8, P625; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6	52	100	108	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1359	1370		10.1096/fasebj.12.13.1359	http://dx.doi.org/10.1096/fasebj.12.13.1359			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761779				2022-12-28	WOS:000076402000011
J	Ikezawa, K; Ohtsubo, M; Norwood, TH; Narayanan, AS				Ikezawa, K; Ohtsubo, M; Norwood, TH; Narayanan, AS			Role of cyclin E and cyclin E-dependent kinase in mitogenic stimulation by cementum-derived growth factor in human fibroblasts	FASEB JOURNAL			English	Article						tooth cementum; CGF; epidermal growth factor; cell cycle phase; gingival fibroblast; mesenchymal cells	DIFFERENTIAL EXPRESSION; MAMMALIAN FIBROBLASTS; SIGNAL TRANSDUCTION; G(1) CYCLINS; FACTOR-I; MECHANISMS; CELLS; PROLIFERATION; OSTEOBLASTS; INHIBITORS	Cementum-derived growth factor (CGF) is a 14 kDa polypeptide sequestered in tooth cementum. It is an IGF-I like molecule that is weakly mitogenic to fibroblasts, but its mitogenic action is synergistically potentiated in the presence of epidermal growth factor (EGF) or serum. We have examined whether the CGF affects cyclin E levels and the activity of cyclin-dependent kinase (Cdk) associated with this cyclin, and whether these changes contribute to the synergism in mitogenic activity between CGF and EGF. Optimal DNA synthesis by serum-starved human gingival fibroblasts required the presence of CGF for 0-12 h and EGF for 0-3 h. Therefore, cells were serum starved for 48 h and then exposed to CGF, EGF, or CGF + EGF. Cells incubated with 10% fetal bovine serum (FBS) served as positive controls. At various time points after the addition of growth factors, cyclin E levels were examined by Western analysis. Cdk associated with cyclin E was immunoprecipitated with anti-cyclin E antibody and kinase activity was measured using H1 histone as substrate. Cyclin E and the HI kinase activity level increased after 8-12 h in cells exposed to CGF and in positive controls exposed to 10% FBS. They returned to basal level 4 h later in cells exposed to CGF alone, whereas in the presence of CGF + EGF and FBS they remained elevated for up to 20 h. The cyclin E levels did not increase in the presence of EGF alone. Cyclin-dependent kinase inhibitors p21(cip1) and p27(kip1) were barely detectable in these cells. Fibroblasts transfected with LXSN-cyclin E, a retroviral vector containing cyclin E cDNA, overexpressed cyclin E and their steady-state cyclin E-Cdk activity was higher than control cells. DNA synthesis by cyclin E overexpressing cells was higher, but optimal DNA synthesis by these cells required the presence of CGF and EGF. These results show that CGF action involves an increase in the level of cyclin E and E-Cdk activity and that the higher levels are maintained in the presence of both CGF and EGF. They also indicate that sustained high cyclin E level and Cdk2 activity during G(1) phase are necessary, but not sufficient, for optimal mitogenic response in human fibroblasts.-Ike-zawa, IC, Ohtsubo, M., Norwood, T. H., Narayanan, A. S. Role of cyclin E and cyclin E-dependent kinase in mitogenic stimulation by cementum-derived growth factor in human fibroblasts.	Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; Kurume Univ, Inst Life Sci, Div Mol Genet, Kurume, Fukuoka 830, Japan	University of Washington; University of Washington Seattle; Kurume University	Narayanan, AS (corresponding author), Univ Washington, Sch Med, Dept Pathol, Box 357470, Seattle, WA 98195 USA.			ohtsubo, motoaki/0000-0002-2479-3178	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229, R01DE010491] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-10491, DE-08229] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; DELANY AM, 1994, J CELL BIOCHEM, V55, P328, DOI 10.1002/jcb.240550309; DeLoia JA, 1997, PLACENTA, V18, P9, DOI 10.1016/S0143-4004(97)90066-7; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Ikezawa K, 1997, CONNECT TISSUE RES, V36, P309, DOI 10.3109/03008209709160230; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Li ZR, 1997, BBA-MOL CELL RES, V1356, P149, DOI 10.1016/S0167-4889(96)00172-3; MACNEIL RL, 1993, J PERIODONTAL RES, V28, P550, DOI 10.1111/j.1600-0765.1993.tb02123.x; NAKAE H, 1991, BIOCHEMISTRY-US, V30, P7047, DOI 10.1021/bi00243a002; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PITARU S, 1994, J PERIODONTAL RES, V29, P81, DOI 10.1111/j.1600-0765.1994.tb01095.x; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SEEDORF K, 1995, METABOLISM, V44, P24, DOI 10.1016/0026-0495(95)90217-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; SMITH E, 1995, CANCER RES, V55, P5019; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; YONEMURA K, 1993, J BIOL CHEM, V268, P26120; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	30	8	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1233	1239		10.1096/fasebj.12.12.1233	http://dx.doi.org/10.1096/fasebj.12.12.1233			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737726				2022-12-28	WOS:000075738500018
J	Jaakkola, P; Kontusaari, S; Kauppi, T; Maatta, A; Jalkanen, M				Jaakkola, P; Kontusaari, S; Kauppi, T; Maatta, A; Jalkanen, M			Wound reepithelialization activates a growth factor-responsive enhancer in migrating keratinocytes	FASEB JOURNAL			English	Article						EGF FiRE; migration; syndecan-1; TGF-alpha; transcription	MOUSE SYNDECAN-1 GENE; TUMOR PROMOTER; MAP KINASE; EXPRESSION; INHIBITOR; CELLS; SKIN; ORGANIZATION; RECEPTORS; INDUCTION	Wound reepithelialization and keratinocyte migration require strictly ordered gene expression, which is assumed to be initiated by locally released mitogens and exposure of the cells to different matrix components. The mechanisms triggering gene expression specifically during reepithelialization are poorly understood. The far upstream AP-1-driven, FGF-inducible response element (FiRE) of the syndecan-1 gene was activated during cutaneous wound healing in transgenic mice, FiRE was induced selectively in migrating but not in proliferating keratinocytes at the wound edge, The activation was initiated at the start of the cell migration, was persistent throughout the merging and stratification phases, and was terminated after completion of reepithelialization. Although FiRE has been found within the gene of syndecan-1, the proximal promoter of syndecan-1 was not required for activation of FiRE in the migrating keratinocytes. The wounding induced activation was inhibited by blocking cell surface growth factor receptors with suramin, However, the activation of FiRE in resting skin required simultaneous growth factor- and stress-induced signals, but could also be elicited by the phosphatase inhibitor, okadaic acid, The activation by both wounding and chemical stimuli was blocked by inhibiting extracellular regulated kinase and p38 MAP kinases, suggesting the involvement of at least two parallel signal transduction pathways in wounding induced gene activation. As FiRE shows specificity for migrating keratinocytes only, it can be a useful tool for future wound healing studies and for targeting genes to injured tissues.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Oulu, Dept Biochem, FIN-90571 Oulu, Finland; Univ Oulu, Biocenter Oulu, FIN-90571 Oulu, Finland	University of Turku; Abo Akademi University; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Jalkanen, M (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6B,BioCity, FIN-20520 Turku, Finland.		Salonurmi, Tuire/L-3637-2018; Jaakkola, Panu M/B-4355-2012	Salonurmi, Tuire/0000-0001-5104-5792; Maatta, Arto/0000-0003-3759-1310; Jaakkola, Panu/0000-0002-2365-4985				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN GL, 1989, NEW ENGL J MED, V321, P76, DOI 10.1056/NEJM198907133210203; CHAMBERLAIN J, 1995, J ANAT, V186, P87; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIDSON JM, 1991, ANN NY ACAD SCI, V638, P306, DOI 10.1111/j.1749-6632.1991.tb49041.x; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; Haynes J H, 1990, J Invest Surg, V3, P349, DOI 10.3109/08941939009140361; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HOGAN B, 1986, MANIPULATING MOUSE E; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARSHALL GM, 1992, VIROLOGY, V188, P373, DOI 10.1016/0042-6822(92)90768-K; MARTIN P, 1992, MECH DEVELOP, V38, P209, DOI 10.1016/0925-4773(92)90054-N; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; STOSCHECK CM, 1992, J INVEST DERMATOL, V99, P645, DOI 10.1111/1523-1747.ep12668143; TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Woodley DT, 1996, MOL CELLULAR BIOL WO, P339	40	44	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					959	969		10.1096/fasebj.12.11.959	http://dx.doi.org/10.1096/fasebj.12.11.959			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707168				2022-12-28	WOS:000075372600006
J	Jaffrezou, JP; Maestre, N; de Mas-Mansat, V; Bezombes, C; Levade, T; Laurent, G				Jaffrezou, JP; Maestre, N; de Mas-Mansat, V; Bezombes, C; Levade, T; Laurent, G			Positive feedback control of neutral sphingomyelinase activity by ceramide	FASEB JOURNAL			English	Article						ERK; daunorubicin; TNF; C6-ceramide	DAUNORUBICIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; GLIOMA-CELLS; STRESS; BCL-2; PATHWAY; DEATH; ACID	While ceramide has emerged as a potent signal transducer, inconsistencies in the kinetics of ceramide generation, or its absence, in response to stimuli have led to confusion and skepticism as to its potential role in apoptosis or proliferation. Here we show that in U937 and HL60 myeloid leukemia cells and in normal skin fibroblasts, cell-permeant ceramides can trigger neutral sphingomyelinase activation, sphingomyelin hydrolysis, and endogenous ceramide generation regardless of Bc12 overexpression, These observations identify neutral sphingomyelinase as a novel target for ceramide and show that this positive feedback mechanism is responsible for signal propagation, as exemplified by mitogen-activated protein kinase activation in daunorubicin-treated cells. This study provides insight into a fundamental process of cell biology. Indeed, such a sustained ceramide-mediated signal throughout the apoptotic process would ensure self-destruction, perhaps by overriding evolutionary conserved primal cell survival mechanisms.	Ctr Claudius Regaud, INSERM, CJF 9503, F-31052 Toulouse, France; Ctr Hosp Univ Rangueil, INSERM, Lab Biochim Med, F-31403 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), Ctr Claudius Regaud, INSERM, CJF 9503, 20 Rue Pont St Pierre, F-31052 Toulouse, France.		Levade, Thierry/O-8948-2014; Bezombes, Christine/G-2743-2017; Bezombes, Christine/AAC-1724-2020; Bezombes, christine/X-8479-2019	Bezombes, christine/0000-0003-4079-4872				ALBOUZ S, 1983, NEUROSCI LETT, V36, P311, DOI 10.1016/0304-3940(83)90018-6; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CHEN M, 1995, CANCER RES, V55, P991; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; IKEDA U, 1994, ATHEROSCLEROSIS, V110, P87, DOI 10.1016/0021-9150(94)90071-X; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MASSON M, 1989, J NEUROCHEM, V52, P1645, DOI 10.1111/j.1471-4159.1989.tb09221.x; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NOKOLOVAKARAKAS.M, 1997, J BIOL CHEM, V272, P18718; OLIVEIRA S, 1992, J VEG SCI, V3, P267; QuilletMary A, 1996, LEUKEMIA, V10, P417; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	27	67	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					999	1006		10.1096/fasebj.12.11.999	http://dx.doi.org/10.1096/fasebj.12.11.999			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707172				2022-12-28	WOS:000075372600010
J	Walker, LA; Gailly, P; Jensen, PE; Somlyo, AV; Somlyo, AP				Walker, LA; Gailly, P; Jensen, PE; Somlyo, AV; Somlyo, AP			The unimportance of being (protein kinase C) epsilon	FASEB JOURNAL			English	Article						calcium sensitization; PKC; myosin light chain kinase; phosphorylation	MYOSIN LIGHT-CHAIN; VASCULAR SMOOTH-MUSCLE; PHORBOL ESTER; SIGNAL-TRANSDUCTION; REGULATORY DOMAIN; 2ND MESSENGERS; CALYCULIN-A; PHOSPHORYLATION; CALCIUM; CONTRACTION	The purpose of our study was to determine the mechanism through which phorbol esters and smooth muscle myosin phosphatase inhibitors can induce contraction of smooth muscle in the absence of Ca2+. Protein kinase C-epsilon (PKC-epsilon) was previously implicated in this process based largely on its supposed absence in the ferret portal vein, and a correlation was drawn between the presence of this isoform and the ability of smooth muscle to contract independently of Ca2+ and phosphorylation of the 20 kDa regulatory light chains of myosin (MLC20). We demonstrate here, with two antibodies, one to the NH2 terminus and the other to the COOH terminus of PKC-epsilon, that Eis present in both ferret portal vein and rabbit portal vein smooth muscle, neither of which exhibits phorbol ester-induced contraction in the absence of Ca2+, However, in the presence of clamped submaximal Ca2+, phorbol ester increased MLC20, phosphorylation from 17.7 +/- 1.7% to 46.4 +/- 3.6% in ferret portal vein smooth muscle and evoked an increase in force, Prolonged (48 h) incubation of ferret portal vein with phorbol esters completely down-regulated PKC-epsilon, as shown by Western blots, and abolished the phorbol ester-evoked contraction at submaximal Ca2+, but not Ca2+-independent, contractions induced by the phosphatase inhibitor microcystin, Contractions induced by microcystin in Ca2+-free solution were associated with increased phosphorylation of myosin light chain kinase (MLCK), Activation of MLCK by autophosphorylation in the absence of Ca2+ occurs in vitro (1). We conclude that PKC-epsilon is neither necessary nor sufficient for Ca2+-independent regulation of myosin II in smooth muscle, but contractions induced by agents: that inhibit smooth muscle myosin phosphatase in the absence of Ca2+ may be mediated by MLCK autophosphorylated or activated by another Ca2+-independent kinase.-Walker, L. A., Gailly, P., Jensen, P. E., Somlyo, A. V., Somlyo, A. P. The unimportance of being (protein kinase C) epsilon.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22906 USA; Catholic Univ Louvain, Dept Physiol, Brussels, Belgium; Sch Nursing, Aarhus, Denmark	University of Virginia; University of Virginia; University of Virginia; Universite Catholique Louvain	Somlyo, AP (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, POB 10011, Charlottesville, VA 22906 USA.	aps2n@aemsun.med.virginia.edu	Walker, Lori/J-7098-2013	Walker, Lori/0000-0003-2556-8076	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANY K, 1992, BIOCHIM BIOPHYS ACTA, V1134, P233, DOI 10.1016/0167-4889(92)90181-A; BIALOJAN C, 1988, J PHYSIOL-LONDON, V398, P81, DOI 10.1113/jphysiol.1988.sp017030; CHATTERJEE M, 1986, AM J PHYSIOL, V251, pC356, DOI 10.1152/ajpcell.1986.251.3.C356; COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; FULGINITI J, 1993, J VASC RES, V30, P315, DOI 10.1159/000159012; Gailly P, 1997, J PHYSIOL-LONDON, V500, P95, DOI 10.1113/jphysiol.1997.sp022002; Gong MC, 1997, MOL BIOL CELL, V8, P279, DOI 10.1091/mbc.8.2.279; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HIMPENS B, 1989, J PHYSIOL-LONDON, V413, P489, DOI 10.1113/jphysiol.1989.sp017665; HORI M, 1993, BRIT J PHARMACOL, V110, P1527, DOI 10.1111/j.1476-5381.1993.tb13996.x; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; Jensen PE, 1996, BIOCHEM J, V318, P469, DOI 10.1042/bj3180469; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KHALIL RA, 1992, J PHYSIOL-LONDON, V455, P585, DOI 10.1113/jphysiol.1992.sp019317; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, ADV EXP MED BIOL, V304, P97; KITAZAWA T, 1989, J BIOL CHEM, V264, P5330; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NIXON GF, 1995, J PHYSIOL-LONDON, V487, P283, DOI 10.1113/jphysiol.1995.sp020879; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; SANDO JJ, 1992, CELL SIGNAL, V4, P595, DOI 10.1016/0898-6568(92)90041-6; SATO K, 1992, J PHARMACOL EXP THER, V261, P497; SINGER HA, 1987, J PHARMACOL EXP THER, V243, P814; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUZUKI A, 1993, BRIT J PHARMACOL, V109, P703, DOI 10.1111/j.1476-5381.1993.tb13631.x; Takuwa Y, 1996, JPN HEART J, V37, P793; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P1392, DOI 10.1139/y94-201; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	42	30	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					813	821		10.1096/fasebj.12.10.813	http://dx.doi.org/10.1096/fasebj.12.10.813			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657521				2022-12-28	WOS:000074580100006
J	Gill, EA; Imaizumi, TA; Carveth, H; Topham, MK; Tarbet, EB; McIntyre, TM; Prescott, SM; Zimmerman, GA				Gill, EA; Imaizumi, TA; Carveth, H; Topham, MK; Tarbet, EB; McIntyre, TM; Prescott, SM; Zimmerman, GA			Bacterial lipopolysaccharide induces endothelial cells to synthesize a degranulating factor for neutrophils	FASEB JOURNAL			English	Article						PMN; polymorphonuclear leukocytes; PMN degranulation; lactoferrin	PLATELET-ACTIVATING-FACTOR; LEUKOCYTE CHEMOATTRACTANT RECEPTORS; CHEMOTACTIC FACTOR; GENE-EXPRESSION; ENDOTOXIN; INTERLEUKIN-8; MECHANISMS; SECRETION; ELASTASE; INJURY	Enzymes and other factors secreted by degranulating neutrophils (polymorphonuclear leukocytes, PMNs) mediate endothelial injury, thrombosis, and vascular remodeling. In bacteremia and sepsis syndrome and their consequent complications (including acute respiratory distress syndrome and systemic ischemia-reperfusion resulting from septic shock), neutrophil degranulation is an important mechanism of injury. In related studies, we found that human endothelial cells regulate neutrophil degranulation and that inflammatory cytokines induce synthesis of degranulating factors by human endothelial cells. Here we show that lipopolysaccharides (LPS) from gram-negative bacteria were the most potent agonists for release of degranulating activity by endothelial cells when compared to several cytokines and stimulatory factors. LPS also induced the release of degranulating signals for PMNs from a human endothelial cell line, EA.hy 926. Interleukin 8 (IL-8) is synthesized by endothelial and EA.hy 926 cells in response to LPS and induces neutrophil degranulation. However, complementary strategies using receptor desensitization, translation of messenger RNA by Xenopus laevis oocytes, and purification and analysis of factors from conditioned supernatants demonstrated that degranulating factors distinct from IL-8 are generated in response to LPS. The characteristics of a partially purified degranulating factor isolated from conditioned supernatants distinguished it from known chemokines and other factors that induce PMN degranulation and are generated by endothelial cells in response to LPS. Thus, cultured human endothelial cells and endothelial cell lines synthesize several unique signaling molecules that can trigger neutrophil granular secretion. If produced in vivo in response to LPS or other pathologic agonists, these degranulating signals may activate PMNs in combination or in sequence, initiating or propagating vascular damage.	Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Zimmerman, GA (corresponding author), Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, 95 S 2000 E Back, Salt Lake City, UT 84112 USA.			Tarbet, Bart/0000-0002-4255-9094	NHLBI NIH HHS [P50 HL50153] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERETZ A, 1989, BIOCHEM J, V259, P35, DOI 10.1042/bj2590035; Bozic CR, 1996, AM J RESP CELL MOL, V14, P302, DOI 10.1165/ajrcmb.14.3.8845182; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; COHEN MS, 1992, J INFECT DIS, V166, P1375, DOI 10.1093/infdis/166.6.1375; DAHINDEN C, 1983, J IMMUNOL, V130, P857; Delclaux C, 1997, AM J PHYSIOL-LUNG C, V272, pL442, DOI 10.1152/ajplung.1997.272.3.L442; DEWALD B, 1986, BIOCHIM BIOPHYS ACTA, V888, P42, DOI 10.1016/0167-4889(86)90069-8; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EMEIS JJ, 1988, BLOOD, V71, P1669; GILL EA, 1992, CURR OPIN INFECT DIS, V5, P381, DOI 10.1097/00001432-199206000-00012; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Green SP, 1996, J BIOL CHEM, V271, P25400, DOI 10.1074/jbc.271.41.25400; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; HARLAN JM, 1985, LAB INVEST, V52, P141; HENSON PM, 1992, INFLAMMATION BASIC P, P511; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Imaizumi TA, 1997, AM J RESP CELL MOL, V17, P181, DOI 10.1165/ajrcmb.17.2.2818; Introna M, 1997, ARTERIOSCL THROM VAS, V17, P423, DOI 10.1161/01.ATV.17.3.423; ISSEKUTZ AC, 1993, IMMUNOLOGY, V79, P600; JAFFE EA, 1988, INFLAMMATION BASIC P, P559; JOCHUM M, 1994, AM J RESP CRIT CARE, V150, pS123, DOI 10.1164/ajrccm/150.6_Pt_2.S123; KEY NS, 1992, ARTERIOSCLER THROMB, V12, P836, DOI 10.1161/01.ATV.12.7.836; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LASKY LA, 1993, CURR BIOL, V3, P366, DOI 10.1016/0960-9822(93)90203-Z; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LUCHI M, 1993, J IMMUNOL, V151, P959; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OFLAHERTY JT, 1979, J CELL BIOL, V80, P564, DOI 10.1083/jcb.80.3.564; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; OSTERGAARD E, 1992, J LEUKOCYTE BIOL, V51, P316, DOI 10.1002/jlb.51.4.316; PATEL KD, 1994, J CLIN INVEST, V94, P631, DOI 10.1172/JCI117379; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; ROCKER GM, 1989, LANCET, V1, P120; SCHRODER JM, 1989, J IMMUNOL, V142, P244; SCOPES RK, 1982, PROTEIN PURIFICATION, P1; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; SMITH WB, 1993, IMMUNOLOGY, V78, P491; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUGGS JE, 1986, BLOOD, V68, P825; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; TOMPKINS DC, 1990, J CLIN INVEST, V85, P1248, DOI 10.1172/JCI114560; Topham MK, 1998, FASEB J, V12, P733, DOI 10.1096/fasebj.12.9.733; VANOOST BA, 1986, BIOCHEM CELL BIOL, V64, P699, DOI 10.1139/o86-096; VARANI J, 1989, AM J PATHOL, V135, P435; WEBSTER RO, 1980, IMMUNOPHARMACOLOGY, V2, P201, DOI 10.1016/0162-3109(80)90050-8; WEISS J, 1978, J BIOL CHEM, V253, P2664; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; YAMADA Y, 1994, P NATL ACAD SCI USA, V91, P10320, DOI 10.1073/pnas.91.22.10320; YI ES, 1992, AM J PATHOL, V140, P659; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1997, LUNG SCI FDN, P289	63	19	20	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					673	684		10.1096/fasebj.12.9.673	http://dx.doi.org/10.1096/fasebj.12.9.673			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619446				2022-12-28	WOS:000074011000006
J	Samec, S; Seydoux, J; Dulloo, AG				Samec, S; Seydoux, J; Dulloo, AG			Role of UCP homologues in skeletal muscles and brown adipose tissue: mediators of thermogenesis or regulators of lipids as fuel substrate?	FASEB JOURNAL			English	Article						obesity; cachexia; muscle; uncoupling protein; FFA	DIET-INDUCED THERMOGENESIS; LOW-CALORIE INTAKE; ENERGY-EXPENDITURE; UNCOUPLING PROTEIN; ADAPTIVE-CHANGES; RAT; RNA; RESTRICTION; BALANCE	The mRNA expressions of UCP2 and UCP3, two newly described genes with high sequence homology to the uncoupling protein UCP1 in brown adipose tissue (BAT), were examined in two skeletal muscles (gastrocnemius and soleus) as well as in interscapular BAT (IBAT) of the rat in response to food deprivation and controlled refeeding. In IBAT (a tissue highly dependent on lipids for thermogenesis), the pattern of mRNA expression of UCP2 and UCP3 closely follows that of UCP1: it was markedly down-regulated during food deprivation (when this tissue's thermogenesis and lipid fuel requirements are decreased) and restored to control levels by day 5 of refeeding. By contrast, in the gastrocnemius muscle (a mixed fiber type muscle with a high capacity to shift between glucose and lipids sis fuel substrate), mRNA expression of both UCP2 and UCP3 mRNA was found to be markedly up-regulated during food deprivation (when this tissue's thermogenesis is also decreased but its lipid fuel utilization is increased). The expressions were subsequently found to be markedly down-regulated upon transition to refeeding, with mRNA levels remaining below control levels on days 3, 5, and 10 of refeeding (period of enhanced efficiency of body fat deposition). In the soleus muscle tan oxidative type muscle with higher dependency on lipids than the gastrocnemius, and hence with a lower capacity to shift between lipids and glucose as fuel substrate), UCP homologues were also found to be up-regulated during food deprivation, but changes in their mRNA expression contrast with those in the gastrocnemius muscle both in their much lower magnitude of response to food deprivation and in their more rapid restoration to control levels during refeeding. Up-regulation of UCP2 and UCP3 gene expressions in skeletal muscle during food deprivation was found to persist at thermoneutrality (i.e., under conditions of reduced thermoregulatory thermogenesis). Together, these tissue-dependent differential mRNA expressions of the UCP homologues in IBAT, gastrocnemius, and soleus muscles during food deprivation and refeeding are much more consistent with a role for UCP2 and UCP3 in the regulation of lipids as fuel substrate rather than as mediators of regulatory thermogenesis.	Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva 4, Switzerland	University of Geneva	Dulloo, AG (corresponding author), CMU, Fac Med, Dept Physiol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.			DULLOO, Abdul/0000-0003-3877-6149				ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; BALDWIN KM, 1973, AM J PHYSIOL, V225, P962, DOI 10.1152/ajplegacy.1973.225.4.962; Benedict FG, 1919, HUMAN VITALITY EFFIC, V280; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOYLE PC, 1981, AM J PHYSIOL, V241, pR392, DOI 10.1152/ajpregu.1981.241.5.R392; Carbonnel F, 1997, AM J CLIN NUTR, V65, P1517, DOI 10.1093/ajcn/65.5.1517; CHAMPIGNY O, 1990, J NUTR, V120, P1730, DOI 10.1093/jn/120.12.1730; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DULLOO AG, 1988, AM J PHYSIOL, V255, pE180, DOI 10.1152/ajpendo.1988.255.2.E180; Dulloo AG, 1996, INT J OBESITY, V20, P393; DULLOO AG, 1990, AM J CLIN NUTR, V52, P415, DOI 10.1093/ajcn/52.3.415; Dulloo AG, 1997, CLIN NUTR, V16, P25, DOI 10.1016/S0261-5614(97)80046-5; DULLOO AG, 1990, AM J PHYSIOL, V259, pE658; DULLOO AG, 1995, AM J PHYSIOL-REG I, V269, pR365, DOI 10.1152/ajpregu.1995.269.2.R365; DULLOO AG, 1993, INT J OBESITY, V17, P115; ENTENMAN C, 1957, METHOD ENZYMOL, V3, P299, DOI 10.1016/S0076-6879(57)03395-9; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; HARRIS PM, 1979, BR J NUTR, V39, P210; HILL JO, 1985, AM J PHYSIOL, V248, pR549, DOI 10.1152/ajpregu.1985.248.5.R549; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; KEESEY RE, 1988, HDB EATING DISORDE 2, P87; Keys A, 1950, BIOL HUMAN STARVATIO; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; MA SWY, 1985, CAN J PHYSL PHARM, V64, P609; MILLER DS, 1982, P NUTR SOC, V41, P193, DOI 10.1079/PNS19820030; MILLER DS, 1959, BRIT J NUTR, V13, P501, DOI 10.1079/BJN19590064; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; ROTHWELL NJ, 1986, BRIT J NUTR, V56, P123, DOI 10.1079/BJN19860092; ROTHWELL NJ, 1982, BIOSCIENCE REP, V2, P543, DOI 10.1007/BF01314214; SALIN B, 1983, HDB PHYSL SKELETAL M, P555; STOCK MJ, 1989, P NUTR SOC, V48, P189, DOI 10.1079/PNS19890029; TRAYHURN P, 1989, P NUTR SOC, V48, P165, DOI 10.1079/PNS19890026; TRAYHURN P, 1995, P NUTR SOC, V54, P39, DOI 10.1079/PNS19950036; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; YOUNG JB, 1982, J CLIN INVEST, V69, P1061, DOI 10.1172/JCI110541; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	40	294	299	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					715	724		10.1096/fasebj.12.9.715	http://dx.doi.org/10.1096/fasebj.12.9.715			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619450				2022-12-28	WOS:000074011000010
J	Maddox, JF; Colgan, SP; Clish, CB; Petasis, NA; Fokin, VV; Serhan, CN				Maddox, JF; Colgan, SP; Clish, CB; Petasis, NA; Fokin, VV; Serhan, CN			Lipoxin B-4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B-4 analogs with increased biologic activity	FASEB JOURNAL			English	Article						eicosanoids; leukocytes; inflammation; lipid mediators	15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; POLYMORPHONUCLEAR CELLS; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; LEUKOTRIENES; ACID; A(4); RECEPTOR	Lipoxins are biologically active products of arachidonic acid that are formed via cell-cell interactions, particularly those involving leukocytes, Lipoxin A(4) and Lipoxin B-4 (LXB4), within similar concentration ranges, each inhibit human neutrophil, activate monocyte adherence and motility, and are rapidly converted by initial dehydrogenation to other inactive metabolites by human monocytes. Here, we exposed LXB4 to isolated recombinant 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and found that it was a good substrate for the enzyme (K-m=6.9 mu M); we identified the major product as 5-oxo-LXB4 via physical methods including Liquid chromatography/tandem mass spectrometry. This is the first evidence of 15-PGDH converting a substrate hydroxyl group at a position other than the omega-6 carbon, Based on these observations, several LXB4 analogs were designed and prepared by total organic synthesis to test as stable mimetics: 5(S)-methyl-LXB4-me, 5(R)-methyl-LXB4-me, and 15-epi-LXB4-me (the aspirin-triggered form of LXB4). Both 5(S)-methyl-LXB4-me and 5(R)-methyl-LXB(4)me were resistant to rapid conversion, In addition, actions of the stable analogs were evaluated separately with human mono-cytic cells and neutrophils, and 5(S)-methyl-LXB4-me was more potent (nM range) than LXB4 for both cell types In contrast, 5(R)-methyl-LXB4-me was potent in inhibiting neutrophil transmigration across endothelial monolayers, but did not stimulate monocyte adherence, These results indicate that LXB4 analogs can be designed to resist rapid transformation and retain bioactivity with both monocytes and neutrophils, Moreover, they suggest that LXB4 stable analogs are useful tools to selectively evaluate the modes of actions of LXB4 with different tissues.	Brigham & Womens Hosp, Dept Anesthesia, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ So Calif, Loker Hydrocarbon Res Inst, Dept Chem, Los Angeles, CA 90089 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Southern California	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Clish, Clary/AAB-7124-2019; Clish, Clary B/ABB-9374-2021; Colgan, Sean P./B-4573-2009; Petasis, Nicos/B-3162-2009	Clish, Clary B/0000-0001-8259-9245; Petasis, Nicos/0000-0002-8864-4446	NIDDK NIH HHS [P01-DK50305] Funding Source: Medline; NIGMS NIH HHS [R01-GM38765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMAN BS, 1992, P SOC EXP BIOL MED, V201, P169; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRAITHWAITE SS, 1975, J BIOL CHEM, V250, P2315; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; ENSOR CM, 1994, BBA-PROTEIN STRUCT M, V1208, P151, DOI 10.1016/0167-4838(94)90172-4; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Griffiths WJ, 1996, RAPID COMMUN MASS SP, V10, P183, DOI 10.1002/(SICI)1097-0231(19960131)10:2<183::AID-RCM456>3.3.CO;2-N; KANTHA SS, 1994, PROSTAG LEUKOTR ESS, V51, P87, DOI 10.1016/0952-3278(94)90083-3; LIU Y, 1985, BIOCHEM BIOPH RES CO, V129, P268, DOI 10.1016/0006-291X(85)91432-9; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Papayianni A, 1996, J IMMUNOL, V156, P2264; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; POPOV GK, 1989, B EXP BIOL MED+, V107, P93, DOI 10.1007/BF00837070; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; STENKE L, 1991, BIOCHEM BIOPH RES CO, V180, P255, DOI 10.1016/S0006-291X(05)81285-9; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; TAKANO T, 1998, IN PRESS J CLIN INVE; THIERAUCH KH, 1994, J HYPERTENS, V12, P1; THOMAS E, 1995, INFLAMM RES, V44, P121, DOI 10.1007/BF01782022; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	27	78	86	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1998	12	6					487	494		10.1096/fasebj.12.6.487	http://dx.doi.org/10.1096/fasebj.12.6.487			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535221				2022-12-28	WOS:000072967300010
J	D'Addario, M; Ahmad, A; Xu, JW; Menezes, J				D'Addario, M; Ahmad, A; Xu, JW; Menezes, J			Epstein-Barr virus envelope glycoprotein gp350 induces NF-kappa B activation and IL-1 beta synthesis in human monocytes-macrophages involving PKC and PI3-K	FASEB JOURNAL			English	Article						EBV gp350; interleukin 1 beta; signal transduction; transcription factors	TUMOR-NECROSIS-FACTOR; BLOOD MONONUCLEAR-CELLS; 2 DISTINCT PATHWAYS; HUMAN LYMPHOCYTES-B; C3D RECEPTOR CR-2; GENE-EXPRESSION; FACTOR-ALPHA; INTERLEUKIN-1-BETA GENE; SIGNAL-TRANSDUCTION; HERPES-SIMPLEX	Epstein-Barr virus (EBV) is a highly immunotropic human herpesvirus with oncogenic potential and is involved in numerous pathologies, EBV utilizes its major envelope glycoprotein gp350 to bind to its receptor CR2/CD21 on target cells for initiating the infection, We have previously shown that EBV is able to modulate transcription and translation of a number of cytokine genes via its gp350-mediated binding to this receptor. However, the effects of the binding of purified gp350 to CR2/CD21 on plastic-adherent monocyte-macrophages (AMM) have not been investigated, These cells are a rich source of potent proinflammatory and immune-modulating cytokines, and express low levels of CR2/CD21, We show here for the first time that recombinant gp350 (rgp350) causes production of the potent proinflammatory cytokine LG-1 beta in human AMM, Surprisingly, rgp350 is comparable in this capacity to the phorbol ester 12-0-tetradecanoylphorbol 13-acetate, This induction of IL-1 beta production was accompanied by increased steady-state levels of its mRNA in gp350-treated AMM, and was dependent on the specific binding of rgp350 to the EBV receptor CR2/CD21, We also show that the signaling pathways resulting in the induction of IL-1 beta synthesis by rgp350 required protein kinase C and phosphatidylinositol 3,4,5 triphosphate kinase activities and occurred via activation of the NF-kappa B family of transcription factors.	Hop St Justine, Lab Immunovirol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Immunol & Microbiol, Lab Immunovirol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Pediat Res Ctr, Montreal, PQ H3T 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Menezes, J (corresponding author), Hop St Justine, Lab Immunovirol, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.			Ahmad, Ali/0000-0001-7689-7115				Ahmad A, 1997, J IMMUNOL, V159, P3984; ANTWERP DJV, 1996, SCIENCE, V274, P787; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAREL M, 1995, MOL IMMUNOL, V32, P389, DOI 10.1016/0161-5890(95)00005-Y; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIRKENBACH M, 1992, J EXP MED, V176, P1405, DOI 10.1084/jem.176.5.1405; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; Bouillie S, 1999, J IMMUNOL, V162, P136; BOUILLIE S, 1995, EUR J IMMUNOL, V25, P2661, DOI 10.1002/eji.1830250939; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen WP, 1996, J VIROL, V70, P4849, DOI 10.1128/JVI.70.7.4849-4853.1996; COGSWELL JP, 1994, J IMMUNOL, V153, P712; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DADDARIO M, 1990, J VIROL, V64, P6080, DOI 10.1128/JVI.64.12.6080-6089.1990; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FINGEROTH JD, 1988, J VIROL, V62, P1442, DOI 10.1128/JVI.62.4.1442-1447.1988; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FRADE R, 1985, P NATL ACAD SCI USA, V82, P1400; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GOSSELIN J, 1992, J IMMUNOL, V149, P181; GOSSELIN J, 1992, J CLIN INVEST, V89, P1849, DOI 10.1172/JCI115789; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; HEDRICK JA, 1994, J IMMUNOL, V153, P4418; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HOFFMAN GJ, 1980, P NATL ACAD SCI-BIOL, V77, P2979, DOI 10.1073/pnas.77.5.2979; INADA S, 1983, P NATL ACAD SCI-BIOL, V80, P2351, DOI 10.1073/pnas.80.8.2351; KASPAR RL, 1994, J IMMUNOL, V153, P277; KHANNA R, 1995, MICROBIOL REV, V59, P387, DOI 10.1128/MMBR.59.3.387-405.1995; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; LINT YZ, 1995, J BIOL CHEM, V270, P14255; Liu Y, 1997, J IMMUNOL, V158, P604; MADEJ M, 1992, VACCINE, V10, P777, DOI 10.1016/0264-410X(92)90513-J; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MENEZES J, 1976, INFECT IMMUN, V13, P303, DOI 10.1128/IAI.13.2.303-310.1976; MILLER G, 1973, J EXP MED, V138, P1398, DOI 10.1084/jem.138.6.1398; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PATERSON RLK, 1995, J IMMUNOL, V154, P1440; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; SAUVAGEAU G, 1990, J GEN VIROL, V71, P379, DOI 10.1099/0022-1317-71-2-379; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; Tanner JE, 1996, J VIROL, V70, P570, DOI 10.1128/JVI.70.1.570-575.1996; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; UNANUE ER, 1996, FUNDAMENTAL VIROLOGY, P111; [No title captured]	56	33	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2203	2213		10.1096/fasebj.13.15.2203	http://dx.doi.org/10.1096/fasebj.13.15.2203			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593868				2022-12-28	WOS:000084310800012
J	Franzini-Armstrong, C				Franzini-Armstrong, C			The sarcoplasmic reticulum and the control of muscle contraction	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		DIHYDROPYRIDINE RECEPTOR CDNA; DYSGENIC SKELETAL-MUSCLE; RYANODINE RECEPTOR; ALPHA SUBUNITS; PROTEIN; CALSEQUESTRIN; LOCALIZATION; RESTORATION; CONNECTION; VESICLES		Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Franzini-Armstrong, C (corresponding author), Univ Penn, Dept Cell & Dev Biol, B1 Anat Chem Bldg, Philadelphia, PA 19104 USA.							Andersson-Cedergren E., 1959, J ULTRASTRUCT RES  S, V1, P5, DOI [10.1016/S0889-1605(59)80002-1, DOI 10.1016/S0889-1605(59)80002-1]; BENNETT HS, 1953, AM J ANAT, V195, P61; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ENDO M, 1966, J PHYSIOL-LONDON, V185, P224, DOI 10.1113/jphysiol.1966.sp007983; FLUCHER BE, 1991, J CELL BIOL, V115, P1345, DOI 10.1083/jcb.115.5.1345; FLUCHER BE, 1996, Proc Natl Acad Sci USA, V93, P265; FRANZINIARMSTRO.C, 1964, J CELL BIOL, V22, P675, DOI 10.1083/jcb.22.3.675; FRANZINIARMSTRO.C, 1988, TRENDS CELL BIOL, V8, P251; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HUXLEY AF, 1971, P ROY SOC LOND B BIO, V1, P27; HUXLEY HE, 1964, NATURE, V202, P10676; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; Ouyang Y, 1997, BRAIN RES, V775, P52, DOI 10.1016/S0006-8993(97)00840-8; PAGE S, 1964, J PHYSIOL-LONDON, V175, pP10; PAGE SG, 1965, J CELL BIOL, V26, P477, DOI 10.1083/jcb.26.2.477; PEACHEY LD, 1965, J CELL BIOL, V25, P209, DOI 10.1083/jcb.25.3.209; PEACHEY LD, 1959, SCIENCE, V129, P721, DOI 10.1126/science.129.3350.721; PORTER KEITH R., 1956, JOUR BIOPHYS AND BIOCHEM CYTOL, V2, P163, DOI 10.1083/jcb.2.4.163; PORTER KR, 1957, J BIOPHYS BIOCHEM CY, V3, P269, DOI 10.1083/jcb.3.2.269; Powell JA, 1996, J CELL BIOL, V134, P375, DOI 10.1083/jcb.134.2.375; Protasi F, 1997, J CELL BIOL, V137, P859, DOI 10.1083/jcb.137.4.859; Protasi F, 1998, J CELL BIOL, V140, P831, DOI 10.1083/jcb.140.4.831; Protasi F, 1996, DEV BIOL, V173, P265, DOI 10.1006/dbio.1996.0022; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROBERTSON JD, 1956, J BIOPHYS BIOCHEM CY, V2, P369, DOI 10.1083/jcb.2.4.369; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKEI K, 1992, J NEUROSCI, V12, P489; TAKEKURA H, 1994, BIOPHYS J, V67, P793, DOI 10.1016/S0006-3495(94)80539-9; TAKEKURA H, 1995, P NATL ACAD SCI USA, V92, P3381, DOI 10.1073/pnas.92.8.3381; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; VILLA A, 1993, EXP CELL RES, V209, P140, DOI 10.1006/excr.1993.1294; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WEBER A, 1959, J BIOL CHEM, V234, P2764	42	65	73	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S266	S270		10.1096/fasebj.13.9002.S266	http://dx.doi.org/10.1096/fasebj.13.9002.S266			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619141				2022-12-28	WOS:000084390200019
J	Koya, D; Dennis, JW; Warren, CE; Takahara, N; Schoen, FJ; Nishio, Y; Nakajima, T; Lipes, MA; King, GL				Koya, D; Dennis, JW; Warren, CE; Takahara, N; Schoen, FJ; Nishio, Y; Nakajima, T; Lipes, MA; King, GL			Overexpression of core 2 N-acetylglycosaminyltransferase enhances cytokine actions and induces hypertrophic myocardium in transgenic mice	FASEB JOURNAL			English	Article						O-linked glycans; diabetes; cardiac hypertrophy; MAP kinase activation	CARDIAC GENE-EXPRESSION; SELECTIN GLYCOPROTEIN LIGAND-1; P-SELECTIN; PROTEIN; SPECIFICITY; ACTIVATION; OLIGOSACCHARIDES; BIOSYNTHESIS; RECEPTORS; DISEASE	Elevated levels of glycocojugates, commonly observed in the myocardium of diabetic animals and patients, are postulated to contribute to the myocardial dysfunction in diabetes. Previously, we reported that UDP-GlcNAc: Gal beta 1-3GalNAc alpha R beta 1-6-N-acetylglucosaminyltransferase (core 2 GlcNAc-T), a developmentally regulated enzyme of O-linked glycans biosynthesis pathway, is specifically increased in the heart of diabetic animals and Is regulated by hyperglycemia and insulin. In this study, transgenic mice overexpressing core 2 GlcNAc-T with severe increase in cardiac core 2 GlcNAc-T activities were normal at birth but showed progressive and significant cardiac hypertrophy at 6 months of age. The heart of transgenic mice showed elevation of sialylated O-glycan and increases of c-fos gene expression and AP-I activity, which are characteristics of cardiac stress. Furthermore, transfection of PC12 cells with core 2 GlcNAc-T also induced c-fos promoter activation, mitogen activated-protein kinase (MAPK) phosphorylation, Trk receptor glycosylation, and cell differentiation. These results suggested a novel role for core 2 GlcNAc-T in the development of diabetic cardiomyopathy and modulation of the MAP kinase pathway in the heart.	Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	King, GL (corresponding author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.	Kingg@joslab.harvard.edu	Koya, Daisuke/J-3257-2014; Takahara, Naminatsu/K-8497-2019; Dennis, James/E-7268-2013		NEI NIH HHS [EY05110] Funding Source: Medline; NIDDK NIH HHS [DK 36836, DK53281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK053281] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barran P, 1997, GLYCOBIOLOGY, V7, P129, DOI 10.1093/glycob/7.1.129; BELL DSH, 1995, DIABETES CARE, V18, P708, DOI 10.2337/diacare.18.5.708; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; FISHMAN GI, 1994, J CLIN INVEST, V93, P1864, DOI 10.1172/JCI117174; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Ihara Y, 1997, J BIOL CHEM, V272, P9629; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; McEvoy LM, 1997, J EXP MED, V185, P1493, DOI 10.1084/jem.185.8.1493; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nesto RW, 1998, CIRCULATION, V97, P811; NISHIO Y, 1995, J CLIN INVEST, V96, P1759, DOI 10.1172/JCI118221; PILLER F, 1988, J BIOL CHEM, V263, P15146; Raman M, 1996, ENDOCRIN METAB CLIN, V25, P425, DOI 10.1016/S0889-8529(05)70331-5; ROGERIEUX F, 1993, ANAL BIOCHEM, V211, P200, DOI 10.1006/abio.1993.1257; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SPIRO MJ, 1992, J MOL CELL CARDIOL, V24, P397, DOI 10.1016/0022-2828(92)93194-O; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	34	21	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2329	2337		10.1096/fasebj.13.15.2329	http://dx.doi.org/10.1096/fasebj.13.15.2329			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593880				2022-12-28	WOS:000084310800024
J	Liu, JP				Liu, JP			Studies of the molecular mechanisms in the regulation of telomerase activity	FASEB JOURNAL			English	Review						telomerase; telomere; structure; function; gene expression; protein phosphorylation; tumorigenesis; cancer; aging	PROTEIN-KINASE-C; HUMAN BREAST-CANCER; IMMORTAL CELL-LINES; SACCHAROMYCES-CEREVISIAE TELOMERES; REVERSE-TRANSCRIPTASE INHIBITORS; CATALYTIC SUBUNIT GENE; TETRAHYMENA TELOMERASE; HEMATOPOIETIC-CELLS; LENGTH REGULATION; MOUSE TELOMERASE	Telomerase, a specialized RNA-directed DNA polymerase that extends telomeres of eukaryotic chromosomes, is repressed in normal human somatic cells but is activated during development and upon neoplasia, Whereas activation is involved in immortalization of neoplastic cells, repression of telomerase permits consecutive shortening of telomeres in a chromosome replication-dependent fashion. This cell. cycle-dependent, unidirectional catabolism of telomeres constitutes a mechanism for cells to record the extent of DNA loss and cell division number; when telomeres become critically short, the cells terminate chromosome replication and enter cellular senescence. Although neither the telomere signaling mechanisms nor the mechanisms whereby telomerase is repressed in normal cells and activated in neoplastic cells have been established, inhibition of telomerase has been shown to compromise the growth of cancer cells in culture; conversely, forced expression of the enzyme in senescent human cells extends their life span to one typical of young cells. Thus, to switch telomerase on and off has potentially important implications in anti-aging and anticancer therapy. There is abundant evidence that the regulation of telomerase is multifactorial in mammalian cells, involving telomerase gene expression, post-translational protein-protein interactions, and protein phosphorylation. Several proto-oncogenes and tumor suppressor genes have been implicated in the regulation of telomerase activity, both directly and indirectly; these include c-Myc, Bcl-2, p21(WAF1), Rb, p53, PKC, Akt/PKB, and protein phosphatase 2A. These findings are evidence for the complexity of telomerase control mechanisms and constitute a point of departure for piecing together an integrated picture of telomerase structure, function, and regulation in aging and tumor development.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute	Liu, JP (corresponding author), Baker Med Res Inst, Mol Signalling Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.			Liu, Jun-Ping/0000-0001-7442-2116				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Avilion AA, 1996, CANCER RES, V56, P645; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bestilny LJ, 1996, CANCER RES, V56, P3796; Bhattacharyya A, 1997, P NATL ACAD SCI USA, V94, P2823, DOI 10.1073/pnas.94.7.2823; Biessmann H, 1997, Ciba Found Symp, V211, P53; BLACKBURN EH, 1990, SCIENCE, V249, P489, DOI 10.1126/science.2200120; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Burger AM, 1998, INT J ONCOL, V13, P1043; CHEN J, 1994, J BIOL CHEM, V269, P7957; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; de Lange T, 1998, NATURE, V392, P753, DOI 10.1038/33790; Faragher RGA, 1998, NAT BIOTECHNOL, V16, P701, DOI 10.1038/nbt0898-701; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fossel M, 1998, JAMA-J AM MED ASSOC, V279, P1732, DOI 10.1001/jama.279.21.1732; Frenck RW, 1998, P NATL ACAD SCI USA, V95, P5607, DOI 10.1073/pnas.95.10.5607; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gollahon LS, 1996, ONCOGENE, V12, P715; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1993, COLD SPRING HARB SYM, V58, P719, DOI 10.1101/SQB.1993.058.01.079; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hande MP, 1997, ONCOGENE, V15, P1747, DOI 10.1038/sj.onc.1201327; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hathcock KS, 1998, J IMMUNOL, V160, P5702; Hayflick L, 1998, EXP GERONTOL, V33, P639, DOI 10.1016/S0531-5565(98)00023-0; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Hu BT, 1997, J IMMUNOL, V159, P1068; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Johnson FB, 1998, CURR OPIN CELL BIOL, V10, P332, DOI 10.1016/S0955-0674(98)80008-2; Joo OH, 1998, MUTAT RES-FUND MOL M, V401, P121, DOI 10.1016/S0027-5107(97)00321-7; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; Kiaris H, 1999, P NATL ACAD SCI USA, V96, P226, DOI 10.1073/pnas.96.1.226; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kipling D, 1997, EUR J CANCER, V33, P792, DOI 10.1016/S0959-8049(97)00060-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Kveiborg M, 1999, MECH AGEING DEV, V106, P261, DOI 10.1016/S0047-6374(98)00114-6; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LEE SA, 1992, CANCER RES, V52, P3750; Lendvay TS, 1996, GENETICS, V144, P1399; Leteurtre F, 1997, LEUKEMIA, V11, P1681, DOI 10.1038/sj.leu.2400784; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI H, 1999, IN PRESS ONCOGENE; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu JP, 1997, CLIN EXP PHARMACOL P, V24, P611, DOI 10.1111/j.1440-1681.1997.tb02101.x; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MEHLE C, 1994, CANCER RES, V54, P236; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nguyen DC, 1999, BBA-GENE STRUCT EXPR, V1445, P207, DOI 10.1016/S0167-4781(99)00044-5; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; NILSSON P, 1994, ONCOGENE, V9, P3043; NURNBERG P, 1993, HUM GENET, V91, P190; ODAGIRI E, 1994, CANCER-AM CANCER SOC, V73, P2978, DOI 10.1002/1097-0142(19940615)73:12<2978::AID-CNCR2820731215>3.0.CO;2-5; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Pennisi E, 1998, SCIENCE, V282, P1395, DOI 10.1126/science.282.5393.1395; Ratnasinghe D, 1998, INT J ONCOL, V13, P79; Reddel RR, 1998, ANN NY ACAD SCI, V854, P8, DOI 10.1111/j.1749-6632.1998.tb09887.x; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; SCHMITT H, 1994, GENE CHROMOSOME CANC, V11, P171, DOI 10.1002/gcc.2870110306; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Strahl C, 1996, MOL CELL BIOL, V16, P53; Sumida T, 1999, INT J CANCER, V80, P1, DOI 10.1002/(SICI)1097-0215(19990105)80:1<1::AID-IJC1>3.0.CO;2-U; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; Takakura M, 1999, CANCER RES, V59, P551; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Terasaki M, 1999, INT J ONCOL, V14, P63; Tsao DA, 1998, GENE, V221, P51, DOI 10.1016/S0378-1119(98)00432-6; Ueda M, 1997, CANCER RES, V57, P370; Ulaner GA, 1998, CANCER RES, V58, P4168; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Von Zglinicki T, 1998, ANN NY ACAD SCI, V854, P318; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; Xu D, 1996, LEUKEMIA, V10, P1354; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yegorov YE, 1996, FEBS LETT, V389, P115, DOI 10.1016/0014-5793(96)00533-9; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; ZAKIAN VA, 1990, TRENDS GENET, V6, P12, DOI 10.1016/0168-9525(90)90043-6	181	208	224	1	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2091	2104		10.1096/fasebj.13.15.2091	http://dx.doi.org/10.1096/fasebj.13.15.2091			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593857				2022-12-28	WOS:000084310800001
J	Schnurr, K; Borchert, A; Kuhn, H				Schnurr, K; Borchert, A; Kuhn, H			Inverse regulation of lipid-peroxidizing and hydroperoxyl lipid-reducing enzymes by interleukins 4 and 13	FASEB JOURNAL			English	Article						cytokines; eicosanoids; carcinogenesis; atherosclerosis; inflammation	LOW-DENSITY-LIPOPROTEIN; GLUTATHIONE-PEROXIDASE; ARACHIDONATE 15-LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; PERITONEAL-MACROPHAGES; OMEGA-6 LIPOXYGENASE; DEFICIENT MICE; EXPRESSION; CDNA; SEQUENCE	12/15-lipoxygenases and phospholipid hydroperoxide glutathione peroxidases are opposite enzymes balancing the intracellular concentration of hydroperoxy lipids. We studied the regulation of both enzymes by interleukins 4 and 13 and found an inverse response. When human lung carcinoma cells A549 were cultured in vitro in the presence of these cytokines, an up-regulation of the 12/15-lipoxygenase and a down-regulation of the phospholipid hydroperoxide glutathione peroxidase were observed, A similar inverse regulation was found in! human peripheral monocytes, Interleukin 4-treated A549 cells exhibited an impaired capability of reducing exogenous hydroperoxyl lipids and their levels of endogenous lipid hydroperoxides were markedly increased. To find out whether these regulatory processes also occur in vivo, arachidonic acid oxygenase and phospholipid hydroperoxide glutathione peroxidase activity was assayed in various tissues of transgenic mice that systemically overexpress interleukin 4, In lung, spleen, kidney, and heart, an increased arachidonic acid oxygenase activity was detected when transgenic mice were compared with inbred controls, The phospholipid hydroperoxide glutathione peroxidase activity was impaired in lung, liver, and spleen of the transgenic animals. These data indicate that lipid-peroxidizing and lipid peroxide-reducing enzymes are inversely regulated in various mammalian cells, Up-regulation of the 12./15-lipoxygenase and simultaneous down-regulation of the phospholipid hydroperoxide glutathione peroxidase may lead to an increased oxidizing potential, which is reflected by an augmented intracellular peroxide tone.	Humboldt Univ, Klinikum Charite, Inst Biochem, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kuhn, H (corresponding author), Humboldt Univ, Klinikum Charite, Inst Biochem, Hess Str 3-4, D-10115 Berlin, Germany.	harmut.kuehn@rz.hu-berlin.de		Borchert, Astrid/0000-0003-3551-5592				BELKNER J, 1993, IN PRESS J BIOL CHE, V273; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Cornicelli JA, 1996, ARTERIOSCL THROM VAS, V16, P1488, DOI 10.1161/01.ATV.16.12.1488; Erb KJ, 1997, J EXP MED, V185, P329, DOI 10.1084/jem.185.2.329; ERB KJ, 1994, EUR J IMMUNOL, V24, P1143, DOI 10.1002/eji.1830240520; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Holzhutter HG, 1997, EUR J BIOCHEM, V245, P608, DOI 10.1111/j.1432-1033.1997.00608.x; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Jones KP, 1997, CYTOKINE, V9, P529, DOI 10.1006/cyto.1996.0197; Kelavkar U, 1998, MOL BIOL REP, V25, P173, DOI 10.1023/A:1006813009006; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1995, J LIPID MEDIAT CELL, V12, P157, DOI 10.1016/0929-7855(95)00016-J; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; LI B, 1991, J EXP MED, V174, P1259, DOI 10.1084/jem.174.5.1259; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nam SY, 1997, GENE, V198, P245, DOI 10.1016/S0378-1119(97)00321-1; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PAUL WE, 1991, BLOOD, V77, P1859; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; RAPOPORT SM, 1990, BLOOD CELL BIOCH, V1, P151; RAPOPORT SM, 1986, RETICULOCYTE; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1992, J BIOL CHEM, V267, P6142; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SIGAL E, 1988, J BIOL CHEM, V263, P5328; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; SUNDE RA, 1993, BIOCHEM BIOPH RES CO, V193, P905, DOI 10.1006/bbrc.1993.1711; TAKAHASHI K, 1986, BLOOD, V68, P640; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1995, METHOD ENZYMOL, V252, P38; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7	57	47	47	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					143	154		10.1096/fasebj.13.1.143	http://dx.doi.org/10.1096/fasebj.13.1.143			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872939				2022-12-28	WOS:000078029500016
J	Roger, M				Roger, M			Influence of host genes on HIV-1 disease progression	FASEB JOURNAL			English	Article						immunopathogenesis of AIDS; risk factors in HIV-1 disease progression	IMMUNODEFICIENCY-VIRUS TYPE-1; TUMOR-NECROSIS-FACTOR; MANNOSE-BINDING-PROTEIN; HISTOCOMPATIBILITY COMPLEX GENES; CD4+ LYMPHOCYTE COUNTS; LONG-TERM SURVIVORS; CLASS-II ALLELES; FACTOR-ALPHA; PROMOTER REGION; STRUCTURAL GENE	The role of host genes in the course of HIV-1 infection has been examined in different populations and among all major risk groups, Two extended human lymphocyte antigen (HLA) haplotypes, HLA A1-Cw7-B8-DR3-DQ2 and HLA A11-Cw4-B35-DR1-DQ1, are found to be associated with a faster progression to AIDS, The complement C4 factor and tumor necrosis factor genes of the major histocompatibility complex, as well as the mannose binding protein gene, have also been suggested to influence the outcome of AIDS. The recent discovery that chemokine receptors could serve as cofactors for HIV-1 cell entry has prompted a search for polymorphisms in chemokine receptor genes, A 32 base pair inactivating deletion in the CCR5 gene and a point mutation within the CCR2b gene resulting in a conservative amino acid substitution have been examined and shown to be independently associated with delayed disease progression, Together, these observations strongly support a genetic component in AIDS pathogenesis. This article synthesizes the current state of knowledge about the influence of host genes on HIV-1 disease progression. It provides a summary of all significant association studies reported so far. The role of the allelic polymorphism in these genes is discussed with regard to the immunopathogenesis of AIDS.	CHU Montreal, Ctr Rech, Dept Microbiol & Infectiol, Montreal, PQ H2L 4M1, Canada	Universite de Montreal	Roger, M (corresponding author), CHU Montreal, Ctr Rech, Dept Microbiol & Infectiol, Campus Notre Dame,1560 Rue Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	rogerm@ere.umontreal.ca						BIRD P, 1988, EUR J IMMUNOL, V18, P1217, DOI 10.1002/eji.1830180811; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Bjorndal A, 1997, J VIROL, V71, P7478; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brinkman BMN, 1997, J INFECT DIS, V175, P188, DOI 10.1093/infdis/175.1.188; CAMERON PU, 1990, HUM IMMUNOL, V29, P282, DOI 10.1016/0198-8859(90)90042-N; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DALFONSO S, 1994, IMMUNOGENETICS, V39, P150; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DEZUBE BJ, 1992, J ACQ IMMUN DEF SYND, V5, P1099; DONALD JA, 1992, TISSUE ANTIGENS, V39, P241, DOI 10.1111/j.1399-0039.1992.tb01942.x; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; FABIO G, 1990, BRIT J HAEMATOL, V75, P531, DOI 10.1111/j.1365-2141.1990.tb07794.x; FUST G, 1991, IMMUNOL INVEST, V20, P231, DOI 10.3109/08820139109050792; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HENTGES F, 1992, CLIN EXP IMMUNOL, V88, P237, DOI 10.1111/j.1365-2249.1992.tb03067.x; Hessol N A, 1996, AIDS, V10 Suppl A, pS69, DOI 10.1097/00002030-199601001-00010; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; ITESCU S, 1992, J ACQ IMMUN DEF SYND, V5, P37; ITESCU S, 1994, P NATL ACAD SCI USA, V91, P11472, DOI 10.1073/pnas.91.24.11472; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; JUST JJ, 1995, J PEDIATR-US, V127, P544, DOI 10.1016/S0022-3476(95)70110-9; Just JJ, 1996, TISSUE ANTIGENS, V47, P313, DOI 10.1111/j.1399-0039.1996.tb02559.x; Just JJ, 1995, HUM IMMUNOL, V44, P156, DOI 10.1016/0198-8859(95)00034-8; KAPLAN C, 1990, HUM HERED, V40, P290, DOI 10.1159/000153947; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KEET IPM, 1997, 4 C RETR OPP INF, V208; Khoo SH, 1997, AIDS, V11, P423, DOI 10.1097/00002030-199704000-00004; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KRONER BL, 1995, AIDS, V9, P275, DOI 10.1097/00002030-199509030-00009; Krowka JF, 1997, CLIN IMMUNOL IMMUNOP, V85, P21, DOI 10.1006/clin.1997.4411; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LOUIE LG, 1991, J ACQ IMMUN DEF SYND, V4, P814; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MAKINO M, 1990, J IMMUNOL, V144, P4347; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; McNeil AJ, 1996, QJM-INT J MED, V89, P177; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; Meyer L, 1997, AIDS, V11, pF73, DOI 10.1097/00002030-199711000-00001; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBST R, 1995, EUR J IMMUNOL, V25, P2170, DOI 10.1002/eji.1830250808; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PHAIR JP, 1994, AIDS RES HUM RETROV, V10, P883, DOI 10.1089/aid.1994.10.883; POCIOT F, 1993, EUR J IMMUNOL, V23, P224, DOI 10.1002/eji.1830230135; POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x; SAHMOUD T, 1993, AIDS, V7, P497, DOI 10.1097/00002030-199304000-00007; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SANTAGOSTINO E, 1996, 11 INT C AIDS VANC C; SANTAMARIA P, 1989, J IMMUNOL, V143, P913; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHORK N, 1996, NONMATHEMATICAL OVER; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Smith MW, 1997, NAT MED, V3, P1052, DOI 10.1038/nm1097-1052c; STEEL CM, 1988, LANCET, V1, P1185; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; Theodorou I, 1997, LANCET, V349, P1219; Tomiyama H, 1997, J IMMUNOL, V158, P5026; TOMLINSON IPM, 1995, TRENDS GENET, V11, P493, DOI 10.1016/S0168-9525(00)89159-3; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Veugelers PJ, 1997, CURR OPIN INFECT DIS, V10, P7, DOI 10.1097/00001432-199702000-00003; WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5; Westby M, 1996, IMMUNOL TODAY, V17, P120, DOI 10.1016/0167-5699(96)80603-7; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	94	53	56	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					625	632		10.1096/fasebj.12.9.625	http://dx.doi.org/10.1096/fasebj.12.9.625			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619442	Bronze			2022-12-28	WOS:000074011000002
J	Minotti, G; Recalcati, S; Mordente, A; Liberi, G; Calafiore, M; Mancuso, C; Preziosi, P; Cairo, G				Minotti, G; Recalcati, S; Mordente, A; Liberi, G; Calafiore, M; Mancuso, C; Preziosi, P; Cairo, G			The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase iron regulatory protein-1 in cytosolic fractions from human myocardium	FASEB JOURNAL			English	Article						IRP-1; cardiotoxicity; doxorubicin; alcohol metabolite; DOXol cluster disassembly; iron-responsive elements	ELEMENT-BINDING-PROTEIN; RNA-BINDING; RESPONSIVE ELEMENT; LIPID-PEROXIDATION; MESSENGER-RNA; OXIDATIVE STRESS; SULFUR CLUSTERS; TUMOR-CELLS; INHIBITION; ANTHRACYCLINES	Anticancer therapy with doxorubicin (DOX) is limited by severe cardiotoxicity, presumably reflecting the intramyocardial formation of drug metabolites that alter cell constituents and functions. In a previous study, we showed that NADPH-supplemented cytosolic fractions from human myocardial samples can enzymatically reduce a carbonyl group in the side chain of DOX, yielding a secondary alcohol metabolite called doxorubicinol (DOXol). Here we demonstrate that DOXol delocalizes low molecular weight Fe(II) from the [4Fe-4S] duster of cytoplasmic aconitase. Iron delocalization proceeds through the reoxidation of DOXol to DOX and liberates DOX-Fe(II) complexes as ultimate by-products. Under physiologic conditions, cluster disassembly abolishes aconitase activity and forms an apoprotein that binds to mRNAs, coordinately increasing the synthesis of transferrin receptor but decreasing that of ferritin. Aconitase is thus converted into an iron regulatory protein-1 (IRP-1) that causes iron uptake to prevail over sequestration, forming a pool of free iron that is used for metabolic functions. Conversely, cluster reassembly converts IRP-1 back to aconitase, providing a regulatory mechanism to decrease free iron when it exceeds metabolic requirements. In contrast to these physiologic mechanisms, DOXol-dependent iron release and cluster disassembly not only abolish aconitase activity, but also affect irreversibly the ability of the apoprotein to function as IRP-1 or to reincorporate iron within new Fe-S motifs. This damage is mediated by DOX-Fe(II) complexes and reflects oxidative modifications of - SH residues having the dual role to coordinate cluster assembly and facilitate interactions of IRP-1 with mRNAs. Collectively, these findings describe a novel mechanism of cardiotoxicity, suggesting that intramyocardial formation of DOXol may perturb the homeostatic processes associated with cluster assembly or disassembly and the reversible switch between aconitase and IRP-1. These results may also provide a guideline to design new drugs that mitigate the cardiotoxicity of DOX.	Univ Cattolica Sacro Cuore, Sch Med, Dept Pharmacol, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Sch Med, Dept Biochem, I-00168 Rome, Italy; Univ Milan, Sch Med, IRCCS, Osped Maggiore,Dept Gastroenterol, I-20122 Milan, Italy; CNR, Ctr Cell Pathol, I-20133 Milan, Italy; Univ G DAnnunzio, Sch Med, Dept Cardiac Surg, Chieti, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Consiglio Nazionale delle Ricerche (CNR); G d'Annunzio University of Chieti-Pescara	Minotti, G (corresponding author), Univ Cattolica Sacro Cuore, Sch Med, Dept Pharmacol, Largo F Vito 1, I-00168 Rome, Italy.	ibifa@rm.unicatt.it	Mancuso, Cesare/GLQ-7160-2022; Cairo, Gaetano/M-5104-2016; Mordente, Alvaro/AAB-7290-2019; recalcati, stefania/M-5045-2016	Mancuso, Cesare/0000-0001-6532-483X; Cairo, Gaetano/0000-0002-8147-4720; recalcati, stefania/0000-0002-2115-8283; Minotti, Giorgio/0000-0002-5678-6175; MORDENTE, Alvaro/0000-0003-3260-9796				AUST SD, 1990, METHOD ENZYMOL, V186, P457; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BEINERT H, 1989, EUR J BIOCHEM, V189, P5; Bouton C, 1997, J BIOL CHEM, V272, P19969, DOI 10.1074/jbc.272.32.19969; BUSS JL, 1993, AGENTS ACTIONS, V40, P86, DOI 10.1007/BF01976756; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210; Dorr RT, 1996, SEMIN ONCOL, V23, P23; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; GARDNER PR, 1995, J BIOL CHEM, V270, P13339; GIANNI L, 1983, REV BIOCHEM TOXICOL, P1; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, TRENDS BIOCHEM SCI, V21, P282, DOI 10.1016/S0968-0004(96)20019-2; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUFFEL MJ, 1992, CANCER CHEMOTH PHARM, V30, P51, DOI 10.1007/BF00686485; Lauble H, 1996, P NATL ACAD SCI USA, V93, P13699, DOI 10.1073/pnas.93.24.13699; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; Minotti G, 1996, J CLIN INVEST, V98, P650, DOI 10.1172/JCI118836; MINOTTI G, 1989, ARCH BIOCHEM BIOPHYS, V268, P398, DOI 10.1016/0003-9861(89)90601-2; MINOTTI G, 1993, CHEM RES TOXICOL, V6, P134, DOI 10.1021/tx00032a001; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MYERS C, 1983, SEMIN ONCOL, V10, P53; Nies AS, 1996, GOODMAN GILMANS PHAR, P43; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; PARASKEVA E, 1996, FEBS LETT, V389, P401; Phillips JD, 1996, BIOCHEMISTRY-US, V35, P15704, DOI 10.1021/bi960653l; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; Schoen FJ, 1994, ROBBINS PATHOLOGIC B, P517; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; TAKANASHI S, 1976, DRUG METAB DISPOS, V4, P79; TORCHINSKY YM, 1981, SULFUR PROTEINS, P48; VILE G, 1990, BIOCHEM PHARMACOL, V39, P769, DOI 10.1016/0006-2952(90)90157-G; WEISS RB, 1992, SEMIN ONCOL, V19, P670; WEITZMAN SA, 1980, CURR THER RES CLIN E, V28, P682	49	129	133	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1998	12	7					541	552		10.1096/fasebj.12.7.541	http://dx.doi.org/10.1096/fasebj.12.7.541			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576481	Bronze			2022-12-28	WOS:000073523100004
J	Morra, M; Zubiaur, M; Terhorst, C; Sancho, J; Malavasi, F				Morra, M; Zubiaur, M; Terhorst, C; Sancho, J; Malavasi, F			CD38 is functionally dependent on the TCR/CD3 complex in human T cells	FASEB JOURNAL			English	Article						T lymphocytes; cell surface molecules; second messengers; signal transduction; apoptosis	CYCLIC ADP-RIBOSE; LYMPHOCYTES-T; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; PHORBOL ESTERS; CA2+ RELEASE; APOPTOSIS; ACTIVATION; THYMOCYTES; RECEPTOR	One of the functions of surface CD38 is the induction of phosphorylation of discrete cytoplasmic substrates and mobilization of cytoplasmic calcium (Ca2+). The present work addresses the issue of whether the signaling mediated via CD38 operates through an independent pathway or, alternatively, is linked to the TCR/CD3 signaling machinery. We studied the signals elicited through CD38 by the specific agonistic IB4 monoclonal antibody (mAb) by monitoring the levels of cytoplasmic Ca2+ and the induced phenotypic and functional variations in T cell growth, IB4 mAb presented the unique ability to increase cytoplasmic Ca2+ levels, which correlated with the phosphorylation of the PLC-gamma 1. These effects were blocked by phorbol 12-myristate 13-acetate (PMA) and were dependent on the presence of a functional TCR/CD3 surface complex, no effects being recorded on mutant Jurkat cells lacking part of the CD3 structures. CD38 signaling appeared to share with TCR/CD3 the ability to induce apoptotic cell death in Jurkat T cells, an event paralleled by specific up-regulation of the Fas molecule and inhibited by cyclosporin A. CD28, a costimulatory molecule, is synergized by increasing CD3-induced apoptotic cell death. The results indicate the existence of a strong functional interdependence between CD38 and TCR/CD3.	Univ Torino, Sch Med, Dept Genet Biol & Med Chem, Cell Biol Lab, I-10126 Turin, Italy; Univ Torino, Sch Med, Postgrad Sch Clin Pathol, I-10126 Turin, Italy; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Harvard Univ, Sch Med, Beth Israel Hosp, Div Immunol, Boston, MA 02115 USA; Univ Ancona, Sch Med, Inst Biol & Genet, I-60131 Ancona, Italy	University of Turin; University of Turin; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Marche Polytechnic University	Malavasi, F (corresponding author), Univ Torino, Sch Med, Dept Genet Biol & Med Chem, Cell Biol Lab, Via Santena 19, I-10126 Turin, Italy.	malvasi@molinette.unito.it	Sancho, Jaime/K-5989-2019; Zubiaur, Mercedes/K-9390-2014; Sancho, Jaime/O-3228-2013; Zubiaur, Mercedes/AAC-5792-2021	Sancho, Jaime/0000-0003-3852-7951; Zubiaur, Mercedes/0000-0002-4127-3027; Sancho, Jaime/0000-0003-3852-7951; Zubiaur, Mercedes/0000-0002-4127-3027; MALAVASI, Fabio/0000-0002-1844-174X	Telethon [E.0662] Funding Source: Medline	Telethon(Fondazione Telethon)		ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; AUSIELLO CM, 1995, EUR J IMMUNOL, V25, P1477, DOI 10.1002/eji.1830250554; Boirivant M, 1996, J CLIN INVEST, V98, P2616, DOI 10.1172/JCI119082; CANTRELL DA, 1989, J IMMUNOL, V143, P3653; Cesano A, 1998, J IMMUNOL, V160, P1106; Deaglio S, 1996, J IMMUNOL, V156, P727; Deaglio S, 1998, J IMMUNOL, V160, P395; DEMONTE LB, 1990, P NATL ACAD SCI USA, V87, P2941, DOI 10.1073/pnas.87.8.2941; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DIANZANI U, 1994, J IMMUNOL, V153, P952; Ferrero E, 1997, J IMMUNOL, V159, P3858; Funaro A, 1996, INT IMMUNOL, V8, P1643; FUNARO A, 1993, EUR J IMMUNOL, V23, P2407, DOI 10.1002/eji.1830231005; Funaro A, 1997, TISSUE ANTIGENS, V49, P7, DOI 10.1111/j.1399-0039.1997.tb02703.x; FUNARO A, 1990, J IMMUNOL, V145, P1; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GUSE AH, 1995, J IMMUNOL, V155, P3353; Hoshino S, 1997, J IMMUNOL, V158, P741; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LEDBETTER JA, 1987, P NATL ACAD SCI USA, V84, P1384, DOI 10.1073/pnas.84.5.1384; LEDBETTER JA, 1990, BLOOD, V75, P1531; Lund FE, 1996, J IMMUNOL, V157, P1455; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; Ruggiero G, 1996, J IMMUNOL, V156, P3737; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SCHMID I, 1988, CYTOMETRY, V9, P533, DOI 10.1002/cyto.990090605; Silvennoinen O, 1996, J IMMUNOL, V156, P100; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; TucekSzabo CL, 1996, J IMMUNOL, V156, P192; TURKA LA, 1990, J IMMUNOL, V144, P1646; VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8; WARD SG, 1990, J IMMUNOL, V144, P3523; WESSELBORG S, 1993, EUR J IMMUNOL, V23, P2707, DOI 10.1002/eji.1830231050; ZHU LQ, 1995, J IMMUNOL, V154, P192; Zubiaur M, 1997, J IMMUNOL, V159, P193; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532; Zupo S, 1996, BLOOD, V88, P1365, DOI 10.1182/blood.V88.4.1365.bloodjournal8841365	47	85	91	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					581	592		10.1096/fasebj.12.7.581	http://dx.doi.org/10.1096/fasebj.12.7.581			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576485	Bronze			2022-12-28	WOS:000073523100008
J	Obin, M; Shang, F; Gong, X; Handelman, G; Blumberg, J; Taylor, A				Obin, M; Shang, F; Gong, X; Handelman, G; Blumberg, J; Taylor, A			Redox regulation of ubiquitin-conjugating enzymes: mechanistic insights using the thiol-specific oxidant diamide	FASEB JOURNAL			English	Article						ubiquitin-proteasome pathway; E1; E2; glutathione; diamide; ubiquitin-activating enzyme	ACTIVATING ENZYME; OXIDATIVE STRESS; DEPENDENT PROTEOLYSIS; KAPPA-B; PROTEIN; DEGRADATION; PATHWAY	The ubiquitin-proteasome pathway (UPP) regulates critical cell processes, including the cell cycle, cytokine-induced gene expression, differentiation, and cell death. Recently we demonstrated that this pathway responds to oxidative stress in mammalian cells and proposed that activities of ubiquitin-activating enzyme (E1) and ubiquitin-conjugating enzymes (E2s) are regulated by cellular redox status (i.e., GSSG:GSH ratio). To test this hypothesis, we altered the GSSG:GSH ratio in retinal pigment epithelial cells with the thiol-specific oxidant, diamide, and assessed activities of the WP. Treatment of cells with diamide resulted in a dose-dependent increase in the GSSG:GSH ratio resulting from loss of GSH and a coincident increase in GSSG. Increases in the GSSG:GSH ratio from 0.02 in untreated cells to greater than or equal to 0.5 in diamide-treated cells were accompanied by dose-dependent reductions in the levels of endogenous Ub-protein conjugates, endogenous E1 similar to ubiquitin thiol esters, and de novo ubiquitin-conjugating activity. As determined by the ability to form E1-ubiquitin and EB-ubiquitin thiol esters, E1 and E2s were both inhibited by elevated GSSG:GSH ratios. Inhibition of E1 was associated with the formation of E1-protein mixed disulfides. Activities of E1 and E2s gradually recovered to preoxidation levels, coincident with gradual recovery of the GSSG:GSH ratio. These data support S-thiolation/dethiolation as a mechanism regulating E1 and E2 activities in response to oxidant insult. Ubiquitin-dependent proteolytic capacity was regulated by the GSSG:GSH ratio in a manner con consistent with altered ubiquitin-conjugating activity. However, ubiquitin-independent proteolysis was unaffected by changes in the GSSG:GSH ratio. Potential adaptive and pathological consequences of redox regulation of UPP activities are discussed.	Tufts Univ, JMUSDA, HNRCA, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tufts Univ, JMUSDA, HNRCA, Antioxidants Res Lab, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA)	Taylor, A (corresponding author), Tufts Univ, JMUSDA, HNRCA, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	Taylor_cl@hnrc.tufts.edu			NATIONAL EYE INSTITUTE [R29EY011735] Funding Source: NIH RePORTER; NEI NIH HHS [EY11735-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BROT N, 1981, P NATL ACAD SCI-BIOL, V78, P2155, DOI 10.1073/pnas.78.4.2155; Carelli S, 1997, SCIENCE, V277, P1681, DOI 10.1126/science.277.5332.1681; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; Di Monte DA, 1992, ANN NEUROL, V32, P111; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jenner P, 1996, PATHOL BIOL, V44, P57; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Liu H, 1996, J BIOL CHEM, V271, P4805; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; TAYLOR A, 1997, VITAMIN C HLTH DIS, P267; VESSEY DA, 1992, J INVEST DERMATOL, V99, P859, DOI 10.1111/1523-1747.ep12614831; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	38	169	172	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					561	569		10.1096/fasebj.12.7.561	http://dx.doi.org/10.1096/fasebj.12.7.561			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576483	Bronze			2022-12-28	WOS:000073523100006
J	Brandt, BH; Roetger, A; Dittmar, T; Nikolai, G; Seeling, M; Merschjann, A; Nofer, JR; Dehmer-Moller, G; Junker, R; Assmann, G; Zaenker, KS				Brandt, BH; Roetger, A; Dittmar, T; Nikolai, G; Seeling, M; Merschjann, A; Nofer, JR; Dehmer-Moller, G; Junker, R; Assmann, G; Zaenker, KS			c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells	FASEB JOURNAL			English	Article						F-actin; gelsolin; epidermal growth factor; HUVEC	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; EGF RECEPTOR; ANTIBODIES INHIBIT; ERBB-2 PROTEIN; HER-2/NEU GENE; POOR-PROGNOSIS; ONCOGENE; ACTIN	Separate mechanisms for oncogenesis and metastasis have been postulated. We show here that prolonged and invasive cell migration, a key mechanism in cancer metastasis, is linked to c-erbB-2 signaling. Cell lines with c-erbB-2 and EGFR expression and transphosphorylation activity display a high transendothelial invasiveness in an endothelial-extracellular matrix model mimicking a capillary vessel wall, in vitro. Tyrosine-phosphorylated c-erbB-2 receptors and EGFR are localized predominantly in areas of the cell with high membrane extension activity. On the molecular level, there is a subtle cross talk between the transmembrane signaling molecule c-erbB-2 and the actin cytoskeleton at multiple levels, including the generation of the second messenger PIP2 and the mobilization of the actin-regulatory protein gelsolin. Our data strongly suggest that c-erbB-2, especially in a heterodimer with EGFR, is closely involved in signaling pathways, inducing alterations in cell morphology that are required for a human breast cancer cell to become motile and conceivably metastatic.-Brandt, B. H., Roetger, A., Dittmar, T., Nikolai, G., Seeling, M., Merschjann, A., Nofer, J.-R., Dehmer-Moller, G., Junker, R., Assmann, G., Zaenker. K. S. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.	Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Witten Herdecke, Inst Immunol, D-58453 Witten, Germany	Witten Herdecke University	Brandt, BH (corresponding author), Inst Klin Chem & Lab Med, Albert Schweitzer Str 33, D-48149 Munster, Germany.	brandt@uni-muenster.de	Junker, Ralf/M-2358-2013; Dittmar, Thomas/T-6679-2019; Dittmar, Thomas/X-3691-2019	Brandt, Burkhard/0000-0003-3681-3049				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BILLAH MM, 1982, J BIOL CHEM, V257, P2705; Brandt B, 1998, INT J CANCER, V76, P824, DOI 10.1002/(SICI)1097-0215(19980610)76:6<824::AID-IJC10>3.0.CO;2-2; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; MARTH C, 1992, INT J CANCER, V52, P311, DOI 10.1002/ijc.2910520226; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Roetger A, 1998, AM J PATHOL, V153, P1797, DOI 10.1016/S0002-9440(10)65694-5; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Tan M, 1997, CANCER RES, V57, P1199; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU D, 1995, MOL BASIS ONCOLOGY, P131; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	42	82	86	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1939	1949		10.1096/fasebj.13.14.1939	http://dx.doi.org/10.1096/fasebj.13.14.1939			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544177				2022-12-28	WOS:000083660700006
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy	FASEB JOURNAL			English	Article						multidrug transporter; protein folding; proteasome inhibitor; endoplasmic reticulum	TRANSMEMBRANE CONDUCTANCE REGULATOR; HIV-1 PROTEASE INHIBITORS; CYSTIC-FIBROSIS; ENDOPLASMIC-RETICULUM; CONFORMATIONAL MATURATION; FUNCTIONAL CONSEQUENCES; CHEMICAL CHAPERONES; QUALITY-CONTROL; IN-VITRO; MUTANTS	The human multidrug resistance P-glycoprotein (P-gp) contributes to the phenomenon of multidrug resistance during cancer and AIDS chemotherapy. A potential novel strategy to circumvent the effects of P-gp during chemotherapy is to prevent maturation of P-gp during biosynthesis so that the transporter does not reach the cell surface. Here we report that immature, core-glycosylated P-gp that is prevented from reaching the cell surface by processing mutations or by proteasome inhibitors such as lactacystin or MG-132 exhibited no detectable drug-stimulated ATPase activity. Disulfide cross-linking analysis also showed that the immature P-gp did not exhibit ATP-induced conformational changes as found in the mature enzyme. In addition, the immature P-gp was more sensitive to trypsin than the mature enzyme. These results suggest that P-gp is unlikely to be functional immediately after synthesis. These differences in the structural and enzymatic properties of the mature and core-glycosylated, immature P-g-p could potentially be used during chemotherapy, and should result in the search for compounds that can specifically inhibit the maturation of P-gp.-Loo, T. W., Clarke, D. M. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Room 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; BIEDLER JL, 1970, CANCER RES, V30, P1174; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHAN HS, 1996, EUR J CANCER, V6, P1051; Charuk JHM, 1998, AM J PHYSIOL-RENAL, V274, pF1127, DOI 10.1152/ajprenal.1998.274.6.F1127; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Fisher GA, 1996, EUR J CANCER, V32A, P1082, DOI 10.1016/0959-8049(96)00111-6; Goldstein LJ, 1996, EUR J CANCER, V32A, P1039, DOI 10.1016/0959-8049(96)00100-1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schuetz EG, 1996, P NATL ACAD SCI USA, V93, P4001, DOI 10.1073/pnas.93.9.4001; SHEN DW, 1986, J BIOL CHEM, V261, P7762; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P207; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	51	75	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1724	1732		10.1096/fasebj.13.13.1724	http://dx.doi.org/10.1096/fasebj.13.13.1724			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506575				2022-12-28	WOS:000083063400007
J	Williams, AB; Decourten-Myers, GM; Fischer, JE; Luo, GJ; Sun, XY; Hasselgren, PO				Williams, AB; Decourten-Myers, GM; Fischer, JE; Luo, GJ; Sun, XY; Hasselgren, PO			Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism	FASEB JOURNAL			English	Article						muscle catabolism; actin; myosin; ubiquitin; proteasome; calpain	END RULE PATHWAY; MYOFIBRILLAR PROTEIN BREAKDOWN; CRITICALLY-ILL PATIENTS; MESSENGER-RNA; DEGRADATION; PROTEASOME; EXERCISE; CALPAIN; INVITRO; STARVATION	Sepsis is associated with a pronounced catabolic response in skeletal muscle, mainly reflecting degradation of the myofibrillar proteins actin and myosin. Recent studies suggest that sepsis-induced muscle proteolysis may reflect ubiquitin-proteasome-dependent protein breakdown. An apparently conflicting observation is that the ubiquitin-proteasome pathway does not degrade intact myofibrils. Thus, it is possible that actin and myosin need to be released from the myofibrils before they can be ubiquitinated and degraded by the proteasome. We tested the hypothesis that sepsis results in disruption of Z-bands, increased expression of calpains, and calcium-dependent release of myofilaments in skeletal muscle. Sepsis induced in rats by cecal ligation and puncture resulted in increased gene expression of mu-calpain, m-calpain, and p94 and in Z-band disintegration in the extensor digitorum longus muscle. The release of myofilaments from myofibrillar proteins was increased in septic muscle. This response to sepsis was blocked by treating the rats with dantrolene, a substance that inhibits the release of calcium from intracellular stores to the cytoplasm. The present results provide evidence that sepsis is associated with Z-band disintegration and a calcium-dependent release of myofilaments in skeletal muscle. Release of myofilaments may be an initial and perhaps rate-limiting component of sepsis-induced muscle breakdown.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Shriners Hosp Children, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hasselgren, PO (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, 231 Bethesda Ave,Mail Locat 0558, Cincinnati, OH 45267 USA.	hasselp@uc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008478] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARACOS V, 1986, AM J PHYSIOL, V250, pE702, DOI 10.1152/ajpendo.1986.250.6.E702; Belcastro A N, 1996, Can J Appl Physiol, V21, P328; Belcastro AN, 1998, MOL CELL BIOCHEM, V179, P135, DOI 10.1023/A:1006816123601; BELCASTRO AN, 1994, MOL CELL BIOCHEM, V135, P51, DOI 10.1007/BF00925960; BELCASTRO AN, 1991, MOL CELL BIOCHEM, V103, P113; BELCASTRO AN, 1993, J APPL PHYSIOL, V74, P1381, DOI 10.1152/jappl.1993.74.3.1381; BENSON DW, 1989, SURGERY, V106, P87; BHATTACHARYYA J, 1993, AM J PHYSIOL, V265, pR487, DOI 10.1152/ajpregu.1993.265.3.R487; BHATTACHARYYA J, 1991, CIRC SHOCK, V35, P117; CHAUDRY IH, 1979, SURGERY, V85, P205; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLMANN B, 1986, BIOCHEM J, V234, P659, DOI 10.1042/bj2340659; Diaz NL, 1998, HISTOL HISTOPATHOL, V13, P121, DOI 10.14670/HH-13.121; DOWNEY RS, 1986, SURGERY, V99, P265; DUNCAN CJ, 1987, J CELL SCI, V87, P581; ETLINGER JD, 1975, NATURE, V255, P259, DOI 10.1038/255259a0; FOSTER PS, 1991, CLIN EXP PHARMACOL P, V18, P489, DOI 10.1111/j.1440-1681.1991.tb01482.x; FRIDEN J, 1983, INT J SPORTS MED, V4, P170, DOI 10.1055/s-2008-1026030; Goldberg A L, 1975, Methods Enzymol, V39, P82; HASSELGREN O, 1990, BIOCHEM J, V267, P33; HASSELGREN PO, 1989, METABOLISM, V38, P634, DOI 10.1016/0026-0495(89)90100-5; HASSELGREN PO, 1993, PROTEIN METABOLISM S; HAUPTMANN S, 1994, VIRCHOWS ARCH, V424, P653, DOI 10.1007/BF01069747; HELLIWELL TR, 1991, J PATHOL, V164, P307, DOI 10.1002/path.1711640406; HERSCH M, 1990, SURGERY, V107, P397; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hobler SC, 1999, AM J PHYSIOL-REG I, V276, pR468, DOI 10.1152/ajpregu.1999.276.2.R468; Hobler SC, 1998, AM J PHYSIOL-REG I, V274, pR30, DOI 10.1152/ajpregu.1998.274.1.R30; HOTCHKISS RS, 1994, P NATL ACAD SCI USA, V91, P3039, DOI 10.1073/pnas.91.8.3039; KOOHMARAIE M, 1992, J ANIM SCI, V70, P3697, DOI 10.2527/1992.70123697x; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL BB, 1986, METABOLISM, V35, P1121, DOI 10.1016/0026-0495(86)90025-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHIEUCOSTELLO O, 1992, RESP PHYSIOL, V89, P113, DOI 10.1016/0034-5687(92)90075-8; PEDERSEN PV, 1989, SURG GYNECOL OBSTET, V168, P148; PELLEGRINO C, 1963, J CELL BIOL, V17, P327, DOI 10.1083/jcb.17.2.327; Reid WD, 1998, MOL CELL BIOCHEM, V179, P63, DOI 10.1023/A:1006803703128; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Squire JM, 1997, CURR OPIN STRUC BIOL, V7, P247, DOI 10.1016/S0959-440X(97)80033-4; STEVENS A, 1993, HISTOLOGY, P58; SUGDEN PH, 1980, BIOCHEM J, V190, P593, DOI 10.1042/bj1900593; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; Tiao G, 1997, AM J PHYSIOL-REG I, V272, pR849, DOI 10.1152/ajpregu.1997.272.3.R849; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; TOMANEK RJ, 1973, J ANAT, V116, P395; VANDERWESTHUYZEN DR, 1981, J BIOL CHEM, V256, P1791; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; VIGOREAUX JO, 1994, J MUSCLE RES CELL M, V15, P237; WING SS, 1994, AM J PHYSIOL, V267, pE39, DOI 10.1152/ajpendo.1994.267.1.E39; WOKKE JHJ, 1988, J NEUROL SCI, V88, P95, DOI 10.1016/0022-510X(88)90208-0	55	135	140	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1435	1443		10.1096/fasebj.13.11.1435	http://dx.doi.org/10.1096/fasebj.13.11.1435			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428767	Bronze			2022-12-28	WOS:000082019100015
J	May, JM				May, JM			Is ascorbic acid an antioxidant for the plasma membrane?	FASEB JOURNAL			English	Article; Proceedings Paper	FASEB Summer Research Conference on Molecular and Biological Mechanisms of Antioxidant Action	AUG, 1998	COPPER MOUNTAIN, CO			ascorbate free radical; dehydroascorbic acid; antioxidant; ferricyanide; oxidoreductase	TRANSMEMBRANE ELECTRON-TRANSFER; HUMAN-ERYTHROCYTE-MEMBRANES; INDEPENDENT IRON TRANSPORT; CHROMAFFIN GRANULE MEMBRANE; ISOPRENOID SIDE-CHAIN; COENZYME-Q REDUCTASE; ALPHA-TOCOPHEROL; DEHYDROASCORBIC ACID; HL-60 CELLS; VITAMIN-E	Ascorbic acid, or vitamin C, is a primary antioxidant in plasma and within cells, but it can also interact with the plasma membrane by donating electrons to the alpha-tocopheroxyl radical and a trans-plasma membrane oxidoreductase activity, Ascorbate-derived reducing capacity is thus transmitted both into and across the plasma membrane. Recycling of alpha-tocopherol by ascorbate helps to protect membrane lipids from peroxidation. However, neither the mechanism nor function of the ascorbate-dependent oxidoreductase activity is known. This activity has typically been studied using extracellular ferricyanide as an electron acceptor. Whereas an NADH:ferricyanide reductase activity is evident in open membranes, ascorbate is the preferred electron donor within cells. The oxidoreductase may be a single membrane-spanning protein or may only partially span the membrane as part of a trans-membrane electron transport chain composed of a cytochrome or even hydrophobic antioxidants such as alpha-tocopherol or ubiquinol-10, Further studies are needed to elucidate the structural components, mechanism, and physiological significance of this activity. Proposed functions for the oxidoreductase include stimulation of cell growth, reduction of the ascorbate free radical outside cells, recycling of alpha-tocopherol, reduction of Lipid hydroperoxides, and reduction of ferric iron prior to iron uptake by a transferrin-independent pathway.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	May, JM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 736 Med Res Bldg 2,2220 Pierce Ave, Nashville, TN 37232 USA.	james.may@mcmail.vanderbilt.edu			NIDDK NIH HHS [DK 50435] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050435] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agutter PS, 1979, BIOCHEM SOC T, V7, P710, DOI 10.1042/bst0070710; ALCAIN FJ, 1991, BIOCHIM BIOPHYS ACTA, V1073, P380, DOI 10.1016/0304-4165(91)90146-8; AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BALDWIN SA, 1982, BIOCHEMISTRY-US, V21, P3836, DOI 10.1021/bi00259a018; BERGMAN DJ, 1990, J STAT PHYS, V58, P1, DOI 10.1007/BF01020283; BIELSKI BHJ, 1975, ANN NY ACAD SCI, V258, P231, DOI 10.1111/j.1749-6632.1975.tb29283.x; BRUDER G, 1980, BIOCHIM BIOPHYS ACTA, V600, P739, DOI 10.1016/0005-2736(80)90477-0; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CHERRY JM, 1981, BIOCHIM BIOPHYS ACTA, V634, P11, DOI 10.1016/0005-2728(81)90123-7; CHOURY D, 1981, J CLIN INVEST, V67, P149, DOI 10.1172/JCI110007; CIRIOLO MR, 1993, EUR J BIOCHEM, V215, P711, DOI 10.1111/j.1432-1033.1993.tb18083.x; CLARK MG, 1982, BIOCHEM J, V204, P795, DOI 10.1042/bj2040795; CONSTANTINESCU A, 1993, J BIOL CHEM, V268, P10906; CRANE FL, 1991, J BIOENERG BIOMEMBR, V23, P773, DOI 10.1007/BF00786001; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRANE FL, 1985, ENZYMES BIOL MEMBR, P465; DOBA T, 1985, BIOCHIM BIOPHYS ACTA, V835, P298, DOI 10.1016/0005-2760(85)90285-1; DORMANDY TL, 1965, J PHYSIOL-LONDON, V180, P684, DOI 10.1113/jphysiol.1965.sp007724; Drake BB, 1942, J BIOL CHEM, V143, P89; ENOMOTO KI, 1977, BIOCHIM BIOPHYS ACTA, V466, P136, DOI 10.1016/0005-2736(77)90214-0; EVANS RM, 1982, BRIT J NUTR, V47, P473, DOI 10.1079/BJN19820059; FUTAMI A, 1979, BIOCHIM BIOPHYS ACTA, V547, P583, DOI 10.1016/0005-2728(79)90035-5; GOLDENBERG H, 1983, BIOCHEM INT, V6, P1; GomezDiaz C, 1997, J BIOENERG BIOMEMBR, V29, P251, DOI 10.1023/A:1022410127104; GOTOTAMURA R, 1976, BIOCHIM BIOPHYS ACTA, V423, P293, DOI 10.1016/0005-2728(76)90186-9; GREBING C, 1984, J BIOENERG BIOMEMBR, V16, P517, DOI 10.1007/BF00743243; HAN O, 1995, J NUTR, V125, P1291; HAUSKA G, 1977, FEBS LETT, V79, P345, DOI 10.1016/0014-5793(77)80817-X; Himmelreich U, 1998, BIOCHEMISTRY-US, V37, P7578, DOI 10.1021/bi970765s; Himmelreich U, 1997, EUR J BIOCHEM, V246, P638, DOI 10.1111/j.1432-1033.1997.t01-1-00638.x; HUGHES RE, 1968, BRIT J HAEMATOL, V14, P247, DOI 10.1111/j.1365-2141.1968.tb01494.x; HULTQUIST DE, 1971, BIOCHIM BIOPHYS ACTA, V229, P33, DOI 10.1016/0005-2795(71)90314-X; ILANI A, 1987, BIOPHYS J, V51, P161, DOI 10.1016/S0006-3495(87)83321-0; INGEBRETSEN OC, 1980, BIOCHIM BIOPHYS ACTA, V628, P182, DOI 10.1016/0304-4165(80)90365-7; INMAN RS, 1993, J BIOL CHEM, V268, P8521; INMAN RS, 1994, BIOCHEMISTRY-US, V33, P11850, DOI 10.1021/bi00205a022; IYANAGI T, 1985, BIOCHIM BIOPHYS ACTA, V806, P255, DOI 10.1016/0005-2728(85)90103-3; JIALAL I, 1990, ATHEROSCLEROSIS, V82, P185, DOI 10.1016/0021-9150(90)90039-L; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; Kakee A, 1996, J PHARMACOL EXP THER, V277, P1550; KITAJIMA S, 1981, ARCH BIOCHEM BIOPHYS, V210, P330, DOI 10.1016/0003-9861(81)90196-X; KOBAYASHI K, 1991, BIOCHEMISTRY-US, V30, P8310, DOI 10.1021/bi00098a005; LAROFF GP, 1972, J AM CHEM SOC, V94, P9062, DOI 10.1021/ja00781a013; LEVINE M, 1983, J BIOL CHEM, V258, P3111; May JM, 1996, J BIOL CHEM, V271, P10577, DOI 10.1074/jbc.271.18.10577; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 1996, FREE RADICAL BIO MED, V20, P543, DOI 10.1016/0891-5849(95)02130-2; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; MAY JM, 1999, IN PRESS BIOCH PHARM; MEDINA MA, 1994, BIOCHEM BIOPH RES CO, V205, P1109, DOI 10.1006/bbrc.1994.2780; MEHLHORN RJ, 1989, J BIOL CHEM, V264, P13448; Mendiratta S, 1998, FREE RADICAL BIO MED, V25, P221, DOI 10.1016/S0891-5849(98)00060-4; Mendiratta S, 1998, FREE RADICAL BIO MED, V24, P789, DOI 10.1016/S0891-5849(97)00351-1; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; Musilkova J, 1998, BBA-BIOMEMBRANES, V1369, P103, DOI 10.1016/S0005-2736(97)00214-9; NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947; NAVAS P, 1994, BBA-REV BIOMEMBRANES, V1197, P1, DOI 10.1016/0304-4157(94)90016-7; NAVAS P, 1992, FEBS LETT, V299, P223, DOI 10.1016/0014-5793(92)80119-2; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; OHNISHI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P357, DOI 10.1016/0005-2728(69)90132-7; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; OWENS CWI, 1965, BIOCHEM J, V94, P705, DOI 10.1042/bj0940705; REGLINSKI J, 1991, CLIN CHIM ACTA, V201, P45, DOI 10.1016/0009-8981(91)90023-6; RODRIGUEZAGUILERA JC, 1993, J BIOL CHEM, V268, P26346; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; SCARPA M, 1984, BIOCHIM BIOPHYS ACTA, V801, P215, DOI 10.1016/0304-4165(84)90070-9; SCHIPFER W, 1985, INT J BIOCHEM, V17, P819, DOI 10.1016/0020-711X(85)90270-8; SCHULZE HU, 1970, H-S Z PHYSIOL CHEM, V351, P809, DOI 10.1515/bchm2.1970.351.2.809; SCHWEINZER E, 1993, FEBS LETT, V334, P106, DOI 10.1016/0014-5793(93)81691-R; SCHWEINZER E, 1992, EUR J BIOCHEM, V206, P807, DOI 10.1111/j.1432-1033.1992.tb16988.x; SCHWEINZER E, 1993, EUR J BIOCHEM, V218, P1057, DOI 10.1111/j.1432-1033.1993.tb18465.x; Schweinzer E, 1996, CELL BIOCHEM FUNCT, V14, P27, DOI 10.1002/(SICI)1099-0844(199603)14:1<27::AID-CBF635>3.3.CO;2-P; SRIVASTAVA M, 1984, J BIOL CHEM, V259, P8072; Steck T L, 1974, Methods Enzymol, V31, P172; STURROCK A, 1990, J BIOL CHEM, V265, P3139; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; SUN IL, 1984, BIOCHEM BIOPH RES CO, V125, P649, DOI 10.1016/0006-291X(84)90588-6; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SZEKELY M, 1952, ACTA PHYSIOL HUNG, V3, P571; TAVERNA RD, 1973, BIOCHIM BIOPHYS ACTA, V323, P207, DOI 10.1016/0005-2736(73)90145-4; THOMAS JP, 1990, J BIOL CHEM, V265, P454; ULRICH EL, 1985, BIOCHEMISTRY-US, V24, P2501, DOI 10.1021/bi00331a016; Upston JM, 1996, J LIPID RES, V37, P2650; Van Duijn MM, 1998, J BIOL CHEM, V273, P13415, DOI 10.1074/jbc.273.22.13415; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VILLALBA JM, 1993, J BIOENERG BIOMEMBR, V25, P411, DOI 10.1007/BF00762467; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WANG CS, 1978, J SUPRAMOL STR CELL, V9, P1, DOI 10.1002/jss.400090102; Waters RE, 1997, FREE RADICAL RES, V26, P373, DOI 10.3109/10715769709097817; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q; YAMAZAKI I, 1961, BIOCHIM BIOPHYS ACTA, V50, P62, DOI 10.1016/0006-3002(61)91060-5; ZAMUDIO I, 1969, ARCH BIOCHEM BIOPHYS, V129, P336, DOI 10.1016/0003-9861(69)90184-2	100	165	174	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					995	1006		10.1096/fasebj.13.9.995	http://dx.doi.org/10.1096/fasebj.13.9.995			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336882	Bronze			2022-12-28	WOS:000080547700004
J	Vegeto, E; Pollio, G; Pellicciari, C; Maggi, A				Vegeto, E; Pollio, G; Pellicciari, C; Maggi, A			Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-alpha-induced apoptosis	FASEB JOURNAL			English	Article						estrogen receptor; progesterone receptor; U937 cells; TNF-alpha; apoptosis	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; MURINE MACROPHAGES; MESSENGER-RNA; GROWTH-FACTOR; MONONUCLEAR-CELLS; GENE-EXPRESSION; RECEPTOR; DEATH	Induction of apoptosis of mononucleated cells is a physiological process for regulating the intensity of the immune response. The female steroid hormones estrogen (E-2) and progesterone (Prog) are known to modulate the reactivity of the immune system; recently it has been demonstrated that they can regulate induction of apoptosis of endothelial cells and osteoblasts. TNF-alpha-mediated induction of apoptosis has been well characterized in myeloid cells. We investigated whether E-2 and Prog could interfere with TNF-alpha-induced apoptosis of the monoblastoid U937 cell line. Treatment with E-2 or Prog increased survival and prevented apoptosis induced by TNF-alpha in both undifferentiated and macrophage-like PMA-differentiated U937 cells, as assessed by trypan blue exclusion cell. counting, thymidine incorporation, AnnexinV labeling, followed by flow cytometry and DNA fragmentation studies. This effect can be associated with the activation of specific hormone receptors, since we observed the expression of the estrogen receptor alpha (ER-alpha), ER-beta, and progesterone receptor (PR) mRNAs; the ER-alpha protein expression was confirmed by immunocytochemical analysis. In addition, hormone-mediated survival against apoptosis was concentration dependent, reaching the half-maximal effect at 10 nM and blocked by the ER antagonist ICI 182,780 in undifferentiated cells, further supporting a receptor-mediated mechanism of cell survival. Other steroid receptor drugs such as Raloxifene, RU486, or the ICI 182,780 in PMA-differentiated cells displayed agonist activity by preventing TNF-alpha-induced apoptosis as efficiently as the hormones alone, providing further evidence to the notion that steroid receptor drugs may manifest agonist or antagonist activities depending on the cellular context in which they are studied. Treatment with E-2 was also associated with a time-dependent decrease in the mRNA level of the proapoptotic Nip-2 protein, supporting: the hypothesis that hormone responsiveness of U937 cells is mediated by target gene transcription. Together, these results demonstrate that ER and PR can be activated by endogenous or exogenous ligands to induce a genetic response that impairs TNF-alpha-induced apoptosis in U937 cells. The data presented here suggest that the female steroid receptors play a role in regulation of the immune response by preventing apoptosis of monoblastoid cells; this effect might have important consequences in the clinical use of steroid receptor drugs.	Univ Milan, Mol Pharmacol Lab, I-20133 Milan, Italy; Univ Pavia, Dept Biol Anim, I-27100 Pavia, Italy; Univ Pavia, CNR, Ctr Study Histochem, I-27100 Pavia, Italy	University of Milan; University of Pavia; Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Maggi, A (corresponding author), Inst Pharmacol Sci, MPL, Via Balzaretti 9, I-20133 Milan, Italy.		Pellicciari, Carlo/Q-1481-2016	Pellicciari, Carlo/0000-0001-7684-0469; Maggi, Adriana/0000-0001-5700-5273	Telethon [E.0600] Funding Source: Medline	Telethon(Fondazione Telethon)		Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; BENHUR H, 1995, AM J REPROD IMMUNOL, V34, P363, DOI 10.1111/j.1600-0897.1995.tb00965.x; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43, DOI 10.1111/j.1600-0897.1994.tb00877.x; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; CUTOLO M, 1995, CLIN EXP RHEUMATOL, V13, P217; DE M, 1990, J ENDOCRINOL, V126, P417, DOI 10.1677/joe.0.1260417; Deshpande R, 1997, AM J REPROD IMMUNOL, V38, P46; FOX HS, 1991, J IMMUNOL, V146, P4362; FRAZIERJESSEN MR, 1995, J IMMUNOL, V154, P1838; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Garnier M, 1997, J NEUROSCI, V17, P4591; GIRASOLE G, 1994, J CLIN INVEST, V95, P2886; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Hayashi T, 1998, J CARDIOVASC PHARM, V31, P292, DOI 10.1097/00005344-199802000-00016; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; HORWITZ KB, J STEROID BIOCH MOL, V53, P509; HU SK, 1988, INT J IMMUNOPHARMACO, V10, P247; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Legdeur MCJC, 1996, EXP HEMATOL, V24, P1530; LYNCH EA, 1994, J IMMUNOL, V153, P300; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; Marbaix E, 1996, P NATL ACAD SCI USA, V93, P9120, DOI 10.1073/pnas.93.17.9120; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815; Miller L, 1996, LIFE SCI, V59, P1, DOI 10.1016/0024-3205(96)00122-1; Miller L, 1996, J LEUKOCYTE BIOL, V59, P442, DOI 10.1002/jlb.59.3.442; Mitchinson MJ, 1996, CURR OPIN LIPIDOL, V7, P324, DOI 10.1097/00041433-199610000-00011; MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nathan L, 1997, ANNU REV PHARMACOL, V37, P477, DOI 10.1146/annurev.pharmtox.37.1.477; Olsen NJ, 1996, ENDOCR REV, V17, P369, DOI 10.1210/edrv-17-4-369; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POLAN ML, 1989, J CLIN ENDOCR METAB, V69, P1200, DOI 10.1210/jcem-69-6-1200; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; RICHER JK, 1998, P 80 ANN M END SOC; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; SHANKER G, 1995, LIFE SCI, V56, P499, DOI 10.1016/0024-3205(94)00479-C; SHANKER G, 1994, LYMPHOKINE CYTOK RES, V13, P377; Spyridopoulos I, 1997, CIRCULATION, V95, P1505; Thatte U, 1997, DRUGS, V54, P511, DOI 10.2165/00003495-199754040-00002; VANDELOOSDRECHT AA, 1993, EXP HEMATOL, V21, P461; Vegeto E, 1996, VITAM HORM, V52, P99, DOI 10.1016/S0083-6729(08)60408-2; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3	46	102	108	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					793	803		10.1096/fasebj.13.8.793	http://dx.doi.org/10.1096/fasebj.13.8.793			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224223				2022-12-28	WOS:000080372500003
J	Luo, J; Jankowski, J; Knobloch, M; Van der Giet, M; Gardanis, K; Russ, T; Vahlensieck, U; Neumann, J; Schmitz, W; Tepel, M; Deng, MC; Zidek, W; Schluter, H				Luo, J; Jankowski, J; Knobloch, M; Van der Giet, M; Gardanis, K; Russ, T; Vahlensieck, U; Neumann, J; Schmitz, W; Tepel, M; Deng, MC; Zidek, W; Schluter, H			Identification and characterization of diadenosine 5 ',5 '''-P-1,P-2-diphosphate and diadenosine 5 ',5 '''-P-1,P-3-triphosphate in human myocardial tissue	FASEB JOURNAL			English	Article						diadenosine polyphosphates; cardiac-specific granules; vasoactivity; force contraction; L-type calcium current	INDUCED INHIBITION; HUMAN-PLATELETS; INDUCED RELEASE; NITRIC-OXIDE; RAT; POLYPHOSPHATES; 5',5'''-P1,P4-TETRAPHOSPHATE; TETRAPHOSPHATE; RECEPTOR; HEXAPHOSPHATE	We examined whether human cardiac tissue contains diadenosine polyphosphates and investigated their physiological role. Extracts from human cardiac tissue from transplant recipients were fractionated by size exclusion-, affinity-, anion exchange- and reversed-phase chromatography. MALDI-MS analysis of two absorbing fractions revealed molecular masses of 676.2 Da and 756.0 Da. The UV spectra of both fractions were identical to that of adenosine. Postsource decay MALDI mass spectrometry indicated that the molecules with a mass of 676.2 Da and 757.0 Da contained AMP and ATP, respectively. As shown by enzymatic cleavage, both molecules consist of two adenosines interconnected by either two or three phosphates in 5'-positions of the riboses. Two substances can be identified as 5',5'''-P-1,P-2-diphosphate (Ap(2)A) and 5',5'''-P-1,P-3-triphosphate (Ap(3)A). Ap(2)A and Ap(3)A, together with ATP and ADP, are stored in myocardial-specific granules in biologically active concentrations. In the isolated perfused rat heart, Ap(2)A and Ap(3)A caused dose-dependent coronary vasodilations. In myocardial preparations, Ap(2)A and Ap(3)A attenuated the effect of isoproterenol, exerting a negative inotropic effect. The calcium current of guinea pig ventricular myocytes, stimulated by isoproterenol, was also attenuated by Ap(2)A and Ap(3)A. The presence of Ap(2)A and Ap(3)A in cardiac-specific granules and the actions of these substances on the myocardium and coronary vessels indicate a role for these substances as endogenous modulators of myocardial functions and coronary perfusion.	Ruhr Univ Bochum, Marien Hosp, Med Klin 1, Univ Klin, D-44625 Herne, Germany; Goethe Univ Frankfurt, Inst Analyt Chem, Frankfurt, Germany; Univ Munster, Inst Pharmakol & Toxikol, Munster, Germany; Univ Munster, Klin & Poliklin Thorax Herz Gefasschirurg, D-4400 Munster, Germany; Univ Munster, Inst Pharmaceut Chem, D-4400 Munster, Germany	Ruhr University Bochum; St. Marien Hospital; University of Munster; University of Munster; University of Munster	Schluter, H (corresponding author), Ruhr Univ Bochum, Marien Hosp, Med Klin 1, Univ Klin, Holkeskampring 40, D-44625 Herne, Germany.	Hartmut.Schlueter@ruhr-uni-bochum.de	Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; Luo, Jiankai/0000-0001-5169-3095; Tepel, Martin/0000-0002-0086-0997				BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBOLD AJ, 1973, CARDIOVASC RES, V7, P351; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; Garrison PN, 1992, AP4A OTHER DINUCLEOS, P29; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; HILDERMAN RH, 1991, J BIOL CHEM, V266, P6915; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; Hoyle CHV, 1996, BRIT J PHARMACOL, V118, P1294, DOI 10.1111/j.1476-5381.1996.tb15536.x; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Jovanovic A, 1996, PFLUG ARCH EUR J PHY, V431, P800, DOI 10.1007/BF02253848; Jovanovic A, 1998, FEBS LETT, V423, P314, DOI 10.1016/S0014-5793(98)00114-8; Jovanovic A, 1996, BRIT J PHARMACOL, V117, P233, DOI 10.1111/j.1476-5381.1996.tb15180.x; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; MAN RYK, 1990, J LIPID MEDIATOR, V2, P75; NORDHOFF E, 1992, RAPID COMMUN MASS SP, V6, P771, DOI 10.1002/rcm.1290061212; OGILVIE A, 1992, AP4A OTHER DINUCLEOS, P229; PINTOR J, 1992, NEUROSCI LETT, V136, P141, DOI 10.1016/0304-3940(92)90034-5; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1995, J NEUROCHEM, V64, P670; PLATEAU P, 1992, AP4A OTHER DINUCLEOS, P63; Ralevic V, 1996, BRIT J PHARMACOL, V118, P428, DOI 10.1111/j.1476-5381.1996.tb15420.x; RALEVIC V, 1995, J PHYSIOL-LONDON, V483, P703, DOI 10.1113/jphysiol.1995.sp020615; ROTILAN P, 1991, FEBS LETT, V280, P371, DOI 10.1016/0014-5793(91)80334-Y; Rubino A, 1996, J PHYSIOL-LONDON, V495, P515, DOI 10.1113/jphysiol.1996.sp021611; Schluter H, 1996, J AUTON PHARMACOL, V16, P357, DOI 10.1111/j.1474-8673.1996.tb00053.x; Schluter H, 1998, J CLIN INVEST, V101, P682, DOI 10.1172/JCI119882; SCHLUTER H, 1993, J CHROMATOGR, V639, P17, DOI 10.1016/0021-9673(93)83083-5; STELLA L, 1995, J CARDIOVASC PHARM, V25, P1001, DOI 10.1097/00005344-199506000-00021; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; Vahlensieck U, 1996, BRIT J PHARMACOL, V119, P835, DOI 10.1111/j.1476-5381.1996.tb15748.x; vanderGiet M, 1997, BRIT J PHARMACOL, V120, P1453, DOI 10.1038/sj.bjp.0701074; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; VIALS A, 1993, BRIT J PHARMACOL, V109, P424, DOI 10.1111/j.1476-5381.1993.tb13586.x; Zamecnik P. C., 1968, REGULATORY MECHANISM, P3; ZIMMERMANN H, 1993, J PHYSIOLOGY-PARIS, V87, P159, DOI 10.1016/0928-4257(93)90027-Q	37	46	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					695	705		10.1096/fasebj.13.6.695	http://dx.doi.org/10.1096/fasebj.13.6.695			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094930				2022-12-28	WOS:000079527200011
J	Meilhac, O; Escargueil-Blanc, I; Thiers, JC; Salvayre, R; Negre-Salvayre, A				Meilhac, O; Escargueil-Blanc, I; Thiers, JC; Salvayre, R; Negre-Salvayre, A			Bcl-2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins	FASEB JOURNAL			English	Article						oxidized LDL; atherosclerosis; DNA ladder; cytosolic calcium concentration; antisense oligonucleotides	HUMAN-ENDOTHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; ATHEROSCLEROTIC PLAQUES; DNA FRAGMENTATION; LIPID PEROXIDES; CYTOCHROME-C; CALCIUM; PATHWAY; LDL	Oxidized low density lipoproteins (oxLDL) participate in atherosclerosis plaque formation, rupture, and subsequent thrombosis. Because oxLDL are toxic to cultured cells and Bcl-2 protein prevents apoptosis, the present work aimed to study whether Bcl-2 may counterbalance the toxicity of oxLDL, Two experimental model systems were used in which Bcl-2 levels were modulated: 1) lymphocytes in which the (high) basal level of Bcl-2 was reduced by antisense oligonucleotides; 2) HL60 and HL60/B (transduced by Bcl-2) expressing low and high Bcl-2 levels, respectively. In cells expressing relatively high Bcl-2 levels (lymphocytes and HL60/B), oxLDL induced mainly primary necrosis, In cells expressing low Bcl-2 levels (antisense-treated lymphocytes, HL60 and ECV-304 endothelial cells), the rate of oxLDL-induced apoptosis was higher than that of primary necrosis. OxLDL evoked a sustained calcium rise, which is a common trigger to necrosis and apoptosis since both types of cell death were blocked by the calcium chelator EGTA, Conversely, a sustained calcium influx elicited by the calcium ionophore A23187 induced necrosis in cells expressing high Bcl-2 levels and apoptosis in cells expressing low Bcl-2 levels. This suggests that Bcl-2 acts downstream from the calcium peak and inhibits only the apoptotic pathway, not the necrosis pathway, thus explaining the apparent shift from oxLDL-induced apoptosis toward necrosis when Bcl-2 is overexpressed.	CHU Rangueil, Biochim Lab, INSERM, U466, F-31403 Toulouse 4, France; CHU Rangueil, Dept Biochem & Mol Biol, F-31403 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Negre-Salvayre, A (corresponding author), CHU Rangueil, Biochim Lab, INSERM, U466, 1 Ave Jean Poulhes,IFR-31, F-31403 Toulouse 4, France.		Meilhac, Olivier/N-4385-2017	Meilhac, Olivier/0000-0002-3740-7539; Negre-Salvayre, Anne/0000-0003-2136-5706				ARENDS MJ, 1990, AM J PATHOL, V136, P593; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; Caspar-Bauguil S, 1998, BIOCHEM J, V330, P659, DOI 10.1042/bj3300659; CATHCART MK, 1989, J IMMUNOL, V142, P1963; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Crisby M, 1997, ATHEROSCLEROSIS, V130, P17, DOI 10.1016/S0021-9150(96)06037-6; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; Dimmeler S, 1997, CIRCULATION, V95, P1760; Dong Z, 1997, AM J PATHOL, V151, P1205; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; FARBER JL, 1990, CHEM RES TOXICOL, V3, P503, DOI 10.1021/tx00018a003; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Harada K, 1997, FEBS LETT, V411, P63, DOI 10.1016/S0014-5793(97)00662-5; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P361, DOI 10.3109/00365517909106120; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P52; ROSS RC, 1993, NATURE, V302, P801; Sambrook J., 1989, MOL CLONING LAB MANU; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; Via D P, 1986, Methods Enzymol, V129, P848; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; WYLLIE AH, 1991, CELL DEATH BIOL PATH, P9; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	54	77	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					485	494		10.1096/fasebj.13.3.485	http://dx.doi.org/10.1096/fasebj.13.3.485			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064615				2022-12-28	WOS:000079016000008
J	Hammel, HT				Hammel, HT			Evolving ideas about osmosis and capillary fluid exchange	FASEB JOURNAL			English	Editorial Material						capillary-interstitial fluid exchange; Hulett's theory; Starling's hypothesis; Starlings's equation	AQUEOUS-SOLUTIONS; WATER; PRESSURE; PLANTS	When a solute is dissolved in water at (T, p(e)(1)), the temperature and external pressure applied to the solution, the water in the solution is altered as is pure Liquid water at (T, p(e)(1) - pi(H2O)(1)). The liquid water and the water in the solution are in equilibrium when pi(H2O)(1) is the osmotic pressure of the water in the solution. Every partial molar property of the water in the solution at (T, p(e)(1)), including its vapor pressure, chemical potential, volume, internal energy, enthalpy and entropy, is identical with the same molar property of pure liquid water at (T, p(e)(1) - pi(H2O)(1)) This elementary fact was deduced by Hulett in 1903 from a thought experiment; he concluded that the internal tension in the force bonding the water is the same in both solution and pure Liquid water, in equilibrium, at these differing applied pressures. Hulett's understanding of osmosis and the means by which the water was altered by the solute were neglected and abandoned. Competing ideas included the notions that the solute attracts the water into the solution and that the solute lowers the activity (or concentration) of the water in the solution. These ideas imply that the solute acts on the solvent at the semipermeable membrane separating the solution and water. Hulett's theory of osmosis requires that the solute alter the water at the free surface of the solution where the solute exerts an internal pressure on the boundary of the solution retaining the solute. Fluid exchange across the capillary endothelium is influenced, in part, by colloidal proteins in the plasma. The role of the proteins in capillary fluid exchange must be reinterpreted based on Hulett's view, the only valid view of osmosis.	Indiana Univ, Sch Med, Med Sci Program, Dept Physiol & Biophys, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Hammel, HT (corresponding author), Indiana Univ, Sch Med, Med Sci Program, Dept Physiol & Biophys, Jordan Hall, Bloomington, IN 47405 USA.	hhammel@indiana.edu						BALLING A, 1990, PLANTA, V182, P325, DOI 10.1007/BF02411382; CANNY MJ, 1995, ANN BOT-LONDON, V75, P343, DOI 10.1006/anbo.1995.1032; Dill DB, 1937, J BIOL CHEM, V118, P635; Dixon H.H., 1914, TRANSPIRATION ASCENT; DIXON HH, 1903, ROY DUBL SOC SCI, V10, P114; DUCLAUX J, 1965, J CHIM PHYS, V62, P435, DOI 10.1051/jcp/1965620435; DUTROCHET H, 1837, MEMOIRES VEGETAUX AN, V1; FERMI E, 1956, THERMODYANMICS, P122; GUYTON A, 1991, TXB MED PHYSL, P49; HAMMEL HT, 1995, AM J PHYSIOL-HEART C, V268, pH2133, DOI 10.1152/ajpheart.1995.268.5.H2133; HAMMEL HT, 1991, PHYS CHEM LIQ, V23, P69, DOI 10.1080/00319109108030636; HAMMEL HT, 1994, J PHYS CHEM-US, V98, P4196, DOI 10.1021/j100066a046; HAMMEL HT, 1973, P NATL ACAD SCI USA, V70, P124, DOI 10.1073/pnas.70.1.124; Hammel HT, 1998, RRD PHYS CHEM, V2, P77; HAMMEL HT, 1979, AM J PHYSIOL, V237, pR95, DOI 10.1152/ajpregu.1979.237.3.R95; HAMMEL HT, 1995, J PHYS CHEM-US, V99, P8392, DOI 10.1021/j100020a077; HAMMEL HT, 1976, OSMOSIS TENSILE SOLV; HAMMEL HT, 1967, INTERACTIONS ENG BIO, P6; HARGENS AR, 1972, SCIENCE, V176, P184, DOI 10.1126/science.176.4031.184; HARGENS AR, 1971, THESIS U CALIFORNIA; Herzfeld KF, 1937, PHYS Z, V38, P58; Hulett GA, 1902, Z PHYS CHEM-STOCH VE, V42, P353; KROGH A, 1959, ANATOMY PHYSL CAPILL, P280; LANDIS EM, 1963, HDB PHYSL 2, V2, P985; Lewis GN, 1908, J AM CHEM SOC, V30, P668, DOI 10.1021/ja01947a002; Lewis GN, 1901, P AM ACAD ARTS SCI, V37, P47; MILLIMAN JD, 1973, BIOL GEOLOGY CORAL R, V1, P1; MYSELS KJ, 1978, J CHEM EDUC, V55, P21, DOI 10.1021/ed055p21; MYSELS KJ, 1959, INTRO COLLOID CHEM; Noyes AA, 1900, Z PHYS CHEM-STOCH VE, V35, P707; RENKIN EM, 1986, AM J PHYSIOL, V250, pH706, DOI 10.1152/ajpheart.1986.250.5.H706; RENNER O, 1911, FLORA, V103, P171; SCHMIDTNIELSEN B, 1995, A M KROGH LIVES SCI; SCHMIDTNIELSEN K, 1997, ANIMAL PHYSL ADAPTAT, P112; SCHOLANDER PF, 1965, SCIENCE, V148, P339, DOI 10.1126/science.148.3668.339; SCHOLANDER PF, 1968, PHYSIOL PLANTARUM, V21, P251, DOI 10.1111/j.1399-3054.1968.tb07248.x; Starling E H, 1896, J Physiol, V19, P312; ZIMMERMANN U, 1993, PHILOS T R SOC B, V341, P19, DOI 10.1098/rstb.1993.0087	38	10	10	0	43	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					213	231		10.1096/fasebj.13.2.213	http://dx.doi.org/10.1096/fasebj.13.2.213			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973310	Bronze			2022-12-28	WOS:000078615200002
J	Del Bello, B; Paolicchi, A; Comporti, M; Pompella, A; Maellaro, E				Del Bello, B; Paolicchi, A; Comporti, M; Pompella, A; Maellaro, E			Hydrogen peroxide produced during gamma-glutamyl transpeptidase activity is involved in prevention of apoptosis and maintenance of proliferation in U937 cells	FASEB JOURNAL			English	Article						oxidative reactions; acivicin; PARP cleavage; poly(ADP-ribose) polymerase	LIPID-PEROXIDATION; OXIDATIVE STRESS; RAT-LIVER; POLY(ADP-RIBOSE) POLYMERASE; TRANSFERASE TRANSPEPTIDASE; PRENEOPLASTIC LESIONS; ADP-RIBOSYLATION; MAMMALIAN-CELLS; GLUTATHIONE; DEATH	It has been reported in several cell lines that exposure to low levels of reactive oxygen species can exert a stimulatory effect on their proliferation. We have previously shown that mild oxidative conditions can also counteract apoptotic stimuli. A constitutive cellular production of low levels of superoxide and hydrogen peroxide originates from various sources; among these, gamma-glutamyl transpeptidase (GGT), the plasma membrane-bound activity in charge of metabolizing extracellular reduced glutathione, has recently been included. Since the inhibition of GGT is a sufficient stimulus for the induction of apoptosis in selected cell lines, we investigated whether this effect might result from the suppression of the mentioned GGT-dependent prooxidant reactions, on the theory that the latter may represent a basal antiapoptotic and proliferative signal for the cell. Experiments showed that: 1) GGT activity in U937 monoblastoid cells is associated with the]production of low levels of hydrogen peroxide, and two independent GGT inhibitors cause a dose-dependent decrease of such GGT-dependent production of H2O2; 2) GGT inhibition with acivicin results in cell growth arrest, and induces cell. death and DNA fragmentation with the ladder appearance of apoptosis; 3) treatment of cells with catalase-and even more with Trolox C-is able to decrease their proliferative rate; 4) GGT inhibition (with suppression of H2O2 production) results in a down-regulation of poly(ADP-ribose) polimerase (PARP) activity, which precedes the proteolytic cleavage of PARP molecule, such as that typically induced by caspases. The reported data suggest that the low H2O2 levels originating as a by-product during GGT activity are able to act as sort of a 'life signal' in U937 cells, insofar as they can maintain cell, proliferation and protect against apoptosis, possibly through an up-regulation of PARP activity.	Univ Siena, Sch Med, Inst Gen Pathol, I-53100 Siena, Italy; Univ Pisa, Sch Med, Dept Expt Biomed, I-56100 Pisa, Italy	University of Siena; University of Pisa	Pompella, A (corresponding author), Univ Siena, Sch Med, Inst Gen Pathol, Via Aldo Moro, I-53100 Siena, Italy.		Pompella, Alfonso/G-6785-2012; Paolicchi, Aldo/K-3946-2018	Pompella, Alfonso/0000-0002-6435-9325; Paolicchi, Aldo/0000-0002-9940-8481				ALTHAUS FR, 1982, NATURE, V300, P366, DOI 10.1038/300366a0; BERGER NA, 1979, BIOCHIM BIOPHYS ACTA, V564, P90, DOI 10.1016/0005-2787(79)90191-6; Briehl M M, 1995, Cell Death Differ, V2, P41; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; BURDON RH, 1992, P ROY SOC EDINB B, V99, P169, DOI 10.1017/S0269727000013129; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHABERT MG, 1993, INT J CANCER, V53, P837, DOI 10.1002/ijc.2910530522; Chateau MT, 1996, FEMS IMMUNOL MED MIC, V13, P19, DOI 10.1016/0928-8244(95)00076-3; CHIBELLI L, 1998, FASEB J, V12, P479; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; GAAL JC, 1985, BIOCHEM J, V230, P1; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GOTOH N, 1994, METHOD ENZYMOL, V233, P154; GRABER R, 1995, INT J CANCER, V62, P443, DOI 10.1002/ijc.2910620414; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GRIFFITHS M, 1993, INT J BIOCHEM, V25, P1749, DOI 10.1016/0020-711X(88)90303-5; GRISK O, 1993, BIOL CHEM H-S, V374, P287, DOI 10.1515/bchm3.1993.374.1-6.287; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HANIGAN MH, 1994, CANCER RES, V54, P286; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; LEHMANN AR, 1974, EXP CELL RES, V83, P63, DOI 10.1016/0014-4827(74)90688-0; Liu M, 1998, CANCER RES, V58, P1723; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu SC, 1996, J CLIN INVEST, V97, P1488, DOI 10.1172/JCI118571; Maellaro E, 1996, EXP CELL RES, V226, P105, DOI 10.1006/excr.1996.0208; MENEGAZZI M, 1990, ARCH BIOCHEM BIOPHYS, V279, P232, DOI 10.1016/0003-9861(90)90486-I; MEREDITH MJ, 1986, J BIOL CHEM, V261, P4986; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; NELL GL, 1979, CANCER RES, V39, P852; OCHI T, 1993, ARCH TOXICOL, V67, P401, DOI 10.1007/BF01977401; Paolicchi A, 1997, FREE RADICAL BIO MED, V22, P853, DOI 10.1016/S0891-5849(96)00422-4; Pompella A, 1996, HISTOCHEM CELL BIOL, V106, P275, DOI 10.1007/s004180050043; Sies H., 1985, OXIDATIVE STRESS, V1; Slater AFG, 1995, TOXICOL LETT, V82-3, P149, DOI 10.1016/0378-4274(95)03474-9; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH TK, 1995, P NATL ACAD SCI USA, V92, P2360, DOI 10.1073/pnas.92.6.2360; SPEAR N, 1994, ARCH BIOCHEM BIOPHYS, V312, P198, DOI 10.1006/abbi.1994.1299; STARK AA, 1994, CARCINOGENESIS, V15, P343, DOI 10.1093/carcin/15.2.343; STARK AA, 1989, MUTAT RES, V224, P89, DOI 10.1016/0165-1218(89)90007-4; STARK AA, 1994, MUTAT RES, V308, P215, DOI 10.1016/0027-5107(94)90156-2; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TATE SS, 1985, METHOD ENZYMOL, V113, P400; Tew KD, 1996, MOL PHARMACOL, V50, P149; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WARREN BS, 1993, P SOC EXP BIOL MED, V202, P9; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176	54	148	149	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					69	79						11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872931				2022-12-28	WOS:000078029500008
J	Sukharev, S				Sukharev, S			Mechanosensitive channels in bacteria as membrane tension reporters	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	ion channel; membrane stretch; gating; subunit structure	ESCHERICHIA-COLI; ION-CHANNEL; HAIR-CELLS; K+ CHANNEL; MSCL; PROTEIN; TRANSDUCTION; STABILITY; PRESSURE; TOPOLOGY	The purpose of this short review is to discuss recent data on the molecular structure and mechanism of gating of MscL, a mechanosensitive channel of large conductance from Escherichia coli, MscL is the first isolated molecule shown to convert mechanical stress of the membrane into a simple response, the opening of a large aqueous pore. The functional complex appears to be a stable homopentamer of 15-kDa subunits, the gating transitions in which are driven by stretch forces conveyed through the lipid bilayer, We have measured the open probability of MscL and the kinetics of transitions as a function of membrane tension, The parameters extracted from the single-channel current recordings and dose-response curves such as the energy difference between the closed, open, and intermediate conducting states, and the transition-related changes in protein dimensions suggest a large conformational rearrangement of the channel complex. The estimations show that in native conditions MscL openings could be driven primarily by forces of osmotic nature. The thermodynamic and spatial parameters reasonably correlate with the available data on the structure of a single MscL subunit and multimeric organization of the complex. Combined with the functional analysis of mutations, these data give grounds to hypotheses on the nature of the channel mechanosensitivity.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Sukharev, S (corresponding author), Univ Maryland, Dept Biol, Bldg 144, College Pk, MD 20742 USA.	ss311@umail.umd.edu		Sukharev, Sergei/0000-0002-4807-9665				Ajouz B, 1998, J BIOL CHEM, V273, P26670, DOI 10.1074/jbc.273.41.26670; Ajouz B, 1998, BIOPHYS J, V74, pA238; Arkin IT, 1998, BBA-BIOMEMBRANES, V1369, P131, DOI 10.1016/S0005-2736(97)00219-8; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; DENK W, 1992, HEARING RES, V60, P89, DOI 10.1016/0378-5955(92)90062-R; Hamill OP, 1996, PHARMACOL REV, V48, P231; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; Hase Claudia C., 1996, Biophysical Journal, V70, pA346; HILLE B, 1992, IONIC CHANNELS EXCIT, P296; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; Le Dain AC, 1998, J BIOL CHEM, V273, P12116, DOI 10.1074/jbc.273.20.12116; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; OPSAHL LR, 1994, BIOPHYS J, V66, P71, DOI 10.1016/S0006-3495(94)80751-9; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Sachs F, 1998, REV PHYSIOL BIOCH P, V132, P1, DOI 10.1007/BFb0004985; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Saint N, 1998, J BIOL CHEM, V273, P14667, DOI 10.1074/jbc.273.24.14667; SOKABE M, 1990, J CELL BIOL, V111, P599, DOI 10.1083/jcb.111.2.599; Sukharev S. I., 1995, Biophysical Journal, V68, pA132; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUKHAREV SI, 1999, IN PRESS J GEN PHYSL; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V	37	39	40	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S55	S61						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352145				2022-12-28	WOS:000080403800007
J	Jensen-Jarolim, E; Leitner, A; Kalchhauser, H; Zurcher, A; Ganglberger, E; Bohle, B; Scheiner, O; Boltz-Nitulescu, G; Breiteneder, H				Jensen-Jarolim, E; Leitner, A; Kalchhauser, H; Zurcher, A; Ganglberger, E; Bohle, B; Scheiner, O; Boltz-Nitulescu, G; Breiteneder, H			Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice	FASEB JOURNAL			English	Article						Bet v 1; allergy; phage; mimotope; oral immunization; monoclonal antibodies	DISCONTINUOUS EPITOPES; MONOCLONAL-ANTIBODIES; AFFINITY PURIFICATION; FILAMENTOUS PHAGE; LIBRARY; BET-V-1; LIGANDS; INDIVIDUALS; EXPRESSION; SELECTION	The major birch pollen allergen Bet v 1 is one of the most extensively characterized allergens both on the molecular and the immunological level. To define conformational B cell epitopes on Bet v 1, we screened filamentous phage libraries expressing circular or linear nonapeptides to select-ligands specific for anti-Bet v 1 murine monoclonal antibodies BIP1 and BIP4. The deduced amino acid sequence of the BIP1 ligand was CFPYCYPSESA, and of the BIP4-ligand, CRQTRTMPGC. Both sequences derived from the circular phage library. Alignments to the sequence of Bet v 1 showed no similarities, indicating that the antibodies most likely recognize discontinuous epitopes. Phages displaying these mimotopes were capable of inhibiting interactions of the anti-Bet v 1 monoclonals with Bet v 1 in a dose-dependent manner in ELISA. In contrast, sequence-identical synthetic peptides were ineffective in blocking the antibody-allergen interactions. This is in agreement with the conformational inhomogeneity of the peptides in solution as observed by nuclear magnetic resonance spectroscopy. Intragastric administration of phages expressing the BIP1 mimotope induced a Bet v 1-specific IgG response in Balb/c mice. We conclude that peptide mimotopes, when displayed on phages, may induce a protective IgG response preventing IgE-mediated allergic reactions, suggesting a possible clinical application.	Univ Vienna, Dept Gen & Expt Pathol, AKH, A-1090 Vienna, Austria; Univ Vienna, Dept Organ Chem, A-1010 Vienna, Austria; Univ Bern, Inst Immunol & Allergol, CH-3012 Bern, Switzerland	University of Vienna; University of Vienna; University of Bern	Jensen-Jarolim, E (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, AKH, EBO-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Bohle, Barbara/0000-0002-5105-7985				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Delmastro P, 1997, VACCINE, V15, P1276, DOI 10.1016/S0264-410X(97)00072-8; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GOVIL G, 1982, CONFORMATION BIOL MO; HAMBURGER RN, 1975, SCIENCE, V189, P389, DOI 10.1126/science.1145208; HAMBURGER RN, 1989, PROGR ALLERGY CLIN I, V1, P109; HASLINGER E, 1984, MONATSH CHEM, V115, P779, DOI 10.1007/BF01120974; Helm BA, 1997, ALLERGY, V52, P1155, DOI 10.1111/j.1398-9995.1997.tb02518.x; Hurd R. E., 1996, ENCY NMR, V3, P1990; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MEOLA A, 1995, J IMMUNOL, V154, P3162; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAULI G, 1992, ACI NEWS, V4, P43; ROHAC M, 1991, MOL IMMUNOL, V28, P879; Schafer T, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04864.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STANWORTH DR, 1991, LANCET, V337, P1608; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1998, IN PRESS INT ARCH AL; Weiss C, 1996, INT ARCH ALLERGY IMM, V110, P282, DOI 10.1159/000237300; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	36	64	76	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1635	1642		10.1096/fasebj.12.15.1635	http://dx.doi.org/10.1096/fasebj.12.15.1635			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837853				2022-12-28	WOS:000077574500005
J	Patel, N; Padera, R; Sanders, GHW; Cannizzaro, SM; Davies, MC; Langer, R; Roberts, CJ; Tendler, SJB; Williams, PM; Shakesheff, KM				Patel, N; Padera, R; Sanders, GHW; Cannizzaro, SM; Davies, MC; Langer, R; Roberts, CJ; Tendler, SJB; Williams, PM; Shakesheff, KM			Spatially controlled cell engineering on biodegradable polymer surfaces	FASEB JOURNAL			English	Article						tissue engineering; neurite extension; integrins; patterning	PERIPHERAL-NERVE REGENERATION; SELF-ASSEMBLED MONOLAYERS; RECOGNITION SEQUENCES; AXONAL REGENERATION; SIGNAL-TRANSDUCTION; LIGAND-BINDING; ADHESION; ATTACHMENT; NETWORKS; RGD	Controlling receptor-mediated interactions between cells and template surfaces is a central principle in many tissue engineering procedures (1-3). Biomaterial surfaces engineered to present cell adhesion ligands undergo integrin-mediated molecular interactions with cells (1, 4, 5), stimulating cell spreading, and differentiation (6-8). This provides a mechanism for mimicking natural cell-to-matrix interactions. Further sophistication in the control of cell interactions can be achieved by fabricating surfaces on which the spatial distribution of ligands is restricted to micron-scale pattern features (9-14). Patterning technology promises to facilitate spatially controlled tissue engineering with applications in the regeneration of highly organized tissues. These new applications require the formation of ligand patterns on biocompatible and biodegradable templates, which control tissue regeneration processes, before removal by metabolism. We have developed a method of generating micron-scale patterns of any biotinylated ligand on the surface of a biodegradable block copolymer, polylactide-poly(ethylene glycol). The technique achieves control of biomolecule deposition with nanometer precision. Spatial control over cell development has been observed when using these templates to culture bovine aortic endothelial cells and PC12 nerve cells. Furthermore, neurite extension on the biodegradable polymer surface is: directed by pattern features composed of peptides containing the IKVAV sequence (15, 16), suggesting that directional control over nerve regeneration on biodegradable biomaterials can be achieved.	Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	University of Nottingham; Massachusetts Institute of Technology (MIT)	Shakesheff, KM (corresponding author), Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England.	kevin.shakesheff@nottingham.ac.uk	Roberts, Clive J/C-6970-2009; Williams, Philip M/C-6947-2009; Shakesheff, Kevin/AAR-6603-2021; Shakesheff, Kevin/O-6371-2018	Roberts, Clive J/0000-0001-9443-3445; Williams, Philip M/0000-0002-1822-2133; Davies, Martyn/0000-0001-7695-0596; Shakesheff, Kevin/0000-0003-3236-2439				BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; Brecknell JE, 1996, BIOL REV, V71, P227, DOI 10.1111/j.1469-185X.1996.tb00748.x; CANNIZZARO SM, 1998, IN PRESS BIOTECHNOL; Cao YL, 1997, PLAST RECONSTR SURG, V100, P297, DOI 10.1097/00006534-199708000-00001; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CIMA LG, 1993, CHEM ENG PROG    JUN, P46; Cook AD, 1997, J BIOMED MATER RES, V35, P513; Decherchi P, 1996, BRAIN RES, V726, P181, DOI 10.1016/0006-8993(96)00331-9; Delamarche E, 1997, ADV MATER, V9, P741, DOI 10.1002/adma.19970090914; DEROSE JA, 1991, SURF SCI, V256, P102, DOI 10.1016/0039-6028(91)91204-B; DRUMHELLER PD, 1994, ANAL BIOCHEM, V222, P380, DOI 10.1006/abio.1994.1506; EVANS PJ, 1994, PROG NEUROBIOL, V43, P187, DOI 10.1016/0301-0082(94)90001-9; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Han DK, 1996, MACROMOLECULES, V29, P5233, DOI 10.1021/ma9601070; HICKMAN JJ, 1994, J VAC SCI TECHNOL A, V12, P607, DOI 10.1116/1.578844; HO SP, 1994, ADV MATER, V6, P130, DOI 10.1002/adma.19940060205; HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; Ide C, 1996, NEUROSCI RES, V25, P101; KIM E, 1995, NATURE, V376, P581, DOI 10.1038/376581a0; KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030; LANGER R, 1995, ANN BIOMED ENG, V23, P101, DOI 10.1007/BF02368317; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Larue L, 1996, DEVELOPMENT, V122, P3185; LEE JS, 1993, BIOMATERIALS, V14, P958, DOI 10.1016/0142-9612(93)90139-S; Lhoest JB, 1996, J BIOMAT SCI-POLYM E, V7, P1039, DOI 10.1163/156856296X00534; Li SM, 1996, MACROMOLECULES, V29, P57, DOI 10.1021/ma950531l; Lopina ST, 1996, BIOMATERIALS, V17, P559, DOI 10.1016/0142-9612(96)88706-0; MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Minuth WW, 1998, CELL TISSUE RES, V291, P1; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775; Nicholls J, 1996, TRENDS NEUROSCI, V19, P229, DOI 10.1016/0166-2236(96)10021-7; OCHI M, 1994, EXP NEUROL, V128, P216, DOI 10.1006/exnr.1994.1130; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; POLLOCK M, 1995, CURR OPIN NEUROL, V8, P354, DOI 10.1097/00019052-199510000-00005; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; RANIERI JP, 1994, INT J DEV NEUROSCI, V12, P725, DOI 10.1016/0736-5748(94)90052-3; RANIERI JP, 1995, J BIOMED MATER RES, V29, P779, DOI 10.1002/jbm.820290614; Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<617::AID-JMR310>3.0.CO;2-D; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHIBUYA Y, 1995, NEUROSCIENCE, V67, P253, DOI 10.1016/0306-4522(95)00015-B; SPARGO BJ, 1994, P NATL ACAD SCI USA, V91, P11070, DOI 10.1073/pnas.91.23.11070; Tamayo J, 1996, LANGMUIR, V12, P4430, DOI 10.1021/la960189l; TASKINEN HS, 1995, ACTA NEUROPATHOL, V89, P144; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Zhao XM, 1997, J MATER CHEM, V7, P1069, DOI 10.1039/a700145b; 1996, J VACUUM SCI TECHNOL, V7	51	210	225	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1447	1454		10.1096/fasebj.12.14.1447	http://dx.doi.org/10.1096/fasebj.12.14.1447			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806753				2022-12-28	WOS:000076749500003
J	Black, AF; Berthod, F; L'Heureux, N; Germain, L; Auger, FA				Black, AF; Berthod, F; L'Heureux, N; Germain, L; Auger, FA			In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent	FASEB JOURNAL			English	Article						angiogenesis; endothelial cell; extracellular matrix; inosculation; skin substitute	FIBROBLAST GROWTH-FACTOR; HUMAN-ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VITRO; EXTRACELLULAR-MATRIX; SERUM-FREE; HUMAN KERATINOCYTES; TUBE FORMATION; ATHYMIC MICE; COLLAGEN; INVITRO	For patients with extensive burns, wound coverage with an autologous in vitro reconstructed skin made of both dermis and epidermis should be the best alternative to split-thickness graft. Unfortunately, various obstacles have delayed the widespread use of composite skin substitutes. Insufficient vascularization has been proposed as the most likely reason for their unreliable survival. Our purpose was to develop a vascular-like network inside tissue-engineered skin in order to improve graft vascularization. To reach this aim, we fabricated a collagen biopolymer in which three human cell types-keratinocytes, dermal fibroblasts, and umbilical vein endothelial cells-were cocultured. We demonstrated that the endothelialized skin equivalent (ESE) promoted spontaneous formation of capillary-like structures in a highly differentiated extracellular matrix. Immunohistochemical analysis and transmission electron microscopy of the ESE showed characteristics associated with the microvasculature in vivo (von Willebrand factor, Weibel-Palade bodies, basement membrane material, and intercellular junctions). We have developed the first endothelialized human tissue-engineered skin in which a network of capillary-like tubes is formed. The transplantation of this ESE on human should accelerate graft revascularization by inosculation of its preexisting capillary-like network with the patient's own blood vessels, as it is observed with autografts. In addition, the ESE turns out to be a promising in vitro angiogenesis model.	Univ Laval, Fac Med, Dept Surg, Quebec City, PQ G1S 4L8, Canada; Univ Laval, Ctr Hosp Affilie, Lab Organogenese Expt, Quebec City, PQ G1S 4L8, Canada	Laval University; Laval University	Auger, FA (corresponding author), Univ Lyon 1, Lab Substituts Cutanes, Federat Biochim, Hop Edouard Herriot, Batiment 5,5 Pl Arsonval, F-69437 Lyon 03, France.	Francois.auger@chg.ulaval.ca	; L'Heureux, Nicolas/K-8669-2015	Berthod, Francois/0000-0003-3580-0297; Germain, Lucie/0000-0001-8883-6491; L'Heureux, Nicolas/0000-0001-8602-3948				ARCHAMBAULT M, 1995, J INVEST DERMATOL, V104, P859, DOI 10.1111/1523-1747.ep12607034; AUGER FA, 1995, IN VITRO CELL DEV-AN, V31, P432; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; BELL E, 1983, J INVEST DERMATOL, V81, P2; Berthod F, 1996, J BIOMED MATER RES, V32, P87, DOI 10.1002/(SICI)1097-4636(199609)32:1<87::AID-JBM10>3.0.CO;2-F; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; Berthod F, 1997, BRIT J DERMATOL, V136, P809, DOI 10.1111/j.1365-2133.1997.tb03917.x; Berthod F, 1997, SKIN SUBSTITUTE PROD, P23; BOYCE ST, 1995, J INVEST DERMATOL, V104, P345, DOI 10.1111/1523-1747.ep12665374; CHALUPOWICZ DG, 1995, J CELL BIOL, V130, P207, DOI 10.1083/jcb.130.1.207; COCKERILL GW, 1995, INT REV CYTOL, V159, P113, DOI 10.1016/S0074-7696(08)62106-3; ConradLapostolle V, 1996, CELL BIOL TOXICOL, V12, P189, DOI 10.1007/BF00438144; COOPER ML, 1991, SURGERY, V109, P198; CUONO CB, 1987, PLAST RECONSTR SURG, V80, P626, DOI 10.1097/00006534-198710000-00029; DAMOUR O, 1994, CLIN MATER, V15, P273, DOI 10.1016/0267-6605(94)90057-4; Deroanne CF, 1996, EXP CELL RES, V224, P215, DOI 10.1006/excr.1996.0131; DIAZFLORES L, 1994, HISTOL HISTOPATHOL, V9, P807; Foda HD, 1996, LAB INVEST, V74, P538; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GERMAIN L, 1995, ENCY HDB BIOMATERIAL, V1, P699; GORDON PB, 1983, IN VITRO CELL DEV B, V19, P661; Gupta K, 1997, EXP CELL RES, V230, P244, DOI 10.1006/excr.1996.3421; Hoying JB, 1996, IN VITRO CELL DEV-AN, V32, P409; Hoying JB, 1996, J CELL PHYSIOL, V168, P294, DOI 10.1002/(SICI)1097-4652(199608)168:2<294::AID-JCP8>3.0.CO;2-K; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; KIENY M, 1984, J EXP ZOOL, V232, P327, DOI 10.1002/jez.1402320220; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LATTERA J, 1990, J CELL PHYSL, V144, P204; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MALLERY SR, 1994, CELL TISSUE RES, V279, P37; MARKS M, 1994, J CLIN INVEST, V93, P131; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1993, J CELL SCI, V105, P1013; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; NICOSIA RF, 1990, LAB INVEST, V63, P115; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROUABHIA M, 1993, TRANSPLANTATION, V56, P259, DOI 10.1097/00007890-199308000-00001; Sahuc Florent, 1996, Wound Repair and Regeneration, V4, P93, DOI 10.1046/j.1524-475X.1996.40116.x; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; SHAHABEDDIN L, 1990, Skin Pharmacology, V3, P107; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; VERNON RB, 1995, AM J PATHOL, V147, P873; VILLASCHI S, 1994, LAB INVEST, V71, P291; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005	55	332	351	1	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1331	1340		10.1096/fasebj.12.13.1331	http://dx.doi.org/10.1096/fasebj.12.13.1331			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761776				2022-12-28	WOS:000076402000008
J	Aigner, S; Ramos, CL; Hafezi-Moghadam, A; Lawrence, MB; Friederichs, J; Altevogt, P; Ley, K				Aigner, S; Ramos, CL; Hafezi-Moghadam, A; Lawrence, MB; Friederichs, J; Altevogt, P; Ley, K			CD24 mediates rolling of breast carcinoma cells on P-selectin	FASEB JOURNAL			English	Article						adhesion; tumor cells; metastasis	HUMAN TUMOR-CELLS; ENDOTHELIAL-CELLS; GLYCOPROTEIN LIGAND-1; MONOCLONAL-ANTIBODY; ADHESION MOLECULE-1; DEPENDENT ADHESION; TYROSINE SULFATION; EXPRESSION CLONING; CANCER METASTASIS; HUMAN NEUTROPHILS	P-selectin mediates rolling of neutrophils and other leukocytes on activated endothelial cells and platelets through binding to P-selectin glycoprotein ligand-l (PSGL-1). Certain PSGL-1 negative tumor cell lines can bind P-selectin under static conditions through the GPI-linked surface mucin, CD24, but the physiological significance of this interaction and whether it can occur under flow conditions is not known. Here, we show that CD24(+) PSGL-1(-) KS breast carcinoma cells attach to and roll on recombinant P-selectin under a continuous wall shear stress, although at a lower density and higher velocity than CD24(+) PSGL-1(+) cells, such as HL-60. Adding excess soluble CD24 or removing CD24 from the cell surface with phosphatidylinositol-phospholipase C (PI-PLC) significantly reduced KS cell rolling on P-selectin. The ability of KS cells to roll on P-selectin was positively correlated with the CD24 expression level. Comparison with three other CD24(+) cell. Lines established that expression of sialyl-Lewis(x) antigen was also necessary for CD24-mediated rolling on P-selectin. CD24 purified from KS cells supported rolling of P-selectin transfectants, but not L-selectin transfectants. Finally, KS cells rolled on vascular endothelium in vivo in a P-selectin-dependent manner. Together our data show that CD24 serves as a ligand for P-selectin under physiological now conditions. Interaction of tumor cells with P-selectin via CD24 may be an important adhesion pathway in cancer metastasis.-Aigner, S., Ramos, C. L., Hafezi-Moghadam, A., Lawrence, M. B., Friederichs, J., Altevogt, P., and Ley, K. CD24 mediates rolling of breast carcinoma cells on P-selectin.	Univ Virginia, Dept Biomed Engn, Ctr Hlth Sci, Charlottesville, VA 22908 USA; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	University of Virginia; Helmholtz Association; German Cancer Research Center (DKFZ)	Ley, K (corresponding author), Univ Virginia, Dept Biomed Engn, Ctr Hlth Sci, Box 377, Charlottesville, VA 22908 USA.	kfl3f@virginia.edu		Hafezi-Moghadam, Ali/0000-0002-5336-0697	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136, R29HL054614, R01HL054614] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09578, HL54136, HL54614] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; AIGNER S, 1995, INT IMMUNOL, V7, P1557, DOI 10.1093/intimm/7.10.1557; AKASHI T, 1994, VIRCHOWS ARCH, V425, P399; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; CELI A, 1991, P SOC EXP BIOL MED, V198, P703; DROZ D, 1990, HUM PATHOL, V21, P536, DOI 10.1016/0046-8177(90)90011-S; FOGH J, 1986, CANCER INVEST, V4, P157, DOI 10.3109/07357908609038260; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; FRIEDRICHS K, 1995, CANCER RES, V55, P901; GAROFALO A, 1995, CANCER RES, V55, P414; GASIC GJ, 1984, CANCER METAST REV, V3, P99, DOI 10.1007/BF00047657; GAZDAR AF, 1980, CANCER RES, V40, P3502; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Goetz DJ, 1996, ANN BIOMED ENG, V24, P87, DOI 10.1007/BF02770998; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P653, DOI 10.1016/0009-2509(67)80048-4; GRIGNANI G, 1986, HAEMATOLOGICA, V71, P245; GROVES RW, 1993, AM J PATHOL, V143, P1220; GUCKEL B, 1995, CYTOKINES MOL THER, V1, P211; HANSKI C, 1990, J CLIN PATHOL, V43, P379, DOI 10.1136/jcp.43.5.379; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; JACKSON D, 1992, CANCER RES, V52, P5264; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KUNZENDORF U, 1994, CANCER RES, V54, P1109; Lafrenie R M, 1993, Cell Biophys, V23, P3; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LAVABREBERTRAND T, 1994, LEUKEMIA, V8, P402; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; MAJURI ML, 1992, BIOCHEM BIOPH RES CO, V182, P1376, DOI 10.1016/0006-291X(92)91885-T; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOULD AP, 1994, J BIOL CHEM, V269, P27224; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PERRI RT, 1983, BLOOD, V61, P871; PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RENEMAN RS, 1992, NATO ADV SCI INST SE, V235, P25; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Snapp KR, 1998, BLOOD, V91, P154, DOI 10.1182/blood.V91.1.154.154_154_164; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; TOZEREN A, 1995, INT J CANCER, V60, P426; VANDENBRENK HA, 1974, BRIT J CANCER, V30, P246, DOI 10.1038/bjc.1974.189; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	62	223	233	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1241	1251		10.1096/fasebj.12.12.1241	http://dx.doi.org/10.1096/fasebj.12.12.1241			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737727				2022-12-28	WOS:000075738500019
J	Lecarpentier, Y; Chemla, D; Blanc, FX; Pourny, JC; Joseph, T; Riou, B; Coirault, C				Lecarpentier, Y; Chemla, D; Blanc, FX; Pourny, JC; Joseph, T; Riou, B; Coirault, C			Mechanics, energetics, and crossbridge kinetics of rabbit diaphragm during congestive heart failure	FASEB JOURNAL			English	Article						myosin; molecular motors; cardiac hypertrophy; muscle efficiency	RESPIRATORY MUSCLE STRENGTH; MYOSIN; CONTRACTION; MOLECULE; DISEASE; DYSPNEA; FORCE; MOTOR	Crossbridge (CB) properties were investigated in isolated diaphragm of rabbits during congestive heart failure (CHF, n = 9) induced by chronic volume and pressure overload. This model induced cardiac hypertrophy and heart failure. Controls (C) were prepared (n = 14). Compared to C, peak tension in CHF fell by 57% in twitch and by 40% in tetanus; V-max declined by 47% in twitch and by 48% in tetanus. Our study provided an analytical means of calculating from A. F. Huxley's equations the rate constants for CB attachment and detachment, CB single force (I-I), CB number per mm(3) (m'), peak mechanical efficiency (Eff,,), and turnover rate of myosin ATPase (k(cat)); m', Pi, and Eff(max) were lower in CHF than in C in both twitch and tetanus. The marked decline in m' and Pi accounted for the fall in diaphragm strength. In the overall population of C and CHF, Eff,, was linearly related to Pi. Conversely, there was no relationship between V-max and k(xat). Dissociation between V-max and k(cat) might be explained by the crucial role attributed to two apparently nonconserved surface 'loops' on the motor domain of myosin head.	LOA ENSTA Ecole Polytech, INSERM, U451, F-91120 Palaiseau, France; CHU Pitie Salpetriere, Dept Anesthesie Reanimat, Paris, France; CHU Bicetre, UFR Paris XI, Serv Physiol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Lecarpentier, Y (corresponding author), Hop Bicetre, Serv Physiol Cardiovasc & Resp, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Coirault, Catherine/I-2979-2016; Blanc, François-Xavier/D-7425-2015; Coirault, Catherine/S-2454-2019	Blanc, François-Xavier/0000-0001-7644-2188; Coirault, Catherine/0000-0002-5594-1057; CHEMLA, Denis/0000-0001-7479-9896				ANGER M, 1995, AM J PHYSIOL-HEART C, V268, pH1947, DOI 10.1152/ajpheart.1995.268.5.H1947; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CHEMLA D, 1992, J PHARMACOL EXP THER, V262, P516; CHUA TP, 1995, BRIT HEART J, V74, P381; CLARK A, 1996, LUNG BIOL HEALTH DIS, V90, P263; Coirault C, 1997, AM J RESP CRIT CARE, V156, P959, DOI 10.1164/ajrccm.156.3.9701051; DETROYER A, 1980, AM J MED, V69, P867, DOI 10.1016/S0002-9343(80)80012-X; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; EVANS SA, 1995, THORAX, V50, P625, DOI 10.1136/thx.50.6.625; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GILSON N, 1990, AM J PHYSIOL, V258, pH634, DOI 10.1152/ajpheart.1990.258.3.H634; HAMMOND MD, 1990, CHEST, V98, P1091, DOI 10.1378/chest.98.5.1091; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOWELL S, 1995, J APPL PHYSIOL, V79, P389, DOI 10.1152/jappl.1995.79.2.389; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; Lecarpentier Y, 1997, AM J RESP CRIT CARE, V155, P630, DOI 10.1164/ajrccm.155.2.9032205; Lindsay DC, 1996, EUR HEART J, V17, P1239; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MCPARLAND C, 1992, AM REV RESPIR DIS, V146, P467, DOI 10.1164/ajrccm/146.2.467; MUSCH TI, 1993, AM J PHYSIOL, V265, pH1721, DOI 10.1152/ajpheart.1993.265.5.H1721; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SULLIVAN MJ, 1990, CIRCULATION, V81, P518, DOI 10.1161/01.CIR.81.2.518; SUPINSKI G, 1994, J APPL PHYSIOL, V76, P2707, DOI 10.1152/jappl.1994.76.6.2707; Tikunov B, 1997, CIRCULATION, V95, P910; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Woledge RC, 1985, MONOGRAPHS PHYSL SOC, V41; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	32	46	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					981	989		10.1096/fasebj.12.11.981	http://dx.doi.org/10.1096/fasebj.12.11.981			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707170				2022-12-28	WOS:000075372600008
J	Forstermann, U; Boissel, JP; Kleinert, H				Forstermann, U; Boissel, JP; Kleinert, H			Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)	FASEB JOURNAL			English	Review						cellular expression; gene structure; transcription factors; transcriptional regulation; RNA stability; protein stability	AORTIC ENDOTHELIAL-CELLS; DUCHENNE MUSCULAR-DYSTROPHY; CEREBELLAR GRANULE CELLS; FOCAL CEREBRAL-ISCHEMIA; LOW-DENSITY-LIPOPROTEIN; RAT PINEAL-GLAND; MESSENGER-RNA; GENE-EXPRESSION; MOLECULAR-CLONING; SPINAL-CORD	Nitric oxide synthase (NOS) exists in three established isoforms, NOS I (NOS1, ncNOS) was originally discovered in neurons. This enzyme and splice variants thereof have since been found in many other cells and tissues. NOS II (NOS2, iNOS) was first identified in murine macrophages, but can also be induced in many other cell. types. NOS III (NOS3, ecNOS) is expressed mainly in endothelial cells. Whereas NOS ZI is a transcriptionally regulated enzyme, NOS I and NOS III are considered constitutively expressed proteins. However, evidence generated in recent years indicates that these two isoforms are also subject to expressional regulation. In view of the important biological functions of these isoforms, changes in their expression may have physiological and pathophysiological consequences. This review recapitulates compounds and conditions that modulate the expression of NOS I and NOS III, summarizes transcriptional and posttranscriptional effects that underlie these changes, and-where known-describes the molecular mechanisms leading to changes in transcription, RNA stability, or translation of these enzymes.-Forstermann, U., Boissel, J.-P., Kleinert, H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III).	Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Forstermann, U (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany.		Kleinert, Hartmut/M-2988-2018	Kleinert, Hartmut/0000-0003-2202-3548				Abe K, 1997, NEUROL RES, V19, P124; Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; Aoki C, 1997, BRAIN RES, V750, P25, DOI 10.1016/S0006-8993(96)01147-X; Arbones ML, 1996, GLIA, V18, P224, DOI 10.1002/(SICI)1098-1136(199611)18:3<224::AID-GLIA6>3.0.CO;2-Z; Arnal JF, 1996, P NATL ACAD SCI USA, V93, P4108, DOI 10.1073/pnas.93.9.4108; ARNAL JF, 1994, AM J PHYSIOL-CELL PH, V267, pC1381, DOI 10.1152/ajpcell.1994.267.5.C1381; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baader SL, 1996, J NEUROSCI, V16, P1440; Baader SL, 1997, DEV NEUROSCI-BASEL, V19, P283, DOI 10.1159/000111217; BAGETTA G, 1993, BIOCHEM BIOPH RES CO, V197, P1132, DOI 10.1006/bbrc.1993.2595; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Bandyopadhyay A, 1997, AM J PHYSIOL-CELL PH, V272, pC1790, DOI 10.1152/ajpcell.1997.272.6.C1790; Barna M, 1996, VIROLOGY, V223, P331, DOI 10.1006/viro.1996.0484; Belhassen L, 1996, J CLIN INVEST, V97, P1908, DOI 10.1172/JCI118622; BHAT GK, 1995, NEUROENDOCRINOLOGY, V62, P187, DOI 10.1159/000127004; BONNARDEAUX A, 1995, CIRCULATION, V91, P96, DOI 10.1161/01.CIR.91.1.96; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Bucher M, 1997, FEBS LETT, V412, P511, DOI 10.1016/S0014-5793(97)00835-1; CALZA L, 1993, NEUROREPORT, V4, P627, DOI 10.1097/00001756-199306000-00006; Calza L, 1997, P NATL ACAD SCI USA, V94, P3368, DOI 10.1073/pnas.94.7.3368; CARDENA GG, 1996, P NATL ACAD SCI USA, V93, P6448; CECCATELLI S, 1993, P NATL ACAD SCI USA, V90, P11292, DOI 10.1073/pnas.90.23.11292; Ceccatelli S, 1996, NEUROENDOCRINOLOGY, V64, P357, DOI 10.1159/000127139; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Chao DS, 1996, METHOD ENZYMOL, V268, P488; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; Chao DS, 1997, NEUROSCIENCE, V76, P665, DOI 10.1016/S0306-4522(96)00367-3; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; Chen K, 1997, LIFE SCI, V61, P1323, DOI 10.1016/S0024-3205(97)00677-2; Colin IM, 1997, EUR J ENDOCRINOL, V136, P649, DOI 10.1530/eje.0.1360649; Comini L, 1996, J MOL CELL CARDIOL, V28, P2241, DOI 10.1006/jmcc.1996.0216; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; Cosentino F, 1997, CIRCULATION, V96, P25; Crabos M, 1997, J MOL CELL CARDIOL, V29, P55, DOI 10.1006/jmcc.1996.0251; DAI A, 1995, CHUNG HUA CHIEH HO H, V18, P164; Deans Z, 1996, J BIOL CHEM, V271, P32153, DOI 10.1074/jbc.271.50.32153; DENG AY, 1995, MAMM GENOME, V6, P824, DOI 10.1007/BF00539015; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUN NJ, 1992, NEUROSCI LETT, V147, P217, DOI 10.1016/0304-3940(92)90599-3; EKBLAD E, 1994, NEUROSCIENCE, V63, P233, DOI 10.1016/0306-4522(94)90019-1; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; Esteban FJ, 1997, NEUROSCI LETT, V226, P99, DOI 10.1016/S0304-3940(97)00262-0; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Flowers MA, 1995, AM J PHYSIOL-HEART C, V269, pH1988, DOI 10.1152/ajpheart.1995.269.6.H1988; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1993, EUR HEART J, V14, P10; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; Gath I, 1997, FEBS LETT, V410, P319, DOI 10.1016/S0014-5793(97)00615-7; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GIUILI G, 1994, DEV BRAIN RES, V81, P269, DOI 10.1016/0165-3806(94)90313-1; Gnanapandithen K, 1996, BBA-GENE STRUCT EXPR, V1308, P103, DOI 10.1016/0167-4781(96)00098-X; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; Goldstein J, 1997, NEUROSCI LETT, V231, P45, DOI 10.1016/S0304-3940(97)00532-6; Grozdanovic Z, 1996, ACTA HISTOCHEM, V98, P61, DOI 10.1016/S0065-1281(96)80051-1; Guo Y, 1997, J NEUROSCI RES, V49, P89, DOI 10.1002/(SICI)1097-4547(19970701)49:1<89::AID-JNR10>3.0.CO;2-#; HALL AV, 1994, J BIOL CHEM, V269, P33082; HARRISON DG, 1997, JPN J PHARMACOL, V75, pP399; Hatakeyama S, 1996, J CHEM NEUROANAT, V11, P243, DOI 10.1016/S0891-0618(96)00166-4; HECKER M, 1994, J NEUROCHEM, V62, P1524; Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108; HERDEGEN T, 1993, J NEUROSCI, V13, P4130; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; Holtzman DM, 1996, NEUROCHEM RES, V21, P861, DOI 10.1007/BF02532310; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Hussain SNA, 1997, J APPL PHYSIOL, V83, P348, DOI 10.1152/jappl.1997.83.2.348; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; IWAI N, 1995, HYPERTENSION, V25, P431, DOI 10.1161/01.HYP.25.3.431; JANSSENS SP, 1992, J BIOL CHEM, V267, P22694; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KADOWAKI K, 1994, ENDOCRINOLOGY, V134, P1011, DOI 10.1210/en.134.3.1011; Kaku Y, 1997, BBA-MOL CELL RES, V1356, P43, DOI 10.1016/S0167-4889(96)00156-5; Kanazawa K, 1996, AM J PATHOL, V148, P1949; Kanda K, 1996, NEUROSCI LETT, V219, P41, DOI 10.1016/S0304-3940(96)13170-0; Keilhoff G, 1996, NEUROSCIENCE, V75, P1193, DOI 10.1016/0306-4522(96)00330-2; Kihara M, 1997, LAB INVEST, V76, P285; KISHIMOTO J, 1993, GENOMICS, V15, P465; KISHIMOTO J, 1992, GENOMICS, V14, P802, DOI 10.1016/S0888-7543(05)80192-2; Kleinert H, 1998, HYPERTENSION, V31, P582, DOI 10.1161/01.HYP.31.2.582; Kolesnikov YA, 1997, P NATL ACAD SCI USA, V94, P8220, DOI 10.1073/pnas.94.15.8220; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOSTYK SK, 1995, AM J PHYSIOL-HEART C, V269, pH1583, DOI 10.1152/ajpheart.1995.269.5.H1583; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lam HHD, 1996, NEUROSCI LETT, V210, P201, DOI 10.1016/0304-3940(96)12702-6; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; Layes E, 1996, NEUROSCI LETT, V212, P71, DOI 10.1016/0304-3940(96)12765-8; LEE CGL, 1995, MAMM GENOME, V6, P56, DOI 10.1007/BF00350898; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; Lee S, 1995, BRAIN RES, V705, P136, DOI 10.1016/0006-8993(95)01142-0; LI H, 1998, IN PRESS MOL PHARM, V53; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; Lin LH, 1997, NEUROSCI LETT, V221, P97, DOI 10.1016/S0304-3940(96)13287-0; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu SF, 1996, CRIT CARE MED, V24, P1219, DOI 10.1097/00003246-199607000-00026; Lizasoain I, 1996, PEDIATR RES, V39, P779, DOI 10.1203/00006450-199605000-00006; LopezFigueroa MO, 1996, NEUROENDOCRINOLOGY, V63, P384, DOI 10.1159/000126979; Luckman SM, 1997, NEUROSCIENCE, V77, P37, DOI 10.1016/S0306-4522(96)00498-8; Lumme A, 1997, EXP NEUROL, V144, P248, DOI 10.1006/exnr.1996.6369; Ma SX, 1997, NEUROSCIENCE, V76, P659; Magee T, 1996, BIOCHEM BIOPH RES CO, V226, P145, DOI 10.1006/bbrc.1996.1324; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MARSDEN PA, 1994, 1 INT C BIOCH MOL BI, V31; Martin PY, 1996, AM J PHYSIOL-RENAL, V270, pF494, DOI 10.1152/ajprenal.1996.270.3.F494; MATSUMOTO T, 1993, DEV BRAIN RES, V73, P199, DOI 10.1016/0165-3806(93)90139-2; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MIYAHARA K, 1994, EUR J BIOCHEM, V223, P719, DOI 10.1111/j.1432-1033.1994.tb19045.x; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Neugarten J, 1997, J AM SOC NEPHROL, V8, P1240; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NORTH AJ, 1994, AM J PHYSIOL, V266, pL635, DOI 10.1152/ajplung.1994.266.6.L635; Northington FJ, 1997, J CEREBR BLOOD F MET, V17, P109, DOI 10.1097/00004647-199701000-00014; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; Ogura T, 1996, NEUROSCI LETT, V204, P89, DOI 10.1016/0304-3940(96)12324-7; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OHARA Y, 1995, HYPERTENSION, V25, P415, DOI 10.1161/01.HYP.25.3.415; Olson SC, 1997, AM J PHYSIOL-LUNG C, V273, pL315, DOI 10.1152/ajplung.1997.273.2.L315; OShea RD, 1996, J NEUROENDOCRINOL, V8, P417, DOI 10.1046/j.1365-2826.1996.04682.x; Phelan MW, 1996, J CELL PHYSIOL, V167, P469, DOI 10.1002/(SICI)1097-4652(199606)167:3<469::AID-JCP11>3.3.CO;2-C; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1993, AM J PHYSIOL, V265, pC1379, DOI 10.1152/ajpcell.1993.265.5.C1379; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prabhakar NR, 1996, ADV EXP MED BIOL, V410, P345; RAVICHANDRAN LV, 1995, FEBS LETT, V374, P295, DOI 10.1016/0014-5793(95)01134-Z; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Reiling N, 1996, EUR J IMMUNOL, V26, P511, DOI 10.1002/eji.1830260302; Reilly CM, 1997, J ANDROL, V18, P110; Reiser PJ, 1997, J APPL PHYSIOL, V82, P1250, DOI 10.1152/jappl.1997.82.4.1250; REUSS S, 1995, BRAIN RES, V695, P257, DOI 10.1016/0006-8993(95)00829-F; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Rodrigo J, 1997, J COMP NEUROL, V378, P522, DOI 10.1002/(SICI)1096-9861(19970224)378:4<522::AID-CNE7>3.0.CO;2-4; Roman V, 1997, IMMUNOLOGY, V91, P643, DOI 10.1046/j.1365-2567.1997.d01-2263.x; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SASE K, 1995, LIFE SCI, V57, P2049, DOI 10.1016/0024-3205(95)02191-K; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Schricker K, 1996, PFLUG ARCH EUR J PHY, V432, P394, DOI 10.1007/s004240050150; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SHARIFF AJ, 1997, ENDOCRINOLOGY, V138, P460; Sharma HS, 1997, ANN NY ACAD SCI, V813, P581, DOI 10.1111/j.1749-6632.1997.tb51749.x; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; SHAUL PW, 1995, AM J RESP CELL MOL, V13, P167, DOI 10.1165/ajrcmb.13.2.7542896; Shimizu Yoshinori, 1997, Journal of Dermatology (Tokyo), V24, P80; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Singh I, 1996, AM J PHYSIOL-RENAL, V270, pF1027, DOI 10.1152/ajprenal.1996.270.6.F1027; SPESSERT R, 1995, BIOCHEM BIOPH RES CO, V212, P70, DOI 10.1006/bbrc.1995.1937; SUGAYA K, 1994, MOL BRAIN RES, V23, P111, DOI 10.1016/0169-328X(94)90217-8; SUSCHEK C, 1994, AM J PATHOL, V145, P685; Takahashi Y, 1997, HUM HERED, V47, P58, DOI 10.1159/000154391; Tascedda F, 1996, MOL BRAIN RES, V40, P171; Thompson CM, 1997, BRAIN RES, V754, P142, DOI 10.1016/S0006-8993(97)00057-7; TOJO A, 1995, JPN HEART J, V36, P389; TOJO A, 1994, J AM SOC NEPHROL, V4, P1438; TORRES G, 1994, BRAIN RES, V647, P1, DOI 10.1016/0006-8993(94)91391-9; TRACEY WR, 1994, AM J PHYSIOL, V266, pC22, DOI 10.1152/ajpcell.1994.266.1.C22; Tseng L, 1996, J SOC GYNECOL INVEST, V3, P33, DOI 10.1016/1071-5576(95)00039-9; Tsuchiya T, 1996, PSYCHONEUROENDOCRINO, V21, P287, DOI 10.1016/0306-4530(95)00054-2; VENEMA RC, 1994, BBA-GENE STRUCT EXPR, V1218, P413, DOI 10.1016/0167-4781(94)90195-3; VILLAR MJ, 1994, BRAIN RES, V650, P219, DOI 10.1016/0006-8993(94)91785-X; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VIZZARD MA, 1994, DEV BRAIN RES, V81, P201, DOI 10.1016/0165-3806(94)90307-7; VIZZARD MA, 1994, CELL TISSUE RES, V278, P299, DOI 10.1007/BF00414174; Vizzard MA, 1997, DEV NEUROSCI-BASEL, V19, P232, DOI 10.1159/000111212; Wallerath T, 1997, THROMB HAEMOSTASIS, V77, P163; Wang H, 1996, NEUROSCIENCE, V74, P1059, DOI 10.1016/S0306-4522(96)00165-0; Wang RJ, 1996, J INVEST DERMATOL, V106, P419, DOI 10.1111/1523-1747.ep12343428; Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1995, Adv Pharmacol, V34, P71; WEBER CM, 1994, J NEUROCHEM, V63, P953; WEINER CP, 1994, AM J OBSTET GYNECOL, V171, P838, DOI 10.1016/0002-9378(94)90108-2; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WU KK, 1997, JPN J PHARMACOL, V75, pA8; WU WT, 1994, NEUROSCI LETT, V179, P157, DOI 10.1016/0304-3940(94)90958-X; Xiao ZS, 1997, J CELL PHYSIOL, V171, P205, DOI 10.1002/(SICI)1097-4652(199705)171:2<205::AID-JCP11>3.3.CO;2-3; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; Xu DL, 1996, AM J PHYSIOL-REG I, V271, pR1739, DOI 10.1152/ajpregu.1996.271.6.R1739; XU WM, 1993, CYTOGENET CELL GENET, V64, P62, DOI 10.1159/000133562; Xu ZM, 1996, ANESTHESIOLOGY, V84, P890, DOI 10.1097/00000542-199604000-00017; Xue C, 1996, AM J PHYSIOL-LUNG C, V270, pL88, DOI 10.1152/ajplung.1996.270.1.L88; XUE C, 1994, J AUTONOM NERV SYST, V49, P1, DOI 10.1016/0165-1838(94)90015-9; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; Young A P, 1995, Adv Pharmacol, V34, P91; Yun HY, 1997, MOL PSYCHIATR, V2, P300, DOI 10.1038/sj.mp.4000272; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; Zhang JL, 1997, COMP BIOCHEM PHYS B, V116, P485, DOI 10.1016/S0305-0491(96)00288-X; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; ZHANG ZG, 1994, BRAIN RES, V654, P85; ZHANG ZG, 1993, STROKE, V24, P2016, DOI 10.1161/01.STR.24.12.2016; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478; Zimmermann H, 1996, J HEPATOL, V25, P567, DOI 10.1016/S0168-8278(96)80218-2; Zini A, 1996, BIOL REPROD, V55, P935, DOI 10.1095/biolreprod55.5.935	210	535	557	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					773	790						18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657518				2022-12-28	WOS:000074580100003
J	Park, JH; Edwards, MR; Schofield, PJ				Park, JH; Edwards, MR; Schofield, PJ			Swelling detection for volume regulation in the primitive eukaryote Giardia intestinalis: a common feature of volume detection in present-day eukaryotes	FASEB JOURNAL			English	Article						NEM; RVD; giardiasis; giardial swelling-activated alanine transport; volume sensor	PERMEABILITY TRANSITION PORE; LAMBLIA INDUCED DIARRHEA; K-CL COTRANSPORT; CELL-VOLUME; TAURINE EFFLUX; TRANSPORT; ACTIVATION; PATHWAY; RELEASE; BAND-3	It is increasingly evident that cell swelling is associated with the triggering of many biological processes, including progression of the cell cycle, hormonal response, and gene expression. However, the mechanism by which cell swelling is initially sensed and converted into intracellular signals is still ill-defined. We report here an early event in the detection of cell swelling and initiation of the volume regulatory response in Giardia intestinalis, an ancient representative of the eukaryotic kingdom, Giardial cell swelling, irrespective of the extent, was sensed at a cell volume of 1.06 X isosmotic volume (the threshold volume), at which the transition of the volume regulatory transport system from the 'resting' to the 'open' state occurred. Irreversible modification by p-chloromercuribenzoate (pCMB) and N-ethylmaleimide (NEM) of reduced thiols affected the threshold volume, but in opposing manners: pCMB increased the threshold volume to 1.14 X and NEM decreased to 0.85 X isosmotic volume. The simple modification of the threshold volume by NEM caused a drastic reduction of giardial cell volume under isosmotic conditions, with a process strikingly similar to the opening of mitochondrial permeability transition pore, a causative event in stress-induced programmed cell death. Substantial evidence supports the hypothesis that modulation of the membrane thiol moieties at the threshold volume, causing the 'all-or-nothing' type of swelling detection, represents the event linking cell swelling to the second messenger systems for volume regulation in present eukaryotes. Pathophysiological implications of alteration of the threshold volume are discussed.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Park, JH (corresponding author), Seattle Biomed Res Inst, 4 Nickerson St, Seattle, WA 98109 USA.	parkjh@u.washington.edu						ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BROWN DM, 1993, MOL BIOCHEM PARASIT, V61, P155, DOI 10.1016/0166-6851(93)90169-X; Bursell JDH, 1996, J MEMBRANE BIOL, V154, P131, DOI 10.1007/s002329900138; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; DALLASTA V, 1994, BBA-MOL CELL RES, V1220, P139, DOI 10.1016/0167-4889(94)90129-5; DARLING TN, 1990, J PROTOZOOL, V37, P493, DOI 10.1111/j.1550-7408.1990.tb01254.x; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; FARTHING MJG, 1992, J MED MICROBIOL, V37, P1, DOI 10.1099/00222615-37-1-1; FIEVET B, 1995, EMBO J, V14, P5158, DOI 10.1002/j.1460-2075.1995.tb00200.x; GOLDSTEIN L, 1991, AM J PHYSIOL, V260, pR1014, DOI 10.1152/ajpregu.1991.260.5.R1014; GOROWARA S, 1994, FEMS MICROBIOL LETT, V120, P231, DOI 10.1111/j.1574-6968.1994.tb07038.x; GOROWARA S, 1992, BIOCHIM BIOPHYS ACTA, V1138, P122, DOI 10.1016/0925-4439(92)90051-N; HAUSSINGER D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P331, DOI 10.1016/0304-4157(91)90001-D; HAZAMA A, 1990, PFLUG ARCH EUR J PHY, V416, P710, DOI 10.1007/BF00370619; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; Kelley SJ, 1996, AM J PHYSIOL-CELL PH, V270, pC1122; KIRK K, 1992, J BIOL CHEM, V267, P23475; KIRK K, 1995, J BIOL CHEM, V270, P24270, DOI 10.1074/jbc.270.41.24270; KOO SP, 1991, J GEN MICROBIOL, V137, P2617, DOI 10.1099/00221287-137-11-2617; KRACKE GR, 1990, P NATL ACAD SCI USA, V87, P8575, DOI 10.1073/pnas.87.21.8575; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; MARTINEZ A, 1994, NEUROSCI LETT, V176, P239, DOI 10.1016/0304-3940(94)90091-4; MINTON AP, 1992, P NATL ACAD SCI USA, V89, P10504, DOI 10.1073/pnas.89.21.10504; PARK JH, 1995, MICROBIOL-UK, V141, P2455, DOI 10.1099/13500872-141-10-2455; Park JH, 1997, EXP PARASITOL, V86, P19, DOI 10.1006/expr.1996.4130; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; PEERCE BE, 1993, AM J PHYSIOL, V264, pG294, DOI 10.1152/ajpgi.1993.264.2.G294; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Philips J, 1997, J CELL BIOL, V138, P961, DOI 10.1083/jcb.138.5.961; ROTHSTEIN A, 1970, CURRENT TOPICS MEMBR, P135; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STARKE LC, 1993, AM J PHYSIOL, V264, pC118, DOI 10.1152/ajpcell.1993.264.1.C118; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; TILLY BC, 1993, J BIOL CHEM, V268, P19919; TILLY BC, 1994, AM J PHYSIOL-CELL PH, V267, pC1271, DOI 10.1152/ajpcell.1994.267.5.C1271; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHEN RG, 1994, J BIOL CHEM, V269, P23342	49	6	6	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					571	579		10.1096/fasebj.12.7.571	http://dx.doi.org/10.1096/fasebj.12.7.571			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576484	Bronze			2022-12-28	WOS:000073523100007
J	Bolz, SS; Fisslthaler, B; Pieperhoff, S; De Wit, C; Fleming, I; Busse, R; Pohl, U				Bolz, SS; Fisslthaler, B; Pieperhoff, S; De Wit, C; Fleming, I; Busse, R; Pohl, U			Antisense oligonucleotides against cytochrome P4502C8 attenuate EDHF-mediated Ca2+ changes and dilation in isolated resistance arteries	FASEB JOURNAL			English	Article						organ culture; cytochrome P450 metabolites; hyperpolarization; endothelium; acetylcholine	EPOXYEICOSATRIENOIC ACIDS; HYPERPOLARIZING FACTOR; ENDOTHELIAL-CELLS; K+ CHANNELS; CORONARY-ARTERIES; SMOOTH-MUSCLE; CALCIUM; MONOOXYGENASE; EXPRESSION; CLONING	Using a novel vessel culture technique in combination with antisense oligonucleotide transfection, we tested whether the endothelium-derived hyperpolarizing factor (EDHF) is a cytochrome P450 (CYP)-related compound. Isolated resistance arteries from hamster gracilis muscle (n = 19) were perfused and exposed to antisense (As), sense (S), or scrambled (Scr) oligonucleotides against the coding region of CYP2C8/9, an isoform expressed in endothelial cells. Thereafter, NO- and prostaglandin-independent, EDHF-mediated vascular responses associated with hyperpolarization [i.e., decrease in smooth muscle calcium (Fura 2) and vasodilation] were studied after the application of acetylcholine (ACh). These EDHF-mediated responses were markedly attenuated (by 70%) by As- but not by S- or Scr-oligonucleotide treatment. However, the responses to norepinephrine (0.3 mu mol/l), the NO donor sodium nitroprusside (1 mu mol/l), and the K-Ca channel activator NS1619 (100 mu mol/l) were unaltered. As treatment, which specifically targeted the endothelial layer (as assessed by confocal microscopy), had no inhibitory effect on increases in endothelial calcium to ACh. It is concluded that a CYP2C8/9-related isoform functions as an EDHF synthase in hamster resistance arteries and that a product of this enzyme is an EDHF, or at least an integral part of the signaling cascade leading to EDHF-mediated responses.	Univ Munich, Inst Physiol, D-80336 Munich, Germany; Goethe Univ Frankfurt, Inst Kardiovasc Physiol, D-6000 Frankfurt, Germany	University of Munich	Bolz, SS (corresponding author), Univ Munich, Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.	bolz@lrz.uni-muenchen.de	de Wit, Cor/A-5560-2009; Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	de Wit, Cor/0000-0003-4621-0399; Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635				Beach JM, 1996, AM J PHYSIOL-HEART C, V270, pH2216, DOI 10.1152/ajpheart.1996.270.6.H2216; Bolz SS, 1997, CARDIOVASC RES, V36, P437, DOI 10.1016/S0008-6363(97)00197-1; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chataigneau T, 1998, BRIT J PHARMACOL, V123, P968, DOI 10.1038/sj.bjp.0701690; Clark SG, 1997, J PHARMACOL EXP THER, V282, P1473; De Wit C, 1999, AM J PHYSIOL-HEART C, V276, pH1527, DOI 10.1152/ajpheart.1999.276.5.H1527; Dora KA, 1997, P NATL ACAD SCI USA, V94, P6529, DOI 10.1073/pnas.94.12.6529; Eckman DM, 1998, BRIT J PHARMACOL, V124, P181, DOI 10.1038/sj.bjp.0701778; Edwards G, 1996, BRIT J PHARMACOL, V119, P691, DOI 10.1111/j.1476-5381.1996.tb15728.x; Gebremedhin D, 1998, J VASC RES, V35, P274, DOI 10.1159/000025594; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Hoebel BG, 1997, BRIT J PHARMACOL, V121, P1579, DOI 10.1038/sj.bjp.0701304; Li PL, 1997, CIRC RES, V80, P877; LIN JHC, 1996, ENDOTHELIUM, V4, P219; LISCHKE V, 1995, BRIT J PHARMACOL, V115, P969, DOI 10.1111/j.1476-5381.1995.tb15905.x; McGahren ED, 1998, AM J PHYSIOL-HEART C, V274, pH60; MEININGER GA, 1991, AM J PHYSIOL, V261, pH950, DOI 10.1152/ajpheart.1991.261.3.H950; Miura H, 1998, CIRC RES, V83, P501, DOI 10.1161/01.RES.83.5.501; MORISHIMA N, 1987, BIOCHEMISTRY-US, V26, P8279, DOI 10.1021/bi00399a039; NAGAO T, 1992, AM J PHYSIOL, V263, pH1090, DOI 10.1152/ajpheart.1992.263.4.H1090; Oltman CL, 1998, CIRC RES, V83, P932; Pieperhoff S, 1998, J VASC RES, V35, P225; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; RITKIND AB, 1995, ARCH BIOCH BOPHYS, V320, P380; SAKUMA T, 1994, MOL PHARMACOL, V45, P228; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551	27	88	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					255	260		10.1096/fasebj.14.2.255	http://dx.doi.org/10.1096/fasebj.14.2.255			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657982				2022-12-28	WOS:000085184800004
J	Borgens, RB; Shi, R				Borgens, RB; Shi, R			Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol	FASEB JOURNAL			English	Article						nerve fusion; nerve repair; neurotrauma	APPLIED ELECTRIC-FIELDS; FUNCTIONAL RECOVERY; GUINEA-PIGS; FUSION; HEMISECTION; MECHANISM; MODEL	A brief application of the hydrophilic polymer polyethylene glycol (PEG) swiftly repairs nerve membrane damage associated with severe spinal cord injury in adult guinea pigs. A 2 min application of PEG to a standardized compression injury to the cord immediately reversed the loss of nerve impulse conduction through the injury in all treated animals while nerve impulse conduction remained absent in all sham-treated guinea pigs. Physiological recovery was associated with a significant recovery of a quantifiable spinal cord dependent behavior in only PEG-treated animals. The application of PEG could be delayed for similar to 8 h without adversely affecting physiological and behavioral recovery which continued to improve for up to 1 month after PEG treatment.-Borgens, R. B., Shi, R. Immediate recovery from spinal cord injury through molecular repair of nerve membranes with polyethylene glycol.	Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Borgens, RB (corresponding author), Purdue Univ, Dept Basic Med Sci, Ctr Paralysis Res, Sch Vet Med, W Lafayette, IN 47907 USA.							AHKONG QF, 1987, J CELL SCI, V88, P389; ALDEWINCKEL TL, 1982, BIOCHIM BIOPHYS ACTA, V689, P548; ASANO T, 1995, J NEUROTRAUM, V12, P993; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BLIGHT AR, 1990, J COMP NEUOL, V60, P446; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; FEHLINGS M, 1995, EXP NEUROL, V132, P123; Griffin John W., 1995, P375; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P528, DOI 10.1097/00004630-199309000-00007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; PONTECORVO G, 1975, SOMAT CELL GENET, V1, P397, DOI 10.1007/BF01538671; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; SHI R, 1997, SOC NEUR ABSTR, V108, P16; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; THIERAULT E, 1988, J NEUROPHYSIOL, V60, P446; Tilcock C PS, 1979, BIOCHEMISTRY-US, V688, P645; YAWO H, 1985, J NEUROSCI, V5, P1626; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	39	94	99	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					27	35		10.1096/fasebj.14.1.27	http://dx.doi.org/10.1096/fasebj.14.1.27			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627277				2022-12-28	WOS:000084784700005
J	Neri, LM; Martelli, AM; Borgatti, P; Colamussi, ML; Marchisio, M; Capitani, S				Neri, LM; Martelli, AM; Borgatti, P; Colamussi, ML; Marchisio, M; Capitani, S			Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC-zeta translocation to the nucleus of NGF-treated PC12 cells	FASEB JOURNAL			English	Article						signal transduction; nuclear translocation	PROTEIN-KINASE-C; NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE-C; GLUCOSE-TRANSPORT; FAMILY MEMBERS; ACTIVATION; DIACYLGLYCEROL; ASSOCIATION	We and others have previously demonstrated the existence of an autonomous nuclear polyphosphoinositide cycle that generates second messengers such as diacylglycerol (DAG), capable of attracting to the nucleus specific protein kinase C (PKC) isoforms (Neri et al. (1998) J. Biol. Chem. 273, 29738-29744). Recently, however, nuclei have also been shown to contain the enzymes responsible for the synthesis of the non-canonical 3-phosphorylated inositides. To clarify a possible role of this peculiar class of inositol lipids we have examined the question of whether nerve growth factor (NGF) induces PKC-zeta nuclear translocation in PC12 cells and whether this translocation is dependent on nuclear phosphatidylinositol 3-kinase (PI 3-K) activity and its product, phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P-3]. NGF increased both the amount and the enzyme activity of immunoprecipitable PI 3-K in PC12 cell nuclei. Activation of the enzyme, but not its translocation, was blocked by PI 3-K inhibitors wortmannin and LY294002. Treatment of PC12 cells for 9 min with NGF led to an increase in the nuclear levels of PtdIns(3,4,5)P-3. Maximal translocation of PKC-zeta from the cytoplasm to the nucleus (as evaluated by immunoblotting, enzyme activity, and confocal microscopy) occurred after 12 min of exposure to NGF and was completely abrogated by either wortmannin or LY294002. Zn contrast, these two inhibitors did not block nuclear translocation of the conventional, DAG-sensitive, PKC-alpha. On the other hand, the specific phosphatidylinositol phospholipase C inhibitor, 1-O-octadeyl-2-O-methyl-sn-glycero-3-phosphocoline was unable to abrogate nuclear translocation of the DAG-insensitive PKC-zeta. These data suggest that a nuclear increase in PI 3-K activity and PtdIns(3,4,5)P-3 production are necessary for the subsequent nuclear translocation of PKC-zeta. Furthermore, they point to the likelihood that PKC-zeta is a putative nuclear downstream target of PI 3-K during NGF-promoted neural differentiation.	Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, I-44100 Ferrara, Italy; CNR, Ist Citomorfol Normale & Patol, IOR, I-40137 Bologna, Italy; Univ Trieste, Dipartimento Morfol Umana Normale, I-34138 Trieste, Italy	University of Ferrara; Consiglio Nazionale delle Ricerche (CNR); University of Trieste	Neri, LM (corresponding author), Univ Ferrara, Dipartimento Morfol & Embriol, Sez Anat Umana, Via Fossato Mortara 66, I-44100 Ferrara, Italy.		Neri, Luca Maria/AAU-1772-2021; Neri, Luca Maria/J-2462-2017	Neri, Luca Maria/0000-0002-7924-1477; CAPITANI, Silvano/0000-0003-2795-6814; Marchisio, Marco/0000-0003-3058-3422				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Bavelloni A, 1999, J CELL SCI, V112, P631; Bertagnolo V, 1999, CANCER RES, V59, P542; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Divecha N, 1998, NATURE, V394, P619, DOI 10.1038/29174; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; Kim SJ, 1998, BIOCHEM MOL BIOL INT, V46, P187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Liu Q, 1998, J IMMUNOL, V160, P1393; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; MARMIROLI S, 1995, BIOL CELL, V86, P121; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Minshall C, 1996, J IMMUNOL, V156, P939; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Neri LM, 1999, HISTOL HISTOPATHOL, V14, P321, DOI 10.14670/HH-14.321; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; Neri LM, 1999, BIOCHEM BIOPH RES CO, V259, P314, DOI 10.1006/bbrc.1999.0786; NERI LM, 1994, CELL MOL BIOL, V40, P619; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; TOKER A, 1994, J BIOL CHEM, V269, P32358; Wooten MW, 1997, J NEUROSCI RES, V49, P393, DOI 10.1002/(SICI)1097-4547(19970815)49:4<393::AID-JNR1>3.0.CO;2-3; Zauli G, 1996, BRIT J HAEMATOL, V93, P542, DOI 10.1046/j.1365-2141.1996.d01-1700.x; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zini N, 1996, HISTOCHEM CELL BIOL, V106, P457, DOI 10.1007/BF02473307	46	99	102	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2299	2310		10.1096/fasebj.13.15.2299	http://dx.doi.org/10.1096/fasebj.13.15.2299			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593877				2022-12-28	WOS:000084310800021
J	Bhatia, SN; Balis, UJ; Yarmush, ML; Toner, M				Bhatia, SN; Balis, UJ; Yarmush, ML; Toner, M			Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells	FASEB JOURNAL			English	Review						liver; coculture; bioartificial liver; hepatocyte morphology	ADULT-RAT HEPATOCYTES; LONG-TERM CULTURES; LIVER PARENCHYMAL-CELLS; JUNCTIONAL INTERCELLULAR COMMUNICATION; CO-CULTIVATION SYSTEM; IN-VITRO; EPITHELIAL-CELLS; GROWTH-FACTOR; GENE-EXPRESSION; TRIGLYCERIDE ACCUMULATION	Heterotypic cell interaction between parenchymal cells and nonparenchymal neighbors has been reported to modulate cell growth, migration, and/or differentiation. in both the developing and adult liver, cell-cell interactions are imperative for coordinated organ function. In vivo, cocultivation of hepatocytes and nonparenchymal cells has been used to preserve and modulate the hepatocyte phenotype, We summarize previous studies in this area as well as recent advances in microfabrication that have allowed for more precise control over cell-cell interactions through 'cellular patterning' or 'micropatterning', Although the precise mechanisms by which nonparenchymal cells modulate the hepatocyte phenotype remain unelucidated, some new insights on the modes of cell signaling, the extent of cell-cell interaction, and the ratio of cell populations are noted, Proposed clinical applications of hepatocyte cocultures, typically extracorporeal bioartificial liver support systems, are reviewed in the context of these new findings, Continued advances in microfabrication and cell culture will allow further study of the role of cell communication in physiological and pathophysiological processes as well as in the development of functional tissue constructs for medical applications.-Bhatia, S. N., Balis, U. J., Yarmush, M. L., Toner, M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA; Shriners Hosp Crippled Children, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Toner, M (corresponding author), Massachusetts Gen Hosp, Ctr Engn Med, Bigelow 1401,55 Fruit St, Boston, MA 02114 USA.	mtoner@sbi.org		Yarmush, Martin/0000-0003-4986-8444; Balis, Ulysses/0000-0002-4168-1477	NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR013322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 13322] Funding Source: Medline; NIDDK NIH HHS [DK 3371] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKRAWI M, 1993, BIOCHEM PHARMACOL, V45, P1583, DOI 10.1016/0006-2952(93)90298-B; AUFDERHEIDE E, 1987, J CELL BIOL, V105, P599, DOI 10.1083/jcb.105.1.599; BAFFET G, 1991, J CELL SCI, V99, P609; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BEDOSSA P, 1994, HEPATOLOGY, V19, P1262, DOI 10.1016/0270-9139(94)90876-1; BEGUE JM, 1984, HEPATOLOGY, V4, P839, DOI 10.1002/hep.1840040507; BERGSTEINSDOTTIR K, 1991, J NEUROIMMUNOL, V34, P15, DOI 10.1016/0165-5728(91)90094-N; Berthiaume F, 1996, FASEB J, V10, P1471, DOI 10.1096/fasebj.10.13.8940293; Bezerra JA, 1998, SEMIN LIVER DIS, V18, P203, DOI 10.1055/s-2007-1007157; Bhatia S N, 1999, Methods Mol Med, V18, P349, DOI 10.1385/0-89603-516-6:349; Bhatia S.N., 1997, ASME HTD, V355, P99; Bhatia SN, 1998, J BIOMAT SCI-POLYM E, V9, P1137, DOI 10.1163/156856298X00695; Bhatia SN, 1998, BIOTECHNOL PROGR, V14, P378, DOI 10.1021/bp980036j; Bhatia SN, 1997, J BIOMED MATER RES, V34, P189, DOI 10.1002/(SICI)1097-4636(199702)34:2<189::AID-JBM8>3.0.CO;2-M; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BILLIAR TR, 1988, J SURG RES, V44, P397, DOI 10.1016/0022-4804(88)90182-5; BILLIAR TR, 1989, ARCH SURG-CHICAGO, V124, P1416; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BRITLAND S, 1992, BIOTECHNOL PROGR, V8, P155, DOI 10.1021/bp00014a010; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; CLARK P, 1993, J CELL SCI, V105, P203; CLEMENS MG, 1994, SHOCK, V2, P1, DOI 10.1097/00024382-199407000-00001; CLEMENT B, 1988, CELL MOL BIOL, V34, P449; CLEMENT B, 1984, HEPATOLOGY, V4, P373, DOI 10.1002/hep.1840040305; CONNER J, 1990, BIOCHEM J, V266, P683, DOI 10.1042/bj2660683; CORLU A, 1994, AM J PATHOL, V145, P715; CORLU A, 1991, J CELL BIOL, V115, P505, DOI 10.1083/jcb.115.2.505; DAVIES PF, 1986, LAB INVEST, V55, P5; Delamarche E, 1998, J AM CHEM SOC, V120, P500, DOI 10.1021/ja973071f; Delamarche E, 1997, SCIENCE, V276, P779, DOI 10.1126/science.276.5313.779; DELAVEGA FM, 1991, BIOCHIMIE, V73, P621, DOI 10.1016/0300-9084(91)90033-W; DONATO MT, 1994, IN VITRO CELL DEV-AN, V30A, P825; DONATO MT, 1991, CELL BIOL TOXICOL, V7, P1, DOI 10.1007/BF00121326; DONATO MT, 1990, IN VITRO CELL DEV B, V26, P1057; DONATO MT, 1991, TOXICOL IN VITRO, V5, P435, DOI 10.1016/0887-2333(91)90067-N; DUNN JCY, 1992, J CELL BIOL, V116, P1043, DOI 10.1083/jcb.116.4.1043; FINI ME, 1994, J BIOL CHEM, V269, P11291; Folch A, 1998, BIOTECHNOL PROGR, V14, P388, DOI 10.1021/bp980037b; FRASLIN JM, 1985, EMBO J, V4, P2487, DOI 10.1002/j.1460-2075.1985.tb03960.x; FRY JR, 1977, BIOCHEM PHARMACOL, V26, P969, DOI 10.1016/0006-2952(77)90476-2; FUJITA M, 1987, HEPATOLOGY, V7, pS1, DOI 10.1002/hep.1840070702; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GERLACH JC, 1995, HEPATOLOGY, V22, P546, DOI 10.1002/hep.1840220226; GILBERT SF, 1991, DEV BIOL, P201; GOULET F, 1988, HEPATOLOGY, V8, P1010, DOI 10.1002/hep.1840080506; Griffith LG, 1997, ANN NY ACAD SCI, V831, P382; GRINNELL AD, 1995, PHYSIOL REV, V75, P789, DOI 10.1152/physrev.1995.75.4.789; GRINNELL F, 1992, J CELL SCI, V101, P1; Guguen-Guillouzo C, 1986, ISOLATED CULTURED HE, P259; GUGUENGUILLOUZO C, 1983, EXP CELL RES, V143, P47, DOI 10.1016/0014-4827(83)90107-6; GUGUENGUILLOUZO C, 1984, DEV BIOL, V105, P211, DOI 10.1016/0012-1606(84)90276-8; GUILLOUZO A, 1993, TOXICOLOGY, V82, P209, DOI 10.1016/0300-483X(93)90065-Z; GUILLOUZO A, 1984, BIOCHEM BIOPH RES CO, V120, P311, DOI 10.1016/0006-291X(84)91255-5; GUILLOUZO A, 1986, ISOLATED CULTURED HE, P313; HAMMARBACK JA, 1986, DEV BIOL, V117, P655, DOI 10.1016/0012-1606(86)90334-9; HAMMARBACK JA, 1988, DEV BIOL, V126, P29, DOI 10.1016/0012-1606(88)90235-7; HERNANDEZ A, 1993, PLANTA MED, V59, P121, DOI 10.1055/s-2006-959625; HOCH HC, 1987, SCIENCE, V235, P1659, DOI 10.1126/science.235.4796.1659; Hornby A. E., 1995, V74, P249; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; JONGEN WMF, 1987, CARCINOGENESIS, V8, P767, DOI 10.1093/carcin/8.6.767; JONGEN WMF, 1987, CARCINOGENESIS, V8, P1239, DOI 10.1093/carcin/8.9.1239; KAPLOWITZ N, 1992, LIVER BILIARY DIS, P5; Kim SS, 1998, ANN SURG, V228, P8, DOI 10.1097/00000658-199807000-00002; Koike M, 1996, ARTIF ORGANS, V20, P186; KURIHARCUCH W, 1989, DIFFERENTIATION, V41, P148, DOI 10.1111/j.1432-0436.1989.tb00742.x; LANGENBACH R, 1978, P NATL ACAD SCI USA, V75, P2864, DOI 10.1073/pnas.75.6.2864; LANGENBACH R, 1979, CANCER RES, V39, P3509; LEBRETON JP, 1986, BIOCHEM J, V235, P421, DOI 10.1042/bj2350421; LEDOUARIN NM, 1975, MED BIOL, V53, P427; Lerche C, 1997, EUR J BIOCHEM, V244, P98, DOI 10.1111/j.1432-1033.1997.00098.x; LESCOAT G, 1985, CELL DIFFER DEV, V16, P259, DOI 10.1016/0045-6039(85)90576-7; LOM B, 1993, J NEUROSCI METH, V50, P385, DOI 10.1016/0165-0270(93)90044-R; LOREAL O, 1993, AM J PATHOL, V143, P538; LOURDESLOPEZ M, 1993, PLANTA MED, V59, P115; MACDONALD C, 1991, Journal of Cell Biology, V115, p79A; MATSUO R, 1992, ACTA MED OKAYAMA, V46, P345; MENDOZAFIGUEROA T, 1988, TOXICOLOGY, V52, P273, DOI 10.1016/0300-483X(88)90132-1; MENDOZAFIGUEROA T, 1989, J TOXICOL ENV HEALTH, V26, P293, DOI 10.1080/15287398909531255; MERTENS K, 1993, ARCH TOXICOL, V67, P680, DOI 10.1007/BF01973691; MESNIL M, 1987, EXP CELL RES, V173, P524, DOI 10.1016/0014-4827(87)90292-8; MICHALOPOULOS G, 1979, IN VITRO CELL DEV B, V15, P796; MICHALOPOULOS G, 1981, CANCER RES, V41, P1873; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONDEN K, 1991, J SURG RES, V50, P72, DOI 10.1016/0022-4804(91)90012-B; Morgan J., 1997, SCI MED, V4, P6; MORIN O, 1986, J CELL PHYSIOL, V129, P103, DOI 10.1002/jcp.1041290115; MORIN O, 1988, CELL BIOL REV, V15, P1; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAUGHTON BA, 1994, BIOTECHNOL BIOENG, V43, P810, DOI 10.1002/bit.260430816; Naughton BA, 1995, BIOMEDICAL ENG HDB, P1710; OLSON M, 1990, CELL INTERCOMMUNICAT, P71; PERROT N, 1991, EUR J BIOCHEM, V200, P255, DOI 10.1111/j.1432-1033.1991.tb21074.x; REID LM, 1984, HEPATOLOGY, V4, P548, DOI 10.1002/hep.1840040332; RINCONSANCHEZ AR, 1992, BIOL CELL, V76, P131, DOI 10.1016/0248-4900(92)90205-F; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Rodwell V. W., 1993, HARPERS BIOCH, P293; ROJKIND M, 1995, AM J PATHOL, V146, P1508; Ruch RJ, 1995, MOL CARCINOGEN, V14, P269, DOI 10.1002/mc.2940140407; SADLER TW, 1990, LANGMANS MED EMBRYOL, P222; SCHRODE W, 1990, EUR J CELL BIOL, V53, P35; SHIMAOKA S, 1987, EXP CELL RES, V172, P228, DOI 10.1016/0014-4827(87)90109-1; SIBILLE JC, 1988, HEPATOLOGY, V8, P296, DOI 10.1002/hep.1840080218; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; STROM S, 1981, CARCINOGENESIS, V2, P709, DOI 10.1093/carcin/2.8.709; TADERERA JV, 1967, DEV BIOL, V16, P489, DOI 10.1016/0012-1606(67)90061-9; TALBOT NC, 1994, IN VITRO CELL DEV-AN, V30A, P851; TRAISER M, 1995, IN VITRO CELL DEV-AN, V31, P266; UTESCH D, 1991, IN VITRO CELL DEV B, V27, P858; vanBreemen C, 1997, CLIN EXP PHARMACOL P, V24, P989; VANDENBERGHE Y, 1992, FEBS LETT, V313, P155, DOI 10.1016/0014-5793(92)81434-N; VANDENBERGHE Y, 1990, MOL PHARMACOL, V37, P372; VANDENBERGHE Y, 1991, FEBS LETT, V284, P103, DOI 10.1016/0014-5793(91)80772-U; VANDENBERGHE Y, 1988, IN VITRO CELL DEV B, V24, P281; VILLAFUERTE BC, 1994, ENDOCRINOLOGY, V134, P2044, DOI 10.1210/en.134.5.2044; WEST MA, 1993, J TRAUMA, V34, P473, DOI 10.1097/00005373-199304000-00001	120	715	768	2	104	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1883	1900		10.1096/fasebj.13.14.1883	http://dx.doi.org/10.1096/fasebj.13.14.1883			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544172				2022-12-28	WOS:000083660700001
J	Alexanian, AR; Bamburg, JR				Alexanian, AR; Bamburg, JR			Neuronal survival activity of S100 beta beta is enhanced by calcineurin inhibitors and requires activation of NF-kappa B	FASEB JOURNAL			English	Article						immunosuppressants; immunophilins; cyclosporin A; FK506; rapamycin; cypermethrin	PROTECTS HIPPOCAMPAL-NEURONS; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; ALZHEIMERS-DISEASE; MOTOR-NEURONS; GROWTH-FACTOR; CELL-DEATH; PROTEINS	S100 beta beta is a calcium binding, neurotrophic protein produced by nonneuronal cells in the nervous system. The pathway by which it enhances neuronal survival is unknown. Here we show that S100 beta beta enhances survival of embryonic chick forebrain neurons in a dose-dependent manner. In the presence of suboptimal amounts of S100 beta beta, neuronal survival is enhanced by the immunosuppressants FK506 and cyclosporin A at concentrations that inhibit calcineurin, which is present in these cells. Rapamycin, an immunosuppressant that does not inhibit calcineurin, did not enhance cell survival, Cypermethrin, a direct and highly specific calcineurin inhibitor, mimicked the immunophilin ligands in its neurotrophic effect. None of the drugs stimulated neuronal survival in the absence of S100 beta beta, In the presence of suboptimal amounts of S100 beta beta, FK506, cyclosporin A, and cypermethrin (but not rapamycin) also increased NF-kappa B activity, as measured by immunofluorescence of cells stained with antibody to the active subunit (p65) and by immunoblotting of nuclear extracts. Antioxidant and glucocorticoid inhibitors of NF-kappa B decreased both the amount of active NF-kappa B and the survival of neurons caused by S100 beta beta alone or in the presence of augmenting drugs. We conclude that S100 beta beta enhances the survival of chick embryo forebrain neurons through the activation of NF-kappa B.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Bamburg, JR (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	jbamburg@vines.colostate.edu		Alexanian, Arshak/0000-0001-6107-9427	FOGARTY INTERNATIONAL CENTER [F05TW005357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035126] Funding Source: NIH RePORTER; FIC NIH HHS [TW05357] Funding Source: Medline; NIGMS NIH HHS [GM35126] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BAUDIER J, 1982, FEBS LETT, V148, P231, DOI 10.1016/0014-5793(82)80813-2; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Boissiere F, 1997, NEUROREPORT, V8, P2849, DOI 10.1097/00001756-199709080-00009; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grothe C, 1996, INT J DEV BIOL, V40, P403; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Hu JR, 1997, J NEUROCHEM, V69, P2294; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kanno T, 1996, J IMMUNOL, V157, P5277; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1989, J BIOL CHEM, V264, P12800; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marinovich M, 1996, EXP CELL RES, V226, P98, DOI 10.1006/excr.1996.0207; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Migheli A, 1997, J NEUROPATH EXP NEUR, V56, P1314, DOI 10.1097/00005072-199712000-00006; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MITTAL CK, 1994, BIOCHEM BIOPH RES CO, V203, P8, DOI 10.1006/bbrc.1994.2141; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PerezOtano I, 1996, GLIA, V16, P306, DOI 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y; PETTMANN B, 1979, NATURE, V281, P378, DOI 10.1038/281378a0; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANELDIK LJ, 1988, CALCIUM CALCIUM BIND, P114; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	61	49	49	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1611	1620		10.1096/fasebj.13.12.1611	http://dx.doi.org/10.1096/fasebj.13.12.1611			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463953				2022-12-28	WOS:000082347600017
J	Tonini, R; Grohovaz, F; Laporta, CAM; Mazzanti, M				Tonini, R; Grohovaz, F; Laporta, CAM; Mazzanti, M			Gating mechanism of the nuclear pore complex channel in isolated neonatal and adult mouse liver nuclei	FASEB JOURNAL			English	Article						NPCs; nuclei isolation; histogram analysis; single-channel currents	IONIC PERMEABILITY; PROTEIN IMPORT; ENVELOPE; TRANSPORT; CELLS; MEMBRANE; CALCIUM; ATP; MICROSCOPY; VOLTAGE	Several types of ionic channels on the outer membrane of the nuclear envelope communicate with the nuclear cisternae. These are distinct from nucleocytoplasmic pathways, the nuclear pores that span the double membrane of the envelope and are the route for RNA and protein traffic in the nucleus. Recent data indicate that the nuclear pores may also function as ion channels. The most probable candidate for nucleocytoplasmic ion flux is a 300-400 pS pathway observed in many nuclear preparations. Morphological and functional studies of nuclear envelope suggest a tight relationship between the large conductance channel and the pore complex. However, there is no direct evidence for gating of the nuclear pore or its ability to open and close as a conventional channel. This study shows that in liver nuclei isolated from newborn mouse, there is a substantial correspondence between the number of pores and the number of channels recorded during patch-clamp. This is not the case for adult nuclei. Although pore density is comparable, some nuclear cytoskeletal components, such as actin and nonmuscle myosin, show a significant increase in the adult preparation. Previous studies demonstrate the presence of these two proteins in association with the pore complex. Here we show that by using actin filament disrupter, we were able to increase the number of active channels in adult isolated nuclei. We suggest that a functional interaction between actin filaments and the nuclear pore complex could regulate nucleocytoplasmic permeability.	Univ La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ Milano 1, Dipartimento Fisiol & Biochim Gen, Milan, Italy; San Raffaele Sci Inst, CNR, Ctr Farmacol Cellulare & Mol & Dibit, San Raffaele, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Mazzanti, M (corresponding author), Univ La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Piazalle A Moro 5, I-00185 Rome, Italy.		Mazzanti, Michele/A-8941-2011; Tonini, Raffaella/J-2960-2012; Grohovaz, Fabio/K-8226-2016; la porta, caterina/K-7345-2013	Grohovaz, Fabio/0000-0003-4635-259X; TONINI, Raffaella/0000-0003-1652-4709; la porta, caterina/0000-0002-3010-8966; Mazzanti, Michele/0000-0002-1819-3811				AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1016/S0022-2836(95)80050-6; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Assandri R, 1997, J MEMBRANE BIOL, V157, P301, DOI 10.1007/s002329900237; Badminton MN, 1998, CELL CALCIUM, V23, P79, DOI 10.1016/S0143-4160(98)90105-1; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; BUSTAMANTE JO, 1994, J MEMBRANE BIOL, V138, P105; BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; Csermely P, 1995, BBA-REV BIOMEMBRANES, V1241, P425, DOI 10.1016/0304-4157(95)00015-1; DALE B, 1994, P ROY SOC B-BIOL SCI, V255, P119, DOI 10.1098/rspb.1994.0017; Danker T, 1997, CELL BIOL INT, V21, P747, DOI 10.1006/cbir.1997.0219; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; Draguhn A, 1997, J MEMBRANE BIOL, V158, P159, DOI 10.1007/s002329900253; Goldberg MW, 1996, J MOL BIOL, V257, P848, DOI 10.1006/jmbi.1996.0206; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; Hille B., 1992, IONIC CHANNELS EXCIT; INNOCENTI B, 1993, J MEMBRANE BIOL, V131, P137, DOI 10.1007/BF02791322; LOEWENST.WR, 1966, ANN NY ACAD SCI, V137, P708, DOI 10.1111/j.1749-6632.1966.tb50192.x; LOEWENSTEIN WR, 1963, J GEN PHYSIOL, V46, P1123, DOI 10.1085/jgp.46.6.1123; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MARUYAMA Y, 1995, PFLUG ARCH EUR J PHY, V430, P148, DOI 10.1007/BF00373851; MATZKE AJM, 1992, FEBS LETT, V302, P81, DOI 10.1016/0014-5793(92)80290-W; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; Mazzanti M, 1998, NEWS PHYSIOL SCI, V13, P44; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1987, BIOPHYS J, V52, P95, DOI 10.1016/S0006-3495(87)83192-2; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; Meldolesi J, 1998, NATURE, V392, P863, DOI 10.1038/31804; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; OBERLEITHNER H, 1992, CLIN INVESTIGATOR, V70, P816; OBERLEITHNER H, 1993, PFLUG ARCH EUR J PHY, V423, P88, DOI 10.1007/BF00374965; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Prat AG, 1996, AM J PHYSIOL-CELL PH, V270, pC1532, DOI 10.1152/ajpcell.1996.270.5.C1532; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; Rousseau E, 1996, BIOPHYS J, V70, P703, DOI 10.1016/S0006-3495(96)79610-8; SAKMANN B, 1995, SINGLECHANNEL RECORD; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; TABARES L, 1991, J MEMBRANE BIOL, V123, P49, DOI 10.1007/BF01993962; UMARTH W, 1974, J MICROSC-OXFORD, V101, P103; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8	44	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1395	1403		10.1096/fasebj.13.11.1395	http://dx.doi.org/10.1096/fasebj.13.11.1395			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428763				2022-12-28	WOS:000082019100011
J	Sawant, SG; Gregoire, V; Dhar, S; Umbricht, CB; Cvilic, S; Sukumar, S; Pandita, TK				Sawant, SG; Gregoire, V; Dhar, S; Umbricht, CB; Cvilic, S; Sukumar, S; Pandita, TK			Telomerase activity as a measure for monitoring radiocurability of tumor cells	FASEB JOURNAL			English	Article						cell kill; ionizing radiation; tumor growth	LIFE-SPAN; CANCER; MARKER; IMMORTALITY	Radiotherapy plays a key role in the treatment of many tumors. It is difficult to determine what fraction of tumor cells survives after treatment with ionizing radiation. A convenient and sensitive biochemical assay could be efficacious in determining the potential success of radiotherapy. Since telomerase activity is frequently associated with the malignant phenotype, we sought to determine whether a correlation existed between ionizing radiation-induced cell killing and telomerase activity. We evaluated telomerase activity in two telomerase-positive and one telomerase-negative human cell line exposed to ionizing radiation. Telomerase activity was determined using a PCR-based telomeric repeat amplification protocol coupled with ELISA We found ionizing radiation treatment to decrease the telomerase activity (in plateau phase cells of RKO, HeLa; and growing cells of RKO) in a dose-dependent manner, which correlated with cell death in in vitro tests as well as during tumor regression in nude mice. In contrast, growing HeLa cells after 24 h postradiation treatment showed an increase in telomerase activity, but there was no increase in the levels of mRNA of hTERT. To assess the sensitivity of the telomerase activity assay, we performed mixing experiments of HeLa and AG1522 cell. extracts. These studies showed that telomerase activity could be detected in lysate equal to a single HeLa cell when mixed with 10,000 AG1522 cells. Our results indicate that even a few surviving neoplastic cells can be detected by telomerase activity assay. Therefore, detection of telomerase activity may be a useful monitor of radiotherapeutic efficacy and an early predictor of outcome.	Columbia Univ, Coll Phys & Surg VC11 213, Ctr Radiol Res, New York, NY 10032 USA; St Luc Univ Hosp, Dept Radiat Oncol, Brussels, Belgium; Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Columbia University; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), Columbia Univ, Coll Phys & Surg VC11 213, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blackburn EH, 1995, TELOMERES; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brandt-Rauf PW, 1998, PHARMACOL THERAPEUT, V77, P135, DOI 10.1016/S0163-7258(97)00111-3; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lee DH, 1998, CLIN CANCER RES, V4, P535; Meeker AK, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1323; MEYERSON M, 1997, CELL, V90, P85; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Ohyashiki K, 1997, CANCER RES, V57, P2100; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; Pandita TK, 1996, ONCOGENE, V13, P1423; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Scates DK, 1997, BRIT J UROL, V80, P263, DOI 10.1046/j.1464-410X.1997.00248.x; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WATSON JD, 1992, NAT, V239, P197; WILLEY JC, 1991, CANCER RES, V51, P5370; Wisman GBA, 1998, J CLIN ONCOL, V16, P2238, DOI 10.1200/JCO.1998.16.6.2238	30	40	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1047	1054		10.1096/fasebj.13.9.1047	http://dx.doi.org/10.1096/fasebj.13.9.1047			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336887				2022-12-28	WOS:000080547700009
J	Vandenburgh, H; Chromiak, J; Shansky, J; Del Tatto, M; Lemaire, J				Vandenburgh, H; Chromiak, J; Shansky, J; Del Tatto, M; Lemaire, J			Space travel directly induces skeletal muscle atrophy	FASEB JOURNAL			English	Article						protein turnover; skeletal myofiber; spaceflight; TCA	GROWTH-FACTOR-I; PROTEIN-TURNOVER; MECHANICAL STIMULATION; SUSPENDED RATS; TISSUE-CULTURE; IGF-I; HORMONE; SPACEFLIGHT; EXERCISE; INVITRO	Space travel causes rapid and pronounced skeletal muscle wasting in humans that reduces their long-term flight capabilities, To develop effective countermeasures, the basis of this atrophy needs to be better understood. Space travel may cause muscle atrophy indirectly by altering circulating levels of factors such as growth hormone, glucocorticoids, and anabolic steroids and/or by a direct effect on the muscle fibers themselves. To determine whether skeletal muscle cells are directly affected by space travel, tissue-cultured avian skeletal muscle cells were tissue engineered into bioartificial muscles and flown in perfusion bioreactors for 9 to 10 days aboard the Space Transportation System (STS, i.e., Space Shuttle). Significant muscle fiber atrophy occurred due to a decrease in protein synthesis rates without alterations in protein degradation, Return of the muscle cells to Earth stimulated protein synthesis rates of both muscle-specific and extracellular matrix proteins relative to ground controls. These results show for the first time that skeletal muscle fibers are directly responsive to space travel and should be a target for countermeasure development.	Brown Univ, Sch Med, Dept Pathol, Providence, RI 02906 USA; Miriam Hosp, Providence, RI 02906 USA; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Brown University	Vandenburgh, H (corresponding author), Brown Univ, Sch Med, Dept Pathol, 164 Summit Ave, Providence, RI 02906 USA.							BOOTH FW, 1985, FED PROC, V44, P2293; CERNY LC, 1986, J CELL BIOL, V103, P2153, DOI 10.1083/jcb.103.6.2153; CHROMIAK JA, 1992, AM J PHYSIOL, V262, pC1471, DOI 10.1152/ajpcell.1992.262.6.C1471; Chromiak JA, 1998, IN VITRO CELL DEV-AN, V34, P694; CHROMIAK JA, 1994, J CELL PHYSIOL, V159, P407, DOI 10.1002/jcp.1041590304; Davis TA, 1996, J LEUKOCYTE BIOL, V60, P69, DOI 10.1002/jlb.60.1.69; EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733; Ferrando AA, 1996, AM J PHYSIOL-ENDOC M, V270, pE627, DOI 10.1152/ajpendo.1996.270.4.E627; GOLDSPINK DF, 1983, BIOCHEM J, V210, P89, DOI 10.1042/bj2100089; GRIGORYEV AI, 1990, KOSM BIOL AVIAK MED, V5, P3; GRINDELAND RE, 1994, AM J PHYSIOL, V267, pR316, DOI 10.1152/ajpregu.1994.267.1.R316; Hintz RL, 1996, ENDOCRIN METAB CLIN, V25, P759, DOI 10.1016/S0889-8529(05)70352-2; Hymer WC, 1996, J APPL PHYSIOL, V80, P955, DOI 10.1152/jappl.1996.80.3.955; KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LINDERMAN JK, 1994, AM J PHYSIOL, V267, pR365, DOI 10.1152/ajpregu.1994.267.2.R365; MCMILLAN DN, 1987, PROSTAGLANDINS, V34, P841, DOI 10.1016/0090-6980(87)90065-7; Meling TR, 1996, AM J MED SCI, V311, P153, DOI 10.1097/00000441-199604000-00001; MIR B, 1990, FASEB J, V4, P64; PERRONE CE, 1995, J BIOL CHEM, V270, P2099, DOI 10.1074/jbc.270.5.2099; REDMOND EM, 1995, IN VITRO CELL DEV-AN, V31, P601; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; Roy R R, 1996, Exerc Sport Sci Rev, V24, P399; Roy RR, 1996, J APPL PHYSIOL, V81, P302, DOI 10.1152/jappl.1996.81.1.302; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; Shansky J, 1997, IN VITRO CELL DEV-AN, V33, P659, DOI 10.1007/s11626-997-0118-y; STEFFEN JM, 1986, AM J PHYSIOL, V251, pR1059, DOI 10.1152/ajpregu.1986.251.6.R1059; Stein TP, 1997, AM J PHYSIOL-ENDOC M, V272, pE688, DOI 10.1152/ajpendo.1997.272.4.E688; Stewart D.M, 1972, REGULATION ORGAN TIS, P77; VandenBurgh H, 1998, HUM GENE THER, V9, P2555, DOI 10.1089/hum.1998.9.17-2555; VANDENBURGH H, 1980, J BIOL CHEM, V255, P5826; Vandenburgh H, 1996, HUM GENE THER, V7, P2195, DOI 10.1089/hum.1996.7.17-2195; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1991, FASEB J, V5, P2860, DOI 10.1096/fasebj.5.13.1916108; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; Vandenburgh HH, 1996, AM J PHYSIOL-CELL PH, V270, pC1284, DOI 10.1152/ajpcell.1996.270.5.C1284; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P166, DOI 10.1007/BF02623542; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; VANDENBURGH HH, 1987, MED SCI SPORT EXER, V19, pS142; VANDENBURGH HH, 1998, METHODS MOL MED TISS, P205; Viru A, 1985, HORMONES MUSCULAR AC; WONG TS, 1990, J APPL PHYSIOL, V69, P1709, DOI 10.1152/jappl.1990.69.5.1709	43	89	95	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1031	1038		10.1096/fasebj.13.9.1031	http://dx.doi.org/10.1096/fasebj.13.9.1031			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336885				2022-12-28	WOS:000080547700007
J	Desgranges, P; Barbaud, C; Caruelle, JP; Barritault, D; Gautron, J				Desgranges, P; Barbaud, C; Caruelle, JP; Barritault, D; Gautron, J			A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle	FASEB JOURNAL			English	Article						skeletal muscle; RGTA; ischemia	FIBROBLAST GROWTH-FACTOR; SKELETAL-MUSCLE; FACTOR-I; DERIVATIVES; INJURY; REPERFUSION; EXPRESSION; INHIBITION; SULFATE; REPAIR	Ischemia and denervation of EDL muscle of adult rat induce a large central zone of degeneration surrounded by a thin zone of peripheral surviving muscle fibers. Muscle regeneration is a complex phenomenon in which many agents interact, such as growth factors and heparan sulfate components of the extracellular matrix. We have shown that synthetic polymers, called RGTA las regenerating agents), which imitate the heparan sulfates, are able to stimulate tissue repair when applied at the site of injury. In crushed muscles, RGTA were found to accelerate both regeneration and reinnervation. In vitro, RGTA act as protectors and potentiators of various heparin binding growth factors (HBGF). It was postulated that in vivo their tissue repair properties were due in part to an increase of bioavailability of endogenously released HBGF. In the present work, we show that ischemic and denervated EDL muscle treated by a unique injection of RGTA differs from the control after 1 wk in several aspects: 1) the epimysial postinflammatory reaction is inhibited and the area of fibrotic tissue among fibers is reduced; 2) the peripheral zone, as measured by the number of intact muscle fibers, was increased by more than twofold; and 3) In the central zone, RGTA enhances the regeneration of the muscle fibers as well as muscle revascularization. These results suggest that RGTA both protects muscle fibers from degeneration and preserves the differentiated state of the surviving fibers. For the first time it is demonstrated that a functionalized polymeric compound can prevent some of the damage resulting from muscle ischemia. RGTA may therefore open a new therapeutic approach for muscle fibrosis and other postischemic muscle pathologies.	Univ Paris 12, Lab Rech Croissance Cellulaire Regenerat & Repara, CNRS, UPRESA 7053, F-94010 Creteil, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Barritault, D (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Regenerat & Repara, CNRS, UPRESA 7053, F-94010 Creteil, France.	barritault@univ-paris12.fr						AAMIRI A, 1995, CR ACAD SCI III-VIE, V318, P1037; Aamiri A, 1995, NEUROSCI LETT, V201, P243, DOI 10.1016/0304-3940(95)12182-X; ANDERSON JE, 1991, MUSCLE NERVE, V14, P268, DOI 10.1002/mus.880140311; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CARLSON BM, 1975, PFLUG ARCH EUR J PHY, V353, P215, DOI 10.1007/BF00584285; CARLSON BM, 1975, ANAT RECORD, V183, P47, DOI 10.1002/ar.1091830106; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; Desgranges F, 1997, INT J ARTIF ORGANS, V20, P589, DOI 10.1177/039139889702001009; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLORINI JA, 1989, AM J PHYSIOL, V125, P701; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; GAUTRON J, 1995, CR ACAD SCI III-VIE, V318, P671; GULATI AK, 1983, J CELL BIOL, V97, P957, DOI 10.1083/jcb.97.4.957; HANSENSMITH FM, 1980, AM J ANAT, V158, P65, DOI 10.1002/aja.1001580107; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; LEFAUCHEUR JP, 1995, J NEUROIMMUNOL, V57, P85, DOI 10.1016/0165-5728(94)00166-L; LETOURNEUR D, 1993, IN VITRO CELL DEV-AN, V29A, P67; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MAUZAC M, 1984, BIOMATERIALS, V5, P301, DOI 10.1016/0142-9612(84)90078-4; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 1996, INT J BIOL MACROMOL, V18, P141, DOI 10.1016/0141-8130(95)01074-2; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; Meddahi A, 1995, BIOCHIMIE, V77, P703, DOI 10.1016/0300-9084(96)88185-5; Mitchell CA, 1996, GROWTH FACTORS, V13, P37, DOI 10.3109/08977199609034565; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; PADUA RR, 1995, MOL CELL BIOCHEM, V143, P129, DOI 10.1007/BF01816946; SCHOLLMEYER JE, 1986, EXP CELL RES, V163, P413, DOI 10.1016/0014-4827(86)90072-8; TARDIEU M, 1992, J CELL PHYSL, V150, P94; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; YAMADA S, 1989, MED SCI SPORT EXER, V21, pS173	33	65	71	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					761	766		10.1096/fasebj.13.6.761	http://dx.doi.org/10.1096/fasebj.13.6.761			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094936				2022-12-28	WOS:000079527200017
J	Khare, S; Kumar, U; Sasi, R; Puebla, L; Calderon, L; Lemstrom, K; Hayry, P; Patel, YC				Khare, S; Kumar, U; Sasi, R; Puebla, L; Calderon, L; Lemstrom, K; Hayry, P; Patel, YC			Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty	FASEB JOURNAL			English	Article						receptor subtypes; smooth muscle cell; SST; leukocyte; MAPK; macrophage	SMOOTH-MUSCLE CELLS; 5'-FLANKING PROMOTER REGION; RIBONUCLEIC-ACID EXPRESSION; GROWTH-FACTOR-I; ARTERIAL INJURY; CORONARY ANGIOPLASTY; SEQUENCE-ANALYSIS; BALLOON INJURY; CELLULAR PROLIFERATION; POTENTIAL TREATMENT	Treatment of restenosis after angioplasty with octapeptide somatostatin (SST) analogs has met with variable success. These analogs bind with high affinity to only two SST receptor (SSTR) subtypes (2 and 5), display moderate affinity for SSTR3, and low affinity for SSTR1 and 4. To optimize the vasculoprotective effect of SST, we have investigated the pattern of expression of all five SSTRs in rat thoracic aorta in the resting state and at 15 min, 3, 7, and 14 days after balloon endothelial denudation. SSTR1-5 were analyzed as mRNA by semiquantitative reverse transcriptase-polymerase chain reaction and as protein by immunocytochemistry. All five SSTRs were expressed in rat aorta both as mRNA and protein and displayed a time-dependent, subtype-selective response to endothelial denudation. mRNA for SSTR1 and 2 increased acutely (SSTR1 > SSTR2) on days 3 and 7, coincident with smooth muscle cell (SMC) proliferation, and declined to basal levels by day 14. SSTR3 and 4 displayed a different pattern with a delayed, more gradual increase in mRNA beginning at days 3-7 and continued to increase thereafter. SSTR5 mRNA was constitutively expressed at a low level and showed no change during the 2 wk postinjury period. By immunohistochemistry, SSTR1-5 antigens were localized predominantly in SMC that were present in the media or had migrated into the intima; antigen expression correlated with receptor mRNA expression. Notably, only SSTR1,3,4 were expressed in the intima: SSTR1 and 4 during the proliferative burst and SSTR3 and 4 after proliferation, when SMC migration into the intima continues. These results demonstrate dynamic changes in SSTR1-5 expression after vascular trauma localized to areas of vascular SMC migration and replication. In view of their early and prominent induction, SSTR1 may be the optimal subtype to target for inhibition of myointimal proliferation, and SSTR3 and 4 for migration and remodeling.	McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Montreal, PQ H3A 1A1, Canada; Univ Helsinki, Haartman Inst, Transplantat Lab, FIN-00014 Helsinki, Finland	McGill University; Royal Victoria Hospital; University of Helsinki	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Fraser Labs, Room M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	patel@rvhmed.lan.megill.ea	Lemström, Karl B/J-8885-2016	Lemström, Karl B/0000-0001-6920-4093				Aguila MC, 1996, ENDOCRINOLOGY, V137, P1585, DOI 10.1210/en.137.5.1585; Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BRUNO JF, 1994, BIOCHEM BIOPH RES CO, V202, P1738, DOI 10.1006/bbrc.1994.2136; Chen JC, 1997, J INVEST SURG, V10, P17, DOI 10.3109/08941939709032120; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DIESMARQUES ML, 1995, ENDOCRINOL METAB, V136, P3444; EMANUELSSON H, 1995, CIRCULATION, V91, P1689, DOI 10.1161/01.CIR.91.6.1689; ERIKSEN UH, 1995, AM HEART J, V130, P1, DOI 10.1016/0002-8703(95)90227-9; FOEGH ML, 1994, J VASC SURG, V19, P1084, DOI 10.1016/S0741-5214(94)70221-7; Foegh ML, 1997, TRANSPLANT P, V29, P2605, DOI 10.1016/S0041-1345(97)00526-5; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GOLDBERG ID, 1979, SCIENCE, V205, P920, DOI 10.1126/science.472713; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; Greenwood MT, 1997, MOL PHARMACOL, V52, P807, DOI 10.1124/mol.52.5.807; GREENWOOD MT, 1994, BIOCHEM BIOPH RES CO, V205, P1883, DOI 10.1006/bbrc.1994.2890; GREENWOOD MT, 1995, GENE, V159, P291, DOI 10.1016/0378-1119(95)00059-F; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; HAYRY P, 1995, FASEB J, V9, P1336; HAYRY P, 1993, IMMUNOL REV, V134, P33, DOI 10.1111/j.1600-065X.1993.tb00639.x; HAYRY P, 1993, FASEB J, V7, P1055, DOI 10.1096/fasebj.7.11.8370476; HOLMES D, 1988, J AM COLL CARDIOL, V22, P1149; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; HONG MK, 1993, CIRCULATION, V88, P638, DOI 10.1161/01.CIR.88.2.638; James RA, 1997, ENDOCRINOLOGY, V138, P719, DOI 10.1210/en.138.2.719; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; KUMAR U, 1997, ENDOCRINOLOGY, V138, P4474; Lemstrom KB, 1997, CIRCULATION, V96, P1240, DOI 10.1161/01.CIR.96.4.1240; LESZCZYNSKI D, 1993, REGUL PEPTIDES, V43, P131, DOI 10.1016/0167-0115(93)90147-Z; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; PATEL YC, 1993, BIOCHEM BIOPH RES CO, V192, P288, DOI 10.1006/bbrc.1993.1412; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; PATEL YC, 1994, J BIOL CHEM, V269, P1506; PATEL YC, 1999, HDB PHYSL; Pscherer A, 1996, EMBO J, V15, P6680, DOI 10.1002/j.1460-2075.1996.tb01058.x; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REUBI JC, 1994, INT J CANCER, V56, P681, DOI 10.1002/ijc.2910560513; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sirois MG, 1997, CIRCULATION, V95, P669, DOI 10.1161/01.CIR.95.3.669; VIDAL C, 1994, MOL PHARMACOL, V46, P97; vonEssen R, 1997, CIRCULATION, V96, P1482, DOI 10.1161/01.CIR.96.5.1482; WAHREN J, 1976, LANCET, V2, P1213; WALTERNG EA, 1991, J SURG RES, V50, P245; Weckbecker G, 1997, TRANSPLANT P, V29, P2599, DOI 10.1016/S0041-1345(97)00523-X; WRIGHTON CJ, 1996, J EXP MED, V183, P1; XU Y, 1995, ENDOCRINOLOGY, V136, P5070, DOI 10.1210/en.136.11.5070; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634; XU Y, 1995, BIOCHEM BIOPH RES CO, V206, P935, DOI 10.1006/bbrc.1995.1132; YURNI K, 1997, LAB INVEST, V76, P329	53	34	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					387	394		10.1096/fasebj.13.2.387	http://dx.doi.org/10.1096/fasebj.13.2.387			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973327				2022-12-28	WOS:000078615200019
J	Zhai, YF; Ni, J; Jiang, GW; Lu, JM; Xing, LL; Lincoln, C; Carter, KC; Janat, F; Kozak, D; Xu, SM; Rojas, L; Aggarwal, BB; Ruben, S; Li, LY; Gentz, R; Yu, GL				Zhai, YF; Ni, J; Jiang, GW; Lu, JM; Xing, LL; Lincoln, C; Carter, KC; Janat, F; Kozak, D; Xu, SM; Rojas, L; Aggarwal, BB; Ruben, S; Li, LY; Gentz, R; Yu, GL			VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo	FASEB JOURNAL			English	Article						TNF; cytokine; anti-tumor; anti-angiogenesis; EST	GENE-TRANSFER; TNF RECEPTOR; LIGAND; APOPTOSIS; CANCER; MEMBER	A novel member of the tumor necrosis factor (TNF) family has been identified from the human umbilical vein endothelial cell cDNA library, named vascular endothelial growth inhibitor (VEGI). The VEGI gene was mapped to human chromosome 9q32. The cDNA for VEGI encodes a protein of 174 amino acid residues with the characteristics of a type II transmembrane protein. Its amino acid sequence is 20-30% identical to other members of the TNF family. Unlike other members of the TNF family, VEGI is expressed predominantly in endothelial cells. Local production of a secreted form of VEGI via gene transfer caused complete suppression of the growth of MC-38 murine colon cancers in syngeneic C57BL/6 mice. Histological examination showed marked reduction of vascularization in MC-38 tumors that expressed soluble but not membrane-bound VEGI or were transfected with control vector. The conditioned media from soluble VEGI-expressing cells showed marked inhibitory effect on in vitro proliferation of adult bovine aortic endothelial cells. Our data suggest that VEGI is a novel angiogenesis inhibitor of the TNF family and functions in part by directly inhibiting endothelial cell proliferation. The results further suggest that VEGI maybe highly valuable toward angiogenesis-based cancer therapy.	Human Genome Sci Inc, Rockville, MD 20850 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA	GlaxoSmithKline; Human Genome Sciences Inc; University of Texas System; UTMD Anderson Cancer Center; Georgetown University	Zhai, YF (corresponding author), Human Genome Sci Inc, 9410 Key W Ave, Rockville, MD 20850 USA.	Yifan_Zhai@hgsi.com	Aggarwal, Bharat B/G-3388-2013; Li, Luyuan/E-8951-2012					ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASHER A, 1987, J IMMUNOL, V138, P963; Baker SJ, 1996, ONCOGENE, V12, P1; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; Hussein AM, 1996, CANCER INVEST, V14, P343, DOI 10.3109/07357909609012162; Lotze MT, 1996, ANN NY ACAD SCI, V795, P440, DOI 10.1111/j.1749-6632.1996.tb52715.x; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Zhai YF, 1998, J CLIN INVEST, V102, P1142, DOI 10.1172/JCI3492	22	147	177	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					181	189		10.1096/fasebj.13.1.181	http://dx.doi.org/10.1096/fasebj.13.1.181			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872942				2022-12-28	WOS:000078029500019
J	Marchesi, VT				Marchesi, VT			http://www.fasebj.org	FASEB JOURNAL			English	Editorial Material																			0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1253	1253		10.1096/fasebj.12.13.1253	http://dx.doi.org/10.1096/fasebj.12.13.1253			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761769				2022-12-28	WOS:000076402000001
J	Gsell, S; Eschenhagen, T; Kaspareit, G; Nose, M; Scholz, H; Behrens, O; Wieland, T				Gsell, S; Eschenhagen, T; Kaspareit, G; Nose, M; Scholz, H; Behrens, O; Wieland, T			Apparent up-regulation of stimulatory G-protein alpha subunits in the pregnant human myometrium is mimicked by elevated smoothelin expression	FASEB JOURNAL			English	Article						epitope sharing; smooth muscle; G alpha(s); mRNA expression; adenylyl cyclase	BETA-ADRENERGIC-RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; ADENYLATE-CYCLASE; RAT MYOMETRIUM; DOWN-REGULATION; PRETERM LABOR; GENE-EXPRESSION; GUINEA-PIG; IDENTIFICATION; ISOFORMS	Sensitization of adenylyl cyclase (AC) by increased expression of large isoforms of the stimulatory G-protein G alpha(s) has been suggested as a mechanism that governs uterine quiescence during pregnancy. We quantified several components of the AC pathway in pregnant (P, n=21) and nonpregnant human myometria (NP, n=10). AC activity was similar to sevenfold higher in P than in NP under basal and stimulated conditions (MnCl2/GTP/GTP + isoproterenol). in addition, relative stimulation (% of basal) by 5'-guanosine-beta gamma-iminotriphosphate and forskolin was twofold higher in P. beta-Adrenoceptor density was low and unaltered in P. G alpha(s) mRNA splice variants did not differ in P. Using antisera against different epitopes of G alpha(s) (carboxyl-/more aminoterminal), we found unchanged expression of G alpha(s) short and long (45, 47 kDa) in P. Two additional proteins in P (51, 59 kDa) were detectable only by the carboxyl-terminal antiserum and lacked GTP binding properties. The 59 kDa protein could be identified as a recently discovered cytoskeletal protein, smoothelin, which was 10-fold increased in P. These data indicate that the apparent up-regulation of large G alpha(s) species in P is mimicked by elevated smoothelin. Therefore, the increase in AC cannot be attributed to changes in G alpha(s)- or beta-adrenoreceptors. Epitope sharing between G alpha(s), and smoothelin should be considered in experiments on smooth muscle tissues.-Gsell, S., Eschenhagen, T., Kaspareit, G., Nose, M., Scholz, H., Behrens, O., Wieland, T. Apparent up-regulation of stimulatory G-protein alpha subunits in the pregnant human myometrium is mimicked by elevated smoothelin expression.	Univ Hamburg, Krankenhaus Eppendorf, Abt Pharmakol, Inst Expt, D-20246 Hamburg, Germany; Univ Hamburg, Krankenhaus Eppendorf, Abt Pharmakol, Klin Pharmakol & Toxikol, D-20246 Hamburg, Germany; Kreiskrankenhaus Rendsburg, Cynakol Abt, D-24768 Rendsburg, Germany	University of Hamburg; University of Hamburg	Eschenhagen, T (corresponding author), Univ Erlangen Nurnberg, Dept Clin Pharmacol, Inst Expt & Clin Pharmacol, Fahrstr 17, D-91054 Erlangen, Germany.	thomas.eschenhagen@pharmakologie.uni-erlangen.de	Wieland, Thomas/Q-1506-2019; Wieland, Thomas/G-1772-2012	Wieland, Thomas/0000-0001-8262-8261; Wieland, Thomas/0000-0001-8262-8261				AbiGerges N, 1997, MOL PHARMACOL, V52, P482, DOI 10.1124/mol.52.3.482; ARKINSTALL SJ, 1990, J ENDOCRINOL, V127, P15, DOI 10.1677/joe.0.1270015; BERNAL AL, 1995, TRENDS PHARMACOL SCI, V16, P129, DOI 10.1016/S0165-6147(00)89000-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BREUILLER M, 1990, J CLIN ENDOCR METAB, V70, P1299, DOI 10.1210/jcem-70-5-1299; BREUILLER M, 1987, GYNECOL OBSTET INVES, V24, P28, DOI 10.1159/000298771; CAVAILLE F, 1986, EUR J BIOCHEM, V160, P507, DOI 10.1111/j.1432-1033.1986.tb10068.x; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; ELWARDYMEREZAK J, 1994, J MOL ENDOCRINOL, V13, P23, DOI 10.1677/jme.0.0130023; Engelhardt S, 1997, J CLIN ENDOCR METAB, V82, P1235, DOI 10.1210/jc.82.4.1235; ESCHENHAGEN T, 1995, J MOL CELL CARDIOL, V27, P357, DOI 10.1016/S0022-2828(08)80033-8; EUROPEFINNER GN, 1993, ENDOCRINOLOGY, V132, P2484, DOI 10.1210/en.132.6.2484; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; EuropeFinner GN, 1996, J CLIN ENDOCR METAB, V81, P1069, DOI 10.1210/jc.81.3.1069; FEINSTEIN DL, 1992, GLIA, V5, P139, DOI 10.1002/glia.440050208; GRANNEMAN JG, 1989, ENDOCRINOLOGY, V125, P2328, DOI 10.1210/endo-125-5-2328; HATJIS CG, 1985, AM J OBSTET GYNECOL, V151, P943, DOI 10.1016/0002-9378(85)90673-8; JAKOBS KH, 1985, ADV CYCLIC NUCLEOTID, V19, P25; KEHLENBACH RH, 1994, NATURE, V372, P804; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LEONI P, 1990, BIOCHEM J, V269, P31, DOI 10.1042/bj2690031; LEVENO KJ, 1992, NEW ENGL J MED, V327, P349, DOI 10.1056/NEJM199207303270510; MATTERA R, 1986, FEBS LETT, V206, P36, DOI 10.1016/0014-5793(86)81336-9; MHAOUTY S, 1995, J BIOL CHEM, V270, P11012, DOI 10.1074/jbc.270.18.11012; Mhaouty-Kodja S, 1997, J BIOL CHEM, V272, P31100, DOI 10.1074/jbc.272.49.31100; Mittmann C, 1998, J MOL MED, V76, P133, DOI 10.1007/s001090050201; MOLNAR M, 1990, J CLIN ENDOCR METAB, V71, P1243, DOI 10.1210/jcem-71-5-1243; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perkins J P, 1973, Adv Cyclic Nucleotide Res, V3, P1; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; RIEMER RK, 1988, MOL PHARMACOL, V33, P389; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SCARPACE PJ, 1990, MECH AGEING DEV, V52, P169, DOI 10.1016/0047-6374(90)90122-V; SCHMIDT A, 1991, J BIOL CHEM, V266, P18025; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TANFIN Z, 1991, FEBS LETT, V278, P4, DOI 10.1016/0014-5793(91)80070-J; vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401; WARSOP H, 1993, J DEV PHYSIOL, V19, P91; Wehrens XHT, 1997, FEBS LETT, V405, P315, DOI 10.1016/S0014-5793(97)00207-X; WIELAND T, 1993, J BIOL CHEM, V268, P18111; ZUMBIHL R, 1994, EUR J PHARM-MOLEC PH, V288, P9, DOI 10.1016/0922-4106(94)90004-3	44	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					17	26		10.1096/fasebj.14.1.17	http://dx.doi.org/10.1096/fasebj.14.1.17			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627276				2022-12-28	WOS:000084784700004
J	Liao, GJ; Kreitzer, G; Cook, TA; Gundersen, GG				Liao, GJ; Kreitzer, G; Cook, TA; Gundersen, GG			A signal transduction pathway involved in microtubule-mediated cell polarization	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		VIMENTIN INTERMEDIATE FILAMENTS; DETYROSINATED MICROTUBULES; SELECTIVE STABILIZATION; ORGANELLE TRANSPORT; ALPHA-TUBULIN; KINESIN; MITOCHONDRIA; FIBROBLASTS; TYROSINE; CHAIN		Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gundersen, GG (corresponding author), Columbia Univ, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.							ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; BALL EH, 1982, P NATL ACAD SCI-BIOL, V79, P123, DOI 10.1073/pnas.79.1.123; BLOSE SH, 1976, J CELL BIOL, V70, P459, DOI 10.1083/jcb.70.2.459; BULINSKI JC, 1991, BIOESSAYS, V13, P285, DOI 10.1002/bies.950130605; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; GUNDERSEN GG, 1994, J CELL SCI, V107, P645; GUNDERSEN GG, 1988, P NATL ACAD SCI USA, V85, P5946, DOI 10.1073/pnas.85.16.5946; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; GURLAND G, 1995, J CELL BIOL, V131, P1275, DOI 10.1083/jcb.131.5.1275; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HALLAK ME, 1977, FEBS LETT, V73, P147, DOI 10.1016/0014-5793(77)80968-X; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Liao GJ, 1998, J BIOL CHEM, V273, P9797, DOI 10.1074/jbc.273.16.9797; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Martys JL, 1999, MOL BIOL CELL, V10, P1289, DOI 10.1091/mbc.10.5.1289; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; NAGASAKI T, 1992, CELL MOTIL CYTOSKEL, V23, P45, DOI 10.1002/cm.970230106; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; RAYBIN D, 1977, BIOCHEMISTRY-US, V16, P2189, DOI 10.1021/bi00629a023; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; VALE RD, 1988, J CELL BIOL, V107, P2233, DOI 10.1083/jcb.107.6.2233; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387	32	13	13	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S257	S260		10.1096/fasebj.13.9002.S257	http://dx.doi.org/10.1096/fasebj.13.9002.S257			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619139				2022-12-28	WOS:000084390200017
J	Frank, S; Stallmeyer, B; Kampfer, H; Kolb, N; Pfeilschifter, J				Frank, S; Stallmeyer, B; Kampfer, H; Kolb, N; Pfeilschifter, J			Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair	FASEB JOURNAL			English	Article						gene expression regulation; skin; inducible nitric oxide synthase	GTP-CYCLOHYDROLASE-I; PERMEABILITY FACTOR; GENE-EXPRESSION; HEALING WOUNDS; HUMAN SKIN; SYNTHASE; CELLS; ARGININE; MITOGEN; PURIFICATION	Recently, we demonstrated a large induction of inducible nitric oxide synthase (iNOS) during cutaneous wound repair. In this study, we investigated the role of nitric oxide (NO) for the expression of vascular endothelial go ivth factor (VEGF), which represents the most important angiogenic factor during the proliferative phase of skin repair. Since keratinocytes are the major source of VEGF production during this process, we used cultured keratinocytes (HaCaT cell line) as an in vitro model to investigate NO action on growth factor-and cytokine-stimulated VEGF expression. Exogenously added NO enhanced transforming growth factor-beta 1-, keratinocyte growth factor-, interleukin-1 beta-, tumor necrosis factor-alpha-, and interferon-gamma-induced VEGF mRNA and protein synthesis in keratinocytes. We could demonstrate that high-level expression of cytokine-induced VEGF mRNA in keratinocytes is dependent on endogenously produced NO, as inhibition of the coinduced iNOS by N-G-monomethyl-L-arginine (L-NMMA) markedly decreased cytokine-triggered VEGF mRNA levels in the cells. We also established an in vivo model in mice to investigate the role of NO during wound healing. During excisional wound repair, mice were treated with L-N-6-(1-iminoethyl)lysine (L-NIL), a selective inhibitor of iNOS enzymatic activity. Compared to control mice, L-NIL-teated animals were characterized by markedly reduced VEGF mRNA levels during the inflammatory phase of repair. Immunohistochemistry demonstrated reduced VEGF protein expression and a completely disorganized pattern of VEGF-expressing keratinocytes within the hyperproliferative epithelium at the wound edge in L-NIL-treated mice. We demonstrate that triggering of VEGF expression is a crucial molecular mechanism underlying NO function during wound healing.-Frank, S., Stallmeyer, B., Kampfer, H., Kolb, N., Pfeilschifter, J. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair.	Univ Frankfurt Klinikum, Zentrum Physiol, Inst Allgemeine Pharmakol & Toxikol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Zentrum Physiol, Inst Allgemeine Pharmakol & Toxikol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Pfeilschifter@em.uni-frankfurt.de	Stallmeyer, Birgit/AAE-3020-2020					ALBINA JE, 1990, J IMMUNOL, V144, P3877; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BARBUL A, 1990, SURGERY, V108, P331; Beck KF, 1999, J EXP BIOL, V202, P645; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1988, AM J PATHOL, V130, P455; BruchGerharz D, 1996, J EXP MED, V184, P2007, DOI 10.1084/jem.184.5.2007; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; COLEMAN DL, 1982, DIABETES, V31, P1; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Frank S, 1999, BIOCHEM J, V338, P367, DOI 10.1042/0264-6021:3380367; Frank S, 1998, J INVEST DERMATOL, V111, P1058, DOI 10.1046/j.1523-1747.1998.00434.x; Frank S, 1998, J INVEST DERMATOL, V111, P1065, DOI 10.1046/j.1523-1747.1998.00433.x; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Goldsmith PC, 1996, J INVEST DERMATOL, V106, P113, DOI 10.1111/1523-1747.ep12328204; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIRK SJ, 1993, SURGERY, V114, P155; KLATT P, 1993, J BIOL CHEM, V268, P14781; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nissen NN, 1998, AM J PATHOL, V152, P1445; Ormerod AD, 1998, ARCH DERMATOL RES, V290, P3, DOI 10.1007/s004030050268; Reichner JS, 1999, AM J PATHOL, V154, P1097, DOI 10.1016/S0002-9440(10)65362-X; Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471, DOI 10.1002/jlb.59.4.471; RomeroGraillet C, 1997, J CLIN INVEST, V99, P635, DOI 10.1172/JCI119206; Rowe A, 1997, BRIT J DERMATOL, V136, P18, DOI 10.1046/j.1365-2133.1997.d01-1136.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SEIFTER E, 1978, SURGERY, V84, P224; Shimizu Yoshinori, 1997, Journal of Dermatology (Tokyo), V24, P80; Sirsjo A, 1996, BRIT J DERMATOL, V134, P643, DOI 10.1111/j.1365-2133.1996.tb06963.x; Stenger S, 1995, EUR J PHARMACOL, V294, P703, DOI 10.1016/0014-2999(95)00618-4; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; Weller R, 1996, J INVEST DERMATOL, V107, P327, DOI 10.1111/1523-1747.ep12363167; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wong H. L., 1989, HUMAN MONOCYTES, P383; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067	57	194	209	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2002	2014		10.1096/fasebj.13.14.2002	http://dx.doi.org/10.1096/fasebj.13.14.2002			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544183	Bronze			2022-12-28	WOS:000083660700012
J	Jensen-Jarolim, E; Wiedermann, U; Ganglberger, E; Zurcher, A; Stadler, BM; Boltz-Nitulescu, G; Scheiner, O; Breiteneder, H				Jensen-Jarolim, E; Wiedermann, U; Ganglberger, E; Zurcher, A; Stadler, BM; Boltz-Nitulescu, G; Scheiner, O; Breiteneder, H			Allergen mimotopes in food enhance type I allergic reactions in mice	FASEB JOURNAL			English	Article						Bet v 1; Bet mim 1; Prof mim 1; type 1 allergy; bacteriophage; mimotope; oral immunization; digestion; food allergen; BALB/c mouse model	BIRCH POLLEN ALLERGEN; MONOCLONAL-ANTIBODIES; IGE BINDING; AFFINITY PURIFICATION; BET-V-1; PHAGE; VEGETABLES; PROFILIN; PROTEINS; MODULATE	BIP1 is a murine IgG antibody capable of enhancing the IgE binding to Bet v 1, the major birch pollen allergen, We have previously generated a mimotope of BIP1, designated Bet mim 1, from a constrained phage display peptide library. We dem onstrated that oral immunization of BALB/c mice with the Bet mim 1 mimotope resulted in the induction of Bet v I-specific IgG, The aim of this study was to test the influence of such an oral immunization with Bet mim 1 on a subsequent type I allergic response to Bet v 1, Phages displaying Bet mim 1 or control mimotopes, or PBS alone, were delivered to BALB/c mice by intragastric gavages prior to systemic sensitization with recombinant Bet v I and AI(OH),, an adjuvant inducing preferentially IgE antibody responses. Only mice fed with Bet mim 1-phages displayed substantially enhanced type I allergic skin reactivity to Bet v 1, as compared to mice pretreated with control mimotopes or PBS, A gastric digestion assay indicated that Bet v I and its homologue from apple, Mal d 1, were degraded within seconds under physiological conditions. In contrast, phage-displayed mimotopes were resistant to digestion. Our data indicate that allergen mimics in the diet that resist digestion, can induce allergen specific IgG able to enhance an allergic response. We therefore conclude that sensitization via the oral route may represent a mechanism for aggravating type I allergic reactions, probably leading to an earlier onset of symptoms even at lower allergen dosage.	Univ Vienna, Dept Gen & Expt Pathol, AKH, EBO 3Q, A-1090 Vienna, Austria; Univ Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	University of Vienna; University of Bern	Jensen-Jarolim, E (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, AKH, EBO 3Q, Waehringer Guertel 18, A-1090 Vienna, Austria.	erika.jensen-jarolim@akh-wien.ac.at	Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Wiedermann, Ursula/0000-0002-1302-3223				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FRICK OL, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P304; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; JensenJarolim E, 1997, CLIN EXP ALLERGY, V27, P1299, DOI [10.1046/j.1365-2222.1997.1580956.x, 10.1111/j.1365-2222.1997.tb01175.x]; Knippels LMJ, 1998, CLIN EXP ALLERGY, V28, P368, DOI 10.1046/j.1365-2222.1998.00242.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, J IMMUNOL, V157, P4953; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; Lehrer SB, 1996, CRIT REV FOOD SCI, V36, P553, DOI 10.1080/10408399609527739; Leitner A, 1998, EUR J IMMUNOL, V28, P2921, DOI 10.1002/(SICI)1521-4141(199809)28:09<2921::AID-IMMU2921>3.0.CO;2-D; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Pastorello EA, 1998, ALLERGY, V53, P48, DOI 10.1111/j.1398-9995.1998.tb04960.x; PAULI G, 1992, ACI NEWS, V4, P43; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Visco V, 1996, J IMMUNOL, V157, P956; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	32	57	64	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1586	1592		10.1096/fasebj.13.12.1586	http://dx.doi.org/10.1096/fasebj.13.12.1586			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463950	Bronze			2022-12-28	WOS:000082347600014
J	Diekman, AB; Norton, EJ; Klotz, KL; Westbrook, VA; Shibahara, H; Naaby-Hansen, S; Flickinger, CJ; Herr, JC				Diekman, AB; Norton, EJ; Klotz, KL; Westbrook, VA; Shibahara, H; Naaby-Hansen, S; Flickinger, CJ; Herr, JC			N-linked glycan of a sperm CD52 glycoform associated with human infertility	FASEB JOURNAL			English	Article						autoimmunity; isoimmunity; glycocalyx; lymphocyte; contraception	HUMAN SEMINAL PLASMA; ANTISPERM ANTIBODIES; MONOCLONAL-ANTIBODIES; HUMAN-SPERMATOZOA; MEMBRANE-GLYCOPROTEINS; EPIDIDYMAL MATURATION; SURFACE GLYCOPROTEINS; PEPTIDE BACKBONE; RAT SPERMATOZOA; CDW52 ANTIGEN	In a benchmark study, Isojima and colleagues established H6-3C4, the first successful heterohybridoma immortalized from the peripheral blood lymphocytes of an infertile woman who exhibited high sperm-immobilizing antibody titers. The present report demonstrates the identity between the glycoprotein antigens recognized by the human H6-3C4 monoclonal antibody (mAb) and the murine S19 mAb, generated in our laboratory to sperm agglutination antigen-1 (SAGA-1). Both mAb's recognize N-linked carbohydrate epitopes on the 15-25 kDa, polymorphic SAGA-I glycoprotein that is localized to all domains of the human sperm surface. Treatment with phosphatidylinositol-specific phospholipase C demonstrated that SAGA-I is anchored in the sperm plasmalemma via a GPI-lipid linkage. Immunoaffinity purification and microsequencing indicated that the core peptide of the SAGA-1 glycoprotein is identical to the sequence of CD52, a GPI-anchored lymphocyte differentiation marker implicated in signal transduction. Comparison of anti-SAGA-1 and anti-CD52 immunoreactivities revealed that the sperm form of CD52 exhibits N-linked glycan epitopes, including the epitope recognized by the infertility-associated H6-3C4 mAb, which are not detected on lymphocyte CD52. Thus, the two populations of the CD52 glycoprotein on lymphocytes and spermatozoa represent glycoforms, glycoprotein isoforms with the same core amino acid sequence but different carbohydrate structures. Furthermore, mAb's to the unique carbohydrate epitopes on sperm CD52 have multiple inhibitory effects on sperm function, including a cytotoxic effect on spermatozoa in the presence of complement. These results are the first to implicate unique carbohydrate moieties of a sperm CD52 glycoform as target epitopes in the anti-sperm immune response of an infertile woman. Furthermore, localization of CD52 on all domains of the sperm surface coupled with the multiple sperm-inhibitory effects of antibodies to its unique carbohydrate moieties suggest opportunities for immunocontraceptive development.	Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Ctr Recombinant Gamete Contracept Vaccinogens, Charlottesville, VA 22908 USA	University of Virginia	Herr, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Ctr Recombinant Gamete Contracept Vaccinogens, Box 439, Charlottesville, VA 22908 USA.			Westbrook, Anne/0000-0003-4570-0126	NICHD NIH HHS [U54 HD 28934, HD U54 29099] Funding Source: Medline; PHS HHS [P30 28934] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029099] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON DJ, 1987, J REPROD IMMUNOL, V10, P231, DOI 10.1016/0165-0378(87)90089-1; BEARER EL, 1990, J ELECTRON MICR TECH, V16, P281, DOI 10.1002/jemt.1060160403; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRONSON RA, 1990, BIOL REPROD, V43, P1019, DOI 10.1095/biolreprod43.6.1019; CINEK T, 1992, J IMMUNOL, V149, P2262; DCRUZ OJ, 1993, J IMMUNOL, V151, P1062; Deshpande PP, 1998, J AM CHEM SOC, V120, P1600, DOI 10.1021/ja9725864; Deshpande PP, 1997, NATURE, V387, P164, DOI 10.1038/387164a0; Diekman AB, 1997, BIOL REPROD, V57, P1136, DOI 10.1095/biolreprod57.5.1136; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; HAMILTON DW, 1986, BIOL REPROD, V34, P925, DOI 10.1095/biolreprod34.5.925; HERR JC, 1992, BIOL REPROD, V47, P11, DOI 10.1095/biolreprod47.1.11; ISOJIMA S, 1989, ARCH ANDROLOGY, V23, P185, DOI 10.3109/01485018908986841; ISOJIMA S, 1987, J REPROD IMMUNOL, V10, P67, DOI 10.1016/0165-0378(87)90051-9; ISOJIMA S, 1990, GAMETE INTERACTION P, P63; KAMEDA K, 1990, Japanese Journal of Fertility and Sterility, V35, P313; KAMEDA K, 1991, J REPROD IMMUNOL, V20, P27, DOI 10.1016/0165-0378(91)90021-H; KAMEDA K, 1992, BIOL REPROD, V46, P349, DOI 10.1095/biolreprod46.3.349; KIRCHHOFF C, 1993, MOL REPROD DEV, V34, P8, DOI 10.1002/mrd.1080340103; Kirchhoff C, 1996, MOL HUM REPROD, V2, P9, DOI 10.1093/molehr/2.1.9; Kirchhoff C, 1996, MOL HUM REPROD, V2, P177, DOI 10.1093/molehr/2.3.177; Kutteh WH, 1996, AM J REPROD IMMUNOL, V35, P429; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN D, 1985, J REPROD IMMUNOL, V8, P329, DOI 10.1016/0165-0378(85)90007-5; MAHONY MC, 1991, J REPROD IMMUNOL, V19, P269, DOI 10.1016/0165-0378(91)90040-W; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; NAABYHANSEN S, 1985, J REPROD IMMUNOL, V7, P41, DOI 10.1016/0165-0378(85)90020-8; NAZ RK, 1995, ARCH ANDROLOGY, V35, P225, DOI 10.3109/01485019508987875; NIP MMC, 1995, HUM REPROD, V10, P2564, DOI 10.1093/oxfordjournals.humrep.a135746; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHL DA, 1995, UROLOGY, V46, P591, DOI 10.1016/S0090-4295(99)80282-9; OLSON GE, 1978, BIOL REPROD, V19, P26, DOI 10.1095/biolreprod19.1.26; PARADISI R, 1995, J REPROD IMMUNOL, V28, P61, DOI 10.1016/0165-0378(94)00911-P; PRIMAKOFF P, 1990, BIOL REPROD, V42, P929, DOI 10.1095/biolreprod42.6.929; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROWAN WC, 1994, INT IMMUNOL, V7, P69; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHAI S, 1992, FERTIL STERIL, V58, P593; SNOW K, 1992, FERTIL STERIL, V58, P1011; Southgate J, 1997, HUM REPROD, V12, P65; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; TSUJI Y, 1988, J EXP MED, V168, P343, DOI 10.1084/jem.168.1.343; WINGATE EW, 1993, J UROLOGY, V149, P1331, DOI 10.1016/S0022-5347(17)36385-1; XIA MQ, 1991, EUR J IMMUNOL, V21, P1677, DOI 10.1002/eji.1830210714; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; Yeung CH, 1997, MOL HUM REPROD, V3, P1045, DOI 10.1093/molehr/3.12.1045; Yeung CH, 1997, MOL REPROD DEV, V48, P267, DOI 10.1002/(SICI)1098-2795(199710)48:2<267::AID-MRD15>3.0.CO;2-V	51	48	54	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1303	1313		10.1096/fasebj.13.11.1303	http://dx.doi.org/10.1096/fasebj.13.11.1303			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428755				2022-12-28	WOS:000082019100003
J	Frei, B				Frei, B			Molecular and biological mechanisms of antioxidant action	FASEB JOURNAL			English	Editorial Material									Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA	Oregon State University	Frei, B (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.							Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Keaney JF, 1999, FASEB J, V13, P965, DOI 10.1096/fasebj.13.9.965; May JM, 1999, FASEB J, V13, P995, DOI 10.1096/fasebj.13.9.995; Upston JM, 1999, FASEB J, V13, P977, DOI 10.1096/fasebj.13.9.977	4	57	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					963	964		10.1096/fasebj.13.9.963	http://dx.doi.org/10.1096/fasebj.13.9.963			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336879	Bronze			2022-12-28	WOS:000080547700001
J	Spittler, A; Reissner, CM; Oehler, R; Gornikiewicz, A; Gruenberger, T; Manhart, N; Brodowicz, T; Mittlboeck, M; Boltz-Nitulescu, G; Roth, E				Spittler, A; Reissner, CM; Oehler, R; Gornikiewicz, A; Gruenberger, T; Manhart, N; Brodowicz, T; Mittlboeck, M; Boltz-Nitulescu, G; Roth, E			Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression	FASEB JOURNAL			English	Article						sepsis; cytokines; antigen expression; tumor necrosis factor; whole blood cell	TUMOR-NECROSIS-FACTOR; T-CELL PROLIFERATION; INTERLEUKIN-1 RECEPTOR ANTAGONIST; INHIBITS CYTOKINE PRODUCTION; MULTICENTER CLINICAL-TRIAL; HUMAN BLOOD MONOCYTES; MONOCLONAL-ANTIBODY; SEPTIC SHOCK; DOUBLE-BLIND; SEPSIS SYNDROME	Cytokines play a pivotal role in the pathogenesis of septic shock. Proinflammatory cytokines such as tumor necrosis factora-alpha (TNF-alpha) and interleukin-1 eta (IL-1 beta) stimulate the progression of septic shock whereas the anti-inflammatory cytokine ILIO has counterregulative potency. The amino acid glycine (GLY) has been shown to protect against endotoxin shock in the rat by inhibiting TNF-alpha production. In the current study we investigated the role of GLY on lipopolysaccharide (LPS) -induced cell surface marker expression, phagocytosis, and cytokine production on purified monocytes from healthy donors. GLY did not modulate the expression of HLA-DR and CD64 on monocytes, whereas CD11b/CD18 expression (P < 0.05) and E. coli phagocytosis (P < 0.05) decreased significantly. GLY decreased LPS-induced TNF-alpha production (P < 0.01) and increased ILIO expression of purified monocytes, Similarly, in a whole blood assay, GLY reduced TNF-alpha (P < 0.0001) and IL-1 beta (P < 0.0001) synthesis and increased IL-10 expression (P < 0.05) in a dose-dependent manner. The inhibitory effects of GLY were neutralized by strychnine, and the production of IL-10 and TNF-alpha was augmented by anti-IL-10 antibodies. Furthermore, GLY decreased the amount of IL-1 beta and TNF-alpha-specific mRNA. Our data indicate that GLY has a potential to be used as an additional immunomodulatory tool in the early phase of sepsis and in different pathophysiological situations related to hypoxia and reperfusion.	Univ Vienna, Dept Surg, Res Labs, AKH, A-1090 Vienna, Austria; Univ Vienna, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Med Comp Sci, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Spittler, A (corresponding author), Univ Vienna, Dept Surg, Res Labs, AKH, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	a.spittler@akh-wien.ac.at	Gruenberger, Thomas/ABA-1661-2020	Gruenberger, Thomas/0000-0002-2671-0540; Mittlboeck, Martina/0000-0003-1097-4047; Oehler, Rudolf/0000-0003-2891-7155; Spittler, Andreas/0000-0003-2657-6836				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BARRON RL, 1993, CLIN PHARMACY, V12, P829; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; Beutler B, 1993, New Horiz, V1, P3; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; DHAINAUT JFA, 1994, CRIT CARE MED, V22, P1720, DOI 10.1097/00003246-199422110-00005; DING L, 1992, J IMMUNOL, V148, P3133; DOHERTY GM, 1992, J IMMUNOL, V149, P1666; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1993, CRIT CARE MED, V21, P318, DOI 10.1097/00003246-199303000-00006; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; Griffiths RD, 1997, NUTRITION, V13, P295; HOUDIJK APJ, 1998, JPEN, V22, pS2; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Ikejima K, 1997, AM J PHYSIOL-GASTR L, V272, pG1581, DOI 10.1152/ajpgi.1997.272.6.G1581; Ikejima K, 1996, AM J PHYSIOL-GASTR L, V271, pG97, DOI 10.1152/ajpgi.1996.271.1.G97; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MARSH DC, 1993, HEPATOLOGY, V17, P91, DOI 10.1016/0270-9139(93)90197-U; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; SPITTLER A, 1995, BLOOD, V86, P1564, DOI 10.1182/blood.V86.4.1564.bloodjournal8641564; SPITTLER A, 1995, IMMUNOLOGY, V85, P311; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; TAGA K, 1992, J IMMUNOL, V148, P1143; Thurman RG, 1997, TRANSPLANTATION, V63, P1661, DOI 10.1097/00007890-199706150-00021; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Wang RX, 1997, J IMMUNOL, V158, P2856; WEINBERG JM, 1987, J CLIN INVEST, V80, P1446, DOI 10.1172/JCI113224; WEINBERG JM, 1991, J CLIN INVEST, V87, P581, DOI 10.1172/JCI115033; Zhong Z, 1996, AM J PHYSIOL-GASTR L, V270, pG332, DOI 10.1152/ajpgi.1996.270.2.G332	38	85	95	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					563	571		10.1096/fasebj.13.3.563	http://dx.doi.org/10.1096/fasebj.13.3.563			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064624				2022-12-28	WOS:000079016000017
J	Webb, SJ; Nicholson, D; Bubb, VJ; Wyllie, AH				Webb, SJ; Nicholson, D; Bubb, VJ; Wyllie, AH			Caspase-mediated cleavage of APC results in an aminoterminal fragment with an intact armadillo repeat domain	FASEB JOURNAL			English	Article						apoptosis; adenomatous polyposis coli; PARP; protein kinase; beta-catenin	APOPTOSIS IN-VITRO; BETA-CATENIN; POLY(ADP-RIBOSE) POLYMERASE; PROTEOLYTIC CLEAVAGE; PROTEIN; EXPRESSION; HOMOLOG; FAMILY; GENE	During the effector phase of apoptosis, caspase activation appears to be responsible for the distinctive structural changes of apoptosis and perhaps for some of the changes in function of the doomed cells. There is therefore interest in identifying caspase substrates and the details of the cleavage events. Here we define precisely the event responsible for generation of a stable 90 kDa fragment from the oncosuppressor protein adenomatous polyposis coli (APC), Using synthetic radiolabeled APC peptides as substrate, we demonstrate cleavage by cytosolic extracts from preapoptotic cells. This cleavage was reproduced by recombinant caspase-3 and blocked by a tetrapeptide inhibitor Ac-DEVD-CHO, which is specific for caspase-3 family members. Inhibitors specific for caspase-1 and -8 however, were less effective in blocking APC cleavage. Mutation of a candidate DNID caspase-3 target site completely abolished cleavage, This cleavage may be of biological importance since the 90 kDa fragment consists of a sequence that is highly conserved in the human, rat, mouse, Xenopus, and Drosophila APC, although wide sequence divergence is observed in Drosophila immediately carboxy-terminal to the DNID site. Furthermore, cleavage at this site separates two significant functional domains: an aminoterminal armadillo repeat and an adjacent series of beta-catenin binding sites. Further circumstantial evidence for the significance of APC-related pathways in apoptosis is provided by the observation that apoptosis also induces cleavage of beta-catenin itself, a protein known to accumulate in cells depleted in functional APC and that appears to link cell-cell signaling to changes in transcription and cell movement.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Merck Frosst Canada Inc, Pointe Claire, PQ H9R 4P8, Canada; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	University of Edinburgh; Merck & Company; University of Cambridge	Webb, SJ (corresponding author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.	sjwebb01@homer.louisville.edu						Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; BROWNE SJ, 1994, INT J CANCER, V59, P56, DOI 10.1002/ijc.2910590113; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Midgley CA, 1997, J PATHOL, V181, P426; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907	19	28	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					339	346		10.1096/fasebj.13.2.339	http://dx.doi.org/10.1096/fasebj.13.2.339			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973322				2022-12-28	WOS:000078615200014
J	De Capoa, A; Febbo, FR; Giovannelli, F; Niveleau, A; Zardo, G; Marenzi, S; Caiafa, P				De Capoa, A; Febbo, FR; Giovannelli, F; Niveleau, A; Zardo, G; Marenzi, S; Caiafa, P			Reduced levels of poly(ADP-ribosyl)ation result in chromatin compaction and hypermethylation as shown by cell-by-cell computer-assisted quantitative analysis	FASEB JOURNAL			English	Article						3-ABA; 5-methylcytosine; poly(ADP)-ribose)polymerase	DNA-BINDING PROTEIN; METHYLATED DNA; IN-VIVO; POLYMERASE; GENE; CPG; EXPRESSION; REPAIR; SITE; RECOGNITION	The unmethylated status of the CpG islands is important for gene expression of correlated housekeeping genes since it is well known that their methylation inhibits transcription process. An interesting question that has been discussed but not solved is how the CpG islands maintain their characteristic unmethylated status even though they are rich in CpG dinucleotides. Our previous in vitro and in vivo research has shown that poly(ADP-ribosyl)ation is involved in protecting CpG dinucleotides from full methylation in genomic DNA and that a block of poly(ADP-ribosyl)ation is also involved in modifying the methylation pattern in the promoter region of Htf9 housekeeping gene. In this study we locked for cytological evidence that in the absence of an active poly(ADP-ribosyl)ation the DNA methylation pattern in L929 and NIH/3T3 mouse fibroblast cell lines is altered. For this purpose, differences in the methylation levels of interphase nuclei from control and treated cultures of two murine cell lines preincubated with 2 mM 3-aminobenzamide, an inhibitor of poly(ADP-ribosyl)ation, were measured in individual cells after indirect immunolabeling with anti-5MeC antibodies. The quantitative analysis allowed us to demonstrate that blocking of the poly(ADP-ribosyl)ation results in a higher number, size, and density of antibody binding regions in treated cells when compared to the controls. Analogously, sequential Giemsa staining and indirect immunolabeling of the same slides showed the heterochromatic regions colocalized with the extended methyl-rich domains.	Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Genet & Mol Biol, Rome, Italy; Univ Rome La Sapienza, Dept Biochem Sci A Rossi Fanelli, Rome, Italy; Univ Grenoble 1, CNRS, Fac Med, Dept Virol,UPRESA 5082, Grenoble, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Sapienza University Rome; Sapienza University Rome; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Caiafa, P (corresponding author), Univ Aquila, Dipartimento Sci & Tecnol Biomed, Via Vetoio,Loc Coppito, I-67100 Laquila, Italy.							Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; ASIEDU CK, 1994, BBA-GENE STRUCT EXPR, V1219, P55, DOI 10.1016/0167-4781(94)90246-1; AUBIN RJ, 1983, EMBO J, V2, P1685, DOI 10.1002/j.1460-2075.1983.tb01643.x; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOULIKAS T, 1989, P NATL ACAD SCI USA, V86, P3499, DOI 10.1073/pnas.86.10.3499; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRUHAT A, 1995, P NATL ACAD SCI USA, V92, P3678, DOI 10.1073/pnas.92.9.3678; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; de Capoa A, 1998, CYTOMETRY, V31, P85, DOI 10.1002/(SICI)1097-0320(19980201)31:2<85::AID-CYTO3>3.3.CO;2-8; deCapoa A, 1996, CHROMOSOME RES, V4, P271, DOI 10.1007/BF02263676; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DErme M, 1996, BIOCHEM J, V316, P475, DOI 10.1042/bj3160475; GRIFFIN RJ, 1995, BIOCHIMIE, V77, P408, DOI 10.1016/0300-9084(96)88154-5; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KHAN R, 1988, J BIOL CHEM, V263, P14374; KUROKAWA T, 1995, BIOCHEM BIOPH RES CO, V215, P808, DOI 10.1006/bbrc.1995.2535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MALANGA M, 1994, J BIOL CHEM, V269, P17691; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Reale A, 1996, BIOCHEM BIOPH RES CO, V227, P768, DOI 10.1006/bbrc.1996.1583; REALINI CA, 1992, J BIOL CHEM, V267, P18858; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHRECK RR, 1974, EXP CELL RES, V88, P31, DOI 10.1016/0014-4827(74)90614-4; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; Thomas J O, 1978, Methods Cell Biol, V18, P429; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zardo G, 1996, BIOCHEM BIOPH RES CO, V220, P102, DOI 10.1006/bbrc.1996.0364; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387	50	54	57	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					89	93						5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872933				2022-12-28	WOS:000078029500010
J	Zimmer, KP; Naim, H; Weber, P; Ellis, HJ; Ciclitira, PJ				Zimmer, KP; Naim, H; Weber, P; Ellis, HJ; Ciclitira, PJ			Targeting of gliadin peptides, CD8, alpha/beta-TCR, and gamma/delta-TCR to Golgi complexes and vacuoles within celiac disease enterocytes	FASEB JOURNAL			English	Article						endoplasmic reticulum; T cell receptor; trans-Golgi network	T-CELL-RECEPTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; INTESTINAL EPITHELIAL-CELLS; HLA-DR; MONOCLONAL-ANTIBODIES; ORGAN-CULTURE; EXPRESSION; ANTIGEN; LYMPHOCYTES; ASSOCIATION	Celiac disease (CD) is characterized by autodestruction of enterocytes after exposure of genetically susceptible individuals to dietary gluten. To define the transport pathways of proteins involved in the celiac immune response, we wished to determine the subcellular compartments of the intestinal mucosa where wheat gliadin peptides colocalize with receptors of T lymphocytes, including alpha/beta-TCR, gamma/delta-TCR, and CD8. Semithin and ultrathin frozen section of jejunal biopsies from CD patients and controls were used to perform immunofluorescence and immunogold labeling as well as in situ hybridization experiments. In patients with active CD, we detected gliadin peptides in vacuoles and Golgi complexes of enterocytes. CD8, alpha/beta-TCR, and gamma/delta-TCR were found in vacuoles and Golgi complexes within these enterocytes in addition to the surface of intraepithelial and mucosal T lymphocytes. In contrast, we observed that the localization of CD4, CD3, T cell-restricted intracellular antigen (TIA.), and leukocyte common antigen (LCA) was restricted to lymphocytes in CD patients. We further detected labeling signals for gliadin peptides, CD8, alpha/beta-TCR, and gamma/delta-TCR at the basal membrane of enterocytes that were interdigitated by extensions of lymphocytes. In situ hybridization experiments revealed that CD8 and gamma/delta-TCR were not expressed by CD enterocytes. We conclude that CD8, alpha/beta-TCR, and y/6TCR are targeted to Golgi complexes and vacuoles of small intestinal enterocytes in active CD. The observed process may be involved in the pathogenesis of CD enterocytes. We propose a mechanism for the uptake of CD8, alpha/beta-TCR, and gamma/delta-TCR by the basolateral membrane of small intestinal enterocytes.	Univ Munster, Kinderklin, D-48149 Munster, Germany; Tierarztlichen Hsch Hannover, Inst Physiol Chem, D-30559 Hannover, Germany; United Med & Dent Sch Guys & St Thomas Hosp, St Thomas Hosp, Gastroenterol Unit, London SE1 7EH, England	University of Munster; University of Veterinary Medicine Hannover, Foundation; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Zimmer, KP (corresponding author), Univ Munster, Kinderklin, Albert Schweitzer Str 33, D-48149 Munster, Germany.	zimmerp@uni-muenster.de	Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020		NIDDK NIH HHS [R01 DK47716] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BLANCO A, 1995, ADV EXP MED BIOL, V371, P1355; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; CICLITIRA PJ, 1985, BRIT J NUTR, V53, P39, DOI 10.1079/BJN19850008; CICLITIRA PJ, 1986, CLIN EXP IMMUNOL, V63, P101; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; ELLIS HJ, 1993, SCAND J GASTROENTERO, V28, P212, DOI 10.3109/00365529309096074; FAIS S, 1992, GUT, V33, P472, DOI 10.1136/gut.33.4.472; FRIIS S, 1992, GUT, V33, P1498; GJERTSEN HA, 1994, HUM IMMUNOL, V39, P243, DOI 10.1016/0198-8859(94)90267-4; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HALSTENSEN TS, 1991, IMMUNOL RES, V10, P493, DOI 10.1007/BF02919747; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOLM K, 1992, LANCET, V339, P1500, DOI 10.1016/0140-6736(92)91262-7; MARLEY NJE, 1987, CLIN EXP IMMUNOL, V70, P386; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811; MOTHES T, 1989, BIOMED BIOCHIM ACTA, V48, P137; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NORMENT AM, 1989, J IMMUNOL, V142, P3312; PETERS PJ, 1990, IMMUNOL TODAY, V11, P28; REGOECZI E, 1982, P NATL ACAD SCI-BIOL, V79, P2226, DOI 10.1073/pnas.79.7.2226; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; RUST C, 1992, SCAND J IMMUNOL, V35, P459, DOI 10.1111/j.1365-3083.1992.tb02881.x; SCRIVASTAVA MD, 1995, RES COMMUN MOL PATH, V87, P21; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; STURGESS R, 1993, CURR OPIN GASTROEN, V9, P242, DOI 10.1097/00001574-199303000-00009; TAKAHASHIIWANAGA H, 1995, CELL TISSUE RES, V280, P491; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TONER PG, 1971, J ULTRA MOL STRUCT R, V34, P329, DOI 10.1016/S0022-5320(71)80076-X; TREJDOSIEWICZ LK, 1995, BAILLIERE CLIN GASTR, V9, P251, DOI 10.1016/0950-3528(95)90031-4; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; TUCKOVA L, 1995, CLIN IMMUNOL IMMUNOP, V74, P170, DOI 10.1006/clin.1995.1025; ULMER JB, 1994, EUR J IMMUNOL, V24, P1590, DOI 10.1002/eji.1830240721; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; WIESER H, 1986, Z LEBENSM UNTERS FOR, V182, P115, DOI 10.1007/BF01454241; YEH CJG, 1990, PLACENTA, V11, P253, DOI 10.1016/S0143-4004(05)80272-3; ZIMMER KP, 1995, GUT, V36, P703, DOI 10.1136/gut.36.5.703	43	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1349	1357		10.1096/fasebj.12.13.1349	http://dx.doi.org/10.1096/fasebj.12.13.1349			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761778				2022-12-28	WOS:000076402000010
J	Facchini, LM; Penn, LZ				Facchini, LM; Penn, LZ			The molecular role of Myc in growth and transformation: recent discoveries lead to new insights	FASEB JOURNAL			English	Review						c-myc; oncogene; transactivation; repression; transcription; cancer; gene regulation	HUMAN C-MYC; MURINE ERYTHROLEUKEMIA-CELLS; TATA-BINDING PROTEIN; ORNITHINE DECARBOXYLASE GENE; ADENOVIRUS E1A PROTEINS; INITIATION-FACTOR 4E; N-TERMINAL DOMAIN; WILD-TYPE P53; E-MU-MYC; DNA-BINDING	A major dilemma facing the Myc researcher is understanding how c-Myc regulation of gene transcription translates into the proliferative and oncogenic activities mediated by c-Myc protein. Indeed, much effort has focused on attempting to link c-Myc activation of gene transcription with both cell cycle progression and transformation mechanisms. Considerable progress has been made in recent years, with the identification of new Myc binding proteins as well as novel cellular targets of Myc-Max complexes. These discoveries have yielded more than a few surprises and challenged those working in the field to rethink traditional paradigms, It is now evident that c-Myc can also repress the transcription of specific genes, and Myc-mediated repression appears to be linked to Myc-dependent transformation. We summarize the evidence on Myc biological and molecular functions with regard to]Myc-Max transcriptional regulation, In addition, we reevaluate current models of Myc transcriptional modulation in light of the discovery of new Myc binding partners and novel downstream target genes, Finally, we explore whether direct transactivation of cellular genes by Myc-Max heterodimers is sufficient for the growth-promoting and transforming activities of Myc or whether other molecular activities of Myc, such as Myc-mediated repression, may play a key role.	Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys,Div Cell & Mol Biol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Penn, LZ (corresponding author), Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys,Div Cell & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@oci.utoronto.ca		Penn, Linda/0000-0001-8133-5459				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bao JX, 1996, ONCOGENE, V12, P2171; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BUCKLE RS, 1995, ONCOGENE, V10, P1249; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; CARUSO M, 1993, ONCOGENE, V8, P267; Chen CH, 1996, ONCOGENE, V13, P1659; Cleveland J L, 1988, Oncogene Res, V3, P357; Constance CM, 1996, MOL CELL BIOL, V16, P3878; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DELGADO MD, 1995, ONCOGENE, V10, P1659; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOERING LC, 1995, DEV BRAIN RES, V89, P56, DOI 10.1016/0165-3806(95)00095-U; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GREGORY CR, 1990, J VET INTERN MED, V4, P1, DOI 10.1111/j.1939-1676.1990.tb00866.x; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KARN J, 1989, ONCOGENE, V4, P773; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOHL NE, 1987, ONCOGENE, V2, P41; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1998, IN PRESS TRANSCRIPTI; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1996, ONCOGENE, V12, P43; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MARTEL C, 1995, ONCOGENE, V10, P2195; MARUYAMA K, 1987, ONCOGENE, V1, P361; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MOORE JP, 1987, ONCOGENE RES, V2, P65; MOSHIER JA, 1993, CANCER RES, V53, P2618; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; PACKHAM G, 1994, CELL MOL BIOL RES, V40, P699; PARR EJ, 1994, NEUROSCIENCE, V58, P807, DOI 10.1016/0306-4522(94)90458-8; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao MS, 1997, J NEUROBIOL, V32, P722, DOI 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; Rosen G, 1996, COMMENTARY, V102, P13; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SETH A, 1992, J BIOL CHEM, V267, P24796; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIGVARDSSON M, 1994, LEUKEMIA, V8, P1157; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; WATERS CM, 1991, ONCOGENE, V6, P797; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu SJ, 1996, ONCOGENE, V12, P621; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	209	317	331	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					633	651		10.1096/fasebj.12.9.633	http://dx.doi.org/10.1096/fasebj.12.9.633			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619443				2022-12-28	WOS:000074011000003
J	Wattanapitayakul, SK; Weinstein, DM; Holycross, BJ; Bauer, JA				Wattanapitayakul, SK; Weinstein, DM; Holycross, BJ; Bauer, JA			Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders	FASEB JOURNAL			English	Article						nitric oxide; vascular; peroxynitrite; endothelium; angiotensin II; oxidation	MANGANESE-SUPEROXIDE-DISMUTASE; CORONARY-ARTERY DISEASE; NITRIC-OXIDE; TYROSINE NITRATION; NADPH OXIDASE; HYPERTENSION; INACTIVATION; MECHANISM; MYELOPEROXIDASE; QUINAPRIL	Angiotensin II (ANG II) is a well-established participant in many cardiovascular disorders, but the mechanisms involved are not clear. Vascular cell experiments suggest that ANG II is a potent stimulator of free radicals such as superoxide anion, an agent known to inactivate nitric oxide and promote the formation of peroxynitrite. Here we hypothesized that ANG II reduces the efficacy of NO-mediated vascular relaxation and promotes vascular peroxynitrite formation in vivo. ANG II was infused in rats at sub-presser doses for 3 days, Systolic blood pressure and heart rate were unchanged on day 3 despite significant reductions in plasma renin activity, Thoracic aorta was isolated for functional and immunohistochemical evaluations. No difference in isolated vascular contractile responses to KCI (125 mM), phenylephrine, or ANG II was observed between groups. In contrast, relaxant response to acetylcholine (ACh) was decreased sixfold without a change in relaxant response to sodium nitroprusside, Extensive prevalence of 3-nitrotyrosine (3-NT, a stable biomarker of tissue peroxynitrite formation) immunoreactivity was observed in ANG II-treated vascular tissues and Tvas specifically confined to the endothelium, Digital image analysis demonstrated a significant inverse correlation between ACh relaxant response and 3-NT immunoreactivity, These data demonstrate that ANG II selectively modifies vascular NO control at sub-presser exposures in vivo. Thus, endothelial dysfunction apparently precedes other established ANG II-induced vascular pathologies, and this may be mediated by peroxynitrite formation in vivo.	Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Bauer, JA (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmacol, Columbus, OH 43210 USA.	Bauer.140@osu.edu			NHLBI NIH HHS [HL59791, HL63067] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059791, R01HL063067] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER JA, 1991, CIRCULATION, V84, P35, DOI 10.1161/01.CIR.84.1.35; Bauer JA, 1997, J PHARMACOL EXP THER, V280, P326; BAUER JA, 1995, NITRIC OXIDE BIOCH M, P361; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Brink M, 1996, J CLIN INVEST, V97, P2509, DOI 10.1172/JCI118698; Britten MB, 1999, J INTERN MED, V245, P315, DOI 10.1046/j.1365-2796.1999.00449.x; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; CROUSER ED, 1998, AM J RESP CRIT CARE, V157, pA104; Dowell FJ, 1996, J HYPERTENS, V14, P177, DOI 10.1097/00004872-199602000-00005; Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FREEMAN B, 1994, CHEST, V105, pS79, DOI 10.1378/chest.105.3_Supplement.79S; Fritz P., 1995, Pathologica (Genoa), V87, P300; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIFFIN SA, 1991, HYPERTENSION, V17, P626, DOI 10.1161/01.HYP.17.5.626; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Jaimes EA, 1998, KIDNEY INT, V54, P775, DOI 10.1046/j.1523-1755.1998.00068.x; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KUYATT BL, 1993, ANAL QUANT CYTOL, V15, P83; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Mancini GBJ, 1996, CIRCULATION, V94, P258, DOI 10.1161/01.CIR.94.3.258; Marumo T, 1998, HYPERTENSION, V32, P1083, DOI 10.1161/01.HYP.32.6.1083; Mihm MJ, 1998, CIRCULATION, V98, P803; MIHM MJ, 1999, J PHARMACOL EXP THER, V291, P350; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; Panza JA, 1997, CLIN CARDIOL, V20, P26; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RATAJSKA A, 1994, J LAB CLIN MED, V124, P408; RUSS JC, 1998, IMAGE PROCESSING HDB, P371; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schlaifer JD, 1997, AM J CARDIOL, V80, P1594, DOI 10.1016/S0002-9149(97)00750-9; Stroth U, 1999, J CARDIOVASC PHARM, V33, pS21, DOI 10.1097/00005344-199900001-00005; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TAN LB, 1991, CIRC RES, V69, P1185, DOI 10.1161/01.RES.69.5.1185; Warnholtz A, 1999, CIRCULATION, V99, P2027, DOI 10.1161/01.CIR.99.15.2027; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; ZAR L, 1985, BIOSTATISTICAL ANAL; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	47	138	141	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					271	278		10.1096/fasebj.14.2.271	http://dx.doi.org/10.1096/fasebj.14.2.271			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657983				2022-12-28	WOS:000085184800006
J	Carvalho, E; Jansson, PA; Axelsen, M; Eriksson, JW; Huang, XD; Groop, L; Rondinone, C; Sjostrom, L; Smith, U				Carvalho, E; Jansson, PA; Axelsen, M; Eriksson, JW; Huang, XD; Groop, L; Rondinone, C; Sjostrom, L; Smith, U			Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM	FASEB JOURNAL			English	Article						diabetes; obesity; insulin receptor substrate 1; insulin signaling; insulin action	NECROSIS-FACTOR-ALPHA; RECEPTOR SUBSTRATE-1; DIABETES-MELLITUS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; 3T3-L1 ADIPOCYTES; OBESITY; MEN; STIMULATION; INTOLERANCE	We examined the gene and protein expression of IRS 1 (insulin receptor substrate 1) in adipocytes from two groups of healthy individuals with an increased propensity for non-insulin-dependent diabetes mellitus (NIDDM): those with two first-degree relatives with diabetes and another group with massive obesity. A low expression of IRS 1 (less than or equal to 50% of the matched control group) was seen in approximate to 30% of both groups and these individuals were characterized by insulin resistance and its hallmarks: higher levels of insulin, glucose, and triglycerides. Two individuals with previously unknown NIDDM were diagnosed and both had low IRS 1 expression. Low TRS I protein expression was associated with low mRNA levels but not with the common Gly972Arg polymorphism of the IRS I gene. Taken together, our present and previous findings show that a low expression of IRS 1 in fat cells predicts insulin resistance and NIDDM. Furthermore, they support the likelihood that an impaired transcriptional activation may play a key role in the pathogenesis of NIDDM.	Sahlgrens Univ Hosp, Dept Internal Med, Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Internal Med, SOS Obes Res Lab, SE-41345 Gothenburg, Sweden; Univ Lund, Malmo Univ Hosp, Dept Endocrinol, Malmo, Sweden	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Lund University; Skane University Hospital	Smith, U (corresponding author), Sahlgrens Univ Hosp, Dept Internal Med, Lundberg Lab Diabet Res, Grona Straket 8, SE-41345 Gothenburg, Sweden.		Eriksson, Jan/AAB-5820-2021; Carvalho, Eugenia/AAV-6868-2021	Carvalho, Eugenia/0000-0001-6264-3632				ATTVALL S, 1987, J CLIN INVEST, V80, P437, DOI 10.1172/JCI113091; AXELSEN M, 1995, J INTERN MED, V237, P449, DOI 10.1111/j.1365-2796.1995.tb00869.x; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; ELBEIN SC, 1991, DIABETES, V40, P1024, DOI 10.2337/diabetes.40.8.1024; ELIASSON B, 1994, ARTERIOSCLER THROMB, V14, P1946, DOI 10.1161/01.ATV.14.12.1946; ERIKSSON KF, 1990, DIABETOLOGIA, V33, P526, DOI 10.1007/BF00404139; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LAPIDUS L, 1992, DIABETES CARE, V15, P1455, DOI 10.2337/diacare.15.11.1455; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; SMITH U, 1972, J LIPID RES, V13, P822; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	26	116	131	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2173	2178		10.1096/fasebj.13.15.2173	http://dx.doi.org/10.1096/fasebj.13.15.2173			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593864	Bronze			2022-12-28	WOS:000084310800008
J	Srivastava, M; Pollard, HB				Srivastava, M; Pollard, HB			Molecular dissection of nucleolin's role in growth and cell proliferation: new insights	FASEB JOURNAL			English	Review						nucleolin; ribosome biogenesis; phosphorylation; proteolysis; binding proteins; ligands; apoptosis; cell cycle	CASEIN KINASE-II; PRE-RIBOSOMAL-RNA; NUCLEIC-ACID-BINDING; AG-NOR PROTEINS; SYSTEMIC LUPUS-ERYTHEMATOSUS; SELF-CLEAVING ACTIVITY; YEAST NSR1 PROTEIN; HEAT-SHOCK PROTEIN; MAMMALIAN NUCLEOLIN; RAT-LIVER	Cells require optimum protein synthetic activity in order to support cell proliferation, maintain homeostatic and metabolic integrity, and repair damage. Since growth depends on protein synthesis through ribosome biogenesis, the control of biosynthesis of ribosomes is necessarily a key element for control of growth. Nucleolin is a major nucleolar protein of exponentially growing eukaryotic cells, which is directly involved in the regulation of ribosome biogenesis and maturation. The highly conserved nucleolin contains three major domains through which it controls the organization of nucleolar chromatin, packaging of pre-RNA, rDNA transcription, and ribosome assembly. Numerous reports have implicated the involvement of nucleolin either directly or indirectly in the regulation of cell proliferation and growth, cytokinesis, replication, embryogenesis, and nucleogenesis, Nucleolin, an RNA binding protein, is also an autoantigen, a transcriptional repressor, and a switch region targeting factor. In addition, nucleolin exhibits autodegradation, DNA and RNA helicase activities, and DNA-dependent ATPase activity. An interesting aspect of nucleolin action is that it is a target for regulation by proteolysis, methylation, ADP-ribosylation, and phosphorylation by CKII, cdc2, PKC-xi, cyclic AMP-dependent protein kinase, and ecto-protein kinase. For these and other reasons, nucleolin is fundamental to the survival and proliferation of cells. Considerable progress has been made in recent years with the identification of new nucleolin binding proteins that may mediate these many nucleolin-dependent functions. Nucleolin also functions as a cell surface receptor, where it acts as a shuttling protein between cytoplasm and nucleus, and thus can even provide a mechanism for extracellular regulation of nuclear events. Exploration of the regulation of this multifaceted protein in a remarkable number of diverse functions is challenginp.-Srivastava, M., Pollard, Il. B. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights.	Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Srivastava, M (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	msnvastava@usuhs.mil						ARENDS MJ, 1990, AM J PATHOL, V136, P593; AZUMGELADE MC, 1994, J CELL SCI, V107, P463; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BALLAL NR, 1975, J BIOL CHEM, V250, P5921; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BARRIJAL S, 1992, NUCLEIC ACIDS RES, V20, P5053, DOI 10.1093/nar/20.19.5053; BAUTZ EKF, 1989, MOL CELL BIOL AUTOAN, V118; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; Bell SA, 1996, BRIT J DERMATOL, V134, P848; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BIGGIOGERA M, 1991, CHROMOSOMA, V100, P162, DOI 10.1007/BF00337245; Bogre L, 1996, PLANT CELL, V8, P417, DOI 10.1105/tpc.8.3.417; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON H, 1983, FEBS LETT, V155, P218, DOI 10.1016/0014-5793(82)80606-6; BOURGEOIS CA, 1988, INT REV CYTOL, V111, P1, DOI 10.1016/S0074-7696(08)61730-1; Bouvet P, 1997, EMBO J, V16, P5235, DOI 10.1093/emboj/16.17.5235; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; BUGLER B, 1987, J BIOL CHEM, V262, P10922; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; CAVILLE J, 1996, NATURE, V383, P732; CHAN EKL, 1989, NUCLEIC ACIDS RES, V17, P2233, DOI 10.1093/nar/17.6.2233; CHEN CM, 1991, J BIOL CHEM, V266, P7754; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DANG CV, 1989, J BIOL CHEM, V264, P18019; DERENZINI M, 1995, LAB INVEST, V73, P497; DEVERDUGO UR, 1995, J VIROL, V69, P6751, DOI 10.1128/JVI.69.11.6751-6757.1995; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; EGYHAZI E, 1988, EXP CELL RES, V178, P264, DOI 10.1016/0014-4827(88)90397-7; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; FUJIKI H, 1991, ENVIRON HEALTH PERSP, V93, P211, DOI 10.2307/3431191; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GEAHLEN RL, 1984, BIOCHIM BIOPHYS ACTA, V804, P169, DOI 10.1016/0167-4889(84)90146-0; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; GILLET G, 1993, ONCOGENE, V8, P565; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GLINEUR C, 1989, ONCOGENE, V4, P1247; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GULLI MP, 1995, NUCLEIC ACIDS RES, V23, P1912, DOI 10.1093/nar/23.11.1912; GUY GR, 1992, J BIOL CHEM, V267, P1846; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; HOFFMANN J, 1989, BIOCHEM J, V263, P785, DOI 10.1042/bj2630785; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JARJOUR WN, 1992, MOL BIOL REP, V16, P263, DOI 10.1007/BF00419666; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; JORDAN P, 1994, BIOCHEMISTRY-US, V33, P14696, DOI 10.1021/bi00253a007; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KHARRAT A, BIOCHEMISTRY, V30, P10329; KIBBEY MC, 1995, J NEUROSCI RES, V42, P314, DOI 10.1002/jnr.490420305; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KONDO K, 1992, J BIOL CHEM, V267, P16259; KONDO K, 1992, J BIOL CHEM, V267, P16252; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRANTZ S, 1995, BBA-MOL CELL RES, V1266, P109, DOI 10.1016/0167-4889(95)00028-Q; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LegerSilvestre I, 1997, CHROMOSOMA, V105, P542, DOI 10.1007/BF02510491; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; Li DX, 1996, J BIOL CHEM, V271, P15662, DOI 10.1074/jbc.271.26.15662; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MARIDOR G, 1990, BIOCHIM BIOPHYS ACTA, V1049, P126, DOI 10.1016/0167-4781(90)90032-W; MCDONALD H, 1992, GENOMICS, V13, P344, DOI 10.1016/0888-7543(92)90251-M; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEHES G, 1995, CELL PROLIFERAT, V28, P329, DOI 10.1111/j.1365-2184.1995.tb00074.x; MESSMER B, 1993, EUR J CELL BIOL, V61, P369; MINOTA S, 1991, J IMMUNOL, V146, P2249; MIRANDA GA, 1995, EXP CELL RES, V217, P294, DOI 10.1006/excr.1995.1090; MURAKAMI T, 1991, PROG CLIN BIOL RES, V366, P65; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOAILLACDEPEYRE J, 1989, BIOL CELL, V67, P27, DOI 10.1111/j.1768-322X.1989.tb03007.x; OHMORI H, 1990, EXP CELL RES, V189, P227, DOI 10.1016/0014-4827(90)90240-B; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3187, DOI 10.1021/bi00282a023; OLSON MOJ, 1990, BIOCHEMISTRY-US, V29, P5682, DOI 10.1021/bi00476a006; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFEIFLE J, 1983, BIOCHIM BIOPHYS ACTA, V762, P86, DOI 10.1016/0167-4889(83)90120-9; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROUSSEL P, 1994, J HISTOCHEM CYTOCHEM, V42, P1513, DOI 10.1177/42.11.7930534; ROUSSEL P, 1994, EXP CELL RES, V214, P465, DOI 10.1006/excr.1994.1283; SAPP M, 1989, EUR J BIOCHEM, V179, P541, DOI 10.1111/j.1432-1033.1989.tb14581.x; SCHEER U, 1990, BIOESSAYS, V12, P14, DOI 10.1002/bies.950120104; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHNEIDER HR, 1989, EUR J BIOCHEM, V180, P449, DOI 10.1111/j.1432-1033.1989.tb14667.x; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; Schwab MS, 1997, EUR J CELL BIOL, V73, P287; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SIPOS K, 1991, BIOCHEM BIOPH RES CO, V177, P673, DOI 10.1016/0006-291X(91)91841-Y; SIRRI V, 1995, J HISTOCHEM CYTOCHEM, V43, P887, DOI 10.1177/43.9.7642962; SMITH MJ, 1994, CLIN EXP PHARM PHYSL, V21, P67; SOMMERVILLE J, 1986, TRENDS BIOCHEM SCI, V11, P438, DOI 10.1016/0968-0004(86)90242-2; SOULARD M, 1989, EXP CELL RES, V182, P482, DOI 10.1016/0014-4827(89)90252-8; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SRIVASTAVA M, 1989, FEBS LETT, V250, P99, DOI 10.1016/0014-5793(89)80692-1; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUZUKI N, 1991, BIOCHIM BIOPHYS ACTA, V1092, P367, DOI 10.1016/S0167-4889(97)90014-8; SUZUKI N, 1987, J BIOL CHEM, V262, P4696; SUZUKI N, 1985, J BIOL CHEM, V260, P8050; SUZUKI N, 1992, J STEROID BIOCHEM, V42, P305, DOI 10.1016/0960-0760(92)90133-4; SUZUKI T, 1993, BIOCHEM J, V289, P109, DOI 10.1042/bj2890109; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TAWFIC S, 1994, PROSTATE, V24, P101, DOI 10.1002/pros.2990240208; Tuteja N, 1997, BIOCHEM BIOPH RES CO, V236, P636, DOI 10.1006/bbrc.1997.7021; TUTEJA N, 1995, GENE, V160, P143, DOI 10.1016/0378-1119(95)00207-M; Valdez BC, 1995, MOL IMMUNOL, V32, P1207, DOI 10.1016/0161-5890(95)00093-3; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; WEISENBERGER D, 1995, J CELL BIOL, V129, P561, DOI 10.1083/jcb.129.3.561; XU XB, 1995, BIOPOLYMERS, V35, P93, DOI 10.1002/bip.360350110; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; YU D, 1998, BIOCHEM BIOPH RES CO, V2471, P86; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	143	410	432	4	31	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1911	1922		10.1096/fasebj.13.14.1911	http://dx.doi.org/10.1096/fasebj.13.14.1911			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544174				2022-12-28	WOS:000083660700003
J	Allen, JW; Knoblach, SM; Faden, AI				Allen, JW; Knoblach, SM; Faden, AI			Combined mechanical trauma and metabolic impairment in vitro induces NMDA receptor-dependent neuronal cell death and caspase-3-dependent apoptosis	FASEB JOURNAL			English	Article						neuronal injury; ischemia; caspases; 3-nitropropionic acid	BRAIN INJURY; 3-NITROPROPIONIC ACID; CEREBRAL-ISCHEMIA; CASPASE-3-LIKE PROTEASE; IN-VITRO; MODEL; ACTIVATION; CULTURES; RAT; INHIBITION	Neuronal necrosis and apoptosis occur after traumatic brain injury (TBI) in animals and contribute to subsequent neurological deficits. In contrast, relatively little apoptosis is found after mechanical injury in vitro, Because in vivo trauma models and clinical head injury have associated cerebral ischemia and/or metabolic impairment, we transiently impaired cellular metabolism after mechanical trauma of neuronal-glial cultures by combining 5-nitropropionic acid treatment with concurrent glucose deprivation, This produced greater neuronal cell death than mechanical trauma alone. Such injury was attenuated by the NMDA receptor antagonist dizocilpine (MK801), In addition, this injury significantly increased the number of apoptotic cells over that accruing from mechanical injury alone. This apoptotic cell. death was accompanied by DNA fragmentation, attenuated by cycloheximide, and associated with an increase in caspase-3-like but not caspase-1-like activity, Cell death was reduced by the pan-caspase inhibitor BAF or the caspase-3 selective inhibitor z-DEVD-fmk, whereas the caspase-1 selective inhibitor z-YVAD-fmk had no effect; z-DEVD-fmk also reduced the number of apoptotic cells after combined injury. Moreover, cotreatment with MK801 and BAF resulted in greater neuroprotection than either drug alone. Thus, in vitro trauma with concurrent metabolic inhibition parallels in vivo TBI, showing both NMDA-sensitive necrosis and caspase-3-dependent apoptosis.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHS [R49 CCR306634-07] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arden S. R., 1997, Society for Neuroscience Abstracts, V23, P2294; BEHRENS MI, 1995, NEUROREPORT, V6, P545, DOI 10.1097/00001756-199502000-00034; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Chen J, 1998, J NEUROSCI, V18, P4914; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CIESLA Z, 1974, MOL GEN GENET, V135, P339, DOI 10.1007/BF00271148; Clark R. S. B., 1998, Society for Neuroscience Abstracts, V24, P251; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HASSEL B, 1995, J NEUROCHEM, V65, P1184; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MIRSA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Namura S, 1998, J NEUROSCI, V18, P3659; Nath R, 1998, J NEUROCHEM, V71, P186; Pang Z, 1997, J NEUROSCI, V17, P3064; PATEL MN, 1993, NEUROTOXICOLOGY, V14, P35; RINK A, 1995, AM J PATHOL, V147, P1575; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIEGEL JH, 1995, TRAUMATIC BRAIN INJU, P85; Sonnewald U, 1996, NEUROCHEM RES, V21, P987, DOI 10.1007/BF02532408; Varming T, 1996, J NEUROSCI RES, V44, P40, DOI 10.1002/(SICI)1097-4547(19960401)44:1<40::AID-JNR5>3.0.CO;2-I; VERITY MA, 1991, MOL CHEM NEUROPATHOL, V15, P217; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	40	53	53	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1875	1882		10.1096/fasebj.13.13.1875	http://dx.doi.org/10.1096/fasebj.13.13.1875			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506592				2022-12-28	WOS:000083063400024
J	Docagne, F; Nicole, O; Marti, HH; MacKenzie, ET; Buisson, A; Vivien, D				Docagne, F; Nicole, O; Marti, HH; MacKenzie, ET; Buisson, A; Vivien, D			Transforming growth factor-beta 1 as a regulator of the serpins/t-PA axis in cerebral ischemia	FASEB JOURNAL			English	Article						TGF-beta; plasminogen activator; neuroserpin; NTN	TISSUE-PLASMINOGEN-ACTIVATOR; BONE MORPHOGENETIC PROTEINS; BETA-INDUCIBLE ELEMENTS; TGF-BETA; RAT-BRAIN; DIFFERENTIAL EXPRESSION; NEUROTROPHIC FACTOR; INHIBITOR GENE; NERVOUS-SYSTEM; RECEPTORS	The tissue type plasminogen activator (t-PA) is a serine protease that is involved in neuronal plasticity and cell death induced by excitotoxins and ischemia in the brain. t-PA activity in the central nervous system is regulated through the activation of serine protease inhibitors (serpins) such as the plasminogen activator inhibitor (PAI-1), the protease nexin-1 (PN-1), and neuroserpin (NSP). Recently we demonstrated in vitro that PAI-1 produced by astrocytes mediates the neuroprotective effect of the transforming growth factor-beta 1 (TGF-beta 1) in NMDA-induced neuronal cell death. To investigate whether serpins may be involved in neuronal cell death after cerebral ischemia, we determined, by using semiquantitative RT-PCR and in situ hybridization, that focal cerebral ischemia in mice induced a dramatic overexpression of PAI-1 without any effect on PN-1, NSP, or t-PA. Then we showed that although the expression of PAI-1 is restricted to astrocytes, PN-1, NSP, and t-PA are expressed in both neurons and astrocytes. Moreover, by using semiquantitative RT-PCR and Western blotting, we observed that only the expression of PAI-1 was modulated by TGF-beta 1 treatment via a TGF-beta-inducible element contained in the PAI-I promoter (CAGA box). Finally, we compared the specificity of TGF-beta 1 action with other members of the TGF-beta family by using luciferase reporter genes. These data show that TGF-beta and activin were able to induce the overexpression of PAI-1 in astrocytes, but that bone morphogenetic proteins, glial cell line-derived neutrophic factor, and neurturin did not. These results provide new insights into the regulation of the serpins/t-PA axis and the mechanism by which TGF-beta may be neuroprotective.	Univ Caen, CNRS, UMR 6551, Neurosci Lab, F-14074 Caen, France; Max Planck Inst Physiol & Klin Forsch, D-61231 Bad Nauheim, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Max Planck Society	Vivien, D (corresponding author), Univ Caen, CNRS, UMR 6551, Neurosci Lab, IFR 47,Bd H Becquerel,BP 5229, F-14074 Caen, France.		Nicole, Olivier/AAZ-2865-2020; Docagne, Fabian/S-8308-2018; Mackenzie, Eric Thomson/L-1938-2015; buisson, alain/AAI-8218-2020	Nicole, Olivier/0000-0001-9981-1820; buisson, alain/0000-0002-4281-7911; Marti, Hugo/0000-0002-8456-334X; Docagne, Fabian/0000-0003-1745-0625; VIVIEN, DENIS/0000-0002-7636-2185; MacKenzie, Eric T/0000-0003-1057-7033				BREIER G, 1992, DEVELOPMENT, V114, P521; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHAO CC, 1992, BRAIN RES, V760, P52; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; CUNNINGHAM DD, 1989, J CELL BIOCHEM, V39, P55, DOI 10.1002/jcb.240390107; DALESSANDRO JS, 1994, GROWTH FACTORS, V11, P45, DOI 10.3109/08977199409015050; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Funaba M, 1997, J NEUROENDOCRINOL, V9, P105, DOI 10.1046/j.1365-2826.1997.00558.x; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; Gualandris A, 1996, J NEUROSCI, V16, P2220; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; IWAHORI Y, 1995, ENDOCRINOLOGY, V136, P2652; JONES CM, 1991, DEVELOPMENT, V111, P531; KALDERON N, 1990, GLIA, V3, P413, DOI 10.1002/glia.440030513; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Krueger SR, 1997, J NEUROSCI, V17, P8984; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; LEHRMANN E, 1995, EXP NEUROL, V131, P114, DOI 10.1016/0014-4886(95)90013-6; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; Mabie PC, 1997, J NEUROSCI, V17, P4112; MASSAGUE J, 1996, CANC SURVEYS, V381, P620; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; PREHN JHM, 1994, NEUROSCIENCE, V60, P7, DOI 10.1016/0306-4522(94)90198-8; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; Rose K, 1993, IN VITRO BIOL METHOD, P46; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Soderstrom S, 1996, CELL TISSUE RES, V286, P269, DOI 10.1007/s004410050697; SUTTON R, 1994, BLOOD COAGUL FIBRIN, V5, P167, DOI 10.1097/00001721-199404000-00002; Tsirka SE, 1997, J NEUROSCI, V17, P543; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; Vivien D, 1998, J NEUROCHEM, V70, P2296; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	57	86	90	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1315	1324		10.1096/fasebj.13.11.1315	http://dx.doi.org/10.1096/fasebj.13.11.1315			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428756	Bronze			2022-12-28	WOS:000082019100004
J	Gardin, A; Auzan, C; Clauser, E; Malherbe, T; Aunis, D; Cremel, G; Hubert, P				Gardin, A; Auzan, C; Clauser, E; Malherbe, T; Aunis, D; Cremel, G; Hubert, P			Substitution of the insulin receptor transmembrane domain with that of glycophorin A inhibits insulin action	FASEB JOURNAL			English	Article						signaling; tyrosine phosphorylation; receptor dimerization; transfection of chimeric receptors	GROWTH-FACTOR RECEPTOR-3; SIGNAL-TRANSDUCTION; POINT MUTATION; TYROSINE KINASE; CRYSTAL-STRUCTURE; A DIMERIZATION; ALPHA-HELICES; NEU ONCOGENE; BETA-SUBUNIT; ACTIVATION	To study the role of transmembrane (TM) domains interactions in the activation of the insulin receptor, we have replaced the insulin receptor TM domain with that of glycophorin A (GpA), an erythrocyte protein that spontaneously forms detergent-resistant dimers through TM-TM interactions. Insulin receptor cDNA sequences with the TM domain replaced by that of GpA were constructed and stably transfected in CHO cells, Insulin binding to cells and solubilized receptors was not modified. Electrophoresis after partial reduction of disulfide bonds revealed an altered structure for the soluble chimeric receptors, seen as an altered mobility apparently due to increased interactions between the beta subunits of the receptor. Insulin signaling was markedly decreased for cells transfected with chimeric receptors compared with cells transfected with normal receptors. A decrease in insulin-induced receptor kinase activity was observed for solubilized chimeric receptors, In conclusion, substitution by the native GpA TM domain of the insulin receptor results in structurally modified chimeric receptors that are unable to transmit the insulin signal properly. It is hypothesized that this substitution may impose structural constraints that prevent the proper changes in conformation necessary for activation of the receptor kinase. Other mutants modifying the structure or the membrane orientation of the glycophorin A TM domain are required to better understand these constraints.	INSERM, U338, F-67084 Strasbourg, France; Coll France, INSERM, U36, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Hubert, P (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Hubert, Pierre/C-6678-2013; Dominique, Aunis/W-1419-2019	Hubert, Pierre/0000-0002-7549-8910; 				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORKE RR, 1990, EUR J BIOCHEM, V191, P473, DOI 10.1111/j.1432-1033.1990.tb19146.x; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; Garnier N, 1997, BIOPOLYMERS, V42, P157, DOI 10.1002/(SICI)1097-0282(199708)42:2<157::AID-BIP5>3.0.CO;2-M; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; Kim H, 1997, J BIOL CHEM, V272, P30741, DOI 10.1074/jbc.272.49.30741; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LECONTE I, 1992, J BIOL CHEM, V267, P17415; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; Lee JS, 1995, J BIOL CHEM, V270, P31136, DOI 10.1074/jbc.270.52.31136; LEMARCHANDBRUST.Y, 1988, INSULIN RECEPTORS A, P163; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LENWERDER K, 1997, PROTEIN SCI SU, V6, P107; LI SC, 1994, BIOCHEMISTRY-US, V33, P14333, DOI 10.1021/bi00251a047; LONGO N, 1992, J BIOL CHEM, V267, P12416; MacKenzie KR, 1998, P NATL ACAD SCI USA, V95, P3583, DOI 10.1073/pnas.95.7.3583; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; Xiong QH, 1996, MOL CELL BIOL, V16, P1509; YAMAGIWA J, 1992, TOPICS PRIMATOLOGY, V2, P267	42	15	15	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1347	1357		10.1096/fasebj.13.11.1347	http://dx.doi.org/10.1096/fasebj.13.11.1347			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428759				2022-12-28	WOS:000082019100007
J	Angeletti, RH; Bonewald, LF; De Jongh, K; Niece, R; Rush, J; Stults, J				Angeletti, RH; Bonewald, LF; De Jongh, K; Niece, R; Rush, J; Stults, J			Research technologies: Fulfilling the promise	FASEB JOURNAL			English	Article									Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA; Univ Calif Irvine, Irvine, CA 92612 USA; Zymogenet Inc, Seattle, WA 98102 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Genentech Inc, S San Francisco, CA 94080 USA	Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine; Zymogenet Inc.; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Roche Holding; Genentech	Angeletti, RH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave,405 Ullmann Bldg, Bronx, NY 10461 USA.		Bonewald, Lynda/Q-3638-2019					ANGELETTI RH, 1998, PROTEINS ANAL DESIGN, P1; BLOOM FE, 1990, FUNDING HLTH SCI; Brinkley WR, 1998, FASEB J, V12, P1431, DOI 10.1096/fasebj.12.14.1431; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Fischman DA, 1998, FASEB J, V12, P621, DOI 10.1096/fasebj.12.9.621; IVANETICH KM, 1993, FASEB J, V7, P1109, DOI 10.1096/fasebj.7.12.8375609; Manning, 1996, RESOURCE SHARING BIO; *NAT CTR RES RES, 1996, 964150 NIH NAT CTR R; *NAT SCI FDN, 1996, NSF96326; *NIH, 1997, AC RES INSTR INSTR N	10	6	7	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					595	601						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094920				2022-12-28	WOS:000079527200001
J	Squire, JM; Morris, EP				Squire, JM; Morris, EP			A new look at thin filament regulation in vertebrate skeletal muscle	FASEB JOURNAL			English	Review						actin; tropomyosin; electron microscopy; troponin-T; TnC	X-RAY-DIFFRACTION; TROPONIN-TROPOMYOSIN COMPLEX; F-ACTIN; MYOSIN SUBFRAGMENT-1; STRUCTURAL-CHANGES; 3-DIMENSIONAL RECONSTRUCTION; COOPERATIVE BINDING; FIBER DIFFRACTION; ATOMIC MODEL; FROG-MUSCLE	It is 30 years since Ebashi and colleagues showed that Ca2+ ions directly affect regulation of the myosin-actin interaction in muscle through the action of tropomyosin and troponin on muscle thin filaments. It is more than 20 years since the idea was put forward that tropomyosin mig ht act, at least in part, by changing its position on actin, thus uncovering or modifying the myosin binding site on actin when troponin molecules take up Ca2+. Since that time, a great deal of evidence for and against this steric blocking mechanism has been published: a structure for actin filaments at close to atomic resolution has been proposed, and the whole regulation story has become both more complicated and more subtle. Here we review structural and biochemical aspects of regulation in vertebrate skeletal muscle. We show that some basic ideas of the steric blocking mechanism remain valid. We also show that additional factors, such as troponin movements and structural changes within the actin monomers themselves, may be crucial, A number of the resulting regulation scenarios need to be distinguished.-Squire, J. M., Morris, E. P. A new look at thin filament regulation in vertebrate skeletal muscle.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BZ, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2BZ, England	Imperial College London; Imperial College London	Squire, JM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BZ, England.			Squire, John/0000-0001-6656-7390; Morris, Edward/0000-0003-3544-0041				ALKHAYAT HA, 1995, J MOL BIOL, V252, P611, DOI 10.1006/jmbi.1995.0524; BREMER A, 1992, Current Opinion in Cell Biology, V4, P20, DOI 10.1016/0955-0674(92)90054-G; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CABRAL-LILLY D, 1991, Biophysical Journal, V59, p581A; DASILVA ACR, 1991, TRENDS BIOCHEM SCI, V16, P53, DOI 10.1016/0968-0004(91)90024-P; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; EGELMAN EH, 1992, CURR OPIN STRUC BIOL, V2, P286; Flicker P F, 1991, Adv Biophys, V27, P185, DOI 10.1016/0065-227X(91)90017-8; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; Hanein D., 1997, Biophysical Journal, V72, pA240; HANSON EJ, 1963, J MOL BIOL, V6, P48; Harford J, 1997, REP PROG PHYS, V60, P1723, DOI 10.1088/0034-4885/60/12/005; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HEAD JG, 1995, EUR J BIOCHEM, V227, P694, DOI 10.1111/j.1432-1033.1995.tb20190.x; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; HILL TL, 1983, BIOPHYS J, V44, P383, DOI 10.1016/S0006-3495(83)84312-4; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; Hodgkinson JL, 1997, BIOPHYS J, V72, P2398, DOI 10.1016/S0006-3495(97)78885-4; Hodgkinson JL, 1997, J MOL BIOL, V273, P150, DOI 10.1006/jmbi.1997.1307; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1996, CURR OPIN STRUC BIOL, V6, P781, DOI 10.1016/S0959-440X(96)80008-X; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; HUXLEY HE, 1971, BIOCHEM J, V125, pP85, DOI 10.1042/bj1250085P; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHMAN W, 1995, J MOL BIOL, V251, P191, DOI 10.1006/jmbi.1995.0425; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LI HC, 1994, BIOCHEMISTRY-US, V33, P14324, DOI 10.1021/bi00251a046; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MAEDA Y, 1992, BIOPHYS J, V63, P815, DOI 10.1016/S0006-3495(92)81648-X; MAEDA Y, 1988, MOL MECHANISM MUSCLE, P381; MARGOSSIAN SS, 1973, J MOL BIOL, V81, P409, DOI 10.1016/0022-2836(73)90150-2; MATSUBARA I, 1984, NATURE, V312, P471, DOI 10.1038/312471a0; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; MENDELSON RA, 1994, J MOL BIOL, V240, P138, DOI 10.1006/jmbi.1994.1428; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOORE PB, 1970, J MOL BIOL, V50, P279, DOI 10.1016/0022-2836(70)90192-0; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; PAN BS, 1989, J BIOL CHEM, V264, P8495; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POOLE KJV, 1995, BIOPHYS J, V66, pA347; Popp D., 1991, Advances in Biophysics, V27, P89, DOI 10.1016/0065-227X(91)90010-B; POPP D, 1987, J MOL BIOL, V197, P679, DOI 10.1016/0022-2836(87)90474-8; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SQUIRE J, 1981, NATURE, V291, P614, DOI 10.1038/291614a0; Squire J, 1981, STRUCTURAL BASIS MUS; SQUIRE JM, 1994, J MUSCLE RES CELL M, V15, P227; Squire JM, 1997, CURR OPIN STRUC BIOL, V7, P247, DOI 10.1016/S0959-440X(97)80033-4; SQUIRE JM, 1975, ANNU REV BIOPHYS BIO, V4, P137, DOI 10.1146/annurev.bb.04.060175.001033; SQUIRE JM, 1993, J CHEM SOC FARADAY T, V89, P2717, DOI 10.1039/ft9938902717; TAYLOR KA, 1981, J MOL BIOL, V147, P297, DOI 10.1016/0022-2836(81)90442-3; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Vibert P, 1997, J MOL BIOL, V266, P8, DOI 10.1006/jmbi.1996.0800; VIBERT PJ, 1972, J MOL BIOL, V71, P757, DOI 10.1016/S0022-2836(72)80036-6; WAKABAYASHI K, 1985, BIOPHYS J, V47, P847, DOI 10.1016/S0006-3495(85)83989-8; WAKABAYASHI K, 1988, MOL MECHANISM MUSCLE, P353; WEBER A, 1973, PHYSIOL REV, V53, P612, DOI 10.1152/physrev.1973.53.3.612; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; YAGI N, 1989, J MOL BIOL, V208, P359, DOI 10.1016/0022-2836(89)90396-3; Yagi N, 1991, Adv Biophys, V27, P35, DOI 10.1016/0065-227X(91)90006-Y; YAGI N, 1988, MOL MECH MUSCLE CONT, P369; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; [No title captured]	81	163	166	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					761	771		10.1096/fasebj.12.10.761	http://dx.doi.org/10.1096/fasebj.12.10.761			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657517				2022-12-28	WOS:000074580100002
J	De Las Alas, MM; De Bruin, RAM; Ten Eyck, L; Los, G; Howell, SB				De Las Alas, MM; De Bruin, RAM; Ten Eyck, L; Los, G; Howell, SB			Prediction-based threading of the hMSH2 DNA mismatch repair protein	FASEB JOURNAL			English	Article						protein model; loop generation; structural homologue; glycogen phosphorylase	NONPOLYPOSIS COLORECTAL-CANCER; HUMAN MSH2 PROTEIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; STRUCTURE ALIGNMENT; NEURAL NETWORKS; TUMOR-CELLS; MUTATIONS; GENE; BINDING	Mutations in the genes whose products participate in DNA mismatch repair underlie the increased risk of cancer in families with. hereditary nonpolyposis colon carcinoma. Mutations in hMSH2 account for approximately 50% of the mutations found in these families, We sought to predict the 3-dimensional structure of hMSH2 by identifying structural homologues using prediction-based threading and by computer modeling using information from these putative structurally related proteins. Prediction-based threading identified three candidate structural homologues: glycogen phosphorylase (gpb), a 70 kDa soluble lyric transglycosylase, and ribonucleotide reductase protein R1. An independent approach utilizing a potential-based threading program also identified gpb as a structural homologue. The models based on the structures of these proteins suggest that the ATP binding domain and helix-turn-helix domain are exposed on the outside of the protein, All known bacterial MutS and hMSH2 mutations appear to be clustered in similar vicinities in the theoretical models of hMSH2; the major site is within the ATP binding domain and near the carboxyl-terminal end, whereas a smaller number map to the region coding for exon 5 and the amino-terminal domain. All point mutations also appear to affect amino acids that are exposed on the outside surface of the protein.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; San Diego Super Comp Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	De Las Alas, MM (corresponding author), 9500 Gilman Dr,0058, La Jolla, CA 92093 USA.	mdelasal@sdcc14.ucsd.edu						Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; *BIOS MSI, 1995, HOM US GUID; BLAKE CCF, 1979, NATURE, V280, P448, DOI 10.1038/280448a0; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Cama A, 1996, TUMORI J, V82, P122, DOI 10.1177/030089169608200206; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DOMBRADI V, 1981, INT J BIOCHEM, V13, P125, DOI 10.1016/0020-711X(81)90147-6; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROGGATT NJ, 1995, J MED GENET, V32, P352, DOI 10.1136/jmg.32.5.352; HABRAKEN Y, 1996, CURR BIOL, V6, P1186; HALL NR, 1994, EUR J CANCER, V30A, P1550, DOI 10.1016/0959-8049(94)00326-Z; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; JONES DT, 1995, PROTEINS, V23, P384; KECK W, 1985, EUR J BIOCHEM, V148, P493, DOI 10.1111/j.1432-1033.1985.tb08866.x; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V54, P4590; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEMER CMR, 1995, PROTEINS, V23, P337, DOI 10.1002/prot.340230308; LESK AM, 1991, PROTEIN ARCHITECTURE; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; MOULT J, 1995, PROTEINS, V23, pR2, DOI 10.1002/prot.340230303; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; ORENGO CA, 1990, J THEOR BIOL, V147, P517, DOI 10.1016/S0022-5193(05)80263-2; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1997, J MOL BIOL, V270, P471, DOI 10.1006/jmbi.1997.1101; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROST B, 1995, 3 INT C INT SYST MOL, P314; ROST B, 1995, PROTEIN FOLDS DISTAN, P132; Russell RB, 1996, J MOL BIOL, V259, P349, DOI 10.1006/jmbi.1996.0325; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHENKIN PS, 1987, BIOPOLYMERS, V26, P2053, DOI 10.1002/bip.360261207; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; Thibodeau SN, 1996, CANCER RES, V56, P4836; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; Weber TK, 1997, CANCER RES, V57, P3798; Whitehouse A, 1997, BIOCHEM BIOPH RES CO, V232, P10, DOI 10.1006/bbrc.1997.6211; Whitehouse A, 1996, BIOCHEM BIOPH RES CO, V229, P147, DOI 10.1006/bbrc.1996.1771; Whitehouse A, 1996, BIOCHEM BIOPH RES CO, V225, P289, DOI 10.1006/bbrc.1996.1168; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	68	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					653	663						11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619444				2022-12-28	WOS:000074011000004
J	Lindner, G; Menrad, A; Gherardi, E; Merlino, G; Welker, P; Handjiski, B; Roloff, B; Paus, R				Lindner, G; Menrad, A; Gherardi, E; Merlino, G; Welker, P; Handjiski, B; Roloff, B; Paus, R			Involvement of hepatocyte growth factor/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling	FASEB JOURNAL			English	Article						apoptosis; hair growth; HGF/SF; keratinocytes; murine hepatocyte growth factor receptor	FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; REGRESSION CATAGEN; MURINE SKIN; TYROSINE KINASE; CYCLOSPORINE-A; ORGAN-CULTURE; BETA-CATENIN; MOUSE SKIN; IN-VIVO	HGF/SF and its receptor (Met) are principal mediators of mesenchymal-epithelial interactions in several different systems and have recently been implicated in the control of hair follicle (HF) growth, We have studied their expression patterns during HF morphogenesis and cycling in C57BL/6 mice, whereas functional hair growth effects of HGF/SF were assessed in vivo by analysis of transgenic mice and in skin organ culture. In normal mouse skin, follicular expression of HGF/SF and Met was strikingly localized: HGF/SF was found only in the HF mesenchyme (dermal papilla fibroblasts) and Met in the neighboring hair bulb keratinocytes, Both HGF/SF and Met expression peaked during the initial phases of HF morphogenesis, the stage of active hair growth (early and mid anagen), and during the apoptosis-driven HF regression (catagen), Met+ cells in the regressing epithelial strand appeared to be protected from undergoing apoptosis. Compared to wild-type controls, transgenic mice overexpressing HGF/SF under the control of the MT-I promoter had twice as many developing HF and displayed accelerated HF development on postnatal day 3, They also showed significant catagen retardation on P17, In organ culture and in vivo, HGF/SF i.c. resulted in a significant catagen retardation. These results demonstrate an important role of HGF/SF and Met in murine hair growth control and suggest that Met-mediated signaling might be exploited for therapeutic manipulation of human hair growth disorders.-Lindner, G., Menrad, A., Gherardi, E., Merlino, G,, Welker, P., Handjiski, B., Roloff, B,, Paus, R. Involvement of hepatocyte growth factor/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling.	Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Humboldt Univ, Dept Dermatol, D-1086 Berlin, Germany; Schering AG, Res Labs, D-1000 Berlin, Germany; MRC Ctr, Growth Factors Grp, Dept Oncol, Cambridge, England; NCI, Mol Biol Lab, Bethesda, MD 20892 USA	University of Hamburg; Humboldt University of Berlin; Schering AG; MRC Laboratory Molecular Biology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Paus, R (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Dermatol, Martinistr 52, D-20246 Hamburg, Germany.		Gherardi, Ermanno/AAB-9608-2022	Lindner, Gerd/0000-0003-2336-2058; GHERARDI, ERMANNO/0000-0002-0016-2945				Balkovetz DF, 1997, J BIOL CHEM, V272, P3471, DOI 10.1074/jbc.272.6.3471; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Jiang WG, 1998, INT J MOL MED, V2, P203; Jiang WG, 1997, HISTOL HISTOPATHOL, V12, P537; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; JINDO T, 1994, J INVEST DERMATOL, V103, P306, DOI 10.1111/1523-1747.ep12394731; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; Longati P, 1996, CELL DEATH DIFFER, V3, P23; MATSUMOTO K, 1991, J GASTROEN HEPATOL, V6, P509, DOI 10.1111/j.1440-1746.1991.tb00897.x; Maurer M, 1997, AM J PATHOL, V150, P1433; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Metcalfe A, 1997, BIOESSAYS, V19, P711, DOI 10.1002/bies.950190812; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Paus R, 1996, CANCER RES, V56, P4438; PAUS R, 1989, LAB INVEST, V60, P365; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1999, IN PRESS J INVEST DE; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Peluso JJ, 1997, BIOCHEM PHARMACOL, V54, P847, DOI 10.1016/S0006-2952(97)00118-4; PethoSchramm A, 1996, ARCH DERMATOL RES, V288, P264, DOI 10.1007/BF02530098; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; SHIMAOKA S, 1995, J CELL PHYSIOL, V165, P333, DOI 10.1002/jcp.1041650214; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; STENN KS, 1988, J INVEST DERMATOL, V90, P409, DOI 10.1111/1523-1747.ep12456517; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; VIELKIND U, 1995, ACTA ANAT, V152, P93; Welker P, 1997, ARCH DERMATOL RES, V289, P554, DOI 10.1007/s004030050239; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Yo Y, 1998, KIDNEY INT, V54, P1128, DOI 10.1046/j.1523-1755.1998.00092.x; YU DW, 1995, J CELL SCI, V108, P3867	71	107	119	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					319	332		10.1096/fasebj.14.2.319	http://dx.doi.org/10.1096/fasebj.14.2.319			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657988				2022-12-28	WOS:000085184800011
J	Inoue, S				Inoue, S			Windows to dynamic fine structures, then and now	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		MICROTUBULE; MICROSCOPE	How can we learn about dynamic fine structures that are far too small to be resolved with the light microscope without destroying the active living cell? Examples spanning the last half century show how polarized light microscopy can-and should-continue to provide an attractive window for such studies. Long before microtubules were found with electron microscopy, or their assembly properties were biochemically characterized in isolated cell-free systems, the dynamic fine structure of the mitotic spindle and assembly properties of its: microtubules were revealed in living cells by polarized light microscopy, More recently, the polarizing microscope was improved, by invention of the new Pol-Scope, so that quantitative measurements of birefringence retardation and axes could be made rapidly for all image pixels independent of their birefringence axis: orientation. In addition, the centrifuge polarizing microscope, just developed, allows us to follow the dynamic ordering of fine structures in living cells as they become stratified or restructured by centrifugal acceleration of up to ten thousand times gravity. The significance of these technological advances is discussed.	Marine Biol Lab, Woods Hole, MA 02543 USA	Marine Biological Laboratory - Woods Hole	Inoue, S (corresponding author), Marine Biol Lab, 7 MBL St, Woods Hole, MA 02543 USA.							[Anonymous], 1952, EXP CELL RES       S, V2, P305, DOI DOI 10.1142/9789812790866_0011; CHAMBERS R, 1951, BIOL BULL, V101, P206; EDGERTON H, 1987, STOPPING TIME PHOTOG, P126; Goda M, 1998, BIOL BULL, V195, P212, DOI 10.2307/1542845; HARVEY EB, 1941, BIOL BULL, V114, P118; HARVEY EB, 1940, BIOL BULL, V166, P187; HIRAMOTO Y, 1995, INT REV CYTOL, V157, P99, DOI 10.1016/S0074-7696(08)62157-9; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; INOUE S, 1967, J GEN PHYSIOL, V50, P259, DOI 10.1085/jgp.50.6.259; INOUE S, 1953, CHROMOSOMA, V5, P487, DOI 10.1007/BF01271498; Inoue S., 1981, Journal of Cell Biology, V91, P131; Inoue S, 1998, MOL BIOL CELL, V9, P1603, DOI 10.1091/mbc.9.7.1603; Inoue S., 1998, Microscopy and Microanalysis, V4, P36, DOI 10.1017/S1431927600020304; Inoue S., 1964, PRIMITIVE MOTILE SYS, P549; Inoue S., 1997, VIDEO MICROSCOPY FUN; Inoue S, 1986, VIDEO MICROSCOPY; Inoue Shinya, 1993, P100; Katoh K, 1997, BIOL BULL, V193, P219, DOI 10.1086/BBLv193n2p219; Oldenbourg R, 1996, NATURE, V381, P811, DOI 10.1038/381811a0; OLDENBOURG R, 1999, METHODS CELL BIOL ST; OLMSTED JB, 1973, BIOCHEMISTRY-US, V12, P4282, DOI 10.1021/bi00745a037; Porter K.R., 1966, CIBA FDN S PRINC BIO, P308; SANGER JM, 1990, CELL MOTIL CYTOSKEL, V17, P356; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104	24	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S185	S190		10.1096/fasebj.13.9002.S185	http://dx.doi.org/10.1096/fasebj.13.9002.S185			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619125	Bronze			2022-12-28	WOS:000084390200003
J	Savarino, A; Bottarel, F; Calosso, L; Fleito, MJ; Bensi, T; Bragardo, M; Rojo, JM; Pugliese, A; Abbate, I; Capobianchi, MR; Dianzani, F; Malavasi, F; Dianzani, U				Savarino, A; Bottarel, F; Calosso, L; Fleito, MJ; Bensi, T; Bragardo, M; Rojo, JM; Pugliese, A; Abbate, I; Capobianchi, MR; Dianzani, F; Malavasi, F; Dianzani, U			Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle	FASEB JOURNAL			English	Article						susceptibility to HIV-1; gp120/CD4-dependent virus binding	IMMUNODEFICIENCY-VIRUS TYPE-1; LYMPHOCYTE SURFACE MOLECULES; 3-COLOR FLOW-CYTOMETRY; CD4(+) T-CELLS; ANTIVIRAL COMPOUNDS; ACTIVATION ANTIGEN; CD28 COSTIMULATION; ADULT-BLOOD; CORD-BLOOD; EXPRESSION	CD38 displays lateral association with the HIV-1 receptor CD4. This association is potentiated by the HIV-1 envelope glycoprotein gp120. The aim of this work was to evaluate the CD38 role in T cell susceptibility to HTV-1 infection. Using laboratory X4 HIV-1 strains and X4 and X4/R5 primary isolates, we found that CD38 expression was negatively correlated to cell susceptibility to infection, evaluated as percentage of infected cells, release of HN p24 in the supernatants, and cytopathogenicity. This correlation was at first suggested by results obtained in a panel of human CD4(+) T cell lines expressing different CD38 levels (MT-4, MT-2, C8166, CEMx174, Supt-1, and H9) and then demonstrated using CD38 transfectants of MT-4 cells (the line with the lowest CD38 expression). To address whether CD38 affected viral binding, we used mouse T cells that are non-permissive for productive infection. Gene transfection in mouse SR.D10.CD4(-).F1 T cells produced four Lines expressing human CD4 and/or CD38. Ability of CD4(+)CD38(+) cells to bind HIV-1 or purified recombinant gp120 was significantly lower than that of CD4(+)CD38(-) cells. These data suggest that CD38 expression inhibits lymphocyte susceptibility to HIV infection, probably by inhibiting gp120/CD4-dependent viral binding to target cells.	Univ A Avogadro Eastern Piedmont, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Med & Surg Sci, I-10124 Turin, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; CSIC, Ctr Invest Biol, Dept Immunol, Madrid, Spain; Univ Ancona, Inst Biol & Genet, I-60128 Ancona, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; Sapienza University Rome; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Marche Polytechnic University	Dianzani, U (corresponding author), Univ A Avogadro Eastern Piedmont, Dept Med Sci, Via Solaroli 17, I-28100 Novara, Italy.		Feito, Maria José/AAE-7813-2020; Dianzani, Umberto/K-1952-2016; Rojo, Jose/ABH-1189-2020; Abbate, Isabella/K-6434-2016	Feito, Maria José/0000-0001-8623-4913; Rojo, Jose M./0000-0001-9032-0072; Savarino, Andrea/0000-0003-0983-3693; Capobianchi, Maria Rosaria/0000-0003-3465-0071; DIANZANI, Umberto/0000-0001-6723-3931; MALAVASI, Fabio/0000-0002-1844-174X				Amlot PL, 1996, CLIN EXP IMMUNOL, V105, P176, DOI 10.1046/j.1365-2249.1996.d01-722.x; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BOFILL M, 1994, J IMMUNOL, V152, P5613; Bragardo M, 1997, J IMMUNOL, V159, P1619; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; Capobianchi MR, 1998, AIDS RES HUM RETROV, V14, P233, DOI 10.1089/aid.1998.14.233; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; CAYOTA A, 1993, CLIN EXP IMMUNOL, V91, P241; Cesano A, 1998, J IMMUNOL, V160, P1106; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Cohen J, 1997, SCIENCE, V275, P1261, DOI 10.1126/science.275.5304.1261; DASILVA CP, 1998, IMMUNOL REV, V161, P79; De Martino M, 1998, PEDIATR RES, V43, P752, DOI 10.1203/00006450-199806000-00007; DIANZANI U, 1995, EUR J IMMUNOL, V25, P1306, DOI 10.1002/eji.1830250526; DIANZANI U, 1994, J IMMUNOL, V153, P952; DIEZOREJAS R, 1994, EMBO J, V13, P90, DOI 10.1002/j.1460-2075.1994.tb06238.x; Dittmar MT, 1997, NATURE, V385, P495, DOI 10.1038/385495a0; Dolei A, 1998, AIDS, V12, P183, DOI 10.1097/00002030-199802000-00008; DUKES CS, 1995, J VIROL, V69, P4000, DOI 10.1128/JVI.69.7.4000-4005.1995; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141; Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151, DOI 10.1002/jlb.65.2.151; Frank I, 1996, AIDS, V10, P1611, DOI 10.1097/00002030-199612000-00004; FURLINI G, 1991, MICROBIOLOGICA, V14, P141; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kitchen SG, 1998, J VIROL, V72, P9054, DOI 10.1128/JVI.72.11.9054-9060.1998; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Liu ZY, 1996, CYTOMETRY, V26, P1; Lund FE, 1996, J IMMUNOL, V157, P1455; Maciaszek JW, 1998, J VIROL, V72, P5862, DOI 10.1128/JVI.72.7.5862-5869.1998; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; MATHESON PB, 1995, AM J EPIDEMIOL, V142, P714, DOI 10.1093/oxfordjournals.aje.a117701; McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Mo HM, 1998, AIDS RES HUM RETROV, V14, P607, DOI 10.1089/aid.1998.14.607; MORRA M, 1998, FASEB J, V330, P1129; MURRAY MF, 1995, BIOCHEM BIOPH RES CO, V210, P954, DOI 10.1006/bbrc.1995.1749; NAKASHIMA H, 1989, J VIROL METHODS, V26, P319, DOI 10.1016/0166-0934(89)90114-6; North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x; ORAVECZ T, 1995, NAT MED, V1, P919, DOI 10.1038/nm0995-919; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; PAUWELS R, 1987, J VIROL METHODS, V16, P171, DOI 10.1016/0166-0934(87)90002-4; Platt EJ, 1997, J VIROL, V71, P883, DOI 10.1128/JVI.71.2.883-890.1997; Savarino A, 1996, J BIOL REG HOMEOS AG, V10, P13; Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P47, DOI 10.1002/(SICI)1099-0844(199903)17:1<47::AID-CBF810>3.0.CO;2-V; SCHEGLOVITOVA O, 1993, ARCH VIROL, V132, P267, DOI 10.1007/BF01309538; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SIRERA R, 1998, 12 WORLD AIDS C GEN, P528; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; SZOLLOSI J, 1984, CYTOMETRY, V5, P210, DOI 10.1002/cyto.990050216; Vigano A, 1998, LANCET, V352, P1905, DOI 10.1016/S0140-6736(05)60396-0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	55	14	17	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2265	2276		10.1096/fasebj.13.15.2265	http://dx.doi.org/10.1096/fasebj.13.15.2265			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593874				2022-12-28	WOS:000084310800018
J	Simoneau, JA; Veerkamp, JH; Turcotte, LP; Kelley, DE				Simoneau, JA; Veerkamp, JH; Turcotte, LP; Kelley, DE			Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss	FASEB JOURNAL			English	Article						carnitine palmitoyl transferase; fatty acid binding proteins; lipoprotein lipase; maximal aerobic power; fatty acid oxidation	LIPOPROTEIN-LIPASE ACTIVITY; DEPENDENT DIABETES-MELLITUS; BINDING PROTEIN; WOMEN; METABOLISM; OXIDATION; GLUCOSE; SENSITIVITY; MEN; TRIGLYCERIDE	A number of biochemical defects have been identified in glucose metabolism within skeletal muscle in obesity, and positive effects of weight loss on insulin resistance are also well established. Less is known about the capacity of skeletal muscle for the metabolism of fatty acids in obesity-related insulin resistance and of the effects of weight loss, though it is evident that muscle contains increased triglyceride. The current study was therefore undertaken to profile markers of human skeletal muscle for fatty acid metabolism in relation to obesity, in relation to the phenotype of insulin-resistant glucose metabolism, and to examine the effects of weight loss. Fifty-five men and women, lean and obese, with normal glucose tolerance underwent percutaneous biopsy of vastus lateralis skeletal muscle for determination of HADH, CPT, heparin-releasable (Hr) and tissue-extractable (Ext) LPL, CS, COX, PFK, and GAPDH enzyme activities, and content of cytosolic and plasma membrane FABP. Insulin sensitivity was measured using the euglycemic clamp method. DEXA was used to measure FM and FFM. In skeletal muscle of obese individuals, CPT, CS, and COX activities were lower while, conversely, they had a higher or similar content of FABP(C) and FABP(PM) than in lean individuals. Hr and Ext LPL activities were similar in both groups. In multivariate and simple regression analyses, there were significant correlations between insulin resistance and several markers of FA metabolism, notably, CPT and FABP(PM). These data suggest that in obesity-related insulin resistance, the metabolic capacity of skeletal muscle appears to be organized toward fat esterification rather than oxidation and that dietary-induced weight loss does not correct this disposition.-Simoneau, J.-A., Veerkamp, J. H., Turcotte, L. P., Kelley, D. E. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss.	Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Div Endocrinol & Metab, Pittsburgh, PA 15213 USA; Univ Laval, Div Kinesiol, Dept Social & Prevent Med, Fac Med, Ste Foy, PQ G1K 7P4, Canada; Catholic Univ Nijmegen, Fac Med Sci, Dept Biochem, NL-6500 HC Nijmegen, Netherlands; Univ So Calif, Dept Exercise Sci, Los Angeles, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Radboud University Nijmegen; University of Southern California	Kelley, DE (corresponding author), Univ Pittsburgh, Dept Med, E-1140 Biomed Sci Tower, Pittsburgh, PA 15213 USA.	Kelley@msx.dept.-med.pitt.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046204, R01DK049200] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1RR00056] Funding Source: Medline; NIDDK NIH HHS [1P30DK46204, R01 DK49200-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS A, 1975, PFLUG ARCH EUR J PHY, V359, P325, DOI 10.1007/BF00581443; BELFRAGE P, 1969, J LIPID RES, V10, P341; BLAAK EE, 1994, AM J PHYSIOL, V267, pE316, DOI 10.1152/ajpendo.1994.267.2.E316; BOGARDUS C, 1985, AM J PHYSIOL, V248, pE286, DOI 10.1152/ajpendo.1985.248.3.E286; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; BRADY PS, 1993, FASEB J, V7, P1039, DOI 10.1096/fasebj.7.11.8370473; CALLESESCANDON J, 1995, LIFE SCI, V58, P19, DOI 10.1016/0024-3205(95)02251-1; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; Cortright RN, 1997, J NUTR BIOCHEM, V8, P228, DOI 10.1016/S0955-2863(97)89660-X; DAGENAIS GR, 1976, J CLIN INVEST, V58, P421, DOI 10.1172/JCI108486; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; ECKEL RH, 1995, INT J OBESITY, V19, pS16; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1995, EUR J CLIN INVEST, V25, P396, DOI 10.1111/j.1365-2362.1995.tb01720.x; EVANS DJ, 1984, J CLIN INVEST, V74, P1515, DOI 10.1172/JCI111565; FELBER JP, 1987, DIABETES, V36, P1341, DOI 10.2337/diabetes.36.11.1341; FERRARO R, 1992, J CLIN INVEST, V90, P780, DOI 10.1172/JCI115951; FERRARO RT, 1993, J CLIN INVEST, V92, P441, DOI 10.1172/JCI116586; Fielding BA, 1998, BRIT J NUTR, V80, P495, DOI 10.1017/S0007114598001585; FINEGOOD DT, 1987, DIABETES, V36, P914, DOI 10.2337/diabetes.36.8.914; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V269, pE150, DOI 10.1152/ajpendo.1995.269.1.E150; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; KELLEY DE, 1993, J CLIN ENDOCR METAB, V77, P1287, DOI 10.1210/jc.77.5.1287; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; KELLEY DE, 1997, OBES RES, V5, pS12; Kiens B, 1997, BIOCHEM BIOPH RES CO, V231, P463, DOI 10.1006/bbrc.1997.6118; LEAN MEJ, 1988, INT J OBESITY, V12, P15; MANDARINO LJ, 1993, AM J PHYSIOL, V265, pE898, DOI 10.1152/ajpendo.1993.265.6.E898; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; OSCAI LB, 1990, J APPL PHYSIOL, V69, P1571, DOI 10.1152/jappl.1990.69.5.1571; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; PETTE D, 1986, FED PROC, V45, P2910; Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7; POLLARE T, 1991, ARTERIOSCLER THROMB, V11, P1192, DOI 10.1161/01.ATV.11.5.1192; Ruderman NB, 1997, ANN NY ACAD SCI, V827, P221, DOI 10.1111/j.1749-6632.1997.tb51837.x; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SIMONEAU JA, 1995, OBES RES, V3, P23; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; SIMONEAU JA, 1995, INT J OBESITY, V19, pS9; Simoneau JA, 1999, PROG OBES R, P411; SIMONEAU JA, 1997, HDB OBESITY, P539; TASKINEN MR, 1980, CLIN CHIM ACTA, V104, P107, DOI 10.1016/0009-8981(80)90140-0; Turcotte LP, 1997, MOL CELL BIOCHEM, V166, P153, DOI 10.1023/A:1006846907394; Turcotte LP, 1998, FASEB J, V12, pA231; Turcotte LP, 1999, INT S SPORT, P201; TURCOTTE LP, 1992, AM J PHYSIOL, V262, pE791; VANNIEUWENHOVEN FA, 1995, CIRCULATION, V92, P2848, DOI 10.1161/01.CIR.92.10.2848; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; Veerkamp JH, 1996, INT J BIOCHEM CELL B, V28, P473, DOI 10.1016/1357-2725(95)00150-6; VORK MM, 1991, BIOCHIM BIOPHYS ACTA, V1075, P199, DOI 10.1016/0304-4165(91)90267-K; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005; ZURLO F, 1990, AM J PHYSIOL, V259, pE650; ZURLO F, 1994, METABOLISM, V43, P481, DOI 10.1016/0026-0495(94)90081-7	59	358	364	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2051	2060		10.1096/fasebj.13.14.2051	http://dx.doi.org/10.1096/fasebj.13.14.2051			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544188				2022-12-28	WOS:000083660700017
J	Feng, JY; Shi, JX; Schinazi, RF; Anderson, KS				Feng, JY; Shi, JX; Schinazi, RF; Anderson, KS			Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP	FASEB JOURNAL			English	Article						transient kinetics; rapid chemical quench; pre-steady-state analysis; RNA-dependent DNA polymerization; incorporation efficiency	IMMUNODEFICIENCY-VIRUS TYPE-1; (-)-2'-DEOXY-3'-THIACYTIDINE 3TC; NONNUCLEOSIDE INHIBITORS; DNA POLYMERIZATION; POLYMERASE-GAMMA; AZT RESISTANCE; ENANTIOMERS; REPLICATION; FIDELITY; ANALOGS	Of all of the nucleoside inhibitors approved by the FDA for treatment of AIDS, (-)-beta-2',3'-dideoxy-3'-thiacytidine (3TC, lamivudine) is the only one with the unnatural (-)-beta-L configuration, The fluorinated derivative (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine [(-)-FTC] and its triphosphate form have also been reported to have excellent antiretroviral activity against HIV-1 reverse transcriptase (RT). Preliminary results of clinical trials suggest that (-)-FTC is 6- to 10-fold more potent than 3TC, However, the molecular mechanism for the observed enhanced clinical potency of (-)-FTC to inhibit viral replication is not understood. The present mechanistic studies used a transient kinetic approach and were designed to compare the incorporation of 3TC-TP and (-)-FTC-TP into DNA by HIV-1 RT and illuminate key features that may play a role in the differential potency. Here we show that (-)-FTC-TP is incorporated 10-fold more efficiently than 3TC-TP during HIV-1 RT-catalyzed RNA-dependent DNA synthesis. The enhanced incorporation efficiency of (-)-FTC-TP may be a key mechanistic feature that, in part, is responsible for the enhanced potency of (-)-FTC observed in ongoing clinical trials.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Emory Univ, Sch Med, Dept Pediat, Biochem Pharmacol Lab,VAMC, Decatur, GA 30033 USA	Yale University; Emory University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.		Schinazi, Raymond F/B-6777-2017		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; Cherrington JM, 1996, ANTIMICROB AGENTS CH, V40, P1270, DOI 10.1128/AAC.40.5.1270; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674, DOI 10.1128/CMR.10.4.674; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; FURMAN PA, 1992, ANTIMICROB AGENTS CH, V36, P2686, DOI 10.1128/AAC.36.12.2686; GRAY NM, 1995, BIOCHEM PHARMACOL, V50, P1043, DOI 10.1016/0006-2952(95)96620-A; HARRIS CH, 1995, QUANTITATIVE CHEM AN, P41; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; LIN TS, 1988, J MED CHEM, V31, P336, DOI 10.1021/jm00397a011; Martin LT, 1997, BIOCHEM PHARMACOL, V53, P75, DOI 10.1016/S0006-2952(96)00653-3; PARKER WB, 1994, J NIH RES, V6, P57; POTTAGE J, 1998, 12 WORLD AIDS C GEN; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2423, DOI 10.1128/AAC.36.11.2423; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; SHEWACH DS, 1993, BIOCHEM PHARMACOL, V45, P1540, DOI 10.1016/0006-2952(93)90058-5; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Vaccaro JA, 1998, BIOCHEMISTRY-US, V37, P14189, DOI 10.1021/bi9810353; VANDRAANEN NA, 1994, ANTIMICROB AGENTS CH, V38, P868, DOI 10.1128/AAC.38.4.868	32	44	50	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1511	1517		10.1096/fasebj.13.12.1511	http://dx.doi.org/10.1096/fasebj.13.12.1511			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463941				2022-12-28	WOS:000082347600005
J	Jimenez-Lara, AM; Aranda, A				Jimenez-Lara, AM; Aranda, A			The vitamin D receptor binds in a transcriptionally inactive form and without a defined polarity on a retinoic acid response element	FASEB JOURNAL			English	Article						retinoid receptor; half-site; heterodimer; retinoid X receptor	NUCLEAR RECEPTOR; THYROID-HORMONE; DIRECT REPEATS; HISTONE DEACETYLASE; LIGAND SENSITIVITY; CO-REPRESSOR; BETA-GENE; HETERODIMERS; TRANSACTIVATION; COMPLEX	Heterodimers of the vitamin D receptor (VDR) with the retinoid X receptor (RXR) bind in a transcriptionally unproductive manner to the retinoic acid response element present in the retinoic acid receptor-Pe promoter. This element is composed of a direct repeat (DR) of the sequence PuGTTCA spaced by five nucleotides, However, the same sequence separated by three nucleotides (DR3) acts as a strong vitamin D response element. Here we show that the polarity of binding of the heterodimers to the DR3 was 5'-RXR-VDR-3', whereas on the DR5, both heterodimeric partners bind indistinctly to the 5' or 3' hemi-sites, These results suggest that the response elements can allosterically regulate the conformation of the receptors to determine positive or negative regulation of gene expression. Despite the altered polarity, the DRS-bound heterodimer was able to recruit the nuclear receptor coactivator ACTR in a vitamin D-dependent fashion. Furthermore, binding of the corepressor SMRT (silencing mediator of retinoid and thyroid hormone receptors) to the RXR/VDR heterodimer on a DR5 was not observed. Binding of RXR/VDR heterodimers to DRs with different transcriptional outcomes may generate selectivity and provide a greater complexity and flexibility to the vitamin D responses.	UAM, CSIC, Inst Invest Biomed, Madrid 29029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), UAM, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 29029, Spain.		Jiménez-Lara, Ana-María/ABF-5639-2020; Aranda, Ana/ABG-8820-2020	Jiménez-Lara, Ana-María/0000-0001-6471-9741; Aranda, Ana/0000-0002-8338-9589				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P455; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JIMENEZLARA AM, 1999, IN PRESS ENDOCRINOLO; KATO S, 1995, MOL CELL BIOL, V15, P5858; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Polly P, 1997, J CELL BIOCHEM, V67, P287, DOI 10.1002/(SICI)1097-4644(19971201)67:3<287::AID-JCB1>3.0.CO;2-S; QUELO I, 1994, DNA CELL BIOL, V13, P1181, DOI 10.1089/dna.1994.13.1181; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	37	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1073	1081		10.1096/fasebj.13.9.1073	http://dx.doi.org/10.1096/fasebj.13.9.1073			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336890				2022-12-28	WOS:000080547700012
J	Donnellan, R; Chetty, R				Donnellan, R; Chetty, R			Cyclin E in human cancers	FASEB JOURNAL			English	Review						cell cycle; cyclins; cyclin-dependent kinase; CKIs	DEPENDENT KINASE INHIBITOR; SQUAMOUS-CELL CARCINOMAS; S-PHASE ENTRY; BREAST-CANCER; RETINOBLASTOMA PROTEIN; PROGNOSTIC IMPLICATIONS; REGULATORY PROTEINS; EPITHELIAL-CELLS; UTERINE CERVIX; MESSENGER-RNA	Regulators of the cell cycle such as cyclin E play an important part in neoplasia. The cyclin E protein forms a partnership with a specific protein kinase. This complex phosphorylates key substrates to initiate DNA synthesis. Cyclin-dependent kinase inhibitors (CKIs) are able to suppress the activity of cyclin E. Various substances (including proteins produced by oncogenic viruses) affect cyclin E directly or indirectly through an interaction with CKIs. These interactions are important in elucidating the mechanisms of neoplasia. They may also provide prognostic information in a wide range of common cancers. Cyclin E may even be a target for treatment of cancers in the future.	Univ KwaZulu Natal, Dept Pathol, Sch Med, ZA-4001 Durban, South Africa	University of Kwazulu Natal	Donnellan, R (corresponding author), Univ KwaZulu Natal, Dept Pathol, Sch Med, Private Bag 7,Congella 4013, ZA-4001 Durban, South Africa.	donnellanr@med.und.ac.za						Ahn HJ, 1998, INT J SURG PATHOL, V6, P205, DOI 10.1177/106689699800600404; Ahn Myung-Ju, 1998, Journal of Korean Medical Science, V13, P513; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; AOYAGI K, 1997, GAN TO KAGAKU RYOHO, V2, P285; Bito T, 1997, J CUTAN PATHOL, V24, P305, DOI 10.1111/j.1600-0560.1997.tb00796.x; Bresnahan WA, 1996, VIROLOGY, V224, P150, DOI 10.1006/viro.1996.0516; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen IT, 1996, ONCOGENE, V12, P595; Cho NH, 1997, INT J GYNECOL PATHOL, V16, P339, DOI 10.1097/00004347-199710000-00008; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; Corroyer S, 1996, J BIOL CHEM, V271, P25117, DOI 10.1074/jbc.271.41.25117; Courjal F, 1996, INT J CANCER, V69, P247; DEMETRICK DJ, 1995, CYTOGENET CELL GENET, V69, P190, DOI 10.1159/000133960; Desrivieres S, 1997, J BIOL CHEM, V272, P2470; Dirks PB, 1997, J NEUROPATH EXP NEUR, V56, P291, DOI 10.1097/00005072-199703000-00008; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Erlanson M, 1998, BLOOD, V92, P770; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; Furihata M, 1998, BRIT J CANCER, V77, P783, DOI 10.1038/bjc.1998.127; Geng Y, 1996, ONCOGENE, V12, P1173; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Harvat BL, 1997, ONCOGENE, V14, P2111, DOI 10.1038/sj.onc.1201055; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; HIRAMA T, 1995, BLOOD, V86, P841; Iida H, 1997, BLOOD, V90, P3707, DOI 10.1182/blood.V90.9.3707; Ikezawa K, 1998, FASEB J, V12, P1233, DOI 10.1096/fasebj.12.12.1233; Ito K, 1998, ANTICANCER RES, V18, P1661; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kanai M, 1998, CANCER, V82, P1709, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1709::AID-CNCR18>3.0.CO;2-8; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Kwon TK, 1998, ONCOGENE, V16, P755, DOI 10.1038/sj.onc.1201586; Langenfeld J, 1996, ONCOGENE, V13, P1983; Langenfeld J, 1996, ONCOGENE, V13, P2743; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lazzereschi D, 1998, INT J CANCER, V76, P806, DOI 10.1002/(SICI)1097-0215(19980610)76:6<806::AID-IJC7>3.0.CO;2-1; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lesaca EE, 1998, ORAL ONCOL, V34, P52, DOI 10.1016/S1368-8375(97)00023-7; Li SF, 1996, CANCER, V77, P321, DOI 10.1002/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3; Li WW, 1996, INT J CANCER, V68, P514, DOI 10.1002/(SICI)1097-0215(19961115)68:4<514::AID-IJC18>3.0.CO;2-4; Li ZR, 1997, BBA-MOL CELL RES, V1356, P149, DOI 10.1016/S0167-4889(96)00172-3; Lu X, 1998, CANCER, V82, P2409; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marches R, 1998, CANCER RES, V58, P691; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Mate JL, 1998, J PATHOL, V184, P83; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Molendini L, 1998, INT J ONCOL, V12, P1007; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Murakami-Mori K, 1998, J IMMUNOL, V161, P1694; Nakamura M, 1997, ANN SURG, V226, P35, DOI 10.1097/00000658-199707000-00005; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Osman I, 1997, CLIN CANCER RES, V3, P2247; Patel V, 1997, INT J CANCER, V73, P551, DOI 10.1002/(SICI)1097-0215(19971114)73:4<551::AID-IJC16>3.0.CO;2-C; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Quade BJ, 1998, MODERN PATHOL, V11, P1238; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B; Sakaida H, 1998, AIDS RES HUM RETROV, V14, P31, DOI 10.1089/aid.1998.14.31; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sasaki H, 1996, Nihon Rinsho, V54, P1049; Sauer K, 1995, Prog Cell Cycle Res, V1, P125; Scott KA, 1997, BRIT J CANCER, V76, P1288, DOI 10.1038/bjc.1997.550; Scuderi R, 1996, BLOOD, V87, P3360, DOI 10.1182/blood.V87.8.3360.bloodjournal8783360; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; SEWING A, 1994, J CELL SCI, V107, P581; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shiozawa T, 1996, MOL HUM REPROD, V2, P745, DOI 10.1093/molehr/2.10.745; Sirzen F, 1997, ANTICANCER RES, V17, P3381; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Stanta G, 1998, VIRCHOWS ARCH, V432, P107, DOI 10.1007/s004280050142; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TAHARA E, 1995, CANCER, V75, P1410, DOI 10.1002/1097-0142(19950315)75:6+<1410::AID-CNCR2820751504>3.0.CO;2-O; Tanikawa M, 1998, J BIOL CHEM, V273, P18522, DOI 10.1074/jbc.273.29.18522; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; vanDiest PJ, 1997, AM J PATHOL, V150, P705; Volm M, 1997, INT J CANCER, V74, P508, DOI 10.1002/(SICI)1097-0215(19971021)74:5<508::AID-IJC5>3.0.CO;2-7; Wakasugi E, 1997, J CLIN PATHOL, V50, P407, DOI 10.1136/jcp.50.5.407; Wang A, 1996, J CANCER RES CLIN, V122, P122, DOI 10.1007/BF01226270; Wang GX, 1997, MICROSCALE THERM ENG, V1, P143; Wang ST, 1998, HUM PATHOL, V29, P1304, DOI 10.1016/S0046-8177(98)90262-3; WIMMEL A, 1994, ONCOGENE, V9, P995; WOLOWIEC D, 1995, LEUKEMIA, V9, P1382; Wu XP, 1996, ONCOGENE, V12, P1397; Yamada H, 1995, MOL CELL BIOCHEM, V152, P149, DOI 10.1007/BF01076077; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x; Yasui W, 1996, VIRCHOWS ARCH, V429, P13; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	110	177	192	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					773	780		10.1096/fasebj.13.8.773	http://dx.doi.org/10.1096/fasebj.13.8.773			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224221				2022-12-28	WOS:000080372500001
J	Patel, NA; Chalfant, CE; Yamamoto, M; Watson, JE; Eichler, DC; Cooper, DR				Patel, NA; Chalfant, CE; Yamamoto, M; Watson, JE; Eichler, DC; Cooper, DR			Acute hyperglycemia regulates transcription and posttranscriptional stability of PKC beta II mRNA in vascular smooth muscle cells	FASEB JOURNAL			English	Article						A10 cells; human AoSMC; acute hyperglycemia; posttranscriptional regulation; glucose	PROTEIN-KINASE-C; CARBOHYDRATE REGULATION; GENE-TRANSCRIPTION; MAMMALIAN-CELLS; SOLEUS MUSCLE; GROWTH-FACTOR; GLUCOSE; EXPRESSION; ATHEROSCLEROSIS; IDENTIFICATION	Acute hyperglycemia may contribute to the progression of atherosclerosis by regulating protein kinase C (PKC) isozymes and by accelerating vascular smooth muscle cell (VSMC) proliferation. We investigated acute glucose regulation of PKC beta gene expression in A10 cells, a rat aortic smooth muscle cell line. Western blot analysis showed that PKC beta II protein levels decreased with high glucose (25 mM) compared to normal glucose (5.5 mM), whereas PKC beta I levels were unaltered. PKC beta mRNA levels were depleted by 60-75% in hyperglycemic conditions. To elucidate whether high glucose regulated PKC beta expression via the common promoter for PKCPI and PKC beta II, deletion constructs of the PKC beta promoter ligated to CAT as reporter gene were transfected into A10 cells, Construct D (-411 to +179CAT) showed quenching in high glucose (25 mM) and suggested the involvement of a carbohydrate response element in the 5' promoter region of the PKC beta gene. In actinomycin D-treated A10 cells, a 60% decrease in PKC beta mRNA with high glucose treatment indicated that posttranscriptional destabilization by glucose was also occurring, We have demonstrated that glucose-induced posttranscriptional destabilization of PKC beta II message is mediated via a nuclease activity present in the cytosol, The specificity of glucose to posttranscriptionally destabilize PKC beta II mRNA, but not the PKC beta I mRNA, was confirmed in both A10 cells and primary cultures from human aorta.	James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Mol Biol, Tampa, FL 33612 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cooper, DR (corresponding author), James A Haley Vet Hosp, VAR 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Patel, Niketa/A-1392-2012; Eichler, Duane/A-1906-2012	Patel, Niketa A./0000-0003-4811-8596				BONINI J, 1992, BIOTECHNIQUES, V11, P708; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; COOPER DR, 1993, ENDOCRINOLOGY, V133, P2241, DOI 10.1210/en.133.5.2241; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; GABBAY RA, 1990, ENDOCRINOLOGY, V127, P1194, DOI 10.1210/endo-127-3-1194; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLER H, 1995, KIDNEY INT, V47, P1057, DOI 10.1038/ki.1995.152; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HUANG FL, 1987, J BIOL CHEM, V262, P15714; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; ISHIZUKA T, 1993, METABOLISM, V42, P420, DOI 10.1016/0026-0495(93)90097-8; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1978, J CELL PHYSIOL, V97, P497, DOI 10.1002/jcp.1040970325; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SUDO Y, 1993, ENDOCRINOLOGY, V133, P1221, DOI 10.1210/en.133.3.1221; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; WILLIAMS B, 1995, J HYPERTENS, V13, P477, DOI 10.1097/00004872-199505000-00001; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; Yamamoto M, 1998, EXP CELL RES, V240, P349, DOI 10.1006/excr.1998.3999; YAMAMOTO M, 1997, DIABETES S1, V46, pA107	44	30	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					103	113		10.1096/fasebj.13.1.103	http://dx.doi.org/10.1096/fasebj.13.1.103			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872935				2022-12-28	WOS:000078029500012
J	Rauen, U; Polzar, B; Stephan, H; Mannherz, HG; de Groot, H				Rauen, U; Polzar, B; Stephan, H; Mannherz, HG; de Groot, H			Cold-induced apoptosis in cultured hepatocytes and liver endothelial cells: mediation by reactive oxygen species	FASEB JOURNAL			English	Article						hypothermia; iron; hydroxyl radical; free radical; cold preservation	MEMBRANE LIPID PERTURBERS; DNA FRAGMENTATION; MAMMALIAN-CELLS; RAT HEPATOCYTES; XYLENOL ORANGE; PRESERVATION; INJURY; HYPOTHERMIA; SHOCK; TRANSPLANTATION	When cultured hepatocytes were incubated in cell culture medium at 4 degrees C for up to 30 h and then returned to 37 degrees C, blebbing of the plasma membrane, cell detachment, chromatin condensation and margination, enhanced nuclear stainability with Hoechst 33342, ruffling of the nuclear membrane, and DNA fragmentation occurred. Similar to hepatocytes, cultured liver endothelial cells exhibited blebbing, chromatin condensation and margination, marked nuclear condensation, and increased stainability with Hoechst 33342 when exposed to hypothermia/rewarming, In both cell types, the occurrence and extent of these alterations were dependent on the duration of the cold incubation period. T1 lis cold-induced apoptosis was inhibited by hypoxia, by an array of free radical scavengers/antioxidiants, and by iron chelators. However, the extent of the protection by the different antioxidants was different in the two cell types: iron chelators provided complete protection in liver endothelial cells but only partial protection in hepatocytes, whereas lipophilic antioxidants such as a-tocopherol provided complete protection in both cell types. During cold incubation, and especially during rewarming, lipid peroxidation occurred. These results suggest that the formation of reactive oxygen species (ROS) is a key mediator of cold-induced apoptosis, with ROS formation being completely iron-mediated in liver endothelial cells and partially iron-mediated in hepatocytes.	Univ Essen Gesamthsch Klinikum, Inst Physiol, D-45122 Essen, Germany; Ruhr Univ Bochum, Abt Anat & Embryol, D-44780 Bochum, Germany	University of Duisburg Essen; Ruhr University Bochum	Rauen, U (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Physiol, Hufelandstr 55, D-45122 Essen, Germany.		Stephan, Harald/AAT-6802-2021; Mannherz, Hans Georg/HHM-2867-2022; Rauen, Ursula/N-2137-2014	Mannherz, Hans Georg/0000-0001-8158-5722				BABBS CF, 1990, METHOD ENZYMOL, V186, P137; BELTZER FO, 1988, TRANSPLANTATION, V45, P673; BELZER FO, 1993, TRANSPLANT P, V25, P2527; BLANKENSTEIJN JD, 1991, HEPATOLOGY, V13, P1235, DOI 10.1002/hep.1840130633; Borghi-Scoazec G, 1997, Liver Transpl Surg, V3, P407, DOI 10.1053/jlts.1997.v3.pm0009346771; CALDWELLKENKEL JC, 1991, HEPATOLOGY, V13, P83, DOI 10.1016/0270-9139(91)90219-L; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; DEGROOT H, 1991, BIOL CHEM H-S, V372, P35, DOI 10.1515/bchm3.1991.372.1.35; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; Gizewski ER, 1997, BIOCHEM J, V322, P693, DOI 10.1042/bj3220693; GRAND RJA, 1995, EXP CELL RES, V218, P439, DOI 10.1006/excr.1995.1177; GREGORY CD, 1994, INT J CANCER, V57, P419, DOI 10.1002/ijc.2910570321; Gressner AM, 1996, HEPATOLOGY, V23, P571; HANSEN TN, 1994, CRYOBIOLOGY, V31, P101, DOI 10.1006/cryo.1994.1013; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; HOCKENBERY D, 1995, AM J PATHOL, V146, P16; IKEDA T, 1992, HEPATOLOGY, V16, P454, DOI 10.1002/hep.1840160226; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KRUMAN II, 1992, J CELL PHYSIOL, V153, P112, DOI 10.1002/jcp.1041530115; KRUUV J, 1983, J CELL PHYSIOL, V115, P179, DOI 10.1002/jcp.1041150212; MARKS RM, 1985, IN VITRO CELL DEV B, V21, P627; MARSH DC, 1989, CRYOBIOLOGY, V26, P524, DOI 10.1016/0011-2240(89)90077-1; Martin A, 1996, FREE RADICAL BIO MED, V21, P505, DOI 10.1016/0891-5849(96)00118-9; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; NAGLE WA, 1990, CRYOBIOLOGY, V27, P439, DOI 10.1016/0011-2240(90)90021-U; NAKAMURA T, 1991, LIPIDS, V26, P765, DOI 10.1007/BF02535628; NOLL T, 1987, ARCH BIOCHEM BIOPHYS, V252, P284, DOI 10.1016/0003-9861(87)90033-6; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; PADDENBERG R, 1996, EUR J CELL BIOL, V69, P105; PATEL T, 1995, HEPATOLOGY, V21, P1725, DOI 10.1002/hep.1840210635; PEROTTI M, 1990, FEBS LETT, V259, P331, DOI 10.1016/0014-5793(90)80040-P; Peters SMA, 1998, TRANSPLANTATION, V65, P625, DOI 10.1097/00007890-199803150-00005; PLOEG RJ, 1993, TRANSPLANT P, V25, P1659; Rauen U, 1997, FREE RADICAL BIO MED, V22, P17, DOI 10.1016/S0891-5849(96)00273-0; Rauen U, 1997, FREE RADICAL BIO MED, V23, P392, DOI 10.1016/S0891-5849(96)00618-1; Rauen U, 1998, FREE RADICAL BIO MED, V24, P1316, DOI 10.1016/S0891-5849(97)00456-5; Rauen U, 1997, HEPATOLOGY, V26, P351, DOI 10.1002/hep.510260215; RAUEN U, 1993, TRANSPLANTATION, V55, P469, DOI 10.1097/00007890-199303000-00002; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; RULE GS, 1978, CRYOBIOLOGY, V15, P408, DOI 10.1016/0011-2240(78)90059-7; Sasaki H, 1997, TRANSPL P, V29, P406, DOI 10.1016/S0041-1345(96)00138-8; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Sies Helmut, 1997, V38, P229; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; SOLOFF BL, 1987, BIOCHEM BIOPH RES CO, V145, P876, DOI 10.1016/0006-291X(87)91046-1; STEFANOVICH P, 1995, CRYOBIOLOGY, V32, P389, DOI 10.1006/cryo.1995.1039; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WAHLBERG JA, 1986, CRYOBIOLOGY, V23, P477, DOI 10.1016/0011-2240(86)90056-8; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Zachariassen K.E., 1991, Arctic Medical Research, V50, P13; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	55	263	271	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					155	168		10.1096/fasebj.13.1.155	http://dx.doi.org/10.1096/fasebj.13.1.155			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872940				2022-12-28	WOS:000078029500017
J	Li, JJ; Oberley, LW; Fan, M; Colburn, NH				Li, JJ; Oberley, LW; Fan, M; Colburn, NH			Inhibition of AP-1 and NF-kappa B by manganese-containing superoxide dismutase in human breast cancer cells	FASEB JOURNAL			English	Article						tumor suppressor gene; redox; transcription factor; MCF-7 cells; TPA	EPIDERMAL GROWTH-FACTOR; PHORBOL ESTER; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; NEOPLASTIC TRANSFORMATION; LUNG FIBROBLASTS; MAMMALIAN-CELLS; MESSENGER-RNA; JB6 CELLS; CIS-FOS	One of the primary antioxidant enzymes, manganese-containing superoxide dismutase (MnSOD), has shown the ability to reverse malignant phenotypes in a variety of human tumor cells that are low or absent in MnSOD expression. We have observed that overexpression of human MnSOD in human breast cancer MCF-7 cells inhibits tumor growth both in vitro and in vivo. The signaling pathway underlying the MnSOD induced tumor suppression is unknown. We demonstrate here that transcriptional and DNA binding ability of AP-1 and NF-kappa B, but not SP-1, were inhibited (by 50%) in the MCF-7 cell line overexpressing MnSOD, When transiently expressing, MnSOD inhibited AP-I but increased NF-kappa B transactivation, which can be abolished by sodium pyruvate, a hydrogen peroxide scavenger. To analyze the target genes responsible for MnSOD-induced tumor suppression, genes related to tumor growth and responsive to AP-1 or NF-kappa B were analyzed. AP-1 responsive collagenase I, stromelysin I, and NF-kappa B responsive IL-1 and IL-6 were down-regulated in the MnSOD stable transfectants compared to the control cell lines. Since TPA induces differentiation in human breast cancer cells and up-regulates MnSOD gene in HeLa cells, MnSOD expression and AP-1 and NF-kappa B activity were measured under TPA treatment. The results showed that TPA induced endogenous MnSOD expression and inhibited both AP-1 and NF-kappa B, Together, these results suggest that tumor suppression by overexpressing MnSOD is related to a modulation of AP-1 and NF-kappa B, which causes a downregulation of genes responsible for tumor malignant phenotype.	NCI, Gene Regulat Sect, Lab Biochem Physiol, Frederick, MD 21702 USA; Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Iowa	Li, JJ (corresponding author), NCI, Gene Regulat Sect, Lab Biochem Physiol, Frederick, MD 21702 USA.	lij@mail.ncifcrf.gov		Li, Jian Jian/0000-0003-3694-9675	NATIONAL CANCER INSTITUTE [R01CA041267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOWDEN GT, 1990, RADIAT RES, V121, P235, DOI 10.2307/3577771; CERUTTI P, 1994, ENVIRON HEALTH PERSP, V102, P123, DOI 10.2307/3432228; CERUTTI PA, 1985, SCIENCE, V227, P7634; Chen JX, 1996, IEEE COMPUT SCI ENG, V3, P13, DOI 10.1109/MCSE.1996.556508; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DONG Z, 1995, MOL CARCINOG, V19, P204; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; FUJII J, 1991, J BIOL CHEM, V266, P23142; GALLEMANN D, 1990, ANAL BIOCHEM, V191, P347, DOI 10.1016/0003-2697(90)90230-7; GUILBAUD N, 1988, MOL CELL ENDOCRINOL, V56, P157, DOI 10.1016/0303-7207(88)90020-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISSANDOU M, 1988, CANCER RES, V48, P6943; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; KENNEDY MJ, 1992, CANCER RES, V52, P1278; Kiningham KK, 1997, CANCER RES, V57, P5265; KOGA M, 1990, CANCER RES, V50, P4849; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; LI JJ, 1995, BIOCHEM BIOPH RES CO, V216, P610, DOI 10.1006/bbrc.1995.2666; MARTIN MB, 1995, J BIOL CHEM, V270, P25244, DOI 10.1074/jbc.270.42.25244; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NAVARRO S, 1991, BLOOD, V77, P461; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OBERLEY LW, 1989, J CELL PHYSIOL, V138, P50, DOI 10.1002/jcp.1041380109; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; OSBORNE CK, 1981, J CLIN INVEST, V67, P943, DOI 10.1172/JCI110144; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; SCHERCK R, 1991, EMBO J, V10, P2247; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHMIDT KN, 1996, BIOL INTERMEDIATES, V5, P63; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SINGH N, 1995, INT J CANCER, V62, P107, DOI 10.1002/ijc.2910620120; SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284; SPITZ DR, 1990, ARCH BIOCHEM BIOPHYS, V279, P249, DOI 10.1016/0003-9861(90)90489-L; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Yan T, 1996, CANCER RES, V56, P2864; YANG MZ, 1994, EUR J BIOCHEM, V222, P651, DOI 10.1111/j.1432-1033.1994.tb18909.x; Zhang N, 1996, BIOCHEM BIOPH RES CO, V220, P171, DOI 10.1006/bbrc.1996.0376	67	96	101	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1713	1723		10.1096/fasebj.12.15.1713	http://dx.doi.org/10.1096/fasebj.12.15.1713			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837861				2022-12-28	WOS:000077574500013
J	Piotrowicz, RS; Hickey, E; Levin, EG				Piotrowicz, RS; Hickey, E; Levin, EG			Heat shock protein 27 kDa expression and phosphorylation regulates endothelial cell migration	FASEB JOURNAL			English	Article						lamellipodia; F-actin; vascular endothelial growth factor; HSP27; wounding	ACTIN MICROFILAMENT DYNAMICS; POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR CHAPERONES; ORGANIZATION; GROWTH; POLYMERIZATION; FILAMENTS; HSP27; REORGANIZATION; DICTYOSTELIUM	The effects of enhanced HSP27 expression or expression of a nonphosphorylatable form of HSP27 on the migration of bovine arterial endothelial cells was assessed. Expression of the wildtype protein enhanced migration by twofold compared to control transfectants, whereas expression of the mutant protein retarded migration by 40%, Since homologs of the small heat shock protein inhibit F-actin polymerization in vitro and may alter basolateral F-actin content in vivo, it was postulated that the 27 kDa heat shock protein affects microfilament extension essential for cell motility. Expression of the wild type protein promoted the generation of long cellular extensions, whereas expression of the dominant negative mutant protein resulted in a marked reduction of lamellipodia and generated aberrant microfilament morphology at the wound edge, Immunofluorescence combined with phalloidin staining demonstrated the colocalization of the HSP27 gene products with lamellipodial microfilament structures. These data suggest that the 27 kDa heat shock protein regulates migration by affecting the generation lamellipodia microfilaments.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Nevada, Dept Biol, Reno, NV 89557 USA	Scripps Research Institute; Scripps Research Institute; Nevada System of Higher Education (NSHE); University of Nevada Reno	Levin, EG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Mail Drop SBR13,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	glevin@scripps.edu			NATIONAL CANCER INSTITUTE [R29CA077670] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040435] Funding Source: NIH RePORTER; NCI NIH HHS [CA77670-01] Funding Source: Medline; NHLBI NIH HHS [HL40435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLERS A, 1994, MOL PHARM, V4, P1077; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DiNubile MJ, 1997, BBA-MOL CELL RES, V1358, P261, DOI 10.1016/S0167-4889(97)00076-1; Garrido C, 1997, CANCER RES, V57, P2661; GEIGER B, 1984, J CELL BIOL, V99, P83; GOTLIEB AI, 1990, TOXICOL PATHOL, V18, P603; Guay J, 1997, J CELL SCI, V110, P357; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; HUOT J, 1995, EUR J BIOCHEM, V227, P418; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Lee TYJ, 1996, J VASC RES, V33, P13, DOI 10.1159/000159127; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; OESTERREICH S, 1993, CANCER RES, V53, P4443; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SHOLLEY MM, 1977, LAB INVEST, V36, P18; Small J V, 1988, Electron Microsc Rev, V1, P155; SMALL JV, 1981, J CELL BIOL, V91, P695, DOI 10.1083/jcb.91.3.695; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1994, ADV EXP MED BIOL, V358, P133; WATTS RG, 1993, BLOOD, V81, P2750; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; WONG MKK, 1990, ARTERIOSCLEROSIS, V10, P76, DOI 10.1161/01.ATV.10.1.76	39	113	114	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1481	1490		10.1096/fasebj.12.14.1481	http://dx.doi.org/10.1096/fasebj.12.14.1481			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806757	Green Submitted			2022-12-28	WOS:000076749500007
J	Romero, MP; Garcia-Perganeda, A; Guerrero, JM; Osuna, C				Romero, MP; Garcia-Perganeda, A; Guerrero, JM; Osuna, C			Membrane-bound calmodulin in Xenopus laevis oocytes as a novel binding site for melatonin	FASEB JOURNAL			English	Article						membranes pd, CaM; indoleamine; protein kinase	NITRIC-OXIDE SYNTHASE; SARCOPLASMIC-RETICULUM; IODINATED MELATONIN; RAT CEREBELLUM; PINEAL-GLAND; RECEPTOR; CALCIUM; CELLS; INHIBITION; LYMPHOCYTES	Melatonin has been suggested as a physiological antagonist of calmodulin. In this work, we have characterized melatonin binding sites in Xenopus laevis oocyte membranes. Binding of [I-125]melatonin by X. laevis oocyte membranes fulfills all criteria for binding to a receptor site. Binding was dependent on time, temperature, and membrane concentration and was stable, reversible, saturable, and specific. The binding site was also pharmacologically characterized. Stoichiometric studies showed a high-affinity binding site with a K-d of 1.18 nM, These data are in close agreement with data obtained from kinetic studies (K-d=0.12 nM), In competition studies, we observed a low-affinity binding site (K-d=63.41 mu M). Moreover, the binding site was characterized as calmodulin. Thus, binding was dependent on calcium and blocked by anti-CaM antibodies in a concentration-dependent manner. Calmodulin inhibitor chlorpromazine also inhibited binding of the tracer. From these results, it is suggested that membrane-bound calmodulin acts as a melatonin binding site in Xenopus laevis oocytes, where it might couple cellular activities to rhythmic circulating levels of melatonin, This hypothesis correlates with the previous findings describing melatonin as a physiological antagonist of calmodulin.	Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, E-41009 Seville, Spain; Virgen Macarena Hosp, E-41009 Seville, Spain	University of Sevilla; Hospital Universitario Virgen Macarena	Osuna, C (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Avda Sanchez Pizjuan 4, E-41009 Seville, Spain.	carmen18@arrakis.es	Guerrero, Josep M./Y-2929-2019; IBIS, NEUROINMUNO/O-9306-2015; Guerrero, Josep M./D-5519-2014	Guerrero, Josep M./0000-0001-5236-4592; Guerrero, Juan Miguel/0000-0001-7553-0119				ANDERSON KW, 1984, J BIOL CHEM, V259, P1487; Anton-Tay F, 1998, J PINEAL RES, V24, P35, DOI 10.1111/j.1600-079X.1998.tb00363.x; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Benitez-King G, 1997, PINEAL UPDATE, P13; BENITEZKING G, 1991, BRAIN RES, V557, P289, DOI 10.1016/0006-8993(91)90146-M; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; BENITEZKING G, 1990, J PINEAL RES, V9, P209, DOI 10.1111/j.1600-079X.1990.tb00709.x; BenitezKing G, 1996, BBA-GEN SUBJECTS, V1290, P191, DOI 10.1016/0304-4165(96)00025-6; BENITEZKING G, 1993, LIFE SCI, V53, P201, DOI 10.1016/0024-3205(93)90670-X; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LD, 1993, J PINEAL RES, V14, P178, DOI 10.1111/j.1600-079X.1993.tb00500.x; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COHEN M, 1978, NATURE, V274, P894, DOI 10.1038/274894a0; DONOWITZ M, 1983, AM J PHYSIOL, V245, pG165, DOI 10.1152/ajpgi.1983.245.2.G165; DUBOCOVICH ML, 1987, P NATL ACAD SCI USA, V84, P3916, DOI 10.1073/pnas.84.11.3916; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; Finocchiaro LME, 1998, J PINEAL RES, V24, P22, DOI 10.1111/j.1600-079X.1998.tb00362.x; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GarciaMaurino S, 1997, J IMMUNOL, V159, P574; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GUERRERO JM, 1981, MOL CELL ENDOCRINOL, V21, P151, DOI 10.1016/0303-7207(81)90052-6; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Jin S, 1995, Shi Yan Sheng Wu Xue Bao, V28, P121; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KRAUSE DN, 1991, ANNU REV PHARMACOL, V31, P549; LEVIN RM, 1979, J PHARMACOL EXP THER, V208, P454; LIN CT, 1980, J CELL BIOL, V85, P473, DOI 10.1083/jcb.85.2.473; LopezGirona A, 1995, BIOCHEM BIOPH RES CO, V217, P566, DOI 10.1006/bbrc.1995.2813; LOUIS CF, 1983, CELL CALCIUM, V4, P107, DOI 10.1016/0143-4160(83)90039-8; MEANS AR, 1980, MOL CELL ENDOCRINOL, V19, P215, DOI 10.1016/0303-7207(80)90052-0; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MEANS AR, 1980, NATURE, V285, P73, DOI 10.1038/285073a0; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Pozo D, 1997, FASEB J, V11, P466, DOI 10.1096/fasebj.11.6.9194527; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; RABBANI GH, 1979, LANCET, V1, P410; Reiter RJ, 1997, HORM METAB RES, V29, P363, DOI 10.1055/s-2007-979057; Rollag M.D., 1988, PINEAL RES REV, V6, P67; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STOCLET JC, 1987, PROG NEUROBIOL, V29, P321, DOI 10.1016/0301-0082(87)90018-9; VAKKURI O, 1984, ANAL BIOCHEM, V142, P284, DOI 10.1016/0003-2697(84)90466-4; VANBELLE H, 1981, CELL CALCIUM, V2, P483, DOI 10.1016/0143-4160(81)90007-5; VINCENZI FF, 1982, CELL CALCIUM, V3, P545, DOI 10.1016/0143-4160(82)90044-6; WEAVER DR, 1988, FEBS LETT, V228, P123, DOI 10.1016/0014-5793(88)80599-4; WEISS B, 1983, METHOD ENZYMOL, V102, P171; WEISS B, 1974, MOL PHARM, V15, P49; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048	50	57	58	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1401	1408		10.1096/fasebj.12.13.1401	http://dx.doi.org/10.1096/fasebj.12.13.1401			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761784				2022-12-28	WOS:000076402000016
J	Ghibelli, L; Fanelli, C; Rotilio, G; Lafavia, E; Coppola, S; Colussi, C; Civitareale, P; Ciriolo, MR				Ghibelli, L; Fanelli, C; Rotilio, G; Lafavia, E; Coppola, S; Colussi, C; Civitareale, P; Ciriolo, MR			Rescue of cells from apoptosis by inhibition of active GSH extrusion	FASEB JOURNAL			English	Article						GSH efflux; puromycin; methionine; cystathionine	ISOLATED RAT HEPATOCYTES; THYMOCYTE APOPTOSIS; DNA FRAGMENTATION; GLUTATHIONE; DEATH; BCL-2; PROTEASE; PATHWAY; INVOLVEMENT; ACTIVATION	Cells induced to apoptosis extrude glutathione in the reduced form concomitantly with (U937 cells) or before (HepG2 cells) the development of apoptosis, much earlier than plasma membrane leakage. Two specific inhibitors of carrier-mediated GSH extrusion, methionine or cystathionine, are able to decrease apoptotic GSH efflux across the intact plasma membrane, demonstrating that in these cell systems GSH extrusion occurs via a specific mechanism. While decreasing GSH efflux, cystathionine or methionine also decrease the extent of apoptosis. They fail to exert anti-apoptotic activity in cells previously deprived of GSH, indicating that the target of the protection is indeed GSH efflux. The cells rescued by methionine or cystathionine remained viable after removal of the apoptogenic inducers and were even able to replicate. This shows that a real rescue to perfect viability and not just a delay of apoptosis is achieved by forcing GSH to stay within the cells during apoptogenic treatment. All this evidence indicates that extrusion of reduced glutathione precedes and is responsible for the irreversible morphofunctional changes of apoptosis, probably by altering the intracellular redox state without intervention of reactive oxygen species, thus giving a rationale for the development of redox-dependent apoptosis under anaerobic conditions.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Chieti, Dipartimento Sci Biomed, I-66013 Chieti, Italy	University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.	ghibelli@UTOVRM.IT	Colussi, Claudia/H-8609-2019; Coppola, Simona/A-6638-2015; Ciriolo, Maria Rosa/K-6572-2016	Coppola, Simona/0000-0001-7851-9409; Ciriolo, Maria Rosa/0000-0002-7863-9029; Colussi, Claudia/0000-0002-7727-8911				AW TY, 1984, J BIOL CHEM, V259, P9355; BEATTY PW, 1980, ARCH BIOCHEM BIOPHYS, V204, P80, DOI 10.1016/0003-9861(80)90009-0; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; COTTER TG, 1992, CANCER RES, V52, P997; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Ghibelli L, 1995, FEBS LETT, V377, P9, DOI 10.1016/0014-5793(95)01284-2; GHIBELLI L, 1995, EXP CELL RES, V221, P470, DOI 10.1006/excr.1995.1398; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GRIERSON AW, 1994, J GEN VIROL, V75, P2761, DOI 10.1099/0022-1317-75-10-2761; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IU SC, 1996, J CLIN INVEST, V97, P1488; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAPLOWITZ N, 1990, AM J PHYSIOL, V258, pG967; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KORSMEYER SJ, 1992, IMMUNOL TODAY, V14, P131; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHEN R, 1995, AM J PHYSIOL-GASTR L, V268, pG592, DOI 10.1152/ajpgi.1995.268.4.G592; Macho A, 1997, J IMMUNOL, V158, P4612; MALORNI W, 1994, IMMUNOL LETT, V43, P209, DOI 10.1016/0165-2478(94)90225-9; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; ROUZER CA, 1982, J BIOL CHEM, V257, P2002; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZENG L, 1995, J CLIN INVEST, V95, P1669; ZUCKERMAN SH, 1991, IMMUNOLOGY, V73, P460	37	283	286	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					479	486		10.1096/fasebj.12.6.479	http://dx.doi.org/10.1096/fasebj.12.6.479			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535220				2022-12-28	WOS:000072967300009
J	Barja, G; Herrero, A				Barja, G; Herrero, A			Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals	FASEB JOURNAL			English	Article						8-hydroxy-deoxyguanosine; longevity; aging; free radical	FREE-RADICAL PRODUCTION; HYDROGEN-PEROXIDE PRODUCTION; CALORIC RESTRICTION; METABOLIC-RATE; NUCLEAR-DNA; LONGEVITY; STRESS; PIGEON; AGE; 8-HYDROXY-2'-DEOXYGUANOSINE	DNA damage is considered of paramount importance in aging, Among causes of this damage, free radical attack, particularly from mitochondrial origin, is receiving special attention. If oxidative damage to DNA is involved in aging, long-lived animals (which age slowly) should show lower levels of markers of this kind of damage than short-lived ones, However, this possibility has not heretofore been investigated. In this study, steady-state levels of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) referred to deoxyguanosine (dG) were measured by high performance liquid chromatography (HPLC) in the mitochondrial (mtDNA) and nuclear (nDNA) DNA from the heart of eight and the brain of six mammalian species ranging in maximum life span (MLSP) from 3.5 to 46 years. Exactly the same digestion of DNA to deoxynucleosides and HPLC protocols was used for mtDNA and nDNA, Significantly higher (three- to ninefold) 8-oxodG/dG values were found in mtDNA than in nDNA in all the species studied in both tissues. 8-oxodG/dG in nDNA did not correlate with MLSP across species either in the heart (r = -0.68; P < 0,06) or brain (r 0.53; P < 0.27). However, 8-oxodG/dG in mtDNA was inversely correlated with MLSP both in heart (r = -0.92; P < 0.001) and brain (r = -0,88; P < 0,016) tissues following the power function y = a(.)x(b), where y is 8-oxodG/dG and x is the MLSP, This agrees with the consistent observation that mitochondrial free radical generation is also lower in long-lived than in short-lived species. The results obtained agree with the notion that oxygen radicals of mitochondrial origin oxidatively damage mtDNA in a way related to the aging rate of each species.	Univ Complutense, Dept Biol Anim & Anim Physiol 2, Fac Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Barja, G (corresponding author), Univ Complutense, Dept Biol Anim & Anim Physiol 2, Fac Biol, E-28040 Madrid, Spain.		Barja, Gustavo/AAA-5903-2019; Gustavo, Barja/B-5591-2012	Barja, Gustavo/0000-0001-5736-4735; 				ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; ALTMAN P, 1972, BIOL DATA BOOK, P229; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; ASUNCION JG, 1996, FASEB J, V10, P333; Barja G, 1998, J BIOENERG BIOMEMBR, V30, P235, DOI 10.1023/A:1020592719405; Barja G, 1998, ANN NY ACAD SCI, V854, P224, DOI 10.1111/j.1749-6632.1998.tb09905.x; BARJA G, 1994, FREE RADICAL RES, V21, P317, DOI 10.3109/10715769409056584; BARJA G, 1999, IN PRESS J BIOENERG; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212; Cadenas S, 1997, CARCINOGENESIS, V18, P2373, DOI 10.1093/carcin/18.12.2373; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; CUTLER G, 1991, AM J CLIN NUTR, V53, pS373; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; DEGREY ADN, 1998, J ANTI-AGING MED, V1, P53; Driggers WJ, 1997, NUCLEIC ACIDS RES, V25, P4362, DOI 10.1093/nar/25.21.4362; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Herrero A, 1998, MECH AGEING DEV, V103, P133, DOI 10.1016/S0047-6374(98)00035-9; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Hirano T, 1996, J GERONTOL A-BIOL, V51, pB303, DOI 10.1093/gerona/51A.5.B303; Kaneko T, 1996, MUTAT RES-DNAGING G, V316, P277, DOI 10.1016/S0921-8734(96)90010-7; Koppele JMT, 1996, NEUROBIOL AGING, V17, P819; Kovalenko SA, 1998, ANN NY ACAD SCI, V854, P171, DOI 10.1111/j.1749-6632.1998.tb09900.x; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; Lightowlers RH, 1999, TRENDS GENET, V15, P91, DOI 10.1016/S0168-9525(98)01684-9; Loft S, 1999, METHOD ENZYMOL, V300, P166; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MIQUEL J, 1991, ARCH GERONTOL GERIAT, V12, P99, DOI 10.1016/0167-4943(91)90022-I; Muscari C, 1996, AGING-CLIN EXP RES, V8, P429, DOI 10.1007/BF03339606; OZAWA T, 1995, EXP GERONTOL, V30, P269, DOI 10.1016/0531-5565(94)00057-A; Ozawa T, 1998, ANN NY ACAD SCI, V854, P128, DOI 10.1111/j.1749-6632.1998.tb09898.x; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAI K, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P139; Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1994, NATURAL ANTIOXIDANTS, P63; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	46	383	404	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					312	318		10.1096/fasebj.14.2.312	http://dx.doi.org/10.1096/fasebj.14.2.312			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657987				2022-12-28	WOS:000085184800010
J	Chang, Z; Meyer, K; Rapraeger, AC; Friedl, A				Chang, Z; Meyer, K; Rapraeger, AC; Friedl, A			Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ	FASEB JOURNAL			English	Article						skin; basement membrane; FGF; cell signaling	CELL-SURFACE; BASEMENT-MEMBRANE; SELF-ASSOCIATION; BASIC FGF; BINDING; EXPRESSION; IDENTIFICATION; MITOGENESIS; SYNDECAN-1; ACTIVATION	Fibroblast growth factors (FGFs) require heparan sulphate proteoglycans (HSPGs) as cofactors for signaling. The heparan sulphate chains (HS) mediate stable high affinity binding of FGFs to their receptor tyrosine kinase (FR) and may specifically regulate FGF activity. A novel in situ binding assay was developed to examine the ability of HSPGs to promote FGF/FR binding using a soluble FR fusion construct (FR1-AP). this fusion protein probe forms a dimer in solution, simulating the dimerization or oligomerization that is thought to occur at the cell surface physiologically. In frozen sections of human skin, FGF-2 binds to keratinocytes and basement membranes of epidermis and dermal blood vessels. In contrast, in skin preincubation with FGF-2, FR1-AP binds avidly to FGF-2 immobilized on keratinocyte cell surface, but fails to bind to basement membranes at the dermo-epidermal junction or dermal microvessels despite the fact that these structures bind large amounts of FGF-2. Apparently, basement membrane and cell surface HSPGs differ in their ability to mediate the assembly of a FGF/FR signaling complex presumably due to structural differences of the heparan sulfate chains.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 6153 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.							AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Carey DJ, 1997, BIOCHEM J, V327, P1; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Friedl A, 1997, AM J PATHOL, V150, P1443; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Risau W, 1996, CANCER METAST REV, V15, P149, DOI 10.1007/BF00437466; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Safaiyan F, 1998, EUR J BIOCHEM, V252, P576, DOI 10.1046/j.1432-1327.1998.2520576.x; SALMIVIRTA M, 1992, J BIOL CHEM, V267, P17606; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	45	94	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					137	144		10.1096/fasebj.14.1.137	http://dx.doi.org/10.1096/fasebj.14.1.137			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627288				2022-12-28	WOS:000084784700016
J	Jimenez-Chillaron, JC; Newgard, CB; Gomez-Foix, AM				Jimenez-Chillaron, JC; Newgard, CB; Gomez-Foix, AM			Increased glucose disposal induced by adenovirus-mediated transfer of glucokinase to skeletal muscle in vivo	FASEB JOURNAL			English	Article						glucose phosphorylating activity; glucokinase expression; GLUT4 expression; non-insulin-dependent diabetes mellitus	GLYCOGEN-SYNTHESIS; TRANSGENIC MICE; INSULIN; EXPRESSION; TRANSPORT; CELLS; RAT; PHOSPHORYLATION; OVEREXPRESSION; INVIVO	In non-insulin-dependent diabetes mellitus, insulin-stimulated glucose uptake is impaired in muscle, contributing in a major way to development of hyperglycemia, We previously showed that expression of the glucose phosphorylating enzyme glucokinase (GK) in cultured human myocytes improved glucose storage and disposal, suggesting that GK delivery to muscle in situ could potentially enhance glucose clearance. Here we have tested this idea directly by intramuscular delivery of an adenovirus containing the liver GK cDNA (AdCMV-GKL) into one hind limb, We injected an adenovirus containing the beta-galactosidase gene (AdCMV-lacZ) into the hind limb of newborn rats. beta-Galactosidase activity was localized in muscle for as long as 1 month after delivery, with a large percentage of fibers staining positive in the gastrocnemius, Using the same approach with AdCMV-GKL, GK protein content was increased from zero to 50-400% of the GK in normal liver sample, and total glucose phosphorylating activity was increased in GK-expressing muscles relative to the counterpart uninfected muscle, Expression of GK in muscle improved glucose tolerance rather than changing basal glycemic control. Glucose levels were reduced by similar to 35% 10 min after administration of a glucose bolus to fed animals treated with AdCMV-GKL relative to AdCMV-lacZ-treated controls. The enhanced rate of glucose clearance was reflected in increases in muscle 2-deoxy glucose uptake and blood lactate levels. We conclude that restricted expression of GK in muscle leads to an enhanced capacity for muscle glucose disposal and whole body glucose tolerance under conditions of maximal glucose-insulin stimulation, suggesting that under these conditions glucose phosphorylation becomes rate-limiting. Our findings also show that gene delivery to a fraction of the whole body is sufficient to improve glucose disposal, providing a rationale for the development of new therapeutic strategies for treatment of diabetes.	Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dallas, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gomez-Foix, AM (corresponding author), Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Marti & Franques 1, E-08028 Barcelona, Spain.		Jimenez-Chillaron, Josep/L-5854-2015					Baque S, 1998, DIABETES, V47, P1185, DOI 10.2337/diabetes.47.8.1185; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; Clark SA, 1997, DIABETES, V46, P958, DOI 10.2337/diabetes.46.6.958; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; JAMES DE, 1985, J CLIN INVEST, V76, P657, DOI 10.1172/JCI112019; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; MacGregor GR, 1991, GENE TRANSFER EXPRES, P217; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; REN JM, 1993, J BIOL CHEM, V268, P16113; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; SPENCE JT, 1983, J BIOL CHEM, V258, P9143; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011	20	16	18	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2153	2160		10.1096/fasebj.13.15.2153	http://dx.doi.org/10.1096/fasebj.13.15.2153			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593862	Bronze			2022-12-28	WOS:000084310800006
J	Gustavsson, J; Parpal, S; Karlsson, M; Ramsing, C; Thorn, H; Borg, M; Lindroth, M; Peterson, KH; Magnusson, K; Stralfors, P				Gustavsson, J; Parpal, S; Karlsson, M; Ramsing, C; Thorn, H; Borg, M; Lindroth, M; Peterson, KH; Magnusson, K; Stralfors, P			Localization of the insulin receptor in caveolae of adipocyte plasma membrane	FASEB JOURNAL			English	Article						cholesterol; signal transduction; insulin resistance; diabetes	GLUCOSE-TRANSPORTER GLUT4; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; TYROSINE KINASE; MEDIATED TRANSPORT; CELL-MEMBRANES; RAT ADIPOCYTES; PROTEIN-KINASE; CHOLESTEROL; TRANSLOCATION	The insulin receptor is a transmembrane protein of the plasma membrane, where it recognizes extracellular insulin and transmits signals into the cellular signaling network. We report that insulin receptors are localized and signal in caveolae microdomains of adipocyte plasma membrane. Immunogold electron microscopy and immunofluorescence microscopy show that insulin receptors are restricted to caveolae and are colocalized with caveolin over the plasma membrane. Insulin receptor was enriched in a caveolae-enriched fraction of plasma membrane. By extraction with beta-cyclodextrin or destruction with cholesterol oxidase, cholesterol reduction attenuated insulin receptor signaling to protein phosphorylation or glucose transport. Insulin signaling was regained by spontaneous recovery or by exogenous replenishment of cholesterol. beta-Cyclodextrin treatment caused a nearly complete annihilation of caveolae invaginations as examined by electron microscopy. This suggests that the receptor is dependent on the caveolae environment for signaling. Insulin stimulation of cells prior to isolation of caveolae or insulin stimulation of the isolated caveolae fraction increased tyrosine phosphorylation of the insulin receptor in caveolae, demonstrating that insulin receptors in caveolae are functional. Our results indicate that insulin receptors are localized to caveolae in the plasma membrane of adipocytes, are signaling in caveolae, and are dependent on caveolae for signaling.-Gustavsson, J., Parpal, S., Karlsson, M., Ramsing, C., Thorn, H., Borg, M., Lindroth, IM., Peterson, K. H., Magnusson, IL-E., Stralfors, P. Localization of the insulin receptor in caveolae of adipocyte plasma membrane.	Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, S-58185 Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Dept Med Microbiol, S-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, S-58185 Linkoping, Sweden.	stralfors@mcb.liu.se	Eckhardt, Erik/G-1567-2010	Magnusson, Karl-Eric/0000-0002-7809-8437; Stralfors, Peter/0000-0002-1196-1806; Parpal, Santiago/0000-0003-2861-0516				ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; CUATRECA.P, 1971, J BIOL CHEM, V246, P6532; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FAN JY, 1983, J CELL SCI, V61, P219; FROST SC, 1987, J BIOL CHEM, V262, P9872; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAMMELTOFT S, 1988, INSULIN RECEPTORS A, P15; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; HAMILTON JG, 1988, LIPIDS, V23, P1150, DOI 10.1007/BF02535282; HEIDER JG, 1978, J LIPID RES, V19, P514; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; Keller R., 1993, IEEE Microwave and Guided Wave Letters, V3, P185, DOI 10.1109/75.219809; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAZAR DF, 1994, P NATL ACAD SCI USA, V91, P9665, DOI 10.1073/pnas.91.21.9665; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OKA Y, 1984, J BIOL CHEM, V259, P8125; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLEFSKY JM, 1982, METABOLISM, V31, P670, DOI 10.1016/0026-0495(82)90197-4; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PARPAL S, 1995, J CELL BIOL, V131, P125, DOI 10.1083/jcb.131.1.125; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMITH RM, 1991, J BIOL CHEM, V266, P17522; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRALFORS P, 1987, J BIOL CHEM, V262, P11486; Stralfors P, 1997, BIOESSAYS, V19, P327, DOI 10.1002/bies.950190410; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	64	291	297	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1961	1971		10.1096/fasebj.13.14.1961	http://dx.doi.org/10.1096/fasebj.13.14.1961			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544179				2022-12-28	WOS:000083660700008
J	Hebb, MO; Denovan-Wright, EM; Robertson, HA				Hebb, MO; Denovan-Wright, EM; Robertson, HA			Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats	FASEB JOURNAL			English	Article						glia; lactation; Sprague-Dawley; epidermal growth factor receptor	HORMONE-RELEASING HORMONE; GROWTH-FACTOR-ALPHA; ACIDIC PROTEIN IMMUNOREACTIVITY; ESTRADIOL VALERATE; EMBRYONIC LETHALITY; PEROXIDASE-ACTIVITY; FEMALE RAT; TGF-ALPHA; NEURONS; ESTROGEN	Huntington's disease (HD) is one of a number of neurodegenerative disorders caused by expansion of polyglutamine-encoding CAG repeats within specific genes. Huntingtin, the protein product of the HD gene, is widely expressed in neural and nonneural human and rodent tissue. The function of the wild-type or mutated form of huntingtin is currently unknown. We have observed that relative to naive and male animals, huntingtin protein was significantly increased in the arcuate nucleus of postpartum rats. Using an oligonucleotide probe, in sih and Northern blot hybridization confirmed the expression of hunting-tin mRNA, Quantification of the in situ hybridization signal in the arcuate nucleus revealed an approximate sevenfold increase in the expression of huntingtin mRNA in postpartum, lactating animals compared with naive female or male animals. Emulsion autoradiography and immunohistochemistry revealed that the cells with elevated huntingtin expression had a stellate conformation that morphologically resembled astrocytes. Dual label immunofluorescence immunohistochemistry demonstrated the colocalization of huntingin and glial fibrillary acidic protein in these cells, confirming that they were astrocytes, Astrocytes expressing huntingtin were consistently found in close apposition to neuronal soma, suggesting interactions between these cell types. During the perinatal and postnatal period, the hypothalamus undergoes alterations in metabolic function. Our results support the idea of glia-induced metabolic changes in the hypothalamus, These results provide the first demonstration of naturally occurring changes in the expression of the Huntington's disease gene in the brain and suggest that huntingtin may play an important role in the processes that regulate neuroendocrine function.	Dalhousie Univ, Dept Pharmacol, Mol Neurobiol Lab, Halifax, NS B3H 4H7, Canada	Dalhousie University	Robertson, HA (corresponding author), Dalhousie Univ, Dept Pharmacol, Mol Neurobiol Lab, Sir Charles Tupper Med Bldg, Halifax, NS B3H 4H7, Canada.							ANDERSON WA, 1975, J CELL BIOL, V64, P668, DOI 10.1083/jcb.64.3.668; BRAWER JR, 1978, ENDOCRINOLOGY, V103, P501, DOI 10.1210/endo-103-2-501; CARLOCK L, 1995, NEUROREPORT, V6, P1121, DOI 10.1097/00001756-199505300-00012; Chowen JA, 1996, CELL MOL NEUROBIOL, V16, P297, DOI 10.1007/BF02088097; Ferrer I, 1996, PROG NEUROBIOL, V49, P99; Folstein S.E., 1989, HUNTINGTONS DIS DISO; GARCIASEGURA LM, 1986, BRAIN RES, V366, P131, DOI 10.1016/0006-8993(86)91287-4; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; HOFFMAN GE, 1994, BRAIN RES, V654, P207, DOI 10.1016/0006-8993(94)90481-2; KEEFE DL, 1991, AM J OBSTET GYNECOL, V164, P959; KING JC, 1994, ENDOCRINOLOGY, V134, P1340, DOI 10.1210/en.134.3.1340; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; LYTTLE CR, 1977, NATURE, V268, P337, DOI 10.1038/268337a0; Ma YJ, 1997, ENDOCRINOLOGY, V138, P19, DOI 10.1210/en.138.1.19; MA YJ, 1994, J NEUROSCI, V14, P5644; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MOORE KE, 1987, BIOL REPROD, V36, P47, DOI 10.1095/biolreprod36.1.47; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; OJEDA SR, 1992, FRONT NEUROENDOCRIN, V13, P120; OJEDA SR, 1990, P NATL ACAD SCI USA, V87, P9698, DOI 10.1073/pnas.87.24.9698; OLMOS G, 1989, NEUROSCIENCE, V32, P663, DOI 10.1016/0306-4522(89)90288-1; PFAFF D, 1973, J COMP NEUROL, V151, P121, DOI 10.1002/cne.901510204; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIPPER HM, 1990, BRAIN RES, V507, P200, DOI 10.1016/0006-8993(90)90273-E; TATTER SB, 1995, NEUROREPORT, V6, P1125, DOI 10.1097/00001756-199505300-00013; TORRESALEMAN I, 1992, GLIA, V6, P180, DOI 10.1002/glia.440060305; TRANQUE PA, 1987, BRAIN RES, V406, P348, DOI 10.1016/0006-8993(87)90805-5; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; WITKIN JW, 1991, ENDOCRINOLOGY, V129, P1083, DOI 10.1210/endo-129-2-1083; WITKIN JW, 1985, PEPTIDES, V6, P263, DOI 10.1016/0196-9781(85)90050-6; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	35	28	28	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1099	1106		10.1096/fasebj.13.9.1099	http://dx.doi.org/10.1096/fasebj.13.9.1099			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336893				2022-12-28	WOS:000080547700015
J	Pirkkala, L; Alastalo, TP; Nykanen, P; Seppa, L; Sistonen, L				Pirkkala, L; Alastalo, TP; Nykanen, P; Seppa, L; Sistonen, L			Differentiation lineage-specific expression of human heat shock transcription factor 2	FASEB JOURNAL			English	Article						HSF2; K562 cells; erythroid differentiation; megakaryocytic differentiation	HSP70 GENE-TRANSCRIPTION; MESSENGER-RNA STABILITY; DNA-BINDING ACTIVITY; LEUKEMIA CELL-LINE; K562 CELLS; ERYTHROID-DIFFERENTIATION; STRESS-RESPONSE; PHORBOL ESTER; MOLECULAR-CLONING; PROTEIN	Differentiation of multipotential hematopoietic cells into lineage-committed precursors involves the selection and maintenance of appropriate programs of gene expression, regulated by specific transcription factors. Using human K562 erythroleukemia cells capable of differentiating along erythroid and megakaryocytic lineages, we explore the differentiation-related role of heat shock transcription factor 2 (HSF2), which belongs to a family of transcription factors generally known to regulate heat shock gene expression. We demonstrate that enhanced HSF2 expression and the acquisition of HSF2 DNA binding activity are strictly specific for erythroid characteristics of K562 cells. Our results reveal a multistep regulatory process of HSF2 gene expression, In K562 cells undergoing hemin-mediated erythroid differentiation, the increase in HSF2 protein levels is preceded by transcriptional induction of the HSF2 gene, accompanied by increased HSF2 mRNA stability. In contrast, during megakaryocytic differentiation induced by the phorbol ester TPA, expression of HSF2 is rapidly down-regulated, leading to a complete loss of the HSF2 protein. These results indicate that the determination of HSF2 expression occurs at the early stages of lineage commitment. Taken together, our data suggest that HSF2 could function as a lineage-restricted transcription factor during differentiation of K562 cells along either the erythroid or the megakaryocytic pathway.	Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Univ Turku, Abo Akad Univ, Dept Biol, FIN-20521 Turku, Finland; Univ Turku, Abo Akad Univ, Dept Anat, FIN-20521 Turku, Finland; Univ Turku, Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland	Abo Akademi University; University of Turku; Abo Akademi University; University of Turku; Abo Akademi University; University of Turku; Abo Akademi University; University of Turku	Sistonen, L (corresponding author), Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, BioCity,5th Floor,Tykistokatu 6, FIN-20521 Turku, Finland.	lea.sistonen@btk.utu.fi		Ostling, Paivi/0000-0001-5501-466X; Sistonen, Lea/0000-0003-1341-2867				Alastalo TP, 1998, EXP CELL RES, V240, P16, DOI 10.1006/excr.1997.3926; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; Belhacene N, 1998, FASEB J, V12, P531; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CIOE L, 1981, CANCER RES, V41, P237; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; DEAN A, 1981, SCIENCE, V212, P459, DOI 10.1126/science.6163216; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLAZER RI, 1994, PROTEIN KINASE C, P171; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Holmberg CI, 1997, J BIOL CHEM, V272, P6792, DOI 10.1074/jbc.272.10.6792; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; Leppa S, 1997, J BIOL CHEM, V272, P30400, DOI 10.1074/jbc.272.48.30400; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAKELA TP, 1987, MOL CELL BIOL, V7, P3656; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; METCALF D, NATURE LONDON, V369, P519; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441	58	25	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					1089	1098		10.1096/fasebj.13.9.1089	http://dx.doi.org/10.1096/fasebj.13.9.1089			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336892				2022-12-28	WOS:000080547700014
J	Spijker, S; Smit, AB; Eipper, BA; Malik, A; Mains, RE; Geraerts, WPM				Spijker, S; Smit, AB; Eipper, BA; Malik, A; Mains, RE; Geraerts, WPM			A molluscan peptide alpha-amidating enzyme precursor that generates five distinct enzymes	FASEB JOURNAL			English	Article						posttranslational modification; neuropeptide alpha-amidation; PAM; mono-oxygenase; mollusk; Lymnaea stagnalis	INTEGRAL MEMBRANE-PROTEIN; CENTRAL-NERVOUS-SYSTEM; HYDROXYLATING MONOOXYGENASE; LYMNAEA-STAGNALIS; CONVERTING ENZYME; MESSENGER-RNA; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; VESICLE MEMBRANE; CYTOSOLIC DOMAIN	Mechanisms underlying the specificity and efficiency of enzymes, which modify peptide messengers, especially with the variable requirements of synthesis in the neuronal secretory pathway, are poorly understood. Here, we examine the process of peptide alpha-amidation in individually identifiable Lymnaea neurons that synthesize multiple proproteins, yielding complex mixtures of structurally diverse peptide substrates, The alpha-amidation of these peptide substrates is efficiently controlled by a multifunctional Lymnaea peptidyl glycine alpha-amidating monooxygenase (LPAM), which contains four different copies of the rate-limiting Lymnaea peptidyl glycine alpha-hydroxylating monooxygenase (LPHM) and a single Lymnaea peptidyl alpha-hydroxyglycine alpha-amidating lyase, Endogenously, this zymogen is converted to yield a mixture of monofunctional isoenzymes, In vitro, each LPHM displays a unique combination of substrate affinity and reaction velocity, depending on the penultimate residue of the substrate. This suggests that the different isoenzymes are generated in order to efficiently amidate the many peptide substrates that are present in molluscan neurons. The cellular expression of the LPAM gene is restricted to neurons that synthesize amidated peptides, which underscores the critical importance of regulation of peptide alpha-amidation.	Vrije Univ Amsterdam, Grad Sch Neurosci Amsterdam, Res Inst Neurosci, Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University of Amsterdam; Vrije Universiteit Amsterdam; Johns Hopkins University	Smit, AB (corresponding author), Vrije Univ Amsterdam, Grad Sch Neurosci Amsterdam, Res Inst Neurosci, Dept Mol & Cellular Neurobiol, Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	absmit@bio.vu.nl	Smit, August B/E-8410-2011; Spijker, Sabine/F-2300-2011	Spijker, Sabine/0000-0002-6814-2019	NIDDK NIH HHS [DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R01DK032949, R37DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BERTELSEN AH, 1990, ARCH BIOCHEM BIOPHYS, V279, P87, DOI 10.1016/0003-9861(90)90466-C; BOGERD J, 1994, MOL BRAIN RES, V23, P66, DOI 10.1016/0169-328X(94)90212-7; BRADBURY AF, 1983, BIOCHEM BIOPH RES CO, V112, P372, DOI 10.1016/0006-291X(83)91473-0; BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; Brezina V, 1996, SCIENCE, V273, P806, DOI 10.1126/science.273.5276.806; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVATT BF, 1995, SCIENCE, V268, P1506, DOI 10.1126/science.7770779; DeLange RPJ, 1997, NEUROSCIENCE, V78, P289, DOI 10.1016/S0306-4522(96)00576-3; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; FELSENSTEIN J, 1995, PHYLYP PHYLOGENY INF; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Hauser F, 1997, BIOCHEM BIOPH RES CO, V241, P509, DOI 10.1006/bbrc.1997.7854; HILSTED L, 1990, REGUL PEPTIDES, V29, P179, DOI 10.1016/0167-0115(90)90081-7; HODGES RS, 1988, J BIOL CHEM, V263, P11768; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; HOOK VYH, 1987, NEUROPEPTIDES, V9, P263, DOI 10.1016/0143-4179(87)90001-1; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Jimenez CR, 1998, BIOCHEMISTRY-US, V37, P2070, DOI 10.1021/bi971848b; KATO I, 1990, FEBS LETT, V269, P319, DOI 10.1016/0014-5793(90)81184-P; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; LI KW, 1994, J BIOL CHEM, V269, P30288; LI KW, 1992, PEPTIDES, V13, P633, DOI 10.1016/0196-9781(92)90166-Z; LI KW, 1994, ENDOCRINOLOGY, V134, P1812, DOI 10.1210/en.134.4.1812; Merkler DJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P430, DOI 10.1006/abbi.1996.0272; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILLER MW, 1993, J NEUROSCI, V13, P3346; Nassel DR, 1996, CURR OPIN NEUROBIOL, V6, P842, DOI 10.1016/S0959-4388(96)80036-5; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; RHODES CH, 1990, J HISTOCHEM CYTOCHEM, V38, P1301, DOI 10.1177/38.9.2387985; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER MKH, 1992, J NEUROSCI, V12, P222; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Smit AB, 1998, PROG NEUROBIOL, V54, P35, DOI 10.1016/S0301-0082(97)00063-4; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; TAMBURINI PP, 1990, INT J PEPT PROT RES, V35, P153; VANKESTEREN RE, 1992, P NATL ACAD SCI USA, V89, P4593, DOI 10.1073/pnas.89.10.4593; Vilim FS, 1996, J NEUROSCI, V16, P8092; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yonekura H, 1996, BIOCHEM BIOPH RES CO, V218, P495, DOI 10.1006/bbrc.1996.0088; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4; YUN HY, 1995, J BIOL CHEM, V270, P30075	60	25	25	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					735	748		10.1096/fasebj.13.6.735	http://dx.doi.org/10.1096/fasebj.13.6.735			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094934				2022-12-28	WOS:000079527200015
J	Buccellato, FR; Miloso, M; Braga, M; Nicolini, G; Morabito, A; Pravettoni, G; Tredici, G; Scalabrino, G				Buccellato, FR; Miloso, M; Braga, M; Nicolini, G; Morabito, A; Pravettoni, G; Tredici, G; Scalabrino, G			Myelinolytic lesions in spinal cord of cobalamin-deficient rats are TNF-alpha-mediated	FASEB JOURNAL			English	Article						myelinolysis; subacute combined degeneration; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRANSFORMING GROWTH FACTOR-BETA-1; TOTALLY GASTRECTOMIZED RATS; CENTRAL-NERVOUS-SYSTEM; SUBACUTE COMBINED DEGENERATION; SIGNAL-TRANSDUCTION PATHWAYS; MULTIPLE-SCLEROSIS; TRANSGENIC MICE; AUTOIMMUNE ENCEPHALOMYELITIS	Repeated intracerebroventricular (i.c.v.) microinjection of tumor necrosis factor-alpha (TNF-alpha) into normal rats causes intramyelin and interstitial edema in the white matter of the spinal cord (SC). This response is identical to that observed in the SC white matter of rats made cobalamin (Cbl) deficient by total gastrectomy (TG). Immunoblot analysis showed that: 1) the level of the biologically active form of the TNF-alpha protein (17 kDa) is higher in the SC of totally gastrectomized (TGX) rats 2 months after TG, i.e., at the postoperative time when edema is observed; 2) SC levels of TNF-alpha protein (17 kDa) in 2-mo-TGX-, Cbl-treated rats are reduced to control. Repeated i.c.v. microinjections of anti-TNF-alpha antibodies, transforming growth factor-beta(1) (TGF-beta(1)) or interleukin-6 (IL-6) into TGX rats, begun shortly after TG, substantially reduced both intramyelin and interstitial edema in the SC white matter. This study provides the first evidence that the hallmark myelin damage of Cbl-deficient central neuropathy, which is a pure myelinolytic disease, is not caused directly by the withdrawal of the vitamin itself, but reflects enhanced production of the biologically active form of TNF-alpha by SC cells. This study thus supports the view that TGF-beta(1) and IL-6 may act as neuroprotective agents in Cbl deficiency central neuropathy.	Univ Milan, Fac Med, Inst Gen Pathol, I-20133 Milan, Italy; Univ Milan, Fac Med, Inst Human Anat, I-20133 Milan, Italy; Univ Milan, Fac Med, Inst Biometr & Med Stat, I-20133 Milan, Italy; Univ Milan, Fac Med, Dept Neurol 2, I-20133 Milan, Italy; Gife Lab, Lugano, Switzerland	University of Milan; University of Milan; University of Milan; University of Milan	Scalabrino, G (corresponding author), Univ Milan, Fac Med, Inst Gen Pathol, Via Mangiagalli 31, I-20133 Milan, Italy.	scalb@imiucca.csi.unimi.it	NIcolini, Gabriella/AAK-9155-2020; Pravettoni, Gabriella/C-6915-2011; Miloso, Mariarosaria/AAC-7373-2021; Pravettoni, Gabriella/AAC-3500-2022	Pravettoni, Gabriella/0000-0002-4843-4663; NICOLINI, GABRIELLA/0000-0002-6241-4538; BRAGA, Massimiliano/0000-0001-8109-1001				AGAMANOLIS DP, 1978, J NEUROPATH EXP NEUR, V37, P273, DOI 10.1097/00005072-197805000-00006; Akassoglou K, 1997, J IMMUNOL, V158, P438; ALLEN RH, 1993, FASEB J, V7, P1344, DOI 10.1096/fasebj.7.14.7901104; Ariga T, 1998, J LIPID RES, V39, P1; ARMITAGE P, 1994, STAT METHODS MED RES, P394; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BARGER SW, 1998, NEUROPROTECTIVE SIGN, P163; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Benveniste EN, 1997, CHEM IMMUNOL, V69, P31; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; Benveniste Etty N., 1995, P700; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; Bottiglieri T, 1996, NUTR REV, V54, P382, DOI 10.1111/j.1753-4887.1996.tb03851.x; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; Brouwer M, 1996, BLOOD, V88, P1857; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1995, INT J DEV NEUROSCI, V13, P275, DOI 10.1016/0736-5748(94)00073-C; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CAMPBELL IL, 1994, J VIROL, V68, P2383, DOI 10.1128/JVI.68.4.2383-2387.1994; DUFFIELD MS, 1990, COMP BIOCHEM PHYS C, V96, P291, DOI 10.1016/0742-8413(90)90010-7; GARRIELI Y, 1992, J CELL BIOL, V119, P493; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; HAMILTON PW, 1995, J PATHOL, V175, P369, DOI 10.1002/path.1711750403; HARTUNG HP, 1995, NEUROLOGY, V45, pS22, DOI 10.1212/WNL.45.6_Suppl_6.S22; HAUSER SL, 1995, ANN NEUROL, V38, P702; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Iwasaki Y, 1997, J NEUROL SCI, V147, P9, DOI 10.1016/S0022-510X(96)05307-5; JOHNS LD, 1991, J IMMUNOL, V147, P1792; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KRIEGLSTEIN K, 1998, NEUROPROTECTIVE SIGN, P119; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; LeVine SM, 1997, J NEUROIMMUNOL, V73, P47, DOI 10.1016/S0165-5728(96)00166-X; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; MARTIN D, 1995, EXP NEUROL, V131, P221, DOI 10.1016/0014-4886(95)90044-6; MARTIN D, 1998, NEUROPROTECTIVE SIGN, P185; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MOKHTARIAN F, 1994, J IMMUNOL, V152, P6003; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; OTTEN U, 1994, PROG BRAIN RES, V103, P293; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; POWELL MB, 1992, TUMOR NECROSIS FACTO, P355; Powers J, 1996, MOL CHEM NEUROPATHOL, V27, P31, DOI 10.1007/BF02815031; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Probert L, 1997, J NEUROIMMUNOL, V72, P113, DOI 10.1016/S0165-5728(96)00176-2; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; RACKE MK, 1991, J IMMUNOL, V146, P3012; Rink L, 1996, INT ARCH ALLERGY IMM, V111, P199, DOI 10.1159/000237369; RODRIGUEZ M, 1994, J IMMUNOL, V153, P3811; Rothwell NJ, 1996, NAT MED, V2, P746, DOI 10.1038/nm0796-746; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SCALABRINO G, 1995, LAB INVEST, V72, P114; SCALABRINO G, 1990, LAB INVEST, V62, P297; Scalabrino G, 1997, EXP NEUROL, V144, P258, DOI 10.1006/exnr.1996.6376; SCHINDLER R, 1990, BLOOD, V75, P40; SCOLDING NJ, 1994, PROG NEUROBIOL, V43, P143, DOI 10.1016/0301-0082(94)90011-6; SCOTT JM, 1994, ACTA NEUROL SCAND, V89, P27, DOI 10.1111/j.1600-0404.1994.tb05406.x; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; SELMAJ K, 1991, ANN NEUROL, V30, P694, DOI 10.1002/ana.410300510; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; SOLIVEN B, 1995, INT J DEV NEUROSCI, V13, P351, DOI 10.1016/0736-5748(95)00019-D; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tredici G, 1998, J SUBMICR CYTOL PATH, V30, P165; Tredici G, 1998, J NEUROL SCI, V156, P18, DOI 10.1016/S0022-510X(98)00005-7; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Walker PR, 1997, CELL DEATH DIFFER, V4, P233, DOI 10.1038/sj.cdd.4400225; WOODROOFE MN, 1995, NEUROLOGY, V45, pS6, DOI 10.1212/WNL.45.6_Suppl_6.S6; WRIGHT JL, 1992, ACTA NEUROPATHOL, V85, P93, DOI 10.1007/BF00304638	82	47	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					297	304		10.1096/fasebj.13.2.297	http://dx.doi.org/10.1096/fasebj.13.2.297			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973317				2022-12-28	WOS:000078615200009
J	Lee, AYW; Chung, SSM				Lee, AYW; Chung, SSM			Contributions of polyol pathway to oxidative stress in diabetic cataract	FASEB JOURNAL			English	Article						aldose reductase; sorbitol dehydrogenase; glutathione; malondialdehyde; transgenic mice	MODELING CORTICAL CATARACTOGENESIS; REDUCTASE INHIBITOR SORBINIL; ALDOSE REDUCTASE; LIPID-PEROXIDATION; VITAMIN-E; RAT LENS; AUTOXIDATIVE GLYCOSYLATION; SORBITOL DEHYDROGENASE; OSMOTIC CHANGES; FREE-RADICALS	There is strong evidence to show that diabetes is associated with increased oxidative stress. However, the source of this oxidative stress remains unclear. Using transgenic mice that overexpress aldose reductase (AK) in their lenses, we found that the flux of glucose through the polyol pathway is the major cause of hyperglycemic oxidative stress in this tissue. The substantial decrease in the level of reduced glutathione (GSH) with concomitant rise in the level of lipid peroxidation product malondialdehyde (MDA) in the lens of transgenic mice, but not in the nontransgenic mice, suggests that glucose autoxidation and nonenzymatic glycation do not contribute significantly to oxidative stress in diabetic lenses. AK reduction of glucose to sorbitol probably contributes to oxidative stress by depleting its cofactor NADPH, which is also required for the regeneration of GSH. Sorbitol dehydrogenase, the second enzyme in the polyol pathway that converts sorbitol to fructose, also contributes to oxidative stress, most likely because depletion of its cofactor NAD(+) leads to more glucose being channeled through the polyol pathway. Despite a more than 100% increase of MDA, oxidative stress plays only a minor role in the development of cataract in this acute diabetic cataract model. However, chronic oxidative stress generated by the polyol pathway is likely to be an important contributing factor in the slow-developing diabetic cataract as well as in the development of other diabetic complications.	Univ Hong Kong, Inst Mol Biol, 8 Sassoon Rd, Hong Kong, Peoples R China	University of Hong Kong	Chung, SSM (corresponding author), Univ Hong Kong, Inst Mol Biol, 8 Sassoon Rd, Hong Kong, Peoples R China.	smchung@hkucc.hku.hk	LEE, Alan Yiu Wah/AAE-1845-2022; Lee, Alan/E-8554-2011	Lee, Alan Yiu Wah/0000-0003-0635-4179				ALTOMARE E, 1995, DIABETES METAB, V21, P173; ANSARI NH, 1994, RES COMMUN CHEM PATH, V84, P93; Ansari NH, 1996, BIOCHEM MOL MED, V59, P68, DOI 10.1006/bmme.1996.0067; BRON AJ, 1993, EYE, V7, P260, DOI 10.1038/eye.1993.60; CHAND D, 1982, EXP EYE RES, V35, P491, DOI 10.1016/0014-4835(82)90045-8; CHENG HM, 1986, METABOLISM, V35, P10, DOI 10.1016/0026-0495(86)90180-0; CHYLACK LT, 1969, INVEST OPHTH VISUAL, V8, P401; COLLIER A, 1990, DIABETIC MED, V7, P27, DOI 10.1111/j.1464-5491.1990.tb01302.x; CREIGHTON MO, 1979, EXP EYE RES, V29, P689, DOI 10.1016/0014-4835(79)90025-3; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; GONZALEZ AM, 1983, DIABETES, V32, P482, DOI 10.2337/diabetes.32.5.482; GONZALEZ AM, 1986, DIABETES, V35, P1200, DOI 10.2337/diabetes.35.11.1200; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRIFFITH OW, 1979, J BIOL CHEM, V254, P1205; HERRMANN RK, 1983, EXP EYE RES, V37, P467, DOI 10.1016/0014-4835(83)90022-2; HUNT JV, 1992, FREE RADICAL BIO MED, V13, P319, DOI 10.1016/0891-5849(92)90179-K; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; KAKKAR R, 1995, MOL CELL BIOCHEM, V151, P113, DOI 10.1007/BF01322333; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KINOSHIT.JH, 1965, J BIOL CHEM, V240, P310; KINOSHITA JH, 1962, NATURE, V194, P1085, DOI 10.1038/1941085a0; KINOSHITA JH, 1962, EXP EYE RES, V1, P405, DOI 10.1016/S0014-4835(62)80030-X; Lee AYW, 1998, INVEST OPHTH VIS SCI, V39, P193; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Lee FK, 1997, GENOMICS, V46, P86, DOI 10.1006/geno.1997.4988; LINKLATER HA, 1986, EXP EYE RES, V43, P305, DOI 10.1016/S0014-4835(86)80068-9; LOU MF, 1988, EXP EYE RES, V46, P517, DOI 10.1016/S0014-4835(88)80009-5; Mitton KP, 1997, CURR EYE RES, V16, P564, DOI 10.1076/ceyr.16.6.564.5078; MITTON KP, 1993, EXP EYE RES, V56, P187, DOI 10.1006/exer.1993.1026; NAGATA M, 1989, EXP EYE RES, V48, P667, DOI 10.1016/0014-4835(89)90008-0; NOBERASCO G, 1991, BIOMED PHARMACOTHER, V45, P193, DOI 10.1016/0753-3322(91)90107-5; NouroozZadeh J, 1997, DIABETOLOGIA, V40, P647, DOI 10.1007/s001250050729; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OHRLOFF C, 1983, OPHTHALMIC RES, V15, P19, DOI 10.1159/000265232; POULSOM R, 1986, BIOCHEM PHARMACOL, V35, P2955, DOI 10.1016/0006-2952(86)90492-2; REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G; REDDY VN, 1976, EXP EYE RES, V23, P483, DOI 10.1016/0014-4835(76)90157-3; ROSE IA, 1966, J BIOL CHEM, V241, P4848; ROSS WM, 1982, CAN J OPHTHALMOL, V17, P61; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SANDLER S, 1982, DIABETOLOGIA, V23, P374; Santini SA, 1997, DIABETES, V46, P1853, DOI 10.2337/diabetes.46.11.1853; SATO Y, 1979, BIOCHEM MED METAB B, V21, P104, DOI 10.1016/0006-2944(79)90061-9; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SESTANJ K, 1984, J MED CHEM, V27, P255, DOI 10.1021/jm00369a003; SLONIM AE, 1983, J CLIN INVEST, V71, P1282, DOI 10.1172/JCI110878; Srivastava S K, 1990, Lens Eye Toxic Res, V7, P161; SRIVASTAVA SK, 1988, DIABETES, V37, P1505, DOI 10.2337/diabetes.37.11.1505; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; VANHEYNINGEN R, 1969, BIOCHEM J, V112, P211, DOI 10.1042/bj1120211; VANHEYNINGEN R, 1962, EXP EYE RES, V1, P396, DOI 10.1016/S0014-4835(62)80029-3; VANHEYNINGEN R, 1959, NATURE, V184, P194, DOI 10.1038/184194b0; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WOLFF SP, 1993, BRIT MED BULL, V49, P642, DOI 10.1093/oxfordjournals.bmb.a072637; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; WOOLLARD ACS, 1990, DIABETES, V39, P1347, DOI 10.2337/diabetes.39.11.1347; YEH LA, 1990, METABOLISM, V39, P619, DOI 10.1016/0026-0495(90)90029-C	59	397	419	2	36	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					23	30		10.1096/fasebj.13.1.23	http://dx.doi.org/10.1096/fasebj.13.1.23			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872926				2022-12-28	WOS:000078029500003
J	Wang, E				Wang, E			Age-dependent atrophy and microgravity travel: what do they have in common?	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	replicative senescence; high-throughput technology; nonlinear dynamics; microchips	SENESCENT HUMAN-FIBROBLASTS; PROGRAMMED CELL-DEATH; HUMAN-DIPLOID FIBROBLASTS; ELONGATION FACTOR-1-ALPHA; C-FOS; REPLICATIVE SENESCENCE; THYMOCYTE APOPTOSIS; KINASE PATHWAY; CYCLE CONTROL; GENE FAMILY	Space travel and extending human lifespan are two of the many advances of the twentieth century. However, both of these scientific wonders exact a price for their gains; i.e. deleterious effects on normal physiological processes, For example, both old age and prolonged microgravity travel are associated with atrophy in heart, muscle, and bone. The underlying signal transduction pathways, the control mechanisms for the processes of proliferation, differentiation, and apoptosis, may prove to be similarly altered in both old age and microgravity travel. We suggest that the mechanical events involved in space travel provide a telescopic compression of lifespan changes in these tissues; if so, space travel provides an excellent opportunity to investigate how long-term degeneration occurs on Earth, With the aid of biochip technology for multi-factorial analysis, a platform can be generated to create therapeutic modalities to contain, retard, reduce, or prevent this tissue atrophy, either in space or on Earth.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University	Wang, E (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Chem Cote St Catherine St, Montreal, PQ H3T 1E2, Canada.				NATIONAL INSTITUTE ON AGING [R01AG009278] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG09278] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ANNAB LA, 1992, MOL CARCINOGEN, V6, P280, DOI 10.1002/mc.2940060410; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8346; BROOKS SV, 1994, MED SCI SPORT EXER, V26, P432; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CARLSON BM, 1995, J GERONTOL A-BIOL, V50, P96; CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; CYRUS V, 1998, GENE DEV, V12, P1551; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Faulkner J A, 1990, Annu Rev Gerontol Geriatr, V10, P147; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS AL, 1992, ADV CANCER RES, V59, P69, DOI 10.1016/S0065-230X(08)60303-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOUWELING A, 1995, 35 ANN M AM SOC CELL; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; KASTAN MB, 1991, CANCER RES, V51, P6034; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEE S, 1992, J BIOL CHEM, V267, P24064; LEE S, 1994, BIOCHEM BIOPH RES CO, V203, P1371, DOI 10.1006/bbrc.1994.2336; LEE S, 1993, J HISTOCHEM CYTOCHEM, V41, P1093, DOI 10.1177/41.7.8515051; LEE S, 1993, J BIOL CHEM, V268, P24453; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Momand J, 1997, J CELL BIOCHEM, V64, P343; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; Paulaitis ME, 1997, CURR OPIN COLLOID IN, V2, P315, DOI 10.1016/S1359-0294(97)80041-6; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Reznikoff CA, 1996, CANCER RES, V56, P2886; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UCKER DS, 1991, NEW BIOL, V3, P103; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG E, 1995, CANCER RES, V55, P2284; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	72	33	35	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S167	S174						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352159				2022-12-28	WOS:000080403800021
J	Juompan, L; Lambin, P; Zouali, M				Juompan, L; Lambin, P; Zouali, M			Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection	FASEB JOURNAL			English	Article						B cell death; immunoglobulin isotypes; disease progression	B-CELL ACTIVATION; IMMUNODEFICIENCY-VIRUS TYPE-1; CIRCULATING IMMUNE-COMPLEXES; HUMAN MONOCLONAL-ANTIBODIES; MOLECULAR CHARACTERIZATION; GENE-PRODUCTS; PROTEIN-A; SERUM; AIDS; IGG	HIV infection is characterized by accelerated apoptosis and progressive loss of B cells. To see whether these abnormalities are related to the property of gp120 to act as a superantigen for V-H(3+) B cells, we probed the temporal development of V-H(3+) antibodies in HTV-1-infected subjects over a 7-year period. We found that VH3+ antibodies specific for the gp120 superantigen binding site are deficient, Since V-H(3+) antibodies impart protective responses to infectious agents, we quantified V-H(3+) antibodies in serum samples from HIV-seropositive slow progressors and from patients who progressed to AIDS-related manifestations, We found that paucity in V-H(3+) antibodies is a marker of rapid clinical decline. Remarkably, anti-gp160 V-H(3+) antibodies showed a gradual decrease in progressors and, with time, varied depending on the viral load. We conclude that disease aggravation is associated with a decrease of the magnitude of the humoral response, that V-H(3+) antibodies play an important role in protection, and that their underexpression may accelerate disease progression. We propose that vaccine preparations able to trigger V-H(3+) antibodies might confer a better protection against HIV infection, This work also represents a novel mechanism of humoral deficiency resulting from the capacity of a viral antigen to affect an important subset of the B cell repertoire and to induce B cell death by apoptosis.	Inst Pasteur, Dept Immunol, F-75015 Paris, France; INTS, Unite Immunol Transfus, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Zouali, M (corresponding author), Inst Pasteur, Dept Immunol, 28 Rue Dr Roux, F-75015 Paris, France.			Zouali, Moncef/0000-0002-8225-456X				AMADORI A, 1989, J IMMUNOL, V143, P2146; AMADORI A, 1991, J IMMUNOL, V146, P57; AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; ANDRIS JS, 1993, MOL IMMUNOL, V30, P1601, DOI 10.1016/0161-5890(93)90452-H; BERBERIAN L, 1991, BLOOD, V78, P175; BERBERIAN L, 1994, J ACQ IMMUN DEF SYND, V7, P641; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; BROWN AE, 1995, J INFECT DIS, V172, P1091, DOI 10.1093/infdis/172.4.1091; Clerici M, 1996, AIDS RES HUM RETROV, V12, P1053, DOI 10.1089/aid.1996.12.1053; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; CROWLEY JJ, 1990, MOL IMMUNOL, V27, P87, DOI 10.1016/0161-5890(90)90063-6; DAVID D, 1995, IMMUNOL LETT, V47, P107, DOI 10.1016/0165-2478(95)00078-J; Ditzel HJ, 1996, J IMMUNOL, V157, P739; Ditzel HJ, 1997, J MOL BIOL, V267, P684, DOI 10.1006/jmbi.1997.0912; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; GOODGLICK L, 1995, J IMMUNOL, V155, P5151; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; IBRAHIM S, 1993, SCAND J IMMUNOL, V37, P257, DOI 10.1111/j.1365-3083.1993.tb01764.x; JANOFF EN, 1991, J IMMUNOL, V147, P2130; JANOFF EN, 1995, J INFECT DIS, V172, P855, DOI 10.1093/infdis/172.3.855; Karray S, 1997, P NATL ACAD SCI USA, V94, P1356, DOI 10.1073/pnas.94.4.1356; KARRAY S, 1998, IN PRESS J IMMUNOL; KOZLOWSKI PA, 1995, J IMMUNOL, V154, P6163; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MARASCO WA, 1992, J CLIN INVEST, V90, P1467, DOI 10.1172/JCI116014; MODROW S, 1987, J VIROL, V61, P570, DOI 10.1128/JVI.61.2.570-578.1987; MORROW WJW, 1986, CLIN IMMUNOL IMMUNOP, V40, P515, DOI 10.1016/0090-1229(86)90196-0; MULLER S, 1993, SCAND J IMMUNOL, V38, P327, DOI 10.1111/j.1365-3083.1993.tb01734.x; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Ng VL, 1997, AIDS RES HUM RETROV, V13, P135, DOI 10.1089/aid.1997.13.135; PROCACCIA S, 1987, CLIN EXP IMMUNOL, V67, P236; QUESNEL A, 1993, CLIN EXP IMMUNOL, V91, P237; Rump JA, 1996, AIDS RES HUM RETROV, V12, P757, DOI 10.1089/aid.1996.12.757; SASSO EH, 1991, J IMMUNOL, V147, P1877; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SEBIRE G, 1993, J IMMUNOL, V150, P1517; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; Silverman GJ, 1997, IMMUNOL TODAY, V18, P379, DOI 10.1016/S0167-5699(97)01101-8; SWEET SP, 1995, AIDS, V9, P1288, DOI 10.1097/00002030-199511000-00014; TAKEDA T, 1994, J IMMUNOL, V153, P4573; TownsleyFuchs J, 1996, J CLIN INVEST, V98, P1794, DOI 10.1172/JCI118979; VANGEMEN B, 1994, J VIROL METHODS, V49, P157, DOI 10.1016/0166-0934(94)90040-X; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; ZOUALI M, 1995, IMMUNOL TODAY, V16, P399, DOI 10.1016/0167-5699(95)80009-3; ZOUALI M, 1994, NAT GENET, V7, P118, DOI 10.1038/ng0694-118	46	26	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1473	1480		10.1096/fasebj.12.14.1473	http://dx.doi.org/10.1096/fasebj.12.14.1473			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806756				2022-12-28	WOS:000076749500006
J	Crist, GH; Xu, BY; Lanoue, KF; Lang, CH				Crist, GH; Xu, BY; Lanoue, KF; Lang, CH			Tissue-specific effects of in vivo adenosine receptor blockade on glucose uptake in Zucker rats	FASEB JOURNAL			English	Article						obesity; euglycemic hyperinsulinemic clamp; 2-deoxyglucose; glucose disposal; insulin resistance; muscle; adipose tissue	NECROSIS-FACTOR-ALPHA; INDUCED INSULIN-RESISTANCE; ADENYLATE-CYCLASE; SOLEUS MUSCLE; ADIPOSE-CELLS; OBESITY; TRANSPORTERS; SENSITIVITY; ACTIVATION; MECHANISM	Previous studies have shown that treatment of obese Zucker rats with the adenosine receptor antagonist 1,3-dipropyl-8-(p-acrylic) phenyl xanthine (BWA1433) improves intraperitoneal glucose tolerance, In this study, a euglycemic hyperinsulinemic clamp was performed on obese (fa/fa) and lean (Fa/fa) Zucker rats that had been treated orally with BWA1433 or vehicle for 1 wk, A constant infusion of [H-3]glucose was initiated in fasted animals to measure basal whole body glucose kinetics. No differences in glucose concentration or rates of glucose production/disappearance were observed between lean or obese animals with or without BWA1433, During the euglycemic hyperinsulinemic clamp, whole body glucose disposal in obese Zucker rats was only 22% of that observed in lean animals. BWA1433 treatment increased glucose disposal by 88% in obese Zucker rats. At the end of the clamp, [C-14]-2-deoxyglucose was injected to determine tissue-specific differences in glucose uptake, Gastrocnemius, soleus, heart, and liver of untreated obese animals had significantly lower glucose uptake than lean controls under hyperinsulinemic conditions. BWA1433 treatment of obese animals increased glucose uptake in gastrocnemius and soleus muscles by 44 and 47%, respectively. Conversely, BWA1433 treatment decreased glucose uptake in adipose tissue by 54 and 49% in obese and lean Zucker rats, respectively. In summary, BWA1433 improves glucose tolerance by increasing glucose uptake in skeletal muscle while decreasing glucose uptake by adipose tissue. This study suggests that insulin resistance in obese Zucker rats is tissue specific and that signaling from adenosine receptors may be a factor contributing to tissue-specific insulin resistance.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Lang, CH (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, POB 850,H166, Hershey, PA 17033 USA.							BERKICH DA, 1995, AM J PHYSIOL-ENDOC M, V268, pE693, DOI 10.1152/ajpendo.1995.268.4.E693; BODEN G, 1997, DIABETES, V45, P3; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; BUDOHOSKI L, 1984, FEBS LETT, V167, P1, DOI 10.1016/0014-5793(84)80820-0; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; CHALLIS RAJ, 1984, BIOCHEM J, V221, P915, DOI 10.1042/bj2210915; DEBAND A, AM J PHYSL, V252, pE273; Dixon AK, 1996, BRIT J PHARMACOL, V118, P1461, DOI 10.1111/j.1476-5381.1996.tb15561.x; Green A, 1997, AM J PHYSIOL-ENDOC M, V273, pE254, DOI 10.1152/ajpendo.1997.273.2.E254; GUERREMILLO M, 1985, J BIOL CHEM, V260, P2197; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; JACOBSON KA, 1992, J MED CHEM, V35, P4143, DOI 10.1021/jm00100a020; LANG CH, 1992, AM J PHYSIOL, V263, pE703, DOI 10.1152/ajpendo.1992.263.4.E703; LANG CH, 1991, ENDOCRINOLOGY, V128, P645, DOI 10.1210/endo-128-2-645; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LANG CH, 1990, METABOLISM, V39, P1096, DOI 10.1016/0026-0495(90)90172-9; LEWIS CD, 1994, GEN PHARMACOL, V25, P1381, DOI 10.1016/0306-3623(94)90162-7; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; LONDOS C, 1985, J BIOL CHEM, V260, P5139; MESZAROS K, 1987, J BIOL CHEM, V262, P10965; O'Doherty RM, 1998, AM J PHYSIOL-ENDOC M, V274, pE287, DOI 10.1152/ajpendo.1998.274.2.E287; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; PEDERSON D, 1992, J CLIN INVEST, V89, P1973; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Prentice DJ, 1997, BRIT J PHARMACOL, V122, P1509, DOI 10.1038/sj.bjp.0701524; ROCCHINI AP, 1995, J NUTR, V125, pS1718; ROHNERJEANRENAUD F, 1995, INT J OBESITY, V19, P517; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; TERRETTAZ J, 1983, ENDOCRINOLOGY, V112, P1346, DOI 10.1210/endo-112-4-1346; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; VIKMAN HL, 1995, INT J OBESITY, V19, P388; Virkamaki A, 1997, DIABETES, V46, P1106, DOI 10.2337/diabetes.46.7.1106; Wang JX, 1997, EUR J PHARMACOL, V320, P241, DOI 10.1016/S0014-2999(96)00901-6; Xu BY, 1998, AM J PHYSIOL-ENDOC M, V274, pE271, DOI 10.1152/ajpendo.1998.274.2.E271; Zierath JR, 1998, DIABETES, V47, P1, DOI 10.2337/diabetes.47.1.1	40	64	66	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1301	1308		10.1096/fasebj.12.13.1301	http://dx.doi.org/10.1096/fasebj.12.13.1301			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761773				2022-12-28	WOS:000076402000005
J	Wang, J; Zhou, J; Bondy, CA				Wang, J; Zhou, J; Bondy, CA			Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy	FASEB JOURNAL			English	Article						glucose transporter; IGF action; insulin; proliferation; epiphysis; short stature	FACTOR-I; SIGNAL-TRANSDUCTION; PLATE; HORMONE; MICE; EXPRESSION; CARTILAGE; RECEPTOR; ZONES; RATS	Longitudinal bone growth, and hence stature, are functions of growth plate chondrocyte proliferation and hypertrophy, Insulin-like growth factor 1 (Igf1) is reputed to augment longitudinal bone growth by stimulating growth plate chondrocyte proliferation. In this study, however, we demonstrate that chondrocyte numbers and proliferation are normal in Igf1 null mice despite a 35% reduction in the rate of long bone growth. Igf1 null hypertrophic chondrocytes differentiate normally in terms of expressing specialized proteins such as collagen X and alkaline phosphatase, but are smaller than wildtype at all levels of the hypertrophic zone, The terminal hypertrophic chondrocytes, which form the scaffold on which long bone growth extends, are reduced in linear dimension by 30% in Igf1 null mice, accounting for most of their decreased longitudinal growth, The expression of the insulin-sensitive glucose transporter, GLUT4, is significantly decreased and the insulin-regulated enzyme glycogen synthase kinase 3 beta (GSK3) is hypo-phosphorylated in ISf1 null chondrocytes, Glycogen levels were significantly decreased and ribosomal RNA levels were reduced by almost 75% in Igf1 null chondrocytes, These data suggest that Igf1 promotes longitudinal bone growth by 'insulin-like' anabolic actions which augment chondrocyte hypertrophy.-Wang, J., Zhou, J., Bendy, C. A. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bondy, CA (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10N262,10 Ctr Dr 1862, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000628] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000628] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; Breur GJ, 1997, CALCIFIED TISSUE INT, V61, P418, DOI 10.1007/s002239900358; BRIGHTON CT, 1969, J BONE JOINT SURG AM, VA 51, P1383, DOI 10.2106/00004623-196951070-00018; BRIGHTON CT, 1983, J BONE JOINT SURG AM, V65, P663, DOI 10.2106/00004623-198365050-00012; Cheng CM, 1998, J NEUROSCI, V18, P5673; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; DAUGHADAY WH, 1972, NATURE, V235, P107, DOI 10.1038/235107a0; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501; GRANT WT, 1985, J BIOL CHEM, V260, P3798; HUNZIKER EB, 1989, J PHYSIOL-LONDON, V414, P55, DOI 10.1113/jphysiol.1989.sp017676; HUNZIKER EB, 1994, J CLIN INVEST, V93, P1078, DOI 10.1172/JCI117058; HUNZIKER EB, 1987, J BONE JOINT SURG AM, V69A, P162, DOI 10.2106/00004623-198769020-00002; KEMBER NF, 1971, NATURE, V229, P428, DOI 10.1038/229428a0; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OHLSSON C, 1992, P NATL ACAD SCI USA, V89, P9826, DOI 10.1073/pnas.89.20.9826; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; PRITCHERD JJ, 1952, J ANAT, V8, P259; Roberts J, 1997, SCIENCE, V278, P2073, DOI 10.1126/science.278.5346.2073; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; WALKER KVR, 1972, CELL TISSUE KINET, V5, P409, DOI 10.1111/j.1365-2184.1972.tb00379.x; WANG EM, 1995, ENDOCRINOLOGY, V136, P2741, DOI 10.1210/en.136.6.2741; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805	27	183	188	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1985	1990		10.1096/fasebj.13.14.1985	http://dx.doi.org/10.1096/fasebj.13.14.1985			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544181				2022-12-28	WOS:000083660700010
J	Keaney, JF; Simon, DI; Freedman, JE				Keaney, JF; Simon, DI; Freedman, JE			Vitamin E and vascular homeostasis: implications for atherosclerosis	FASEB JOURNAL			English	Article; Proceedings Paper	FASEB Summer Research Conference on Molecular and Biological Mechanisms of Antioxidant Action	AUG, 1998	COPPER MOUNTAIN, CO			LDL; vascular homeostasis; alpha-tocopherol; nitric oxide	PROTEIN-KINASE-C; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; CHOLESTEROL-FED RABBITS; ENDOTHELIUM-DEPENDENT VASODILATION; CORONARY HEART-DISEASE; NITRIC-OXIDE SYNTHASE; HERITABLE HYPERLIPIDEMIC RABBIT; POSTMENOPAUSAL ESTROGEN THERAPY; ALPHA-TOCOPHEROL	Considerable epidemiologic data suggest that dietary consumption of vitamin E reduces the incidence of cardiovascular disease. The precise mechanisms are not clear, but emerging data indicate that vitamin E has numerous activities that may, in part, explain its effect on vascular disease. Ln particular, vitamin E enhances the bioactivity of nitric oxide, inhibits smooth muscle proliferation, and limits platelet aggregation, One common mechanism to account for these effects of vitamin E is the inhibition of protein kinase C stimulation, In the setting of atherosclerosis, inhibition of protein kinase C by vitamin E would be expected to maintain normal vascular homeostasis and thus reduce the clinical incidence of cardiovascular disease.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02114 USA; Georgetown Univ, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA	Boston University; Boston University; Harvard University; Brigham & Women's Hospital; Georgetown University; Georgetown University	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W507, Boston, MA 02118 USA.	jkeaney@bu.edu		Keaney, John/0000-0002-0866-1837	NHLBI NIH HHS [HL03195, HL03556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; ANDERSSON TLG, 1994, ATHEROSCLEROSIS, V111, P39, DOI 10.1016/0021-9150(94)90189-9; AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; Azzi A, 1998, BIOFACTORS, V7, P3, DOI 10.1002/biof.5520070102; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOSCOBOINIK D, 1991, ARCH BIOCHEM BIOPHYS, V286, P264, DOI 10.1016/0003-9861(91)90039-L; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DAUGHERTY A, 1989, BRIT J PHARMACOL, V98, P612, DOI 10.1111/j.1476-5381.1989.tb12635.x; DAVIES MJ, 1985, BRIT HEART J, V53, P363; Devaraj S, 1996, J CLIN INVEST, V98, P756, DOI 10.1172/JCI118848; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ELLIOTT TG, 1995, AM J CARDIOL, V76, P1188, DOI 10.1016/S0002-9149(99)80335-X; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FARUQI R, 1994, J CLIN INVEST, V94, P592, DOI 10.1172/JCI117374; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; Freedman JE, 1997, J CLIN INVEST, V100, P350, DOI 10.1172/JCI119540; Freedman JE, 1996, J CLIN INVEST, V97, P979, DOI 10.1172/JCI118522; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; Freedman JE, 1998, CIRCULATION, V98, P802; FREEDMAN JE, 1998, CIRCULATION, V98, P1; FREEDMAN JE, 1999, IN PRESS J AM COLL C, V33; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GILLIGAN DM, 1994, J AM COLL CARDIOL, V24, P1611, DOI 10.1016/0735-1097(94)90164-3; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Graier WF, 1997, HORM METAB RES, V29, P622, DOI 10.1055/s-2007-979113; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HECKER M, 1993, J CELL PHYSIOL, V156, P571, DOI 10.1002/jcp.1041560317; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIGASHI O, 1974, TOHOKU J EXP MED, V112, P271, DOI 10.1620/tjem.112.271; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; HODIS HN, 1995, JAMA-J AM MED ASSOC, V273, P1849, DOI 10.1001/jama.273.23.1849; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JANDAK J, 1989, BLOOD, V73, P141; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; Keaney JF, 1996, J CLIN INVEST, V98, P386, DOI 10.1172/JCI118804; KEANEY JF, 1995, J CLIN INVEST, V95, P2520, DOI 10.1172/JCI117953; KEANEY JF, 1994, NATURAL ANTIOXIDANTS, P303; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KOCKMANN V, 1988, PROSTAGLANDINS, V36, P607, DOI 10.1016/0090-6980(88)90007-X; Koh KK, 1998, CIRCULATION, V98, P660; Koya D, 1998, BIOFACTORS, V7, P69, DOI 10.1002/biof.5520070110; KROLL MH, 1993, J BIOL CHEM, V268, P3520; KUBES P, 1994, AM J PHYSIOL, V267, pH931, DOI 10.1152/ajpheart.1994.267.3.H931; Kugiyama K, 1998, CIRCULATION, V97, P2519, DOI 10.1161/01.CIR.97.25.2519; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUNISAKI M, 1995, AM J PHYSIOL-ENDOC M, V269, pE239, DOI 10.1152/ajpendo.1995.269.2.E239; KUNISAKI M, 1994, DIABETES, V43, P1372, DOI 10.2337/diabetes.43.11.1372; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIEBERMAN EH, 1994, ANN INTERN MED, V121, P936, DOI 10.7326/0003-4819-121-12-199412150-00005; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Ma XL, 1997, CIRC RES, V80, P894; MAHONEY CW, 1988, BIOCHEM BIOPH RES CO, V154, P694, DOI 10.1016/0006-291X(88)90195-7; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; MCDOWELL IFW, 1994, EUR J CLIN INVEST, V24, P759, DOI 10.1111/j.1365-2362.1994.tb01073.x; Motoyama T, 1998, CIRCULATION, V98, P851; Motoyama T, 1998, CIRCULATION, V98, P175; MUGGE A, 1991, CIRC RES, V69, P1293, DOI 10.1161/01.RES.69.5.1293; Neunteufl T, 1998, J AM COLL CARDIOL, V32, P711, DOI 10.1016/S0735-1097(98)00295-2; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OHARA Y, 1995, HYPERTENSION, V25, P415, DOI 10.1161/01.HYP.25.3.415; OHGUSHI M, 1993, ARTERIOSCLER THROMB, V13, P1525, DOI 10.1161/01.ATV.13.10.1525; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Ozer NK, 1998, FREE RADICAL BIO MED, V24, P226, DOI 10.1016/S0891-5849(97)00136-6; OZER NK, 1993, FEBS LETT, V322, P307, DOI 10.1016/0014-5793(93)81592-N; PACKHAM MA, 1993, BIOCHEM J, V290, P849, DOI 10.1042/bj2900849; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RADOMSKI MW, 1990, BRIT J PHARMACOL, V101, P325, DOI 10.1111/j.1476-5381.1990.tb12709.x; Rao N, 1997, BIOPHARM DRUG DISPOS, V18, P1, DOI 10.1002/(SICI)1099-081X(199701)18:1<1::AID-BDD996>3.0.CO;2-0; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SASAHARA M, 1994, J CLIN INVEST, V94, P155, DOI 10.1172/JCI117301; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sirikci O, 1996, ATHEROSCLEROSIS, V126, P253, DOI 10.1016/0021-9150(96)05909-6; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; SRIVASTAVA KC, 1986, PROSTA LEUKOTR MED, V21, P177, DOI 10.1016/0262-1746(86)90151-4; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, 1983, THROMB HAEMOSTASIS, V49, P73; STEINER M, 1976, J CLIN INVEST, V57, P732, DOI 10.1172/JCI108331; Steiner M, 1997, J CELL PHYSIOL, V172, P351; STEWARTLEE AL, 1994, ARTERIOSCLER THROMB, V14, P494, DOI 10.1161/01.ATV.14.3.494; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; Toss H, 1997, CIRCULATION, V96, P4204; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; Weisbrod RM, 1997, ARTERIOSCL THROM VAS, V17, P394, DOI 10.1161/01.ATV.17.2.394; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; Williams JK, 1998, J AM COLL CARDIOL, V31, P684, DOI 10.1016/S0735-1097(97)00537-8; WILSON PW, 1980, AM J CARDIOL, V46, P649, DOI 10.1016/0002-9149(80)90516-0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	123	126	128	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					965	975		10.1096/fasebj.13.9.965	http://dx.doi.org/10.1096/fasebj.13.9.965			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336880	Bronze			2022-12-28	WOS:000080547700002
J	Hughes-Fulford, M; Gilbertson, V				Hughes-Fulford, M; Gilbertson, V			Osteoblast fibronectin mRNA, protein synthesis, and matrix are unchanged after exposure to microgravity	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	growth activation; spaceflight; mRNA expression	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; SHAPE CHANGES; CELL-SHAPE; DIFFERENTIATION; BONE	The well-defined osteoblast line, MC3T3-E1 was used to examine fibronectin (FN) mRNA levels, protein synthesis, and extracellular FN matrix accumulation after growth activation in spaceflight. These osteoblasts produce FN extracellular matrix (ECM) known to regulate adhesion, differentiation, and function in adherent cells. Changes in bone ECM and osteoblast cell shape occur in spaceflight. To determine whether altered FN matrix is a factor in causing these changes in spaceflight, quiescent osteoblasts were launched into microgravity and were then sera activated with and without a 1-gravity field. Synthesis of FN mRNA, protein, and matrix were measured after activation in microgravity, FN mRNA synthesis is significantly reduced in microgravity (0-G) when compared to ground (GR) osteoblasts flown in a centrifuge simulating earth's gravity (1-G) field 2.5 h after activation. However, 27.5 h after activation there were no significant differences in mRNA synthesis. A small but significant reduction of FN protein was found in the 0-G samples 2.5 h after activation. Total FN protein 27.5 h after activation showed no significant difference between any of the gravity conditions, however, there was a fourfold increase in absolute amount of protein synthesized during the incubation. Using immunofluorescence, we found no significant differences in the amount or in the orientation of the FN matrix after 27.5 h in microgravity, These results demonstrate that FN is made by sera-activated osteoblasts even during exposure to microgravity. These data also suggest that after a total period of 43 h of spaceflight FN transcription, translation, or altered matrix assembly is not responsible for the altered cell shape or altered matrix formation of osteoblasts.	Vet Adm Med Ctr, Lab Cell Growth & Differentiat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Med Ctr, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Hughes-Fulford, M (corresponding author), Vet Adm Med Ctr, Lab Cell Growth 151F, 4150 Clement St, San Francisco, CA 94121 USA.	milliehf@spacedu.com		Hughes-Fulford, Millie/0000-0002-0756-068X				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BOONSTRA J, 1997, ESA PUBLICATION; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; Fitzgerald J, 1999, FASEB J, V13, P553, DOI 10.1096/fasebj.13.3.553; Globus RK, 1998, J CELL SCI, V111, P1385; GUIGNANDON A, 1995, CELL STRUCT FUNCT, V20, P369, DOI 10.1247/csf.20.369; HUGHESFULFORD M, 1993, RECEPTOR, V3, P145; HUGHESFULFORD M, 1991, EXP GERONTOL, V26, P247, DOI 10.1016/0531-5565(91)90017-G; HUGHESFULFORD M, 1999, IN PRESS EFFECT MICR; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KACENA MA, 1997, GRAVITATIONAL SPACE, V11, P15; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; Leong J, 1996, EXP CELL RES, V224, P79, DOI 10.1006/excr.1996.0113; MACK PB, 1971, AEROSPACE MED, V42, P828; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Moursi AM, 1996, J CELL SCI, V109, P1369; Nicogossian AE., 1989, SPACE PHYSL MED, V2nd/4th Edition; ROBERTS WE, 1987, AM J PHYSIOL, V252, pR247, DOI 10.1152/ajpregu.1987.252.2.R247; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; TURNER RT, 1985, P SOC EXP BIOL MED, V180, P544; VOSE GP, 1974, AM J ROENTGENOL, V121, P1; WEISS RE, 1980, P NATL ACAD SCI-BIOL, V77, P2074, DOI 10.1073/pnas.77.4.2074; WINNARD RG, 1995, J BONE MINER RES, V10, P1969	28	22	25	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S121	S127						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352153				2022-12-28	WOS:000080403800015
J	Malinda, KM; Nomizu, M; Chung, M; Delgado, M; Kuratomi, Y; Yamada, Y; Kleinman, HK; Ponce, ML				Malinda, KM; Nomizu, M; Chung, M; Delgado, M; Kuratomi, Y; Yamada, Y; Kleinman, HK; Ponce, ML			Identification of laminin alpha 1 and beta 1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting	FASEB JOURNAL			English	Article						angiogenesis; basement membrane; synthetic peptides	EXPERIMENTAL METASTASIS FORMATION; AMINO-ACID-SEQUENCE; A-CHAIN; TUMOR-GROWTH; ANGIOGENESIS; MATRIGEL; DIFFERENTIATION; INHIBITION; ATTACHMENT; BINDING	Laminin-1 is a basement membrane glycoprotein that promotes several biological activities including cell attachment, tumor metastasis, and angiogenesis. Angiogenesis plays an important role in tissue formation, reproduction, wound healing,;md several pathological conditions. In this study, we screened 405 synthetic peptides from the al and pi chains to identify potential sites on laminin-l active with endothelial cells, Peptides were initially screened by testing both endothelial cell adhesion to peptide-coated wells and tube formation on Matrigel in the presence of soluble peptide. Twenty active peptides were identified in these screens, A secondary screen using the rat aortic ring sprouting assay identified 13 of the 20 peptides that stimulated endothelial sprouting, Several of these active peptides were also found to stimulate human umbilical vein endothelial cell migration in Boyden chamber assays. Differences in the amount of peptide needed for the response and in the resultant morphologies/responses were observed between the peptides in all of the assays. Our results suggest that several active domains on laminin-1 may play important roles in stimulating different steps in angiogenesis.	NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Kleinman, HK (corresponding author), NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Room 433, Bethesda, MD 20892 USA.							AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BATTEGAY EJ, 1995, J MOL MED, V73, P333; CID MC, 1993, J CLIN INVEST, V91, P977, DOI 10.1172/JCI116319; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GRANT DS, 1995, J CELL SCI, V108, P3685; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KAWASAKI K, 1991, BIOCHEM BIOPH RES CO, V174, P1159, DOI 10.1016/0006-291X(91)91542-K; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KLEINMAN HK, 1993, VITAM HORM, V47, P161, DOI 10.1016/S0083-6729(08)60446-X; NAKAI M, 1992, CANCER RES, V52, P5395; NICOSIA RF, 1990, IN VITRO CELL DEV B, V26, P119; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; NURCOMBE V, 1992, PHARMACOL THERAPEUT, V56, P247, DOI 10.1016/0163-7258(92)90019-V; SAKAMOTO N, 1991, CANCER RES, V51, P903; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P161; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YAMADA KM, 1997, ENCY HUMAN BIOL, P873	26	158	166	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					53	62		10.1096/fasebj.13.1.53	http://dx.doi.org/10.1096/fasebj.13.1.53			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872929				2022-12-28	WOS:000078029500006
J	Lubec, B; Hermon, M; Hoeger, H; Lubec, G				Lubec, B; Hermon, M; Hoeger, H; Lubec, G			Aromatic hydroxylation in animal models of diabetes mellitus	FASEB JOURNAL			English	Article						hydroxyl radical; streptozotocin; db/db mouse; BB rat; KK mouse; o-tyrosine; glycoxidation; pentosidine; carboxymethyllysine; malondialdehyde; lipid peroxidation	N-EPSILON-CARBOXYMETHYLLYSINE; MAILLARD REACTION-PRODUCTS; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; BB RAT; COLLAGEN ACCUMULATION; SKIN COLLAGEN; O-TYROSINE; STREPTOZOTOCIN; PENTOSIDINE	Although the involvement of oxidative stress is well documented in the diabetic state, the individual active oxygen species generated have mot been demonstrated in animal models of diabetes currently used. Since streptozotocin-induced diabetes mellitus in animals still serves as an animal model of diabetes mellitus, but streptozotocin induces diabetes and generates oxidative stress per se, we decided to study whether aromatic hydroxylation reflecting hydroxyl radical attack was found in three animal models of diabetes mellitus without streptozotocin induction or in streptozotocin-induced diabetes only, For this purpose, we compared lipid peroxidation, aromatic hydroxylation of phenylalanine, glycoxidation in genetically determined diabetic mouse strains db/db and kk, and the diabetic BE rat to these parameters in the streptozotocin-treated rat. Kidney malondialdehyde concentrations, reflecting lipid peroxidation, pentosidine, and N-epsilon-caboxymethyllysine concentrations, reflecting glycoxidation, were significantly elevated in all diabetic groups as compared to their nondiabetic mates, Aromatic hydroxylation was significantly elevated in the streptozotocin-induced diabetic state exclusively. We conclude that biochemical, pathophysiological, and treatment studies in the streptozotocin model of diabetes mellitus may be confounded by the presence of products, reactions, and tissue damage generated by aromatic hydroxylation reflecting hydroxyl radical attack. We suggest it is not the diabetic state but streptozotocin that generates the hydroxyl radical, as reflected by aromatic hydroxylation in this model.	Univ Vienna, Dept Pediat, A-1090 Vienna, Austria; Univ Vienna, Dept Neonatol & Intens Care, A-1090 Vienna, Austria; Univ Vienna, Inst Anim Breeding, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Lubec, G (corresponding author), Univ Vienna, Dept Pediat, Waehringer Guertel 18 A, A-1090 Vienna, Austria.	gert.lubec@akh-wien.ac.at	YAMAMOTO, MASAHIRO/F-9094-2011; Hermon, Michael/H-9495-2019	YAMAMOTO, MASAHIRO/0000-0003-3859-0125; Lubec, Gert/0000-0002-6333-9461				AWATA T, 1995, ENDOCRINOLOGY, V136, P5731, DOI 10.1210/en.136.12.5731; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BENNETT RA, 1981, CANCER RES, V41, P2786; CAMERON NE, 1993, DIABETOLOGIA, V36, P299, DOI 10.1007/BF00400231; CARUBELLI R, 1995, FREE RADICAL BIO MED, V18, P265, DOI 10.1016/0891-5849(94)E0134-5; Coleman D L, 1967, Diabetologia, V3, P238, DOI 10.1007/BF01222201; CROUCH R, 1978, DIABETOLOGIA, V15, P53, DOI 10.1007/BF01219329; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Frischer T, 1997, FREE RADICAL BIO MED, V22, P201, DOI 10.1016/S0891-5849(96)00292-4; FU MX, 1992, DIABETES, V41, P42, DOI 10.2337/diab.41.2.S42; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GANDY SE, 1982, J CLIN INVEST, V70, P650, DOI 10.1172/JCI110659; Halliwell B., 1991, FREE RADICALS BIOL M; Hardmeier R, 1997, P NATL ACAD SCI USA, V94, P7572, DOI 10.1073/pnas.94.14.7572; HIRAMOTO K, 1993, MUTAT RES, V285, P191, DOI 10.1016/0027-5107(93)90106-P; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HUNT JV, 1991, FREE RADICAL RES COM, V12-3, P115, DOI 10.3109/10715769109145775; ISHIMITSU S, 1986, J CHROMATOGR, V378, P222, DOI 10.1016/S0378-4347(00)80716-1; JAIN SK, 1990, METABOLISM, V39, P971, DOI 10.1016/0026-0495(90)90310-9; JUNOD A, 1967, P SOC EXP BIOL MED, V126, P201; KARAM LR, 1991, FREE RADICAL RES COM, V12-3, P11, DOI 10.3109/10715769109145762; KELLY FJ, 1995, PEDIATR RES, V38, P286, DOI 10.1203/00006450-199509000-00003; KHAIDAR A, 1994, CIRCULATION, V90, P479, DOI 10.1161/01.CIR.90.1.479; KRAJNIK P, 1995, Z NATURFORSCH A, V50, P864, DOI 10.1515/zna-1995-0912; LIARDON R, 1987, J AGR FOOD CHEM, V35, P427, DOI 10.1021/jf00075a035; LUBEC B, 1993, J PEDIATR-US, V123, P748, DOI 10.1016/S0022-3476(05)80852-2; Lubec B, 1997, FREE RADICAL BIO MED, V22, P355, DOI 10.1016/S0891-5849(96)00386-3; Lubec B, 1997, NEPHRON, V75, P213, DOI 10.1159/000189534; Lubec B, 1996, FREE RADICAL BIO MED, V21, P219, DOI 10.1016/0891-5849(96)00018-4; LUBEC G, 1994, FASEB J, V8, P1166, DOI 10.1096/fasebj.8.14.7958623; Lubec G, 1996, J INVEST MED, V44, P324; LYONS TJ, 1991, J CLIN INVEST, V87, P1910, DOI 10.1172/JCI115216; MARLISS EB, 1982, DIABETOLOGIA, V22, P225, DOI 10.1007/BF00281296; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587; NONODA K, 1993, JPN HEART J, V34, P591; OHKUWA T, 1995, LIFE SCI, V56, P1789, DOI 10.1016/0024-3205(95)00150-5; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; PITKANEN OM, 1992, LIFE SCI, V50, P335, DOI 10.1016/0024-3205(92)90434-Q; POUSSIER P, 1982, ENDOCRINOLOGY, V110, P1825, DOI 10.1210/endo-110-5-1825; RERUP C C, 1970, Pharmacological Reviews, V22, P485; ROBBINS MJ, 1980, DIABETOLOGIA, V18, P55, DOI 10.1007/BF01228303; SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; SHAH G, 1994, LIFE SCI, V55, P1343, DOI 10.1016/0024-3205(94)00767-5; SLONIM AE, 1976, DIABETES, V25, P216, DOI 10.2337/diabetes.25.3.216; SLONIM AE, 1977, DIABETES, V26, P417; TAKAHASHI M, 1993, DIABETOLOGIA, V36, P664, DOI 10.1007/BF00404078; TOMINO Y, 1991, NEPHRON, V59, P632, DOI 10.1159/000186656; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; WENINGER M, 1992, NEPHRON, V62, P80, DOI 10.1159/000187000; WONG SHY, 1987, CLIN CHEM, V33, P214; YAGUCHI Y, 1990, NEPHRON, V54, P368, DOI 10.1159/000185904	58	23	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1581	1587		10.1096/fasebj.12.14.1581	http://dx.doi.org/10.1096/fasebj.12.14.1581			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806767				2022-12-28	WOS:000076749500017
J	Estevez, R; Camps, M; Rojas, AM; Testar, X; Deves, R; Hediger, MA; Zorzano, A; Palacin, M				Estevez, R; Camps, M; Rojas, AM; Testar, X; Deves, R; Hediger, MA; Zorzano, A; Palacin, M			The amino acid transport system y(+)L/4F2hc is a heteromultimeric complex	FASEB JOURNAL			English	Article						oocyte; mutagenesis; erythrocyte; y(+)L transport activity; homologous protein	XENOPUS-LAEVIS OOCYTES; RENAL CYSTINE TRANSPORTER; MONOCLONAL-ANTIBODY 4F2; MINK POTASSIUM CHANNELS; CELL-SURFACE ANTIGEN; HEAVY-CHAIN; RAT-KIDNEY; EXPRESSION CLONING; HUMAN ERYTHROCYTES; HIGH-AFFINITY	4F2hc is an almost ubiquitous transmembrane protein in mammalian cells; upon expression in Xenopus laevis oocytes, it induces amino acid transport with characteristics of system y(+)L. Indirect evidence fostered speculation that function requires the association of 4F2hc with another protein endogenous to oocytes and native tissues. We show that expression of system y(+)L-like amino acid transport activity by 4F2hc in oocytes is Limited by an endogenous factor and that direct covalent modification of external cysteine residue(s) of an oocyte membrane protein blocks system y(+)L/4F2hc transport activity, based on the following. I) Induction of system y(+)L-like activity saturates at very low doses of human 4F2hc cRNA (0.1 ng/oocyte). This saturation occurs with very low expression of 4F2hc at the oocyte surface, and further increased expression of the protein at the cell surface does not result in higher induction of system y(+)L-like activity. 2) Human 4F2hc contains only two cysteine residues (C109 and C330). We mutated these residues, singly and in combination, to serine (C109S; CS1, C330S; CS2 and C109S-C330S, Cys-less). Mutation CS2 had no effect on the expressed system y(+)L-like transport activity, whereas C109S-containing mutants (CS1 and Cys-less) retained only partial y(+)L-like transport activity (30 to 50% of wild type). 3) Hg2+, the organic mercury com pounds pCMB, and the membrane-impermeant pCMBS almost completely inactivated system y(+)L-like induced by human 4F2hc wild type and all the mutants studied. This was reversed by P-mercaptoethanol, indicating that external cysteine residue(s) are the target of this inactivation. 4) Sensitivity to Hg2+ inactivation is increased by pretreatment of oocytes with P-mercaptoethanol or in the C109S-containing mutants (CS1 and Cys-less). The increased Hg2+ reactivity of C109S-containing mutants supports the possibility that C109 may be linked by a disulfide bond to the Hg2+-targeted cysteine residue of the associated protein. These results indicate that 4F2hc is intimately associated with a membrane oocyte protein for the expression of system y(+)L amino acid transport activity. To our knowledge, this is the first direct evidence for a heteromultimeric protein structure of an organic solute carrier in mammals.	Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Brigham & Womens Hosp, Div Renal, Harvard Inst Med, Boston, MA 02115 USA; Univ Chile, Fac Med, Dept Fisiol & Biofis, Santiago 7, Chile	University of Barcelona; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidad de Chile	Palacin, M (corresponding author), Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Camps, Marta/F-6557-2016; Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Estevez, Raul/D-8610-2015	Camps, Marta/0000-0001-5392-1792; Estevez, Raul/0000-0003-1579-650X; Palacin, Manuel/0000-0002-8670-293X; Hediger, Matthias/0000-0003-1946-027X				Ahmed A, 1997, J BIOL CHEM, V272, P125; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Bisceglia L, 1997, AM J HUM GENET, V60, P611; Broeer S., 1997, Amino Acids (Vienna), V13, P45; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; BROER S, 1994, BBA-BIOMEMBRANES, V1192, P95, DOI 10.1016/0005-2736(94)90147-3; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chillaron J, 1997, J BIOL CHEM, V272, P9543; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GEERING K, 1989, AM J PHYSIOL, V257, P851; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEMLER ME, 1982, J IMMUNOL, V129, P623; Kakuda DK, 1993, TRANSGENE, V1, P91; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; Miyamoto K, 1996, J BIOL CHEM, V271, P16758, DOI 10.1074/jbc.271.28.16758; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; MORA S, 1996, THESIS U BARCELONA S; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Peter GJ, 1996, BIOCHEM J, V318, P915, DOI 10.1042/bj3180915; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SEGAL S, 1995, METABOLIC MOL BASES, P3581; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Tate SS, 1996, AMINO ACIDS, V11, P209, DOI 10.1007/BF00813861; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; WALDEGGER S, 1995, KIDNEY INT, V47, P1677, DOI 10.1038/ki.1995.232; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; Wartenfeld R, 1997, AM J HUM GENET, V60, P617; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	47	67	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1319	1329		10.1096/fasebj.12.13.1319	http://dx.doi.org/10.1096/fasebj.12.13.1319			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761775				2022-12-28	WOS:000076402000007
J	Sell, DR; Kleinman, NR; Monnier, VM				Sell, DR; Kleinman, NR; Monnier, VM			Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice	FASEB JOURNAL			English	Article						aging; biomarker; glucose; oxidation; Maillard reaction	AGE-DEPENDENT ACCUMULATION; DIETARY RESTRICTION; CALORIC RESTRICTION; MAILLARD REACTION; CAENORHABDITIS-ELEGANS; ULCERATIVE DERMATITIS; GLYCEMIC CONTROL; RHESUS-MONKEYS; LIFE-SPAN; INSULIN	In 1998, the National Institute on Aging launched a 10-year program aimed at identification of biomarkers of aging. Previous results from our laboratory showed that pentosidine, an advanced glycation product, formed in skin collagen at a rate inversely related to maximum life span across several mammalian species. As part of the Biomarkers Program, we investigated the hypothesis that longitudinal determination of glycation and glycoxidation rates in skin collagen could predict longevities in ad libitum-fed (AL) and caloric restricted (CR) mice. C57BL/6NNia male mice were biopsied at age 20 months and at natural death. Glycation (furosine method) was assessed by gas chromatography/mass spectrometry (GC/MS) and the glycoxidation products carboxymethyllysine (CML) and pentosidine were determined by GC/MS and HPLC, respectively. CR vs AL significantly (P<0.0001) increased both means (34 vs. 27 months) and maximum (47 vs. 31 months) life spans. Skin collagen levels of furosine (pmol/mu mol) lysine) were similar to 2.5-fold greater than CML levels and 100-fold greater than pentosidine. Individual accumulation rates modeled as linear equations were significantly (P<0.001) inhibited by CR vs. AL for all parameters and in all cases varied inversely with longevity (P<0.1 to <0.0001). The incidence of three tissue pathologies (lymphoma, dermatitis, and seminal vesiculitis) was found to be attenuated by CR and the latter pathology correlated significantly with longevities(r=0.54, P=0.002). The finding that markers of skin collagen glycation and glycoxidation rates can predict early deaths in AL and CR C57BL/6NNia mice strongly suggests that an age-related deterioration in glucose tolerance is a life span-determining process.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Anim Resource Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sell, DR (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Monnier, Vincent M/B-1371-2009; YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL INSTITUTE ON AGING [R01AG011080, R01AG005601] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11080, AG-05601] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; ANDREWS AG, 1994, VET PATHOL, V31, P293, DOI 10.1177/030098589403100301; BAKER GT, 1988, EXP GERONTOL, V23, P223, DOI 10.1016/0531-5565(88)90025-3; Barzilai N, 1996, AM J PHYSIOL-ENDOC M, V270, pE930, DOI 10.1152/ajpendo.1996.270.6.E930; Baynes J. W., 1989, MAILLARD REACTION AG, P43; BEISSWENGER PJ, 1993, DIABETES CARE, V16, P689, DOI 10.2337/diacare.16.5.689; BODKIN NL, 1995, J GERONTOL A-BIOL, V50, pB142, DOI 10.1093/gerona/50A.3.B142; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; CEFALU WT, 1995, J GERONTOL A-BIOL, V50, pB337, DOI 10.1093/gerona/50A.6.B337; CERAMI A, 1985, J AM GERIATR SOC, V33, P624; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; FEUERS RJ, 1991, BIOL EFFECTS DIETARY, P198; FINCH CE, 1974, J GERONTOL, V29, P134, DOI 10.1093/geronj/29.2.134; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; FURTH AJ, 1988, ANAL BIOCHEM, V175, P347, DOI 10.1016/0003-2697(88)90558-1; Gerstein HC, 1999, J AM COLL CARDIOL, V33, P612, DOI 10.1016/S0735-1097(98)00637-8; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HARLAN LC, 1987, AM J EPIDEMIOL, V126, P674, DOI 10.1093/oxfordjournals.aje.a114707; HART RW, 1996, LAB ANIMAL       MAR, P29; KALANT N, 1988, MECH AGEING DEV, V46, P89, DOI 10.1016/0047-6374(88)90117-0; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LAGOPOULOS L, 1991, CARCINOGENESIS, V12, P311, DOI 10.1093/carcin/12.2.311; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941; Levi B, 1998, J NUTR, V128, P1442, DOI 10.1093/jn/128.9.1442; LYONS TJ, 1991, J CLIN INVEST, V87, P1910, DOI 10.1172/JCI115216; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; MASORO EJ, 1993, J AM GERIATR SOC, V41, P994, DOI 10.1111/j.1532-5415.1993.tb06767.x; MATTS JP, 1995, J CLIN EPIDEMIOL, V48, P389, DOI 10.1016/0895-4356(94)00145-G; McClearn GE, 1997, EXP GERONTOL, V32, P87, DOI 10.1016/S0531-5565(96)00067-8; Miller RA, 1997, J GERONTOL A-BIOL, V52, pB39, DOI 10.1093/gerona/52A.1.B39; Mlekusch W, 1996, MECH AGEING DEV, V92, P43, DOI 10.1016/S0047-6374(96)01801-5; MONNIER VM, 1983, ACS SYM SER, V215, P431; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; MONNIER VM, 1989, MAILLARD REACTION AG, P1; MOORADIAN AD, 1990, J GERONTOL, V45, pB183, DOI 10.1093/geronj/45.6.B183; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MURTAGHMARK CM, 1995, J GERONTOL A-BIOL, V50, pB148, DOI 10.1093/gerona/50A.3.B148; Paolisso G, 1996, AM J PHYSIOL-ENDOC M, V270, pE890, DOI 10.1152/ajpendo.1996.270.5.E890; PARKENING TA, 1988, J GERONTOL, V43, pB79, DOI 10.1093/geronj/43.3.B79; Parr T, 1996, MECH AGEING DEV, V88, P75, DOI 10.1016/0047-6374(96)01723-X; Pearline RV, 1996, HEPATOLOGY, V24, P838; Perkins SN, 1998, J INVEST DERMATOL, V111, P292, DOI 10.1046/j.1523-1747.1998.00270.x; Sell DR, 1997, MECH AGEING DEV, V95, P81, DOI 10.1016/S0047-6374(97)01863-0; Sell DR, 1997, J GERONTOL A-BIOL, V52, pB277, DOI 10.1093/gerona/52A.5.B277; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; SELL DR, 1995, PHYSL AGING, P235; Sprott Richard L., 1996, P3; Sprott RL, 1997, EXP GERONTOL, V32, P205, DOI 10.1016/S0531-5565(96)00065-4; TURTURRO A, 1992, EXP GERONTOL, V27, P583, DOI 10.1016/0531-5565(92)90013-P; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; Witt W. M., 1989, Laboratory Animal Science, V39, P470; WITT WM, 1991, BIOL EFFECTS DIETARY, P73	58	77	77	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					145	156		10.1096/fasebj.14.1.145	http://dx.doi.org/10.1096/fasebj.14.1.145			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627289				2022-12-28	WOS:000084784700017
J	Jenkinson, AM; Collins, AR; Duthie, SJ; Wahle, KWJ; Duthie, GG				Jenkinson, AM; Collins, AR; Duthie, SJ; Wahle, KWJ; Duthie, GG			The effect of increased intakes of polyunsaturated fatty acids and vitamin E on DNA damage in human lymphocytes	FASEB JOURNAL			English	Article						PUFA; lipid peroxidation; comet assay; oxidized pyrimidines	DIETARY; ADDUCTS; CANCER	The effect of increasing dietary intakes of polyunsaturated fatty acids (PUFAs) and vitamin E on indices of oxidative DNA damage was investigated. Twenty-one healthy male, nonsmokers aged 28.9 +/- 1.3 years participated in a free-living, split plot/change over trial in which half the volunteers consumed diets containing 5% PUFA as food energy for 4 wk and, after a 10 wk washout period, consumed a 15% PUFA diet for another 4 wk. The other volunteers followed an identical protocol, except that they consumed the 15% PUFA diet first. The diets were provided to volunteers either with or without an additional 80 mg d alpha-tocopherol acetate/day; otherwise total fat, carbohydrates, protein, and basal vitamin E contents remained unchanged. DNA damage induced by 200 mu M H2O2 in lymphocytes from volunteers as well as endogenous DNA damage in the form of oxidized pyrimidines, measured by alkaline single-cell gel electrophoresis (the comet assay), significantly decreased after consumption of the 5% PUFA diet (P<0.001 and P=0.01, respectively), but significantly increased after consumption of the 15% PUFA diet when cx-tocopherol levels were in the range of 5-7 mg/day (P=0.008 and P=0.03, respectively). These changes were abolished by an additional 80 mg d alpha-tocopherol/day. This study indicates that increasing dietary levels of PUFA to 15% may adversely affect some indices of DNA stability. However, increasing the dietary intake of vitamin E by 80 mg/day ameliorates the damaging effects of PUFA.	Rowett Res Inst, Bucksburn AB21 9SB, Aberdeen, Scotland	University of Aberdeen	Jenkinson, AM (corresponding author), Rowett Res Inst, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.			Duthie, Susan/0000-0002-7990-4437				Arthur J. R., 1982, Rowett Research Institute Annual report of studies in animal nutrition and allied sciences, Volume 38., P124; BANKSON DD, 1993, CLIN LAB MED, V13, P463, DOI 10.1016/S0272-2712(18)30449-9; Duthie SJ, 1996, CANCER RES, V56, P1291; Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V393, P223, DOI 10.1016/S1383-5718(97)00107-1; Fang JL, 1996, CARCINOGENESIS, V17, P1035, DOI 10.1093/carcin/17.5.1035; Gregory J., 1990, DIETARY NUTR SURVEY; HAEGELE AD, 1994, FREE RADICAL BIO MED, V16, P111, DOI 10.1016/0891-5849(94)90247-X; HARTMANN A, 1995, MUTAT RES LETT, V346, P195, DOI 10.1016/0165-7992(95)90035-7; HESS D, 1991, INT J VITAM NUTR RES, V61, P232; KAIZER L, 1989, NUTR CANCER, V12, P61, DOI 10.1080/01635588909514002; Nair J, 1997, CANCER EPIDEM BIOMAR, V6, P597; *NAT RES COUNC, 1989, SUBC 10 ED RDAS, P284; OLIVER MF, 1996, ACTA CARDIOL, V6, P467; STETINA R, 1997, P INT S ENV EP CENTR; SUMMERFIELD FW, 1984, ARCH BIOCHEM BIOPHYS, V233, P408, DOI 10.1016/0003-9861(84)90462-4	15	66	70	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2138	2142		10.1096/fasebj.13.15.2138	http://dx.doi.org/10.1096/fasebj.13.15.2138			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593860	Bronze			2022-12-28	WOS:000084310800004
J	Rasola, A; Far, DF; Hofman, P; Rossi, B				Rasola, A; Far, DF; Hofman, P; Rossi, B			Lack of intenucleosomal DNA fragmentation is related to C1(-) efflux impairment in hematopoietic cell apoptosis	FASEB JOURNAL			English	Article						CAD; DFF; hyperosmotic shock; ICAD	CASPASE-ACTIVATED DNASE; CYTOCHROME-C; CHROMATIN CONDENSATION; CD95-INDUCED APOPTOSIS; DEPENDENT ACTIVATION; ICE/CED-3 PROTEASE; CHLORIDE CHANNEL; PLASMA-MEMBRANE; IN-VIVO; MITOCHONDRIAL	The heterodimeric DNA fragmentation factor (DFF) is responsible for DNA degradation into nucleosomal units during apoptosis, This process needs the caspase-dependent release of ICAD/DFF-45, the inhibitory subunit of DFF, Here we report that triggering apoptosis via a hyperosmotic shock in hematopoietic cells causes the appearance of mitochondrial and cytosolic alterations, activation of caspases, chromatin condensation, nuclear disruption, and DNA fragmentation, However, oligonucleosomal but not high molecular weight (50-150 kb) DNA cleavage is abolished if Cl- efflux is prevented by using NaCl to raise extracellular osmolarity or by Cl- channel blockers, even when apoptosis is initiated by other agents (staurosporine, anti-Fas antibody), In these conditions, all the apoptosis hallmarks investigated remain detectable, including the cleavage of ICAD/DFF-45. In vitro assays with lysates of cells in which Cl- efflux is blocked confirm the lack of internucleosomal DNA degradation, These findings establish that neither caspase activation nor ICAD/DFF-45 processing per se is sufficient to induce oligonucleosomal DNA fragmentation and that high molecular weight DNA degradation and chromatin condensation appear independently of it, Finally, they suggest that Cl- efflux is a necessary cofactor that intervenes specifically in the activation of the DFF endonuclease.-Rasola, A., Farahi Far, D., Hofman, P., Rossi, B. Lack of internucleosomal DNA fragmentation is related to Cl- efflux impairment in hematopoietic cell apoptosis.	Fac Med, Inserm U364, Unite Rech Immunol Cellulaire & Mol, F-06107 Nice 2, France; Hop Louis Pasteur, Anat Pathol Lab, F-06002 Nice 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice	Rossi, B (corresponding author), Fac Med, Inserm U364, Unite Rech Immunol Cellulaire & Mol, Ave Valombrose, F-06107 Nice 2, France.	1anteri@unice.fr	Hofman, Paul/P-7654-2018	Hofman, Paul/0000-0003-0431-9353; Rasola, Andrea/0000-0003-4522-3008				Benson RSP, 1996, AM J PHYSIOL-CELL PH, V270, pC1190, DOI 10.1152/ajpcell.1996.270.4.C1190; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; Castedo M, 1996, J IMMUNOL, V157, P512; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Dallaporta B, 1998, J IMMUNOL, V160, P5605; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GALIETTA LJV, 1991, BIOCHEM BIOPH RES CO, V179, P1155, DOI 10.1016/0006-291X(91)91692-6; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LUKACS GL, 1991, FEBS LETT, V288, P17, DOI 10.1016/0014-5793(91)80992-C; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; McCarthy JV, 1997, CELL DEATH DIFFER, V4, P756, DOI 10.1038/sj.cdd.4400296; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; RASOLA A, 1992, BIOCHIM BIOPHYS ACTA, V1139, P319, DOI 10.1016/0925-4439(92)90108-Y; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Walker PR, 1997, BIOCHEM CELL BIOL, V75, P287, DOI 10.1139/bcb-75-4-287; Wyllie A, 1998, NATURE, V391, P20, DOI 10.1038/34040; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	43	45	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1711	1723		10.1096/fasebj.13.13.1711	http://dx.doi.org/10.1096/fasebj.13.13.1711			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506574				2022-12-28	WOS:000083063400006
J	Suttner, DM; Dennery, PA				Suttner, DM; Dennery, PA			Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron	FASEB JOURNAL			English	Article						heme; hyperoxia; doxycycline; carbon monoxide; bilirubin	FIBROBLAST GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; HEME OXYGENASE GENE; CARBON-MONOXIDE; OXIDANT STRESS; MESSENGER-RNA; BIOLOGICAL-SYSTEMS; ENDOTHELIAL-CELLS; GUANYLYL CYCLASE; EPITHELIAL-CELLS	It is often postulated that the cytoprotective nature of heme oxygenase (HO-1) explains the inducible nature of this enzyme, However, the mechanisms by which protection occurs are not verified by systematic evaluation of the physiological effects of HO. To explain how induction of HO-1 results in protection against oxygen toxicity, hamster fibroblasts (HA-1) were stably transfected with a tetracycline response plasmid containing the full-length rat HO-1 cDNA construct to allow for regulation of gene expression by varying concentrations of doxycycline (Dox), Transfected cells were exposed to hyperoxia (95% O-2/5% CO2) for 24 h and several markers of oxidative injury were measured. With varying concentrations of Dox, HO activity was regulated between 3- and 17-fold. Despite cytoprotection with low (less than fivefold) HO activity, high levels of HO-1 expression (greater than 15-fold) were associated with significant oxygen cytotoxicity. Levels of non-heme reactive iron correlated with cellular injury in hyperoxia whereas lower levels of heme were associated with cytoprotection, Cellular levels of cyclic GMP and bilirubin were not significantly altered by modification of HO activity, precluding a substantial role for activation of guanylate cyclase by carbon monoxide or for accumulation of bile pigments in the physiological consequences of HO-1 overexpression. Inhibition of HO activity or chelation of cellular iron prior to hyperoxic exposure decreased reactive iron levels in the samples and significantly reduced oxygen toxicity, We conclude that there is a beneficial threshold of HO-1 overexpression related to the accumulation of reactive iron released in the degradation of heme. Therefore, despite the ready induction of HO-1 in oxidant stress, accumulation of reactive iron formed makes it unlikely that exaggerated expression of HO-1 is a cytoprotective response..	Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA	Stanford University	Dennery, PA (corresponding author), Stanford Univ, Sch Med, Dept Pediat, 750 Welch Rd 315, Palo Alto, CA 94304 USA.		Dennery, Phyllis/GQG-9113-2022		NHLBI NIH HHS [HL25701] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; APPLEGATE LA, 1991, CANCER RES, V51, P974; BALLA G, 1992, J BIOL CHEM, V267, P18148; Bloch KD, 1997, AM J PHYSIOL-LUNG C, V272, pL400, DOI 10.1152/ajplung.1997.272.3.L400; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Coceani F, 1996, BRIT J PHARMACOL, V118, P1689, DOI 10.1111/j.1476-5381.1996.tb15593.x; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dennery PA, 1996, AM J PHYSIOL-LUNG C, V271, pL672, DOI 10.1152/ajplung.1996.271.4.L672; EISENSTEIN RS, 1990, ENZYME, V44, P42, DOI 10.1159/000468746; EVANS PJ, 1994, METHOD ENZYMOL, V233, P82; EWING JF, 1992, J NEUROCHEM, V58, P1140, DOI 10.1111/j.1471-4159.1992.tb09373.x; FERREIRA GC, 1995, BIOCHEM BIOPH RES CO, V214, P875, DOI 10.1006/bbrc.1995.2368; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; GLADSTONE IM, 1994, PEDIATRICS, V93, P764; GUTTERIDGE JM, 1982, BIOCHEM J, V206, P625; GUTTERIDGE JMC, 1994, THORAX, V49, P707, DOI 10.1136/thx.49.7.707; GUTTERIDGE JMC, 1981, BIOCHEM J, V199, P263, DOI 10.1042/bj1990263; Gutteridge JMC, 1996, BIOCHEM BIOPH RES CO, V229, P806, DOI 10.1006/bbrc.1996.1884; Hsu PI, 1997, ANTICANCER RES, V17, P2803; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; Inoue Y, 1996, AM J PATHOL, V149, P2037; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Liebler JM, 1997, GROWTH FACTORS, V14, P25, DOI 10.3109/08977199709021508; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; Madden SL, 1996, CANCER RES, V56, P5384; McDonagh AF, 1998, MONATSH CHEM, V129, P649, DOI 10.1007/PL00013473; NUTTER LM, 1994, J LAB CLIN MED, V123, P506; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; RAHMAN IU, 1991, AM J PHYSIOL, V260, pL412, DOI 10.1152/ajplung.1991.260.6.L412; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Ryan TP, 1997, FREE RADICAL BIO MED, V22, P901, DOI 10.1016/S0891-5849(96)00483-2; SCHACTER E, 1994, FREE RADICAL BIO MED, V17, P429; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUTTNER DM, 1999, AM J PHYSIOL, V276, P463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaillant P, 1996, Monaldi Arch Chest Dis, V51, P145; VARSILA E, 1995, ACTA PAEDIATR, V84, P1296, DOI 10.1111/j.1651-2227.1995.tb13552.x; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VIGNE P, 1995, BIOCHEM BIOPH RES CO, V214, P1, DOI 10.1006/bbrc.1995.2248; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; Willis D., 1995, Inflammation Research, V44, pS218, DOI 10.1007/BF01778342; WRIGHT JR, 1981, ARCH BIOCHEM BIOPHYS, V206, P296, DOI 10.1016/0003-9861(81)90095-3; Yee EL, 1996, AM J PHYSIOL-LUNG C, V271, pL512, DOI 10.1152/ajplung.1996.271.4.L512; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; ZAIDI A, 1995, EUR J PHARM-MOLEC PH, V290, P133, DOI 10.1016/0922-4106(95)90025-X; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140, DOI 10.1164/ajrccm.156.4.96-08056	62	338	350	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1800	1809		10.1096/fasebj.13.13.1800	http://dx.doi.org/10.1096/fasebj.13.13.1800			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506583				2022-12-28	WOS:000083063400015
J	Cheng, WH; Fu, YX; Porres, JM; Ross, DA; Lei, XG				Cheng, WH; Fu, YX; Porres, JM; Ross, DA; Lei, XG			Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein	FASEB JOURNAL			English	Article						F-2-isoprostanes; carbonyl; knockout; antioxidation; SOD	RADICAL-CATALYZED MECHANISM; CU/ZN-SUPEROXIDE-DISMUTASE; PARAQUAT RESISTANCE; HYDROGEN-PEROXIDE; TRANSGENIC MICE; DEFICIENT RATS; LIVER NECROSIS; VITAMIN-E; STRESS; TOXICITY	Since Our prior work indicated that Se-dependent cellular glutathione peroxidase (GPX1) was necessary for protection against paraquat lethality, the present studies were to elucidate the biochemical mechanisms related to that protection. Four groups of mice [Se-deficient or -adequate GPX1 knockout and wild-type (WT)] were injected (i.p.) with 50 mg paraquat/kg body weight and tissues were collected 0, 0.5, 1, 2, 3, or 4 h after the injection. Whereas the ratios of NADPH/NADP and NADH/NAD in lung were reduced by 50-70% only 0.5 h after the injection in all groups, these two ratios in liver of the Se-adequate WT were significantly higher than those of the three GPX1 knockout or deficient groups 2-4 h after the injection. The paraquat-induced pulmonary lipid peroxidation and hepatic protein oxidation, measured as F-2-isoprostanes and carbonyl contents, respectively, peaked at 1 h in these three groups. No such oxidative events were shown in any tissue of the Se-adequate WT throughout the time course. Whereas the F-2-isoprostane formation was accelerated by both GPX1 knockout and Se deficiency in liver, it was not significantly elevated by the paraquat treatment in brain of any group. The paraquat injection also resulted in temporal changes in lung GPX activity and GPX1 protein in the Se-adequate WT, and significant reductions in lung total SOD activity in the GPX1 knockout or deficient groups. In conclusion, GPX1 plays a critical role in maintaining the redox status of mice under acute oxidative stress, and protects against paraquat-induced oxidative destruction of lipids and protein in vivo. These protections of GPX1 seem to be inducible and coordinated with those of other antioxidant enzymes.	Cornell Univ, Dept Anim Sci, Ithaca, NY 14853 USA	Cornell University	Lei, XG (corresponding author), Cornell Univ, Dept Anim Sci, 252 Morrison Hall, Ithaca, NY 14853 USA.		FOULQUIE, JESUS MARIA PORRES/B-6442-2018	FOULQUIE, JESUS MARIA PORRES/0000-0001-5657-0764; fu, yang-xin/0000-0001-8441-6617	NIDDK NIH HHS [DK53018, R01 DK053018] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMSTAD P, 1994, J BIOL CHEM, V269, P1606; AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BEHNE D, 1983, J NUTR, V113, P456, DOI 10.1093/jn/113.2.456; Benzie IFF, 1996, INT J FOOD SCI NUTR, V47, P233, DOI 10.3109/09637489609012586; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1995, HEPATOLOGY, V21, P561; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; CAGEN SZ, 1977, TOXICOL APPL PHARM, V40, P193, DOI 10.1016/0041-008X(77)90090-4; Cheng WH, 1998, BIOFACTORS, V7, P311, DOI 10.1002/biof.5520070403; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Cheng WH, 1998, J NUTR, V128, P1070, DOI 10.1093/jn/128.7.1070; COWAN DB, 1993, J BIOL CHEM, V268, P26904; Davies DS, 1977, P EUR SOC TOXICOL, V18, P21; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; Garberg P, 1996, CHEM-BIOL INTERACT, V99, P165, DOI 10.1016/0009-2797(95)03667-9; GOLDSTEIN BD, 1979, BIOCHEM PHARMACOL, V28, P27, DOI 10.1016/0006-2952(79)90265-X; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; KALHORN TF, 1985, ANAL BIOCHEM, V151, P343, DOI 10.1016/0003-2697(85)90185-X; KEELING PL, 1982, BIOCHEM PHARMACOL, V31, P3243, DOI 10.1016/0006-2952(82)90557-3; KELNER MJ, 1990, FREE RADICAL BIO MED, V9, P149, DOI 10.1016/0891-5849(90)90118-3; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KRALL J, 1991, ARCH BIOCHEM BIOPHYS, V286, P311, DOI 10.1016/0003-9861(91)90045-K; Kunapuli P, 1997, J BIOL CHEM, V272, P27147, DOI 10.1074/jbc.272.43.27147; LAWRENCE RA, 1974, EXP EYE RES, V18, P563, DOI 10.1016/0014-4835(74)90062-1; Levander OA, 1996, J NUTR, V126, pS2427; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MASER RL, 1994, J BIOL CHEM, V269, P27066; MERCURIO SD, 1986, J NUTR, V116, P1726, DOI 10.1093/jn/116.9.1726; MERCURIO SD, 1986, BIOCHEM PHARMACOL, V35, P4505, DOI 10.1016/0006-2952(86)90771-9; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; NEUZIL J, 1993, BIOCHEM J, V293, P601; PeledKamar M, 1997, P NATL ACAD SCI USA, V94, P3883, DOI 10.1073/pnas.94.8.3883; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; SHEN QC, 1993, J BIOL CHEM, V268, P11463; SINET PM, 1981, ARCH BIOCHEM BIOPHYS, V212, P411, DOI 10.1016/0003-9861(81)90382-9; SMITH LL, 1987, HUM TOXICOL, V6, P31, DOI 10.1177/096032718700600105; Sunde R. A., 1994, Selenium in biology and human health., P45; Ukeda H, 1997, ANAL BIOCHEM, V251, P206, DOI 10.1006/abio.1997.2273; WINTER ML, 1991, J BIOL CHEM, V266, P14446; WITSCHI H, 1977, CHEM-BIOL INTERACT, V19, P143, DOI 10.1016/0009-2797(77)90027-8	56	102	103	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1467	1475		10.1096/fasebj.13.11.1467	http://dx.doi.org/10.1096/fasebj.13.11.1467			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428770				2022-12-28	WOS:000082019100018
J	D'Adamo, MC; Imbrici, P; Sponcichetti, F; Pessia, M				D'Adamo, MC; Imbrici, P; Sponcichetti, F; Pessia, M			Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K+ channel function	FASEB JOURNAL			English	Article						potassium channel gating; hKv1.1; hKv1.2; myokymia; cerebellum	POTASSIUM-CHANNEL; MYOKYMIA SYNDROME; XENOPUS-OOCYTES; BINDING-SITE; SHAKER; KV1.1; TERMINALS; PORE; CHANNELOPATHIES; LOCALIZATION	Episodic ataxia type-1 syndrome (EA-1) is an autosomal dominant neurological disorder that manifests itself during infancy and results from point mutations in the voltage-gated potassium channel gene hKv1.1. The hallmark of the disease is continuous myokymia and episodic attacks of spastic contractions of the skeletal muscles, which cause permanent disability. Coexpression of hKv1.1 and hKv1.2 subunits produces heteromeric potassium channels with biophysical and pharmacological properties intermediate between the respective homomers. By using tandemly linked subunits, we demonstrate that hKv1.1 subunits bearing the EA-1 mutations V408A and E325D combine with hKv1.2 to produce channels with altered kinetics of activation, deactivation, C-type inactivation, and voltage dependence. Moreover, hKv1.1V408A single-channel analysis reveals a similar to threefold reduction of the mean open duration of the channel compared with the wild-type, and this mutation alters the open-state stability of both homomeric and heteromeric channels. The results demonstrate that human Kv1.2 and Kv1.1 subunits coassemble to form a novel channel with distinct gating properties that are altered profoundly by EA-1 mutations, thus uncovering novel physiopathogenetic mechanisms of episodic ataxia type-1 myokymia syndrome.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Pharmacol & Mol Pathol, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Pessia, M (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Pharmacol & Mol Pathol, I-66030 Santa Maria Imbaro, Chieti, Italy.		imbrici, paola/J-6855-2018; D'Adamo, Maria Cristina/AAD-3701-2022	imbrici, paola/0000-0001-9140-5350; D'Adamo, Maria Cristina/0000-0002-6758-6064; Pessia, Mauro/0000-0002-2857-6795	Telethon [1083] Funding Source: Medline	Telethon(Fondazione Telethon)		Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BROWNE DL, 1995, HUM MOL GENET, V4, P1671, DOI 10.1093/hmg/4.9.1671; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BRUNT ERP, 1990, BRAIN, V113, P1361, DOI 10.1093/brain/113.5.1361; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; CHRISTIE MJ, 1990, NEURON, V2, P405; Comu S, 1996, ANN NEUROL, V40, P684, DOI 10.1002/ana.410400422; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; D'Adamo MC, 1998, EMBO J, V17, P1200, DOI 10.1093/emboj/17.5.1200; Gancher S T, 1986, Mov Disord, V1, P239, DOI 10.1002/mds.870010404; Gordon N, 1998, BRAIN DEV-JPN, V20, P9, DOI 10.1016/S0387-7604(97)00086-7; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1992, IONIC CHANNELS EXCIT; HOPKINS WF, 1994, PFLUG ARCH EUR J PHY, V428, P382, DOI 10.1007/BF00724522; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KORN H, 1980, P NATL ACAD SCI-BIOL, V77, P6244, DOI 10.1073/pnas.77.10.6244; Laube G, 1996, MOL BRAIN RES, V42, P51, DOI 10.1016/S0169-328X(96)00120-9; LITT M, 1994, AM J HUM GENET, V55, P702; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MCNAMARA NMC, 1993, NEUROSCIENCE, V57, P1039, DOI 10.1016/0306-4522(93)90047-J; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; Scheffer H, 1998, HUM GENET, V102, P464, DOI 10.1007/s004390050722; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Southan AP, 1998, J NEUROSCI, V18, P948; VANDYKE DH, 1975, J NEUROL SCI, V25, P109, DOI 10.1016/0022-510X(75)90191-4; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Zerr P, 1998, FEBS LETT, V431, P461, DOI 10.1016/S0014-5793(98)00814-X; Zerr P, 1998, J NEUROSCI, V18, P2842; Zhou L, 1998, J NEUROSCI, V18, P7200	37	62	63	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1335	1345		10.1096/fasebj.13.11.1335	http://dx.doi.org/10.1096/fasebj.13.11.1335			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428758				2022-12-28	WOS:000082019100006
J	Brigelius-Flohe, R; Traber, MG				Brigelius-Flohe, R; Traber, MG			Vitamin E: function and metabolism	FASEB JOURNAL			English	Review							ALPHA-TOCOPHERYL ACETATE; PROTEIN-KINASE-C; LOW-DENSITY-LIPOPROTEIN; CHAIN-BREAKING ANTIOXIDANT; STRESS IN-VIVO; E-DEFICIENCY; GAMMA-TOCOPHEROL; HUMAN-PLASMA; RESORPTION-GESTATION; LIPID-PEROXIDATION	Although vitamin E has been known as an essential nutrient for reproduction since 1922, we are far from understanding the mechanisms of its physiological functions. Vitamin E is the term for a group of tocopherols and tocotrienols, of which alpha-tocopherol has the highest biological activity. Due to the potent antioxidant properties of tocopherols, the impact of alpha-tocopherol in the prevention of chronic diseases believed to be associated with oxidative stress has often been studied, and beneficial effects have been demonstrated, Recent observations that the alpha-tocopherol transfer protein in the liver specifically sorts out RRR-alpha-tocopherol from all incoming tocopherols for incorporation into plasma Lipoproteins, and that alpha-tocopherol has signaling functions in vascular smooth muscle cells that cannot be exerted by other forms of tocopherol with similar antioxidative properties, have raised interest in the roles of vitamin E beyond its antioxidative function, Also, gamma-tocopherol might have functions apart from being an antioxidant, It is a nucleophile able to trap electrophilic mutagens in lipophilic compartments and generates a metabolite that facilitates natriuresis, The metabolism of vitamin E is equally unclear, Excess a-tocopherol is converted into alpha-CEHC and excreted in the urine, Other tocopherols, like gamma- and delta-tocopherol, are almost quantitatively degraded and excreted in the urine as the corresponding CEHCs. All rac alpha-tocopherol compared to RRR-alpha-tocopherol is preferentially degraded to alpha-CEHC. Thus, there must be a specific, molecular role of RRR-alpha-tocopherol that is regulated by a system that sorts, distributes, and degrades the different forms of vitamin E, but has not yet been identified, In this article we try to summarize current knowledge on the function of vitamin E, with emphasis on its antioxidant vs. other properties, the preference of the organism for RRR-alpha-tocopherol, and its metabolism to CEHCs.	German Inst Human Nutr, D-14558 Bergholz Rehbrucke, Germany; Oregon State Univ, Linus Pauling Inst Sci & Med, Dept Nutr & Food Management, Corvallis, OR 97330 USA	Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Oregon State University	Brigelius-Flohe, R (corresponding author), German Inst Human Nutr, Arthur Scheunert Allee 114-116, D-14558 Bergholz Rehbrucke, Germany.	Flohe@www.dife.de	Traber, Maret G./ABI-2511-2020	Traber, Maret G./0000-0002-2892-4024				ACUFF RV, 1994, AM J CLIN NUTR, V60, P397, DOI 10.1093/ajcn/60.3.397; Acuff RV, 1998, AM J CLIN NUTR, V67, P459, DOI 10.1093/ajcn/67.3.459; [Anonymous], 1982, EUR J BIOCHEM, V123, P473; AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; Azzi A, 1998, BIOFACTORS, V7, P3, DOI 10.1002/biof.5520070102; BAKER H, 1986, AM J CLIN NUTR, V43, P382, DOI 10.1093/ajcn/43.3.382; BOSCOBOINIK D, 1991, ARCH BIOCHEM BIOPHYS, V286, P264, DOI 10.1016/0003-9861(91)90039-L; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BRIN MF, 1986, NEUROLOGY, V36, P669, DOI 10.1212/WNL.36.5.669; BUNYAN J, 1961, BRIT J NUTR, V15, P253, DOI 10.1079/BJN19610030; BURCK U, 1981, NEUROPEDIATRICS, V12, P267, DOI 10.1055/s-2008-1059657; BURTON GW, 1983, ARCH BIOCHEM BIOPHYS, V221, P281, DOI 10.1016/0003-9861(83)90145-5; Burton GW, 1998, AM J CLIN NUTR, V67, P669, DOI 10.1093/ajcn/67.4.669; BURTON GW, 1988, LIPIDS, V23, P834, DOI 10.1007/BF02536201; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BURTON GW, 1983, CIBA F SYMP, V101, P4; Cachia O, 1998, J BIOL CHEM, V273, P32801, DOI 10.1074/jbc.273.49.32801; Chan AC, 1998, J NUTR, V128, P1593, DOI 10.1093/jn/128.10.1593; CHAN AC, 1981, AM J CLIN NUTR, V34, P2341, DOI 10.1093/ajcn/34.11.2341; Chan AC, 1998, AKT ERNAHR MED, V23, P1; CHIKU S, 1984, J LIPID RES, V25, P40; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; Cominacini L, 1997, FREE RADICAL BIO MED, V22, P117, DOI 10.1016/S0891-5849(96)00271-7; COONEY RV, 1995, FREE RADICAL BIO MED, V19, P259, DOI 10.1016/0891-5849(95)00019-T; COONEY RV, 1993, P NATL ACAD SCI USA, V90, P1771, DOI 10.1073/pnas.90.5.1771; Davi G, 1997, ARTERIOSCL THROM VAS, V17, P3230, DOI 10.1161/01.ATV.17.11.3230; Delanty N, 1996, BRIT J CLIN PHARMACO, V42, P15, DOI 10.1046/j.1365-2125.1996.03804.x; Devaraj S, 1996, J CLIN INVEST, V98, P756, DOI 10.1172/JCI118848; DIMITROV NV, 1991, AM J CLIN NUTR, V53, P723, DOI 10.1093/ajcn/53.3.723; DREVON CA, 1991, FREE RADICAL RES COM, V14, P229, DOI 10.3109/10715769109088952; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; FARRELL PM, 1977, J CLIN INVEST, V60, P233, DOI 10.1172/JCI108760; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; GILBERT VA, 1983, HORM METAB RES, V15, P320, DOI 10.1055/s-2007-1018709; GOTODA T, 1995, NEW ENGL J MED, V333, P1313, DOI 10.1056/NEJM199511163332003; Ham AJL, 1997, ARCH BIOCHEM BIOPHYS, V339, P157, DOI 10.1006/abbi.1996.9856; HANDELMAN GJ, 1985, J NUTR, V115, P807, DOI 10.1093/jn/115.6.807; HAYASHI T, 1992, BIOCHEM PHARMACOL, V44, P489; Hoglen NC, 1997, CHEM RES TOXICOL, V10, P401, DOI 10.1021/tx960200h; Hosomi A, 1997, FEBS LETT, V409, P105, DOI 10.1016/S0014-5793(97)00499-7; INGOLD KU, 1987, ARCH BIOCHEM BIOPHYS, V259, P224, DOI 10.1016/0003-9861(87)90489-9; INGOLD KU, 1987, LIPIDS, V22, P163, DOI 10.1007/BF02537297; JIALAL I, 1995, ARTERIOSCL THROM VAS, V15, P190, DOI 10.1161/01.ATV.15.2.190; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; Kantoci D, 1997, J PHARMACOL EXP THER, V282, P648; Kayden H J, 1965, Trans Assoc Am Physicians, V78, P334; Kiyose C, 1997, AM J CLIN NUTR, V65, P785, DOI 10.1093/ajcn/65.3.785; KIYOSE C, 1995, LIPIDS, V30, P1015, DOI 10.1007/BF02536286; Klein T, 1997, J PHARMACOL EXP THER, V282, P1658; KOHLSCHUTTER A, 1988, J INHERIT METAB DIS, V11, P149, DOI 10.1007/BF01804221; Kontush A, 1996, J LIPID RES, V37, P1436; Koya D, 1997, J AM SOC NEPHROL, V8, P426; Koya D, 1998, BIOFACTORS, V7, P69, DOI 10.1002/biof.5520070110; KRENDEL DA, 1987, NEUROLOGY, V37, P538, DOI 10.1212/WNL.37.3.538; KUNISAKI M, 1994, DIABETES, V43, P1372, DOI 10.2337/diabetes.43.11.1372; LAPLANTE P, 1984, CAN J NEUROL SCI, V11, P561, DOI 10.1017/S0317167100035046; Larnaout A, 1997, ACTA NEUROPATHOL, V93, P633, DOI 10.1007/s004010050662; Liebler DC, 1996, ANAL BIOCHEM, V236, P27, DOI 10.1006/abio.1996.0127; LIEBLER DC, 1993, CRIT REV TOXICOL, V23, P147, DOI 10.3109/10408449309117115; LOSOWSKY MS, 1967, GUT, V8, P539, DOI 10.1136/gut.8.6.539; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1989, LIPIDS, V24, P721, DOI 10.1007/BF02535211; MAIORINO M, 1999, IN PRESS BIOFACTORS; Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821; MORROW JD, 1994, BBA-LIPID LIPID MET, V1210, P244, DOI 10.1016/0005-2760(94)90128-7; Motoyama T, 1998, J AM COLL CARDIOL, V32, P1672, DOI 10.1016/S0735-1097(98)00447-1; MULLER DPR, 1985, J INHERIT METAB DIS, V8, P88, DOI 10.1007/BF01800666; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; PYKE DD, 1990, ARCH BIOCHEM BIOPHYS, V277, P429, DOI 10.1016/0003-9861(90)90600-4; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SCHONFELD A, 1993, NAHRUNG, V37, P498; Schuelke M, 1999, J PEDIATR-US, V134, P240, DOI 10.1016/S0022-3476(99)70424-5; Schultz M, 1997, METHOD ENZYMOL, V282, P297; SCHULTZ M, 1995, AM J CLIN NUTR, V62, P1527, DOI 10.1093/ajcn/62.6.1527S; SCHWARZ K, 1965, FED PROC, V24, P58; Sheppard Alan J., 1993, P9; Simon E, 1998, ATHEROSCLEROSIS, V138, P375, DOI 10.1016/S0021-9150(98)00039-2; SIMON EJ, 1956, J BIOL CHEM, V221, P797; SIMON EJ, 1956, J BIOL CHEM, V221, P807; SOKOL RJ, 1988, J LAB CLIN MED, V111, P548; SOKOL RJ, 1985, NEW ENGL J MED, V313, P1580, DOI 10.1056/NEJM198512193132505; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STUMPF DA, 1987, NEUROLOGY, V37, P68, DOI 10.1212/WNL.37.1.68; Swanson JE, 1998, FASEB J, V12, pA658; SZCZEKLIK A, 1985, THROMB HAEMOSTASIS, V54, P425; TAPPEL AL, 1962, VITAM HORM, V20, P493, DOI 10.1016/S0083-6729(08)60732-3; Traber MG, 1998, AM J CLIN NUTR, V68, P847, DOI 10.1093/ajcn/68.4.847; Traber MG, 1998, FEBS LETT, V437, P145, DOI 10.1016/S0014-5793(98)01210-1; TRABER MG, 1994, P NATL ACAD SCI USA, V91, P10005, DOI 10.1073/pnas.91.21.10005; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; TRABER MG, 1987, NEW ENGL J MED, V317, P262, DOI 10.1056/NEJM198707303170502; TRABER MG, 1994, ATHEROSCLEROSIS, V108, P27, DOI 10.1016/0021-9150(94)90035-3; Tramer F, 1998, BIOL REPROD, V59, P753, DOI 10.1095/biolreprod59.4.753; TRAN K, 1990, BIOCHIM BIOPHYS ACTA, V1043, P189, DOI 10.1016/0005-2760(90)90295-9; Tran K, 1996, BIOCHEM J, V319, P385, DOI 10.1042/bj3190385; TRAN K, 1994, BBA-LIPID LIPID MET, V1212, P193, DOI 10.1016/0005-2760(94)90253-4; UPSTON JM, 1999, IN PRESS FASEB J, V13; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; Wechter WJ, 1996, P NATL ACAD SCI USA, V93, P6002, DOI 10.1073/pnas.93.12.6002; WEISER H, 1986, INT J VITAM NUTR RES, V56, P45; Weiser H, 1996, J NUTR, V126, P2539, DOI 10.1093/jn/126.10.2539; WEISER H, 1982, INT J VITAM NUTR RES, V52, P351; WEISER H, 1981, INT J VITAM NUTR RES, V51, P100; WU SH, 1973, BIOL REPROD, V8, P625, DOI 10.1093/biolreprod/8.5.625	112	1120	1207	5	210	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1145	1155		10.1096/fasebj.13.10.1145	http://dx.doi.org/10.1096/fasebj.13.10.1145			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385606	Bronze			2022-12-28	WOS:000081264800004
J	Desrumaux, C; Deckert, V; Athias, A; Masson, D; Lizard, G; Palleau, V; Gambert, P; Lagrost, L				Desrumaux, C; Deckert, V; Athias, A; Masson, D; Lizard, G; Palleau, V; Gambert, P; Lagrost, L			Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells	FASEB JOURNAL			English	Article						acetylcholine; aorta; lipid transfer protein; oxidized LDL; vitamin E	LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-FED RABBITS; DEPENDENT ARTERIAL RELAXATION; ESTER TRANSFER PROTEIN; VITAMIN-E; LIPID-PEROXIDATION; OXIDIZED LDL; NITRIC-OXIDE; IN-VITRO; INHIBITION	alpha-tocopherol, the most potent antioxidant form of vitamin E, is mainly bound to lipoproteins in plasma and its incorporation into the vascular wall can prevent the endothelium dysfunction at an early stage of atherogenesis. In the present study, the plasma phospholipid transfer protein (PLTP) was shown to promote the net mass transfer of alpha-tocopherol from high density lipoproteins (HDL) and alpha-tocopherol-albumin complexes toward alpha-tocopherol-depleted, oxidized low density lipoproteins (LDL). The facilitated transfer reaction of alpha-tocopherol could be blocked by specific anti-PLTP antibodies. These observations indicate that PLTP may restore the antioxidant potential of plasma LDL at an early stage of the oxidation cascade that subsequently leads to cellular damages. In addition, the present study demonstrated that the PLTP-mediated net mass transfer of alpha-tocopherol can constitute a new mechanism for the incorporation of alpha-tocopherol into the vascular wall in addition to the previously recognized LDL receptor and lipoprotein lipase pathways. In ex vivo studies on rabbit aortic segments, the impairment of the endothelium-dependent arterial relaxation induced by oxidized LDL was found to be counteracted by a pretreatment with purified PLTP and alpha-tocopherol-albumin complexes, and both the maximal response and the sensitivity to acetylcholine were significantly improved. We conclude that PLTP, by supplying oxidized LDL and endothelial cells with alpha-tocopherol through a net mass transfer reaction may play at least two distinct beneficial roles in preventing endothelium damage, i.e., the antioxidant protection of LDL and the preservation of a normal relaxing function of vascular endothelial cells.	Hop Bocage, Lab Biochim Lipoprot, INSERM U498, F-21034 Dijon, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lagrost, L (corresponding author), Hop Bocage, Lab Biochim Lipoprot, INSERM U498, BP 1542, F-21034 Dijon, France.		MASSON, David/AAC-8896-2022; Desrumaux, Catherine/O-1925-2018; Lizard, Gerard/B-2439-2012; Masson, David/R-6633-2019; MASSON, David/R-4557-2017	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; DECKERT, Valerie/0000-0001-5728-1710				ANDERSSON TLG, 1994, ATHEROSCLEROSIS, V111, P39, DOI 10.1016/0021-9150(94)90189-9; AZZI A, 1992, LIPID SOLUBLE ANTIOX, P122; BEHRENS WA, 1982, AM J CLIN NUTR, V35, P691, DOI 10.1093/ajcn/35.4.691; BOSCOBOINIK D, 1991, J CLIN INVEST, V98, P386; CHATELAIN E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P83, DOI 10.1016/0167-4889(93)90181-N; Chow SE, 1998, FASEB J, V12, P823, DOI 10.1096/fasebj.12.10.823; DECKERT V, 1994, BRIT J PHARMACOL, V112, P939, DOI 10.1111/j.1476-5381.1994.tb13171.x; Deckert V, 1998, ARTERIOSCL THROM VAS, V18, P1054, DOI 10.1161/01.ATV.18.7.1054; Deckert V, 1997, CIRCULATION, V95, P723, DOI 10.1161/01.CIR.95.3.723; Desrumaux C, 1999, ARTERIOSCL THROM VAS, V19, P266, DOI 10.1161/01.ATV.19.2.266; ESTEBAN JM, 1991, MODERN PATHOL, V4, P53; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FARUQI R, 1994, J CLIN INVEST, V94, P592, DOI 10.1172/JCI117374; FRYER MJ, 1995, REDOX REP, V1, P159, DOI 10.1080/13510002.1995.11746975; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLE J, 1994, HYPERTENSION, V23, P556, DOI 10.1161/01.HYP.23.5.556; Goti D, 1998, BIOCHEM J, V332, P57, DOI 10.1042/bj3320057; GRANOT E, 1988, LIPIDS, V23, P17, DOI 10.1007/BF02535298; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; HENNIG B, 1987, NUTR RES, V7, P1253, DOI 10.1016/S0271-5317(87)80085-4; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; JESSUP W, 1990, BIOCHEM J, V265, P399, DOI 10.1042/bj2650399; KAYDEN HJ, 1993, J LIPID RES, V34, P343; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; Keaney JF, 1996, J CLIN INVEST, V98, P386, DOI 10.1172/JCI118804; KOSTNER GM, 1995, BIOCHEM J, V305, P659, DOI 10.1042/bj3050659; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAGROST L, 1994, J LIPID RES, V35, P825; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P429, DOI 10.1161/01.ATV.17.3.429; MATSUDA Y, 1993, CIRC RES, V72, P1103, DOI 10.1161/01.RES.72.5.1103; MCCORMICK EC, 1960, J LIPID RES, V1, P221; MILLER KW, 1985, ANAL BIOCHEM, V145, P21, DOI 10.1016/0003-2697(85)90321-5; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Nishida HI, 1997, J BIOL CHEM, V272, P6959, DOI 10.1074/jbc.272.11.6959; OGIHARA T, 1988, CLIN CHIM ACTA, V174, P299, DOI 10.1016/0009-8981(88)90056-3; OHTA Y, 1997, AM J PHYSIOL, V273, pH1215; Rao R, 1997, BIOCHEMISTRY-US, V36, P3645, DOI 10.1021/bi962776b; REAVEN PD, 1995, ENDOCRINOLOGIST, V5, P44, DOI 10.1097/00019616-199501000-00007; ROMANCHIK JE, 1995, J NUTR, V125, P2610; SATO Y, 1991, FEBS LETT, V288, P41, DOI 10.1016/0014-5793(91)80999-J; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; STEWARTLEE AL, 1994, ARTERIOSCLER THROMB, V14, P494, DOI 10.1161/01.ATV.14.3.494; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TAKAHASHI Y, 1977, J NUTR SCI VITAMINOL, V23, P201; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TRABER MG, 1992, LIPIDS, V27, P657, DOI 10.1007/BF02536020; TRABER MG, 1984, AM J CLIN NUTR, V40, P747, DOI 10.1093/ajcn/40.4.747; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; YOKOYAMA M, 1990, BIOCHEM BIOPH RES CO, V168, P301, DOI 10.1016/0006-291X(90)91708-Z	60	74	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					883	892		10.1096/fasebj.13.8.883	http://dx.doi.org/10.1096/fasebj.13.8.883			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224231				2022-12-28	WOS:000080372500011
J	Ram, JL; Muller, CT; Beckmann, M; Hardege, JD				Ram, JL; Muller, CT; Beckmann, M; Hardege, JD			The spawning pheromone cysteine-glutathione disulfide ('nereithione') arouses a multicomponent nuptial behavior and electrophysiological activity in Nereis succinea males	FASEB JOURNAL			English	Article						cysteine-glutathione disulfide; pheromone; spawning behavior; sperm release	CILIATE EUPLOTES-RAIKOVI; OXIDIZED GLUTATHIONE; MONOCLONAL-ANTIBODIES; PHYSIOLOGICAL SLEEP; HYDRA; BINDING; ACID; CHEMORECEPTION; PURIFICATION; DEPRESS	The pheromone nereithione (cysteine-glutathione disulfide), which is released by swimming females of the polychaete Nereis succinea to activate spawning behavior of N. succinea males, has recently been identified and synthesized. Nereithione activates sperm release at less than 10(-6) M, one to two orders of magnitude less than oxidized glutathione or any other glutathione derivative tested. The glutathione fragment gamma-glu-cys inhibited sperm release. Nereithione aroused three components of the male nuptial behavior: circling, sperm release, and accelerated swimming. Electrophysiological activity elicited by nereithione near the sperm release site consisted of initial large spikes, cyclic bursting activity, and small spikes lasting up to a minute and was dose dependent, rapid, reversible, and repeatable. This preparation is an excellent model system for characterizing the receptors and functions of a marine pheromone.	Wayne State Univ, Dept Physiol, Gordon H Scott Hall Basic Med Sci, Detroit, MI 48201 USA; Univ Wales, Cardiff CF1 3TL, S Glam, Wales	Wayne State University; Cardiff University	Ram, JL (corresponding author), Wayne State Univ, Dept Physiol, Gordon H Scott Hall Basic Med Sci, 540 E Canfield Ave, Detroit, MI 48201 USA.		Beckmann, Manfred/AAX-9979-2021; Müller, Carsten T/A-7114-2010	Müller, Carsten T/0000-0003-0455-7132				BELLIS SL, 1991, BIOCHIM BIOPHYS ACTA, V1061, P89, DOI 10.1016/0005-2736(91)90272-A; BOILLYMARER Y, 1978, J EXP ZOOL, V205, P119, DOI 10.1002/jez.1402050114; BOILLYMARER Y, 1980, J EXP ZOOL, V213, P33, DOI 10.1002/jez.1402130106; COBB MH, 1982, MOL PHARMACOL, V21, P629; GROSVENOR W, 1992, BIOCHIM BIOPHYS ACTA, V1117, P120, DOI 10.1016/0304-4165(92)90068-6; HANAI K, 1986, COMP BIOCHEM PHYS A, V83, P313; HARDEGE JD, 1990, MAR BIOL, V104, P291, DOI 10.1007/BF01313270; HARDEGE JD, 1998, IN PRESS ECOSICNECE, V5; HCARDEGE JD, 1997, POLYCHAETE RES, V17, P18; HONDA K, 1994, BRAIN RES, V636, P253, DOI 10.1016/0006-8993(94)91024-3; HONDA K, 1991, SLEEP RES A, V20, P139; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; Kimura M, 1998, BRAIN RES BULL, V45, P545, DOI 10.1016/S0361-9230(97)00441-3; KOMODA Y, 1990, CHEM PHARM BULL, V38, P2057; LACH H, 1986, ACTA BIOL HUNG, V37, P93; LENHOFF HM, 1961, NATURE, V189, P486, DOI 10.1038/189486a0; Lillie FR, 1913, BIOL BULL-US, V24, P147, DOI 10.2307/1535996; OHTA K, 1992, BIOCHIM BIOPHYS ACTA, V1117, P136, DOI 10.1016/0304-4165(92)90071-2; Painter SD, 1998, BIOL BULL-US, V194, P120, DOI 10.2307/1543042; RAFFIONI S, 1987, EXP CELL RES, V172, P417, DOI 10.1016/0014-4827(87)90399-5; RAFFIONI S, 1988, J BIOL CHEM, V263, P18152; RAFFIONI S, 1989, BIOCHEMISTRY-US, V28, P5250, DOI 10.1021/bi00438a049; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P2071, DOI 10.1073/pnas.89.6.2071; ROELOFS WL, 1995, P NATL ACAD SCI USA, V92, P44, DOI 10.1073/pnas.92.1.44; SAKAGUCHI M, 1991, J COMP PHYSIOL A, V168, P409, DOI 10.1007/BF00199601; STEWART AE, 1992, PROTEIN SCI, V1, P777, DOI 10.1002/pro.5560010609; TOWNSEND G, 1939, THESIS U CHICAGO CHI; Zeeck E, 1998, J CHEM ECOL, V24, P13, DOI 10.1023/A:1022328610423; Zeeck E, 1996, NATURE, V382, P214, DOI 10.1038/382214a0; Zeeck E, 1998, CHEMOECOLOGY, V8, P33, DOI 10.1007/PL00001801	30	38	38	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					945	952		10.1096/fasebj.13.8.945	http://dx.doi.org/10.1096/fasebj.13.8.945			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224237				2022-12-28	WOS:000080372500017
J	Meynell, HM; Thomas, NW; James, PS; Holland, J; Taussig, MJ; Nicoletti, C				Meynell, HM; Thomas, NW; James, PS; Holland, J; Taussig, MJ; Nicoletti, C			Up-regulation of microsphere transport across the follicle-associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a	FASEB JOURNAL			English	Article						M cell; enterocyte; mucosal immunity; FAE; antigen delivery	M-CELLS; IMMUNE-RESPONSES; INFECTION; ANTIGEN; BACTERIUM; MICE	Transport of antigens through the follicle-associated epithelium (FAE) of Peyer's patch (PP) is the critical first step in the induction of mucosal immune responses. We have previously described that short-term exposure to Streptococcus pneumoniae R36a induced dramatic morphological alterations of the FAE in rabbit PP. These results prompted us to investigate whether the pneumococci-induced modifications were accompanied by enhanced ability of the FAE to transport antigens. We addressed this problem by evaluating the ability of the FAE to bind, internalize, and transport fluorescent polystyrene microparticles, highly specific to rabbit M cells, after exposure to S. pneumoniae. Quantitative study revealed a marked increase in the number of microspheres in PP tissues exposed to S. pneumoniae compared to tissues exposed to either phosphate-buffered saline or Escherichia coli DH5 alpha as controls. No sign of bacterially induced damage to the epithelial barrier was observed. Further confocal microscopy analysis of the FAE surface showed that a significant increase in the number of cells that showed both morphological and functional features of M cells took place within pneumococci-treated PP tissues. These data provide the first direct evidence that the FAE-specific antigen sampling function may be manipulated to improve antigen and drug delivery to the intestinal immune system.	Babraham Inst, Lab Mol Recognit, Cambridge CB2 4AT, England; Babraham Inst, Lab Cell Signaling, Cambridge, England; Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England; Queens Med Ctr, Dept Human Anat & Cell Biol, Nottingham NG7 2UH, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Nottingham; University of Nottingham	Nicoletti, C (corresponding author), Babraham Inst, Lab Mol Recognit, Cambridge CB2 4AT, England.	claudio.nicoletti@bbsrc.ac.uk						Borghesi C, 1996, J PATHOL, V180, P326, DOI 10.1002/(SICI)1096-9896(199611)180:3<326::AID-PATH656>3.0.CO;2-6; Gebert A, 1996, INT REV CYTOL, V167, P91, DOI 10.1016/S0074-7696(08)61346-7; JEPSON MA, 1993, CELL TISSUE RES, V271, P399, DOI 10.1007/BF02913722; JEPSON MA, 1992, HISTOCHEM J, V24, P33, DOI 10.1007/BF01043285; Jepson MA, 1998, TRENDS MICROBIOL, V6, P359, DOI 10.1016/S0966-842X(98)01337-7; Jepson MA, 1993, J DRUG TARGET, V1, P245, DOI 10.3109/10611869308996082; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; LAGRANDERIE M, 1993, VACCINE, V11, P1283, DOI 10.1016/0264-410X(93)90096-G; Madara JL, 1997, SCIENCE, V277, P910, DOI 10.1126/science.277.5328.910; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NEUTRA MR, 1993, J CELL SCI, P209; REGOLI M, 1995, ANN ANAT, V177, P119, DOI 10.1016/S0940-9602(11)80057-9; REGOLI M, 1994, ANAT REC, V239, P47, DOI 10.1002/ar.1092390106; Robinson K, 1997, NAT BIOTECHNOL, V15, P653, DOI 10.1038/nbt0797-653; Sansonetti PJ, 1996, INFECT IMMUN, V64, P2752, DOI 10.1128/IAI.64.7.2752-2764.1996; SAVIDGE TC, 1991, AM J PATHOL, V139, P177; SMITH MW, 1987, AM J PATHOL, V128, P385; SMITH MW, 1988, HISTOCHEM J, V20, P443, DOI 10.1007/BF01002430	20	67	68	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					611	619		10.1096/fasebj.13.6.611	http://dx.doi.org/10.1096/fasebj.13.6.611			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094922				2022-12-28	WOS:000079527200003
J	Cursio, R; Gugenheim, J; Ricci, JE; Crenesse, D; Rostagno, P; Maulon, L; Saint-Paul, MC; Ferrua, B; Auberger, P				Cursio, R; Gugenheim, J; Ricci, JE; Crenesse, D; Rostagno, P; Maulon, L; Saint-Paul, MC; Ferrua, B; Auberger, P			A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis	FASEB JOURNAL			English	Article						caspases; tumor necrosis factor; aminotransferases; DNA fragmentation	INTERLEUKIN-1-BETA CONVERTING-ENZYME; NECROSIS-FACTOR RECEPTOR; FAS-MEDIATED APOPTOSIS; ICE/CED-3 PROTEASE; CELL-DEATH; CPP32-LIKE PROTEASES; HEPATOCYTE APOPTOSIS; CD95 FAS/APO-1; TNF RECEPTOR; ICE-LIKE	Apoptosis is activated during the early phase of reperfusion after liver ischemia and after Liver transplantation in animals. However, the molecular basis of ischemia-induced cell death remains poorly understood. In this study we show that hepatocytes from ischemic liver lobes undergo apoptosis after reperfusion. In vivo pretreatment of rats with a specific inhibitor of caspases abrogates the apoptotic response in ischemic liver lobes. Inhibition of apoptosis can be accounted for by total inhibition of caspase activation as assessed in an enzymatic assay and by specific affinity labeling. Treatment with a caspase inhibitor fully protects rats from death induced by ischemia/reperfusion. These findings indicate that liver injury after ischemia/reperfusion can be prevented by inhibition of caspases. Thus, caspase inhibitors may have important therapeutic implications in liver ischemic diseases and after liver transplantation.	Fac Med, INSERM, CJF 96 05, F-06107 Nice, France; Univ Nice Sophia Antipolis, Fac Med, Lab Rech Chirurg, F-06107 Nice 2, France; Univ Nice Sophia Antipolis, Fac Med, Parasitol Lab, F-06107 Nice 2, France; Ctr Antoine Lacassagne, Lab Cytometrie, F-06189 Nice 2, France; Hop Louis Pasteur, Fac Med, Serv Anat Pathol, F-06000 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; CHU Nice	Auberger, P (corresponding author), Fac Med, INSERM, CJF 96 05, Ave Valombrose, F-06107 Nice, France.	auberger@unice.fr	Ricci, Jean Ehrland/I-7117-2016; RICCI, Jean Ehrland/AAS-4379-2020; AUBERGER, Patrick/G-1491-2013	Ricci, Jean Ehrland/0000-0003-1585-8117; RICCI, Jean Ehrland/0000-0003-1585-8117; AUBERGER, Patrick/0000-0002-2481-8275				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BAKER HD, 1956, J PATHOL BACTERIOL, V71, P135, DOI 10.1002/path.1700710118; BISMUTH H, 1989, ANN SURG, V210, P13, DOI 10.1097/00000658-198907000-00002; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BULKLEY GB, 1986, AM J SURG, V151, P87, DOI 10.1016/0002-9610(86)90017-6; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Feldmann G, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80491-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LEIST M, 1995, J IMMUNOL, V154, P1307; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Sasaki H, 1997, TRANSPL P, V29, P406, DOI 10.1016/S0041-1345(96)00138-8; Sasaki H, 1996, TRANSPLANT P, V28, P1908; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Smith S L, 1992, Crit Care Nurs Clin North Am, V4, P131; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THURMAN RG, 1988, TRANSPLANTATION, V46, P502, DOI 10.1097/00007890-198810000-00006; Trieb K, 1997, TRANSPL P, V29, P416, DOI 10.1016/S0041-1345(96)00159-5; VANDERMEER C, 1976, CIRC SHOCK, V3, P191; WYLLIE AH, 1987, ARCH TOXICOL, P3	48	204	208	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					253	261		10.1096/fasebj.13.2.253	http://dx.doi.org/10.1096/fasebj.13.2.253			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973313				2022-12-28	WOS:000078615200005
J	Ranjeva, R; Graziana, A; Mazars, C				Ranjeva, R; Graziana, A; Mazars, C			Plant graviperception and gravitropism: a newcomer's view	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	auxin; calcium; gravisensing; plants; response specificity	LIGHT-REGULATED GRAVITROPISM; PROTEIN-KINASE HOMOLOG; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; ROOT GRAVITROPISM; SHOOT GRAVITROPISM; CALCIUM CHANNELS; SEEDLING ROOTS; CHARA RHIZOIDS; CELL-WALL	Gravitropism is an adaptable mechanism corresponding to the directed growth by which plants orient in response to the gravity vector. The overall process is generally divided into three distinct stages: graviperception, gravitransduction, and asymmetric growth response. The phenomenology of these different steps has been described by using refined cell biology approaches combined with formal and molecular genetics. To date, it clearly appears that the cellular organization plays crucial roles in gravisensing and that gravitropism is genetically different between organs, Moreover, while interfering with other physical or chemical stimuli and sharing probably some common intermediary steps in the transduction pathway, gravity has its own perception and transduction systems. The intimate mechanisms involved in these processes have to be unveiled at the molecular level and their biological relevance addressed at the cellular and whole plant levels under normal and microgravitational conditions.	UPS, CNRS, UMR 5546, Signaux & Massages Cellulaires Vegetaux, F-31326 Castanet Tolosan, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Ranjeva, R (corresponding author), UPS, CNRS, UMR 5546, Signaux & Massages Cellulaires Vegetaux, BP 17 Auzeville, F-31326 Castanet Tolosan, France.	ranjeva@cict.fr		Mazars, Christian/0000-0002-0670-6042				ALLAN E, 1985, PLANTA, V165, P493, DOI 10.1007/BF00398094; Baluska F, 1997, PLANTA, V203, pS69, DOI 10.1007/PL00008117; Baluska F, 1996, PLANTA, V198, P310, DOI 10.1007/BF00206258; BASKIN TI, 1986, PLANT PHYSIOL, V94, P1763; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; Braam J, 1997, PLANTA, V203, pS35, DOI 10.1007/s004250050162; Busk PK, 1998, PLANT MOL BIOL, V37, P425, DOI 10.1023/A:1006058700720; Canut H, 1998, PLANT J, V16, P63, DOI 10.1046/j.1365-313x.1998.00276.x; DAUWALDER M, 1986, PLANTA, V168, P461, DOI 10.1007/BF00392265; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; EVANS ML, 1991, PLANT PHYSIOL, V95, P1, DOI 10.1104/pp.95.1.1; FELDMAN LJ, 1987, PLANT PHYSIOL, V83, P241, DOI 10.1104/pp.83.2.241; Fischer K, 1998, PLANT J, V15, P119, DOI 10.1046/j.1365-313X.1998.00173.x; Fischer WN, 1998, TRENDS PLANT SCI, V3, P188, DOI 10.1016/S1360-1385(98)01231-X; Fowler JE, 1997, ANNU REV CELL DEV BI, V13, P697, DOI 10.1146/annurev.cellbio.13.1.697; Fukaki H, 1997, PLANT CELL PHYSIOL, V38, P804, DOI 10.1093/oxfordjournals.pcp.a029238; Fukaki H, 1996, PLANT PHYSIOL, V110, P945, DOI 10.1104/pp.110.3.945; Fukaki H, 1996, PLANT PHYSIOL, V110, P933, DOI 10.1104/pp.110.3.933; GALAUD JP, 1993, PLANT MOL BIOL, V23, P839, DOI 10.1007/BF00021538; Golan A, 1996, PLANT PHYSIOL, V112, P901, DOI 10.1104/pp.112.3.901; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; Ingber D, 1999, FASEB J, V13, pS3; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; Katembe WJ, 1997, PHYSIOL PLANTARUM, V99, P7, DOI 10.1034/j.1399-3054.1997.990102.x; Kiss JZ, 1996, PHYSIOL PLANTARUM, V97, P237, DOI 10.1034/j.1399-3054.1996.970205.x; Kiss JZ, 1998, PHYSIOL PLANTARUM, V102, P493, DOI 10.1034/j.1399-3054.1998.1020403.x; KISS JZ, 1994, PLANT PHYSIOL, V105, P937, DOI 10.1104/pp.105.3.937; Legue V, 1997, PLANT PHYSIOL, V114, P789, DOI 10.1104/pp.114.3.789; LEITZ G, 1995, PLANTA, V197, P278; Lu YT, 1996, PLANTA, V199, P18; Lu YT, 1997, PLANTA, V203, pS91, DOI 10.1007/PL00008121; Malho R, 1996, PLANT CELL, V8, P1935, DOI 10.1105/tpc.8.11.1935; MASSON PH, 1995, BIOESSAYS, V17, P119, DOI 10.1002/bies.950170207; Mazars C, 1997, CELL CALCIUM, V22, P413, DOI 10.1016/S0143-4160(97)90025-7; MCCLURE BA, 1989, SCIENCE, V243, P91, DOI 10.1126/science.11540631; Nover L, 1997, CELL MOL LIFE SCI, V53, P80, DOI 10.1007/PL00000583; OKADA K, 1992, CELL, V70, P369, DOI 10.1016/0092-8674(92)90159-A; Okada K., 1994, ARABIDOPSIS, P665; PARKER KE, 1990, PLANT PHYSIOL, V94, P1763, DOI 10.1104/pp.94.4.1763; Perbal G, 1997, PLANTA, V203, pS57, DOI 10.1007/PL00008115; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; RAYLE DL, 1992, PLANT PHYSIOL, V99, P1271, DOI 10.1104/pp.99.4.1271; ROBERTS JA, 1992, CURR PLANT SCI BIOT, V13, P913; Robson PRH, 1996, PLANT PHYSIOL, V110, P211, DOI 10.1104/pp.110.1.211; ROUX SJ, 1987, CRC CR REV PLANT SCI, V5, P205, DOI 10.1080/07352688709382240; Sack FD, 1997, PLANTA, V203, pS63, DOI 10.1007/PL00008116; SACK FD, 1991, INT REV CYTOL, V127, P193; Sievers A, 1996, TRENDS PLANT SCI, V1, P273; Sievers A, 1997, PLANTA, V203, pS1, DOI 10.1007/PL00008096; SIEVERS A, 1997, PLANTA S, V203; SIMMONS C, 1995, PHYSIOL PLANTARUM, V93, P790, DOI 10.1111/j.1399-3054.1995.tb05133.x; Sinclair W, 1996, PLANTA, V199, P343, DOI 10.1007/BF00195725; Sinclair W, 1997, PLANTA, V203, pS85, DOI 10.1007/PL00008120; Somerville C, 1997, PLANT PHYSIOL, V113, P1015, DOI 10.1104/pp.113.4.1015; Staves MP, 1997, PLANTA, V203, pS79, DOI 10.1007/PL00008119; Thion L, 1998, PLANT J, V13, P603, DOI 10.1046/j.1365-313X.1998.00062.x; Thuleau P, 1998, CURR OPIN PLANT BIOL, V1, P424, DOI 10.1016/S1369-5266(98)80267-7; THULEAU P, 1994, EMBO J, V13, P2970, DOI 10.1002/j.1460-2075.1994.tb06595.x; TREWAVAS A, 1994, PLANT MOL BIOL, V26, P1329, DOI 10.1007/BF00016478; Volkmann D, 1999, FASEB J, V13, pS143; Von Arnim Albrecht, 1996, Bioessays, V18, P905, DOI 10.1002/bies.950181109; Wang W, 1996, PLANT MOL BIOL, V31, P87, DOI 10.1007/BF00020609; Yamauchi Y, 1997, PLANT CELL PHYSIOL, V38, P530, DOI 10.1093/oxfordjournals.pcp.a029201; YOUNG LM, 1994, PLANT GROWTH REGUL, V14, P235, DOI 10.1007/BF00024798	66	8	8	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S135	S141						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352155				2022-12-28	WOS:000080403800017
J	Ji, WDR; Castellino, FJ; Chang, Y; Deford, ME; Gray, H; Villarreal, X; Kondri, ME; Marti, DN; Llinas, M; Schaller, J; Kramer, RA; Trail, PA				Ji, WDR; Castellino, FJ; Chang, Y; Deford, ME; Gray, H; Villarreal, X; Kondri, ME; Marti, DN; Llinas, M; Schaller, J; Kramer, RA; Trail, PA			Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis	FASEB JOURNAL			English	Article						plasminogen; kringle; BCE cells; fibroblast growth factor	FIBROBLAST GROWTH-FACTOR; TUMOR-GROWTH; HUMAN-PLASMINOGEN; IN-VIVO; BINDING; INHIBITOR; CANCER; ACTIVATOR; H-1-NMR; SUPPRESSION	Angiogenesis is a complex process that involves endothelial cell proliferation, migration, basement membrane degradation, and neovessel organization. Angiostatin, consisting of four homologous triple-disulfide bridged kringle domains, has previously been shown to exhibit profound inhibition of endothelial cell proliferation in vitro and angiogenesis in vivo. It was also demonstrated that angiostatin could suppress the growth of a variety of tumors via the blocking of angiogenesis. The primary aim of our study was to characterize the kringle domains of angiostatin for their inhibitory activities of endothelial cell migration in order to elucidate their contributions to the anti-angiogenic function of angiostatin. In this report, we demonstrate for the first time that the kringles of angiostatin play different roles in inhibiting endothelial cell migration, a crucial process in angiogenesis. Kringle 4, which has only marginal anti-proliferative activity, is among the most potent fragments in inhibiting endothelial cell. migration (IC50 Of approximately 500 nM). In contrast, kringle 1-3, which is equivalent to angiostatin in inhibiting endothelial cell proliferation, manifests only a modest anti-migratory effect. The combination of kringle 1-3 and kringle 4 results in an anti-migratory activity comparable to that of angiostatin. When kringle 1 is removed from kringle 1-3, the resulting kringle 2-3 becomes more potent than kringle 1-3. This implies that kringle 1, although virtually ineffective in inhibiting endothelial cell migration, may influence the conformation of kringle 1-3 to alter its anti-migratory activity. We also show that disruption of the kringle structure by reducing/alkylating agents markedly attenuates the anti-migratory activity of angiostatin, demonstrating the significance of kringle conformation in maintaining the anti-angiogenic activity of angiostatin. Our data suggest that different kringle domains may contribute to the overall anti-angiogenic function of angiostatin by their distinct anti-migratory activities.	Bristol Myers Squibb Pharmaceutical Inc, Dept Oncol Drug Discovery, Princeton, NJ 08543 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Bern, Dept Biochem & Chem, CH-3012 Bern, Switzerland	Bristol-Myers Squibb; Carnegie Mellon University; University of Notre Dame; University of Bern	Ji, WDR (corresponding author), Bristol Myers Squibb Pharmaceutical Inc, Dept Oncol Drug Discovery, Provinceline & Route 206, Princeton, NJ 08543 USA.	rji@ussmtp.bms.com						BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; Chang Y, 1997, BIOCHEMISTRY-US, V36, P7652, DOI 10.1021/bi970197g; CLAEYS H, 1976, FEBS LETT, V61, P20, DOI 10.1016/0014-5793(76)80161-5; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GROSS JL, 1993, J NATL CANCER I, V85, P121, DOI 10.1093/jnci/85.2.121; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lannutti BJ, 1997, CANCER RES, V57, P5277; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; LLINAS M, 1983, EUR J BIOCHEM, V135, P379, DOI 10.1111/j.1432-1033.1983.tb07665.x; LUCAS MA, 1983, J BIOL CHEM, V258, P4249; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAGNUSSON S, 1976, PROTEOLYSIS PHYSL RE, P203; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; MARTZ FA, 1994, P FORAG GR, V3, P219; MILES LA, 1988, J BIOL CHEM, V263, P11928; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Nilsen SL, 1997, BIOTECHNOL APPL BIOC, V25, P63, DOI 10.1111/j.1470-8744.1997.tb00415.x; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; Sim BKL, 1997, CANCER RES, V57, P1329; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; THORSEN S, 1981, BIOCHIM BIOPHYS ACTA, V668, P377, DOI 10.1016/0005-2795(81)90171-9; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; URANO T, 1987, P NATL ACAD SCI USA, V84, P4031, DOI 10.1073/pnas.84.12.4031; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032	46	111	131	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1731	1738		10.1096/fasebj.12.15.1731	http://dx.doi.org/10.1096/fasebj.12.15.1731			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837863				2022-12-28	WOS:000077574500015
J	Xue, BZ; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB				Xue, BZ; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB			The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+-dependent mechanism	FASEB JOURNAL			English	Article						calcium; agouti polypeptide; MSH; melanocortin receptor	MELANOCYTE-STIMULATING-HORMONE; CYTOSOLIC FREE CALCIUM; RAT ADIPOCYTES; INSULIN RESISTANCE; OBESITY; PROTEIN; RECEPTOR; MICE; EXPRESSION	Overexpression of the murine agouti gene results in obesity, The human homologue of agouti is expressed primarily in human adipocytes, and we have shown recombinant agouti protein to increase adipocyte intracellular Ca2+([Ca2+](i)) and thereby stimulate Lipogenesis. However, since recent data demonstrate that increasing adipocyte [Ca2+](i) may also inhibit Lipolysis, we have investigated the role of agouti-induced [Ca2+](i) increases in regulating lipolysis in human adipocytes, Short-term (1 h) exposure to recombinant agouti (100 nM) protein had no effect on basal lipolysis, although longer term treatment (24 h) caused a 60% decrease in basal lipolysis (P<0.0001), Short-term agouti treatment totally inhibited ACTH-induced lipolysis (P<0.05), Since melanocortin receptors (MCR) are involved in some actions of agouti, we next determined whether agouti's antilipolytic effect is exerted through competitive antagonism of the ACTH receptor (MCR-2), Forskolin (1 mu M), an adenylate cyclase activator, induced a 48% increase in Lipolysis in human adipocytes (P<0.05); this effect was reversed by 100 nM agouti (P<005), demonstrating that the antilipolytic effect of agouti is distal to the ACTH receptor, To determine the role of [Ca2+]i in the antilipolytic effect of agouti, human adipocytes were treated with KCI or arginine vasopressin to stimulate voltage- and receptor-stimulated Ca2+ influx, respectively, Both agents caused inhibition of forskolin-induced lipolysis (P<0.005), Furthermore, agouti's antilipolytic effect was also blocked by the Ca2+ channel blocker nitrendipine. These data demonstrate that agouti exerts a potent antilipolytic effect in human adipocytes via a Ca2+-dependent mechanism. This effect, combined with agouti-induced lipogenesis, represents a coordinate control of adipocyte lipid metabolism that may contribute to an agouti-induced obesity syndrome.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; Univ Tennessee, Dept Med, Knoxville, TN 37996 USA; ZenBio Inc, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Health Science Center	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,Rm 229, Knoxville, TN 37996 USA.	mzemel@utk.edu	Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030; Zemel, Michael/0000-0003-4104-5750				BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; Boston BA, 1996, ENDOCRINOLOGY, V137, P2043, DOI 10.1210/en.137.5.2043; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; Claycombe K. J., 1997, FASEB Journal, V11, pA352; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GALBRAITH DB, 1964, J EXP ZOOL, V155, P71, DOI 10.1002/jez.1401550106; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; IZAWA T, 1994, AM J PHYSIOL, V266, pE418, DOI 10.1152/ajpendo.1994.266.3.E418; JACKSON IJ, 1991, BIOESSAYS, V13, P439, DOI 10.1002/bies.950130903; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; KATOCS AS, 1974, J BIOL CHEM, V249, P2000; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; KLEBIG ML, 1994, MOL GENETIC ASPECTS; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Moustaid N, 1996, J NUTR, V126, P865, DOI 10.1093/jn/126.4.865; OELOFSEN W, 1983, ARCH BIOCHEM BIOPHYS, V225, P414, DOI 10.1016/0003-9861(83)90048-6; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1958, J EXP ZOOL, V137, P189, DOI 10.1002/jez.1401370110; STEELEY RJ, 1997, NATURE, V390, P349; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; YEN T T T, 1970, Hormone and Metabolic Research, V2, P200; YEN TT, 1984, INT J OBESITY, V8, P65; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; YEN TT, 1983, LIFE SCI, V32, P1515, DOI 10.1016/0024-3205(83)90918-9; ZEMEL MB, 1998, IN PRESS INT J OBESI; ZEMEL MB, 1995, OBES RES, V3, pS338	36	130	150	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1391	1396		10.1096/fasebj.12.13.1391	http://dx.doi.org/10.1096/fasebj.12.13.1391			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761782				2022-12-28	WOS:000076402000014
J	Besset, S; Vincourt, JB; Amalric, F; Girard, JP				Besset, S; Vincourt, JB; Amalric, F; Girard, JP			Nuclear localization of PAPS synthetase 1: a sulfate activation pathway in the nucleus of eukaryotic cells	FASEB JOURNAL			English	Article						sulfation; sulfate activation; PAPS synthesis; subcellular localization	HIGH ENDOTHELIAL VENULES; L-SELECTIN; TYROSINE SULFATION; P-SELECTIN; TYROSYLPROTEIN SULFOTRANSFERASE; CYTOSOLIC SULFOTRANSFERASES; 5'-PHOSPHOSULFATE KINASE; SACCHAROMYCES-CEREVISIAE; HEPARAN-SULFATE; ATP SULFURYLASE	Sulfation is a major modification of many molecules in eukaryotes that is dependent on the enzymatic synthesis of an activated sulfate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS). While sulfate activation has long been assumed to occur in the cytosol, we show in this study that human PAPS synthetase 1 (PAPSS1), a bifunctional ATP sulfurylase/adenosine 5'-phosphosulfate (APS) kinase enzyme sufficient for PAPS synthesis, accumulates in the nucleus of mammalian cells, Nuclear targeting of the enzyme is mediated by its APS kinase domain and requires a catalytically dispensable 21 amino acid sequence at the amino terminus. Human PAPSS1 and Drosophila melanogaster PAPSS localize to the nucleus in yeast and relieve the methionine auxotrophy of ATP sulfurylase- or APS kinase-deficient strains, suggesting that PAPSS1 is fully functional in vivo when targeted to the nucleus. A second PAPS synthetase gene, designated PAPSS2, has recently been described, mutations of which are responsible for abnormal skeletal development in human spondyloepimetaphyseal dysplasia and murine brachymorphism. We found that PAPSS2, which localizes to the cytoplasm when ectopically expressed in mammalian cells, is relocated to the nucleus when coexpressed with PAPSS1. Taken together, these results indicate that a sulfation pathway might exist in the nucleus of eukaryotic cells.	CNRS, Inst Pharmacol & Biol Struct, Lab Biol Vasc, F-31077 Toulouse 4, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Girard, JP (corresponding author), CNRS, Inst Pharmacol & Biol Struct, Lab Biol Vasc, 205 Route Narbonne, F-31077 Toulouse 4, France.		GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BHAVANANDAN VP, 1975, P NATL ACAD SCI USA, V72, P2032, DOI 10.1073/pnas.72.6.2032; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; BRION F, 1987, J NEUROCHEM, V48, P1171, DOI 10.1111/j.1471-4159.1987.tb05643.x; COATES SW, 1980, J BIOL CHEM, V255, P9225; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; DONG JF, 1995, BLOOD, V86, P4175, DOI 10.1182/blood.V86.11.4175.bloodjournal86114175; Falany CN, 1997, FASEB J, V11, P1; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FAROOQUI AA, 1980, INT J BIOCHEM, V12, P529, DOI 10.1016/0020-711X(80)90003-8; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; FERRARO A, 1991, BIOCHEM BIOPH RES CO, V178, P1365, DOI 10.1016/0006-291X(91)91044-D; Franzon VL, 1999, INT J BIOCHEM CELL B, V31, P613, DOI 10.1016/S1357-2725(98)00155-1; Girard JP, 1998, ADV EXP MED BIOL, V435, P55; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOOPER LV, 1999, CHEM BIOL, V6, pR9; IMAI Y, 1993, NATURE, V361, P555; ISAAC RE, 1982, BIOCHEM J, V204, P127, DOI 10.1042/bj2040127; Jullien D, 1997, MECH DEVELOP, V68, P179, DOI 10.1016/S0925-4773(97)00136-6; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; KOIZUMI T, 1969, BIOCHIM BIOPHYS ACTA, V184, P106, DOI 10.1016/0304-4165(69)90104-4; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MARGOLIS RK, 1976, BIOCHIM BIOPHYS ACTA, V451, P465, DOI 10.1016/0304-4165(76)90141-0; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	50	45	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					345	354		10.1096/fasebj.14.2.345	http://dx.doi.org/10.1096/fasebj.14.2.345			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657990				2022-12-28	WOS:000085184800013
J	Copeland, DE				Copeland, DE			Origins of cell biology in the United States	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB				Tulane Univ, New Orleans, LA 70118 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Tulane University; Marine Biological Laboratory - Woods Hole	Copeland, DE (corresponding author), 41 Fern Lane, Woods Hole, MA 02543 USA.								0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S181	S184						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619124				2022-12-28	WOS:000084390200002
J	Hortelano, S; Alvarez, AM; Bosca, L				Hortelano, S; Alvarez, AM; Bosca, L			Nitric oxide induces tyrosine nitration and release of cytochrome c preceding an increase of mitochondrial transmembrane potential in macrophages	FASEB JOURNAL			English	Article						apoptosis; NO; nitric oxide synthase; mitochondria	PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION; APOPTOSIS; PEROXYNITRITE; BCL-2; RESPIRATION; INHIBITION; PATHWAYS; COMPLEX; INFLAMMATION	Treatment of elicited peritoneal macrophages or the macrophage cell line RAW 264.7 with high concentrations of nitric oxide donors is followed by apoptotic cell death. Analysis of the changes in the mitochondrial transmembrane potential (Delta Psi(m)) with specific fluorescent probes showed a rapid and persistent increase of Delta Psi(m), potential that usually decreases in cells undergoing apoptosis through mitochondrial-dependent mechanisms. Using confocal microscopy, the release of cytochrome c from the mitochondria to the cytosol was characterized as an early event preceding the rise of Delta Psi(m). The cytochrome c from cells treated with nitric oxide donors was modified chemically, probably through the formation of nitrotyrosine residues, suggesting the synthesis of peroxynitrite in the mitochondria, These results indicate that nitric oxide-dependent apoptosis in macrophages occurs in the presence of a sustained increase of Delta Psi(m), and that the chemical modification and release of cytochrome c from the mitochondria precede the changes of Delta Psi(m).	Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto,CSIC, E-28040 Madrid, Spain; Univ Complutense Madrid, Fac Farm, Ctr Citometria Flujo & Microscopia Confocal, E-28040 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid	Bosca, L (corresponding author), Univ Complutense Madrid, Fac Farm, Inst Bioquim, Ctr Mixto,CSIC, E-28040 Madrid, Spain.		Bosca, Lisardo/A-2059-2008; Hortelano, Sonsoles/A-7954-2010; Alvarez-Barrientos, Alberto/L-9299-2014	Bosca, Lisardo/0000-0002-0253-5469; Hortelano, Sonsoles/0000-0003-2528-0072; Alvarez-Barrientos, Alberto/0000-0003-4761-0212				Albina JE, 1998, CANCER METAST REV, V17, P39, DOI 10.1023/A:1005904704618; Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; ASCENZI P, 1994, J INORG BIOCHEM, V53, P273, DOI 10.1016/0162-0134(94)85114-X; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brown GC, 1997, MOL CELL BIOCHEM, V174, P189, DOI 10.1023/A:1006800322719; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Davey GP, 1996, J NEUROCHEM, V66, P1617; Dugas B, 1995, RES IMMUNOL, V146, P664, DOI 10.1016/0923-2494(96)84914-5; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467; Hashimoto S, 1998, P NATL ACAD SCI USA, V95, P3094, DOI 10.1073/pnas.95.6.3094; Hortelano S, 1999, BRIT J PHARMACOL, V126, P1139, DOI 10.1038/sj.bjp.0702422; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroemer Guido, 1997, P1111; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIMBACH KJ, 1985, NUCLEIC ACIDS RES, V13, P617, DOI 10.1093/nar/13.2.617; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mallozzi C, 1997, FASEB J, V11, P1281, DOI 10.1096/fasebj.11.14.9409547; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MOLLOY A, 1994, J EXP MED, V180, P1499, DOI 10.1084/jem.180.4.1499; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Sarti P, 1999, FASEB J, V13, P191, DOI 10.1096/fasebj.13.1.191; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Velasco M, 1997, J IMMUNOL, V158, P4437; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Williams G T, 1994, Trends Microbiol, V2, P463, DOI 10.1016/0966-842X(94)90648-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	51	120	122	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2311	2317		10.1096/fasebj.13.15.2311	http://dx.doi.org/10.1096/fasebj.13.15.2311			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593878	Bronze			2022-12-28	WOS:000084310800022
J	Peet, NM; Grabowski, PS; Laketic-Ljubojevic, I; Skerry, TM				Peet, NM; Grabowski, PS; Laketic-Ljubojevic, I; Skerry, TM			The glutamate receptor antagonist MK801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiation	FASEB JOURNAL			English	Article						osteoclast; differentiation; electrophysiology; glutamate receptor; MK801 maleate (Dizocilpine)	VASOACTIVE-INTESTINAL-PEPTIDE; TYROSINE PHOSPHORYLATION; SEALING ZONE; NITRIC-OXIDE; CELLS; EXPRESSION; HORMONES	Recent identification in bone of transporters, receptors, and components of synaptic signaling suggests a role for glutamate in the skeleton. We investigated effects of glutamate and its antagonist MK801 on osteoclasts in vitro. Glutamate applied to patch clamped osteoclasts induced significant increases in whole-cell membrane currents (P<0.01) in the presence of the coagonist glycine. Agonist-elicited currents were significantly decreased after application of MK801 (100 mu M, P<0.01), but MK801 had no effect on actin ring formation necessary for osteoclast polarization, attachment, and resorption. In cocultures of bone marrow cells and osteoblasts in which osteoclasts develop, MK801 inhibited osteoclast differentiation and reduced resorption of pits in dentine (3 to 100 mu M; P<0.001). MK801 added early in the culture (for as little as 2-4 days) was as effective as addition for the entire culture period. Addition of MK801 for any time after day 7 of culture was ineffective in reducing osteoclast activity. Using; rat and rabbit mature osteoclasts cultured on dentine or explants of mouse calvariae prelabeled with Ca-45, we could not detect significant effects of MK801 on osteoclastic resorption. These data show clearly that glutamate receptor function is critical during osteoclastogenesis and suggest that glutamate is less important in regulating mature osteoclast activity.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Peet, NM (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.			Skerry, Timothy/0000-0003-1319-5575				Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; CHAMBERS TJ, 1985, ENDOCRINOLOGY, V116, P234, DOI 10.1210/endo-116-1-234; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GENEVER PG, 1999, IN PRESS BLOOD; GENEVER PG, 1999, IN PRESS J INVEST DE; GOLDRING MB, 1990, CLIN ORTHOP RELAT R, P245; Hamill OP, 1996, PHARMACOL REV, V48, P231; HOHMANN EL, 1984, ENDOCRINOLOGY, V114, P1321, DOI 10.1210/endo-114-4-1321; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ilvesaro JM, 1998, EXP CELL RES, V242, P75, DOI 10.1006/excr.1998.4081; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Konttinen YT, 1996, ACTA ORTHOP SCAND, V67, P632, DOI 10.3109/17453679608997772; LAKETICLJUBOJEV.I, 1999, IN PRESS BONE; MALONE JD, 1986, P NATL ACAD SCI USA, V83, P3307, DOI 10.1073/pnas.83.10.3307; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; MULLER G, 1998, EXCITATORY AMINO ACI, V23, P109; MUNDY GR, 1994, NATURE, V367, P216, DOI 10.1038/367216a0; Murthy VN, 1998, NATURE, V392, P497, DOI 10.1038/33152; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; PATTON AJ, 1997, BONE, V20, P225; RAHMAN S, 1992, REGUL PEPTIDES, V37, P111, DOI 10.1016/0167-0115(92)90660-M; RAHMAN S, 1992, BIOCHIM BIOPHYS ACTA, V1135, P97, DOI 10.1016/0167-4889(92)90172-8; RALSTON SH, 1995, J BONE MINER RES, V10, P1040; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Said SI, 1996, P NATL ACAD SCI USA, V93, P4688, DOI 10.1073/pnas.93.10.4688; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; WALSH CA, 1991, J BONE MINER RES, V6, P661; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006-8993(86)90046-6	36	81	83	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2179	2185		10.1096/fasebj.13.15.2179	http://dx.doi.org/10.1096/fasebj.13.15.2179			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593865				2022-12-28	WOS:000084310800009
J	Padera, R; Venkataraman, G; Berry, D; Godavarti, R; Sasisekharan, R				Padera, R; Venkataraman, G; Berry, D; Godavarti, R; Sasisekharan, R			FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling	FASEB JOURNAL			English	Article						FGF receptor; thermodynamic parameters; extracellular matrix	FIBROBLAST GROWTH; HEPARAN-SULFATE; CELL-SURFACE; FACTOR-II; BINDING; PROTEOGLYCAN; MITOGENESIS; RECEPTORS; AFFINITY; BFGF	Heparin-like glycosaminoglycans (HLGAGs) play a central role in the biological activity and signaling behavior of basic fibroblast growth factor (FGF-P), Recent studies, however, indicate that FGF-2 may be able to signal in the absence of HLGAG, raising the question of the nature of the role of HLGAG in FGF-2 signaling, In this study, we present a conceptual framework for FGF-2 signaling and derive a simple model from it that describes signaling via both HLGAG-independent and HLGAG-dependent pathways. The model is validated with F32 cell proliferation data using wild-type FGF-S, heparin binding mutants (K26A, K119A/R120A, K125A), and receptor binding mutants (Y103A, Y111A/W114A). In addition, this model can predict the cellular response of FGF-2 and its mutants as a function of FGF-2 and HLGAG concentration based on experimentally determined thermodynamic parameters. We show that FGF-2-mediated cellular response is a function of both FGF-2 and HLGAG concentrations and that a reduction of one of the components can be compensated for by an increase in the other to achieve the same measure of cellular response, Analysis of the mutant FGF-S molecules show that reduction in heparin binding interactions and primary receptor site binding interactions can also be compensated for in the same manner. These results suggest a molecular mechanism that could be used by cells in physiological systems to modulate the FGF-2-mediated cellular response by controlling HLGAG expression.-Padera, R., Venkataraman, G., Berry, D., Godavarti, R., Sasisekharan, R. FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling.	MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Bioengn & Environm Hlth, 77 Massachusetts Ave,Bldg 16-561, Cambridge, MA 02139 USA.							AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BIKFALVI A, 1997, ANGIOGENESIS, V1, P155; CONRAD E, 1998, HEPARIN BINDING PROT, P301; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Higuchi R., 1990, PCR PROTOCOLS GUIDE; KAN M, 1993, SCIENCE, V259, P19918; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klein S, 1997, EXS, V79, P159; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; LI LY, 1994, BIOCHEMISTRY-US, V34, P731; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	34	44	47	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1677	1687		10.1096/fasebj.13.13.1677	http://dx.doi.org/10.1096/fasebj.13.13.1677			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506571				2022-12-28	WOS:000083063400003
J	Lu, SC				Lu, SC			Regulation of hepatic glutathione synthesis: current concepts and controversies	FASEB JOURNAL			English	Review						gamma-glutamylcysteine synthetase; cysteine availability; detoxification; antioxidant	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ISOLATED RAT HEPATOCYTES; AMINO-ACID-SEQUENCE; EPITHELIAL L2 CELLS; HEAVY SUBUNIT GENE; MRP/GS-X PUMP; NAPHTHOFLAVONE-INDUCED EXPRESSION; TRANSCRIPTIONAL UP-REGULATION; ANTIOXIDANT RESPONSE ELEMENT; INDUCED OXIDATIVE STRESS	Glutathione (GSH) is an important intracellular peptide with multiple functions ranging from antioxidant defense to modulation of cell proliferation. GSH is synthesized in the cytosol of all mammalian cells in a tightly regulated manner, The major determinants of GSH synthesis are the availability of cysteine, the sulfur amino acid precursor, and the activity of the rate-limiting enzyme, gamma-glutamylcysteine synthetase (GCS), In the liver, major factors that determine the availability of cysteine are diet, membrane transport activities of the three sulfur amino acids cysteine, cystine and methionine, and the conversion of methionine to cysteine via the trans-sulfuration pathway. Many conditions alter GSH level via changes in GCS activity and GCS gene expression. These include oxidative stress, activators of Phase II detoxifying enzymes, antioxidants, drug-resistant tumor cell lines, hormones, cell proliferation, and diabetes mellitus. Since the molecular cloning of GCS, much has been learned about the regulation of this enzyme. Both transcriptional and post-transcriptional mechanisms modulate the activity of this critical cellular enzyme.	Univ So Calif, Sch Med, Dept Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Lu, SC (corresponding author), Univ So Calif, Sch Med, Dept Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis, HMR Rm 415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@hsc.usc.edu			NIDDK NIH HHS [DK45334] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045334, R29DK045334, R56DK045334] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arsalane K, 1997, AM J RESP CELL MOL, V17, P599, DOI 10.1165/ajrcmb.17.5.2833; AW TY, 1986, AM J PHYSIOL, V251, pG354, DOI 10.1152/ajpgi.1986.251.3.G354; BANNAI S, 1986, HEPATOLOGY, V6, P1361, DOI 10.1002/hep.1840060624; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; BANNAI S, 1986, J BIOL CHEM, V261, P2256; BANNAI S, 1981, J BIOL CHEM, V256, P5770; Bannai S., 1989, GLUTATHIONE CENTENNI, P407; BEATTY PW, 1980, ARCH BIOCHEM BIOPHYS, V204, P80, DOI 10.1016/0003-9861(80)90009-0; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; CAI JX, 1995, MOL PHARMACOL, V48, P212; Chang LS, 1996, J PROTEIN CHEM, V15, P321, DOI 10.1007/BF01887121; CHEN Y, 1995, P SOC EXP BIOL MED, V210, P102, DOI 10.3181/00379727-210-43928; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L; Delneste Y, 1996, EUR J IMMUNOL, V26, P2981, DOI 10.1002/eji.1830261225; ESTRELA JM, 1988, AM J PHYSIOL, V255, pE801, DOI 10.1152/ajpendo.1988.255.6.E801; FERNANDEZCHECA J, 1992, HEPATIC ANION TRANSP, P363; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; FINKELSTEIN JD, 1982, J NUTR, V112, P1011, DOI 10.1093/jn/112.5.1011; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Galloway DC, 1997, BIOCHEM J, V328, P99; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Gomi A, 1997, BIOCHEM BIOPH RES CO, V239, P51, DOI 10.1006/bbrc.1997.7423; Grant CM, 1997, MOL BIOL CELL, V8, P1699, DOI 10.1091/mbc.8.9.1699; HARRIS JW, 1973, J CELL PHYSIOL, V81, P91, DOI 10.1002/jcp.1040810111; HIDALGO J, 1990, J PHARMACOL EXP THER, V255, P554; HIROTA M, 1989, GASTROENTEROLOGY, V97, P853, DOI 10.1016/0016-5085(89)91488-1; HOLMGREN A, 1981, CURR TOP CELL REGUL, V19, P47; HOROWITZ JH, 1981, GASTROENTEROLOGY, V81, P668; HUANG CS, 1995, P NATL ACAD SCI USA, V92, P1232, DOI 10.1073/pnas.92.4.1232; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; Huang ZZ, 1998, HEPATOLOGY, V27, P147, DOI 10.1002/hep.510270123; Hutter DE, 1997, EXP CELL RES, V232, P435, DOI 10.1006/excr.1997.3527; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; IWATA S, 1994, J IMMUNOL, V152, P5633; Kijima H, 1998, BIOCHEM BIOPH RES CO, V247, P697, DOI 10.1006/bbrc.1998.8878; KILBERG MS, 1982, J MEMBRANE BIOL, V69, P1, DOI 10.1007/BF01871236; KILBERG MS, 1979, BIOCHEM BIOPH RES CO, V88, P744, DOI 10.1016/0006-291X(79)92110-7; Kohno T, 1996, J IMMUNOL, V156, P4722; KONDO T, 1993, J BIOL CHEM, V268, P20366; Kuo MT, 1998, BIOCHEM PHARMACOL, V55, P605, DOI 10.1016/S0006-2952(97)00494-2; Kuo PC, 1996, AM J PHYSIOL-CELL PH, V271, pC851, DOI 10.1152/ajpcell.1996.271.3.C851; LAUTERBURG BH, 1982, HEPATOLOGY, V2, P8; LEE FYF, 1988, CANCER RES, V48, P3661; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEW H, 1985, FEBS LETT, V185, P262, DOI 10.1016/0014-5793(85)80919-4; LIU CW, 1994, J CONTAM HYDROL, V15, P345, DOI 10.1016/0169-7722(94)90034-5; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; Liu RM, 1996, AM J RESP CELL MOL, V14, P186, DOI 10.1165/ajrcmb.14.2.8630269; LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286; LU SC, 1990, J BIOL CHEM, V265, P16088; LU SC, 1994, BIOCHEM PHARMACOL, V47, P859, DOI 10.1016/0006-2952(94)90486-3; LU SC, 1992, J CLIN INVEST, V90, P524, DOI 10.1172/JCI115890; Lu SC, 1998, GASTROENTEROLOGY, V114, P403, DOI 10.1016/S0016-5085(98)70494-9; Lu SC, 1996, HEPATOLOGY, V24, P253, DOI 10.1053/jhep.1996.v24.pm0008707271; LU SC, 1992, AM J PHYSIOL, V263, pC1181, DOI 10.1152/ajpcell.1992.263.6.C1181; Mato JM, 1997, HEPATOLOGY, V26, P489; Mato Jose M., 1994, P461; MEISTER A, 1988, LIVER BIOL PATHOBIOL, P401; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MESSINA JP, 1989, J IMMUNOL, V143, P1974; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Morales A, 1998, FEBS LETT, V427, P15, DOI 10.1016/S0014-5793(98)00381-0; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MULCAHY RT, 1994, MOL PHARMACOL, V46, P909; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; MULCAHY RT, 1994, CANCER CHEMOTH PHARM, V34, P67, DOI 10.1007/s002800050105; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; NAKAMURA T, 1983, P NATL ACAD SCI-BIOL, V80, P7229, DOI 10.1073/pnas.80.23.7229; NEUHAUSERBERTHOLD M, 1988, METABOLISM, V37, P796, DOI 10.1016/0026-0495(88)90017-0; Oguri T, 1998, BRIT J CANCER, V77, P1089, DOI 10.1038/bjc.1998.181; Ookhtens M, 1998, SEMIN LIVER DIS, V18, P313, DOI 10.1055/s-2007-1007167; OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80, DOI 10.1152/ajplung.1998.275.1.L80; Rahman I, 1998, FEBS LETT, V427, P129, DOI 10.1016/S0014-5793(98)00410-4; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; REED DJ, 1980, REV BIOCHEM TOXICOL, P213; SCKHAR KR, 1997, RADIAT RES, V147, P592; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sekhar KR, 1997, BIOCHEM BIOPH RES CO, V234, P588, DOI 10.1006/bbrc.1997.6697; SHAN XQ, 1989, TOXICOL APPL PHARM, V101, P261, DOI 10.1016/0041-008X(89)90275-5; SHAW JP, 1986, J CELL PHYSIOL, V129, P193, DOI 10.1002/jcp.1041290210; SHI MM, 1994, J BIOL CHEM, V269, P26512; Shimizu T, 1998, CELL MOL NEUROBIOL, V18, P299, DOI 10.1023/A:1022525214871; SNOKE JE, 1953, J BIOL CHEM, V201, P573; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; TAKADA A, 1984, J BIOL CHEM, V259, P2441; Tanaka T, 1998, BIOCHEM BIOPH RES CO, V246, P398, DOI 10.1006/bbrc.1998.8631; Tarver H, 1939, J BIOL CHEM, V130, P67; TATEISHI N, 1974, J BIOCHEM, V75, P93, DOI 10.1093/oxfordjournals.jbchem.a130387; Tateishi N., 1983, GLUTATHIONE STORAGE, P13; TATEISHI N, 1989, GLUTATHIONE CENTENNI, P57; TESHIGAWARA M, 1995, RES EXP MED, V195, P55, DOI 10.1007/BF02576774; Tian L, 1997, ARCH BIOCHEM BIOPHYS, V342, P126, DOI 10.1006/abbi.1997.9997; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Tomonari A, 1997, BIOCHEM BIOPH RES CO, V236, P616, DOI 10.1006/bbrc.1997.7020; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VENDEMIALE G, 1989, SCAND J GASTROENTERO, V24, P407, DOI 10.3109/00365528909093067; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; YAN N, 1990, J BIOL CHEM, V265, P1588; YANARI S, 1953, J BIOL CHEM, V201, P561; YAO KS, 1995, CANCER RES, V55, P4367	123	694	724	3	73	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1169	1183		10.1096/fasebj.13.10.1169	http://dx.doi.org/10.1096/fasebj.13.10.1169			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385608				2022-12-28	WOS:000081264800006
J	Nair, S; Guerra, C; Satir, P				Nair, S; Guerra, C; Satir, P			A Sec7-related protein in Paramecium	FASEB JOURNAL			English	Article						guanine nucleotide exchange factor; GEF; IQ motifs; cilia	YEAST GOLGI-APPARATUS; EXCHANGE FACTOR; SIGNALING PROTEINS; SECRETORY PATHWAY; HOMOLOGY DOMAINS; LIGHT-CHAIN; SEC7 DOMAIN; DYNEIN; CYTOHESIN-1; PLECKSTRIN	We have cloned and sequenced a SEC7-related gene in Paramecium tetraurelia that contains an open reading frame for 1135 amino acids encoding a 133 kDa protein, PSec7. Sec7, first identified in vesicular trafficking mutants in yeast, and its phylogenetic homologues function as guanine-nucleotide exchange factors for small G-proteins such as ARF (ADP-ribosylation factor). The deduced amino acid sequence in PSec7 for the motifs that form the ARF binding site are more than 70% identical to yeast Sec7 and similarly identical to ARNO, the human ARF exchange factor, with correct positioning of the critical glutamic acid residue within the motif region, Overall, the identity of PSec7 to yeast Sec7 is 32%. The deduced amino acid sequence also has five sequences that resemble IQ motifs, EF hand binding domains found in all myosins, and two pleckstrin homology domains. Similar sequences are present in yeast Sec7 and other Sec7-related molecules. A protein kinase A phosphorylation site may also be present. Southern blots suggest that a single gene encodes PSec7, Northern blots show that the message encoding PSec7 is induced on deciliation, followed by ciliogenesis, which suggests a role for PSec7 in cilia such as transport or targeting of ciliary membrane components.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Satir, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	satir@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218, P01DK041918] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09875] Funding Source: Medline; NIDDK NIH HHS [DK07218, DK41918] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; ASAI DJ, 1994, J CELL SCI, V107, P839; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BONINI NM, 1991, ADV SEC MESS PHOSPH, V23, P227; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GUERMEUR Y, 1999, IN PRESS BIOINFORMAT; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LEDIZET M, 1995, MOL BIOL CELL, V6, P713, DOI 10.1091/mbc.6.6.713; LEFEBVRE PA, 1980, CELL, V20, P469, DOI 10.1016/0092-8674(80)90633-9; Levin S, 1998, BIOINFORMATICS, V14, P374, DOI 10.1093/bioinformatics/14.4.374; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OTTER T, 1989, CELL MOVEMENT, V1, P281; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; SANDERS MA, 1989, J CELL BIOL, V108, P1751, DOI 10.1083/jcb.108.5.1751; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SUBRAMANIAN SV, 1994, P NATL ACAD SCI USA, V91, P9832, DOI 10.1073/pnas.91.21.9832; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	31	12	12	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1249	1257		10.1096/fasebj.13.10.1249	http://dx.doi.org/10.1096/fasebj.13.10.1249			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385615	Bronze			2022-12-28	WOS:000081264800013
J	Boonstra, J				Boonstra, J			Growth factor-induced signal transduction in adherent mammalian cells is sensitive to gravity	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	microgravity; cell proliferation; protein kinase C; actin microfilaments; cytoskeleton	PROTEIN-KINASE-C; GTP-BINDING PROTEINS; FACTOR RECEPTOR; SPACE-FLIGHT; A431 CELLS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MECHANICAL-PROPERTIES; GUANINE-NUCLEOTIDES; ALTERED GRAVITY	Epidermal growth factor (EGF) activates a well-characterized signal transduction cascade in a wide variety of cells. This activation leads to increased cell proliferation in most cell types. Among the early effects evoked by EGF are receptor clustering, cell rounding, and early gene expression. The influence of gravity on EGF-induced EGF receptor clustering and gene expression as well as on actin polymerization and cell rounding have been investigated in adherent A431 epithelial cells with the use of sounding rockets to create microgravity conditions. EGF-induced c-fos and c-jun expression decreased in microgravity. This was caused by alteration of the EGF receptor and protein kinase C-mediated signal transduction pathways. In contrast, neither the binding of EGF to the receptor nor the receptor clustering were changed under microgravity conditions, Because cell morphology was also modulated under microgravity conditions, and the growth factor-induced signal transduction cascades have been demonstrated to be linked to the actin microfilament system, it is tempting to suggest that the actin microfilament system constitutes the gravity-sensitive cell component.	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands	Utrecht University	Boonstra, J (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.							BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Bikle DD, 1997, ENDOCRINOLOGIST, V7, P10, DOI 10.1097/00019616-199707010-00003; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOONSTRA J, 1985, J CELL PHYSIOL, V123, P347, DOI 10.1002/jcp.1041230309; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BOONSTRA J, 1997, FRONTIERS BIOL SCI S, P2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUNGO MW, 1985, AVIAT SPACE ENVIR MD, V56, P985; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CLAASSEN DE, 1994, INT REV CYTOL, V156, P301, DOI 10.1016/S0074-7696(08)62257-3; COCHET C, 1988, J BIOL CHEM, V263, P3290; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; CONVERTINO VA, 1989, AVIAT SPACE ENVIR MD, V60, P653; DASILVA PP, 1984, J CELL BIOL, V99, P1156, DOI 10.1083/jcb.99.3.1156; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; DEGROOT RP, 1990, J CELL SCI, V97, P33; DEGROOT RP, 1991, AVIAT SPACE ENVIR MD, V62, P37; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GUMDER FK, 1988, APPL MICROGRAVITY TE, V9, P115; Gutkind JS, 1996, SEMIN CELL DEV BIOL, V7, P683, DOI 10.1006/scdb.1996.0084; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Heldin CH, 1996, CANCER SURV, V27, P7; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; ITO M, 1989, BIOCHEM BIOPH RES CO, V160, P1344, DOI 10.1016/S0006-291X(89)80151-2; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANDRETH GE, 1985, J CELL BIOL, V101, P1341, DOI 10.1083/jcb.101.4.1341; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lim L, 1996, SEMIN CELL DEV BIOL, V7, P699, DOI 10.1006/scdb.1996.0086; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Marais R, 1996, CANCER SURV, V27, P101; Massague J, 1996, CANCER SURV, V27, P41; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; PAVLATH GK, 1993, CELL STRUCT FUNCT, V18, P151, DOI 10.1247/csf.18.151; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; Pippia P, 1996, J BIOTECHNOL, V47, P215, DOI 10.1016/0168-1656(96)01387-9; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; REBILLARD M, 1987, EXP CELL RES, V172, P432, DOI 10.1016/0014-4827(87)90401-0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rijken P J, 1994, Adv Space Biol Med, V4, P159; RIJKEN PJ, 1995, EXP CELL RES, V218, P223, DOI 10.1006/excr.1995.1150; Rijken PJ, 1998, EXP CELL RES, V243, P254, DOI 10.1006/excr.1998.4142; RIJKEN PJ, 1991, J CELL SCI, V100, P491; RIJKEN PJ, 1993, EXP CELL RES, V204, P373, DOI 10.1006/excr.1993.1045; RIJKEN PJ, 1991, AVIAT SPACE ENVIR MD, V62, P32; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; SPOONER BS, 1990, AVIAT SPACE ENVIR MD, V61, P725; van der Heyden MA, 1997, BBA-MOL CELL RES, V1359, P211, DOI 10.1016/S0167-4889(97)00105-5; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WIEGANT FAC, 1986, J CELL BIOL, V103, P87, DOI 10.1083/jcb.103.1.87; WOODS KM, 1994, EXP CELL RES, V211, P171, DOI 10.1006/excr.1994.1074; ZAMBETTI G, 1991, EXP CELL RES, V192, P93, DOI 10.1016/0014-4827(91)90162-N; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	77	56	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S35	S42		10.1096/fasebj.13.9001.s35	http://dx.doi.org/10.1096/fasebj.13.9001.s35			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352143				2022-12-28	WOS:000080403800005
J	Carmeliet, G; Bouillon, R				Carmeliet, G; Bouillon, R			The effect of microgravity on morphology and gene expression of osteoblasts in vitro	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	bone formation; spaceflight; growth factors; matrix proteins	MESSENGER-RNA LEVELS; MECHANICAL STRAIN; BONE-FORMATION; SPACE-FLIGHT; MATRIX PROTEINS; GROWING RATS; SPACEFLIGHT; CELLS; DIFFERENTIATION; CULTURE	The mass and architecture of the skeletal system adapt, to some extent, to their mechanical environment. A site-specific bone loss of 1-2% is observed in astronauts and in-flight animals after 1 month of spaceflight, Biochemical data of astronauts and histomorphometric analysis of rat bones show that the change in bone mass is a result of decreased bone formation in association with normal (or in creased) bone resorption, The changes in bone formation appear to be due in part to decreased osteoblast differentiation, matrix maturation, and mineralization, Recent data show that spaceflight alters the mRNA level for several bone-specific proteins in rat bone, suggesting that the characteristics of osteoblasts are altered during spaceflight. A possible underlying mechanism is that osteoblasts themselves are sensitive to altered gravity levels as suggested by several studies investigating the effect of microgravity on osteoblasts in vitro. Changes in cell and nuclear morphology were observed as well as alterations in the expression of growth factors (interleukin-6 and insulin-like growth factor binding proteins) and matrix proteins (collagen type I and osteocalcin), Taken together, this altered cellular function in combination with differences in local or systemic factors may mediate the effects of spaceflight on bone physiology.	Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Louvain, Belgium	KU Leuven	Carmeliet, G (corresponding author), LEGENDO Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.	Geert.Carmeliet@med.kuleuven.ac.be						Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; BIKLE DD, 1994, AM J PHYSIOL-ENDOC M, V267, pE822, DOI 10.1152/ajpendo.1994.267.6.E822; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P320, DOI 10.2106/00004623-199173030-00002; Caillot-Augusseau A, 1998, CLIN CHEM, V44, P578; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; Carmeliet G, 1998, BONE, V22, p139S, DOI 10.1016/S8756-3282(98)00007-6; CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; Cavolina JM, 1997, ENDOCRINOLOGY, V138, P1567, DOI 10.1210/en.138.4.1567; Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756-3282(97)00052-5; Damien E, 1998, J BONE MINER RES, V13, P1275, DOI 10.1359/jbmr.1998.13.8.1275; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; DUNCAN RL, 1994, AM J PHYSIOL-RENAL, V267, pF909, DOI 10.1152/ajprenal.1994.267.6.F909; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; Guignandon A, 1997, BONE, V20, P109, DOI 10.1016/S8756-3282(96)00337-7; Guignandon A, 1997, EXP CELL RES, V236, P66, DOI 10.1006/excr.1997.3703; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; JEE WSS, 1983, AM J PHYSIOL, V244, pR310, DOI 10.1152/ajpregu.1983.244.3.R310; Kamata A, 1998, BIOCHEM BIOPH RES CO, V246, P404, DOI 10.1006/bbrc.1998.8632; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; KLEINNULEND J, 1995, J CELL PHYSIOL, V163, P115, DOI 10.1002/jcp.1041630113; Kumei Y, 1998, J APPL PHYSIOL, V85, P139, DOI 10.1152/jappl.1998.85.1.139; Kumei Y, 1996, J BIOTECHNOL, V47, P313, DOI 10.1016/0168-1656(96)01412-5; Lafage-Proust MH, 1998, AM J PHYSIOL-REG I, V274, pR324, DOI 10.1152/ajpregu.1998.274.2.R324; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; NeidlingerWilke C, 1995, J BIOMECH, V28, P1411, DOI 10.1016/0021-9290(95)00089-5; OZAWA H, 1990, J CELL PHYSIOL, V142, P177, DOI 10.1002/jcp.1041420122; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; SHAW SR, 1988, AM J PHYSIOL, V254, pR78, DOI 10.1152/ajpregu.1988.254.1.R78; SIMMONDS N W, 1986, Journal of Natural Rubber Research, V1, P1; SPENGLER DM, 1983, P SOC EXP BIOL MED, V174, P224; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; TILTON FE, 1980, AVIAT SPACE ENVIR MD, V51, P1209; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; TURNER RT, 1985, P SOC EXP BIOL MED, V180, P544; VAILAS AC, 1990, FASEB J, V4, P47, DOI 10.1096/fasebj.4.1.2295378; VICO L, 1988, AM J PHYSIOL, V255, pR243, DOI 10.1152/ajpregu.1988.255.2.R243; VICO L, 1992, J BONE MINER RES, V7, pS445, DOI 10.1002/jbmr.5650071415; WESTERLIND KC, 1995, J BONE MINER RES, V10, P843; WRONSKI TJ, 1987, AM J PHYSIOL, V252, pR252, DOI 10.1152/ajpregu.1987.252.2.R252; WRONSKI TJ, 1983, AM J PHYSIOL, V244, pR305, DOI 10.1152/ajpregu.1983.244.3.R305; Wronski TJ, 1998, J APPL PHYSIOL, V85, P279, DOI 10.1152/jappl.1998.85.1.279; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; Zerath E, 1991, Physiologist, V34, pS194; Zerath E, 1996, J APPL PHYSIOL, V81, P194, DOI 10.1152/jappl.1996.81.1.194; Zerath E, 1996, J APPL PHYSIOL, V81, P164, DOI 10.1152/jappl.1996.81.1.164; Zhuang HM, 1996, BIOCHEM BIOPH RES CO, V229, P449, DOI 10.1006/bbrc.1996.1824; Ziambaras K, 1998, J BONE MINER RES, V13, P218, DOI 10.1359/jbmr.1998.13.2.218	53	69	74	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S129	S134		10.1096/fasebj.13.9001.s129	http://dx.doi.org/10.1096/fasebj.13.9001.s129			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352154				2022-12-28	WOS:000080403800016
J	Yen, CLE; Mar, MH; Zeisel, SH				Yen, CLE; Mar, MH; Zeisel, SH			Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase	FASEB JOURNAL			English	Article						CDP-choline; PtdCho; sphingomyelin; DAG; DNA ladders	PROTEIN-KINASE-C; RAT HEPATOCYTES; PHOSPHOLIPASE-C; SPATIAL MEMORY; KAPPA-B; SUPPLEMENTATION; DEATH; 1-O-OCTADECYL-2-O-METHYL-RAC-GLYCERO-3-PHOSPHOCHOLINE; LYSOPHOSPHATIDYLCHOLINE; 1,2-SN-DIRADYLGLYCEROL	It is not well appreciated that nutritional status can modulate apoptosis, a process that eliminates unwanted or damaged cells. Choline is an essential nutrient, and its absence induces apoptosis. When PC12 cells were cultivated in a choline-free medium, apoptosis was induced (27.4% of cells apoptotic at 72 h as compared to 4.4% in control medium). In choline-free medium at 72 h, there was a 49% decrease in phosphatidylcholine concentration (P<0.01) and a 34% decrease in sphingomyelin concentration (P<0.01); however, there was no change in phosphatidylethanolamine concentration. Before detecting increased apoptosis in choline-deficient cells, we measured a significant increase in ceramide (218% control) and diacyglycerol (155% control) concentrations. The addition of a cell-permeable ceramide to cells in control medium induced apoptosis; however, adding a cell-permeable diacyglycerol did not induce apoptosis. Caspase is a common mediator of apoptosis, and choline deficiency-induced apoptosis was prevented completely by replacing choline or adding a caspase inhibitor into the medium within 48 h of initial choline deprivation. In those cells rescued by replacing choline at 36 h, the concentrations of phosphatidylcholine, sphingomyelin, ceramide, and diacyglycerol returned to levels of control cells. In those cells rescued by adding a caspase inhibitor at 36 h, the concentrations of sphingomyelin and ceramide returned to control levels, but the concentrations of phosphatidylcholine and diacyglycerol did not return to normal. We propose that availability of dietary factors (choline in this model) can modulate apoptosis. Mechanisms that we identify using this model may help us to explain why dietary choline influences brain development.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NIA NIH HHS [AG09525] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albright CD, 1996, FASEB J, V10, P510, DOI 10.1096/fasebj.10.4.8647350; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DACOSTA KA, 1995, CARCINOGENESIS, V16, P327, DOI 10.1093/carcin/16.2.327; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1997, NEUROREPORT, V8, P2831, DOI 10.1097/00001756-199709080-00005; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; *NAT AC SCI US, 1998, DIET REF INT FOL THI; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; POMFRET EA, 1989, ANAL BIOCHEM, V180, P85, DOI 10.1016/0003-2697(89)90091-2; Potten CS, 1996, BRIT J CANCER, V74, P1743, DOI 10.1038/bjc.1996.624; PREISS J, 1986, J BIOL CHEM, V261, P8597; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shin OH, 1997, J CELL BIOCHEM, V64, P196, DOI 10.1002/(SICI)1097-4644(199702)64:2<196::AID-JCB3>3.0.CO;2-S; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SVANBORG A, 1961, ACTA MED SCAND, V169, P43; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WYLLIE AH, 1987, INT REV CYTOL, P755; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zeisel SH, 1997, CARCINOGENESIS, V18, P731, DOI 10.1093/carcin/18.4.731; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; Zeisel SH, 1996, ADV EXP MED BIOL, V399, P131	50	121	124	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					135	142		10.1096/fasebj.13.1.135	http://dx.doi.org/10.1096/fasebj.13.1.135			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872938	Green Submitted			2022-12-28	WOS:000078029500015
J	Steed, PM; Clark, KL; Boyar, WC; Lasala, DJ				Steed, PM; Clark, KL; Boyar, WC; Lasala, DJ			Characterization of human PLD2 and the analysis of PLD isoform splice variants	FASEB JOURNAL			English	Article						PH domains; tissue distribution; alternate splicing; enzyme regulation	PHOSPHOLIPASE-D ACTIVITY; PLECKSTRIN HOMOLOGY DOMAIN; ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; D ACTIVATION; RAT-BRAIN; D DEFINES; BINDING; CLONING; CELLS	Phospholipase D (PLD) cleaves phosphatidylcholine in response to a variety of cell stimuli to release phosphatidic acid, which is associated with a number of cellular responses including regulated secretion, mitogenesis, and cytoskeletal changes. Recent advances in this field include the reports of cDNA sequences for two mammalian PLD isoforms: human PLD1 and rodent PLD2, We report the characterization of cDNA encoding human PLD2, In these experiments, we uncovered alternate splice variants of both human isoforms and evaluated the relative abundance of these messages by reverse transcriptase polymerase chain reaction, thereby indicating the physiologically relevant forms. Further, Northern hybridization experiments defined the tissue distribution of the human PLD messages. Human PLD1 does not appear to be an abundant message in any tissue tested whereas levels of human PLD2 mRNA apparently were higher and more variable. The specific activity and regulation of recombinant human PLD2 are indistinguishable from that of recombinant mouse PLD2, Analysis of the amino acid sequences of both human isoforms revealed important putative Pleckstrin homology domains and identified additional members of the PLD gene family that help to delimit the catalytic domain. The presence of Pleckstrin homology domains in the PLDs resolves several contradictory observations regarding PLD regulation and the domain structure of the proteins.	Novartis Inst Biomed Res, Summit, NJ 07901 USA	Novartis	Steed, PM (corresponding author), Novartis Inst Biomed Res, 556 Morris Ave, Summit, NJ 07901 USA.	paul.steed@pharma.novartis.com						BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; CARRASCOMARIN E, 1994, EUR J IMMUNOL, V24, P2031, DOI 10.1002/eji.1830240915; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; CLARK KL, 1991, THESIS KANSAS STATE; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; KANOH H, 1992, J BIOL CHEM, V267, P25309; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; Natarajan V, 1997, CHEM PHYS LIPIDS, V86, P65, DOI 10.1016/S0009-3084(97)02660-1; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; REDINA OE, 1998, IN PRESS BIOCH J; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519	30	98	105	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1309	1317		10.1096/fasebj.12.13.1309	http://dx.doi.org/10.1096/fasebj.12.13.1309			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761774				2022-12-28	WOS:000076402000006
J	Trusolino, L; Pugliese, L; Comoglio, PM				Trusolino, L; Pugliese, L; Comoglio, PM			Interactions between scatter factors and their receptors: hints for therapeutic applications	FASEB JOURNAL			English	Review						hepatocyte growth factor scatter factor; macrophage stimulating protein; c-MET; RON; tyrosine kinases; growth factors	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE-ACTIVITY; C-MET RECEPTOR; FULMINANT HEPATIC-FAILURE; MOLECULAR-CLONING; BLOOD-COAGULATION; EPITHELIAL-CELLS; HGF-RECEPTOR; PROTEOLYTIC CLEAVAGE	The scatter factors, which include hepatocyte growth factor and macrophage stimulating protein, stand out from other cytokines because of their uncommon biological properties. In addition to promoting cell growth and protection from apoptosis, they are involved in the control of cell dissociation, migration into extracellular matrices, and a unique process of differentiation called 'branching morphogenesis'. Through the concerted regulation of these complex phenomena, scatter factors promote development, regeneration, and reconstruction of normal organ architecture. In transformed epithelia, scatter factors can mediate tumor invasive growth, a harmful feature of neoplastic progression in which cancer cells invade surrounding tissues, penetrate across the vascular walls, and eventually disseminate throughout the body, giving rise to systemic metastases. A much-debated issue in basic biology, which has strong implications for experimental medicine, is how to dissociate the favorable effects of growth factors from their adverse ones. Accordingly, to find agonists or antagonists with potential therapeutic applications is a crucial undertaking for current research. Domain-mapping analyses of growth factor molecules can help to isolate specific structural requirements for the induction of selective biological effects. Based on the observation that certain growth factors must undergo posttranslational modifications to exert a full response, it is possible to interfere with their activation mechanisms to modulate their functions. Finally, the identification of cell type-specific coreceptors able to potentiate their activity allows drawing of a functional body map, where some organs or tissues may be more responsive than others to growth factors. This review is focused on how, and to what extent, scatter factors can behave 'well' or 'badly' according to their molecular structure, the way they are activated, and the way they interact with cell surface receptors and coreceptors.	Univ Turin, IRCC, Div Mol Oncol, Inst Canc Res,Sch Med, I-10060 Candiolo, TO, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Comoglio, PM (corresponding author), Univ Turin, IRCC, Div Mol Oncol, Inst Canc Res,Sch Med, Str Prov 142,Km 3095, I-10060 Candiolo, TO, Italy.	pcomoglio@ircc.unito.it	Trusolino, Livio/A-3896-2011	Trusolino, Livio/0000-0002-6379-3365; Comoglio, Paolo/0000-0002-7056-5328				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARDIN AD, METHODS ENZYMOL, V203, P556; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Eguchi S, 1996, HEPATOLOGY, V24, P1452; FALETTO DL, 1992, ONCOGENE, V7, P1149; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1990, BIOCHIM BIOPHYS ACTA, V1053, P21, DOI 10.1016/0167-4889(90)90020-E; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HAMANOUE M, 1992, HEPATOLOGY, V16, P1485, DOI 10.1002/hep.1840160626; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Han S, 1993, EXS, V65, P81; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HEIMARK RL, 1980, NATURE, V286, P456, DOI 10.1038/286456a0; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; JOANNIDIS M, 1994, AM J PHYSIOL, V267, pF231, DOI 10.1152/ajprenal.1994.267.2.F231; Kaido T, 1996, BIOCHEM BIOPH RES CO, V218, P1, DOI 10.1006/bbrc.1996.0001; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KINOSHITA T, 1989, BIOCHEM BIOPH RES CO, V165, P1229, DOI 10.1016/0006-291X(89)92733-2; KOBAYASHI T, 1994, J BIOL CHEM, V269, P9817; LEE CC, 1995, J BIOL CHEM, V270, P507, DOI 10.1074/jbc.270.2.507; LEV S, 1992, J BIOL CHEM, V267, P15970; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; LONGATI P, 1994, ONCOGENE, V9, P49; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARS WM, 1993, AM J PATHOL, V143, P949; Massague J, 1996, NATURE, V382, P29, DOI 10.1038/382029a0; MATSUDA Y, 1995, J BIOCHEM-TOKYO, V118, P643, DOI 10.1093/oxfordjournals.jbchem.a124958; Matsuda Y, 1997, HEPATOLOGY, V26, P81; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; Matsumoto K, 1993, EXS, V65, P225; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MILLER SB, 1994, AM J PHYSIOL, V266, pF129, DOI 10.1152/ajprenal.1994.266.1.F129; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Ohshiro K, 1996, BIOCHEM BIOPH RES CO, V227, P273, DOI 10.1006/bbrc.1996.1500; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PELICCI G, 1995, ONCOGENE, V10, P1631; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sakamoto O, 1997, J CLIN INVEST, V99, P701, DOI 10.1172/JCI119214; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI M, 1995, J CLIN INVEST, V95, P1994, DOI 10.1172/JCI117884; Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565; Takayama H, 1997, LAB INVEST, V77, P131; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TAKEBAYASHI T, 1995, J CELL BIOL, V129, P1411, DOI 10.1083/jcb.129.5.1411; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TSUBOUCHI H, 1989, HEPATOLOGY, V9, P875, DOI 10.1002/hep.1840090615; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANZONNEVELD AJ, 1986, J CELL BIOCHEM, V32, P169, DOI 10.1002/jcb.240320302; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; Waltz SE, 1997, J BIOL CHEM, V272, P30526, DOI 10.1074/jbc.272.48.30526; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Yaekashiwa M, 1997, AM J RESP CRIT CARE, V156, P1937, DOI 10.1164/ajrccm.156.6.9611057; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yasuda H, 1996, HEPATOLOGY, V24, P636, DOI 10.1002/hep.510240328; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHEN Z, 1994, ONCOGENE, V9, P1691; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	150	74	80	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1267	1280		10.1096/fasebj.12.13.1267	http://dx.doi.org/10.1096/fasebj.12.13.1267			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761771				2022-12-28	WOS:000076402000003
J	Van Schooten, FJ; Hirvonen, A; Maas, LM; De Mol, BA; Kleinjans, JCS; Bell, DA; Durrer, JD				Van Schooten, FJ; Hirvonen, A; Maas, LM; De Mol, BA; Kleinjans, JCS; Bell, DA; Durrer, JD			Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue	FASEB JOURNAL			English	Article						smoking related DNA adducts; genetic polymorphisms; CAD	HUMAN ATHEROSCLEROTIC LESIONS; WHITE BLOOD-CELLS; HEART-DISEASE; VITAMIN-D; CANCER BIOMARKERS; SERUM-CHOLESTEROL; CIGARETTE-SMOKING; LUNG-CANCER; FOLLOW-UP; RISK	Cancer and cardiovascular diseases share risk factors such as smoking, and the onset of both diseases have been suggested to have a common mechanistic basis. The binding of carcinogens to DNA (carcinogen-DNA adducts), genetic polymorphisms in carcinogen-detoxifying enzymes glutathione Stransferases (GSTs), and genetic polymorphisms in the vitamin D receptor (VDR) are among the candidates for modifiers of cancer risk. We determined whether these biomarkers could be related to individual characteristics of patients suffering from cardiovascular diseases. For that purpose, DNA from the right atrial appendage of 41 patients who underwent open heart surgery was analyzed for smoking-related DNA adducts and polymorphisms in GSTM1, GSTT1, and VDR genes. Statistical analysis was used to identify any patient's characteristics associated with these molecular markers. Our results showed that heart tissue of cigarette smokers contained a variety of aromatic DNA adducts in significantly elevated levels compared to ex-smokers (P<0.01) or nonsmokers (P<0.001). A linear relationship was observed between DNA adduct levels and daily cigarette smoking (r(s)=0.73; P=0.0003). Since cardiac myocytes are terminally differentiated cells that have lost their ability to divide and seemingly have limited DNA repair capacities, their levels might accumulate with time and thereby affect heart cell function or viability. Substantial interindividual differences between DNA adduct levels were observed, and persons with severe coronary artery disease (CAD), as assessed by coronary angiography, had higher DNA adduct levels than persons with no or mild CAD (P=0.04). As polymorphisms in GST genes have been shown to modulate DNA adduct levels and risk for lung cancer in smokers, we explored for the first time whether the GST polymorphisms could also explain deviating; heart DNA adduct levels wand CAD risk. However, no relation could be found between these covariants. In contrast, a VDR genotype, which has been associated with decreased serum levels of the active hormonal form of vitamin D and increased risk for certain cancers, seemed to be related to severity of CAD (P=0.025). Our findings support the hypothesis that smoking-related DNA damage may be involved in the onset of cardiovascular diseases and suggest that VDR genotype may be a useful susceptibility marker of CAD.	Univ Limburg, Dept Hlth Risk Anal & Toxicol, NL-6200 MD Maastricht, Netherlands; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Helsinki, Finland; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiothorac Surg, NL-1105 AZ Amsterdam, Netherlands; NIEHS, Biochem Risk Anal Lab, Res Triangle Pk, NC 27709 USA	Hasselt University; Maastricht University; Finnish Institute of Occupational Health; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Van Schooten, FJ (corresponding author), Univ Limburg, Dept Hlth Risk Anal & Toxicol, NL-6200 MD Maastricht, Netherlands.	f.vanschooten@grat.unimaas.nl	Kleinjans, Jos C.S./E-7241-2015; Bell, Douglas A/C-7687-2019	Bell, Douglas A/0000-0001-7700-0840; de Mol, Bastian/0000-0001-6888-9430				BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BOARD PG, 1981, AM J HUM GENET, V33, P36; BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; DAGOSTINI F, 1995, CANCER EPIDEM BIOMAR, V4, P111; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; EVERSON RB, 1988, J NATL CANCER I, V80, P567, DOI 10.1093/jnci/80.8.567; FRASER DR, 1995, LANCET, V345, P104, DOI 10.1016/S0140-6736(95)90067-5; Gaubatz JW, 1997, J NUTR BIOCHEM, V8, P490, DOI 10.1016/S0955-2863(97)00080-6; GINSBERG GL, 1990, CANCER RES, V50, P1189; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HALL M, 1990, CHEM CARCINOGENESIS, V1, P327; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTZ AJ, 1984, NEW ENGL J MED, V311, P1201, DOI 10.1056/NEJM198411083111901; HIRVONEN A, 1993, CARCINOGENESIS, V14, P1479, DOI 10.1093/carcin/14.7.1479; Hoffmann D., 1990, CHEM CARCINOGENESIS, P63, DOI [10.1007/978-3-642-74775-5_3, DOI 10.1007/978-3-642-74775-5_3]; IZZOTTI A, 1994, CANCER RES, V54, pS1994; IZZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; LEWTAS J, 1993, ENVIRON HEALTH PERSP, V99, P89, DOI 10.2307/3431463; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; PENN A, 1986, P NATL ACAD SCI USA, V83, P7951, DOI 10.1073/pnas.83.20.7951; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; PUTNAM JB, 1991, ANN THORAC SURG, V51, P906, DOI 10.1016/0003-4975(91)91003-E; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; SADHU D, 1993, ANTIMUTAGENESIS ANTI, P263; SANDGREN ME, 1991, BIOCHEM BIOPH RES CO, V181, P611, DOI 10.1016/0006-291X(91)91234-4; SCHULTE PA, 1993, MOL EPIDEMIOLOGY PRI, P341; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; SCRAGG R, 1992, ANN EPIDEMIOL, V2, P679; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STUDZINSKI GP, 1995, CANCER RES, V55, P4014; Taylor JA, 1996, CANCER RES, V56, P4108; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P5397, DOI 10.1073/pnas.91.12.5397; TROLL W, 1993, 4TH P INT C ANT RAD, P72; VanSchooten FJ, 1997, MUTAT RES-FUND MOL M, V378, P65, DOI 10.1016/S0027-5107(97)00098-5; VANSCHOOTEN FJ, 1990, CARCINOGENESIS, V11, P1677, DOI 10.1093/carcin/11.9.1677; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WARWICK A, 1994, CARCINOGENESIS, V15, P2841, DOI 10.1093/carcin/15.12.2841; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8	56	82	86	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1409	1417		10.1096/fasebj.12.13.1409	http://dx.doi.org/10.1096/fasebj.12.13.1409			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761785				2022-12-28	WOS:000076402000017
J	Beck, MA; Esworthy, RS; Ho, YS; Chu, FF				Beck, MA; Esworthy, RS; Ho, YS; Chu, FF			Glutathione peroxidase protects mice from viral-induced myocarditis	FASEB JOURNAL			English	Article						selenium; GPX-1; malondialdehyde; virus titer; cardiac pathology	SELENIUM-DEFICIENT MICE; COXSACKIEVIRUS B3; HUMAN ENTEROVIRUS; KESHAN DISEASE; RNA; CATALASE; MALONDIALDEHYDE; EVOLUTION; INFECTION; VIRULENT	Glutathione peroxidase 1 (GPX-1) is a selenium-dependent enzyme with antioxidant properties, Previous investigations determined that mice deficient in selenium developed myocarditis when infected with a benign strain of coxsackievirus B3 (CVB3/0), To determine whether this effect was mediated by GPX-1, mice with a disrupted Gpx1 gene (Glbx1(-/-)) were infected with CVB3/0, Gpx1(-/-) mice developed myocarditis after CVB3/0 infection, whereas infected wild-type mice (Gpx1(+/+)) were resistant. Sequencing of viruses recovered from Gpx1(-/-)-infected mice demonstrated seven nucleotide changes in the viral genome, of which three occurred at the G residue, the most easily oxidized base, No changes were found in virus isolated from Gpx1(+/+) mice. These results demonstrate that GPX-1 provides protection against viral-induced damage in vivo due to mutations in the viral genome of a benign virus.	Univ N Carolina, Dept Pediat, FPG Child Dev Ctr, Chapel Hill, NC 27599 USA; City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA 91010 USA; Wayne State Univ, Inst Chem Toxicol, Detroit, MI 48201 USA	University of North Carolina; University of North Carolina Chapel Hill; City of Hope; Wayne State University	Beck, MA (corresponding author), Univ N Carolina, Dept Pediat, FPG Child Dev Ctr, 105 Smith Level Rd,CB 8180, Chapel Hill, NC 27599 USA.	melinda_beck@unc.edu		Esworthy, Steve/0000-0002-4111-3349	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54123] Funding Source: Medline; NIDDK NIH HHS [DK46921] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6693] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AKMAN SA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P70, DOI 10.1016/0167-4781(89)90080-8; ALBRO PW, 1987, LIPIDS, V22, P751, DOI 10.1007/BF02533976; BECK MA, 1994, J INFECT DIS, V170, P351, DOI 10.1093/infdis/170.2.351; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; Beck MA, 1996, J NUTR BIOCHEM, V7, P683, DOI 10.1016/S0955-2863(96)00132-5; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; BECK MA, 1994, J NUTR, V124, P345, DOI 10.1093/jn/124.3.345; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chapman NM, 1997, J MED VIROL, V52, P258; CHAPMAN NM, 1994, ARCH VIROL, V135, P115, DOI 10.1007/BF01309769; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHU FF, 1993, J BIOL CHEM, V268, P2571; COMBS GF, 1984, ANNU REV NUTR, V4, P257, DOI 10.1146/annurev.nu.04.070184.001353; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Domingo E, 1997, BIOL TRACE ELEM RES, V56, P23, DOI 10.1007/BF02778981; Domingo E, 1995, MOL EVOLUTION VIRUSE, P181; Domingo Esteban, 1994, P161; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; GE KY, 1983, VIRCHOWS ARCH A, V401, P1, DOI 10.1007/BF00644785; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; JANERO DR, 1988, LIPIDS, V23, P452, DOI 10.1007/BF02535519; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; LIN FB, 1993, ARCH BIOCHEM BIOPHYS, V305, P176, DOI 10.1006/abbi.1993.1408; MARTINO TA, 1977, HUMAN ENTEROVIRUS IN, P291; RAES M, 1987, FREE RADICAL BIO MED, V3, P3, DOI 10.1016/0891-5849(87)90032-3; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SCHWARZ K, 1957, J AM CHEM SOC, V79, P3292, DOI 10.1021/ja01569a087; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SPALLHOLZ JE, 1990, ANN NY ACAD SCI, V587, P123, DOI 10.1111/j.1749-6632.1990.tb00140.x; STEINHAUER DA, 1992, GENE, V122, P281, DOI 10.1016/0378-1119(92)90216-C; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TU ZG, 1995, J VIROL, V69, P4607, DOI 10.1128/JVI.69.8.4607-4618.1995; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320; ZHANG LP, 1989, BIOCHIM BIOPHYS ACTA, V1006, P140, DOI 10.1016/0005-2760(89)90336-6	43	156	166	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1143	1149		10.1096/fasebj.12.12.1143	http://dx.doi.org/10.1096/fasebj.12.12.1143			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737717				2022-12-28	WOS:000075738500009
J	Hu, YH; Bock, G; Wick, G; Xu, QB				Hu, YH; Bock, G; Wick, G; Xu, QB			Activation of PDGF receptor alpha in vascular smooth muscle cells by mechanical stress	FASEB JOURNAL			English	Article						phosphorylation; MAP kinases; shear stress; AP-1 binding; platelet-derived growth factor receptor	ENDOTHELIAL-CELLS; PROTEIN-KINASES; SHEAR-STRESS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HYPERTENSION RESEARCH; B-CHAIN; GROWTH; STRAIN; ARTERIES	Hypertension increases mechanical force on the arterial wall by as much as 30%, resulting in marked alterations in signal transductions and gene expression in vascular smooth muscle cells (VSMCs) that contribute to matrix protein synthesis, cell proliferation, and differentiation. How the mechanical stimuli are converted into a biological signal in cells has yet to be studied. We investigated the role of both cyclic strain and shear stresses in initiating the cellular signaling on cultured VSMCs and found that mechanical forces evoked activation of mitogen-activated protein kinases, followed by enhanced DNA binding activity of transcription factor AP-1, Physical forces rapidly induced phosphorylation of platelet-derived growth factor receptor (PDGFR) alpha, an activated state. When GRB2, an adapter protein, was immunoprecipitated from treated VSMCs followed by Western blot analysis with anti-phosphotprosine, -PDGFR alpha, and -GRB2 antibodies, respectively, phosphotyrosine positive staining was observed on PDGFR alpha bands of the same blot in stretch-stressed VSMCs, supporting the mechanical stress-induced activation of PDGFR alpha, Conditioned medium from stretch-stressed VSMCs did not result in PDGFR alpha phosphorylation, and antibodies binding to all forms of PDGFs did not block stress-induced PDGFR alpha activation. Thus, mechanical stresses may directly perturb the cell surface or alter receptor conformation, thereby initiating signaling pathways normally used by growth factors.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Univ Innsbruck, Sch Med, Inst Gen & Expt Pathol, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; University of Innsbruck	Xu, QB (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.	qingbo.xu@oeaw.ac.at						ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANTONIADES HN, 1981, P NATL ACAD SCI-BIOL, V78, P7314, DOI 10.1073/pnas.78.12.7314; BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BENES AJ, 1985, J CELL SCI, V75, P35; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DWORKIN B, 1988, BEHAVIOURAL MED CARD, P27; DZAU VJ, 1994, HYPERTENSION, V23, P1132, DOI 10.1161/01.HYP.23.6.1132; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FOLKOW B, 1995, J HYPERTENS, V13, P5; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FRANGOS JA, 1993, PHYSICAL FORCES MAMM; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HENRY JP, 1990, J HYPERTENS, V8, P783, DOI 10.1097/00004872-199009000-00001; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Hu YH, 1997, J BIOL CHEM, V272, P9113; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LIU MY, 1995, AM J PHYSIOL-LUNG C, V269, pL178, DOI 10.1152/ajplung.1995.269.2.L178; Liu YS, 1996, J BIOL CHEM, V271, P3604; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PATRICK CW, 1995, BLOOD PURIFICAT, V13, P112; PICKERING TG, 1988, BEHAVIOURAL MED CARD, P71; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Xu QB, 1996, LAB INVEST, V74, P178; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zou YP, 1998, INT J MOL MED, V1, P827	49	169	182	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1135	1142		10.1096/fasebj.12.12.1135	http://dx.doi.org/10.1096/fasebj.12.12.1135			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737716				2022-12-28	WOS:000075738500008
J	Marlovits, TC; Zechmeister, T; Gruenberger, M; Ronacher, B; Schwihla, H; Blaas, D				Marlovits, TC; Zechmeister, T; Gruenberger, M; Ronacher, B; Schwihla, H; Blaas, D			Recombinant soluble law density lipoprotein receptor fragment inhibits minor group rhinovirus infection in vitro	FASEB JOURNAL			English	Article						human rhinovirus; LDLR; viral inhibition; baculovirus expression	INTERCELLULAR-ADHESION MOLECULE-1; LDL RECEPTOR; NEUTRALIZING ANTIBODY; PROTEIN; EXPRESSION; SEROTYPE-2; BINDING; SIGNAL; ICAM-1; CELLS	A fragment of the low density lipoprotein receptor encompassing the seven ligand binding repeats was expressed in Sf9 insect cells as a fusion protein with a carboxyl-terminally linked hexa-his tag by using a baculovirus vector, Up to 10 mg/l of the fusion protein was secreted into the medium. The material was soluble in the absence of detergent and active in binding beta very low density lipoprotein and a member of the minor group of human rhinoviruses (HRV2) in ligand blots from sodium dodecyl sulfate-polyacrylamide gels run under nonreducing conditions, The receptor fragment specifically inhibits viral infection of HeLa cells by minor group HRVs in a concentration-dependent manner. Viral infectivity is neutralized by aggregation.	Univ Vienna, Inst Biochem, A-1030 Vienna, Austria; Univ Agr Forestry & Renewable Nat Resources, Inst Appl Genet, A-1190 Vienna, Austria	University of Vienna	Blaas, D (corresponding author), Univ Vienna, Inst Biochem, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.		Marlovits, Thomas/A-3568-2019	Marlovits, Thomas/0000-0001-8106-4038				ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; ARRUDA E, 1992, ANTIMICROB AGENTS CH, V36, P1186, DOI 10.1128/AAC.36.6.1186; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; GREVE JM, 1991, J VIROL, V65, P6015, DOI 10.1128/JVI.65.11.6015-6023.1991; GRUENBERGER M, 1995, J VIROL, V69, P7244, DOI 10.1128/JVI.69.11.7244-7247.1995; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; HOFER F, 1994, P NATL ACAD SCI USA, V91, P18839; HOOVERLITTY H, 1993, J VIROL, V67, P390, DOI 10.1128/JVI.67.1.390-397.1993; KORANT BD, 1972, VIROLOGY, V48, P71, DOI 10.1016/0042-6822(72)90115-8; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MISCHAK H, 1988, J GEN VIROL, V69, P2653, DOI 10.1099/0022-1317-69-10-2653; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; PATEL DD, 1995, BBA-LIPID LIPID MET, V1255, P285, DOI 10.1016/0005-2760(94)00243-R; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; PRCHLA E, 1994, J VIROL, V68, P3713, DOI 10.1128/JVI.68.6.3713-3723.1994; PRCHLA E, 1995, J CELL BIOL, V131, P111, DOI 10.1083/jcb.131.1.111; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SMITH TJ, 1993, J VIROL, V67, P1148, DOI 10.1128/JVI.67.3.1148-1158.1993; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299	28	35	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					695	703		10.1096/fasebj.12.9.695	http://dx.doi.org/10.1096/fasebj.12.9.695			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619448				2022-12-28	WOS:000074011000008
J	Lyall, F; Barber, A; Myatt, L; Bulmer, JN; Robson, SC				Lyall, F; Barber, A; Myatt, L; Bulmer, JN; Robson, SC			Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function	FASEB JOURNAL			English	Article						pregnancy; spiral artery; HO-1; H0-2; protoporphyrin	NITRIC-OXIDE SYNTHASE; HEME OXYGENASE INHIBITORS; FETAL GROWTH-RETARDATION; HSP32 MESSENGER-RNA; CARBON-MONOXIDE; SPIRAL ARTERIES; BLOOD-FLOW; PREGNANCY; RAT; PROTEIN	The purpose of this study was to examine the expression of hemeoxygenases HO-1 and HO-2, which are responsible for the production of carbon monoxide (CO), in the human placenta and placental bed and to determine the role of inhibitors of HO on placental perfusion pressure. We hypothesized that HO is expressed within the placenta and that invading cytotrophoblast cells (CTB) express HO isoforms. The expression of HO-1 and HO-2 was studied on placenta and placental bed biopsies, obtained using a transcervical sampling technique, from normal human pregnancies between 8 and 19 wk gestation and at term. in the placenta, HO-2 immunostaining was prominent in syncytiotrophoblast in the first trimester and reduced toward term (P<0.0005). HO-2 endothelial immunostaining was weak in the first trimester, but increased by term (P<0.0005). Within the placental bed, HO-2 was expressed by CTB in cell columns, the cytotrophoblast shell, and cell islands. Both intravascular CTB and interstitial CTB expressed HO-2. HO-1 immunostaining was low in the placenta but intense on the CTB within the placental bed. A striking feature was the absence of HO-1 from the proximal layers of cell columns, with strong expression on the more distal CTB layers of the cell columns. in placental perfusion studies, a significant dose-dependent increase in perfusion pressure was observed in the presence of zinc protoporphyrin, an inhibitor of HO. These results suggest a role for CO in placental function, trophoblast invasion, and spiral artery transformation. Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function.	Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of Glasgow; University System of Ohio; University of Cincinnati; Newcastle University - UK	Lyall, F (corresponding author), Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland.							Barber A, 1999, AM J PATHOL, V155, P831, DOI 10.1016/S0002-9440(10)65182-6; BLANKENSHIP TN, 1993, CELL TISSUE RES, V274, P135, DOI 10.1007/BF00327994; BOURA ALA, 1994, CLIN EXP PHARMACOL P, V21, P737, DOI 10.1111/j.1440-1681.1994.tb02441.x; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P569, DOI 10.1002/path.1700930218; BROSENS IA, 1977, CLIN OBSTET GYNAECOL, V4, P573; Chakder S, 1996, J PHARMACOL EXP THER, V277, P1376; Conrad KP, 1995, PLACENTA, V16, P691, DOI 10.1016/0143-4004(95)90013-6; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; Craven CM, 1998, PLACENTA, V19, P241, DOI 10.1016/S0143-4004(98)90055-8; CRUSE I, 1988, J BIOL CHEM, V263, P2348; DEWOLF F, 1973, AM J OBSTET GYNECOL, V117, P833, DOI 10.1016/0002-9378(73)90500-0; DEWOLF F, 1980, BRIT J OBSTET GYNAEC, V87, P177; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; GAILLARD DA, 1993, ARCH PATHOL LAB MED, V117, P1022; GLANCE DG, 1984, AM J OBSTET GYNECOL, V149, P450, DOI 10.1016/0002-9378(84)90161-3; GUDE NM, 1990, LANCET, V336, P1589, DOI 10.1016/0140-6736(90)93374-X; HAXTON MJ, 1983, BRIT J OBSTET GYNAEC, V90, P501, DOI 10.1111/j.1471-0528.1983.tb08955.x; HUSTIN J, 1990, PLACENTA, V11, P477, DOI 10.1016/S0143-4004(05)80193-6; JAUNIAUX E, 1994, HUM REPROD, V9, P2432, DOI 10.1093/oxfordjournals.humrep.a138465; JOHNSON RA, 1995, HYPERTENSION, V25, P166, DOI 10.1161/01.HYP.25.2.166; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KHONG TY, 1987, BRIT J OBSTET GYNAEC, V94, P649, DOI 10.1111/j.1471-0528.1987.tb03169.x; KHONG TY, 1995, FETUS NEONATE, V3; Kingdom J, 1998, PLACENTA, V19, P347, DOI 10.1016/S0143-4004(98)90073-X; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; KUTTY RK, 1989, ARCH BIOCHEM BIOPHYS, V268, P100, DOI 10.1016/0003-9861(89)90569-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERE RD, 1993, AM J HEMATOL, V43, P19, DOI 10.1002/ajh.2830430106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNELL NO, 1979, GYNECOL OBSTET INVES, V10, P106, DOI 10.1159/000299924; Lyall F, 1999, AM J PATHOL, V154, P1105, DOI 10.1016/S0002-9440(10)65363-1; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; MAINES MD, 1988, FASEB J, V2, P2257; Mancuso C, 1997, MOL BRAIN RES, V45, P294, DOI 10.1016/S0169-328X(96)00258-6; MANSOURI A, 1982, THROMB HAEMOSTASIS, V48, P286; MCFADYEN IR, 1986, BRIT J OBSTET GYNAEC, V93, P476, DOI 10.1111/j.1471-0528.1986.tb07933.x; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MICHEL MZ, 1990, BRIT J OBSTET GYNAEC, V97, P984, DOI 10.1111/j.1471-0528.1990.tb02468.x; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MUHLHAUSER J, 1995, J HISTOCHEM CYTOCHEM, V43, P579, DOI 10.1177/43.6.7539466; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; MYATT L, 1992, AM J OBSTET GYNECOL, V166, P224, DOI 10.1016/0002-9378(92)91863-6; MYATT L, 1993, PLACENTA, V14, P373, DOI 10.1016/S0143-4004(05)80459-X; MYATT L, 1991, AM J OBSTET GYNECOL, V164, P687, DOI 10.1016/S0002-9378(11)80047-5; MYATT L, 1992, PLACENTA, V13, P1; Ni X, 1997, J CLIN ENDOCR METAB, V82, P4171, DOI 10.1210/jc.82.12.4171; Odrcich MJ, 1998, PLACENTA, V19, P509, DOI 10.1016/S0143-4004(98)91044-X; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; PIJNENBORG R, 1983, PLACENTA, V4, P397, DOI 10.1016/S0143-4004(83)80043-5; PIJNENBORG R, 1980, PLACENTA, V1, P3, DOI 10.1016/S0143-4004(80)80012-9; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SCHNEIDER H, 1991, PLACENTAL TOXICOLOGY, P1; Serfas L, 1998, ARCH BIOCHEM BIOPHYS, V359, P8, DOI 10.1006/abbi.1998.0887; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; SHEPPARD BL, 1976, BRIT J OBSTET GYNAEC, V83, P948, DOI 10.1111/j.1471-0528.1976.tb00781.x; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Vreman HJ, 1996, CAN J PHYSIOL PHARM, V74, P278, DOI 10.1139/cjpp-74-3-278; WIECZOREK KM, 1995, AM J OBSTET GYNECOL, V173, P708, DOI 10.1016/0002-9378(95)90327-5; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	64	123	133	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					208	219		10.1096/fasebj.14.1.208	http://dx.doi.org/10.1096/fasebj.14.1.208			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627295				2022-12-28	WOS:000084784700023
J	Antic, S; Cohen, LB; Lam, YW; Wachowiak, M; Zecevic, D; Zochowski, M				Antic, S; Cohen, LB; Lam, YW; Wachowiak, M; Zecevic, D; Zochowski, M			Fast multisite optical measurement of membrane potential: three examples	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		VOLTAGE-SENSITIVE DYES; GILL-WITHDRAWAL REFLEX; CENTRAL NERVOUS-SYSTEM; FUNCTIONAL-ORGANIZATION; NEURONAL-ACTIVITY; OLFACTORY-BULB; APLYSIA; CELL; FLUORESCENCE; DENDRITES		Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Antic, S (corresponding author), 333 Cedar St, New Haven, CT 06520 USA.	antic@fred.med	Zecevic, Dejan/A-9824-2008	Zecevic, Dejan/0000-0002-8917-5784; Antic, Srdjan/0000-0001-7102-4710; Zochowski, Michal/0000-0002-1722-986X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008437] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08437] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRIAN ED, 1950, ELECTROEN CLIN NEURO, V2, P377, DOI 10.1016/0013-4694(50)90075-7; ANTIC S, 1995, J NEUROSCI, V15, P1392; Antic S, 1997, BIOL BULL, V193, P261, DOI 10.1086/BBLv193n2p261; Antic S, 1999, J NEUROPHYSIOL, V82, P1615, DOI 10.1152/jn.1999.82.3.1615; COHEN LB, 1978, REV PHYSIOL BIOCH P, V83, P35, DOI 10.1007/3-540-08907-1_2; DAVILA HV, 1973, NATURE-NEW BIOL, V241, P159, DOI 10.1038/newbio241159a0; FREEMAN WJ, 1986, BEHAV NEUROSCI, V100, P753, DOI 10.1037/0735-7044.100.5.753; FREEMAN WJ, 1978, ELECTROEN CLIN NEURO, V44, P586, DOI 10.1016/0013-4694(78)90126-8; GRINVALD A, 1987, BIOPHYS J, V51, P643, DOI 10.1016/S0006-3495(87)83389-1; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HICKIE C, 1996, ABS SOC NEUR, V22, P321; KAMINO K, 1991, PHYSIOL REV, V71, P53, DOI 10.1152/physrev.1991.71.1.53; LAM YW, 1998, ELECTROPHYSIOLOGICAL; LAM YW, 1998, ABS SOC NEUR, V24, P909; LAM YW, 1997, ABS SOC NEUR, V23, P1269; LOEW LM, 1985, BIOPHYS J, V47, P71, DOI 10.1016/S0006-3495(85)83878-9; LOEW LM, 1994, NEUROPROTOCOLS, V5, P72; MAGEE JC, 1995, J NEUROPHYSIOL, V74, P1335, DOI 10.1152/jn.1995.74.3.1335; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; MOMOSESATO Y, 1995, J MEMBRANE BIOL, V144, P167, DOI 10.1007/bf00232802; NAKASHIMA M, 1992, IEEE T BIO-MED ENG, V39, P26, DOI 10.1109/10.108124; NIRENBERG S, 1993, J NEUROSCI, V13, P3238, DOI 10.1523/jneurosci.13-08-03238.1993; ORBACH HS, 1983, J NEUROSCI, V3, P2251; ROSS WN, 1977, J MEMBRANE BIOL, V33, P141, DOI 10.1007/BF01869514; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; Siegel MS, 1997, NEURON, V19, P735, DOI 10.1016/S0896-6273(00)80955-1; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Tsau Y, 1996, J NEUROSCI METH, V70, P121, DOI 10.1016/S0165-0270(96)00109-4; TSAU Y, 1994, J NEUROSCI, V14, P4167; Wenner P, 1996, J NEUROSCI METH, V70, P111, DOI 10.1016/S0165-0270(96)00108-2; Wu J.-Y., 1993, FLUORESCENT LUMINESC, P389; Wu JY, 1998, HISTOCHEM J, V30, P169, DOI 10.1023/A:1003295319615; WU JY, 1994, J NEUROSCI, V14, P1366, DOI 10.1523/JNEUROSCI.14-03-01366.1994; Zecevic D, 1996, NATURE, V381, P322, DOI 10.1038/381322a0; ZECEVIC D, 1989, J NEUROSCI, V9, P3681	35	7	7	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S271	S276		10.1096/fasebj.13.9002.S271	http://dx.doi.org/10.1096/fasebj.13.9002.S271			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619142				2022-12-28	WOS:000084390200020
J	Hess, DA; Sisson, ME; Suria, H; Wijsman, J; Puvanesasingham, R; Madrenas, J; Reider, MJ				Hess, DA; Sisson, ME; Suria, H; Wijsman, J; Puvanesasingham, R; Madrenas, J; Reider, MJ			Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole	FASEB JOURNAL			English	Article						cytochrome P450; MACS; apoptosis; cell viability	ADVERSE DRUG-REACTIONS; ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; IN-VITRO CYTOTOXICITY; TRIMETHOPRIM-SULFAMETHOXAZOLE; HYPERSENSITIVITY REACTIONS; HOSPITALIZED-PATIENTS; ANNEXIN-V; TUMOR-NECROSIS; HIV-INFECTION	Treatment with sulfonamide antibiotics in HIV-infected patients is associated with a high incidence (> 40%) of adverse drug events, including severe hypersensitivity reactions. Sulfonamide reactive metabolites have been implicated in the pathogenesis of these adverse reactions, Sulfamethoxazole hydroxylamine (SMX-HA) induces lymphocyte toxicity and suppression of proliferation in vitro; the mechanism(s) of these immunomodulatory effects remain unknown, We investigated the cytotoxicity of SMX-HA via apoptosis on human peripheral blood mononuclear cells and purified cell subpopulations in vitro. CD19(+), CD4(+), and CD8(+) cells were isolated from human peripheral blood by positive selection of cell surface molecules by magnetic bead separation. SMX-HA induced significant CD8(+) cell death (67 +/- 7%) at 100 mu M SMX-HA, with only minimal CD4(+) cell death (8 +/- 4%). No significant subpopulation toxicity was shown when incubated with parent drug (SMX). Flow cytometry measuring phosphatidylserine externalization 24 h after treatment with 100 mu M and 400 mu M SMX-HA revealed 14.1 +/- 0.7% and 25.6 +/- 4.2% annexin-positive cells, respectively, compared to 3.7 +/- 1.2% in control PBMCs treated with 400 mu M SMX. Internucleosomal DNA fragmentation was observed in quiescent and stimulated PBMCs 48 h after incubation with SMX-HA. Our data show that CD8(+) cells are highly susceptible to the toxic effects of SMX-HA through enhanced cell death by apoptosis.-Hess, D. A., Sisson, M. E., Suria, H., Wijsman, J., Puvanesasingham, R., Madrenas, J., Rieder, M. J. Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole.	Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pediat, John P Robarts Res Inst,Gene Therapy & Mol Virol, London, ON N6J 1Y5, Canada; Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pharmacol & Toxicol, John P Robarts Res Inst,Gene Therapy & Mol Virol, London, ON N6J 1Y5, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON, Canada; Univ Western Ontario, John P Robarts Res Inst, Transplantat & Immunobiol Grp, Dept Med, London, ON, Canada; Univ Western Ontario, John P Robarts Res Inst, Transplantat & Immunobiol Grp, Dept Immunol & Microbiol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Reider, MJ (corresponding author), Univ Western Ontario, Childrens Hosp Western Ontario, Dept Pediat, John P Robarts Res Inst,Gene Therapy & Mol Virol, 800 Commissioners Rd E, London, ON N6J 1Y5, Canada.	mrieder@julian.uwo.ca	Madrenas, Quim/P-5008-2019; Hess, David A/M-2828-2013; Rieder, Michael J/L-2397-2013					Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BATTYE FL, 1991, CURR OPIN IMMUNOL, V3, P238; CAMPBELL ME, 1987, CLIN PHARMACOL THER, V42, P157, DOI 10.1038/clpt.1987.126; CARR A, 1993, CLIN EXP IMMUNOL, V94, P21; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; CARR A, 1994, AIDS, V8, P333, DOI 10.1097/00002030-199403000-00006; CARR A, 1993, J ACQ IMMUN DEF SYND, V6, pS56; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Cotter T G, 1992, Semin Immunol, V4, P399; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; COTTER TG, 1992, ANTICANCER RES, V12, P773; CRIBB AE, 1990, MOL PHARMACOL, V38, P744; CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406; Cribb AE, 1997, J PHARMACOL EXP THER, V282, P1064; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; CRIBB AE, 1993, BIOCHEM PHARMACOL, V45, P1277, DOI 10.1016/0006-2952(93)90280-A; CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784; FADOK VA, 1992, J IMMUNOL, V148, P2207; FERNANDES RS, 1994, BIOCHEM PHARMACOL, V48, P675, DOI 10.1016/0006-2952(94)90044-2; FURIE MB, 1995, AM J PATHOL, V146, P1287; Green D R, 1992, Semin Immunol, V4, P355; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; Gruchalla RS, 1998, J ALLERGY CLIN IMMUN, V101, P371, DOI 10.1016/S0091-6749(98)70250-7; HAUSNER MA, 1993, J IMMUNOL METHODS, V157, P181, DOI 10.1016/0022-1759(93)90085-L; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; Hess DA, 1998, CLIN PHARMACOL THER, V63, P138; Hess DA, 1997, J PHARMACOL EXP THER, V281, P540; KIZAKI H, 1992, IMMUNOPHARMACOLOGY, V24, P219, DOI 10.1016/0162-3109(92)90077-P; Lawrence DA, 1996, J LEUKOCYTE BIOL, V60, P611, DOI 10.1002/jlb.60.5.611; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEEDER JS, 1988, J PHARMACOL EXP THER, V245, P956; LEEDER JS, 1991, BIOCHEM PHARMACOL, V41, P575; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Mannel D, 1996, IMMUNOL TODAY, V17, P254, DOI 10.1016/0167-5699(96)80539-1; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; RADBRUCH A, 1994, METHOD CELL BIOL, V42, P387; Reilly TP, 1998, BIOCHEM PHARMACOL, V55, P803, DOI 10.1016/S0006-2952(97)00547-9; RIEDER MJ, 1992, INT J IMMUNOPHARMACO, V14, P1175, DOI 10.1016/0192-0561(92)90052-M; RIEDER MJ, 1995, TOXICOLOGY, V95, P141, DOI 10.1016/0300-483X(94)02900-F; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1993, J CLIN PHARMACOL, V33, P316, DOI 10.1002/j.1552-4604.1993.tb04663.x; RIEDER MJ, 1995, J ACQ IMMUN DEF SYND, V8, P134, DOI 10.1097/00042560-199502000-00004; Rieder MJ, 1997, PEDIATR CLIN N AM, V44, P93, DOI 10.1016/S0031-3955(05)70465-X; RIEDER MJ, 1994, DRUG SAFETY, V11, P196, DOI 10.2165/00002018-199411030-00005; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3; RIEDER MJ, 1992, CAN J PHYSIOL PHARM, V70, P719, DOI 10.1139/y92-094; Rieder MJ, 1997, PEDIATR INFECT DIS J, V16, P1028, DOI 10.1097/00006454-199711000-00005; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; Rudin C M, 1996, Curr Opin Hematol, V3, P35; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; Schlegel RA, 1996, ADV EXP MED BIOL, V406, P21; SHEAR NH, 1985, BRIT J DERMATOL, V113, P112, DOI 10.1111/j.1365-2133.1985.tb15637.x; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; Sisson ME, 1997, INT J IMMUNOPHARMACO, V19, P299, DOI 10.1016/S0192-0561(97)00027-1; SPIELBERG SP, 1985, CAN J PHYSIOL PHARM, V63, P468, DOI 10.1139/y85-081; THOMAS TE, 1992, J IMMUNOL METHODS, V154, P245, DOI 10.1016/0022-1759(92)90198-3; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; Zhang GH, 1997, BIOTECHNIQUES, V23, P525, DOI 10.2144/97233pf01	72	49	53	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1688	1698		10.1096/fasebj.13.13.1688	http://dx.doi.org/10.1096/fasebj.13.13.1688			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506572				2022-12-28	WOS:000083063400004
J	Shi, H; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB				Shi, H; Moustaid-Moussa, N; Wilkison, WO; Zemel, MB			Role of the sulfonylurea receptor in regulating human adipocyte metabolism	FASEB JOURNAL			English	Article						adipocytes; intracellular Ca2+; fatty acid synthase; SUR	CYTOSOLIC FREE CALCIUM; OBESE ZUCKER RATS; INSULIN-RESISTANCE; GLUCOSE-TRANSPORT; K+-CHANNELS; AGOUTI GENE; DIAZOXIDE; STIMULATION; GLIMEPIRIDE; UPDATE	A regulatory role for intracellular Ca2+ ([Ca2+](i)) in adipocyte lipogenesis, lipolysis and triglyceride accumulation has been demonstrated. Compounds acting on the pancreatic sulfonylurea receptor (SUR) to increase (e.g., glibenclamide) or decrease (e.g., diazoxide) [Ca2+](i) cause corresponding increases and decreases in weight gain. However, these weight gain and loss effects have been attributed to insulin release rather than to the primary effects of these compounds on the adipocyte SUR and its associated K-ATP channel, Accordingly, we have evaluated the direct role of the human adipocyte SUR in regulating adipocyte metabolism. We used RT-PCR with primers for a highly conserved region of SUR1 to demonstrate that human adipocytes express SUR1. The PCR product was confirmed by sequence analysis and used as a probe to demonstrate adipocyte SUR1 expression by Northern blot analysis, Adipocytes exhibited glibenclamide dose-responsive (0-20 mM) increases in [Ca2+](i) (P<0.05). Similarly, glibenclamide (10 mM) caused a 67% increase in adipocyte fatty acid synthase activity (P<0.001), a 48% increase in glycerol-3-phosphate dehydrogenase activity (P<0.01) and a 68% inhibition in lipolysis (P<0.01), whereas diazoxide (10 mM) completely prevented each of these effects, These data demonstrate that human adipocytes express a SUR that regulates [Ca2+](i) and, consequently, exerts coordinate control over lipogenesis and lipolysis. Accordingly, the adipocyte SUR1 may represent an important target for the development of therapeutic interventions in obesity.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; ZenBio Inc, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.		Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030; Zemel, Michael/0000-0003-4104-5750				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alemzadeh R, 1996, METABOLISM, V45, P334, DOI 10.1016/S0026-0495(96)90287-5; ALEMZADEH R, 1993, ENDOCRINOLOGY, V133, P705, DOI 10.1210/en.133.2.705; Alemzadeh R, 1998, J CLIN ENDOCR METAB, V83, P1911, DOI 10.1210/jc.83.6.1911; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; Chagnon YC, 1998, OBES RES, V6, P76, DOI 10.1002/j.1550-8528.1998.tb00318.x; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, DIABETES, V36, P174, DOI 10.2337/diabetes.36.2.174; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; GILON P, 1993, J BIOL CHEM, V268, P22265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hani E, 1997, DIABETES, V46, P688, DOI 10.2337/diabetes.46.4.688; INAGAKI N, 1996, SCIENCE, V270, P1167; JACOBS DB, 1985, J BIOL CHEM, V260, P2593; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Jones BH, 1997, ENDOCRINOLOGY, V138, P1512, DOI 10.1210/en.138.4.1512; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; MALOFF BL, 1981, J CLIN INVEST, V68, P85, DOI 10.1172/JCI110257; MARTZ A, 1989, J BIOL CHEM, V264, P13672; Moustaid N, 1996, J NUTR, V126, P865, DOI 10.1093/jn/126.4.865; Muller G, 1996, HORM METAB RES, V28, P469, DOI 10.1055/s-2007-979839; MULLER G, 1994, BIOCHEM PHARMACOL, V48, P985, DOI 10.1016/0006-2952(94)90369-7; PHILIPSON LH, 1995, SCIENCE, V270, P1159, DOI 10.1126/science.270.5239.1159; RAJAN AS, 1994, ENDOCRINOLOGY, V134, P1581, DOI 10.1210/en.134.3.1581; STURGESS NC, 1985, LANCET, V2, P474; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	32	53	59	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1833	1838		10.1096/fasebj.13.13.1833	http://dx.doi.org/10.1096/fasebj.13.13.1833			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506587				2022-12-28	WOS:000083063400019
J	Vila-Coro, AJ; Rodriguez-Frade, JM; De Ana, AM; Moreno-Ortiz, MC; Martinez, C; Mellado, M				Vila-Coro, AJ; Rodriguez-Frade, JM; De Ana, AM; Moreno-Ortiz, MC; Martinez, C; Mellado, M			The chemokine SDF-1 alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway	FASEB JOURNAL			English	Article						chemotactic response; tyrosine phosphorylation; Shp1; G-proteins	CELL-DERIVED FACTOR-1; LYMPHOCYTE CHEMOATTRACTANT; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; T-CELLS; PROTEIN; KINASE; SDF-1; HIV-1	The chemokine stromal cell-derived factor (SDF-1 alpha), the ligand for the CXCR4 receptor, induces a wide variety of effects that include calcium mobilization, chemotactic responses, bone marrow myelopoiesis, neuronal patterning, and prevention of HIV-1 infection. Nonetheless, little is known of the biochemical pathways required to achieve this variety of responses triggered after receptor- chemokine interaction. We developed a set of monoclonal antibodies that specifically recognize the CXCR4 receptor and used them to identify the signaling pathway activated after SDF-1 alpha binding in human T cell lines. Here we demonstrate that SDF-1 alpha activation promotes the physical association of G alpha(i) with the CXCR4, Furthermore, within seconds of SDF-1 alpha activation, the CXCR4 receptor becomes tyrosine phosphorylated through the activation and association with the receptor of JAK2 and JAK3 kinases. After SDF-1 alpha binding, JAK2 and JAK3 associate with CXCR4 and are activated, probably by transphosphorylation, in a G alpha(i)-independent manner. This activation enables the recruitment and tyrosine phosphorylation of several members of the STAT family of transcription factors. Finally, we have also observed SDF-1 alpha-induced activation and association of the tyrosine phosphatase Shp1 with the CXCR4 in a G alpha(i)-dependent manner, As occurs with the cytokine receptors in response to cytokines, the CXCR4 undergoes receptor dimerization after SDF-1 alpha binding and is a critical step in triggering biological responses. We present compelling evidence that the chemokines signal through mechanisms similar to those activated by cytokines.-Vila-Coro, A. J., Rodriguez-Frade, J. M., Martin de Ana, A., Moreno-Ortiz, M. C., Martinez-A., C., Mellado, M. The chemokine SDF-1 alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Martinez, C (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Frade, Jose Miguel Rodriguez/K-4266-2014; Mellado, Mario/M-9893-2014	Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Mellado, Mario/0000-0001-6325-1630				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENKIRANE M, 1997, J BIOL CHEM, V272, P30602; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; FRADE JMR, 1997, J CLIN INVEST, V100, P1; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; KENNEDY J, 1995, J IMMUNOL, V155, P203; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 1996, J CLIN ENDOCR METAB, V81, P1613, DOI 10.1210/jc.81.4.1613; Mellado M, 1997, IMMUNOLOGY METHODS M, P1145; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Petricoin E, 1996, MOL CELL BIOL, V16, P1419; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	47	424	441	0	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1699	1710		10.1096/fasebj.13.13.1699	http://dx.doi.org/10.1096/fasebj.13.13.1699			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506573	Bronze			2022-12-28	WOS:000083063400005
J	Warpeha, KM; Xu, W; Liu, L; Charles, IG; Patterson, CC; Ah-Fat, F; Harding, S; Hart, PM; Chakravarthy, U; Hughes, AE				Warpeha, KM; Xu, W; Liu, L; Charles, IG; Patterson, CC; Ah-Fat, F; Harding, S; Hart, PM; Chakravarthy, U; Hughes, AE			Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy	FASEB JOURNAL			English	Article						microvascular; transcription; NOS2A promoter; pentanucleotide repeat	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; HIGH-GLUCOSE; GENE; EXPRESSION; PROMOTER; MELLITUS; CLONING; AORTA	Accumulating evidence shows that the severity and rapidity of onset of diabetic retinopathy are influenced by genetic factors. Expression of the nitric oxide synthases is altered in the retinal vasculature in the early stages of diabetic retinopathy. We analyzed the allele distribution of a polymorphic pentanucleotide repeat within the 5' upstream promoter region of the NOS2A gene in samples of diabetic patients. In diabetic patients from Northern Ireland, the 14-repeat allele of the NOS2A marker was significantly associated with the absence of diabetic retinopathy. Carriers of this repeat had 0.21-fold the relative risk of developing diabetic retinopathy than noncarriers of this allele. They also had significantly fewer renal and cardiovascular complications. The ability of differing numbers of (CCTTT)(n) pentanucleotide repeats to induce transcription of the NOS2A gene was analyzed using a luciferase reporter gene assay in transfected colonic carcinoma cells. Interleukin 1b (IL-1b) induction was most effective in constructs carrying the 14-repeat allele. When cells were incubated in 25 mM glucose to mimic the diabetic state, IL-1 beta induction was inhibited in all cases, but to a significantly lesser extent with the 14-repeat allele. These unique properties of the 14-repeat allele may confer selective advantages in diabetic individuals, which may delay or prevent microvascular complications of diabetes.	Queens Univ Belfast, Dept Med Genet, Belfast, Antrim, North Ireland; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland; Royal Liverpool Hosp, Eye Unit, Liverpool L7 8XP, Merseyside, England; UCL, Rayne Inst, Wolfson Inst Biomed Res, London, England	Queens University Belfast; Queens University Belfast; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of London; King's College London; University College London	Chakravarthy, U (corresponding author), Inst Clin Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.		Hughes, Anne/A-1307-2012; Xu, Weiming/A-6274-2008	Xu, Weiming/0000-0002-7085-7814; Chakravarthy, Usha/0000-0002-2606-3734; Harding, Simon/0000-0003-4676-1158				Agardh D, 1996, DIABETOLOGIA, V39, P1313, DOI 10.1007/s001250050575; AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; Chakravarthy U, 1997, INVEST OPHTH VIS SCI, V38, P2144; Chakravarthy U, 1998, DIABETES, V47, P945, DOI 10.2337/diabetes.47.6.945; Chappey O, 1996, CELL BIOL TOXICOL, V12, P199, DOI 10.1007/BF00438146; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; DORNAN TL, 1982, DIABETES, V31, P226, DOI 10.2337/diabetes.31.3.226; FEENER EP, 1997, LANCET S1, V350, P9; GELLER DA, 1995, J IMMUNOL, V155, P4890; GRAIER WF, 1993, DIABETES, V42, P2497; Guillausseau PJ, 1997, DIABETES METAB, V23, P14; HUGHES AE, 1993, GENOMICS, V15, P433, DOI 10.1006/geno.1993.1083; JEANPIERRE M, 1993, AM J HUM GENET, V53, P757; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; LESLIE RDG, 1982, DIABETES, V31, P19, DOI 10.2337/diabetes.31.1.19; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061; MULHERN M, 1989, BRIT J PHARMACOL, V97, P1007, DOI 10.1111/j.1476-5381.1989.tb12555.x; Muniyappa R, 1998, HYPERTENSION, V31, P289, DOI 10.1161/01.HYP.31.1.289; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nunokawa Y, 1996, BIOCHEM BIOPH RES CO, V223, P347, DOI 10.1006/bbrc.1996.0897; PALMER RMJ, 1993, BIOCHEM BIOPH RES CO, V193, P398, DOI 10.1006/bbrc.1993.1637; POSTON L, 1995, CLIN SCI, V88, P245, DOI 10.1042/cs0880245; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Sheng H, 1996, PHARMACOL RES, V33, P29, DOI 10.1006/phrs.1996.0005; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Stehouwer CDA, 1997, CARDIOVASC RES, V34, P55, DOI 10.1016/S0008-6363(96)00272-6; TESFAMARIAM B, 1990, J CLIN INVEST, V85, P929, DOI 10.1172/JCI114521; VIALETTES B, 1994, DIABETES METAB, V20, P229; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008; Xu WM, 1997, GENE, V204, P165, DOI 10.1016/S0378-1119(97)00538-6; Xu WM, 1996, BIOCHEM BIOPH RES CO, V219, P784, DOI 10.1006/bbrc.1996.0311; YE XO, 1990, INVEST OPHTH VIS SCI, V31, P1731	38	129	138	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1825	1832		10.1096/fasebj.13.13.1825	http://dx.doi.org/10.1096/fasebj.13.13.1825			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506586				2022-12-28	WOS:000083063400018
J	Olivera, A; Edsall, L; Poulton, S; Kazlauskas, A; Spiegel, S				Olivera, A; Edsall, L; Poulton, S; Kazlauskas, A; Spiegel, S			Platelet-derived growth factor-induced activation of sphingosine kinase requires phosphorylation of the PDGF receptor tyrosine residue responsible for binding of PLC gamma	FASEB JOURNAL			English	Article						platelet-derived growth factor; SPP; DNA synthesis; DMS	PHOSPHOLIPASE C-GAMMA; PROGRAMMED CELL-DEATH; FACTOR-BETA RECEPTOR; PHOSPHATIDYLINOSITOL-3 KINASE; CALCIUM MOBILIZATION; SIGNAL-TRANSDUCTION; 3T3 FIBROBLASTS; 2ND MESSENGER; PROTEIN; 1-PHOSPHATE	Sphingosine-1-phosphate, a sphingolipid metabolite, is involved in the mitogenic response of platelet-derived growth factor (PDGF) and is formed by activation of sphingosine kinase. We examined the effect of PDGF on sphingosine kinase activation in TRMP cells expressing wild-type or various mutant beta PDGF receptors. Sphingosine kinase was stimulated by PDGF in cells expressing wild-type receptors but not in cells expressing kinase-inactive receptors (R634). Cells expressing mutated PDGF receptors with phenylalanine substitutions at five major tyrosine phosphorylation sites 740/751/771/1009/1021 (F5 mutants), which are unable to associate with PLC gamma, phosphatidylinositol 3-kinase, Ras GTPase-activating protein, or protein tyrosine phosphatase SHP-2, not only failed to increase DNA synthesis in response to PDGF but also did not activate sphingosine kinase. Moreover, mutation of tyrosine-1021 of the PDGF receptor to phenylalanine, which impairs its association with PLC gamma, abrogated PDGF-induced activation of sphingosine kinase. In contrast, PDGF was still able to stimulate sphingosine kinase in cells expressing the PDGF receptor mutated at tyrosines 740/751 and 1009, responsible for binding of phosphatidylinositol 3-kinase and SHP-2, respectively. In agreement, PDGF did not stimulate sphingosine kinase activity in F5 receptor 'add-back' mutants in which association with the Pas GTPase-activating protein, phosphatidylinositol 3-kinase, or SHP-2 was individually restored. However, a mutant PDGF receptor that was able to bind PLC gamma (tyrosine-1021), but not other signaling proteins, restored sphingosine kinase sensitivity to PDGF. These data indicate that the tyrosine residue responsible for binding of PLC gamma is required for PDGF-induced activation of sphingosine kinase. Moreover, calcium mobilization downstream of PLC gamma, but not protein kinase C activation, appears to be required for stimulation of sphingosine kinase by PDGF.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Georgetown University; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Spiegel, S (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA61774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Bosch RR, 1998, EUR J PHARMACOL, V346, P345, DOI 10.1016/S0014-2999(98)00070-3; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Choi OH, 1996, NATURE, V380, P634; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DESAI NN, 1992, J BIOL CHEM, V267, P23122; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 1997, J NEUROSCI, V17, P6952; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kleuser B, 1998, CANCER RES, V58, P1817; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; Mathias RS, 1997, J BIOL CHEM, V272, P29076, DOI 10.1074/jbc.272.46.29076; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pulcinelli FM, 1998, BIOCHEM PHARMACOL, V56, P1481, DOI 10.1016/S0006-2952(98)00146-4; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; SU Y, 1994, J BIOL CHEM, V269, P16512; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wang F, 1996, GLYCOCONJUGATE J, V13, P937, DOI 10.1007/BF01053189; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; YEO EJ, 1994, J BIOL CHEM, V269, P27823	33	68	68	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1593	1600		10.1096/fasebj.13.12.1593	http://dx.doi.org/10.1096/fasebj.13.12.1593			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463951				2022-12-28	WOS:000082347600015
J	Jovanovic, N; Jovanovic, S; Jovanovic, A; Terzic, A				Jovanovic, N; Jovanovic, S; Jovanovic, A; Terzic, A			Gene delivery of Kir6.2/SUR2A in conjunction with pinacidil handles intracellular Ca2+ homeostasis under metabolic stress	FASEB JOURNAL			English	Article						K-ATP channels; ischemia; gene therapy; potassium channel opener	SENSITIVE K+ CHANNEL; MAMMALIAN-CELL LINE; ATP-CHANNEL; SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; INSULIN-SECRETION; CARDIAC-CELLS; PHARMACOLOGICAL APPROACH; SARCOPLASMIC-RETICULUM; HYPOXIA-REOXYGENATION	Metabolic injury is a complex process affecting various tissues, with intracellular Ca2+ loading recognized as a common precipitating event leading to cell death. We have recently observed that cells overexpressing recombinant ATP-sensitive K+ (K-ATP) channel subunits may acquire resistance against metabolic stress, To examine whether, under metabolic challenge, intracellular Ca2+ homeostasis can be maintained by an activator of channel proteins, we delivered Kir6.2 and SUR2A genes, which encode K-ATP channel subunits, into a somatic cell line lacking native K-ATP channels, Hypoxia-reoxygenation was simulated by application and removal of the mitochondrial poison 2,4 dinitrophenol, Under such metabolic stress, Ca2+ loading was induced by Ca2+ influx during hypoxia and release of Ca2+ from intracellular stores during reoxygenation. Delivery of Kir6.2/SUR2A genes, in conjunction with the K-ATP channel activator pinacidil, prevented intracellular Ca2+ loading irrespective of whether the channel opener was applied throughout the duration of hypoxia-reoxygenation or transiently during the hypoxic or reoxygenation stage, In all stages of injury, the effect of pinacidil was inhibited by the selective antagonist of K-ATP channel, 5-hydroxydecanoate. The present study provides evidence that combined use of gene delivery and pharmacological targeting of recombinant proteins can handle intracellular Ca2+ homeostasis under hypoxia-reoxygenation irrespective of the stage of the metabolic insult.	Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Terzic, A (corresponding author), Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Guggenheim 7F,200 1st St SW, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; BALESTRINO M, 1995, J NEUROSCI METH, V59, P99, DOI 10.1016/0165-0270(94)00199-Q; BEHLING RW, 1995, J MOL CELL CARDIOL, V27, P1809, DOI 10.1016/0022-2828(95)90004-7; Brady PA, 1996, EUR J PHARMACOL, V308, P343, DOI 10.1016/0014-2999(96)00327-5; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; French BA, 1998, CURR OPIN CARDIOL, V13, P205; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; Grover GJ, 1997, CAN J PHYSIOL PHARM, V75, P309, DOI 10.1139/cjpp-75-4-309; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HEARSE DJ, 1995, CARDIOVASC RES, V30, P1; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Ishii T, 1996, J PHYSIOL-LONDON, V493, P371, DOI 10.1113/jphysiol.1996.sp021389; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jovanovic A, 1998, LAB INVEST, V78, P1101; Jovanovic A, 1996, EUR J PHARMACOL, V298, P63, DOI 10.1016/0014-2999(95)00738-5; Jovanovic A, 1997, ANN THORAC SURG, V63, P153; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; JUEDES MJ, 1992, FEBS LETT, V313, P39, DOI 10.1016/0014-5793(92)81179-P; Kim JS, 1998, TRANSPLANTATION, V65, P369, DOI 10.1097/00007890-199802150-00012; KIRBY MS, 1992, J BIOL CHEM, V267, P12545; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kusuoka H, 1998, JPN CIRC J, V62, P611, DOI 10.1253/jcj.62.611; Lauritzen I, 1997, J NEUROCHEM, V69, P1570; Levitsky J, 1998, J CLIN PHARMACOL, V38, P887, DOI 10.1002/j.1552-4604.1998.tb04383.x; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Lopez JR, 1996, J THORAC CARDIOV SUR, V112, P820, DOI 10.1016/S0022-5223(96)70070-3; LOPEZ JR, 1995, BIOCHEM BIOPH RES CO, V214, P781, DOI 10.1006/bbrc.1995.2354; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; Maxwell SRJ, 1997, INT J CARDIOL, V58, P95, DOI 10.1016/S0167-5273(96)02854-9; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; MILLER TW, 1995, CARDIOVASC RES, V29, P85, DOI 10.1016/S0008-6363(96)88551-8; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOTSU T, 1992, J PHARMACOL EXP THER, V260, P702; Okuyama Y, 1998, PFLUG ARCH EUR J PHY, V435, P595, DOI 10.1007/s004240050559; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; WATTS JA, 1986, J MOL CELL CARDIOL, V18, P71, DOI 10.1016/S0022-2828(86)80030-X; YANAGISAWA T, 1990, BRIT J PHARMACOL, V101, P157, DOI 10.1111/j.1476-5381.1990.tb12106.x; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	45	53	53	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					923	929		10.1096/fasebj.13.8.923	http://dx.doi.org/10.1096/fasebj.13.8.923			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224235				2022-12-28	WOS:000080372500015
J	Robertson, AP; Bjorn, HE; Martin, RJ				Robertson, AP; Bjorn, HE; Martin, RJ			Resistance to levamisole resolved at the single-channel level	FASEB JOURNAL			English	Article						Oesophagostomum dentatum; nAChR; patch; clamp; heterogeneity; subtypes	NICOTINIC ACETYLCHOLINE-RECEPTORS; PARASITE ASCARIS-SUUM; SUBUNIT GENE TAR-1; OESOPHAGOSTOMUM-DENTATUM; TRICHOSTRONGYLUS-COLUBRIFORMIS; MUSCLE; DIVERSITY; MEMBRANE; CURRENTS; SEQUENCE	Levamisole is commonly used to treat nematode parasite infections but therapy is limited by resistance. The purpose of this study was to determine the mechanism of resistance to this selective nicotinic drug. Levamisole receptor channel currents in muscle patches from levamisole-sensitive and levamisole-resistant isolates of the parasitic nematode Oesophagostomum dentatum were compared. The number of channels present in patches of sensitive and resistant isolates was similar at 10 mu M levamisole, but at 30 mu M and 100 mu M the resistant isolate contained fewer active patches, suggesting desensitization. Mean P-o and open times were reduced in resistant isolates, The distribution of conductances of channels in the sensitive isolate revealed a heterogeneous receptor population and the presence of G25, G35, G40, and G45 subtypes. A G35 subtype was missing in the resistant isolate. Resistance to levamisole was produced by changes in the averaged properties of the levamisole receptor population, with some receptors from sensitive and resistant isolates having indistinguishable characteristics.	Univ Edinburgh, Dept Preclin Vet Sci, RDSVS, Edinburgh EH9 1QH, Midlothian, Scotland; Royal Vet & Agr Univ, Danish Ctr Expt Parasitol, Dept Pharmacol & Toxicol, Frederiksberg C, Denmark	University of Edinburgh; University of Copenhagen	Robertson, AP (corresponding author), Univ Edinburgh, Dept Preclin Vet Sci, RDSVS, Edinburgh EH9 1QH, Midlothian, Scotland.	alanr@lab0.vet.ed.ac.uk	Martin, Richard John/A-1783-2011	Martin, Richard John/0000-0003-2422-1847	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACEVES J, 1970, BRIT J PHARMACOL, V38, P602, DOI 10.1111/j.1476-5381.1970.tb10601.x; ALBERT A, 1985, SELECTIVE TOXICITY, P206; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; BLOUIN MS, 1995, GENETICS, V141, P1007; BROWNING C, 1907, BRIT MED J, V2, P1405; CamposCaro A, 1997, BIOCHEMISTRY-US, V36, P2709, DOI 10.1021/bi9623486; CHANGEAU JP, 1996, SCIENCE, V225, P1335; Corringer PJ, 1998, J NEUROSCI, V18, P648; COVERNTON PJO, 1994, J PHYSIOL-LONDON, V481, P27, DOI 10.1113/jphysiol.1994.sp020416; DUNN AM, 1969, VET HELMINTHOLOY; Ehrlich P, 1909, BER DTSCH CHEM GES, V42, P17, DOI 10.1002/cber.19090420105; EHRLICH P, 1904, BERL KLIN WOCHENSCHR, V22, P329; Fleming JT, 1997, J NEUROSCI, V17, P5843; Hoekstra R, 1997, MOL BIOCHEM PARASIT, V84, P179, DOI 10.1016/S0166-6851(96)02793-4; HOLLAND CV, 1989, PARASITOLOGY, V99, P275, DOI 10.1017/S003118200005873X; KAN SC, 1979, J PROTOZOOL, V26, P660, DOI 10.1111/j.1550-7408.1979.tb04216.x; KAO CY, 1996, J BIOL CHEM, V261, P8085; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Martin RJ, 1996, PARASITOLOGY, V113, pS137, DOI 10.1017/S0031182000077945; Martin RJ, 1997, PARASITOLOGY, V114, pS111, DOI 10.1017/S0031182097001029; Martin RJ, 1997, EUR J PHARMACOL, V322, P249, DOI 10.1016/S0014-2999(96)00996-X; MARTIN RJ, 1980, BRIT J PHARMACOL, V71, P99, DOI 10.1111/j.1476-5381.1980.tb10914.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; ROBERTSON SJ, 1993, PESTIC SCI, V37, P293, DOI 10.1002/ps.2780370310; SANGSTER N, 1996, PARASITOLOGY, V113, pS210; Slotved HC, 1996, VET PARASITOL, V63, P237, DOI 10.1016/0304-4017(95)00916-7; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; Varady M, 1997, INT J PARASITOL, V27, P77, DOI 10.1016/S0020-7519(96)00159-2; Wiley LJ, 1996, GENE, V182, P97, DOI 10.1016/S0378-1119(96)00520-3; Wiley LJ, 1997, MOL BIOCHEM PARASIT, V90, P415, DOI 10.1016/S0166-6851(97)00179-5; YORKE WARRINGTON, 1931, Annals of Tropical Medicine and Parasitology, V25, P351	34	69	73	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					749	760		10.1096/fasebj.13.6.749	http://dx.doi.org/10.1096/fasebj.13.6.749			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094935				2022-12-28	WOS:000079527200016
J	Hageman, GS; Mullins, RF; Russell, SR; Johnson, LV; Anderson, DH				Hageman, GS; Mullins, RF; Russell, SR; Johnson, LV; Anderson, DH			Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells	FASEB JOURNAL			English	Article						age-related macular degeneration; retinal pigment epithelium; extracellular matrix; heparan sulfate proteoglycan	AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; BRUCHS MEMBRANE; MULTIMERIC VITRONECTIN; ELECTRON-MICROSCOPY; RISK-FACTORS; S-PROTEIN; BINDING; TISSUE; NEOVASCULARIZATION	Age-related macular degeneration (AMD) leads to dysfunction and degeneration of retinal photoreceptor cells. This disease is characterized, in part, by the development of extracellular deposits called drusen, The presence of drusen is correlated with the development of AMD, although little is known about drusen composition or biogenesis, Drusen form within Bruch's membrane, a stratified extracellular matrix situated between the retinal pigmented epithelium and choriocapillaris. Because of this association, we sought to determine whether drusen contain known extracellular matrix constituents. Antibodies directed against a battery of extracellular matrix molecules were screened on drusen-containing sections from human donor eyes, including donors with clinically documented AMD, Antibodies directed against vitronectin, a plasma protein and extracellular matrix component, exhibit intense and consistent reactivity with drusen; antibodies to the conformationally distinct, heparin binding form of human vitronectin are similarly immunoreactive, No differences in vitronectin immunoreactivity between hard and soft drusen, or between macular and extra macular regions, have been observed. RT-PCR analyses revealed that vitronectin mRNA is expressed in the retinal pigmented epithelium (RPE)-choroidal complex and cultured RPE cells. These data document that vitronectin is a major constituent of human ocular drusen and that vitronectin mRNA is synthesized locally, Based on these data,we propose that vitronectin may participate in the pathogenesis of AMD.	Univ Iowa, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, Iowa City, IA 52242 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA	University of Iowa; University of California System; University of California Santa Barbara	Hageman, GS (corresponding author), Univ Iowa, Dept Ophthalmol & Visual Sci, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.	gregory_hagerman@uiowa.edu	Mullins, Robert F/I-6717-2013	Mullins, Robert/0000-0002-5006-0891; Russell, Stephen/0000-0003-3776-1367				AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552; BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006; BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035; Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAHLBACK K, 1988, ACTA DERM-VENEREOL, V68, P107; DAHLBACK K, 1993, J INVEST DERMATOL, V100, P166, DOI 10.1111/1523-1747.ep12462792; FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9; FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7; FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708; FINE BS, 1981, AM J OPHTHALMOL, V91, P469, DOI 10.1016/0002-9394(81)90234-8; GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; HALE IL, 1993, METHOD CELL BIOL, V38, P289; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; Hyman L, 1992, AGE RELATED MACULAR, P1; ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5; JANSEN JH, 1993, AM J PATHOL, V143, P1356; JOHNSON LV, 1984, CURR EYE RES, V3, P969, DOI 10.3109/02713688409167215; KINCAID M, 1992, AGE RELATED MACULAR; KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025; KLEIN R, 1995, OPHTHALMOLOGY, V102, P371; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128; Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021; LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098; Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4; NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548; Pauleikhoff D., 1994, Ophthalmologe, V91, P730; PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106; SARKS S, 1989, RETINA, V2; SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324; SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414; SEIFFERT D, 1994, J BIOL CHEM, V269, P19836; SOLEM M, 1991, MOL CELL BIOCHEM, V100, P141; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STONE E, 1993, MOL GENETICS INHERIT; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278; VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657; VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436; VINDING T, 1990, ACTA OPHTHALMOL, V68, P410; VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648; VOLKER W, 1993, J HISTOCHEM CYTOCHEM, V41, P1823, DOI 10.1177/41.12.7504009; YASUMITSU H, 1993, IN VITRO CELL DEV-AN, V29A, P403; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645	54	158	168	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					477	484		10.1096/fasebj.13.3.477	http://dx.doi.org/10.1096/fasebj.13.3.477			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064614				2022-12-28	WOS:000079016000007
J	Li, J; Gilmour, RS; Saunders, JC; Dauncey, MJ; Fowden, AL				Li, J; Gilmour, RS; Saunders, JC; Dauncey, MJ; Fowden, AL			Activation of the adult mode of ovine growth hormone receptor gene expression by cortisol during late fetal development	FASEB JOURNAL			English	Article						fetus; GHR; fetal plasma cortisol; GH binding; riboprobe; insulin-like growth factor; glucocorticoid response element	MESSENGER-RIBONUCLEIC-ACID; GH-BINDING-PROTEIN; LIVER-SPECIFIC PROMOTER; FACTOR-I GENE; RNA EXPRESSION; SHEEP FETUS; IGF-I; ONTOGENY; MECHANISMS; GESTATION	The developmental and tissue-specific regulation of growth hormone receptor (GI-W) mRNA expression is complex and involves alternate leader exon usage. The transcript composition of hepatic GHR mRNA has therefore been determined in fetal sheep during late gestation and after experimental manipulation of fetal plasma cortisol levels by fetal adrenalectomy and exogenous cortisol infusion, using RNase protection assays and a riboprobe containing exons 1A, 2, and 3 of the ovine GHR gene, Expression of the adult liver-specific GHR mRNA transcript containing exon 1A was not detected earlier than 138 days of gestation (term 145 +/- 2 days). Thereafter, expression of this leader exon increased and accounted for 25-30% of the total GHR mRNA in the fetal liver at term, Hepatic GHR mRNA derived from leader exons other than 1A was detectable at 97 days and increased in abundance toward term in parallel with the normal prepartum rise in fetal plasma cortisol, Abolition of this cortisol surge by fetal adrenalectomy prevented both the activation of exon 1A expression and the prepartum rise in GHR mRNA derived from the other leader exons in fetal ovine liver. Conversely, raising cortisol levels by exogenous infusion earlier in gestation prematurely activated exon 1A expression and enhanced the abundance of GHR mRNA transcripts derived from the other leader exons, Cortisol therefore appears to activate the adult mode of GHR gene expression in fetal ovine liver during late gestation. These observations have important implications for the maturation of the somatotrophic axis and for the onset of GH-dependent growth after birth.	Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Babraham Inst, Dept Cellular Physiol, Cambridge CB2 4AT, England	University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Fowden, AL (corresponding author), Univ Cambridge, Dept Physiol, Downing St, Cambridge CB2 3EG, England.							ADAMS TE, 1995, MOL CELL ENDOCRINOL, V108, P23, DOI 10.1016/0303-7207(95)92575-9; ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; Armitage P., 1971, STAT METHODS MED RES, V1; BAUMBACH WR, 1995, ENDOCRINOLOGY, V136, P749, DOI 10.1210/en.136.2.749; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMLINE RS, 1972, J PHYSIOL-LONDON, V222, P233, DOI 10.1113/jphysiol.1972.sp009795; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Duchamp C, 1996, EUR J ENDOCRINOL, V134, P524, DOI 10.1530/eje.0.1340524; FOWDEN AL, 1995, REPROD FERT DEVELOP, V7, P351, DOI 10.1071/RD9950351; Fowden AL, 1998, P NUTR SOC, V57, P113, DOI 10.1079/PNS19980017; GABRIELSSON BG, 1995, ENDOCRINOLOGY, V136, P209, DOI 10.1210/en.136.1.209; GARCIA E, 1992, FOCUS DIVERSITY, V1, P1; GLUCKMAN PD, 1983, ENDOCRINOLOGY, V112, P1607, DOI 10.1210/endo-112-5-1607; GLUCKMAN PD, 1995, FETUS NEONATE PHYSL, V3, P971; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HERINGTON AC, 1994, MOL CELL ENDOCRINOL, V100, P39, DOI 10.1016/0303-7207(94)90276-3; HILL DJ, 1992, J CLIN ENDOCR METAB, V75, P646, DOI 10.1210/jc.75.2.646; KLEMPT M, 1993, ENDOCRINOLOGY, V132, P1071, DOI 10.1210/en.132.3.1071; LEE CY, 1993, MOL CELL ENDOCRINOL, V93, P71, DOI 10.1016/0303-7207(93)90141-6; Li J, 1996, ENDOCRINOLOGY, V137, P1650, DOI 10.1210/en.137.5.1650; LI J, 1997, J ENDOCRINOL S, V152, P123; MAES M, 1983, ENDOCRINOLOGY, V113, P1325, DOI 10.1210/endo-113-4-1325; Martini JF, 1997, J BIOL CHEM, V272, P18951, DOI 10.1074/jbc.272.30.18951; MESIANO S, 1989, ENDOCRINOLOGY, V124, P1485, DOI 10.1210/endo-124-3-1485; Min SH, 1996, ENDOCRINOLOGY, V137, P1129, DOI 10.1210/en.137.3.1129; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; PEKHLETSKY RI, 1992, MOL CELL ENDOCRINOL, V90, P103, DOI 10.1016/0303-7207(92)90107-H; PRATT SL, 1995, ENDOCRINOLOGY, V136, P2150, DOI 10.1210/en.136.5.2150; SAUNDERS JC, 1991, J MOL ENDOCRINOL, V7, P233, DOI 10.1677/jme.0.0070233; SchnoebelenCombes S, 1996, J ENDOCRINOL, V148, P249, DOI 10.1677/joe.0.1480249; SOUTHARD JN, 1995, ENDOCRINOLOGY, V136, P2913, DOI 10.1210/en.136.7.2913; WELLER PA, 1994, AM J PHYSIOL, V266, pE776, DOI 10.1152/ajpendo.1994.266.5.E776; YMER SI, 1992, MOL CELL ENDOCRINOL, V83, P39, DOI 10.1016/0303-7207(92)90193-A; Zogopoulos G, 1996, J CLIN ENDOCR METAB, V81, P775, DOI 10.1210/jc.81.2.775; Zogopoulos G, 1996, CANCER RES, V56, P2949; Zou LL, 1997, ENDOCRINOLOGY, V138, P1771, DOI 10.1210/en.138.4.1771	37	26	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					545	552		10.1096/fasebj.13.3.545	http://dx.doi.org/10.1096/fasebj.13.3.545			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064621				2022-12-28	WOS:000079016000014
J	Lanvers, C; Hempel, G; Blaschke, G; Boos, J				Lanvers, C; Hempel, G; Blaschke, G; Boos, J			Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells	FASEB JOURNAL			English	Article						cellular pharmacokinetics; retinoid X receptor; 13-cis-RA; retinoic acid receptor	ACUTE PROMYELOCYTIC LEUKEMIA; ALL-TRANS; 9-CIS-RETINOIC ACID; 13-CIS-RETINOIC ACID; NONENZYMATIC ISOMERIZATION; INTERFERON ALPHA-2A; THERAPY; PROLIFERATION; EXPRESSION; RECEPTORS	The successful introduction of 13-cis-retinoic acid (13-cis-RA) and all-trans-retinoic acid (all-trans-RA) in the chemoprevention and treatment of cancer along with the discovery of different retinoic acid receptors transactivated by different retinoic acid isomers resulted in a number of in vitro studies of the antitunor effects of single retinoic acid isomers, Since the formation of retinoic acid isomers with different receptor affinities might modulate retinoic acid response in vitro, we determined retinoic acid disposition in HL-60 cells and cell culture medium during incubation with 13-cis-, 9-cis-, and all-trans-RA, In medium, retinoic acids underwent a thiol-radical mediated isomerization resulting in a mixture of 13-cis-, 9-cis-, 9,13-di-cis-, and all-trans-RA. Except for the 9,13-di-cis-RA, all isomers generated in medium were also detected in HL-60 cells. Whereas 9-cis-RA and 13-cis-RA showed similar cellular pharmacokinetics, all-trans-RA reached about fourfold higher concentrations in HL-60 cells com pared to 9-cis-RA and 1-3cis-RA. Due to its better uptake, all-trans-RA. became the main isomer within cells as it was formed in the medium when incubated with 13-cis-RA and 9-cis-RA. Thus, due to the simple chemically induced isomerization and its profound influence on cellular retinoic acid concentrations, studies of the efficacy of single retinoic acid isomers in vitro should be interpreted with caution.	Univ Munster, Dept Pediat Hematol & Oncol, D-48149 Munster, Germany; Univ Munster, Dept Pharmaceut Chem, D-48149 Munster, Germany	University of Munster; University of Munster	Boos, J (corresponding author), Univ Munster, Ctr Pediat, Dept Hematol & Oncol, Albert Schweitzer Str 33, D-48149 Munster, Germany.	boosj@uni-muenster.de	Lanvers-Kaminsky, Claudia/AAY-2071-2021					AGADIR A, 1995, J CLIN ONCOL, V13, P2517, DOI 10.1200/JCO.1995.13.10.2517; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLLINS SJ, 1987, BLOOD, V70, P1233; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; FRICKEL F, 1984, RETINOIDS, P210; Giannini F, 1997, INT J CANCER, V70, P194; Gudas Lorraine J., 1994, P443; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JONES CS, 1994, NUTR CANCER, V21, P83, DOI 10.1080/01635589409514306; KALIN JR, 1982, DRUG METAB DISPOS, V10, P391; KALIN JR, 1981, DRUG METAB DISPOS, V9, P196; KIZAKI M, 1993, BLOOD, V82, P3592; KOJIMA R, 1994, J BIOL CHEM, V269, P32700; Lanvers C, 1996, J CHROMATOGR B, V685, P233, DOI 10.1016/S0378-4347(96)00192-2; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUCEK RW, 1985, CLIN PHARMACOKINET, V10, P38, DOI 10.2165/00003088-198510010-00002; Mangelsdorf David J., 1994, P319; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; MUINDI JRF, 1997, CANCER RES, V52, P2138; NILSSON B, 1984, BRIT J HAEMATOL, V57, P365, DOI 10.1111/j.1365-2141.1984.tb02910.x; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; REDFERN CPF, 1995, EUR J CANCER, V31A, P486, DOI 10.1016/0959-8049(95)00066-R; REPA JJ, 1993, P NATL ACAD SCI USA, V90, P7293, DOI 10.1073/pnas.90.15.7293; Reynolds CP, 1994, ADV NEUROBLASTOMA RE, V4, P237; SASS JO, 1995, DRUG METAB DISPOS, V23, P887; SHARMA S, 1994, CANCER RES, V54, P5848; Shih TW, 1997, DRUG METAB DISPOS, V25, P27; SHIH TW, 1986, DRUG METAB DISPOS, V14, P698; TZIMAS G, 1994, DRUG METAB DISPOS, V22, P928; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; URBACH J, 1994, FEBS LETT, V351, P429, DOI 10.1016/0014-5793(94)00090-5; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZHU J, 1995, LEUKEMIA, V9, P302	40	22	22	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1627	1633		10.1096/fasebj.12.15.1627	http://dx.doi.org/10.1096/fasebj.12.15.1627			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837852				2022-12-28	WOS:000077574500004
J	Spinozzi, F; Agea, E; Fizzotti, M; Bassotti, G; Russano, A; Droetto, S; Bistoni, O; Grignani, F; Bertotto, A				Spinozzi, F; Agea, E; Fizzotti, M; Bassotti, G; Russano, A; Droetto, S; Bistoni, O; Grignani, F; Bertotto, A			Role of T-helper type 2 cytokines in down-modulation of Fas mRNA and receptor on the surface of activated CD4(+) T cells: molecular basis for the persistence of the allergic immune response	FASEB JOURNAL			English	Article						apoptosis; PBMC; interferon; interleukin; transforming growth factor	MEDIATED APOPTOSIS; BRONCHIAL-ASTHMA; GENE; LYMPHOCYTES; DISEASE; INTERLEUKIN-4; EXPRESSION; LIGAND; DEATH; MICE	The mechanisms responsible for persistence of T lymphocytes at the sites of allergic inflammation are not completely understood. Activated T cells, usually expressing Fas on their surface, undergo activation-induced apoptotic death, thus limiting the dangerous consequences of a persistent immune reaction. We have previously shown that pulmonary T lymphocytes from untreated asthmatic subjects do not express surface Fas receptors nor do they contain Fas mRNA,yet they display normal levels of Fas ligand. This: is not an inherited defect and is confined to mucosal T cells. To gain insights into the mechanism responsible for these findings, we performed a set of experiments with both purified Dermatophagoides pteronyssinus allergen and recombinant human cytokines: interleukin 2 (IL-2), IL-4, IL-5, transforming growth factor beta(1), interferon gamma, and granulocyte-macrophage colony-stimulating factor (GM-CSF). In vitro exposure of purified CD4(+) lymphocytes to allergen yielded only transient up-regulation of surface Fas but did not influence susceptibility to Fas-mediated cell death. T-helper type 2 cytokines (IL-4, IL-5, and GMCSF) had a dose-dependent and specific inhibitory effect on Fas mRNA, suggesting a new fundamental biological role in the survival of inflammatory cells during allergen exposure.	Univ Perugia, Sch Med, Lab Allergol & Clin Immunol, Dept Clin & Expt Med, I-06122 Perugia, Italy; Univ Perugia, Sch Med, Mol Biol Lab, Dept Clin & Expt Med, I-06122 Perugia, Italy; Univ Perugia, Sch Med, Lab Gastroenterol, Dept Clin & Expt Med, I-06122 Perugia, Italy; Univ Perugia, Sch Med, Dept Pediat, I-06122 Perugia, Italy	University of Perugia; University of Perugia; University of Perugia; University of Perugia	Spinozzi, F (corresponding author), Monteluce Policlin, Lab Allergy & Clin Immunol, Inst Internal Med & Oncol Sci, I-06122 Perugia, Italy.		bistoni, onelia/G-8234-2011					Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ADACHI T, 1995, AM J RESP CRIT CARE, V151, P618; Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; DeLibero G, 1997, IMMUNOL TODAY, V18, P22, DOI 10.1016/S0167-5699(97)80010-2; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; HOLGATE ST, 1997, LANCET S2, V350, pS115; KAY AB, 1997, PROG ALLERGY CLIN IM, V4, P396; Kong LP, 1997, ARTHRITIS RHEUM, V40, P87, DOI 10.1002/art.1780400113; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MIGLIORATI G, 1993, BLOOD, V81, P1352; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MYSLER E, 1994, J CLIN INVEST, V93, P1029, DOI 10.1172/JCI117051; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; RICI M, 1997, ACI INT, V9, P141; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SANDFORD A, 1996, AM J RESP CRIT CARE, V153, P1794; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPINOZZI F, 1995, MOL MED, V1, P821, DOI 10.1007/BF03401896; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; Spinozzi F, 1998, ANN INTERN MED, V128, P363, DOI 10.7326/0003-4819-128-5-199803010-00004; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Spinozzi F, 1998, IMMUNOL TODAY, V19, P22, DOI 10.1016/S0167-5699(97)01182-1; SPINOZZI F, 1995, IMMUNOLOGY, V86, P379; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Vaishnaw AK, 1997, ARTHRITIS RHEUM, V40, P1917, DOI 10.1002/art.1780401102; Van Parijs L, 1998, SCIENCE, V280, P243; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; Vella AT, 1998, P NATL ACAD SCI USA, V95, P3810, DOI 10.1073/pnas.95.7.3810; Wen L, 1998, J IMMUNOL, V160, P1965; Wong B, 1997, J EXP MED, V186, P1939, DOI 10.1084/jem.186.11.1939	42	19	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1747	1753		10.1096/fasebj.12.15.1747	http://dx.doi.org/10.1096/fasebj.12.15.1747			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837865				2022-12-28	WOS:000077574500017
J	Surette, ME; Dallaire, N; Jean, N; Picard, S; Borgeat, P				Surette, ME; Dallaire, N; Jean, N; Picard, S; Borgeat, P			Mechanisms of the priming effect of lipopolysaccharides on the biosynthesis of leukotriene B-4 in chemotactic peptide-stimulated human neutrophils	FASEB JOURNAL			English	Article						priming; polymorphonuclear leukocytes; free arachidonic acid; translocation	CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID RELEASE; PLATELET-ACTIVATING-FACTOR; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; COMPLEMENT COMPONENT C5A; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; FACTOR GM-CSF; 5-LIPOXYGENASE ACTIVATION; BACTERIAL LIPOPOLYSACCHARIDE	The goal of this study was to explain the priming effect of lipopolysaccharides (LPS) in human polymorphonuclear leukocytes on leukotriene B-4 (LTB4) biosynthesis after stimulation with the receptor-mediated agonist formyl-methionyl-leucyl-phenylalanine (fMLP), This priming effect for LTB4 biosynthesis was maximal after a 30 min preincubation with LPS but was lost when incubations were extended to 90 min or longer, Priming with LPS resulted in an enhanced maximal activation of 5-lipoxygenase (5- to 15-fold above unprimed cells) as well as a prolonged activation of the enzyme after stimulation with fMLP compared to that measured in unprimed cells. The activation of 5-lipoxygenase was associated with its translocation to the nuclear fraction of the cell, after stimulation of LPS-primed cells but not of unprimed cells, Priming of cells with LPS also resulted in an enhanced capacity (fivefold increase) for arachidonic acid (AA) release after stimulation with fMLP compared to unprimed cells as measured by mass spectrometry, This release of AA was very efficiently blocked in a dose-dependent manner by the 85 kDa cytosolic phospholipase A(2) (PLA(2)) inhibitor MAFP (IC50=10nM) but not by the 14 kDa secretory PLA(2) inhibitor SE 203347 (up to 5 mu M), indicating that the 85 kDa cPLA(2) is the PLA(2) responsible for AA release in response to receptor-mediated agonists, In accord with inhibitor studies, the LPS-mediated phosphorylation of cPLA(2) followed the same kinetics as the priming for AA release, and a measurable fMLP-induced translocation of cPLA(2) was observed only in primed cells, As with AA release and LTB4 biosynthesis, both the phosphorylation and capacity to translocate CPLA(2) were reversed when the preincubation period with LPS was extended to 120 min. These results explain some of the cellular events responsible for the potentiation and subsequent decline of functional responses of human polymorphonuclear leukocytes recruited to inflammatory foci.	CHU Laval, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Surette, ME (corresponding author), CHU Laval, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier,Pavillon CHUL, Quebec City, PQ G1V 4G2, Canada.	marc.surette@crchul.ulaval.ca	Surette, Marc/AAW-1078-2021					ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BAULDRY SA, 1991, J IMMUNOL, V146, P1277; Bauldry SA, 1996, BBA-LIPID LIPID MET, V1299, P223, DOI 10.1016/0005-2760(95)00207-3; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BORGEAT P, 1990, METHOD ENZYMOL, V187, P98; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DIPERSIO JF, 1988, PROSTAGLANDINS, V36, P673, DOI 10.1016/0090-6980(88)90013-5; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; KRUMP E, 1994, BBA-LIPID LIPID MET, V1213, P135, DOI 10.1016/0005-2760(94)90019-1; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MCCOLL SR, 1991, J IMMUNOL, V146, P1204; MCDONALD PP, 1993, J LIPID MEDIATOR, V6, P59; MCDONALD PP, 1991, BIOCHEM J, V280, P379, DOI 10.1042/bj2800379; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; Nahas N, 1996, BIOCHEM J, V313, P503, DOI 10.1042/bj3130503; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; Nixon AB, 1997, BBA-LIPID LIPID MET, V1347, P219, DOI 10.1016/S0005-2760(97)00077-5; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; PALMANTIER R, 1994, LAB INVEST, V70, P696; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; QIU ZH, 1993, J BIOL CHEM, V268, P24506; ROSENTHAL MD, 1995, BIOCHEM BIOPH RES CO, V208, P650, DOI 10.1006/bbrc.1995.1388; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Winkler JD, 1997, BBA-LIPID LIPID MET, V1346, P173, DOI 10.1016/S0005-2760(97)00032-5; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; XU XX, 1994, J BIOL CHEM, V269, P31693	62	62	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1521	1531		10.1096/fasebj.12.14.1521	http://dx.doi.org/10.1096/fasebj.12.14.1521			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806761				2022-12-28	WOS:000076749500011
J	Zlatanova, J; Yaneva, J; Leuba, SH				Zlatanova, J; Yaneva, J; Leuba, SH			Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin	FASEB JOURNAL			English	Review						anticancer drugs; DNA adducts; DDP transplatin	HMG-DOMAIN PROTEINS; ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); MOBILITY GROUP-1 PROTEIN; INTERSTRAND CROSS-LINK; IN-VIVO; EXCISION NUCLEASE; BINDING PROTEINS; OVARIAN-CANCER; STRANDED-DNA; BASE-PAIRS	Cisplatin, but not its trans geometric isomer, is a potent anticancer drug whose biological activity is a consequence of the formation of covalent adducts between the platinum compound and certain bases in DNA, Two classes of proteins have recently been identified that bind preferentially to damaged sites: proteins that specifically recognize those sites as a first step in their repair, and those that bind to such sites by virtue of structural similarity between the modified DNA and their own natural binding sites. Both classes of proteins may be involved, perhaps in opposing ways, in the cytotoxic effect of the drug.-Zlatanova, J., Yaneva, J., Leuba, S. H. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Bulgarian Acad Sci, Inst Genet, BU-1113 Sofia, Bulgaria; Bulgarian Acad Sci, Inst Mol Biol, BU-1113 Sofia, Bulgaria	Oregon State University; Bulgarian Academy of Sciences; Bulgarian Academy of Sciences	Leuba, SH (corresponding author), Arizona State Univ, Dept Phys & Astron, POB 871504, Tempe, AZ 85287 USA.	leuba@green.la.asu.edu	Zlatanova, Jordanka/B-3273-2009	Leuba, Sanford/0000-0003-0278-7997	FIC NIH HHS [TW00568-02] Funding Source: Medline; NIGMS NIH HHS [GM50276] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050276] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BILLINGS PC, 1992, BIOCHEM BIOPH RES CO, V188, P1286, DOI 10.1016/0006-291X(92)91371-V; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1993, NUCLEIC ACIDS RES, V21, P1643, DOI 10.1093/nar/21.7.1643; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CLUGSTON CK, 1992, CANCER RES, V52, P6375; Comess K.M., 1993, MOL ASPECTS ANTICANC, P134; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; EINHORN LH, 1994, SEMIN ONCOL, V21, P47; FOX ME, 1994, MOL CELL BIOL, V14, P8071, DOI 10.1128/MCB.14.12.8071; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Kane SA, 1996, BIOCHEMISTRY-US, V35, P2180, DOI 10.1021/bi952240a; Kuraoka I, 1996, MUTAT RES-DNA REPAIR, V362, P87, DOI 10.1016/0921-8777(95)00038-0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAWRENCE DL, 1993, J BIOL CHEM, V268, P23940; LENG M, 1994, IARC SCI PUBL, V125, P339; Lilley DMJ, 1996, J BIOL INORG CHEM, V1, P189, DOI 10.1007/s007750050042; LOCKER D, 1995, J MOL BIOL, V246, P243, DOI 10.1006/jmbi.1994.0079; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MUGGIA FM, 1991, SEMIN ONCOL, V18, P1; MUGGIA FM, 1994, SEMIN ONCOL, V21, P35; MURCHIE AIH, 1993, J MOL BIOL, V233, P77, DOI 10.1006/jmbi.1993.1486; MYMRYK JS, 1995, P NATL ACAD SCI USA, V92, P2076, DOI 10.1073/pnas.92.6.2076; Ozer Z, 1995, BIOCHEMISTRY-US, V34, P15886, DOI 10.1021/bi00049a002; Paquet F, 1996, J BIOMOL STRUCT DYN, V14, P67, DOI 10.1080/07391102.1996.10508930; PEREZ RP, 1993, CANCER, V71, P1571, DOI 10.1002/cncr.2820710424; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; SORENSON CM, 1988, CANCER RES, V48, P6703; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; Turchi JJ, 1996, BIOCHEMISTRY-US, V35, P2992, DOI 10.1021/bi951843j; Turchi JJ, 1996, J BIOL CHEM, V271, P13861, DOI 10.1074/jbc.271.23.13861; VAISMAN A, 1995, BIOCHEMISTRY-US, V34, P105, DOI 10.1021/bi00001a013; Vaisman A, 1996, ONCOL RES, V8, P7; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, BIOESSAYS, V18, P697, DOI 10.1002/bies.950180903; Yaneva J, 1997, P NATL ACAD SCI USA, V94, P13448, DOI 10.1073/pnas.94.25.13448; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; ZLATANOVA J, 1998, IN PRESS FASEB J	63	110	112	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					791	799		10.1096/fasebj.12.10.791	http://dx.doi.org/10.1096/fasebj.12.10.791			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657519				2022-12-28	WOS:000074580100004
J	Norfleet, AM; Clarke, CH; Gametchu, B; Watson, CS				Norfleet, AM; Clarke, CH; Gametchu, B; Watson, CS			Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors	FASEB JOURNAL			English	Article						nongenomic effects; membrane steroid receptors; immunocytochemistry	GLUCOCORTICOID RECEPTOR; PROGESTERONE; PROLIFERATION; ACTIVATION; PATHWAY; BINDING; CAMP	Antibodies (Abs) raised against the estrogen receptor-alpha (ER alpha) were used to investigate the role of ER alpha proteins located at the plasma membrane in mediating the rapid, estrogen-stimulated secretion of prolactin (PRL) from rat pituitary GH(3)/B6/F10 cells. Exposure of the cells to 1 nM 17 beta-estradiol (E-2) significantly increased PRL release after 3 or 6 min. When ER alpha Abs that bind specifically to ER alpha but are too large to diffuse into cells were tested for activity at the cell membrane, Ab R4, targeted to an ER alpha hinge region sequence, increased PRL release in a time-, and concentration-dependent fashion. Ab H151, directed against a different hinge region epitope, decreased PRL release and blocked the stimulatory action of E-2. Abs raised against the DNA binding domain (H226) or the carboxyl terminus (C542) were not biologically active. When each Ab was examined for recognition of ER alpha on the cell surface by immunocytochemistry, all except H151 generated immunostaining in aldehyde-fixed cells. In live cells, however, Ab H151 but not Ab R4 blocked the membrane binding of fluorescently tagged E-2-BSA. Overall, the data indicate that plasma membrane ER alpha proteins mediate estrogen-stimulated PRL release from GH(3)/B6/F10 cells. These results may also convey information about conformationally sensitive areas of the membrane form of ER alpha involved in rapid, nongenomic responses to estrogens,-Norfleet, A. M., Clarke, C. H., Gametchu, B., Watson, C. S. Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin	Watson, CS (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.				NICHD NIH HHS [R01 HD032481-04, HD32481] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032481] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; BRUBAKER KD, 1994, BIOCHEM BIOPH RES CO, V200, P899, DOI 10.1006/bbrc.1994.1535; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Morey AK, 1997, ENDOCRINOLOGY, V138, P3330, DOI 10.1210/en.138.8.3330; NAKHLA AM, 1994, P NATL ACAD SCI USA, V91, P5402, DOI 10.1073/pnas.91.12.5402; NENCI I, 1980, PERSPECTIVES STEROID, P61; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; PIETRAS RJ, 1980, BIOCHEM J, V191, P743, DOI 10.1042/bj1910743; Ramirez VD, 1996, CELL MOL NEUROBIOL, V16, P175, DOI 10.1007/BF02088175; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; Sabeur K, 1996, BIOL REPROD, V54, P993, DOI 10.1095/biolreprod54.5.993; Selye H, 1941, P SOC EXP BIOL MED, V46, P116; Somjen D, 1997, J CELL BIOCHEM, V65, P53, DOI 10.1002/(SICI)1097-4644(199704)65:1<53::AID-JCB6>3.0.CO;2-Y; SZEGO CM, 1994, ENDOCRINE, V2, P1079; TESARIK J, 1992, FEBS LETT, V308, P116, DOI 10.1016/0014-5793(92)81256-L; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VAN OE, 1981, MOL CELL ENDOCRINOL, V22, P277; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WATSON CS, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432507; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wu WX, 1996, BIOL REPROD, V54, P230, DOI 10.1095/biolreprod54.1.230; ZYZEK E, 1981, BIOCHEM BIOPH RES CO, V102, P1151, DOI 10.1016/S0006-291X(81)80132-5	36	100	100	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					157	165		10.1096/fasebj.14.1.157	http://dx.doi.org/10.1096/fasebj.14.1.157			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627290	Green Accepted			2022-12-28	WOS:000084784700018
J	Gudi, T; Hong, GKP; Vaandrager, AB; Lohmann, SM; Pilz, RB				Gudi, T; Hong, GKP; Vaandrager, AB; Lohmann, SM; Pilz, RB			Nitric oxide and cGMP regulate gene expression in neuronal and glial cells by activating type II cGMP-dependent protein kinase	FASEB JOURNAL			English	Article						NO/cGMP signaling; nervous system; fos promoter	INDUCE C-FOS; TRANSMEMBRANE CONDUCTANCE REGULATOR; LONG-TERM POTENTIATION; NERVOUS-SYSTEM; INCREASES PHOSPHORYLATION; PC12 CELLS; RAT-BRAIN; TRANSCRIPTION; MEMBRANE; CAMP	Nitric oxide (NO) and cGMP have been implicated in many neuronal functions, including regulation of gene expression, but little is known about the downstream targets of NO/cGMP in the nervous system, We found that type II cGMP-dependent protein kinase (G-kinase), which is widely expressed in the brain, mediated NO- and cGMP-induced activation of the fos promoter in cells of neuronal and glial origin; the enzyme was ineffective in regulating gene expression in fibroblast-like cells, The effect of G-kinase II on gene expression did not require calcium uptake but was synergistically enhanced by calcium, G-kinase II was membrane associated and did not translocate to the nucleus; however, a soluble G-kinase II mutant translocated to the nucleus and regulated gene expression in fibroblast-like cells, Soluble G-kinase I also regulates fos promoter activity, but membrane targeting of G-kinase I prevented the enzyme from translocating to the nucleus and regulating transcription in multiple cell types, including glioma cells; this suggests that cell type-specific factor(s) that mediate the transcriptional effects of extranuclear G-kinase II are not regulated by G-kinase I, Our results suggest that G-kinase I and II control gene expression by different mechanisms and that NO effects on neuronal plasticity may involve G-kinase II regulation of gene expression.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Ctr Canc, La Jolla, CA 92093 USA; Erasmus Univ, NL-3000 DR Rotterdam, Netherlands; Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of California System; University of California San Diego; Erasmus University Rotterdam; University of Wurzburg	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rpilz@ucsd.edu		Vaandrager, Arie/0000-0001-9394-9239	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIDDK NIH HHS [2T32DK07233] Funding Source: Medline; NIGMS NIH HHS [1RO1-GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Amir S, 1997, NEUROSCIENCE, V77, P623; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Calabresi P, 1999, J NEUROSCI, V19, P2489; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P174; El-Husseini AE, 1998, J NEUROCHEM, V71, P676; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HABY C, 1994, J NEUROCHEM, V62, P496; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; JOHNSTON HM, 1995, MOL BRAIN RES, V31, P141, DOI 10.1016/0169-328X(95)00046-U; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; LevRam V, 1997, NEURON, V18, P1025, DOI 10.1016/S0896-6273(00)80340-2; Lewin MR, 1999, NAT NEUROSCI, V2, P18, DOI 10.1038/4520; Li H, 1996, MOL CELL ENDOCRINOL, V122, P159, DOI 10.1016/0303-7207(96)03881-6; Lincoln Thomas M., 1995, P51, DOI 10.1016/B978-012721985-1/50006-X; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; OHKI K, 1995, BRAIN RES, V696, P140, DOI 10.1016/0006-8993(95)00914-C; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Qian YF, 1996, J NEUROSCI, V16, P3130; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Snyder SH, 1998, BRAIN RES REV, V26, P167, DOI 10.1016/S0165-0173(97)00032-5; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Thiriet N, 1997, NEUROREPORT, V8, P399, DOI 10.1097/00001756-199701200-00003; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Vaandrager AB, 1997, J BIOL CHEM, V272, P11816, DOI 10.1074/jbc.272.18.11816; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Wang X, 1997, J NEUROCHEM, V68, P443; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	59	64	64	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2143	2152		10.1096/fasebj.13.15.2143	http://dx.doi.org/10.1096/fasebj.13.15.2143			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593861				2022-12-28	WOS:000084310800005
J	Stoffler, D; Steinmetz, MO; Aebi, U				Stoffler, D; Steinmetz, MO; Aebi, U			Imaging biological matter across dimensions: from cells to molecules and atoms	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		NUCLEAR-PORE COMPLEX; SINGLE MYOSIN MOLECULE; FORCE MICROSCOPY; F-ACTIN; SUBNANOMETER RESOLUTION; CONFORMATIONAL CHANGE; ELECTRON-MICROSCOPY; BACTERIORHODOPSIN; RECONSTRUCTIONS; CRYSTALLOGRAPHY		Univ Basel, Biozentrum, ME Miller Inst Struct Biol, CH-4056 Basel, Switzerland	University of Basel	Aebi, U (corresponding author), Univ Basel, Biozentrum, ME Miller Inst Struct Biol, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687				AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; Aebi U., 1998, Microscopy and Microanalysis, V4, P956, DOI 10.1017/S1431927600024909; BREMER A, 1992, ULTRAMICROSCOPY, V46, P85, DOI 10.1016/0304-3991(92)90008-8; BREMER A, 1994, J MOL BIOL, V242, P683, DOI 10.1006/jmbi.1994.1617; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GOLDIE KN, 1994, J VAC SCI TECHNOL B, V12, P1482, DOI 10.1116/1.587321; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; Hoenger A, 1996, J STRUCT BIOL, V117, P99, DOI 10.1006/jsbi.1996.0075; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; Kuehlbrandt W., 1994, NATURE, V367, P614; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Ludwig M, 1997, BIOPHYS J, V72, P445, DOI 10.1016/S0006-3495(97)78685-5; Muller DJ, 1996, J BACTERIOL, V178, P3025; MULLER DJ, 1995, J MOL BIOL, V249, P239, DOI 10.1006/jmbi.1995.0292; MULLER DJ, 1995, BIOPHYS J, V68, P1681, DOI 10.1016/S0006-3495(95)80345-0; Muller DJ, 1997, J STRUCT BIOL, V119, P149, DOI 10.1006/jsbi.1997.3878; Muller DJ, 1997, BIOSENS BIOELECTRON, V12, P867, DOI 10.1016/S0956-5663(97)00051-1; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Pante N, 1996, CRIT REV BIOCHEM MOL, V31, P153, DOI 10.3109/10409239609106583; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; SASE I, 1997, P NATL ACAD SCI USA, V94, P5656; Schutt CE, 1997, NAT STRUCT BIOL, V4, P169, DOI 10.1038/nsb0397-169; Steinmetz MO, 1998, J MOL BIOL, V278, P703, DOI 10.1006/jmbi.1998.1717; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; Steinmetz MO, 1998, J MOL BIOL, V276, P1, DOI 10.1006/jmbi.1997.1529; Steinmetz MO, 1997, J STRUCT BIOL, V119, P295, DOI 10.1006/jsbi.1997.3873; Steinmetz MO, 1998, BIOL BULL, V194, P337, DOI 10.2307/1543106; Stoffler D, 1999, J MOL BIOL, V287, P741, DOI 10.1006/jmbi.1999.2637; VANDEKERCKHOVE J, 1985, EMBO J, V4, P2815, DOI 10.1002/j.1460-2075.1985.tb04008.x	36	6	6	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S195	S200		10.1096/fasebj.13.9002.S195	http://dx.doi.org/10.1096/fasebj.13.9002.S195			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619127	Bronze			2022-12-28	WOS:000084390200005
J	Abraham, MR; Jahangir, A; Alekseev, AE; Terzic, A				Abraham, MR; Jahangir, A; Alekseev, AE; Terzic, A			Channelopathies of inwardly rectifying potassium channels	FASEB JOURNAL			English	Review						ion channel disease; persistent hyperinsulinemic hypoglycemia of infancy; Bartter's syndrome; weaver phenotype	SENSITIVE K+ CHANNELS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; LONG-QT SYNDROME; SULFONYLUREA RECEPTOR GENE; CEREBELLAR GRANULE CELLS; BETA-GAMMA-SUBUNITS; BARTTERS-SYNDROME; FAMILIAL HYPERINSULINISM; ATP CHANNEL; CARDIAC-ARRHYTHMIA	Mutations in genes encoding ion channels have increasingly been identified to cause disease conditions collectively termed channelopathies. Recognizing the molecular basis of an ion channel disease has provided new opportunities for screening, early diagnosis, and therapy of such conditions. This synopsis provides an overview of progress in the identification of molecular defects in inwardly rectifying potassium (Kir) channels. Structurally and functionally distinct from other channel families, Kir channels are ubiquitously expressed and serve functions as diverse as regulation of resting membrane potential, maintenance of K+ homeostasis, control of heart rate, and hormone secretion. In humans, persistent hyperinsulinemic hypoglycemia of infancy, a disorder affecting the function of pancreatic beta cells, and Bartter's syndrome, characterized by hypokalemic alkalosis, hypercalciuria, increased serum aldosterone, and plasma renin activity, are the two major diseases Linked so far to mutations in a Kir channel or associated protein. In addition, the weaver phenotype, a neurological disorder in mice, has also been associated with mutations in a Kir channel subtype. Further genetic linkage analysis and full understanding of the consequence that a defect in a Kir channel would have on disease pathogenesis are among the priorities in this emerging field of molecular medicine.-Abraham, M. R., Jahangir, A., Alekseev, A. E., Terzic, A. Channelopathies of inwardly rectifying potassium channels.	Mayo Clin & Mayo Fdn, Dept Internal Med & Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Terzic, A (corresponding author), Mayo Clin, Guggenheim 701,200 1st St SW, Rochester, MN 55904 USA.		Alekseev, Alexey/I-5346-2013; Jahangir, Arshad/M-7916-2016					Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; Brady PA, 1998, J AM COLL CARDIOL, V31, P950, DOI 10.1016/S0735-1097(98)00038-2; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Cooper EC, 1999, P NATL ACAD SCI USA, V96, P4759, DOI 10.1073/pnas.96.9.4759; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Derst C, 1997, BIOCHEM BIOPH RES CO, V230, P641, DOI 10.1006/bbrc.1996.6024; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Doyle JL, 1998, TRENDS GENET, V14, P92, DOI 10.1016/S0168-9525(97)01370-X; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Edwards G, 1997, Prog Drug Res, V49, P93; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GEORGE AL, 1995, KIDNEY INT, V48, P1180, DOI 10.1038/ki.1995.401; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; GREGORY JW, 1993, BAILLIERE CLIN ENDOC, V7, P683, DOI 10.1016/S0950-351X(05)80214-9; Hebert SC, 1998, AM J MED, V104, P87, DOI 10.1016/S0002-9343(97)00358-6; Hibino H, 1997, J NEUROSCI, V17, P4711; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOFFMAN EP, 1995, ANNU REV MED, V46, P431; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jovanovic A, 1998, LAB INVEST, V78, P1101; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; Kane C, 1997, J CLIN INVEST, V100, P1888, DOI 10.1172/JCI119718; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Karolyi L, 1998, J MOL MED, V76, P317, DOI 10.1007/s001090050223; KATZ B, 1949, ARCH SCI PHYSL, V2, P285; Keating MT, 1996, CURR OPIN GENET DEV, V6, P326, DOI 10.1016/S0959-437X(96)80010-4; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; Kurtz CL, 1997, J AM SOC NEPHROL, V8, P1706; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Navarro B, 1999, CURR TOP MEMBR, V46, P295; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schwalbe RA, 1998, HUM MOL GENET, V7, P975, DOI 10.1093/hmg/7.6.975; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Schwartz PJ, 1998, NEW ENGL J MED, V338, P1709, DOI 10.1056/NEJM199806113382401; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Service FJ, 1999, J CLIN ENDOCR METAB, V84, P1582, DOI 10.1210/jc.84.5.1582; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; Simon DB, 1998, CURR OPIN CELL BIOL, V10, P450, DOI 10.1016/S0955-0674(98)80057-4; Simon DB, 1998, CURR OPIN NEPHROL HY, V7, P43, DOI 10.1097/00041552-199801000-00008; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Slesinger PA, 1997, P NATL ACAD SCI USA, V94, P12210, DOI 10.1073/pnas.94.22.12210; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Stanley CA, 1997, PEDIATR CLIN N AM, V44, P363, DOI 10.1016/S0031-3955(05)70481-8; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Surmeier DJ, 1996, P NATL ACAD SCI USA, V93, P11191, DOI 10.1073/pnas.93.20.11191; Terwindt GM, 1998, EUR J HUM GENET, V6, P297, DOI 10.1038/sj.ejhg.5200206; TERZIC A, 1994, NEURON, V12, P1049, DOI 10.1016/0896-6273(94)90313-1; TERZIC A, 1994, NEURON, V12, P885, DOI 10.1016/0896-6273(94)90340-9; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tucker SJ, 1998, CURR OPIN NEUROBIOL, V8, P316, DOI 10.1016/S0959-4388(98)80055-X; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404	104	54	61	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1901	1910						10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544173				2022-12-28	WOS:000083660700002
J	Scalabrino, G; Nicolini, G; Buccellato, FR; Peracchi, M; Tredici, G; Manfridi, A; Pravettoni, G				Scalabrino, G; Nicolini, G; Buccellato, FR; Peracchi, M; Tredici, G; Manfridi, A; Pravettoni, G			Epidermal growth factor as a local mediator of the neurotrophic action of vitamin B-12 (cobalamin) in the rat central nervous system	FASEB JOURNAL			English	Article						cerebrospinal fluid; epidermal growth factor; subacute combined degeneration; totally gastrectomized rat	TOTALLY GASTRECTOMIZED RATS; SUBACUTE COMBINED DEGENERATION; VASOACTIVE-INTESTINAL-PEPTIDE; NECROSIS-FACTOR-ALPHA; ORNITHINE DECARBOXYLASE; NEUROPEPTIDE RECEPTORS; SPINAL-CORDS; GLIAL-CELLS; BRAIN; DEFICIENCY	We have recently demonstrated that the myelinolytic lesions in the spinal cord (SC) of rats made deficient in vitamin B-12 (cobalamin) (Cbl) through total gastrectomy (TG) are tumor necrosis factor-alpha (TNF-alpha)-mediated. We investigate whether or not permanent Cbl deficiency, induced in the rat either through TG or by chronic feeding of a Cbl-deficient diet, might modify the levels of three physiological neurotrophic factors-epidermal growth factor (EGF), vasoactive intestinal peptide (VIP), and somatostatin (SS)-in the cerebrospinal fluid (CSF) of these rats. We also investigated the ability of the central nervous system (CNS) in these Cbl-deficient rats to synthesize EGF mRNA and of the SC to take up labeled Cbl in vivo. Cbl-deficient rats, however the vitamin deficiency is induced, show a selective decrease in EGF CSF levels and an absence of EGF mRNA in neurons and glia in various CNS areas. In contrast, radiolabeled Cbl is almost exclusively taken up by the SC white matter, but to a much higher degree in totally gastrectomized (TGX) rats. Chronic administration of Chl to TGX rats restores to normal both the EGF CSF level and EGF mRNA expression in the various CNS areas examined. This in vivo study presents the first evidence that the neurotrophic action of Cbl in the CNS of TGX rats is mediated by stimulation of the EGF synthesis in the CNS itself, It thus appears that Cbl inversely regulates the expression of EGF and TNF-alpha genes in the CNS of TGX rats.-Scalabrino, G., Nicolini, G., Buccellato, F. R., Peracchi, M., Tredici, G., Manfridi, A., Pravettoni, G, Epidermal growth factor as a local mediator of the neurotrophic action of vitamin B-12 (cobalamin) in the rat central nervous system.	Univ Milan, Inst Gen Pathol, Fac Med, I-20133 Milan, Italy; Univ Milan, Inst Human Anat, Fac Med, I-20133 Milan, Italy; Univ Milan, Inst Med Sci, Fac Med, I-20133 Milan, Italy; Univ Milan, Inst Human Physiol 2, Fac Med, I-20133 Milan, Italy; Gife Lab, Lugano, Switzerland	University of Milan; University of Milan; University of Milan; University of Milan	Scalabrino, G (corresponding author), Univ Milan, Inst Gen Pathol, Fac Med, Via Mangiagalli 31, I-20133 Milan, Italy.		manfridi, alfredo/D-3398-2013; NIcolini, Gabriella/AAK-9155-2020; Pravettoni, Gabriella/AAC-3500-2022; Pravettoni, Gabriella/C-6915-2011	Pravettoni, Gabriella/0000-0002-4843-4663; NICOLINI, GABRIELLA/0000-0002-6241-4538				BARRECA T, 1988, ACTA ENDOCRINOL-COP, V117, P130, DOI 10.1530/acta.0.1170130; Beck W S, 1991, Adv Intern Med, V36, P33; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; Buccellato FR, 1999, FASEB J, V13, P297, DOI 10.1096/fasebj.13.2.297; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CHANARIN I, 1992, J CLIN PATHOL, V45, P277, DOI 10.1136/jcp.45.4.277; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; ERMISCH A, 1993, PHYSIOL REV, V73, P489, DOI 10.1152/physrev.1993.73.3.489; FISCHER DA, 1989, ANNU REV PHYSIOL, V51, P67; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; HAN VKM, 1992, ENDOCRINOLOGY, V131, P1134, DOI 10.1210/en.131.3.1134; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; HERBERT V, 1985, LAB INVEST, V52, P3; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HUFF KR, 1990, INT J DEV NEUROSCI, V8, P255, DOI 10.1016/0736-5748(90)90031-V; KAR S, 1995, J COMP NEUROL, V354, P253, DOI 10.1002/cne.903540208; Koli K, 1996, ADV CANCER RES, V70, P63, DOI 10.1016/S0065-230X(08)60872-6; Kordek R, 1996, P NATL ACAD SCI USA, V93, P9754, DOI 10.1073/pnas.93.18.9754; KRISCH B, 1994, INT REV CYTOL, V148, P119, DOI 10.1016/S0074-7696(08)62407-9; Labourdette G., 1995, P441; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MAZZONI IE, 1992, DRUG DEVELOP RES, V26, P111, DOI 10.1002/ddr.430260202; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; METZ J, 1992, ANNU REV NUTR, V12, P59, DOI 10.1146/annurev.nu.12.070192.000423; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MULLER JM, 1995, MOL NEUROBIOL, V10, P115, DOI 10.1007/BF02740671; PANT SS, 1968, ACTA NEUROL SCAN S35, V44, P8; Peracchi M, 1997, AM J GASTROENTEROL, V92, P1884; PEZACKA EH, 1992, BIOCHEM BIOPH RES CO, V184, P832, DOI 10.1016/0006-291X(92)90665-8; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; Powers J, 1996, MOL CHEM NEUROPATHOL, V27, P31, DOI 10.1007/BF02815031; QURESHI AA, 1994, CRIT REV ONCOL HEMAT, V17, P133, DOI 10.1016/1040-8428(94)90022-1; Reichlin S., 1998, WILLIAMS TXB ENDOCRI, P165; Rothwell NJ, 1997, BRIT J PHARMACOL, V121, P841, DOI 10.1038/sj.bjp.0701248; Said SI, 1996, J CLIN INVEST, V97, P2163, DOI 10.1172/JCI118655; SCALABRINO G, 1995, LAB INVEST, V72, P114; SCALABRINO G, 1990, LAB INVEST, V62, P297; Scalabrino G, 1997, EXP NEUROL, V144, P258, DOI 10.1006/exnr.1996.6376; Scalabrino G, 1998, BRIT J HAEMATOL, V100, P615; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SWANSON LW, 1995, TRENDS NEUROSCI, V18, P471, DOI 10.1016/0166-2236(95)92766-J; Tredici G, 1998, J SUBMICR CYTOL PATH, V30, P165; Tredici G, 1998, J NEUROL SCI, V156, P18, DOI 10.1016/S0022-510X(98)00005-7; VIEIRAMAKINGS E, 1991, BIOCHEM J, V275, P585, DOI 10.1042/bj2750585; WASS JAH, 1995, ENDOCRINOLOGY, P266; WEIR DG, 1995, BAILLIERE CLIN HAEM, V8, P479, DOI 10.1016/S0950-3536(05)80217-3; WILLIAMS MA, 1977, PRACTICAL METHODS EL, V6, P85; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; YOUNG M, 1995, AM J PHYSIOL-ENDOC M, V269, pE657, DOI 10.1152/ajpendo.1995.269.4.E657; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; Yuen EC, 1996, ANN NEUROL, V40, P346, DOI 10.1002/ana.410400304	57	50	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2083	2090		10.1096/fasebj.13.14.2083	http://dx.doi.org/10.1096/fasebj.13.14.2083			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544191				2022-12-28	WOS:000083660700020
J	De Benedictis, G; Rose, G; Carrieri, G; De Luca, M; Falcone, E; Passarino, G; Bonafe, M; Monti, D; Baggio, G; Bertolini, S; Mari, D; Mattace, R; Franceschi, C				De Benedictis, G; Rose, G; Carrieri, G; De Luca, M; Falcone, E; Passarino, G; Bonafe, M; Monti, D; Baggio, G; Bertolini, S; Mari, D; Mattace, R; Franceschi, C			Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans	FASEB JOURNAL			English	Article						MtDNA haplogroup; mitochondria; sex-specific mtDNA/longevity association	POPULATIONS; ANCIENT; HAPLOGROUPS; MIGRATIONS; SEQUENCE; REVEALS; DISEASE; MTDNA	Mitochondrial DNA (mtDNA) is characterized by high variability, maternal inheritance, and absence of recombination. Studies of human populations have revealed ancestral associated polymorphisms whose combination defines groups of mtDNA types (haplogroups) that are currently used to reconstruct human evolution lineages. We used such inherited mtDNA markers to compare mtDNA population pools between a sample of individuals selected for successful aging and longevity (212 subjects older than 100 years and in good clinical condition) and a sample of 275 younger individuals (median age 38 years) carefully matched as to sex and geographic origin (northern and southern Italy). All nine haplogroups that are typical of Europeans were found in both samples, but male centenarians emerged in northern Italy as a particular sample: I) mtDNA haplogroup frequency distribution was different between centenarians and younger individuals (P=0.017 by permutation tests); and 2) the frequency of the J haplogroup was notably higher in centenarians than in younger individuals (P=0.0052 by Fisher exact test). Since haplogroups are defined on the basis of inherited variants, these data show that mtDNA inherited variability could play a role in successful aging and longevity.	Univ Calabria, Dept Cell Biol, I-87030 Arcavacata, Italy; Italian Natl Res Ctr Aging, Ancona, Italy; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; Univ Sassari, Dept Geriatr, I-07100 Sassari, Italy; Univ Milan, Maggiore Hosp, IRCCS, Inst Internal Med, Milan, Italy; Univ Catanzaro, Dept Geriatr, Catanzaro, Italy	University of Calabria; IRCCS INRCA; Universita di Modena e Reggio Emilia; University of Sassari; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Magna Graecia University of Catanzaro	De Benedictis, G (corresponding author), Univ Calabria, Dept Cell Biol, I-87030 Arcavacata, Italy.		Monti, Daniela/G-9556-2012; Franceschi, Claudio/L-4484-2017; /V-4899-2019; Mari, Daniela/K-5663-2016	Monti, Daniela/0000-0001-8651-8123; Franceschi, Claudio/0000-0001-9841-6386; Mari, Daniela/0000-0002-6950-0789; Rose, Giuseppina/0000-0002-4264-4184				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BALLINGER SW, 1992, GENETICS, V130, P139; BRAND FN, 1992, J CLIN EPIDEMIOL, V45, P169, DOI 10.1016/0895-4356(92)90009-C; CAVALLISFORZA LL, 1993, HIST GEOGRAPHY HUMAN, P277; CHEN YS, 1995, AM J HUM GENET, V57, P133; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; De Benedictis G, 1998, EUR J HUM GENET, V6, P534, DOI 10.1038/sj.ejhg.5200222; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Herskind AM, 1996, HUM GENET, V97, P319, DOI 10.1007/s004390050042; Ivanova R, 1998, HUM MOL GENET, V7, P187, DOI 10.1093/hmg/7.2.187; KADENBACH B, 1995, MUTAT RES-DNAGING G, V338, P161, DOI 10.1016/0921-8734(95)00021-W; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Martin GM, 1996, EXP GERONTOL, V31, P49, DOI 10.1016/0531-5565(95)02021-7; MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Torroni A, 1996, GENETICS, V144, P1835; TORRONI A, 1994, AM J HUM GENET, V55, P760; TORRONI A, 1992, GENETICS, V130, P153; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WEIR BS, 1996, GENETIC DATA ANAL, V2, P165	24	306	318	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1532	1536		10.1096/fasebj.13.12.1532	http://dx.doi.org/10.1096/fasebj.13.12.1532			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463944				2022-12-28	WOS:000082347600008
J	Roberts, LJ; Salomon, RG; Morrow, JD; Brame, CJ				Roberts, LJ; Salomon, RG; Morrow, JD; Brame, CJ			New developments in the isoprostane pathway: identification of novel highly reactive gamma-ketoaldehydes (isolevuglandins) and characterization of their protein adducts	FASEB JOURNAL			English	Review						free radical; oxidant injury; lipid peroxidation; aldehyde	LIPID-PEROXIDATION; IN-VIVO; PROSTAGLANDIN ENDOPEROXIDES; PROSTANOIDS F2-ISOPROSTANES; ALZHEIMERS-DISEASE; COVALENT BINDING; LEVUGLANDIN E(2); OXYGEN-TENSION; CROSS-LINKS; GENERATION	The bicyclic endoperoxide prostaglandin (PG) H-2 undergoes nonenzymatic rearrangement not only to PGE(2) and PGD(2), but also to levuglandins (LG) E-2 and D-2, which are highly reactive gamma-ketoaldehydes. Isoprostanes (IsoPs) are PG-like compounds that are produced by nonenzymatic peroxidation of arachidonic acid. PGH(2)-like endoperoxides are intermediates in this pathway. Therefore, we explored whether the IsoP endoperoxides also undergo rearrangement to form IsoLGs. Oxidation of arachidonic acid in vitro resulted in the formation of abundant quantities of compounds that were established to be IsoLGs by using mass spectrometric analyses. However, the formation of IsoLGs could not be detected in biological systems subjected to an oxidant stress. We hypothesized that this was due to extremely rapid adduction of IsoLGs to proteins. This notion was supported by the finding that LGE(2) adducted to albumin at a rate that exceeded that of 4-hydroxynonenal by several orders of magnitude: >50% of LGE(2) had adducted within 20 s, We therefore undertook to characterize the nature of LG adducts. Using liquid chromatography electrospray tandem mass spectrometry, we established that LGs form oxidized pyrrole adducts (lactams and hydroxylactams) with the epsilon-amino group of lysine. Oxidation of low density lipoprotein resulted in readily detectable IsoLG adducts on apolipoprotein B after enzymatic digestion of the protein to individual amino acids. These studies identify a novel class of ketoaldehydes produced by the IsoP pathway that form covalent protein adducts at a rate that greatly exceeds that of other known aldehyde products of lipid peroxidation. Elucidation of the nature of the adducts formed by IsoLGs provides the basis to explore the formation of IsoLGs in vivo and investigate the potential biological ramifications of their formation in settings of oxidant injury.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Vanderbilt University; Vanderbilt University; Case Western Reserve University	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	jack.roberts@mcmail.vanderbilt.edu	Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, R01GM042056, R37GM042056, P01GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48831] Funding Source: Medline; NIGMS NIH HHS [GM 42056, GM 15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; CURZIO M, 1986, BIOL CHEM H-S, V367, P321, DOI 10.1515/bchm3.1986.367.1.321; DECAPRIO AP, 1982, TOXICOL APPL PHARM, V65, P440, DOI 10.1016/0041-008X(82)90389-1; DYRKS T, 1992, J BIOL CHEM, V267, P18210; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GRAHAM DG, 1995, CRIT REV TOXICOL, V25, P91, DOI 10.3109/10408449509021609; Hoppe G, 1997, BBA-LIPID LIPID MET, V1344, P1, DOI 10.1016/S0005-2760(96)00160-9; IYER RS, 1994, J ORG CHEM, V59, P6038, DOI 10.1021/jo00099a039; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; IYER RS, 1990, J ORG CHEM, V55, P3175, DOI 10.1021/jo00297a037; JIROUSEK MR, 1990, PROSTAGLANDINS, V40, P187, DOI 10.1016/0090-6980(90)90083-8; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MILLS GL, 1984, GUIDEBOOK LIPOPROTEI; Montine TJ, 1996, AM J PATHOL, V148, P89; Montine TJ, 1998, ANN NEUROL, V44, P410, DOI 10.1002/ana.410440322; MONTINE TJ, 1999, IN PRESS NEUROLOGY; Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; NUTGEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Roberts LJ, 1999, CURR INFLAMMAT RES, P141; Roberts LJ, 1997, BBA-LIPID LIPID MET, V1345, P121, DOI 10.1016/S0005-2760(96)00162-2; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Salem N. Jr., 1986, Health effects of polyunsaturated fatty acids in seafoods, P263; SALOMON RG, 1987, PROSTAGLANDINS, V34, P643, DOI 10.1016/0090-6980(87)90289-9; SALOMON RG, 1984, J AM CHEM SOC, V106, P6049, DOI 10.1021/ja00332a049; SKINNER ER, 1993, BRAIN, V116, P717, DOI 10.1093/brain/116.3.717; SMITH EB, 1967, J ORG CHEM, V32, P3330, DOI 10.1021/jo01286a012; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; TRONCOSO JC, 1993, BRAIN RES, V613, P313, DOI 10.1016/0006-8993(93)90918-D	40	32	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1157	1168		10.1096/fasebj.13.10.1157	http://dx.doi.org/10.1096/fasebj.13.10.1157			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385607	Bronze			2022-12-28	WOS:000081264800005
J	Linskens, MHK; Grootenhuis, PDJ; Blaauw, M; Huisman-De Winkel, B; Van Ravestein, A; Van Haastert, PJM; Heikoop, JC				Linskens, MHK; Grootenhuis, PDJ; Blaauw, M; Huisman-De Winkel, B; Van Ravestein, A; Van Haastert, PJM; Heikoop, JC			Random mutagenesis and screening of complex glycoproteins: expression of human gonadotropins in Dictyostelium discoideum	FASEB JOURNAL			English	Article						heterologous protein expression; follicle-stimulating hormone; infertility	INTERSUBUNIT DISULFIDE BONDS; HUMAN CHORIONIC-GONADOTROPIN; RECOMBINANT GLYCOPROTEINS; HUMAN CHORIOGONADOTROPIN; RECEPTOR; SUBUNIT; PROTEIN; HORMONES; AFFINITY	The soil amoeba Dictyostelium discoideum is a host cell that provides simple genetics in combination with complex protein synthesis. We show that the complex human heterodimeric gonadotropins can be produced and secreted by this organism, Furthermore, both follicle stimulation hormone and choriogonadotropin produced by D. dictyostelium bind to their human receptors and elicit a biological response comparable to the wild-type hormones, We also show that structure-function analysis using random mutagenesis and screening of recombinant glycoprotein hormones is feasible. Thus, expression of gonadotropins in D. dictyostelium opens the way to the engineering of potential new therapeutic analogues.	Univ Groningen, GBB, Cell Engn Facil, NL-9747 AG Groningen, Netherlands; NV Organon, NL-5340 BH Oss, Netherlands	University of Groningen	Linskens, MHK (corresponding author), Univ Groningen, GBB, Cell Engn Facil, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	m.linskens@chem.rug.nl						CHEN F, 1991, J BIOL CHEM, V266, P6904; Cohen NR, 1996, BIOCHEM J, V315, P971, DOI 10.1042/bj3150971; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; DINGERMANN T, 1991, APPL MICROBIOL BIOT, V35, P496; *GLAX WELLC, 1996, NATURE S, V384, P1; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; Heikoop JC, 1998, EUR J BIOCHEM, V253, P354, DOI 10.1046/j.1432-1327.1998.2530354.x; Heikoop JC, 1998, EUR J BIOCHEM, V256, P359, DOI 10.1046/j.1432-1327.1998.2560359.x; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; Heikoop JC, 1997, EUR J BIOCHEM, V245, P656, DOI 10.1111/j.1432-1033.1997.00656.x; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUANG JN, 1993, MOL CELL ENDOCRINOL, V90, P211, DOI 10.1016/0303-7207(93)90154-C; HUGHES JE, 1994, MOL CELL BIOL, V14, P6117, DOI 10.1128/MCB.14.9.6117; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Jennings JC, 1996, DRUGS, V52, P313, DOI 10.2165/00003495-199652030-00002; Jung E, 1997, BIOTECHNOL APPL BIOC, V25, P3, DOI 10.1111/j.1470-8744.1997.tb00407.x; Kim JY, 1997, J BIOL CHEM, V272, P2060; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MOORE WT, 1980, CHORIONIC GONADOTROP, P89; PLUNKETT MJ, 1997, SCI AM           APR, P55; SHARP PM, 1989, NUCLEIC ACIDS RES, V17, P5029, DOI 10.1093/nar/17.13.5029; Shoham Z, 1996, FERTIL STERIL, V66, P187; Slade MB, 1997, BIOTECHNOL GENET ENG, V14, P1; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; VOITH G, 1995, BIO-TECHNOL, V13, P1225, DOI 10.1038/nbt1195-1225; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381	28	18	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					639	645		10.1096/fasebj.13.6.639	http://dx.doi.org/10.1096/fasebj.13.6.639			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094924				2022-12-28	WOS:000079527200005
J	Holthofer, H; Kretzler, M; Haltia, A; Solin, ML; Taanman, JW; Schagger, H; Kriz, W; Kerjaschki, D; Schlondorff, D				Holthofer, H; Kretzler, M; Haltia, A; Solin, ML; Taanman, JW; Schagger, H; Kriz, W; Kerjaschki, D; Schlondorff, D			Altered gene expression and functions of mitochondria in human nephrotic syndrome	FASEB JOURNAL			English	Article						proteinuria; congenital nephrotic syndrome; glomerular disease; differential display; cytochrome c oxidase	CYTOCHROME-C-OXIDASE; BLUE NATIVE ELECTROPHORESIS; COMPLEX-I DEFICIENCY; FINNISH TYPE; OXIDATIVE-PHOSPHORYLATION; MOLECULAR MECHANISMS; LIPID-PEROXIDATION; GLOMERULAR INJURY; HEYMANN NEPHRITIS; MESSENGER-RNA	The molecular basis of glomerular permselectivity remains largely unknown. The congenital nephrotic syndrome of the Finnish type (CNF) characterized by massive proteinuria already present but without extrarenal symptoms is a unique human disease model of pure proteinuria, In search of genes and pathophysiologic mechanisms associated with proteinuria, we used differential display-PCR to identify differences in gene expression between glomeruli from CNF and control kidneys, A distinctly underexpressed PCR product of the CNF kidneys showed over 98% identity with a mitochondrially encoded cytochrome c oxidase (COX I), Using a full-length COX I cDNA probe, we verified down-regulation of COX I mRNA to 1/4 of normal kidney values on Northern blots, In addition, transcripts of other mitochondrially encoded respiratory chain complexes showed a similar down-regulation whereas the respective nuclearly encoded complexes were expressed at comparable levels, Additional studies using histochemical, immunohistochemical, in situ hybridization, RT-PCR, and biochemical and electron microscopic methods all showed a mitochondrial involvement in the diseased kidneys but not in extrarenal blood vessels, As a secondary sign of mitochondrial dysfunction, excess lipid peroxidation products were found in glomerular structures in CNF samples, Our data suggest that mitochondrial dysfunction occurs in the kidneys of patients with CNF, with subsequent lipid peroxidation at the glomerular basement membrane, Our additional studies have revealed similar down-regulation of mitochondrial functions in experimental models of proteinuria, Thus, mitochondrial dysfunction may be a crucial pathophysiologic factor in this symptom.	Univ Helsinki, Div Bacteriol & Immunol, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Munich, Med Poliklin, D-8000 Munich, Germany; Univ Vienna, Dept Pathol, Vienna, Austria; Univ London, Dept Clin Neurosci, London, England; Univ Frankfurt, D-6000 Frankfurt, Germany; Univ Heidelberg, Dept Anat, Heidelberg, Germany	University of Helsinki; University of Munich; University of Vienna; University of London; Goethe University Frankfurt; Ruprecht Karls University Heidelberg	Holthofer, H (corresponding author), Univ Helsinki, Div Bacteriol & Immunol, Haartman Inst, Dept Bacteriol & Immunol, PB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Harry.Holthofer@Helsinki.fi	Taanman, Jan W/A-5379-2011	Taanman, Jan W/0000-0002-5476-9785				ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; BANCROFT JD, 1975, HISTOCHEMICAL TECHNI, P280; BENTLAGE H, 1995, EUR J BIOCHEM, V227, P909, DOI 10.1111/j.1432-1033.1995.tb20218.x; BRESOLIN N, 1994, MITOCHONDRIA DNA PRO, P221; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAMOND JR, 1992, AM J KIDNEY DIS, V19, P292, DOI 10.1016/S0272-6386(13)80013-3; GABAI VL, 1993, FEBS LETT, V327, P247, DOI 10.1016/0014-5793(93)80997-9; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HALLMAN NIILO, 1967, ACTA PAEDIAT SCAND SUPPL, V172., P75; Haltia A, 1996, PEDIATR RES, V40, P652, DOI 10.1203/00006450-199611000-00002; HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984; HOLTHOFER H, 1994, KIDNEY INT, V45, P123, DOI 10.1038/ki.1994.14; Hsieh F, 1996, J AM SOC NEPHROL, V7, P647; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; JOHNSON RJ, 1994, KIDNEY INT, V45, P352, DOI 10.1038/ki.1994.45; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; KERJASCHKI D, 1994, KIDNEY INT, V45, P300, DOI 10.1038/ki.1994.39; Kerjaschki D, 1996, J AM SOC NEPHROL, V7, P2518; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; KIM K, 1995, BIOCHEM J, V306, P353, DOI 10.1042/bj3060353; KRETZLER M, 1996, AM J PHYSIOL, V271, P770; LANG H, 1994, BIOCHEM J, V299, P393, DOI 10.1042/bj2990393; LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; Mannikko M, 1996, J AM SOC NEPHROL, V7, P2700; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MCCORMACK JG, 1994, MITOCHONDRIA DNA PRO, P221; MOGGIO M, 1989, INT J DEV NEUROSCI, V7, P5, DOI 10.1016/0736-5748(89)90040-3; Montine TJ, 1996, AM J PATHOL, V148, P89; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NEALE TJ, 1994, J CLIN INVEST, V94, P1577, DOI 10.1172/JCI117499; PABST R, 1983, KIDNEY INT, V24, P626, DOI 10.1038/ki.1983.203; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; RAPOLA J, 1987, PEDIATR NEPHROL, V1, P441, DOI 10.1007/BF00849252; RENNKE HG, 1994, KIDNEY INT, V45, pS58; Sambrook J., 1989, MOL CLONING, pA1; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHAPIRA AHV, 1994, MITOCHONDRIA DNA PRO, P241; Shirato I, 1996, AM J PATHOL, V148, P1283; Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935; TAANMAN JW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P95, DOI 10.1016/0925-4439(93)90128-N; Taanman JW, 1996, BBA-MOL BASIS DIS, V1315, P199, DOI 10.1016/0925-4439(95)00127-1; VANBIERVLIET JPGM, 1977, PEDIATR RES, V11, P1088, DOI 10.1203/00006450-197711100-00005; VOOS W, 1994, MITOCHONDRIA DNA PRO, P221; WALLACE DC, 1995, AM J HUM GENET, V57, P201	49	47	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					523	532		10.1096/fasebj.13.3.523	http://dx.doi.org/10.1096/fasebj.13.3.523			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064619				2022-12-28	WOS:000079016000012
J	Jackson, M; Howie, SEM; Weller, R; Sabin, E; Hunter, JAA; McKenzie, RC				Jackson, M; Howie, SEM; Weller, R; Sabin, E; Hunter, JAA; McKenzie, RC			Psoriatic keratinocytes show reduced IRF-1 and STAT-1 alpha activation in response to gamma-IFN	FASEB JOURNAL			English	Article						psoriasis; gamma-interferon; fibronectin; KC; GAS sites	REGULATORY FACTOR-I; RECOMBINANT INTERFERON-GAMMA; STAT SIGNALING PATHWAY; NITRIC-OXIDE SYNTHASE; GROWTH-INHIBITION; T-LYMPHOCYTES; EXPRESSION; RECEPTOR; SKIN; APOPTOSIS	Psoriasis is a chronic inflammatory dermatosis characterized by hyperproliferative keratinocytes (MC), The skin lesions are infiltrated by T cells, which secrete gamma interferon (gamma-IFN) and are believed to be necessary to maintain the psoriatic phenotype, In normal KC, gamma-IFN is a potent inhibitor of proliferation, but proliferation of KC persists in psoriatic plaques despite the presence of gamma-lFN, Immunostaining of interferon regulatory factor-1 (IRF-1) revealed that IRF-1 was localized to the basal cells of the epidermis in normal and in nonlesional psoriatic skin, but was suprabasal or completely absent in lesional psoriatic skin. This finding led to the hypothesis that abnormal signaling in the gamma-IFN pathway may occur in psoriatic KC. To test this hypothesis, we measured activation of IRF-1 and signal transducer and activator of transcription (STAT)-1 alpha transcription factors in KC after stimulation with gamma-IFN, Primary cultures of KC from normal and nonlesional psoriatic skin were stimulated with gamma-IFN and subsequent transcription factor activation was measured by electrophoretic mobility shift assay, Psoriatic KC showed a reduced induction of IRF-1 and STAT-1 alpha activation after stimulation with gamma-IFN, compared with normal KC, Reduced activation of IRF-1 and STAT-lar in response to gamma-IFN indicates a fundamental defect in the growth and differentiation control of psoriatic KC in the absence of the influence of other cell types.	Univ Edinburgh, Dept Dermatol, RIE, Edinburgh EH3 9YW, Midlothian, Scotland; Univ Edinburgh, Dept Pathol, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	McKenzie, RC (corresponding author), Univ Edinburgh, Dept Dermatol, RIE, Lauriston Bldg, Edinburgh EH3 9YW, Midlothian, Scotland.							ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; BARKER J N W N, 1991, Journal of Dermatological Science, V2, P106, DOI 10.1016/0923-1811(91)90019-T; BARKER JNWN, 1993, AM J PATHOL, V142, P1091; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; ELDER JT, 1994, ARCH DERMATOL, V130, P216, DOI 10.1001/archderm.130.2.216; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FIERLBECK G, 1990, ARCH DERMATOL, V126, P351, DOI 10.1001/archderm.126.3.351; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hobart M, 1997, J IMMUNOL, V158, P4260; Howie SEM, 1996, J INVEST DERMATOL, V106, P1218, DOI 10.1111/1523-1747.ep12348507; JONES JL, 1994, J PATHOL, V174, P77, DOI 10.1002/path.1711740203; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KRUEGER GG, 1981, J CLIN INVEST, V68, P1548, DOI 10.1172/JCI110409; LIU SCC, 1983, J INVEST DERMATOL, V81, P54, DOI 10.1111/1523-1747.ep12538884; LOOK DC, 1994, J BIOL CHEM, V269, P8952; LORRE K, 1994, CLIN IMMUNOL IMMUNOP, V70, P81, DOI 10.1006/clin.1994.1014; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MORHENN VB, 1987, ARCH DERMATOL, V123, P1633, DOI 10.1001/archderm.123.12.1633; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sato T, 1997, BLOOD, V90, P4749, DOI 10.1182/blood.V90.12.4749.4749_4749_4758; Saunders N, 1996, J DERMATOL SCI, V13, P98, DOI 10.1016/S0923-1811(96)00535-X; SCHEYNIUS A, 1992, J INVEST DERMATOL, V98, P255, DOI 10.1111/1523-1747.ep12556086; Sirsjo A, 1996, BRIT J DERMATOL, V134, P643, DOI 10.1111/j.1365-2133.1996.tb06963.x; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANDENOORD JJ, 1995, PATHOL RES PRACT, V191, P530, DOI 10.1016/S0344-0338(11)80872-1; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421	38	40	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					495	502		10.1096/fasebj.13.3.495	http://dx.doi.org/10.1096/fasebj.13.3.495			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064616				2022-12-28	WOS:000079016000009
J	Jansen, RP				Jansen, RP			RNA-cytoskeletal associations	FASEB JOURNAL			English	Review						translation; RNA localization; RNA binding proteins; microtubules; microfilaments	AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR 1-ALPHA; MATERNAL MESSENGER-RNA; IN-SITU HYBRIDIZATION; BINDING-PROTEIN; DROSOPHILA OOCYTE; XENOPUS OOCYTES; BOUND POLYSOMES; ASYMMETRIC LOCALIZATION; CELL DIVISIONS	It has become evident over the past years that a large fraction of messenger RNAs is tightly associated with the cytoskeleton. Whereas microtubules are involved in RNA-cytoskeletal association in large cells like oocytes, neurons, or oligodendrocytes, microfilaments play the major role in smaller somatic cell types. Association of RNA with cytoskeletal filaments clearly is required for mRNA transport, but also appears to be crucial for efficient protein synthesis. Recent data now shed light on how mRNAs attach to the cytoskeleton. Messenger RNA seems to interact with microtubules or microfilaments in the form of large ribonucleoprotein particles, which in some cases also contain components of the protein synthesis apparatus. Recently, a number of RNA binding proteins have been identified in flies, amphibians, and mammals that are essential for the interaction of mRNA with cytoskeletal filaments or with microtubule- or actin-associated proteins. Such proteins include heterologous ribonucleoproteins, which are also involved in nuclear export of RNA.	Heidelberg Univ, ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Jansen, RP (corresponding author), Heidelberg Univ, ZMBH, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	r.jansen@mail.zmbh.uni-heidelberg.de						AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Antic D, 1998, J CELL SCI, V111, P183; BARBARESE E, 1995, J CELL SCI, V108, P2781; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; Bassell GJ, 1998, J NEUROSCI, V18, P251; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; Bershadsky AD., 1988, CYTOSKELETON, V1st; BIEGEL D, 1992, J CELL BIOCHEM, V48, P98, DOI 10.1002/jcb.240480114; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; BOUGET FY, 1995, DEV BIOL, V171, P258, DOI 10.1006/dbio.1995.1277; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; BROWN S, 1976, J SUPRAMOL STR CELL, V5, P119, DOI 10.1002/jss.400050203; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DeFranco C, 1998, MOL BIOL CELL, V9, P1695, DOI 10.1091/mbc.9.7.1695; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; ERICKSON PA, 1992, J STRUCT BIOL, V108, P148, DOI 10.1016/1047-8477(92)90014-2; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Gavis ER, 1996, DEV BIOL, V176, P36, DOI 10.1006/dbio.1996.9996; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; Glotzer JB, 1996, SEMIN CELL DEV BIOL, V7, P357, DOI 10.1006/scdb.1996.0045; HAARER BK, 1994, J CELL SCI, V107, P1055; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Han JW, 1997, J CELL BIOL, V137, P871, DOI 10.1083/jcb.137.4.871; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; HESKETH JE, 1991, CELL BIOL INT REP, V15, P141, DOI 10.1016/0309-1651(91)90105-R; Hesketh JE, 1996, EXP CELL RES, V225, P219, DOI 10.1006/excr.1996.0172; HEUIJERJANS JH, 1989, EXP CELL RES, V181, P317, DOI 10.1016/0014-4827(89)90091-8; HEUSER JE, 1980, J CELL BIOL, V86, P212, DOI 10.1083/jcb.86.1.212; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; HOVLAND R, 1995, BIOCHEM J, V310, P193, DOI 10.1042/bj3100193; HOWE JG, 1984, CELL, V37, P85; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; Kimura T, 1996, BIOCHIMIE, V78, P1075, DOI 10.1016/S0300-9084(97)86732-6; King ML, 1996, DEV GENET, V19, P183, DOI 10.1002/(SICI)1520-6408(1996)19:3<183::AID-DVG1>3.0.CO;2-5; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; LIPSHITZ HD, 1995, LOCALIZED RNAS, P1; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUBYPHELPS K, 1994, CURR OPIN CELL BIOL, V6, P3, DOI 10.1016/0955-0674(94)90109-0; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; Manseau L, 1996, DEVELOPMENT, V122, P2109; Micklem DR, 1995, DEV BIOL, V172, P377, DOI 10.1006/dbio.1995.8048; MICKLEM DR, 1998, THESIS CAMBRIDGE; Montana G, 1997, EUR J BIOCHEM, V247, P183, DOI 10.1111/j.1432-1033.1997.00183.x; MOON RT, 1983, DEV BIOL, V95, P447, DOI 10.1016/0012-1606(83)90046-5; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; OBERMAN F, 1995, TRENDS GENET, V11, P83; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; Rodionov VI, 1998, CURR BIOL, V8, P165, DOI 10.1016/S0960-9822(98)70064-8; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Romancino DP, 1998, EXP CELL RES, V238, P101, DOI 10.1006/excr.1997.3836; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Schroeder KE, 1996, DEV GENET, V19, P268, DOI 10.1002/(SICI)1520-6408(1996)19:3<268::AID-DVG10>3.0.CO;2-W; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Schumacher JM, 1998, BIOL REPROD, V59, P69, DOI 10.1095/biolreprod59.1.69; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; SHESTAKOVA EA, 1993, CELL BIOL INT, V17, P417, DOI 10.1006/cbir.1993.1080; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SIVARAM P, 1990, P NATL ACAD SCI USA, V87, P3665, DOI 10.1073/pnas.87.10.3665; Stapulionis R, 1997, J BIOL CHEM, V272, P24980, DOI 10.1074/jbc.272.40.24980; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; VALLIERES M, 1991, COMPUTATIONAL NUCLEA, V1, P1; VANVENROOIJ WJ, 1981, EXP CELL RES, V135, P79, DOI 10.1016/0014-4827(81)90301-3; VEDELER A, 1991, MOL CELL BIOCHEM, V100, P183; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WANG SZ, 1995, J CELL BIOL, V128, P761, DOI 10.1083/jcb.128.5.761; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WICHE G, 1984, EMBO J, V3, P991, DOI 10.1002/j.1460-2075.1984.tb01918.x; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZAMBETTI G, 1985, J CELL PHYSIOL, V125, P345, DOI 10.1002/jcp.1041250225; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhou Y, 1996, DEV BIOL, V179, P173, DOI 10.1006/dbio.1996.0249; ZUMBE A, 1982, P NATL ACAD SCI-BIOL, V79, P2927, DOI 10.1073/pnas.79.9.2927	107	135	139	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					455	466		10.1096/fasebj.13.3.455	http://dx.doi.org/10.1096/fasebj.13.3.455			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064612				2022-12-28	WOS:000079016000005
J	Volkmann, D; Baluska, F; Lichtscheidl, I; Driss-Ecole, D; Perbal, G				Volkmann, D; Baluska, F; Lichtscheidl, I; Driss-Ecole, D; Perbal, G			Statoliths motions in gravity-perceiving plant cells: does actomyosin counteract gravity	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	statocytes; microgravity	GROWN IN-SPACE; CRESS ROOTS; STATOCYTE POLARITY; MAIZE ROOTS; LENTIL ROOT; F-ACTIN; MICROGRAVITY; GRAVISENSITIVITY; MISSION; MICROFILAMENTS	Statocytes from plant root caps are characterized by a polar arrangement of cell organelles and sedimented statoliths. Cortical microtubules and actin microfilaments contribute to development and maintenance of this polarity, whereas the lack of endoplasmic microtubules and prominent bundles of actin microfilaments probably facilitates sedimentation of statoliths, High-resolution video microscopy shows permanent motion of statoliths even when sedimented, After immunofluorescence microscopy using antibodies against actin and myosin II the most prominent labeling was observed at and around sedimented statoliths, Experiments under microgravity have demonstrated that the positioning of statoliths depends on the external gravitational force and on internal forces, probably exerted by the actomyosin complex, and that transformation of the gravistimulus evidently occurs in close vicinity to the statoliths. These results suggest that graviperception occurs dynamically within the cytoplasm via small-distance sedimentation rather than statically at the lowermost site of sedimentation, It is hypothesized that root cap cells are comparing randomized motions with oriented motions of statoliths and thereby perceiving gravity.	Univ Bonn, Inst Bot, D-53115 Bonn, Germany; Univ Paris 06, Lab CEMV, Paris, France; Slovak Acad Sci, Inst Bot, Bratislava, Slovakia; Univ Vienna, Inst Pflanzenphysiol, A-1010 Vienna, Austria	University of Bonn; UDICE-French Research Universities; Sorbonne Universite; Slovak Academy of Sciences; University of Vienna	Volkmann, D (corresponding author), Univ Bonn, Inst Bot, Venusbergweg 22, D-53115 Bonn, Germany.	unb110@uni-bonn.de	Baluska, Frantisek/AAQ-1358-2021					ANDERSLAND JM, 1992, CELL MOTIL CYTOSKEL, V22, P245, DOI 10.1002/cm.970220404; Baluska F, 1996, PLANT PHYSIOL, V112, P3, DOI 10.1104/pp.112.1.3; Baluska F, 1997, PROTOPLASMA, V196, P212, DOI 10.1007/BF01279569; Baluska F, 1997, PLANTA, V203, pS69, DOI 10.1007/PL00008117; Baluska F, 1997, EUR J CELL BIOL, V72, P113; BARLOW PW, 1985, PLANTA, V165, P134, DOI 10.1007/BF00392222; Braun M, 1996, PROTOPLASMA, V191, P1, DOI 10.1007/BF01280820; BUCHEN B, 1993, PROTOPLASMA, V172, P38, DOI 10.1007/BF01403719; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DARBELLEY N, 1986, PHYSIOL PLANTARUM, V67, P460, DOI 10.1111/j.1399-3054.1986.tb05763.x; DRISSECOLE D, 1999, IN PRESS ESA; Evans ML, 1997, PLANTA, V203, pS115, DOI 10.1007/PL00008099; HEJNOWICZ Z, 1981, PROTOPLASMA, V108, P117, DOI 10.1007/BF01276887; HENSEL W, 1985, PROTOPLASMA, V129, P178, DOI 10.1007/BF01279915; HENSEL W, 1988, PLANTA, V173, P142, DOI 10.1007/BF00394498; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P559; ISHIKAWA H, 1991, PLANTA, V183, P381; Jahn T, 1998, PHYSIOL PLANTARUM, V104, P311, DOI 10.1034/j.1399-3054.1998.1040304.x; Janssen M, 1996, PROTOPLASMA, V191, P158; KOROPP K, 1994, EUR J CELL BIOL, V64, P153; Laurinavicius R, 1996, Adv Space Res, V17, P91, DOI 10.1016/0273-1177(95)00617-N; Legue V, 1996, J BIOTECHNOL, V47, P129, DOI 10.1016/0168-1656(96)01356-9; LORENZI G, 1990, BIOL CELL, V68, P259, DOI 10.1016/0248-4900(90)90317-V; LORENZI G, 1990, PHYSIOL PLANTARUM, V78, P532, DOI 10.1111/j.1399-3054.1990.tb05238.x; Lynch TM, 1998, PROTOPLASMA, V201, P92, DOI 10.1007/BF01280715; MENZEL D, 1994, NEW PHYTOL, V128, P369, DOI 10.1111/j.1469-8137.1994.tb02984.x; PERBAL G, 1989, PHYSIOL PLANTARUM, V75, P518, DOI 10.1111/j.1399-3054.1989.tb05618.x; PERBAL G, 1987, PHYSIOL PLANTARUM, V70, P119, DOI 10.1111/j.1399-3054.1987.tb06120.x; PERBAL G, 1986, NATURWISSENSCHAFTEN, V73, P444, DOI 10.1007/BF00367293; Perbal G, 1997, PLANTA, V203, pS57, DOI 10.1007/PL00008115; PERBAL G, 1994, PHYSIOL PLANTARUM, V90, P313, DOI 10.1111/j.1399-3054.1994.tb00393.x; SACK FD, 1986, AM J BOT, V73, P1692, DOI 10.2307/2444235; Sack FD, 1997, PLANTA, V203, pS63, DOI 10.1007/PL00008116; SACK FD, 1991, INT REV CYTOL, V127, P193; SHROPSHIRE W, 1979, ENCY PLANT PHYSL, V7, P10; SIEVERS A, 1989, PLANTA, V179, P275, DOI 10.1007/BF00393699; Sievers A, 1996, TRENDS PLANT SCI, V1, P273; Sievers A., 1991, CYTOSKELETAL BASIS P, P169; Smith JD, 1997, PLANT J, V12, P1361, DOI 10.1046/j.1365-313x.1997.12061361.x; Vitha S, 1997, J HISTOCHEM CYTOCHEM, V45, P89, DOI 10.1177/002215549704500112; VOLKMANN D, 1991, PLANTA, V185, P153, DOI 10.1007/BF00194056; Volkmann D., 1979, Encyclopedia of Plant Physiology, New Series, Volume 7. Physiology of movements [Haupt, W.; Feinleib, M.E. (Editors)]., P573; VOLKMANN D, 1986, NATURWISSENSCHAFTEN, V73, P438, DOI 10.1007/BF00367291; Volkmann D, 1998, ADV SPACE RES-SERIES, V21, P1209, DOI 10.1016/S0273-1177(97)00637-6; Volkmann D, 1996, PLANT CELL ENVIRON, V19, P1195, DOI 10.1111/j.1365-3040.1996.tb00435.x; WENDT M, 1987, PLANTA, V172, P321, DOI 10.1007/BF00398660; WILLIAMSON RE, 1993, ANNU REV PLANT PHYS, V44, P181, DOI 10.1146/annurev.pp.44.060193.001145; WITSCH MO, 1998, EUR J CELL BIOL, V77, P303; WUNSCH C, 1993, EUR J CELL BIOL S, V61, P46; ZIESCHANG HE, 1991, PLANTA, V184, P468, DOI 10.1007/BF00197894	51	34	35	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S143	S147						5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352156				2022-12-28	WOS:000080403800018
J	Massova, I; Kotra, LP; Fridman, R; Mobashery, S				Massova, I; Kotra, LP; Fridman, R; Mobashery, S			Matrix metalloproteinases: structures, evolution, and diversification	FASEB JOURNAL			English	Review						extracellular matrix; MMP; hemopexin; tissue inhibitor of matrix metalloproteinase	INHIBITED CATALYTIC DOMAIN; HEMOPEXIN-LIKE DOMAIN; TISSUE INHIBITOR; IV COLLAGENASE; GELATINASE-A; HUMAN STROMELYSIN-1; MOLECULAR-CLONING; ZINC-PEPTIDASES; XENOPUS-LAEVIS; ACTIVATION	A comprehensive sequence alignment of 64 members of the family of matrix metalloproteinases (MMPs) for the entire sequences, and subsequently the catalytic and the hemopexin-like domains, have been performed. The 64 MMPs were selected from plants, invertebrates, and vertebrates. The analyses disclosed that as many as 23 distinct subfamilies of these proteins are known to exist. Information from the sequence alignments: was correlated with structures, both crystallographic as well as computational, of the catalytic domains for the 23 representative members of the MMP family. A survey of the metal binding sites and two loops containing variable sequences of amino acids, which are important for substrate interactions, are discussed. The collective data support the proposal that the assembly of the domains into multidomain enzymes was likely to be an early evolutionary event. This:was followed by diversification, perhaps in parallel among the MMPs, in a subsequent evolutionary time scale. Analysis indicates that a retrograde structure simplification may have accounted for the evolution of MMPs with simple domain constituents, such as matrilysin, from the larger and more elaborate enzymes.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA; Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Mobashery, S (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.				NCI NIH HHS [CA-61986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartlett JD, 1996, GENE, V183, P123, DOI 10.1016/S0378-1119(96)00525-2; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; Bernot A, 1997, NAT GENET, V17, P25; Bode W, 1996, ADV EXP MED BIOL, V389, P1; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DESOUZA SJ, 1993, J MOL EVOL, V36, P596, DOI 10.1007/BF00556364; Franco AA, 1997, INFECT IMMUN, V65, P1007, DOI 10.1128/IAI.65.3.1007-1013.1997; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; KOHN EC, 1995, CANCER RES, V55, P1856; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; Massova I, 1998, BIOORG MED CHEM LETT, V8, P853, DOI 10.1016/S0960-894X(98)00128-0; MCGEEHAN G, 1992, PLANT PHYSIOL, V99, P1179, DOI 10.1104/pp.99.3.1179; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miyazaki K, 1996, P NATL ACAD SCI USA, V93, P6819, DOI 10.1073/pnas.93.13.6819; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; MURPHY G, 1992, J BIOL CHEM, V267, P9616; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; NAMURA K, 1991, BIOCHEMISTRY-US, V30, P6115; NAMURA K, 1997, BIOCHEMISTRY-US, V36, P7225; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Puente XS, 1996, CANCER RES, V56, P944; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; STOCKER W, 1995, PROTEIN SCI, V4, P823; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yang MZ, 1997, J BIOL CHEM, V272, P13527, DOI 10.1074/jbc.272.21.13527; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006	58	656	723	0	57	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1075	1095		10.1096/fasebj.12.12.1075	http://dx.doi.org/10.1096/fasebj.12.12.1075			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737711				2022-12-28	WOS:000075738500003
J	Paoletti, F; Tombaccini, D				Paoletti, F; Tombaccini, D			Proteolytic imbalance in Alzheimer fibroblasts as potential pathological trait of disease	FASEB JOURNAL			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; CULTURED SKIN FIBROBLASTS; BETA-PROTEIN; NEXIN-II; BRAIN; INHIBITOR; CALCIUM; ALPHA-1-ANTICHYMOTRYPSIN; IMMUNOREACTIVITY; CYSTATINS		Univ Florence, Ist Patol Gen, I-50134 Florence, Italy	University of Florence	Paoletti, F (corresponding author), Univ Florence, Ist Patol Gen, Viale GB Morgagni 50, I-50134 Florence, Italy.	paoletti@ats.it						ABRAHAM CR, 1989, ANN MED, V21, P77, DOI 10.3109/07853898909149188; BANNER CDB, 1992, ANN NEW YORK ACAD SC, V674; Bernstein HG, 1996, MOL CHEM NEUROPATHOL, V27, P225, DOI 10.1007/BF02815106; BERNSTEIN HG, 1994, BRAIN RES BULL, V33, P477, DOI 10.1016/0361-9230(94)90071-X; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ETCHEBERRIGARAY R, 1993, P NATL ACAD SCI USA, V90, P8209, DOI 10.1073/pnas.90.17.8209; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; Gibson G, 1996, LIFE SCI, V59, P477, DOI 10.1016/0024-3205(96)00327-X; GOLLIN PA, 1992, NEUROREPORT, V3, P201, DOI 10.1097/00001756-199202000-00020; GOVONI S, 1993, NEUROLOGY, V43, P2581, DOI 10.1212/WNL.43.12.2581; HAAS U, 1994, NEUROBIOL AGING, V15, pS57; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; Haass C, 1998, NATURE, V391, P339, DOI 10.1038/34800; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUANG HM, 1991, NEUROBIOL AGING, V12, P469, DOI 10.1016/0197-4580(91)90075-U; II K, 1993, VIRCHOWS ARCH A, V423, P185, DOI 10.1007/BF01614769; IQBAL K, 1986, LANCET, V2, P421; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; Paoletti F, 1997, J CELL PHYSIOL, V172, P63, DOI 10.1002/(SICI)1097-4652(199707)172:1<63::AID-JCP7>3.3.CO;2-F; PAOLETTI F, 1990, BIOCHEM BIOPH RES CO, V172, P396, DOI 10.1016/0006-291X(90)90686-H; PAOLETTI F, 1991, J NEUROL SCI, V105, P211, DOI 10.1016/0022-510X(91)90147-Y; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P7999, DOI 10.1073/pnas.83.20.7999; PETERSON C, 1985, NEW ENGL J MED, V312, P1063; SAITOH T, 1992, ANN NY ACAD SCI, V674, P180, DOI 10.1111/j.1749-6632.1992.tb27487.x; SCOTT RB, 1993, J AM GERIATR SOC, V41, P205; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAGAWA K, 1991, BIOCHEM BIOPH RES CO, V177, P377, DOI 10.1016/0006-291X(91)91994-N; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; UEDA K, 1989, ANN NEUROL, V25, P246, DOI 10.1002/ana.410250307; VANHUYNH T, 1989, ARCH NEUROL-CHICAGO, V46, P1195, DOI 10.1001/archneur.1989.00520470049026; VANNOSTRAND WE, 1989, NATURE, V341, P546; ZHANG H, 1989, P NATL ACAD SCI USA, V86, P8045, DOI 10.1073/pnas.86.20.8045	40	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					925	927		10.1096/fasebj.12.11.925	http://dx.doi.org/10.1096/fasebj.12.11.925			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707164				2022-12-28	WOS:000075372600002
J	Laharrague, P; Larrouy, D; Fontanilles, AM; Truel, N; Campfield, A; Tenenbaum, R; Galitzky, J; Corberand, JX; Penicaud, L; Casteilla, L				Laharrague, P; Larrouy, D; Fontanilles, AM; Truel, N; Campfield, A; Tenenbaum, R; Galitzky, J; Corberand, JX; Penicaud, L; Casteilla, L			High expression of leptin by human bone marrow adipocytes in primary culture	FASEB JOURNAL			English	Article						adipose tissue; ob; corticosteroids; hematopoiesis	ADIPOSE-TISSUE; CELL-LINE; HUMAN LEUKOCYTES; OBESE GENE; OB GENE; DIFFERENTIATION; PROLIFERATION; BETA(3)-ADRENOCEPTORS; PHOSPHATASE; ISOENZYME	Adipocytes participate in the microenvironment of the bone marrow (BM), but their exact role remains to be determined. It has recently been shown that leptin, a hormone secreted from extramedullary adipocytes, could be involved in hematopoiesis. Therefore we have developed a primary culture system of human BM adipocytes to characterize their differentiation and determine whether leptin is also secreted from these adipocytes. BM cells were cultured with fetal calf and horse sera. In the presence of dexamethasone, cells with vesicles containing lipids appeared within 15 days. They expressed glycerol phosphate dehydrogenase activity and a lipolytic activity in response to isoproterenol, but expressed neither the adrenergic beta 3 receptor nor the mitochondrial uncoupling protein UCP1. The addition of insulin alone to the culture media did not promote adipocyte differentiation. Leptin was expressed and secreted at high levels during adipocyte differentiation. Acute exposure of differentiated adipocytes to insulin had little effect on leptin expression whereas forskolin strongly inhibited it. These results show that although human BM adipocytes differ from extramedullary adipose tissues in their sensitivity to different effecters, they are a secondary source of leptin production. They suggest that BM adipocytes could contribute to hematopoiesis via the secretion of leptin in the vicinity of hematopoietic stem cells.	Fac Med, IFR L Bugnard, CNRS, UPRESA 5018, Toulouse, France; Fac Med, IFR L Bugnard, INSERM, U317, Toulouse, France; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Roche Holding	Laharrague, P (corresponding author), Hop Toulouse Rangueil, CNRS, UPRESA 5018, F-31403 Toulouse, France.		Galitzky, Jean/R-6599-2017	Casteilla, Louis/0000-0001-9647-3248; Larrouy, Dominique/0000-0002-4120-5593				Barbe P, 1996, BRIT J PHARMACOL, V117, P907, DOI 10.1111/j.1476-5381.1996.tb15279.x; BATHIJA A, 1978, AM J HEMATOL, V5, P315, DOI 10.1002/ajh.2830050406; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; BENNETT JH, 1991, J CELL SCI, V99, P131; Campfield LA, 1996, HORM METAB RES, V28, P619, DOI 10.1055/s-2007-979867; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Cheng SL, 1996, J CELL BIOCHEM, V61, P182, DOI 10.1002/(SICI)1097-4644(19960501)61:2<182::AID-JCB3>3.0.CO;2-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DORHEIM MA, 1993, J CELL PHYSIOL, V154, P317, DOI 10.1002/jcp.1041540215; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; FOREST C, 1987, EXP CELL RES, V168, P218, DOI 10.1016/0014-4827(87)90430-7; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GIMBLE J M, 1990, New Biologist, V2, P304; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; GIMBLE JM, 1990, EUR J IMMUNOL, V20, P379, DOI 10.1002/eji.1830200222; HANGOC G, 1993, EXP HEMATOL, V21, P502; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; KAPLOW LS, 1965, BLOOD-J HEMATOL, V26, P215, DOI 10.1182/blood.V26.2.215.215; KAPLOW LS, 1963, AM J CLIN PATHOL, V39, P439; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; LANOTTE M, 1981, J CELL SCI, V50, P281; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LI CY, 1970, J HISTOCHEM CYTOCHEM, V18, P901, DOI 10.1177/18.12.901; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; MARKO O, 1995, ENDOCRINOLOGY, V136, P4582, DOI 10.1210/en.136.10.4582; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; Mikhail AA, 1997, BLOOD, V89, P1507, DOI 10.1182/blood.V89.5.1507.1507_1507_1512; Oreffo ROC, 1997, EUR J CELL BIOL, V74, P251; PETRAKIS NL, 1966, AM J PHYS ANTHROPOL, V25, P119, DOI 10.1002/ajpa.1330250203; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; ROZMAN C, 1989, EXP HEMATOL, V17, P34; SHEEHAN HL, 1947, J PATHOL BACTERIOL, V59, P336, DOI 10.1002/path.1700590142; ViguerieBascands N, 1996, J CLIN ENDOCR METAB, V81, P368, DOI 10.1210/jc.81.1.368; WEISS LP, 1956, ANAT REC, V123, P143; WISE LS, 1979, J BIOL CHEM, V254, P273; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	39	151	163	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					747	752		10.1096/fasebj.12.9.747	http://dx.doi.org/10.1096/fasebj.12.9.747			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619453				2022-12-28	WOS:000074011000014
J	Zhao, WQ; Meiri, N; Xu, H; Cavallaro, S; Quattrone, A; Zhang, L; Alkon, DL				Zhao, WQ; Meiri, N; Xu, H; Cavallaro, S; Quattrone, A; Zhang, L; Alkon, DL			Spatial learning induced changes in expression of the ryanodine type II receptor in the rat hippocampus	FASEB JOURNAL			English	Article						water maze task; learning and memory; calcium; mRNA; in situ hybridization	CALCIUM RELEASE CHANNEL; LONG-TERM POTENTIATION; DENTATE GYRUS; MEMORY; CA2+; KINASE; BRAIN; IDENTIFICATION; LOCALIZATION; DEPRESSION	Calcium signaling critical to neural functions is mediated through Ca2+ channels localized on both the plasma membrane and intracellular organelles such as endoplasmic reticulum, Whereas Ca2+ influx occurs via the voltage- or/and ligand-sensitive Ca2+ channels, Ca2+ release from intracellular stores that amplifies further the Ca2+ signal is thought to be involved in more profound and lasting changes in neurons, The ryanodine receptor, one of the two major intracellular Ca2+ channels, has been an important target for studying Ca2+ signaling in brain functions, including learning and memory, due to its characteristic Ca2+-induced Ca2+ release, In this study, we report regional and cellular distributions of the type-2 ryanodine receptor (RyR2) mRNA in the rat brain, and effects of spatial learning on RyR2 gene expression at mRNA and protein levels in the rat hippocampus, Using in situ hybridization, reverse transcription polymerase chain reaction, and ribonuclease protection assays, significant increases in RyR2 mRNA were found in the hippocampus of rats trained in an intensive water maze task, With immunoprecipitation and immunoblotting, protein levels of RyR2 were also demonstrated to be increased in the microsomal fractions prepared from hippocampi of trained rats, These results suggest that RyR2, and hence the RyR2-mediated Ca2+ signals, may be involved in memory processing after spatial learning. The increases in RyR2 mRNA and protein at 12 and 24 h after training could contribute to more permanent changes such as structural modifications during long-term memory storage.	NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20892 USA; NIMH, Behav Endocrinol Branch, NIH, Bethesda, MD 20892 USA; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel; CNR, Inst Bioimaging & Pathophysiol Cent Nervous Syst, Catania, Italy; IRCCS, Oasai Inst Res Mental Retardat & Brain Aging, Troina, EN, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Consiglio Nazionale delle Ricerche (CNR)	Zhao, WQ (corresponding author), NINDS, Lab Adapt Syst, NIH, Bldg 36,Room 4A22,36 Convent Dr, Bethesda, MD 20892 USA.		Cavallaro, Sebastiano/F-3104-2010; Cavallaro, Sebastiano/AFM-7125-2022	Cavallaro, Sebastiano/0000-0001-7590-1792; Cavallaro, Sebastiano/0000-0001-7590-1792; Quattrone, Alessandro/0000-0003-3333-7630				ACOSTAURQUIDI J, 1984, SCIENCE, V224, P1254, DOI 10.1126/science.6328653; AIREY JA, 1990, J BIOL CHEM, V265, P14187; Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; Amaral David G., 1995, P443; ARAI M, 1992, AM J PHYSIOL, V262, pH614; Cavallaro S, 1997, P NATL ACAD SCI USA, V94, P9669, DOI 10.1073/pnas.94.18.9669; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FAGNOU DD, 1995, MOL CELL BIOCHEM, V149, P279, DOI 10.1007/BF01076589; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; FREIL DD, 1992, NEURON, V8, P1109; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Gruol DL, 1996, J NEUROPHYSIOL, V76, P3325, DOI 10.1152/jn.1996.76.5.3325; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1988, MOL CELL BIOCHEM, V82, P59; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P484; MOLANDER C, 1995, RAT NERVOUS SYSTEM, P33; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Muller RU, 1996, HIPPOCAMPUS, V6, P709, DOI 10.1002/(SICI)1098-1063(1996)6:6<709::AID-HIPO13>3.0.CO;2-4; MURPHY SN, 1989, MOL PHARMACOL, V35, P671; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; OMARA SM, 1995, NEUROSCIENCE, V68, P621, DOI 10.1016/0306-4522(95)00233-9; PADUA RA, 1992, J CHEM NEUROANAT, V5, P63, DOI 10.1016/0891-0618(92)90034-N; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Reyes M, 1996, J NEUROSCI, V16, P5951; ROSENZWEIG MR, 1993, BEHAV BRAIN RES, V57, P193, DOI 10.1016/0166-4328(93)90135-D; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKASAGO T, 1991, J BIOLCH TOKYO, V109, P103; Traub R.D., 1991, NEURONAL NETWORKS HI; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; VanderZee EA, 1997, PROG NEURO-PSYCHOPH, V21, P379, DOI 10.1016/S0278-5846(97)00010-9; Wang Y, 1996, J PHYSIOL-LONDON, V495, P755, DOI 10.1113/jphysiol.1996.sp021631; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Zhao WQ, 1999, J BIOL CHEM, V274, P34893, DOI 10.1074/jbc.274.49.34893; ZHAO WQ, 1999, IN PRESS J NEUROSCI	43	73	83	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					290	300		10.1096/fasebj.14.2.290	http://dx.doi.org/10.1096/fasebj.14.2.290			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657985				2022-12-28	WOS:000085184800008
J	Borisy, GG; Rodionov, VI				Borisy, GG; Rodionov, VI			Lessons from the melanophore	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		PIGMENT GRANULES; INTRACELLULAR-TRANSPORT; MICROTUBULE POLARITY; ORGANELLE TRANSPORT; MOTILITY; CHROMATOPHORES; CENTROSOMES; DIRECTION; MOVEMENT; ACTIN		Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Borisy, GG (corresponding author), Univ Wisconsin, Mol Biol Lab, 1525 Linden Dr, Madison, WI 53706 USA.			Borisy, Gary/0000-0002-0266-8018	NIGMS NIH HHS [GM-25062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025062, R01GM025062] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKERLE MC, 1982, NATURE, V295, P701, DOI 10.1038/295701a0; BIKLE D, 1966, PROTOPLASMA, V61, P322, DOI 10.1007/BF01248988; EUTENEUER U, 1981, P NATL ACAD SCI-BIOL, V78, P372, DOI 10.1073/pnas.78.1.372; HAIMO LT, 1994, BIOESSAYS, V16, P727, DOI 10.1002/bies.950161007; KARSENTI E, 1984, J CELL BIOL, V98, P1763, DOI 10.1083/jcb.98.5.1763; MARGOLIS RL, 1978, CELL, V13, P1, DOI 10.1016/0092-8674(78)90132-0; Matthews SA, 1931, J EXP ZOOL, V58, P471, DOI 10.1002/jez.1400580121; MCNIVEN MA, 1986, J CELL BIOL, V103, P1547, DOI 10.1083/jcb.103.4.1547; MCNIVEN MA, 1984, CELL, V37, P753, DOI 10.1016/0092-8674(84)90411-2; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MURPHY DB, 1974, J CELL BIOL, V61, P757, DOI 10.1083/jcb.61.3.757; PORTER KEITH R., 1966, CIBA FOUND SYMP, P308; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov VI, 1997, NATURE, V386, P170, DOI 10.1038/386170a0; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; Rodionov VI, 1998, CURR BIOL, V8, P165, DOI 10.1016/S0960-9822(98)70064-8; Rogers SL, 1997, P NATL ACAD SCI USA, V94, P3720, DOI 10.1073/pnas.94.8.3720; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Schliwa M., 1984, Cell and Muscle Motility, V5, P1; SCHLIWA M, 1983, AM ZOOL, V23, P479; SCHLIWA M, 1978, J CELL BIOL, V76, P605, DOI 10.1083/jcb.76.3.605; SCHLIWA M, 1981, J CELL BIOL, V89, P267, DOI 10.1083/jcb.89.2.267; SHAY JW, 1974, P NATL ACAD SCI USA, V71, P3059, DOI 10.1073/pnas.71.8.3059; Tuma MC, 1998, J CELL BIOL, V143, P1547, DOI 10.1083/jcb.143.6.1547; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3	26	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S221	S224		10.1096/fasebj.13.9002.S221	http://dx.doi.org/10.1096/fasebj.13.9002.S221			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619131				2022-12-28	WOS:000084390200009
J	Hay, ED				Hay, ED			Biogenesis and organization of extracellular matrix	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		COLLAGEN; CYTOSKELETON; FIBROBLASTS; MIGRATION		Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hay, ED (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 220 Longwood Ave, Boston, MA 02115 USA.				NEI NIH HHS [EY09721] Funding Source: Medline; NICHD NIH HHS [HD00143] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000143] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009721] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		GODMAN GC, 1960, J BIOPHYS BIOCHEM CY, V8, P719, DOI 10.1083/jcb.8.3.719; Harkin DG, 1996, CELL MOTIL CYTOSKEL, V35, P345, DOI 10.1002/(SICI)1097-0169(1996)35:4<345::AID-CM6>3.0.CO;2-5; Hay E.D., 1983, Modern Cell Biology, V2, P509; Hay E. D., 1991, CELL BIOL EXTRACELLU, P468; HAY ED, 1963, DEV BIOL, V7, P152, DOI 10.1016/0012-1606(63)90114-3; Hay ED, 1995, ACTA ANAT, V154, P8; HYNES RO, 1978, CELL, V15, P875, DOI 10.1016/0092-8674(78)90272-6; NADOL JB, 1969, DEV BIOL, V20, P304, DOI 10.1016/0012-1606(69)90017-7; NIST C, 1975, J CELL BIOL, V65, P75, DOI 10.1083/jcb.65.1.75; PORTER KR, 1959, J BIOPHYS BIOCHEM CY, V5, P153, DOI 10.1083/jcb.5.1.153; PORTER KR, 1949, P SOC EXP BIOL MED, V71, P513; PORTER KR, 1964, BIOPHYS J, V4, P167, DOI 10.1016/S0006-3495(64)86936-8; PORTER KR, 1966, CELLULAR CONCEPTS RH, P6; REVEL JP, 1963, Z ZELLFORSCH MIK ANA, V61, P110, DOI 10.1007/BF00341524; ROSS R, 1965, J CELL BIOL, V27, P83, DOI 10.1083/jcb.27.1.83; ROSS R, 1962, J CELL BIOL, V15, P99, DOI 10.1083/jcb.15.1.99; SEIKEVITZ P, 1960, J BIOPHYS BIOCH CYTO, V7, P619; SUGRUE SP, 1981, J CELL BIOL, V91, P45, DOI 10.1083/jcb.91.1.45; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOMASEK JJ, 1984, J CELL BIOL, V99, P536, DOI 10.1083/jcb.99.2.536; WEINSTOCK M, 1974, J CELL BIOL, V60, P92, DOI 10.1083/jcb.60.1.92	21	10	12	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S281	S283		10.1096/fasebj.13.9002.S281	http://dx.doi.org/10.1096/fasebj.13.9002.S281			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619144				2022-12-28	WOS:000084390200022
J	Pappas, GD				Pappas, GD			Fine structure of host-graft relationships between transplanted chromaffin cells and CNS	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		RAT PERIAQUEDUCTAL GRAY; CHRONIC PAIN; CANCER PAIN; SURVIVAL; IMPLANTS	Our laboratory studies have shown that transplantation of adrenal medullary tissue or isolated chromaffin cells into central nervous system (CNS) pain modulatory regions (i.e., periaqueductal gay and subarachnoid lumbar spinal cord) can reduce pain sensitivity of rats in both acute and chronic pain. The analgesia produced by these transplants is thought to result from release of both opiate peptides and catecholamines, Morphologically, these animal studies also suggest that there is no development of tolerance over long periods of time, and the transplanted chromaffin cells appear to be robust and well integrated with the host tissue. In our initial clinical studies, where allografts of adrenal medullary tissue were transplanted intrathecally to relieve intractable cancer pain, patients obtained significant and long-lasting pain relief. Increased cerebrospinal fluid (CSF) levels of metenkephalin were correlated with the decreased pain scores. Histology of;autopsy tissue obtained from two patients with 1 year transplants revealed viable transplanted chromaffin cells. Because of the limited availability of human adrenal glands, sources of xenogeneic chromaffin cells will need to be identified if effective transplantation therapy for chronic pain is to be developed further.	Univ Illinois, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pappas, GD (corresponding author), Univ Illinois, Inst Psychiat, Dept Psychiat, 1601 W Taylor St M-C 912, Chicago, IL 60612 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028931] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-28931] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bes JC, 1998, CELL TRANSPLANT, V7, P227, DOI 10.1016/S0963-6897(97)00161-9; Czech KA, 1997, EXP NEUROL, V147, P66, DOI 10.1006/exnr.1997.6589; Lazorthes Y, 1995, ADV STER F, V11, P97; Lazorthes Y, 1991, Adv Tech Stand Neurosurg, V18, P143; Michalewicz P., 1997, Society for Neuroscience Abstracts, V23, P1455; Ortega J D, 1992, Cell Transplant, V1, P33; ORTEGA JD, 1994, J NEURAL TRANSP PLAS, V5, P31, DOI 10.1155/NP.1994.31; ORTEGA JD, 1992, J COMP NEUROL, V323, P13, DOI 10.1002/cne.903230103; Pappas G. D., 1998, ADRENAL CHROMAFFIN C, P343; Pappas GD, 1997, NEUROL RES, V19, P71; PAPPAS GD, 1988, PROG BRAIN RES, V78, P513; SAGEN J, 1990, J NEUROCYTOL, V19, P697, DOI 10.1007/BF01188038; SAGEN J, 1987, ANN NY ACAD SCI, V495, P306, DOI 10.1111/j.1749-6632.1987.tb23683.x; SAGEN J, 1990, PAIN, V42, P69, DOI 10.1016/0304-3959(90)91093-X; Unsicker K, 1996, PROG NEUROBIOL, V48, P307, DOI 10.1016/0301-0082(95)00045-3; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WASFIE T, 1991, TRANSPLANT P, V23, P378; WILSON SP, 1982, J NEUROSCI, V2, P1150; WINNIE AP, 1993, ANESTHESIOLOGY, V79, P644, DOI 10.1097/00000542-199310000-00004	19	4	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S277	S280		10.1096/fasebj.13.9002.S277	http://dx.doi.org/10.1096/fasebj.13.9002.S277			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619143				2022-12-28	WOS:000084390200021
J	Ball, T; Fuchs, T; Sperr, WR; Valent, P; Vangelista, L; Kraft, D; Valenta, R				Ball, T; Fuchs, T; Sperr, WR; Valent, P; Vangelista, L; Kraft, D; Valenta, R			B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy	FASEB JOURNAL			English	Article						type I allergy; allergen gene fragmentation; immunotherapy; blocking antibodies	GROUP-I ALLERGENS; SITE-DIRECTED MUTAGENESIS; IGG BLOCKING ANTIBODIES; DUST MITE ALLERGEN; IMMUNOLOGICAL CHARACTERIZATION; IMMUNOGLOBULIN-E; RYE-GRASS; INTERLEUKIN-4 PRODUCTION; POTENTIAL USE; SKIN-TEST	Group I grass pollen allergens are recognized by IgE antibodies of almost 40% of allergic individuals and therefore belong to the most important elicitors of Type I allergy worldwide. We have previously isolated the cDNA coding for the group 1 allergen from timothy grass, Phl p 1, and demonstrated that recombinant Phl p 1 contains most of the B cell as well as T cell epitopes of group 1 allergens from a variety of grass and corn species. Here we determine continuous B cell epitopes of Phl p 1 by gene fragmentation. IgE antibodies of grass pollen allergic patients identified five continuous epitope-containing areas that on an average bound 40% of Phl p 1-specific ISE antibodies and were stably recognized in the course of disease. in contrast to untreated patients, patients undergoing grass pollen immunotherapy started to mount IgG, antibodies to the recombinant IgE-defined fragments in the course of immunotherapy. The protective role of these IgG, antibodies is demonstrated by observations that 1) increases in rPhl p 1 fragment-specific IgG, were in parallel with decreases in Phl p 1-specific IgE, and 2) preincubation of rPhl p 1 with patients sera containing rPhl p 1 fragment-specific IgG, blocked histamine release from basophils of an untreated grass pollen allergic patient, We propose to use recombinant Phl p 1 fragments for active immunotherapy in order to induce protective IgG responses against IgE epitopes in grass pollen allergic patients. This concept may be applied for the development of allergy vaccines whenever the primary sequence or structure of an allergen is available.	Univ Vienna, AKH, Dept Gen & Expt Pathol, Div Immunopathol,Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Gottingen, Dept Dermatol, D-3400 Gottingen, Germany; Univ Vienna, AKH, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1010 Vienna, Austria; EMBL, Struct Biol Programme, Heidelberg, Germany	University of Vienna; University of Gottingen; University of Vienna; European Molecular Biology Laboratory (EMBL)	Valenta, R (corresponding author), Univ Vienna, AKH, Dept Gen & Expt Pathol, Div Immunopathol,Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, PV/U-9451-2019; Test, Test/Y-7921-2019; Sperr, Mast/V-4767-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Vangelista, Luca/0000-0003-0764-5031; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365				AALBERSE RC, 1983, J IMMUNOL, V130, P722; ADKINSON NF, 1979, J IMMUNOL, V122, P965; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; BALL T, 1994, J BIOL CHEM, V269, P28323; BIRKNER T, 1990, ALLERGY, V45, P418, DOI 10.1111/j.1398-9995.1990.tb01092.x; BROADWATER AH, 1993, GENE, V131, P227, DOI 10.1016/0378-1119(93)90297-G; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GLEICH GJ, 1981, J IMMUNOL, V126, P575; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427, DOI 10.1177/42.3.8308259; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; Hiller KM, 1997, J ALLERGY CLIN IMMUN, V100, P335, DOI 10.1016/S0091-6749(97)70246-X; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Kay A.B., 1997, ALLERGY ALLERGIC DIS; Kobayashi I, 1996, J ALLERGY CLIN IMMUN, V97, P638, DOI 10.1016/S0091-6749(96)70309-3; KOLBE L, 1991, INT ARCH ALLER A IMM, V95, P202, DOI 10.1159/000235430; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LAFFER S, 1996, J ALLERGY CLIN IMMUN, V98, P625; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Loveless MH, 1943, J IMMUNOL, V47, P165; Loveless MH, 1940, J IMMUNOL, V38, P25; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; PEREZ M, 1990, J BIOL CHEM, V265, P16210; REST B, 1994, PROTEINS, V20, P216; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; Schreihofer AM, 1997, FASEB J, V11, P99; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; SHCHERBAN TY, 1995, P NATL ACAD SCI USA, V92, P9245, DOI 10.1073/pnas.92.20.9245; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Tame A, 1996, CLIN EXP ALLERGY, V26, P43, DOI 10.1111/j.1365-2222.1996.tb00055.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 1998, INT ARCH ALLERGY IMM, V116, P167, DOI 10.1159/000023942; VALENTA R, 1992, INT ARCH ALLERGY, V26, P50; Valenta R, 1997, IGE REGULATION MOL M, P225; Vanderlugt CJ, 1996, CURR OPIN IMMUNOL, V8, P831, DOI 10.1016/S0952-7915(96)80012-4; Vercelli D, 1998, INT ARCH ALLERGY IMM, V116, P1, DOI 10.1159/000023918; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; XU HL, 1995, GENE, V164, P255, DOI 10.1016/0378-1119(95)00527-D	65	67	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1277	1290		10.1096/fasebj.13.11.1277	http://dx.doi.org/10.1096/fasebj.13.11.1277			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428753				2022-12-28	WOS:000082019100001
J	Weitkamp, B; Cullen, P; Plenz, G; Robenek, H; Rauterberg, J				Weitkamp, B; Cullen, P; Plenz, G; Robenek, H; Rauterberg, J			Human macrophages synthesize type VIII collagen in vitro and in the atherosclerotic plaque	FASEB JOURNAL			English	Article						double in situ hybridization; atherosclerosis; matrix metalloproteinase; fluorescence staining	MONOCYTE-DERIVED MACROPHAGES; SMOOTH-MUSCLE CELLS; X COLLAGEN; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; ARTICULAR-CARTILAGE; ENDOTHELIAL-CELLS; MESSENGER-RNA; MAST-CELLS	Type VIII collagen is a short-chain collagen that is present in increased amounts in atherosclerotic lesions. Although the physiological function of this matrix protein is unclear, recent data suggest an important role in tissue remodeling. Type VIII collagen in the atherosclerotic lesion is mainly derived from smooth muscle cells. We now show that macrophages in the atherosclerotic vessel wall and monocytes in adjacent mural thrombi also express type VIII collagen. We demonstrated this using a novel combined fluorescence technique that simultaneously stains, within the same tissue section, specific RNAs by in situ hybridization and proteins by indirect immunofluorescence. In culture, human monocyte/macrophages expressed type VIII collagen at all time points from 1 h to 3 wk after isolation. Western blotting and immunoprecipitation also revealed secretion of type VIII collagen into the medium of 14-day-old macrophages. Because this is the first report of secretion of a collagen by macrophages, we tested the effect of lipopolysaccharide (LPS) and interferon gamma, substances that stimulate macrophages to secrete lyric enzymes, on macrophage expression of type VIII collagen. LPS and interferon gamma decreased expression of type VIII collagen. By contrast, secretion of matrix metalloproteinase 1 (MMP 1) was increased, indicating a switch from a collagen-producing to a degradative phenotype. Double in situ hybridization studies of expression of type VIII collagen and MMP 1 in human coronary arteries showed that in regions important for plaque stability, the ratio of MMP 1 RNA to macrophage type VIII collagen RNA varies widely, indicating that the transition from one phenotype to the other that we observed in vitro may also occur in vivo.	Inst Arterioskleroseforsch, D-48149 Munster, Germany		Rauterberg, J (corresponding author), Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.							ADACHI K, 1988, AM J PATHOL, V133, P193; AIGNER T, 1993, VIRCHOWS ARCH B, V63, P205, DOI 10.1007/BF02899263; BARNES JL, 1994, AM J PATHOL, V145, P585; Bendeck MP, 1996, CIRC RES, V79, P524, DOI 10.1161/01.RES.79.3.524; BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; Bjerrum OJ., 1986, ELECTROPHORESIS 86, P315; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DING GH, 1993, AM J PHYSIOL, V264, pF577, DOI 10.1152/ajprenal.1993.264.4.F577; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HIROTA S, 1993, AM J PATHOL, V143, P1003; KAPOOR R, 1988, J CELL BIOL, V107, P721, DOI 10.1083/jcb.107.2.721; KATSUDA S, 1994, AM J PATHOL, V145, P1208; KIRSCH T, 1990, BIOCHEM J, V265, P453, DOI 10.1042/bj2650453; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee RT, 1996, ARTERIOSCL THROM VAS, V16, P1070, DOI 10.1161/01.ATV.16.8.1070; LERAT H, 1993, BLOOD, V82, P1480; LEVITT D, 1983, J CELL BIOL, V97, P351, DOI 10.1083/jcb.97.2.351; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LIPTAY MJ, 1993, J CLIN INVEST, V91, P588, DOI 10.1172/JCI116238; Loffler JA, 1995, EUR ARCH OTO-RHINO-L, V252, P475, DOI 10.1007/BF02114754; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MURAGAKI Y, 1992, EUR J BIOCHEM, V207, P895, DOI 10.1111/j.1432-1033.1992.tb17122.x; MURRAY HW, 1988, ANN INTERN MED, V108, P595, DOI 10.7326/0003-4819-108-4-595; NERLICH AG, 1992, HISTOCHEMISTRY, V98, P275, DOI 10.1007/BF00270010; Nikkari ST, 1996, AM J PATHOL, V149, P1427; OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; PLENZ G, 1994, HUM GENET, V93, P575; PLENZ G, 1993, CELL TISSUE RES, V273, P381, DOI 10.1007/BF00312841; RAINES EW, 1996, ATHEROSCLEROSIS CORO, P539; RUGER B, 1994, INT J EXP PATHOL, V75, P397; Ruger BM, 1996, DIABETOLOGIA, V39, P1215, DOI 10.1007/BF02658509; SAGE H, 1980, BIOCHEMISTRY-US, V19, P5747, DOI 10.1021/bi00566a013; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHLESINGER L, 1984, J EXP MED, V159, P1289, DOI 10.1084/jem.159.4.1289; SCHMITZ G, 1990, ARTERIOSCLEROSIS, V10, P1010, DOI 10.1161/01.ATV.10.6.1010; SHAH PK, 1995, CIRCULATION, V92, P1565; Sibinga NES, 1997, CIRC RES, V80, P532, DOI 10.1161/01.RES.80.4.532; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; Sukhova GK, 1996, CIRCULATION, V94, P98; VANDERREST M, 1993, CURR OPIN STRUC BIOL, V3, P430, DOI 10.1016/S0959-440X(05)80117-4; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WICHA MS, 1983, EXP CELL RES, V143, P475, DOI 10.1016/0014-4827(83)90077-0; ZUCKERMAN SH, 1979, IMMUNOLOGY, V38, P401; ZWADLO G, 1985, J IMMUNOL, V134, P1487	51	56	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1445	1457		10.1096/fasebj.13.11.1445	http://dx.doi.org/10.1096/fasebj.13.11.1445			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428768				2022-12-28	WOS:000082019100016
J	Bouloumie, A; Marumo, T; Lafontan, M; Busse, R				Bouloumie, A; Marumo, T; Lafontan, M; Busse, R			Leptin induces oxidative stress in human endothelial cells	FASEB JOURNAL			English	Article						Jun kinase; MCP-1; AP-1; NF-kappa B; atherosclerosis; obesity	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; ADHESION MOLECULE-1; OBESE GENE; ANTIOXIDANTS; ACTIVATION; KINASES; INDUCTION	Human umbilical vein endothelial cells (HUVEC) express functional receptors to leptin, the product of the ob gene. As human obesity is associated with atherosclerosis and hyperleptinemia, we investigated whether leptin, in addition to its angiogenic properties, exerts atherogenic effects through the generation of oxidative stress in endothelial cells. In HUVEC leptin increased the accumulation of reactive oxygen species (ROS), as assessed by the oxidation of 2',7'- dichlorodihydrofluorescein, in a time- and concentration-dependent manner. In addition, leptin activated the NH2-terminal c-Jun kinase/stress-activated protein kinase pathway as demonstrated by enhanced JNK activity and AP-1 DNA binding. Both effects were sensitive to antioxidant treatment with N-acetylcysteine, NF-KB, another redox-sensitive transcription factor, was also activated by leptin stimulation in an oxidant-dependent manner, Finally, activation of both AP-1 and NF-KB was associated with an enhanced expression of the monocyte chemoattractant protein-1 in HUVEC, These findings demonstrate that ROS are second messengers involved in leptin-induced signaling in endothelial cells. Thus, chronic oxidative stress in endothelial cells under hyperleptinemia may activate atherogenic processes and contribute to the development of vascular pathology.	Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, D-60590 Frankfurt, Germany; CHU Rangueil, Inst Louis Bugnard, INSERM U317, F-31054 Toulouse, France	Goethe University Frankfurt; Goethe University Frankfurt Hospital; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bouloumie, A (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Bouloumie-Diehl, Anne/M-4446-2017	Bouloumie-Diehl, Anne/0000-0001-5496-8891				BENETT BD, 1996, CURR BIOL, V6, P1170; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cimino F, 1997, CURR TOP CELL REGUL, V35, P123, DOI 10.1016/S0070-2137(97)80005-2; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Cominacini L, 1997, FREE RADICAL BIO MED, V22, P117, DOI 10.1016/S0891-5849(96)00271-7; delArco PG, 1996, J BIOL CHEM, V271, P26335; Faruqi RM, 1997, AM J PHYSIOL-HEART C, V273, pH817, DOI 10.1152/ajpheart.1997.273.2.H817; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Marumo T, 1998, HYPERTENSION, V32, P1083, DOI 10.1161/01.HYP.32.6.1083; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	36	560	600	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1231	1238		10.1096/fasebj.13.10.1231	http://dx.doi.org/10.1096/fasebj.13.10.1231			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385613				2022-12-28	WOS:000081264800011
J	Moalem, G; Monsonego, A; Shani, Y; Cohen, IR; Schwartz, M				Moalem, G; Monsonego, A; Shani, Y; Cohen, IR; Schwartz, M			Differential T cell response in central and peripheral nerve injury: connection with immune privilege	FASEB JOURNAL			English	Article						T lymphocytes; CNS; PNS; Fas ligand; major histocompatibility complex	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RAT OPTIC-NERVE; FAS LIGAND; ANTIGEN PRESENTATION; MULTIPLE-SCLEROSIS; MICROGLIAL CELLS; BRAIN-BARRIER; CD95 LIGAND; SYSTEM	The central nervous system (CNS), unlike the peripheral nervous system (PNS), is an immune-privileged site in which local immune responses are restricted. Whereas immune privilege in the intact CNS has been studied intensively, Little is known about its effects after trauma. In this study, we examined the influence of CNS immune privilege on T cell response to central nerve injury. Immunocytochemistry revealed a significantly greater accumulation of endogenous T cells in the injured rat sciatic nerve than in the injured rat optic nerve (representing PNS and CNS white matter trauma, respectively). Use of the in situ terminal deoxytransferase-catalyzed DNA nick end labeling (TUNEL) procedure revealed extensive death of accumulating T cells in injured CNS nerves as well as in CNS nerves of rats with acute experimental autoimmune encephalomyelitis, but not in injured PNS nerves, Although Fas ligand (FasL) protein was expressed in white matter tissue of both systems, it was more pronounced in the CNS, Expression of major histocompatibility complex (MHC) class II antigens was found to be constitutive in the PNS, but in the CNS was induced only after injury, Our findings suggest that the T cell response to central nerve injury is restricted by the reduced expression of MHC class II antigens, the pronounced Fast expression, and the elimination of infiltrating lymphocytes through cell death.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Cohen, Irun R/B-3542-2009; Moalem-Taylor, Gila/C-3116-2008	Moalem-Taylor, Gila/0000-0003-3828-9527				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BENNUN A, 1982, J IMMUNOL, V129, P303; BERGSTEINSDOTTIR K, 1992, J NEUROCYTOL, V21, P382, DOI 10.1007/BF01191706; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CSERR HF, 1992, BRAIN PATHOL, V2, P269, DOI 10.1111/j.1750-3639.1992.tb00703.x; CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; FIERZ W, 1985, J IMMUNOL, V134, P3785; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Glass A, 1996, J IMMUNOL, V156, P3638; Gold R, 1997, TRENDS NEUROSCI, V20, P399, DOI 10.1016/S0166-2236(97)01079-5; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HIRSHFELD T, 1970, FEBS LETT, V7, P317; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; KSANDER BR, 1994, CHEM IMMUNOL, V58, P117; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MONACO S, 1992, J NEUROCYTOL, V21, P623, DOI 10.1007/BF01191724; NAPARSTEK Y, 1983, EUR J IMMUNOL, V13, P418, DOI 10.1002/eji.1830130513; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; POLTORAK M, 1991, ANN NEUROL, V29, P377, DOI 10.1002/ana.410290408; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAO K, 1989, TRANSPLANTATION, V48, P1018, DOI 10.1097/00007890-198912000-00025; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Sabelko KA, 1997, J IMMUNOL, V159, P3096; SCHMIED M, 1993, AM J PATHOL, V143, P446; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; Smith T, 1996, J AUTOIMMUN, V9, P167, DOI 10.1006/jaut.1996.0020; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Waldner H, 1997, J IMMUNOL, V159, P3100; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P1031, DOI 10.1002/eji.1830220423; WUCHERPFENNIG KW, 1994, CLIN IMMUNOL IMMUNOP, V72, P293, DOI 10.1006/clin.1994.1145; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; YU LT, 1990, J NEUROIMMUNOL, V30, P121, DOI 10.1016/0165-5728(90)90095-5	58	130	136	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1207	1217		10.1096/fasebj.13.10.1207	http://dx.doi.org/10.1096/fasebj.13.10.1207			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385611				2022-12-28	WOS:000081264800009
J	Fitzgerald, J; Hughes-Fulford, M				Fitzgerald, J; Hughes-Fulford, M			Mechanically induced c-fos expression is mediated by cAMP in MC3T3-E1 osteoblasts	FASEB JOURNAL			English	Article						gene expression; signal transduction; gravity; mechanical stimulation; PGE(2) synthesis	MESSENGER-RNA EXPRESSION; GENE-EXPRESSION; TRANSGENIC MICE; CELLS; BONE; DIFFERENTIATION; HYPERGRAVITY; RESPONSES; INVITRO	In serum-deprived MC3T3-E1 osteoblasts, mechanical stimulation caused by mild (287 x g) centrifugation induced a 10-fold increase in mRNA levels of the proto-oncogene, c-fos, Induction of c-fos was abolished by the cAMP-dependent protein kinase inhibitor H-89, suggesting that the transient c-fos mRNA increase is mediated by cAMP, Down-regulation of protein kinase C (PKC) activity by chronic TPA treatment failed to significantly reduce c-fos induction, suggesting that TPA-sensitive isoforms of PKC are not responsible for c-fos up regulation, In addition, 287 x g centrifugation increased intracellular prostaglandin E-2 (PGE(2)) levels 2.8-fold (P < 0.005), Since we have previously shown that prostaglandin E-2 (PGE(2)) can induce c-fos expression via a cAMP-mediated mechanism, we asked whether the increase in c-fos mRNA was due to centrifugation-induced PGE(2) release. Pretreatment with the cyclooxygenase inhibitors indomethacin and flurbiprofen did not hinder the early induction of c-fos by mechanical stimulation, We conclude that c-fos expression induced by mild mechanical loading is dependent primarily on cAMP, not PKC, and initial induction of c-fos is not necessarily dependent on the action of newly synthesized PGE(2).	Vet Affairs Med Ctr, Dept Med, Lab Cell Growth, San Francisco, CA 94121 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hughes-Fulford, M (corresponding author), Vet Affairs Med Ctr, Dept Med, Lab Cell Growth, Mail Code 151F,4150 Clement St, San Francisco, CA 94121 USA.			Hughes-Fulford, Millie/0000-0002-0756-068X				CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; CLOSS EI, 1990, J CELL BIOL, V111, P1313, DOI 10.1083/jcb.111.3.1313; DANESCH U, 1994, J BIOL CHEM, V269, P27258; Fitzgerald J, 1996, EXP CELL RES, V228, P168, DOI 10.1006/excr.1996.0313; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V217, P264, DOI 10.1006/bbrc.1995.2773; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KUMEI Y, 1989, J CELL SCI, V93, P221; NOSE K, 1994, EXP CELL RES, V211, P168, DOI 10.1006/excr.1994.1073; RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Shanfeld J L, 1985, Prog Clin Biol Res, V187, P331; SIMONSON MS, 1994, EXP CELL RES, V215, P137, DOI 10.1006/excr.1994.1325; STANFORD CM, 1995, J ORTHOPAED RES, V13, P664, DOI 10.1002/jor.1100130505; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; ZAMAN G, 1992, CALCIFIED TISSUE INT, V51, P132, DOI 10.1007/BF00298501	27	40	53	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					553	557		10.1096/fasebj.13.3.553	http://dx.doi.org/10.1096/fasebj.13.3.553			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064622				2022-12-28	WOS:000079016000015
J	Ji, GJ; Fleischmann, BK; Bloch, W; Feelisch, M; Andressen, C; Addicks, K; Hescheler, J				Ji, GJ; Fleischmann, BK; Bloch, W; Feelisch, M; Andressen, C; Addicks, K; Hescheler, J			Regulation of the L-type Ca2+ channel during cardiomyogenesis: switch from NO to adenylyl cyclase-mediated inhibition	FASEB JOURNAL			English	Article						ES cell-derived cardiomyocytes; patch-clamp; nitric oxide; switch in the regulation of I-Ca during development	NITRIC-OXIDE SYNTHASE; DEPENDENT PROTEIN-KINASE; EMBRYONIC STEM-CELLS; CHICK HEART-CELLS; CARDIAC MYOCYTES; VENTRICULAR MYOCYTES; CALCIUM CURRENT; CYCLIC-AMP; SELECTIVE-INHIBITION; GUANYLATE-CYCLASE	In adult mammalian cardiomyocytes, stimulation of muscarinic receptors counterbalances the beta-adrenoceptor-mediated increase in myocardial contractility and heart rate by decreasing the L-type Ca2+ current (I-Ca) (1, 2). This effect is mediated via inhibition of adenylyl cyclase and subsequent reduction of cAMP-dependent phosphorylation of voltage-dependent L-type Ca2+ channels (3). Little is known, however, about the nature and origin of this pivotal inhibitory pathway. Using embryonic stem cells as an in vitro model of cardiomyogenesis, we found that muscarinic agonists depress I-Ca by 58 +/- 3% (n=34) in early stage cardiomyocytes lacking functional beta-adrenoceptors. The cholinergic inhibition is mediated by the nitric oxide (NO)/cGMP system since it was abolished by application of NOS inhibitors (L-NMA, L-NAME), an inhibitor of the soluble guanylyl cyclase (ODQ), and a selective phosphodiesterase type II antagonist (EHNA). The NO/cGMP-mediated I-Ca depression was dependent on a reduction of cAMP/ protein kinase A (PKA) levels since application of the catalytic subunit of PKA or of the PKA inhibitor PK) prevented the carbachol effect. In late development stage cells, as reported for ventricular cardiomyocytes (2, 4), muscarinic agonists had no effect on basal I-Ca but antagonized beta-adrenoceptor-stimulated I-Ca by 43 +/- 4% (n=16). This switch in signaling pathways during development is associated with distinct changes in expression of the two NO-producing isoenzymes, eNOS and iNOS, respectively. These findings indicate a fundamental role for NO as a signaling molecule during early embryonic development and demonstrate a switch in the signaling cascades governing I-Ca regulation.	Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Univ Cologne, Inst Anat 1, D-5000 Cologne, Germany; UCL, Wolfson Inst Biomed Res, London, England	University of Cologne; University of Cologne; University of London; University College London	Hescheler, J (corresponding author), Univ Cologne, Inst Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	jh@physiologie.uni-koeln.de	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158				An RH, 1996, CIRC RES, V78, P371, DOI 10.1161/01.RES.78.3.371; Arnhold S, 1997, NEUROSCI LETT, V229, P165, DOI 10.1016/S0304-3940(97)00457-6; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FABIATO A, 1979, ANNU REV PHYSIOL, V41, P473, DOI 10.1146/annurev.ph.41.030179.002353; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Gouge RC, 1998, BIOL REPROD, V58, P875, DOI 10.1095/biolreprod58.4.875; HADDAD GE, 1995, MOL CELL BIOCHEM, V148, P89, DOI 10.1007/BF00929507; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Han X, 1998, J PHYSIOL-LONDON, V509, P741, DOI 10.1111/j.1469-7793.1998.741bm.x; Han X, 1996, CIRC RES, V78, P998, DOI 10.1161/01.RES.78.6.998; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Hare JM, 1998, J CLIN INVEST, V101, P1424, DOI 10.1172/JCI1012; HARE JM, 1995, CIRCULATION, V92, P2198, DOI 10.1161/01.CIR.92.8.2198; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hu H, 1997, CIRC RES, V81, P742; IIJIMA T, 1985, J PHYSIOL-LONDON, V359, P485, DOI 10.1113/jphysiol.1985.sp015598; ISENBERG G, 1982, PFLUG ARCH EUR J PHY, V395, P6, DOI 10.1007/BF00584963; KUMAR R, 1994, J MOL CELL CARDIOL, V26, P1537, DOI 10.1006/jmcc.1994.1174; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MERY PF, 1993, J BIOL CHEM, V268, P26286; MERY PF, 1995, MOL PHARMACOL, V48, P121; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MONCADA S, 1991, PHARMACOL REV, V43, P109; OSTERRIEDER W, 1982, NATURE, V298, P576, DOI 10.1038/298576a0; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SLOTKIN TA, 1994, TOXICOL APPL PHARM, V129, P223, DOI 10.1006/taap.1994.1247; SUMII K, 1995, CIRC RES, V77, P803, DOI 10.1161/01.RES.77.4.803; TOHSE N, 1991, CIRC RES, V69, P325, DOI 10.1161/01.RES.69.2.325; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TRIPATHI O, 1991, J DEV PHYSIOL, V16, P309; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	48	84	88	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					313	324		10.1096/fasebj.13.2.313	http://dx.doi.org/10.1096/fasebj.13.2.313			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973319				2022-12-28	WOS:000078615200011
J	Stein, GS; Van Wijnen, AJ; Stein, JL; Lian, JB; Pockwinse, SH; McNeil, S				Stein, GS; Van Wijnen, AJ; Stein, JL; Lian, JB; Pockwinse, SH; McNeil, S			Implications for interrelationships between nuclear architecture and control of gene expression under microgravity conditions	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	transcription; chromatin; nucleosomes; nuclear matrix	ACUTE MYELOID-LEUKEMIA; PROTEIN-PROTEIN INTERACTIONS; MATRIX TARGETING SIGNAL; RUNT HOMOLOGY DOMAIN; DNA-BINDING PROTEINS; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTORS; OSTEOCALCIN GENE; HISTONE ACETYLATION; CHROMATIN STRUCTURE	Components of nuclear architecture ape functionally interrelated with control of gene expression. There is growing appreciation that multiple levels of nuclear organization integrate the regulatory cues that support activation and suppression of genes as well as the processing of gene transcripts. The linear representation of genes and promoter elements provide the potential for responsiveness to physiological regulatory signals. Parameters of chromatin structure and nucleosome organization support synergism between activities at independent regulatory sequences and render promoter elements accessible or refractory to transcription factors. Association of genes, transcription factors, and the machinery for transcript processing with the nuclear matrix facilitates fidelity of gene expression within the three-dimensional context of nuclear architecture. Mechanisms must be defined that couple nuclear morphology with enzymatic parameters of gene expression. The recent characterization of factors that mediate chromatin remodeling and identification of intranuclear targeting signals that direct transcription factors to subnuclear domains where gene expression occurs link genetic and structural components of transcriptional control. Nuclear reorganization and aberrant intranuclear trafficking of transcription factors for developmental and tissue-specific control occurs in tumor cells and in neurological disorders. Compromises in nuclear structure-function interrelationships can occur as a consequence of microgravity-mediated perturbations in cellular architecture.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Ctr Canc, Dept Cell Biol, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Stein, GS (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01605 USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, P01AR042262] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39588, AR42262] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alvarez M, 1997, ENDOCRINOLOGY, V138, P482, DOI 10.1210/en.138.1.482; BAE SC, 1993, ONCOGENE, V8, P809; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Berezney R, 1996, J CELL BIOCHEM, V62, P223, DOI 10.1002/(SICI)1097-4644(199608)62:2<223::AID-JCB10>3.3.CO;2-M; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BIDWELL JP, 1994, CANCER RES, V54, P28; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; Chen HY, 1996, BIOCHEM J, V320, P257, DOI 10.1042/bj3200257; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DWORETZKY SI, 1990, P NATL ACAD SCI USA, V87, P4605, DOI 10.1073/pnas.87.12.4605; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Frank R, 1995, ONCOGENE, V11, P2667; GETZENBERG RH, 1991, CANCER RES, V51, P6514; GETZENBERG RH, 1990, MOL ENDOCRINOL, V4, P1336, DOI 10.1210/mend-4-9-1336; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; Grande MA, 1997, J CELL SCI, V110, P1781; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HO IC, 1989, P NATL ACAD SCI USA, V86, P6714, DOI 10.1073/pnas.86.17.6714; Jackson DA, 1997, MOL BIOL REP, V24, P209, DOI 10.1023/A:1006873614521; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lindenmuth DM, 1997, J CELL BIOCHEM, V66, P123; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nardozza TA, 1996, J CELL BIOCHEM, V61, P467, DOI 10.1002/(SICI)1097-4644(19960601)61:3<467::AID-JCB14>3.3.CO;2-W; NELKIN BD, 1980, NUCLEIC ACIDS RES, V8, P5623, DOI 10.1093/nar/8.23.5623; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; NICKERSON JA, 1995, STRUCTURAL FUNCTIONA, P67; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; PIENTA KJ, 1991, CANCER, V68, P2012, DOI 10.1002/1097-0142(19911101)68:9<2012::AID-CNCR2820680928>3.0.CO;2-C; Pombo A, 1996, EXP CELL RES, V229, P201, DOI 10.1006/excr.1996.0360; ROBINSON SI, 1982, CELL, V28, P99, DOI 10.1016/0092-8674(82)90379-8; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Rogaia D, 1997, CANCER RES, V57, P799; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1990, P NATL ACAD SCI USA, V87, P147, DOI 10.1073/pnas.87.1.147; Spelsberg TC, 1996, RECENT PROG HORM RES, V51, P63; Stein GS, 1996, J CELL BIOCHEM, V62, P198, DOI 10.1002/(SICI)1097-4644(199608)62:2<198::AID-JCB8>3.3.CO;2-3; STEIN GS, 1994, J CELL BIOCHEM, V55, P4, DOI 10.1002/jcb.240550103; STEIN GS, 1997, NUCL STRUCTURE GENE, P178; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Tang L, 1998, J STRUCT BIOL, V123, P83, DOI 10.1006/jsbi.1998.4016; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; van Holde K.E., 1988, CHROMATIN; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZLATANOVA J S, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P211	84	25	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S157	S166						10	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352158				2022-12-28	WOS:000080403800020
J	Goetzl, EJ; An, SZ				Goetzl, EJ; An, SZ			Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate	FASEB JOURNAL			English	Review						lysoglycerophospholipids lysosphingophospholipids; G-protein-coupled receptors; signal transduction; apoptosis	PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; CROSS-TALK; CELLS; ACTIVATION; SPHINGOSINE-1-PHOSPHATE; IDENTIFICATION	The lysophospholipid (LPL) mediators lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are generated by enzymatic cleavage of stores of glycerophospholipids and sphingomyelin, respectively, in membranes of stimulated cells. LPLs are albumin bound, distributed widely in mammalian tissues, and increased in concentration by physiological activation of platelets and some other cells, tissue injury, inflammation, and neoplasia. The principal effects of LPA and S1P are growth related, including induction of cellular proliferation, alterations in differentiation and survival, and suppression of apoptosis. LPA and S1P also evoke cellular effector functions, which are dependent on cytoskeletal responses such as contraction, secretion, adhesion, and chemotaxis. The extracellular mediator activities of LPLs are transduced by subfamilies of G-protein-coupled receptors (GPCRs), of which the most completely characterized are those encoded by the endothelial differentiation genes (edgs). One homology cluster composed of Edg-1, -3, and 5 recognizes and responds to S1P, and the other cluster of Edg-2 and -4 is dedicated to LPA. Edg proteins are developmentally regulated and differ in tissue distribution, but couple similarly to multiple types of G-proteins to signal through ras and mitogen-activated protein kinase, rho, phospholipase C, and several protein tyrosine kinases. Numerous interactions between glycerophospholipids and sphingolipids are observed in their biosynthetic and signaling pathways. Many of the cellular effects of LPA and S1P are attributable to modifications in the content and/or activity of a major functional protein. Examples are increases in nuclear levels of transcription factors that regulate the serum response element, suppression of death caspase activities in apoptosis, and elevation of membrane content of heparin binding-epidermal growth factor-like growth factor, which serves as an autocrine and juxtacrine stimulus of proliferation. These ubiquitous LPL mediators of cellular growth, differentiation, and activities thus act directly through complex subfamilies of GPCRs and by regulating expression of biologically critical proteins.	Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, Box 0711,533 Parnassus, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL-31809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AN S, 1998, IN PRESS MOL PHARM; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Brindley DN, 1996, BIOCHEM CELL BIOL, V74, P469, DOI 10.1139/o96-051; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gaits F, 1996, J BIOL CHEM, V271, P20151; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; GOETZL EJ, IN PRESS J IMMUNOL; GOETZL EJ, 1998, IN PRESS EICOSANOIDS; GOETZL EJ, IN PRESS P ASS AM PH; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HLA T, 1990, J BIOL CHEM, V265, P9308; Inoue CN, 1997, P SOC EXP BIOL MED, V216, P370; KAWASAWA Y, 1998, FASEB J, V12, P1460; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; PIAZZA GA, 1995, EXP CELL RES, V216, P51, DOI 10.1006/excr.1995.1007; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SU Y, 1994, J BIOL CHEM, V269, P16512; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; TIGYI GJ, 1998, IN PRESS LIPID 2 MES; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Umansky SR, 1997, CELL DEATH DIFFER, V4, P608, DOI 10.1038/sj.cdd.4400282; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; Wang AJ, 1997, J BIOL CHEM, V272, P22030, DOI 10.1074/jbc.272.35.22030; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	52	477	494	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1589	1598		10.1096/fasebj.12.15.1589	http://dx.doi.org/10.1096/fasebj.12.15.1589			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837849				2022-12-28	WOS:000077574500001
J	Jakubowski, H				Jakubowski, H			Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels	FASEB JOURNAL			English	Article						homocysteine thiolactone; atherosclerosis	TRANSFER-RNA-SYNTHETASES; ESCHERICHIA-COLI; PROOFREADING INVIVO; THIOLACTONE; DISEASE; INHIBITION; PATHWAYS	Homocysteine thiolactone, a cyclic thioester, is synthesized by certain aminoacyl-tRNA synthetases in editing or proofreading reactions that prevent translational incorporation of homocysteine into proteins. Although homocysteine thiolactone is expected to acylate amino groups in proteins, virtually nothing is known regarding reactivity of the thiolactone. Here it is shown that reactions of the thiolactone with protein lysine residues were robust under physiological conditions. In human serum incubated with homocysteine thiolactone, protein homocysteinylation was a major reaction that could be observed with as little as 10 nM thiolactone, Individual proteins were homocysteinylated at rates proportional to their lysine contents. Homocysteinylation led to protein damage, manifested as multimerization and precipitation of extensively modified proteins. Model enzymes, such as methionyl-tRNA synthetase and trypsin, were inactivated by homocysteinylation, Metabolic conversion of homocysteine to the thiolactone, protein homocysteinylation, and resulting protein damage may underlie involvement of Hey in the pathology of vascular disease.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.		Jakubowski, Hieronim/A-2510-2017; Jakubowski, Hieronim/AAA-6834-2019	Jakubowski, Hieronim/0000-0001-5845-4409; 				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Baernstein HD, 1934, J BIOL CHEM, V106, P451; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V1, P515; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; DUDMAN NPB, 1991, ARTERIOSCLER THROMB, V11, P663, DOI 10.1161/01.ATV.11.3.663; Ferguson E, 1998, J LIPID RES, V39, P925; GAO WW, 1994, BIOCHEMISTRY-US, V33, P11528, DOI 10.1021/bi00204a015; HARRINGTON CR, 1994, NATURE, V370, P247, DOI 10.1038/370247a0; HAWKINS D, 1969, J CLIN INVEST, V48, P536, DOI 10.1172/JCI106011; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; Jacobsen DW, 1998, CLIN CHEM, V44, P1833; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1997, BIOCHEMISTRY-US, V36, P11077, DOI 10.1021/bi970589n; JAKUBOWSKI H, 1993, FEBS LETT, V317, P593; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; YVON M, 1988, FEBS LETT, V239, P237, DOI 10.1016/0014-5793(88)80924-4	20	317	322	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2277	2283		10.1096/fasebj.13.15.2277	http://dx.doi.org/10.1096/fasebj.13.15.2277			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593875				2022-12-28	WOS:000084310800019
J	Satir, P				Satir, P			The cilium as a biological nanomachine	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		CILIARY BEAT FREQUENCY; MICROTUBULE TRANSLOCATION; LIGHT-CHAIN; 22S DYNEIN; CYCLIC-AMP; PHOSPHORYLATION; PARAMECIUM; INNER		Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Satir, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BONINI NM, 1986, CELL MOTIL CYTOSKEL, V6, P256, DOI 10.1002/cm.970060303; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; FAWCETT DW, 1954, J MORPHOL, V94, P221, DOI 10.1002/jmor.1050940202; GIBBONS IR, 1995, CELL MOTIL CYTOSKEL, V32, P136, DOI 10.1002/cm.970320214; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Hamasaki T, 1995, BIOPHYS J, V69, P2569, DOI 10.1016/S0006-3495(95)80128-1; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; HAMASAKI T, 1995, CELL MOTIL CYTOSKEL, V32, P121, DOI 10.1002/cm.970320210; HENNESSEY T, 1985, EUR J CELL BIOL, V36, P153; HOLWILL MEJ, 1994, CELL MOTIL CYTOSKEL, V27, P287, DOI 10.1002/cm.970270402; MANTON I, 1952, SYM SOC EXP BIOL, V6, P306; Porter ME, 1996, CURR OPIN CELL BIOL, V8, P10, DOI 10.1016/S0955-0674(96)80042-1; SATIR P, 1997, HDB PHYSIOL 14, P787; Satir Peter, 1993, Trends in Cell Biology, V3, P409, DOI 10.1016/0962-8924(93)90092-F; SEDAR AW, 1955, J BIOPHYS BIOCHEM CY, V1, P583, DOI 10.1083/jcb.1.6.583; SUGRUE P, 1991, J CELL SCI, V98, P5; Taylor HC, 1999, CELL MOTIL CYTOSKEL, V43, P167, DOI 10.1002/(SICI)1097-0169(1999)43:2<167::AID-CM8>3.3.CO;2-H; [No title captured]	19	13	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S235	S237		10.1096/fasebj.13.9002.S235	http://dx.doi.org/10.1096/fasebj.13.9002.S235			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619134	Bronze			2022-12-28	WOS:000084390200012
J	Bulfone-Paus, S; Bulanova, E; Pohl, T; Budagian, V; Durkop, H; Ruckert, R; Kunzendorf, U; Paus, R; Krause, H				Bulfone-Paus, S; Bulanova, E; Pohl, T; Budagian, V; Durkop, H; Ruckert, R; Kunzendorf, U; Paus, R; Krause, H			RETRACTED: Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15R alpha chain (Retracted Article. See vol 25, pg 1118, 2011)	FASEB JOURNAL			English	Article; Retracted Publication						cell death; TNFR1; L929; I kappa B	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; SIGNALS CELL-DEATH; BETA-CHAIN; IMMUNE-RESPONSES; KILLER-CELLS; KINASE RIP; DOMAIN; PROTEIN; INTERACTS	Interleukin-15 (IL-15) is a potent inhibitor of several apoptosis pathways. One prominent path toward apoptosis is the ligand-induced association of TNF receptor 1 (TNFR1) with death domain adaptor proteins. Studying if and how IL-15 blocks TNFR1-mediated apoptosis in a murine fibroblast cell line (L929), we show here that IL-15 blocks TNFR1-induced apoptosis tia IL-15R alpha chain signaling. The intracellular tail of IL-15R alpha shows sequence homologies to the TRAF2 binding motifs of CD30 and CD40. Most important, binding of IL-15 to IL-15R alpha successfully competes with the TNFR1 complex for TRAF2 binding, which may impede assembly of key adaptor proteins to the TNFR1 complex, and induces I kappa B alpha phosphorylation, Thus, IL-15R alpha chain stimulation is a powerful deflector of cell death very early in the apoptosis signaling cascade, while TNF-alpha and IL-15 surface as major opponents in apoptosis control.	Free Univ Berlin, Hosp Benjamin Franklin, Inst Immunol, D-12200 Berlin, Germany; Free Univ Berlin, Hosp Benjamin Franklin, Dept Urol, D-12200 Berlin, Germany; Free Univ Berlin, Hosp Benjamin Franklin, Dept Pathol, D-12200 Berlin, Germany; Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Univ Erlangen Nurnberg, Dept Internal Med 4, D-8520 Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University of Erlangen Nuremberg	Bulfone-Paus, S (corresponding author), Free Univ Berlin, Hosp Benjamin Franklin, Inst Immunol, Hindenburgdamm 30, D-12200 Berlin, Germany.	bulfone@zedat.fu-berlin.de	Kunzendorf, Ulrich/A-8257-2010	Krause, Hans/0000-0001-8713-8229				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baichwal V. R., 1997, CURR BIOL, V7, P94; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHINNAIYAN AM, 1996, SCIENCE, V264, P707; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Coligan JE., 1994, CURRENT PROTOCOLS IM; DiSanto JP, 1997, CURR BIOL, V7, pR424, DOI 10.1016/S0960-9822(06)00208-9; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Girard D, 1996, BLOOD, V88, P3176, DOI 10.1182/blood.V88.8.3176.bloodjournal8883176; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1998, CURR BIOL, V8, pR418, DOI 10.1016/S0960-9822(98)70267-2; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Kunzendorf U, 1996, J CLIN INVEST, V97, P1204, DOI 10.1172/JCI118534; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LINDNER G, 1998, J INVEST DERMATOL, V141, P101; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Onu A, 1997, J IMMUNOL, V158, P255; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIE KP, 1993, INT J ONCOL, V3, P1043	55	130	133	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1575	1585		10.1096/fasebj.13.12.1575	http://dx.doi.org/10.1096/fasebj.13.12.1575			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463949	Bronze			2022-12-28	WOS:000082347600013
J	Zardo, G; Marenzi, S; Perilli, M; Caiafa, P				Zardo, G; Marenzi, S; Perilli, M; Caiafa, P			Inhibition of poly(ADP-ribosyl)ation introduces an anomalous methylation pattern in transfected foreign DNA	FASEB JOURNAL			English	Article						poly(ADP . ribose) polymerase; 5; methylcytosine; 3; aminobenzamide; transfection	CPG BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE ACETYLATION; CHROMATIN STRUCTURE; GENE; PROMOTER; SEQUENCES; ISLANDS; SITE; CIS	The aim of this paper is to verify whether the control played by poly(ADP-ribosyl)-ation on genomic DNA methylation, and in particular on CpG islands, can also be seen on foreign DNA transfected in cells where inhibition of the poly(ADP-ribosyl)ation process was obtained by treating them with 2 mM 3-aminobenzamide for 24 h. The CPG island-like pVHCk plasmid containing the bacterial chloramphenicol acyltransferase (CAT) gene under the control of SV40 early promoter was transfected in L929 mouse fibroblast cells. The bisulfite reaction, which is capable of immortalizing the methylation state of cytosine on DNA, was performed before amplification of the plasmid DNA fragment, then used for sequence analysis. Our results have shown that I) when transfected in control cells, the plasmid maintains its characteristic unmethylated pattern, whereas this pattern is lost when the plasmid is transfected in cells treated with S-aminobenzamide; and 2) the presence of new methyl groups on plasmid DNA is paralleled by a decrease of CAT reporter gene expression. These data confirm that Poly(ADP-ribosyl)ation is a process tightly involved in protecting genomic DNA from full methylation and suggest the use of 3-aminobenzamide as a possible experimental strategy to mime other conditions of DNA hypermethylation in cells.	Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy; Univ Rome La Sapienza, Dept Biol Sci A Rossi Fanelli, Rome, Italy; CNR, Ctr Biol Mol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)	Caiafa, P (corresponding author), Univ Aquila, Dipartimento Sci & Tecnol Biomed, Loc Coppito,Via Vetoio, I-67100 Laquila, Italy.							ADAMS RLP, 1985, SPRINGER SERIES MOL; ALTHAUS FR, 1997, BASE EXCISION REPAIR, P1669; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRUHAT A, 1995, P NATL ACAD SCI USA, V92, P3678, DOI 10.1073/pnas.92.9.3678; BRYANS M, 1992, FEBS LETT, V309, P97, DOI 10.1016/0014-5793(92)80748-6; CAIAFA P, 1991, BIOCHIM BIOPHYS ACTA, V1090, P38, DOI 10.1016/0167-4781(91)90034-J; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; De Capoa A, 1999, FASEB J, V13, P89; DErme M, 1996, BIOCHEM J, V316, P475, DOI 10.1042/bj3160475; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; Jones PB, 1998, PETROL GEOSCI, V4, P187, DOI 10.1144/petgeo.4.2.187; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KHAN R, 1988, J BIOL CHEM, V263, P14374; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Lindsay H, 1996, BIOCHEM J, V320, P473, DOI 10.1042/bj3200473; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCH CELL BIOL, V10, P4396; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Zardo G, 1998, BIOL CHEM, V379, P647; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s; Zardo G, 1996, BIOCHEM BIOPH RES CO, V220, P102, DOI 10.1006/bbrc.1996.0364; ZHANG XY, 1995, NUCLEIC ACIDS RES, V23, P3026, DOI 10.1093/nar/23.15.3026; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387	54	20	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1518	1522		10.1096/fasebj.13.12.1518	http://dx.doi.org/10.1096/fasebj.13.12.1518			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463942	Bronze			2022-12-28	WOS:000082347600006
J	Huck, S; Deveaud, E; Namane, A; Zouali, M				Huck, S; Deveaud, E; Namane, A; Zouali, M			Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis	FASEB JOURNAL			English	Article						autoimmunity; SLE; GC%; C2-ceramide	SYSTEMIC LUPUS-ERYTHEMATOSUS; ALU FAMILY MEMBERS; B-CELLS; IMMUNE-COMPLEXES; CIRCULATING DNA; ANTIBODIES; ANTIGEN; EXPRESSION; FRAGMENTS; SUBSET	Systemic lupus erythematosus (SLE) is characterized by an accelerated apoptosis of peripheral lymphocytes and an impairment of the clearance of apoptotic cells, Since changes in DNA methylation and in deoxycytosine and deoxyguanine (GC) content have been shown to enhance the potential of DNA to activate murine and human B lymphocytes, we tested the capacity of lymphocytes undergoing apoptosis (under conditions that mimic the deletion of self-reactive cells after antigen receptor engagement) to generate nucleosomes with a particular base composition. Using two cell culture systems and four apoptosis triggers, we found an increase of deoxymethylcytosine in fragmented chromosomal DNA of apoptotic B and T lymphocytes. However, this increase was not associated with modulation of DNA (cytosine-5) methyltransferase, the enzyme that methylates eukaryotic DNA, which suggests that the changes in DNA methylation patterns are not linked to the process of de novo DNA methylation during cell death. In addition, we could not detect a unique methylation pattern in highly repetitive Alu sequences present in the human genome of SLE subjects, as compared with controls, However, the abnormal DNA methylation of apoptotic nucleosomes was associated with an unusual pattern of nuclease-resistant, GC-rich regions in these DNA fragments. We propose that the combination of an accelerated apoptosis with a defect in the clearance of apoptotic cells results in release of increased amounts of nucleosomes with abnormally methylated, GC-rich DNA and provides an autologous stimulation that could bypass tolerance to self in systemic autoimmune diseases. These findings support the concept that the structure and dynamics of nucleosomes are critical in determining their immunogenicity in SLE.	Inst Pasteur, Dept Immunol, F-75015 Paris, France; Inst Pasteur, Unite Immunochim Analyt, F-75015 Paris, France; Inst Pasteur, Lab Chim Struturale Macromol, F-75015 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Zouali, M (corresponding author), Inst Pasteur, Dept Immunol, 28 Rue Dr Roux, F-75015 Paris, France.		Namane, Abdelkader/O-1857-2013	Namane, Abdelkader/0000-0001-7180-7619; Zouali, Moncef/0000-0002-8225-456X				AMASAKI Y, 1995, CLIN EXP IMMUNOL, V99, P245; BATZER MA, 1990, NUCLEIC ACIDS RES, V18, P6793, DOI 10.1093/nar/18.23.6793; BATZER MA, 1991, NUCLEIC ACIDS RES, V19, P3619, DOI 10.1093/nar/19.13.3619; BELL DA, 1990, J CLIN INVEST, V85, P1487, DOI 10.1172/JCI114595; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bertino L, 1996, DEV BRAIN RES, V95, P38, DOI 10.1016/0165-3806(96)00059-4; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Cabrespines A, 1998, J AUTOIMMUN, V11, P19, DOI 10.1006/jaut.1997.0172; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CORVETTA A, 1991, J CHROMATOGR-BIOMED, V566, P481, DOI 10.1016/0378-4347(91)80265-E; EMLEN W, 1994, J IMMUNOL, V152, P3685; FOURNIE GJ, 1988, KIDNEY INT, V33, P487, DOI 10.1038/ki.1988.25; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HESS EV, 1993, SYSTEMIC LUPUS ERYTH, P893; Hossain MM, 1997, EXP TOXICOL PATHOL, V49, P201, DOI 10.1016/S0940-2993(97)80008-5; Huck S, 1998, J AUTOIMMUN, V11, P449, DOI 10.1006/jaut.1998.0226; Huck S, 1996, CLIN IMMUNOL IMMUNOP, V80, P1, DOI 10.1006/clin.1996.0087; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KRAPF F, 1989, CLIN EXP IMMUNOL, V75, P336; KRIEG AM, 1995, J CLIN IMMUNOL, V15, P284, DOI 10.1007/BF01541318; LI JZ, 1989, ARTHRITIS RHEUM-US, V32, P726, DOI 10.1002/anr.1780320610; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; Miniou P, 1997, HUM GENET, V99, P738, DOI 10.1007/s004390050441; Mizugaki M, 1997, CLIN EXP IMMUNOL, V110, P265; MYSLER E, 1994, J CLIN INVEST, V93, P1029, DOI 10.1172/JCI117051; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; RICHARDSON B, 1990, ARTHRITIS RHEUM, V33, P1665, DOI 10.1002/art.1780331109; RICHARDSON BC, 1992, ARTHRITIS RHEUM, V35, P647, DOI 10.1002/art.1780350608; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; RUMORE PM, 1990, J CLIN INVEST, V86, P69, DOI 10.1172/JCI114716; Saitoh F, 1995, ANTICANCER RES, V15, P2137; SANO H, 1982, J IMMUNOL, V128, P1341; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; SANO H, 1985, J CLIN INVEST, V76, P1314, DOI 10.1172/JCI112105; SANO H, 1983, J IMMUNOL, V130, P187; SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613; STOLLAR BD, 1994, FASEB J, V8, P337, DOI 10.1096/fasebj.8.3.7511550; Sun SQ, 1997, J IMMUNOL, V159, P3119; TERADA K, 1991, CLIN EXP IMMUNOL, V85, P66; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Utz PJ, 1997, J EXP MED, V185, P843, DOI 10.1084/jem.185.5.843; YOSHIDA H, 1990, EUR J IMMUNOL, V20, P1989, DOI 10.1002/eji.1830200917; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61; ZOUALI M, 1989, EUR J IMMUNOL, V19, P1757, DOI 10.1002/eji.1830190934	49	48	57	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1415	1422		10.1096/fasebj.13.11.1415	http://dx.doi.org/10.1096/fasebj.13.11.1415			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428765				2022-12-28	WOS:000082019100013
J	Esteve, JM; Mompo, J; De La Asuncion, JG; Sastre, J; Asensi, M; Boix, J; Vina, JR; Vina, J; Pallardo, FV				Esteve, JM; Mompo, J; De La Asuncion, JG; Sastre, J; Asensi, M; Boix, J; Vina, JR; Vina, J; Pallardo, FV			Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro	FASEB JOURNAL			English	Article						oxidative stress; mtDNA; mammary gland; glutathione	PERFORMANCE LIQUID-CHROMATOGRAPHY; PROGRAMMED CELL-DEATH; FLOW-CYTOMETRY; OXIDIZED GLUTATHIONE; ASCORBIC-ACID; CYTOCHROME-C; HEPATOCYTES; GENERATION; OXYGEN; BLOOD	Free radicals may be involved in apoptosis although this is the subject of some controversy. Furthermore, the source of free radicals in apoptotic cells is not certain. The aim of this study was to elucidate the role of oxidative stress in the induction of apoptosis in serum-deprived fibroblast cultures and in weaned lactating mammary glands as in vitro and in vivo experimental models, respectively. Oxidative damage to mtDNA is higher in apoptotic cells than in controls. Oxidized glutathione (GSSG) levels in mitochondria from lactating mammary gland are also higher in apoptosis, There is a direct relationship between mtDNA damage and the GSSG/reduced glutathione (GSH) ratio, Furthermore, whole cell GSH is decreased and GSSG is increased in both models of apoptosis, Glutathione oxidation precedes nuclear DNA fragmentation. These signs of oxidative stress are caused, at least in part, by an increase in peroxide production by mitochondria from apoptotic cells. We report a direct relationship between glutathione oxidation and mtDNA damage in apoptosis, Our results support the role of mitochondrial oxidative stress in the induction of apoptosis.	Univ Valencia, Fac Med, Dept Fisiol, Valencia 46010, Spain; Univ Valencia, Dept Patol, Valencia 46010, Spain; Univ Valencia, Dept Bioquim & Biol Mol, Valencia 46010, Spain	University of Valencia; University of Valencia; University of Valencia	Pallardo, FV (corresponding author), Univ Valencia, Fac Med, Dept Fisiol, Ave Blasco Ibanez 17, Valencia 46010, Spain.		Vina, Jose/AAB-3069-2021; Viña, Juan R/ABE-5698-2021; Miralles, Miguel A Asensi/I-2756-2015; Pallardo, Federico V./T-1156-2017	Vina, Jose/0000-0001-9709-0089; Viña, Juan R/0000-0002-4035-3615; Miralles, Miguel A Asensi/0000-0003-1922-7777; Pallardo, Federico V./0000-0003-3715-1980				ANDERSON ME, 1989, ANAL BIOCHEM, V183, P16, DOI 10.1016/0003-2697(89)90164-4; ASENSI M, 1994, METHOD ENZYMOL, V234, P367; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2326; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JUAN G, 1994, CYTOMETRY, V15, P335, DOI 10.1002/cyto.990150409; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LATORRE A, 1986, P NATL ACAD SCI USA, V83, P8649, DOI 10.1073/pnas.83.22.8649; MILLS BJ, 1990, ANAL BIOCHEM, V184, P263, DOI 10.1016/0003-2697(90)90678-3; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; RICKWOOD DW, 1987, MITOCHONDRIA PRACTIC, P4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vina J., 1990, GLUTATHIONE METABOLI; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	31	146	148	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1055	1064		10.1096/fasebj.13.9.1055	http://dx.doi.org/10.1096/fasebj.13.9.1055			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336888	Bronze			2022-12-28	WOS:000080547700010
J	Vitovski, S; Read, RC; Sayers, JR				Vitovski, S; Read, RC; Sayers, JR			Invasive isolates of Neisseria meningitidis possess enhanced immunoglobulin A1 protease activity compared to colonizing strains	FASEB JOURNAL			English	Article						human; bacterial infections; virulence; meningitis; carrier state	BACTERIAL IGA PROTEASES; FAB-ALPHA FRAGMENTS; MOLECULAR MECHANISMS; DEFENSE-MECHANISMS; GONORRHOEAE; GENE; PATHOGENESIS; INFLUENZAE; SECRETION; PROTEINS	Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae possess the ability to cleave human IgA1 antibodies, and all successfully colonize and occasionally invade the human upper respiratory tract. N. meningitidis invades the bloodstream after a period of nasopharyngeal colonization. We directly compared levels of IS-AI protease activity in strains (n=52) derived from the cerebrospinal fluid or blood of patients with meningococcal disease with strains of N. meningitidis obtained from asymptomatic carriers (n=25). IgA1 protease activity was determined by a sensitive semiquantitative ELISA assay, Levels of IgA1 protease activity were significantly higher (P< 0.0001) in strains associated with invasive meningococcal disease (98% with detectable activity, mean = 580 mU) than with those obtained from asymptomatic carriers (76% with detectable activity, mean = 280 mU), Despite marked variation in enzyme activity, almost all strains (96%) possessed the gene for IgA1 protease, Given the panmictic population structure of the bacterial isolates investigated, these data, obtained from two groups infected with N. meningitidis, but with markedly different clinical outcomes, provide the first quantitative evidence that IgA1 protease activity is a virulence determinant that contributes to the pathogenic phenotype, and suggest IS AI protease as a potential target for prophylaxis.	Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Sayers, JR (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England.	j.r.sayers@sheffield.ac.uk	Sayers, Jon R/AAP-6179-2020; Sayers, Jon R/I-8974-2012	Sayers, Jon R/0000-0002-5082-1443; Sayers, Jon R/0000-0002-5082-1443; Read, Robert/0000-0002-4297-6728	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHL T, 1991, INFECT IMMUN, V59, P563, DOI 10.1128/IAI.59.2.563-569.1991; BRANDTZAEG P, 1995, APMIS, V103, P1, DOI 10.1111/j.1699-0463.1995.tb01073.x; CHILDERS NK, 1989, ANNU REV MICROBIOL, V43, P503, DOI 10.1146/annurev.mi.43.100189.002443; COOPER MD, 1984, J INFECT DIS, V150, P737, DOI 10.1093/infdis/150.5.737; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; HALTER R, 1984, EMBO J, V3, P1595, DOI 10.1002/j.1460-2075.1984.tb02016.x; Hauck CR, 1997, FEBS LETT, V405, P86, DOI 10.1016/S0014-5793(97)00163-4; Kilian M, 1996, APMIS, V104, P321, DOI 10.1111/j.1699-0463.1996.tb00724.x; KILIAN M, 1983, ANN NY ACAD SCI, V409, P612, DOI 10.1111/j.1749-6632.1983.tb26903.x; KILIAN M, 1983, B EUR PHYSIOPATH RES, V19, P99; KILIAN M, 1988, MICROBIOL REV, V52, P296, DOI 10.1128/MMBR.52.2.296-303.1988; KILIAN M, 1979, INFECT IMMUN, V26, P143, DOI 10.1128/IAI.26.1.143-149.1979; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; KOOMEY JM, 1982, P NATL ACAD SCI-BIOL, V79, P7881, DOI 10.1073/pnas.79.24.7881; KOOMEY JM, 1984, INFECT IMMUN, V43, P101, DOI 10.1128/IAI.43.1.101-107.1984; KORNFELD SJ, 1981, REV INFECT DIS, V3, P521; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; LAMM ME, 1995, APMIS, V103, P241, DOI 10.1111/j.1699-0463.1995.tb01101.x; Lin SK, 1997, MOLECULES, V2, P1, DOI 10.3390/jan97p1; LOMHOLT H, 1992, P NATL ACAD SCI USA, V89, P2120, DOI 10.1073/pnas.89.6.2120; LOMHOLT H, 1995, MOL MICROBIOL, V15, P495, DOI 10.1111/j.1365-2958.1995.tb02263.x; MANSA B, 1986, INFECT IMMUN, V52, P171, DOI 10.1128/IAI.52.1.171-174.1986; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; METHA SK, 1973, J IMMUNOL, V111, P1274; MULKS MH, 1978, NEW ENGL J MED, V299, P973, DOI 10.1056/NEJM197811022991802; MULKS MH, 1987, INFECT IMMUN, V55, P931, DOI 10.1128/IAI.55.4.931-936.1987; MULKS MH, 1994, METHOD ENZYMOL, V235, P543; MULKS MH, 1980, J EXP MED, V152, P1442, DOI 10.1084/jem.152.5.1442; PLAUT AG, 1994, METHOD ENZYMOL, V244, P137; PLAUT AG, 1975, SCIENCE, V190, P1103, DOI 10.1126/science.810892; POHLNER J, 1995, MOL MICROBIOL, V17, P1073, DOI 10.1111/j.1365-2958.1995.mmi_17061073.x; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; Read RC, 1996, INFECT IMMUN, V64, P3210, DOI 10.1128/IAI.64.8.3210-3217.1996; READ RC, 1995, J MED MICROBIOL, V42, P353, DOI 10.1099/00222615-42-5-353; REINHOLDT J, 1983, J IMMUNOL METHODS, V63, P367, DOI 10.1016/S0022-1759(83)80010-6; Reinholdt J, 1997, INFECT IMMUN, V65, P4452, DOI 10.1128/IAI.65.11.4452-4459.1997; TUNKEL AR, 1993, CLIN MICROBIOL REV, V6, P118, DOI 10.1128/CMR.6.2.118-136.1993; Virji M, 1995, MOL MICROBIOL, V18, P741, DOI 10.1111/j.1365-2958.1995.mmi_18040741.x	39	37	42	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					331	337		10.1096/fasebj.13.2.331	http://dx.doi.org/10.1096/fasebj.13.2.331			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973321				2022-12-28	WOS:000078615200013
J	Budisa, N; Minks, C; Alefelder, S; Wenger, W; Dong, FM; Moroder, L; Huber, R				Budisa, N; Minks, C; Alefelder, S; Wenger, W; Dong, FM; Moroder, L; Huber, R			Toward the experimental codon reassignment in vivo: protein building with an expanded amino acid repertoire	FASEB JOURNAL			English	Article						genetic code; protein folding; translation	TRANSFER-RNA-SYNTHETASE; SITE-SPECIFIC INCORPORATION; ESCHERICHIA-COLI; GENETIC-CODE; IN-VIVO; SUBSTITUTION; BIOSYNTHESIS; ANALOGS; TELLUROMETHIONINE; SELENOCYSTEINE	The high precision and fidelity of the genetic message transmission are ensured by numerous proofreading steps, from DNA replication and transcription to protein translation. The key event for translational fidelity is the proper codon assignment for 20 canonical amino acids. An experimental codon reassignment is possible for noncanonical amino acids in vivo using artificially constructed expression hosts under efficient selective pressure. However, such amino acids may interfere with the cellular metabolism and thus do not belong to the 'first' or restricted' part of the universal code, but rather to a second or 'relaxed' part, which is limited mainly by the downstream proofreading in the natural translational machinery. Correspondingly, not all possible a-amino acids can be introduced into proteins. The aim of this study is to discuss biological and evolutionary constraints on possible candidates for this second coding level of the universal code. Engineering of such a 'second' code is expected to have great academic as well as practical impact, ranging from protein folding studies to biomedicine.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	Max Planck Society	Budisa, N (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.	budisa@biochem.mpg.de	Budisa, Nediljko/T-4812-2017; Budisa, Nediljko/AAA-4634-2022; Budisa, Nediljko/AAG-7291-2019	Budisa, Nediljko/0000-0001-8437-7304; Budisa, Nediljko/0000-0001-8437-7304; Moroder, Luis/0000-0001-9570-5713				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baron Christian, 1995, P529; Beiboer SHW, 1996, PROTEIN ENG, V9, P345, DOI 10.1093/protein/9.4.345; Besse D, 1997, BIOL CHEM, V378, P211; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRICK P, 1987, J MOL BIOL, V194, P287, DOI 10.1016/0022-2836(87)90376-7; BRONSKILL PM, 1988, BIOCHEM J, V249, P305, DOI 10.1042/bj2490305; Budisa N, 1998, EUR J BIOCHEM, V253, P1, DOI 10.1046/j.1432-1327.1998.2530001.x; Budisa N, 1998, P NATL ACAD SCI USA, V95, P455, DOI 10.1073/pnas.95.2.455; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Budisa N, 1997, J MOL BIOL, V270, P616, DOI 10.1006/jmbi.1997.1132; Calderone TL, 1996, J MOL BIOL, V262, P407, DOI 10.1006/jmbi.1996.0524; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; COWIE DB, 1957, BIOCHIM BIOPHYS ACTA, V26, P252, DOI 10.1016/0006-3002(57)90003-3; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DEMARCO C, 1977, BIOCHIM BIOPHYS ACTA, V478, P156, DOI 10.1016/0005-2787(77)90179-4; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; FERSHT AR, 1981, PROC R SOC SER B-BIO, V212, P351, DOI 10.1098/rspb.1981.0044; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; Forman MD, 1998, PROTEIN SCI, V7, P500; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; HUBER RE, 1967, ARCH BIOCHEM BIOPHYS, V122, P164, DOI 10.1016/0003-9861(67)90136-1; IBBA M, 1994, BIO-TECHNOL, V12, P678, DOI 10.1038/nbt0794-678; IBBA M, 1995, FEBS LETT, V364, P272, DOI 10.1016/0014-5793(95)00408-2; JACK RW, 1995, TRENDS BIOTECHNOL, V13, P269, DOI 10.1016/S0167-7799(00)88962-3; KOTHAKOTA S, 1995, J AM CHEM SOC, V117, P536, DOI 10.1021/ja00106a064; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; LADENSTEIN R, 1979, J MOL BIOL, V134, P199, DOI 10.1016/0022-2836(79)90032-9; LEMEIGNAN B, 1993, J MOL BIOL, V231, P161, DOI 10.1006/jmbi.1993.1269; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MENDEL D, 1995, ANNU REV BIOPH BIOM, V24, P435, DOI 10.1146/annurev.bb.24.060195.002251; MULLER S, 1994, BIOCHEMISTRY-US, V33, P3404, DOI 10.1021/bi00177a034; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; Richards FM, 1997, CELL MOL LIFE SCI, V53, P790, DOI 10.1007/s000180050100; RICHMOND MH, 1962, BACTERIOL REV, V26, P398, DOI 10.1128/MMBR.26.4.398-420.1962; RING M, 1985, BIOCHEM BIOPH RES CO, V131, P675, DOI 10.1016/0006-291X(85)91290-2; ROGERS KC, 1995, J MOL EVOL, V40, P476; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; Ross JBA, 1997, METHOD ENZYMOL, V278, P151; Schimmel P, 1996, P NATL ACAD SCI USA, V93, P4521, DOI 10.1073/pnas.93.10.4521; Schimmel P, 1997, P NATL ACAD SCI USA, V94, P10007, DOI 10.1073/pnas.94.19.10007; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; Wong CY, 1998, BIOCHEMISTRY-US, V37, P8938, DOI 10.1021/bi971862o; WONG JTF, 1988, MICROBIOL SCI, V5, P174; YOSHIKAWA E, 1994, MACROMOLECULES, V27, P5471, DOI 10.1021/ma00097a029	50	67	107	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					41	51		10.1096/fasebj.13.1.41	http://dx.doi.org/10.1096/fasebj.13.1.41			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872928				2022-12-28	WOS:000078029500005
J	Schluter, KD; Piper, HM				Schluter, KD; Piper, HM			Regulation of growth in the adult cardiomyocytes	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	andrenoceptors; mechanotransduction; microgravity; MAP kinase; PI3-kinase	RIBOSOMAL-RNA SYNTHESIS; RAT-HEART CELLS; VENTRICULAR CARDIOMYOCYTES; CARDIAC MYOCYTES; HYPERTROPHIC GROWTH; PROTEIN-SYNTHESIS; ORNITHINE DECARBOXYLASE; PHORBOL ESTER; STIMULATION; CATECHOLAMINES	Cardiomyocytes of adult myocardium increase their cellular mass in response to growth stimuli. They undergo hypertrophic growth but they do not proliferate in contrast to immature cardiomyocytes. Growth stimuli of the adult cardiomyocytes include classical growth hormones, various neuroendocrine factors, and the increase in mechanical load. The signal transduction of alpha(1)-adrenoceptor stimulation has been investigated in greatest detail and may therefore be taken as a reference for other humoral stimuli. It involves the activation of protein kinase C (PKC) and, downstream of PKC activation, of two separate signaling pathways, one including the mitogen-activated protein kinase and another including PI3-kinase and p70(s6k), key steps. Activation of the first pathway leads to re-expression of fetal genes, activation of the second pathway to a general activation of protein synthesis, and cellular growth. In neonatal cardiomyocytes, mechanical stretch causes growth By an activation of an autocrine mechanism including angiotensin II and endothelin. This mechanism does not operate, however, in adult cardiomyocytes. A mechanism of mechanotransduction has not yet been identified on adult cardiomyocytes but integrins may play a part. In microgravity, the scenario of myocardial growth stimulation is altered, On the systemic level, there are changes in hemodynamic and neuroendocrine regulation that erect indirect effects on the myocardium, Microgravity may also exert a direct cellular effect by the absence of a constant gravitational load component.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Schluter, KD (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Klaus-Dieter.Schlueter@physiologie.med.uni-giessen.de						Akins RE, 1997, IN VITRO CELL DEV-AN, V33, P337; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BARTOLOME J, 1980, SCIENCE, V210, P793, DOI 10.1126/science.6449079; BELL D, 1995, J MOL CELL CARDIOL, V27, P2433, DOI 10.1006/jmcc.1995.0231; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; CLARK WA, 1993, AM J PHYSIOL, V264, pH573, DOI 10.1152/ajpheart.1993.264.2.H573; CLARK WA, 1991, AM J PHYSIOL, V261, pC530, DOI 10.1152/ajpcell.1991.261.3.C530; DANKOWSKI BA, 1992, J CELL BIOL, V118, P1411; Decker ML, 1997, AM J PHYSIOL-HEART C, V272, pH2902, DOI 10.1152/ajpheart.1997.272.6.H2902; DECKER RS, 1993, AM J PHYSIOL, V265, pH329, DOI 10.1152/ajpheart.1993.265.1.H329; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; FULLER SJ, 1990, BIOCHEM J, V266, P727, DOI 10.1042/bj2660727; FURNIVAL CM, 1971, J PHYSIOL-LONDON, V214, P15, DOI 10.1113/jphysiol.1971.sp009416; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Goldberg Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1207, DOI 10.1152/ajpcell.1998.275.5.C1207; GU XH, 1992, J CARDIOVASC PHARM, V19, P764; HANEDA T, 1991, MOL CELL BIOCHEM, V104, P169; HANNAN RD, 1991, BASIC RES CARDIOL, V86, P154, DOI 10.1007/BF02190548; HILL LS, 1979, BRIT J CLIN PHARMACO, V7, pS255, DOI 10.1111/j.1365-2125.1979.tb04698.x; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; PINSON A, 1993, J MOL CELL CARDIOL, V25, P477, DOI 10.1006/jmcc.1993.1053; Pinson Arie, 1997, Journal of Molecular and Cellular Cardiology, V29, pA61; RILEY DA, 1987, MUSCLE NERVE, V10, P560, DOI 10.1002/mus.880100612; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; SCHLUTER KD, 1995, AM J PHYSIOL-CELL PH, V269, pC1311, DOI 10.1152/ajpcell.1995.269.5.C1311; SCHLUTER KD, 1992, AM J PHYSIOL, V263, pH1739, DOI 10.1152/ajpheart.1992.263.6.H1739; Schluter KD, 1998, CARDIOVASC RES, V40, P174, DOI 10.1016/S0008-6363(98)00171-0; SCHLUTER KD, 1997, PFLUEGERS ARCH S33, V433, pR50; SCHWARZFELD TA, 1981, J MOL CELL CARDIOL, V13, P563, DOI 10.1016/0022-2828(81)90327-8; Simm A, 1998, J MOL CELL CARDIOL, V30, P2059, DOI 10.1006/jmcc.1998.0768; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; TORAASON M, 1990, J MOL CELL CARDIOL, V22, P637; VILLARREAL FJ, 1992, AM J PHYSIOL, V262, pH1861, DOI 10.1152/ajpheart.1992.262.6.H1861; Wada H, 1996, AM J PHYSIOL-HEART C, V271, pH29, DOI 10.1152/ajpheart.1996.271.1.H29; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wagner J, 1998, CLIN EXP HYPERTENS, V20, P205, DOI 10.3109/10641969809053215; Zhou XJ, 1996, MOL CELL BIOCHEM, V164, P211, DOI 10.1007/BF00408660; ZIMMER HG, 1995, CARDIOSCIENCE, V6, P47	42	41	42	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S17	S22						6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352141				2022-12-28	WOS:000080403800003
J	Buisson, A; Nicole, O; Docagne, F; Sartelet, H; MacKenzie, ET; Vivien, D				Buisson, A; Nicole, O; Docagne, F; Sartelet, H; MacKenzie, ET; Vivien, D			Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta 1	FASEB JOURNAL			English	Article						excitotoxicity; serpins; neuronal cell death; apoptosis	NEURONAL DEATH; EXPRESSION; APOPTOSIS; TGF-BETA-1; DISEASE; INJURY; GENE; GROWTH-FACTOR-BETA-1; NEUROTOXICITY; DEGENERATION	Serine proteases play a key role in the fundamental biology of the central nervous system (CNS), and recent data suggest their involvement in the pathophysiology of neurodegenerative diseases, Little is known about the physiological regulation of these proteases in the CNS, Among the multiple growth factors present in the brain, transforming growth factor beta 1 (TGF-beta 1) has been described as an injury-related growth factor. However, its beneficial or deleterious role remains unclear. In the present study, we investigated the influence of TGF-beta 1 in apoptosis and necrosis, two mechanisms involved in ischemic neuronal death. We show that TGF-beta 1 exerts a neuroprotective role restricted to necrosis induced by N-methyl-D-aspartate. This effect is observable only in the obligatory presence of TGF-beta 1-responsive astrocytes, We demonstrate that this neuroprotective activity is mediated through an up-regulation of a serine protease inhibitor (PAI-1) in astrocytes, These results underline the involvement of serine proteases and extracellular matrix components such as the PAI-1/t-PA axis in the excitotoxic cascade, Moreover, regardless of the underlying mechanisms of t-PA involvement in excitotoxic injury, our observations might warn against the use of tissular plasminogen activator as an alternative therapy for the treatment of hypoxic-ischemic injury in the brain.	Univ Caen, CNRS UMR 6551, Neurosci Lab, F-14074 Caen, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie	Buisson, A (corresponding author), Univ Caen, CNRS UMR 6551, Neurosci Lab, Bd H Becquerel,BP 5229, F-14074 Caen, France.		Docagne, Fabian/S-8308-2018; buisson, alain/AAI-8218-2020; Mackenzie, Eric Thomson/L-1938-2015; Nicole, Olivier/AAZ-2865-2020	buisson, alain/0000-0002-4281-7911; Nicole, Olivier/0000-0001-9981-1820; VIVIEN, DENIS/0000-0002-7636-2185; Docagne, Fabian/0000-0003-1745-0625; MacKenzie, Eric T/0000-0003-1057-7033				AGID Y, 1991, LANCET, V337, P1321, DOI 10.1016/0140-6736(91)92989-F; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DEBROCK S, 1997, BIOCHIM BIOPHYS ACTA, V1337, P267; deLuca A, 1996, J NEUROSCI, V16, P4174; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KRIEGLSTEIN K, 1998, NEUROPROTECTIVE SIGN, P119; LEHRMANN E, 1995, EXP NEUROL, V131, P114, DOI 10.1016/0014-4886(95)90013-6; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; PREHN JHM, 1994, NEUROSCIENCE, V60, P7, DOI 10.1016/0306-4522(94)90198-8; Rose K, 1993, IN VITRO BIOL METHOD, P46; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNTON AJ, 1994, CANCER RES, V54, P1337; Tsirka SE, 1997, J NEUROSCI, V17, P543; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	32	110	113	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1683	1691		10.1096/fasebj.12.15.1683	http://dx.doi.org/10.1096/fasebj.12.15.1683			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837858				2022-12-28	WOS:000077574500010
J	Cohen, AD; Boyer, JD; Weiner, DB				Cohen, AD; Boyer, JD; Weiner, DB			Modulating the immune response to genetic immunization	FASEB JOURNAL			English	Review						immune modulation; plasmid; DNA vaccine; CpG motifs; cytokines	COLONY-STIMULATING-FACTOR; PLASMID DNA IMMUNIZATION; CELL-MEDIATED-IMMUNITY; HERPES-SIMPLEX-VIRUS; MARROW-DERIVED CELLS; NUCLEIC-ACID IMMUNIZATION; CYTOTOXIC T-LYMPHOCYTES; IN-VIVO; CPG MOTIFS; COSTIMULATORY MOLECULES	Genetic immunization, also known as DNA or polynucleotide immunization, is a novel strategy for vaccine development in which plasmid DNA encoding either individual or a collection of antigens is directly administered to a host. Such immunization leads to host expression of the delivered foreign gene, resulting in the induction of a specific immune response against the in vivo produced antigen. DNA immunization has been shown to induce protective immune responses in several infectious disease and cancer experimental model systems. Furthermore, DNA vaccines have recently entered the clinic for analysis as both prophylactic and therapeutic agents. Although the mechanisms of immunity to DNA have not yet been fully elucidated, it has become apparent that the immune response achieved by DNA vaccination is quite malleable, and can be manipulated by altering the conditions under which the vaccine is administered. Either through changing the method or location of immunization, altering the number of immunostimulatory sequences in the plasmid, altering the immunization regimen, or coadministering genes for cytokines or costimulatory molecules, one can modulate both the magnitude and orientation of the subsequent immune response. Through maximization of this feature of DNA immunization, we will likely be able to design vaccines and immunotherapeutic agents that are tailored to the correlates of protection for a particular disease, resulting in a new generation of more focused and effective immune stimulating agents.	Hosp Univ Penn, Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Weiner, DB (corresponding author), Hosp Univ Penn, Sch Med, Dept Pathol, 505 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.	dbweiner@mail.med.upenn.edu	Cohen, Adam D/F-6729-2012; Weiner, David B/H-8579-2014	Cohen, Adam/0000-0003-0939-3843				ABAI AM, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P77; Agadjanyan MG, 1997, AIDS RES HUM RETROV, V13, P1561, DOI 10.1089/aid.1997.13.1561; Angus CW, 1996, J EUKARYOT MICROBIOL, V43, pS117, DOI 10.1111/j.1550-7408.1996.tb05034.x; Armas JCG, 1996, J VIROL, V70, P7921; Bagarazzi ML, 1997, J MED PRIMATOL, V26, P27, DOI 10.1111/j.1600-0684.1997.tb00316.x; BARRY MA, 1995, NATURE, V377, P632, DOI 10.1038/377632a0; Barry MA, 1997, VACCINE, V15, P788, DOI 10.1016/S0264-410X(96)00265-4; Bliss J, 1996, J IMMUNOL, V156, P887; Bourne N, 1996, J INFECT DIS, V173, P800, DOI 10.1093/infdis/173.4.800; Boyer JD, 1997, J INFECT DIS, V176, P1501, DOI 10.1086/514148; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; Bright RK, 1996, CANCER RES, V56, P1126; Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481; Chattergoon M, 1997, FASEB J, V11, P753, DOI 10.1096/fasebj.11.10.9271360; Chattergoon MA, 1998, J IMMUNOL, V160, P5707; Chow YH, 1998, J IMMUNOL, V160, P1320; Chow YH, 1997, J VIROL, V71, P169, DOI 10.1128/JVI.71.1.169-178.1997; CONRY RM, 1995, CANCER GENE THER, V2, P33; Conry RM, 1996, GENE THER, V3, P67; Corr M, 1997, J IMMUNOL, V159, P4999; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; Donnelly JJ, 1996, LIFE SCI, V60, P163, DOI 10.1016/S0024-3205(96)00502-4; Fazio VM, 1997, RES VIROLOGY, V148, P101, DOI 10.1016/S0923-2516(97)89892-5; Feltquate DM, 1997, J IMMUNOL, V158, P2278; FULLER DH, 1994, AIDS RES HUM RETROV, V10, P1433, DOI 10.1089/aid.1994.10.1433; Fuller DH, 1997, IMMUNOL CELL BIOL, V75, P389, DOI 10.1038/icb.1997.61; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GATELY MK, 1992, CELL IMMUNOL, V143, P127, DOI 10.1016/0008-8749(92)90011-D; Geissler M, 1997, J IMMUNOL, V158, P1231; Gerloni M, 1997, NAT BIOTECHNOL, V15, P876, DOI 10.1038/nbt0997-876; Hassett DE, 1996, TRENDS MICROBIOL, V4, P307, DOI 10.1016/0966-842X(96)10048-2; HERRMANN JE, J INFECT DIS S1, V174, pS93; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; Huang AYC, 1996, J EXP MED, V183, P769, DOI 10.1084/jem.183.3.769; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Irvine KR, 1996, J IMMUNOL, V156, P238; Iwasaki A, 1997, J IMMUNOL, V158, P4591; Iwasaki A, 1997, J IMMUNOL, V159, P11; Janeway C., 1994, IMMUNOBIOLOGY IMMUNE; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KIM J, 1998, 12 WORLD AIDS C GE S, P15; Kim JJ, 1997, J IMMUNOL, V158, P816; Kim JJ, 1997, NAT BIOTECHNOL, V15, P641; Kim JJ, 1998, EUR J IMMUNOL, V28, P1089, DOI 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L; Kim JJ, 1998, J CLIN INVEST, V102, P1112, DOI 10.1172/JCI3986; Klinman DM, 1997, J IMMUNOL, V158, P3635; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1996, J LAB CLIN MED, V128, P128, DOI 10.1016/S0022-2143(96)90004-9; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kuklin N, 1997, J VIROL, V71, P3138, DOI 10.1128/JVI.71.4.3138-3145.1997; Leclerc C, 1997, CELL IMMUNOL, V179, P97, DOI 10.1006/cimm.1997.1161; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; Liu MA, 1997, VACCINE, V15, P909, DOI 10.1016/S0264-410X(96)00280-0; LOWRIE DB, 1994, VACCINE, V12, P1537, DOI 10.1016/0264-410X(94)90080-9; Lu S, 1996, J VIROL, V70, P3978, DOI 10.1128/JVI.70.6.3978-3991.1996; MACGREGOR RR, 1998, IN PRESS J INFECT DI; Maecker HT, 1997, VACCINE, V15, P1687, DOI 10.1016/S0264-410X(97)00088-1; Manickan E, 1997, CRIT REV IMMUNOL, V17, P139, DOI 10.1615/CritRevImmunol.v17.i2.20; MANICKAN E, 1995, J IMMUNOL, V155, P259; Mendoza RB, 1997, J IMMUNOL, V159, P5777; MOR G, 1995, J IMMUNOL, V155, P2039; MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113; Okada E, 1997, J IMMUNOL, V159, P3638; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; Pasquini S, 1997, IMMUNOL CELL BIOL, V75, P397, DOI 10.1038/icb.1997.62; PERTMER TM, 1995, VACCINE, V13, P1427, DOI 10.1016/0264-410X(95)00069-D; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Pisetsky DS, 1997, NAT MED, V3, P829, DOI 10.1038/nm0897-829; Prayaga SK, 1997, VACCINE, V15, P1349, DOI 10.1016/S0264-410X(97)00036-4; RAZ E, 1993, P NATL ACAD SCI USA, V90, P4523, DOI 10.1073/pnas.90.10.4523; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Sin JI, 1997, VACCINE, V15, P1827, DOI 10.1016/S0264-410X(97)88856-1; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Torres CAT, 1997, J IMMUNOL, V158, P4529; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Tsuji T, 1997, IMMUNOLOGY, V90, P1, DOI 10.1046/j.1365-2567.1997.00117.x; Tsuji T, 1997, J IMMUNOL, V158, P4008; Tuting T, 1998, J IMMUNOL, V160, P1139; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Ulmer JB, 1997, VACCINE, V15, P839, DOI 10.1016/S0264-410X(96)00256-3; Ulmer JB, 1996, IMMUNOLOGY, V89, P59, DOI 10.1046/j.1365-2567.1996.d01-718.x; Wang B, 1997, VACCINE, V15, P821; WANG B, 1995, VIROLOGY, V211, P102, DOI 10.1006/viro.1995.1383; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; WATANABE A, 1993, J IMMUNOL, V151, P2871; WILLIAMS WV, 1994, IMMUNOL RES, V13, P145, DOI 10.1007/BF02918275; Wolf SF, 1995, RES IMMUNOL, V146, P486, DOI 10.1016/0923-2494(96)83021-5; Wolff JA, 1997, NEUROMUSCULAR DISORD, V7, P314, DOI 10.1016/S0960-8966(97)00055-2; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; XIANG ZQ, 1995, VIROLOGY, V209, P569, DOI 10.1006/viro.1995.1289; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; XU D, 1995, IMMUNOLOGY, V84, P173; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; Yasutomi Y, 1996, J VIROL, V70, P678, DOI 10.1128/JVI.70.1.678-681.1996	111	144	156	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1611	1626		10.1096/fasebj.12.15.1611	http://dx.doi.org/10.1096/fasebj.12.15.1611			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837851				2022-12-28	WOS:000077574500003
J	Froy, O; Gurevitz, M				Froy, O; Gurevitz, M			Membrane potential modulators: a thread of scarlet from plants to humans	FASEB JOURNAL			English	Article						neurotoxins; structural motifs; evolution; MCD peptide	INSECT DEFENSINS; ANTIBACTERIAL PEPTIDE; PYRULARIA THIONIN; STRUCTURAL MOTIF; SCORPION TOXINS; ENDOTHELIN; CELLS; CHANNELS; COMMON; VENOM	The preservation along evolution of specific core motifs in proteins of diverse functions and taxonomic origins pinpoints a possible developmental advantage at the structural level. Such a preservation was observed in a group of membrane potential modulators including plant gamma-thionins, scorpion toxins, insect and scorpion defensins, bee venom apamin and MCD peptide, snake sarafotoxins, and human endothelins. These substances are short polypeptides of various lengths and nonhomologous sequences that affect organisms of distant phyla, Despite the structural differences, comparative analysis reveals commonality at three levels: 1) effect on membrane potential; 2) a common cysteine-stabilized a-helical (CSH) motif; and 3) similar gene organization (except for insect defensins), i.e., an intron that splits a codon toward the end of the leader sequence, We thus propose that these modulators, divided into two groups differing in their CSH motif orientation, have either diverged from two independent ancestors or have evolved by gene diversification via exon shuffling and subsequent modifications. To enforce protein synthesis through the secretory pathway and enable disulfide bond formation and secretion, insertion sites downstream of preexisting leader sequences have been a prerequisite. What seems advantageous for evolution, may also be exploited in attempts to 'accelerate evolution' by protein design using the conserved CSH core as a suitable scaffold for reshaping molecular exteriors.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gurevitz, M (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.		Froy, Oren/C-3550-2009					ANDERSEN NH, 1992, BIOCHEMISTRY-US, V31, P1280, DOI 10.1021/bi00120a003; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DEBIN JA, 1993, AM J PHYSIOL, V264, pC361, DOI 10.1152/ajpcell.1993.264.2.C361; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; EVANS J, 1989, P NATL ACAD SCI USA, V86, P5849, DOI 10.1073/pnas.86.15.5849; Garcia-Olmedo F., 1989, OXFORD SURV PLANT MO, V6, P31; GMACHL M, 1995, J BIOL CHEM, V270, P12704, DOI 10.1074/jbc.270.21.12704; GUALDIE J, 1978, EUR J BIOCHEM, V83, P405; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; KARUNANANDAA B, 1994, PLANT MOL BIOL, V26, P459, DOI 10.1007/BF00039555; KOBAYASHI Y, 1991, BIOPOLYMERS, V31, P1213, DOI 10.1002/bip.360311009; KUMAR NV, 1988, BIOPHYS CHEM, V31, P113, DOI 10.1016/0301-4622(88)80015-2; LANDAN G, 1991, TOXICON, V29, P237, DOI 10.1016/0041-0101(91)90108-4; LIN WW, 1991, J PHARMACOL EXP THER, V257, P1053; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MENDEZ E, 1990, EUR J BIOCHEM, V194, P533, DOI 10.1111/j.1432-1033.1990.tb15649.x; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MILLS RG, 1994, J BIOL CHEM, V269, P23413; PEASE JHB, 1988, BIOCHEMISTRY-US, V27, P8491, DOI 10.1021/bi00422a029; SIMONSON MS, 1990, BIOCHIM BIOPHYS ACTA, V1055, P63, DOI 10.1016/0167-4889(90)90091-Q; TAKASAKI C, 1988, TOXICON, V26, P543, DOI 10.1016/0041-0101(88)90234-6; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; VERNON LP, 1992, J TOXICOL-TOXIN REV, V11, P169, DOI 10.3109/15569549209115819; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG CM, 1994, J RECEPTOR RES, V14, P423, DOI 10.3109/10799899409101513; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810	33	51	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1793	1796		10.1096/fasebj.12.15.1793	http://dx.doi.org/10.1096/fasebj.12.15.1793			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837870				2022-12-28	WOS:000077574500022
J	Hartsfield, CL; Alam, J; Choi, AMK				Hartsfield, CL; Alam, J; Choi, AMK			Transcriptional regulation of the heme oxygenase 1 gene by pyrrolidine dithiocarbamate	FASEB JOURNAL			English	Article						antioxidants; gene transcription; activator protein 1; gene expression	NF-KAPPA-B; LUNG INJURY; INTRACELLULAR LEVEL; INTACT-CELLS; BASAL LEVEL; AP-1; INDUCTION; ANTIOXIDANTS; EXPRESSION; ACTIVATION	Heme oxygenase 1 (HO-1), a stress response protein, is highly induced in response tn various agents causing oxidative stress including ultraviolet irradiation, sodium arsenite, hyperoxia, and glutathione depletors, We recently characterized the induction of HO-1 gene expression by nitric oxide (NO) and postulated that the addition of an antioxidant, such as pyrrolidine dithiocarbamate (PDTC), would attenuate HO-1 induction in response to NO, Surprisingly, PDTC was a very potent inducer of HO-1 gene expression, causing increases in the steady-state level of HO-1 mRNA in rat aortic vascular smooth muscle (aVSM) cells in a time- and concentration-dependent manner, PDTC-induced HO-1 gene expression correlated with a rise in protein levels and was dependent on both increased gene transcription and mRNA stability, Deletional analyses of the proximal promoter and the entire 5' distal upstream region of the HO-1 gene (11 kbp) were performed including the two 5' distal enhancers, SX2 and AB1, located 4 kbp and 10 kbp upstream of the transcription site, respectively. Plasmid vectors containing various fragments of this region were linked to a chloramphenicol acetyl transferase (CAT) reporter gene, stably transfected into RAW 264.7 cells, and transfectants were assayed for CAT activity after treatment with PDTC, We show that the AB1 distal enhancer plays an important role in mediating PDTC-induced HO-1 gene transcription, Mutational analyses of this enhancer showed that the activator protein 1 (AP-1) regulatory element is crucial for PDTC-induced HO-1 gene transcription, Electrophoretic mobility shift assays supported this data, demonstrating increased AP-1 DNA binding activity after PDTC treatment, Taken together, our data demonstrate that the antioxidant PDTC enhances HO-1 gene transcription and that the induction appears to be mediated by AP-1 activation of regulatory elements specific to the distal enhancer AB1.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Connecticut VA HealthCare Syst, W Haven, CT 06516 USA; Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Louisiana State Univ, Dept Biochem & Mol Biol, Ctr Med, New Orleans, LA 70121 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Johns Hopkins University; Ochsner Health System; Louisiana State University System	Choi, AMK (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St,LCI 105, New Haven, CT 06520 USA.	augus-tine.choi@yale.edu	Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NHLBI NIH HHS [R29 HL-55330] Funding Source: Medline; NIAID NIH HHS [R01 AI-42365] Funding Source: Medline; NIDDK NIH HHS [DK 43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; delArco PG, 1996, J BIOL CHEM, V271, P26335; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nathens AB, 1997, AM J RESP CELL MOL, V17, P608, DOI 10.1165/ajrcmb.17.5.2661; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; Otterbein L, 1997, AM J PHYSIOL-LUNG C, V272, pL268; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P2865; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	32	88	88	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1675	1682		10.1096/fasebj.12.15.1675	http://dx.doi.org/10.1096/fasebj.12.15.1675			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837857				2022-12-28	WOS:000077574500009
J	Widegren, U; Jiang, XJ; Krook, A; Chibalin, AV; Bjornholm, M; Tally, M; Roth, RA; Henriksson, J; Wallberg-Henriksson, H; Zierath, JR				Widegren, U; Jiang, XJ; Krook, A; Chibalin, AV; Bjornholm, M; Tally, M; Roth, RA; Henriksson, J; Wallberg-Henriksson, H; Zierath, JR			Divergent effects of exercise on metabolic and mitogenic signaling pathways in human skeletal muscle	FASEB JOURNAL			English	Article						insulin action; mitogen-activated protein kinase; Akt kinase; calcium-dependent tyrosine kinase	PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; GLUCOSE-TRANSPORT CAPACITY; FOCAL ADHESION KINASE; TYROSINE KINASE; MAP-KINASE; C-JUN; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; STIMULATED GLUCOSE	The molecular signaling mechanisms by which muscle contractions lead to changes in glucose metabolism and gene expression remain largely undefined. We assessed whether exercise activates MAP kinase proteins (ERK1/2, SEK1, and p38 MAP kinase) as well as Akt and PYK2 in skeletal muscle from healthy volunteers obtained during and after one-leg cycle ergometry at similar to 70% VO2max. Exercise led to a marked increase in ERK1/2 phosphorylation, which rapidly decreased to resting levels upon recovery. Exercise increased phosphorylation of SEK1 and p38 MAP kinase to a lesser extent than ERK1/2, In contrast to ERK1/2, p38 MAP kinase phosphorylation was increased in nonexercised muscle upon cessation of exercise. Phosphorylation of the transcription factor CREB was increased in nonexercised muscle upon cessation of exercise. Exercise did not activate Akt or increase tyrosine phosphorylation of PYK2. Thus, exercise has divergent effects on parallel MAP kinase pathways, of which only p38 demonstrated a systemic response. However, our data do not support a role of Akt or PYK2 in exercise/contraction-induced signaling in human skeletal. Activation of the different MAP kinase pathways by physical exercise appears to be important in the regulation of transcriptional events in skeletal muscle.	Karolinska Hosp, Dept Clin Physiol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, SE-11486 Stockholm, Sweden; Univ Stockholm, Dept Human Biol, Coll Phys Educ & Sports, SE-11486 Stockholm, Sweden; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University; Stanford University	Zierath, JR (corresponding author), Karolinska Hosp, Dept Clin Physiol, SE-17176 Stockholm, Sweden.		Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Zierath, Juleen/0000-0001-6891-7497; Chibalin, Alexander/0000-0002-6339-6271	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BALON TW, 1990, AM J PHYSIOL, V258, pE92, DOI 10.1152/ajpendo.1990.258.1.E92; BANG P, 1991, ACTA ENDOCRINOL-COP, V124, P620, DOI 10.1530/acta.0.1240620; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V3, P1468; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; Boudewijn MT, 1995, NATURE, V376, P599; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLAUSEN T, 1975, BIOCHIM BIOPHYS ACTA, V375, P292, DOI 10.1016/0005-2736(75)90197-2; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLOSZY JO, 1967, J GEN PHYSIOL, V50, P551, DOI 10.1085/jgp.50.3.551; Host HH, 1998, J APPL PHYSIOL, V84, P798, DOI 10.1152/jappl.1998.84.3.798; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Krook A, 1997, DIABETES, V46, P2110, DOI 10.2337/diabetes.46.12.2110; Krook A, 1998, DIABETES, V47, P1281, DOI 10.2337/diabetes.47.8.1281; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Lowry OH, 1972, FLEXIBLE SYSTEM ENZY, P174; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; POVOA G, 1984, ACTA ENDOCRINOL-COP, V107, P563, DOI 10.1530/acta.0.1070563; REN JM, 1994, J BIOL CHEM, V269, P14396; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; RICHTER EA, 1982, J CLIN INVEST, V69, P785, DOI 10.1172/JCI110517; RODGERS MA, 1988, DIABETES CARE, V11, P613; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shepherd PR, 1997, DIABETOLOGIA, V40, P1172, DOI 10.1007/s001250050803; STUGILL TW, 1988, NATURE, V334, P715; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TREADWAY JL, 1989, AM J PHYSIOL, V256, pE138, DOI 10.1152/ajpendo.1989.256.1.E138; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; WALLBERGHENRIKS.H, 1987, ACTA PHYSL SCAND S, V131, P564; WALLBERGHENRIKSSON H, 1986, ACTA PHYSIOL SCAND, V127, P39, DOI 10.1111/j.1748-1716.1986.tb07873.x; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; WONG TS, 1990, J APPL PHYSIOL, V69, P1718, DOI 10.1152/jappl.1990.69.5.1718; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN MH, 1994, NATURE, V372, P798; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUN JH, 1994, AM J PHYSIOL-REG I, V267, pR888, DOI 10.1152/ajpregu.1994.267.4.R888; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zierath Juleen R., 1995, Acta Physiologica Scandinavica, V155, P1	81	188	197	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1379	1389		10.1096/fasebj.12.13.1379	http://dx.doi.org/10.1096/fasebj.12.13.1379			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761781				2022-12-28	WOS:000076402000013
J	Monsonego, A; Mizrahi, T; Eitan, S; Moalem, G; Bardos, H; Adany, R; Schwartz, M				Monsonego, A; Mizrahi, T; Eitan, S; Moalem, G; Bardos, H; Adany, R; Schwartz, M			Factor XIIIa as a nerve-associated transglutaminase	FASEB JOURNAL			English	Article						FXIIIa; thrombin; CNS; PNS; nerve regeneration	COAGULATION-FACTOR-XIII; PERIPHERAL-NERVE; BLOOD-COAGULATION; CELL-DEATH; PROTEASE NEXIN-1; CROSS-LINKING; INJURY; OLIGODENDROCYTES; SUBUNIT; NEURONS	Recent findings have led to changes in the traditional concept of nerve recovery, including the realization that injured nerves, like any other injured tissue, need the assistance of blood-derived cells and factors in order to heal. We show that factor XIIIa (FXIIIa, the potentially active a(2)-subunit of factor XIII), an enzyme that participates in blood coagulation by stabilizing the fibrin clot, is also active in the nervous system where it may play a key role in the healing of injured tissue. We demonstrate that the plasma, macrophages and nerves of fish contain a 55 kDa form of transglutaminase that cross-reacts immunologically with the a-subunit of FXIII in mammals (80 kDa). The fish enzyme in the plasma, unlike its mammalian counterpart, is active, pointing to a difference in control of the coagulation pathway in the two species. Analysis of FXIIIa expression in mammalian neural tissues and their response to injury revealed high levels of the enzyme in media conditioned by peripheral nerves as compared with medium conditioned by nerves of the central nervous system. Furthermore, similarity was observed in the postinjury behavior of FXIIIa in regenerating nerve tissues (peripheral nervous system of mammals and the central nervous system of fish). We suggest that the postinjury level of factor XIIIa in the nervous system may be related to the tissue's regenerative capacity, and that FXIIIa may therefore be a link underlying a possible association between the processes of blood coagulation and nerve healing.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Dept Hyg & Epidemiol, Debrecen, Hungary	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnschwar@weizmann.weizmann.ac.il	Moalem-Taylor, Gila/C-3116-2008; Helga, Bárdos/AAH-4049-2021	Moalem-Taylor, Gila/0000-0003-3828-9527; 				Adany R, 1996, THROMB HAEMOSTASIS, V76, P74; Adany Roza, 1996, Seminars in Thrombosis and Hemostasis, V22, P399, DOI 10.1055/s-2007-999038; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DEWITT DA, 1994, BRAIN RES, V656, P205, DOI 10.1016/0006-8993(94)91386-2; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; KIESSELBACH TH, 1972, ANN NY ACAD SCI, V202, P318, DOI 10.1111/j.1749-6632.1972.tb16344.x; LAI TS, 1994, PROTEIN EXPRES PURIF, V5, P125, DOI 10.1006/prep.1994.1019; LIU DX, 1994, J NEUROCHEM, V62, P37; LORAND L, 1981, METHOD ENZYMOL, V80, P333; Mahoney SA, 1996, BIOCHEM BIOPH RES CO, V224, P147, DOI 10.1006/bbrc.1996.0998; MANN KG, 1993, METHOD ENZYMOL, V222, P1; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; MUSZBEK L, 1985, THROMB RES, V37, P401, DOI 10.1016/0049-3848(85)90069-6; Muszbek L, 1996, CRIT REV CL LAB SCI, V33, P357, DOI 10.3109/10408369609084691; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; Pike CJ, 1996, J NEUROCHEM, V66, P1374; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHWARTZ M, 1995, MOL MED TODAY, V1, P60, DOI 10.1016/S1357-4310(95)92274-1; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9; SPIEGLER OL, 1996, FASEB J, V10, P1296; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; TOIDA M, 1995, HISTOCHEM J, V27, P440; TOIDA M, 1995, HISTOCHEM J, V27, P449; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720	36	17	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1163	1171		10.1096/fasebj.12.12.1163	http://dx.doi.org/10.1096/fasebj.12.12.1163			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737719				2022-12-28	WOS:000075738500011
J	Baccetti, B; Collodel, G; Costantino-Ceccarini, E; Eshkol, A; Gambera, L; Moretti, E; Strazza, M; Piomboni, P				Baccetti, B; Collodel, G; Costantino-Ceccarini, E; Eshkol, A; Gambera, L; Moretti, E; Strazza, M; Piomboni, P			Localization of human follicle-stimulating hormone in the testis	FASEB JOURNAL			English	Article						FSHR mRNA; FSH antibody; human testis cells; mouse testis cells; ultrastructure	RECEPTOR MESSENGER-RNA; RAT TESTIS; FSH RECEPTOR; IMMUNOCYTOCHEMICAL LOCALIZATION; CELL-PROLIFERATION; SERTOLI CELLS; EXPRESSION; INTERNALIZATION; CLONING	Localization of the follicle-stimulating hormone (FSH) molecule and its receptor (FSHR), as well as the role of FSH in Sertoli cell mitosis and maturation, has been demonstrated by several investigators in human and murine testis by detecting the localization of anti-FSH antibodies or [I-131]-labeled FSH and by detecting FSH receptor (FSHR) mRNA by in situ hybridization, or FSHR by anti-FSHR antibodies. The presence of FSH in germinal cells is controversial or, in humans, excluded. We have investigated the distribution of the human FSH molecule and its receptor in human and mouse testicular cells under different experimental conditions, at the submicroscopical level, by using a better antigenicity conservative procedure. Thus, the distribution of FSH and of the messenger RNA for its receptor in Sertoli cells has now been clarified, In germinal cells, our observations demonstrate the presence of FSH and the FSHR mRNA: the first on the plasma membrane and in endocytotic vesicles, and the second scattered in the cytoplasm. The cells presenting the higher amount of positivity ranged from spermatogonia to spermatocytes, including round spermatids. Penetration was by the endocytosis via membrane vesicles in which the FSHR is present, whereas its messenger is largely present in the cytoplasm and is responsible for the binding and subsequent internalization of the FSH molecule. As a control, human FSH was administered in vitro to the Y1 mouse cell line, which was stably transfected with cDNA for FSHR and devoid of endogenous FSH. The FSH molecule has been localized by monoclonal antibodies on plasma membranes and vesicles, and the FSHR mRNA was found scattered in the cytoplasm after in situ hybridization. We can now conclude that FSH is present in Sertoli cells and in round germinal cells, both expressing the FSHR. FSH penetrates in a similar way in both kinds of cells via endocytosis, and is therefore subsequently localized in the same membranous organelles.	Univ Siena, Inst Gen Biol, I-53100 Siena, Italy; CNR, Ctr Study Germinal Cells, I-53100 Siena, Italy; Ares Serv SA, CH-1211 Geneva 20, Switzerland	University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Baccetti, B (corresponding author), Univ Siena, Inst Gen Biol, Via T Pendola 62, I-53100 Siena, Italy.		piomboni, paola/AAB-9868-2019; collodel, giulia/AAW-5217-2021	collodel, giulia/0000-0003-1587-0159; Moretti, Elena/0000-0002-9467-0501				BACCETTI B, 1995, ZYGOTE, V3, P207, DOI 10.1017/S0967199400002604; BOCKERS TM, 1994, CELL TISSUE RES, V278, P595; BOITANI C, 1993, BIOL REPROD, V48, P761, DOI 10.1095/biolreprod48.4.761; CARLEMALM E, 1985, J MICROSC-OXFORD, V140, P55, DOI 10.1111/j.1365-2818.1985.tb02660.x; CASTRO AE, 1970, P SOC EXP BIOL MED, V133, P582; CASTRO AE, 1972, J ENDOCRINOL, V52, P129, DOI 10.1677/joe.0.0520129; DATTATREYAMURTY B, 1993, ENDOCRINOLOGY, V133, P1593, DOI 10.1210/en.133.4.1593; Fritz I., 1978, BIOCHEM ACTION HORM, V5, P249; HECKERT L, 1993, RECENT PROG HORM RES, V48, P61; HECKERT LL, 1991, MOL ENDOCRINOL, V5, P670, DOI 10.1210/mend-5-5-670; HON CA, 1983, AM J ANAT, V167, P441, DOI 10.1002/aja.1001670403; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KLIESCH S, 1992, MOL CELL ENDOCRINOL, V84, pR45, DOI 10.1016/0303-7207(92)90039-9; KULKARNI SA, 1992, ARCH ANDROLOGY, V29, P87, DOI 10.3109/01485019208987713; MANCINI RE, 1967, J HISTOCHEM CYTOCHEM, V15, P516, DOI 10.1177/15.9.516; MEHTA MK, 1995, INT J FERTIL MENOP S, V40, P39; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; ORTH J, 1977, ENDOCRINOLOGY, V101, P262, DOI 10.1210/endo-101-1-262; ORTH J, 1978, ENDOCRINOLOGY, V103, P1944, DOI 10.1210/endo-103-5-1944; ORTH JM, 1984, ENDOCRINOLOGY, V115, P1248, DOI 10.1210/endo-115-4-1248; Sallese M, 1997, J BIOL CHEM, V272, P10188; SHIMIZU A, 1989, J BIOL CHEM, V264, P13632; SHIMIZU A, 1987, ENDOCRINOL JAPON, V34, P431; WAHLSTROM T, 1983, J CLIN ENDOCR METAB, V57, P825, DOI 10.1210/jcem-57-4-825; YOON DJ, 1987, ACTA ENDOCRINOL-COP, V116, P333, DOI 10.1530/acta.0.1160333	25	32	36	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1998	12	11					1045	1054		10.1096/fasebj.12.11.1045	http://dx.doi.org/10.1096/fasebj.12.11.1045			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707177				2022-12-28	WOS:000075372600015
J	Dollinger, MM; Howie, SEM; Plevris, JN; Graham, AM; Hayes, PC; Harrison, DJ				Dollinger, MM; Howie, SEM; Plevris, JN; Graham, AM; Hayes, PC; Harrison, DJ			Intrahepatic proliferation of 'naive' and 'memory' T cells during liver allograft rejection: primary immune response within the allograft	FASEB JOURNAL			English	Article						T lymphocytes; liver allograft rejection; transplantation; leukocyte	RENAL-ALLOGRAFTS; RECEPTOR; TRANSPLANTATION; INFILTRATION; EXPRESSION; APOPTOSIS; CD45RO; ALPHA	Liver allograft rejection is mediated by a primary response of T lymphocytes, followed by infiltration of the graft with a mixed inflammatory reaction. Using single and double label immunocytochemistry, we examined the proliferation index and the phenotype of leukocytes on liver biopsies from 10 patients with acute rejection before and after treatment with i.v. steroids, 10 patients with chronic rejection, 10 patients without rejection posttransplant, and 15 nongrafted, nonimmunosuppressed patients. Proliferation of mononuclear leukocytes (assessed by expression of Ki-67, a nuclear antigen associated with the cell cycle) inside the allograft was a prominent feature of acute and chronic rejection and was down-regulated by steroid treatment. Leukocytes in cell cycle were located predominantly in the portal tracts at the site of the inflammatory infiltrate. The majority of 'naive' (CD45RA+) and 'memory' (CD45RO+) CD4+ T lymphocytes were also periportally distributed. In contrast, CD8+ T lymphocytes, CD57+ natural killer cells, and CD68+ macrophages were located intraparenchymally throughout the liver lobules, whereas CD20+ B lymphocytes were only present in some of the portal tracts. Predominantly CD4+ and occasionally CD8+ lymphocytes were proliferating (assessed by double staining). The proliferating CD4+ cells were of both naive (CD4+, CD45RA+) and memory (CD4+, CD45RO+) phenotypes. To our knowledge, this is the first description of proliferating naive T lymphocytes in situ in Liver allografts. These findings suggest that there may be a primary immune response generated within the allograft as well as in draining lymphatic tissue. This implicates not only intrahepatic proliferation of T lymphocytes as a prominent feature of rejection, but also suggests that the liver has a special immunological status comparable to that of lymphatic tissue.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Royal Infirm, Dept Med, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Dollinger, MM (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	M.Dollinger@ed.ac.uk	Plevris, John N/O-3517-2014	harrison, david/0000-0001-9041-9988				ABBAS AK, 1994, CELLULAR MOL IMMUNOL, P431; BALAN V, 1997, HEPATOLOGY S4, V26, pA124; Bianchi E, 1997, IMMUNOL TODAY, V18, P586, DOI 10.1016/S0167-5699(97)01162-6; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; Coates PJ, 1996, J PATHOL, V178, P71; Collins C, 1996, EUR J IMMUNOL, V26, P3114, DOI 10.1002/eji.1830261243; Crispe IN, 1996, IMMUNOL TODAY, V17, P522, DOI 10.1016/S0167-5699(96)80906-6; DEMETRIS AJ, 1991, AM J PATHOL, V138, P609; Dollinger M. M., 1998, Journal of Hepatology, V28, P61, DOI 10.1016/S0168-8278(98)80442-X; Dollinger M. M., 1997, Journal of Hepatology, V26, P149; Fabre JW, 1996, IMMUNOL REV, V154, P21, DOI 10.1111/j.1600-065X.1996.tb00928.x; Fisher L R, 1995, Liver Transpl Surg, V1, P10, DOI 10.1002/lt.500010104; FORBES RDC, 1986, J EXP MED, V164, P1239, DOI 10.1084/jem.164.4.1239; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GERDES J, 1984, J IMMUNOL, V133, P1710; HAYRY P, 1983, TRANSPLANTATION CLIN, V15, P124; IBRAHIM S, 1993, AM J PATHOL, V142, P1794; IBRAHIM S, 1995, TRANSPLANTATION, V59, P724, DOI 10.1097/00007890-199503150-00015; ITOH N, 1993, J IMMUNOL, V151, P621; KAMADA N, 1981, NATURE, V292, P840, DOI 10.1038/292840a0; Knolle PA, 1997, HEPATOLOGY, V26, P1267; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; LUDWIG J, 1995, HEPATOLOGY, V22, P648; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MAKINO Y, 1993, J EXP MED, V177, P1399, DOI 10.1084/jem.177.5.1399; NEMLANDER A, 1982, J EXP MED, V156, P1087, DOI 10.1084/jem.156.4.1087; NEUBERGER J, 1995, J HEPATOL, V23, P54; OppenheimerMarks N, 1997, IMMUNOL TODAY, V18, P456, DOI 10.1016/S0167-5699(97)82723-5; Pape KA, 1997, IMMUNOL REV, V156, P67, DOI 10.1111/j.1600-065X.1997.tb00959.x; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; QUIAN S, 1997, J IMMUNOL, V158, P4654; SATO K, 1995, J EXP MED, V182, P759, DOI 10.1084/jem.182.3.759; SAYEGH MH, 1994, TRANSPLANTATION, V58, P125; Starzl TE, 1996, IMMUNOL TODAY, V17, P577, DOI 10.1016/S0167-5699(96)10070-0; SZEKANECZ Z, 1992, J CELL SCI, V101, P885; VONWILLEBRAND E, 1983, TRANSPLANT P, V15, P1195; WOO J, 1994, TRANSPLANTATION, V58, P484, DOI 10.1097/00007890-199408270-00015	38	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					939	947		10.1096/fasebj.12.11.939	http://dx.doi.org/10.1096/fasebj.12.11.939			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707166				2022-12-28	WOS:000075372600004
J	Hermann, M; Lindstedt, KA; Foisner, R; Morwald, S; Mahon, MG; Wandl, R; Schneider, WJ; Nimpf, J				Hermann, M; Lindstedt, KA; Foisner, R; Morwald, S; Mahon, MG; Wandl, R; Schneider, WJ; Nimpf, J			Apolipoprotein A-I production by chicken granulosa cells	FASEB JOURNAL			English	Article						follicle; vitellogenesis; oocyte	DENSITY-LIPOPROTEIN RECEPTOR; GALLUS-DOMESTICUS; OOCYTE RECEPTOR; PROTEIN; VITELLOGENIN; BIOSYNTHESIS; CHOLESTEROL; DEPOSITION; METABOLISM; SECRETION	In avian species such as the chicken, development of the oocyte is associated with massive deposition of yolk in this cell. Oocytes grow within the follicle, a compartment consisting of a very specialized set of cells and acellular structures. The oocyte is surrounded by the perivitelline layer and granulosa cells, which are separated from the thecae by a pronounced basement membrane. In addition to the production of yolk precursors in the liver, we have long implied that cells within the follicle make a direct contribution to the growth of the oocyte. Here we show that chicken granulosa cells express and actively secrete apolipoprotein A-I (apoA-I) as a part of particles with very high density. The ganulosa cell-derived, apoA-I-containing material is different from the small portion of yolk high density lipoprotein that arises via transfer from the peripheral circulation. We propose that the ApoA-I-containing particles secreted by granulosa cells 1) support the growth of the rapidly growing germ cell, possibly by direct lipid transfer to the plasma membrane of the oocyte, and/or 2) deliver cholesteryl eaters to the steroid-producing cells of the theca layer. These findings are discussed with respect to the proposed functions of apoE (an apolipoprotein not found in chicken) within the mammalian follicle.-Hermann, M., Lindstedt, K. A., Foisner, R., Morwald, S., Mahon, M. G., Wandl, R., Schneider, W. J., Nimpf, J. Apolipoprotein A-I production by chicken granulosa cells.	Bioctr, Dept Mol Genet, A-1030 Vienna, Austria; Univ Vienna, Vienna, Austria; Bioctr, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna; University of Vienna	Nimpf, J (corresponding author), Bioctr, Dept Mol Genet, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.	JNIMPF@mol.univie.ac.at	Foisner, Roland/AAD-1833-2019	Hermann, Marcela/0000-0003-2298-4269; Foisner, Roland/0000-0003-4734-4647; Nimpf, Johannes/0000-0002-9273-3492				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ASEM EK, 1993, POULTRY SCI, V72, P1961, DOI 10.3382/ps.0721961; BAIN JM, 1969, AUST J BIOL SCI, V22, P653; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; DYER CA, 1988, J BIOL CHEM, V263, P10965; ETCHES RJ, 1990, J EXP ZOOL, P112, DOI 10.1002/jez.1402560419; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; GORDON DA, 1989, J INVEST DERMATOL, V92, P96, DOI 10.1111/1523-1747.ep13071302; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; Lindstedt KA, 1997, J BIOL CHEM, V272, P30221, DOI 10.1074/jbc.272.48.30221; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SCHULER LA, 1979, J BIOL CHEM, V254, P8662; SHEN XY, 1993, CELL TISSUE RES, V272, P459, DOI 10.1007/BF00318552; SMITH LC, 1978, ANNU REV BIOCHEM, V47, P751, DOI 10.1146/annurev.bi.47.070178.003535; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; TARUGI P, 1991, J BIOL CHEM, V266, P7714; VIEIRA PM, 1995, J LIPID RES, V36, P601; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WYNE KL, 1989, J BIOL CHEM, V264, P981	35	23	24	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					897	903		10.1096/fasebj.12.10.897	http://dx.doi.org/10.1096/fasebj.12.10.897			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657529				2022-12-28	WOS:000074580100014
J	Izzotti, A; Balansky, RM; Blagoeva, PM; Mircheva, ZI; Tulimiero, L; Cartiglia, C; De Flora, S				Izzotti, A; Balansky, RM; Blagoeva, PM; Mircheva, ZI; Tulimiero, L; Cartiglia, C; De Flora, S			DNA alterations in rat organs after chronic exposure to cigarette smoke and/or ethanol ingestion	FASEB JOURNAL			English	Article						alcohol; synergisms; DNA adducts; lung cancer; esophageal cancer; heart diseases	N-ACETYLCYSTEINE; TOBACCO-SMOKE; P-32-POSTLABELING ANALYSIS; ALVEOLAR MACROPHAGES; ALCOHOL-CONSUMPTION; ADDUCTS; DAMAGE; LUNG; CARCINOGENS; CANCER	In spite of the epidemiological evidence supporting a synergism between alcohol consumption and cigarette smoking in the pathogenesis of cancers of the aerodigestive tract, there is a paucity of experimental studies evaluating the effects of these agents under well-controlled conditions and exploring the mechanisms involved. We exposed groups of female BD6 rats, aged 8 months, to ethanol (5% in drinking water for 8 consecutive months) and/or whole-body to mainstream cigarette smoke (1 h/day, 5 days/week for 8 months). DNA was purified from different organs and analyzed for the presence of DNA-protein crosslinks and P-32-postlabeled DNA adducts after butanol enrichment. No significant increase of DNA-protein crosslinks, compared to untreated controls, was induced by any treatment in liver, lung, or heart. 'Spontaneous' nucleotidic modifications were detected by P-32-postlabeling in organs of untreated rats, with the highest levels occurring in the heart. Ingestion of ethanol did not affect DNA adduct levels in any of the organs examined: esophagus, liver, lung, and heart. Exposure to cigarette smoke induced formation of DNA adducts in the lung and heart, but not in the esophagus or liver. The combined ingestion of ethanol resulted in a significant formation of smoke-related DNA adducts in the esophagus and in their further, dramatic increase in the heart. It thus appears that ethanol consumption increases the bioavailability of DNA binding smoke components in the upper digestive tract and favors their systemic distribution. The mechanisms responsible for the interaction between ethanol and smoke and for the selective localization of DNA alterations in different organs are discussed. Formation of DNA adducts in the organs examined may be relevant in the pathogenesis of lung and esophageal cancers as well as in the pathogenesis of other types of chronic degenerative diseases, such as chronic obstructive pulmonary diseases and cardiomyopathies.	Univ Genoa, Inst Hyg & Prevent Med, I-16132 Genoa, Italy; Natl Oncol Ctr, Sofia 1756, Bulgaria	University of Genoa; National Oncology Center - Bulgaria	De Flora, S (corresponding author), Univ Genoa, Inst Hyg & Prevent Med, Via Pastore 1, I-16132 Genoa, Italy.			izzotti, alberto/0000-0002-8588-0347				ALEXANDROV K, 1992, CANCER RES, V52, P6248; ANDERSON LM, 1995, ALCOHOL, V12, P97, DOI 10.1016/0741-8329(94)00089-1; BAGNASCO M, 1992, MUTAGENESIS, V7, P295, DOI 10.1093/mutage/7.4.295; Balansky R, 1996, CANCER RES, V56, P1642; BALANSKY RB, 1992, CANCER LETT, V64, P123, DOI 10.1016/0304-3835(92)90072-4; BALANSKY RM, 1989, MUTAT RES, V223, P1, DOI 10.1016/0165-1218(89)90056-6; BALANSKY RM, 1993, CANCER LETT, V72, P183, DOI 10.1016/0304-3835(93)90127-U; BALANSKY RM, 1988, MUTAT RES, V208, P237, DOI 10.1016/0165-7992(88)90067-X; BALANSKY RM, 1987, MUTAT RES, V188, P13, DOI 10.1016/0165-1218(87)90109-1; BARTSCH H, 1986, ANTIMUTAGENESIS ANTI, V39, P87; BLOT WJ, 1992, CANCER RES, V52, pS2119; CARMICHAEL PL, 1992, CARCINOGENESIS, V13, P1127, DOI 10.1093/carcin/13.7.1127; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; Chen LH, 1996, BIOCHEM ARCH, V12, P95; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; DEFLORA S, 1995, MUTAGENESIS, V10, P47; FOILES PG, 1989, CARCINOGENESIS, V10, P1429, DOI 10.1093/carcin/10.8.1429; GAIROLA CG, 1991, ENVIRON MOL MUTAGEN, V17, P253, DOI 10.1002/em.2850170406; GAUBATZ JW, 1986, J MOL CELL CARDIOL, V18, P1317, DOI 10.1016/S0022-2828(86)80435-7; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUPTA RC, 1985, CANCER RES, V45, P5656; *INT AG RES CANC, 1986, IARC MON EV CARC RIS, V44; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; IZZOTTI A, 1991, CARCINOGENESIS, V12, P1281, DOI 10.1093/carcin/12.7.1281; IZZOTTI A, 1995, CARCINOGENESIS, V16, P669, DOI 10.1093/carcin/16.3.669; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; IZZOTTI A, 1998, IN PRES FREE RAD RES; JOHNSON KA, 1992, INT J ADDICT, V27, P749, DOI 10.3109/10826089209068767; KNASMULLER S, 1994, CARCINOGENESIS, V15, P263, DOI 10.1093/carcin/15.2.263; LEWTAS J, 1993, ENV HLTH PERSPECT, V99, P88; LIEBER CS, 1987, MUTAT RES, V186, P201, DOI 10.1016/0165-1110(87)90004-2; MISSLBECK N, 1986, DIET NUTRITION CANCE, V2, P101; MUFTI SI, 1988, BIOCHEM BIOPH RES CO, V152, P423, DOI 10.1016/S0006-291X(88)80731-9; MUFTI SI, 1989, CARCINOGENESIS, V10, P303, DOI 10.1093/carcin/10.2.303; Muller T, 1997, CARCINOGENESIS, V18, P295, DOI 10.1093/carcin/18.2.295; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; RANDERATH E, 1988, CARCINOGENESIS, V9, P75, DOI 10.1093/carcin/9.1.75; ROTHMAN KJ, 1980, PREV MED, V9, P174, DOI 10.1016/0091-7435(80)90072-9; SWANN PF, 1987, MUTAT RES, V186, P261, DOI 10.1016/0165-1110(87)90008-X; TSUSUMI M, 1989, HEPATOLOGY, V10, P437; WronskaNofer T, 1997, MUTAT RES-GEN TOX EN, V392, P229, DOI 10.1016/S1383-5718(97)00067-3; ZHITKOVICH A, 1992, CARCINOGENESIS, V13, P1485, DOI 10.1093/carcin/13.8.1485	44	45	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					753	758		10.1096/fasebj.12.9.753	http://dx.doi.org/10.1096/fasebj.12.9.753			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619454	Bronze			2022-12-28	WOS:000074011000015
J	Bailey, JM				Bailey, JM			RNA-directed amino acid homochirality	FASEB JOURNAL			English	Article						aminoacylation; protein synthesis; biopolymer; chiroselection; aminoacyl-tRNA synthase translation; L-amino acids; evolution; codon; stereoisomerism	STEREOSELECTIVE AMINOACYLATION; SYNTHETASES; ENZYME; LIFE	The phenomenon of L-amino acid homochirality was analyzed on the basis that protein synthesis evolved in an environment in which ribose nucleic acids preceded proteins, so that selection of L-amino acids may have arisen as a consequence of the properties of the RNA molecule, Aminoacylation of RNA is the primary mechanism for selection of amino acids for protein synthesis, and models of this reaction with both D-and L-amino acids have been constructed, It was confirmed, as observed by others, that the aminoacylation of RNA by amino acids in free solution is not predictably stereoselective, However, when the RNA molecule is constrained on a surface (mimicking prebiotic surface monolayers), it becomes automatically selective for the L-enantiomers, Conversely, L-ribose RNA would have been selective for the D-isomers, Only the 2' aminoacylation of surface-bound RNA would have been stereoselective, This finding may explain the origin of the redundant 2' aminoacylation still undergone by a majority of today's amino acids before conversion to the 3' species required for protein synthesis, It is concluded that L-amino acid homochirality was predetermined by the prior evolution of D-ribose RNA and probably was chirally directed by the orientation of early RNA molecules in surface monolayers.	George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA	George Washington University	Bailey, JM (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, 2300 Eye St NW, Washington, DC 20037 USA.							Bolli M, 1997, CHEM BIOL, V4, P309, DOI 10.1016/S1074-5521(97)90074-0; BONNER W, 1996, PHYSICAL ORIGIN HOMO; BRACK A, 1980, J MOL EVOL, V15, P231, DOI 10.1007/BF01732950; BRACK A, 1981, ORIGINS LIFE EVOL B, V11, P135, DOI 10.1007/BF00928004; BURBAUM JJ, 1991, J BIOL CHEM, V266, P16965; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CECH TR, 1986, SCI AM, V255, P64, DOI 10.1038/scientificamerican1186-64; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; Ferris JP, 1996, NATURE, V381, P59, DOI 10.1038/381059a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HEGSTROM RA, 1987, BIOSYSTEMS, V20, P49, DOI 10.1016/0303-2647(87)90019-0; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; Miller S. L., 1974, ORIGINS LIFE EARTH; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; OGSTON AG, 1948, NATURE, V162, P963, DOI 10.1038/162963b0; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; PROFY AT, 1984, J AM CHEM SOC, V106, P5030, DOI 10.1021/ja00329a080; PROFY AT, 1984, J MOL EVOL, V20, P147, DOI 10.1007/BF02257375; SPRINZL M, 1975, P NATL ACAD SCI USA, V72, P3049, DOI 10.1073/pnas.72.8.3049; Szathmary E, 1997, NATURE, V387, P662, DOI 10.1038/42610; TAIJI M, 1985, J BIOCHEM-TOKYO, V98, P1447, DOI 10.1093/oxfordjournals.jbchem.a135413	22	21	22	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					503	507		10.1096/fasebj.12.6.503	http://dx.doi.org/10.1096/fasebj.12.6.503			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535223				2022-12-28	WOS:000072967300012
J	Kinosita, K				Kinosita, K			Real time imaging of rotating molecular machines	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		SINGLE MYOSIN MOLECULE; FLAGELLAR MOTOR; ACTIN FILAMENT; ATP SYNTHASE; F-ATPASE; F1-ATPASE; MECHANISM; STEPS; FORCE	Observation of true rotation has been relatively rare in living systems, but there may be many molecular machines that rotate. Molecular rotations accompanying function can be imaged in real time under an optical microscope by attaching to the protein machine either a small tag such as a single fluorophore or a tag that is huge compared with the size of the protein. As an example of the former approach, axial rotation of an actin filament sliding over myosin has been measured quantitatively by attaching a fluorophore rigidly to the filament and imaging the orientation of the fluorophore continuously by polarization microscopy, As a huge tag in the latter approach, an actin filament turned out to be quite useful. Using this tag, the enzyme F-1-ATPase has been shown to be a rotary stepper motor made of a single molecule. Further, the efficiency of this ATP-fueled motor has been shown to reach almost 100%. The two examples above demonstrate that one can now image conformational changes, which necessarily involve reorientation, in a single protein molecule during function. Single-molecule physiology is no longer a dream.	Keio Univ, Fac Sci & Technol, Dept Phys, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, CREST Genet Programming Team 13, Kawasaki, Kanagawa 2160001, Japan	Keio University; Japan Science & Technology Agency (JST); Teikyo University	Kinosita, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Kohoku Ku, Hiyoshi 3-14-1, Yokohama, Kanagawa 2238522, Japan.	kazuhiko@phys.keio.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BERG HC, 1973, NATURE, V245, P380, DOI 10.1038/245380a0; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Harada Y, 1998, METHOD CELL BIOL, V55, P117; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; JONES CJ, 1991, ADV MICROB PHYSIOL, V32, P109, DOI 10.1016/S0065-2911(08)60007-7; Kinosita K, 1998, CELL, V93, P21, DOI 10.1016/S0092-8674(00)81142-3; KINOSITA K, 1991, J CELL BIOL, V115, P67, DOI 10.1083/jcb.115.1.67; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MIYATA H, 1995, BIOPHYS J, V68, pS286; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; NISHIZAKA T, 1993, NATURE, V361, P269, DOI 10.1038/361269a0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SILVERMAN M, 1974, NATURE, V249, P73, DOI 10.1038/249073a0; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAMM SL, 1974, P NATL ACAD SCI USA, V71, P4589, DOI 10.1073/pnas.71.11.4589; TILNEY LG, 1987, J CELL BIOL, V104, P407, DOI 10.1083/jcb.104.3.407; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	31	21	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S201	S208						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619128				2022-12-28	WOS:000084390200006
J	Nelson, EL; Strobl, S; Subleski, J; Prieto, D; Kopp, WC; Nelson, PJ				Nelson, EL; Strobl, S; Subleski, J; Prieto, D; Kopp, WC; Nelson, PJ			Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of the current 'maturation' paradigm and implications for in vivo immunoregulation	FASEB JOURNAL			English	Article						antigen presenting cells; cytokines; chemokines; and dendritic cell activation	NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; IN-VITRO; T-CELLS; HUMAN BLOOD; IMMUNE-RESPONSE; CYTOKINE; PROGENITORS; GENERATION; ACTIVATION	Dendritic cells (DCs) are potent antigen presenting cells reported to undergo irreversible functional 'maturation' in response to inflammatory signals such as TNF-alpha. The current paradigm holds that this DC maturation event is required for full functional capacity and represents terminal differentiation of this cell type, culminating in apoptotic cell death. This provides a possible mechanism for avoiding dysregulated immunostimulatory activity, but imposes constraints on the capacity of DCs to influence subsequent immune responses and to participate in immunological memory. We report that the cell surface and functional effects induced by TNF-alpha are reversible and reinducible. These effects are accompanied by a concordant modulation of cytokine mRNA expression that includes the induction of proinflammatory factors (IL-15, IL-12, LT-a!, LT-beta, TNF-alpha, RANTES) which is coincident with the down-regulation of counter-regulatory cytokines (IL-10, TGF-beta 1, TGF-beta 2, IL-1 RA, MCP-1). The resultant net effect is a dendritic cell activation state characterized by a transient proinflammatory posture. These results demonstrate that 1) human DCs do not undergo terminal 'maturation' in response to TNF-alpha, 2) DC phenotypes are more pleiotropic than previously thought, and 3) DCs are potential immunoregulatory effector cells with implications for control of immune responses in both in vivo and in vitro systems.-Nelson, E. L., Strobl, S., Subleski, J., Prieto, D., Kopp, W. C., Nelson, P. J. Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of the current 'maturation' paradigm and implications for in vivo immunoregulation. Cycling of human dendritic cell effector phenotypes in response to TNF-alpha modification of the current 'maturation' paradigm and implications for in vivo immunoregulation.	NCI, Immunotherapy Lab, FCRDC, Div Clin Sci, Frederick, MD 21702 USA; NCI, Clin Support Lab, FCRDC, Div Clin Sci, Frederick, MD 21702 USA; Univ Munich, Med Poliklin, D-8000 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Munich	Nelson, EL (corresponding author), NCI, Immunotherapy Lab, FCRDC, Div Clin Sci, Bldg 1050,Boyles St, Frederick, MD 21702 USA.	enelson@mail.ncifcrf.gov		Nelson, Edward/0000-0001-7887-032X	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELL EB, 1979, IMMUNOLOGY, V38, P797; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chapuis F, 1997, EUR J IMMUNOL, V27, P431, DOI 10.1002/eji.1830270213; Chen BG, 1998, BLOOD, V91, P4652, DOI 10.1182/blood.V91.12.4652.412a03_4652_4661; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; DiRosa F, 1996, J EXP MED, V183, P2153, DOI 10.1084/jem.183.5.2153; Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3; GALEY A, 1995, IMMUNITY, V3, P459; Ghanekar S, 1996, J IMMUNOL, V157, P4028; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Herbst B, 1996, BLOOD, V88, P2541, DOI 10.1182/blood.V88.7.2541.bloodjournal8872541; JAFFE R, 1993, PEDIATR PATHOL, V13, P821, DOI 10.3109/15513819309048268; Jonuleit H, 1997, J IMMUNOL, V158, P2610; KNIGHT SC, 1982, EUR J IMMUNOL, V12, P1057, DOI 10.1002/eji.1830121214; Langerhans P, 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI [DOI 10.1007/BF01959006, 10.1007/BF01959006]; Morse MA, 1997, ANN SURG, V226, P6, DOI 10.1097/00000658-199707000-00002; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; REID CDL, 1993, ADV EXP MED BIOL, V329, P257; Rescigno M, 1997, J LEUKOCYTE BIOL, V61, P415, DOI 10.1002/jlb.61.4.415; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santiago-Schwarz F, 1998, BLOOD, V92, P745, DOI 10.1182/blood.V92.3.745.415k35_745_755; Schuler G, 1997, INT ARCH ALLERGY IMM, V112, P317, DOI 10.1159/000237474; Siena S, 1995, EXP HEMATOL, V23, P1463; Sozzani S, 1998, J IMMUNOL, V161, P1083; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Steptoe RJ, 1996, CLIN EXP IMMUNOL, V105, P397, DOI 10.1046/j.1365-2249.1996.d01-779.x; Thomas R, 1996, IMMUNOL TODAY, V17, P559, DOI 10.1016/S0167-5699(96)20030-1; VanderMeide PH, 1996, BIOTHERAPY, V8, P243, DOI 10.1007/BF01877210; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Wu JH, 1996, J IMMUNOL, V157, P3404; ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	46	37	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2021	2030		10.1096/fasebj.13.14.2021	http://dx.doi.org/10.1096/fasebj.13.14.2021			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544185				2022-12-28	WOS:000083660700014
J	Ron, D; Kazanietz, MG				Ron, D; Kazanietz, MG			New insights into the regulation of protein kinase C and novel phorbol ester receptors	FASEB JOURNAL			English	Review						PKC; signal transduction; phorbol ester; chimaerin; anchoring proteins	GTPASE-ACTIVATING PROTEIN; PLECKSTRIN HOMOLOGY DOMAIN; CYSTEINE-RICH REGION; SIGNAL-TRANSDUCTION PATHWAY; HIGH-AFFINITY RECEPTOR; BINDING-PROTEIN; TYROSINE PHOSPHORYLATION; IN-VIVO; CAENORHABDITIS-ELEGANS; N-CHIMAERIN	Protein kinase C (PKC), a family of related serine-threonine kinases, is a key player in the cellular responses mediated by the second messenger diacylglycerol (DAG) and the phorbol ester tumor promoters, The traditional view of PKCs as DAG/phospholipid-regulated proteins has expanded in the last few years by three seminal discoveries, First, PRC activity and maturation is controlled by autophosphorylation and transphosphorylation mechanisms, which includes phosphorylation of PKC isozymes by phosphoinositide- dependent protein kinases (PDKs) and tyrosine kinases. Second, PKC activity and localization are regulated by direct interaction with different types of interacting proteins. Protein-protein interactions are now recognized as important mechanisms that target individual PKCs to different intracellular compartments and confer selectivity by associating individual isozymes with specific substrates. Last, the discovery of novel phorbol ester receptors lacking kinase activity allows us to speculate that some of the biological responses elicited by phorbol esters or by activation of receptors coupled to elevation in DAG levels could be mediated by PKC-independent pathways.-Ron, D., Kazanietz, M. G. New insights into the regulation of protein kinase C and novel phorbol ester receptors.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94110 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	dorit@itsa.ucsf.edu; marcelo@spirit.gcrc.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER; NCI NIH HHS [CA74197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, CAENORHABDITIS ELEGA; ARECES LB, 1994, J BIOL CHEM, V269, P19553; ASHENDEL CL, 1983, CANCER RES, V43, P4333; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Betz A, 1997, J BIOL CHEM, V272, P2520; Blobe GC, 1996, J BIOL CHEM, V271, P30297; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BLUMBERG PM, 1988, CANCER RES, V48, P1; Bogi K, 1998, CANCER RES, V58, P1423; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Bornancin F, 1997, J BIOL CHEM, V272, P13458; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Caloca MJ, 1997, J BIOL CHEM, V272, P26488, DOI 10.1074/jbc.272.42.26488; CALOCA MJ, 1999, IN PRESS P NATL ACAD; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Cong YS, 1997, J BIOL CHEM, V272, P16482, DOI 10.1074/jbc.272.26.16482; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Csukai M, 1998, METH MOL B, V88, P133; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; GarciaRocha M, 1997, EXP CELL RES, V230, P1, DOI 10.1006/excr.1996.3364; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Hurley JH, 1997, PROTEIN SCI, V6, P477; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P10777, DOI 10.1074/jbc.270.18.10777; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KONIG B, 1985, J CELL BIOCHEM, V27, P255, DOI 10.1002/jcb.240270307; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEACH KL, 1983, P NATL ACAD SCI-BIOL, V80, P4208, DOI 10.1073/pnas.80.14.4208; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEUNG T, 1993, J BIOL CHEM, V268, P3813; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Meller N, 1996, MOL CELL BIOL, V16, P5782; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Nakhost A, 1998, J NEUROCHEM, V71, P1221; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Parissenti AM, 1998, J BIOL CHEM, V273, P8940, DOI 10.1074/jbc.273.15.8940; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; RODRIGUEZ M, 1999, IN PRESS BIOCHEMISTR; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Smith BL, 1996, J BIOL CHEM, V271, P16753, DOI 10.1074/jbc.271.28.16753; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TANJI M, 1994, J NEUROCHEM, V63, P1908; Tatematsu K, 1998, BIOCHEM BIOPH RES CO, V247, P392, DOI 10.1006/bbrc.1998.8795; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Tokunaga C, 1998, BIOCHEM BIOPH RES CO, V244, P353, DOI 10.1006/bbrc.1998.8270; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1994, J BIOL CHEM, V269, P19578; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	183	524	538	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1658	1676		10.1096/fasebj.13.13.1658	http://dx.doi.org/10.1096/fasebj.13.13.1658			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506570				2022-12-28	WOS:000083063400002
J	Georges, D; Schwabe, C				Georges, D; Schwabe, C			Porcine relaxin, a 500 million-year-old hormone? The tunicate Ciona intestinalis has porcine relaxin	FASEB JOURNAL			English	Article						relaxin coding region; DNA polymerase; genomic potential hypothesis	MESSENGER-RNA; EXPRESSION; PURIFICATION; EVOLUTION; SEQUENCE; PEPTIDE	The fossil record of tunicates reaches back to the upper Cambrian period. Ascidians have mobile, tadpole-like juvenile forms with a notochord, which inspired the classification of tunicates as Urochordata, i.e., predecessors of vertebrates. The genome of the tunicate Ciona intestinalis contains a relaxin coding region that is organized like a mammalian gene, i.e., signal peptide, B-chain domain, connecting peptide domain, followed by the A-chain domain with a stop codon after cysteine A-22, RNA-derived cDNA encodes a relaxin that is identical to the circulating form of the porcine hormone. In contrast to the porcine gene, the ascidian gene has no intron in the C-peptide domain, and in that respect is similar to the bombyxin gene of the silkworm. During the spawning period, only enough relaxin could be extracted and isolated from gonads of C. intestinalis for a partial sequence analysis. Remarkable as it may be, these findings suggest that relaxin is identical in pigs, whales, and the tunicate C, intestinalis.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ Grenoble 1, UFR Biol, Grenoble, France	Medical University of South Carolina; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Schwabe, C (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHENCHIK A, 1995, CLONTECHNIQUES, V9, P9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GEORGES D, 1990, GEN COMP ENDOCR, V79, P429, DOI 10.1016/0016-6480(90)90073-U; GEORGES D, 1990, GEN COMP ENDOCR, V79, P423, DOI 10.1016/0016-6480(90)90072-T; GOWAN LK, 1981, FEBS LETT, V129, P80, DOI 10.1016/0014-5793(81)80760-0; HALEY J, 1987, J BIOL CHEM, V262, P11940; Hisaw FL, 1926, P SOC EXP BIOL MED, V23, P661; KIMURAKAWAKAMI M, 1992, GEN COMP ENDOCR, V86, P257, DOI 10.1016/0016-6480(92)90109-W; NEUWINGER J, 1990, ANDROLOGIA, V22, P335; Parry LJ, 1997, BIOL REPROD, V57, P119, DOI 10.1095/biolreprod57.1.119; REDDY GK, 1992, ARCH BIOCHEM BIOPHYS, V294, P579, DOI 10.1016/0003-9861(92)90728-F; Reinecke M, 1999, CELL TISSUE RES, V295, P331, DOI 10.1007/s004410051239; SCHWABE C, 1986, TRENDS BIOCHEM SCI, V11, P280, DOI 10.1016/0968-0004(86)90024-1; SCHWABE C, 1989, J BIOL CHEM, V264, P940; SCHWABE C, 1983, J BIOL CHEM, V258, P2778; SCHWABE C, 1990, COMPUT MATH APPL, V20, P287, DOI 10.1016/0898-1221(90)90334-G	17	15	15	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1269	1275		10.1096/fasebj.13.10.1269	http://dx.doi.org/10.1096/fasebj.13.10.1269			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385617				2022-12-28	WOS:000081264800015
J	Clark, RSB; Kochanek, PM; Chen, MZ; Watkins, SC; Marion, DW; Chen, J; Hamilton, RL; Loeffert, JE; Graham, SH				Clark, RSB; Kochanek, PM; Chen, MZ; Watkins, SC; Marion, DW; Chen, J; Hamilton, RL; Loeffert, JE; Graham, SH			Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury	FASEB JOURNAL			English	Article						apoptosis; Bax; Bclx(L); Cpp32; interleukin-1 beta converting enzyme	INTERLEUKIN-1-BETA CONVERTING-ENZYME; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CEREBRAL-ISCHEMIA; TRANSGENIC MICE; RAT-BRAIN; REGULATING APOPTOSIS; PROTOONCOGENE BCL-2; ALZHEIMERS-DISEASE; GLOBAL-ISCHEMIA	The bcl-2 and caspase families are important regulators of programmed cell death in experimental models of ischemic, excitotoxic, and traumatic brain injury. The Bcl-2 family members Bcl-2 and Bcl-x(L) suppress programmed cell death, whereas Bax promotes programmed cell death. Activated caspase-1 (interleukin-1 beta converting enzyme) and caspase-3 (Yama/Apopain/Cpp32) cleave proteins that are important in maintaining cytoskeletal integrity and DNA repair, and activate deoxyribonucleases, producing cell death with morphological features of apoptosis. To address the question of whether these Bcl-2 and caspase family members participate in the process of delayed neuronal death in humans, we examined brain tissue samples removed from adult patients during surgical decompression for intracranial hypertension in the acute phase after traumatic brain injury (n=8) and com pared these samples to brain tissue obtained at autopsy from non-trauma patients (n=6). An increase in Bcl-2 but not Bcl-x(L) or Bax, cleavage of caspase-1, up-regulation and cleavage of caspase-3, and evidence for DNA fragmentation with both apoptotic and necrotic morphologies were found in tissue from traumatic brain injury patients compared with controls. These findings are the first to demonstrate that programmed cell death occurs in human brain after acute injury, and identify potential pharmacological and molecular targets for the treatment of human head injury.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Dept Vet Affairs Med Ctr, Neurol Serv 127, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave Pittsburgh, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021; Watkins, Simon/ABG-2590-2021	Kochanek, Patrick M/0000-0002-2627-913X; Watkins, Simon/0000-0003-4092-1552; Chen, Jun/0000-0002-8077-3403	NICHD NIH HHS [5P30 HD28836] Funding Source: Medline; NINDS NIH HHS [1KO8 NS01946, 1RO1 NS 38620-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001946, R01NS038620] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Ashkenas J, 1996, J EXP MED, V183, P1947, DOI 10.1084/jem.183.5.1947; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Hayasaki K, 1997, ACT NEUR S, V70, P75; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JENNETT B, 1985, LANCET, V1, P480; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/S0304-3940(96)12961-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; SHAW K, 1998, J NEUROTRAUM, V15, P871; Smith F. M., 1998, Journal of Neurotrauma, V15, P54; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	51	180	191	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					813	821		10.1096/fasebj.13.8.813	http://dx.doi.org/10.1096/fasebj.13.8.813			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224225				2022-12-28	WOS:000080372500005
J	Frank, S; Zacharowski, K; Wray, GM; Thiemermann, C; Pfeilschifter, J				Frank, S; Zacharowski, K; Wray, GM; Thiemermann, C; Pfeilschifter, J			Identification of copper zinc superoxide dismutase as a novel nitric oxide-regulated gene in rat glomerular mesangial cells and kidneys of endotoxemic rats	FASEB JOURNAL			English	Article						gene expression regulation; glomerular mesangium; superoxide anion; endotoxemia	SYNTHASE MESSENGER-RNA; L-ARGININE; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GROWTH-FACTOR; CYCLIC-AMP; EXPRESSION; INDUCTION; ACTIVATION; ALPHA	To define the mechanism of nitric oxide (NO) action in the glomerulus, we attempted to identify genes that are regulated by NO in rat glomerular mesangial cells, We identified a Cu/Zn superoxide dismutase (SOD) that was strongly induced in these cells by treatment with S-nitroso-glutathione as a NO-donating agent. Bacterial lipopolysaccharide (LPS) acutely decreased Cu/Zn SOD mRNA levels, The LPS-mediated decrease in Cu/Zn SOD is reversed by endogenously produced NO, as LPS also induced a delayed strong iNOS expression in these cells in vitro, which is accompanied by increased Cu/Zn SOD expression. NO dependency of Cu/Zn SOD mRNA recovery could be demonstrated by inhibition of this process by L-N-G-monomethylarginine, an inhibitor of NOS enzymatic activity, To demonstrate the in vivo relevance of our observations, we have chosen LPS-treated rats as a model for induction of a systemic inflammatory response. In these animals, we demonstrate a direct coupling of Cu/Zn SOD expression levels to the presence of NO, as Cu/Zn SOD mRNA levels declined during acute inflammation in the presence of a selective inhibitor of iNOS, We propose that the up-regulation of Cu/Zn SOD by endogenous NO may serve as an adaptive, protective mechanism to prevent the formation of toxic quantities of per oxynitrite in conditions associated with iNOS induction during endotoxic shock.	Univ Frankfurt Klinikum, Inst Allgemeine Pharmakol & Toxikol, Zentrum Pharmakol, D-60590 Frankfurt, Germany; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, London EC1 6BD, England	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of London; Queen Mary University London	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Inst Allgemeine Pharmakol & Toxikol, Zentrum Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Pfeilschifter@em.uni-frankfurt.de		Thiemermann, Christoph/0000-0003-4228-9722				BAUD L, 1992, J AM SOC NEPHROL, V2, pS132; BAUD L, 1986, AM J PHYSIOL, V251, pF765, DOI 10.1152/ajprenal.1986.251.5.F765; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CAMUSSI G, 1995, J IMMUNOL, V155, P316; CATTELL V, 1993, EXP NEPHROL, V1, P265; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROW JP, 1995, NITRIC OXIDE BIOCH M, P17; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DUQUE I, 1992, AM J PHYSIOL, V263, pF466, DOI 10.1152/ajprenal.1992.263.3.F466; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GWINNER W, 1995, KIDNEY INT, V48, P354, DOI 10.1038/ki.1995.303; HO YS, 1987, NUCLEIC ACIDS RES, V15, P10070, DOI 10.1093/nar/15.23.10070; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KASHGARIAN M, 1992, KIDNEY INT, V41, P524, DOI 10.1038/ki.1992.74; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; KUNZ D, 1994, BIOCHEM J, V304, P337, DOI 10.1042/bj3040337; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; MUHL H, 1994, BRIT J PHARMACOL, V112, P1; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; Nitsch DD, 1997, AM J PATHOL, V150, P889; PFEILSCHIFTER J, 1995, KIDNEY INT, V48, pS50; PFEILSCHIFTER J, 1992, EUR J BIOCHEM, V203, P251, DOI 10.1111/j.1432-1033.1992.tb19854.x; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; PFEILSCHIFTER J, 1993, NEPHRON, V64, P518, DOI 10.1159/000187394; Pluss C, 1996, BIOCHEM J, V318, P665; Puga A, 1987, Free Radic Res Commun, V3, P337, DOI 10.3109/10715768709088074; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; Sandau K, 1997, J IMMUNOL, V158, P4938; SAURA M, 1995, KIDNEY INT, V47, P500, DOI 10.1038/ki.1995.63; Schlondorff D, 1996, KIDNEY INT, V49, P1583, DOI 10.1038/ki.1996.229; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHULTZ PJ, 1994, KIDNEY INT, V46, P683, DOI 10.1038/ki.1994.321; Stephanz GB, 1996, EXP NEPHROL, V4, P151; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wray GM, 1998, SHOCK, V9, P329, DOI 10.1097/00024382-199805000-00003; XIE QW, 1994, J BIOL CHEM, V269, P4705; YOSHIOKA T, 1994, KIDNEY INT, V46, P405, DOI 10.1038/ki.1994.288	54	51	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					869	882		10.1096/fasebj.13.8.869	http://dx.doi.org/10.1096/fasebj.13.8.869			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224230				2022-12-28	WOS:000080372500010
J	Jabrane-Ferrat, N; Bloom, D; Wu, A; Li, L; Lo, D; Sreedharan, SP; Turck, CW; Goetzl, EJ				Jabrane-Ferrat, N; Bloom, D; Wu, A; Li, L; Lo, D; Sreedharan, SP; Turck, CW; Goetzl, EJ			Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells	FASEB JOURNAL			English	Article						neuropeptide; receptors; G-proteins; cytokines; lymphocytes	MODEL BASEMENT-MEMBRANE; MESSENGER-RNA; EXPRESSION; NEUROPEPTIDES; RECEPTOR; LYMPHOCYTES; CHEMOTAXIS; NEUROIMMUNOMODULATION; SPECIFICITY; MOLECULES	Vasoactive intestinal peptide (VIP) is a neuroendocrine mediator in immune tissues that affects many T cell functions through two homologous high-affinity G-protein-coupled receptors, termed VIPR1 and VIPR2. Antigen-stimulated secretion of gamma-interferon (IFN-gamma) by sperm whale myoglobin-specific Th1 cells of DBA/2 mouse I-E(d)-restricted clones, which express VIPR1 and VIPR2, was enhanced by 10(-10) M to 10(-7) M VIP. Enhancement of IFN-gamma secretion reached a mean maximum of fourfold for VIP and threefold for a VIPR2-selective agonist, without any effect of a VIPR1-selective agonist. Secretion of IFN-gamma by PMA and ionomycin-stimulated clones of Th1 cells was not altered by VIP. Antigen-stimulated secretion of IFN-gamma by T cell receptor-transgenic, influenza hemagglutinin-specific, and cytokine-differentiated mouse lymph node Th1 cells, which also express VIPR1 and VIPR2, was enhanced by 10(-10) M to 10(-8) M VIP. Enhancement of IFN-gamma secretion increased to a maximum of 14-fold for VIP, 14-fold for the VIPR2-selective agonist, and 20-fold for the VIPR1-selective agonist. In contrast to VIP suppression of interleukin production and lack of effect on IFN-gamma production by T cells stimulated with anti-CD3 antibody or a mitogenic lectin, generation of IFN-gamma by antigen-stimulated T cells is enhanced significantly by physiological concentrations of VIP.	Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Microbiol Immunol, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Scripps Research Institute	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Jabrane-Ferrat, Nabila/K-1224-2014	Jabrane-Ferrat, Nabila/0000-0003-4809-7836; Li, Li/0000-0001-9844-7692	NIAID NIH HHS [AI29912] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APNKHANIYA R, 1998, FASEB J, V12, P119; BARNES D, 1991, QUAL ASSUR GOOD PRAC, V1, P1; BOIRIVANT M, 1994, GASTROENTEROLOGY, V106, P576, DOI 10.1016/0016-5085(94)90688-2; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DEGERMANN S, 1994, EUR J IMMUNOL, V24, P3155, DOI 10.1002/eji.1830241236; Delgado M, 1996, J NEUROIMMUNOL, V68, P27, DOI 10.1016/0165-5728(96)00063-X; FINK T, 1988, NEUROSCI LETT, V90, P39, DOI 10.1016/0304-3940(88)90783-5; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; GANEA D, 1993, J NEUROIMMUNOL, V47, P147, DOI 10.1016/0165-5728(93)90025-T; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; GERMAIN RN, 1986, NATURE, V320, P72, DOI 10.1038/320072a0; GOETZL EJ, 1992, FASEB J, V6, P2646, DOI 10.1096/fasebj.6.9.1612288; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; HASSNER A, 1993, J ALLERGY CLIN IMMUN, V92, P891, DOI 10.1016/0091-6749(93)90067-P; ICHIKAWA S, 1994, REGUL PEPTIDES, V54, P385, DOI 10.1016/0167-0115(94)90536-3; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; LITWIN DK, 1992, REGUL PEPTIDES, V40, P63, DOI 10.1016/0167-0115(92)90084-8; MATTHEW RC, 1992, J IMMUNOL, V148, P3572; Metwali A, 1996, J IMMUNOL, V157, P265; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; NIO DA, 1993, J IMMUNOL, V150, P5281; OTTAWAY CA, 1991, GASTROENTEROL CLIN N, V20, P511; RUBERTI G, 1992, J EXP MED, V175, P157, DOI 10.1084/jem.175.1.157; SAID SI, 1994, CL ALLER IM, V4, P143; SMITH CH, 1993, J IMMUNOL, V151, P3274; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; TANG H, 1995, J INTERF CYTOK RES, V15, P993, DOI 10.1089/jir.1995.15.993; Wang HY, 1996, J IMMUNOL, V156, P3243; WEINSTOCK JV, 1992, CLIN IMMUNOL IMMUNOP, V64, P17, DOI 10.1016/0090-1229(92)90053-Q; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; Xia MH, 1996, J CELL BIOCHEM, V61, P452, DOI 10.1002/(SICI)1097-4644(19960601)61:3<452::AID-JCB12>3.3.CO;2-9; Xia MH, 1996, J IMMUNOL, V157, P1132; Xia MH, 1996, J IMMUNOL, V156, P160; YU YL, 1991, J CLIN LAB ANAL, V5, P262	37	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					347	353		10.1096/fasebj.13.2.347	http://dx.doi.org/10.1096/fasebj.13.2.347			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973323				2022-12-28	WOS:000078615200015
J	Sarti, P; Lendaro, E; Ippolito, R; Bellelli, A; Benedetti, PA; Brunori, M				Sarti, P; Lendaro, E; Ippolito, R; Bellelli, A; Benedetti, PA; Brunori, M			Modulation of mitochondrial respiration by nitric oxide: investigation by single cell fluorescence microscopy	FASEB JOURNAL			English	Article						NO; cell respiration; mitochondria; cytochrome oxidase; NOR1; neuroblastoma	CYTOCHROME-C-OXIDASE; LIVING CELLS; SKELETAL-MUSCLE; INHIBITION; OXYGEN; APOPTOSIS; MECHANISM; RHODAMINE-123; LOCALIZATION; ASTROCYTES	With the electro-driven import of rhodamine 123, we used single cell fluorescence microscopy to single out the contribution of nitric oxide (NO) in controlling mitochondrial membrane potential expressed by (stationary growing) rhabdomyosarcoma and neuroblastoma cells in culture. The experimental design and the computer-aided image analysis detected and quantitated variations of fluorescence signals specific to mitochondria. We observed that 1) the two cell lines display changes of fluorescence dependent on mitochondrial ermelgization states; 2) mitochondrial fluorescence decreases after exposure of the cells to a NO releaser; 4) the different fluorescence intensity measured under stationary growing conditions, or after activation and inhibition of constitutive NO synthase, is consistent with a steady-state production of NO. Direct comparison of single cell fluorescence with bulk cytofluorimetry proved that the results obtained by the latter method may be misleading because of the intrinsic-to-measure lack of information about distribution of fluorescence within different cell compartments. The kinetic parameters describing the reactions between cytochrome oxidase, NO, and 02 may account for the puzzling (20-fold) increase of the RM for 02 reported for cells and tissues as compared to purified cytochrome c oxidase, allowing an estimate of in vive NO flux.	Univ Rome La Sapienza, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy; Univ Rome La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy; CNR, Inst Biophys, I-56100 Pisa, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Sarti, P (corresponding author), Univ Rome La Sapienza, Dept Biochem Sci A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	sarti@axrma.uniroma1.it	Sarti, Paolo/D-2946-2009; Bellelli, Andrea/D-2785-2009	IPPOLITI, RODOLFO/0000-0003-0652-3470; Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827				BOLANOS JP, 1994, J NEUROCHEM, V63, P910; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROWN GC, 1995, NEUROSCI LETT, V193, P201, DOI 10.1016/0304-3940(95)11703-Y; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Brunori M, 1997, J BIOL CHEM, V272, P19870, DOI 10.1074/jbc.272.32.19870; CARR GJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P57, DOI 10.1016/0005-2728(90)90178-7; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; Dawson VL, 1996, NEUROCHEM INT, V29, P97, DOI 10.1016/0197-0186(95)00149-2; Frandsen U, 1996, BIOCHEM BIOPH RES CO, V227, P88, DOI 10.1006/bbrc.1996.1472; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Kurose I, 1997, FREE RADICAL BIO MED, V22, P229, DOI 10.1016/S0891-5849(96)00332-2; Laffranchi R, 1995, BIOCHEM BIOPH RES CO, V217, P584, DOI 10.1006/bbrc.1995.2815; LENDARO E, 1994, FEBS LETT, V344, P99, DOI 10.1016/0014-5793(94)00255-X; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nicholls D.G., 1982, BIOENERGETICS INTRO; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; RICHTER C, 1994, BIOCHEM BIOPH RES CO, V205, P1143, DOI 10.1006/bbrc.1994.2785; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; SHEN WQ, 1995, FASEB J, V9, pA557; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAKEHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P27, DOI 10.1006/abbi.1995.0005; TAMURA M, 1989, ANNU REV PHYSIOL, V51, P813, DOI 10.1146/annurev.ph.51.030189.004121; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P300, DOI 10.1006/abbi.1994.1241; Xie Yi-Wu, 1995, FASEB Journal, V9, pA557	37	66	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					191	197		10.1096/fasebj.13.1.191	http://dx.doi.org/10.1096/fasebj.13.1.191			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872943				2022-12-28	WOS:000078029500020
J	Duthie, SJ; Hawdon, A				Duthie, SJ; Hawdon, A			DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro	FASEB JOURNAL			English	Article						DNA breaks; misincorporated uracil; DNA repair; oxidized pyrimidines; comet assay	FACTORS INFLUENCING MUTATION; HAMSTER OVARY CELLS; FOLATE-DEFICIENCY; ULCERATIVE-COLITIS; HPRT LOCUS; VITAMIN-C; DAMAGE; CANCER; SUPPLEMENTATION; DYSPLASIA	Folic acid is essential for the synthesis and repair of DNA. We report the effects of folate depletion on DNA stability in normal human lymphocytes in vitro. DNA strand breakage, uracil misincorporation, oxidative DNA base damage, and DNA repair capability were determined using variants of the comet assay (single cell gel electrophoresis), Lymphocyte proliferation was measured as an indicator of normal replication. Lymphocytes isolated from human venous blood were stimulated to grow in either complete medium containing folic acid (1 ng/ml-2 mu g/ml) or medium deficient in folic acid for up to 10 days. Cells prepared for comet analysis were treated either with the bacterial DNA repair enzyme endonuclease III to determine the level of oxidized pyrimidines in lymphocyte DNA or with uracil DNA glycosylase, which detects misincorporated uracil, Cell number and viability were measured. Normal human lymphocyte DNA contained detectable amounts of misincorporated uracil (estimated as approximately 1000 per cell). DNA strand breakage and uracil misincorporation increased in a time- and concentration-dependent manner after lymphocytes were cultured with decreasing amounts: of folic acid. DNA damage was induced at folic acid concentrations routinely observed in plasma from the human population (1-10 ng/ml), Lymphocytes cultured under folate-deficient conditions failed to grow normally compared with control cells. However, all lymphocytes remained viable as measured by Trypan blue exclusion. Cells deprived of folate were unable to efficiently repair oxidative DNA damage induced by hydrogen peroxide. Inhibition of repair was maximal after 8 days in culture. Folate supply had no effect on the level of oxidized pyrimidines in lymphocyte DNA, even after 10 days in culture, suggesting that folate deficiency increases uracil misincorporation relatively specifically. These in vitro results: help to determine the mechanism(s) through which folic acid maintains DNA stability.	Rowett Res Inst, Bucksburn AB21 9SB, Aberdeen, Scotland	University of Aberdeen	Duthie, SJ (corresponding author), Rowett Res Inst, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.	sd@rri.sari.ac.uk		Duthie, Susan/0000-0002-7990-4437				BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; BLOUNT BC, 1995, BAILLIERE CLIN HAEM, V8, P461, DOI 10.1016/S0950-3536(05)80216-1; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BRANDA RF, 1993, CANCER RES, V53, P5401; BRANDA RF, 1992, ENVIRON MOL MUTAGEN, V19, P274, DOI 10.1002/em.2850190403; BRANDA RF, 1991, CANCER RES, V51, P6603; BUTTERWORTH CE, 1982, AM J CLIN NUTR, V35, P73, DOI 10.1093/ajcn/35.1.73; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; DOETSCH PW, 1987, MOL CELL BIOL, V7, P26, DOI 10.1128/MCB.7.1.26; Duthie SJ, 1996, CANCER RES, V56, P1291; Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V393, P223, DOI 10.1016/S1383-5718(97)00107-1; Duthie SJ, 1997, CARCINOGENESIS, V18, P1709, DOI 10.1093/carcin/18.9.1709; EVERSON RB, 1988, JNCI-J NATL CANCER I, V80, P525, DOI 10.1093/jnci/80.7.525; Fang JY, 1997, J GASTROENTEROL, V32, P171, DOI 10.1007/BF02936363; FENECH M, 1994, CARCINOGENESIS, V15, P1405, DOI 10.1093/carcin/15.7.1405; Fenech MF, 1997, CARCINOGENESIS, V18, P1329, DOI 10.1093/carcin/18.7.1329; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HEIMBURGER DC, 1988, JAMA-J AM MED ASSOC, V259, P1525; JAMES S J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P16; JAMES SJ, 1994, CANCER RES, V54, P5075; Lashner BA, 1997, GASTROENTEROLOGY, V112, P29, DOI 10.1016/S0016-5085(97)70215-4; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; MACGREGOR JT, 1990, P NATL ACAD SCI USA, V87, P9962, DOI 10.1073/pnas.87.24.9962; MILLER AB, 1990, REV ONCOL, V3, P87; NEGRI E, 1991, INT J CANCER, V48, P350, DOI 10.1002/ijc.2910480307; POGRIBNY IP, 1995, CANCER RES, V55, P1894; REIDY JA, 1987, MUTAT RES, V192, P217, DOI 10.1016/0165-7992(87)90059-5; WAINFAN E, 1992, CANCER RES, V52, pS2071	31	244	252	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1491	1497		10.1096/fasebj.12.14.1491	http://dx.doi.org/10.1096/fasebj.12.14.1491			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806758				2022-12-28	WOS:000076749500008
J	Kiang, JG; Gist, ID; Tsokos, GC				Kiang, JG; Gist, ID; Tsokos, GC			Cytoprotection and regulation of heat shock proteins induced by heat shock in human breast cancer T47-D cells: role of [Ca2+](i) and protein kinases	FASEB JOURNAL			English	Article						viability; heat; protein kinase C; protein kinase A	HUMAN EPIDERMOID-A-431 CELLS; HSP-72 SYNTHESIS; A-431 CELLS; ACTIVATION; INCREASES; INDUCTION; CA2+; RESISTANCE; DAMAGE; GENE	Overexpression of heat shock protein 70 kDa alters the susceptibility of tumor cells to chemotherapeutic agents. We conducted experiments to study the regulation of expression of heat shock proteins (HSPs) in heat shock-treated T47-D cells, a human breast cancer cell line that expresses estrogen receptors, Cells exposed to heat shock at 44 degrees C displayed increased expression of heat shock protein 72 kDa (HSP-72), glucose-regulated protein 78 kDa (GRP-78), and GRP-94 in a time-dependent manner, as shown by [S-35]methionine incorporation and Western blotting experiments, The maximal rate of synthesis occurred between 2 and 4 h after heat shock. Removal of external Ca2+ inhibited the synthesis of the heat shock-induced GRP-78 but not of HSP-72 and GRP-94, whereas treatment of cells with BAPTA (a Ca2+ chelator) inhibited HSP-72 and GRP-78, Treatment with H89 (a protein kinase A inhibitor) blocked the heat shock-induced GRP-78 synthesis, whereas GF-109203X (a protein kinase C inhibitor) attenuated the heat shock-induced HSP-72 synthesis and com pletely blocked synthesis of GRP-78 but not of GRP-94, These results indicate that protein kinase C is involved in regulation of the heat shock-induced synthesis of HSP-72, whereas PKA and PKC are involved in the regulation of GRP-78 synthesis. Cells overexpressing HSP-72 and GRPs after heat shock displayed resistance against lethal temperature (47 degrees C for 50 min) -induced death, which was diminished after removal of external Ca2+ and treatment with GF-109203X, Heat shock increased intracellular free Ca2+ concentration ([Ca2+](i)) in a temperature- and heating duration-dependent fashion, and the increase was inhibited in the absence of external [Ca2+](i) and significantly reduced by pretreatment with H89 and GF-109203X, The results suggest that different pathways are involved in the induction of synthesis of HSP-72, GRP-78, and GRP-94 by heat shock. It is highly likely that only HSP-72 and GRP-78 are involved in the process of cytoprotection from the thermal injury.	Walter Reed Army Inst Res, Dept Clin Physiol, Div Med, Washington, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Kiang, JG (corresponding author), Walter Reed Army Inst Res, Dept Clin Physiol, Div Med, Bldg 40,Rm 3117A, Washington, DC 20307 USA.	Dr._Juliann-Kiang@WRSMTP-ccmail.army.mil	tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360				ADAMS DJ, 1983, ENDOCRINOLOGY, V113, P415, DOI 10.1210/endo-113-1-415; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; CIOCCA DR, 1991, BREAST CANCER RES TR, V20, P33, DOI 10.1007/BF01833355; CIOCCA DR, 1982, CANCER RES, V42, P4256; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; Ding XZ, 1996, J INVEST MED, V44, P144; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; Edwards D P, 1981, Breast Cancer Res Treat, V1, P209, DOI 10.1007/BF01806261; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; FUCHER C, 1993, J BIOL CHEM, V268, P15168; FUHR JE, 1976, J NATL CANCER I, V56, P89; Hahn G., 1982, HYPERTHERMIA CANC; Hahn GM, 1990, STRESS PROTEINS BIOL, P79; HAHN GM, 1983, RATIONAL BASIS CHEMO, P427; KHANNA A, 1995, ENDOCRINOLOGY, V136, P1775, DOI 10.1210/en.136.4.1775; Kiang JG, 1996, J INVEST MED, V44, P53; KIANG JG, 1994, TOXICOL APPL PHARM, V127, P173, DOI 10.1006/taap.1994.1151; KIANG JG, 1992, AM J PHYSIOL, V263, pC30, DOI 10.1152/ajpcell.1992.263.1.C30; KIANG JG, 1991, BIOCHEM J, V276, P683, DOI 10.1042/bj2760683; Kiang JG, 1996, THYROID, V6, P475, DOI 10.1089/thy.1996.6.475; KIANG JG, 1994, AM J PHYSIOL, V267, pC104, DOI 10.1152/ajpcell.1994.267.1.C104; KIANG JG, 1998, IN PRESS PHARMACOL; Kiang Juliann G., 1997, Chinese Journal of Physiology, V40, P213; Kiang Juliann Gong, 1996, Journal of Biomedical Science, V3, P379, DOI 10.1007/BF02258043; Liossis SNC, 1997, J IMMUNOL, V158, P5668; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAKAMURA K, 1991, GASTROENTEROLOGY, V101, P161, DOI 10.1016/0016-5085(91)90473-X; PERDRIZET GA, 1990, TRANSPLANT P, V22, P460; POLLA BS, 1987, AM J PHYSIOL, V252, pC640, DOI 10.1152/ajpcell.1987.252.6.C640; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RICE GC, 1987, CANCER CHEMOTH PHARM, V20, P183, DOI 10.1007/BF00570481; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHER E, 1981, BIOCHEM J, V200, P315, DOI 10.1042/bj2000315; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; STOJADINOVIC A, 1995, GASTROENTEROLOGY, V109, P505, DOI 10.1016/0016-5085(95)90339-9; Stojadinovic A, 1997, CRIT CARE MED, V25, P309, DOI 10.1097/00003246-199702000-00020; VILLAR J, 1994, CRIT CARE MED, V22, P914; WALLNER K, 1986, INT J RADIAT ONCOL, V12, P829, DOI 10.1016/0360-3016(86)90043-X; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752	43	23	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1571	1579		10.1096/fasebj.12.14.1571	http://dx.doi.org/10.1096/fasebj.12.14.1571			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806766				2022-12-28	WOS:000076749500016
J	Minshall, RD; Miyagawa, K; Chadwick, CC; Novy, MJ; Hermsmeyer, K				Minshall, RD; Miyagawa, K; Chadwick, CC; Novy, MJ; Hermsmeyer, K			In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones	FASEB JOURNAL			English	Article						estrogen; progesterone; coronary artery reactivity; ischemic heart disease	PROTEIN-KINASE-C; FUNCTIONAL ESTROGEN-RECEPTORS; SMOOTH-MUSCLE; ARTERY SPASM; POSTMENOPAUSAL WOMEN; RHESUS-MONKEYS; HEART-DISEASE; PROGESTERONE; 17-BETA-ESTRADIOL; PROLIFERATION	Susceptibility to drug-induced coronary vasospasm in rhesus monkeys increases after removal of the ovaries and can be normalized by adding back physiological levels of estradiol-17 beta (E-2) and/or natural progesterone (P) in vivo as reported recently by our group. Furthermore, the reactivity status (Ca2+ and protein kinase C responses) of freshly isolated and primary culture coronary artery vascular muscle cells (VMC) mimic the intact coronary artery responses to 5-HT + U46619. Since coronary reactivity is maintained in the isolated VMC, we hypothesized that the reactivity state inherent in the VMC was modulated directly by ovarian steroids in vitro as in the whole animal. To test this hypothesis, we treated hyperreactive VMC from ovariectomized (ovx) mon keys in vitro with Ea or P and measured VMC reactivity to combined stimulation with 5-HT and U46619, as determined by the amplitude and especially the duration of intracellular Ca2+ signals, as well as protein kinase C (PKC) activation/translocation. VMC were treated for 12-96 h with 3-100 pg/ml E-2 (10-365 pM) and/or 0.3-3 ng/ml P (0.95-9.5 nM). Hyperreactive responses to the combination of 5-HT and U46619 in untreated VMC were significantly and dose-dependently reduced by treatment in vitro with physiological levels of either Ep or P for at least 24 h, Both the early transient and late sustained increases in intracellular Ca2+ and PKC translocation were blunted, and the effects of 0.2 nM E-2 and 3.2 nM P were specifically antagonized by the receptor blockers ICI 182,780 (200 nM) and RU486 (15 nM), respectively. Antibodies to the estrogen receptor and progesterone receptor labeled nuclei in VMC, which were also positively labeled by a smooth muscle myosin heavy chain monoclonal antibody. These data indicate that natural ovarian steroids directly reduce hyperreactive 5-HT and thromboxane A(2)-stimulated Ca2+ and PKC responses of coronary artery VMC from surgically menopausal rhesus macaques, We hypothesize that vascular hyperreactivity, which may be a critical factor involved in the increased incidence of coronary artery vasospasm and ischemic heart disease in postmenopausal women, can be normalized by E-2 and/or P through direct actions on coronary artery vascular muscle cells.	Oregon Reg Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA; Wyeth Ayerst Res, Dept Endocrinol, Womens Hlth Res Inst, Radnor, PA 19084 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Dev & Cell Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center; Pfizer; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Hermsmeyer, K (corresponding author), Oregon Reg Primate Res Ctr, Div Reprod Sci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	rkh@compuserve.com			NHLBI NIH HHS [HL 51723] Funding Source: Medline; NICHD NIH HHS [HD18185, HD06159] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006159, R01HD006159] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BAYARD F, 1995, ENDOCRINOLOGY, V136, P1523, DOI 10.1210/en.136.4.1523; Bei M, 1996, J STEROID BIOCHEM, V58, P83, DOI 10.1016/0960-0760(96)00005-2; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Bielefeldt K, 1996, AM J PHYSIOL-GASTR L, V271, pG370, DOI 10.1152/ajpgi.1996.271.2.G370; Bory M, 1996, EUR HEART J, V17, P1015; Duckles SP, 1996, J PHARMACOL EXP THER, V279, P1; ELLIS EF, 1976, SCIENCE, V193, P1135, DOI 10.1126/science.959827; Espinosa E, 1996, BIOCHEM BIOPH RES CO, V221, P8, DOI 10.1006/bbrc.1996.0535; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; FORESTA C, 1995, BIOCHEM BIOPH RES CO, V206, P408, DOI 10.1006/bbrc.1995.1056; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GRABER R, 1993, CELL SIGNAL, V5, P181, DOI 10.1016/0898-6568(93)90069-X; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; HARDER DR, 1979, J CELL PHYSIOL, V100, P375, DOI 10.1002/jcp.1041000218; Hermsmeyer K, 1997, J AM COLL CARDIOL, V29, P671, DOI 10.1016/S0735-1097(96)00524-4; HERMSMEYER K, 1977, AM J PHYSIOL, V233, pC172, DOI 10.1152/ajpcell.1977.233.5.C172; HERMSMEYER K, 1996, J VASC RES, P33; HERMSMEYER K, 1997, ENDOTHELIAL CELL RES, V3, P237; HESS DL, 1981, BIOL REPROD, V24, P609, DOI 10.1095/biolreprod24.3.609; HORWITZ KB, 1982, J CLIN INVEST, V69, P750, DOI 10.1172/JCI110513; INGEGNO MD, 1988, LAB INVEST, V59, P353; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KALSNER S, 1995, BIOCHEM PHARMACOL, V49, P859, DOI 10.1016/0006-2952(94)00447-T; KARAS RH, 1994, CIRCULATION, V89, P1943, DOI 10.1161/01.CIR.89.5.1943; KASKI JC, 1989, J AM COLL CARDIOL, V14, P1456, DOI 10.1016/0735-1097(89)90382-3; KHALIL RA, 1991, CIRC RES, V69, P1626, DOI 10.1161/01.RES.69.6.1626; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; Kolodgie FD, 1996, AM J PATHOL, V148, P969; Lee WS, 1997, NAT MED, V3, P1005, DOI 10.1038/nm0997-1005; LIOU YM, 1994, AM J PHYSIOL-CELL PH, V267, pC980, DOI 10.1152/ajpcell.1994.267.4.C980; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; MARVIN WJ, 1979, CIRC RES, V45, P528, DOI 10.1161/01.RES.45.4.528; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MEIZEL S, 1991, MOL CELL ENDOCRINOL, V11, pR1; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Minshall RD, 1998, J CLIN ENDOCR METAB, V83, P649, DOI 10.1210/jc.83.2.649; Miyagawa K, 1997, NAT MED, V3, P324, DOI 10.1038/nm0397-324; Miyagawa K, 1997, AM J PHYSIOL-HEART C, V272, pH2645, DOI 10.1152/ajpheart.1997.272.6.H2645; Moraghan T, 1996, ENDOCRINOLOGY, V137, P5174, DOI 10.1210/en.137.11.5174; NAKAO J, 1981, ATHEROSCLEROSIS, V38, P75, DOI 10.1016/0021-9150(81)90105-2; ORIMO A, 1993, BIOCHEM BIOPH RES CO, V195, P730, DOI 10.1006/bbrc.1993.2106; PERROTAPPLANAT M, 1995, CIRCULATION, V92, P2975, DOI 10.1161/01.CIR.92.10.2975; PRESS MF, 1988, ENDOCRINOLOGY, V122, P1165, DOI 10.1210/endo-122-3-1165; PRICE RJ, 1994, CIRC RES, V75, P520, DOI 10.1161/01.RES.75.3.520; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; RESKO JA, 1975, ENDOCRINOLOGY, V97, P425, DOI 10.1210/endo-97-2-425; Ruehlmann Dietrich O., 1997, Biochemical Society Transactions, V25, p112S; RUSCH NJ, 1995, PHYSL PATHOPHYSIOLOG, P999; RUSCH NJ, 1994, ION TRANSPORT HYPERT, P197; RYLANCE PB, 1985, BRIT MED J, V290, P13, DOI 10.1136/bmj.290.6461.13; SELF DA, 1994, J VASC RES, V31, P359, DOI 10.1159/000159064; SLAYDEN OD, 1993, ENDOCRINOLOGY, V132, P1845, DOI 10.1210/en.132.4.1845; STANCZYK FZ, 1995, MENOPAUSE, V2, P137; STANCZYK FZ, 1984, TREATMENT POSTMENOPA, P69; TAKAHASHI I, 1989, BIOCHEM BIOPH RES CO, V165, P1207, DOI 10.1016/0006-291X(89)92730-7; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WILLERSON JT, 1986, J AM COLL CARDIOL, V8, P245, DOI 10.1016/S0735-1097(86)80121-8; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	66	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1419	1429		10.1096/fasebj.12.13.1419	http://dx.doi.org/10.1096/fasebj.12.13.1419			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761786				2022-12-28	WOS:000076402000018
J	Dubocovich, ML; Yun, K; Al-Ghoul, WM; Benloucif, S; Masana, MI				Dubocovich, ML; Yun, K; Al-Ghoul, WM; Benloucif, S; Masana, MI			Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms	FASEB JOURNAL			English	Article						melatonin receptors; suprachiasmatic nucleus; C3H/HeN mouse; luzindole; 4P-ADOT; 4P-PDOT; mt(1); Mel(1a); Mel(1b)	RAT SUPRACHIASMATIC NUCLEI; SUBTYPES; RETINA; CLOCK; LOCALIZATION; PHARMACOLOGY; INHIBITION; MODULATION; RESPONSES; BINDING	This study demonstrates the involvement of the MT2 (Mel(1b)) melatonin receptor in mediating phase advances of circadian activity rhythms by melatonin, In situ hybridization histochemistry with digoxigenin-labeled oligonucleotide probes revealed for the first time the expression of mt(1) and MT2 melatonin receptor mRNA within the suprachiasmatic nucleus of the C3H/HeN mouse. Melatonin (0.9 to 30 mu g/mouse, s.c.) administration during 3 days at the end of the subjective day (CT 10) to C3H/HeN mice kept in constant dark phase advanced circadian rhythms of wheel running activity in a dose-dependent manner [EC50=0.72 mu g/mouse; 0.98+/-0.08 h (n=15) maximal advance at 9 mu g/mouse], Neither the selective MT2 melatonin receptor antagonists 4P-ADOT and 4P-PDOT (90 mu/mouse, s.c.) nor luzindole (300 mu g/mouse, s.c.), which shows 25-fold higher affinity for the MTS than the mt(1) subtype, affected the phase of circadian activity rhythms when given alone at CT 10, All three antagonists, however, shifted to the right the dose-response curve to melatonin, as they significantly reduced the phase shifting effects of 0.9 and 3 mu g melatonin, This is the first study to demonstrate that melatonin phase advances circadian rhythms by activation of a membrane-bound melatonin receptor and strongly suggests that this effect is mediated through the MT2 melatonin receptor subtype within the circadian timing system. We conclude that the MT2 melatonin receptor subtype is a novel therapeutic target for the development of subtype-selective analogs for the treatment of circadian sleep and mood-related disorders.-Dubocovich, M. L., Yun, K., Al-Ghoul, W. M., Benloucif, S., Masana, M, I. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms.	Northwestern Univ, Dept Mol Pharmacol & Biol Chem S215, Sch Med, Drug Discovery Program, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA	Northwestern University; Northwestern University	Dubocovich, ML (corresponding author), Northwestern Univ, Dept Mol Pharmacol & Biol Chem S215, Sch Med, Drug Discovery Program, 303 E Chicago Ave, Chicago, IL 60611 USA.	dubo@nwu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052685, R01MH042922] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES 07124] Funding Source: Medline; NIMH NIH HHS [R01 MH052685-05, R01 MH042922-14, MH 52685, R01 MH052685, R01 MH042922, MH 42922] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG SM, 1993, MELATONIN BIOSYNTHES, P187; Benloucif S, 1997, AM J PHYSIOL-REG I, V273, pR1855, DOI 10.1152/ajpregu.1997.273.6.R1855; Benloucif S, 1996, J BIOL RHYTHM, V11, P113, DOI 10.1177/074873049601100204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cassone V M, 1986, J Biol Rhythms, V1, P219, DOI 10.1177/074873048600100304; CASSONE VM, 1990, TRENDS NEUROSCI, V13, P457, DOI 10.1016/0166-2236(90)90099-V; CASSONE VM, 1987, NEUROSCI LETT, V81, P29, DOI 10.1016/0304-3940(87)90335-1; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Conway S, 1997, FEBS LETT, V407, P121, DOI 10.1016/S0014-5793(97)00315-3; Doolen S, 1998, EUR J PHARMACOL, V345, P67, DOI 10.1016/S0014-2999(98)00064-8; DUBOCOVICH ML, 1983, NATURE, V306, P782, DOI 10.1038/306782a0; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Dubocovich ML, 1996, BEHAV BRAIN RES, V73, P141; DUBOCOVICH ML, 1988, J PHARMACOL EXP THER, V246, P902; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; DUBOCOVICH ML, 1993, PHARM LIBR, V20, P285; DUBOCOVICH ML, 1998, MELATONIN RECEPTORS, P187; Foulkes NS, 1997, TRENDS NEUROSCI, V20, P487, DOI 10.1016/S0166-2236(97)01109-0; GOTO M, 1989, J PINEAL RES, V7, P195, DOI 10.1111/j.1600-079X.1989.tb00667.x; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; Horn A. S., 1992, [No title captured], Patent No. [US5151446, 5151446]; KRAUSE DN, 1995, EUR J PHARMACOL, V276, P207, DOI 10.1016/0014-2999(95)00028-J; LAITINEN JT, 1990, ENDOCRINOLOGY, V126, P2110, DOI 10.1210/endo-126-4-2110; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; Masana MI, 1998, INT CONGR SER, V1152, P301; McArthur AJ, 1997, ENDOCRINOLOGY, V138, P627, DOI 10.1210/en.138.2.627; MILLER JA, 1987, NEUROSCI LETT, V81, P345, DOI 10.1016/0304-3940(87)90408-3; MIRANDA RC, 1992, CEREB CORTEX, V2, P1, DOI 10.1093/cercor/2.1.1; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SACK RL, 1992, J CLIN ENDOCR METAB, V75, P127, DOI 10.1210/jcem.75.1.1619000; SIUCIAK JA, 1990, EUR J PHARMACOL, V180, P387, DOI 10.1016/0014-2999(90)90328-4; STARKEY SJ, 1995, NEUROREPORT, V6, P1947, DOI 10.1097/00001756-199510020-00029; Vanhoutte PM, 1996, PHARMACOL REV, V48, P1; Wirz-Justice Anna, 1995, P999; WittEnderby PA, 1996, MOL PHARMACOL, V50, P166; Ying SW, 1996, EUR J PHARMACOL, V296, P33, DOI 10.1016/0014-2999(95)00684-2; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	41	316	341	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1211	1220		10.1096/fasebj.12.12.1211	http://dx.doi.org/10.1096/fasebj.12.12.1211			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737724				2022-12-28	WOS:000075738500016
J	Kothapalli, D; Hayashi, N; Grotendorst, GR				Kothapalli, D; Hayashi, N; Grotendorst, GR			Inhibition of TGF-beta-stimulated CTGF gene expression and anchorage-independent growth by cAMP identifies a CTGF-dependent restriction point in the cell cycle	FASEB JOURNAL			English	Article						signal transduction; promoter; wound repair; fibrosis; growth regulation	INDUCIBLE GENE; PROLIFERATION; FIBROBLASTS; PLATELETS; PATHWAYS; PROTEIN; FAMILY; ARREST; AMP	CTGF is a 38 kDa cysteine-rich peptide whose synthesis and secretion are selectively induced by transforming growth factor beta (TGF-beta) in connective tissue cells. We have investigated the sig naling pathways controlling the TGF-beta induction of connective tissue growth factor (CTGF) gene expression. Our studies indicate that inhibitors of tyrosine kinases and protein kinase C do not block the signaling pathway used by TGF-beta to induce CTGF gene expression. In contrast, elevation of cAMP levels within the target cells by a variety of methods blocked the induction of CTGF by TGF-beta, Furthermore, agents that elevate cAMP blocked the induction of anchorage-independent growth (AIG) by TGF-beta, Inhibition of AIG could be overcome by the addition of CTGF, indicating that it was not a general inhibition of growth but a selective inhibition of CTGF synthesis that is responsible for the inhibition of TGF-beta-induced AIG by cAMP, Kinetic studies of the induction of DNA synthesis by CTGF in cells arrested by cAMP indicate that the block occurs in very late G(1), These and other studies in monolayer cultures suggest that the CTGF restriction point in the cell cycle is distinct from the adhesion-dependent arrest point.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA	University of Miami	Grotendorst, GR (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, 1600 NW 10th Ave, Miami, FL 33136 USA.				NIGMS NIH HHS [GM37223] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; ASSOIAN RK, 1993, CELL BIOL BIOTECHNOL; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHILDS CB, 1982, P NATL ACAD SCI-BIOL, V79, P5312, DOI 10.1073/pnas.79.17.5312; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; EDWARDS DR, 1991, HORMONAL CONTROL REG, V16; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; HAMMES MS, 1995, KIDNEY INT, V48, P501, DOI 10.1038/ki.1995.320; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; HOWE PH, 1989, CANCER RES, V49, P6024; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; THALACKER FW, 1992, BIOCHEM J, V287, P855, DOI 10.1042/bj2870855; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	34	96	100	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1151	1161		10.1096/fasebj.12.12.1151	http://dx.doi.org/10.1096/fasebj.12.12.1151			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737718				2022-12-28	WOS:000075738500010
J	Wolff, GL; Kodell, RL; Moore, SR; Cooney, CA				Wolff, GL; Kodell, RL; Moore, SR; Cooney, CA			Maternal epigenetics and methyl supplements affect agouti gene expression in A(vy)/a mice	FASEB JOURNAL			English	Article						maternal diet; methyl supplementation; DNA methylation; epigenetic regulation of gene expression; yellow mice	X-CHROMOSOME INACTIVATION; NEURAL-TUBE DEFECTS; DNA METHYLTRANSFERASE; MOUSE; PARTICLE; MUTATION; CHOLINE; INHERITANCE; METABOLISM; METHIONINE	'Viable yellow' (A(vy)/alpha) mice are larger, obese, hyperinsulinemic, more susceptible to cancer, and, on average, shorter lived than their non-yellow siblings. They are epigenetic mosaics ranging from a yellow phenotype with maximum ectopic agouti overexpression, through a continuum of mottled agouti/yellow phenotypes with partial agouti overexpression, to a pseudoagouti phenotype with minimal ectopic expression. Pseudoagouti A(vy)/a mice are lean, healthy, and longer lived than their yellow siblings. Here we report that feeding pregnant black a/a dams methyl-supplemented diets alters epigenetic regulation of agouti expression in their offspring, as indicated by increased agouti/black mottling in the direction of the pseudoagouti phenotype, We also present confirmatory evidence that epigenetic phenotypes are maternally heritable. Thus A(vy) expression, already known to be modulated by imprinting, strain-specific modification, and maternal epigenetic inheritance, is also modulated by maternal diet. These observations suggest, at least in this special case, that maternal dietary supplementation may positively affect health and longevity of the offspring, Therefore, this experimental system should be useful for identifying maternal factors that modulate epigenetic mechanisms, especially DNA methylation, in developing embryos.	US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; US FDA, Div Biometry & Risk Assessment, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; Univ Arkansas Med Sci, Dept Biochem Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pharmacol Interdisciplinary Toxicol, Little Rock, AR 72205 USA; Bionet Corp, Jefferson, AR 72079 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Wolff, GL (corresponding author), US FDA, Div Biochem Toxicol, Natl Ctr Toxicol Res, 3900 NCTR Rd, Jefferson, AR 72079 USA.			Cooney, Craig/0000-0003-4279-557X				Adams R. L. P., 1985, MOL BIOL DNA METHYLA; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; Argeson AC, 1996, GENETICS, V142, P557; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BULTMAN SJ, 1994, GENE DEV, V8, P481, DOI 10.1101/gad.8.4.481; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Conover William Jay, 1998, PRACTICAL NONPARAMET, V350; COONEY CA, 1993, GROWTH DEVELOP AGING, V57, P261; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FEENSTRA A, 1986, NUCLEIC ACIDS RES, V14, P4343, DOI 10.1093/nar/14.10.4343; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FUNG KY, 1994, RISK ANAL, V14, P639, DOI 10.1111/j.1539-6924.1994.tb00277.x; GARNER SC, 1995, J NUTR, V125, P2851; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; Henikoff S, 1997, TRENDS GENET, V13, P293, DOI 10.1016/S0168-9525(97)01219-5; Jablonka E., 1995, EPIGENETIC INHERITAN; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jamieson RV, 1996, INT J DEV BIOL, V40, P1065; Jaspan JB, 1996, J CLIN ENDOCR METAB, V81, P2271, DOI 10.1210/jc.81.6.2271; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Koetsier PA, 1996, TRANSGENIC RES, V5, P235, DOI 10.1007/BF01972877; LANDIS RJ, 1978, INT STAT REV, V46, P237; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; MAYSHOOPES LL, 1983, MOL CELL BIOL, V3, P1371, DOI 10.1128/MCB.3.8.1371; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Mills JL, 1996, J NUTR, V126, pS756, DOI 10.1093/jn/126.suppl_3.756S; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; MINTZ B, 1991, P NATL ACAD SCI USA, V88, P9643, DOI 10.1073/pnas.88.21.9643; Moephuli SR, 1997, P NATL ACAD SCI USA, V94, P543, DOI 10.1073/pnas.94.2.543; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Petronis A, 1996, BIOESSAYS, V18, P587, DOI 10.1002/bies.950180710; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; *SAS I INC, 1993, SAS STAT US GUID, V2; SELLER MJ, 1994, CIBA F SYMP, V181, P161; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; SPERGEL G, 1975, METABOLISM, V24, P1311, DOI 10.1016/0026-0495(75)90048-7; Stewart CL, 1997, REPROD TOXICOL, V11, P309; VANSTRAATEN HWM, 1995, J NUTR, V125, P2733; Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791; Weichman K, 1997, MOL CELL BIOL, V17, P5269, DOI 10.1128/MCB.17.9.5269; WOLFF GL, 1987, CARCINOGENESIS, V8, P1889, DOI 10.1093/carcin/8.12.1889; Wolff GL, 1996, FUND APPL TOXICOL, V29, P176, DOI 10.1006/faat.1996.0019; WOLFF GL, 1978, GENETICS, V88, P529; Wu M, 1997, P NATL ACAD SCI USA, V94, P890, DOI 10.1073/pnas.94.3.890; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zeisel SH, 1996, ADV EXP MED BIOL, V399, P131	53	757	779	3	96	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					949	957		10.1096/fasebj.12.11.949	http://dx.doi.org/10.1096/fasebj.12.11.949			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707167				2022-12-28	WOS:000075372600005
J	Gangur, V; Simons, FER; Hayglass, KT				Gangur, V; Simons, FER; Hayglass, KT			Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses	FASEB JOURNAL			English	Article						environmental antigens; Th1/Th2 subsets; chemokine; TNF; interleukin; interferon gamma	INTERFERON-INDUCIBLE PROTEIN-10; PERIPHERAL-BLOOD LYMPHOCYTES; IMMUNE-RESPONSE; T-LYMPHOCYTES; IN-VIVO; CHEMOKINES; EXPRESSION; CYTOKINE; RANTES; PROLIFERATION	Human interferon-inducible protein 10 (IP-10) differs from most chemokines in its apparent specificity for activated T lymphocytes, We hypothesized that LP-10 was relevant not only for recruiting T cells to inflammatory sites, but also for regulating cytokine synthesis patterns. We examined the effect of recombinant human LP-10 (rhIP-10) on human interferon gamma (IFN-gamma) and interleukin 4 (IL-4) production by fresh peripheral blood mononuclear cells. We demonstrate for the first time that this CXC chemokine selectively up-regulates human T cell cytokine synthesis, with enhancement selectively targeted to promotion of Th1-like dominance. Superantigen (TSST-1), soluble anti-CD3 mAb, and phytohemagglutinin were used to activate distinct intracellular signaling pathways, thereby inducing quantitatively different IFN-gamma:IL-4 ratios. Selective enhancement of IFN-gamma responses was consistently observed, with median increases of 105-470%. Environmental antigens (Ag) were used to evaluate IP-10's effect on CD4-dependent, chloroquine-sensitive cytokine synthesis. Ag-driven IFN-gamma responses exhibited median 19- to 30-fold increases in the presence of nanomolar concentrations of rhIP-10, IL-4 responses were neither enhanced nor inhibited under any of the conditions tested. These findings suggest a potential role for this T cell-focused chemokine in maintenance of the default Th1-like responses usually seen to environmental Ag and indicate a potential application in the modulation of Ag-driven responses in vivo.	Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Hayglass, KT (corresponding author), Univ Manitoba, Dept Immunol, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	HayGlass@ms.umanitoba.ca		HayGlass, Kent/0000-0002-4621-7737				Abe M, 1996, J INVEST DERMATOL, V107, P360, DOI 10.1111/1523-1747.ep12363337; Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Amichay D, 1996, J IMMUNOL, V157, P4511; Angiolillo AL, 1996, ANN NY ACAD SCI, V795, P158, DOI 10.1111/j.1749-6632.1996.tb52664.x; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cassatella MA, 1997, EUR J IMMUNOL, V27, P111, DOI 10.1002/eji.1830270117; CONLON K, 1995, EUR J IMMUNOL, V25, P751, DOI 10.1002/eji.1830250319; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; IMADA M, 1995, INT IMMUNOL, V7, P229, DOI 10.1093/intimm/7.2.229; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; Karpus WJ, 1997, J IMMUNOL, V158, P4129; Lloyd AR, 1996, J IMMUNOL, V156, P932; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lukacs NW, 1997, AM J PATHOL, V150, P1861; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; MireSluis AR, 1996, J IMMUNOL METHODS, V194, P13, DOI 10.1016/0022-1759(96)00069-5; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; SARRIS AH, 1995, BLOOD, V86, P651, DOI 10.1182/blood.V86.2.651.bloodjournal862651; SARRIS AH, 1993, J EXP MED, V178, P1127, DOI 10.1084/jem.178.3.1127; Schrum S, 1996, J IMMUNOL, V157, P3598; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; Strieter RM, 1996, J IMMUNOL, V156, P3583; Tannenbaum CS, 1996, J IMMUNOL, V156, P693; Taub DD, 1996, J IMMUNOL, V156, P2095; Taub DD, 1996, BLOOD, V87, P1423, DOI 10.1182/blood.V87.4.1423.bloodjournal8741423; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Taub DD, 1996, J LEUKOCYTE BIOL, V59, P81, DOI 10.1002/jlb.59.1.81; vanAcker FAA, 1996, MEDIAT INFLAMM, V5, P393, DOI 10.1155/S0962935196000567	40	123	124	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					705	713		10.1096/fasebj.12.9.705	http://dx.doi.org/10.1096/fasebj.12.9.705			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619449				2022-12-28	WOS:000074011000009
J	Suc, I; Meilhac, O; Lajoie-Mazenc, I; Vandaele, J; Jurgens, G; Salvayre, R; Negre-Salvayre, A				Suc, I; Meilhac, O; Lajoie-Mazenc, I; Vandaele, J; Jurgens, G; Salvayre, R; Negre-Salvayre, A			Activation of EGF receptor by oxidized LDL	FASEB JOURNAL			English	Article						signaling; 4-hydroxynonenal; tyrosine phosphorylation	LOW-DENSITY-LIPOPROTEIN; EPIDERMAL GROWTH-FACTOR; FACTOR GENE-EXPRESSION; MACROPHAGE-LIKE CELLS; PHOSPHOTYROSINE PHOSPHATASE; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; PROTEIN-KINASE; SH2 DOMAINS	Oxidized low density lipoproteins (oxLDL) are thought to play a major role: in atherosclerosis, OxLDL exhibit a wide variety of biological effects resulting from their ability to interfere with intracellular signaling, The cellular targets and primary signaling events of oxLDL are unknown. We report that oxLDL elicit, in intact cells, tyrosine phosphorylation of the epithelial growth factor receptor (EGFR) and activation of its signaling pathway. This activation triggered by oxLDL was associated with derivatization of reactive amino groups of EGFR and was mimicked by 4-hydroxynonenal (4-HNE, a major lipid peroxidation product of oxLDL), Immunopurified EGFR was derivatized and activated in vitro by oxLDL lipid extracts and 4-HNE, thus indicating that 1) EGFR may be a primary target of oxidized lipids and 2) EGFR derivatization may be associated with activation. The reported data suggest that EGFR acts as a sensor for oxidized lipids. We therefore propose a novel concept of the mechanism by which oxidized lipids (contained in oxLDL or more generally produced during oxidative stress) are able to activate receptor tyrosine kinase and subsequent signaling pathways, resulting finally in a gain of function.	CHU Rangueil, INSERM, U466, IFR 31, F-31403 Toulouse 4, France; CHU Rangueil, Inst Louis Bugnard, Dept Biochem, F-31403 Toulouse, France; Karl Franzens Univ Graz, Inst Med Biochem, Graz, Austria	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; University of Graz	Negre-Salvayre, A (corresponding author), CHU Rangueil, INSERM, U466, IFR 31, 1 Ave Jean Pouhles, F-31403 Toulouse 4, France.		Meilhac, Olivier/N-4385-2017; Jürgens, Günther/B-8818-2011; Lajoie-Mazenc, Isabelle/M-4636-2014	Meilhac, Olivier/0000-0002-3740-7539; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; COFFER PJ, 1995, ONCOGENE, V11, P561; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; KASLAUKAS A, 1994, CURR OPIN GENE DEV, V4, P5; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NATARAJAN V, 1995, J LIPID RES, V36, P2005; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; TAN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1001, DOI 10.1006/bbrc.1994.2028; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	45	124	127	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					665	671		10.1096/fasebj.12.9.665	http://dx.doi.org/10.1096/fasebj.12.9.665			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619445				2022-12-28	WOS:000074011000005
J	Susini, S; van Haasteren, G; Li, SL; Prentki, M; Schlegel, W				Susini, S; van Haasteren, G; Li, SL; Prentki, M; Schlegel, W			Essentiality of intron control in the induction of c-fos by glucose and glucoincretin peptides in INS-1 beta-cells	FASEB JOURNAL			English	Article						immediate-early response genes; proto-oncogenes; intragenic response element; glucagon-like peptide 1; intracellular Ca2+	GENE-EXPRESSION; INSULIN-SECRETION; PROINSULIN BIOSYNTHESIS; INTRACELLULAR CA2+; TRANSCRIPTION; CALCIUM; GROWTH; ACTIVATION; APOPTOSIS; PROMOTER	Glucose controls long-term processes in the pancreatic beta-cell such as metabolic enzymes gene expression, cell growth, and apoptosis. Such control is likely mediated via the expression of immediate-early response genes since several of these genes including c-fos are strongly induced by glucose in the beta-cell line INS-1, provided costimulation with cAMP-raising glucoincretin hormones. this study addresses the mechanism of c-fos gene activation by glucose. Glucose in the presence of chlorophenylthio-cAMP generated a low threefold induction of the c-fos/basic luciferase reporter gene, which includes only the c-fos promoter. In contrast, the c-fos/intron construct containing the first intron in addition to promoter elements showed a pronounced 16-fold induction, comparable to the increased c-fos mRNA accumulation. Similar observations were made with glucose in combination with the glucoincretins glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and pituitary adenylyl cyclase-activating peptide 38. Deletion of a 119 bp region in intron 1 that includes a transcriptional arrest site did not affect the inductive process. In contrast, a 534 bp deletion comprising a major part of the intron reduced the induction by 75%. At the promoter level, mutating the cAMP response element reduced by more than 60% the transcriptional activation whereas mutating the serum response element had no effect . Inhibitors of protein kinase A and Ca2+/calmodulin-dependent protein kinase each reduced by 50% the reporter gene activation and together fully prevented the glucose-glucoincretin effect. In conclusion, the strong induction of c-fos by glucose and glucoincretins results from Ca2+ and cAMP signaling pathways addressing both the CRE in the promoter and essential response element(s) in the first intron that are unrelated to the transcription arrest site.	Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland; Univ Montreal, Ctr Rech LC Simard, Dept Nutr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Ctr Rech LC Simard, Inst Canc, Montreal, PQ H2L 4M1, Canada	University of Geneva; Universite de Montreal; Universite de Montreal	van Haasteren, G (corresponding author), Univ Geneva, Fdn Rech Med, 64 Ave Roseraie, CH-1211 Geneva, Switzerland.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLANCHARD JM, 1992, M S-MED SCI, V8, P455, DOI 10.4267/10608/3162; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BUTEAU J, 1999, IN PRESS DIABETOLOGI; Carrion AM, 1998, MOL CELL BIOL, V18, P6921, DOI 10.1128/MCB.18.12.6921; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; COLLART MA, 1991, MOL CELL BIOL, V11, P2862; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FRODIN M, 1995, J BIOL CHEM, V270, P7885; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MARIE S, 1993, J BIOL CHEM, V268, P23881; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; Mollard P, 1996, TRENDS ENDOCRIN MET, V7, P361, DOI 10.1016/S1043-2760(96)00186-5; PHILIKPPE J, 1991, ENDOCR REV, V3, P252; Polakowska RR, 1999, J CELL BIOCHEM, V73, P355; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; THORENS B, 1993, DIABETES, V42, P1219, DOI 10.2337/diabetes.42.9.1219; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1990, CANCER BIOL, V1, P47; van Haasteren G, 1999, J RECEPT SIGNAL TR R, V19, P481, DOI 10.3109/10799899909036666; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WERLEN G, 1993, J BIOL CHEM, V268, P16596; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YADA T, 1994, J BIOL CHEM, V269, P1290; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	45	28	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					128	136		10.1096/fasebj.14.1.128	http://dx.doi.org/10.1096/fasebj.14.1.128			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627287				2022-12-28	WOS:000084784700015
J	Bounpheng, MA; Dimas, JJ; Dodds, SG; Christy, BA				Bounpheng, MA; Dimas, JJ; Dodds, SG; Christy, BA			Degradation of Id proteins by the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article						helix-loop-helix; dominant-negative regulators; 26S proteasome	CELL-CYCLE; TRANSCRIPTION FACTORS; 3T3 CELLS; IN-VIVO; APOPTOSIS; MECHANISM; LACTACYSTIN; PROTEOLYSIS; EXPRESSION; THREONINE	Id proteins act as negative regulators of bHLH transcription factors by forming; transcriptionally inactive protein complexes. The proposed function of these proteins includes promotion of cell growth and cell cycle progression, induction of apoptosis, and inhibition of cellular differentiation. We investigated the role of the ubiquitin-mediated proteolytic pathway in the degradation of the Id3 protein. We found Id3 to be a short-lived protein and estimated the half-life to be similar to 20 min in 293 cells, Using specific inhibitors of the 26S proteasome and mutant fibroblast cells with a temperature-sensitive defect in the essential El ubiquitin-activating enzyme, we show that Id3 and the related Idl and Id2 proteins are degraded through the ubiquitin-proteasome pathway. We found the Id4 protein to be much less sensitive to inhibitors of the 26S proteasome, but its degradation was dependent on the El enzyme. In addition, we observed that coexpression of the bHLH protein E47 with Id3 significantly reduced the rate of degradation of Id3, suggesting that Id3 is less susceptible to degradation by the 26S proteasome when complexed to a bHLH protein.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Struct & Cellular Biol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Christy, BA (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	christy@uthscsa.edu		Dodds, Sherry/0000-0002-7987-9542	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029850] Funding Source: NIH RePORTER; NICHD NIH HHS [R29HD29850] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DEED RW, 1994, BBA-GENE STRUCT EXPR, V1219, P160, DOI 10.1016/0167-4781(94)90261-5; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Loveys DA, 1996, NUCLEIC ACIDS RES, V24, P2813, DOI 10.1093/nar/24.14.2813; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Oyama F, 1998, NEUROSCI RES, V31, P1, DOI 10.1016/S0168-0102(98)00020-0; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815	38	105	106	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2257	2264		10.1096/fasebj.13.15.2257	http://dx.doi.org/10.1096/fasebj.13.15.2257			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593873				2022-12-28	WOS:000084310800017
J	Cardier, JE; Schulte, T; Kammer, H; Kwak, S; Cardier, M				Cardier, JE; Schulte, T; Kammer, H; Kwak, S; Cardier, M			Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells	FASEB JOURNAL			English	Article						Fas-L; LEC-1; liver; HUVEC	TUMOR-NECROSIS-FACTOR; STAPHYLOCOCCAL-ENTEROTOXIN-B; ANTIBODY-MEDIATED APOPTOSIS; FACTOR RECEPTOR; NATURAL-KILLER; DIFFERENTIAL EXPRESSION; HEPATOCYTE APOPTOSIS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; SURFACE ANTIGEN	The Fas (CD95, APO-1) receptor is a membrane-associated polypeptide that can mediate apoptosis in various cell types. Although Fas receptor is expressed in endothelial cells (EC), little is known about its function in these cells. The expression of Fas by liver endothelial cells (LEC) suggests that upon stimulation, apoptosis may occur in these cells. We show that Fas is highly and constitutively expressed in cloned murine liver endothelial cells (LEC-1). In contrast, Fast expression was not detected at the protein and mRNA level in these cells. Our results show that Fas ligation in LEC-1 induces apoptotic cell death, indicating that Fas receptor is functional in these cells. The doses of Fas agonist required to induce LEC-1 apoptosis were higher than those used previously in other cells, including hepatocytes, suggesting that LEC-1 are highly resistant to the Fas apoptotic pathway. TNF treatment of LEC-1 induced up-regulation of Fas receptor on these cells. In contrast, TNF did not induce the expression of Fast on LEC-1. An increased susceptibility to Fas-mediated apoptosis was observed in TNF-treated LEC-1. Enhanced susceptibility to Fas-mediated apoptosis was also observed in LEC-1 pretreated with actinomycin D, suggesting that transcription of message coding for protective proteins is necessary to protect these cells against Fas-mediated apoptosis. Up regulation of VCAM-1 and ICAM-1 was observed in LEC-1 treated with a dose of Fas agonist that does not induce apoptosis. To our knowledge, this is the first report that Fas mediates apoptosis in LEG, suggesting that apoptosis of these cells may participate in the liver damage observed in animals after receiving anti-Fas mAb or soluble Fast. Our findings also suggest that the Fas/FasL system may transduce activating signals independently of cell death in LEG1.-Cardier, J. E., Schulte, T., Kammer, H., Kwak, J., Cardier, M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells.	Inst Venezolano Invest Cient, Lab Fisiopatol, Ctr Med Expt, Caracas 1020A, Venezuela; Hipple Canc Res Ctr, Dayton, OH 45439 USA; Hosp Risquez, Caracas, Venezuela	Venezuelan Institute Science Research	Cardier, JE (corresponding author), Inst Venezolano Invest Cient, Lab Fisiopatol, Ctr Med Expt, Apartado Postal 21827, Caracas 1020A, Venezuela.		Cardier, Jose/ABD-6349-2020					AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Cardier JE, 1998, BLOOD, V91, P923, DOI 10.1182/blood.V91.3.923.923_923_929; Cardier JE, 1997, HEPATOLOGY, V26, P165; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; Dong CM, 1996, LAB INVEST, V74, P921; ESSER P, 1995, BIOCHEM BIOPH RES CO, V213, P1026, DOI 10.1006/bbrc.1995.2231; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gallop JR, 1995, CERN REPORT, V95, P1; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hartmann K, 1997, J IMMUNOL, V159, P4006; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1994, J IMMUNOL, V153, P1778; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MACHIZUKI K, 1996, J HEPATOL, V24, P1; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; Mohan RR, 1997, EXP EYE RES, V65, P575, DOI 10.1006/exer.1997.0371; Muschen M, 1998, HEPATOLOGY, V27, P200, DOI 10.1002/hep.510270131; NAGAKI M, 1994, GASTROENTEROLOGY, V106, P450, DOI 10.1016/0016-5085(94)90604-1; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Orange JS, 1997, J VIROL, V71, P9248, DOI 10.1128/JVI.71.12.9248-9258.1997; Oshimi Y, 1996, J IMMUNOL, V157, P2909; PILARO AM, 1994, J IMMUNOL, V153, P333; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rafi AQ, 1998, J IMMUNOL, V161, P3077; RENSINGEHL A, 1995, J INFLAMM, V45, P161; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Tsutsui H, 1996, J IMMUNOL, V157, P3967; Urayama S, 1997, BIOCHEM BIOPH RES CO, V239, P782, DOI 10.1006/bbrc.1997.7535; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	54	61	61	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1950	1960		10.1096/fasebj.13.14.1950	http://dx.doi.org/10.1096/fasebj.13.14.1950			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544178				2022-12-28	WOS:000083660700007
J	Haroon, ZA; Hettasch, JM; Lai, TS; Dewhirst, MW; Greenberg, CS				Haroon, ZA; Hettasch, JM; Lai, TS; Dewhirst, MW; Greenberg, CS			Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis	FASEB JOURNAL			English	Article						tissue repair; extracellular matrix; cross-linking; endothelial cells; TGF-beta	CROSS-LINKING; FACTOR-XIII; II TRANSGLUTAMINASE; BINDING-PROTEIN; CELLS; FIBRONECTIN; FIBRINOGEN; STABILIZATION; DERIVATIVES; PUTRESCINE	Tissue transglutaminase (TG) is an enzyme that stabilizes the structure of tissues by covalently ligating extracellular matrix molecules, Expression and localization of TG are not well established during wound healing; We performed punch biopsy wounds on anesthetized rats and monitored the wound healing process by histological and immunohistochemical methods. The TG antigen and activity are expressed at sites of neovascularization in the provisional fibrin matrix within 24 h of wounding. Endothelial cells, macrophages, and skeletal muscle cells expressed TG throughout the healing process. The TG antigen within the wound was active in vivo based on the detection of isopeptide bonds. The TG antigen increased four- to fivefold by day 3 postwounding and was proteolytically degraded, TG expression occurred in association with TGF-beta, TNF-alpha, IL-6, and VEGF production in the wound. Recombinant TG increased vessel length density (a measure of angiogenesis) when applied topically in rat dorsal skin flap window chambers. We have established that TG is an important tissue stabilizing enzyme that is active during wound healing and can function to promote angiogenesis.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Greenberg, CS (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Box 2603,MSRB, Durham, NC 27710 USA.	green032@mc.duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; , Thung-Shen/0000-0002-8791-9698	NATIONAL CANCER INSTITUTE [P50CA068438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P50HL026309] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA 68438] Funding Source: Medline; NHLBI NIH HHS [HL 26309, HL 38245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achyuthan KE, 1996, MOL CELL BIOCHEM, V162, P43; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BOWNESS JM, 1988, BIOCHIM BIOPHYS ACTA, V967, P234; BOWNESS JM, 1987, CONNECT TISSUE RES, V16, P57, DOI 10.3109/03008208709001994; CLARK RAF, 1993, DERMATOL CLIN, V11, P647, DOI 10.1016/S0733-8635(18)30218-3; COHEN I, 1982, J CELL BIOL, V93, P775, DOI 10.1083/jcb.93.3.775; DEWHIRST MW, 1992, RADIAT RES, V130, P345, DOI 10.2307/3578380; DOLYNCHUK KN, 1994, PLAST RECONSTR SURG, V93, P567, DOI 10.1097/00006534-199493030-00020; ELALAOUI S, 1993, FACTOR, V8, P135; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; GIBRAN NS, 1995, J SURG RES, V59, P378, DOI 10.1006/jsre.1995.1179; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IKURA K, 1994, BIOSCI BIOTECH BIOCH, V58, P1540, DOI 10.1271/bbb.58.1540; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Jones LN, 1996, DERMATOL CLIN, V14, P633, DOI 10.1016/S0733-8635(05)70390-9; Kong LP, 1997, CLIN EXP METASTAS, V15, P426, DOI 10.1023/A:1018406422727; Kuncio GS, 1998, AM J PHYSIOL-GASTR L, V274, pG240, DOI 10.1152/ajpgi.1998.274.2.G240; LAI TS, 1994, J BIOL CHEM, V269, P24596; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; MOSHER DF, 1979, J CLIN INVEST, V64, P781, DOI 10.1172/JCI109524; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; ROCH AM, 1991, INT J CANCER, V48, P215, DOI 10.1002/ijc.2910480211; SANE DC, 1988, BIOCHEM BIOPH RES CO, V157, P115, DOI 10.1016/S0006-291X(88)80020-2; Sheehan D.C., 1980, THEORY PRACTICE HIST; VALENZUELA R, 1992, AM J PATHOL, V141, P861; VOLLBERG TM, 1992, AM J RESP CELL MOL, V7, P10, DOI 10.1165/ajrcmb/7.1.10; Watanabe Y, 1997, EXP CELL RES, V233, P340, DOI 10.1006/excr.1997.3583	39	210	217	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1787	1795		10.1096/fasebj.13.13.1787	http://dx.doi.org/10.1096/fasebj.13.13.1787			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506581				2022-12-28	WOS:000083063400013
J	Bornstein, SR; Tajima, T; Eisenhofer, G; Haidan, A; Aguilera, G				Bornstein, SR; Tajima, T; Eisenhofer, G; Haidan, A; Aguilera, G			Adrenomedullary function is severely impaired in 21-hydroxylase-deficient mice	FASEB JOURNAL			English	Article						21-OH deficiency; adrenal medulla; catecholamine synthesis	CONGENITAL ADRENAL-HYPERPLASIA; NEURAL CREST DERIVATIVES; CHROMAFFIN CELLS; ADRENOCORTICAL-CELLS; SPLANCHNIC NERVE; INTRAADRENAL INTERACTIONS; LEARNING-DISABILITIES; PRENATAL TREATMENT; CORTICAL-CELLS; GROWTH-FACTORS	Deficiency of 21-hydroxylase (21-OH), one of the most common genetic defects in humans, causes low glucocorticoid and mineralocorticoid production by the adrenal cortex, but the effect of this disorder on the adrenomedullary system is unknown. Therefore, we analyzed the development, structure, and function of the adrenal medulla in 21-OH-deficient mice, an animal model resembling human congenital adrenal hyperplasia, Chromaffin cells of el-OH-deficient mice exhibited ultrastructural features of neuronal transdifferentiation with reduced granules, increased rough endoplasmic reticulum and small neurite outgowth. Migration of chromaffin cells in the adrenal to form a central medulla was impaired. Expression of phenylethanolamine-N-methyltransferase (PNMT) was reduced to 27 +/- 9% (P<0.05), as determined by quantitative TaqMan polymerase chain reaction, and there was a significant reduction of cells staining positive for PNMT in the adrenal medulla of the 21-OH-deficient mice, Adrenal contents of epinephrine were decreased to 30 +/- 2% (P<0.01) whereas norepinephrine and dopamine levels were reduced to 57 +/- 4% (P<0.01) and 50 +/- 9% (P<0.05), respectively. 21-OH-deficient mice demonstrate severe adrenomedullary dysfunction, with alterations in chromaffin cell migration, development, structure, and catecholamine synthesis. This hitherto unrecognized mechanism may contribute to the frequent clinical, mental, and therapeutic problems encountered in humans with this genetic disease.	NICHD, Dev Endocrinol Branch, NIH, Sect Endocrine Physiol, Bethesda, MD 20892 USA; NINDS, NIH, Bethesda, MD 20892 USA; Univ Leipzig, Dept Internal Med, D-7010 Leipzig, Germany	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Leipzig University	Bornstein, SR (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Sect Endocrine Physiol, Bldg 10,Rm 10n262,10 Ctr Dr MSC 1862, Bethesda, MD 20892 USA.	Bornstes@mail.nih.gov	Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000631] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000631] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMSTERDAM JD, 1987, PSYCHIAT RES, V21, P189, DOI 10.1016/0165-1781(87)90022-9; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; BELLONI AS, 1994, BIOMED RES-TOKYO, V15, P95, DOI 10.2220/biomedres.15.95; BORNSTEIN SR, 1990, ENDOCRINOLOGY, V127, P900, DOI 10.1210/endo-127-2-900; BORNSTEIN SR, 1992, ENDOCRINOLOGY, V131, P3126, DOI 10.1210/en.131.6.3126; BORNSTEIN SR, 1995, CLIN ENDOCRINOL, V42, P215, DOI 10.1111/j.1365-2265.1995.tb01866.x; BORNSTEIN SR, 1994, J CLIN ENDOCR METAB, V78, P225, DOI 10.1210/jcem.78.1.7507122; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BORNSTEIN SR, 1991, CELL TISSUE RES, V265, P1, DOI 10.1007/BF00318133; Bosinski HAG, 1997, PSYCHONEUROENDOCRINO, V22, P361, DOI 10.1016/S0306-4530(97)00033-4; CALOGERO AE, 1992, METABOLISM, V41, P839, DOI 10.1016/0026-0495(92)90164-6; CUTLER GB, 1990, NEW ENGL J MED, V323, P1806; DALLMAN MF, 1985, ENDOCR RES, V10, P213, DOI 10.1080/07435808409036499; DALLMAN MF, 1976, AM J PHYSIOL, V231, P408, DOI 10.1152/ajplegacy.1976.231.2.408; Dijkstra I, 1996, ENDOCRINOLOGY, V137, P540, DOI 10.1210/en.137.2.540; DONALDSON MDC, 1994, ARCH DIS CHILD, V70, P214, DOI 10.1136/adc.70.3.214; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; EhrhartBornstein M, 1997, HORM METAB RES, V29, P30, DOI 10.1055/s-2007-978976; EISENHOFER G, 1995, J CLIN ENDOCR METAB, V80, P3009, DOI 10.1210/jc.80.10.3009; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Engeland WC, 1998, HORM METAB RES, V30, P311, DOI 10.1055/s-2007-978890; Eranko L, 1977, Adv Biochem Psychopharmacol, V16, P519; Eranko O, 1977, Adv Biochem Psychopharmacol, V16, P525; EVINGER MJ, 1992, CELL MOL NEUROBIOL, V12, P193, DOI 10.1007/BF00712926; Forest MG, 1998, TRENDS ENDOCRIN MET, V9, P284, DOI 10.1016/S1043-2760(98)00067-8; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; FUKUSHI M, 1987, ADV NEONATAL SCREENI, P303; GONZALEZHERNANDEZ JA, 1995, CLIN EXP IMMUNOL, V99, P137; GONZALEZHERNANDEZ JA, 1994, CELL TISSUE RES, V278, P201, DOI 10.1007/s004410050208; GOODMAN R, 1978, J CELL BIOL, V78, pR1, DOI 10.1083/jcb.78.1.R1; GOTOH H, 1994, ENDOCRINOLOGY, V135, P1470, DOI 10.1210/en.135.4.1470; GOTOH H, 1988, ENDOCRINOLOGY, V123, P1923, DOI 10.1210/endo-123-4-1923; GUPTA P, 1992, ENDOCRINOLOGY, V130, P2129, DOI 10.1210/en.130.4.2129; Haidan A, 1998, ENDOCRINOLOGY, V139, P772, DOI 10.1210/en.139.2.772; Hanna GL, 1996, J CHILD ADOL PSYCHOP, V6, P63, DOI 10.1089/cap.1996.6.63; HARLAN RE, 1988, MOL NEUROBIOL, V2, P183, DOI 10.1007/BF02935345; HASBAK P, 1995, J HYPERTENS, V13, P235; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JASPER MS, 1994, NEUROENDOCRINOLOGY, V59, P97, DOI 10.1159/000126645; JERN S, 1991, HYPERTENSION, V18, P467, DOI 10.1161/01.HYP.18.4.467; JOHANSSON G, 1976, BIOL PSYCHOL, V4, P157, DOI 10.1016/0301-0511(76)90001-6; Krahenbuhl G S, 1975, J Sports Med, V3, P117; Lange DL, 1998, HYPERTENSION, V31, P403, DOI 10.1161/01.HYP.31.1.403; LEFEBVRE H, 1993, J CLIN ENDOCR METAB, V77, P1662, DOI 10.1210/jc.77.6.1662; LORIAUX DL, 1974, J CLIN ENDOCR METAB, V39, P627, DOI 10.1210/jcem-39-4-627; Marx C, 1998, NEUROIMMUNOMODULAT, V5, P5, DOI 10.1159/000026320; Marx C, 1997, J CLIN ENDOCR METAB, V82, P3136, DOI 10.1210/jc.82.9.3136; Marx C, 1998, HORM METAB RES, V30, P416, DOI 10.1055/s-2007-978907; MEFFORD IN, 1998, PROG NEUROPSYCHOPHAR, V12, P365; Merke DP, 1997, JAMA-J AM MED ASSOC, V277, P1073, DOI 10.1001/jama.277.13.1073; Miller WL, 1998, TRENDS ENDOCRIN MET, V9, P290, DOI 10.1016/S1043-2760(98)00068-X; Murray SA, 1997, MICROSC RES TECHNIQ, V36, P510; NASS R, 1991, J CHILD NEUROL, V6, P306, DOI 10.1177/088307389100600404; New MI, 1998, ANNU REV MED, V49, P311, DOI 10.1146/annurev.med.49.1.311; PHAMHUUTRUNG MT, 1973, ACTA ENDOCRINOL-COP, V73, P316; Plante E, 1996, DEV MED CHILD NEUROL, V38, P423; Remy-Jouet I, 1998, HORM METAB RES, V30, P341, DOI 10.1055/s-2007-978895; REMYJOUET I, 1994, J STEROID BIOCHEM, V50, P55, DOI 10.1016/0960-0760(94)90172-4; RITTMASTER RS, 1987, ANN INTERN MED, V106, P95, DOI 10.7326/0003-4819-106-1-95; RUDMAN D, 1981, J CLIN ENDOCR METAB, V53, P722, DOI 10.1210/jcem-53-4-722; SHIROISHI T, 1987, P NATL ACAD SCI USA, V84, P2819, DOI 10.1073/pnas.84.9.2819; SIPPELL WG, 1980, PEDIATR RES, V14, P39, DOI 10.1203/00006450-198014010-00010; UDELSMAN R, 1986, NATURE, V319, P147, DOI 10.1038/319147a0; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; VANZIJDERVELD GA, 1993, BIOL PSYCHOL, V36, P157, DOI 10.1016/0301-0511(93)90016-2; VERMES I, 1995, J CLIN ENDOCR METAB, V80, P1238, DOI 10.1210/jc.80.4.1238; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301; WURTMAN RJ, 1972, PHARMACOL REV, P411	71	54	55	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1185	1194		10.1096/fasebj.13.10.1185	http://dx.doi.org/10.1096/fasebj.13.10.1185			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385609	Bronze			2022-12-28	WOS:000081264800007
J	Li, NX; Karin, M				Li, NX; Karin, M			Is NF-kappa B the sensor of oxidative stress?	FASEB JOURNAL			English	Review						I kappa B degradation; IKK; reactive oxygen species; tumor necrosis factor; GSH	TUMOR-NECROSIS-FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; TRANSCRIPTION FACTOR; KINASE COMPLEX; IKK-ALPHA; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; BETA; ANTIOXIDANT	NF-kappa B is a dimeric transcription factor that is involved in the regulation of a large number of genes that control various aspects of the immune and inflammatory response. It is activated by a variety of stimuli ranging from cytokines, to various forms of radiation, to oxidative stress (such as exposure to H2O2). Recent studies have advanced our understanding of the signal transduction pathway leading to NF-kappa B activation by cytokines and will provide insights for the mechanism by which NF-kappa B is regulated by oxidative stress. An important question that is yet to be answered is whether reactive oxygen species play a physiological role in NF-kappa B activation.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES006376, R01ES004151] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04151, ES 06376] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gilman AG, 1985, GOODMAN GILMANS PHAR, V7th; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kretz-Remy C, 1998, J BIOL CHEM, V273, P3180, DOI 10.1074/jbc.273.6.3180; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MENON SD, 1995, J BIOL CHEM, V270, P18881; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sies H., 1991, OXIDATIVE STRESS OXI; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	55	707	731	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1137	1143		10.1096/fasebj.13.10.1137	http://dx.doi.org/10.1096/fasebj.13.10.1137			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385605				2022-12-28	WOS:000081264800003
J	Niederberger, V; Hayek, B; Vrtala, S; Laffer, S; Twardosz, A; Vangelista, L; Sperr, WR; Valent, P; Rumpold, H; Kraft, D; Ehrenberger, K; Valenta, R; Spitzauer, S				Niederberger, V; Hayek, B; Vrtala, S; Laffer, S; Twardosz, A; Vangelista, L; Sperr, WR; Valent, P; Rumpold, H; Kraft, D; Ehrenberger, K; Valenta, R; Spitzauer, S			Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7	FASEB JOURNAL			English	Article						Type I allergy; allergen; EF-hand protein; conformational epitopes; circular dichroism spectroscopy; cross-reactivity; pollen-specific expression	IMMUNOGOLD ELECTRON-MICROSCOPY; CYTOSOLIC-FREE CALCIUM; ACTIN-BINDING PROTEIN; BIRCH POLLEN; IGE-BINDING; MOLECULAR CHARACTERIZATION; PRATENSE POLLEN; IMMUNOLOGICAL CHARACTERIZATION; RECOMBINANT ALLERGENS; CRYSTAL-STRUCTURE	Type I allergy, an immunodisorder that affects almost 20% of the population worldwide, is based on the immunoglobulin E (IgE) recognition of per se innocuous antigens (allergens). Pollen from wind-pollinated plants belong to the most potent allergen sources. We report the isolation of a cDNA coding for a 8.6 kDa two EF-hand calcium binding allergen, Phl p 7, from a timothy grass (Phleum pratense) pollen expression cDNA library, using serum IgE from a grass pollen allergic patient. Sequence analysis identified Phl p 7 as a member of a recently discovered subfamily of pollen-specific calcium binding proteins. Recombinant Phl p 7 was expressed in Escherichia coli and purified to homogeneity as determined by mass spectroscopy. Approximately 10% of pollen allergic patients displayed IgE reactivity to rPhl p 7 and Phl p 7-homologous allergens present in pollens of monocotyledonic and dicotyledonic plants. Circular dichroism analysis of the calcium-bound and apo-rPhl p 7 indicated that differences in IgE recognition may be due to calcium-induced changes in the protein conformation. The fact that patients mount IgE antibodies against different protein conformations is interpreted as a footprint of a preferential sensitization against either form. The biological activity of rPhl p 7 was demonstrated by its ability to induce basophil histamine release and immediate type skin reactions in sensitized individuals. In conclusion, IgE binding to Phl p 7 represents an example for the conformation-dependent IgE recognition of an allergen. Recombinant Phl p 7 may be used for diagnosis and perhaps treatment of a group of patients who suffer from allergy to pollens of many unrelated plant species.	Univ Vienna, Mol Immunopathol Grp, Inst Gen & Expt Pathol, AKH,Med Sch, A-1090 Vienna, Austria; Univ Vienna, Dept Otorhinolaryngol, AKH, A-1090 Vienna, Austria; Univ Vienna, Inst Med & Chem Lab Diagnost, AKH, A-1090 Vienna, Austria; European Mol Biol Lab, Heidelberg, Germany; Univ Vienna, Dept Internal Med 1, Div Hematol, AKH, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; European Molecular Biology Laboratory (EMBL); University of Vienna	Valenta, R (corresponding author), Univ Vienna, Mol Immunopathol Grp, Inst Gen & Expt Pathol, AKH,Med Sch, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019; Valent, Peter/B-8533-2016; Sperr, Mast/V-4767-2019; Test, PV/U-9451-2019	Gamperl, Susi/0000-0003-0456-5095; Valent, Peter/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Vangelista, Luca/0000-0003-0764-5031; Sperr, Wolfgang/0000-0003-3288-8027; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243				Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BLUM HE, 1977, J BIOL CHEM, V252, P2834; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BREWBAKE JL, 1963, AM J BOT, V50, P859, DOI 10.2307/2439772; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; FRANKLINTONG VE, 1993, PLANT J, V4, P163, DOI 10.1046/j.1365-313X.1993.04010163.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Grote M, 1998, J ALLERGY CLIN IMMUN, V101, P60, DOI 10.1016/S0091-6749(98)70194-0; GROTE M, 1993, J HISTOCHEM CYTOCHEM, V41, P745, DOI 10.1177/41.5.8468456; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427, DOI 10.1177/42.3.8308259; Hayek B, 1998, J IMMUNOL, V161, P7031; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; Kay A.B., 1997, ALLERGY ALLERGIC DIS; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, J IMMUNOL, V157, P4953; MALHO R, 1994, PLANT J, V5, P331, DOI 10.1111/j.1365-313X.1994.00331.x; Messerli M, 1997, J CELL SCI, V110, P1269; MILLER DD, 1992, J CELL SCI, V101, P7; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Smith PM, 1997, INT ARCH ALLERGY IMM, V114, P265, DOI 10.1159/000237678; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; Thorn KS, 1997, STRUCTURE, V5, P19, DOI 10.1016/S0969-2126(97)00163-9; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVE G, 1995, EMBO J, V14, P4922, DOI 10.1002/j.1460-2075.1995.tb00175.x; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	62	89	98	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					843	856		10.1096/fasebj.13.8.843	http://dx.doi.org/10.1096/fasebj.13.8.843			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224228				2022-12-28	WOS:000080372500008
J	Albini, A; Florio, T; Giunciuglio, D; Masiello, L; Carlone, S; Corsaro, A; Thellung, S; Cai, T; Noonan, DM; Schettini, G				Albini, A; Florio, T; Giunciuglio, D; Masiello, L; Carlone, S; Corsaro, A; Thellung, S; Cai, T; Noonan, DM; Schettini, G			Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis	FASEB JOURNAL			English	Article						endothelial cells; monocytes; macrophages; invasion; neovascularization; somatostatin receptors	PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY; VASCULAR ENDOTHELIAL-CELLS; MONOCYTE CHEMOTAXIS; TAT PROTEIN; TYROSINE-PHOSPHATASE; PANCREATIC-CANCER; BASEMENT-MEMBRANE; IN-VITRO; PROLIFERATION; RECEPTOR	Somatostatin and its analogs are active in the inhibition of SST receptor-positive endocrine neoplasms, but their activity and mechanism in non endocrine tumors is not clear. Somatostatin potently inhibited growth of a Kaposi's sarcoma xenograft in nude mice, yet in vitro the tumor cells did not express any known somatostatin receptors and were not growth inhibited by somatostatin. Histological examination revealed limited vascularization in the somatostatin-treated tumors as compared with the controls. Somatostatin was a potent inhibitor of angiogenesis in an in vivo assay. In vitro, somatostatin inhibited endothelial cell growth and invasion. Migration of monocytes, important mediators of the angiogenic cascade, was also inhibited by somatostatin. Both cells types expressed somatostatin receptor mRNAs. These data demonstrate that somatostatin is a potent antitumor angiogenesis compound directly affecting both endothelial and monocytic cells. The debated function of somatostatin in tumor treatment and the design of therapeutic protocols should be reexamined considering these data.	Ist Nazl Ric Canc, Modulo Progress Neoplast, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Serv Farmacol & Neurosci, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol, Sez Farmacol, I-16132 Genoa, Italy; Ctr Biotecnol Avanzate, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Albini, A (corresponding author), Ist Nazl Ric Canc, Adv Biotechnol Ctr, Tumor Progress Sect, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		FLORIO, TULLIO/ABG-3182-2020; Noonan, Douglas M/A-8620-2010; Thellung, Stefano/L-8802-2015; Florio, Tullio/A-2211-2012	Noonan, Douglas M/0000-0001-8058-0719; Thellung, Stefano/0000-0002-2010-331X; Florio, Tullio/0000-0002-2394-996X; Albini, Adriana/0000-0002-9624-5103; Corsaro, Alessandro/0000-0003-4565-7914				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ALBINI A, 1992, INT J CANCER, V52, P234, DOI 10.1002/ijc.2910520214; Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895; BENELLI R, 1994, RES VIROLOGY, V145, P251, DOI 10.1016/S0923-2516(07)80030-6; Benelli R, 1998, AIDS, V12, P261, DOI 10.1097/00002030-199803000-00003; BENSAID M, 1992, INT J CANCER, V50, P796, DOI 10.1002/ijc.2910500522; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHEUNG NW, 1995, ENDOCRINOLOGY, V136, P4174, DOI 10.1210/en.136.10.4174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Danesi R, 1997, CLIN CANCER RES, V3, P265; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Fisher WE, 1998, J NATL CANCER I, V90, P322, DOI 10.1093/jnci/90.4.322; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; FLORIO T, 1992, J BIOL CHEM, V267, P24169; Florio T, 1996, J MOL ENDOCRINOL, V17, P89, DOI 10.1677/jme.0.0170089; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Keri G, 1996, P NATL ACAD SCI USA, V93, P12513, DOI 10.1073/pnas.93.22.12513; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MARTINET Y, 1994, J IMMUNOL METHODS, V174, P209, DOI 10.1016/0022-1759(94)90024-8; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; PASSANITI A, 1992, LAB INVEST, V67, P519; POLVERINI PJ, 1997, REGULATION ANGIOGENE, P11; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; Reardon DB, 1997, MOL ENDOCRINOL, V11, P1062, DOI 10.1210/me.11.8.1062; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; REUBI JC, 1994, INT J CANCER, V56, P681, DOI 10.1002/ijc.2910560513; REUBI JC, 1995, TRENDS PHARMACOL SCI, V16, P110, DOI 10.1016/S0165-6147(00)88992-0; Robbins RJ, 1996, METABOLISM, V45, P98, DOI 10.1016/S0026-0495(96)90096-7; SCHALLY AV, 1988, CANCER RES, V48, P6977; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THOMPSON EW, 1991, CANCER RES, V51, P2670; WIEDERMANN CJ, 1993, BLOOD, V82, P954; WOLTERING E, 1990, J SURG RES, V50, P245	45	107	114	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					647	655		10.1096/fasebj.13.6.647	http://dx.doi.org/10.1096/fasebj.13.6.647			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094925				2022-12-28	WOS:000079527200006
J	Shimura, M; Tanaka, Y; Nakamura, S; Minemoto, Y; Yamashita, K; Hatake, K; Takaku, F; Ishizaka, Y				Shimura, M; Tanaka, Y; Nakamura, S; Minemoto, Y; Yamashita, K; Hatake, K; Takaku, F; Ishizaka, Y			Micronuclei formation and aneuploidy induced by Vpr, an accessory gene of human immunodeficiency virus type 1	FASEB JOURNAL			English	Article						HIV-1/Vpr; multinucleation; genomic instability	CELL-CYCLE CONTROL; WILD-TYPE P53; VIRION-ASSOCIATED PROTEIN; PRODUCTIVE INFECTION; MAMMALIAN-CELLS; HIV-1 VPR; TRANSCRIPTIONAL ACTIVATION; CHECKPOINT CONTROL; HUMAN-LYMPHOCYTES; GROWTH ARREST	Vpr, an accessory gene of HIV-1, induces cell cycle abnormality with accumulation at G2/M phase and increased ploidy, Since abnormality of mitotic checkpoint control provides a molecular basis of genomic instability, we studied the effects of Vpr on genetic integrity using a stable clone, named MIT-23, in which Vpr expression is controlled by the tetracycline-responsive promoter. Treatment of MIT-23 cells with doxycycline (DOX) induced Vpr expression with a giant multinuclear cell formation. Increased micronuclei (MIN) formation was also detected in these cells. Abolishment of Vpr expression by DOX removal induced numerous asynchronous cytokinesis in the multinuclear cells with leaving MIN in cytoplasm, suggesting that the transient Vpr expression could cause genetic unbalance. Consistent with this expectation, MIT-23 cells, originally pseudodiploid cells, became aneuploid after repeated expression of Vpr, Experiments using deletion mutants of Vpr revealed that the domain inducing MIN formation as well as multinucleation was located in the carboxy-terminal region of Vpr protein. These results suggest that Vpr induces genomic instability, implicating the possible role in the development of AIDS-related malignancies.	Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Bunkyo Ku, Tokyo 1138613, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol Biol & Cellular Biol, Kanazawa, Ishikawa 9200934, Japan; Jichi Med Sch, Minami Kawachi, Tochigi 3290498, Japan	National Center for Global Health & Medicine - Japan; Tokyo Metropolitan Institute of Medical Science; Kanazawa University; Jichi Medical University	Ishizaka, Y (corresponding author), Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.imcj.go.jp						ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Andreassen PR, 1996, MUTAT RES-FUND MOL M, V372, P181, DOI 10.1016/S0027-5107(96)00138-8; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; BENN PA, 1992, HUMAN CYTOGENETICS P, P91; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; Biggar RJ, 1996, INT J CANCER, V68, P754; Bodeus M, 1997, RES VIROLOGY, V148, P207, DOI 10.1016/S0923-2516(97)83990-8; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen EA, 1996, CURR TOP MICROBIOL, V214, P219; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; EASTMOND DA, 1989, ENVIRON MOL MUTAGEN, V13, P34, DOI 10.1002/em.2850130104; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gu JR, 1997, MOL CELL BIOL, V17, P4033, DOI 10.1128/MCB.17.7.4033; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; Macreadie IG, 1997, FEBS LETT, V410, P145, DOI 10.1016/S0014-5793(97)00542-5; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARZIO PD, 1995, J VIROL, V69, P7909; MAYER V, 1995, EUR J CANCER PREV, V4, P211, DOI 10.1097/00008469-199506000-00001; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; Ohtsuki T, 1997, BIOCHEM BIOPH RES CO, V230, P81, DOI 10.1006/bbrc.1996.5887; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; PENN I, 1978, SURGERY, V83, P492; PLANELLES V, 1995, J VIROL, V69, P5883, DOI 10.1128/JVI.69.9.5883-5889.1995; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Shimura M, 1997, FEBS LETT, V417, P379, DOI 10.1016/S0014-5793(97)01327-6; SPECTOR BD, 1978, CLIN IMMUNOL IMMUNOP, V11, P12, DOI 10.1016/0090-1229(78)90200-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Wang LL, 1996, GENE, V178, P7, DOI 10.1016/0378-1119(96)00312-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; Zhang CS, 1997, VIROLOGY, V230, P103, DOI 10.1006/viro.1997.8459; ZHAO LJ, 1994, J BIOL CHEM, V269, P15577	70	41	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					621	637		10.1096/fasebj.13.6.621	http://dx.doi.org/10.1096/fasebj.13.6.621			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094923				2022-12-28	WOS:000079527200004
J	Piredda, L; Farrace, MG; Lo Bello, M; Malorni, W; Melino, G; Petruzzelli, R; Piacentini, M				Piredda, L; Farrace, MG; Lo Bello, M; Malorni, W; Melino, G; Petruzzelli, R; Piacentini, M			Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis	FASEB JOURNAL			English	Article						cell death; human neuroblastoma cells; staurosporine; histone H2B; microtubules; chromatin; glutathione	PLACENTAL GLUTATHIONE TRANSFERASE; HUMAN NEUROBLASTOMA-CELLS; CROSS-LINKING; S-TRANSFERASES; RAT-LIVER; DEATH; LOCALIZATION; STIMULATION; EXPRESSION; ANTIBODIES	Overexpression of 'tissue' transglutaminase (tTG) in the human neuroblastoma cells increases spontaneous apoptosis and renders these cells highly susceptible to death induced by various stimuli, We used immunoprecipitation to identify cellular proteins that interact specifically with tTG in SK-N-BE(2)-derived stable transfectants, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis showed that tTG binding proteins have molecular masses of 110, 50, 22, 14, and 12 kDa. Microsequencing and computer search analyses allowed us to identify these polypeptides as the beta-tubulin (50 kDa), the histone H2B (14 kDa), and two GST P1-l-truncated forms (22 and 12 kDa), The specificity of the interaction between tTG and these proteins was confirmed by competing tTG binding with purified enzyme and by detecting tTG in immunoprecipitates obtained using beta-tubulin or GST P1-l mAb's, Here we demonstrate that the GST P1-1 acts as an efficient acyl donor as well as acceptor tTG substrate both in cells and in vitro. The tTG-catalyzed polymerization of GST P1-l leads to its functional inactivation and is competitively inhibited by GSH, By contrast, the tTG-beta-tubulin interaction does not result in the cross-linking of this cytoskeletal protein, which suggests that microtubules act as the anchorage site for tTG and GST P1-1 interaction.	Univ Rome Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Super Sanita, Ultrastrutture Lab, I-00161 Rome, Italy; IRCCS, IDI, Biochem Lab, Rome, Italy; Univ GD Annunsio, Dept Biomed Sci, Chieti, Italy; IRCCS, Cell Biol Lab L Spallanzani, Rome, Italy	University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Piacentini, M (corresponding author), Univ Rome Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	mauro.piacentini@UniRoma2.it	Malorni, Walter/G-5874-2016; Piacentini, Mauro/I-2411-2016	Piacentini, Mauro/0000-0003-2919-1296; malorni, walter/0000-0002-1223-7000				Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; BATTISTONI A, 1995, PROTEIN EXPRES PURIF, V6, P579, DOI 10.1006/prep.1995.1076; ELBARBARY A, 1993, HEARING RES, V71, P80; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; Gorza L, 1997, AM J PATHOL, V150, P2087; GREEN F, 1992, NEW STATESMAN SOC, V5, P30; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KIM H, 1979, J CELL BIOL, V80, P226; Kletsas D, 1998, BIOCHEM BIOPH RES CO, V243, P416, DOI 10.1006/bbrc.1997.7975; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; MASSOUD R, 1991, HYBRIDOMA, V10, P89, DOI 10.1089/hyb.1991.10.89; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; MITHIEUX G, 1986, BIOCHIM BIOPHYS ACTA, V888, P49, DOI 10.1016/0167-4889(86)90070-4; Nagy L, 1997, CELL DEATH DIFFER, V4, P534, DOI 10.1038/sj.cdd.4400290; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; PIACENTINI M, 1986, BIOCHEM J, V234, P435, DOI 10.1042/bj2340435; Piacentini M, 1996, J PATHOL, V180, P415, DOI 10.1002/(SICI)1096-9896(199612)180:4<415::AID-PATH684>3.0.CO;2-A; PIACENTINI M, 1994, APOPTOSIS MOL BASIS, P143; Piredda L, 1997, CELL DEATH DIFFER, V4, P463, DOI 10.1038/sj.cdd.4400267; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Shimizu T, 1996, NATURE, V380, P32, DOI 10.1038/380032a0; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; TIMMS BG, 1986, AM J ANAT, V175, P267, DOI 10.1002/aja.1001750211; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471	48	93	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					355	364		10.1096/fasebj.13.2.355	http://dx.doi.org/10.1096/fasebj.13.2.355			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973324	Bronze			2022-12-28	WOS:000078615200016
J	Tash, JS; Bracho, GE				Tash, JS; Bracho, GE			Microgravity alters protein phosphorylation changes during initiation of sea urchin sperm motility	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	space flight; phosphoamino acids; Western immunoblot	INNER-ARM DYNEIN; HUMAN-SPERMATOZOA; ACTIVATION; CALCIUM; HYPERACTIVATION; IDENTIFICATION; PHOSPHATASES; GRAVITROPISM; COMPONENTS; MUTANTS	European Space Agency (ESA) studies demonstrated that bull sperm swim with higher velocity in microgravity (mu G) than at 1 G, Coupling between protein phosphorylation and sperm motility during activation in mu G and at 1 G was examined in the ESA Biorack on two space shuttle missions. Immotile sperm were activated to swim (86-90% motility) at launch +20 h by dilution into artificial seawater (ASW), Parallel ground controls were performed 2 h after the flight experiment. Activation after 0, 30, and 60 s was terminated with electrophoresis sample buffer and samples analyzed for phosphoamino acids by Western blotting. Phosphorylation of a 130-kDa phosphothreonine-containing protein (FP130) occurred three to four times faster in mu C than at 1 G, A 32-kDa phosphoserine-containing protein was significantly stimulated at 30 s but returned to 1 G control levels at 60 s, The rate of FP130 phosphorylation in mu G was attenuated by D2O, suggesting that changes in water properties participate in altering signal transduction, Changes in FP130 phosphorylation triggered by the egg peptide speract were delayed in mu G. These results demonstrate that previously observed effects of mu G on sperm motility are coupled to changes in phosphorylation of specific flagellar proteins and that early events of sperm activation and fertilization are altered in mu G.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Tash, JS (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NICHD NIH HHS [HD-33994] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD K, 1995, ARCH ANDROLOGY, V35, P187, DOI 10.3109/01485019508987871; BENTLEY JK, 1987, J BIOL CHEM, V262, P15708; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; Bracho GE, 1998, BIOCHEM BIOPH RES CO, V242, P231, DOI 10.1006/bbrc.1997.7937; Bracho GE, 1997, BIOCHEM BIOPH RES CO, V237, P59, DOI 10.1006/bbrc.1997.7074; BROOKS DE, 1970, J REPROD FERTIL, V23, P525, DOI 10.1530/jrf.0.0230525; COGOLI A, 1996, J BIOTECHNOL, P1; De Maziere A, 1996, Adv Space Res, V17, P219, DOI 10.1016/0273-1177(95)00638-U; ENGELMANN U, 1992, J ANDROL, V13, P433; Habermacher G, 1997, J CELL BIOL, V136, P167, DOI 10.1083/jcb.136.1.167; Jennings R T, 1990, Obstet Gynecol Surv, V45, P7, DOI 10.1097/00006254-199001000-00006; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; Kiss JZ, 1997, PLANT CELL PHYSIOL, V38, P518, DOI 10.1093/oxfordjournals.pcp.a029199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDEMANN CB, 1990, MOL REPROD DEV, V26, P69, DOI 10.1002/mrd.1080260111; LONGDON N, 1987, BIORACK SPACEHAB D1; Lu YT, 1996, PLANTA, V199, P18; Lu YT, 1997, PLANTA, V203, pS91, DOI 10.1007/PL00008121; MAKLER A, 1993, INT J ANDROL, V16, P251, DOI 10.1111/j.1365-2605.1993.tb01188.x; Mann T, 1981, MALE REPROD FUNCTION; MATTOK C, 1995, BIORACK SPACEHAB IML; Merkys A, 1997, Adv Space Biol Med, V6, P213, DOI 10.1016/S1569-2574(08)60084-2; SAPP WJ, 1990, FASEB J, V4, P101, DOI 10.1096/fasebj.4.1.2295370; SCHWUCHOW J, 1994, CELL MOTIL CYTOSKEL, V29, P366, DOI 10.1002/cm.970290409; Serova L V, 1989, Physiologist, V32, pS29; SUAREZ SS, 1993, P NATL ACAD SCI USA, V90, P4660, DOI 10.1073/pnas.90.10.4660; Sullivan R, 1996, ACTA OBSTET GYN SCAN, V75, P372, DOI 10.3109/00016349609033334; Tash JS, 1998, BIOCHEM BIOPH RES CO, V251, P557, DOI 10.1006/bbrc.1998.9516; TASH JS, 1973, PROC R SOC SER B-BIO, V184, P109, DOI 10.1098/rspb.1973.0036; TASH JS, 1994, J ANDROL, V15, P505; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; WHITE DR, 1989, GAMETE RES, V22, P163, DOI 10.1002/mrd.1120220205; WINET H, 1984, J REPROD FERTIL, V70, P511	34	25	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S43	S54						12	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352144				2022-12-28	WOS:000080403800006
J	Guissouma, H; Ghorbel, MT; Seugnet, I; Ouatas, T; Demeneix, BA				Guissouma, H; Ghorbel, MT; Seugnet, I; Ouatas, T; Demeneix, BA			Physiological regulation of hypothalamic TRH transcription in vivo is T-3 receptor isoform specific	FASEB JOURNAL			English	Article						nonviral gene transfer; polyethylenimine; thyroid hormone; mouse; central nervous system	THYROID-HORMONE RECEPTOR; THYROTROPIN-RELEASING-HORMONE; DIFFERENTIAL EXPRESSION; NEGATIVE REGULATION; GENE PROMOTER; RAT-BRAIN; BETA; ALPHA; ACTIVATION; PITUITARY	Thyroid hormone (tri-iodo-thyronine, T-3) exerts transcriptional effects on target genes in responsive cells. These effects are determined by DNA/protein interactions governed by the type of T-3 receptors (TRs) in the cell. As TRs show tissue and developmental variations, regulation is best addressed in an integrated in vivo model. We examined TR subtype effects on thyrotropin-releasing hormone (TRH) transcription and on the pituitary/thyroid axis end point: thyroid hormone secretion. Polyethylenimine sewed to transfect a TRH-luciferase construct containing 554 bp of the rat TRH promoter into the hypothalami of newborn mice. Transcription from the TRH promoter was regulated in a physiologically faithful manner, being significantly increased in hypothyroidism and decreased in T-3-treated animals. Moreover, when various ligand binding forms of mouse or chicken TR beta and TR alpha were expressed with TRH-luciferase, all forms of TR beta gave T-3-dependent regulation of TRH transcription, whereas transcription was T-3 insensitive with each TR alpha tested. Moreover, chicken TR alpha increased TRH transcription sixfold, whereas mouse TR alpha decreased transcription. These transcriptional effects had correlated physiological consequences: expression of the chicken TR alpha in the hypothalamus of newborn mice raised circulating T-4 levels by fourfold, whereas mouse TR alpha had opposite effects. Thus, TR subtypes have distinct, physiologically relevant effects on TRH transcription.	Museum Natl Hist Nat, Lab Physiol Gen & Comparee, URA CNRS 90, F-75231 Paris 5, France	Museum National d'Histoire Naturelle (MNHN)	Demeneix, BA (corresponding author), Museum Natl Hist Nat, Lab Physiol Gen & Comparee, URA CNRS 90, 7 Rue Cuvier, F-75231 Paris 5, France.	demeneix@mnhn.fr						Balkan W, 1998, ENDOCRINOLOGY, V139, P252, DOI 10.1210/en.139.1.252; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; DEMENEIX BA, 1978, GEN COMP ENDOCR, V35, P77, DOI 10.1016/0016-6480(78)90170-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goula D, 1998, GENE THER, V5, P712, DOI 10.1038/sj.gt.3300635; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; KOLLER KJ, 1987, P NATL ACAD SCI USA, V84, P7329, DOI 10.1073/pnas.84.20.7329; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; McNabb F.M.A., 1992, THYROID HORMONES, P283; SAKURAI A, 1992, BIOCHEM BIOPH RES CO, V185, P78, DOI 10.1016/S0006-291X(05)80957-X; Schwartz B, 1995, HUM GENE THER, V6, P1515, DOI 10.1089/hum.1995.6.12-1515; SEGERSON TP, 1987, ENDOCRINOLOGY, V121, P98, DOI 10.1210/endo-121-1-98; SJOBERG M, 1992, DEVELOPMENT, V114, P39; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840	29	35	37	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1755	1764		10.1096/fasebj.12.15.1755	http://dx.doi.org/10.1096/fasebj.12.15.1755			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837866				2022-12-28	WOS:000077574500018
J	Natter, S; Seiberler, S; Hufnagl, P; Binder, BR; Hirschl, AM; Ring, J; Abeck, D; Schmidt, T; Valent, P; Valenta, R				Natter, S; Seiberler, S; Hufnagl, P; Binder, BR; Hirschl, AM; Ring, J; Abeck, D; Schmidt, T; Valent, P; Valenta, R			Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients	FASEB JOURNAL			English	Article						IgE autoimmunity; cDNA cloning; expression in Escherichia coli	BIRCH POLLEN ALLERGEN; FC-EPSILON-RI; II KERATIN; CELLS; PROFILIN; SEQUENCE; IDENTIFICATION; PROTEINS; ACTIN; GENE	Recently we demonstrated that a high percentage of atopic dermatitis (AD) patients displayed specific immunoglobulin E reactivity to human proteins. Here we show that IgE autoreactivity is found predominantly in AD patients with severe skin manifestations and reveal the molecular mature of four IgE autoantigens, An expression cDNA library constructed from a human epithelial cell line (A 431) was screened with serum IgE from two AD patients. DNA sequence analysis of three IgE-reactive domes identified the alpha-chain of the nascent polypeptide-associated complex, cytokeratin type II, and the BCL7B oncogen as atopy-related IgE; autoantigens (ara). The fourth cDNA coded for an IgE autoantigen containing a typical calcium binding motif that occurred in histogenetically different cells and tissues (keratinocytes, muscle, brain). Recombinant Escherichia coli-expressed IgE autoantigens bound IgE from AD but not from patients with other immunologically mediated disorders (graft vs. host disease, systemic lupus erythematosus) and elicited immediate type skin reactions in AD patients. In serum samples collected from an AD patient over a period of 5 years, IgE anti-ara NAC antibody levels peaked during disease exacerbation. Our finding that ara BCL7B was detected in serum bound to ISE antibodies suggests that intracellular IgE autoantigens can become released after tissue damage and may occur as IgE immune complexes, Via binding to antigen presenting cells as well as to effector cells, IgE autoantigen immune complexes may contribute to exacerbation and/or perpetuation of severe atopic diseases even in the absence of exogenous allergens.	Univ Vienna, AKH, Dept Gen & Expt Pathol, Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Univ Vienna, AKH, Dept Clin Microbiol, A-1090 Vienna, Austria; Tech Univ Munich, GSF, Dermatol Clin, D-8000 Munich, Germany; Univ Vienna, AKH, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Vienna	Valenta, R (corresponding author), Univ Vienna, AKH, Dept Gen & Expt Pathol, Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Test, Test/Y-7921-2019; Ring, Johannes/GLN-4341-2022; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Ring, Johannes/0000-0001-8236-3152; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365				Ausubel FM., 1988, CURRENT PROTOCOLS MO; Battey, 1986, BASIC METHODS MOL BI; Berrens L, 1970, Prog Allergy, V14, P259, DOI 10.1159/000289384; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Casolaro V, 1996, CURR OPIN IMMUNOL, V8, P796, DOI 10.1016/S0952-7915(96)80007-0; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; COOPER KD, 1989, IMMUNE MECHANISMS CU, P247; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GLASS C, 1985, J CELL BIOL, V101, P2366, DOI 10.1083/jcb.101.6.2366; HAMPTON STANLEY F., 1941, JOUR ALLERGY, V13, P63, DOI 10.1016/S0021-8707(41)90008-4; HANIFIN JM, 1986, J AM ACAD DERMATOL, V15, P703, DOI 10.1016/S0190-9622(86)80097-4; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LEUNG DYM, 1993, CURR OPIN IMMUNOL, V5, P956, DOI 10.1016/0952-7915(93)90112-6; Leung DYM, 1993, DERMATOLOGY GEN MED, P1543; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Ring J, 1996, ALLERGY, V51, P206, DOI 10.1111/j.1398-9995.1996.tb04595.x; RUZICKA T, 1991, HDB ATOPIC ECEMA; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; Simon F, 1944, J ALLERGY, V15, P338, DOI DOI 10.1016/S0021-8707(44)90143-7; SIMON FA, 1947, J INVEST DERMATOL, V9, P329, DOI 10.1038/jid.1947.106; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; VALENTA R, 1993, J BIOL CHEM, V268, P22777; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124	48	103	110	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1559	1569		10.1096/fasebj.12.14.1559	http://dx.doi.org/10.1096/fasebj.12.14.1559			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806765				2022-12-28	WOS:000076749500015
J	Shilatifard, A				Shilatifard, A			Factors regulating the transcriptional elongation activity of RNA polymerase II	FASEB JOURNAL			English	Review						negative elongation factor; mRNA synthesis; ELL-associated proteins; transcriptional arrest	TUMOR-SUPPRESSOR PROTEIN; ACUTE MYELOID-LEUKEMIA; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; FACTOR-SIII; IN-VITRO; P-TEFB; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIBING POLYMERASE; DROSOPHILA-TRITHORAX	The synthesis of mature and functional messenger RNA by eukaryotic RNA polymerase II (Pol II) is a complex, multistage process requiring the cooperative action of many cellular proteins. This process, referred to collectively as the transcription cycle, proceeds via five stages: preinitiation, initiation, promoter clearance, elongation, and termination. During the past few years, fundamental studies of the elongation stage of transcription have demonstrated the existence of several families of Pol II elongation factors governing the activity of Pol II. It is now clear that the elongation stage of transcription is a critical stage for the regulation of gene expression. In fact, two of these elongation factors, ELL and elongin, have been implicated in human cancer, This article will review the proteins involved in the regulation of the elongation stage of transcription by Pol II, describing the recent experimental finding that have propelled vigorous research on the properties and function of the elongating RNA polymerase II.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA	Saint Louis University	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.	shilatia@wpogate.slu.edu						Basrai MA, 1996, MOL CELL BIOL, V16, P2838; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CONAWAY WJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, pM49; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Edmondson DG, 1996, FASEB J, V10, P1173, DOI 10.1096/fasebj.10.10.8751719; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GNARRAJR, 1996, BIOCH BIOPHYS ACTA, V1242, P201; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HjorthSorensen B, 1997, LEUKEMIA, V11, P1588, DOI 10.1038/sj.leu.2400758; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Malagon F, 1996, CURR GENET, V30, P101, DOI 10.1007/s002940050107; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RUBNITZ JE, 1994, BLOOD, V84, P1747; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEHGAL PB, 1976, SCIENCE, V194, P431, DOI 10.1126/science.982026; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Shilatifard A, 1998, J BIOL CHEM, V273, P11212, DOI 10.1074/jbc.273.18.11212; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; SPENCER CA, 1990, ONCOGENE, V5, P777; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; TAMM I, 1979, P NATL ACAD SCI USA, V76, P5750, DOI 10.1073/pnas.76.11.5750; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe A. P., 1997, Current Biology, V7, P796, DOI 10.1016/S0960-9822(06)00408-8; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	84	95	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1437	1446		10.1096/fasebj.12.14.1437	http://dx.doi.org/10.1096/fasebj.12.14.1437			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806752				2022-12-28	WOS:000076749500002
J	Hahn, T; Barth, S; Weiss, U; Mosgoeller, W; Desoye, G				Hahn, T; Barth, S; Weiss, U; Mosgoeller, W; Desoye, G			Sustained hyperglycemia in vitro down-regulates the GLUT1 glucose transport system of cultured human term placental trophoblast: a mechanism to protect fetal development?	FASEB JOURNAL			English	Article; Proceedings Paper	FASEB Summer Research Conference on Glucose Transporter Biology	JUN 08-13, 1997	COPPER MT, CO	FASEB		placenta; glucose; transport	CONGENITAL-MALFORMATIONS; GENE-EXPRESSION; SKELETAL-MUSCLE; MESSENGER-RNA; CELLS; INSULIN; INVITRO; LOCALIZATION; FAMILY; RAT	The trophoblast of human placenta is directly exposed to the maternal circulation. It forms the main barrier to maternal-fetal glucose transport. The present study investigated the effect of sustained hyperglycemia in vitro on the glucose transport system of these cells. Trophoblasts isolated from term placentas and immunopurified were cultured for 24, 48, and 96 h in DMEM containing either 5.5 (normoglycemia) or 25 mmol/l D-glucose (hyperglycemia), respectively. Initial uptake of glucose was measured using 3-O-[C-14]methyl-D-glucose. Kinetic parameters were calculated as K-M = 73 mmol/l and V-max = 29 fmol s(-1) per trophoblast cell. Uptake rates of cells cultured under hyperglycemic conditions did not differ at exogenous D-glucose concentrations in the physiological range (1, 5.5, 10, and 15 mmol/l), but were significantly decreased by 25% (P<0.05) at diabetes-like concentrations (20 and 25 mmol/l) as compared to normoglycemic conditions. This effect was due to a decrease in V-max (-50%), whereas K-M remained virtually unaffected. GLUT1 mRNA levels were lower by 50% (P<0.05; Northern blotting) and GLUT1 protein was reduced by 16% (P<0.05; Western blotting) in trophoblast cells cultured under hyperglycemic vs, normoglycemic conditions. We conclude that prolonged hyperglycemia in vitro reduces trophoblast glucose uptake at substrate concentrations corresponding to blood levels of poorly controlled diabetic gravidas. This effect is due to diminished GLUT1 mRNA and protein expression in the trophoblast.-Hahn, T., Earth, S., Weiss, U., Mosgoeller, W., Desoye, G. Sustained hyperglycemia in vitro down-regulates the GLUT1 glucose transport system of cultured human term placental trophoblast: a mechanism to protect fetal development?.	Graz Univ, Sch Med, Dept Obstet & Gynecol, A-8036 Graz, Austria; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria	University of Graz; University of Vienna	Hahn, T (corresponding author), Graz Univ, Inst Histol & Embryol, Harrachgasse 21, A-8010 Graz, Austria.	tom.hahn@kfunigraz.ac.at		Mosgoller, Wilhelm/0000-0003-1436-1504				AGHAYAN M, 1992, DEVELOPMENT, V115, P305; BALDWIN SA, 1980, BIOCHEM BIOPH RES CO, V94, P1401, DOI 10.1016/0006-291X(80)90575-6; BARROS LF, 1995, PLACENTA, V16, P623, DOI 10.1016/0143-4004(95)90031-4; BEARD RW, 1979, PLACENTAL TRANSFER, P202; BEHAM A, 1988, PLACENTA, V9, P479, DOI 10.1016/0143-4004(88)90020-3; BIGORNIA L, 1986, BIOCHIM BIOPHYS ACTA, V885, P335, DOI 10.1016/0167-4889(86)90249-1; BISSONNETTE J M, 1979, Journal of Developmental Physiology (Eynsham), V1, P415; Bloxam DL, 1997, PLACENTA, V18, P99, DOI 10.1016/S0143-4004(97)90080-1; BOILEAU P, 1995, J CLIN INVEST, V96, P309, DOI 10.1172/JCI118036; BRUNETTE MG, 1990, MOL CELL ENDOCRINOL, V69, P59, DOI 10.1016/0303-7207(90)90089-Q; Buchanan T A, 1994, Curr Ther Endocrinol Metab, V5, P278; Cervar M, 1996, EUR J CLIN INVEST, V26, P30, DOI 10.1046/j.1365-2362.1996.87238.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarson LH, 1997, PLACENTA, V18, P333, DOI 10.1016/S0143-4004(97)80068-9; DEMOUZON SH, 1994, PLACENTA, V15, P35, DOI 10.1016/S0143-4004(05)80234-6; DESOYE G, 1994, MOL ASPECTS MED, V15, P505, DOI 10.1016/0098-2997(94)90004-3; DESOYE G, 1996, DIABETES REV, V4, P70; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; DEVASKAR SU, 1994, AM J OBSTET GYNECOL, V171, P1316, DOI 10.1016/0002-9378(94)90154-6; DEVES R, 1978, BIOCHIM BIOPHYS ACTA, V510, P339, DOI 10.1016/0005-2736(78)90034-2; ERIKSSON UJ, 1991, DIABETOLOGIA, V34, P325, DOI 10.1007/BF00405004; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; GAITHER K, 1997, J SOC GYNECOL INVEST, V4, pA103; GARDNER HG, 1995, REPROD FERT DEVELOP, V7, P41, DOI 10.1071/RD9950041; GORDON MC, 1995, AM J OBSTET GYNECOL, V173, P1089, DOI 10.1016/0002-9378(95)91332-7; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HAHN T, 1995, CELL TISSUE RES, V280, P49, DOI 10.1007/s004410050329; Hahn T, 1996, Early Pregnancy, V2, P168; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HAUGUEL S, 1986, PEDIATR RES, V20, P269, DOI 10.1203/00006450-198603000-00015; HaugueldeMouzon S, 1997, J CLIN ENDOCR METAB, V82, P2689, DOI 10.1210/jc.82.8.2689; HAY WW, 1991, DIABETES, V40, P44, DOI 10.2337/diab.40.2.S44; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; Herrera E, 1985, Diabetes, V34 Suppl 2, P42; HOARE DG, 1972, J PHYSIOL-LONDON, V221, P311, DOI 10.1113/jphysiol.1972.sp009753; JANSSON T, 1993, J CLIN ENDOCR METAB, V77, P1554, DOI 10.1210/jc.77.6.1554; JOHNSON LW, 1980, AM J PHYSIOL, V238, pC160, DOI 10.1152/ajpcell.1980.238.5.C160; KAHN BB, 1986, ANN NY ACAD SCI, V488, P356; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KITAGAWA T, 1995, J CELL SCI, V108, P3735; Kitzmiller JL, 1996, DIABETES CARE, V19, P514, DOI 10.2337/diacare.19.5.514; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; LANG I, 1993, CELL TISSUE RES, V274, P211, DOI 10.1007/BF00318740; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALL AL, 1982, P NATL ACAD SCI-BIOL, V79, P5406, DOI 10.1073/pnas.79.17.5406; MCGOWAN KM, 1995, PHARMACOL THERAPEUT, V66, P465, DOI 10.1016/0163-7258(95)00007-4; MCMAHON RJ, 1995, J BIOL CHEM, V270, P12094, DOI 10.1074/jbc.270.20.12094; McMahon RJ, 1996, AM J PHYSIOL-ENDOC M, V270, pE640, DOI 10.1152/ajpendo.1996.270.4.E640; MEDDINGS JB, 1990, J CLIN INVEST, V85, P1099, DOI 10.1172/JCI114541; MILLS JL, 1979, DIABETES, V28, P292, DOI 10.2337/diabetes.28.4.292; Pedersen J, 1977, PREGNANT DIABETIC HE, P211; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; ROBINSON JWL, 1983, J PHYSIOL-LONDON, V344, P177, DOI 10.1113/jphysiol.1983.sp014932; RYBAKOWSKI C, 1991, Placenta, V12, P431; Sasson S, 1997, DIABETOLOGIA, V40, P30, DOI 10.1007/s001250050639; SCHMON B, 1991, J CLIN ENDOCR METAB, V73, P888, DOI 10.1210/jcem-73-4-888; SCHNEIDER H, 1981, PLACENTA S, V2, P129; SHAFRIR E, 1996, DIABETES REV, V4, P114; SHORTER SC, 1993, PLACENTA, V14, P571, DOI 10.1016/S0143-4004(05)80210-3; SIBLEY CP, 1988, OXFORD REV REPROD B, V10, P382; SIBLEY CP, 1992, FETAL NEONATAL PHYSL, V1, P62; STEINER M, 1994, HISTOCHEM J, V26, P934; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; TOYODA N, 1987, J BIOL CHEM, V262, P2737; TUAN RS, 1991, J CELL SCI, V98, P333	69	79	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1221	1231		10.1096/fasebj.12.12.1221	http://dx.doi.org/10.1096/fasebj.12.12.1221			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737725				2022-12-28	WOS:000075738500017
J	Girard, JP; Baekkevold, ES; Amalric, F				Girard, JP; Baekkevold, ES; Amalric, F			Sulfation in high endothelial venules: cloning and expression of the human PAPS synthetase	FASEB JOURNAL			English	Article						ATP sulfurylase; APS kinase; endothelium; lymphocyte recirculation	L-SELECTIN; ATP-SULFURYLASE; P-SELECTIN; TYROSINE SULFATION; SIALOMUCIN CD34; AMINO-TERMINUS; GENE ENCODES; LIGAND; BINDING; PROTEIN	High endothelial venules (HEVs) are specialized postcapillary venules found in lymphoid organs and chronically inflamed tissues that support high levels of lymphocyte extravasation from the blood, Studies with chlorate, a metabolic inhibitor of sulfation, had previously revealed that production of PAPS (3'-phosphoadenosine-5'-phosphosulfate), the high-energy donor of sulfate, is required for sulfation and high-affinity recognition of HEV sialomucins GlyCAM-1 and CD34 by the lymphocyte homing receptor L-selectin, Here, we report the molecular characterization of a novel 2.5 kb human cDNA from MECA-79(+) HEV-derived endothelial cells that encodes the target of chlorate, PAPS synthetase, a multifunctional enzyme containing domains for both ATP sulfurylase and adenosine-5'-phosphosulfate kinase, Functional expression of the isolated cDNA in Chinese hamster ovary cells results in high levels of PAPS synthesis, which is abolished by treatment of the transfected cells with chlorate, Northern blot analysis reveals a wide tissue distribution of PAPS synthetase mRNA in the human body, suggesting that human PAPS synthetase may be important for sulfation not only of HEV sialomucins, but also of many other molecules, including mucins such as the P-selectin ligand PSGL-1, proteoglycans, hormones, neurotransmitters, drugs, and xenobiotics.	CNRS, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Univ Oslo, Rikshosp, Inst Pathol, LIIPAT, Oslo, Norway	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Oslo; National Hospital Norway	Girard, JP (corresponding author), CNRS, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.	girard@ibcg.biotoul.fr	GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS P, 1982, J CELL SCI, V57, P277; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BAUMHUETER S, 1994, BLOOD, V84, P2554; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GELLER DH, 1987, J BIOL CHEM, V262, P7374; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; IMAI Y, 1993, NATURE, V361, P555; Klaassen CD, 1997, FASEB J, V11, P404, DOI 10.1096/fasebj.11.6.9194521; KLONUS D, 1994, PLANT J, V6, P105, DOI 10.1046/j.1365-313X.1994.6010105.x; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; MICHIE SA, 1993, AM J PATHOL, V143, P1688; MURILLO M, 1995, ARCH BIOCHEM BIOPHYS, V323, P195, DOI 10.1006/abbi.1995.0026; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; POUPOT R, 1995, FEBS LETT, V368, P536, DOI 10.1016/0014-5793(95)00737-T; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Von Andrian Ulrich H., 1996, Microcirculation (Philadelphia), V3, P287, DOI 10.3109/10739689609148303; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677	38	47	52	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1998	12	7					603	612		10.1096/fasebj.12.7.603	http://dx.doi.org/10.1096/fasebj.12.7.603			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576487	Bronze			2022-12-28	WOS:000073523100010
J	Garrison, HH; Lahiri, S; Stephens, D				Garrison, HH; Lahiri, S; Stephens, D			A profile of the members of FASEB societies: NIH-awards, degrees, and institutional affiliations, 1999	FASEB JOURNAL			English	Article								Data from the FASEB Directory of Members and NIH were used to develop a statistical profile of the members of FASEB Societies. For the U.S.-based scientists (exclusive of retired and student members), the most frequently reported degree was a research doctorate (69.6%), A substantial fraction, however, reported medical degrees (19.2%) or both research and medical degrees (8.0%). The majority of members of FASEB Societies listed academic affiliations in the directory. Industrial affiliations were reported, however, in 9.7% of the entries with smaller fractions listing associations with hospitals, independent research institutes, and government agencies. Just over one-fourth of the members of FASEB Societies were principal investigators on NIH research grants, These investigators received one-half of all NIH grants and nearly 60% of the RO1 grants-Garrison, H. H., Lahiri, S., Stephens, D. A profile of the members of FASEB societies: NIH awards, degrees, and institutional affiliations, 1999.	FASED, Off Publ Affairs, Bethesda, MD 20814 USA; FASED, Off Commun & Informat Serv, Bethesda, MD 20814 USA		Garrison, HH (corresponding author), FASED, Off Publ Affairs, 9650 Rockville Pike, Bethesda, MD 20814 USA.			Garrison, Howard/0000-0001-9455-3527				GARRISON HH, 1995, FASEB J, V9, P703, DOI 10.1096/fasebj.9.9.7601333; KLAUS RW, 1987, FED PROC, V48, P243	2	2	2	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					2	5		10.1096/fasebj.14.1.2	http://dx.doi.org/10.1096/fasebj.14.1.2			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627274				2022-12-28	WOS:000084784700002
J	Hall, DM; Oberley, TD; Moseley, PM; Buettner, GR; Oberley, LW; Weindruch, R; Kregel, KC				Hall, DM; Oberley, TD; Moseley, PM; Buettner, GR; Oberley, LW; Weindruch, R; Kregel, KC			Caloric restriction improves thermotolerance and reduces hyperthermia-induced cellular damage in old rats	FASEB JOURNAL			English	Article						free radicals; oxidative stress; stress proteins; HSP70; aging; antioxidant enzymes	SYRIAN-HAMSTER TISSUES; IMMUNOHISTOCHEMICAL LOCALIZATION; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; KIDNEY DEVELOPMENT; FISCHER-344 RATS; OXIDATIVE STRESS; HEAT-SHOCK; LIVER; AGE	Adult-onset, long-term caloric restriction (CR) prolongs maximum life span in laboratory rodents. However, the effect of this intervention on an organism's ability to cope with a physical challenge has not been explored. We investigates the influence of CR and aging on stress tolerance in old rats exposed to an environmental heating protocol on two consecutive days. We hypothesized that CR would increase heat tolerance by reducing cellular stress and subsequent accrual of oxidative injury. All calorically restricted rats survived both heat exposures compared with only 50% of their control-fed counterparts. CR also decreased heat-induced radical generation, stress protein accumulation, and cellular injury in the liver. In addition, heat stress stimulated marked induction of the antioxidant enzymes manganese-containing superoxide dismutase and catalase, along with strong nuclear catalase expression in liver samples from samples from rats subjected to CR. In contrast, stress-related induction of antioxidant enzymes was blunted, and nuclear catalase expression was unchanged from euthermic conditions in the control-fed group. These data suggest that CR reduces cellular injury and improves heat tolerance of old animals by lowering radical production and preserving cellular ability to adapt to stress through antioxidant enzyme induction and translocation of these proteins to the nucleus.	Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, Iowa City, IA 52242 USA; Univ Iowa, Free Rad Res Inst, Iowa City, IA 52242 USA; Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA; Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; VA Hosp, Pathol & Lab Med Serv, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI 53705 USA; Vet Adm Geriat Res, Educ & Clin Ctr, Madison, WI 53705 USA	University of Iowa; University of Iowa; University of Iowa; University of New Mexico; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center	Kregel, KC (corresponding author), Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, 532 FH, Iowa City, IA 52242 USA.	kevin-kregel@uiowa.edu		Moseley, Pope/0000-0002-3723-9950; Buettner, Garry/0000-0002-5594-1903	NATIONAL INSTITUTE ON AGING [R29AG012350, R01AG012350, R01AG010536, R01AG014687] Funding Source: NIH RePORTER; NIA NIH HHS [AG10536, AG14687, AG12350] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ASH DE, 1982, J BIOL CHEM, V257, P9261; BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; Christianson DW, 1997, PROG BIOPHYS MOL BIO, V67, P217, DOI 10.1016/S0079-6107(97)88477-5; Chui C-.J., 1970, ARCH SURG-CHICAGO, V101, P478; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HARRIS ED, 1992, FASEB J, V6, P2675, DOI 10.1096/fasebj.6.9.1612291; HASS MA, 1988, J BIOL CHEM, V263, P776; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; HERZFELD A, 1976, BIOCHEM J, V153, P469, DOI 10.1042/bj1530469; KEW M, 1970, AM J MED, V49, P192, DOI 10.1016/S0002-9343(70)80075-4; Kregel K. C., 1996, J APPL PHYSIOL, V80, P262; KREGEL KC, 1990, J APPL PHYSIOL, V68, P1337, DOI 10.1152/jappl.1990.68.4.1337; KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673; KUBES P, 1993, AM J PHYSIOL, V264, pG143, DOI 10.1152/ajpgi.1993.264.1.G143; LEE PC, 1983, P NATL ACAD SCI-BIOL, V80, P7496, DOI 10.1073/pnas.80.24.7496; LEVINE JA, 1969, AM J MED, V47, P251, DOI 10.1016/0002-9343(69)90151-X; MATSUO M, 1992, MECH AGEING DEV, V64, P273, DOI 10.1016/0047-6374(92)90084-Q; OBERLEY TD, 1991, AM J PATHOL, V139, P355; OBERLEY TD, 1990, AM J PATHOL, V137, P199; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; PRIVALLE CT, 1987, P NATL ACAD SCI USA, V84, P2723, DOI 10.1073/pnas.84.9.2723; RYAN AJ, 1995, MED SCI SPORTS EXERC, V28, P423; SANDERSONJP, 1997, J GERONTOL BIOL SCI, V52, pB20; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SKIBBA JL, 1991, INT J HYPERTHER, V7, P749, DOI 10.3109/02656739109056444; SLINKER BK, 1988, AM J PHYSIOL, V255, pR353, DOI 10.1152/ajpregu.1988.255.3.R353; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; VANDERKRAAIJ AMM, 1989, BIOCHEM J, V264, P687, DOI 10.1042/bj2640687; Weindruch R., 1988, RETARDATION AGING DI; WEINDRUCH RH, 1980, MECH AGEING DEV, V12, P375, DOI 10.1016/0047-6374(80)90070-6; XIA EN, 1995, J NUTR, V125, P195; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130	37	80	81	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					78	86		10.1096/fasebj.14.1.78	http://dx.doi.org/10.1096/fasebj.14.1.78			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627282				2022-12-28	WOS:000084784700010
J	Hungerford, JE; Sessa, WC; Segal, SS				Hungerford, JE; Sessa, WC; Segal, SS			Vasomotor control in arterioles of the mouse cremaster muscle	FASEB JOURNAL			English	Article						microcirculation; vasodilation; vasoconstriction; conduction	ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION; HAMSTER STRIATED-MUSCLE; SMOOTH-MUSCLE; K+ CHANNELS; EPOXYEICOSATRIENOIC ACIDS; CONDUCTED VASODILATION; MESENTERIC-ARTERY; CEREBRAL-ARTERIES; NITRIC-OXIDE; BLOOD-FLOW	Recent advances in transgenic mouse technology provide novel models to study cardiovascular physiology and pathophysiology. In light of these developments, there is an increasing need for understanding cardiovascular function and blood flow control in normal mice. To this end we have used intravital microscopy to investigate vasomotor control in arterioles of the superfused cremaster muscle preparation of anesthetized C57B16 mice. Spontaneous resting tone increased with branch order and was enhanced by oxygen. Norepinephrine and acetylcholine (ACh) caused concentration-dependent vasoconstriction and vasodilation, respectively, Microiontophoresis of ACh evoked vasodilation that conducted along arterioles; the local (direct) response was inhibited by N-w-nitro-L-arginine (LNA), and both local and conducted responses were inhibited by 17-octadecynoic acid (17-ODYA), Microejection of KCI evoked a biphasic response: a transient conducted vasoconstriction (inhibited by nifedipine), followed by a conducted vasodilation that was insensitive to LNA, indomethacin, and 17-ODYA, Phenylephrine evoked focal vasoconstriction that did not conduct. Perivascular sympathetic nerve stimulation evoked constriction along arterioles that was inhibited by tetrodotoxin. These findings indicate that for arterioles in the mouse cremaster muscle, nitric oxide and endothelial-derived hyperpolarizing factor (as shown by LNA and 17-ODYA interventions, respectively) mediate vasodilatory responses to ACh but not to KCI, and that vasomotor responses spread along; arterioles by multiple pathways of cell-to-cell communication.	Yale Univ, Sch Med, John B Pierce Lab, New Haven, CT 06519 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06519 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA	Yale University; The John B Pierce Laboratory, Inc; Yale University; Yale University	Segal, SS (corresponding author), Yale Univ, Sch Med, John B Pierce Lab, 290 Congress Ave, New Haven, CT 06519 USA.	sssegal@jbpierce.org	babakinejad, babak/G-2674-2012; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Segal, Steven/0000-0001-5667-2154	NHLBI NIH HHS [R01 HL57665, R01 HL41026] Funding Source: Medline; PHS HHS [R01 JL56786] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041026, R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEZ S, 1973, MICROVASC RES, V5, P384, DOI 10.1016/0026-2862(73)90054-X; Beach JM, 1998, AM J PHYSIOL-HEART C, V275, pH1489, DOI 10.1152/ajpheart.1998.275.4.H1489; BURNSTOCK G, 1994, BRIT J PLAST SURG, V47, P527, DOI 10.1016/0007-1226(94)90136-8; Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chen GF, 1996, CIRC RES, V79, P827, DOI 10.1161/01.RES.79.4.827; CHEN GF, 1990, J PHYSIOL-LONDON, V421, P521, DOI 10.1113/jphysiol.1990.sp017959; CHEN GTJ, 1992, J METEOROL SOC JPN, V70, P25, DOI 10.2151/jmsj1965.70.1_25; CHRIST GJ, 1993, J PHARMACOL EXP THER, V266, P1054; Christensen G, 1997, AM J PHYSIOL-HEART C, V272, pH2513, DOI 10.1152/ajpheart.1997.272.6.H2513; Clark SG, 1997, J PHARMACOL EXP THER, V282, P1473; COWEN T, 1985, HISTOCHEMISTRY, V82, P205, DOI 10.1007/BF00501396; Doevendans PA, 1998, CARDIOVASC RES, V39, P34, DOI 10.1016/S0008-6363(98)00073-X; Doyle MP, 1997, AM J PHYSIOL-HEART C, V272, pH1364, DOI 10.1152/ajpheart.1997.272.3.H1364; Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388; Faraci FM, 1998, AM J PHYSIOL-HEART C, V274, pH564, DOI 10.1152/ajpheart.1998.274.2.H564; Godecke A, 1998, CIRC RES, V82, P186; Haas TL, 1997, MICROVASC RES, V53, P113, DOI 10.1006/mvre.1996.1999; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; Harder DR, 1996, CIRC RES, V79, P54, DOI 10.1161/01.RES.79.1.54; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; James JF, 1998, CIRC RES, V82, P407, DOI 10.1161/01.RES.82.4.407; Kass DA, 1998, CIRC RES, V82, P519, DOI 10.1161/01.RES.82.4.519; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KURJIAKA DT, 1995, CIRC RES, V76, P885, DOI 10.1161/01.RES.76.5.885; Li PL, 1997, CIRC RES, V80, P877; LINDVALL O, 1974, HISTOCHEMISTRY, V39, P97, DOI 10.1007/BF00492041; LITTLE TL, 1995, CIRC RES, V76, P498, DOI 10.1161/01.RES.76.3.498; Lombard JH, 1999, AM J PHYSIOL-HEART C, V276, pH503, DOI 10.1152/ajpheart.1999.276.2.H503; MCCARRON JG, 1990, AM J PHYSIOL, V259, pH902, DOI 10.1152/ajpheart.1990.259.3.H902; Meng W, 1996, AM J PHYSIOL-HEART C, V271, pH1145, DOI 10.1152/ajpheart.1996.271.3.H1145; OLESEN SP, 1988, CIRC RES, V62, P1059, DOI 10.1161/01.RES.62.6.1059; PROCTOR KG, 1985, AM J PHYSIOL, V249, pH34, DOI 10.1152/ajpheart.1985.249.1.H34; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Randall MD, 1998, TRENDS PHARMACOL SCI, V19, P55, DOI 10.1016/S0165-6147(97)01161-9; RHODIN JAG, 1967, J ULTRA MOL STRUCT R, V18, P181, DOI 10.1016/S0022-5320(67)80239-9; Rosenblum WI, 1998, MICROCIRCULATION, V5, P129; SEGAL SS, 1989, AM J PHYSIOL, V256, pH838, DOI 10.1152/ajpheart.1989.256.3.H838; Segal SS, 1996, J PHYSIOL-LONDON, V496, P229, DOI 10.1113/jphysiol.1996.sp021680; SEGAL SS, 1991, AM J PHYSIOL, V261, pH181, DOI 10.1152/ajpheart.1991.261.1.H181; SEGAL SS, 1989, AM J PHYSIOL, V256, pH832, DOI 10.1152/ajpheart.1989.256.3.H832; SEGAL SS, 1986, SCIENCE, V234, P868, DOI 10.1126/science.3775368; Segal SS, 1999, J PHYSIOL-LONDON, V516, P283, DOI 10.1111/j.1469-7793.1999.283aa.x; Shimokawa H, 1996, J CARDIOVASC PHARM, V28, P703, DOI 10.1097/00005344-199611000-00014; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Vanheel B, 1997, J PHYSIOL-LONDON, V501, P331, DOI 10.1111/j.1469-7793.1997.331bn.x; Welsh DG, 1996, CIRC RES, V79, P551, DOI 10.1161/01.RES.79.3.551; Welsh DG, 1998, AM J PHYSIOL-HEART C, V274, pH178, DOI 10.1152/ajpheart.1998.274.1.H178; Xia J, 1998, AM J PHYSIOL-HEART C, V274, pH323, DOI 10.1152/ajpheart.1998.274.1.H323; Xia J, 1995, AM J PHYSIOL-HEART C, V269, pH2022, DOI 10.1152/ajpheart.1995.269.6.H2022; ZOU AP, 1994, J PHARMACOL EXP THER, V268, P474	51	73	76	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					197	207		10.1096/fasebj.14.1.197	http://dx.doi.org/10.1096/fasebj.14.1.197			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627294				2022-12-28	WOS:000084784700022
J	Li, CG; Hampson, IN; Hampson, L; Kumar, P; Bernabeu, C; Kumar, S				Li, CG; Hampson, IN; Hampson, L; Kumar, P; Bernabeu, C; Kumar, S			CD105 antagonizes the inhibitory signaling of transforming growth factor beta 1 on human vascular endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; TGF beta 1; HUVEC	TGF-BETA; UP-REGULATION; CELLULAR-RESPONSES; BINDING-PROTEIN; IN-VITRO; ENDOGLIN; ANGIOGENESIS; EXPRESSION; TGF-BETA-1; RECEPTORS	CD105 (endoglin), a receptor for transforming growth factor beta (TGF beta), is highly expressed in tissue-cultured, activated endothelial cells in vitro and in tissues undergoing angiogenesis in vivo. The absence of CD105 in knockout mice leads to their death from defective vascular development, but the role of CD105 in the modulation of angiogenesis has not been elucidated. TGF beta 1 is a well-recognized regulator of angiogenesis. Using an antisense approach, we have shown that inhibition of CD105 protein translation in cultured human endothelial cells enhances the ability of TGF beta 1 to suppress growth and migration in these cells. The ability of endothelial cells to form capillary tubes was evaluated by the use of a 3-dimensional collagen matrix system where TGF beta 1 not only reduced the length of capillary-like structures, but also caused massive mortality in CD105-deficient cells compared to control cultures. These results provide direct evidence that CD105 antagonizes the inhibitory effects of TGF beta 1 on human vascular endothelial cells and that normal cellular levels of CD105 are required for the formation of new blood vessels.	Univ Manchester, Sch Med, Dept Pathol Sci, Manchester M13 9PT, Lancs, England; St Marys Hosp, Manchester M13 0JH, Lancs, England; Paterson Inst Canc Res, Manchester M20 9BX, Lancs, England; CSIC, E-28006 Madrid, Spain	University of Manchester; University of Manchester; Paterson Institute for Cancer Research; Consejo Superior de Investigaciones Cientificas (CSIC)	Kumar, S (corresponding author), Univ Manchester, Sch Med, Dept Pathol Sci, Stopford Bldg, Manchester M13 9PT, Lancs, England.	MDDPSCL2@FS1.SCG.MAN.AC.UK	Bernabeu, Carmelo/P-4662-2019; Bernabeu, Carmelo/L-3226-2014	Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Hampson, Lynne/0000-0002-0656-0127				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; BATTEGAY EJ, 1995, J MOL MED, V73, P333; Bodey B, 1998, ANTICANCER RES, V18, P1485; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; Folkman J, 1997, EXS, V79, P1; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KANZAWA S, 1993, ANN PLAS SURG, V30, P244, DOI 10.1097/00000637-199303000-00008; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEINSOYER C, 1992, BIOL CELL, V75, P155, DOI 10.1016/0248-4900(92)90136-O; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Kumar P, 1996, J PATHOL, V178, P363, DOI 10.1002/(SICI)1096-9896(199604)178:4<363::AID-PATH491>3.0.CO;2-8; Kumar S, 1999, CANCER RES, V59, P856; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 1999, INT J CANCER, V84, P155, DOI 10.1002/(SICI)1097-0215(19990420)84:2<155::AID-IJC11>3.0.CO;2-S; Li CG, 1997, INFLAMM RES, V46, P348, DOI 10.1007/s000110050200; Li CG, 1998, INT J CANCER, V79, P455, DOI 10.1002/(SICI)1097-0215(19981023)79:5<455::AID-IJC2>3.3.CO;2-K; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; Matsuno F, 1999, CLIN CANCER RES, V5, P371; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miyazono K, 1997, INT J HEMATOL, V65, P97; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; RULO HFC, 1995, J DERMATOL SCI, V10, P103, DOI 10.1016/0923-1811(95)00397-B; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SUTTON AB, 1991, J CELL SCI, V99, P777; SZEKANECZ Z, 1995, CLIN IMMUNOL IMMUNOP, V76, P187, DOI 10.1006/clin.1995.1114; TADA K, 1994, BBA-GEN SUBJECTS, V1201, P135, DOI 10.1016/0304-4165(94)90033-7; Takashima S, 1996, J BIOL CHEM, V271, P24901, DOI 10.1074/jbc.271.40.24901; WANG JM, 1995, INT J CANCER, V62, P791, DOI 10.1002/ijc.2910620624; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	40	207	231	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					55	64		10.1096/fasebj.14.1.55	http://dx.doi.org/10.1096/fasebj.14.1.55			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627280				2022-12-28	WOS:000084784700008
J	Goldman, RD; Chou, YH; Prahlad, V; Yoon, M				Goldman, RD; Chou, YH; Prahlad, V; Yoon, M			Intermediate filaments: dynamic processes regulating their assembly, motility, and interactions with other cytoskeletal systems	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		EPIDERMOLYSIS-BULLOSA; MUSCULAR-DYSTROPHY; STRESS FIBERS; NETWORKS; PROTEIN; ACTIN; VIMENTIN; PLECTIN; CELLS; GENE		Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University	Goldman, RD (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.			Prahlad, Veena/0000-0002-0413-6074				CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chou YH, 1997, CURR OPIN CELL BIOL, V9, P49, DOI 10.1016/S0955-0674(97)80151-2; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; Dang M, 1998, LAB INVEST, V78, P195; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GOLDMAN RD, 1970, SCIENCE, V169, P286, DOI 10.1126/science.169.3942.286; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GORBSKY GJ, 1989, J CELL BIOL, V109, P653, DOI 10.1083/jcb.109.2.653; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; Houseweart MK, 1998, CURR OPIN CELL BIOL, V10, P93, DOI 10.1016/S0955-0674(98)80091-4; JAMNEY PA, 1991, J CELL BIOL, V113, P155; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129; MCKENNA NM, 1986, EXP CELL RES, V167, P95, DOI 10.1016/0014-4827(86)90207-7; McLean WHI, 1996, GENE DEV, V10, P1724, DOI 10.1101/gad.10.14.1724; MILLER RK, 1993, J CELL BIOL, V122, P123, DOI 10.1083/jcb.122.1.123; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Moir RD, 1995, INT REV CYTOL, V162B, P141; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; PARRY DAD, 1995, INTERMEDIATE FILAMEN; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; VIKSTROM KL, 1992, J CELL BIOL, V118, P121, DOI 10.1083/jcb.118.1.121; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; Yoon M, 1998, J CELL BIOL, V143, P147, DOI 10.1083/jcb.143.1.147	32	51	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S261	S265		10.1096/fasebj.13.9002.S261	http://dx.doi.org/10.1096/fasebj.13.9002.S261			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619140	Bronze			2022-12-28	WOS:000084390200018
J	Ghibelli, L; Coppola, S; Fanelli, C; Rotilio, G; Civitareale, P; Scovassi, AI; Ciriolo, MR				Ghibelli, L; Coppola, S; Fanelli, C; Rotilio, G; Civitareale, P; Scovassi, AI; Ciriolo, MR			Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis	FASEB JOURNAL			English	Article						caspase 3; redox modulation; PARP; apoptotic cytochrome c release; puromycin	PERMEABILITY TRANSITION; GSH EXTRUSION; ION-CHANNEL; BAX; MITOCHONDRIA; FRAGMENTATION; TRANSLOCATION; ACTIVATION; CASPASE-3; PROTEASE	We demonstrate here that the release of mature cytochrome c from mitochondria is a cellular response to the depletion of glutathione, the main intracellular antioxidant, independently from the destiny of the cells, i.e., apoptosis or survival. On the one hand, cytosolic cytochrome c was detected in cells where the inhibition of glutathione synthesis led to glutathione depletion without impairing viability or in tight concomitance with glutathione depletion prior to puromycin-induced apoptosis. Removal of the apoptogenic agent prior to apoptosis, but after glutathione extrusion and cytochrome c release, led to recovery of preapoptotic cells, which resume healthy features, i.e., restoration of normal glutathione levels and disappearance of cytosolic cytochrome c. On the other hand, in an example of apoptosis occurring without glutathione depletion, no translocation of cytochrome c from mitochondria to cytosol was detected. Unlike the other instances of apoptosis, in this case caspase 3 was not activated, thus suggesting the following oxidant-related apoptotic pathway: glutathione depletion, cytochrome c release, and caspase 3 activation. These results show that cytochrome c release is not a terminal event leading cells to apoptosis, but rather is the consequence of a redox disequilibrium that, under some circumstances, may be associated with apoptosis.-Ghibelli, L., Coppola, S., Fanelli, C., Rotilio, G., Civitareale, P., Scovassi, A. I., Ciriolo, M. R. Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Univ Chieti, Dipartimento Sci Biomed, I-66013 Chieti, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); G d'Annunzio University of Chieti-Pescara	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.		Scovassi, Anna Ivana/F-2458-2010; Ciriolo, Maria Rosa/K-6572-2016; Coppola, Simona/A-6638-2015	Scovassi, Anna Ivana/0000-0003-3484-9881; Coppola, Simona/0000-0001-7851-9409; Ciriolo, Maria Rosa/0000-0002-7863-9029				Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ghibelli L, 1995, FEBS LETT, V377, P9, DOI 10.1016/0014-5793(95)01284-2; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARZULLI D, 1995, ARCH BIOCHEM BIOPHYS, V319, P36, DOI 10.1006/abbi.1995.1264; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas A, 1996, ONCOGENE, V12, P1055; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Yang JC, 1998, BIOCHEM BIOPH RES CO, V250, P454, DOI 10.1006/bbrc.1998.9333; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	28	122	125	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2031	2036		10.1096/fasebj.13.14.2031	http://dx.doi.org/10.1096/fasebj.13.14.2031			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544186				2022-12-28	WOS:000083660700015
J	Walzog, B; Weinmann, P; Jeblonski, F; Scharffetter-Kochanek, K; Bommert, K; Gaehtgens, P				Walzog, B; Weinmann, P; Jeblonski, F; Scharffetter-Kochanek, K; Bommert, K; Gaehtgens, P			A role for beta(2) integrins (CD11/CD18) in the regulation of cytokine gene expression of polymorphonuclear neutrophils during the inflammatory response	FASEB JOURNAL			English	Article						inflammation; adhesion; host defense; interleukin 8; interleukin 1	PROTEIN-TYROSINE PHOSPHORYLATION; SURFACE-ADHERENT PLATELETS; MONOCLONAL-ANTIBODIES; ADHESION MOLECULES; PERIPHERAL-BLOOD; COUNTER-RECEPTOR; CELL FUNCTION; L-SELECTIN; ACTIVATION; CD11B/CD18	Growing evidence supports the idea that adhesion via beta(2) integrins not only allows cellular targeting, but also induces intracellular signaling, which in turn activates functional responses of adherent cells. This study investigates whether beta(2) integrin-mediated adhesion of human polymorphonuclear neutrophils (PMN) has a functional impact on cytokine production. Aggregation of the b(2) integrin Mac-1 (CD11b/CD18) by antibody cross-linking was found to induce substantial de novo synthesis of IL-8 mRNA as measured by semiquantitative RT-PCR and Northern blotting technique, respectively. Induction of IL-8 mRNA was also observed upon adhesion of PMN to immobilized fibrinogen, a functional equivalent of its clotting product fibrin that serves as a native ligand of Mac-1. Results were confirmed using PMN derived from CD18-deficient mice, which were unable to produce MIP-2 mRNA, a homologue of human IL-8, in the presence of immobilized fibrinogen, In contrast, a substantial increase of MIP-2 mRNA was observed when wild-type PMN were incubated on immobilized fibrinogen, In human PMN, ELISA technique showed that the gene activation that required tyrosine kinase activity resulted in a substantial production and secretion of biologically active IL-8 and IL-1 beta. In contrast, no TNF-alpha or IL-6 production was found, revealing that beta(2), integrins mediate differential expression of proinflammatory cytokines, The biological relevance of the present findings was confirmed in an in vivo model of acute inflammation. Altogether, the present findings provide evidence for a functional link between clotting and inflammatory responses that may contribute to the recruitment and/or activation of PMN and other cells at sites of lesion.	Free Univ Berlin, Dept Physiol, D-14195 Berlin, Germany; Univ Cologne, Dept Dermatol, D-5000 Cologne, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; University of Cologne; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Walzog, B (corresponding author), Free Univ Berlin, Dept Physiol, Arnimallee 22, D-14195 Berlin, Germany.		Bommert, Kurt/G-9247-2011					ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BOWEN TJ, 1982, J PEDIATR-US, V101, P932, DOI 10.1016/S0022-3476(82)80013-9; CASSATELLA MA, 1992, J IMMUNOL, V148, P3216; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835, DOI 10.1002/jlb.59.6.835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DANILENKO DM, 1995, J IMMUNOL, V155, P35; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; Diacovo TG, 1996, BLOOD, V88, P146; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DOSQUET C, 1995, J CARDIOVASC PHAR S2, V25, P13; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; HAWKINS HK, 1992, PEDIATR PATHOL, V12, P119, DOI 10.3109/15513819209023288; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kuijper PHM, 1997, BLOOD, V89, P2131, DOI 10.1182/blood.V89.6.2131; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; Lub M, 1996, J LEUKOCYTE BIOL, V59, P648, DOI 10.1002/jlb.59.5.648; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARCUS AJ, 1994, SEMIN HEMATOL, V31, P261; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Nakagawa M, 1998, CIRCULATION, V98, P2307, DOI 10.1161/01.CIR.98.21.2307; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NAWROTH PP, 1986, P NATL ACAD SCI USA, V83, P3460, DOI 10.1073/pnas.83.10.3460; PAYNE CM, 1994, MICROSC RES TECHNIQ, V28, P327, DOI 10.1002/jemt.1070280408; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; SCHWAGER I, 1994, BLOOD, V83, P152, DOI 10.1182/blood.V83.1.152.bloodjournal831152; STRIETER RM, 1995, J BIOL CHEM, V270, P27248; TECAMPOLSON P, 1990, J EXP MED, V172, P911; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Walzog B, 1996, J LEUKOCYTE BIOL, V59, P747, DOI 10.1002/jlb.59.5.747; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; Walzog B, 1997, FASEB J, V11, P1177, DOI 10.1096/fasebj.11.13.9367353; WALZOG B, 1999, AM J PHYSIOL, V276, pC1125; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; Weinmann P, 1999, BLOOD, V93, P3106; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	50	86	92	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1855	1865		10.1096/fasebj.13.13.1855	http://dx.doi.org/10.1096/fasebj.13.13.1855			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506590				2022-12-28	WOS:000083063400022
J	Crespo, E; Macias, M; Pozo, D; Escames, G; Martin, M; Vives, F; Guerrero, JM; Acuna-Castroviejo, D				Crespo, E; Macias, M; Pozo, D; Escames, G; Martin, M; Vives, F; Guerrero, JM; Acuna-Castroviejo, D			Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats	FASEB JOURNAL			English	Article						iNOS; endotoxic shock; genomic effects	NITRIC-OXIDE SYNTHASE; L-ARGININE; NUCLEAR RECEPTOR; GENE-EXPRESSION; SEPTIC SHOCK; MICE; ANTIOXIDANT; PATHOPHYSIOLOGY; THERAPY; DAMAGE	We evaluated the role of melatonin in endotoxemia caused by lipopolysaccharide (LPS) in unanesthetized rats. The expression of inducible isoform of nitric oxide synthase (iNOS) and the increase in the oxidative stress seem to be responsible for the failure of lungs, liver, and kidneys in endotoxemia, Bacterial LPS (10 mg/kg b.w) was i.v. injected 6 h before rats were killed and melatonin (10-60 mg/kg b.w.) was i.p. injected before and/or after LPS, Endotoxemia was associated with a significant rise in the serum levels of aspartate and alanine aminotransferases, gamma-glutamyl-transferase, alkaline phosphatase, creatinine, urea, and uric acid, and hence liver and renal dysfunction. LPS also increased serum levels of cholesterol and triglycerides and reduced glucose levels. Melatonin administration counteracted these organ and metabolic alterations at doses ranging between 20 and 60 mg/kg b.w. Melatonin significantly decreased lung lipid peroxidation and counteracted the LPS induced NO levels in lungs and liver. Our results also show an inhibition of iNOS activity in rat lungs by melatonin in a dose-dependent manner. Expression of iNOS mRNA in lungs and liver was significantly decreased by melatonin (60 mg/kg b.w., 58-65%), We conclude that melatonin inhibits NO production mainly by inhibition of iNOS expression. The inhibition of NO levels may account for the protection of the indoleamine against LPS-induced endotoxemia in rats.	Fac Med, Dept Fisiol, Inst Biotecnol, E-18012 Granada, Spain; Univ Sevilla, Dept Bioquim Med & Biol Mol, Fac Med, Seville, Spain	University of Sevilla	Acuna-Castroviejo, D (corresponding author), Fac Med, Dept Fisiol, Inst Biotecnol, Avda Madrid 11, E-18012 Granada, Spain.		Pozo, David/C-2149-2017; Guerrero, Josep M./D-5519-2014; Crespo-Lopez, Maria Elena/X-7912-2018; Guerrero, Josep M./Y-2929-2019; IBIS, NEUROINMUNO/O-9306-2015; Acuña-Castroviejo, Dario/N-7456-2016; Escames, Germaine/N-7501-2016	Pozo, David/0000-0002-3732-4960; Guerrero, Josep M./0000-0001-5236-4592; Crespo-Lopez, Maria Elena/0000-0002-1335-6853; Acuña-Castroviejo, Dario/0000-0002-9680-1560; Escames, Germaine/0000-0003-1256-7656; Guerrero, Juan Miguel/0000-0001-7553-0119				ACUNACASTROVIEJO D, 1995, J PINEAL RES, V19, P57; ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARRON RL, 1993, CLIN PHARMACY, V12, P829; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; HARBRECHT RG, 1994, AM J PHYSIOL, V266, pG1004; Iuvone T, 1996, LIFE SCI, V59, pPL207; LAEMMLI UK, 1970, NATURE, V263, P789; Leon J, 1998, J NEUROENDOCRINOL, V10, P297, DOI 10.1046/j.1365-2826.1998.00203.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maestroni GJM, 1996, J PINEAL RES, V20, P84, DOI 10.1111/j.1600-079X.1996.tb00244.x; MARTIN M, 1997, J PHYSL BIOCH, V53, P179; MCCALLUM RE, 1973, INFECT IMMUN, V7, P642, DOI 10.1128/IAI.7.4.642-654.1973; Melchiorri Daniela, 1995, Life Sciences, V56, P83, DOI 10.1016/0024-3205(94)00417-Q; MENENDEZPELAEZ A, 1993, J PINEAL RES, V15, P9; MOHAUPT MG, 1994, KIDNEY INT, V46, P653, DOI 10.1038/ki.1994.318; MolinaCarballo A, 1997, J PINEAL RES, V23, P97, DOI 10.1111/j.1600-079X.1997.tb00341.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; Pablos MI, 1995, J PINEAL RES, V19, P111, DOI 10.1111/j.1600-079X.1995.tb00178.x; PARKS DA, 1983, SURGERY, V94, P428; Pierre C., 1994, LIFE SCI, V55, P271; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; SAKAGUCHI O, 1979, MICROBIOL IMMUNOL, V23, P71, DOI 10.1111/j.1348-0421.1979.tb00443.x; SAKAGUCHI S, 1981, MICROBIOL IMMUNOL, V25, P229, DOI 10.1111/j.1348-0421.1981.tb00026.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SEWERYNEK E, 1995, EUR J PHARM-ENVIRON, V293, P327, DOI 10.1016/0926-6917(95)90052-7; SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3; STADLER J, 1993, J LEUKOCYTE BIOL, V53, P165, DOI 10.1002/jlb.53.2.165; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; SUGINO K, 1989, SURGERY, V105, P200; Szabo C, 1995, New Horiz, V3, P2; Thiemermann C, 1994, Adv Pharmacol, V28, P45, DOI 10.1016/S1054-3589(08)60493-7; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; Tracey K.J., 1992, TUMOR NECROSIS FACTO, P255; TRACEY WR, 1995, J PHARMACOL EXP THER, V272, P1011; VESLEY DL, 1997, AM J PHYSIOL, V314, P311; Vijayalaxmi Russel J. Reiter, 1995, Mutation Research, V346, P23; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; EXPERIENTIA, V45, P739; [No title captured]	59	249	264	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1537	1546		10.1096/fasebj.13.12.1537	http://dx.doi.org/10.1096/fasebj.13.12.1537			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463945				2022-12-28	WOS:000082347600009
J	Honda, Y; Honda, S				Honda, Y; Honda, S			The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans	FASEB JOURNAL			English	Article						life extension mutant; Mn-SOD; C. elegans; nematode	FREE-RADICAL THEORY; LIFE-SPAN; DAUER FORMATION; INSULIN-RESISTANCE; METHYL VIOLOGEN; FAMILY MEMBER; NEMATODE; GLUCOSE; OXYGEN; AGE-1	Longevity is regulated by the daf-2 gene network in Caenorhabditis elegans, Mutations in the daf-2 gene, which encodes a member of the insulin receptor family, confer the life extension (Age) phenotype and the constitutive dauer (a growth-arrested larval form specialized for dispersal) formation phenotype, The Age phenotype is mutually potentiated by two life extension mutations in the daf-2 gene and the clk-1 gene, a homologue of yeast CAT5/COQ7 known to regulate ubiquinone biosynthesis, Zn this study, we demonstrated that the daf-2 mutation also conferred an oxidative stress resistance (Oxr) phenotype, which was also enhanced by the clk-1 mutation, Similar to the Age phenotype, the Oxr phenotype was regulated by the genetic pathway of insulin-like signaling from daf-2 to the daf-16 gene, a homologue of the HNF-3/forkhead transcription factor, These findings led us to examine whether the insulin-like signaling pathway regulates the gene expression of antioxidant defense enzymes. We found that the mRNA level of the sod-3 gene, which encodes Mn-superoxide dismutase (SOD), was much higher in daf-2 mutants than in the wild type. Moreover, the increased sod-3 gene expression phenotype is regulated by the insulin-like signaling pathway. Although the clk-1 mutant itself did not display Oxr and the increased sod-3 expression phenotypes, the clk-1 mutation enhanced them in the daf-2 mutant, suggesting that clk-1 is involved in longevity in two ways: clk-1 composes the original clk-1 longevity program and the daf-2 longevity program. These observations suggest that the daf-2 gene network controls longevity by regulating the MnSOD-associated antioxidant defense system, This system appears to play a role in efficient life maintenance at the dauer stage.	Tokyo Metropolitan Inst Gerontol, Itabashi Ku, Tokyo 1730015, Japan	Tokyo Metropolitan Institute of Gerontology	Honda, S (corresponding author), Tokyo Metropolitan Inst Gerontol, Itabashi Ku, 35-2 Sakaecho, Tokyo 1730015, Japan.	hondas@center.tmig.or.jp	HONDA, Yoko/F-4558-2018	HONDA, Yoko/0000-0002-9978-8672				ANDERSON GL, 1982, CAN J ZOOL, V60, P288, DOI 10.1139/z82-038; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BRENNER S, 1974, GENETICS, V77, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; DARR D, 1995, FREE RADICAL BIO MED, V18, P195, DOI 10.1016/0891-5849(94)00118-4; DORMAN JB, 1995, GENETICS, V141, P1399; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIEDMAN DB, 1988, GENETICS, V118, P75; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; GOTTLIEB S, 1994, GENETICS, V137, P107; HARMAN D, 1994, ANN NY ACAD SCI, V717, P1, DOI 10.1111/j.1749-6632.1994.tb12069.x; HARTMAN P, 1995, J GERONTOL A-BIOL, V50, pB322, DOI 10.1093/gerona/50A.6.B322; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HAYFLICK L, 1987, MODERN BIOL THEORIES, P21; Ho YS, 1996, AM J PHYSIOL-LUNG C, V270, pL810, DOI 10.1152/ajplung.1996.270.5.L810; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HONDA S, 1992, MECH AGEING DEV, V63, P235, DOI 10.1016/0047-6374(92)90002-U; Hunter T, 1997, J BIOL CHEM, V272, P28652, DOI 10.1074/jbc.272.45.28652; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KENYON C, 1997, C ELEGANS, V2, P791; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Malone EA, 1996, GENETICS, V143, P1193; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Papadopoulos MC, 1997, BRAIN RES, V748, P151, DOI 10.1016/S0006-8993(96)01293-0; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; RAMIREZ R, 1995, MOL CELL BIOCHEM, V142, P43, DOI 10.1007/BF00928912; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; Riddle DL, 1997, C ELEGANS, P739; Sacher G. A., 1978, The genetics of aging., P151; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Suzuki N, 1996, DNA Res, V3, P171, DOI 10.1093/dnares/3.3.171; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; THOR H, 1982, J BIOL CHEM, V257, P2419; Tissenbaum HA, 1998, GENETICS, V148, P703; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE MF, 1994, JOSLINS DIABETES MEL, P139; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	61	566	592	4	71	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1385	1393		10.1096/fasebj.13.11.1385	http://dx.doi.org/10.1096/fasebj.13.11.1385			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428762				2022-12-28	WOS:000082019100010
J	Mason, CAE; Chang, P; Fallery, C; Rabinovitch, M				Mason, CAE; Chang, P; Fallery, C; Rabinovitch, M			Nitric oxide mediates LC-3-dependent regulation of fibronectin in ductus arteriosus intimal cushion formation	FASEB JOURNAL			English	Article						extracellular matrix; cell migration; microtubule; atherosclerosis	SMOOTH-MUSCLE CELLS; ENDOTHELIAL GROWTH-FACTOR; RNA-BINDING PROTEIN; MICROTUBULE-ASSOCIATED PROTEIN-1; ACTIVATED PROTEIN-KINASE-1 BMK1; MESSENGER-RNA; IN-VIVO; POSTTRANSCRIPTIONAL REGULATION; TRANSPLANT ARTERIOSCLEROSIS; 3'-UNTRANSLATED REGION	Ductus arteriosus intimal cushion formation is characterized by fibronectin-dependent smooth muscle cell (SMC) migration. Enhanced fibronectin synthesis in ductus SMC is regulated by the interaction of LC-3, a microtubule-associated protein, with an AU-rich element (ARE) in the 3'-untranslated region of fibronectin mRNA, facilitating its recruitment to polyribosomes for translation. Since nitric oxide (NO) is implicated in posttranscriptional gene regulation and is produced in the ductus, we investigated its mechanistic role in LC-3-mediated fibronectin synthesis, NO production was sevenfold higher in ductus vs. aortic SMC (P<0.005) associated with increased neuronal NO synthase (nNOS) expression. The NOS inhibitor L-NMMA decreased fibronectin synthesis by similar to 45-50% (P<0.05), whereas the NO donor, SNAP, increased ductus fibronectin synthesis similar to onefold (P<0.05); neither agent altered fibronectin mRNA levels. Immunoblotting revealed that SNAP increased and GNMMA reduced a membrane-associated phosphorylated form of LC-3. RNA gel mobility shift assays confirmed that NO enhanced LC-3 binding to the fibronectin mRNA ARE. Our studies indicate a tissue-specific program in the ductus arteriosus whereby elevated nNOS expression and NO production regulate the posttranscriptional increase in fibronectin synthesis required for SMC motility.	Hosp Sick Children, Res Inst, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Rabinovitch, M (corresponding author), Hosp Sick Children, Res Inst, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	MR@sickkids.on.ca						Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; Akyurek LM, 1996, AM J PATHOL, V149, P1981; Arthur JF, 1997, ARTERIOSCL THROM VAS, V17, P737, DOI 10.1161/01.ATV.17.4.737; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BOUDREAU N, 1991, DEV BIOL, V143, P235, DOI 10.1016/0012-1606(91)90074-D; BOUDREAU N, 1992, LAB INVEST, V67, P350; BOUDREAU N, 1991, LAB INVEST, V64, P187; Brown C, 1998, FASEB J, V12, pA704; BRUGG B, 1993, NEUROSCIENCE, V52, P489, DOI 10.1016/0306-4522(93)90401-Z; CALVERT R, 1985, EMBO J, V4, P1171, DOI 10.1002/j.1460-2075.1985.tb03756.x; CLAUSELL N, 1994, CIRCULATION, V89, P2768, DOI 10.1161/01.CIR.89.6.2768; CLAUSELL N, 1995, BRIT HEART J, V73, P534; Clyman RI, 1998, PEDIATR RES, V43, P633, DOI 10.1203/00006450-199805000-00012; COCEANI F, 1994, CAN J PHYSIOL PHARM, V72, P82, DOI 10.1139/y94-013; CORNFIELD DN, 1992, AM J PHYSIOL, V262, pH1474, DOI 10.1152/ajpheart.1992.262.5.H1474; Farhadian F, 1996, CARDIOVASC RES, V32, P433, DOI 10.1016/S0008-6363(96)00119-8; Fox JJ, 1996, AM J PHYSIOL-HEART C, V271, pH2638, DOI 10.1152/ajpheart.1996.271.6.H2638; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAN JR, 1995, P NATL ACAD SCI USA, V92, P9550, DOI 10.1073/pnas.92.21.9550; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Hynes RO, 1990, FIBRONECTINS; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; Lau YT, 1996, BIOCHEM BIOPH RES CO, V221, P670, DOI 10.1006/bbrc.1996.0654; LEE KH, 1994, J BIOL CHEM, V269, P14371; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; LopezFigueroa MO, 1996, NEUROENDOCRINOLOGY, V63, P384, DOI 10.1159/000126979; Luoma JS, 1998, ARTERIOSCL THROM VAS, V18, P157, DOI 10.1161/01.ATV.18.2.157; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mason CAE, 1999, NAT MED, V5, P176, DOI 10.1038/5538; MASSON D, 1995, J CELL BIOL, V131, P1015, DOI 10.1083/jcb.131.4.1015; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; MOLOSSI S, 1995, J CELL PHYSIOL, V163, P19, DOI 10.1002/jcp.1041630104; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Nelson PR, 1998, J VASC SURG, V27, P117, DOI 10.1016/S0741-5214(98)70298-8; Noiri E, 1997, J BIOL CHEM, V272, P1747, DOI 10.1074/jbc.272.3.1747; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Poppa V, 1998, ARTERIOSCL THROM VAS, V18, P1312, DOI 10.1161/01.ATV.18.8.1312; RABINOVITCH M, 1988, DEV BIOL, V130, P250, DOI 10.1016/0012-1606(88)90431-9; Rairigh RL, 1998, J CLIN INVEST, V101, P15, DOI 10.1172/JCI1228; Ravalli S, 1997, TRANSPLANT P, V29, P2579, DOI 10.1016/S0041-1345(97)00516-2; RONDON IJ, 1995, FEBS LETT, V359, P267, DOI 10.1016/0014-5793(95)00066-I; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; RUSSELL ME, 1995, CIRCULATION, V92, P457, DOI 10.1161/01.CIR.92.3.457; Sarkar R, 1996, CIRC RES, V78, P225, DOI 10.1161/01.RES.78.2.225; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SMITH GCS, 1993, CARDIOVASC RES, V27, P2205, DOI 10.1093/cvr/27.12.2205; STANDART N, 1990, GENE DEV, V4, P2157, DOI 10.1101/gad.4.12a.2157; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TALEGHANY N, 1992, J NEUROSCI RES, V33, P257, DOI 10.1002/jnr.490330209; URSELL PC, 1995, INT J CARDIOL, V50, P217, DOI 10.1016/0167-5273(95)02380-F; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Walker J, 1996, DEV BIOL, V173, P292, DOI 10.1006/dbio.1996.0024; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; ZAIDI SHE, 1995, J BIOL CHEM, V270, P17292, DOI 10.1074/jbc.270.29.17292; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862; Zhou B, 1998, CIRC RES, V83, P481, DOI 10.1161/01.RES.83.5.481; ZHU L, 1993, LAB INVEST, V68, P321; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	77	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1423	1434		10.1096/fasebj.13.11.1423	http://dx.doi.org/10.1096/fasebj.13.11.1423			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428766				2022-12-28	WOS:000082019100014
J	Viard, P; Exner, T; Maier, U; Mironneau, J; Nurnberg, B; Macrez, N				Viard, P; Exner, T; Maier, U; Mironneau, J; Nurnberg, B; Macrez, N			G beta gamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase	FASEB JOURNAL			English	Article						G-protein; PI3K; protein kinase C; smooth muscle	PROTEIN-KINASE-C; PORTAL-VEIN MYOCYTES; VOLTAGE-DEPENDENT POTENTIATION; CALCIUM CHANNELS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; COUPLED RECEPTORS; ALPHA(1) SUBUNIT; CELLS; ACTIVATION; MODULATION	We have previously reported that, in venous myocytes, G beta gamma scavengers inhibit angiotensin AT(1A) receptor-induced stimulation of L-type Ca2+ channels (1). Here, we demonstrate that intracellular infusion of purified G beta gamma complexes stimulates the L-type Ca2+ channel current in a concentration-dependent manner. Additional intracellular dialysis of GDP-bound inactive G alpha(o) or of a peptide corresponding to the G beta gamma binding region of the beta-adrenergic receptor kinase completely inhibited the G beta gamma-induced stimulation of Ca2+ channel currents. The gating properties of the channel were not affected by intracellular application of G beta gamma, suggesting that G beta gamma increased the whole-cell calcium conductance. In addition, both the angiotensin AT(1A) receptor- and the G beta gamma-induced stimulation of L-type Ca2+ channels were blocked by pretreatment of the cells with wortmannin, at nanomolar concentrations. Correspondingly, intracellular infusion of an enzymatically active purified recombinant G beta gamma-sensitive phosphoinositide 3-kinase, PI3K gamma, mimicked G beta gamma-induced stimulation of Ca2+ channels. Both G beta gamma- and PI3K gamma-induced stimulations of Ca2+ channel currents were reduced by protein kinase C inhibitors suggesting that the G beta gamma/PI3K gamma-activated transduction pathway involves a protein kinase C. These results indicate for the first time that G beta gamma dimers stimulate the vascular L-type Ca2+ channels through a G beta gamma-sensitive PI3K.	Univ Bordeaux 2, Lab Physiol Cellulaire & Pharmacol Mol, CNRS, F-33076 Bordeaux, France; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin	Macrez, N (corresponding author), Univ Bordeaux 2, Lab Physiol Cellulaire & Pharmacol Mol, CNRS, ESA 5017,146 Rue Leo Saignat, F-33076 Bordeaux, France.			MACREZ, Nathalie/0000-0002-3844-4403; Nurnberg, Bernd/0000-0002-5995-6555				Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HELL JW, 1993, J BIOL CHEM, V268, P19451; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAIR LA, 1995, CIRC RES, V76, P832, DOI 10.1161/01.RES.76.5.832; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NURNBERG B, 1994, BIOCHEM J, V300, P387; Page KM, 1998, J NEUROSCI, V18, P4815; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; YANO H, 1993, J BIOL CHEM, V268, P25846; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; ZANG WJ, 1993, J PHYSIOL-LONDON, V464, P649, DOI 10.1113/jphysiol.1993.sp019656	47	102	103	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					685	694		10.1096/fasebj.13.6.685	http://dx.doi.org/10.1096/fasebj.13.6.685			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094929				2022-12-28	WOS:000079527200010
J	Lasko, P				Lasko, P			RNA sorting in Drosophila oocytes and embryos	FASEB JOURNAL			English	Review						RNA localization; posterior pole; oogenesis; cytoskeleton; oocyte nucleus	OSKAR MESSENGER-RNA; LARGE RIBOSOMAL-RNA; POSTERIOR POLE ACCUMULATION; PAIR-RULE TRANSCRIPTS; GERM-CELL FORMATION; TRANSLATIONAL REGULATION; ANTERIOR-POSTERIOR; BICOID RNA; BICAUDAL-D; CYTOPLASMIC DYNEIN	Many RNAs involved in determination of the oocyte, specification of embryonic axes, and establishment of germ cells in Drosophila are localized asymmetrically within the developing egg or syncytial embryo, Here I review the current state of knowledge about the cis-acting sequences involved in RNA targeting, RNA binding proteins; gene activities implicated in localizing specific RNAs, and the role of the tubulin and actin cytoskeletons in RNA sorting within the oocyte, Targeted RNAs are often under complex translational control, and the translational control of two RNAs that localize to the posterior of the oocyte, oskar and nanos, is also discussed. Prospects for filling gaps in our knowledge about the mechanisms of localizing RNAs and the importance of RNA sorting in regulating gene expression are also explored.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1B1, Canada	McGill University; McGill University	Lasko, P (corresponding author), McGill Univ, Dept Biol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.	Paul_Lasko@maclan.mcgill.ca	Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501				BARDSLEY A, 1993, DEVELOPMENT, V119, P207; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Breitwieser W, 1996, GENE DEV, V10, P2179, DOI 10.1101/gad.10.17.2179; Capri M, 1997, MECH DEVELOP, V68, P91, DOI 10.1016/S0925-4773(97)00130-5; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Clark IE, 1997, DEVELOPMENT, V124, P461; Clegg NJ, 1997, DEVELOPMENT, V124, P4661; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; Dahanukar A, 1996, GENE DEV, V10, P2610, DOI 10.1101/gad.10.20.2610; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DALBY B, 1992, DEVELOPMENT, V115, P989; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DING D, 1994, DEV BIOL, V163, P503, DOI 10.1006/dbio.1994.1166; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Dubowy J, 1998, MECH DEVELOP, V70, P193, DOI 10.1016/S0925-4773(97)00185-8; Edgar BA, 1996, GENE DEV, V10, P1966, DOI 10.1101/gad.10.15.1966; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Gavis ER, 1996, DEV BIOL, V176, P36, DOI 10.1006/dbio.1996.9996; Gavis ER, 1996, DEVELOPMENT, V122, P2791; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P2837; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; HAY B, 1988, DEVELOPMENT, V103, P625; Iida T, 1998, P NATL ACAD SCI USA, V95, P11274, DOI 10.1073/pnas.95.19.11274; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; King R. C., 1970, OVARIAN DEV DROSOPHI; KOBAYASHI S, 1995, DEV BIOL, V169, P384, DOI 10.1006/dbio.1995.1153; KOBAYASHI S, 1993, SCIENCE, V260, P1521, DOI 10.1126/science.7684857; KOCH EA, 1983, CELL TISSUE RES, V228, P21; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LANTZ V, 1994, MOL CELL BIOL, V14, P2235, DOI 10.1128/MCB.14.4.2235; LANTZ V, 1992, DEVELOPMENT, V115, P75; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Larkin MK, 1996, DEVELOPMENT, V122, P3639; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LIANG L, 1994, DEVELOPMENT, V120, P1201; Macdonald PM, 1998, MOL CELL BIOL, V18, P3788, DOI 10.1128/MCB.18.7.3788; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1995, P NATL ACAD SCI USA, V92, P10787, DOI 10.1073/pnas.92.23.10787; Macdonald PM, 1997, RNA, V3, P1413; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Manseau L, 1996, DEVELOPMENT, V122, P2109; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; Markussen FH, 1997, COLD SPRING HARB SYM, V62, P13; McGrail M, 1997, DEVELOPMENT, V124, P2409; Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Nakamura A, 1996, SCIENCE, V274, P2075, DOI 10.1126/science.274.5295.2075; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Newmark PA, 1997, DEVELOPMENT, V124, P3197; Paillard L, 1998, EMBO J, V17, P278, DOI 10.1093/emboj/17.1.278; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RAN B, 1994, DEVELOPMENT, V120, P1233; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; RONGO C, 1995, DEVELOPMENT, V121, P2737; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Ruden DM, 1997, DEV BIOL, V191, P284, DOI 10.1006/dbio.1997.8726; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; RUOHOLABAKER H, 1994, TRENDS GENET, V10, P89, DOI 10.1016/0168-9525(94)90231-3; Saffman EE, 1998, MOL CELL BIOL, V18, P4855, DOI 10.1128/MCB.18.8.4855; SERANO T, 1995, DEVELOPMENT, V121, P3809; SERANO TL, 1995, DEVELOPMENT, V121, P3013; Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; Styhler S, 1998, DEVELOPMENT, V125, P1569; SURDEJ P, 1994, ANNU REV GENET, V28, P263; Surdej P, 1998, MOL CELL BIOL, V18, P2892, DOI 10.1128/MCB.18.5.2892; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Swan A, 1996, DEVELOPMENT, V122, P3577; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Theurkauf WE, 1998, DEVELOPMENT, V125, P3655; Tinker R, 1998, DEV BIOL, V199, P1, DOI 10.1006/dbio.1998.8941; Tomancak P, 1998, DEVELOPMENT, V125, P1723; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510; Wharton RP, 1998, MOL CELL, V1, P863, DOI 10.1016/S1097-2765(00)80085-4; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; Wilson JE, 1996, DEVELOPMENT, V122, P1631; Zamore PD, 1997, RNA, V3, P1421	109	64	65	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					421	433		10.1096/fasebj.13.3.421	http://dx.doi.org/10.1096/fasebj.13.3.421			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064609				2022-12-28	WOS:000079016000002
J	Bobanovic, F; Bootman, MD; Berridge, MJ; Parkinson, NA; Lipp, P				Bobanovic, F; Bootman, MD; Berridge, MJ; Parkinson, NA; Lipp, P			Elementary [Ca2+](i) signals generated by electroporation functionally mimic those evoked by hormonal stimulation	FASEB JOURNAL			English	Article						Ca2+ puffs; Ca2+ waves; HeLa cells; confocal microscopy; InsP(3) receptors	1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; CYTOSOLIC CA2+; CELL-MEMBRANES; CALCIUM; EVENTS; MUSCLE	The generation of oscillations and global Ca2+ waves relies on the spatio-temporal recruitment of elementary Ca2+ signals, such as 'Ca2+ puffs', Each elementary signal contributes a small amount of Ca2+ into the cytoplasm, progressively promoting neighboring Ca2+ release sites into an excitable state, Previous studies have indicated that increases in frequency or amplitude of such hormone-evoked elementary Ca2+ signals: are necessary to initiate Ca2+ wave propagation. In the present study, an electroporation device was used to rapidly and reversibly permeabilize the plasma membrane of HeLa cells and to allow a limited influx of Ca2+, With low held intensities (100-500 V/cm), brief (50-100 mu s) electroporation triggered localized Ca2+ signals that resembled hormone-evoked Ca2+ puffs, but not global signals. With such low intensity electroporative pulses, the Ca2+ influx component was usually undetectable, confirming that the electroporation-induced local signals represented Ca2+ puffs arising from the opening of intracellular Ca2+ release channels. Increasing either the frequency at which low-intensity electroporative pulses were applied, or the intensity of a single electroporative pulse (>500 V/cm), resulted in caffeine-sensitive regenerative Ca2+ waves. We suggest that Ca2+ puffs caused by electroporation functionally mimic hormone-evoked elementary events and can activate global Ca2+ signals if they provide a sufficient trigger.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Ljubljana, Fac Elect Engn, Lab Biocybernet, Ljubljana 61000, Slovenia; Univ Cambridge, Dept Zool, Cambridge, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Ljubljana; University of Cambridge	Bootman, MD (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	martin.bootman@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOBANOVIC F, 1998, FLUORESCENT LUMINESC; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBINO M, 1993, BIOPHYS J, V64, P1789, DOI 10.1016/S0006-3495(93)81550-9; Huser J, 1996, PFLUG ARCH EUR J PHY, V433, P194, DOI 10.1007/s004240050267; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINOSITA K, 1988, BIOPHYS J, V53, P1015, DOI 10.1016/S0006-3495(88)83181-3; Kotnik T, 1997, BIOELECTROCH BIOENER, V43, P285, DOI 10.1016/S0302-4598(97)00023-8; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; Park JT, 1996, MICROB DRUG RESIST, V2, P105, DOI 10.1089/mdr.1996.2.105; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; SUN FZ, 1992, DEVELOPMENT, V115, P947; TEKLE E, 1994, P NATL ACAD SCI USA, V91, P11512, DOI 10.1073/pnas.91.24.11512; Teruel MN, 1997, BIOPHYS J, V73, P1785, DOI 10.1016/S0006-3495(97)78209-2; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; Weaver JC, 1996, BIOELECTROCH BIOENER, V41, P135, DOI 10.1016/S0302-4598(96)05062-3; WEAVER JC, 1993, J CELL BIOCHEM, V51, P426, DOI 10.1002/jcb.2400510407; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	36	21	21	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					365	376		10.1096/fasebj.13.2.365	http://dx.doi.org/10.1096/fasebj.13.2.365			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973325				2022-12-28	WOS:000078615200017
J	Closs, EI; Enseleit, F; Koesling, D; Pfeilschifter, JM; Schwarz, PM; Forstermann, U				Closs, EI; Enseleit, F; Koesling, D; Pfeilschifter, JM; Schwarz, PM; Forstermann, U			Coexpression of inducible NO synthase and soluble guanylyl cyclase in colonic enterocytes: a pathophysiologic signaling pathway for the initiation of diarrhea by gram-negative bacteria?	FASEB JOURNAL			English	Article						NO synthase mRNA; ribonuclease protection analysis; anti-NO synthase antibodies; dexamethasone; aminoguanidine; lipopolysaccharide	NITRIC-OXIDE SYNTHASE; PIG SKELETAL-MUSCLE; GLUCOCORTICOIDS INHIBIT; SELECTIVE-INHIBITION; KAPPA-B; EXPRESSION; INDUCTION; AMINOGUANIDINE; TRANSDUCTION; PURIFICATION	Infectious diarrhea is often caused by the exotoxins of gram-negative bacteria such as Escherichia coli. However, these organisms also contain lipopolysaccharide (LPS) endotoxin. LPS induces nitric oxide synthase II (NOS II, inducible NOS) in various types of cells. We now demonstrate by RNase protection analysis, Western blot, and immunohistochemistry that the expression of NOS II mRNA and protein is markedly induced in colonic enterocytes of mice that ingest LPS with their drinking water. Using the same techniques, significant levels of soluble guanylyl cyclase (GC-S), the effector enzyme of NO, were found constitutively expressed in the mucosa. This creates a pathophysiologic autocrine pathway producing increased levels of cyclic GMP and leading to hypersecretion and diarrhea. In fact, the LPS-induced diarrhea developed in parallel with the NOS II induction. Diarrhea could be controlled with orally administered dexamethasone, which prevented the LPS-stimulated induction of NOS II (RNase protection analysis and Western blot). Diarrhea was also blocked by oral aminoguanidine, an inhibitor of NOS II activity. These data suggest that in addition to the known heat-labile and heat-stable exotoxins, gram-negative bacteria may induce diarrhea through the release of endotoxins that induce a NOS II-GC-S autocrine pathway in mucosal epithelium.	Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany; Free Univ Berlin, Dept Pharmacol, D-14195 Berlin, Germany; Univ Frankfurt, Dept Pharmacol, D-60509 Frankfurt, Germany	Johannes Gutenberg University of Mainz; Free University of Berlin; Goethe University Frankfurt	Forstermann, U (corresponding author), Univ Mainz, Dept Pharmacol, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.		Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				BLANKENSHIP LL, 1991, MICROCIRC ENDOTH LYM, V7, P57; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; Ford H, 1997, J PEDIATR SURG, V32, P275, DOI 10.1016/S0022-3468(97)90194-9; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Gath I, 1997, FEBS LETT, V410, P319, DOI 10.1016/S0014-5793(97)00615-7; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GRIFFITHS MJD, 1993, BRIT J PHARMACOL, V110, P963, DOI 10.1111/j.1476-5381.1993.tb13907.x; GUTHMANN F, 1992, N-S ARCH PHARMACOL, V346, P537; Hoffman RA, 1997, AM J PHYSIOL-GASTR L, V272, pG383, DOI 10.1152/ajpgi.1997.272.2.G383; JANN K, 1987, REV INFECT DIS, V9, pS517; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P283; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; Nitsch DD, 1997, AM J PATHOL, V150, P889; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Schwarz PM, 1998, NEUROSCIENCE, V82, P255; SCHWARZ PM, 1998, IN PRESS MOL PHARM, V54; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X	34	17	17	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1643	1649		10.1096/fasebj.12.15.1643	http://dx.doi.org/10.1096/fasebj.12.15.1643			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837854				2022-12-28	WOS:000077574500006
J	Schimmel, P; Tao, JS; Hill, J				Schimmel, P; Tao, JS; Hill, J			Aminoacyl tRNA synthetases as targets for new anti-infectives	FASEB JOURNAL			English	Review						antibiotic resistance; translation apparatus; pathogen-specific inhibitor; vancomycin; mainline antibiotics	TRANSFER-RNA-SYNTHETASE; PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; PSEUDOMONIC ACID; CRYSTAL-STRUCTURE; EVOLUTIONARY RELATIONSHIPS; STAPHYLOCOCCUS-AUREUS; GENETIC-CODE; RECOGNITION; SEQUENCE	Because resistance has developed to mainline antibiotics, including vancomycin, new antibiotics are now being aggressively sought, For this purpose, aminoacyl tRNA synthetases are being pursued as targets for new drug, These enzymes are universal and are essential for cell viability. The key to their usefulness lies in being able to find drugs that inhibit a pathogen synthetase but not its human cell. counterpart. The possibility for species-specific inhibition was originally demonstrated with a natural product and has now been demonstrated with prototypical drug that are based on the structure of an intermediate of the aminoacylation reaction. Efficacy of a rationally designed inhibitor has been shown in vivo with a pathogen infection established in an animal model, Although many challenges remain, these early results suggest that synthetases will continue to be of major interest for development of new anti-infectives.	Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, La Jolla, CA 92037 USA; Cubist Pharmaceut Inc, Cambridge, MA 02139 USA	Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, Beckman Ctr, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Schimmel@Scripps.edu						AULD DS, 1995, SCIENCE, V267, P1994, DOI 10.1126/science.7701322; Auld DS, 1996, EMBO J, V15, P1142, DOI 10.1002/j.1460-2075.1996.tb00452.x; AUMERCIER M, 1992, J ANTIMICROB CHEMOTH, V30, P9, DOI 10.1093/jac/30.suppl_A.9; BAINES PJ, 1984, ROYAL SOC MED INT C, V80, P13; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Baquero F, 1997, J ANTIMICROB CHEMOTH, V39, P1, DOI 10.1093/jac/39.suppl_1.1; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BOYCE JM, 1997, STAPHYLOCOCCI HUMAN, P309, DOI DOI 10.1002/9781444308464.CH15; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CASEWELL MW, 1985, J ANTIMICROB CHEMOTH, V15, P523, DOI 10.1093/jac/15.5.523; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CAVARELLI J, 1993, BIOCHIMIE, V75, P1117, DOI 10.1016/0300-9084(93)90011-G; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; CUSACK S, 1993, BIOCHIMIE, V75, P1077, DOI 10.1016/0300-9084(93)90006-E; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DOOLITTLE WF, 1994, P NATL ACAD SCI USA, V91, P6721, DOI 10.1073/pnas.91.15.6721; DYKE KGH, 1991, FEMS MICROBIOL LETT, V77, P195, DOI 10.1111/j.1574-6968.1991.tb04346.x; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Fersht A., 1985, ENZYME STRUCTURE MEC; Freist W, 1997, BIOL CHEM, V378, P1103; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; FULLER AT, 1971, NATURE, V234, P416, DOI 10.1038/234416a0; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Gruneberg RN, 1997, DRUGS, V54, P29; HAYES JD, 1990, BIOCHEM J, V272, P281, DOI 10.1042/bj2720281; Hill AL, 1996, WEED RES, V36, P15, DOI 10.1111/j.1365-3180.1996.tb01796.x; Hill J. M., 1998, U.S.A. Patent, Patent No. [5,726,195, 5726195]; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KONISHI M, 1989, J ANTIBIOT, V42, P1749, DOI 10.7164/antibiotics.42.1749; KONRAD I, 1977, FEBS LETT, V83, P341, DOI 10.1016/0014-5793(77)81037-5; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; NAGEL GM, 1995, J MOL EVOL, V40, P487; NASS G, 1969, BIOCHEM BIOPH RES CO, V34, P84, DOI 10.1016/0006-291X(69)90532-4; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; OGILVIE A, 1975, BIOCHEM J, V152, P511, DOI 10.1042/bj1520511; OHRUI H, 1975, J AM CHEM SOC, V97, P4602, DOI 10.1021/ja00849a023; PAETZ W, 1973, EUR J BIOCHEM, V35, P331, DOI 10.1111/j.1432-1033.1973.tb02843.x; QUINN CL, 1995, BIOCHEMISTRY-US, V34, P12489, DOI 10.1021/bi00039a001; RAHMAN M, 1990, J MED MICROBIOL, V33, P97, DOI 10.1099/00222615-33-2-97; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; Sassanfar M, 1996, BIOCHEMISTRY-US, V35, P9995, DOI 10.1021/bi9603027; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; Shiba K, 1997, TRENDS BIOCHEM SCI, V22, P453, DOI 10.1016/S0968-0004(97)01135-3; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Steitz TA, 1991, CURR OPIN STRUC BIOL, V1, P139, DOI 10.1016/0959-440X(91)90022-L; TANAKA K, 1969, BIOCHIM BIOPHYS ACTA, V195, P244, DOI 10.1016/0005-2787(69)90621-2; TESTA RT, 1993, ANTIMICROB AGENTS CH, V37, P2270, DOI 10.1128/AAC.37.11.2270; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WERNER RG, 1976, EUR J BIOCHEM, V68, P1, DOI 10.1111/j.1432-1033.1976.tb10758.x; YANAGISAWA T, 1994, J BIOL CHEM, V269, P24304; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2; 1997, CDC MORBIDITY MORTAL, V46, P765	78	147	155	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1599	1609		10.1096/fasebj.12.15.1599	http://dx.doi.org/10.1096/fasebj.12.15.1599			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837850				2022-12-28	WOS:000077574500002
J	Collins, AR; Gedik, CM; Olmedilla, B; Southon, S; Bellizzi, M				Collins, AR; Gedik, CM; Olmedilla, B; Southon, S; Bellizzi, M			Oxidative DNA damage measured in human lymphocytes: large differences between sexes and between countries, and correlations with heart disease mortality rates	FASEB JOURNAL			English	Article						molecular epidemiology; oxidative DNA damage; coronary heart disease; cancer		The 'antioxidant hypothesis' proposes that vitamin C, vitamin E, carotenoids, and other antioxidants occurring in fruit and vegetables afford protection against heart disease and cancer by preventing oxidative damage to lipids and to DNA, respectively. To test elements of this hypothesis, we have measured blood levels of dietary antioxidants, and 8-oxodeoxyguanosine (8-oxo-dG) concentrations in lymphocyte DNA, in healthy men and women from five European countries: France, Ireland, The Netherlands, Spain, and the U.K. Volunteers, aged 25-45, all nonsmokers, gave blood samples before and after a 12-wk carotenoid supplementation regime. Vitamin C was measured in plasma and vitamin E and carotenoids were measured in serum by high-performance liquid chromatography (HPLC). 8-oxo-dG was assayed by HPLC (with coulometric detection) in DNA isolated from lymphocytes from the same blood samples. Mean values were calculated for groups of volunteers at each sampling time according to country, sex, and supplementation (between 9 and 24 individual samples contributing to each mean). We found that 8-oxo-dG levels in lymphocyte DNA vary significantly according to sex and country. A low mean 8-oxo-dG concentration is seen in DNA of women from all five countries, and of men from France and Spain. 8-oxo-dG is significantly higher (up to about threefold) in lymphocyte DNA from men in Ireland and the U.K. Oxidative DNA damage is not significantly affected by carotenoid supplementation; nor is there any association with mean baseline levels of antioxidants, which are generally similar in the five countries. The five countries sampled lie on an axis from northern to southern Europe with a steep gradient:in terms of premature heart disease. There is a strong association between premature coronary heart disease mortality in men and the mean levels of 8-oxo-dG for the five countries (r = 0.95, P < 0.01). Women have low coronary heart disease mortality rates, which do not correlate with 8-oxo-dG. In terms of cancer deaths, only colorectal cancer in men shows a significant positive correlation (r = 0.91, P < 0.05), and stomach cancer in women is negatively correlated with DNA oxidation (r = -0.92, P = 0.01).	Rowett Res Inst, DNA Instabil Grp, Bucksburn AB21 9SB, Aberdeen, Scotland; Clin Puerta Hierro, Serv Nutr, Madrid 28035, Spain; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of Aberdeen; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Collins, AR (corresponding author), Rowett Res Inst, DNA Instabil Grp, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.		Olmedilla-Alonso, Begoña/D-1337-2012	Olmedilla-Alonso, Begoña/0000-0002-4913-5171				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; Collins A, 1997, CARCINOGENESIS, V18, P1833, DOI 10.1093/carcin/18.9.1833; Collins AR, 1996, ENVIRON HEALTH PERSP, V104, P465, DOI 10.2307/3432805; DUTHIE SJ, 1995, MUTAT RES-FUND MOL M, V331, P55, DOI 10.1016/0027-5107(95)00051-J; FINGLAS PM, 1993, BRIT J NUTR, V69, P563, DOI 10.1079/BJN19930056; Olmedilla B, 1997, CLIN CHEM, V43, P1066; RENAUD S, 1994, REPROD NUTR DEV, V34, P599, DOI 10.1051/rnd:19940606; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465	9	132	133	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1397	1400		10.1096/fasebj.12.13.1397	http://dx.doi.org/10.1096/fasebj.12.13.1397			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761783				2022-12-28	WOS:000076402000015
J	Mergler, S; Steinhausen, K; Wiederholt, M; Strauss, O				Mergler, S; Steinhausen, K; Wiederholt, M; Strauss, O			Altered regulation of L-type channels by protein kinase C and protein tyrosine kinases as a pathophysiologic effect in retinal degeneration	FASEB JOURNAL			English	Article						retinal pigment epithelium; bFGF; calcium channels; retinal pigment epithelium; RCS rats	PIGMENT EPITHELIAL-CELLS; SMOOTH-MUSCLE CELLS; FIBROBLAST GROWTH-FACTOR; ROD OUTER SEGMENTS; RCS RAT RPE; CALCIUM CHANNELS; CULTURED RAT; INOSITOL TRIPHOSPHATE; PHORBOL ESTERS; ROYAL-COLLEGE	The effect of protein tyrosine kinases (PTK) on L-type calcium channels in cultured retinal pigmented epithelium (RPE) from rats with retinal dystrophy was investigated. Barium currents through Bay K 8644 (10(-6) M) sensitive L-type channels were measured using the patch-clamp technique. The current density of L-type currents is twice as high and the inactivation time constants are much slower than in cells from nondystrophic control rats. Application of the PTK blockers genistein, lavendustin A, and herbimycin A (all 5X10(-6) M) led to an increase of Lr type currents. Intracellular application of pp60c-src (30 U/ml) via the patch pipette led to a transient decrease of L-type currents. The protein kinase A (PKA) and PKG blocker H9 (10(-6) M) showed no effect on L-type currents, However, the protein kinase C blocker chelerythrine (10(-5) M) reduced these currents. Up-regulation of PKC by 10(-6) M 4 beta-phorbol- 12 myristate-13-acetate (PMA) led to a decrease of C type currents. Additional application of genistein led to a further decrease of these currents. However, intracellular application of pp60(c-src) in PMA-treated cells led to a transient increase of L-type currents. Investigating the calcium response to bFGF application showed that RPE cells from RCS rats used different pathways than control RPE cells to increase cytosolic free calcium. This different pathway does not involve the activation of L-type channels. The present study with RPE cells from rats with retinal dystrophy shows a changed integration of PTK and PKC in channel regulation, Considering the altered response to bFGF in RCS-RPE cells, this disturbed regulation of L-type channels by tyrosine kinases is involved in the etiology of retinal degeneration in RCS rats.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Mergler, S (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, Hindenburgdamm 30, D-12200 Berlin, Germany.	wiederho@zedat.fu-berlin.de	Strauss, Olaf/AAA-6485-2019	Mergler, Stefan/0000-0001-8608-648X; Strauss, Olaf/0000-0002-6272-8596				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; Bechem M., 1997, Life Sciences, V60, P107; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T; BOST LM, 1994, EXP EYE RES, V58, P545, DOI 10.1006/exer.1994.1048; Cataldi M, 1996, J BIOL CHEM, V271, P9441, DOI 10.1074/jbc.271.16.9441; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; Chiang CE, 1996, BIOCHEM BIOPH RES CO, V223, P598, DOI 10.1006/bbrc.1996.0941; Chik CL, 1996, FASEB J, V10, P1310, DOI 10.1096/fasebj.10.11.8836045; CONNOLLY SE, 1992, CURR EYE RES, V11, P1005, DOI 10.3109/02713689209033499; DETURCO EBR, 1992, EXP EYE RES, V55, P719, DOI 10.1016/0014-4835(92)90176-S; DOERNER D, 1992, BRAIN RES, V597, P30, DOI 10.1016/0006-8993(92)91502-6; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; ELHIFNAWI E, 1987, ADV BIOSCI, V62, P417; FACTOROVICH EG, 1990, NATURE, V347, P83; FACTOROVICH EG, 1992, J NEUROSCI, V12, P3554; GALIZZI JP, 1987, J BIOL CHEM, V262, P6947; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLDMAN AI, 1978, SCIENCE, V201, P1023, DOI 10.1126/science.567376; GREGORY CY, 1992, INVEST OPHTH VIS SCI, V33, P3121; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL MO, 1991, EXP EYE RES, V52, P591, DOI 10.1016/0014-4835(91)90061-I; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERRON WL, 1969, INVEST OPHTH VISUAL, V8, P595; HETH CA, 1994, INVEST OPHTH VIS SCI, V35, P409; HETH CA, 1992, INVEST OPHTH VIS SCI, V33, P2839; HETH CA, 1992, INVEST OPHTH VIS SCI, V33, P1203; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; KOH SWM, 1992, CELL BIOL INT REP, V16, P1003, DOI 10.1016/S0309-1651(06)80053-6; LAVAIL MM, 1995, INVEST OPHTH VIS SCI, V36, pS211; MALECAZE F, 1993, J CELL PHYSIOL, V154, P631, DOI 10.1002/jcp.1041540323; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; McLaren MJ, 1997, FEBS LETT, V412, P21, DOI 10.1016/S0014-5793(97)00566-8; McLaren MJ, 1996, FEBS LETT, V387, P63, DOI 10.1016/0014-5793(96)00461-9; MCLAREN MJ, 1992, INVEST OPHTH VIS SCI, V33, P1027; MERGLER S, 1997, PFLUEGERS ARCH S, V433, pR168; MERGLER S, 1996, PFLUEGERS ARCH, V431, pR114; Miceli M. V., 1997, Investigative Ophthalmology and Visual Science, V38, pS329; NASH MS, 1995, NEUROCHEM INT, V27, P253, DOI 10.1016/0197-0186(95)00040-F; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; SATOH T, 1992, J BIOL CHEM, V267, P2537; Shuttleworth TJ, 1997, J EXP BIOL, V200, P303; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STRAUSS O, 1993, PFLUG ARCH EUR J PHY, V425, P68, DOI 10.1007/BF00374505; Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484; STRAUSS O, 1994, J CELL PHYSIOL, V160, P89, DOI 10.1002/jcp.1041600111; Strauss O., 1997, Investigative Ophthalmology and Visual Science, V38, pS468; UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WEN R, 1995, J NEUROSCI, V15, P7377; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; WIJETUNGE S, 1992, BIOCHEM BIOPH RES CO, V189, P1620, DOI 10.1016/0006-291X(92)90262-J	58	34	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1125	1134		10.1096/fasebj.12.12.1125	http://dx.doi.org/10.1096/fasebj.12.12.1125			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737715				2022-12-28	WOS:000075738500007
J	Pouliot, M; Gilbert, C; Borgeat, P; Poubelle, PE; Bourgoin, S; Creminon, C; Maclouf, J; McColl, SR; Naccache, PH				Pouliot, M; Gilbert, C; Borgeat, P; Poubelle, PE; Bourgoin, S; Creminon, C; Maclouf, J; McColl, SR; Naccache, PH			Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils	FASEB JOURNAL			English	Article						thromboxane; dexamethasone; lipopolysaccharide; cyclooxygenase	HUMAN AMNION CELLS; PHOSPHOLIPASE-D; H SYNTHASE-2; POLYMORPHONUCLEAR LEUKOCYTES; CYCLOOXYGENASE-2 EXPRESSION; GLUCOCORTICOIDS STIMULATE; INDUCIBLE CYCLOOXYGENASE; SUPEROXIDE GENERATION; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS	Proinflammatory agents were assessed for their capacity to stimulate the expression of the for their capacity to stimulate the expression of the inducible cyclooxygenase isoform (COX-2) in human neutrophils. A number of agents, including PMA, opsonized bacteria and zymosan, LPS, GM-CSF, TNF-alpha, and fMLP, induced COX-2 protein expression through signaling pathways involving transcription and protein synthesis events. Northern blots showed that freshly isolated neutrophils expressed low levels of COX-2 mRNA, which rapidly increased after incubation with inflammatory agents. A characterization of the signal transduction pathways leading to COX-2 protein expression was initiated. In LPS-treated neutrophils, efficient induction of COX-2 required the presence of serum and involved ligand binding to the CD14 surface antigen. The specific inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), SE 203580, had little effect on the induction of COX-2 expression in neutrophils, in contrast to what had been previously observed with other inflammatory cell types. Depending on the agonist present, ethanol differentially blocked the stimulated expression of COX-2, raising the possibility that phospholipase D activation might take part in the process of COX-2 induction. Major COX-2-derived prostanoids synthesized by inflammatory neutrophils were identified by liquid-chromatography and tandem mass-spectrometry as TXA(2) and PGE(2). The agonist-induced synthesis of TXA2 and PGE2 was effectively blocked by cycloheximide and by the specific COX-2 inhibitor NS-398. These results show that COX-2 can be induced in an active state by different classes of inflammatory mediators in the neutrophil. They support the concept that, in these cells, the COX-2 isoform is preeminent over COX-1 for the stimulated-production of prostanoids, and also suggest that neutrophil COX-2 displays a distinct profile of expression among circulatory cells.	CHU Laval, Ctr Rech, Ctr Rech Rhumatol & Immunol, Quebec City, PQ, Canada; Univ Laval, Quebec City, PQ G1K 7P4, Canada; CENS, CEA, SPI, DRM, F-91191 Gif Sur Yvette, France; Fac Med, Dept Med, F-91191 Gif Sur Yvette, France; Fac Med, Dept Physiol, F-91191 Gif Sur Yvette, France; Hop Lariboisiere, INSERM U348, F-7547 Paris 10, France; Univ Adelaide, Dept Microbiol & Immunol, Adelaide, SA, Australia	Laval University; Laval University; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Adelaide	Pouliot, M (corresponding author), Brigham & Womens Hosp, Dept Anesthesia, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.	pouliot@zeus.bwh.harvard.edu	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424; Gilbert, Caroline/0000-0003-2722-1180; Bourgoin, Sylvain/0000-0001-9779-0368				Akarasereenont P, 1996, BIOCHEM BIOPH RES CO, V220, P181, DOI 10.1006/bbrc.1996.0377; ALBERT TJ, 1994, PROSTAGLANDINS, V48, P401, DOI 10.1016/0090-6980(94)90006-X; ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CHABOT MC, 1992, BIOCHEM J, V286, P693, DOI 10.1042/bj2860693; Crofford LJ, 1997, J RHEUMATOL, V24, P15; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dayton ET, 1996, J NEUROIMMUNOL, V71, P11, DOI 10.1016/S0165-5728(96)00111-7; DELLABIANCA V, 1991, BIOCHEM BIOPH RES CO, V177, P948, DOI 10.1016/0006-291X(91)90630-P; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GLASER KB, 1995, BIOCHEM PHARMACOL, V50, P913, DOI 10.1016/0006-2952(95)00211-H; Godessart N, 1996, J INVEST DERMATOL, V107, P726, DOI 10.1111/1523-1747.ep12365616; GOLDSTEIN IM, 1978, J EXP MED, V148, P787, DOI 10.1084/jem.148.3.787; HABIB A, 1993, J BIOL CHEM, V268, P23448; HERRMANN F, 1990, EUR J IMMUNOL, V20, P2513, DOI 10.1002/eji.1830201124; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LYONSGIORDANO B, 1993, EXP CELL RES, V206, P58, DOI 10.1006/excr.1993.1120; Maloney CG, 1998, J IMMUNOL, V160, P1402; Margalit A, 1996, ANAL BIOCHEM, V235, P73, DOI 10.1006/abio.1996.0093; MASFERRER JL, 1994, RECEPTOR, V4, P25; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OTTO JC, 1993, J BIOL CHEM, V268, P18234; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; POTESTIO FA, 1988, J CLIN ENDOCR METAB, V67, P1205, DOI 10.1210/jcem-67-6-1205; POULIOT M, 1994, J IMMUNOL, V152, P851; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Pouliot M, 1997, J IMMUNOL, V158, P4930; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Ridley SH, 1997, J IMMUNOL, V158, P3165; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; Sato T, 1996, J BONE MINER RES, V11, P392; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SIMMONS PM, 1983, BIOCHEM PHARMACOL, V32, P1353, DOI 10.1016/0006-2952(83)90446-X; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith W.L.B.P., 1991, BIOCH LIPIDS LIPOPRO, P297, DOI [10.1016/S0167-7306(08)60338-5, DOI 10.1016/S0167-7306(08)60338-5]; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; Vane JR, 1996, SCAND J RHEUMATOL, P9; Vigano T, 1997, AM J RESP CRIT CARE, V155, P864, DOI 10.1164/ajrccm.155.3.9117018; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YUCELLINDBERG T, 1995, INFLAMMATION, V19, P549, DOI 10.1007/BF01539135; ZAKAR T, 1989, J DEV PHYSIOL, V12, P269; ZAKAR T, 1995, ENDOCRINOLOGY, V136, P1610, DOI 10.1210/en.136.4.1610; Zurier R B, 1975, Inflammation, V1, P93, DOI 10.1007/BF00918062	65	102	102	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1109	1123		10.1096/fasebj.12.12.1109	http://dx.doi.org/10.1096/fasebj.12.12.1109			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737714				2022-12-28	WOS:000075738500006
J	Heyes, MP; Saito, K; Lackner, A; Wiley, CA; Achim, CL; Markey, SP				Heyes, MP; Saito, K; Lackner, A; Wiley, CA; Achim, CL; Markey, SP			Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques	FASEB JOURNAL			English	Article						macrophages; astrocytes; indoleamine-2,3-dioxygenase; kynurenine-3-hydroxylase; kynureninase; kynurenine aminotransferase; L-tryptophan; L-kynurenine; kynurenic acid; retrovirus; blood-brain barrier; cytokines; nonhuman primates	HUMAN-IMMUNODEFICIENCY-VIRUS; KYNURENINE PATHWAY METABOLITES; COMPLEX PARTIAL SEIZURES; CENTRAL-NERVOUS-SYSTEM; CONVERT L-TRYPTOPHAN; CEREBROSPINAL-FLUID; NEUROLOGICAL DISEASE; IMMUNE ACTIVATION; NEUROACTIVE KYNURENINES; CEREBRAL-ISCHEMIA	This: study investigated the sources of quinolinic acid, a neurotoxic tryptophan-kynurenine pathway metabolite, in the brain and blood of HIV-infected patients and retrovirus-infected macaques.In brain, quinolinic acid concentrations in HIV-infected patients were elevated by >300-fold to concentrations that exceeded cerebrospinal fluid (CSF) by 8.9-fold. There were no significant correlations between elevated serum quinolinic acid levels with those in CSF and brain parenchyma. Because nonretrovirus-induced encephalitis confounds the interpretation of human postmortem data, rhesus macaques infected with retrovirus were used to examine the mechanisms of increased quinolinic acid accumulations and determine the relationships of quinolinic acid to encephalitits and systemic responses. The largest kynurenine pathway responses in brain were associated with encephalitis and were independent of systemic responses. CSF quinolinic acid levels were also elevated in all infected macaques, but particularly those with retrovirus-induced encephalitis. In contrast to the brain changes, there was no difference in any systemic measure between macaques with encephalitis: vs. those without. Direct measures of the amount of quinolinic acid in brain derived from blood in a macaque with encephalitis showed that almost all quinolinic acid (>98%) was synthesized locally within the brain. These results demonstrate a role for induction of indoleamine-2,3-dioxygenase in accelerating the local formation of quinolinic acid within the brain tissue, particularly in areas of encephalitis, rather than entry of quinolinic acid into the brain from the meninges or blood. Strategies to reduce QUIN production, targeted at intracerebral sites, are potential approaches to therapy.-Heyes, M. P., Saito, K., Lackner, A., Wiley, C. A., Achim, C. L., Markey, S. P. Sources of the neurotoxin quinolinic acid in the brain of HIV-l-infected patients and retrovirus-infected macaques.	NIMH, Lab Neurotoxicol, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Presbyterian Univ Hosp, Div Neuropathol, Pittsburgh, PA 15213 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	Heyes, MP (corresponding author), NIMH, Lab Neurotoxicol, Bldg 10,Room 3D40,9000 Rockville Pike, Bethesda, MD 20892 USA.				NCRR NIH HHS [RR00169, RR00168] Funding Source: Medline; NINDS NIH HHS [NS30769] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168, P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030769] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1993, J CLIN INVEST, V91, P2769, DOI 10.1172/JCI116518; Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; BASILE AS, 1995, GASTROENTEROLOGY, V108, P818, DOI 10.1016/0016-5085(95)90456-5; Beagles KE, 1998, J NEUROCHEM, V70, P281; BENDER DA, 1982, MOL ASPECTS MED, V6, P101; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; BONI RL, 1989, 6 INT STUD GROUP TRY, P481; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BREW BJ, 1995, J NEUROVIROL, V1, P328; BROUWERS P, 1993, J INFECT DIS, V168, P1380, DOI 10.1093/infdis/168.6.1380; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; DEMITRACK MA, 1995, BIOL PSYCHIAT, V37, P512, DOI 10.1016/0006-3223(94)00173-Z; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; Espey MG, 1997, NEUROREPORT, V8, P431, DOI 10.1097/00001756-199701200-00011; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Giulian D, 1996, J NEUROSCI, V16, P3139; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; HAYES MP, 1997, BIOCHEM J, V326, P351; HAYMAN M, 1993, NEUROSCIENCE, V53, P1, DOI 10.1016/0306-4522(93)90278-N; HEYES MP, 1994, EPILEPSIA, V35, P251, DOI 10.1111/j.1528-1157.1994.tb02428.x; HEYES MP, 1992, J NEUROIMMUNOL, V40, P71, DOI 10.1016/0165-5728(92)90214-6; HEYES MP, 1990, J CHROMATOGR-BIOMED, V530, P108, DOI 10.1016/S0378-4347(00)82308-7; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; Heyes MP, 1996, BIOCHEM J, V320, P595, DOI 10.1042/bj3200595; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1992, BRAIN RES, V570, P237, DOI 10.1016/0006-8993(92)90587-Y; Heyes MP, 1997, J NEUROCHEM, V68, P280; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; Heyes MP, 1997, J NEUROCHEM, V69, P1519; HEYES MP, 1991, NEUROSCI LETT, V122, P265, DOI 10.1016/0304-3940(91)90874-S; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; HEYES MP, 1989, ANN NEUROL, V26, P275; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HEYES MP, 1988, BIOMED ENVIRON MASS, V15, P291, DOI 10.1002/bms.1200150509; HEYES MP, 1990, EPILEPSIA, V31, P172, DOI 10.1111/j.1528-1167.1990.tb06302.x; HEYES MP, 1990, J NEUROCHEM, V55, P338, DOI 10.1111/j.1471-4159.1990.tb08857.x; Kerr SJ, 1997, NEUROLOGY, V49, P1671, DOI 10.1212/WNL.49.6.1671; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Lane JH, 1996, J NEUROVIROL, V2, P423, DOI 10.3109/13550289609146909; MARTIN A, 1992, J NEUROPSYCH CLIN N, V4, P270; Martin A., 1993, NEUROPSYCHOLOGY, V7, P149, DOI DOI 10.1037/0894-4105.7.2.149; MILSTIEN S, 1994, J NEUROCHEM, V63, P1178; MOURDIAN MM, 1989, NEUROSCI LETT, V105, P233, DOI 10.1016/0304-3940(89)90043-8; Namboodiri AMA, 1996, J NEUROVIROL, V2, P433, DOI 10.3109/13550289609146910; NARITSIN DB, 1995, J NEUROCHEM, V65, P2217; Nottet HSLM, 1996, J NEUROVIROL, V2, P111, DOI 10.3109/13550289609146544; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; RAUSCH DM, 1994, J NEUROPATH EXP NEUR, V53, P165, DOI 10.1097/00005072-199403000-00008; Reinhard J F Jr, 1994, Adv Pharmacol, V30, P85, DOI 10.1016/S1054-3589(08)60173-8; SAITO K, 1993, BIOCHEM J, V291, P11, DOI 10.1042/bj2910011; SAITO K, 1992, NEUROSCIENCE, V51, P25, DOI 10.1016/0306-4522(92)90467-G; SAITO K, 1993, J NEUROCHEM, V60, P180, DOI 10.1111/j.1471-4159.1993.tb05836.x; SAITO K, 1993, J BIOL CHEM, V268, P15496; SAITO K, 1993, J NEUROCHEM, V61, P2061, DOI 10.1111/j.1471-4159.1993.tb07443.x; SAITO K, 1991, BRAIN RES, V546, P151, DOI 10.1016/0006-8993(91)91171-V; SAITO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P104, DOI 10.1006/abbi.1993.1567; SEI S, 1995, J INFECT DIS, V172, P638, DOI 10.1093/infdis/172.3.638; Sei Y, 1996, J NEUROCHEM, V66, P296; SMITH MO, 1995, LAB INVEST, V72, P547; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; STONE TW, 1993, PHARMACOL REV, V45, P309; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; Vogelgesang SA, 1996, J RHEUMATOL, V23, P850; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Yates J. R., 1997, Society for Neuroscience Abstracts, V23, P1384	71	119	126	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					881	896		10.1096/fasebj.12.10.881	http://dx.doi.org/10.1096/fasebj.12.10.881			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657528				2022-12-28	WOS:000074580100013
J	Topham, MK; Carveth, HJ; McIntyre, TM; Prescott, SM; Zimmerman, GA				Topham, MK; Carveth, HJ; McIntyre, TM; Prescott, SM; Zimmerman, GA			Human endothelial cells regulate polymorphonuclear leukocyte degranulation	FASEB JOURNAL			English	Article						monoclonal antibodies; neutrophils; PMN adhesion; cytokine; tumor necrosis factor	PLATELET-ACTIVATING-FACTOR; TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; HUMAN NEUTROPHIL ADHERENCE; TRANSENDOTHELIAL MIGRATION; SUBCELLULAR-LOCALIZATION; CHEMOTACTIC FACTOR; RESPIRATORY BURST; MAC-1 CD11B/CD18; DE-GRANULATION	Neutrophil degranulation is an important event in inflammatory responses. We examined the regulation of neutrophil (PMN) degranulation by resting and activated human endothelial cells. Whereas PMNs adherent to endothelial cells that were stimulated to express P-selectin and platelet-activating factor did not release the specific granule marker lactoferrin or the primary granule enzyme, elastase, PMNs adherent to endothelial cells stimulated with interleukin-1 (IL-1) or tumor necrosis factor secreted both. PMN degranulation was dependent on the time of incubation of endothelial cells with the cytokine, its concentration, and the time of incubation of the PMNs with endothelial cells. Degranulation of PMNs and their adhesion to stimulated endothelial cells are correlated events, but they could be dissociated by blocking the tethering molecules used by the endothelial cells and neutrophils under these conditions. This suggested that paracrine signaling molecules that induce PMN degranulation are produced by cytokine-stimulated endothelial cells. We found that endothelial cells stimulated with IL-1 release newly synthesized degranulating factors that require transcription and translation. IL-8 was synthesized, released, and signaled granular secretion by PMNs, However, experiments with blocking antibodies indicated the presence of an additional degranulating factor not accounted for by IL-8. These experiments demonstrate that human endothelial cells regulate degranulation of neutrophils by generating signaling factors that are expressed differentially depending on the endothelial agonist and other features. Active modification of neutrophil granular secretion by endothelial cells can influence physiologic acute inflammatory responses but may also contribute to pathologic vascular and tissue damage.	Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Zimmerman, GA (corresponding author), Univ Utah, Sch Med, Nora Eccles Harrison Cardiovasc Res & Training In, 95 S 2000 E Back, Salt Lake City, UT 84112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R01HL034127] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL076, R01 HL34127, R01 HL44525] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BOXER LA, 1982, J CLIN INVEST, V70, P1049, DOI 10.1172/JCI110692; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BROCK J, 1995, IMMUNOL TODAY, V16, P417, DOI 10.1016/0167-5699(95)80016-6; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; DEWALD B, 1986, BIOCHIM BIOPHYS ACTA, V888, P42, DOI 10.1016/0167-4889(86)90069-8; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; ENGLISH D, 1992, BLOOD, V80, P776; FEHR J, 1985, J CLIN INVEST, V76, P535, DOI 10.1172/JCI112003; FURIE MB, 1992, J IMMUNOL, V148, P2395; GALLIN JI, 1978, J CLIN INVEST, V62, P1364, DOI 10.1172/JCI109257; GALLIN JI, 1985, ANNU REV MED, V36, P263; GALLIN JI, 1980, J CLIN INVEST, V65, P298, DOI 10.1172/JCI109672; Gill EA, 1998, FASEB J, V12, P673, DOI 10.1096/fasebj.12.9.673; HAKKERT BC, 1991, BLOOD, V78, P2721, DOI 10.1182/blood.V78.10.2721.bloodjournal78102721; HARLAN JM, 1981, J CLIN INVEST, V68, P1394, DOI 10.1172/JCI110390; HARLAN JM, 1985, LAB INVEST, V52, P141; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HENSON PM, 1992, INFLAMMATION BASIC P, P511; HIBBS MS, 1989, J CLIN INVEST, V84, P1395, DOI 10.1172/JCI114312; HOFFSTEIN ST, 1982, J CELL BIOL, V95, P234, DOI 10.1083/jcb.95.1.234; HUBER AR, 1989, J CLIN INVEST, V83, P1122, DOI 10.1172/JCI113992; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; HUGHES BJ, 1992, J CLIN INVEST, V90, P1687, DOI 10.1172/JCI116041; Imaizumi TA, 1997, AM J RESP CELL MOL, V17, P181, DOI 10.1165/ajrcmb.17.2.2818; Introna M, 1997, ARTERIOSCL THROM VAS, V17, P423, DOI 10.1161/01.ATV.17.3.423; KISHIMOTO TK, 1991, BLOOD, V78, P805; KOBAYASHI T, 1991, J CELL BIOL, V113, P743, DOI 10.1083/jcb.113.4.743; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; KUIJPERS TW, 1991, J IMMUNOL, V147, P1369; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARTICH GD, 1991, J EXP MED, V173, P1021, DOI 10.1084/jem.173.4.1021; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OSEAS R, 1981, BLOOD, V57, P939; OZAKI Y, 1987, J LEUKOCYTE BIOL, V42, P621, DOI 10.1002/jlb.42.6.621; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHLEIFFENBAUM B, 1989, J IMMUNOL, V142, P3537; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPERTINI O, 1991, J IMMUNOL, V147, P2565; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; TODD RF, 1984, J CLIN INVEST, V74, P1280, DOI 10.1172/JCI111538; VARANI J, 1989, AM J PATHOL, V135, P435; VERCELLOTTI GM, 1989, J LEUKOCYTE BIOL, V45, P483, DOI 10.1002/jlb.45.6.483; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WALTZ G, 1990, SCIENCE, V250, P1132; Watson F, 1997, J BIOL CHEM, V272, P17944, DOI 10.1074/jbc.272.29.17944; WRIGHT DG, 1979, J IMMUNOL, V123, P285; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; ZIMMERMAN GA, 1990, METHOD ENZYMOL, V187, P520; ZIMMERMAN GA, 1988, J CLIN INVEST, V81, P531, DOI 10.1172/JCI113351; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	77	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					733	746		10.1096/fasebj.12.9.733	http://dx.doi.org/10.1096/fasebj.12.9.733			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619452				2022-12-28	WOS:000074011000013
J	Dzeja, PP; Terzic, A				Dzeja, PP; Terzic, A			Phosphotransfer reactions in the regulation of ATP-sensitive K+ channels	FASEB JOURNAL			English	Review						K-ATP channel; adenylate kinase; creatine kinase; pyruvate kinase; glycolysis; metabolic signaling	ADENYLATE KINASE-ACTIVITY; GLUCOSE-INDUCED CHANGES; PANCREATIC BETA-CELLS; GUINEA-PIG; SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; INSULIN-SECRETION; NUCLEOSIDE DIPHOSPHATE; METABOLIC-REGULATION; PHOSPHORYL TRANSFER	ATP-sensitive K+ (K-ATP) channels are nucleotide-gated channels that couple the metabolic status of a cell with membrane excitability and regulate a number of cellular functions, including hormone secretion and cardioprotection, Although intracellular ATP is the endogenous inhibitor of K-ATP channels and ADP serves as the channel activator, it is still a matter of debate whether changes in the intracellular concentrations of ATP, ADP, and/or in the ATP/ADP ratio could account for the transition from the ATP-liganded to the ADP-liganded channel state. Here, we overview evidence for the role of cellular phosphotransfer cascades in the regulation of K-ATP channels. The microenvironment of the K-ATP channel harbors several phosphotransfer enzymes, including adenylate, creatine, and pyruvate kinases, as well as other glycolytic enzymes that are able to transfer phosphoryls between ATP and ADP in the absence of major changes in cytosolic levels of adenine nucleotides, These phosphotransfer reactions are governed by the metabolic status of a cell, and their phosphotransfer rate closely correlates with K-ATP channel activity. Adenylate kinase catalysis accelerates the transition from ATP to ADP, leading to K-ATP channel opening, while phosphotransfers driven by creatine and pyruvate kinases promote ADP to ATP transition and channel closure. Thus, through delivery and removal of adenine nucleotides at the channel site, phosphotransfer reactions could regulate ATP/ADP balance in the immediate vicinity of the channel and thereby the probability of K-ATP channel opening. In this way, phosphotransfer reactions could provide a transduction mechanism coupling cellular metabolic signals with K-ATP channel-associated functions.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenheim 7, Rochester, MN 55905 USA.				NHLBI NIH HHS [T32 HL 07111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007111] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BLISS CR, 1994, LIFE SCI, V55, P423, DOI 10.1016/0024-3205(94)90053-1; BOUME HR, 1991, NATURE, V349, P117; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; DECKING UKM, 1995, AM J PHYSIOL-HEART C, V269, pH734, DOI 10.1152/ajpheart.1995.269.2.H734; Decking UKM, 1997, CIRC RES, V81, P154, DOI 10.1161/01.RES.81.2.154; Detimary P, 1996, ENDOCRINOLOGY, V137, P4671, DOI 10.1210/en.137.11.4671; DETIMARY P, 1995, J CLIN INVEST, V96, P1738, DOI 10.1172/JCI118219; DEUTSCH N, 1991, AM J PHYSIOL, V261, pH671, DOI 10.1152/ajpheart.1991.261.3.H671; DZEJA P, 1985, BIOCHEM INT, V10, P259; DZEJA P, 1998, IN PRESS MOL CELL BI; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; FINDLAY I, 1994, J CARDIOVASC PHARM, V24, pS6, DOI 10.1097/00005344-199424014-00002; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; GHOSH A, 1991, J BIOL CHEM, V266, P22887; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; GUTIERREZ JA, 1995, J BACTERIOL, V177, P390, DOI 10.1128/jb.177.2.390-400.1995; HEIDBUCHEL H, 1993, PFLUG ARCH EUR J PHY, V422, P316, DOI 10.1007/BF00374286; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Jovanovic A, 1996, PFLUG ARCH EUR J PHY, V431, P800, DOI 10.1007/BF02253848; Jovanovic A, 1996, N-S ARCH PHARMACOL, V353, P241; KREMEN A, 1982, J THEOR BIOL, V96, P425, DOI 10.1016/0022-5193(82)90119-9; KUBO S, 1974, EUR J BIOCHEM, V48, P325, DOI 10.1111/j.1432-1033.1974.tb03772.x; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LAZDUNSKI M, 1994, J CARDIOVASC PHARM, V24, pS1; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; LORENZ L, 1998, IN PRESS MOL CELL BI; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; NOTSU T, 1992, J PHARMACOL EXP THER, V260, P702; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; Olson LK, 1996, J BIOL CHEM, V271, P16544, DOI 10.1074/jbc.271.28.16544; OLSON LK, 1991, THESIS U MINNESOTA, P15; Papas KK, 1997, BIOCHEM J, V326, P807, DOI 10.1042/bj3260807; Priebe L, 1996, J PHYSIOL-LONDON, V492, P405, DOI 10.1113/jphysiol.1996.sp021317; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SEINO S, 1996, DIABETES REV, V4, P177; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; TERZIC A, 1994, NEURON, V12, P1049, DOI 10.1016/0896-6273(94)90313-1; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; TOREN A, 1994, BRIT J HAEMATOL, V87, P376, DOI 10.1111/j.1365-2141.1994.tb04925.x; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Tuganowski W, 1996, PFLUG ARCH EUR J PHY, V431, P652; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; VEUTHEY AL, 1987, BIOPHYS CHEM, V26, P19, DOI 10.1016/0301-4622(87)80003-0; VITKEVICIUS KT, 1990, B EXP BIOL MED+, V110, P1039, DOI 10.1007/BF00840080; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; WEISS JN, 1993, CARDIOVASC DRUG THER, V7, P499, DOI 10.1007/BF00877614; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WELCH GR, 1978, MICROENVIRONMENTS ME, P323; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311	72	123	123	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					523	529		10.1096/fasebj.12.7.523	http://dx.doi.org/10.1096/fasebj.12.7.523			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576479	Bronze			2022-12-28	WOS:000073523100002
J	Jackson, DA; Pombo, A; Iborra, F				Jackson, DA; Pombo, A; Iborra, F			The balance sheet for transcription: an analysis of nuclear RNA metabolism in mammalian cells	FASEB JOURNAL			English	Review						gene expression; RNA polymerase; nascent transcripts; transcript profiles; nuclear structure	PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; POLYMERASE-II; GENE-EXPRESSION; NASCENT TRANSCRIPTS; HELA-CELLS; RIBOSOMAL-RNA; STABILITY; SITES; COMPARTMENTALIZATION	The control of RNA synthesis from protein-coding genes is fundamental in determining the various cell types of higher eukaryotes. The activation of these genes is driven by promoter complexes, and RNA synthesis is performed by an enzyme mega-complex--the RNA polymerase II holoenzyme. These two complexes are the fundamental components required to initiate gene expression and generate the primary transcripts that, after processing, yield mRNAs that pass to the cytoplasm where protein synthesis occurs. But although this gene expression pathway has been studied intensively, aspects of RNA metabolism remain difficult to comprehend. In particular, it is unclear why >95% of RNA polymerized by polymerase II remains in the nucleus, where it is recycled. To explain this apparent paradox, this review presents a detailed description of nuclear RNA (nRNA) metabolism in mammalian cells. We evaluate the number of active transcription units, discuss the distribution of polymerases on active genes, and assess the efficiency with which the products mature and pass to the cytoplasm. Differences between the behavior of mRNAs on this productive pathway and primary transcripts that never leave the nucleus lead us to propose that these represent distinct populations. We discuss possible roles for nonproductive RNAs and present a model to describe the metabolism of these RNAs in the nuclei of mammalian cells.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Jackson, DA (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	Dean.Jackson@Path.ox.ac.uk	iborra, francisco j/K-9313-2015; Pombo, Ana/A-1045-2010; Iborra, Francisco J/A-2943-2009	iborra, francisco j/0000-0002-0692-3696; Pombo, Ana/0000-0002-7493-6288; 				ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; Arn EA, 1998, CELL, V95, P151, DOI 10.1016/S0092-8674(00)81745-6; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BEYER AL, 1981, J MOL BIOL, V147, P269, DOI 10.1016/0022-2836(81)90441-1; BISHOP JO, 1974, NATURE, V250, P199, DOI 10.1038/250199a0; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BONNEROT C, 1990, P NATL ACAD SCI USA, V87, P6331, DOI 10.1073/pnas.87.16.6331; BRANDHORST BP, 1974, J MOL BIOL, V85, P451, DOI 10.1016/0022-2836(74)90444-6; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Cmarko D, 1999, MOL BIOL CELL, V10, P211, DOI 10.1091/mbc.10.1.211; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P185, DOI 10.1016/0005-2787(74)90183-X; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; COUPAR BEH, 1978, EUR J BIOCHEM, V84, P611, DOI 10.1111/j.1432-1033.1978.tb12204.x; DERMAN E, 1976, CELL, V9, P465, DOI 10.1016/0092-8674(76)90091-X; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; EMERSON CP, 1971, NATURE-NEW BIOL, V232, P101, DOI 10.1038/newbio232101a0; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; Fakan S, 1980, Int Rev Cytol, V65, P255; Fay FS, 1997, EXP CELL RES, V231, P27, DOI 10.1006/excr.1996.3460; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Fraser P, 1998, CURR OPIN CELL BIOL, V10, P361, DOI 10.1016/S0955-0674(98)80012-4; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GREENBERG H, 1966, J MOL BIOL, V21, P527, DOI 10.1016/0022-2836(66)90025-8; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; HARRIS H, 1963, PROG NUCLEIC ACID RE, V2, P19, DOI 10.1016/S0079-6603(08)60308-6; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; HOLLAND CA, 1980, J MOL BIOL, V138, P755, DOI 10.1016/0022-2836(80)90064-9; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; HUNT JA, 1976, BIOCHEM J, V160, P727, DOI 10.1042/bj1600727; Iborra FJ, 1998, J CELL SCI, V111, P2269; Iborra FJ, 1996, J CELL SCI, V109, P1427; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; Jackson DA, 1997, MOL BIOL REP, V24, P209, DOI 10.1023/A:1006873614521; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jacobson MR, 1997, J CELL SCI, V110, P829; JELINEK W, 1973, J MOL BIOL, V75, P515, DOI 10.1016/0022-2836(73)90458-0; Jolly C, 1999, J CELL BIOL, V145, P1133, DOI 10.1083/jcb.145.6.1133; Jolly C, 1998, EXP CELL RES, V238, P299, DOI 10.1006/excr.1997.3838; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kimura H, 1999, MOL CELL BIOL, V19, P5383; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LEWIN B, 1980, GENE EXPRESSION, V2; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; MAQUAT LE, 1995, RNA, V1, P453; MARZLUFF WF, 1974, BIOCHEMISTRY-US, V13, P3689, DOI 10.1021/bi00715a011; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MILLER OL, 1972, ACTA ENDOCRINOL-COP, P155; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; MOEN PT, 1995, HUM MOL GENET, V4, P1779, DOI 10.1093/hmg/4.suppl_1.1779; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; Nellen W, 1996, MOL BIOTECHNOL, V6, P7, DOI 10.1007/BF02762319; NEUBERGER MS, 1988, NUCLEIC ACIDS RES, V16, P6713, DOI 10.1093/nar/16.14.6713; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; PENMAN S, 1968, J MOL BIOL, V34, P49, DOI 10.1016/0022-2836(68)90234-9; Politz JC, 1999, CURR BIOL, V9, P285, DOI 10.1016/S0960-9822(99)80136-5; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; PUVION E, 1978, EXP CELL RES, V115, P79, DOI 10.1016/0014-4827(78)90404-4; Puvion E, 1996, EXP CELL RES, V229, P217, DOI 10.1006/excr.1996.0363; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ryo A, 1998, NUCLEIC ACIDS RES, V26, P2586, DOI 10.1093/nar/26.11.2586; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Shuman S, 1997, P NATL ACAD SCI USA, V94, P12758, DOI 10.1073/pnas.94.24.12758; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; Smith KP, 1999, J CELL BIOL, V144, P617, DOI 10.1083/jcb.144.4.617; SOEIRO R, 1968, J CELL BIOL, V39, P112, DOI 10.1083/jcb.39.1.112; Strouboulis J, 1996, J CELL SCI, V109, P1991; Taylor MV, 1998, CURR BIOL, V8, pR356, DOI 10.1016/S0960-9822(98)70221-0; Tennyson CN, 1996, NUCLEIC ACIDS RES, V24, P3059, DOI 10.1093/nar/24.15.3059; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; UDVARDY A, 1976, EUR J BIOCHEM, V62, P353, DOI 10.1111/j.1432-1033.1976.tb10167.x; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WOLGEMUTH DJ, 1981, J MOL BIOL, V147, P247, DOI 10.1016/0022-2836(81)90440-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	103	113	118	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					242	254		10.1096/fasebj.14.2.242	http://dx.doi.org/10.1096/fasebj.14.2.242			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657981				2022-12-28	WOS:000085184800003
J	Galea, E; Feinstein, DL				Galea, E; Feinstein, DL			Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP	FASEB JOURNAL			English	Review						transcription factors; gene expression; promoter; gene structure; mRNA expression; cytokines; endotoxin	SMOOTH-MUSCLE CELLS; NF-KAPPA-B; GLOMERULAR MESANGIAL CELLS; MURINE PERITONEAL-MACROPHAGES; ENHANCER-BINDING-PROTEIN; RAT CARDIAC MYOCYTES; TRANSCRIPTIONAL REGULATION; PROSTAGLANDIN E(2); MOLECULAR-CLONING; GENE-EXPRESSION	The enzyme nitric oxide synthase 2 (NOS2), often called inducible NOS, plays a central role in the inflammatory reactions that follow infection or tissue damage, NOS2 has been detected in virtually every cell type, and the NO it produces can perform both beneficial and detrimental actions, It is thus conceivable that regulatory mechanisms exist which control the timing and intensity of NO production by NOS2 in order to outweigh protective effects against detrimental ones. Since cyclic AMP inhibits numerous immunological reactions, studies have been carried out to determine whether cAMP-dependent pathways could inhibit NOS2 expression as well, Pharmacological studies in cultured cells show that, depending on the cell type examined, increased cAMP can exert opposite effects on the endotoxin- or cytokine-induced expression of NOS2, being either stimulatory or inhibitory in macrophages, stimulatory in adipocytes, smooth muscle, skeletal muscle, and brain endothelial cells, and inhibitory in pancreatic, liver, and brain glial cells, Regulation of NOS2 gene transcription appears to be the primary mechanism of action of cAMP, and whether it is stimulatory or inhibitory hinges on the cell-specific regulation of transcription factors including CREB, NF-kappa B, and C/EBP, Cyclic AMP must therefore be considered a modulator rather than a suppressor of NOS2 expression, This review summarizes evidence derived from in vitro studies, considers regulation of NOS2 by cAMP in vivo, and discusses possible therapeutic applications of cAMP treatment.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Galea, E (corresponding author), Univ Illinois, Dept Anesthesiol, 1819 W Polk St, Chicago, IL 60612 USA.		Galea, Elena/E-1362-2011; feinstein, doug/M-9414-2019	Galea, Elena/0000-0003-4537-9897; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031556] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31556-01A3] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO A, 1995, J IMMUNOL, V154, P6475; Andersen HU, 1996, EUR J ENDOCRINOL, V134, P251, DOI 10.1530/eje.0.1340251; ARMSTRONG R, 1995, MOL CELL BIOL, V15, P1826; Aymerich MS, 1998, BIOCHEM BIOPH RES CO, V245, P717, DOI 10.1006/bbrc.1998.8127; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BIRCH RE, 1982, CLIN EXP IMMUNOL, V48, P218; Boese M, 1996, BRIT J PHARMACOL, V119, P707, DOI 10.1111/j.1476-5381.1996.tb15730.x; Broug-Holub E, 1998, AM J RESP CELL MOL, V19, P842, DOI 10.1165/ajrcmb.19.5.3103; Buchwalow IB, 1997, ACTA HISTOCHEM, V99, P231, DOI 10.1016/S0065-1281(97)80046-3; BULUT V, 1993, BIOCHEM BIOPH RES CO, V195, P1134, DOI 10.1006/bbrc.1993.2162; Burgher KL, 1997, NEUROCHEM INT, V30, P483, DOI 10.1016/S0197-0186(96)00085-X; Bushnik T, 1996, BIOCHEM SOC T, V24, P1014, DOI 10.1042/bst0241014; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; Cohen Z, 1997, J CEREBR BLOOD F MET, V17, P894, DOI 10.1097/00004647-199708000-00008; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DeGroot CJA, 1997, J NEUROPATH EXP NEUR, V56, P10, DOI 10.1097/00005072-199701000-00002; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DORHEIM MA, 1994, BIOCHEM BIOPH RES CO, V205, P659, DOI 10.1006/bbrc.1994.2716; Dubey RK, 1998, HYPERTENSION, V31, P296, DOI 10.1161/01.HYP.31.1.296; DURANTE W, 1994, THROMB RES, V75, P63, DOI 10.1016/0049-3848(94)90140-6; DURIEUTRAUTMANN O, 1993, ADV EXP MED BIOL, V331, P205; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; FEINSTEIN DL, 1993, J NEUROCHEM, V60, P1945, DOI 10.1111/j.1471-4159.1993.tb13425.x; Feinstein DL, 1998, J NEUROCHEM, V70, P1484; Friedman EM, 1997, PHARMACOL THERAPEUT, V74, P27, DOI 10.1016/S0163-7258(96)00200-8; FROHMAN EM, 1988, J NEUROIMMUNOL, V17, P89, DOI 10.1016/0165-5728(88)90017-3; GAILLARD T, 1992, BIOL CHEM H-S, V373, P897, DOI 10.1515/bchm3.1992.373.2.897; GAILLARD T, 1991, PATHOBIOLOGY, V59, P280, DOI 10.1159/000163663; Galea E, 1995, FASEB J, V9, P1632, DOI 10.1096/fasebj.9.15.8529843; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Galea E, 1998, AM J PHYSIOL-HEART C, V274, pH2035, DOI 10.1152/ajpheart.1998.274.6.H2035; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHERSA P, 1994, J BIOL CHEM, V269, P29129; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; Grabowski PS, 1997, BRIT J RHEUMATOL, V36, P651; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Greenberg SS, 1998, ALCOHOL CLIN EXP RES, V22, p260S, DOI 10.1111/j.1530-0277.1998.tb04014.x; Greenberg SS, 1997, J PHARMACOL EXP THER, V282, P1044; HABENER JF, 1995, ENDOCRINOLOGY, P77; Harbrecht BG, 1996, ARCH SURG-CHICAGO, V131, P1266; HARBRECHT BG, 1995, J SURG RES, V58, P625, DOI 10.1006/jsre.1995.1098; Hecker M, 1999, GEN PHARMACOL, V32, P9, DOI 10.1016/S0306-3623(98)00082-2; HIROKAWA K, 1994, BRIT J PHARMACOL, V112, P396, DOI 10.1111/j.1476-5381.1994.tb13085.x; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iimura O, 1996, EUR J PHARMACOL, V296, P319, DOI 10.1016/0014-2999(95)00712-1; Ikeda U, 1996, J MOL CELL CARDIOL, V28, P789, DOI 10.1006/jmcc.1996.0073; Ikeda U, 1997, AM J PHYSIOL-HEART C, V273, pH59, DOI 10.1152/ajpheart.1997.273.1.H59; IMAI T, 1994, J CLIN INVEST, V93, P543, DOI 10.1172/JCI117005; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jeon YJ, 1996, MOL PHARMACOL, V50, P334; JOLY GA, 1992, J CARDIOVASC PHARM, V20, pS151, DOI 10.1097/00005344-199204002-00043; Ju WK, 1998, J NEUROVIROL, V4, P445; Kinugawa K, 1997, CIRC RES, V81, P911; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; KNUDSEN PJ, 1986, J IMMUNOL, V137, P3189; KOIDE M, 1993, J BIOL CHEM, V268, P24959; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; Lahdenpohja N, 1996, SCAND J IMMUNOL, V43, P640, DOI 10.1046/j.1365-3083.1996.d01-268.x; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; MAUEL J, 1995, J LEUKOCYTE BIOL, V58, P217, DOI 10.1002/jlb.58.2.217; MESSMER UK, 1994, CELL SIGNAL, V6, P17; MILANO S, 1995, PROSTAG OTH LIPID M, V49, P105, DOI 10.1016/0090-6980(94)00004-G; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MUHL H, 1994, BRIT J PHARMACOL, V112, P1; Mullet D, 1997, J Immunol, V158, P897; Mustafa SB, 1998, J BIOL CHEM, V273, P5073, DOI 10.1074/jbc.273.9.5073; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Nisoli E, 1997, ENDOCRINOLOGY, V138, P676, DOI 10.1210/en.138.2.676; Nusing RM, 1996, BIOCHEM J, V313, P617, DOI 10.1042/bj3130617; Oda H, 1997, J NEUROCHEM, V69, P669; Oddis CV, 1995, AM J PHYSIOL-HEART C, V269, pH2044, DOI 10.1152/ajpheart.1995.269.6.H2044; OKUDA S, 1997, AM J PHYSIOL, V41, pC3; Oleszak EL, 1997, J VIROL, V71, P3228, DOI 10.1128/JVI.71.4.3228-3235.1997; OROPEZARENDON RL, 1980, J IMMUNOPHARMACOL, V2, P133, DOI 10.3109/08923978009026393; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Park YC, 1997, CELL IMMUNOL, V179, P41, DOI 10.1006/cimm.1997.1144; Parry GCN, 1997, J IMMUNOL, V159, P5450; PFEILSCHIFTER J, 1993, NEPHRON, V64, P518, DOI 10.1159/000187394; RADDASSI K, 1993, CELL IMMUNOL, V149, P50, DOI 10.1006/cimm.1993.1135; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; Ruan J, 1996, FASEB J, V10, P2296; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505; SCHINIKERTH VB, 1994, AM J PHYSIOL-HEART C, V267, pH2483, DOI 10.1152/ajpheart.1994.267.6.H2483; SCOTTBURDEN T, 1994, MOL PHARMACOL, V46, P274; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V188, P997, DOI 10.1016/0006-291X(92)91330-S; Smith FS, 1997, BIOCHEM J, V326, P187, DOI 10.1042/bj3260187; SOWA G, 1994, EUR J PHARM-MOLEC PH, V266, P125, DOI 10.1016/0922-4106(94)90101-5; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; TAMIR S, 1995, CANCER RES, V55, P4391; TETSUKA T, 1994, J AM SOC NEPHROL, V5, P686; Vallance P, 1993, New Horiz, V1, P77; VanEldik LJ, 1996, MOL BIOL CELL, V7, P1033; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WILLIAMS G, 1994, PEDIATR RES, V35, pA61; WILLIS SA, 1995, J IMMUNOL, V154, P1399; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YONG MZ, 1993, J VIROL, V67, P5786; Zhang HF, 1998, BIOCHEM PHARMACOL, V55, P1873, DOI 10.1016/S0006-2952(98)00078-1; Zhang XO, 1996, J LEUKOCYTE BIOL, V59, P575, DOI 10.1002/jlb.59.4.575	117	129	135	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2125	2137		10.1096/fasebj.13.15.2125	http://dx.doi.org/10.1096/fasebj.13.15.2125			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593859				2022-12-28	WOS:000084310800003
J	Ryder, JW; Kawano, Y; Galuska, D; Fahlman, R; Wallberg-Henriksson, H; Charron, MJ; Zierath, JR				Ryder, JW; Kawano, Y; Galuska, D; Fahlman, R; Wallberg-Henriksson, H; Charron, MJ; Zierath, JR			Postexercise glucose uptake and glycogen synthesis in skeletal muscle from GLUT4-deficient mice	FASEB JOURNAL			English	Article						metabolism; glucose transport; glycogen synthase; electrical stimulation; physical exercise	TRANSGENIC MICE; INSULIN ACTION; DIABETIC RATS; ENDURANCE EXERCISE; TRANSPORTER GLUT4; METABOLISM; ACCUMULATION; CONTRACTION; DISTINCT; COMPLEMENTATION	To determine the role of GLUT4 on postexercise glucose transport and glycogen resynthesis in skeletal muscle, GLUT4-deficient and wild-type mice were studied after a 3 h swim exercise. In wildtype mice, insulin and swimming each increased 2-deoxyglucose uptake by twofold in extensor digitorum longus muscle. In contrast, insulin did not increase 2-deoxyglucose glucose uptake in muscle from GLUT4-null mice. Swimming increased glucose transport twofold in muscle from fed GLUT4-null mice, with no effect noted in fasted GLUT4-null mice. This exercise-associated 2-deoxyglucose glucose uptake was not accompanied by increased cell surface GLUT1 content. Glucose transport in GLUT4-null muscle was increased 1.6-fold over basal levels after electrical stimulation. Contraction-induced glucose transport activity was fourfold greater in wild-type vs. GLUT4-null muscle. Glycogen content in gastrocnemius muscle was similar between wild-type and GLUT4-null mice and was reduced similar to 50% after exercise. After 5 h carbohydrate refeeding, muscle glycogen content was fully restored in wild-type, with no change in GLUT4-null mice. After 24 h carbohydrate refeeding, muscle glycogen in GLUT4-null mice was restored to fed levels. In conclusion, GLUT4 is the major transporter responsible for exercise-induced glucose transport. Also, postexercise glycogen resynthesis in muscle was greatly delayed; unlike wild-type mice, glycogen supercompensation was not found. GLUT4 it is not essential for glycogen repletion since muscle glycogen levels in previously exercised GLUT4-null mice were totally restored after 24 h carbohydrate refeeding.	Karolinska Hosp, Dept Clin Physiol, King Gustaf V Res Inst, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Yeshiva University; Albert Einstein College of Medicine	Zierath, JR (corresponding author), Karolinska Hosp, Dept Clin Physiol, King Gustaf V Res Inst, S-17176 Stockholm, Sweden.			Zierath, Juleen/0000-0001-6891-7497	NHLBI NIH HHS [HL58119] Funding Source: Medline; NIDDK NIH HHS [DK47425] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREASSON K, 1991, ACTA PHYSIOL SCAND, V142, P255, DOI 10.1111/j.1748-1716.1991.tb09154.x; Aslesen R, 1998, AM J PHYSIOL-ENDOC M, V275, pE448, DOI 10.1152/ajpendo.1998.275.3.E448; BERGSTROM J, 1966, NATURE, V210, P309, DOI 10.1038/210309a0; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CONSTABLE SH, 1988, J APPL PHYSIOL, V64, P2329, DOI 10.1152/jappl.1988.64.6.2329; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FRIEDMAN JE, 1991, DIABETES, V40, P150, DOI 10.2337/diabetes.40.1.150; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5435; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; GULVE EA, 1990, AM J PHYSIOL, V259, pE685, DOI 10.1152/ajpendo.1990.259.5.E685; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; HANDBERG A, 1992, AM J PHYSIOL, V262, pE721, DOI 10.1152/ajpendo.1992.262.5.E721; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; Hickner RC, 1997, J APPL PHYSIOL, V83, P897, DOI 10.1152/jappl.1997.83.3.897; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JUE T, 1989, P NATL ACAD SCI USA, V92, P8535; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AD, 1995, FEBS LETT, V361, P54; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Lowery OH, 1972, FLEXIBLE SYSTEM ENZY; LUND S, 1994, AM J PHYSIOL, V267, pE461, DOI 10.1152/ajpendo.1994.267.3.E461; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Manchester J, 1996, P NATL ACAD SCI USA, V93, P10707, DOI 10.1073/pnas.93.20.10707; Nakatani A, 1997, J APPL PHYSIOL, V82, P711, DOI 10.1152/jappl.1997.82.2.711; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; REN JM, 1993, J BIOL CHEM, V268, P16113; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615; Ryder JW, 1999, BIOCHEM J, V342, P321, DOI 10.1042/0264-6021:3420321; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; WALLBERGHENRIKSSON H, 1986, ACTA PHYSIOL SCAND, V127, P39, DOI 10.1111/j.1748-1716.1986.tb07873.x; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504; Zierath JR, 1998, J BIOL CHEM, V273, P20910, DOI 10.1074/jbc.273.33.20910	56	58	59	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2246	2256		10.1096/fasebj.13.15.2246	http://dx.doi.org/10.1096/fasebj.13.15.2246			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593872				2022-12-28	WOS:000084310800016
J	Hatcher, HC; Wright, NM; Chao, J; Chao, L; Ma, JX				Hatcher, HC; Wright, NM; Chao, J; Chao, L; Ma, JX			Kallikrein-binding protein is induced by growth hormone in the dwarf rat	FASEB JOURNAL			English	Article						growth hormone deficiency; serpins; tissue kallikrein	HUMAN TISSUE KALLIKREIN; HUMAN OCULAR-TISSUES; MESSENGER-RNA; CELLULAR-LOCALIZATION; DIABETES-MELLITUS; TRANSGENIC MICE; FACTOR-I; GENE; KALLISTATIN; EXPRESSION	Rat kallikrein-binding protein (KBP), a member of the serpin family, is a tissue kallikrein inhibitor, It has been shown to be a potential pathogenic factor of diabetic retinopathy and may play a role in animal development and growth. To determine whether reduced KBP expression is involved in retarded animal growth, we examined the in vivo effect of growth hormone (GH) deficiency on the expression of KBP in the Lewis dwarf (dw/dw), We found that serum levels of functionally active KBP were reduced in the dwarf rat (P<0.05) as determined by complex formation assay between serum KBP and I-125-labeled rat tissue kallikrein. Enzyme-linked immunosorbent assay showed that KBP levels were significantly reduced in the serum of the dwarf rat compared to the Lewis rat (213.8 ng/ml vs. 413.8 ng/ml, n=4, P<0.01), The decreased KBP levels were confirmed by Western blot analysis, Moreover, treatment of the dwarf rat with recombinant human GH for 4 wk resulted in a significant increase in KBP activity (P<0.01) and serum KBP levels compared with the untreated dwarf rat (549.8 ng/ml, n=5, vs. 213.8 ng/ml, n=4, P<0.02), Northern blot analysis and densitometry showed that liver KBP mRNA levels were reduced by fivefold in the dwarf rat compared to the Lewis rat and the decrease was reversed by the GH treatment. These results indicate that the KBP levels are regulated at the RNA level. Furthermore, in vitro studies using cultured rat hepatocytes showed that GH may have a direct regulatory effect on KBP expression since KBP levels increased in the conditioned media of cells treated with GH. These results demonstrated that KBP is reduced in the genetic dwarf rat and is restored to normal by GH; therefore, KBP is a GH-dependent protein and may be a new target for studying the mechanism of pathological animal growth.	Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Div Endocrinol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Ma, JX (corresponding author), Med Univ S Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA.				NATIONAL EYE INSTITUTE [R01EY012600] Funding Source: NIH RePORTER; NEI NIH HHS [EY12600] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERRY SA, 1984, ENDOCRINOLOGY, V115, P1164, DOI 10.1210/endo-115-3-1164; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BLUETPAJOT MT, 1983, NEUROENDOCRINOLOGY, V36, P307, DOI 10.1159/000123472; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; Chao J, 1995, BIOL CHEM H-S, V376, P705; CHAO S, 1989, BIOTECHNIQUES, V7, P68; CHARLTON HM, 1988, J ENDOCRINOL, V119, P51, DOI 10.1677/joe.0.1190051; CHATTERJEE B, 1983, J BIOL CHEM, V258, P688; CHEN LM, 1995, KIDNEY INT, V48, P690, DOI 10.1038/ki.1995.339; Chen LM, 1996, J BIOL CHEM, V271, P27590, DOI 10.1074/jbc.271.44.27590; DERCOLE AJ, 1987, SER S BAS CLIN ASP G, P259; DONAHUE LR, 1993, J ENDOCRINOL, V136, P91, DOI 10.1677/joe.0.1360091; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Handa H, 1989, Adv Exp Med Biol, V247B, P443; HARVEY JN, 1992, DIABETOLOGIA, V35, P857, DOI 10.1007/BF00399932; Hatcher HC, 1997, INVEST OPHTH VIS SCI, V38, P658; JAFFA AA, 1992, KIDNEY INT, V41, P789, DOI 10.1038/ki.1992.122; KURTZ DT, 1977, P NATL ACAD SCI USA, V74, P4791, DOI 10.1073/pnas.74.11.4791; LAPERCHE Y, 1983, CELL, V32, P453, DOI 10.1016/0092-8674(83)90465-8; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087; Ma JX, 1996, CURR EYE RES, V15, P1117, DOI 10.3109/02713689608995143; Ma JX, 1996, BBA-GENE STRUCT EXPR, V1307, P285, DOI 10.1016/0167-4781(96)81374-1; MAES M, 1983, DIABETES, V32, P1060, DOI 10.2337/diabetes.32.11.1060; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MAYFIELD RK, 1985, DIABETES, V34, P22, DOI 10.2337/diabetes.34.1.22; ROY AK, 1982, SERONO S, V51, P35; RUSSELLJONES DL, 1993, ACTA ENDOCRINOL-COP, V128, P44; SCOTT CD, 1985, ENDOCRINOLOGY, V116, P1102, DOI 10.1210/endo-116-3-1102; SINHA YN, 1979, P SOC EXP BIOL MED, V161, P78, DOI 10.3181/00379727-161-40494; TANNENBAUM GS, 1981, ENDOCRINOLOGY, V108, P76, DOI 10.1210/endo-108-1-76; TECCE MF, 1986, BIOCHEMISTRY-US, V25, P5831, DOI 10.1021/bi00367a073; WRIGHT NM, 1995, J BONE MINER RES, V10, P127; XIONG W, 1992, TOHOKU J EXP MED, V171, P135; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	40	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1839	1844		10.1096/fasebj.13.13.1839	http://dx.doi.org/10.1096/fasebj.13.13.1839			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506588				2022-12-28	WOS:000083063400020
J	Carr, A; Frei, B				Carr, A; Frei, B			Does vitamin C act as a pro-oxidant under physiological conditions?	FASEB JOURNAL			English	Article; Proceedings Paper	FASEB Summer Research Conference on Molecular and Biological Mechanisms of Antioxidant Action	AUG, 1998	COPPER MOUNTAIN, CO			iron; DNA; protein; lipid; antioxidant	LOW-DENSITY-LIPOPROTEIN; OXIDATIVE DNA-DAMAGE; HUMAN-BLOOD-PLASMA; DIETARY ASCORBIC-ACID; HUMAN ATHEROSCLEROTIC LESIONS; PROTEIN CARBONYL FORMATION; GUINEA-PIG LIVER; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; IN-VITRO	Vitamin C readily scavenges reactive oxygen and nitrogen species and may thereby prevent oxidative damage to important biological macromolecules such as DNA, lipids, and proteins. Vitamin C also reduces redox active transition metal ions in the active sites of specific biosynthetic enzymes. The interaction of vitamin C with 'free', catalytically active metal ions could contribute to oxidative damage through the production of hydroxyl and alkoxyl radicals; whether these mechanisms occur in vivo, however, is uncertain. To examine this issue, we reviewed studies that investigated the role of vitamin C, both in the presence and absence of metal ions, in oxidative DNA, Lipid, and protein damage. We found compelling evidence for antioxidant protection of lipids by vitamin C in biological fluids, animals, and humans, both with and without iron cosupplementation, Although the data on protein oxidation in humans are sparse and inconclusive, the available data in animals consistently show an antioxidant role of vitamin C, The data on vitamin C and DNA oxidation in vivo are inconsistent and conflicting, but some of the discrepancies can be explained by flaws in experimental design and methodology. These and other important issues discussed here need to be addressed in future studies of the role of vitamin C in oxidative damage.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Frei, B (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.	balz.frei@orst.edu		, Anitra/0000-0002-5890-2977	NHLBI NIH HHS [HL-56170, HL-49954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056170, R29HL049954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessio HM, 1997, INT J SPORT NUTR, V7, P1; ANDERSON D, 1994, MUTAT RES, V307, P261, DOI 10.1016/0027-5107(94)90300-X; Anderson D, 1997, ENVIRON MOL MUTAGEN, V30, P161, DOI 10.1002/(SICI)1098-2280(1997)30:2<161::AID-EM9>3.0.CO;2-Q; Atalay A, 1998, BIOCHIMIE, V80, P283, DOI 10.1016/S0300-9084(98)80068-0; BARJA G, 1994, FREE RADICAL BIO MED, V17, P105, DOI 10.1016/0891-5849(94)90108-2; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; BENDICH A, 1990, TOXICOL LETT, V51, P189, DOI 10.1016/0378-4274(90)90210-D; Berger TM, 1997, J BIOL CHEM, V272, P15656, DOI 10.1074/jbc.272.25.15656; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BLOCK G, 1991, AM J CLIN NUTR, V53, pS270, DOI 10.1093/ajcn/53.1.270S; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BURTON GW, 1990, LIPIDS, V25, P199, DOI 10.1007/BF02535748; Cadenas S, 1997, CARCINOGENESIS, V18, P2373, DOI 10.1093/carcin/18.12.2373; Cadenas S, 1996, FREE RADICAL RES, V24, P485, DOI 10.3109/10715769609088047; Cadenas S, 1996, PHARMACOL TOXICOL, V79, P247, DOI 10.1111/j.1600-0773.1996.tb00268.x; Cadenas S, 1998, PHARMACOL TOXICOL, V82, P11, DOI 10.1111/j.1600-0773.1998.tb01391.x; Cadet J, 1997, ENVIRON HEALTH PERSP, V105, P1034, DOI 10.2307/3433836; CHESNEY JA, 1991, ANAL BIOCHEM, V196, P262, DOI 10.1016/0003-2697(91)90463-4; CHOU PT, 1983, BIOCHEM BIOPH RES CO, V115, P932, DOI 10.1016/S0006-291X(83)80024-2; Collins A, 1997, CARCINOGENESIS, V18, P1833, DOI 10.1093/carcin/18.9.1833; Collis CS, 1997, FREE RADICAL RES, V27, P113, DOI 10.3109/10715769709097844; Collis CS, 1996, FREE RADICAL RES, V25, P87, DOI 10.3109/10715769609145658; Cooke MS, 1998, FEBS LETT, V439, P363, DOI 10.1016/S0014-5793(98)01403-3; COONEY RV, 1986, CANCER LETT, V32, P83, DOI 10.1016/0304-3835(86)90042-X; CROSS CE, 1993, ANN NY ACAD SCI, V686, P72, DOI 10.1111/j.1749-6632.1993.tb39157.x; CROSS CE, 1994, ENVIRON HEALTH PERSP, V102, P185, DOI 10.2307/3432237; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; DASGUPTA A, 1992, LIFE SCI, V50, P875, DOI 10.1016/0024-3205(92)90206-5; De Zwart LL, 1999, FREE RADICAL BIO MED, V26, P202, DOI 10.1016/S0891-5849(98)00196-8; Dean RT, 1997, BIOCHEM J, V324, P1; DILLARD CJ, 1982, ARCH BIOCHEM BIOPHYS, V216, P204, DOI 10.1016/0003-9861(82)90205-3; Drouin R, 1996, FREE RADICAL BIO MED, V21, P261, DOI 10.1016/0891-5849(96)00037-8; Edge R, 1997, NUTRITION, V13, P992, DOI 10.1016/S0899-9007(97)00346-8; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Enstrom J. E., 1997, Vitamin C in health and disease., P381; Fiala ES, 1996, EXPERIENTIA, V52, P922, DOI 10.1007/BF01938881; FISCHERNIELSEN A, 1993, CARCINOGENESIS, V14, P2431, DOI 10.1093/carcin/14.11.2431; FISCHERNIELSEN A, 1992, FREE RADICAL BIO MED, V13, P121, DOI 10.1016/0891-5849(92)90073-P; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; Franco RF, 1998, BRIT J HAEMATOL, V102, P1172; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, ADV EXP MED BIOL, V264, P155; FREI B, 1993, J LIPID RES, V34, P2135; FREI B, 1988, ANAL BIOCHEM, V175, P120, DOI 10.1016/0003-2697(88)90369-7; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; Frei B., 1997, VITAMIN C HLTH DIS, P163; Fu S, 1998, BIOCHEM J, V333, P519, DOI 10.1042/bj3330519; Fuller CJ, 1996, ATHEROSCLEROSIS, V119, P139, DOI 10.1016/0021-9150(95)05659-9; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; Gokce N, 1998, CIRCULATION, V98, P175; GREEN MHL, 1994, MUTAT RES-DNAGING G, V316, P91, DOI 10.1016/0921-8734(94)90011-6; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Harats D, 1998, AM J CLIN NUTR, V67, P240, DOI 10.1093/ajcn/67.2.240; HARATS D, 1990, ATHEROSCLEROSIS, V85, P47, DOI 10.1016/0021-9150(90)90181-H; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Helen A, 1997, J APPL TOXICOL, V17, P289, DOI 10.1002/(SICI)1099-1263(199709)17:5&lt;289::AID-JAT448&gt;3.0.CO;2-9; HERBERT V, 1994, AM J CLIN NUTR, V60, P157, DOI 10.1093/ajcn/60.2.157; HU ML, 1993, J LAB CLIN MED, V121, P257; Hu ML, 1997, FREE RADICAL RES, V26, P585, DOI 10.3109/10715769709097828; Jacob RA, 1996, J NUTR, V126, P2268, DOI 10.1093/jn/126.9.2268; Jenner A, 1998, BIOCHEM J, V331, P365, DOI 10.1042/bj3310365; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; Kang SA, 1998, FREE RADICAL RES, V28, P93, DOI 10.3109/10715769809097880; Kiechl S, 1997, CIRCULATION, V96, P3300; KIMURA H, 1992, J NUTR, V122, P1904, DOI 10.1093/jn/122.9.1904; KUNERT KJ, 1983, LIPIDS, V18, P271, DOI 10.1007/BF02534701; Kveder M, 1997, CHEM PHYS LIPIDS, V85, P1, DOI 10.1016/S0009-3084(96)02636-9; Lee BM, 1998, CANCER LETT, V132, P219, DOI 10.1016/S0304-3835(98)00227-4; Lee KW, 1998, EXP EYE RES, V67, P95, DOI 10.1006/exer.1998.0500; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; Levine M, 1998, NATURE, V395, P231, DOI 10.1038/26137; LICHT WR, 1988, CARCINOGENESIS, V9, P365, DOI 10.1093/carcin/9.3.365; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Linetsky M, 1998, ARCH BIOCHEM BIOPHYS, V351, P180, DOI 10.1006/abbi.1997.0548; Livrea MA, 1996, BLOOD, V88, P3608, DOI 10.1182/blood.V88.9.3608.bloodjournal8893608; LOVSTAD RA, 1987, INT J BIOCHEM, V19, P309, DOI 10.1016/0020-711X(87)90003-6; Lykkesfeldt J, 1997, AM J CLIN NUTR, V65, P959, DOI 10.1093/ajcn/65.4.959; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; LYNCH SM, 1996, ASCORBIC ACID BIOCH, P331; Mannick EE, 1996, CANCER RES, V56, P3238; May JM, 1998, J BIOL CHEM, V273, P23039, DOI 10.1074/jbc.273.36.23039; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 1998, ARCH BIOCHEM BIOPHYS, V349, P281, DOI 10.1006/abbi.1997.0473; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MENZEL DB, 1971, ARCH ENVIRON HEALTH, V23, P149, DOI 10.1080/00039896.1971.10665973; MINETTI M, 1992, BIOCHEM J, V282, P459, DOI 10.1042/bj2820459; Miyata T, 1998, FEBS LETT, V437, P24, DOI 10.1016/S0014-5793(98)01079-5; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; Mulholland CW, 1996, INT J FOOD SCI NUTR, V47, P227, DOI 10.3109/09637489609012585; Naidoo D, 1998, NUTR RES, V18, P953, DOI 10.1016/S0271-5317(98)00078-5; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; Noroozi M, 1998, AM J CLIN NUTR, V67, P1210, DOI 10.1093/ajcn/67.6.1210; Nyyssonen K, 1997, EUR J CLIN NUTR, V51, P154, DOI 10.1038/sj.ejcn.1600376; ORTWERTH BJ, 1997, VITAMIN C HLTH DIS, P123; Otero P, 1997, FREE RADICAL RES, V27, P619, DOI 10.3109/10715769709097865; Panayiotidis M, 1997, FREE RADICAL RES, V27, P533, DOI 10.3109/10715769709065793; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Pflaum M, 1998, MUTAT RES-DNA REPAIR, V408, P137, DOI 10.1016/S0921-8777(98)00029-9; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; Podmore ID, 1998, NATURE, V395, P232, DOI 10.1038/26141; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; Poulsen HE, 1998, NATURE, V395, P231, DOI 10.1038/26139; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Prieme H, 1997, AM J CLIN NUTR, V65, P503, DOI 10.1093/ajcn/65.2.503; Reddy VN, 1998, INVEST OPHTH VIS SCI, V39, P344; Rehman A, 1998, BIOCHEM BIOPH RES CO, V246, P293, DOI 10.1006/bbrc.1998.8592; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; Retsky KL, 1999, FREE RADICAL BIO MED, V26, P90, DOI 10.1016/S0891-5849(98)00151-8; RETSKY KL, 1995, BBA-LIPID LIPID MET, V1257, P279, DOI 10.1016/0005-2760(95)00089-U; REZNICK AZ, 1992, BIOCHEM J, V286, P607, DOI 10.1042/bj2860607; RIFICI VA, 1993, J AM COLL NUTR, V12, P631; Samman S, 1997, EUR J CLIN NUTR, V51, P472, DOI 10.1038/sj.ejcn.1600431; Sanchez-Quesada JL, 1998, CORONARY ARTERY DIS, V9, P249, DOI 10.1097/00019501-199809050-00002; Singh NP, 1997, MUTAT RES-FUND MOL M, V375, P195, DOI 10.1016/S0027-5107(97)00014-6; Smith MA, 1997, J NEUROSCI, V17, P2653; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Suarna C, 1997, FREE RADICAL RES, V27, P397, DOI 10.3109/10715769709065779; Tanaka K, 1997, J NUTR, V127, P2060, DOI 10.1093/jn/127.10.2060; Taylor A., 1997, Vitamin C in health and disease., P231; THOMAS SR, 1995, AM J CLIN NUTR, V62, P1357, DOI 10.1093/ajcn/62.6.1357S; Thomas SR, 1998, CHEM RES TOXICOL, V11, P484, DOI 10.1021/tx970173a; Tsao C. S., 1997, Vitamin C in health and disease., P25; TSAO CS, 1990, OPHTHALMIC RES, V22, P106, DOI 10.1159/000267008; TSAO CS, 1987, J NUTR, V117, P291, DOI 10.1093/jn/117.2.291; Varma SD, 1997, J OCUL PHARMACOL TH, V13, P179, DOI 10.1089/jop.1997.13.179; WAYNER DDM, 1986, BIOCHIM BIOPHYS ACTA, V884, P119, DOI 10.1016/0304-4165(86)90234-5; Wei HC, 1998, CARCINOGENESIS, V19, P1013, DOI 10.1093/carcin/19.6.1013; Wells W. W., 1997, Vitamin C in health and disease., P109; Wen Y, 1997, BRIT J CLIN PHARMACO, V44, P94, DOI 10.1046/j.1365-2125.1997.00623.x; WINTERBOURN CC, 1981, BIOCHEM J, V198, P125, DOI 10.1042/bj1980125; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023; Woodall A. A., 1997, Vitamin C in health and disease., P193; Yamaguchi T, 1997, EUR J BIOCHEM, V245, P233, DOI 10.1111/j.1432-1033.1997.00233.x; Yan LJ, 1996, ARCH BIOCHEM BIOPHYS, V327, P330, DOI 10.1006/abbi.1996.0130; YOUNG IS, 1994, FREE RADICAL BIO MED, V16, P393, DOI 10.1016/0891-5849(94)90041-8	148	642	665	0	56	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					1007	1024		10.1096/fasebj.13.9.1007	http://dx.doi.org/10.1096/fasebj.13.9.1007			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336883				2022-12-28	WOS:000080547700005
J	Bichet, S; Wenger, RH; Camenisch, G; Rolfs, A; Ehleben, W; Porwol, T; Acker, H; Fandrey, J; Bauer, C; Gassmann, M				Bichet, S; Wenger, RH; Camenisch, G; Rolfs, A; Ehleben, W; Porwol, T; Acker, H; Fandrey, J; Bauer, C; Gassmann, M			Oxygen tension modulates beta-globin switching in embryoid bodies	FASEB JOURNAL			English	Article						embryonic stem cells; hemoglobin; hypoxia-inducible factor; erythropoietin	INDUCIBLE FACTOR-I; STEM-CELLS; GENE-EXPRESSION; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC DEVELOPMENT; VITRO DIFFERENTIATION; INVITRO DEVELOPMENT; ENDOTHELIAL-CELLS; HEPATOMA-CELLS; MESSENGER-RNA	Little is known about the factors influencing the hemoglobin switch in vertebrates during develop ment. Inasmuch as the mammalian conceptus is exposed to changing oxygen tensions in utero, we examined the effect of different oxygen concentrations on beta-globin switching. We used an in vitro model of mouse embryogenesis based on the differentiation of blastocyst-derived embryonic stem cells to embryoid bodies (EBs). Cultivation of EBs at increasing oxygen concentrations (starting at 1% O-2) did not influence the temporal expression pattern of embryonic (beta H1) globin compared to the normoxic controls (20% O-2). In contrast, when compared to normoxically grown EBs, expression of fetal/adult (beta(maj)) globin in EBs cultured at varying oxygen concentrations was delayed by about 2 days and persisted throughout differentiation. Quantitation of hemoglobin in EBs using a 2,7-diaminofluorene-based colorimetric assay revealed the appearence of hemoglobin in two waves, an early and a late one. This observation was verified by spectrophotometric analysis of hemoglobin within single EBs. These two waves might reflect the switch of erythropoiesis from yolk sac to fetal liver. Reduced oxygenation is known to activate the hypoxia-inducible factor-1 (HIF-1), which in turn specifically induces expression of a variety of genes among them erythropoietin (EPO). Although EBs increased EPO expression upon hypoxic exposure, the altered beta-globin appearance was not related to EPO levels as determined in EBs overexpressing EPO. Since mRNA from both mouse HIF-1 alpha isoforms was detected in all EBs tested at different differentiation stages, we propose that HIV-1 modulates beta-globin expression during development.	Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland; Max Planck Inst Mol Physiol, D-44026 Dortmund, Germany; Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Zurich; Max Planck Society; University of Lubeck	Gassmann, M (corresponding author), Univ Zurich Irchel, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	labbauer@physiol.unizh.ch	Acker, Helmut Anton Josef/AAS-6841-2020; Wenger, Roland H./B-7953-2009; Acker, Helmut/AAJ-8332-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; Wenger, Roland H./0000-0001-7592-4839; Fandrey, Joachim/0000-0001-9585-0531				ALLEN DW, 1960, J CLIN INVEST, V39, P1107, DOI 10.1172/JCI104125; ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CALLUS BA, 1995, HEMOGLOBIN, V19, P7; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; CHANCE B, 1975, ANAL BIOCHEM, V66, P498, DOI 10.1016/0003-2697(75)90617-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESIMONE J, 1978, P NATL ACAD SCI USA, V75, P2937, DOI 10.1073/pnas.75.6.2937; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V93, P2867; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; Ehleben W, 1997, KIDNEY INT, V51, P483, DOI 10.1038/ki.1997.67; FISCHER B, 1993, J REPROD FERTIL, V99, P673, DOI 10.1530/jrf.0.0990673; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; GASSMANN M, 1995, TOXICOL IN VITRO, V9, P429, DOI 10.1016/0887-2333(95)00036-8; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; GORLACH A, 1993, BIOCHEM J, V290, P771; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JAHN CL, 1980, CELL, V21, P159, DOI 10.1016/0092-8674(80)90123-3; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; KONKEL DA, 1979, CELL, V18, P865, DOI 10.1016/0092-8674(79)90138-7; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOVACH JS, 1967, J MOL BIOL, V25, P131, DOI 10.1016/0022-2836(67)90284-7; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEDER P, 1980, SCIENCE, V209, P1336, DOI 10.1126/science.7414319; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MCCLANAHAN T, 1993, BLOOD, V81, P2903; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; PENNATHURDAS R, 1987, BLOOD, V69, P899; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; TAN CC, 1992, AM J PHYSIOL, V263, pF474, DOI 10.1152/ajprenal.1992.263.3.F474; THOMAS ED, 1960, NATURE, V185, P396, DOI 10.1038/185396a0; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Weiss MJ, 1996, J CLIN INVEST, V97, P591, DOI 10.1172/JCI118454; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432-1033.1997.t01-1-00155.x; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; WENGER RH, 1994, ANAL BIOCHEM, V221, P416, DOI 10.1006/abio.1994.1436; Wenger RH, 1997, BIOL CHEM, V378, P609; WHITELAW E, 1989, HEMOGLOBIN SWITCHI A, P323; WILES MV, 1991, DEVELOPMENT, V111, P259; Wood WG, 1996, TRENDS GENET, V12, P204, DOI 10.1016/0168-9525(96)30043-7; WORTHINGTON RE, 1987, EXP HEMATOL, V15, P85; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZON LI, 1995, BLOOD, V86, P2876	65	26	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					285	295		10.1096/fasebj.13.2.285	http://dx.doi.org/10.1096/fasebj.13.2.285			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973316	Green Accepted			2022-12-28	WOS:000078615200008
J	Vogel, W				Vogel, W			Discoidin domain receptors: structural relations and functional implications	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	receptor tyrosine kinase; collagen signaling	TYROSINE KINASE GENE; SPONGE GEODIA-CYDONIUM; COAGULATION FACTOR-V; FACTOR-VIII; HUMAN-MILK; DICTYOSTELIUM-DISCOIDEUM; MOLECULAR-CLONING; BINDING PROTEIN; CELL-ADHESION; GROWTH-FACTOR	Multicellular life relies on the presence of extracellular matrix to provide scaffolding for cells and tissue compartments. To provide communication between cells and tissues, a multitude of cell surface receptors are triggered by soluble ligands and components of the extracellular matrix. A large family of these receptors transmit signals through the use of an intrinsic tyrosine kinase function. The subgroup of discoidin domain receptors (DDRs) is distinguished from other members of the receptor tyrosine kinase family by a discoidin homology repeat in their extracellular domains that is also found in a variety of other transmembrane and secreted proteins. Sequence comparisons show that non-mammalian orthologs of DDRs exist: three closely related genes in Caenorhabditis and one in the sponge Geodia cydonium. Recently, various types of collagen have been identified as the Ligands for the two mammalian discoidin domain receptor tyrosine kinases, DDR1 and DDR2. The binding of collagen to DDRs results in a delayed but sustained tyrosine kinase activation. Both receptors display several potential tyrosine phosphorylation sites that are able to relay the signal by interacting with cytoplasmic effector proteins. The potential cross-talk to other receptors for collagen and the clinical aspects of DDR function are discussed.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Vogel, W (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.							ALVES F, 1995, ONCOGENE, V10, P609; BARKER KT, 1995, ONCOGENE, V10, P569; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Broberg A, 1996, EXP CELL RES, V228, P29, DOI 10.1006/excr.1996.0295; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; DAVID S, 1997, INTEGRIN LIGAND INTE, P241; den Dunnen JT, 1998, HUM MOL GENET, V7, P1185; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Ensslin M, 1998, BIOL REPROD, V58, P1057, DOI 10.1095/biolreprod58.4.1057; Gamulin V, 1997, J MOL EVOL, V44, P242, DOI 10.1007/PL00006141; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Giuffrida MG, 1998, J PROTEIN CHEM, V17, P143, DOI 10.1023/A:1022531500370; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KARN T, 1993, ONCOGENE, V8, P3433; LAI C, 1994, ONCOGENE, V9, P877; Lambert CA, 1998, J BIOL CHEM, V273, P23143, DOI 10.1074/jbc.273.36.23143; LAROCCA D, 1991, CANCER RES, V51, P4994; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Moroi Masaaki, 1998, Frontiers in Bioscience, V3, pD719; Muller W.E.G., 1996, Progress in Molecular and Subcellular Biology, V17, P183; NEMOTO T, 1997, PATHOBIOL, V65, P165; Ohno I, 1996, BIOCHEM BIOPH RES CO, V228, P411, DOI 10.1006/bbrc.1996.1675; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PEREZ JL, 1994, ONCOGENE, V9, P211; Perez JL, 1996, ONCOGENE, V12, P1469; Playford MP, 1996, GENOME RES, V6, P620, DOI 10.1101/gr.6.7.620; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; ROSEN SD, 1973, P NATL ACAD SCI USA, V70, P2554, DOI 10.1073/pnas.70.9.2554; Sakuma S, 1996, FEBS LETT, V398, P165, DOI 10.1016/S0014-5793(96)01234-3; SAKUMA S, 1995, RADIAT RES, V143, P1, DOI 10.2307/3578919; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; Sauer CG, 1997, NAT GENET, V17, P164, DOI 10.1038/ng1097-164; SHELLING AN, 1995, GENOMICS, V25, P584, DOI 10.1016/0888-7543(95)80065-T; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Svineng G, 1998, BIOCHEM J, V330, P1255, DOI 10.1042/bj3301255; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Valent A, 1996, HUM GENET, V98, P12, DOI 10.1007/s004390050152; Villoutreix BO, 1998, J MOL MODEL, V4, P268, DOI 10.1007/s008940050084; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weiner HL, 1996, PEDIATR NEUROSURG, V25, P64, DOI 10.1159/000121099; ZERLIN M, 1993, ONCOGENE, V8, P2731	49	233	261	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S77	S82		10.1096/fasebj.13.9001.s77	http://dx.doi.org/10.1096/fasebj.13.9001.s77			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352148				2022-12-28	WOS:000080403800010
J	Zimmermann, P; David, G				Zimmermann, P; David, G			The syndecans, tuners of transmembrane signaling	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	focal adhesions; microfilaments; PDZ domains; kinases	PROTEIN-KINASE-C; HEPARAN-SULFATE PROTEOGLYCANS; MOLECULE HB-GAM; CELL-SURFACE; CYTOPLASMIC DOMAIN; GROWTH-FACTOR; FOCAL CONTACTS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE PHOSPHORYLATION; NEURITE OUTGROWTH	Syndecans, a family of transmembrane proteoglycans, are putative integrators of extracellular signals. The interaction of syndecans with extracellular ligands via particular motifs in their heparan sulfate chains, their clustering, association with particular cytoskeletal structures, binding to cytoplasmic effectors, and intracellular phosphorylation represent as many means to bring this role to a successful conclusion. In this review, we will briefly address the characteristics of syndecans as heparan sulfate proteoglycans (HSPGs) and focus mainly on the properties, binding interactions, and potential signaling functions of the cytoplasmic domains of these molecules.	Catholic Univ Louvain, Ctr Human Genet, Lab Glycobiol & Dev Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Louvain, Belgium	Universite Catholique Louvain	David, G (corresponding author), Catholic Univ Louvain, Ctr Human Genet, Lab Glycobiol & Dev Genet, Herestr 49, B-3000 Louvain, Belgium.	guido.david@med.kuleuven.ac.be	Zimmermann, Pascale/P-4190-2017					Asundi VK, 1997, BIOCHEM BIOPH RES CO, V240, P502, DOI 10.1006/bbrc.1997.7684; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; Carey DJ, 1997, BIOCHEM J, V327, P1; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Guignandon A, 1997, EXP CELL RES, V236, P66, DOI 10.1006/excr.1997.3703; Habuchi H, 1998, TRENDS GLYCOSCI GLYC, V10, P65, DOI 10.4052/tigg.10.65; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; Itano N, 1996, BIOCHEM J, V315, P925, DOI 10.1042/bj3150925; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Lee D, 1998, J BIOL CHEM, V273, P13022, DOI 10.1074/jbc.273.21.13022; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; MALI M, 1994, J BIOL CHEM, V269, P27795; Martinho RG, 1996, MOL BIOL CELL, V7, P1771, DOI 10.1091/mbc.7.11.1771; MIETTINEN HM, 1994, MOL BIOL CELL, V5, P1325, DOI 10.1091/mbc.5.12.1325; Mochly-Rosen D, 1998, FASEB J, V12, P35; NOLO R, 1995, NEUROSCI LETT, V191, P39, DOI 10.1016/0304-3940(94)11551-1; Oh ES, 1997, ARCH BIOCHEM BIOPHYS, V344, P67, DOI 10.1006/abbi.1997.0180; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; PAP EHW, 1993, BIOCHEMISTRY-US, V32, P13310, DOI 10.1021/bi00211a044; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prasthofer T, 1995, BIOCHEM MOL BIOL INT, V36, P793; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER AC, 1982, EXTRACELLULAR MATRIX, P265; RAULO E, 1994, J BIOL CHEM, V269, P12999; REILAND J, 1993, J CELL SCI, V105, P1085; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Rijken P J, 1994, Adv Space Biol Med, V4, P159; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Sun DZ, 1998, INT J DEV BIOL, V42, P733; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YANAGISHITA M, 1998, TRENDS GLYCOSCI GLYC, V10, P57	79	188	194	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.		1999	13			S			S91	S100						10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352150				2022-12-28	WOS:000080403800012
J	Belhacene, N; Maulon, L; Guerin, S; Ricci, JE; Mari, B; Colin, Y; Cartron, JP; Auberger, P				Belhacene, N; Maulon, L; Guerin, S; Ricci, JE; Mari, B; Colin, Y; Cartron, JP; Auberger, P			Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin	FASEB JOURNAL			English	Article						protein kinase C; CD10 activity; Kell; cell proliferation; K562 differentiation; PMA; cells; hemin	NEUTRAL ENDOPEPTIDASE 24.11; TYROSINE KINASE-ACTIVITY; BOMBESIN-LIKE PEPTIDES; HUMAN-LEUKEMIC-CELLS; ERYTHROID-DIFFERENTIATION; GENE-EXPRESSION; DOWN-REGULATION; HEL CELLS; MEGAKARYOCYTIC DIFFERENTIATION; HUMAN-NEUTROPHILS	The erythroleukemic cell line K562 can undergo further differentiation in erythroid or megakaryocytic lineage depending on the nature of the stimulus. Phorbol ester (PMA) stimulates megakaryocytic development whereas hemin promotes erythroid differentiation of these cells. We have examined the effect of PMA and hemin on the expression of the Kell blood group and CD10 antigens, two related proteins that belong to a family of membrane-bound neutral metalloendopeptidases. We show here that differentiation of K562 cells by PMA in the megakaryocytic lineage results in abolishment of Kell mRNA accumulation and protein expression and, in parallel, the induction of CD10 mRNA accumulation, protein expression, and enzymatic activity, Conversely, differentiation of these cells by hemin in the erythroid lineage is accompanied by an up-regulation of Kell mRNA and protein expression, with no changes in CD10 mRNA. and protein expression. Thus, CD10 and Kell can be regarded as specific markers of the differentiation of K562 cells in the megakaryocytic and erythroid lineages, respectively.	Fac Med Nice, INSERM, CJF 96 05, F-06107 Nice 2, France; INTS, INSERM, U76, F-75739 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), Fac Med Nice, INSERM, CJF 96 05, Ave Vallombrose, F-06107 Nice 2, France.	auberger@unice.fr	Mari, Bernard/Q-5832-2019; Mari, Bernard P/GVS-3100-2022; Ricci, Jean Ehrland/I-7117-2016; Mari, Bernard P/F-8960-2013; RICCI, Jean Ehrland/AAS-4379-2020; Mari, Bernard P/D-7445-2015; AUBERGER, Patrick/G-1491-2013; colin, yves/O-1910-2017	Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Ricci, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; RICCI, Jean Ehrland/0000-0003-1585-8117; Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; colin, yves/0000-0001-5196-4254				ANAFI M, 1993, BLOOD, V82, P3524; Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; BELHACENE N, 1993, EUR J IMMUNOL, V23, P1948, DOI 10.1002/eji.1830230833; BORSON DB, 1991, AM J PHYSIOL, V260, pL83, DOI 10.1152/ajplung.1991.260.2.L83; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONNELLY JC, 1985, P NATL ACAD SCI USA, V82, P8737, DOI 10.1073/pnas.82.24.8737; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; ERDOS EG, 1989, J BIOL CHEM, V264, P14519; GAHMBERG CG, 1984, P NATL ACAD SCI-BIOL, V81, P6752, DOI 10.1073/pnas.81.21.6752; GANJU R, 1996, BLOOD, V88, P4149; Guerin S, 1997, CELL IMMUNOL, V175, P85, DOI 10.1006/cimm.1996.1045; Guerin S, 1997, FASEB J, V11, P376, DOI 10.1096/fasebj.11.5.9141505; Guerin S, 1997, FASEB J, V11, P1003, DOI 10.1096/fasebj.11.12.9337153; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; HONMA Y, 1989, CANCER RES, V49, P331; ISHIMARU F, 1995, BLOOD, V85, P3199, DOI 10.1182/blood.V85.11.3199.bloodjournal85113199; Ishimaru F, 1996, EXP HEMATOL, V24, P43; JABER A, 1991, BRIT J HAEMATOL, V79, P311, DOI 10.1111/j.1365-2141.1991.tb04539.x; KIEFFER N, 1986, J BIOL CHEM, V261, P5854; LEBIEN TW, 1982, J IMMUNOL, V128, P1316; LEBIEN TW, 1989, BLOOD, V73, P625; LEE S, 1995, BLOOD, V85, P1364, DOI 10.1182/blood.V85.5.1364.bloodjournal8551364; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; Loflin PT, 1996, BIOCHEM PHARMACOL, V52, P1065, DOI 10.1016/0006-2952(96)00446-7; LUMELSKY NL, 1991, MOL CELL BIOL, V11, P3528, DOI 10.1128/MCB.11.7.3528; MAKELA TP, 1987, MOL CELL BIOL, V7, P3656; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; Mari B, 1997, FASEB J, V11, P869, DOI 10.1096/fasebj.11.11.9285485; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MARI B, 1994, IMMUNOLOGY, V82, P433; Mari B, 1996, FASEB J, V10, P309, DOI 10.1096/fasebj.10.2.8641564; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MURATE T, 1993, EXP CELL RES, V208, P35, DOI 10.1006/excr.1993.1219; OGURA M, 1988, BLOOD, V72, P49; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROWLEY PT, 1992, INT J CELL CLONING, V10, P232, DOI 10.1002/stem.5530100406; RUSSO DCW, 1994, BLOOD, V84, P3518; SALLES G, 1993, P NATL ACAD SCI USA, V90, P7618, DOI 10.1073/pnas.90.16.7618; SALLES G, 1992, BLOOD, V80, P2021; SAMID D, 1992, BLOOD, V80, P1576; SHIPP MA, 1991, P NATL ACAD SCI USA, V88, P10662, DOI 10.1073/pnas.88.23.10662; SHIPP MA, 1991, BLOOD, V78, P1834; SHIPP MA, 1990, NATURE, V347, P394, DOI 10.1038/347394a0; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; VILLEVAL JL, 1989, CANCER RES, V49, P2626; WERB Z, 1989, J BIOL CHEM, V264, P9111; WERFEL T, 1991, J IMMUNOL, V147, P3909; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	53	35	37	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					531	539						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576480				2022-12-28	WOS:000073523100003
J	Szabo, I; Bathori, G; Tombola, F; Coppola, A; Schmehl, I; Brini, M; Ghazi, A; De Pinto, V; Zoratti, M				Szabo, I; Bathori, G; Tombola, F; Coppola, A; Schmehl, I; Brini, M; Ghazi, A; De Pinto, V; Zoratti, M			Double-stranded DNA can be translocated across a planar membrane containing purified mitochondrial porin	FASEB JOURNAL			English	Article						DNA transport; channels; VDAC; mitochondria	SINGLE-ION CHANNEL; ESCHERICHIA-COLI; OUTER-MEMBRANE; TRANSFER-RNA; CONTACT SITES; GENE-THERAPY; PROTEIN; DISEASES; IMPORT; LOCALIZATION	The transport of genetic material across biomembranes is a process of great relevance for several fields of study. However, much remains to be learned about the mechanisms underlying transport, one of which implies the involvement of proteic DNA-conducting pores. Entry of genetic material into mitochondria has been observed under both physiological and pathological conditions. We report here that double-stranded DNA can move through a planar bilayer membrane containing isolated mitochondrial porin (voltage-dependent anion channel). The transport is driven by the applied electrical field, and the presence of DNA is associated with a decrease of current conduction by the pores. The passage of DNA does not take place if the bilayer has not been doped with any protein or in the presence of both reconstituted porin and anti-porin antibody. Translocation does not occur if the bilayer contains Shigella sonnei maltoporin, gramicidin A channels, or a 30 pS anion-selective channel plus other proteins. These results show that mitochondrial porin is capable of mediating the transport of genetic material, revealing a new property of this molecule and futher confirming the idea that DNA can move through proteic pores.	Univ Padua, CNR, Dept Biomed Sci, Unit Biomembranes, I-35121 Padua, Italy; Univ Paris Sud, Lab Biomembranes, CNRS, ERS 571, Paris, France; Univ Catania, Inst Biochem & Pharmaceut Sci, I-95124 Catania, Italy; Semmelweis Univ Med, Dept Physiol, H-1085 Budapest, Hungary; Eotvos Lorand Univ, Dept Atom Phys, Budapest, Hungary	Consiglio Nazionale delle Ricerche (CNR); University of Padua; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Catania; Semmelweis University; Eotvos Lorand University	Szabo, I (corresponding author), Univ Padua, CNR, Dept Biomed Sci, Unit Biomembranes, Viale G Colombo 3, I-35121 Padua, Italy.	zoratti@civ.bio.unipd.it	De Pinto, Vito/AAC-2634-2019; Tombola, Francesco/C-7311-2011; Szabo, Ildiko/AAW-5972-2021; Brini, Marisa/K-5189-2016; Padova, Ildiko/K-5344-2016; Tombola, Francesco/ABA-6002-2020	Szabo, Ildiko/0000-0002-3637-3947; Tombola, Francesco/0000-0002-9315-0352; De Pinto, Vito/0000-0001-5513-2906; Brini, Marisa/0000-0001-5141-0243	Telethon [711, A.059] Funding Source: Medline	Telethon(Fondazione Telethon)		Alvarez O., 1986, ION CHANNEL RECONSTI, P115; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BENZ R, 1992, BIOL CHEM H-S, V373, P295, DOI 10.1515/bchm3.1992.373.1.295; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; CITOVSKY V, 1993, ANNU REV MICROBIOL, V47, P167, DOI 10.1146/annurev.mi.47.100193.001123; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DERMIETZEL R, 1994, P NATL ACAD SCI USA, V91, P499, DOI 10.1073/pnas.91.2.499; DREISEIKELMANN B, 1994, MICROBIOL REV, V58, P293, DOI 10.1128/MMBR.58.3.293-316.1994; FEUCHT A, 1990, J BIOL CHEM, V265, P18561; FRANCIS G, 1991, BIOCHIM BIOPHYS ACTA, V1067, P89, DOI 10.1016/0005-2736(91)90029-8; GLASERWUTTKE G, 1989, BIOCHIM BIOPHYS ACTA, V985, P239, DOI 10.1016/0005-2736(89)90408-2; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HAUSER R, 1995, EMBO J, V14, P4212, DOI 10.1002/j.1460-2075.1995.tb00095.x; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; KORCHEV YE, 1995, J MEMBRANE BIOL, V147, P233; LANDER ES, 1990, CELL, V61, P925, DOI 10.1016/0092-8674(90)90055-J; LI K, 1994, J CELL BIOL, V124, P871, DOI 10.1083/jcb.124.6.871; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Meyer JEW, 1997, J MOL BIOL, V266, P761, DOI 10.1006/jmbi.1996.0823; OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z; PEROSA F, 1990, J IMMUNOL METHODS, V74, P385; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; ROA M, 1976, VIROLOGY, V72, P182, DOI 10.1016/0042-6822(76)90322-6; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; SOMASUNDARAN M, 1994, J CELL BIOL, V126, P1353, DOI 10.1083/jcb.126.6.1353; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Szabo I, 1997, J BIOL CHEM, V272, P25275, DOI 10.1074/jbc.272.40.25275; TAKETANI S, 1995, J BIOCHEM-TOKYO, V117, P875, DOI 10.1093/oxfordjournals.jbchem.a124790; TARASSOV I, 1995, EMBO J, V14, P3461, DOI 10.1002/j.1460-2075.1995.tb07352.x; TARASSOV I, 1995, J MOL BIOL, V245, P315, DOI 10.1006/jmbi.1994.0026; THINNES FP, 1992, J BIOENERG BIOMEMBR, V24, P71, DOI 10.1007/BF00769533; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; ZAMECNIK P, 1994, P NATL ACAD SCI USA, V91, P3156, DOI 10.1073/pnas.91.8.3156; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	56	53	55	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1998	12	6					495	502		10.1096/fasebj.12.6.495	http://dx.doi.org/10.1096/fasebj.12.6.495			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZG118	9535222				2022-12-28	WOS:000072967300011
J	Dunder, U; Kaartinen, V; Valtonen, P; Vaananen, E; Kosma, VM; Heisterkamp, N; Groffen, J; Mononen, I				Dunder, U; Kaartinen, V; Valtonen, P; Vaananen, E; Kosma, VM; Heisterkamp, N; Groffen, J; Mononen, I			Enzyme replacement therapy in a mouse model of aspartylglycosaminuria	FASEB JOURNAL			English	Article						aspartylglycosylaminase; recombinant proteins; lysosomal storage diseases; animal disease models; lysosomes	MUCOPOLYSACCHARIDOSIS TYPE-VII; RECOMBINANT BETA-GLUCURONIDASE; HUMAN FIBROBLASTS; LYSOSOMAL ENZYME; GAUCHER-DISEASE; GLYCOSYLASPARAGINASE; MICE; ASSAY; LEADS	Aspartylglycosaminuria (AGU), the most common lysosomal disorder of glycoprotein degradation, is caused by deficient activity of glycosylasparaginase (AGA), AGA-deficient mice share most of the clinical, biochemical and histopathologic characteristics of human AGU disease. In the current study, recombinant human AGA administered i.v. to adult AGU mice disappeared from the systemic circulation of the animals in two phases predominantly into non-neuronal tissues, which were rapidly cleared from storage compound aspartylglucosamine. Even a single AGA injection reduced the amount of aspartylglucosamine in the Liver and spleen of AGU mice by 90% and 80%, respectively. Quantitative biochemical analyses along with histological and immunohistochemical studies demonstrated that the pathophysiologic characteristics of AGU were effectively corrected in non-neuronal tissues of AGU mice during 2 wk of AGA therapy. At the same time, AGA activity increased to 10% of that in normal brain tissue and the accumulation of aspartylglucosamine was reduced by 20% in total brain of the treated animals. Immunohistochemical studies suggested that the corrective enzyme was widely distributed within the brain tissue. These findings suggest that AGU may be correctable by enzyme therapy.	Kuopio Univ Hosp, Dept Clin Chem, FIN-70211 Kuopio, Finland; Univ So Calif, Sch Med, Dept Pathol, Childrens Hosp,Res Inst, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Div Haematol Oncol, Childrens Hosp,Res Inst, Los Angeles, CA 90027 USA; Univ Kuopio, Dept Pathol & Forens Med, FIN-70210 Kuopio, Finland; Turku Univ Hosp, Dept Clin Chem & Hematol, FIN-20521 Turku, Finland	Kuopio University Hospital; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Eastern Finland; University of Turku	Mononen, I (corresponding author), Kuopio Univ Hosp, Dept Clin Chem, POB 1777, FIN-70211 Kuopio, Finland.		Kaartinen, Vesa/AAU-5396-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X				ARVIO M, 1997, CLIN MANIFESTATIONS, P19; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEAUDET LL, 1989, DISORDERS GLYCOPROTE, P1603; BEUTLER E, 1995, GAUCHER DIS, P2641; BOVE KE, 1995, HUM PATHOL, V26, P1040, DOI 10.1016/0046-8177(95)90097-7; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; Gonzalez-Gomez I, 1998, AM J PATHOL, V153, P1293, DOI 10.1016/S0002-9440(10)65674-X; Kaartinen V, 1998, J INHERIT METAB DIS, V21, P207, DOI 10.1023/A:1005387215224; Kaartinen V, 1996, NAT MED, V2, P1375, DOI 10.1038/nm1296-1375; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; KAARTINEN V, 1990, CLIN CHIM ACTA, V191, P15, DOI 10.1016/0009-8981(90)90053-U; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; MONONEN I, 1997, LYSOSOMAL STORAGE DI; MONONEN IT, 1993, ANAL BIOCHEM, V208, P372, DOI 10.1006/abio.1993.1063; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; Prows CA, 1997, AM J MED GENET, V71, P16, DOI 10.1002/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.3.CO;2-U; SANDO GN, 1977, CELL, V12, P619, DOI 10.1016/0092-8674(77)90262-8; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; Sands MS, 1997, J CLIN INVEST, V99, P1596, DOI 10.1172/JCI119322; SHULL RM, 1994, P NATL ACAD SCI USA, V91, P12937, DOI 10.1073/pnas.91.26.12937; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; Vogler C, 1996, PEDIATR RES, V39, P1050, DOI 10.1203/00006450-199606000-00019; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028	24	60	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					361	367		10.1096/fasebj.14.2.361	http://dx.doi.org/10.1096/fasebj.14.2.361			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657992				2022-12-28	WOS:000085184800015
J	Camps, M; Nichols, A; Arkinstall, S				Camps, M; Nichols, A; Arkinstall, S			Dual specificity phosphatases: a gene family for control of MAP kinase function	FASEB JOURNAL			English	Review						MAP kinases; protein phosphatases; dual specificity phosphatases; signal transduction	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; SIGNAL-REGULATED KINASE; TYROSINE-PHOSPHATASE; GROWTH-FACTOR; IN-VIVO; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL REGULATION; INDUCED APOPTOSIS	Mitogen-activated protein (MAP) kinases are important players in signal transduction pathways activated by a range of stimuli and mediate a number of physiological and pathological changes in cell function. MAP kinase activation requires phosphorylation on a threonine and tyrosine residue located within the activation loop of kinase subdomain VIII, This process is reversible even in the continued presence of activating stimuli, indicating that protein phosphatases provide an important mechanism for MAP kinase control. Dual specificity phosphatases (DSPs) are an emerging subclass of the protein tyrosine phosphatase (PTP) gene superfamily, which appears to be selective for dephosphorylating the critical phosphothreonine and phosphotyrosine residues within MAP kinases, Some DSPs are localized to different subcellular compartments and moreover, certain family members appear highly selective for inactivating distinct MAP kinase isoforms. This enzymatic specificity is due in part to powerful catalytic activation of the DSP phosphatase after tight binding of its amino-terminal to the target MAP kinase. DSP gene expression is induced strongly by various growth factors and/or cellular stresses, providing a sophisticated transcriptional mechanism for targeted inactivation of selected MAP kinase activities.-Camps, M., Nichols, A., Arkinstall, S, Dual specificity phosphatases: a gene family for control of MAP kinase function.	Ares Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	Merck & Company; Serono International S.A.	Arkinstall, S (corresponding author), Ares Serono Int SA, Serono Pharmaceut Res Inst, 1228 Plans Ouates, CH-1228 Geneva, Switzerland.	steve.arkinstall@serono.com		Camps, Montserrat/0000-0002-9849-8657				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Boschert U, 1998, NEUROREPORT, V9, P4081, DOI 10.1097/00001756-199812210-00014; Boschert U, 1997, NEUROREPORT, V8, P3077, DOI 10.1097/00001756-199709290-00014; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 1998, FEBS LETT, V425, P271, DOI 10.1016/S0014-5793(98)00250-6; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dorfman K, 1996, ONCOGENE, V13, P925; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; King AG, 1995, ONCOGENE, V11, P2553; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smith A, 1997, GENOMICS, V42, P524, DOI 10.1006/geno.1997.4756; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; van Huijsduijnen RH, 1998, GENE, V225, P1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YI H, 1994, GENOMICS, V28, P92; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	91	688	729	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					6	16		10.1096/fasebj.14.1.6	http://dx.doi.org/10.1096/fasebj.14.1.6			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627275				2022-12-28	WOS:000084784700003
J	Langford, GM				Langford, GM			ER transport on actin filaments in squid giant axon: implications for signal transduction at synapse	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		BRAIN MYOSIN-V; LOCALIZATION; ORGANELLES; MOVEMENT; MOTILITY	The smooth endoplasmic reticulum (SER) is transported on actin filaments in the giant axon of the squid, The identity of the myosin motors that transport S-ER in the squid giant axon has been determined, Our recent studies have shown that the motor for movement of S-ER vesicles on actin filaments is Myosin-V (1), These findings grew out of a series of studies that began with the initial observation that vesicles in the giant axon of the squid move on both microtubules and actin filaments (2). These initial studies documented the ability of individual vesicles to move from microtubules to actin filaments and led to the development of the dual filament model of vesicle transport (3, 4), The model proposes that long-range movement of vesicles occurs on microtubules and short-range movement: on actin filaments. S-ER vesicles were identified as the major population of vesicles in the axon that use myosin-V for movement on actin filaments. The S-ER is the primary site of calcium storage, and it regulates the local cytosolic calcium concentration. Calcium release from the S-ER iu neurons couples electrical excitation to signal transduction cascades, The signaling cascades triggered by the release of calcium from S-ER in dendritic spines are postulated to initiate the cellular mechanisms that lead to learning and memory.	Dartmouth Coll, Dept Biol Sci, Gilman Lab 6044, Hanover, NH 03755 USA	Dartmouth College	Langford, GM (corresponding author), Dartmouth Coll, Dept Biol Sci, Gilman Lab 6044, Hanover, NH 03755 USA.			Langford, George/0000-0001-9737-2182	PHS HHS [9842948, 9506279] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; KUZNETSOV SA, 1994, CELL MOTIL CYTOSKEL, V28, P231, DOI 10.1002/cm.970280306; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; Langford GM, 1998, BRAIN RES REV, V28, P1, DOI 10.1016/S0165-0173(98)00020-4; LANGFORD GM, 1995, CURR OPIN CELL BIOL, V7, P82, DOI 10.1016/0955-0674(95)80048-4; Molyneaux BJ, 1997, BIOL BULL, V193, P222, DOI 10.1086/BBLv193n2p222; Svoboda K, 1999, NEURON, V22, P427, DOI 10.1016/S0896-6273(00)80698-4; Tabb JS, 1998, J CELL SCI, V111, P3221; Tabb JS, 1996, BIOL BULL, V191, P274, DOI 10.1086/BBLv191n2p274; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; WOLENSKI JS, 1995, J CELL SCI, V108, P1489	16	9	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S248	S250		10.1096/fasebj.13.9002.S248	http://dx.doi.org/10.1096/fasebj.13.9002.S248			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619137				2022-12-28	WOS:000084390200015
J	Delaughter, MC; Taffet, GE; Fiorotto, ML; Entman, ML; Schwartz, RJ				Delaughter, MC; Taffet, GE; Fiorotto, ML; Entman, ML; Schwartz, RJ			Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice	FASEB JOURNAL			English	Article						IGF-I; SIS2 transgene; systolic function; hypertension	MYOCYTE PROLIFERATION; VENTRICULAR HYPERTROPHY; HEART-FAILURE; UP-REGULATION; HORMONE; PERFORMANCE; CARDIOMYOCYTES; INFARCTION; INDUCTION; SYSTEM	In the present study we determined the long-term effects of persistent, local insulin-like growth factor I (IGF-I) expression on cardiac function in the SIS2 transgenic mouse. Cardiac mass/tibial length was increased in SIS2 mice by 10 wk of age; this cardiac hypertrophy became more pronounced later in life, Peak aortic outflow velocity, a correlate of cardiac output, was increased at 10 wk in SIS2 mice but was decreased at 52 wk, 72 wk SIS2 mouse hearts exhibited wide variability in the extent of cardiac hypertrophy and enlargement of individual cardiac myofibers, Sirius red staining revealed increased fibrosis in 72 wk SIS:! hearts, Persistent local ICE-I expression is sufficient to initially induce an analog of physiological cardiac hypertrophy in which peak aortic outflow velocity is increased relative to controls in the absence of any observed detrimental histological changes. However, this hypertrophy progresses to a pathological condition characterized by decreased systolic performance and increased fibrosis, Our results confirm the shortterm systolic performance benefit of increased ICE-I, but our demonstration that ICE-I ultimately diminishes systolic performance raises doubt about the therapeutic value of chronic ICE-I administration. Considering these findings, limiting temporal exposure to ICE-I seems the most likely means of delivering IGF-I's potential benefits while avoiding its deleterious side effects.-Delaughter, M. C,, Taffet, G. E., Fiorotto, M, L., Entman, M, L., Schwartz, R. J. Local insulinlike growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Sci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42550] Funding Source: Medline; NIA NIH HHS [5 T32 AG000183] Funding Source: Medline; NIDDK NIH HHS [2 T32 DK07696] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Butt RP, 1997, J MOL CELL CARDIOL, V29, P1141, DOI 10.1006/jmcc.1996.0347; CHANSON P, 1990, ANN INTERN MED, V113, P921, DOI 10.7326/0003-4819-113-12-921; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; DIEZ J, 1994, J HUM HYPERTENS, V8, pS21; Donath MY, 1998, J CLIN ENDOCR METAB, V83, P3177, DOI 10.1210/jc.83.9.3177; DONATH MY, 1994, P NATL ACAD SCI USA, V91, P1686, DOI 10.1073/pnas.91.5.1686; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; FAZIO S, 1994, J CLIN ENDOCR METAB, V79, P441, DOI 10.1210/jc.79.2.441; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; KAJSTURA J, 1994, EXP CELL RES, V215, P273, DOI 10.1006/excr.1994.1343; KARDAMI E, 1990, MOL CELL BIOCHEM, V92, P129; Lombardi G, 1997, J PEDIATR ENDOCR MET, V10, P553; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; REISS K, 1994, J CELL PHYSIOL, V158, P160, DOI 10.1002/jcp.1041580120; REISS K, 1994, EXP CELL RES, V213, P463, DOI 10.1006/excr.1994.1224; Sacca L, 1997, CARDIOVASC RES, V36, P3, DOI 10.1016/S0008-6363(97)00127-2; Stromer H, 1996, CIRC RES, V79, P227, DOI 10.1161/01.RES.79.2.227; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang L, 1998, ENDOCRINOLOGY, V139, P1354, DOI 10.1210/en.139.3.1354; YANG RH, 1995, CIRCULATION, V92, P262, DOI 10.1161/01.CIR.92.2.262	25	126	130	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1923	1929		10.1096/fasebj.13.14.1923	http://dx.doi.org/10.1096/fasebj.13.14.1923			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544175				2022-12-28	WOS:000083660700004
J	Pollack, R				Pollack, R			Wisdom versus knowledge: an agenda for a more humane medical science	FASEB JOURNAL			English	Editorial Material									Columbia Univ, Ctr Study Sci & Relig, New York, NY 10027 USA	Columbia University	Pollack, R (corresponding author), Mailcode 2419,1212 Amsterdam Ave, New York, NY 10027 USA.								0	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1477	1480		10.1096/fasebj.13.12.1477	http://dx.doi.org/10.1096/fasebj.13.12.1477			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463937				2022-12-28	WOS:000082347600001
J	Rato, AG; Pedrero, JG; Martinez, MA; Del Rio, B; Lazo, PS; Ramos, S				Rato, AG; Pedrero, JG; Martinez, MA; Del Rio, B; Lazo, PS; Ramos, S			Melatonin blocks the activation of estrogen receptor for DNA binding	FASEB JOURNAL			English	Article						antiestrogen; breast cancer; estradiol; MCF7 cells	BREAST-CANCER-CELLS; PINEAL HORMONE MELATONIN; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; RESPONSE ELEMENTS; RETINOIC ACID; CALMODULIN; INHIBITION; ESTRADIOL; INVITRO	The present study shows that melatonin prevents, within the first cell cycle, the estradiol-induced growth of synchronized MCF7 breast cancer cells. By using nuclear extracts of these cells, we first examined the binding of estradiol-estrogen receptor complexes to estrogen-responsive elements and found that the addition of estradiol to whole cells activates the binding of the estrogen receptor to DNA whereas melatonin blocks this interaction. By contrast, melatonin neither affects the binding of estradiol to its receptor nor the receptor nuclear localization. Moreover, we also show that addition of estradiol to nuclear extracts stimulates the binding of estrogen receptor to DNA, but this activation is also prevented by melatonin. The inhibitory effect caused by melatonin is saturable at nanomolar concentrations and does not appear to be mediated by RZR nuclear receptors. The effect is also specific, since indol derivatives do not cause significant inhibition. Furthermore, we provide evidence that melatonin does not interact with the estrogen receptor in the absence of estradiol. Together, these results demonstrate that melatonin interferes with the activation of estrogen receptor by estradiol. The effect of melatonin suggests the presence of a receptor that, upon melatonin addition, destabilizes the binding of the estradiol-estrogen receptor complex to the estrogen responsive element.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain; Hosp de Jove, Gijon 33212, Spain	University of Oviedo	Rato, AG (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, E-33006 Oviedo, Spain.		Lazo, Pedro/C-4087-2008; del Rio, beatriz/L-3082-2014; Pedrero, Juana María García/AAP-4251-2021; Lazo, Pranvera/I-5299-2019	Lazo, Pedro/0000-0002-1278-6878; del Rio, beatriz/0000-0001-8107-1975; Pedrero, Juana María García/0000-0002-5891-9488; Lazo, Pranvera/0000-0002-7202-4058				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BENITEZKING G, 1991, BRAIN RES, V557, P289, DOI 10.1016/0006-8993(91)90146-M; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BROWN M, 1990, J BIOL CHEM, V265, P11238; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Castano E, 1997, BIOCHEM J, V326, P149, DOI 10.1042/bj3260149; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; Conway S, 1997, FEBS LETT, V407, P121, DOI 10.1016/S0014-5793(97)00315-3; COS S, 1989, J PINEAL RES, V6, P221, DOI 10.1111/j.1600-079X.1989.tb00418.x; DANFORTH DN, 1983, NATURE, V305, P323, DOI 10.1038/305323a0; DEMIRPENCE E, 1994, CANCER RES, V54, P1458; Gilad E, 1997, J CLIN ENDOCR METAB, V82, P2535, DOI 10.1210/jc.82.8.2535; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; Godson C, 1997, ENDOCRINOLOGY, V138, P397, DOI 10.1210/endo.138.1.4824; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hardcastle IR, 1996, J MED CHEM, V39, P999, DOI 10.1021/jm9505472; HILL SM, 1988, CANCER RES, V48, P6121; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JORDAN VC, 1990, CANCER PREVENTION, P1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LISSONI P, 1995, BRIT J CANCER, V71, P854, DOI 10.1038/bjc.1995.164; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; MEDIAVILLA MD, 1992, J PINEAL RES, V13, P13, DOI 10.1111/j.1600-079X.1992.tb00049.x; MEYER ME, 1989, CELL, V37, P432; MIGLIACCIO S, 1993, MOL ENDOCRINOL, V7, P1133, DOI 10.1210/me.7.9.1133; MOLIS TM, 1995, J PINEAL RES, V18, P93, DOI 10.1111/j.1600-079X.1995.tb00146.x; MOLLIS TM, 1994, MOL ENDOCRINOL, V8, P1681; MORREY KM, 1994, J IMMUNOL, V153, P2671; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Pratt MAC, 1996, J BIOL CHEM, V271, P20346, DOI 10.1074/jbc.271.34.20346; Reiter R J, 1980, Endocr Rev, V1, P109; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; Romero MP, 1998, FASEB J, V12, P1401, DOI 10.1096/fasebj.12.13.1401; Sainz RM, 1995, J PINEAL RES, V19, P178, DOI 10.1111/j.1600-079X.1995.tb00187.x; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANCHEZBARCELO EJ, 1990, P SOC EXP BIOL MED, V194, P103, DOI 10.3181/00379727-194-43063; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay GB, 1998, CANCER RES, V58, P877; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; WILSON ST, 1992, J CLIN ENDOCR METAB, V75, P669, DOI 10.1210/jc.75.2.669; YANGMIN N, 1996, MOL ENDOCRINOL, V10, P14	49	103	104	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					857	868		10.1096/fasebj.13.8.857	http://dx.doi.org/10.1096/fasebj.13.8.857			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224229				2022-12-28	WOS:000080372500009
J	Cho, MR; Thatte, HS; Silvia, MT; Golan, DE				Cho, MR; Thatte, HS; Silvia, MT; Golan, DE			Transmembrane calcium influx induced by ac electric fields	FASEB JOURNAL			English	Article						intracellular calcium; stretch-activated cation channels; signal transduction	ACTIVATED ION CHANNELS; EMBRYONIC MUSCLE-CELL; RAT-LIVER CELLS; INDUCED REDISTRIBUTION; INTRACELLULAR CALCIUM; CATION CHANNELS; SHAPE CHANGES; CA2+ INFLOW; MEMBRANE; RECEPTORS	Exogenous electric fields induce cellular responses including redistribution of integral membrane proteins, reorganization of microfilament structures, and changes in intracellular calcium ion concentration ([Ca2+](i)). Although increases in [Ca2+](i) caused by application of direct current electric fields have been documented, quantitative measurements of the effects of alternating current (ac) electric fields on [Ca2+](i) are lacking and the Ca2+ pathways that mediate such effects remain to be identified, Using epifluorescence microscopy, we have examined in a model cell type the [Ca2+](i) response to ac electric fields. Application of a 1 or 10 Hz electric field to human hepatoma (Hep3B) cells induces a fourfold increase in [Ca2+](i) (from 50 nM to 200 nM) within 30 min of continuous field exposure. Depletion of Ca2+ in the extracellular medium prevents the electric field-induced increase in [Ca2+](i), suggesting that Ca2+ influx across the plasma membrane is responsible for the [Ca2+](i) increase. Incubation of cells with the phospholipase C inhibitor U73122 does not inhibit ac electric field-induced increases in [Ca2+](i), suggesting that receptor-regulated release of intracellular Ca2+ is not important for this effect. Treatment of cells with either the stretch-activated cation channel inhibitor GdCl3 or the nonspecific calcium channel blocker CoCl2 partially inhibits the [Ca2+](i) increase induced by ac electric fields, and concomitant treatment with both GdCl3 and CoCl2 completely inhibits the field-induced [Ca2+](i) increase. Since neither Gd3+ nor Co2+ is efficiently transported across the plasma membrane, these data suggest that the increase in [Ca2+](i) induced by ac electric fields depends entirely on Ca2+ influx from the extracellular medium.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Golan, DE (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	dgolan@hms.harvard.edu		Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-15157, HL-32854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157, R01HL032854, R37HL032854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERVEN LA, 1995, BIOCHEM PHARMACOL, V49, P1373, DOI 10.1016/0006-2952(95)00050-A; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; BROWN MJ, 1994, J CELL BIOL, V127, P117, DOI 10.1083/jcb.127.1.117; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; CARSON JJL, 1990, AM J PHYSIOL, V259, pC687, DOI 10.1152/ajpcell.1990.259.4.C687; CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677; Cho MR, 1996, FASEB J, V10, P1552, DOI 10.1096/fasebj.10.13.8940302; DOCHERTY RJ, 1988, J PHYSIOL-LONDON, V398, P33, DOI 10.1113/jphysiol.1988.sp017027; FERNANDO KC, 1995, BBA-MOL CELL RES, V1268, P97, DOI 10.1016/0167-4889(95)00041-P; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GIUGNI TD, 1987, J CELL BIOL, V104, P1291, DOI 10.1083/jcb.104.5.1291; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; JAFFE LF, 1977, NATURE, V265, P600, DOI 10.1038/265600a0; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LAUB F, 1984, BIOCHIM BIOPHYS ACTA, V803, P308, DOI 10.1016/0167-4889(84)90122-8; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P319, DOI 10.1097/00004630-199305000-00003; LEE RC, 1993, BIOPHYS J, V64, P44, DOI 10.1016/S0006-3495(93)81339-0; LUTHER PW, 1983, NATURE, V303, P61, DOI 10.1038/303061a0; MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006-3495(81)84838-2; ONUMA EK, 1985, CELL CALCIUM, V6, P281, DOI 10.1016/0143-4160(85)90012-0; ONUMA EK, 1988, J CELL BIOL, V106, P2067, DOI 10.1083/jcb.106.6.2067; Perelson A. S., 1984, CELL SURFACE DYNAMIC, P223; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; POO MM, 1978, J CELL BIOL, V76, P483, DOI 10.1083/jcb.76.2.483; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; ROBERTSON B, 1992, BIOCHEMISTRY-US, V31, P138, DOI 10.1021/bi00116a020; ROBERTSON B, 1990, BIOPHYS J, V58, P969, DOI 10.1016/S0006-3495(90)82441-3; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; RYAN TA, 1988, SCIENCE, V239, P61, DOI 10.1126/science.2962287; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SANCHEZBUENO A, 1990, ADV SEC MESS PHOSPH, V24, P115; SAWANOBORI T, 1989, J CELL PHYSIOL, V139, P580, DOI 10.1002/jcp.1041390318; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; TSONG TY, 1988, METHOD ENZYMOL, V157, P240; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WESTERHOFF HV, 1986, P NATL ACAD SCI USA, V83, P4734, DOI 10.1073/pnas.83.13.4734; WOFSY C, 1992, MATH BIOSCI, V112, P115, DOI 10.1016/0025-5564(92)90090-J; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	53	115	121	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					677	683		10.1096/fasebj.13.6.677	http://dx.doi.org/10.1096/fasebj.13.6.677			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094928				2022-12-28	WOS:000079527200009
J	Witting, PK; Pettersson, K; Ostlund-Lindqvist, AM; Westerlund, C; Eriksson, AW; Stocker, R				Witting, PK; Pettersson, K; Ostlund-Lindqvist, AM; Westerlund, C; Eriksson, AW; Stocker, R			Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice	FASEB JOURNAL			English	Article						antioxidants; coantioxidation; LDL; alpha-tocopherol	TOCOPHEROL-MEDIATED PEROXIDATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; CHOLESTEROL-FED RABBITS; ALPHA-TOCOPHEROL; VITAMIN-E; OXIDIZED LIPOPROTEINS; DEFICIENT MICE; SCREENING-TEST; OXIDATION; LDL	Antioxidants can inhibit atherosclerosis in animals, though it is not clear whether this is due to the inhibition of aortic lipoprotein lipid (per)oxidation, Coantioxidants inhibit radical-induced, tocopherol-mediated peroxidation of lipids in lipoproteins through elimination of tocopheroxyl radical. Here we tested the effect of the bisphenolic probucol metabolite and coantioxidant H 212/43 on atherogenesis in apolipoprotein E and low density lipoprotein (LDL) receptor gene double knockout (apoE-/-;LDLr-/-) mice, and how this related to aortic lipid (per)oxidation measured by specific HPLC analyses. Dietary supplementation with H 212/43 resulted in circulating drug levels of similar to 200 mu M, increased plasma total cholesterol slightly and decreased plasma and aortic a-tocopherol significantly relative to age-matched control mice. Treatment with H 212/43 increased the antioxidant capacity of plasma, as indicated by prolonged inhibition of peroxyl radical-induced, ex vivo lipid peroxidation. Aortic tissue from control apoE-/-;LDLr-/- mice contained lipid hydro(pero)xides and substantial atherosclerotic lesions, both of which were decreased strongly by supplementation of the animals with H 212/43, The results show that a coantioxidant effectively inhibits in vivo lipid peroxidation and atherosclerosis in apoE-/-;LDLr-/- mice, consistent with though not proving a causal relationship between aortic lipoprotein lipid oxidation and atherosclerosis in this model of the disease.	Heart Res Inst, Biochem Grp, Camperdown, NSW 2050, Australia; AB Hassle, S-43183 Molndal, Sweden	University of Sydney; Heart Research Institute	Stocker, R (corresponding author), Heart Res Inst, Biochem Grp, 145 Missenden Rd, Camperdown, NSW 2050, Australia.	r.stocker@hri.org.au	Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020; Stocker, Roland/AAV-4489-2021	Witting, Paul/0000-0003-2237-7004; 				Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bird DA, 1998, J LIPID RES, V39, P1079; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; Cynshi O, 1998, P NATL ACAD SCI USA, V95, P10123, DOI 10.1073/pnas.95.17.10123; FRANK JS, 1989, J LIPID RES, V30, P967; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; FRUEBIS J, 1995, ATHEROSCLEROSIS, V117, P217, DOI 10.1016/0021-9150(95)05574-G; Fruebis J, 1997, J LIPID RES, V38, P2455; Hazell LJ, 1997, FEBS LETT, V414, P541, DOI 10.1016/S0014-5793(97)01066-1; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LINDQVIST AM, 1997, 97535465199749 WPI; LYNCH SM, 1994, NATURAL ANTIOXIDANTS, P353; Munday JS, 1998, ARTERIOSCL THROM VAS, V18, P114, DOI 10.1161/01.ATV.18.1.114; Neuzil J, 1998, J LIPID RES, V39, P354; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; OLeary VJ, 1996, ATHEROSCLEROSIS, V119, P169, DOI 10.1016/0021-9150(95)05644-0; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; PELTER A, 1988, TETRAHEDRON LETT, V29, P677, DOI 10.1016/S0040-4039(00)80182-3; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SHAISH A, 1995, J CLIN INVEST, V96, P2075, DOI 10.1172/JCI118256; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEIN Y, 1989, ATHEROSCLEROSIS, V75, P145, DOI 10.1016/0021-9150(89)90171-8; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUARNA C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P163, DOI 10.1016/0005-2760(93)90092-N; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H; Witting PK, 1996, J LIPID RES, V37, P853; Witting PK, 1998, SUB CELL BIOCHEM, V30, P345; Witting PK, 1999, METHOD ENZYMOL, V299, P362; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WITZTUM JL, 1993, J CLIN INVEST, V92, P536, DOI 10.1172/JCI116619; XIU RJ, 1994, J CLIN INVEST, V93, P2732, DOI 10.1172/JCI117288; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	47	82	83	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					667	675		10.1096/fasebj.13.6.667	http://dx.doi.org/10.1096/fasebj.13.6.667			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094927				2022-12-28	WOS:000079527200008
J	Blasko, I; Marx, F; Steiner, E; Hartmann, T; Grubeck-Loebenstein, B				Blasko, I; Marx, F; Steiner, E; Hartmann, T; Grubeck-Loebenstein, B			TNF alpha plus IFN gamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs	FASEB JOURNAL			English	Article						tumor necrosis factor alpha; interferon gamma; beta APP; amyloid beta; Alzheimer's disease; glycosylation	NECROSIS-FACTOR-ALPHA; PRECURSOR PROTEIN; KAPPA-B; DISEASE; CELLS; COMPLEMENT; ACTIVATION; BINDING; GROWTH; BRAIN	The appearance of inflammatory markers associated with amyloid plaques indicates a state of chronic inflammation in Alzheimer's disease (AD), Multiple epidemiological studies also suggest that patients taking anti-inflammatory drugs have a decreased risk of developing AD. Here we present evidence that inflammatory cytokines can alter the metabolism of the beta-amyloid precursor protein (beta APP), We show that the combination of tumor necrosis factor alpha and interferon gamma triggers the production of beta-amyloid peptides and inhibits the secretion of soluble APPs by human neuronal and extraneuronal cells. The results demonstrate a new mechanism by which inflammatory components can exacerbate the fundamental pathology in AD.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Heidelberg Univ, Ctr Mol Biol Heidelberg, ZMBH, Heidelberg, Germany	Austrian Academy of Sciences; Ruprecht Karls University Heidelberg	Grubeck-Loebenstein, B (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.	Beatrix.Grubeck@oeaw.ac.at	Hartmann, Tobias/AAB-8297-2022	Hartmann, Tobias/0000-0001-7481-6430; Marx, Florentine/0000-0002-8408-1842				BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Blasko I, 1997, NEUROSCI LETT, V238, P17, DOI 10.1016/S0304-3940(97)00845-8; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; COOK GC, 1997, NAT MED, V9, P1021; Galli C, 1998, P NATL ACAD SCI USA, V95, P1247, DOI 10.1073/pnas.95.3.1247; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRUBECKLOEBENSTEIN B, 1994, INT ARCH ALLERGY IMM, V104, P232, DOI 10.1159/000236671; GRUBECKLOEBENSTEIN B, 1989, J CLIN INVEST, V83, P764, DOI 10.1172/JCI113955; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; JIANG HX, 1994, J IMMUNOL, V152, P5050; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 1996, ANN NY ACAD SCI, V777, P213, DOI 10.1111/j.1749-6632.1996.tb34421.x; MONNING U, 1994, FEBS LETT, V342, P267, DOI 10.1016/0014-5793(94)80514-8; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Pappolla MA, 1998, AM J PATHOL, V152, P871; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Rothwell NJ, 1996, NAT MED, V2, P746, DOI 10.1038/nm0796-746; SCHMITT TL, 1995, J CLIN ENDOCR METAB, V80, P3513, DOI 10.1210/jc.80.12.3513; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Yazaki M, 1996, NEUROSCI LETT, V221, P57, DOI 10.1016/S0304-3940(96)13285-7	31	235	249	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					63	68		10.1096/fasebj.13.1.63	http://dx.doi.org/10.1096/fasebj.13.1.63			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872930				2022-12-28	WOS:000078029500007
J	Hemmersbach, R; Hader, DP				Hemmersbach, R; Hader, DP			Graviresponses of certain ciliates and flagellates	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	gravitaxis; gravikinesis; gravity sensing; microgravity; protists	EUGLENA-GRACILIS; PARAMECIUM-CAUDATUM; GRAVITACTIC ORIENTATION; LOXODES; WEIGHTLESSNESS; HYPERGRAVITY; VELOCITY; GRAVIPERCEPTION; GRAVIRECEPTION; ACCELERATIONS	Protozoa are eukaryotic cells and represent suitable model systems to study the mechanisms of gravity perception and signal transduction due to their clear gravity-induced responses (gravitaxis and gravikinesis). Among protists, parallel evolution for graviperception mechanisms have been identified: either sensing by distinct state-organelles (e.g., the Muller vesicles of the ciliate Loxodes) or by sensing the density difference between the whole cytoplasm and the extracellular medium (as proposed for Paramecium and Euglena), These two models are supported by experiments in density-adjusted media, as the gravitaxis of Loxodes was not affected, whereas the orientation of Paramecium and Euglena was completely disturbed. Both models include the involvement of ion channels in the cell membrane. Diverse experiments gave new information on the mechanism of graviperception in unicellular systems, such as threshold values in the range of 10% of gravity, relaxation of the responses after removal of the stimulus, and no visible adaptation phenomena during exposure to hypergravity or microgravity conditions for up to 12 days.	German Aerosp Res Estab, Inst Aerosp Med, D-51170 Cologne, Germany; Univ Erlangen Nurnberg, Inst Bot & Pharmaceut Biol, Erlangen, Germany	Helmholtz Association; German Aerospace Centre (DLR); University of Erlangen Nuremberg	Hemmersbach, R (corresponding author), German Aerosp Res Estab, Inst Aerosp Med, D-51140 Cologne, Germany.							Aderhold R, 1888, JENAISCHE Z MED NATU, V22, P311; Bean B., 1984, P163; BEAN B, 1977, J PROTOZOOL, V24, P394, DOI 10.1111/j.1550-7408.1977.tb04759.x; BEDINI C, 1973, J PROTOZOOL, V24, P394; BRAUCKER R, 1994, J EXP BIOL, V197, P271; Braucker R, 1998, J EXP BIOL, V201, P2103; BRAUCKER R, 1992, EUR J PROTISTOL, V28, P238, DOI 10.1016/S0932-4739(11)80053-2; Briegleb W, 1992, ASGSB Bull, V5, P23; BRIEGLEB W, 1988, PHYSIOLOGIST, V31, P44; Cogoli M, 1992, ASGSB Bull, V5, P59; CREUTZ C, 1976, J PROTOZOOL, V23, P552, DOI 10.1111/j.1550-7408.1976.tb03838.x; FENCHEL T, 1984, J EXP BIOL, V110, P17; FENCHEL T, 1986, J PROTOZOOL, V33, P69, DOI 10.1111/j.1550-7408.1986.tb05560.x; FOX HM, 1925, P CAMB PHIL SOC BIOL, V1, P219; FREIBERGER N, 1998, IN PRESS J EUKARYOT; Hader D-P, 1987, PLANT PHYSIOL, V6, P169; Hader DP, 1997, MICROGRAVITY SCI TEC, V10, P53; Hader DP, 1996, J BIOTECHNOL, V47, P261, DOI 10.1016/0168-1656(96)01374-0; HADER DP, 1987, ARCH MICROBIOL, V147, P179, DOI 10.1007/BF00415281; HADER DP, 1991, J MATH BIOL, V30, P63, DOI 10.1007/BF00168007; Hader DP, 1997, PLANTA, V203, pS7, DOI 10.1007/PL00008118; Hemmersbach R, 1996, J EXP BIOL, V199, P2199; Hemmersbach R, 1999, J PLANT PHYSIOL, V154, P1; Hemmersbach R, 1996, J BIOTECHNOL, V47, P271, DOI 10.1016/0168-1656(96)01337-5; Hemmersbach R, 1998, ADV SPACE RES-SERIES, V21, P1285, DOI 10.1016/S0273-1177(97)00400-6; HEMMERSBACH R, 1996, ESA SPECIAL PUBLICAT, P193; HEMMERSBACH R, 1998, ESA SP, V222; Hemmersbach-Krause R., 1992, Physiologist, V35, P23; HEMMERSBACHKRAUSE R, 1993, ACTA PROTOZOOL, V32, P229; HEMMERSBACHKRAUSE R, 1993, J EUKARYOT MICROBIOL, V40, P439, DOI 10.1111/j.1550-7408.1993.tb04937.x; HEMMERSBACHKRAUSE R, 1991, EUR J PROTISTOL, V27, P278, DOI 10.1016/S0932-4739(11)80065-9; Jennings H.S., 1906, BEHAV LOWER ORGANISM; Kessler J.O., 1986, PROG PHYCOL RES, V4, P258; Klaus DM, 1998, ADV SPACE RES, V21, P1315, DOI 10.1016/S0273-1177(97)00404-3; KUMEI Y, 1991, EXP CELL RES, V192, P492, DOI 10.1016/0014-4827(91)90068-6; KUZNICKI L, 1968, Acta Protozoologica, V6, P109; Lebert M, 1996, NATURE, V379, P590, DOI 10.1038/379590a0; Lebert M, 1997, J PLANT PHYSIOL, V150, P685, DOI 10.1016/S0176-1617(97)80284-2; Lebert M, 1997, J PLANT PHYSIOL, V150, P153, DOI 10.1016/S0176-1617(97)80195-2; Machemer H., 1985, Progress in Sensory Physiology, V5, P81; MACHEMER H, 1993, ARCH PROTISTENKD, V143, P285, DOI 10.1016/S0003-9365(11)80325-8; MACHEMER H, 1992, ACTA PROTOZOOL, V31, P185; Machemer H., 1993, Microgravity Science and Technology, V5, P221; MACHEMER H, 1991, J COMP PHYSIOL A, V168, P1, DOI 10.1007/BF00217099; MACHEMERROHNISCH S, 1993, J COMP PHYSIOL A, V171, P779, DOI 10.1007/BF00213074; MachemerRohnisch S, 1996, J COMP PHYSIOL A, V179, P213; MELI A, 1998, IN PRESS BIOCHIMIE; Moore A, 1903, AM J PHYSIOL, V9, P238, DOI 10.1152/ajplegacy.1903.9.4.238; MULLER HJ, 1959, SCIENCE, V128, P772; Naitoh Y., 1984, P113; Neubert J, 1998, ADV SPACE RES-SERIES, V22, P265, DOI 10.1016/S0273-1177(98)80018-5; NEUGEBAUER DC, 1997, CELL TISSUE RES, V287, P277; OOYA M, 1992, J EXP BIOL, V163, P153; Penard E., 1917, Revue Suisse de Zoologie, V25; RHIEL E, 1988, PLANT CELL PHYSIOL, V29, P755; RIEDER N, 1977, VERH DT ZOOL GES, V254; Schultz JE, 1997, J MEMBRANE BIOL, V156, P251, DOI 10.1007/s002329900205; SIEVERS A, 1979, ENCY PLANT PHYSL, V7, P567; STALLWITZ E, 1994, EUR J PROTISTOL, V30, P18, DOI 10.1016/S0932-4739(11)80194-X; Vogel K., 1993, Microgravity Science and Technology, V5, P232; WINET H, 1974, J THEOR BIOL, V46, P449, DOI 10.1016/0022-5193(74)90008-3	61	33	34	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S69	S75						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352147				2022-12-28	WOS:000080403800009
J	Simoneau, JA; Kelley, DE; Neverova, M; Warden, CH				Simoneau, JA; Kelley, DE; Neverova, M; Warden, CH			Overexpression of muscle uncoupling protein 2 content in human obesity associates with reduced skeletal muscle lipid utilization	FASEB JOURNAL			English	Article						UCP; body fat; substrate utilization; insulin sensitivity; energy expenditure	BROWN ADIPOSE-TISSUE; GENE-EXPRESSION; FATTY-ACIDS; INSULIN; THERMOGENESIS; LINKAGE; MARKERS; CLONING; HOMOLOG; HORMONE	Uncoupling proteins (UCP) may influence thermogenesis. Since skeletal muscle plays an important role in energy homeostasis and substrate oxidation, this study was undertaken to test the hypotheses that skeletal muscle UCP2 content is altered in obesity and could be linked to basal energy expenditure, insulin sensitivity, or substrate oxidation within skeletal muscle under postabsorptive (fasting) conditions. To examine these possibilities, limb basal energy expenditure and respiratory quotient (bRQ) were measured in 18 obese nondiabetic (Ob) and lean individuals (L). Total body fat (%) ranged from 11% to 46%, In addition, insulin-stimulated rates of glucose disposal (Rd) were measured under euglycemic hyperinsulinemic conditions. Biopsy of vastus lateralis muscle was used to measure cytochrome c oxidase (COX) enzyme activity and UCP2 content. Whereas low muscle COX activity was found in the Ob compared to L (6.9+/-1.6 vs, 9.6+/-1.2 U/g; P<0.001), skeletal muscle UCP2 content in Ob was significantly higher than in L (48+/-9 vs. 33+/-12 arbitrary units/g; P<0.05). Moreover, UCP2 content was positively correlated with percent of total body fat (r=0.57; P<0.05) and bRQ (r=0.59; P<0.01), but not with visceral fat (r=0.17; P=0.49), basal energy expenditure (r=0.07; P=0.79) or Rd (r=-0.23; P=0.34). In summary, these results indicate that if development of obesity in humans is mediated by defective expression of UCP2 within skeletal muscle, then this effect is not observed in people with established obesity. The present study also suggests that skeletal muscle UCP2 content is not related to basal energy expenditure or insulin sensitivity in humans, However, the increased content of UCP2 within skeletal muscle in obesity appears to coincide with a reduced postabsorptive lipid utilization by muscle.	Univ Laval, Dept Prevent & Social Med, Div Kinesiol, St Foy, PQ G1K 7P4, Canada; Univ Pittsburgh, Dept Endocrinol, Pittsburgh, PA 15261 USA; Univ Calif Davis, Rowe Program Genet, Livermore, CA 95616 USA; Univ Calif Davis, Dept Pediat, Livermore, CA 95616 USA; Univ Calif Davis, Dept Biol Chem, Livermore, CA 95616 USA; Univ Calif Davis, Dept Med, Livermore, CA 95616 USA	Laval University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Simoneau, JA (corresponding author), Univ Laval, Dept Prevent & Social Med, Div Kinesiol, St Foy, PQ G1K 7P4, Canada.	Jean-Aime.Simoneau@kin.msp.ulaval.ca			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052581, R01DK049200] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49200, DK52581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argyropoulos G, 1998, DIABETES, V47, P685, DOI 10.2337/diabetes.47.4.685; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; Elbein SC, 1997, DIABETES, V46, P2105, DOI 10.2337/diab.46.12.2105; EVANS WJ, 1982, MED SCI SPORT EXER, V14, P101; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HEATON JM, 1972, J ANAT, V112, P35; HIKADA S, 1998, BIOCHIM BIOPHYS ACTA, V1389, P178; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; KELLEY D, 1997, OBES RES, V5, pS21; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Lanni A, 1997, FEBS LETT, V418, P171, DOI 10.1016/S0014-5793(97)01375-6; Liu QY, 1998, GENE, V207, P1, DOI 10.1016/S0378-1119(97)00596-9; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Masaki T, 1997, FEBS LETT, V418, P323, DOI 10.1016/S0014-5793(97)01404-X; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Norman RA, 1997, AM J HUM GENET, V60, P166; Otabe S, 1998, DIABETES, V47, P840, DOI 10.2337/diabetes.47.5.840; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; Stich V, 1997, J CLIN ENDOCR METAB, V82, P739, DOI 10.1210/jc.82.3.739; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; THAETE FL, 1995, INT J OBESITY, V19, P464; Urhammer SA, 1997, DIABETOLOGIA, V40, P1227, DOI 10.1007/s001250050811; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; [No title captured]	40	52	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1739	1745		10.1096/fasebj.12.15.1739	http://dx.doi.org/10.1096/fasebj.12.15.1739			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837864				2022-12-28	WOS:000077574500016
J	Costa, C; Solanes, G; Visa, J; Bosch, F				Costa, C; Solanes, G; Visa, J; Bosch, F			Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus	FASEB JOURNAL			English	Article						bovine growth hormone; IGF; PEPCK; hyperglycemia	FUSION GENES; FACTOR-I; MICE; HISTOPATHOLOGY; EXPRESSION; METABOLISM; ACID; GH	Transgenic rabbits expressing the bovine growth hormone (bGH) gene in liver and kidney were obtained to study the long-term effects of chronic exposure to GH in nonrodent animals, These rabbits presented high levels of bGH and insulin-like growth factor I in serum. In spite of chronic exposure to bGH, transgenic rabbits had similar body weight to controls. However, enlargement of the head and limbs and reduction of visceral fat were observed in these animals. They also showed marked hyperinsulinemia, hyperglycemia, and hypertriglyceridemia, indicating that they developed insulin resistance, Furthermore, serious histopathological alterations, including marked fibrosis, were observed in liver, kidney, and skeletal muscle. These anatomical, metabolic, and histological alterations closely resemble those found in patients with acromegaly, Thus, transgenic rabbits overexpressing GH may be a good model of the human disease.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra, Spain	Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra, Spain.		Costa, Cristina/AAP-4005-2020	Costa, Cristina/0000-0002-1837-4268; BOSCH, FATIMA/0000-0002-7705-5515				BODEN G, 1968, METABOLISM, V17, P1, DOI 10.1016/S0026-0495(68)80002-2; BUHLER TA, 1990, BIO-TECHNOL, V8, P140, DOI 10.1038/nbt0290-140; CHANGDEMORANVILLE BM, 1992, ENDOCRIN METAB CLIN, V21, P649, DOI 10.1016/S0889-8529(18)30207-X; CHEN NY, 1995, ENDOCRINOLOGY, V136, P660, DOI 10.1210/en.136.2.660; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOUGLAS RG, 1990, BRIT J SURG, V77, P785, DOI 10.1002/bjs.1800770722; FROHMAN LA, 1991, J CLIN ENDOCR METAB, V72, P1175, DOI 10.1210/jcem-72-6-1175; GANDA OP, 1993, DIABETES REV, V1, P286; JADRESIC A, 1982, Q J MED NS L1, V202, P189; MASTAGLIA FL, 1973, ACTA NEUROPATHOL, V24, P273, DOI 10.1007/BF00685584; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MERIMEE TJ, 1995, PRINCIPLES PRACTICE; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; OSULLIVAN AJ, 1994, J CLIN ENDOCR METAB, V78, P381, DOI 10.1210/jc.78.2.381; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; PICKETT JBE, 1975, NEUROLOGY, V25, P638, DOI 10.1212/WNL.25.7.638; PINKERT CA, 1994, TRANSGENIC RES, V3, P401, DOI 10.1007/BF01976771; PRESS M, 1988, DIABETES METAB REV, V4, P391, DOI 10.1002/dmr.5610040406; Pursel V G, 1990, J Reprod Fertil Suppl, V40, P235; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RIEN M, 1982, J CLIN ENDOCR METAB, V55, P147; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SHEA BT, 1990, GENET RES, V56, P21, DOI 10.1017/S0016672300028846; Steele FR, 1996, NAT MED, V2, P369, DOI 10.1038/nm0496-369; THORNER MO, 1992, TXB ENDOCRINOLOGY; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; WASS JAH, 1980, CLIN ENDOCRINOL, V12, P53, DOI 10.1111/j.1365-2265.1980.tb03132.x; WIEGHART M, 1990, J REPROD FERTIL S, V41, P89; YUN JS, 1990, P SOC EXP BIOL MED, V194, P308	32	34	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1455	1460		10.1096/fasebj.12.14.1455	http://dx.doi.org/10.1096/fasebj.12.14.1455			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806754				2022-12-28	WOS:000076749500004
J	Muller, FU; Boknik, P; Knapp, J; Neumann, J; Vahlensieck, U; Oetjen, E; Scheld, HH; Schmitz, W				Muller, FU; Boknik, P; Knapp, J; Neumann, J; Vahlensieck, U; Oetjen, E; Scheld, HH; Schmitz, W			Identification and expression of a novel isoform of cAMP response element modulator in the human heart	FASEB JOURNAL			English	Article						cyclic AMP; transcription factor; DNA binding proteins; base sequence	TRANSCRIPTION FACTOR CREB; BINDING-PROTEIN CREB; GENE; SPERMATOGENESIS; CELLS; PHOSPHORYLATION; LOCALIZATION; INDUCIBILITY; ANTAGONIST; ACTIVATOR	In end-stage human heart failure, excessive beta-adrenergic stimulation of the cAMP-dependent signaling pathway due to enhanced endogenous catecholamines is hypothesized to contribute to expressional alterations of myocardial regulatory proteins. The cAMP response element modulator (CREM) regulates the transcription of cAMP-responsive genes and might be involved in the regulation of cardiac gem expression. Using the reverse transcription polymerase chain reaction, we identified a novel CREM mRNA, CREM-Ib Delta C-X, in the human heart. Overexpression of CREM-Ib Delta C-X decreased cAMP response element (CRE) -mediated gene transcription in HIT-T15 cells, and this activity was assigned to the part of the sequence encoding putative internally translated proteins. Two of three possible internally translated proteins were immunologically identified in cells overexpressing CREM-Ib Delta C-X tagged with the hemagglutinin epitope of the influenza virus. Both proteins were expressed in bacteria and showed CRE-specific DNA binding, formation of heterodimers with the cAMP response element binding protein (CREB), and inhibition of CREB's binding to the CRE. CREM expression was detected on the mRNA and protein levels in the human heart. We conclude that CREM-Ib Delta C-X generates internally translated repressors of CRE-mediated gem transcription, suggesting the first example for the existence and function of human cardiac CREM.-Muller, F. U., Boknik, P., Knapp, J., Neumann, J., Vahlensieck, U., Oetjen, E., Scheld, H. H., Schmitz, W. Identification and expression of a novel isoform of cAMP response element modulator in the human heart.	Univ Munster, Inst Pharmakol & Toxikol, D-48129 Munster, Germany; Univ Gottingen, Abt Mol Pharmakol, D-37070 Gottingen, Germany; Univ Munster, Klin & Poliklin Thorax Herz & Gefasschirug, D-48129 Munster, Germany	University of Munster; University of Gottingen; University of Munster	Muller, FU (corresponding author), Univ Munster, Inst Pharmakol & Toxikol, Domagkstr 12, D-48129 Munster, Germany.	mullerf@uni-muenster.de						BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMOLLE D, 1990, MOL PHARMACOL, V37, P827; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; Girardet C, 1996, MOL ENDOCRINOL, V10, P879, DOI 10.1210/me.10.7.879; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MASQUILIER D, 1993, CELL GROWTH DIFFER, V4, P931; MEYER TE, 1992, NUCLEIC ACIDS RES, V20, P6106, DOI 10.1093/nar/20.22.6106; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOTOMURA S, 1990, BRIT J PHARMACOL, V101, P363, DOI 10.1111/j.1476-5381.1990.tb12715.x; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; MULLER FU, 1993, CIRC RES, V72, P696, DOI 10.1161/01.RES.72.3.696; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WAEBER G, 1992, ENDOCRINOLOGY, V131, P2010, DOI 10.1210/en.131.4.2010; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423	28	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1191	1199						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737722				2022-12-28	WOS:000075738500014
J	Muralikrishnan, D; Mohanakumar, KP				Muralikrishnan, D; Mohanakumar, KP			Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice	FASEB JOURNAL			English	Article						MPTP; hydroxyl radicals; dopamine neurotoxicity; neuroprotection; GSH; free radical scavenger; antioxidant enzymes	OXYGEN RADICAL FORMATION; HYDROXYL FREE-RADICALS; MPTP-TREATED MICE; LIPID-PEROXIDATION; PARKINSONS-DISEASE; MONOAMINE-OXIDASE; SUBSTANTIA-NIGRA; RECEPTOR AGONISTS; MPP(+) TOXICITY; MOUSE-BRAIN	Mice were treated with l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg i.p. twice, 16 h apart), This resulted in changes in motor performance and toxic insult of nigral neurons as evidenced by dopamine depletion in nucleus caudatus putamen, In vitro and in vivo treatment of MPTP caused the generation of hydroxyl radicals ( OH) as measured by a sensitive salicylate hydroxylation procedure, A dopamine agonist, bromocriptine (10 mu M and 10 mg/kg i,p.), blocked OH formation caused by MPTP in vitro (20 mu M) and in vivo (30 mg/kg i,p,), An MPTP-induced increase in the activity of catalase and superoxide dismutase in substantia nigra on the seventh day was reduced by bromocriptine pretreatment, Bromocriptine blocked MPTP-induced behavioral dysfunction as well as glutathione and dopamine depletion, indicating its potent neuroprotective action, This study suggests that bromocriptine stimulates antioxidant mechanisms in the brain and acts as a free radical scavenger in addition to its action at dopamine receptors, thus indicating its strength as a valuable neuroprotectant, -Muralikrishnan, D., Mohanakumar, K. P. Neuroprotection by bromocriptine against 1-methyl-4-phhenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.	Indian Inst Chem Biol, Div Pharmacol & Expt Therapeut, Neurochem Lab, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Muralikrishnan, D (corresponding author), Indian Inst Chem Biol, Div Pharmacol & Expt Therapeut, Neurochem Lab, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.		Mohanakumar, Kochupurackal P/ABE-8492-2020	Mohanakumar, Kochupurackal P/0000-0002-4985-1100				ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P181, DOI 10.1016/0891-5849(93)90057-2; AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; ARAI N, 1995, J NEURAL TRANSM-PARK, V10, P55, DOI 10.1007/BF02256629; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BURKI HR, 1978, J PHARM PHARMACOL, V30, P261; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; CALNE DB, 1974, BMJ-BRIT MED J, V4, P442, DOI 10.1136/bmj.4.5942.442; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; CHIUEH CC, 1994, ANN NY ACAD SCI, V738, P25; CLEMENS JA, 1994, ANN NY ACAD SCI, V738, P250; COHEN G, 1974, J BIOL CHEM, V249, P2447; COHN VH, 1966, ANAL BIOCHEM, V14, P434, DOI 10.1016/0003-2697(66)90286-7; DESOLE MS, 1993, NEUROSCI LETT, V161, P121, DOI 10.1016/0304-3940(93)90274-O; DEXTER D, 1986, LANCET, V2, P639; DEXTER DT, 1987, LANCET, V2, P1219; FELTEN DL, 1992, NEUROBIOL AGING, V13, P339, DOI 10.1016/0197-4580(92)90048-3; FREDRIKSSON A, 1994, PHARMACOL TOXICOL, V75, P36, DOI 10.1111/j.1600-0773.1994.tb00321.x; GAGNON C, 1990, EUR J PHARMACOL, V178, P115, DOI 10.1016/0014-2999(90)94802-5; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; JACKSON DM, 1988, PSYCHOPHARMACOLOGY, V95, P433; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; KISH SJ, 1985, NEUROSCI LETT, V58, P343, DOI 10.1016/0304-3940(85)90078-3; KONDO T, 1994, ANN NY ACAD SCI, V738, P222; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARZATICO F, 1993, NEUROCHEM RES, V18, P1101, DOI 10.1007/BF00966691; MITRA N, 1992, BRAIN RES BULL, V28, P355, DOI 10.1016/0361-9230(92)90035-V; MITRA N, 1994, J NEUROCHEM, V62, P1906; MIZUNO Y, 1988, NEUROSCI LETT, V91, P349, DOI 10.1016/0304-3940(88)90705-7; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; Mohanakumar K.P., 1994, NEW TRENDS CLIN NEUR, V8, P50, DOI [10.1111/j.1749-6632.1994.tb21828.x, DOI 10.1111/J.1749-6632.1994.TB21828.X]; MOHANAKUMAR KP, 1994, ANN NY ACAD SCI, V738, P392; MOHANAKUMAR KP, 1990, NEUROSCI LETT, V120, P91, DOI 10.1016/0304-3940(90)90175-9; NAKAMURA H, 1989, ACTA NEUROPATHOL, V77, P489, DOI 10.1007/BF00687250; OBATA T, 1992, J NEURAL TRANSM-GEN, V89, P139, DOI 10.1007/BF01245361; OGAWA N, 1994, BRAIN RES, V657, P207, DOI 10.1016/0006-8993(94)90969-5; OISHI T, 1993, J NEURAL TRANSM-PARK, V6, P45, DOI 10.1007/BF02252622; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; PRZEDBORSKI S, 1995, MOVEMENT DISORD, V10, P312, DOI 10.1002/mds.870100314; SZIRAKI I, 1998, IN PRESS NEUROSCIENC; TEMLETT JA, 1994, J NEUROCHEM, V62, P134; THIFFAULT C, 1995, J NEUROCHEM, V65, P2725; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; WEIHMULLER FB, 1988, NEUROSCI LETT, V85, P137, DOI 10.1016/0304-3940(88)90443-0; WU RM, 1994, ANN NY ACAD SCI, V738, P214; Wullner U, 1996, NEUROREPORT, V7, P921; YOSHIKAWA T, 1994, J NEUROCHEM, V62, P1034; ZANG LY, 1993, J BIOL CHEM, V268, P16504	51	198	203	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					905	912		10.1096/fasebj.12.10.905	http://dx.doi.org/10.1096/fasebj.12.10.905			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657530				2022-12-28	WOS:000074580100015
J	Nicol, CJ; Zielenski, J; Tsui, LC; Wells, PG				Nicol, CJ; Zielenski, J; Tsui, LC; Wells, PG			An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis	FASEB JOURNAL			English	Article						reactive oxygen species; development; birth defects; phenytoin; human risk	G6PD DEFICIENCY; PHENYTOIN; MALARIA; ENZYME; GLUTATHIONE; METABOLISM; CATALASE; EMBRYOS; DAMAGE; RAT	The primary recognised health risk from common deficiencies in glucose-6-phosphate dehydrogenase (G6PD), a cytoprotective enzyme for oxidative stress, is red blood cell hemolysis. Here we show that litters from untreated pregnant mutant mice with a hereditary G6PD deficiency had increased prenatal death. When treated with the anticonvulsant drug phenytoin, a human teratogen that is commonly used in pregnant women and causes embryonic oxidative stress, G6PD-deficient dams had higher embryonic DNA oxidation and more fetal death and birth defects. The reported G6PD gene mutation was confirmed and used to genotype fetal resorptions, which were primarily G6PD deficient. This is the first evidence that G6PD is a developmentally critical cytoprotective enzyme for both endogenous and xenobiotic-initiated embryopathic oxidative stress and DNA damage. G6PD deficiencies accordingly may have a boarder biological relevance as important determinants of infertility, in utero and postnatal death, and teratogenesis.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.		Tsui, Lap-chee/A-1081-2010					ABUOSBA YK, 1989, J PEDIATR-US, V114, P748, DOI 10.1016/S0022-3476(89)80131-3; AKSU O, 1968, TERATOLOGY, V1, P93, DOI 10.1002/tera.1420010110; ALTMAN PL, 1972, BIOL DATA BOOK, P176; BALAZS L, 1994, NEUROCHEM RES, V19, P1131, DOI 10.1007/BF00965146; Beutler E, 1996, BLOOD CELL MOL DIS, V22, P49, DOI 10.1006/bcmd.1996.0008; BEUTLER E, 1993, AM J HEMATOL, V42, P53, DOI 10.1002/ajh.2830420111; BEUTLER E, 1959, BLOOD, V14, P103, DOI 10.1182/blood.V14.2.103.103; BEUTLER E, 1986, GLUCOSE 6 PHOSPHATE, P3; BURT AM, 1961, DEV BIOL, V3, P84, DOI 10.1016/0012-1606(61)90011-2; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; CLOUGH JR, 1983, J EMBRYOL EXP MORPH, V74, P133; Cooper AJL, 1997, BIOL CHEM, V378, P793; ECKMAN JR, 1979, NATURE, V278, P754, DOI 10.1038/278754a0; EDWARDS RG, 1959, J EXP ZOOL, V141, P299, DOI 10.1002/jez.1401410206; Erel O, 1997, CLIN BIOCHEM, V30, P631, DOI 10.1016/S0009-9120(97)00119-7; FINNELL RH, 1984, AM J MED GENET, V19, P463, DOI 10.1002/ajmg.1320190307; FRIEDMAN MJ, 1979, NATURE, V280, P245, DOI 10.1038/280245a0; Ganshirt D, 1998, FETAL DIAGN THER, V13, P276, DOI 10.1159/000020854; Graf WD, 1995, EUR J PEDIATR SURG, V5, P8, DOI 10.1055/s-2008-1066253; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUYTON AC, 1987, HUMAN PHYSL MECH DIS, P195; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Jenner P, 1996, PATHOL BIOL, V44, P57; JOLLEY RL, 1958, J BIOL CHEM, V233, P1289; JOLLEY RL, 1959, BIOCHIM BIOPHYS ACTA, V33, P64, DOI 10.1016/0006-3002(59)90498-6; Kim PM, 1996, MOL PHARMACOL, V49, P172; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KOSOWER NS, 1970, LANCET, V2, P1343; LAPOSA RR, 1995, TOXICOLOGIST, V15, P161; LAPOSA RR, 1996, FUNDAM APPL TOXIC S1, V30, P195; Lucas AM, 1961, ATLAS AVIAN HEMATOLO, P17; LUZZATTO L, 1995, METABOLIC MOL BASIS, V7, P3367; Martini G, 1996, BIOESSAYS, V18, P631, DOI 10.1002/bies.950180806; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MAYES PA, 1996, HARPERS BIOCH, P216; MEHTA AB, 1994, POSTGRAD MED J, V70, P871, DOI 10.1136/pgmj.70.830.871; NEWBURGH RW, 1962, ARCH BIOCHEM BIOPHYS, V97, P94, DOI 10.1016/0003-9861(62)90048-6; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PAPACONSTANTINO.J, 1967, BIOCH ANIMAL DEV, V2, P57; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; PRETSCH W, 1988, BIOCHEM GENET, V26, P89, DOI 10.1007/BF00555491; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; Robkin MA, 1997, INT J DEV BIOL, V41, P283; ROTH EF, 1983, P NATL ACAD SCI-BIOL, V80, P298, DOI 10.1073/pnas.80.1.298; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Sanders S, 1997, MUTAT RES-FUND MOL M, V374, P79, DOI 10.1016/S0027-5107(96)00222-9; SHIGENAGA MK, 1991, FREE RADICAL BIO MED, V10, P211, DOI 10.1016/0891-5849(91)90078-H; SINCLAIR AJ, 1975, P NUTR SOC, V34, P287, DOI 10.1079/PNS19750051; SINGH M, 1989, TERATOLOGY, V40, P453, DOI 10.1002/tera.1420400507; SMITH JE, 1976, ENZYME, V21, P379, DOI 10.1159/000458882; SODEINDE O, 1992, BAILLIERE CLIN HAEM, V5, P367, DOI 10.1016/S0950-3536(11)80024-7; TANIMURA T, 1970, P SOC EXP BIOL MED, V135, P51; Ursini MV, 1997, BIOCHEM J, V323, P801, DOI 10.1042/bj3230801; WASHINGTON EC, 1995, SOUTHERN MED J, V88, P776, DOI 10.1097/00007611-199507000-00019; WEBER GF, 1991, LANCET, V337, P1443, DOI 10.1016/0140-6736(91)93130-2; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; Wells PG, 1997, MUTAT RES-FUND MOL M, V396, P65, DOI 10.1016/S0027-5107(97)00175-9; WELLS PG, 1996, HDB EXPT PHARM DRU 1, V124, P453; WERTH G, 1967, KLIN WOCHENSCHR, V45, P265, DOI 10.1007/BF01747608; WEST JD, 1993, HUM REPROD, V8, P1316, DOI 10.1093/oxfordjournals.humrep.a138249; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; Winn LM, 1995, EUR J NEUROL, V2, P5; WINN LM, 1995, MOL PHARMACOL, V48, P112; YUTHAVONG Y, 1990, BLOOD CELLS, V16, P591; Zollo M, 1993, DNA Seq, V3, P319, DOI 10.3109/10425179309020830	70	142	148	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					111	127		10.1096/fasebj.14.1.111	http://dx.doi.org/10.1096/fasebj.14.1.111			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627286				2022-12-28	WOS:000084784700014
J	Haase, H; Podzuweit, T; Lutsch, G; Hohaus, A; Kostka, S; Lindschau, C; Kott, M; Kraft, R; Morano, I				Haase, H; Podzuweit, T; Lutsch, G; Hohaus, A; Kostka, S; Lindschau, C; Kott, M; Kraft, R; Morano, I			Signaling from beta-adrenoceptor to L-type calcium channel: identification of a novel cardiac protein kinase A target possessing similarities to AHNAK	FASEB JOURNAL			English	Article						cAMP kinase; protein phosphorylation; cardiomyocytes	HUMAN GENE AHNAK; CAMP-DEPENDENT PHOSPHORYLATION; SUBUNIT HETEROGENEITY; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; CA2+ CHANNELS; MUSCLE; HEART; BRAIN; RAT	A novel calcium channel-associated protein of similar to 700 kDa has been identified in mammalian cardiomyocytes that undergoes substantial cAMP-dependent protein kinase (PKA) phosphorylation. It was therefore designated as phosphoprotein 700 (pp700). The pp700 interacts specifically with the beta(2) subunit of cardiac L-type calcium channels as revealed by coprecipitation experiments using affinity-purified antibodies against different calcium channel subunits. It is surprising that amino acid sequence analysis of pig pp700 revealed homology to AHNAK-encoded protein, which was originally identified in human cell lines of neural crest origin as 700-kDa phosphoprotein. Cardiac AHNAK expression was assessed on mRNA level by reverse transcriptase-polymerase chain reaction. Sequence-directed antibodies raised against human AHNAK recognized pp700 in immunoblotting and immunoprecipitation experiments, confirming the homology between both proteins. Anti-AHNAK antibodies labeled preferentially the plasma membrane of cardiomyocytes in cryosections of rat cardiac tissue and isolated cardiomyocytes. Sarcolemmal pp700/AHNAK localization was not influenced by stimulation of either the PKA or the protein kinase C pathway. In back-phosphorylation studies with cardiac biopsies, we identified distinct pp700 pools. The membrane-associated fraction of pp700 underwent substantial in vivo phosphorylation on beta-adrenergic receptor stimulation by isoproterenol, whereas the cytoplasmic fraction of pp700 was not accessible to endogenous PKA. It is important that in vivo phosphorylation occurred in that pp700 fraction which coprecipitated with the calcium channel beta subunit. We hypothesize that both phosphorylation of pp700 and its coupling to the beta subunit play a physiological role in cardiac beta-adrenergic signal transduction.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Physiol & Clin Res, D-6350 Bad Nauheim, Germany; Humboldt Univ, Franz Volhard Clin, Max Delbruck Ctr Mol Med, Berlin, Germany; Humboldt Univ, Inst Physiol, Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Humboldt University of Berlin	Morano, I (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	imorano@mdc-berlin.de	Lindschau, Carsten/G-1798-2011; Lindschau, Carsten/AAE-6721-2020	Lindschau, Carsten/0000-0003-1960-099X; 				CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; Charnet P, 1995, BIOCHIMIE, V77, P957, DOI 10.1016/0300-9084(95)80008-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dai SP, 1999, FEBS LETT, V442, P70, DOI 10.1016/S0014-5793(98)01632-9; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gollasch M, 1998, FASEB J, V12, P593, DOI 10.1096/fasebj.12.7.593; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1996, J MOL MED-JMM, V74, P99; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Hase H, 1996, MOL CELL BIOCHEM, V164, P99, DOI 10.1007/BF00408645; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kameyama A, 1996, J BIOCHEM-TOKYO, V120, P170; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; Kraft R, 1997, SPRING LAB MAN, P61; Lutsch G, 1997, CIRCULATION, V96, P3466; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; PEREZREYES E, 1994, FEBS LETT, V342, P119, DOI 10.1016/0014-5793(94)80484-2; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PODZUWEIT T, 1980, BASIC RES CARDIOL, V75, P772, DOI 10.1007/BF01910455; PODZUWEIT T, 1982, EARLY ARRHYTHMIAS RE, P171; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; REUTER H, 1974, J PHYSIOL-LONDON, V242, P429, DOI 10.1113/jphysiol.1974.sp010716; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; Vetter R, 1998, MOL CELL BIOCHEM, V188, P177, DOI 10.1023/A:1006850724830; Vogt AM, 1996, BASIC RES CARDIOL, V91, P389; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; ZONG XG, 1995, PFLUG ARCH EUR J PHY, V430, P340, DOI 10.1007/BF00373908	41	60	65	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2161	2172		10.1096/fasebj.13.15.2161	http://dx.doi.org/10.1096/fasebj.13.15.2161			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593863				2022-12-28	WOS:000084310800007
J	Henley, JR; Cao, H; McNiven, MA				Henley, JR; Cao, H; McNiven, MA			Participation of dynamin in the biogenesis of cytoplasmic vesicles	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		TEMPERATURE-SENSITIVE MUTANT; GTP-BINDING PROTEINS; TRANS-GOLGI NETWORK; MEDIATED ENDOCYTOSIS; REVERSIBLE BLOCKAGE; MEMBRANE RETRIEVAL; MAMMALIAN-CELLS; MICROTUBULES; DROSOPHILA; CLATHRIN	Dynamin is a 100-kDa GTPase that has been implicated in endocytosis, To extend our understanding of its cellular functions, we have microinjected specific affinity-purified anti-dynamin antibodies into cultured mammalian epithelial cells, Using this approach, dynamin function can be inhibited specifically and rapidly in single cells. Effects of microinjected inhibitory antibodies on distinct endocytic processes and plasmalemmal morphology were then assayed by fluorescence microscopy (FM) and ultrastructural analysis. Microinjected antibodies inhibit the clathrin-mediated endocytosis of fluorophore-labeled transferrin and cause a marked imagination of the plasma membrane. Many of these long plasmalemmal invaginations had clathrin-coated pits along their cytoplasmic surface. A number of distinct noncoated pits resembling plasmalemmal caveolae also accumulated in anti-dynamin antibody-injected cells, Further, the cellular uptake of cholera toxin B, which normally occurs by the internalization of caveolae, was inhibited in these cells. In support of these observations, immunoisolation techniques, double-label immuno-FM, and immunoelectron microscopy (immuno-EM) provided biochemical and morphological evidence that dynamin associates with plasmalemmal caveolae. Together, these observations indicate that dynamin mediates scission from the plasma membrane of both clathrin-coated pits and caveolae during distinct endocytic processes. These results demonstrate that dynamin isoforms are involved in an additional endocytic process that is distinct from clathrin-mediated endocytosis and provide significant insights into the molecular mechanisms governing the GTP-mediated internalization of caveolae, Evidence is provided demonstrating that dynamin isoforms have a differential distribution in mammalian cells. Targeting information for these isoforms is provided at least in part by regions of alternative splicing. Thus, the different dynamin isoforms may be localized to distinct cellular compartments but provide a similar scission function during the biogenesis of nascent cytoplasmic vesicles.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.		Henley, John/D-7171-2011	Henley, John/0000-0003-1846-5941				Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Radhakrishna H., 1993, Molecular Biology of the Cell, V4, p211A; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VANDEURS B, 1993, TRENDS CELL BIOL, V3, P241; Warnock DE, 1997, MOL BIOL CELL, V8, P2553, DOI 10.1091/mbc.8.12.2553; WATTS C, 1992, J CELL SCI, V103, P1; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5	42	46	47	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S243	S247		10.1096/fasebj.13.9002.S243	http://dx.doi.org/10.1096/fasebj.13.9002.S243			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619136				2022-12-28	WOS:000084390200014
J	Jorquera, R; Tanguay, RM				Jorquera, R; Tanguay, RM			Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis	FASEB JOURNAL			English	Article						cell cycle; caspase; cytochrome c; glutathione; cell death	TYROSINEMIA TYPE-I; DNA-DAMAGE CHECKPOINT; CELL-CYCLE; HEREDITARY TYROSINEMIA; CYTOCHROME-C; FLOW-CYTOMETRY; GLUTATHIONE; P34(CDC2); INDUCTION; ENZYME	Hereditary tyrosinemia type I is the most severe metabolic disease of the tyrosine catabolic pathway mainly affecting the liver. It is caused by deficiency of fumarylacetoacetate hydrolase, which prevents degradation of the toxic metabolite fumarylacetoacetate (FAA). We report here that FAA induces common effects (i.e., cell cycle arrest and apoptosis) in both human (HepG2) and rodent (Chinese hamster V79) cells, effects that seem to be temporally related. Both the antiproliferative and apoptosis-inducing activities of FAA are dose dependent and enhanced by glutathione (GSH) depletion with L-buthionine-(S,R)-sulfoximine (BSO). Short treatment (2 h) with 35 mu M FAA/+BSO or 100 mu M FAA/-BSO induced a transient cell cycle arrest at the G2/M transition (20% and 37%, respectively) 24 h post-treatment. In cells treated with 100 mu M FAA/-BSO, an inactivation, followed by a rapid over-induction of cyclin B-dependent kinase occurred, which peaked 24 h post-treatment. Maximum levels of caspase-1 and caspase-3 activation were detected at 3 h and 32 h, respectively, whereas release of mitochondrial cytochrome c was maximal at 24-32 h post-treatment. The G2/M peak declined 24 h later, concomitantly with the appearance of a sub-G I, apoptotic population showing typical nucleosomal-sized DNA fragmentation and reduced mitochondrial transmembrane potential (Delta psi(m)). These events were prevented by the general caspase inhibitor z-VAD-fmk, whereas G2/M arrest and subsequent apoptosis were abolished by GSH-monoethylester or N-acetylcysteine. Other tyrosine metabolites, maleylacetoacetate and succinylacetone, had no antiproliferative effects and induced only very low levels of apoptosis. These results suggest a modulator role of GSH in FAA-induced cell cycle disturbance and apoptosis Ft here activation of cyclin B-dependent kinase and caspase-1 are early events preceding mitochondrial cytochrome c release, caspase-3 activation, and Delta psi(m) loss.	Univ Laval, Lab Cell & Dev Genet, Dept Med, St Foy, PQ G1K 7P4, Canada; CHU Laval, Res Ctr, St Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Tanguay, RM (corresponding author), Univ Laval, Lab Cell & Dev Genet, Dept Med, Pav CE Marchand, St Foy, PQ G1K 7P4, Canada.							Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DUKE RC, 1992, CURR PROT IMMUNOL, V1; EDGREN M, 1981, INT J RADIAT BIOL, V40, P355, DOI 10.1080/09553008114551311; EDWARDS SW, 1955, METHOD ENZYMOL, V2, P292; Endo F, 1997, J BIOL CHEM, V272, P24426, DOI 10.1074/jbc.272.39.24426; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GORCZYCA W, 1993, CANCER RES, V53, P3186; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; Kubo S, 1998, P NATL ACAD SCI USA, V95, P9552, DOI 10.1073/pnas.95.16.9552; Laberge C., 1986, Essential nutrients in carcinogenesis, P209; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitchell G, 1995, METABOLIC MOL BASES, P1077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; Poon RYC, 1997, CANCER RES, V57, P5168; Prieto-Alamo MJ, 1998, P NATL ACAD SCI USA, V95, P12614, DOI 10.1073/pnas.95.21.12614; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; StLouis M, 1997, HUM MUTAT, V9, P291, DOI 10.1002/(SICI)1098-1004(1997)9:4<291::AID-HUMU1>3.0.CO;2-9; STONER E, 1984, PEDIATR RES, V18, P1332, DOI 10.1203/00006450-198412000-00023; TANGUAY RM, 1990, AM J HUM GENET, V47, P308; Tanguay RM, 1996, ACTA BIOCHIM POL, V43, P209; Ueda S, 1998, J IMMUNOL, V161, P6689; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4; WHITACRE CM, 1995, CANCER RES, V55, P3697; Yao SL, 1996, CANCER RES, V56, P4551	49	52	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2284	2298		10.1096/fasebj.13.15.2284	http://dx.doi.org/10.1096/fasebj.13.15.2284			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593876				2022-12-28	WOS:000084310800020
J	Van Hooser, AA; Mancini, MA; Allis, CD; Sullivan, KF; Brinkley, RB				Van Hooser, AA; Mancini, MA; Allis, CD; Sullivan, KF; Brinkley, RB			The mammalian centromere: structural domains and the attenuation of chromatin modeling	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		INNER KINETOCHORE PLATE; ALPHA-SATELLITE DNA; HISTONE ACETYLATION; CENP-A; CHROMOSOME CONDENSATION; METAPHASE CHROMOSOMES; H3; PHOSPHORYLATION; SCLERODERMA; PROTEIN	The centromere-kinetochore complex can be divided into distinct domains based on structure and function. Previous work has used CREST auto-antibodies with various microscopic techniques to map the locations of proteins within the centromere-kinetochore complex and to analyze the maturation of prekinetochores before mitosis, Here we have focused on the centromere-specific histone Centromere Protein (CENP)-A and its spatial relationship to other histones and histone modifications found in condensed chromatin. We demonstrate that the phosphorylation of histone H3 is essentially excluded from a specific region of centromeric chromatin, defined by the presence of CENP-A, Interspersion of CENP-B with phosphorylated H3 in the inner centromere indicates that the exclusion of H3 modification is not a general property of cc-satellite DNA, We also demonstrate that these regions are functionally distinct by fragmenting mitotic chromatin into motile centromere-kinetochore fragments that contain CENP-A with little or no phosphorylated H3 and nonmotile fragments that contain exclusively phosphorylated H3, The sequence of CENP-A diverges from H3 in a number of key residues involved in chromosome condensation and in transcription, potentially allowing a more specialized chromatin structure within centromeric heterochromatin, on which kinetochore plates may nucleate and mature. This specialized centromere subdomain would be predicted to have a very tight and static nucleosome structure as a result of the absence of H3 phosphorylation and acetylation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Charlottesville, VA 22908 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Baylor College of Medicine; University of Virginia; Scripps Research Institute	Brinkley, RB (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.			Sullivan, Kevin/0000-0002-5374-8245	NATIONAL CANCER INSTITUTE [R01CA041424, R37CA041424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039068, R29GM039068, R01GM040922] Funding Source: NIH RePORTER; NCI NIH HHS [CA41424] Funding Source: Medline; NIGMS NIH HHS [GM40922, GM39068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belyaev ND, 1996, HUM GENET, V97, P573; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brinkley B R, 1992, Trends Cell Biol, V2, P15, DOI 10.1016/0962-8924(92)90139-E; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; BRINKLEY BR, 1988, NATURE, V336, P251, DOI 10.1038/336251a0; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; Csink AK, 1998, TRENDS GENET, V14, P200, DOI 10.1016/S0168-9525(98)01444-9; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Faulkner NE, 1998, HUM MOL GENET, V7, P671, DOI 10.1093/hmg/7.4.671; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; HANKS SK, 1983, EXP CELL RES, V148, P293, DOI 10.1016/0014-4827(83)90153-2; He DC, 1998, CHROMOSOMA, V107, P189, DOI 10.1007/s004120050296; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; SULLIVAN KF, 1998, MECH CELL DIVISION F; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Vafa O, 1997, CURR BIOL, V7, P897, DOI 10.1016/S0960-9822(06)00381-2; VALDIVIA MM, 1985, J CELL BIOL, V101, P1124, DOI 10.1083/jcb.101.3.1124; Van Hooser A, 1999, METHOD CELL BIOL, V61, P57; Van Hooser A, 1998, J CELL SCI, V111, P3497; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Wolffe AP, 1996, TRENDS GENET, V12, P58, DOI 10.1016/0168-9525(96)81401-6	43	38	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S216	S220		10.1096/fasebj.13.9002.S216	http://dx.doi.org/10.1096/fasebj.13.9002.S216			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619130				2022-12-28	WOS:000084390200008
J	Garrido, C; Bruey, JM; Fromentin, A; Hammann, A; Arrigo, AP; Solary, E				Garrido, C; Bruey, JM; Fromentin, A; Hammann, A; Arrigo, AP; Solary, E			HSP27 inhibits cytochrome c-dependent activation of procaspase-9	FASEB JOURNAL			English	Article						apoptosis; cell death; etoposide; drug resistance; leukemia	HEAT-SHOCK-PROTEIN; INDUCED CELL-DEATH; ETOPOSIDE-INDUCED APOPTOSIS; TNF-ALPHA; DOXORUBICIN RESISTANCE; BREAST-CANCER; BCL-2; EXPRESSION; RELEASE; DNA	We have previously shown that the small heat shock protein HSP27 inhibited apoptotic pathways triggered by a variety of stimuli in mammalian cells. The present study demonstrates that HSP27 overexpression decreases U937 human leukemic cell sensitivity to etoposide-induced cytotoxicity by preventing apoptosis. As observed for Bcl-2, HSP27 overexpression delays poly(ADP-ribose)polymerase cleavage and procaspase-3 activation. In contrast with Bcl-2, HSP27 overexpression does not prevent etoposide-induced cytochrome c release from the mitochondria. In a cell-free system, addition of cytochrome c and dATP to cytosolic extracts from untreated cells induces the proteolytic activation of procaspase-3 in both control and bcl-2-transfected U937 cells but fails to activate procaspase-3 in HSP27-overexpressing cells. Immunodepletion of HSP27 from cytosolic extracts increases cytochrome c/dATP-mediated activation of procaspase-3. Overexpression of HSP27 also prevents procaspase-9 activation. In the cell-free system, immunodepletion of HSP27 increases LEDH-AFC peptide cleavage activity triggered by cytochrome c/dATP treatment. We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATP-triggered activity of caspase-9, downstream of cytochrome c release.-Garrido, C., Bruey, J.-M., Fromentin, A., Hammann, A,, Arrigo, A. P., Solary, E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9.	Fac Med & Pharm Dijon, INSERM U517, Grp Biol & Therapie Canc JE 515, F-21033 Dijon, France; Univ Lyon 1, Stress Lab, CNRS UMR 5534, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Garrido, C (corresponding author), Fac Med & Pharm Dijon, INSERM U517, Grp Biol & Therapie Canc JE 515, 7 Blvd Jeanne DArc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022	Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; CHAMPLIN R, 1987, BLOOD, V69, P1551; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HARRISON JD, 1991, BRIT J SURG, V78, P334, DOI 10.1002/bjs.1800780321; HOUT J, 1992, INT J ONCOL, V1, P31; HOUT J, 1996, CANCER RES, V56, P273; HUOT J, 1991, CANCER RES, V51, P5245; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140; Marchetti P, 1996, CANCER RES, V56, P2033; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OESTERREICH S, 1993, CANCER RES, V53, P4443; PARSELL DA, 1990, BIOL HEAT SHOCK PROT, P457; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SOLARY E, 1991, LEUKEMIA, V5, P592; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	51	427	449	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2061	2070		10.1096/fasebj.13.14.2061	http://dx.doi.org/10.1096/fasebj.13.14.2061			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544189				2022-12-28	WOS:000083660700018
J	Martinez-Botas, J; Suarez, Y; Ferruelo, AJ; Gomez-Coronado, D; Lasuncion, MA				Martinez-Botas, J; Suarez, Y; Ferruelo, AJ; Gomez-Coronado, D; Lasuncion, MA			Cholesterol starvation decreases P34(cdc2) kinase activity and arrests the cell cycle at G2	FASEB JOURNAL			English	Article						SKF 104976; cholesterol synthesis; cell proliferation; low density lipoprotein; caffeine	DENSITY-LIPOPROTEIN RECEPTOR; SMOOTH-MUSCLE CELLS; DIPHOSPHATE SYNTHASE GENE; CDC2 PROTEIN-KINASE; HMG-COA REDUCTASE; LYMPHOCYTE-PROLIFERATION; S-PHASE; MEVALONATE PATHWAY; MOLECULAR-CLONING; STEROL SYNTHESIS	As a major component of mammalian cell plasma membranes, cholesterol is essential for cell growth. Accordingly, the restriction of cholesterol provision has been Shown to result in cell proliferation inhibition. We explored the potential regulatory role of cholesterol on cell cycle progression. MOLT-4 and HL-60 cell lines were cultured in a cholesterol-deficient medium and simultaneously exposed to SKF 104976, which is a specific inhibitor of lanosterol 14-alpha demethylase. Through HPLC analyses with on-line radioactivity detection, we found that SKF 104976 efficiently blocked the [C-14]-acetate incorporation into cholesterol, resulting in an accumulation of lanosterol and dihydrolanosterol, without affecting the synthesis of mevalonic acid. The inhibitor also produced a rapid and intense inhibition of cell proliferation (IC50 = 0.1 mu M), as assessed by both [H-3]-thymidine incorporation into DNA and cell counting. Flow cytometry and morphological examination showed that treatment with SKF 104976 for 48 h or longer resulted in the accumulation of cells specifically at G2 phase, whereas both the GI traversal and the transition through S were unaffected. The G2 arrest was accompanied by an increase in the hyperphosphorylated form of p34(cdc2) and a reduction of its activity, as determined by assaying the H1 histone phosphorylating activity of p34(cdc2) immunoprecipitates. The persistent deficiency of cholesterol induced apoptosis. However, supplementing the medium with cholesterol, either in the form of LDL or free cholesterol dissolved in ethanol, completely abolished these effects, whereas mevalonate was ineffective. Caffeine, which abrogates the G2 checkpoint by preventing p34(cdc2) phosphorylation, reduced the accumulation in G2 when added to cultures containing cells on transit to G2, but was ineffective in cells arrested at G2 by sustained cholesterol starvation. Cells arrested in G2, however, were still viable and responded to cholesterol provision by activating p34(cdc2) and resuming the cell cycle. We conclude that in both lymphoblastoid and promyelocytic cells, cholesterol availability governs the G2 traversal, probably by affecting p34(cdc2) activity.	Hosp Ramon & Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain; Univ Alcala de Henares, Dept Bioquim & Biol Mol, Alcala De Henares 99775, Spain	Hospital Universitario Ramon y Cajal; Universidad de Alcala	Lasuncion, MA (corresponding author), Hosp Ramon & Cajal, Serv Bioquim Invest, Ctra Colmenar,Km 9, E-28034 Madrid, Spain.	miguel.a.lasuncion@hrs.es	Martinez-Botas, Javier/AAD-8733-2021; Lasunción, Miguel A./K-6167-2014	Martinez-Botas, Javier/0000-0002-5190-3619; Lasunción, Miguel A./0000-0003-0299-9391; Ferruelo, Antonio/0000-0001-9840-3569; Suarez, Yajaira/0000-0003-4549-2953				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BUTTKE TM, 1992, J BIOL CHEM, V267, P8819; BUTTKE TM, 1980, J BACTERIOL, V144, P124, DOI 10.1128/JB.144.1.124-130.1980; Carrero P, 1998, BIOCHEM PHARMACOL, V55, P1125, DOI 10.1016/S0006-2952(97)00635-7; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; CHEN HW, 1975, P NATL ACAD SCI USA, V72, P1950, DOI 10.1073/pnas.72.5.1950; CHEN HW, 1974, NATURE, V251, P419, DOI 10.1038/251419a0; CHEN HY, 1988, ULTRASOUND MED BIOL, V14, P263, DOI 10.1016/0301-5629(88)90091-9; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CORSINI A, 1993, ATHEROSCLEROSIS, V101, P117, DOI 10.1016/0021-9150(93)90107-6; Crick DC, 1997, EXP CELL RES, V231, P302, DOI 10.1006/excr.1997.3480; CUTHBERT JA, 1990, J BIOL CHEM, V265, P18568; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DAHL JS, 1983, P NATL ACAD SCI-BIOL, V80, P692, DOI 10.1073/pnas.80.3.692; DAHL JS, 1980, BIOCHEMISTRY-US, V19, P1467, DOI 10.1021/bi00548a032; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; FAUST JR, 1991, J BIOL CHEM, V266, P9961; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORGULAFITTE ME, 1992, CANCER RES, V52, P6827; GRANA X, 1995, ONCOGENE, V11, P211; GrayBablin J, 1997, CANCER RES, V57, P604; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HAEFFNER EW, 1984, CANCER RES, V44, P2668; HAIN J, 1993, CANCER RES, V53, P1507; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KEYOMARSI K, 1991, CANCER RES, V51, P3602; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LANGAN TJ, 1991, J CELL PHYSIOL, V149, P284, DOI 10.1002/jcp.1041490215; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; LOCK RB, 1994, CANCER RES, V54, P4933; MAYER RJ, 1991, J BIOL CHEM, V266, P20070; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PALACIN M, 1988, J LIPID RES, V29, P26; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; Raiteri M, 1997, J PHARMACOL EXP THER, V281, P1144; RAMGOPAL M, 1983, P NATL ACAD SCI-BIOL, V80, P712, DOI 10.1073/pnas.80.3.712; RODRIGUEZ RJ, 1982, BIOCHEM BIOPH RES CO, V106, P435, DOI 10.1016/0006-291X(82)91129-9; Rogler G, 1995, BASIC RES CARDIOL, V90, P443, DOI 10.1007/BF00788536; RUJANAVECH C, 1986, J BIOL CHEM, V261, P7196; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAWAMURA M, 1993, CLIN EXP PHARMACOL P, V20, P509, DOI 10.1111/j.1440-1681.1993.tb01733.x; SCHULZ S, 1994, EUR J IMMUNOL, V24, P301, DOI 10.1002/eji.1830240204; SCHULZ S, 1992, CANCER RES, V52, P1372; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sindermann J, 1997, J IMMUNOL METHODS, V202, P205, DOI 10.1016/S0022-1759(97)00007-0; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TABACIK C, 1989, BIOCHIM BIOPHYS ACTA, V1011, P149, DOI 10.1016/0167-4889(89)90202-4; VITOLS S, 1994, BLOOD, V84, P2689; Vogt A, 1996, ONCOGENE, V13, P1991; WEJDE J, 1993, J CELL PHYSIOL, V155, P539, DOI 10.1002/jcp.1041550312; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140	62	64	64	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1359	1370		10.1096/fasebj.13.11.1359	http://dx.doi.org/10.1096/fasebj.13.11.1359			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428760				2022-12-28	WOS:000082019100008
J	Jourdan, KB; Evans, TW; Goldstraw, P; Mitchell, JA				Jourdan, KB; Evans, TW; Goldstraw, P; Mitchell, JA			Isoprostanes and PGE(2) production in human isolated pulmonary artery smooth muscle cells: concomitant and differential release	FASEB JOURNAL			English	Article						8-iso PGF(2 alpha a); indomethacin; L-745,337; sepsis; lung vasculature	PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; CYCLOOXYGENASE-DEPENDENT FORMATION; STRESS IN-VIVO; 8-EPI PROSTAGLANDIN-F2-ALPHA; LIPID-PEROXIDATION; 8-EPI-PROSTAGLANDIN F2-ALPHA; PROSTANOIDS F2-ISOPROSTANES; OXIDATIVE STRESS; HUMAN MONOCYTES; HUMAN PLATELETS	The isoprostanes are a group of biologically active arachidonic acid metabolites initially thought to be formed under conditions of oxidative stress and independently of cyclooxygenase, However, recent studies have demonstrated isoprostane production under conditions in which cyclooxygenase is intentionally activated/induced. Here we describe for the first time formation of isoprostanes by human vascular cells via independent pathways of oxidative stress and cyclooxygenase induction. We compared the release of the isoprostane with that of the traditional prostaglandin, prostaglandin E-2. Cyclooxygenase-2 induction was confirmed by Western blot. When cells were stimulated with cytokines, the release of isoprostanes was inhibited by the cyclooxygenase-l and -2 inhibitor indomethacin as well by as the cyclooxygenase-2 selective inhibitor L-745,337, However, treatment of cells with the superoxide-producing enzyme xanthine oxidase also resulted in isoprostane release, which was not affected by cyclooxygenase inhibition, unlike PGE(2) release under the same condition, Thus, two independent pathways relating to oxidative stress and cyclooxygenase-2 induction form isoprostanes, These findings may have particular importance in diseases such as sepsis and ARDS in which oxidant stress occurs and cyclooxygenase is induced.	Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Crit Care Unit, London SW3 6NP, England	Imperial College London; Royal Brompton Hospital	Mitchell, JA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, Crit Care Unit, Sydney St, London SW3 6NP, England.		Mitchell, Jane A/A-1991-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AWAD JA, 1994, J PHARMACOL EXP THER, V270, P858; AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; BishopBailey D, 1997, BRIT J PHARMACOL, V121, P125, DOI 10.1038/sj.bjp.0701100; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CRANKSHAW D, 1995, EUR J PHARMACOL, V285, P151, DOI 10.1016/0014-2999(95)00398-5; DABBAGH AJ, 1994, BIOCHEM J, V300, P799, DOI 10.1042/bj3000799; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; FUKUMOTO S, 1993, MATER SCI TECH SER, V9, P264, DOI 10.1179/026708393790171962; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; GOPAUL NK, 1995, FEBS LETT, V368, P225, DOI 10.1016/0014-5793(95)00649-T; GOPAUL NK, 1994, FEBS LETT, V348, P297, DOI 10.1016/0014-5793(94)00628-8; HAZBUN ME, 1993, AM J RESP CELL MOL, V9, P568, DOI 10.1165/ajrcmb/9.5.568; Jourdan KB, 1997, BRIT J PHARMACOL, V120, P1280, DOI 10.1038/sj.bjp.0701052; Jourdan KB, 1997, BIOCHEM BIOPH RES CO, V233, P668, DOI 10.1006/bbrc.1997.6523; KANG KH, 1993, J APPL PHYSIOL, V74, P460, DOI 10.1152/jappl.1993.74.1.460; Kawikova I, 1996, AM J RESP CRIT CARE, V153, P590, DOI 10.1164/ajrccm.153.2.8564103; Klein T, 1997, J PHARMACOL EXP THER, V282, P1658; Kromer BM, 1996, BRIT J PHARMACOL, V119, P1276, DOI 10.1111/j.1476-5381.1996.tb16033.x; Lynch SM, 1996, CIRCULATION, V94, P4133; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1991, FREE RADICAL BIO MED, V10, P195, DOI 10.1016/0891-5849(91)90076-F; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Natarajan R, 1996, AM J PHYSIOL-HEART C, V271, pH159, DOI 10.1152/ajpheart.1996.271.1.H159; Patrignani P, 1996, BRIT J PHARMACOL, V118, P1285, DOI 10.1111/j.1476-5381.1996.tb15535.x; PRATICO D, 1995, ADV PROSTAG THROMB L, V23, P229; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1996, J BIOL CHEM, V271, P14916, DOI 10.1074/jbc.271.25.14916; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; PRATICO D, 1994, ANN NY ACAD SCI, V744, P139, DOI 10.1111/j.1749-6632.1994.tb52730.x; REILLY M, 1996, CIRCULATION, V94, P9; Reilly MP, 1996, CIRCULATION, V94, P3727; Siegle I, 1998, ARTHRITIS RHEUM-US, V41, P122, DOI 10.1002/1529-0131(199801)41:1<122::AID-ART15>3.3.CO;2-#; SWIERKOSZ TA, 1994, POL J PHARMACOL, V46, P7; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; VACCHIANO CA, 1994, J APPL PHYSIOL, V77, P2912, DOI 10.1152/jappl.1994.77.6.2912; YIN K, 1994, J PHARMACOL EXP THER, V270, P1192	44	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1025	1030		10.1096/fasebj.13.9.1025	http://dx.doi.org/10.1096/fasebj.13.9.1025			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336884	Bronze			2022-12-28	WOS:000080547700006
J	Binas, B; Danneberg, H; McWhir, J; Mullins, L; Clark, AJ				Binas, B; Danneberg, H; McWhir, J; Mullins, L; Clark, AJ			Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization	FASEB JOURNAL			English	Article						metabolism; heart; hypertrophy; gene targeting; mice	CARNITINE PALMITOYLTRANSFERASE-I; RAT-HEART; HYPERTROPHIC CARDIOMYOPATHY; TISSUE DISTRIBUTION; SKELETAL-MUSCLE; GENE; TRANSPORT; CLONING; SYSTEM; LIVER	Nonenzymatic cytosolic fatty acid binding proteins (FABPs) are abundantly expressed in many animal tissues with high rates of fatty acid metabolism. No physiological role has been demonstrated for any FABP, although these proteins have been implicated in transport of free long-chain fatty acids (LCFAs) and protection against LCFA toxicity, We report here that mice lacking heart-type FABP (H-FABP) exhibit a severe defect of peripheral (nonhepatic, non-fat) LCFA utilization, In these mice, the heart is unable to efficiently take up plasma LCFAs, which are normally its main fuel, and switches to glucose usage, Altered plasma levels of LCFAs, glucose, lactate and beta-hydroxybutyrate are consistent with depressed peripheral LCFA utilization, intensified carbohydrate usage, and increased hepatic LCFA oxidation; these changes are most pronounced under conditions favoring LCFA oxidation. H-FABP deficiency is only incompletely compensated, however, causing acute exercise intolerance and, at old age, a localized cardiac hypertrophy. These data establish a requirement for H-FABP in cardiac intracellular lipid transport and fuel selection and a major role in metabolic homeostasis. This new animal model should be particularly useful for investigating the significance of peripheral LCFA utilization for heart function, insulin sensitivity, and blood pressure.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Roslin Inst, Div Mol Biol, Roslin EH25 9PS, Midlothian, Scotland; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	Helmholtz Association; Max Delbruck Center for Molecular Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh	Binas, B (corresponding author), Max Delbruck Ctr Mol Med, Franz Gross Haus 134 D,Wiltbergstr 50, D-13122 Berlin, Germany.	binasb@mdc-berlin.de		Mullins, Linda/0000-0002-6743-8707				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Baier LJ, 1996, J BIOL CHEM, V271, P10892, DOI 10.1074/jbc.271.18.10892; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Borkan SC, 1996, AM J PHYSIOL-RENAL, V271, pF527, DOI 10.1152/ajprenal.1996.271.3.F527; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLAFFEY KP, 1987, BIOCHEMISTRY-US, V26, P7900, DOI 10.1021/bi00398a054; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; KELLY DP, 1994, NEW ENGL J MED, V330, P913; Knapp F F Jr, 1996, Q J Nucl Med, V40, P252; KUSAKA Y, 1995, J MOL CELL CARDIOL, V27, P1605, DOI 10.1016/S0022-2828(95)90524-3; Kuwajima M, 1998, J MOL CELL CARDIOL, V30, P773, DOI 10.1006/jmcc.1998.0641; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLER WC, 1988, P SOC EXP BIOL MED, V189, P183; MISHKIN S, 1972, BIOCHEM BIOPH RES CO, V47, P997, DOI 10.1016/0006-291X(72)90931-X; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; Ohta K, 1996, CIRCULATION, V94, P785, DOI 10.1161/01.CIR.94.4.785; PANOS TC, 1953, J NUTR, V49, P397, DOI 10.1093/jn/49.3.397; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; RUPP H, 1992, FASEB J, V6, P2349, DOI 10.1096/fasebj.6.6.1531968; SAKAI K, 1995, EUR J BIOCHEM, V229, P201, DOI 10.1111/j.1432-1033.1995.tb20456.x; Sambrook J, 1989, MOL CLONING; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; SWISLOCKI A, 1994, AM J HYPERTENS, V7, P739, DOI 10.1093/ajh/7.8.739; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TWEEDIE S, 1989, NUCLEIC ACIDS RES, V17, P4374, DOI 10.1093/nar/17.11.4374; VORK MM, 1993, J THEOR BIOL, V160, P207, DOI 10.1006/jtbi.1993.1014; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	35	230	245	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					805	812		10.1096/fasebj.13.8.805	http://dx.doi.org/10.1096/fasebj.13.8.805			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224224				2022-12-28	WOS:000080372500004
J	Akdis, CA; Blaser, K				Akdis, CA; Blaser, K			IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy	FASEB JOURNAL			English	Review						interleukin-10; T cell epitopes; microenvironments; bee venom	BEE VENOM PHOSPHOLIPASE-A2; MAST-CELLS; IN-VITRO; INTERLEUKIN-10 PRODUCTION; ALLERGEN IMMUNOTHERAPY; BLOOD EOSINOPHILS; MEDIATOR RELEASE; SENSITIZED MICE; HONEYBEE VENOM; GROWTH-FACTOR	Specific immunotherapy (SIT) is widely used for treatment of allergic diseases and could potentially be applied in other immunological disorders. Induction of specific unresponsiveness (anergy) in peripheral T cells and recovery by cytokines from the tissue microenvironment represent two key steps in SIT with whole allergen or antigenic T cell. peptides (PIT), The anergy is directed against the T cell epitopes of the respective antigen and characterized by suppressed proliferative and cytokine responses, It is initiated by autocrine action of IL-10, which is increasing-ly produced by the antigen-specific T cells. Later in therapy, B cells and monocytes also produce IL-10. The anergic T cells can be reactivated by different cytokines, Whereas IL-15 and IL-2 generate Th1 cytokine profile and an IgG4 antibody response, IL-4 reactivates a Th2 cytokine pattern and IgE antibodies. Increased IL-10 suppresses IgE and enhances IgG4 synthesis, resulting in a decreased antigen-specific IgE:IgG4 ratio, as observed normally in patients after SIT or PIT, The same state of anergy against the major bee venom allergen, phospholipase A(2), can be observed in subjects naturally anergized after multiple bee stings, Together, these data demonstrate the pivotal role of autocrine IL-10 in induction of specific T cell anergy and the important participation of the cytokine microenvironment in SIT, Furthermore, knowledge of the mechanisms explaining reasons for success or failure of SIT may enable possible predictive measures of the treatment.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				AALBERSE RC, 1983, J IMMUNOL, V130, P722; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 1997, STRATEGIES FOR IMMUNOINTERVENTIONS IN DERMATOLOGY, P131; Akdis CA, 1997, EUR J IMMUNOL, V27, P2351, DOI 10.1002/eji.1830270933; Akdis CA, 1997, J ALLERGY CLIN IMMUN, V99, P345, DOI 10.1016/S0091-6749(97)70052-6; Arock M, 1996, EUR J IMMUNOL, V26, P166, DOI 10.1002/eji.1830260126; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1992, IMMUNOTHERAPY IGE ME, P13; DADAGLIO G, 1994, J EXP MED, V179, P413, DOI 10.1084/jem.179.2.413; DE WMR, 1991, J EXP MED, V174, P1209; DELPRETE G, 1993, J IMMUNOL, V150, P353; DING L, 1992, J IMMUNOL, V148, P3133; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; ESSERY G, 1988, IMMUNOLOGY, V64, P413; Faith A, 1997, J IMMUNOL, V159, P53; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259, DOI 10.1016/S1081-1206(10)63012-8; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREENSTEIN JL, 1992, J ALLERGY CLIN IMMUN, V89, P322; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; IPPOLITI F, 1997, ALLERG IMMUNOL PARIS, V29, P123; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAGEYSABOTKA A, 1976, J ALLERGY CLIN IMMUN, V57, P29; KUNA P, 1993, J IMMUNOL, V150, P1932; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LUCAS AH, 1990, SPRINGER SEMIN IMMUN, V12, P385; Mahanty S, 1996, J INFECT DIS, V173, P769, DOI 10.1093/infdis/173.3.769; Marcotte GV, 1998, J ALLERGY CLIN IMMUN, V101, P506, DOI 10.1016/S0091-6749(98)70358-6; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; MULLER U, 1993, ALLERGY          S14, V48, P36; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TSAI LC, 1991, CLIN EXP ALLERGY, V21, P367, DOI 10.1111/j.1365-2222.1991.tb01670.x; Van Parijs L, 1998, SCIENCE, V280, P243; VARNEY VA, 1991, BRIT MED J, V302, P489; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WANG P, 1994, J IMMUNOL, V153, P811; WARD SG, 1993, EUR J IMMUNOL, V23, P2572, DOI 10.1002/eji.1830231029; WETTERWALD A, 1985, INT ARCH ALLER A IMM, V77, P195, DOI 10.1159/000233784; WYSS M, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb00690.x; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	72	186	198	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					603	609		10.1096/fasebj.13.6.603	http://dx.doi.org/10.1096/fasebj.13.6.603			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094921				2022-12-28	WOS:000079527200002
J	Friedmann, I; Faber-Elman, A; Yoles, E; Schwartz, M				Friedmann, I; Faber-Elman, A; Yoles, E; Schwartz, M			Injury-induced gelatinase and thrombin-like activities in regenerating and nonregenerating nervous systems	FASEB JOURNAL			English	Article						thrombin; matrix metalloproteases; CNS; PNS	FIBROBLAST GROWTH-FACTOR; GLIA-DERIVED NEXIN; MATRIX METALLOPROTEINASE EXPRESSION; NEURITE OUTGROWTH; PERIPHERAL-NERVE; EXTRACELLULAR-MATRIX; CEREBROSPINAL-FLUID; RAT ASTROBLASTS; PRIMARY CULTURE; CELL-CULTURES	It is now widely accepted that injured nerves, like any other injured tissue, need assistance from their extracellular milieu in order to heal. We compared the postinjury activities of thrombin and gelatinases, two types of proteolytic activities known to be critically involved in tissue healing, in nonregenerative (rat optic nerve) and regenerative (fish optic nerve and rat sciatic nerve) neural tissue. Unlike gelatinases, whose induction pattern was comparable in all three nerves, thrombin-like activity differed clearly between regenerating and nonregenerating nervous systems. Postinjury levels of this latter activity seem to dictate whether it will display beneficial or detrimental effects on the capacity of the tissue for repair. The results of this study further highlight the fact that tissue repair and nerve regeneration are closely linked and that substances that are not unique to the nervous system, but participate in wound healing in general, are also crucial for regeneration or its failure in the nervous system.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.							APODACA G, 1990, CANCER RES, V50, P2322; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Debeir T, 1996, BRAIN RES, V708, P159, DOI 10.1016/0006-8993(95)01237-0; DESCHEPPER CF, 1991, MOL BRAIN RES, V11, P355, DOI 10.1016/0169-328X(91)90045-Y; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; Donovan FM, 1997, J NEUROSCI, V17, P5316; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; ELMAN AF, 1995, J NEUROCHEM, V65, P1524; ELMAN AF, 1996, J CLIN INVEST, V97, P162; Gallagher S, 1997, CURRENT PROTOCOLS MO, P1081, DOI DOI 10.8.110.8.21; GIJBELS K, 1993, J NEUROSCI RES, V36, P432, DOI 10.1002/jnr.490360409; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; GLOOR S, 1986, CELL, V47, P687; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; GRABHAM PW, 1991, EUR J NEUROSCI, V3, P663, DOI 10.1111/j.1460-9568.1991.tb00852.x; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; Halkier T., 1991, MECH BLOOD COAGULATI; HIRSCHBERG DL, 1995, J NEUROIMMUNOL, V61, P89, DOI 10.1016/0165-5728(95)00087-I; KNOOPS B, 1991, BRAIN RES, V540, P183, DOI 10.1016/0006-8993(91)90506-Q; KRANE SM, 1994, ANN NY ACAD SCI, V732, P1, DOI 10.1111/j.1749-6632.1994.tb24719.x; LaFleur M, 1996, J EXP MED, V184, P2311; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; LORET C, 1989, J BIOL CHEM, V264, P8319; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONARD D, 1983, PROG BRAIN RES, V58, P359, DOI 10.1016/S0079-6123(08)60037-0; Monsonego A, 1998, FASEB J, V12, P1163, DOI 10.1096/fasebj.12.12.1163; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; MUIR D, 1994, EXP CELL RES, V210, P243, DOI 10.1006/excr.1994.1036; NEVEU I, 1993, J NEUROCHEM, V60, P858, DOI 10.1111/j.1471-4159.1993.tb03230.x; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PITTMAN RN, 1989, DEV NEUROSCI-BASEL, V11, P361, DOI 10.1159/000111912; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; RICHMOND G, 1980, PROG SURF SCI, V28, P1; ROSENBERG GA, 1994, LAB INVEST, V71, P417; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; SEKIYA F, 1994, J BIOL CHEM, V269, P32441; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; Shikamoto Y, 1997, FEBS LETT, V412, P526, DOI 10.1016/S0014-5793(97)00852-1; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SOWER LE, 1995, J IMMUNOL, V155, P895; STAMATOGLOU SC, 1987, J CELL BIOL, V105, P2417, DOI 10.1083/jcb.105.5.2417; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WEINBERG EL, 1979, BRAIN RES, V162, P273, DOI 10.1016/0006-8993(79)90289-0; WILLIAMS LR, 1983, J COMP NEUROL, V218, P460, DOI 10.1002/cne.902180409; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZURN AD, 1988, DEV NEUROSCI-BASEL, V10, P17, DOI 10.1159/000111951	60	32	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					533	543		10.1096/fasebj.13.3.533	http://dx.doi.org/10.1096/fasebj.13.3.533			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064620				2022-12-28	WOS:000079016000013
J	Raisanen, SR; Lehenkari, P; Tasanen, M; Rahkila, P; Harkonen, PL; Vaananen, HK				Raisanen, SR; Lehenkari, P; Tasanen, M; Rahkila, P; Harkonen, PL; Vaananen, HK			Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis	FASEB JOURNAL			English	Article						oxidative stress; skeleton muscle; overexpression	S-THIOLATION; OXIDATIVE STRESS; PHOSPHATASE-ACTIVITY; RAT-LIVER; RESPIRATORY BURST; ACTIVATION; GENE; SUPEROXIDE; EXPRESSION; PROTEINS	Carbonic anhydrase III (CA III; EC 4.2.1.1) is a cytoplasmic enzyme that exhibits a relatively low carbon dioxide hydratase activity. It is expressed at a very high level in skeletal muscle, where physical exercise has been shown to increase free radical production. In this work we show the effect of overexpression of CA III on cellular response to oxidative stress. Rat CA III cDNA was transfected to NIH/3T3 cells, which have no endogenous CA III expression. The isolated clones expressed CA III mRNA and protein. The protein was localized to cytoplasm and nuclei, Compared to parental cells, transfected cells showed lower basal oxidized state as judged by measurement of intracellular reactive oxygen species (ROS) using fluorescent dye and an image analysis system. Addition of exogenous H2O2 to cells induced a rapid increase of ROS in control but not in CA III overexpressing cells, Association of this phenomenon with CA III expression was further confirmed by showing that overexpression of CA II could not prevent H2O2-stimulated increase of ROS, In proliferation assays, CA III overexpressing cells grew faster and were more resistant to cytotoxic concentrations of H2O2 than control cells. After a 16 h exposure to oxidative stress, the number of apoptotic cells was also reduced in transfectants, Our results suggest that CA III functions as an oxyradical scavenger and thus protects cells from oxidative damage. A lower level of free radicals in CA III overexpressing cells may also affect growth signaling pathways.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, Medcity Res Lab, FIN-20520 Turku, Finland	University of Turku; University of Turku	Vaananen, HK (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	kalervo.vaananen@utu.fi	Lehenkari, Petri/O-3009-2016	Lehenkari, Petri/0000-0002-0055-5183				BASS DA, 1983, J IMMUNOL, V133, P3303; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P364; CHATTERJEE B, 1981, J BIOL CHEM, V256, P5939; Cote CH, 1997, AM J PHYSIOL-REG I, V273, pR1211, DOI 10.1152/ajpregu.1997.273.4.R1211; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DARBRE PD, 1930, BREAST CANC CELLULAR, P307; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; DEHAAN J, 1996, HUM MOL GENET, V2, P283; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODGSON SJ, 1993, J APPL PHYSIOL, V75, P1186, DOI 10.1152/jappl.1993.75.3.1186; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; JENKINS RR, 1988, SPORTS MED, V5, P156, DOI 10.2165/00007256-198805030-00003; JENKINS RR, 1993, INT J SPORT NUTR, V3, P356, DOI 10.1123/ijsn.3.4.356; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOESTER MK, 1981, ARCH BIOCHEM BIOPHYS, V211, P632, DOI 10.1016/0003-9861(81)90499-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; MACLIN LJ, 1987, FASEB J, V1, P441; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAREN TH, 1967, PHYSIOL REV, V47, P595, DOI 10.1152/physrev.1967.47.4.595; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; Miyamoto T, 1996, J BIOCHEM, V120, P725; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PASTOREK J, 1994, ONCOGENE, V9, P2877; ROKUTAN K, 1991, J IMMUNOL, V147, P260; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sambrook J., 2002, MOL CLONING LAB MANU; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1995, EXP CELL RES, V218, P132, DOI 10.1006/excr.1995.1139; Sly WS, 1995, ANNU REV BIOCHEM, V64, P365; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPICER SS, 1990, AM J ANAT, V187, P55, DOI 10.1002/aja.1001870107; Stangel M, 1996, J NEUROPATH EXP NEUR, V55, P36, DOI 10.1097/00005072-199601000-00004; STARKE PE, 1985, J BIOL CHEM, V260, P99; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; Tashian RE, 1991, CARBONIC ANHYDRASES, P247, DOI DOI 10.1007/978-1-4899-0750-9_21; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; VAANANEN HK, 1985, HISTOCHEMISTRY, V83, P231, DOI 10.1007/BF00953989	49	179	185	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					513	522		10.1096/fasebj.13.3.513	http://dx.doi.org/10.1096/fasebj.13.3.513			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064618				2022-12-28	WOS:000079016000011
J	Cavallaro, U; Wu, ZH; Di Palo, A; Montesano, R; Pepper, MS; Maier, JAM; Soria, MR				Cavallaro, U; Wu, ZH; Di Palo, A; Montesano, R; Pepper, MS; Maier, JAM; Soria, MR			FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor	FASEB JOURNAL			English	Article						TTB cell migration; hepatocyte growth factor; FGF; uPAR relocalization	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; C-MET PROTOONCOGENE; ENDOTHELIAL-CELLS; TRANSGENIC MICE; PLASMINOGEN-ACTIVATOR; SPINDLE CELLS; TAT PROTEIN; IN-VITRO; EXPRESSION	The spindle-shaped cell line TTB was recently isolated from highly vascularized skin lesions of BKV/HIV-1 tat transgenic mice and shown to possess an autocrine loop for hepatocyte growth factor (HGF), We show that fibroblast growth factor-2 (FGF-2) stimulates TTB cell migration and promotes polarization of uPAR at the leading edge of migrating cells. FGF-stimulated TTB cells presented the typical migratory phenotype, with a triangular cell shape and concomitant breakdown of actin stress fibers and smooth muscle-specific actin isoform, FGF-2-stimulated migration was blocked by antibodies against urokinase-type plasminogen activator (uPA) or uPA receptor (uPAR) and by neutralizing anti-HGF antibodies, The latter also inhibited uPAR relocalization at the cell surface of FGF-2-treated TTB cells. This points to a crosstalk between FGF-2 and HGF that might mediate TTB cell migration by modulating the localization of cell surface uPAR.	San Raffaele Sci Inst, Dept Biol & Technol Res, Dibit, I-20132 Milan, Italy; Univ Geneva, Med Ctr, Dept Morphol, Geneva, Switzerland; Univ Milan, Dept Biomed Sci & Technol, Milano, Italy	University of Geneva; University of Milan	Cavallaro, U (corresponding author), San Raffaele Sci Inst, Dept Biol & Technol Res, Dibit, Via Olgettina 58, I-20132 Milan, Italy.		Maier, Jeanette AM/H-4820-2012; Cavallaro, Ugo/J-9745-2012; Pepper, Michael S./M-6143-2014	Maier, Jeanette AM/0000-0002-6326-9221; Cavallaro, Ugo/0000-0002-0884-6460; Pepper, Michael S./0000-0001-6406-2380				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Cavallaro U, 1996, AIDS, V10, P1211, DOI 10.1097/00002030-199609000-00006; Cavallaro U., 1993, DRUG DELIV, V1, P119, DOI 10.3109/10717549309022765; CORALLINI A, 1993, CANCER RES, V53, P5569; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Ganem D, 1996, SEMIN VIROL, V7, P325, DOI 10.1006/smvy.1996.0040; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; KENAGY RD, 1995, THROMB RES, V77, P55, DOI 10.1016/0049-3848(95)90864-C; Maier JAM, 1996, ONCOGENE, V13, P1009; Maier JAM, 1996, FIBRINOLYSIS, V10, P309, DOI 10.1016/S0268-9499(96)80012-9; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; Nakamura Y, 1996, J HYPERTENS, V14, P1067, DOI 10.1097/00004872-199609000-00004; Nakamura Y, 1996, HYPERTENSION, V28, P409, DOI 10.1161/01.HYP.28.3.409; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PERANTONI AO, 1995, P NATL ACAD SCI USA, V92, P4696, DOI 10.1073/pnas.92.10.4696; POLVERINI PJ, 1995, ADV CANCER RES, V66, P235, DOI 10.1016/S0065-230X(08)60256-0; PYKE C, 1991, AM J PATHOL, V138, P1059; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; Roletto F, 1996, J CELL PHYSIOL, V166, P105, DOI 10.1002/(SICI)1097-4652(199601)166:1<105::AID-JCP12>3.0.CO;2-E; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	40	17	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1027	1034		10.1096/fasebj.12.11.1027	http://dx.doi.org/10.1096/fasebj.12.11.1027			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707175				2022-12-28	WOS:000075372600013
J	Yang, CR; Wilson-Van Patten, C; Planchon, SM; Wuerzberger-Davis, SM; Davis, TW; Cuthill, S; Miyamoto, S; Boothman, DA				Yang, CR; Wilson-Van Patten, C; Planchon, SM; Wuerzberger-Davis, SM; Davis, TW; Cuthill, S; Miyamoto, S; Boothman, DA			Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation	FASEB JOURNAL			English	Article						PLDR; Sp1; retinoblastoma control protein; NF-kappa B; p53; ionizing radiation; genomic instability; aneuploid/polyploid; apoptosis	DEPENDENT PROTEIN-KINASE; RETINOBLASTOMA GENE-PRODUCT; BETA-LAPACHONE; DNA-BINDING; RB PROTEIN; SP1-MEDIATED TRANSCRIPTION; PLASMINOGEN-ACTIVATOR; NUCLEAR-LOCALIZATION; TOPOISOMERASE-I; MAMMALIAN-CELLS	Regulation of transcriptional responses in growth-arrested human cells under conditions that promote potentially lethal damage repair after ionizing radiation (TR) is poorly understood. Sp1/retinoblastoma control protein (RCP) DNA binding increased within 30 min and peaked at 2-4 h after IR (450-600 cGy) in confluent radioresistant human malignant melanoma (U1-Mel) cells. Increased phosphorylation of Spl directly corresponded to Sp1/RCP binding and immediate-early gene induction, whereas pRb remained hypophosphorylated. Transfection of U1-Mel cells with the human papillomavirus E7 gene abrogated Sp1/RCP induction and G(0)/G(1) cell cycle checkpoint arrest responses, increased apoptosis and radiosensitivity, and augmented genetic instability (i.e., increased polyploidy cells) after IR. Increased NF-KB DNA binding in U1-Mel cells after LR treatment lasted much longer (i.e., >20 h). U1-Mel cells overexpressing dominant-negative I kappa R alpha S32/36A mutant protein were significantly more resistant to IR exposure and retained both G(2)/M and G(0)/G(1) cell cycle checkpoint responses without significant genetic instability (i.e., polyploid cell populations were not observed). Nuclear p53 protein levels and DNA binding activity increased only after high doses of IR (>1200 cGy). Disruption of p53 responses in U1-Mel cells by E6 transfection also abrogated G(0)/G(1) cell cycle checkpoint arrest responses and increased polyploidy after IR, but did not alter radiosensitivity. These data suggest that abrogation of individual components of this coordinate IR-activated transcription factor response may lead to divergent alterations in cell cycle checkpoints, genomic instability, apoptosis, and survival. Such coordinate transcription factor activation in human cancer cells is reminiscent of prokaryotic SOS responses, and further elucidation of these events should shed light on the initial molecular events in the chromosome instability phenotype.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Response, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Lab Mol Stress Response, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Comprehens Canc Ctr, Lab Mol Stress Response, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53792 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA; DeRoche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Roche Holding	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Response, 10900 Euclid Ave,BRB 326, Cleveland, OH 44106 USA.		Boothman, David/Q-7776-2019; Planchon, Sarah/A-5731-2009		NCI NIH HHS [CA-78530, CA-EY67995, R01 CA078530] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067995, R01CA078530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1999, MOL CELL BIOL, V19, P1961; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Bakker TR, 1999, INT J CANCER, V80, P320; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; BOOTHMAN DA, 1994, CANCER RES, V54, P4618; BOOTHMAN DA, 1989, CANCER RES, V49, P605; BOOTHMAN DA, 1994, RADIAT RES, V138, pS68, DOI 10.2307/3578765; Boothman DA, 1997, STEM CELLS, V15, P27; BOOTHMAN DA, 1989, CANCER RES, V49, P2871; BOOTHMAN DA, 1987, CANCER RES, V47, P5361; BOOTHMAN DA, 1992, INT J RADIAT ONCOL, V24, P939, DOI 10.1016/0360-3016(92)90478-Z; BOOTHMAN DA, 1991, CANCER RES, V51, P5587; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fujimoto M, 1997, DNA Res, V4, P151, DOI 10.1093/dnares/4.2.151; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOODRICH DW, 1992, NATURE, V360, P6403; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALLAHAN DE, 1991, INT J RADIAT ONCOL, V21, P1677, DOI 10.1016/0360-3016(91)90352-5; HALLAHAN DE, 1992, INT J RADIAT ONCOL, V22, P829; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jung M, 1997, CANCER RES, V57, P24; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Ludwig DL, 1997, GENE, V199, P181, DOI 10.1016/S0378-1119(97)00366-1; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROBBINS PD, 1991, NATURE, V351, P6325; RUBIN P, 1993, CLIN ONCOLOGY MULTID, V306, P72; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SUMMERS WC, 1985, CANCER SURV, V4, P517; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; UEDA A, 1994, J IMMUNOL, V153, P2052; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WEICHSELBAUM RR, 1985, P NATL ACAD SCI USA, V82, P4732, DOI 10.1073/pnas.82.14.4732; WEICHSELBAUM RR, 1992, INT J RADIAT ONCOL, V24, P565, DOI 10.1016/0360-3016(92)91075-X; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU RL, 1994, J BIOL CHEM, V269, P28450; Wuerzberger SM, 1998, CANCER RES, V58, P1876	62	70	72	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					379	390		10.1096/fasebj.14.2.379	http://dx.doi.org/10.1096/fasebj.14.2.379			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657994				2022-12-28	WOS:000085184800017
J	Segui, B; Bezombes, C; Uro-Coste, E; Medin, JA; Andrieu-Abadie, N; Auge, N; Brouchet, A; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T				Segui, B; Bezombes, C; Uro-Coste, E; Medin, JA; Andrieu-Abadie, N; Auge, N; Brouchet, A; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T			Stress-induced apoptosis is not mediated by endolysosomal ceramide	FASEB JOURNAL			English	Article						sphingomyelin; sphingomyelinase; Farber disease; ceramidase; lysosome; signal transduction	TUMOR-NECROSIS-FACTOR; NIEMANN-PICK DISEASE; FACTOR-KAPPA-B; ACID SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; LYSOSOMAL SPHINGOMYELINASE; CELL-PROLIFERATION; IONIZING-RADIATION; HUMAN FIBROBLASTS; PHOSPHOLIPASE-C	A major lipid-signaling pathway in mammalian cells implicates the generation of ceramide from the ubiquitous sphingolipid sphingo-mylein (SM). hydrolysis of SM by a sphingomyleinase present in acidic compartments has been reported to mediate, via the production of ceramide, the apoptotic cell death triggered by stress-reducing agents. In the present study, we investigate whether the ceramide formed within or accumulated in lysosomes indeed triggers apoptosis. A series of observations strongly suggests that ceramide involved in stress-induced apoptosis is not endolysosomal: 1) Although short-chain ceramides induced through apoptosis, loading cells with natural ceramide through receptor-mediated endocytosis did not result in cell death. 2) Neither TNF-alpha nor anti-CD95 induced the degradation to ceramide of a natural SM that had been first introduced selectively into acidic compartments. 3) Stimulation of SV40-transformed fibroblasts by TNF-alpha or CD40 ligand resulted in apoptosis equally well in cells derived from control individuals and from patients affected with Farber disease, having a genetic defect of acid ceramidase activity leading to lysosomal accumulation of ceramide. Also, induction of apoptosis using anti-CD95 (Fas) or anti-CD40 antibodies, TNF-alpha, daunorubicin, and ionizing radiation was similar in control and Farber disease lymphoidcells. in all cases, apoptosis was preceeded by a comparable increase of intracellular ceramide levels. 4) Retro-viral-mediated gene transfer and overexpression of acid ceramidase in Farber fibroblasts,which led to complete metabolic correction of the ceramide catabolic defect, did not affect the cell response to TNF-alpha and CD40 ligand.	CHU Rangueil, Inst Louis Bugnard, Lab Biochim Maladies Metabol, INSERM U 466, F-31403 Toulouse 4, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; Univ Illinois, Hematol Oncol Sect, Chicago, IL USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Levade, T (corresponding author), CHU Rangueil, Inst Louis Bugnard, Lab Biochim Maladies Metabol, INSERM U 466, Bat L3,1 Ave Jean Poulhes, F-31403 Toulouse 4, France.		Bezombes, christine/X-8479-2019; Andrieu-Abadie, Nathalie/N-6793-2013; Bezombes, Christine/G-2743-2017; Bezombes, Christine/AAC-1724-2020; Levade, Thierry/O-8948-2014; Ségui, Bruno/O-8957-2014	Bezombes, christine/0000-0003-4079-4872; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Ségui, Bruno/0000-0002-6119-1889; Auge, Nathalie/0000-0003-2088-7211				Adam D, 1998, BIOCHEM J, V333, P343, DOI 10.1042/bj3330343; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; Antonarakis S, 1983, PEDIATR RES, V17, p206A; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chatelut M, 1996, CLIN CHIM ACTA, V245, P61, DOI 10.1016/0009-8981(95)06173-8; Chatelut M, 1997, CLIN CHIM ACTA, V262, P61, DOI 10.1016/S0009-8981(97)06527-3; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DECOCK JGR, 1998, J BIOL CHEM, V273, P7560; DULANEY JT, 1977, PRACTICAL ENZYMOLOGY, P283; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GRABER D, 1994, J NEUROCHEM, V63, P1060; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jaffrezou JP, 1998, LEUKEMIA LYMPHOMA, V29, P453, DOI 10.3109/10428199809050905; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1996, J LIPID RES, V37, P2525; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Manthey CL, 1998, CYTOKINE, V10, P654, DOI 10.1006/cyto.1998.0344; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; Medin JA, 1999, HUM GENE THER, V10, P1321, DOI 10.1089/10430349950018003; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MOSER HW, 1995, METABOLIC MOL BASES, P2589; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Stoffel B, 1998, EUR J IMMUNOL, V28, P874, DOI 10.1002/(SICI)1521-4141(199803)28:03<874::AID-IMMU874>3.0.CO;2-T; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Woodle ES, 1997, J IMMUNOL, V158, P2156; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	72	47	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					36	47		10.1096/fasebj.14.1.36	http://dx.doi.org/10.1096/fasebj.14.1.36			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627278				2022-12-28	WOS:000084784700006
J	Liu, DX; Wen, J; Liu, J; Li, LP				Liu, DX; Wen, J; Liu, J; Li, LP			The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids	FASEB JOURNAL			English	Article						mutation of Cu,Zn-superoxide dismutase gene; transgenic mouse; hydrogen peroxide; hydroxyl radical; superoxide anion	CU,ZN SUPEROXIDE-DISMUTASE; RAT SPINAL-CORD; PERFORMANCE LIQUID-CHROMATOGRAPHY; MODEL COMBINING MICRODIALYSIS; METAL-CATALYZED OXIDATION; TRANSGENIC MOUSE MODEL; IN-VIVO; ELECTROCHEMICAL DETECTION; HYDROGEN-PEROXIDE; SALICYLATE HYDROXYLATION	TO explore whether reactive oxygen species (ROS) play a role in the pathogenesis of amyotrophic lateral sclerosis (ALS), a unique microdialysis or microcannula sampling technique was used in mice transfected with a mutant Cu,Zn-superoxide dismutase (SOD1) gene from humans with familial ALS, mice transfected with the normal human SOD1 gene, and normal mice. We demonstrate for the first time that the levels of hydrogen peroxide (H2O2) and the hydroxyl radical ((OH)-O-.) are significantly higher, and the level of the superoxide anion (O-2(.-)) is significantly lower in ALS mutant mice than in controls, supporting; by in vivo evidence the hypothesis that the mutant enzyme catalyzes (OH)-O-. formation by the sequence: O-2(.-) --> H2O2 --> (OH)-O-.. This removes doubts regarding the relevance of elevated ROS in FALS raised by in vitro experiments. The levels of oxidation products are also significantly higher in the mutant mice than in controls, consistent with some previous reports. Only the superoxide concentration differs between two controls among all the measurements. Our findings correlate in vivo a gene mutation to both elevated H2O2 and (OH)-O-. and increased oxidation of cellular constituents. The elevated H2O2 in mutant mice indicates impairment of its detoxification pathways, perhaps by changed interactions between SOD1 and H2O2 detoxification enzymes.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Liu, DX (corresponding author), Univ Texas, Med Branch, Dept Neurol, Gail Borden Bldg,Route 0653, Galveston, TX 77555 USA.	DLiu@utmb.edu		liu, danxia/0000-0001-8172-2344				Aguirre T, 1998, ANN NEUROL, V43, P452, DOI 10.1002/ana.410430407; AMICI A, 1989, J BIOL CHEM, V264, P3341; Andrus PK, 1998, J NEUROCHEM, V71, P2041; BELAND FA, 1979, J CHROMATOGR, V174, P177, DOI 10.1016/S0021-9673(00)87048-X; BELLEROCHE J, 1996, J NEUROPATHOL EXP NE, V55, P747; BERGERON C, 1994, BRAIN RES, V659, P272, DOI 10.1016/0006-8993(94)90892-3; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FLOYD RA, 1988, ARCH BIOCHEM BIOPHYS, V262, P266, DOI 10.1016/0003-9861(88)90188-9; FLOYD RA, 1984, J BIOCHEM BIOPH METH, V10, P221, DOI 10.1016/0165-022X(84)90042-3; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; Halliwell B, 1997, FREE RADICAL RES, V27, P239, DOI 10.3109/10715769709065762; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; INGELMANSUNDBERG M, 1991, BIOCHEM J, V276, P753, DOI 10.1042/bj2760753; IWASAKI Y, 1993, LANCET, V342, P1118, DOI 10.1016/0140-6736(93)92104-2; Kaur H, 1997, FREE RADICAL RES, V26, P71, DOI 10.3109/10715769709097786; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LIU D, 1997, J NEUROTRAUM, V14, P785; LIU D, FREE RAD BIOL MED, V27, P478; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1995, FREE RADICAL BIO MED, V18, P571, DOI 10.1016/0891-5849(94)00154-C; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Liu DX, 1998, J NEUROCHEM, V70, pS7; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Marklund SL, 1997, J NEUROCHEM, V69, P675; Marsala M, 1995, J NEUROSCI METH, V62, P43, DOI 10.1016/0165-0270(95)00053-4; Narayan M, 1997, FREE RADICAL RES, V27, P63, DOI 10.3109/10715769709097839; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Przedborski S, 1996, NEURODEGENERATION, V5, P57; Qian H, 1997, NEUROCHEM RES, V22, P1231, DOI 10.1023/A:1021980929422; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland L. P., 1995, MERRITTS TXB NEUROLO, P742; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	66	158	162	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2318	2328		10.1096/fasebj.13.15.2318	http://dx.doi.org/10.1096/fasebj.13.15.2318			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593879				2022-12-28	WOS:000084310800023
J	Cordelier, P; Esteve, JP; Rivard, N; Marletta, M; Vaysse, N; Susini, C; Buscail, L				Cordelier, P; Esteve, JP; Rivard, N; Marletta, M; Vaysse, N; Susini, C; Buscail, L			The activation of neuronal NO synthase is mediated by G-protein beta gamma subunit and the tyrosine phosphatase SHP-2	FASEB JOURNAL			English	Article						cholecystokinin; nitric oxide; cell growth; G beta gamma complex	NITRIC-OXIDE SYNTHASE; PANCREATIC ACINAR-CELLS; SOMATOSTATIN RECEPTOR; L-ARGININE; IN-VIVO; GROWTH; RAT; CHOLECYSTOKININ; PROLIFERATION; STIMULATION	In CHO cells we had found that CCK positively regulated cell proliferation via the activation of a soluble guanylate cyclase, Here we demonstrate that CCK stimulated a nitric oxide synthase (NOS) activity. The production of NO was involved in the proliferative response elicited by CCK regarding the inhibitory effect of NOS inhibitors L-NAME and alpha-guanidinoglutaric acid. We identified the NOS activated by the peptide as the neuronal isoform: the expression of the C415A neuronal NOS mutant inhibited both CCK-induced stimulation of NOS activity and cell proliferation, These two effects were also inhibited after expression of the C459S tyrosine phosphatase SHP-2 mutant and the beta ARK1 (495-689) sequestrant peptide, indicating the requirement of activated SHP-2 and G-beta gamma subunit, Kinetic analysis (Western blot after coimmunoprecipitation and specific SHP-2 activity) revealed that in response to CCK-treatment, SHP-2 associated to G-beta 1 subunit, became activated, and then dephosphorylated the neuronal NOS through a direct association, These data demonstrate that the neuronal NOS is implicated in proliferative effect evoked by CCK, A novel growth signaling pathway is described, involving the activation of neuronal NOS by dephosphorylation of tyrosyl residues.-Cordelier P., Esteve, J.-P., Rivard, N., Marletta, M., Vaysse, N., Susini, C., Buscail, L. The activation of neuronal no synthase is mediated by G-protein beta gamma subunit and the tyrosine phosphatase SHP-2.	CHU Rangueil, INSERM U151, Inst Louis Bugnard, F-31403 Toulouse 4, France; Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1K 2R1, Canada; Univ Michigan, Howard Hughes Med Inst, Sch Med, Ann Arbor, MI 48109 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Sherbrooke; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Buscail, L (corresponding author), CHU Rangueil, INSERM U151, Inst Louis Bugnard, 1 Ave J Poulhes,IFR 31, F-31403 Toulouse 4, France.		Cordelier, Pierre/D-1150-2014	Cordelier, Pierre/0000-0003-2096-7967	NATIONAL CANCER INSTITUTE [R01CA050414] Funding Source: NIH RePORTER; NCI NIH HHS [CA50414] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; Cuadra AE, 1998, J NEUROCHEM, V71, P571; Du M, 1997, BIOCHEM MOL BIOL INT, V41, P625; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; POVOSKI SP, 1994, GASTROENTEROLOGY, V107, P1135, DOI 10.1016/0016-5085(94)90239-9; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RIVARD N, 1991, ENDOCRINOLOGY, V129, P2867, DOI 10.1210/endo-129-6-2867; RIVARD N, 1994, AM J PHYSIOL, V266, pG1130, DOI 10.1152/ajpgi.1994.266.6.G1130; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; Thippeswamy T, 1997, BRAIN RES, V774, P116, DOI 10.1016/S0006-8993(97)81694-0; Wang Y, 1995, Curr Opin Nephrol Hypertens, V4, P12, DOI 10.1097/00041552-199501000-00003; Yoshida H, 1997, PFLUG ARCH EUR J PHY, V434, P25, DOI 10.1007/s004240050359; Yu ZB, 1997, J BIOL CHEM, V272, P7519, DOI 10.1074/jbc.272.11.7519; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	39	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2037	2050		10.1096/fasebj.13.14.2037	http://dx.doi.org/10.1096/fasebj.13.14.2037			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544187	Green Submitted			2022-12-28	WOS:000083660700016
J	Miosge, N; Sasaki, T; Timpl, R				Miosge, N; Sasaki, T; Timpl, R			Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls	FASEB JOURNAL			English	Article						binding assays; extracellular matrix; immunogold staining	HEPARAN-SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE ZONES; GLOBULAR DOMAIN; COLLAGEN-XVIII; MOUSE KIDNEY; FIBULIN-2; PROTEIN; GROWTH; TROPOELASTIN; EXPRESSION	The endothelial cell inhibitor endostatin (22 kDa) is part of the carboxyl-terminal globular domain of collagen XVIII and shows a widespread tissue distribution. Immunohistology of adult mouse tissues demonstrated a preferred localization in many vessel walls and some other basement membrane zones. A strong immunogold staining was observed across elastic fibers in the multiple elastic membranes of aorta and other large arteries. Staining was less strong along sparse elastic fibers of veins and almost none was observed in the walls of arterioles and capillaries. Strong evidence was also obtained for some intracellular and basement membrane associations. Immunogold double staining of elastic fibers showed a close colocalization of endostatin with fibulin-2, fibulin-1, and nidogen-2, but not with perlecan. Reasonable amounts of endostatin could be extracted from aorta and skin by EDTA, followed by detergents, with aorta being the richest source of the inhibitor identified so far. Solubilizations with collagenase and elastase were similar to fivefold less efficient. Immunoblots of aortic extracts detected major endostatin components of 22-25 kDa whereas skin extracts also contained some larger components. Solid-phase assays demonstrated distinct binding of recombinant mouse endostatin to the fibulins and nidogen-2, consistent with their tissue colocalization. Together, the data indicate several different ways for endostatin to be associated with the extracellular matrix, and its release may determine biological activation. This also defines a novel function for some elastic tissues. -Miosge, N., Sasaki, T., Timpl, R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Gottingen, Abt Histol, Zentrum Anat, D-37075 Gottingen, Germany	Max Planck Society; University of Gottingen	Timpl, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	TIMPL@biochem.mpg.de	Miosge, Nicolai/E-3244-2010					Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HERKEN R, 1987, HISTOCHEMISTRY, V87, P59, DOI 10.1007/BF00518725; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MIOSGE N, 1995, J HISTOCHEM CYTOCHEM, V43, P675, DOI 10.1177/43.7.7608521; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Musso O, 1998, HEPATOLOGY, V28, P98, DOI 10.1002/hep.510280115; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PasqualiRonchetti I, 1995, CIBA F SYMP, V192, P31; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RAGHUNATH M, 1999, IN PRESS J INVEST DE, V112; REHN M, 1994, J BIOL CHEM, V269, P13929; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; Sasaki T, 1996, J CELL SCI, V109, P2895; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1997, EMBO J, V16, P3035, DOI 10.1093/emboj/16.11.3035; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; SLOT JW, 1981, J CELL BIOL, V90, P533, DOI 10.1083/jcb.90.2.533; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x	44	112	119	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1743	1750		10.1096/fasebj.13.13.1743	http://dx.doi.org/10.1096/fasebj.13.13.1743			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506577				2022-12-28	WOS:000083063400009
J	Thevenod, F; Friedmann, JM				Thevenod, F; Friedmann, JM			Cadmium-mediated oxidative stress in kidney proximal tubule cells induces degradation of Na+/K+-ATPase through proteasomal and endo-/lysosomal proteolytic pathways	FASEB JOURNAL			English	Article						nephrotoxicity; heavy metals; oxygen radicals; Fanconi syndrome; ubiquitin	DIFFERENT SENSITIVITIES; HYDROGEN-PEROXIDE; PROTEIN OXIDATION; MAMMALIAN-CELLS; AMINO-ACID; MECHANISMS; SUBUNIT; RATS; UBIQUITINATION; COTRANSPORT	The mechanisms of cadmium (Cd) -dependent nephrotoxicity were studied in a rat proximal tubule (PT) cell line. CdCl2 (5 mu M) increased the production of reactive oxygen species (ROS), as determined by oxidation of dihydrorhodamine 123 to fluorescent rhodamine 123. The levels of ubiquitin-conjugated cellular proteins were increased by Cd in a time-dependent fashion (maximum at 24-48 h). This was prevented by coincubation with the thiol antioxidant N-acetylcysteine (NAC, 15 mM). Cd also increased apoptosis (controls: 2.4+/-1.6%; Cd: 8.1+/-1.9%), but not necrosis (controls: 0.5 +/- 0.3%; Cd: 1.4+/- 2,5%). Exposure of PT cells with Cd decreased protein levels of the catalytic subunit (alpha 1) of Na+/ K+-ATPase, a long-lived membrane protein (t(1/2) >48 h) that drives reabsorption of ions and nutrients through Na+-dependent transporters in PT, Incubation of PT cells for 48 h with Cd decreased Na+/ K+-ATPase alpha 1-subunit, as determined by immunoblotting, by approximate to 50%, and NAC largely prevented this effect, Inhibitors of the proteasome such as MG-132 (20 mu M) or lactacystin (10 mu M), as well as lysosomotropic weak bases such as chloroquine (0.2 mM) or NH4Cl (30 mM), significantly reduced the decrease of Na+/K+-ATPase alpha 1-subunit induced by Cd, and in combination abolished the effect of Cd on Na+/ K+-ATPase. Immunofluorescence labeling of Na+/ K+-ATPase showed a reduced expression of the protein in the plasma membrane of Cd-exposed cells. After addition of lactacystin and chloroquine to Cd-exposed PT cells, immunoreactive material accumulated into intracellular vesicles. The data indicate that micromolar concentrations of Cd can increase ROS production and exert a toxic effect on PT cells. Oxidative damage increases the degradation of Na+/K+-ATPase through both the proteasomal and endo-/lysosomal proteolytic pathways. Degradation of oxidatively damaged Na+/K+-ATPase may contribute to the 'Fanconi syndrome'-like Nat-dependent transport defects associated with Cd-nephrotoxicity. -Thevenod, F., Friedmann, J. M. Cadmium-mediated oxidative stress in kidney proximal tubule cells induces degradation of Na+/K+-ATPase through proteasomal and endo-/lysosomal proteolytic pathways.	Univ Saarlandes, Inst Physiol 2, Fak Med, Dept Physiol 2, D-66421 Homburg, Germany	Saarland University	Thevenod, F (corresponding author), Univ Saarlandes, Inst Physiol 2, Fak Med, Dept Physiol 2, D-66421 Homburg, Germany.							ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; CHAMBERS SK, 1992, BLOOD, V80, P1559; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coppi MV, 1997, FEBS LETT, V405, P281, DOI 10.1016/S0014-5793(97)00182-8; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GonzalezFlecha B, 1996, BBA-GEN SUBJECTS, V1290, P46, DOI 10.1016/0304-4165(95)00186-7; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HAMADA T, 1994, NEPHRON, V68, P104, DOI 10.1159/000188227; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; Hauser IA, 1998, KIDNEY INT, V54, P1139, DOI 10.1046/j.1523-1755.1998.00095.x; HERSHKO A, 1982, ANNU REV BIOCHEM, V51, P335, DOI 10.1146/annurev.bi.51.070182.002003; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUANG WH, 1994, BBA-BIOMEMBRANES, V1190, P108, DOI 10.1016/0005-2736(94)90039-6; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KIM YK, 1988, PHARMACOL TOXICOL, V63, P342, DOI 10.1111/j.1600-0773.1988.tb00966.x; Kinne RKH, 1995, TOXICOL APPL PHARM, V135, P216, DOI 10.1006/taap.1995.1226; Klaassen CD, 1997, DRUG METAB REV, V29, P79, DOI 10.3109/03602539709037574; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Liu J, 1998, TOXICOL APPL PHARM, V153, P48, DOI 10.1006/taap.1998.8506; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Messler P, 1996, J NEUROSCI METH, V69, P137, DOI 10.1016/S0165-0270(96)00032-5; O'Brien P, 1998, ARCH TOXICOL, V72, P690, DOI 10.1007/s002040050562; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PISCATOR M, 1986, CADMIUM HDB EXPT PHA, V80, P194; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIMADA H, 1991, J PHARMACOBIO-DYNAM, V14, P555, DOI 10.1248/bpb1978.14.555; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SUN XM, 1992, ANAL BIOCHEM, V204, P351, DOI 10.1016/0003-2697(92)90251-2; TANAKA M, 1995, VET HUM TOXICOL, V37, P203; Thevenod F, 1996, J BIOL CHEM, V271, P3300, DOI 10.1074/jbc.271.6.3300; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; Wagner CA, 1996, AM J PHYSIOL-RENAL, V271, pF926, DOI 10.1152/ajprenal.1996.271.4.F926; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; ZOLOTARJOVA N, 1994, BBA-BIOMEMBRANES, V1192, P125, DOI 10.1016/0005-2736(94)90152-X	52	182	187	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1751	1761		10.1096/fasebj.13.13.1751	http://dx.doi.org/10.1096/fasebj.13.13.1751			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506578				2022-12-28	WOS:000083063400010
J	Bellio, M; Oliveira, ACSC; Mermelstein, CS; Capella, MAM; Viola, JPB; Levraud, JP; Dosreis, GA; Previato, JO; Mendonca-Previato, L				Bellio, M; Oliveira, ACSC; Mermelstein, CS; Capella, MAM; Viola, JPB; Levraud, JP; Dosreis, GA; Previato, JO; Mendonca-Previato, L			Costimulatory action of glycoinositolphospholipids from Trypanosoma cruzi: increased interleukin 2 secretion and induction of nuclear translocation of the nuclear factor of activated T cells 1	FASEB JOURNAL			English	Article						T cell activation; ceramide; costimulation; Chagas' disease; cytosolic calcium	TRANSCRIPTION FACTOR NFAT1; GENE-EXPRESSION; KAPPA-B; LEISHMANIA-DONOVANI; SIGNAL TRANSDUCTION; IFN-GAMMA; IN-VITRO; CERAMIDE; MACROPHAGES; SPHINGOSINE	The effects of the glycoinositolphospholipids (GIPLs) from Trypanosoma cruzi on T lymphocyte activation were investigated in a mouse T cell hybridoma (DO-11.10), Purified GIPLs from T. cruzi strains Y and G markedly increased IL-2 mRNA transcripts and IL-2 secretion induced by mitogenic anti-CD3 and anti-Thy1 mAbs, This costimulatory function was also revealed by the induction of IL-2 secretion after the simultaneous addition of the T, cruzi GIPLs and either the calcium ionophore A23187 or phorbol ester, The capacity of the GIPL molecule to induce an increase in cytoplasmic calcium levels was also demonstrated, After exposure of T cell hybridoma to GIPL, the nuclear transcription factor NFAT1 became partially dephosphorylated, and its nuclear localization was demonstrated both in the T cell hybridoma and in Balb/c CD3(+) cells. These results demonstrate that T. cruzi GIPL molecules are capable of signaling to T cells and therefore could be valuable tools for the study of T cell activation, besides playing a potential role in subverting the T lymphocyte immune response during T, cruzi infection.	UFRJ, Dept Imunol, Inst Microbiol Prof Paulo de Goes, BR-21941590 Rio De Janeiro, Brazil; UFRJ, ICB, Dept Histol & Embriol, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil; Inst Nacl Canc, Programa Med Expt, Rio De Janeiro, Brazil; Inst Pasteur, ISERM U277, F-75724 Paris 15, France	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Cancer Institute (Inca); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bellio, M (corresponding author), UFRJ, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS Bl 1-2 Andar Sala 12-053, BR-21941590 Rio De Janeiro, Brazil.		Capella, Marcia/F-1097-2013; Oliveira, Ana Carolina/GRF-1435-2022; Oliveira, Ana Carolina/O-6791-2014; Viola, Joao P.B./AAP-4125-2020; mermelstein, Claudia S/C-1464-2010; Bellio, Maria/N-8525-2018	Capella, Marcia/0000-0001-8407-9235; Oliveira, Ana Carolina/0000-0002-0036-3720; Viola, Joao P.B./0000-0002-0698-3146; mermelstein, Claudia S/0000-0002-8897-8526; Bellio, Maria/0000-0002-3360-2740; DosReis, George/0000-0002-8924-4727; Previato, Jose Osvaldo/0000-0002-9233-9954; Mendonca Previato, Lucia/0000-0003-3927-3244				Azuara V, 1997, EUR J IMMUNOL, V27, P544, DOI 10.1002/eji.1830270228; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bento CAM, 1996, J IMMUNOL, V157, P4996; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Burleigh BA, 1998, CURR OPIN MICROBIOL, V1, P461, DOI 10.1016/S1369-5274(98)80066-0; Camargo MM, 1997, J IMMUNOL, V159, P6131; Carreira JC, 1996, GLYCOCONJUGATE J, V13, P955, DOI 10.1007/BF01053191; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DELASSUS S, 1994, J IMMUNOL, V152, P2411; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DESCOTEAUX A, 1991, J IMMUNOL, V146, P2747; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Freire-de-Lima CG, 1998, J IMMUNOL, V161, P4909; Gazzinelli RT, 1997, CHEM IMMUNOL, V68, P136; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; GOLGHER DB, 1993, MOL BIOCHEM PARASIT, V60, P249, DOI 10.1016/0166-6851(93)90136-L; Gomes NA, 1996, J IMMUNOL, V156, P628; GOTTLIEB M, 1978, EXP PARASITOL, V45, P200, DOI 10.1016/0014-4894(78)90060-7; GOTTLIEB M, 1977, J IMMUNOL, V119, P465; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hashizume T, 1998, BIOCHEM MOL BIOL INT, V44, P489; HO AM, 1994, J BIOL CHEM, V269, P28181; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KAPPLER J, 1986, HDB EXPT IMMUNOLOGY, V2; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; LOPES MF, 1995, J IMMUNOL, V154, P744; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATTHIAS S, 1993, SCIENCE, V259, P519; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; Michel C, 1997, FEBS LETT, V416, P153, DOI 10.1016/S0014-5793(97)01187-3; MINOPRIO P, 1989, IMMUNOL REV, V112, P187; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Routier Francoise, 1993, Ciencia e Cultura (Sao Paulo), V45, P66; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SMITH SW, 1974, J BIOL CHEM, V249, P3395; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tokura Y, 1996, J INVEST DERMATOL, V107, P34, DOI 10.1111/1523-1747.ep12297849; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; XAVIER MT, 1991, CULT J BRAZ ASS ADV, V43, P49; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3; YANG ZH, 1993, J BIOL CHEM, V268, P20520	57	13	13	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1627	1636		10.1096/fasebj.13.12.1627	http://dx.doi.org/10.1096/fasebj.13.12.1627			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463955				2022-12-28	WOS:000082347600019
J	Klatt, P; Molina, EP; De Lacoba, MG; Padilla, CA; Martinez-Galisteo, E; Barcena, JA; Lamas, S				Klatt, P; Molina, EP; De Lacoba, MG; Padilla, CA; Martinez-Galisteo, E; Barcena, JA; Lamas, S			Redox regulation of c-Jun DNA binding by reversible S-glutathiolation	FASEB JOURNAL			English	Article						glutathione; redox regulation; S; thiolation; transcription factor	THIOLTRANSFERASE GLUTAREDOXIN; INSULIN DISULFIDES; OXIDATIVE STRESS; NITRIC-OXIDE; RAT-LIVER; PROTEIN; FOS; THIOREDOXIN; THIOLATION; REDUCTION	Redox control of the transcription factor c-Jun maps to a single cysteine in its DNA binding domain. However, the nature of the oxidized state of this cysteine and, thus, the potential molecular mechanisms accounting for the redox regulation of c-Jun DNA binding remain unclear. To address this issue, we have analyzed the purified recombinant c-Jun DNA binding domain for redox-dependent thiol modifications and concomitant changes in DNA binding activity. We show that changes in the ratio of reduced to oxidized glutathione provide the potential to oxidize c-Jun sulfhydryls by mechanisms that include both protein disulfide formation and S-glutathiolation, We provide evidence that S-glutathiolation, which is specifically targeted to the cysteine residue located in the DNA binding site of the protein, may account for the reversible redox regulation of c-Jun DNA binding. Furthermore, based on a molecular model of the S-glutathiolated protein, we discuss the structural elements facilitating S-glutathiolation and how this modification interferes with DNA binding, Given the structural similarities between the positively charged cysteine-containing DNA binding motif of c-Jun and the DNA binding site of related oxidant-sensitive transcriptional activators, the unprecedented phenomenon of redox-triggered S-thiolation of a transcription factor described in this report suggests a novel role for protein thiolation in the redox control of transcription.	CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Inst Reina Invest Nefrol, E-28006 Madrid, Spain; Univ Cordoba, Fac Vet, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Cordoba	Klatt, P (corresponding author), CSIC, Ctr Invest Biol, Dept Estructura & Func Prot, Inst Reina Invest Nefrol, Velazquez 144, E-28006 Madrid, Spain.		Padilla, C. Alicia/H-4736-2015; Bárcena, José Antonio/I-2622-2015; Lamas, Santiago/G-7308-2015; Pineda-Molina, Estela/K-9969-2014	Padilla, C. Alicia/0000-0002-9503-8284; Bárcena, José Antonio/0000-0002-5626-5943; Lamas, Santiago/0000-0001-5166-4155; Pineda-Molina, Estela/0000-0002-4266-0192				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BUSHWELLER JH, 1997, EUR J BIOCHEM, V235, P1585; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; OEHLER T, 1993, ONCOGENE, V8, P1141; Padilla CA, 1996, FEBS LETT, V378, P69; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; PEREIRA MEF, 1998, J BIOL CHEM, V273, P12703; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, METHOD ENZYMOL, V234, P163; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	37	232	236	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1481	1490		10.1096/fasebj.13.12.1481	http://dx.doi.org/10.1096/fasebj.13.12.1481			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463938				2022-12-28	WOS:000082347600002
J	Schliess, F; Wiese, S; Haussinger, D				Schliess, F; Wiese, S; Haussinger, D			Osmotic regulation of the heat shock response in H4IIE rat hepatoma cells	FASEB JOURNAL			English	Article						MAP kinase; JNK; heat; c-Jun; Hsp70; MKP-1; cell volume; arsenite	PROTEIN-KINASE; TAUROCHOLATE EXCRETION; HSP70 EXPRESSION; STRESS PROTEINS; GENE-EXPRESSION; PATHWAY; LIVER; ACTIVATION; VOLUME; THERMOTOLERANCE	The influence of cell hydration on the heat shock response was investigated in H4IIE hepatoma cells at the levels of HSP70 expression, MAP kinase activation, induction of c-jun and the RAP kinase phosphatase MKP-1, heat resistance, and development of tolerance/sensitization to arsenite after a priming heat treatment. Induction of HSP70, MKP-1, and c-jun by heat was delayed, but more pronounced or sustained, under hyperosmotic conditions compared with normo- and hypo-osmotically exposed cells. Anisosmolarity per sc was ineffective to induce HSP70; some expression of the mRNAs for MKP-1 and c-jun in response to hyperosmolarity nas found, but was small compared with the response to heat. Heat-induced activation of JNK-1 was increased under hyperosmotic conditions and more sustained than the JNK-activity induced by hyperosmolarity at 37 degrees C, A prominent Erk-2 activation was found immediately after heat shock under hypo- and normo-osmotic conditions, but Erk-2 activation was weak in hyperosmolarity-exposed cells. Despite anisosmotic alterations of the heat shock response at the molecular level, the heat resistance of H4IIE cells toward heat shock was not affected by ambient osmolarity, However, an osmolarity-dependent sensitization to arsenite was: induced by a priming heat shock. The osmodependence of the H4IIE cell response to heat differs from that recently found in primary rat hepatocytes, The data are discussed in terms of cellular adaption mechanisms and their physiological relevance.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Dusseldorf, Med Einrichtungen, Klin Gastroenterol, Moorenstr 5, D-40225 Dusseldorf, Germany.							Bisht K. S., 1996, Indian Journal of Experimental Biology, V34, P1183; Cantoni O, 1996, FEBS LETT, V389, P285, DOI 10.1016/0014-5793(96)00605-9; Caruccio L, 1997, BIOCHEM J, V327, P341, DOI 10.1042/bj3270341; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; COWLEY DB, 1995, AM J PHYSIOL, V269, pF854; FINKENZELLER G, 1994, FEBS LETT, V340, P163, DOI 10.1016/0014-5793(94)80129-0; HALLBRUCKER C, 1992, BIOCHEM J, V281, P593, DOI 10.1042/bj2810593; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; Hightower LE, 1997, HEPATOLOGY, V25, P1279, DOI 10.1002/hep.510250539; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KLEMPERER NS, 1989, J BIOL CHEM, V264, P19245; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LI DX, 1995, EUR J BIOCHEM, V231, P454, DOI 10.1111/j.1432-1033.1995.tb20719.x; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; PARSELL DA, 1993, PHILOS T R SOC B, V339, P279, DOI 10.1098/rstb.1993.0026; PETRONINI PG, 1993, BIOCHEM J, V293, P553, DOI 10.1042/bj2930553; Rauchman MI, 1997, AM J PHYSIOL-RENAL, V273, pF9, DOI 10.1152/ajprenal.1997.273.1.F9; SAHA N, 1992, EUR J BIOCHEM, V209, P437, DOI 10.1111/j.1432-1033.1992.tb17307.x; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATO N, 1991, ENDOCRINOLOGY, V129, P2541, DOI 10.1210/endo-129-5-2541; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wettstein M, 1997, HEPATOLOGY, V26, P1560; Wiese S, 1998, BIOL CHEM, V379, P667, DOI 10.1515/bchm.1998.379.6.667; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	35	19	19	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1557	1564		10.1096/fasebj.13.12.1557	http://dx.doi.org/10.1096/fasebj.13.12.1557			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463947				2022-12-28	WOS:000082347600011
J	Schmid, E; Hotz-Wagenblatt, A; Hack, V; Droge, W				Schmid, E; Hotz-Wagenblatt, A; Hack, V; Droge, W			Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming	FASEB JOURNAL			English	Article						insulin responsiveness; redox regulation; signal transduction; tyrosine kinase	DEPENDENT DIABETES-MELLITUS; PROTEIN-TYROSINE KINASE; CRYSTAL-STRUCTURE; SKELETAL-MUSCLE; GLUCOSE-TOLERANCE; RAT ADIPOCYTES; FREE-RADICALS; BETA-SUBUNIT; INTACT-CELLS; AUTOPHOSPHORYLATION	Signaling by insulin requires autophosphorylation of the insulin receptor kinase (IRK) at Tyr1158, Tyr1162, and Tyr1163, Earlier experiments with P-32-gamma-ATP indicated that the nonphosphorylated IRK (IRK-0P) is relatively inactive, and crystallogaphic data indicated that the ATP binding site of IRK-OP is blocked by its activation loop. We now show that phosphocreatine (PCr) in combination with hydrogen peroxide serves as an alternative phosphate donor and that ATP and PCr use distinct binding sites. Whereas phosphorylation of the Wt by ATP is inhibited by the nonhydrolyzable competitor adenylyl-imidodiphosphate, phosphorylation by PCr is enhanced, The IRK mutant Try1158Phe showed no phosphorylation with PCr but almost normal phosphorylation with ATP, whereas: Tyr1162Phe was phosphorylated well with PCr but less then normal with ATP, 3-Dimensional models of IRK-OP revealed that the conversion of any of the four cysteine residues 1056, 1138, 1234, and 1245 into sulfenic acid produces structural changes that bring Tyr1158 into close contact with Asp1083 and render the well-known catalytic site at Asp1132 and Tyr1162 accessible from a direction that differs from the known ATP binding site. The mutant Cys1158Ala, in contrast, showed relatively inaccessible catalytic sites and weak catalytic activity in functional experiments, Taken together, these findings indicate that 'redox priming' of the IRK facilitates its autophosphorylation by PCr in the activation loop.	Deutsch Krebsforschungszentrum, Div Immunochem, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Biophys, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Droge, W (corresponding author), Deutsch Krebsforschungszentrum, Div Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; CAHILL GF, 1971, DIABETES, V20, P785, DOI 10.2337/diab.20.12.785; Carvalho CRO, 1996, ENDOCRINOLOGY, V137, P151, DOI 10.1210/en.137.1.151; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; DeFronzo RA, 1997, DIABETES REV, V5, P177; DICKENS M, 1992, BIOCHEM BIOPH RES CO, V186, P244, DOI 10.1016/S0006-291X(05)80799-5; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; FUKAGAWA NK, 1989, AM J PHYSIOL, V256, pE288, DOI 10.1152/ajpendo.1989.256.2.E288; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; HAGLER AT, 1974, J AM CHEM SOC, V96, P5327, DOI 10.1021/ja00824a005; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KANEMITSU F, 1982, CLIN CHIM ACTA, V119, P307; KING DS, 1995, J APPL PHYSIOL, V78, P17, DOI 10.1152/jappl.1995.78.1.17; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LEW H, 1985, FEBS LETT, V185, P262, DOI 10.1016/0014-5793(85)80919-4; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MACAULAY SL, 1985, BIOCHEM J, V306, P811; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; POOLE LB, 1989, J BIOL CHEM, V264, P12330; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; Schmid E, 1998, FASEB J, V12, P863, DOI 10.1096/fasebj.12.10.863; SCHNEIDER SH, 1992, DIABETES CARE, V15, P1800, DOI 10.2337/diacare.15.11.1800; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; SEN CK, 1994, J APPL PHYSIOL, V77, P2177, DOI 10.1152/jappl.1994.77.5.2177; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STEPHENS RM, 1994, NEURON, V12, P1; Supinski G, 1998, MOL CELL BIOCHEM, V179, P99, DOI 10.1023/A:1006859920875; TAKAYAMA S, 1988, J CLIN ENDOCR METAB, V66, P992, DOI 10.1210/jcem-66-5-992; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; VERTECHY M, 1989, EXP GERONTOL, V24, P211, DOI 10.1016/0531-5565(89)90012-0; Wallberg-Henriksson H, 1992, Exerc Sport Sci Rev, V20, P339; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	62	69	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1491	1500		10.1096/fasebj.13.12.1491	http://dx.doi.org/10.1096/fasebj.13.12.1491			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463939				2022-12-28	WOS:000082347600003
J	Kooby, DA; Carew, JF; Halterman, MW; Mack, JE; Bertino, JR; Blumgart, LH; Federoff, HJ; Fong, YM				Kooby, DA; Carew, JF; Halterman, MW; Mack, JE; Bertino, JR; Blumgart, LH; Federoff, HJ; Fong, YM			Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)	FASEB JOURNAL			English	Article						attenuated virus; gene therapy; hepatobiliary tumors; replication; competent	RIBONUCLEOTIDE REDUCTASE; COLONIC-CARCINOMA; THYMIDINE KINASE; DELETION MUTANT; INVIVO BEHAVIOR; DNA-SYNTHESIS; GENE-THERAPY; REPLICATION; CELLS; GROWTH	G207 is a multi-mutated, replication-competent type-1 herpes simplex virus designed to target, infect, and lyse neurological tumors. This study examines the feasibility of using G207 in the treatment of human colorectal cancer and defines the biological determinants of its antitumor efficacy. This virus was tested on five human colorectal cancer cell lines in vitro to determine efficacy of infection and tumor cell kill. These results were correlated to measures of tumor cell proliferation. In vivo testing was performed through direct injections of G207 into xenografts of human colorectal cancer tumors grown in flanks of athymic rats. To evaluate an alternate method of administration, hepatic portal vein infusion of G207 was performed in a syngeneic model of liver metastases in Buffalo rats. Among the five cell lines tested, infection rates ranged between 10% and 90%, which correlated directly with S-phase fraction (8.6%-36.6%) and was proportional to response to G207 therapy in vitro (1%-93%). Direct injection of G207 into nude rat flank tumors suppressed tumor growth significantly vs. control (0.58 +/- 0.60 cm(3) vs. 9.16 +/- 3.70 cm(3), P<0. 0001). In vivo tumor suppression correlated with in vitro effect. In the syngeneic liver tumor model, portal infusion resulted in significant reduction in number of liver nodules (13 +/- 10 nodules in G207-treated livers vs. 80 +/- 30 nodules in control livers, P<0.05). G207 infects and kills human colorectal cancer cells efficiently. In vitro cytotoxicity assay and tumor S-phase fraction can be used to predict response to treatment in vivo. This antineoplastic agent can be delivered effectively by both direct tumor injection and regional vascular infusion. G207 should be investigated further as therapy for colorectal cancer and liver metastases.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurosci, Rochester, NY 14642 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester; University of Rochester	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	fongy@mskcc.org			NCI NIH HHS [T32 CA 09685, T32 CA 09501, CA 76416] Funding Source: Medline; NIMH NIH HHS [F30 MH012305, F30 MH012305-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009685, T32CA009501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH012305] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Advani SJ, 1998, GENE THER, V5, P160, DOI 10.1038/sj.gt.3300546; AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; Carroll NM, 1996, ANN SURG, V224, P323, DOI 10.1097/00000658-199609000-00008; CARUSO M, 1993, P NATL ACAD SCI USA, V90, P7024, DOI 10.1073/pnas.90.15.7024; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; DEBRAUW LM, 1987, J SURG ONCOL, V34, P81, DOI 10.1002/jso.2930340204; Fong Y, 1996, SEMIN SURG ONCOL, V12, P219, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<219::AID-SSU3>3.0.CO;2-8; Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GOLDSTEIN DJ, 1988, J VIROL, V62, P2970, DOI 10.1128/JVI.62.8.2970-2977.1988; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; JIA WWG, 1994, J NATL CANCER I, V86, P1209, DOI 10.1093/jnci/86.16.1209; Karpoff HM, 1997, J CLIN INVEST, V99, P799, DOI 10.1172/JCI119226; KENNEY S, 1994, J NATL CANCER I, V86, P1185, DOI 10.1093/jnci/86.16.1185; Kucharczuk JC, 1997, CANCER RES, V57, P466; LAFRENIERE R, 1986, J NATL CANCER I, V76, P309; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; MEIGNIER B, 1990, J INFECT DIS, V162, P313, DOI 10.1093/infdis/162.2.313; MEIGNIER B, 1988, J INFECT DIS, V158, P602, DOI 10.1093/infdis/158.3.602; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Miyatake SI, 1997, CANCER GENE THER, V4, P222; PANIS Y, 1992, BRIT J SURG, V79, P221, DOI 10.1002/bjs.1800790309; Roizman B, 1996, P NATL ACAD SCI USA, V93, P11307, DOI 10.1073/pnas.93.21.11307; Roizman B, 1997, J NEUROVIROL, V3, pS1; Toda M, 1998, HUM GENE THER, V9, P2177, DOI 10.1089/hum.1998.9.15-2177; Toda M, 1998, J IMMUNOL, V160, P4457; Tung C, 1996, HUM GENE THER, V7, P2217, DOI 10.1089/hum.1996.7.18-2217; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600; WILLETT CG, 1984, ANN SURG, V200, P685, DOI 10.1097/00000658-198412000-00001; Wood C B, 1976, Clin Oncol, V2, P285; YAZAKI T, 1995, CANCER RES, V55, P4752	38	151	153	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1325	1334		10.1096/fasebj.13.11.1325	http://dx.doi.org/10.1096/fasebj.13.11.1325			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428757				2022-12-28	WOS:000082019100005
J	Levy, BD; Fokin, VV; Clark, JM; Wakelam, MJO; Petasis, NA; Serhan, CN				Levy, BD; Fokin, VV; Clark, JM; Wakelam, MJO; Petasis, NA; Serhan, CN			Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A(4)	FASEB JOURNAL			English	Article						eicosanoids; lipid mediators; inflammation; PMN	HUMAN-NEUTROPHILS; 15-EPI-LIPOXIN A(4); STABLE ANALOGS; LEUKOTRIENE B-4; CELLS; BIOSYNTHESIS; ACTIVATION; LEUKOCYTES; RECEPTORS; OXIDASE	It is of wide interest to understand how opposing extracellular signals (positive or negative) are translated into intracellular signaling events. Receptor-ligand interactions initiate the generation of bioactive lipids by human neutrophils (PMN), which serve as signals to orchestrate cellular responses important in host defense and inflammation. We recently identified a novel polyisoprenyl phosphate (PIPP) signaling pathway and found that one of its components, presqualene diphosphate (PSDP), is a potent negative intracellular signal in PMN that regulates superoxide anion generation by several stimuli, including phosphatidic acid, We determined intracellular PIPP signaling by autocoids with opposing actions on PMN: leukotriene B-4 (LTB4), a potent chemoattractant, and lipoxin A(4) (IXA(4)), a 'stop signal' for recruitment, LTB4 receptor activation initiated a rapid decrease in PSDP levels concurrent with activation of PLD and cellular responses. In sharp contrast, activation of the LXA(4) receptor reversed LTB4-initiated PSDP remodeling, leading to an accumulation of PSDP and potent inhibition of both PLD and superoxide anion generation, Thus, an inverse relationship was established for PSDP levers and PLD activity with two PMN ligands that evoke opposing responses. In addition, PSDP directly inhibited both isolated human recombinant (K-i = 6 nM) and plant (K-i = 20 nM) PLD, Together, these findings link PIPP remodeling to intracellular regulation of PMN function and suggest a role for PIPPs as lipid repressors in signal transduction, a novel mechanism that may also explain aspirin's suppressive actions in vivo in cell signaling.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; Univ Birmingham, Inst Canc Studies, Birmingham B15 2TH, W Midlands, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Southern California; University of Birmingham	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St,Thorn 724, Boston, MA 02115 USA.		Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446; Wakelam, Michael/0000-0003-4059-9276	NHLBI NIH HHS [HL-56383] Funding Source: Medline; NIDDK NIH HHS [DK-50305] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSALHAM A, 1993, BIOCHIM BIOPHYS ACTA, V1158, P1, DOI 10.1016/0304-4165(93)90088-P; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BORGEAT P, 1990, CLIN BIOCHEM, V23, P459, DOI 10.1016/0009-9120(90)90272-V; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; FIORE S, 1993, BLOOD, V81, P3395; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; Herschman HR, 1998, TRENDS CARDIOVAS MED, V8, P145, DOI 10.1016/S1050-1738(98)00004-8; ISAKSON P, 1995, ADV PROSTAG THROMB L, V23, P49; Jarstfer MB, 1996, J AM CHEM SOC, V118, P13089, DOI 10.1021/ja963308s; Levy BD, 1997, NATURE, V389, P985, DOI 10.1038/40180; MARCUS AJ, 1995, NEW ENGL J MED, V333, P656, DOI 10.1056/NEJM199509073331011; Martin A, 1997, BIOCHEM SOC T, V25, P1157, DOI 10.1042/bst0251157; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RABINOWITZ JL, 1992, LIPIDS, V27, P311, DOI 10.1007/BF02536483; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SHECHTER I, 1980, J LIPID RES, V21, P277; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Vainio H, 1997, PHARMACOL TOXICOL, V81, P151, DOI 10.1111/j.1600-0773.1997.tb02060.x; Wakelam MJO, 1997, ADV ENZYME REGUL, V37, P29, DOI 10.1016/S0065-2571(96)00023-4; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHOU HL, 1993, BIOCHEM PHARMACOL, V46, P139	35	92	94	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					903	911		10.1096/fasebj.13.8.903	http://dx.doi.org/10.1096/fasebj.13.8.903			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224233				2022-12-28	WOS:000080372500013
J	Schett, G; Steiner, CW; Groger, M; Winkler, S; Graninger, W; Smolen, J; Xu, QB; Steiner, G				Schett, G; Steiner, CW; Groger, M; Winkler, S; Graninger, W; Smolen, J; Xu, QB; Steiner, G			Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70	FASEB JOURNAL			English	Article						Fas activation; antibody; heat shock element; apoptosis hsp	TUMOR-NECROSIS-FACTOR; STRESS-INDUCED APOPTOSIS; SHOCK-PROTEIN HSP70; MEDIATED APOPTOSIS; MONOCLONAL-ANTIBODY; ICE/CED-3 PROTEASE; DEATH FACTOR; ICE-LIKE; CELLS; EXPRESSION	Activation of heat shock factor (HSF) 1-DNA binding and inducible heat shock protein (hsp) 70 (also called hsp72) expression enables cells to resist various forms of stress and survive. Fas, a membrane-bound protein, is a central proapoptotic factor; its activation leads to a cascade of events, resulting in programmed cell death. These two mechanisms with contradictory functions, promoting either cell survival or death, were examined for their potential to inhibit each other's activation. Induction of FAS-mediated signaling was followed by a rapid decrease in HSF1-DNA binding and inducible hsp70 expression. Inhibition of HSF1-DNA binding was demonstrated to be based on absent hyperphosphorylation of HSF1 during FAS signaling. These effects of FAS activation on the HSF1/hsp70 stress response were blocked by ICE (caspase 1) inhibitors, suggesting an ICE-mediated process. Furthermore, inhibition of HSF1/hsp70 was accompanied by an increase in apoptosis rates from 20% to 50% in response to heat stress. When analyzing the effects of HSF1/hsp70 activation on Fas-mediated apoptosis, protection from apoptosis was seen in cells with induced hsp70 protein levels, but not in cells that were just induced for HSF1-DNA binding. Thus, we conclude that inhibition of HSF1/hsp70 stress response during Fas-mediated apoptosis and vice versa may facilitate a cell. to pass a previously chosen pathway, stress resistance or apoptosis, without the influence of inhibitory signals.	Univ Vienna, Div Rheumatol, Dept Internal Med 3, A-1090 Vienna, Austria; Univ Vienna, Dept Immunodermatol, A-1090 Vienna, Austria; Univ Vienna, Div Infectiol, Dept Internal Med 1, A-1090 Vienna, Austria; Austrian Acad Sci, Inst Biomed Aging Res, Innsbruck, Austria; Ludwig Boltzmann Inst Rheumatol & Balneol, Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; Austrian Academy of Sciences; Ludwig Boltzmann Institute	Schett, G (corresponding author), Univ Vienna, Div Rheumatol, Dept Internal Med 3, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Graninger, Winfried/AAI-7192-2020	Graninger, Winfried/0000-0002-3489-3439; Steiner, Guenter/0000-0002-5089-7405				BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Chant ID, 1996, BRIT J HAEMATOL, V93, P898, DOI 10.1046/j.1365-2141.1996.d01-1737.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Ding XZ, 1998, FASEB J, V12, P451, DOI 10.1096/fasebj.12.6.451; Ding XZ, 1997, J CLIN INVEST, V99, P136, DOI 10.1172/JCI119124; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FILIPPOVICH I, 1994, BIOCHEM BIOPH RES CO, V198, P257, DOI 10.1006/bbrc.1994.1036; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Kuo ML, 1997, MOL CARCINOGEN, V18, P221, DOI 10.1002/(SICI)1098-2744(199704)18:4<221::AID-MC6>3.0.CO;2-G; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liossis SNC, 1997, J IMMUNOL, V158, P5668; Liossis SNC, 1998, CLIN IMMUNOL IMMUNOP, V86, P235, DOI 10.1006/clin.1997.4482; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Morimoto RI, 1990, STRESS PROTEINS BIOL; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OguriHyakumachi N, 1995, INT J IMMUNOPHARMACO, V17, P913, DOI 10.1016/0192-0561(95)00082-8; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Schett G, 1995, J CLIN INVEST, V96, P2569, DOI 10.1172/JCI118320; Schett G, 1998, J CLIN INVEST, V102, P302, DOI 10.1172/JCI2465; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; WEI YQ, 1994, CANCER RES, V54, P4952; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu QB, 1996, LAB INVEST, V74, P178; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	43	67	72	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					833	842		10.1096/fasebj.13.8.833	http://dx.doi.org/10.1096/fasebj.13.8.833			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224227	Bronze			2022-12-28	WOS:000080372500007
J	Deissler, H; Blass-Kampmann, S; Bruyneel, E; Mareel, M; Rajewsky, MF				Deissler, H; Blass-Kampmann, S; Bruyneel, E; Mareel, M; Rajewsky, MF			Neural cell surface differentiation antigen gp130(RB13-6) induces fibroblasts and glioma cells to express astroglial proteins and invasive properties	FASEB JOURNAL			English	Article						glial cells; astrocytes; GFAP; invasion; neurooncogenesis	FIBRILLARY ACIDIC PROTEIN; MEMBRANE GLYCOPROTEIN PC-1; PRENATAL RAT-BRAIN; LONG-TERM CULTURES; CDNA CLONING; PROGENITOR CELLS; INSULIN-RECEPTOR; GROWTH-FACTORS; THY-1 ANTIGEN; MESSENGER-RNA	Transient expression of the differentiation and tumor cell surface antigen gp130(RB13-6) characterizes a subset of rat glial progenitor cells susceptible to ethylnitrosourea-induced neurooncogenesis, gp130(RB13-6) is as a member of an emerging protein family of ecto-phosphodiesterases/nucleotide pyrophosphatases that includes PC-1 and the tumor cell motility factor autotaxin. We have investigated the potential role of gp130(RB13-6), glial differentiation by transfection of three cell lines of different origin that do not express endogenous gp130(RB13-6) (NIH-3T3 mouse fibroblasts; C6 and BT7Ca rat glioma cells) with the cDNA encoding gp130(RB13-6). The effect of gp130(RB13-6) expression was analyzed in terms of overall cell morphology, the expression of glial cell-specific marker proteins, and invasiveness. Transfectant sublines, consisting of 100% gp130(RB13-6)-positive cells, exhibited an altered, bipolar morphology. Fascicular aggregates of fibroblastoid cells subsequently developed into mesh-like patterns. Contrary to the parental NIH-3T3 and BT7Ca cells, the transfectant cells invaded into collagen type I. As shown by immunofluorescence staining of the transfectant sublines as well as of primary cultures composed of gp130(RB13-6)-positive and -negative cells, expression of gp130(RB13-6) induced coexpression of proteins typical for glial cells and their precursors, i.e., glial fibrillary acidic protein, the low affinity nerve growth factor receptor, and the neural proteins Thy-1, Ran-2, and S-100. In accordance with its expression in the immature rat nervous system, gp130(RB13-6) may thus have a significant role in the glial differentiation program and its subversion in neurooncogenesis.	Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium	University of Duisburg Essen; Ghent University; Ghent University Hospital	Rajewsky, MF (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, Hufelandstr 55, D-45122 Essen, Germany.	rajewsky@uni-essen.de						BARTLETT PF, 1981, BRAIN RES, V204, P339, DOI 10.1016/0006-8993(81)90593-X; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; Blass-Kampmann S, 1998, NEUROPATH APPL NEURO, V24, P9; BlassKampmann S, 1997, J NEUROSCI RES, V48, P95, DOI 10.1002/(SICI)1097-4547(19970415)48:2<95::AID-JNR2>3.0.CO;2-7; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; BROWN RH, 1984, BRAIN RES, V296, P87, DOI 10.1016/0006-8993(84)90513-4; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CHIU FC, 1985, J NEUROIMMUNOL, V8, P283, DOI 10.1016/S0165-5728(85)80067-9; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; Deissler H, 1996, J NEUROSCI RES, V43, P664, DOI 10.1002/(SICI)1097-4547(19960315)43:6<664::AID-JNR3>3.3.CO;2-L; DIMANCHEBOITREL MT, 1994, CANCER LETT, V85, P171, DOI 10.1016/0304-3835(94)90271-2; DUX R, 1991, CYTOMETRY, V12, P422, DOI 10.1002/cyto.990120507; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; GOLDMAN JE, 1984, J NEUROCHEM, V42, P175, DOI 10.1111/j.1471-4159.1984.tb09714.x; GRUPE A, 1995, J BIOL CHEM, V270, P22085, DOI 10.1074/jbc.270.38.22085; INAGAKI M, 1994, BRAIN PATHOL, V4, P239, DOI 10.1111/j.1750-3639.1994.tb00839.x; JinHua P, 1997, GENOMICS, V45, P412, DOI 10.1006/geno.1997.4949; Kettenhofen R, 1998, J MOL BIOL, V279, P323, DOI 10.1006/jmbi.1998.1768; KILPATRICK TJ, 1995, MOL CELL NEUROSCI, V6, P2, DOI 10.1006/mcne.1995.1002; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; LAERUM OD, 1977, Z KREBSFORSCH KLIN O, V89, P273, DOI 10.1007/BF00283783; LAPING NJ, 1994, BRAIN PATHOL, V4, P259, DOI 10.1111/j.1750-3639.1994.tb00841.x; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MORRISON RS, 1983, DEV BRAIN RES, V9, P337, DOI 10.1016/0165-3806(83)90030-5; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; MURATA J, 1994, J BIOL CHEM, V269, P30479; ODA Y, 1991, J BIOL CHEM, V266, P16791; PRUSS RM, 1979, NATURE, V280, P688, DOI 10.1038/280688a0; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RUTKA JT, 1988, INT J CANCER, V42, P419, DOI 10.1002/ijc.2910420319; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Scott LJ, 1997, HEPATOLOGY, V25, P995, DOI 10.1002/hep.510250434; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; Stefan C, 1996, DIABETES, V45, P980, DOI 10.2337/diabetes.45.7.980; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; VAKAET L, 1991, INVAS METAST, V11, P249; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882	42	38	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					657	666		10.1096/fasebj.13.6.657	http://dx.doi.org/10.1096/fasebj.13.6.657			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094926				2022-12-28	WOS:000079527200007
J	Cousin, B; Munoz, O; Andre, M; Fontanilles, AM; Dani, C; Cousin, JL; Laharrague, P; Casteilla, L; Penicaud, L				Cousin, B; Munoz, O; Andre, M; Fontanilles, AM; Dani, C; Cousin, JL; Laharrague, P; Casteilla, L; Penicaud, L			A role for preadipocytes as macrophage-like cells	FASEB JOURNAL			English	Article						tumor necrosis factor; cell culture; ROS; stromal cells; antigens; SOD	TUMOR-NECROSIS-FACTOR; ADIPOSE-TISSUE; MONOCLONAL-ANTIBODIES; DIFFERENTIATION; ADIPOCYTES; EXPRESSION; COMPLEMENT; RAT; HETEROGENEITY; FIBROBLAST	Several lines of evidence have supported a link betweeen adipose tissue and immunocompetent cells. This link is illustrated in obesity, where excess adiposity and impaired immune function have been described in both humans and genetically obese rodents. In addition, numerous factors involved in inflammatory response are secreted by both preadipocytes and macrophages. Here we show that proliferating preadipocytes in cell lines and primary cultures, develop phagocytic activity toward microorganisms. This is demonstrated by phagocytosis assays and confocal microscopy. This function disappears when preadipocytes stop proliferating and differentiate into adipocytes. After phagocytosis, preadipocytes show microbicide activity via an oxygen-dependent mechanism. In addition, preadipocytes as well as adipocytes are stained with MOMA-2, a marker of monocyte-macrophage lineage, but are negative for specific mature macrophage markers (F4/80 and Mac-1). These results suggest that preadipocytes could function as macrophage-like cells and raise the possibility of a potential direct involvement of adipose tissue in inflammatory processes.	CHU Rangueil, CNRS, UPRESA 5018, IFR 31,ESA 5018 UPS, F-31403 Toulouse, France; Hop Archet, INSERM, U343, F-06202 Nice 3, France; Univ Nice Sophia Antipolis, CNRS, UMR 6543, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Cousin, B (corresponding author), CHU Rangueil, CNRS, UPRESA 5018, IFR 31,ESA 5018 UPS, 1 Av J Poulhes, F-31403 Toulouse, France.	cousinb@rangueil.inserm.fr	DANI, Christian/G-3639-2014	DANI, Christian/0000-0003-3228-0230; Casteilla, Louis/0000-0001-9647-3248; Cousin, Beatrice/0000-0003-2952-4601				BEUTLER B, 1988, ENDOCR REV, V9, P57, DOI 10.1210/edrv-9-1-57; BJORNTORP P, 1978, J LIPID RES, V19, P316; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY PJ, 1987, AM J PATHOL, V128, P505; BURYSEK L, 1993, FEBS LETT, V334, P229, DOI 10.1016/0014-5793(93)81717-E; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY LN, 1992, J BIOL CHEM, V267, P12736; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; DIJKSTRA CD, 1994, J IMMUNOL METHODS, V174, P21, DOI 10.1016/0022-1759(94)90006-X; HOFMAN FM, 1984, CELL IMMUNOL, V88, P61, DOI 10.1016/0008-8749(84)90052-2; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; KRAWISZ BR, 1981, CANCER RES, V41, P2891; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KRISHNAN EC, 1982, J SURG RES, V33, P89, DOI 10.1016/0022-4804(82)90012-9; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; NAITO M, 1993, ARCH HISTOL CYTOL, V56, P331, DOI 10.1679/aohc.56.331; NISHIKAWA M, 1993, BLOOD, V81, P1184; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Peake PW, 1997, EUR J CLIN INVEST, V27, P922, DOI 10.1046/j.1365-2362.1997.2090759.x; Plotkin BJ, 1996, J MED MICROBIOL, V44, P277, DOI 10.1099/00222615-44-4-277; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SHAW DR, 1981, METHODS STUDYING MON, P511; SPEERT DP, 1992, NATURAL IMMUNE SYSTE, P215; STALLONE DD, 1994, NUTR REV, V52, P37; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; Takao S, 1996, AM J PHYSIOL-CELL PH, V271, pC1278, DOI 10.1152/ajpcell.1996.271.4.C1278; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Xing H, 1997, ENDOCRINOLOGY, V138, P2776, DOI 10.1210/en.138.7.2776	35	245	258	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					305	312		10.1096/fasebj.13.2.305	http://dx.doi.org/10.1096/fasebj.13.2.305			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973318	Bronze			2022-12-28	WOS:000078615200010
J	Ramos, RA; Meilandt, WJ; Wang, EC; Firestone, GL				Ramos, RA; Meilandt, WJ; Wang, EC; Firestone, GL			Dysfunctional glucocorticoid receptor with a single point mutation ablates the CCAAT/enhancer binding protein-dependent growth suppression response in a steroid-resistant rat hepatoma cell variant	FASEB JOURNAL			English	Article						glucocorticoid receptor mutation; C/EBP alpha 2; steroid resistance; growth suppression	PRIMARY CORTISOL RESISTANCE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ALPHA-1-ACID GLYCOPROTEIN GENE; HORMONE RECEPTORS; DEOXYRIBONUCLEIC-ACID; CYCLE ARREST; INITIATION COMPLEX; LIVER-REGENERATION; NUCLEAR FACTOR; DNA-BINDING	We used glucocorticoid-resistant and sensitive hepatoma cell variants to characterize the mechanism of hepatoma cell, resistance to the growth inhibitory effects of glucocorticoids. BDS1 hepatoma cells express transcriptionally active glucocorticoid receptors and undergo a stringent G1 cell cycle arrest in response to glucocorticoids that is dependent on the induced expression of the CCAAT/enhancer binding protein alpha (C/EBP alpha) transcription factor. In contrast, EDR1 hepatoma cells, which express normal levels of glucocorticoid receptors, fail to growth arrest or express C/EBP alpha when treated with glucocorticoids. Ectopic expression of wild-type rat glucocorticoid receptors into EDR1 cells restored the growth suppression response, suggesting a defect in the EDR1 receptor. DNA sequence analysis revealed a single point mutation causing a cysteine-to-tyrosine substitution at amino acid position 457 (C457Y-GR) in the zinc finger region of the glucocorticoid receptor that mediates both receptor-DNA and receptor-protein interactions. Glucocorticoid activation of the alpha(1)-acid glycoprotein (AGP) promoter, a liver acute-phase response gene, requires receptor-DNA binding as well as an interaction with C/EBP alpha. In contrast to the wild-type glucocorticoid receptor, ectopic expression of C/EBP alpha in EDR1 cells, or coexpression of C/EBP alpha along with the C457Y-GR into receptor-deficient EDR3 cells was required to partially restore glucocorticoid responsiveness of the AGP promoter by the EDR1 glucocorticoid receptor. Constitutive expression of the wild-type glucocorticoid receptor, but not the C457Y-GR mutant, was sufficient to restore the glucocorticoid growth suppression response to receptor-deficient EDR3 cells. Thus, we have identified a glucocorticoid-resistant hepatoma cell variant with a single point mutation in the zinc finger region of the glucocorticoid receptor gene that ablates the glucocorticoid growth suppression response and attenuates transcriptional activation of the AGP promoter.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 Life Sci Addit, Berkeley, CA 94720 USA.				NCI NIH HHS [1 F32 CA1577-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1993, ADV EXP MED BIOL, V348, P7; ALAM T, 1993, J BIOL CHEM, V268, P15681; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BENRAFAEL Z, 1987, J CLIN ENDOCR METAB, V65, P602, DOI 10.1210/jcem-65-4-602; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRONNEGARD M, 1986, J CLIN INVEST, V78, P1270, DOI 10.1172/JCI112711; Chen H, 1997, J BIOL CHEM, V272, P25873, DOI 10.1074/jbc.272.41.25873; CHROUSOS GP, 1982, J CLIN INVEST, V69, P1261, DOI 10.1172/JCI110565; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Csoka M, 1997, PEDIATR HEMAT ONCOL, V14, P433, DOI 10.3109/08880019709028773; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DARBRE PD, 1987, CELL, V51, P521, DOI 10.1016/0092-8674(87)90121-8; DELAUNOIT Y, 1991, CANCER RES, V51, P5165; DeRijk R, 1997, ANN MED, V29, P79, DOI 10.3109/07853899708998746; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; DIEKEN ES, 1990, MOL CELL BIOL, V10, P4574, DOI 10.1128/MCB.10.9.4574; DONG XF, 1991, ENDOCRINOLOGY, V129, P2719, DOI 10.1210/endo-129-5-2719; FABER S, 1993, J BIOL CHEM, V268, P24976; FERNBERG JO, 1991, ANTI-CANCER DRUG, V2, P565, DOI 10.1097/00001813-199112000-00007; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GARVY BA, 1993, IMMUNOLOGY, V80, P587; GAYNON PS, 1995, J PEDIAT HEMATOL ONC, V17, P1, DOI 10.1097/00043426-199502000-00001; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HATAKEYAMA S, 1991, CELL BIOL INT REP, V15, P55, DOI 10.1016/0309-1651(91)90082-T; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IIDA S, 1985, J CLIN ENDOCR METAB, V60, P967, DOI 10.1210/jcem-60-5-967; IMAI E, 1993, J BIOL CHEM, V268, P5353; Ito C, 1996, J CLIN ONCOL, V14, P2370, DOI 10.1200/JCO.1996.14.8.2370; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karl M, 1996, P ASSOC AM PHYSICIAN, V108, P296; KASPERS GJL, 1994, LEUKEMIA LYMPHOMA, V13, P187, DOI 10.3109/10428199409056282; Kawakubo A, 1995, Nagoya J Med Sci, V58, P143; KLUMPER E, 1995, BLOOD, V86, P3861, DOI 10.1182/blood.V86.10.3861.bloodjournal86103861; LAMBERTS SWJ, 1992, J CLIN ENDOCR METAB, V74, P313, DOI 10.1210/jc.74.2.313; LEFFERT HL, 1979, GASTROENTEROLOGY, V76, P1470; LEUNG P, 1982, ENDOCRINOLOGY, V111, P1121, DOI 10.1210/endo-111-4-1121; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MALCHOFF CD, 1990, J CLIN ENDOCR METAB, V70, P503, DOI 10.1210/jcem-70-2-503; MALCHOFF DM, 1993, J CLIN INVEST, V91, P1918, DOI 10.1172/JCI116410; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; NAWATA H, 1987, J CLIN ENDOCR METAB, V65, P219, DOI 10.1210/jcem-65-2-219; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; RABINDRAN SK, 1987, MOL CELL BIOL, V7, P4211, DOI 10.1128/MCB.7.12.4211; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SMITH RG, 1985, J BIOL CHEM, V260, P2454; SOUFI M, 1995, EXP CLIN ENDOCR DIAB, V103, P175, DOI 10.1055/s-0029-1211347; SPYDEVOLD O, 1990, BIOCHIM BIOPHYS ACTA, V1052, P221, DOI 10.1016/0167-4889(90)90080-W; STRATAKIS CA, 1994, ANN NY ACAD SCI, V746, P362; TOURAY M, 1991, ONCOGENE, V6, P1227; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VINTERMYR OK, 1989, J CELL PHYSIOL, V138, P29, DOI 10.1002/jcp.1041380106; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Watkins PJ, 1996, CANCER RES, V56, P1063; WOLLENBERG GK, 1991, INT J CANCER, V47, P311, DOI 10.1002/ijc.2910470223; ZAWYDIWSKI R, 1983, CANCER RES, V43, P3865; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	75	15	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					169	180		10.1096/fasebj.13.1.169	http://dx.doi.org/10.1096/fasebj.13.1.169			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872941				2022-12-28	WOS:000078029500018
J	Brinkley, WR; Wood, J; Garrison, HH				Brinkley, WR; Wood, J; Garrison, HH			Increased funding for NIH: A biomedical science perspective	FASEB JOURNAL			English	Article									Baylor Coll Med, Houston, TX 77030 USA; Federat Amer Soc Expt Biol, Off Publ Affairs, Bethesda, MD 20814 USA	Baylor College of Medicine	Brinkley, WR (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.			Garrison, Howard/0000-0001-9455-3527				BROWN KM, 1998, DOWNSIZIN SCI WILL U; *COMM PRIOR SETT I, 1998, SCI OPP PUBL NEEDS I; *FED AM SOC EXPT B, 1997, GRAD ED CONS C REP F; Kornberg A, 1997, SCIENCE, V278, P1863, DOI 10.1126/science.278.5345.1863; *NAT I HLTH, 1998, ACC PAC DISC; *NAT SCI FDN, 1996, 96333 NSF NAT SCI FD; *OFF MAN BUDG, 1998, HIST TABL BUDG US GO; *PAN FED SCI TECHN, 1997, FED SCI TECHN BUDG R; *RES AM L HARR ASS, 1995, PUBL ATT MED RES; Stokes D. E., 1997, PASTEURS QUADRANT BA	10	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1431	1435		10.1096/fasebj.12.14.1431	http://dx.doi.org/10.1096/fasebj.12.14.1431			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806751				2022-12-28	WOS:000076749500001
J	Franco, L; Guida, L; Bruzzone, S; Zocchi, E; Usai, C; De Flora, A				Franco, L; Guida, L; Bruzzone, S; Zocchi, E; Usai, C; De Flora, A			The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes	FASEB JOURNAL			English	Article						proteoliposomes; intracellular calcium homeostasis; transmembrane enzymes; catalytic channels	HUMAN-ERYTHROCYTES; NAD+ GLYCOHYDROLASE; SELF-AGGREGATION; CYCLASE ACTIVITY; OUTER SURFACE; ANTIGEN CD38; HYDROLYSIS; PROTEIN; CELLS; INVOLVEMENT	CD38 is a type II transmembrane glycoprotein expressed in many vertebrate cells. It is a bifunctional ectoenzyme that catalyzes both the synthesis of Cyclic ADP-ribose (cADPR) from NAD(+) and the degradation of cADPR to ADP-ribose by means of its ADP-ribosyl cyclase and cADPR-hydrolase activities, respectively. The cyclase also converts NGD(+) to cyclic GDP-ribose (cGDPR), which is refractory to cADPR-hydrolase, cADPR, but not cGDPR, is a potent calcium mobilizer from intracellular stores. It has been demonstrated to be a new second messenger involved in the regulation of calcium homeostasis in many cell types, from plants to mammals. The number of physiological processes shown to be regulated by cADPR is steadily increasing. A topological paradox exists because ectocellularly generated cADPR acts intracellularly. Here we demonstrate that the catalytic functioning of CD38 is accompanied by a cADPR (cGDPR) -transporting activity across natural and artificial membranes. In resealed membranes from CD38(+) human erythrocytes, transport of catalytically generated cADPR or cGDPR was saturation dependent and occurred against a concentration gradient. Likewise, CD38-reconstituted proteoliposomes were active in concentrating NAD(+) (NGD(+))-derived cADPR (cGDPR) inside the vesicle compartment. Moreover, the cADpR-transporting activity in CD38 proteoliposomes prevented the hydrolase-catalyzed degradation to ADPR that occurs conversely with detergent-solubilized CD38, resulting in selective influx of cADPR. In the CD38 proteoliposomes, catalytically active CD38 exhibited monomeric, dimeric, and tetrameric structures. In CD38 sense- but not in antisense-transfected HeLa cells, externally added NAD+ resulted in significant, transient increases in cytosolic calcium. These data suggest that transmembrane juxtaposition of two or four CD38 monomers can generate a catalytically active channel for selective formation and influx of cADPR (cGDPR) to reach cADPR-responsive intracellular calcium stores.	Univ Genoa, Inst Biochem, I-16132 Genoa, Italy; CNR, Inst Cybernet & Biophys, I-16149 Genoa, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)	De Flora, A (corresponding author), Univ Genoa, Inst Biochem, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1984, J BIOL CHEM, V259, P150; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; DeFlora A, 1997, J BIOL CHEM, V272, P12945, DOI 10.1074/jbc.272.20.12945; DEFLORA A, 1981, ACTA BIOL MED GER, V40, P563; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; FRANCO L, 1994, BIOCHEM BIOPH RES CO, V202, P1710, DOI 10.1006/bbrc.1994.2132; FUNARO A, 1990, J IMMUNOL, V145, P2390; Funaro A, 1998, J IMMUNOL, V160, P2238; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GUIDA L, 1995, FEBS LETT, V368, P481, DOI 10.1016/0014-5793(95)00715-L; Hoshino S, 1997, J IMMUNOL, V158, P741; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM UH, 1993, BIOCHIM BIOPHYS ACTA, V1178, P121, DOI 10.1016/0167-4889(93)90001-6; KONDO T, 1989, METHOD ENZYMOL, V171, P217; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LUND AK, 1995, J TRAUMA, V38, P469, DOI 10.1097/00005373-199504000-00001; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; MARSH JB, 1966, J LIPID RES, V7, P574; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; MULLER HM, 1987, BIOCHEM J, V246, P319, DOI 10.1042/bj2460319; NANRI H, 1983, J BIOL CHEM, V258, P5985; PLAGEMANN PGW, 1982, J BIOL CHEM, V257, P2069; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; SALHANY JM, 1983, J BIOL CHEM, V258, P245; SHAHID U, 1996, J BIOL CHEM, V271, P15922; STECK TL, 1974, METHOD ENZYMOL, V31, P176; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOHGO A, 1994, J BIOL CHEM, V269, P28555; WIDDAS WF, 1989, METHODS ENZYMOLOGY, V173, P231; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; ZATMAN LJ, 1953, J BIOL CHEM, V200, P197; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; ZOCCHI E, 1995, FEBS LETT, V359, P35, DOI 10.1016/0014-5793(95)00005-T; Zocchi E, 1996, FEBS LETT, V396, P327, DOI 10.1016/0014-5793(96)01125-8; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	51	101	117	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1507	1520						14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806760				2022-12-28	WOS:000076749500010
J	Frillingos, S; Sahin-Toth, M; Wu, JH; Kaback, HR				Frillingos, S; Sahin-Toth, M; Wu, JH; Kaback, HR			Cys-scanning mutagenesis: a novel approach to structure-function relationships in polytopic membrane proteins	FASEB JOURNAL			English	Review						active transport; bioenergetics; membrane protein structure; site-directed mutagenesis; ligand binding; conformational change	LAC CARRIER PROTEIN; SITE-DIRECTED FLUORESCENCE; DISULFIDE CROSS-LINKING; COLI LACTOSE CARRIER; METAL-TETRACYCLINE/H+ ANTIPORTER; FLANKING HYDROPHILIC DOMAINS; DEPENDENT PROTON TRANSPORT; SUBSTRATE-BINDING SITE; CYTOCHROME-C-OXIDASE; AMINO-ACID-RESIDUES	The entire lactose permease of Escherichia coli, a polytopic membrane transport protein that catalyzes beta-galactoside/H+ symport, has been subjected to Cys-scanning mutagenesis in order to determine which residues play an obligatory role in the mechanism and to create a library of mutants with a single-Cys residue at each position of the molecule for structure/function studies, Analysis of the mutants has led to the following: 1) only six amino acid side chains play an irreplaceable role in the transport mechanism; 2) positions where the reactivity of the Cys replacement is increased upon ligand binding are identified; 3) positions where the reactivity of the Cys replacement is decreased by ligand binding are identified; 4) helix packing, helix tilt, and ligand-induced conformational changes are determined by using the Library of mutants in conjunction with a battery of site-directed techniques; 5) the permease is a highly flexible molecule; and 6) a working model that explains coupling between beta-galactoside and H+ translocation.	Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Physiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Kaback, HR (corresponding author), Univ Calif Los Angeles, HHMI, MacDonald Res Labs, Box 951662, Los Angeles, CA 90095 USA.	RonaldK@HHMI.UCLA.edu	Frillingos, Stathis/AAQ-3148-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131, R56DK051131] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51131] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; Arkin IT, 1996, NAT STRUCT BIOL, V3, P240, DOI 10.1038/nsb0396-240; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; ASLANIDIS C, 1989, J BACTERIOL, V171, P6753, DOI 10.1128/jb.171.12.6753-6763.1989; BROOKER RJ, 1986, J BIOL CHEM, V261, P1765; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DORNMAIR K, 1985, EMBO J, V4, P3633, DOI 10.1002/j.1460-2075.1985.tb04127.x; DOWNER NW, 1986, J BIOL CHEM, V261, P3640; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P6408, DOI 10.1021/bi970233b; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P10166, DOI 10.1021/bi960995r; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P5333, DOI 10.1021/bi953068d; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P13363, DOI 10.1021/bi961453c; Frillingos S, 1997, PROTEIN SCI, V6, P438; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HE MM, 1995, BIOCHEMISTRY-US, V34, P15661, DOI 10.1021/bi00048a009; He MM, 1997, BIOCHEMISTRY-US, V36, P13688, DOI 10.1021/bi9715324; He MM, 1997, BIOCHEMISTRY-US, V36, P13682, DOI 10.1021/bi971531b; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HOLMAN CM, 1994, BIOCHEMISTRY-US, V33, P2672, DOI 10.1021/bi00175a041; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; JUNG H, 1994, PROTEIN SCI, V3, P1052, DOI 10.1002/pro.5560030707; JUNG H, 1994, BIOCHEMISTRY-US, V33, P12160, DOI 10.1021/bi00206a019; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12273, DOI 10.1021/bi00097a001; KABACK HR, 1987, BIOCHEMISTRY-US, V26, P2071, DOI 10.1021/bi00382a001; Kaback HR, 1997, CURR OPIN STRUC BIOL, V7, P537, DOI 10.1016/S0959-440X(97)80119-4; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KABACK HR, 1996, EUKARYOTIC PROKARYOT, V2, P203; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3691, DOI 10.1021/bi00584a009; KACZOROWSKI GJ, 1979, BIOCHEMISTRY-US, V18, P3697, DOI 10.1021/bi00584a010; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KING SC, 1989, J BIOL CHEM, V264, P7390; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1990, J BIOL CHEM, V265, P3153; KING SC, 1989, BIOCHIM BIOPHYS ACTA, V982, P253, DOI 10.1016/0005-2736(89)90062-X; le Coutre J, 1998, P NATL ACAD SCI USA, V95, P6114, DOI 10.1073/pnas.95.11.6114; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; LEE JI, 1994, BIOCHEM BIOPH RES CO, V203, P1882, DOI 10.1006/bbrc.1994.2407; LEE JI, 1992, J BIOL CHEM, V267, P20758; LIS LJ, 1982, BIOPHYS J, V37, P667; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MATZKE EA, 1992, J BIOL CHEM, V267, P19095; MCKENNA E, 1992, P NATL ACAD SCI USA, V89, P11954, DOI 10.1073/pnas.89.24.11954; MCKENNA E, 1992, J BIOL CHEM, V267, P6471; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; MCMORROW I, 1988, BIOCHIM BIOPHYS ACTA, V945, P315, DOI 10.1016/0005-2736(88)90494-4; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P162, DOI 10.1016/0006-291X(85)91002-2; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P1132, DOI 10.1021/bi00378a022; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P6638, DOI 10.1021/bi00395a012; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; ROEPE PD, 1989, P NATL ACAD SCI USA, V86, P3992, DOI 10.1073/pnas.86.11.3992; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SAHINTOTH M, 1994, PROTEIN SCI, V3, P2302, DOI 10.1002/pro.5560031215; SAHINTOTH M, 1993, BIOCHEMISTRY-US, V32, P10027, DOI 10.1021/bi00089a019; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SAHINTOTH M, 1994, PROTEIN SCI, V3, P240; Sun JZ, 1996, BIOCHEMISTRY-US, V35, P990, DOI 10.1021/bi952166w; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P274, DOI 10.1021/bi962292f; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; UJWAL ML, 1994, MEMBR MOL BIOL, V1, P9; VANIWAARDEN PR, 1991, J BIOL CHEM, V266, P15688; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; VENKATESAN P, 1998, IN PRESS P NATL ACAD; VIITANEN P, 1983, BIOCHEMISTRY-US, V22, P2531, DOI 10.1021/bi00279a034; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Voss J, 1998, BIOCHEMISTRY-US, V37, P8191, DOI 10.1021/bi9802667; Voss J, 1995, P NATL ACAD SCI USA, V92, P12295, DOI 10.1073/pnas.92.26.12295; Voss J, 1995, P NATL ACAD SCI USA, V92, P12300, DOI 10.1073/pnas.92.26.12300; Voss J, 1998, BIOCHEMISTRY-US, V37, P211, DOI 10.1021/bi972152l; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j; Wang QD, 1997, BIOCHEMISTRY-US, V36, P14120, DOI 10.1021/bi9716433; Wang QD, 1998, BIOCHEMISTRY-US, V37, P4910, DOI 10.1021/bi972990f; WEITZMAN C, 1995, PROTEIN SCI, V4, P2310, DOI 10.1002/pro.5560041108; WU J, 1998, IN PRESS J MOL BIOL; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1994, PROTEIN SCI, V3, P2294, DOI 10.1002/pro.5560031214; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; Wu JH, 1997, J MOL BIOL, V270, P285, DOI 10.1006/jmbi.1997.1099; Wu JH, 1996, P NATL ACAD SCI USA, V93, P10123, DOI 10.1073/pnas.93.19.10123; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	118	311	322	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1281	1299		10.1096/fasebj.12.13.1281	http://dx.doi.org/10.1096/fasebj.12.13.1281			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761772				2022-12-28	WOS:000076402000004
J	Lass, A; Sohal, RS				Lass, A; Sohal, RS			Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals	FASEB JOURNAL			English	Article						antioxidants; free radicals; oxidative stress; aging	VITAMIN-E; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; MODEL-COMPOUND; UBIQUINONE; GENERATION; LONGEVITY; RESTRICTION; PARTICLES; HOMOLOGS	The effects of coenzyme Q(10) (CoQ(10)) and alpha-tocopherol at the rate of mitochondrial superoxide anion radical (O-2(.-)) geration were examined in skeletal muscle, liver and kidney of 24-day-month mice. Mice were orally administered alpha-tocopherol (200 mg.kg(-1).day(-1)) alone, CoQ(10) (123 mg.kg(-1).day(-1)) alone, or the two together for 13 wk. Administration of alpha-tocopherol resulted in a similar to sevenfold elevation of mitochondrial alpha-tocopherol content. Intake of alpha-tocopherol alone caused an similar to fivefold increase in CoQ content (CoQ(9) and/or CoQ(10)) and alpha-tocopherol of mitochondria. The rate of O-2 generation by sub mitochondrial particles (SMPs) was inversely related to their alpha-tocopherol content but unrelated to CoQ content. Experimental in vitro augmentation of SMPs with varying amounts of alpha-tocopherol caused an up to similar to 50% decrease in the rate of O2T generation. Similar in vitro augmentations of SMPs with CoQ(10) had previously been found to have no effect on O2+ generation The CoQ(10)-induced elevation of alpha-tocopherol in the present study was inferred to be due to a sparing/regeneration by CoQ. results indicate the involvement of alpha-tocopherol in the elimination of mitochondrially generated O2T.-Lass A., Sohal, R. S. Effect of coenzyme Q(10) and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals. .	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Sohal, RS (corresponding author), So Methodist Univ, Dept Biol Sci, 220 Fondren Sci Bldg, Dallas, TX 75275 USA.	rsohal@mail.smu.edu	Lass, Achim/C-3332-2008	Lass, Achim/0000-0002-8190-7151	NIA NIH HHS [R01 AG13563, R01 AG7657] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007657, R01AG013563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; BOVERIS A, 1980, SUPEROXIDE DISMUTASE, V2, P16; BURLAKOVA EB, 1979, BIOFIZIKA+, V24, P965; CADENAS E, 1989, FEBS LETT, V253, P235, DOI 10.1016/0014-5793(89)80966-4; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FUKUZAWA K, 1983, ARCH BIOCHEM BIOPHYS, V226, P242, DOI 10.1016/0003-9861(83)90290-4; GOTOH N, 1992, BIOCHIM BIOPHYS ACTA, V1115, P201, DOI 10.1016/0304-4165(92)90054-X; KAGAN V, 1990, BIOCHEM BIOPH RES CO, V169, P851, DOI 10.1016/0006-291X(90)91971-T; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LASH LH, 1993, MITOCHONDRIAL DYSFUN, V2, P8; Lass A, 1998, ARCH BIOCHEM BIOPHYS, V352, P229, DOI 10.1006/abbi.1997.0606; Lass A, 1997, J BIOL CHEM, V272, P19199, DOI 10.1074/jbc.272.31.19199; MAGUIRE JJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P47, DOI 10.1016/0003-9861(92)90049-3; NAUMOV V V, 1983, Biophysics (English Translation of Biofizika), V28, P774; OZAWA T, 1978, BIOCHIM BIOPHYS ACTA, V531, P72; OZAWA T, 1985, BIOCHEM BIOPH RES CO, V126, P873, DOI 10.1016/0006-291X(85)90266-9; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; SOHAL RS, 1995, FREE RADICAL BIO MED, V19, P499, DOI 10.1016/0891-5849(95)00037-X; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0	30	102	108	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					87	94		10.1096/fasebj.14.1.87	http://dx.doi.org/10.1096/fasebj.14.1.87			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627283				2022-12-28	WOS:000084784700011
J	Frey, BM; Reber, BFX; Vishwanath, BS; Escher, G; Frey, FJ				Frey, BM; Reber, BFX; Vishwanath, BS; Escher, G; Frey, FJ			Annexin I modulates cell functions by controlling intracellular calcium release	FASEB JOURNAL			English	Article						phospholipase A; phospholipase C; E-cadherin; tumor; MCF-7; Ca2+; homeostasis	FOCAL ADHESION KINASE; BREAST-CANCER CELLS; E-CADHERIN FUNCTION; LIPOCORTIN-I; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; U937 CELLS; PERITONEAL LEUKOCYTES; GROWTH FACTOR; PROTEIN; EXPRESSION	Annexin I is an intracellular protein in search of a function. Ex vivo it has calcium- and phospholipid-binding properties. To evaluate its role in vivo, MCF-7 cells were stably transfected with annexin I in sense or antisense orientations, In cells overexpressing annexin I, calcium release was abrogated on stimulation of purinergic or bradykinin receptors, whereas non-transfected cells or cells with down-regulated annexin I released calcium within seconds. Basal calcium and calcium stores were not affected, The impaired calcium release was paralleled by a down-regulation of the activities of phospholipase C, group II phospholipase A2, and E-cadherin with altered adhesion and enhanced tumor growth on soft agar, Significantly smaller tumors, with the histologically most differentiated cells, were observed in nude mice inoculated with cells transfected with the antisense rather than with the sense plasmid, These observations indicate that annexin I modulates cell functions by controlling intracellular calcium release.	Univ Bern, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland; Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland	University of Bern; University of Bern	Frey, BM (corresponding author), Inselspital Bern, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland.	brigitte.frey@dkf2.unibe.ch		Escher, Genevieve/0000-0002-5125-2262				AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIENKOWSKI MJ, 1989, J BIOL CHEM, V264, P6536; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BRACKE ME, 1994, CANCER RES, V54, P4607; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; BRONNEGARD M, 1988, MOL ENDOCRINOL, V2, P732, DOI 10.1210/mend-2-8-732; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; Buckingham JC, 1997, MOL MED TODAY, V3, P296, DOI 10.1016/S1357-4310(97)88908-3; Buckland AG, 1998, BIOCHEM J, V329, P369; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; Cary LA, 1996, J CELL SCI, V109, P1787; Charlier C, 1996, EUR J PHARMACOL, V317, P413, DOI 10.1016/S0014-2999(96)00816-3; Chen HY, 1997, J CELL SCI, V110, P345; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; CROXTALL JD, 1995, BIOCHEM PHARMACOL, V50, P465, DOI 10.1016/0006-2952(95)00156-T; Donnelly SR, 1998, BIOCHEM J, V332, P681, DOI 10.1042/bj3320681; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FREY BM, 1991, BIOCHEM J, V275, P219, DOI 10.1042/bj2750219; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLON G, 1989, CELL SIGNAL, V1, P541, DOI 10.1016/0898-6568(89)90062-4; GunteskiHamblin AM, 1996, AM J PHYSIOL-HEART C, V270, pH1091, DOI 10.1152/ajpheart.1996.270.3.H1091; HAYASHI J, 1993, BIOCHEM MOL BIOL INT, V31, P143; HOFFMAN R, 1979, Journal of the Biological Photographic Association, V47, P111; Hunt NCA, 1997, VIRCHOWS ARCH, V430, P285, DOI 10.1007/BF01092751; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LAKSHMI V, 1985, J STEROID BIOCHEM, V22, P331, DOI 10.1016/0022-4731(85)90435-2; MCLEOD JD, 1995, BIOCHEM PHARMACOL, V50, P1103, DOI 10.1016/0006-2952(95)00234-Q; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81; MOSS SE, 1992, RES MONOGRAPH; MOSS SE, 1992, ANNEXINS RES MONOGRA; MOUILLAC B, 1989, BIOCHEM BIOPH RES CO, V159, P953, DOI 10.1016/0006-291X(89)92201-8; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; OWENS LV, 1995, CANCER RES, V55, P2752; PARENTE L, 1992, Pharmacological Research, V26, P44, DOI 10.1016/1043-6618(92)90591-X; PEERS SH, 1993, BRIT J PHARMACOL, V108, P66, DOI 10.1111/j.1476-5381.1993.tb13441.x; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PERRETTI M, 1993, J IMMUNOL, V150, P992; PILTCH A, 1989, BIOCHEM J, V261, P395, DOI 10.1042/bj2610395; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; ROYCHOUDHURY S, 1988, P NATL ACAD SCI USA, V85, P2014, DOI 10.1073/pnas.85.6.2014; SCHLAEPFER DD, 1987, J BIOL CHEM, V262, P6931; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Solito E, 1998, BRIT J PHARMACOL, V124, P1675, DOI 10.1038/sj.bjp.0701991; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; Tharin S, 1996, J CELL PHYSIOL, V166, P547, DOI 10.1002/(SICI)1097-4652(199603)166:3<547::AID-JCP9>3.0.CO;2-P; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; VISHWANATH BS, 1993, J CLIN INVEST, V92, P1974, DOI 10.1172/JCI116791; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; Willmott NJ, 1997, BRIT J PHARMACOL, V122, P1055, DOI 10.1038/sj.bjp.0701490; WU CC, 1995, P NATL ACAD SCI USA, V92, P3473, DOI 10.1073/pnas.92.8.3473; Zschiesche W, 1997, ANTICANCER RES, V17, P561	75	35	36	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2235	2245		10.1096/fasebj.13.15.2235	http://dx.doi.org/10.1096/fasebj.13.15.2235			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593871				2022-12-28	WOS:000084310800015
J	Gorbsky, GJ; Kallio, M; Daum, JR; Topper, LM				Gorbsky, GJ; Kallio, M; Daum, JR; Topper, LM			Protein dynamics at the kinetochore: cell cycle regulation of the metaphase to anaphase transition	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		CYCLOSOME/ANAPHASE-PROMOTING COMPLEX; SACCHAROMYCES-CEREVISIAE; SPINDLE CHECKPOINT; BUDDING YEAST; UNATTACHED KINETOCHORES; MITOTIC FORCES; MAD2; MITOSIS; CDC20; MICROINJECTION	The spindle checkpoint blocks the initiation of anaphase in mitosis and meiosis if chromosomes are not aligned at the metaphase plate, The checkpoint functions by preventing a ubiquitin ligase called the anaphase-promoting complex/cyclosome (APC/C) from ubiquitinylating proteins whose destruction is required for anaphase onset, The spindle checkpoint signal originates at the kinetochores of unaligned chromosomes and is broadcast to the rest of the cell. Although the spindle checkpoint is not understood in detail, several components of the checkpoint-signaling pathway have been identified. Many of these components associate transiently with the kinetochores of unaligned chromosomes, We propose a model in which kinetochores that lack stable attachments to the spindle microtubules serve as catalytic staging areas for the assembly of inhibitor complexes. These inhibitor complexes then leave the kinetochores and block activity of the APC/C throughout the cell. We suggest that microtubule occupancy at kinetochores or physical tension induced by microtubule capture turns off the capability of the kinetochore to produce the APC/C inhibitor. Subsequently, the inhibitor concentration in the cell wanes and anaphase initiates.	Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Gorbsky, GJ (corresponding author), Univ Virginia, Ctr Hlth Sci, Box 439 UVA, Charlottesville, VA 22908 USA.			Gorbsky, Gary/0000-0003-3076-4725; Kallio, Marko/0000-0002-6345-1680				CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CohenFix O, 1997, CURR OPIN CELL BIOL, V9, P800, DOI 10.1016/S0955-0674(97)80080-4; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193	25	17	17	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S231	S234		10.1096/fasebj.13.9002.S231	http://dx.doi.org/10.1096/fasebj.13.9002.S231			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619133	Bronze			2022-12-28	WOS:000084390200011
J	Kiningham, KK; Oberley, TD; Lin, SM; Mattingly, CA; St Clair, DK				Kiningham, KK; Oberley, TD; Lin, SM; Mattingly, CA; St Clair, DK			Overexpression of manganese superoxide dismutase protects against mitochondrial-initiated poly(ADP-ribose) polymerase-mediated cell death	FASEB JOURNAL			English	Article						apoptosis; reactive oxygen species; caspase 3; antimycin	CYTOCHROME-C; OXIDATIVE STRESS; INDUCED APOPTOSIS; NEURONAL APOPTOSIS; HYDROGEN-PEROXIDE; DNA-DAMAGE; IN-VIVO; OXYGEN; BCL-2; NUCLEAR	Mitochondria have recently been shown to serve a central role in programmed cell death. In addition, reactive oxygen species (ROS) have been implicated in cell death pathways upon treatment with a variety of agents; however, the specific cellular source of the ROS generation is unknown. We hypothesize that mitochondria-derived free radicals play a critical role iu apoptotic cell death. To directly test this hypothesis, we treated murine fibrosarcoma cell lines, which expressed a range of mitochondrial manganese superoxide dismutase (MnSOD) activities, with respiratory chain inhibitors, Apoptosis was confirmed by DNA fragmentation analysis and electron microscopy, MnSOD overexpression specifically protected against cell death upon treatment with rotenone or antimycin. We examined bcl-x(L), p53 and poly(ADP-ribose) polymerase (PARP) to identify specific cellular pathways that might contribute to the mitochondrial-initiated ROS-mediated tell death. Cells overexpressing MnSOD contained less bcl-x(L) within the mitochondria compared to control (NEO) cells, therefore excluding the role of bcl-x(L), p53 was undetectable by Western analysis and examination of the proapoptotic protein bax, a p53 target gene, did not increase with treatment, Activation of caspase-3 (CPP-32) occurred in the NEO cells independent of cytochrome c release from the mitochondria, PARP, a target protein of CPP-32 activity, was cleaved to a 64 kDa fragment in the NEO cells prior to generation of nucleosomal fragments. Taken together, these findings suggest that mitochondrial-mediated ROS generation is a key event by which inhibition of respiration causes cell death, and identifies CPP-32 and the PARP-linked pathway as targets of mitochondrial-derived ROS-induced cell death.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Wisconsin, Vet Adm Hosp, Dept Pathol, Sch Med, Madison, WI USA	University of Kentucky; University of Wisconsin System; University of Wisconsin Madison	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 360 Hlth Sci Res Bldg, Lexington, KY 40536 USA.				NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NCI NIH HHS [CA49797, CA59835] Funding Source: Medline; NHLBI NIH HHS [HL03544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; Atabay C, 1996, J NEUROSCI RES, V43, P465; BASS DA, 1983, J IMMUNOL, V130, P1910; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Hagar H, 1996, KIDNEY INT, V49, P355, DOI 10.1038/ki.1996.52; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Keller JN, 1998, J NEUROSCI, V18, P687; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kiningham KK, 1997, CANCER RES, V57, P5265; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman I, 1997, J NEUROSCI, V17, P5089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MAJIMA H, 1992, INT J RADIAT ONCOL, V22, P1019, DOI 10.1016/0360-3016(92)90802-O; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marin MC, 1996, ONCOGENE, V12, P2259; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SAFFORD SE, 1994, CANCER RES, V54, P4261; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; URANO M, 1995, CANCER RES, V55, P2490; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; [No title captured]	54	91	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1601	1610		10.1096/fasebj.13.12.1601	http://dx.doi.org/10.1096/fasebj.13.12.1601			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463952				2022-12-28	WOS:000082347600016
J	Grone, HJ; Weber, C; Weber, KSC; Grone, EF; Rabelink, T; Klier, CM; Wells, TNC; Proudfoot, AE; Schlondorff, D; Nelson, PJ				Grone, HJ; Weber, C; Weber, KSC; Grone, EF; Rabelink, T; Klier, CM; Wells, TNC; Proudfoot, AE; Schlondorff, D; Nelson, PJ			Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment	FASEB JOURNAL			English	Article						chemokine receptors; inflammation; monocyte; endothelium	PLATELET-ACTIVATING-FACTOR; ALLOGRAFT-REJECTION; CHEMOKINE EXPRESSION; ENDOTHELIAL-CELLS; ADHESION; ANTAGONIST; INFLAMMATION; LYMPHOCYTES; KIDNEY; FLOW	Chemokines are thought to contribute to the cellular infiltrate characteristic of renal transplant rejection. We show that Met-RANTES, a chemokine receptor antagonist, suppresses recruitment of inflammatory cells into renal allografts. In a renal transplant model (Fisher RT1v1 rat kidney into Lewis RT1 rat) where no additional immune suppressant was used, Met-RANTES-treated animals showed a significant reduction in vascular injury score (16.10 +/- 5.20 vs. 62.67 +/- 18.64) and tubular damage score (15.70 +/- 5.22 vs. 33.00 +/- 6.44) relative to untreated animals. In a more severe rejection model (Brown-Norway RT1v1 rat kidney into Lewis RT1(1) rat), Met-RANTES significantly augmented low-dose cyclosporin A treatment to reduce all aspects of renal injury including interstitial inflammation (score 71.00 +/- 6.10 vs. 157.30 +/- 21.30). The majority of infiltrating cells in these models (60-70%) consisted of monocytes. Potential mechanisms of action of Met-RANTES were tested using monocyte attachment assays on microvascular endothelium under physiological flow conditions. Preexposure of microvascular endothelium to RANTES resulted in RANTES immobilization and RANTES-induced firm adhesion of monocytes only after prestimulation of the endothelium with IL-1 beta. Met-RANTES completely inhibited this RANTES-mediated arrest. Thus, Met-RANTES may counter acute rejection by blocking leukocyte firm adhesion to inflamed endothelium.	Univ Munich, Med Poliklin, AG Klin Biochem, D-80336 Munich, Germany; German Canc Res Ctr, Dept Expt Pathol, Heidelberg, Germany; Univ Utrecht, NL-3508 TC Utrecht, Netherlands; Univ Munich, Inst Prophylaxis & Epidemiol, D-80539 Munich, Germany; Serono Pharmaceut Inst, Geneva, Switzerland	University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Utrecht University; University of Munich	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, AG Klin Biochem, Schillerstr 42, D-80336 Munich, Germany.	nelson@medpoli.med.uni-muenchen.de	Rabelink, Ton J./A-5316-2008; Weber, Christian/AAW-2153-2020	Rabelink, Ton J./0000-0001-6780-5186; Weber, Christian/0000-0003-4610-8714; Wells, Timothy/0000-0001-9796-847X				ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; ALPERS CE, 1993, KIDNEY INT, V44, P805, DOI 10.1038/ki.1993.315; BASADONNA GP, 1993, TRANSPLANTATION, V55, P993, DOI 10.1097/00007890-199305000-00007; Bennett William M., 1996, P587; BISHOP GA, 1986, KIDNEY INT, V29, P708, DOI 10.1038/ki.1986.56; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Castro M C, 1998, Transpl Int, V11 Suppl 1, pS15; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; ERL W, 1995, ATHEROSCLEROSIS, V113, P99, DOI 10.1016/0021-9150(94)05434-K; FISHER B, 1965, SURGERY, V58, P904; Gibbs P, 1993, Transpl Immunol, V1, P109, DOI 10.1016/0966-3274(93)90003-Q; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GRONE HJ, 1996, DIALYSIS TRANSPLANT, V11, P1916; HEAF JG, 1998, TRANSPL INT, V1, pS26; KAMEYOSHI Y, 1994, INT ARCH ALLERGY IMM, V104, P49, DOI 10.1159/000236751; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688; KooijmansCoutinho MF, 1996, TRANSPLANTATION, V61, P1338, DOI 10.1097/00007890-199605150-00009; Kukreti S, 1997, BLOOD, V89, P4104, DOI 10.1182/blood.V89.11.4104; Lloyd CM, 1997, J LEUKOCYTE BIOL, V62, P676, DOI 10.1002/jlb.62.5.676; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Lukacs NW, 1996, J LEUKOCYTE BIOL, V59, P13, DOI 10.1002/jlb.59.1.13; LUSCINSKAS FW, 1994, J IMMUNOL, V156, P326; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mantovani A, 1997, IMMUNOL TODAY, V18, P231, DOI 10.1016/S0167-5699(97)81662-3; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MOREL D, 1993, TRANSPLANTATION, V55, P773, DOI 10.1097/00007890-199304000-00017; NADEAU KC, 1995, P NATL ACAD SCI USA, V92, P8729, DOI 10.1073/pnas.92.19.8729; Nagano H, 1997, TRANSPLANTATION, V63, P1101, DOI 10.1097/00007890-199704270-00009; Nelson PJ, 1998, CURR OPIN IMMUNOL, V10, P265, DOI 10.1016/S0952-7915(98)80164-7; Nelson PJ, 1998, CYTOKINES, P433, DOI 10.1016/B978-012498340-3/50030-0; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nickerson P, 1997, TRANSPLANTATION, V63, P489, DOI 10.1097/00007890-199702270-00001; Oppenheim Joost J., 1996, P187; PATTISON J, 1994, LANCET, V343, P209, DOI 10.1016/S0140-6736(94)90992-X; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Pober Jordan S., 1996, P127; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Schlondorff D, 1997, KIDNEY INT, V51, P610, DOI 10.1038/ki.1997.90; SCHMEELK J, 1995, KLUW T MATH, V10, P1; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SIMON M, 1995, AM J PHYSIOL-RENAL, V268, pF240, DOI 10.1152/ajprenal.1995.268.2.F240; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stojanovic T, 1996, LAB INVEST, V74, P496; Strom TB, 1996, CURR OPIN IMMUNOL, V8, P688, DOI 10.1016/S0952-7915(96)80087-2; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Valente JF, 1998, SURG CLIN N AM, V78, P1, DOI 10.1016/S0039-6109(05)70631-9; vonLuettichau I, 1996, CYTOKINE, V8, P89, DOI 10.1006/cyto.1996.0012; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; WEBER C, 1995, J IMMUNOL, V155, P445; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; WEBER KSC, 1999, IN PRESS ARTERIOSCL; WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	59	200	214	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1999	13	11					1371	1383		10.1096/fasebj.13.11.1371	http://dx.doi.org/10.1096/fasebj.13.11.1371			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428761	Bronze			2022-12-28	WOS:000082019100009
J	Eppenberger, HM; Zuppinger, C				Eppenberger, HM; Zuppinger, C			In vitro reestablishment of cell-cell contacts in adult rat cardiomyocytes. Functional role of transmembrane components in the formation of new intercalated disk-like cell contacts	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	cardiomyocytes; N-cadherin; gap junction; GFP	ATRIAL-NATRIURETIC-FACTOR; GENE-EXPRESSION; CARDIAC MYOCYTE; MUSCLE-CELLS; N-CADHERIN; IGF-I; CULTURE; MICROGRAVITY; PROTEIN; ALPHA	Primary adult rat cardiomyocytes (ARC) in culture are shown to be a model system for cardiac cell hypertrophy in vitro, ARC undergo a process of morphological transformation and grow only by increase in cell size, however, without loss of the cardiac phenotype, The isolated cells spread and establish new cell-cell contacts, eventually forming a two-dimensional heart tissue-like synchronously beating cell, sheet. The reformation of specific cell contacts (intercalated disks) is shown also between ventricular and atrial cardiomyocytes by using antibodies against the gap junction protein connexin-43 and after microinjection into ARC of N-cadherin cDNA fused to reporter green fluorescent protein (GFP) cDNA. The expressed fusion protein allowed the study of live cell cultures and of the dynamics of the adherens junction protein N-cadherin during the formation of new cell-cell contacts. The possible use of the formed ARC cell-sheet cells under microgravity conditions as a test system for the reformation of the cytoskeleton of heart muscle cells is proposed.	ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Eppenberger, HM (corresponding author), ETH Honggerberg, Inst Cell Biol, Dept Biol, CH-8093 Zurich, Switzerland.		Zuppinger, Christian/H-4452-2019	Zuppinger, Christian/0000-0003-1786-0800				Akins RE, 1997, IN VITRO CELL DEV-AN, V33, P337; BOHELER KR, 1992, TRENDS CARDIOVAS MED, V2, P176, DOI 10.1016/1050-1738(92)90046-U; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLAYCOMB WC, 1983, DEV BIOL, V99, P331, DOI 10.1016/0012-1606(83)90283-X; Connold AL, 1997, J MUSCLE RES CELL M, V18, P63, DOI 10.1023/A:1018680900305; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EPPENBERGER ME, 1988, DEV BIOL, V130, P1, DOI 10.1016/0012-1606(88)90408-3; EPPENBERGEREBERHARDT M, 1990, DEV BIOL, V139, P269, DOI 10.1016/0012-1606(90)90296-U; EppenbergerEberhardt M, 1997, J MOL CELL CARDIOL, V29, P2027, DOI 10.1006/jmcc.1997.0408; Freed LE, 1997, IN VITRO CELL DEV-AN, V33, P381; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gerdes A M, 1992, J Fla Med Assoc, V79, P253; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; Harder BA, 1996, J MOL CELL CARDIOL, V28, P19, DOI 10.1006/jmcc.1996.0003; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Hertig CM, 1996, J CELL SCI, V109, P1; Hertig CM, 1996, J CELL SCI, V109, P11; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; Ludin B, 1998, TRENDS CELL BIOL, V8, P72, DOI 10.1016/S0962-8924(97)01169-0; MESSERLI JM, 1993, HISTOCHEMISTRY, V100, P193, DOI 10.1007/BF00269092; MOSES RL, 1982, J ULTRA MOL STRUCT R, V81, P358, DOI 10.1016/S0022-5320(82)90064-8; Scorsin M, 1996, CIRCULATION, V94, P337; SEVERS NJ, 1989, CIRC RES, V65, P22, DOI 10.1161/01.RES.65.1.22; SEVERS NJ, 1990, J MUSCLE RES CELL M, V11, P154, DOI 10.1007/BF01766494; Vandenburgh HH, 1996, AM J PHYSIOL-CELL PH, V270, pC1284, DOI 10.1152/ajpcell.1996.270.5.C1284	28	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S83	S89						7	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352149				2022-12-28	WOS:000080403800011
J	Fanelli, C; Coppola, S; Barone, R; Colussi, C; Gualandi, G; Volpe, P; Ghibelli, L				Fanelli, C; Coppola, S; Barone, R; Colussi, C; Gualandi, G; Volpe, P; Ghibelli, L			Magnetic fields increase cell survival by inhibiting apoptosis via modulation of Ca2+ influx	FASEB JOURNAL			English	Article						MFs; endoplasmic reticulum; viable cells; etoposide	CALCIUM; INVOLVEMENT; SIGNAL	Static magnetic fields with intensities starting from 6 gauss (6X10(-4) tesla, T) were found to decrease in an intensity-dependent fashion, reaching a plateau at 6 X 10(-3) T, the extent of cell death by apoptosis induced by several agents in different human cell systems. This is not due to a change in the mode of cell death (i,e., to necrosis) or to a delay of the process itself; rather, the presence of magnetic fields allows the indefinite survival and replication of the cells hit by apoptogenic agents. The protective effect was found to be mediated by the ability of the fields to enhance Ca2+ influx from the extracellular medium; accordingly, it was limited to those cell systems where Ca2+ influx was shown to have an antiapoptotic effect. Magnetic fields thus might interfere with human health by altering/restoring the equilibrium between cell death and proliferation; indeed, the rescue of damaged cells may be the mechanism explaining why magnetic fields that are not mutagenic per se are often able to increase mutation and tumor frequencies.,	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Tuscia, DABAC, Viterbo, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy	University of Rome Tor Vergata; Tuscia University; Consiglio Nazionale delle Ricerche (CNR)	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.	lina.ghibelli@seneca.uniroma2.it	Coppola, Simona/A-6638-2015; Colussi, Claudia/H-8609-2019	Coppola, Simona/0000-0001-7851-9409; Colussi, Claudia/0000-0002-7727-8911				Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Cantoni O, 1996, BIOCHEM MOL BIOL INT, V38, P527; CLARKE AR, 1994, ONCOGENE, V9, P1767; Eremenko T, 1997, BIOELECTROMAGNETICS, V18, P58, DOI 10.1002/(SICI)1521-186X(1997)18:1<58::AID-BEM9>3.0.CO;2-4; FIORANI M, 1992, MUTAT RES, V282, P25, DOI 10.1016/0165-7992(92)90069-T; GALLI C, 1995, J NEUROSCI, V15, P1172; Ghibelli L, 1995, FEBS LETT, V377, P9, DOI 10.1016/0014-5793(95)01284-2; GHIBELLI L, 1994, FEBS LETT, V344, P35, DOI 10.1016/0014-5793(94)00287-8; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Lacy-Hulbert A, 1998, FASEB J, V12, P395, DOI 10.1096/fasebj.12.6.395; LIBURDY RP, 1992, FEBS LETT, V301, P53, DOI 10.1016/0014-5793(92)80209-Y; LIBURDY RP, 1993, FEBS LETT, V334, P301, DOI 10.1016/0014-5793(93)80699-U; LIBURDY RP, 1993, J PINEAL RES, V14, P89, DOI 10.1111/j.1600-079X.1993.tb00491.x; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; MCCANN J, 1993, MUTAT RES, V297, P61, DOI 10.1016/0165-1110(93)90008-B; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; Miyakoshi J, 1996, MUTAT RES-FUND MOL M, V349, P109, DOI 10.1016/0027-5107(95)00166-2; Morandi MA, 1996, LIFE SCI, V59, P263, DOI 10.1016/0024-3205(96)00291-3; NORDENSON I, 1994, BIOELECTROMAGNETICS, V15, P293, DOI 10.1002/bem.2250150404; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; PARADISI S, 1993, BIOELECTROMAGNETICS, V14, P247, DOI 10.1002/bem.2250140308; PHILLIPS JL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P140, DOI 10.1016/0167-4781(92)90004-J; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Reipert BM, 1997, LIFE SCI, V61, P1571, DOI 10.1016/S0024-3205(97)00736-4; Repacholi MH, 1997, RADIAT RES, V147, P631, DOI 10.2307/3579630; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Willmott NJ, 1996, FEBS LETT, V394, P159, DOI 10.1016/0014-5793(96)00939-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	32	194	210	2	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					95	102		10.1096/fasebj.13.1.95	http://dx.doi.org/10.1096/fasebj.13.1.95			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872934				2022-12-28	WOS:000078029500011
J	Masuda, MO; Levin, M; de Oliveira, SF; dos Santos Costa, PC; Bergami, PL; dos Santos Almeida, NA; Pedrosa, RC; Ferrari, I; Hoebeke, J; de Carvalho, CC				Masuda, MO; Levin, M; de Oliveira, SF; dos Santos Costa, PC; Bergami, PL; dos Santos Almeida, NA; Pedrosa, RC; Ferrari, I; Hoebeke, J; de Carvalho, CC			Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens	FASEB JOURNAL			English	Article						immunoglobulin; heart block; ribosomal P proteins; muscarinic receptor	IDIOPATHIC DILATED CARDIOMYOPATHY; PROTEIN-COUPLED RECEPTORS; RIBOSOMAL-P-PROTEIN; HEART-DISEASE; AUTOANTIBODIES; IDENTIFICATION; DETERMINANTS; EXPRESSION; EPITOPES; BINDING	Antibodies of chronic chagasic patients have been shown to interfere with electric and mechanical activities of cardiac embryonic myocytes in culture and with whole mammalian hearts. A mechanism proposed for this effect involves interaction of the antibodies with G-protein-linked membrane receptors, thus leading to activation of beta adrenergic and muscarinic receptors; more specifically, IgG of chagasic patients would interact with the negatively charged regions of the second extracellular loop of these receptors. We performed competition experiments to test this hypothesis. We evaluated the effect of sera/IgG from patients previously known to depress electrogenesis and/or atrioventricular conduction in isolated rabbit hearts after incubation with live and lysed parasites, the peptide corresponding to the second extracellular loop (O2) of the M2 receptor, and different peptides derived from two ribosomal proteins of T. cruzi: PO and P2 beta. Our results indicate that I) the antigenic factor inducing the functionally active IgGs in the chagasic patients is probably an intracellular T. cruzi antigen; 2) IgG/serum is interacting with the O2 region of the M2 receptor in the rabbit heart; and 3) the negative charges present in the ribosomal proteins of T. cruzi are important in mediating the interaction between the patients' serum/IgG and the receptor.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, CCS, Hosp Clementino Fraga Filho, Rio de Janeiro, Brazil; Inst Invest Ingn Genet & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; CNRS, Lab Enzymol & Chim Prot, F-37032 Tours, France	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Centre National de la Recherche Scientifique (CNRS)	de Carvalho, CC (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, Bloco G,Ilha Fundao, BR-21949900 Rio De Janeiro, Brazil.	acarlos@ibccf.biof.ufrj.br	de Carvalho, Antonio Carlos Campos/A-3152-2008	de Carvalho, Antonio Carlos Campos/0000-0002-0062-3043; dos Santos Costa, Patricia Cristina/0000-0003-0111-6980				AFFRANCHINO JL, 1989, MOL BIOCHEM PARASIT, V34, P221, DOI 10.1016/0166-6851(89)90050-9; ANDRADE ZA, 1983, CIBA F SYMP, V99, P214; Bergami PL, 1997, FEMS IMMUNOL MED MIC, V18, P75, DOI 10.1016/S0928-8244(97)00026-6; BORDA E, 1984, CLIN EXP IMMUNOL, V57, P679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER Z, 1994, SCI PUBLICATION, V547, P30; Chagas C., 1909, Memorias do Instituto Oswaldo Cruz, V1; CHIALE PA, 1995, J AM COLL CARDIOL, V26, P864, DOI 10.1016/0735-1097(95)00262-2; COTRIM PC, 1990, J CLIN MICROBIOL, V28, P519, DOI 10.1128/JCM.28.3.519-524.1990; deOliveira SF, 1997, CIRCULATION, V96, P2031, DOI 10.1161/01.CIR.96.6.2031; Dias J. C. P., 1984, Memorias do Instituto Oswaldo Cruz, V79, P85, DOI 10.1590/S0074-02761984000500017; Elies R, 1996, J IMMUNOL, V157, P4203; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; Ferrari I, 1997, LANCET, V350, P262, DOI 10.1016/S0140-6736(05)62226-X; Goin JC, 1997, FASEB J, V11, P77, DOI 10.1096/fasebj.11.1.9034169; Hoebeke J, 1995, M S-MED SCI, V11, P1661, DOI 10.4267/10608/2366; HOEBEKE J, 1995, REV ARGENT CARDIOL, V63, P221; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; Koberle F., 1968, Advances in Parasitology, V6, P63, DOI 10.1016/S0065-308X(08)60472-8; LAFAILLE JJ, 1989, MOL BIOCHEM PARASIT, V35, P127, DOI 10.1016/0166-6851(89)90115-1; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LEVIN MJ, 1990, IMMUNOL LETT, V24, P69, DOI 10.1016/0165-2478(90)90038-R; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LEVIN MJ, 1991, FEMS MICROBIOL IMMUN, V89, P11, DOI 10.1111/j.1574-6968.1991.tb04965.x; LEVIN MJ, 1989, AM J TROP MED HYG, V41, P530, DOI 10.4269/ajtmh.1989.41.530; LOPES ER, 1975, REV SOC BRAS MED TRO, V6, P269; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; Matsui S, 1997, J MOL CELL CARDIOL, V29, P641, DOI 10.1006/jmcc.1996.0307; Mijares A, 1996, FEBS LETT, V399, P188, DOI 10.1016/S0014-5793(96)01321-X; PEREZ MA, 1984, BRAZ J MED BIOL RES, V17, P189; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; STERINBORDA L, 1991, CLIN IMMUNOL IMMUNOP, V61, P387, DOI 10.1016/S0090-1229(05)80010-8	32	46	51	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1998	12	14					1551	1558		10.1096/fasebj.12.14.1551	http://dx.doi.org/10.1096/fasebj.12.14.1551			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806764				2022-12-28	WOS:000076749500014
J	Gu, CH; Castellino, A; Chan, JYH; Chao, MV				Gu, CH; Castellino, A; Chan, JYH; Chao, MV			BRE: a modulator of TNF-alpha action	FASEB JOURNAL			English	Article						brain; reproduction; PCR; maltese binding protein	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; FACTOR RECEPTOR; ACTIVATION; KINASE; IDENTIFICATION; DOMAIN; DEATH	A stress-responsive gene highly expressed in brain and reproductive organs (BRE) is down-regulated after UV irradiation, DNA damaging agents, or retinoic acid treatment. The human BRE gene encodes a mRNA of 1.9 kb, which gives rise to a protein of 383 amino acids with a molecular size of 44 kilodaltons, BRE is not homologous to any known gene and its function has not been defined. Here we report that BRE was identified multiple times in a yeast two-hybrid screen of a murine cerebellar cDNA library, using the juxtamembrane domain of the p55 tumor necrosis factor a (TNF) receptor, The interaction between the p55 receptor and BRE was verified by an in vitro biochemical assay by using recombinant fusion proteins and by co-immunoprecipitation of transfected mammalian cells. In the yeast two-hybrid assay, BRE specifically interacted with p55 TNF receptor but not with other TNF family members such as the Fas receptor, the p75 TNF receptor, and p75 neurotrophin receptor. Overexpression of BRE inhibited TNF-induced NF kappa B activation, indicating that the interaction of BRE protein with the cytoplasmic region of p55 TNF receptor may modulate signal transduction by TNF-alpha.	Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA; Chinese Univ Hong Kong, Dept Clin Oncol, Prince Wales Hosp, Shatin, Peoples R China	Cornell University; Chinese University of Hong Kong; Prince of Wales Hospital	Chao, MV (corresponding author), NYU, Med Ctr, Skirball Inst, 540 1st Ave, New York, NY 10016 USA.	chao@saturn.med.nyu.edu		Chao, Moses/0000-0002-6969-3744	NCI NIH HHS [CA45670] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HSU KC, 1993, J BIOL CHEM, V268, P16430; LI L, 1995, BIOCHEM BIOPH RES CO, V206, P764, DOI 10.1006/bbrc.1995.1108; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NIKOLAI L, 1997, NATURE, V385, P539; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Robinson J. P., 1991, MEASURES PERSONALITY, V1, P1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRIPP ML, 1989, MOL MICROBIOL, V3, P1319, DOI 10.1111/j.1365-2958.1989.tb00113.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	27	45	49	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1101	1108		10.1096/fasebj.12.12.1101	http://dx.doi.org/10.1096/fasebj.12.12.1101			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737713				2022-12-28	WOS:000075738500005
J	Howie, SEM; Cotton, GJ; Heslop, I; Martin, NJ; Harrison, DJ; Ramage, R				Howie, SEM; Cotton, GJ; Heslop, I; Martin, NJ; Harrison, DJ; Ramage, R			Synthetic peptides representing discontinuous CD4 binding epitopes of HIV-1 gp120 that induce T cell apoptosis and block cell death induced by gp120	FASEB JOURNAL			English	Article						TFA; phycoerythrin; IgG; optical density	IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN GP120; CONFORMATIONAL SWITCH; CROSS-LINKING; RECEPTOR; INFECTION; AIDS; LYMPHOCYTES; ANTIGEN; REGION	A vaccine against HIV-1 virus would block initial infection and must target conserved residues. Since initial infection depends on binding of the viral envelope protein gp120 to CD4 on the cell surface, the CD4 binding site of gp120 is a target for vaccine design, To identify the optimal biologically active site, we synthesized a series of 32-mer peptides, based on conserved residues in the C3 and C4 regions of gp120. These included three of five sequence discontinuous residues known to be involved in CD4 binding, one or two of which were substituted with alanine, We also synthesized a 44-mer peptide with an additional branch to incorporate an extra C4 region sequence including a fourth CD4 binding residue. All these peptides used an oxidized Cys-X-Cys bridge to link the discontinuous sequence elements in a manner suggested by the known conserved disulfide bridges in gp120, Polyclonal sera raised to these peptides indicate that they all contain both B and T lymphocyte epitopes, Binding of the peptides to CD4-transfected HeLa cells reveals a hierarchy dependent on the number of relevant CD4 binding residues present. Furthermore, antibody cross-linking of peptides bound to the surface of human T cells results in apoptosis that is similar to the known properties of gp120, The peptide incorporating three CD4 binding residues competitively inhibited gp120-induced T lymphocyte apoptosis, Thus, we have synthesized novel, branched peptides incorporating conserved discontinuous sequences from two different conserved domains of HIV-1 gp120 that contain T and B lymphocyte epitopes and mimic biological functions of the native protein, These synthetic peptides are candidates for future vaccine development.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr Prot Technol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Howie, SEM (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.e.m.howie@ed.ac.uk						AMEISEN JC, 1994, IMMUNOL REV, V142, P9, DOI 10.1111/j.1600-065X.1994.tb00882.x; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BYCROFT BW, 1993, J CHEM SOC CHEM COMM, V5, P283; CORBEIL J, 1995, J GEN VIROL, V76, P681, DOI 10.1099/0022-1317-76-3-681; CORDONNIER A, 1989, NATURE, V340, P574; Cotton GJ, 1996, MOL IMMUNOL, V33, P171, DOI 10.1016/0161-5890(95)00110-7; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DOWBENKO D, 1988, J VIROL, V62, P4703, DOI 10.1128/JVI.62.12.4703-4711.1988; FUJII N, 1989, J CHEM SOC CHEM COMM, P283, DOI 10.1039/c39890000283; FUJII N, 1987, J CHEM SOC CHEM COMM, P1676, DOI 10.1039/c39870001676; FYFE L, 1991, IMMUNOLOGY, V74, P467; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOWIE SEM, 1994, IMMUNOL REV, V142, P141, DOI 10.1111/j.1600-065X.1994.tb00887.x; HOWIE SEM, 1994, CLIN EXP IMMUNOL, V95, P195; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LAURENTCRAWFORD AG, 1993, AIDS RES HUM RETROV, V9, P761, DOI 10.1089/aid.1993.9.761; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; MALDARELLI F, 1995, J VIROL, V69, P6457, DOI 10.1128/JVI.69.10.6457-6465.1995; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; OYAIZU N, 1993, BLOOD, V82, P3392; OYAIZU N, 1994, BLOOD, V84, P2622; POLLARD SR, 1992, EMBO J, V11, P585, DOI 10.1002/j.1460-2075.1992.tb05090.x; RAMAGE R, 1994, BIOCHEM J, V299, P151, DOI 10.1042/bj2990151; REED J, 1991, BIOCHEMISTRY-US, V30, P4521, DOI 10.1021/bi00232a022; REED J, 1993, P NATL ACAD SCI USA, V90, P6761, DOI 10.1073/pnas.90.14.6761; SYU WJ, 1990, P NATL ACAD SCI USA, V87, P3695, DOI 10.1073/pnas.87.10.3695; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; vonStosch AG, 1996, BIOCHEMISTRY-US, V35, P411, DOI 10.1021/bi952045w; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1553, DOI 10.1002/eji.1830240715; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	37	14	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	1998	12	11					991	998		10.1096/fasebj.12.11.991	http://dx.doi.org/10.1096/fasebj.12.11.991			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707171				2022-12-28	WOS:000075372600009
J	Varga, K; Wagner, JA; Bridgen, DT; Kunos, G				Varga, K; Wagner, JA; Bridgen, DT; Kunos, G			Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension	FASEB JOURNAL			English	Article						anandamide; 2-arachidonyl glyceride; CB1 cannabinoid receptors; vasodilation	NEUROBLASTOMA-CELLS; ENZYMATIC-SYNTHESIS; IMMUNE FUNCTION; ANANDAMIDE; RECEPTOR; BRAIN; RAT; CB1; BIOSYNTHESIS; DEGRADATION	Macrophages are the primary cellular targets of bacterial lipopolysaccharide (LPS), but the role of macrophage-derived cytokines in LPS-induced septic shock is uncertain. Recent evidence indicates that activation of peripheral CB1 cannabinoid receptors contributes to hemorrhagic hypotension and that macrophage-derived anandamide as well as unidentified platelet-derived substances may be contributing factors. Here we demonstrate that rat platelets contain the endogenous cannabinoid 2-arachidonyl glyceride (2-AG), as identified by reverse phase high-performance liquid chromatography, gas chromatography, and mass spectrometry, and that in vitro exposure of platelets to LPS (200 mu g/ml) markedly increases 2-AG levels, LPS-stimulated, but not control, macrophages contain anandamide, which is undetectable in either control or LPS-stimulated platelets. Prolonged hypotension and tachycardia are elicited in urethane-anesthetized rats treated 1) with LPS (15 mg/kg i.v.); 2) with macrophages plus platelets isolated from 3 ml of blood from an LPS-treated donor rat; or 3) with rat macrophages or 4) platelets preincubated in vitro with LPS (200 mu g/ml). In all four cases, the hypotension but not the tachycardia is prevented by pretreatment of the recipient rat with the CB1 receptor antagonist SR141716A (3 mg/kg i.v.), which also inhibits the hypotensive response to anandamide or 2-AG, The hypotension elicited by LPS-treated macrophages or platelets remains unchanged in the absence of sympathetic tone or after blockade of nitric oxide synthase, These findings indicate that platelets and macrophages generate different endogenous cannabinoids, and that both 2-AG and anandamide may be paracrine mediators of endotoxin-induced hypotension via activation of vascular CB1 receptors.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Virginia Commonwealth University	Kunos, G (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NHLBI NIH HHS [HL 59257] Funding Source: Medline; NIAAA NIH HHS [AA-09719] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009719] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AMRUTHESH SC, 1992, J NEUROCHEM, V58, P503, DOI 10.1111/j.1471-4159.1992.tb09749.x; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1997, EUR J PHARMACOL, V337, pR1, DOI 10.1016/S0014-2999(97)01297-1; Cummings CJ, 1997, AM J RESP CRIT CARE, V156, P431, DOI 10.1164/ajrccm.156.2.9509017; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; Di Marzo V, 1998, BIOCHEM J, V331, P15; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; DORMAN T, 1994, CRIT CARE MED, V22, P1069, DOI 10.1097/00003246-199407000-00001; Ellis EF, 1995, AM J PHYSIOL-HEART C, V269, pH1859, DOI 10.1152/ajpheart.1995.269.6.H1859; GEBREMEDHIN G, 1996, FASEB J, V10, pA302; HALLING JL, 1992, INFECT IMMUN, V60, P845, DOI 10.1128/IAI.60.3.845-852.1992; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Junger WG, 1996, J TRAUMA, V40, P702, DOI 10.1097/00005373-199605000-00004; KUMAR GS, 1998, FEBS LETT, V422, P69; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; Malinowska B, 1997, N-S ARCH PHARMACOL, V356, P197, DOI 10.1007/PL00005041; McCuskey RS, 1996, CARDIOVASC RES, V32, P752, DOI 10.1016/S0008-6363(96)00113-7; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; Patrini G, 1997, J NEUROIMMUNOL, V80, P143, DOI 10.1016/S0165-5728(97)00149-5; Peitzman AB, 1995, CURR PROB SURG, V32, P927; Plane F, 1997, BRIT J PHARMACOL, V121, P1509, DOI 10.1038/sj.bjp.0701361; Pratt PF, 1998, AM J PHYSIOL-HEART C, V274, pH375, DOI 10.1152/ajpheart.1998.274.1.H375; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Randall MD, 1996, BIOCHEM BIOPH RES CO, V229, P114, DOI 10.1006/bbrc.1996.1766; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Schatz AR, 1997, TOXICOL APPL PHARM, V142, P278, DOI 10.1006/taap.1996.8034; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; Stein EA, 1996, BRIT J PHARMACOL, V119, P107, DOI 10.1111/j.1476-5381.1996.tb15683.x; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sun XM, 1997, AM J PHYSIOL-GASTR L, V273, pG56, DOI 10.1152/ajpgi.1997.273.1.G56; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	49	344	349	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1035	1044		10.1096/fasebj.12.11.1035	http://dx.doi.org/10.1096/fasebj.12.11.1035			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707176				2022-12-28	WOS:000075372600014
J	Aandahl, EM; Aukrust, P; Skalhegg, BS; Muller, F; Froland, SS; Hansson, V; Tasken, K				Aandahl, EM; Aukrust, P; Skalhegg, BS; Muller, F; Froland, SS; Hansson, V; Tasken, K			Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients	FASEB JOURNAL			English	Article						cAMP; PKA; AIDS; Rp-8-Br-cAMPS	LYMPHOCYTE ACTIVATION; SURFACE MOLECULES; RI-ALPHA; CAMP; RESTORATION; PATHWAY; REPLICATION; RECEPTOR; ANALOGS; VITRO	Cyclic AMP-dependent protein kinase A (PKA) type I has been established as an acute inhibitor of T cell activation. For this reason, we investigated the possible role of PKA. type I in HIV-induced T cell dysfunction, T cells from HIV-infected patients have increased levels of cAMP and are more sensitive to inhibition by cAMP analog than are normal T cells. A PKA type I-selective antagonist increases the impaired proliferation of T cells from HIV-infected patients to normal or subnormal levels (up to 2.8-fold). Follow-up of patients after initiation of highly active antiretroviral treatment revealed that a majority of patients have a persistent T cell dysfunction that is normalized by incubation of T cells with Rp-8-Br-cAMPS, These observations imply that increased activation of PKA. type I may contribute to the progressive T cell dysfunction in HIV infection and that PKA. type I may be a potential target for immunomodulating therapy.-Aandahl, E. M., Aukrust, P., Skalhegg, B. S., Muller, F., Froland, S. S., Hansson, V., Tasken, K. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients.	Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Internal Med Res Inst, N-0317 Oslo, Norway; Natl Hosp Norway, Dept Med A, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Tasken, K (corresponding author), Univ Oslo, Inst Med Biochem, POB 1112, N-0317 Oslo, Norway.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Aandahl, Einar Martin/0000-0002-0115-8382; Tasken, Kjetil/0000-0003-2841-4697				CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Dayal AK, 1996, ARTHRITIS RHEUM-US, V39, P23, DOI 10.1002/art.1780390104; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; HOFMANN B, 1993, AIDS, V7, P659, DOI 10.1097/00002030-199305000-00008; HOFMANN B, 1993, P NATL ACAD SCI USA, V90, P6676, DOI 10.1073/pnas.90.14.6676; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KAMMER GM, 1994, J CLIN INVEST, V94, P422, DOI 10.1172/JCI117340; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; LAXMINARAYANA D, 1993, J CLIN INVEST, V92, P2207, DOI 10.1172/JCI116823; Laxminarayana D, 1996, J IMMUNOL, V156, P497; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; Levy FO, 1996, EUR J IMMUNOL, V26, P1290, DOI 10.1002/eji.1830260617; NOKTA MA, 1992, AIDS RES HUM RETROV, V8, P1255, DOI 10.1089/aid.1992.8.1255; Pantaleo G, 1997, NAT MED, V3, P483, DOI 10.1038/nm0597-483; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; TASKEN K, 1993, J BIOL CHEM, V268, P23483; TASKEN K, 1993, J BIOL CHEM, V268, P21276; Torgersen KM, 1997, J BIOL CHEM, V272, P5495, DOI 10.1074/jbc.272.9.5495	25	96	107	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					855	862		10.1096/fasebj.12.10.855	http://dx.doi.org/10.1096/fasebj.12.10.855			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657525				2022-12-28	WOS:000074580100010
J	Kwon, BS; Wang, SA; Udagawa, N; Haridas, V; Lee, ZH; Kim, KK; Oh, KO; Greene, J; Li, YL; Su, J; Gentz, R; Aggarwal, BB; Ni, J				Kwon, BS; Wang, SA; Udagawa, N; Haridas, V; Lee, ZH; Kim, KK; Oh, KO; Greene, J; Li, YL; Su, J; Gentz, R; Aggarwal, BB; Ni, J			TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption	FASEB JOURNAL			English	Article						TNFR; anti-TR1 mAb; osteoclast; immunization; monoclonal antibody	NERVE GROWTH-FACTOR; OSTEOBLASTIC CELLS; RUFFLED BORDERS; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; MECHANISM; PROTEINS; FAMILY; GENES	A newly identified member of the tumor necrosis factor receptor (TNFR) superfamily shows activities associated with osteoclastogenesis inhibition and fibroblast proliferation. This new member, called TR1, was identified from a search of an expressed sequence tag database, and encodes 401 amino acids with a 21-residue signal sequence. Unlike other members of TNFR, TR1 does not contain a transmembrane domain and is secreted as a 62 kDa glycoprotein. TR1 gem maps to chromosome 8q23-24.1 and its mRNA is abundantly expressed on primary osteoblasts, osteogenic sarcoma cell lines, and primary fibroblasts. The receptors for TR1 were detected on a monocytic cell line (THP-1) and in human fibroblasts. Scatchard analyses indicated two classes of high and medium-high affinity receptors with a kD of approximately 45 and 320 pM, respectively. Recombinant TRI induced proliferation of human foreskin fibroblasts and potentiated TNF-induced proliferation in these cells. In a coculture system of osteoblasts and bone marrow cells, recombinant TR1 completely inhibited the differentiation of osteoclast-like multinucleated cell formation in the presence of several bone-resorbing factors. TR1 also strongly inhibited bone-resorbing function on dentine slices by mature osteoclasts and decreased Ca-45 release in fetal long-bone organ cultures. Anti-TR1 monoclonal antibody promoted the formation of osteoclasts in mouse marrow culture assays. These results indicate that TRI has broad biological activities in fibroblast growth and in osteoclast differentiation and its functions.-Kwon, B. S., Wang, S., Udagawa, N., Haridas, V., Lee, Z. H., Rim, K. K., Oh, K.-O., Greene, J., Li, Y., Su, J., Gentz., R., Aggarwal, B. B., Ni, J. TR1, a new member of tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 142, Japan; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Chosun Univ, Sch Dent, Dept Microbiol, Kwangju 501759, South Korea; Seoul Natl Univ, Sch Dent, Dept Oral Microbiol, Chongro Ku, Seoul, South Korea; Human Genome Sci Inc, Rockville, MD 20850 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Showa University; University of Texas System; UTMD Anderson Cancer Center; Chosun University; Seoul National University (SNU); GlaxoSmithKline; Human Genome Sciences Inc	Kwon, BS (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,MS 255, Indianapolis, IN 46202 USA.	kkwon@sunflower.bio.indiana.edu	Kim, Kack-Kyun/C-5031-2012; Aggarwal, Bharat B/G-3388-2013	Kim, Kack-Kyun/0000-0002-1279-5387; 	NIAID NIH HHS [AI 28175, AI 42379] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028175, R03AI042379] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; AKATSU T, 1991, J BONE MINER RES, V6, P183; AKATSU T, 1992, J BONE MINER RES, V7, P1297; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BAUM PR, 1994, EMBO J, V13, P3992, DOI 10.1002/j.1460-2075.1994.tb06715.x; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DOWER SK, 1984, J IMMUNOL, V132, P751; DUNSTAN CR, 1997, J BONE MINER RES  S1, V12, pS136; JIMI E, 1995, ENDOCRINOLOGY, V136, P806; KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756-3282(90)90082-A; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272; KWON BS, 1989, P NATL ACAD SCI USA, V86, P1963, DOI 10.1073/pnas.86.6.1963; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756-3282(95)00150-6; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; POLLOK KE, 1993, J IMMUNOL, V150, P771; SASAKI T, 1989, ANAT REC, V224, P379, DOI 10.1002/ar.1092240307; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHATCHARD G, 1949, ANN NY ACAD SCI, V51, P660; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda Tatsuo, 1996, P87; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAMURA T, 1993, J BONE MINER RES, V8, P953; TARTAGLIA LA, 1993, CELL, V74; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461	38	139	151	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					845	854		10.1096/fasebj.12.10.845	http://dx.doi.org/10.1096/fasebj.12.10.845			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657524				2022-12-28	WOS:000074580100009
J	Anson, RM; Hudson, E; Bohr, VA				Anson, RM; Hudson, E; Bohr, VA			Mitochondrial endogenous oxidative damage has been overestimated	FASEB JOURNAL			English	Article						8-hydroxy-2 '-deoxyguanosine; 8-hydroxydeoxy-guanosine; 8-oxoguanine; 8-oxodG; aging; mitochondria	FORMAMIDOPYRIMIDINE DNA GLYCOSYLASE; NUCLEAR-DNA; CELLS; REPAIR; DISEASE	The oxidatively induced DNA lesion 8-oxo-dG in mitochondrial DNA (mtDNA) is commonly used as a marker for oxidative damage to mitochondria, which in turn is thought to be a fundamental cause of aging. For years, mitochondrial levels of 8-oxo-dG were believed to be similar to 10-fold higher in mtDNA than in nuclear DNA even in normal, young animals. However, studies in our own and other laboratories have shown that this lesion is efficiently repaired. Also, mutational consequences specific to 8-oxo-dG (G to T transversions) are rarely reported, In the present study, we showed that the levels of damage measured using high-pressure liquid chromatography/electrochemical detection and an enzymatic/Southern blot assay were comparable. The latter assay does not require isolation of mitochondria, and so this assay was then used to determine the level of in vivo damage present in rat Liver mtDNA both with and without organelle isolation. Levels of 8-oxo-dG are approximately threefold higher when measured in mtDNA purified from isolated mitochondria than when measured without prior mitochondrial isolation. Furthermore, most genomes were free of endogenous enzyme-sensitive sites (i.e., they did not contain 8-oxo-dG), and only after mitochondrial isolation were levels higher in mtDNA than in a nuclear sequence.	NIA, Mol Genet Lab, GRC, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020	Anson, Robert/0000-0002-7913-3644				Anson RM, 1998, NUCLEIC ACIDS RES, V26, P662, DOI 10.1093/nar/26.2.662; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; Beckman KB, 1999, MUTAT RES-FUND MOL M, V424, P51, DOI 10.1016/S0027-5107(99)00007-X; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; CORRALDEBRINSKI M, 1992, MUTAT RES, V275, P169, DOI 10.1016/0921-8734(92)90021-G; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Denepoux S, 1997, IMMUNITY, V6, P35, DOI 10.1016/S1074-7613(00)80240-X; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FASMAN GD, 1975, HDB BIOCH MOL BIOL N, V2, P268; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HEGLER J, 1993, CARCINOGENESIS, V14, P2309, DOI 10.1093/carcin/14.11.2309; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; Saljoughi S, 1997, FASEB J, V11, pA1250; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; TAKASAWA M, 1993, EXP GERONTOL, V28, P269, DOI 10.1016/0531-5565(93)90034-B	25	69	73	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					355	360		10.1096/fasebj.14.2.355	http://dx.doi.org/10.1096/fasebj.14.2.355			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657991				2022-12-28	WOS:000085184800014
J	Duncan, MR; Frazier, KS; Abramson, S; Williams, S; Klapper, H; Huang, XF; Grotendorst, GR				Duncan, MR; Frazier, KS; Abramson, S; Williams, S; Klapper, H; Huang, XF; Grotendorst, GR			Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: downregulation by cAMP	FASEB JOURNAL			English	Article						fibrosis; wound repair; granulation tissue; cholera toxin; transgenic	FACTOR GENE-EXPRESSION; ANCHORAGE-INDEPENDENT GROWTH; HUMAN DERMAL FIBROBLASTS; NECROSIS FACTOR-ALPHA; STEADY-STATE LEVELS; NUCLEAR FACTOR-I; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; SYSTEMIC-SCLEROSIS; WOUND REPAIR	Connective tissue growth factor (CTGF) is a cysteine-rich peptide synthesized and secreted by fibroblastic cells after activation with transforming growth factor beta (TGF-beta) that acts as a downstream mediator of TGF-beta-induced fibroblast proliferation. We performed in vitro and in vivo studies to determine whether CTGF is also essential for TGF-beta-induced fibroblast collagen synthesis. lit vitro studies with normal rat kidney (NRK) fibroblasts demonstrated CTGF potently induces collagen synthesis and transfection with an antisense CTGF gene blocked TGF-beta stimulated collagen synthesis. Moreover, TGF-beta-induced collagen synthesis in both NRK and human foreskin fibroblasts was effectively blocked with specific anti-CTGF antibodies and by suppressing TGF-beta-induced CTGF gene expression by elevating: intracellular cAMP levels with either membrane-permeable 8-Br-cAMP or an adenylyl cyclase activator, cholera toxin (CTX). cAMP also inhibited collagen synthesis induced by CTGF itself, in contrast to its previously reported lack of effect on CTGF-induced DNA synthesis. In animal assays, CTX injected intradermally in transgenic mice suppressed TGF-beta activation of a human CTGF promoter/lacZ reporter transgene. Both 8-Br-cAMP and CTX blocked TGF-beta-induced collagen deposition in a wound chamber model of fibrosis in rats. CTX also reduced dermal granulation tissue fibroblast population increases induced by TGF-beta in neonatal mice, but not increases induced by CTGF or TGF-beta com bined with CTGF. Our data indicate that CTGF mediates TGF-beta-induced fibroblast collagen synthesis and that in vivo blockade of CTGF synthesis or action reduces TGF-beta-induced granulation tissue formation by inhibiting both collagen synthesis and fibroblast accumulation.	Univ Miami, Sch Med R124, Dept Anat & Cell Biol, Miami, FL 33136 USA; Cleveland Clin, Ft Lauderdale, FL 33309 USA; FibroGen Inc, S San Francisco, CA 94080 USA	University of Miami; Cleveland Clinic Foundation; FibroGen	Grotendorst, GR (corresponding author), Univ Miami, Sch Med R124, Dept Anat & Cell Biol, 1600 NW 10th Ave, Miami, FL 33136 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037223] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07057-01A1] Funding Source: Medline; NIGMS NIH HHS [GM37223] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALKAN W, 1992, P NATL ACAD SCI USA, V89, P3347, DOI 10.1073/pnas.89.8.3347; BERMAN B, 1992, J INVEST DERMATOL, V98, P706, DOI 10.1111/1523-1747.ep12499916; BERMAN B, 1989, J INVEST DERMATOL, V92, P605, DOI 10.1111/1523-1747.ep12712140; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CIVITELLI R, 1989, ENDOCRINOLOGY, V124, P2928, DOI 10.1210/endo-124-6-2928; CLARK RAF, 1993, J DERMATOL SURG ONC, V19, P693, DOI 10.1111/j.1524-4725.1993.tb00413.x; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P282, DOI 10.1111/1523-1747.ep12612819; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GORDON J, 1992, ILAR NEWS, V34, P45; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; GROTENDORST GR, 1985, J CLIN INVEST, V76, P2323, DOI 10.1172/JCI112243; GROTENDORST GR, 1996, CELL GROWTH DIFFER, V7, P1; HANRAHAN D, 1989, MANIPULATING MOUSE E, P174; HUNT TK, 1967, AM J SURG, V114, P302, DOI 10.1016/0002-9610(67)90388-1; IGARASHI A, 1995, J INVEST DERMATOL, V105, P280, DOI 10.1111/1523-1747.ep12318465; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; KELLY D, 1989, DIFFERENTIATION, V41, P34, DOI 10.1111/j.1432-0436.1989.tb00729.x; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; NAGY P, 1991, HEPATOLOGY, V14, P269, DOI 10.1002/hep.1840140211; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Oemar BS, 1997, CIRCULATION, V95, P831; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Peterson TC, 1996, IMMUNOPHARMACOLOGY, V31, P183, DOI 10.1016/0162-3109(95)00048-8; Preaux AM, 1997, HEPATOLOGY, V26, P315, DOI 10.1002/hep.510260210; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SCHILLING JA, 1959, SURGERY, V46, P702; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SMITH EA, 1990, J INVEST DERMATOL, V95, pS125, DOI 10.1111/1523-1747.ep12874998; SPORN MB, 1983, SCIENCE, V219, P1329, DOI 10.1126/science.6572416; THALACKER FW, 1992, BIOCHEM J, V287, P855, DOI 10.1042/bj2870855; VADJY M, 1992, IMMUNOLOGY, V75, P488; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WASSARMAN PM, 1992, METHOD ENZYMOL, V225, P459; WEBSTER DF, 1979, ANAL BIOCHEM, V96, P220, DOI 10.1016/0003-2697(79)90576-1	54	521	590	0	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1774	1786		10.1096/fasebj.13.13.1774	http://dx.doi.org/10.1096/fasebj.13.13.1774			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506580				2022-12-28	WOS:000083063400012
J	Andrieu-Abadie, N; Jaffrezou, JP; Hatem, S; Laurent, G; Levade, T; Mercadier, JJ				Andrieu-Abadie, N; Jaffrezou, JP; Hatem, S; Laurent, G; Levade, T; Mercadier, JJ			L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation	FASEB JOURNAL			English	Article						staurosporine; cardiotoxicity; oxidative stress; tumor necrosis factor	DAUNORUBICIN-INDUCED APOPTOSIS; GROWTH-FACTOR-I; CELL-DEATH; CARDIOMYOCYTE APOPTOSIS; KAPPA-B; ADRIAMYCIN; CARDIOTOXICITY; ISCHEMIA; NECROSIS; STRESS	Besides the well-documented effect of the chemotherapeutic drug doxorubicin on free radical generation, the exact signaling mechanisms by which it causes cardiac damage remain largely unknown and are of fundamental importance in understanding anthracycline cardiotoxicity In this study, we describe that a 1 h treatment of isolated adult rat cardiac myocytes with doxorubicin (0.5 mu M) induced DNA fragmentation associated with the classical morphological features of apoptosis observed after 7 days of culture, The doxorubicin toxicity was preceded by an increase in intracellular ceramide levels with a concurrent decrease in sphingomyelin, Anthracycline-induced ceramide accumulation resulted from the activation of a sphingomyelinase assayed under acidic conditions, an effect related to an increase in V-max. Pretreatment of cardiac myocytes with L-carnitine (200 mu g/ml), a compound known for its protective effect on cardiac metabolic injuries, was found to dose-dependently inhibit the doxorubicin-induced sphingomyelin hydrolysis and ceramide generation as well as subsequent cell death. However, L-carnitine did not protect cardiac myocytes from apoptosis induced by exogenous cell-permeant ceramide, L-carnitine pretreatment did not affect the sphingomyelinase basal activity but abolished the doxorubicin-induced increase in V-max. Moreover, in vitro studies conducted on cell extracts or with purified acid sphingomyelinase demonstrated that L-carnitine exerted a dose-dependent, sphingomyelinase inhibitory effect (through V-max reduction). Taken together, these findings show that by inhibiting a (perhaps novel) drug-activated acid sphingomyelinase and ceramide generation, L-carnitine can prevent doxorubicin-induced apoptosis of cardiac myocytes.	INSERM U460, UFR Med X Bichat, F-75870 Paris 18, France; CHU Rangueil, Lab Biochim Med, INSERM U466, F-31054 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Andrieu-Abadie, N (corresponding author), INSERM U460, UFR Med X Bichat, 16 Rue Henri Huchard, F-75870 Paris 18, France.	andrieu@bichat.inserm.fr	Levade, Thierry/O-8948-2014; Andrieu-Abadie, Nathalie/N-6793-2013	Andrieu-Abadie, Nathalie/0000-0003-2698-1970; hatem, stephane/0000-0002-9790-0755				AbdelAleem S, 1997, J MOL CELL CARDIOL, V29, P789, DOI 10.1006/jmcc.1996.0323; ALESSE E, 1997, CARNITINE TODAY, P105; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; Bromme HJ, 1996, MOL CELL BIOCHEM, V164, P261; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cossarizza A, 1997, AIDS, V11, P19, DOI 10.1097/00002030-199701000-00004; Delpy E, 1998, CIRCULATION, V98, P742; DiMarzio L, 1997, P ASSOC AM PHYSICIAN, V109, P154; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ETTINGHAUSEN SE, 1986, ARCH SURG-CHICAGO, V121, P1445; FOLCH J, 1957, J BIOL CHEM, V226, P497; GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOLDSMITH MA, 1979, CANCER TREAT REP, V63, P558; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1991, J BIOL CHEM, V266, P19858; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kawasaki N, 1996, J Card Fail, V2, P293, DOI 10.1016/S1071-9164(96)80016-9; KISIC A, 1974, J LIPID RES, V15, P179; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; KUMARI SS, 1987, INDIAN J EXP BIOL, V25, P419; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; MACCARI F, 1981, BIOMED EXPRESS, V35, P65; MCFALLS EO, 1986, LIFE SCI, V38, P497, DOI 10.1016/0024-3205(86)90028-7; MEDIN JA, 1999, IN PRESS HUM GENE TH; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; NERI B, 1986, ANTICANCER RES, V6, P659; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLSON HM, 1974, AM J PATHOL, V77, P439; OLSON RD, 1981, LIFE SCI, V29, P1393, DOI 10.1016/0024-3205(81)90001-1; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; PATERNA S, 1984, INT J TISSUE REACT, V6, P91; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; PRIGENT P, 1993, J IMMUNOL METHODS, V160, P139, DOI 10.1016/0022-1759(93)90018-3; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAJAGOPALAN S, 1988, CANCER RES, V48, P4766; REVOLTELLA RP, 1994, BBA-MOL CELL RES, V1224, P333, DOI 10.1016/0167-4889(94)90265-8; ROSENOFF SH, 1975, BIOCHEM PHARMACOL, V24, P1898, DOI 10.1016/0006-2952(75)90413-X; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; SHUG AL, 1978, ARCH BIOCHEM BIOPHYS, V187, P25, DOI 10.1016/0003-9861(78)90003-6; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SPETH PAJ, 1987, CANCER CHEMOTH PHARM, V20, P311; Tatlican O, 1998, CARDIOVASC SURG, V6, P145, DOI 10.1016/S0967-2109(97)00138-5; Umansky SR, 1997, CELL DEATH DIFFER, V4, P608, DOI 10.1038/sj.cdd.4400282; VANVELDHOVEN PP, 1995, BIOCHEM MOL BIOL INT, V36, P21; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Yue TL, 1998, CIRC RES, V82, P166; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614	65	156	169	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1501	1510		10.1096/fasebj.13.12.1501	http://dx.doi.org/10.1096/fasebj.13.12.1501			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463940				2022-12-28	WOS:000082347600004
J	Scalia, R; Booth, G; Lefer, DJ				Scalia, R; Booth, G; Lefer, DJ			Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide	FASEB JOURNAL			English	Article						intravital microscopy; inflammation; neutrophil; microcirculation; mesentery	MYOCARDIAL ISCHEMIA-REPERFUSION; GENE-TRANSFER; P-SELECTIN; ANGIOGENESIS; EXPRESSION; ADHESION; RELEASE; MICROCIRCULATION; ADHERENCE; PROTECTS	Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein that induces vasodilation and increases endothelial release of nitric oxide (NO). NO is also reported to modulate leukocyte-endothelium interaction. Therefore, we hypothesized that VEGF might inhibit leukocyte-endothelium interaction via increased release of NO from the vascular endothelium. We used intravital microscopy of the rat mesenteric microcirculation to measure leukocyte-endothelium interactions 2, 4, and 24 h after systemic administration of VEGF to the rat (120 mu g/kg, i.v., bolus). Superfusion of the rat mesentery with either 0.5 U/ml thrombin or 50 mu M L-NAME consistently increased the number of rolling, adhering, and transmigrated leukocytes (P<0.01 vs, control mesenteries superfused with Krebs-Henseleit buffer). At 4 and 24 h posttreatment, VEGF significantly attenuated thrombin-induced and L-NAME-induced leukocyte rolling, adherence, and transmigration in rat mesenteric venules. In addition, adherence of isolated rat PMNs to thrombin-stimulated mesenteric artery segments in vitro was significantly reduced in mesenteric arteries isolated from VEGF-treated rats (P<0.001 vs. control rats). Direct measurement of NO demonstrated a threefold increase in basal NO release from aortic tissue of rats injected with VEGF, at 4 and 24 h posttreatment (P<0.01 vs, aortic tissue from control rats). Finally, systemic administration of VEGF to ecNOS-deficient mice failed to inhibit leukocyte-endothelium interactions observed in peri-intestinal venules. We concluded that VEGF is a potent inhibitor of leukocyte-endothelium interaction, and this effect is specifically correlated to augmentation of NO release from the vascular endothelium.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA; Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Jefferson University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Scalia, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.		Lefer, David/A-6372-2012	Lefer, David/0000-0003-2293-7278; Scalia, Rosario/0000-0002-1829-943X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI N, 1990, AM J PHYSIOL, V258, pG275, DOI 10.1152/ajpgi.1990.258.2.G275; Asahara T, 1996, CIRCULATION, V94, P3291, DOI 10.1161/01.CIR.94.12.3291; BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802; BORDERS JL, 1984, MICROVASC RES, V27, P117, DOI 10.1016/0026-2862(84)90047-5; BROCK TA, 1991, AM J PATHOL, V138, P213; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; GRANGER DN, 1989, AM J PHYSIOL, V257, pG685; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Hood JD, 1998, AM J PHYSIOL, V274, P1054; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUROSE I, 1993, HEPATOLOGY, V18, P380, DOI 10.1002/hep.1840180223; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Luo ZY, 1997, ANN THORAC SURG, V64, P993, DOI 10.1016/S0003-4975(97)00715-7; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Scalia R, 1997, CARDIOVASC PATHOBIOL, V1, P160; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; Thompson RC, 1996, J AM COLL CARDIOL, V27, P8, DOI 10.1016/0735-1097(95)00436-X; vanderZee R, 1997, CIRCULATION, V95, P1030; WEYRICH AS, 1992, CIRCULATION, V86, P279, DOI 10.1161/01.CIR.86.1.279; WILLIAMS JH, 1987, J LEUKOCYTE BIOL, V42, P455, DOI 10.1002/jlb.42.5.455; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Yang RH, 1998, J PHARMACOL EXP THER, V284, P103; YUAN Y, 1990, MICROVASC RES, V40, P218, DOI 10.1016/0026-2862(90)90021-I; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	37	58	59	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1039	1046		10.1096/fasebj.13.9.1039	http://dx.doi.org/10.1096/fasebj.13.9.1039			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336886				2022-12-28	WOS:000080547700008
J	Biebermann, H; Schoneberg, T; Schulz, A; Krause, G; Gruters, A; Schultz, G; Gudermann, T				Biebermann, H; Schoneberg, T; Schulz, A; Krause, G; Gruters, A; Schultz, G; Gudermann, T			A conserved tyrosine residue (Y601) in transmembrane domain 5 of the human thyrotropin receptor serves as a molecular switch to determine G-protein coupling	FASEB JOURNAL			English	Article						G-protein-coupled receptor; molecular modeling; receptor conformation; thyroid; TSH receptor allele	LUTROPIN CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; TSH RECEPTOR; CONGENITAL HYPOTHYROIDISM; CONSTITUTIVE ACTIVITY; AMINO-ACID; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION	In the human thyroid, the wild-type thyrotropin receptor (TSHR) couples to adenylyl cyclase and phospholipase C and constitutively increases intracellular cAMP levels. The first human TSHR sequence submitted differs from subsequently cloned wild-type receptors by an exchange of a conserved Y residue within transmembrane domain 5 (TM5) for an H residue. We did not detect the Y601H mutant in 263 European individuals, but confirmed the homozygous occurrence of TSHR-Y601. Expression of TSHR-Y601H in COS-7 cells revealed a loss of constitutive cAMP production and selective lack of TSH-induced phosphoinositide hydrolysis, whereas agonist-induced cAMP formation remained unaltered. Analysis of several mutant receptors (Y601A, Y601D, Y601F, Y601K, Y601P, Y601S, Y601W, Y601 Delta) did not show restoration of constitutive activity and dual signaling, thus suggesting a functional role of a properly spaced hydroxyl group at position 601. Molecular modeling revealed that the formation of a hydrogen bond between the hydroxyl group of Y601 in TM5 and the carbonyl oxygen of A623 in the peptide backbone of TM6 is critical for the receptor to adopt active conformations that impart wild-type signaling properties. Our finding indicate that multiple active receptor states underlie coupling of a G-protein-coupled receptor to different G-proteins.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Humboldt Univ, Klin & Poliklin Kinderheilkunde, Klinikum Rudolf Virchow, Berlin, Germany; Inst Mol Pharmakol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gudermann, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	guderman@zedat.fu-berlin.de		Biebermann, Heike/0000-0002-2024-7778				Abramowicz MJ, 1997, J CLIN INVEST, V99, P3018, DOI 10.1172/JCI119497; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Arey BJ, 1997, MOL ENDOCRINOL, V11, P517, DOI 10.1210/me.11.5.517; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Biebermann H, 1997, J CLIN ENDOCR METAB, V82, P3471, DOI 10.1210/jc.82.10.3471; Biebermann H, 1997, NEW ENGL J MED, V336, P1390, DOI 10.1056/NEJM199705083361914; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CliftonBligh RJ, 1997, J CLIN ENDOCR METAB, V82, P1094, DOI 10.1210/jc.82.4.1094; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fernandez LM, 1996, BIOCHEMISTRY-US, V35, P3986, DOI 10.1021/bi952421c; Fernandez LM, 1996, J BIOL CHEM, V271, P925, DOI 10.1074/jbc.271.2.925; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Higuchi R., 1989, PCR TECHNOLOGY, P61; HITT M, 1995, VIRAL GENE TECHNIQUE, P13; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; JOHNSTONE AP, 1994, MOL CELL ENDOCRINOL, V105, pR1, DOI 10.1016/0303-7207(94)90175-9; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1995, ENDOCR J, V42, P587, DOI 10.1507/endocrj.42.587; KRAUSE G, 1995, QSAR MOL MODELLING, P530; Kristinsdottir BP, 1996, ENG OPTIMIZ, V26, P1, DOI 10.1080/03052159608941107; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; SAMANA P, 1993, J BIOL CHEM, V288, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; TAKESHITA A, 1994, THYROID, V4, P255, DOI 10.1089/thy.1994.4.255; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a	53	79	80	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1461	1471		10.1096/fasebj.12.14.1461	http://dx.doi.org/10.1096/fasebj.12.14.1461			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806755				2022-12-28	WOS:000076749500005
J	Lykkesfeldt, J; Hagen, TM; Vinarsky, V; Ames, BN				Lykkesfeldt, J; Hagen, TM; Vinarsky, V; Ames, BN			Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes - reversal with (R)-alpha-lipoic acid supplementation	FASEB JOURNAL			English	Article						biomarker; oxidative stress; aging	ALPHA-LIPOIC ACID; TERT-BUTYL HYDROPEROXIDE; DEHYDROASCORBIC ACID; OXIDATIVE STRESS; METABOLIC ANTIOXIDANT; MITOCHONDRIAL DECAY; LIPID-PEROXIDATION; DIHYDROLIPOIC ACID; LIVER-MITOCHONDRIA; VITAMIN-E	Ascorbic acid recycling from dehydroascorbic acid and biosynthesis from gulono-1,4 lactone were used as measures of cellular response capacity to increased oxidative stress induced by tertbutylhydroperoxide. The hepatic ascorbic acid concentration was 54% lower in cells from old rats when compared to cells isolated from young rats (P<0.0005). Freshly isolated hepatocytes from old rats exhibited a significantly decreased ascorbic acid recycling capacity in response to oxidative stress (P<0.005) compared to cells from young rats. Ascorbic acid synthesis in these cells from old animals was unaffected by various concentrations of tert-butylhydroperoxide, but amounted to only approximately half of the biosynthetic rate when compared to cells from young animals (P<0.001). Cells from young animals were not significantly affected by the tert-butyl-hydroperoxide treatments. The results demonstrate a declining ability with age to respond to increased oxidative stress. (R)-alpha-Lipoic acid, a mitochondrial coenzyme, is a powerful antioxidant. A two-week dietary supplementation of old animals with 0.5% (R)-alpha-lipoic acid prior to cell, isolation almost completely reversed the age-associated effects on ascorbic acid concentration (P<0.0001), recycling (P<0.05) and biosynthesis after oxidative stress. These results provide further evidence for the potential of a-lipoic acid in treatment of diseases related to oxidative stress. Furthermore, the study extends the value of ascorbic acid as a biomarker of oxidative stress. Lyk-kesfeldt, J., Hagen, T. M., Vinarsky, V., Ames, B. N. Age-associated decline in ascorbic acid concentration, recycling, and biosynthesis in rat hepatocytes-reversal with (R)-alpha-lipoic acid supplementation.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Ames, BN (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.		Lykkesfeldt, Jens/A-1072-2011	Lykkesfeldt, Jens/0000-0002-6514-8407	NATIONAL CANCER INSTITUTE [R35CA039910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Banhegyi G, 1996, FEBS LETT, V381, P39, DOI 10.1016/0014-5793(96)00077-4; Banhegyi G, 1997, FREE RADICAL BIO MED, V23, P793, DOI 10.1016/S0891-5849(97)00062-2; Barja G, 1996, Subcell Biochem, V25, P157; BECKMAN KB, 1998, IN PRESS PHYSL REV, V71; BELLOMO G, 1984, FEBS LETT, V168, P38, DOI 10.1016/0014-5793(84)80202-1; BELLOMO G, 1982, P NATL ACAD SCI-BIOL, V79, P6842, DOI 10.1073/pnas.79.22.6842; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bluck LJC, 1996, J MASS SPECTROM, V31, P741; Braun L, 1996, FEBS LETT, V388, P173, DOI 10.1016/0014-5793(96)00548-0; DE AK, 1991, MECH AGEING DEV, V59, P123, DOI 10.1016/0047-6374(91)90078-E; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DEVASAGAYAM TPA, 1986, FEBS LETT, V205, P246, DOI 10.1016/0014-5793(86)80906-1; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; Haramaki N, 1995, BIOCHEM MOL BIOL INT, V37, P591; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Kitazawa M, 1997, PHOTOCHEM PHOTOBIOL, V65, P355, DOI 10.1111/j.1751-1097.1997.tb08571.x; Lykkesfeldt J, 1997, AM J CLIN NUTR, V65, P959, DOI 10.1093/ajcn/65.4.959; Lykkesfeldt J, 1996, BMJ-BRIT MED J, V313, P91, DOI 10.1136/bmj.313.7049.91; LYKKESFELDT J, 1995, ANAL BIOCHEM, V229, P329, DOI 10.1006/abio.1995.1421; MAITRA I, 1995, FREE RADICAL BIO MED, V18, P823, DOI 10.1016/0891-5849(94)00195-P; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; Moldeus P, 1978, Methods Enzymol, V52, P60; MOORE GA, 1983, FEBS LETT, V153, P289, DOI 10.1016/0014-5793(83)80626-7; Nishikimi M, 1979, Methods Enzymol, V62, P24; PACKER L, 1994, ANN NY ACAD SCI, V738, P257; Packer L, 1997, Adv Pharmacol, V38, P79; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1; Rikans LE, 1996, MECH AGEING DEV, V91, P165, DOI 10.1016/S0047-6374(96)01784-8; Roy S, 1997, BIOCHEM PHARMACOL, V53, P393, DOI 10.1016/S0006-2952(96)00764-2; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; SATO P, 1976, BIOCHEM BIOPH RES CO, V71, P293, DOI 10.1016/0006-291X(76)90281-3; SCHOLICH H, 1989, BIOCHIM BIOPHYS ACTA, V1001, P256, DOI 10.1016/0005-2760(89)90108-2; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; SEARLS RL, 1960, J BIOL CHEM, V235, P2485; Sen CK, 1997, FREE RADICAL BIO MED, V22, P1241, DOI 10.1016/S0891-5849(96)00552-7; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SUZUKI YJ, 1993, FREE RADICAL RES COM, V18, P115, DOI 10.3109/10715769309147348; TSAO CS, 1989, LIFE SCI, V45, P1553, DOI 10.1016/0024-3205(89)90421-9; Xu DP, 1996, J BIOENERG BIOMEMBR, V28, P77; YU BP, 1989, OXYGEN RADICALS BIOL, P1067	48	120	126	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1183	1189		10.1096/fasebj.12.12.1183	http://dx.doi.org/10.1096/fasebj.12.12.1183			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737721				2022-12-28	WOS:000075738500013
J	Susini, S; Roche, E; Prentki, M; Schlegel, W				Susini, S; Roche, E; Prentki, M; Schlegel, W			Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells	FASEB JOURNAL			English	Article						glucagon-like peptide-1; pituitary adenylate cyclase-activating polypeptide; immediate-early response genes; proto-oncogenes; intracellular Ca2+	CYCLASE-ACTIVATING POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; NERVE GROWTH-FACTOR; INSULIN-SECRETION; BETA-CELLS; PROINSULIN BIOSYNTHESIS; RESPONSE GENES; RECEPTOR; LINE; NUR77	To link glucose signaling to its longterm pleiotropic effects in the pancreatic p-cen, we have investigated whether glucose regulates immediate-early response genes (IEGs) coding for transcription factors implicated in cell proliferation and differentiation. Glucose causes a coordinated transcriptional activation of the IEGs c-fos, c-jun,JunB, zif-268, and nur-77 in the pancreatic beta-cell line INS-1. This activation is entirely dependent on the presence of the cell-permeant cAMP analog chlorophenylthio-cAMP, which has only a modest effect by itself. The accumulation of c-fos, JunB, and nur-77 mRNA occurs at physiological concentrations of glucose (3 to 11 mM), requires a 1-2 h period, and is mimicked by other nutrient stimuli including mannose, leucine plus glutamine, and pyruvate. Glucose is synergistic with the glucoincretin peptides GLP-1 and PACAP-38, whereas these neurohormonal agents have no effect at low (3 mM) glucose. Mechanistically, the synergy between glucose and the glucoincretins is not based on cAMP alone as glucose does not further increase intracellular cAMP in response to GLP-1 and PACAP-38. A role for Ca2+ signaling is inferred, since the L-type Ca2+ channel blocker nifedipine markedly reduces the induction of c-fos and nur-77 by glucose and GLP-1. The induction of IEGs by glucose and chlorophenylthioc-cAMP or GLP-1 and the inhibitory effect of nifedipine are also observed in the beta HC9 cell Line. The results indicate that GLP-1 and PACAP-38 act as competence factors for the action of glucose on c-fos,JunB, and nur-77. It is suggested that the synergistic effect of glucose and glucoincretins on IEG expression plays an important role in the adaptive processes of the beta-cell to hyperglycemia.	Univ Montreal, Dept Nutr, Ctr Rech LC Simard, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc, Ctr Rech LC Simard, Montreal, PQ H2L 4M1, Canada; Univ Geneva, Fondat Rech Med, CH-1211 Geneva, Switzerland	Universite de Montreal; Universite de Montreal; University of Geneva	Prentki, M (corresponding author), Univ Montreal, Dept Nutr, Ctr Rech LC Simard, 1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	PRENTKIM@ERE.UMONTREAL.CA	Roche, Enrique/V-5738-2017	Roche, Enrique/0000-0001-5128-1672				ALARCON C, 1993, J BIOL CHEM, V268, P4276; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BLANCHARD JM, 1992, M S-MED SCI, V8, P455, DOI 10.4267/10608/3162; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; Bruce WR, 1996, EUR J CANCER PREV, V5, P41, DOI 10.1097/00008469-199612002-00007; BRUN T, 1993, J BIOL CHEM, V268, P18905; COFFER P, 1994, ONCOGENE, V9, P911; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MacDonald MJ, 1996, MOL CELL ENDOCRINOL, V123, P199, DOI 10.1016/S0303-7207(96)03918-4; MARIE S, 1993, J BIOL CHEM, V268, P23881; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; SHUPPIN GT, 1996, BIOCHEM J, V313, P259; Sjoholm A, 1996, J INTERN MED, V239, P211, DOI 10.1046/j.1365-2796.1996.377740000.x; Thorens B, 1995, DIABETES METAB, V21, P311; WAEBER G, 1994, J BIOL CHEM, V269, P26912; WIDMANN C, 1994, MOL PHARMACOL, V45, P1029; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; YADA T, 1994, J BIOL CHEM, V269, P1290; YOON JK, 1993, J BIOL CHEM, V268, P9148	41	121	126	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1173	1182		10.1096/fasebj.12.12.1173	http://dx.doi.org/10.1096/fasebj.12.12.1173			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737720				2022-12-28	WOS:000075738500012
J	Swamynathan, SK; Nambiar, A; Guntaka, RV				Swamynathan, SK; Nambiar, A; Guntaka, RV			Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes	FASEB JOURNAL			English	Review						regulation of transcription; gene expression; S1-sensitive sites; supercoiled DNA; eukaryotic promoters	ROUS-SARCOMA VIRUS; NUCLEASE-SENSITIVE REGION; CCAAT-BINDING-PROTEINS; ENHANCER FACTOR GENES; COLD SHOCK DOMAIN; CLASS-I ANTIGENS; PDGF A-CHAIN; S1 NUCLEASE; MESSENGER-RNA; MDR1 GENE	Single-stranded regions, known to be important for optimal rates of transcription, have been observed in the promoters of several cellular genes as well as in the promoters of many pathogenic viruses. Several host-encoded, single-stranded DNA binding proteins capable of binding these regions have been purified and their genes isolated. In this review, information available about single-stranded regions present within various promoters and the interaction of a novel class of single-stranded DNA binding transcription factors belonging to the Y-box family of proteins is reviewed. Mechanisms by which these proteins influence transcription of both cellular and viral genes are proposed.	Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Guntaka, RV (corresponding author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA.			Swamynathan, Shivalingappa/0000-0002-9158-1511	NCI NIH HHS [R01 CA54192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDULKADIR SA, 1995, FASEB J, V9, P1429, DOI 10.1096/fasebj.9.14.7589984; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BACOLLA A, 1991, NUCLEIC ACIDS RES, V19, P1639, DOI 10.1093/nar/19.7.1639; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bayarsaihan D, 1996, BIOCHEM J, V319, P203, DOI 10.1042/bj3190203; BOULDEN A, 1990, VIROLOGY, V174, P204, DOI 10.1016/0042-6822(90)90069-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; Brockmann D, 1996, ONCOGENE, V12, P1715; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Cleavinger PJ, 1996, VIROLOGY, V222, P133, DOI 10.1006/viro.1996.0404; Cress WD, 1996, MOL CELL BIOL, V16, P2119; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GE RW, 1994, VIROLOGY, V203, P389, DOI 10.1006/viro.1994.1499; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; GOGUSEV J, 1987, FOLIA BIOL-PRAGUE, V33, P325; GOGUSEV J, 1988, P NATL ACAD SCI USA, V85, P203, DOI 10.1073/pnas.85.1.203; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GOLLER M, 1994, NUCLEIC ACIDS RES, V22, P1885, DOI 10.1093/nar/22.10.1885; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; HSU T, 1993, P NATL ACAD SCI USA, V90, P6488, DOI 10.1073/pnas.90.14.6488; IMAMURA Y, 1993, BIOCHIM BIOPHYS ACTA, V1216, P273, DOI 10.1016/0167-4781(93)90154-6; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; Jiang WN, 1997, J BIOL CHEM, V272, P196; Juan G, 1996, EXP CELL RES, V227, P197, DOI 10.1006/excr.1996.0267; KAHN JD, 1993, COLD SPRING HARB SYM, V58, P115, DOI 10.1101/SQB.1993.058.01.015; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KANDALA JC, 1994, VIROLOGY, V198, P514, DOI 10.1006/viro.1994.1062; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KATO M, 1990, BIOCHEM J, V268, P175, DOI 10.1042/bj2680175; Kim EL, 1996, J NEUROCHEM, V67, P26; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; Krajewski WA, 1996, MOL GEN GENET, V252, P249; KRAJEWSKI WA, 1995, FEBS LETT, V358, P13, DOI 10.1016/0014-5793(94)01377-D; Ladomery M, 1997, NUCLEIC ACIDS RES, V25, P965, DOI 10.1093/nar/25.5.965; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LENZ J, 1990, P NATL ACAD SCI USA, V87, P3396, DOI 10.1073/pnas.87.9.3396; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Li Y, 1997, NUCLEIC ACIDS RES, V25, P283, DOI 10.1093/nar/25.2.283; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MERIC F, 1997, J BIOL CHEM, V270, P30499; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MIZUTA TR, 1993, NUCLEIC ACIDS RES, V21, P1761, DOI 10.1093/nar/21.8.1761; MORROW CS, 1994, J BIOL CHEM, V269, P10739; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; Nambiar A, 1998, J VIROL, V72, P900, DOI 10.1128/JVI.72.2.900-909.1998; Nambiar A, 1998, BBA-GENE STRUCT EXPR, V1395, P1, DOI 10.1016/S0167-4781(97)00141-3; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; Ohga T, 1996, CANCER RES, V56, P4224; OHMORI M, 1995, ENDOCRINOLOGY, V136, P269, DOI 10.1210/en.136.1.269; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; OZER J, 1990, J BIOL CHEM, V265, P22143; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; SAKURA H, 1988, GENE, V73, P499; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SANTRA M, 1994, J BIOL CHEM, V269, P579; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SHARROCKS AD, 1995, NUCLEIC ACIDS RES, V23, P2442, DOI 10.1093/nar/23.13.2442; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Swamynathan SK, 1997, J VIROL, V71, P2873, DOI 10.1128/JVI.71.4.2873-2880.1997; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; WANG ZY, 1994, BIOCHEM BIOPH RES CO, V198, P103, DOI 10.1006/bbrc.1994.1015; Wang ZY, 1996, PROG NUCLEIC ACID RE, V55, P227, DOI 10.1016/S0079-6603(08)60195-6; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YAN C, 1991, P NATL ACAD SCI USA, V88, P144, DOI 10.1073/pnas.88.1.144; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; ZACHOW KR, 1992, J VIROL, V66, P1959, DOI 10.1128/JVI.66.4.1959-1970.1992; ZELEZNIKLE NJ, 1991, P NATL ACAD SCI USA, V88, P1873, DOI 10.1073/pnas.88.5.1873	101	84	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					515	522		10.1096/fasebj.12.7.515	http://dx.doi.org/10.1096/fasebj.12.7.515			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576478				2022-12-28	WOS:000073523100001
J	Dupont, G; Tordjmann, T; Clair, C; Swillens, S; Claret, M; Combettes, L				Dupont, G; Tordjmann, T; Clair, C; Swillens, S; Claret, M; Combettes, L			Mechanism of receptor-oriented intercellular calcium wave propagation in hepatocytes	FASEB JOURNAL			English	Article						liver; phase wave; gap junctions; inositol 1,4,5-triphosphate	REGULATORY CA2+-BINDING SITES; INOSITOL 1,4,5-TRISPHOSPHATE; RAT HEPATOCYTES; CA2+ WAVES; PERMEATION PATHWAY; GAP-JUNCTIONS; OSCILLATIONS; MODEL; CELLS; LIVER	Intercellular calcium signals are propagated in multicellular hepatocyte systems as well as in the intact liver, The stimulation of connected hepatocytes by glycogenolytic agonists induces reproducible sequences of intracellular calcium concentration increases, resulting in unidirectional intercellular calcium waves. Hepatocytes are characterized by a gradient of vasopressin binding sites from the periportal to perivenous areas of the cell plate in hepatic lobules, Also, coordination of calcium signals between neighboring cells requires the presence of the agonist at each cell surface as well as gap junction permeability, We present a model based on the junctional coupling of several hepatocytes differing in sensitivity to the agonist and thus in the intrinsic period of calcium oscillations. In this model, each hepatocyte displays repetitive calcium spikes with a slight phase shift with respect to neighboring cells, giving rise to a phase wave. The orientation of the apparent calcium wave is imposed by the direction of the gradient of hormonal sensitivity. Calcium spikes are coordinated by the diffusion across junctions of small amounts of inositol 1,4,5-trisphosphate (InsP(3)), Theoretical predictions from this model are confirmed experimentally. Thus, major physiological insights may be gained from this model for coordination and spatial orientation of intercellular signals.	Univ Paris 11, Unite Rech U442, Inst Natl Rech Sci Sante, F-91405 Orsay, France; Free Univ Brussels, Fac Sci CP231, B-1050 Brussels, Belgium; Free Univ Brussels, IRIBHN, Fac Med, B-1050 Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Combettes, L (corresponding author), Univ Paris 11, Unite Rech U442, Inst Natl Rech Sci Sante, Ba 443, F-91405 Orsay, France.	laurent.combettes@ibaic.u-psud.fr	Tordjmann, Thierry/K-4706-2013; Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574				ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Bird GSJ, 1997, CELL CALCIUM, V21, P253, DOI 10.1016/S0143-4160(97)90049-X; Charles AC, 1996, MOL CELL NEUROSCI, V7, P337, DOI 10.1006/mcne.1996.0025; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; DAndrea P, 1997, FEBS LETT, V400, P58, DOI 10.1016/S0014-5793(96)01356-7; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; Dupont G, 1996, BIOPHYS J, V71, P1714, DOI 10.1016/S0006-3495(96)79373-6; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; Goldbeter A., 1996, BIOCH OSCILLATIONS C; HANSEN M, 1993, J CELL SCI, V106, P995; HANSEN M, 1995, J CELL SCI, V108, P2583; JAFRI MS, 1994, P NATL ACAD SCI USA, V91, P9485, DOI 10.1073/pnas.91.20.9485; Jungermann K, 1996, ANNU REV NUTR, V16, P179, DOI 10.1146/annurev.nu.16.070196.001143; Keener J., 1999, MATH PHYSL; Lindqvist SM, 1998, GASTROENTEROLOGY, V115, P1131, DOI 10.1016/S0016-5085(98)70084-8; LOESSBERG PA, 1993, J BIOL CHEM, V268, P19769; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MOTTA PM, 1988, BIOPATHOLOGY LIVER U; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; Nathanson M H, 1996, Prog Liver Dis, V14, P1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; OSTROWSKI NL, 1993, ENDOCRINOLOGY, V133, P1849, DOI 10.1210/en.133.4.1849; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; Sanderson MJ, 1996, NEWS PHYSIOL SCI, V11, P262, DOI 10.1152/physiologyonline.1996.11.6.262; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Sneyd J, 1998, BIOPHYS CHEM, V72, P101, DOI 10.1016/S0301-4622(98)00126-4; SNEYD J, 1995, AM J PHYSIOL-CELL PH, V268, pC1537, DOI 10.1152/ajpcell.1995.268.6.C1537; Spray David C., 1994, P951; SWILLENS S, 1994, P NATL ACAD SCI USA, V91, P10074, DOI 10.1073/pnas.91.21.10074; Tang YH, 1996, BIOPHYS J, V70, P246, DOI 10.1016/S0006-3495(96)79567-X; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Tordjmann T, 1996, GASTROENTEROLOGY, V111, P1343, DOI 10.1053/gast.1996.v111.pm8898649; Venance L, 1997, J NEUROSCI, V17, P1981; Wilkins M, 1998, J THEOR BIOL, V191, P299, DOI 10.1006/jtbi.1997.0585; Yule DI, 1996, AM J PHYSIOL-CELL PH, V271, pC1285, DOI 10.1152/ajpcell.1996.271.4.C1285	45	72	76	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					279	289		10.1096/fasebj.14.2.279	http://dx.doi.org/10.1096/fasebj.14.2.279			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657984				2022-12-28	WOS:000085184800007
J	Zemlo, TR; Garrison, HH; Partridge, NC; Ley, TJ				Zemlo, TR; Garrison, HH; Partridge, NC; Ley, TJ			The physician-scientist: Career issues and challenges at the year 2000	FASEB JOURNAL			English	Article							CLINICAL INVESTIGATOR		Washington Univ, Sch Med, Div Bone Marrow Transplantat & Stem Cell Biol, St Louis, MO 63110 USA; Fed Amer Soc Expt Biol, Off Publ Affairs, Bethesda, MD 20814 USA; St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Washington University (WUSTL); Saint Louis University	Ley, TJ (corresponding author), Washington Univ, Sch Med, Div Bone Marrow Transplantat & Stem Cell Biol, 660 S Euclid, St Louis, MO 63110 USA.			Garrison, Howard/0000-0001-9455-3527; Partridge, Nicola/0000-0002-5406-4814				ARIAS IM, 1989, NEW ENGL J MED, V321, P972, DOI 10.1056/NEJM198910053211412; *COMM FUND TASK FO, 1999, BENCH BEDS PERS RES; *COMM FUND YOUNG I, 1994, FUND YOUNG INV BIOL; *FED AM SOC EXP BI, 1997, GRAD ED CONS C REP; GILL GN, 1984, AM SCHOLAR, V53, P353; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Heinig SJ, 1999, ACAD MED, V74, P726, DOI 10.1097/00001888-199906000-00024; *NIGMS, 1997, REP NIH WORK GROUP N; *NIGMS, 1998, CAR PROF ACT GRAD NI; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Schechter AN, 1998, JAMA-J AM MED ASSOC, V280, P1440, DOI 10.1001/jama.280.16.1440; Sutton J, 1996, ACAD MED, V71, P454, DOI 10.1097/00001888-199605000-00013; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303	13	178	183	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					221	230		10.1096/fasebj.14.2.221	http://dx.doi.org/10.1096/fasebj.14.2.221			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657979				2022-12-28	WOS:000085184800001
J	Schiavone, N; Rosini, P; Quattrone, A; Donnini, M; Lapucci, A; Citti, L; Bevilacqua, A; Nicolin, A; Capaccioli, S				Schiavone, N; Rosini, P; Quattrone, A; Donnini, M; Lapucci, A; Citti, L; Bevilacqua, A; Nicolin, A; Capaccioli, S			A conserved AU-rich element in the 3 ' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis	FASEB JOURNAL			English	Article						bcl-2 regulation; RNA decay; RNA half-life; gene regulation	MESSENGER-RNA DEGRADATION; NECROSIS-FACTOR-ALPHA; HUMAN FOLLICULAR LYMPHOMA; LEUKEMIA-CELL-LINES; PROTEIN-KINASE-C; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; IN-VIVO; B-CELLS; BINDING PROTEINS	The control of mRNA stability is becoming recognized as a crucial point of gene expression regulation. A common element responsible for mRNA decay modulation is the adenine- and uracil-rich element that is found in the 3' untranslated region of numerous mRNAs subjected to fast expression changes in response to various stimuli. Previously we identified a post-transcriptional regulation level for the antiapoptotic bcl-2 gene, which could be involved in t(14;18) lymphoma-associated bcl-2 overexpression. Here we demonstrate that bcl-2 mRNA is endowed with an adenine- and uracil-rich element (ARE) characterized by high evolutionary conservation not only among all chordates examined, but even between chordates and the nematode Caenorhabditis elegans (ced-9 gene). As for other well-established destabilizing AREs, the insertion of the bcl-2 ARE downstream from stable beta-globin mRNA causes an enhanced decay of the beta-globin transcript, which proves its functional role. This possibility is corroborated by the fact that the pathway leading to the modulating activity of bcl-2 ARE is influenced by PKC, since the addition of DAG and TPA markedly attenuated the bcl-2 ARE destabilizing potential. Conversely, it is noteworthy that when C-2-ceramide is added to the culture medium as the apoptotic agent, the beta-globin transcript harboring the bcl-2 ARE undergoes a dramatic increase in decay. This observation clearly indicates that the destabilizing function of bcl-2 ARE is enhanced by apoptotic stimuli and suggests that this element could be involved in a post-transcriptional mechanism of bcl-2 down-regulation during apoptosis. The half-life of the mRNA of bcl-2 in Jurkat cells is prolonged by PKC stimulation and shortened by C-2-ceramide addition, strongly supporting the view that bcl-2 mRNA stability plays a physiological role in modulating bcl-2 expression, particularly in its down-regulation during apoptosis. Thus, this element becomes a new candidate for mediating those bcl-2 gene expression changes-from apoptosis-associated down-regulation to tumor-associated overexpression-observed thus far that profoundly influence single cell fate and tissue homeostasis. Schiavone, N., Rosini, P., Quattrone, A., Donnini, M., Lapucci, A., Citti, L., Bevilacqua, A., Nicolin, A., Capaccioli, S. A conserved AU-rich element in the 3' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis.	Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; CNR, Ist Mutagenesis & Differentiat, Pisa, Italy; Univ Milan, Dept Pharmacol, Milan, Italy	University of Florence; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Nicolin, A (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	angelo.nicolin@unimi.it; sergio@cesit1.unifi.it	Lapucci, Andrea/AAA-6645-2019; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Schiavone, Nicola/0000-0002-1592-4244; LAPUCCI, Andrea/0000-0001-9613-7164; Quattrone, Alessandro/0000-0003-3333-7630				AGHIB DF, 1990, ONCOGENE, V5, P707; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; Belasco J.G., 2012, CONTROL MESSENGER RN; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; Blagosklonny MV, 1997, CANCER RES, V57, P130; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Capaccioli S, 1996, ONCOGENE, V13, P105; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN M, 1995, CANCER RES, V55, P991; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GENESTIER L, 1995, INT IMMUNOL, V7, P533, DOI 10.1093/intimm/7.4.533; Haldar S, 1996, CANCER RES, V56, P1253; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Harigai M, 1996, ONCOGENE, V12, P1369; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERNANDEZCASELLES T, 1995, HUM IMMUNOL, V43, P181, DOI 10.1016/0198-8859(94)00168-P; IWAI Y, 1991, J BIOL CHEM, V266, P17959; JEWELL AP, 1994, BRIT J HAEMATOL, V88, P268, DOI 10.1111/j.1365-2141.1994.tb05017.x; Konig A, 1997, LEUKEMIA, V11, P258, DOI 10.1038/sj.leu.2400556; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARR F, 1996, J BIOL CHEM, V271, P26074; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Monni O, 1997, BLOOD, V90, P1168, DOI 10.1182/blood.V90.3.1168.1168_1168_1174; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; Ochiai K, 1997, CLIN EXP IMMUNOL, V107, P198, DOI 10.1046/j.1365-2249.1997.d01-884.x; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Quattrone A, 1995, HAEMATOLOGICA, V80, P495; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; Suzuki A, 1996, ONCOGENE, V13, P31; Suzuki A, 1997, CARCINOGENESIS, V18, P883, DOI 10.1093/carcin/18.5.883; Tangye SG, 1997, IMMUNOL CELL BIOL, V75, P127, DOI 10.1038/icb.1997.17; Teague TK, 1997, J IMMUNOL, V158, P5791; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	60	94	98	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					174	184		10.1096/fasebj.14.1.174	http://dx.doi.org/10.1096/fasebj.14.1.174			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627292				2022-12-28	WOS:000084784700020
J	Copani, A; Condorelli, F; Caruso, A; Vancheri, C; Sala, A; Stella, AMG; Canonico, PL; Nicoletti, F; Sortino, MA				Copani, A; Condorelli, F; Caruso, A; Vancheri, C; Sala, A; Stella, AMG; Canonico, PL; Nicoletti, F; Sortino, MA			Mitotic signaling by beta-amyloid causes neuronal death	FASEB JOURNAL			English	Article						neuronal apoptosis; cell cycle; Alzheimer's disease	CYCLIN-DEPENDENT KINASES; MAMMALIAN-CELL CYCLE; ALZHEIMERS-DISEASE BRAIN; PC12 CELLS; SYMPATHETIC NEURONS; INDUCED APOPTOSIS; CULTURED NEURONS; SENILE PLAQUES; G1 PHASE; A-BETA	Aggregates of beta-amyloid peptide (beta AP), the main constituent of amyloid plaques in Alzheimer's brain, kill neurons by a not yet defined mechanism, leading to apoptotic death, Here, we report that both full-length beta AP((1-40)) or ((1-42)) and its active fragment beta AP((25-35)) act as proliferative signals for differentiated cortical neurons, driving them into the cell cycle. The cycle followed some of the steps observed in proliferating cells, including induction of cyclin D1, phosphorylation of retinoblastoma, and induction of cyclin E and A, but did not progress beyond S phase. Inactivation of cyclin-dependent protein kinase-4 or -2 prevented both the entry into S phase and the development of apoptosis in beta AP((25-35))-treated neurons. We conclude that neurons must cross the G1/S transition before succumbing to PAP signaling, and therefore multiple steps within this pathway may be targets for neuroprotective agents.	Univ Catania, Sch Pharm, Dept Pharmaceut Sci, Pharmacol Sect, I-95125 Catania, Italy; Univ Catania, Sch Med, I-95125 Catania, Italy; Osped Tomaselli, Inst Resp Dis, I-95125 Catania, Italy; Consorzio Mario Negri Sud, I-66030 Chieti, Italy; Univ Pavia, Dept Internal Med & Med Therapy, I-27100 Pavia, Italy; INM Neuromed, I-86077 Pozzilli, Isernia, Italy	University of Catania; University of Catania; Consorzio Mario Negri Sud; University of Pavia; IRCCS Neuromed	Nicoletti, F (corresponding author), Univ Catania, Sch Pharm, Dept Pharmaceut Sci, Pharmacol Sect, Viale A Doria 6, I-95125 Catania, Italy.		sala, arturo/C-4959-2008; Condorelli, Fabrizio/AAT-1953-2020; VANCHERI, Carlo/K-9417-2016; Nicoletti, Ferdinando/A-2446-2010	Condorelli, Fabrizio/0000-0002-9943-0857; Sala, Arturo/0000-0002-2841-7866; VANCHERI, Carlo/0000-0002-5120-9926; NICOLETTI, Ferdinando/0000-0003-3366-7269; Sortino, Maria Angela/0000-0002-2734-1521; Nicoletti, Ferdinando/0000-0003-0917-443X				ANDERSON AJ, 1995, J NEUROCHEM, V65, P1487; ANDERSON AJ, 1994, EXP NEUROL, V125, P286, DOI 10.1006/exnr.1994.1031; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Arendt T, 1996, NEUROREPORT, V7, P3047; BHAT NR, 1992, J NEUROSCI RES, V32, P340, DOI 10.1002/jnr.490320306; BI N, 1994, EXP CELL RES, V212, P105, DOI 10.1006/excr.1994.1124; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BOZYCZKOCOINE D, 1997, SOC NEUROSCI ABSTR, V23; BRODIE C, 1993, CANCER RES, V53, P3968; Busser J, 1998, J NEUROSCI, V18, P2801; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; COPANI A, 1995, MOL PHARMACOL, V47, P890; COPANI A, 1996, SOC NEUROSCI ABSTR, V22; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; ElKhoury J, 1996, NATURE, V382, P716; Estus S, 1997, J NEUROSCI, V17, P7736; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Ferrer I, 1996, NEUROPATH APPL NEURO, V22, P521, DOI 10.1111/j.1365-2990.1996.tb01130.x; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McShea A, 1997, AM J PATHOL, V150, P1933; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; Narita M, 1997, J NEUROCHEM, V69, P1904; Nuydens R, 1998, J NEUROCHEM, V70, P1124; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PIKE CJ, 1994, NEUROSCIENCE, V63, P517, DOI 10.1016/0306-4522(94)90547-9; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SABO S, 1995, NEUROSCI LETT, V184, P25, DOI 10.1016/0304-3940(94)11159-G; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Shirvan A, 1997, J NEUROCHEM, V69, P539; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Suzuki A, 1997, EXP CELL RES, V234, P507, DOI 10.1006/excr.1997.3639; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZHANG C, 1994, J BIOL CHEM, V269, P25247	52	235	254	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2225	2234		10.1096/fasebj.13.15.2225	http://dx.doi.org/10.1096/fasebj.13.15.2225			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593870	Bronze			2022-12-28	WOS:000084310800014
J	Piek, E; Heldin, CH; Ten Dijke, P				Piek, E; Heldin, CH; Ten Dijke, P			Specificity, diversity, and regulation in TGF-beta superfamily signaling	FASEB JOURNAL			English	Review						activin; bone; morphogenetic protein; signal transduction; Smad; transforming growth factor-beta	TRANSFORMING-GROWTH-FACTOR; BONE-MORPHOGENETIC PROTEIN; N-TERMINAL KINASE; RECEPTOR SERINE-THREONINE; TUMOR-SUPPRESSOR SMAD4; FAMILY MEDIATOR SMAD1; DNA-BINDING PROTEIN; MAD-RELATED PROTEIN; I RECEPTOR; OSTEOGENIC PROTEIN-1	Transforming growth factor-beta (TGF-beta) superfamily members are multifunctional cell-cell signaling proteins that play pivotal roles in tissue homeostasis and development of multicellular animals, They mediate their pleiotropic effects from membrane to nucleus through distinct combinations of type I and type II serine/threonine kinase receptors and their downstream effecters, known as Smad proteins. Certain Smads, termed receptor-regulated Smads, become phosphorylated by activated type I receptors and form heteromeric complexes with a common-partner Smad4, which translocates into the nucleus to control gene transcription, In addition to these signal transducing Smads, inhibitory Smads have been identified that inhibit the activation of receptor-regulated Smads, In contrast to the still growing TGF-beta superfamily (with similar to 30 members in mammals), relatively few type I and type II receptors as well as Smads have been identified. We will focus on recent insights into the molecular mechanisms by which signaling specificity between different TGF-beta superfamily members is achieved and regulated, and how a single family member can elicit a broad scala of biological responses.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ten Dijke, P (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	ptdijke@nki.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; AnglesCano E, 1997, BRAZ J MED BIOL RES, V30, P1271, DOI 10.1590/S0100-879X1997001100002; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Brummel T, 1999, GENE DEV, V13, P98, DOI 10.1101/gad.13.1.98; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; BUTZOW R, 1993, J CELL BIOL, V122, P721, DOI 10.1083/jcb.122.3.721; Candia AF, 1997, DEVELOPMENT, V124, P4467; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Das P, 1998, DEVELOPMENT, V125, P1519; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Erlacher L, 1998, J BONE MINER RES, V13, P383, DOI 10.1359/jbmr.1998.13.3.383; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inoue H, 1998, MOL BIOL CELL, V9, P2145, DOI 10.1091/mbc.9.8.2145; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; JULLIEN P, 1989, INT J CANCER, V43, P886, DOI 10.1002/ijc.2910430525; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Koli KM, 1997, J BIOL CHEM, V272, P6423, DOI 10.1074/jbc.272.10.6423; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Krishna S, 1999, DEVELOPMENT, V126, P251; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LEDAI J, 1998, CANCER RES, V58, P4592; LeSuer JA, 1999, DEVELOPMENT, V126, P137; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XJ, 1998, CANCER RES, V58, P4752; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MACKAY K, 1991, J BIOL CHEM, V266, P9907; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Masuyama N, 1999, J BIOL CHEM, V274, P12163, DOI 10.1074/jbc.274.17.12163; Mather JP, 1996, HORM RES, V45, P207, DOI 10.1159/000184789; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nakayama T, 1998, DEVELOPMENT, V125, P857; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Piek E, 1997, J CELL PHYSIOL, V173, P447, DOI 10.1002/(SICI)1097-4652(199712)173:3<447::AID-JCP17>3.0.CO;2-8; Piek E, 1999, J CELL PHYSIOL, V180, P141, DOI 10.1002/(SICI)1097-4652(199908)180:2<141::AID-JCP1>3.0.CO;2-I; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAFTERY LA, 1995, GENETICS, V139, P241; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; Renucci A, 1996, DEVELOPMENT, V122, P3735; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1991, CIBA F SYMP, V157, P7; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; Saitoh M, 1996, J BIOL CHEM, V271, P2769, DOI 10.1074/jbc.271.5.2769; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHAH M, 1995, J CELL SCI, V108, P985; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Shoji H, 1998, BIOCHEM BIOPH RES CO, V246, P320, DOI 10.1006/bbrc.1998.8613; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; SUZUKI A, 1994, FEBS LETT, V355, P19, DOI 10.1016/0014-5793(94)01156-7; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; ten Dijke P, 1999, NATURE, V397, P109; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thisse C, 1999, DEVELOPMENT, V126, P229; Thomsen GH, 1997, TRENDS GENET, V13, P209, DOI 10.1016/S0168-9525(97)01117-7; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wells RG, 1997, J BIOL CHEM, V272, P11444; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; XU JM, 1994, P NATL ACAD SCI USA, V91, P7957, DOI 10.1073/pnas.91.17.7957; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAGUCHI K, 1999, EMBO J, V19, P1821; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yelick PC, 1998, DEV DYNAM, V211, P352, DOI 10.1002/(SICI)1097-0177(199804)211:4<352::AID-AJA6>3.0.CO;2-G; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; YUE J, 1999, ONCOGENE, V58, P4752; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191	227	688	744	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2105	2124		10.1096/fasebj.13.15.2105	http://dx.doi.org/10.1096/fasebj.13.15.2105			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593858				2022-12-28	WOS:000084310800002
J	Waterman-Storer, CM; Salmon, ED				Waterman-Storer, CM; Salmon, ED			Fluorescent speckle microscopy of microtubules: how low can you go?	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		PROTEIN; ACTIN; CELLS	Fluorescent speckle microscopy (FSM) is a new technique for visualizing the movement, assembly, and turnover of macromolecular assemblies like the cytoskeleton in living cells. In this method, contrast is created by coassembly of a small fraction of fluorescent subunits in a pool of unlabeled subunits, Random variation in association creates a nonuniform "fluorescent speckle" pattern. Fluorescent speckle movements in time-lapse recordings stand out to the eye and can be measured, Because fluorescent speckles represent fiduciary marks on the polymer lattice, FSM provides the opportunity for the first time to see the 2- land 3-dimensional trajectories of lattice movements within large arrays of polymers as well as identifying sites of assembly and disassembly of individual polymers, The technique works with either microinjection of fluorescently labeled subunits or expression of subunits ligated to green fluorescent protein (GFP). We have found for microtubules assembled in vitro that speckles containing one fluorophore can be detected and recorded using a conventional wide-field epi-fluorescence light microscope and digital imaging with a low noise cooled CCD camera. In living cells, optimal speckle contrast occurs at fractions of labeled tubulin of similar to 0.1-0.5% where the fluorescence of each speckle corresponds to one to seven fluorophores per resolvable unit (similar to 0.27 mu m) in the microscope. This small fraction of labeled subunits significantly reduces out-of-focus fluorescence and greatly improves visibility of fluorescently labeled structures and their dynamics in thick regions of living cells.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute	Salmon, ED (corresponding author), Univ N Carolina, Dept Biol, Biol CB3280, Chapel Hill, NC 27599 USA.	tsalmon@email.unc.edu		Waterman, Clare/0000-0001-6142-6775	NIGMS NIH HHS [GM24364] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024364, R01GM024364] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULINSKI JC, 1994, J CELL SCI, V107, P2839; FAIRE K, 1999, IN PRESS J CELL SCI; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Maddox P, 1999, J CELL BIOL, V144, P977, DOI 10.1083/jcb.144.5.977; PIECE DW, 1998, NATURE, V388, P1933; Salmon ED, 1998, METHOD CELL BIOL, V56, P185, DOI 10.1016/S0091-679X(08)60427-6; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SASE I, 1995, BIOPHYS J, V69, P323, DOI 10.1016/S0006-3495(95)79937-4; Waterman-Storer C, 1999, METHOD CELL BIOL, V61, P155; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; Waterman-Storer CM, 1998, BIOPHYS J, V75, P2059, DOI 10.1016/S0006-3495(98)77648-9; WatermanStorer CM, 1997, TRENDS CELL BIOL, V7, P503, DOI 10.1016/S0962-8924(97)01171-9; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; WATERMANSTORER CM, 1998, IN BIOL MOL BIOL CEL	14	22	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S225	S230		10.1096/fasebj.13.9002.S225	http://dx.doi.org/10.1096/fasebj.13.9002.S225			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619132				2022-12-28	WOS:000084390200010
J	Bernhard, D; Ausserlechner, MJ; Tonko, M; Loffler, M; Hartmann, BL; Csordas, A; Kofler, R				Bernhard, D; Ausserlechner, MJ; Tonko, M; Loffler, M; Hartmann, BL; Csordas, A; Kofler, R			Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts	FASEB JOURNAL			English	Article						caspase; c-myc; bcl-2; p16/INK4A; CCRF-CEM	GLUCOCORTICOID-INDUCED APOPTOSIS; CELL-LINE; GENE-EXPRESSION; C-MYC; MYELOGENOUS LEUKEMIA; MAMMALIAN-CELLS; CARCINOMA CELLS; FLOW-CYTOMETRY; TRICHOSTATIN-A; CANCER CELLS	The histone deacetylase inhibitor and potential anti-cancer drug sodium butyrate is a general inducer of growth arrest, differentiation, and in certain cell types, apoptosis. In human CCRF-CEM, acute T lymphoblastic leukemia cells, butyrate, and other histone deacetylase inhibitors caused G2/M cell cycle arrest as well as apoptotic cell death. Forced G0/G1 arrest by tetracycline-regulated expression of transgenic p16/INK4A protected the cells from butyrate-induced cell death without affecting the extent of histone hyperacetylation, suggesting that the latter may be necessary, but not sufficient, for cell death induction. Nuclear apoptosis, but not G2/M arrest, was delayed but not prevented by the tripeptide broad-range caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD) and, to a lesser extent, by the tetrapeptide 'effector caspase' inhibitors benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Glu-Ile-Asp.fluoromethyl-ketone (VEID); however, the viral protein inhibitor of 'inducer caspases', crmA, had no effect. Bcl-2 overexpression partially protected stably transfected CCRF-CEM sublines from butyrate-induced apoptosis, but showed no effect on butyrate-induced growth inhibition, further distinguishing these two butyrate effects. c-myc, constitutively expressed in CCRF-CEM cells, was down-regulated by butyrate, but this was not causative for cell death. On the contrary, tetracycline-induced transgenic c-myc sensitized stably transfected CCRF-CEM derivatives to butyrate-induced cell death.-Bernhard, D., Ausserlechner, M. J., Tonko, M., Loffler, M., Hartmann, B. L., Csordas, A., Kofler, R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.	Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Sch Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Med Chem & Biochem, Sch Med, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Sch Med, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Reinhard.Kofler@uibk.ac.at		Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; AUSSERLECHNER MJ, 1999, UNPUB TETRACYCLINE R, P16; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Conley BA, 1998, CLIN CANCER RES, V4, P629; Csordas A., 1995, ROLE GUT BACTERIA HU, P105; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GarciaBermejo L, 1997, EXP CELL RES, V236, P268, DOI 10.1006/excr.1997.3725; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, CANCER RES, V56, P5033; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; Hague A, 1997, INT J CANCER, V72, P898, DOI 10.1002/(SICI)1097-0215(19970904)72:5<898::AID-IJC30>3.0.CO;2-2; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Kasukabe T, 1997, BRIT J CANCER, V75, P850, DOI 10.1038/bjc.1997.151; Kruh J., 1995, P275; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Martin Seamus J., 1996, P107; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; Medina V, 1997, CANCER RES, V57, P3697; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTSUKI T, 1995, CANCER RES, V55, P1436; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Soldatenkov VA, 1998, CELL DEATH DIFFER, V5, P307, DOI 10.1038/sj.cdd.4400345; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Urbano A, 1998, LEUKEMIA, V12, P930, DOI 10.1038/sj.leu.2401031; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang XM, 1998, ANN SURG, V227, P922, DOI 10.1097/00000658-199806000-00016; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	57	113	123	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1991	2001		10.1096/fasebj.13.14.1991	http://dx.doi.org/10.1096/fasebj.13.14.1991			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544182	Bronze			2022-12-28	WOS:000083660700011
J	De Jong-Brink, M; Reid, CN; Tensen, CP; Ter Maat, A				De Jong-Brink, M; Reid, CN; Tensen, CP; Ter Maat, A			Parasites flicking the NPY gene on the host's switchboard: why NPY?	FASEB JOURNAL			English	Article						host interaction; LyNPY; reproduction; food intake; glycogen storage	SNAIL LYMNAEA-STAGNALIS; HYPOTHALAMIC NEUROPEPTIDE-Y; FRESH-WATER SNAIL; CILIARY NEUROTROPIC FACTOR; GROWTH-HORMONE SECRETION; CENTRAL-NERVOUS-SYSTEM; PEPTIDE YY; TRICHOBILHARZIA-OCELLATA; PANCREATIC-POLYPEPTIDE; LUTEINIZING-HORMONE	It was investigated whether up-regulation of the NPY gene by the schistosome Trichobilharzia ocellata in its snail host Lymnaea stagnalis redirects the host's energy flows. We cloned the cDNA encoding Lymnaea NPY (LyNPY), purified and sequenced the peptide, and used synthesized peptide for physiological and morphological studies. Increasing the LyNPY titer in nonparasitized snails (mimicking parasitosis) by 1) implantation of slow-release pellets and 2) injections suppressed reproductive activity and reduced growth in a dose- and time-dependent manner without affecting food intake. When the LyNPY titer was back to normal, reproduction and growth were resumed, coinciding with a transient increase of food intake serving to replenish glycogen stores, Observations on double-immunostained whole mount preparations of brains support these data. A close association was found between LyNPY-positive axons and axons both from ovulation hormone-producing neurons and molluscan insulin-like peptide-producing neurons involved in regulation of growth. As no synaptic(-like) contacts were observed, it is supposed that LyNPY acts noasynaptically. No morphological interaction was found between LyNPY-positive axons and motoneurons innervating the feeding apparatus. Our data explain why it is an advantageous strategy for endoparasites to up-regulate the highly conserved NPY gene in their host.-de Jong-Brink, M., Reid, C. N., Tensen, C. P., Ter Maat, A. Parasites flicking the NPY gene on the host's switchboard: why NPY?.	Free Univ Amsterdam, Fac Biol, Dept Dev Neurobiol, NL-1081 HV Amsterdam, Netherlands; Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT7 1NN, Antrim, North Ireland; Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Dermatol, Amsterdam Leiden Inst Immunol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Queens University Belfast; Vrije Universiteit Amsterdam	De Jong-Brink, M (corresponding author), Free Univ Amsterdam, Fac Biol, Dept Dev Neurobiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	mdejong@bio.vu.nl		Tensen, Cornelis/0000-0002-5325-1888				BAYOMY MFF, 1989, P K NED AKAD C BIOL, V92, P137; Benjamin P.R., 1985, P87; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; de Jong-Brink Marijke, 1997, P57; DEJONGBRINK M, 1995, ADV PARASIT, V35, P177, DOI 10.1016/S0065-308X(08)60072-X; DeLange RPJ, 1997, NEUROSCIENCE, V78, P289, DOI 10.1016/S0306-4522(96)00576-3; FRANKISH HM, 1995, PEPTIDES, V16, P757, DOI 10.1016/0196-9781(94)00200-P; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; GERAERTS WPM, 1981, EXPERIENTIA, V37, P1168, DOI 10.1007/BF01989899; GERAERTS WPM, 1992, GEN COMP ENDOCR, V86, P433, DOI 10.1016/0016-6480(92)90068-U; GERAERTS WPM, 1988, NEUROHORMONES INVERT, P261; Haynes JM, 1997, BRIT J PHARMACOL, V122, P1530, DOI 10.1038/sj.bjp.0701544; HEMMINGA MA, 1985, COMP BIOCHEM PHYS A, V82, P239, DOI 10.1016/0300-9629(85)90733-9; HERMANN PM, 1994, J EXP BIOL, V197, P79; Hoek RM, 1996, EUR J IMMUNOL, V26, P939, DOI 10.1002/eji.1830260433; Hoek RM, 1997, P NATL ACAD SCI USA, V94, P14072, DOI 10.1073/pnas.94.25.14072; HORBURY SR, 1995, J NEUROENDOCRINOL, V7, P867, DOI 10.1111/j.1365-2826.1995.tb00728.x; HORDIJK PL, 1992, NEUROSCI LETT, V136, P193, DOI 10.1016/0304-3940(92)90047-B; Horvath TL, 1999, J NEUROSCI, V19, P1072; Hurd H., 1990, Advances in Parasitology, V29, P271, DOI 10.1016/S0065-308X(08)60108-6; Jansen RF, 1997, J NEUROPHYSIOL, V78, P3415, DOI 10.1152/jn.1997.78.6.3415; JOOSSE J, 1986, EXP PARASITOL, V62, P1, DOI 10.1016/0014-4894(86)90002-0; Judd SJ, 1998, REPROD FERT DEVELOP, V10, P65, DOI 10.1071/R98024; Kalra SP, 1998, NEUROSCI LETT, V240, P45, DOI 10.1016/S0304-3940(97)00896-3; Kalra SP, 1996, FRONT NEUROENDOCRIN, V17, P371, DOI 10.1006/frne.1996.0010; LANGE RPJ, 1998, J COMP NEUROL, V390, P564; Larhammar D, 1996, REGUL PEPTIDES, V65, P165, DOI 10.1016/0167-0115(96)00110-3; Larhammar D, 1996, REGUL PEPTIDES, V62, P1, DOI 10.1016/0167-0115(95)00169-7; Leibowitz SF, 1998, ENDOCRINOLOGY, V139, P1771, DOI 10.1210/en.139.4.1771; LEUNG PS, 1992, REGUL PEPTIDES, V41, P71, DOI 10.1016/0167-0115(92)90515-V; MALVEN PV, 1995, J ANIM SCI, V73, P2105; MAULE AG, 1995, HYDROBIOLOGIA, V305, P297, DOI 10.1007/BF00036410; McShane TM, 1999, J GERONTOL A-BIOL, V54, pB14, DOI 10.1093/gerona/54.1.B14; Morley JE, 1995, AM ZOOL, V35, P437; Phares K, 1996, J PARASITOL, V82, P210, DOI 10.2307/3284147; RAJPARA SM, 1992, NEURON, V9, P505, DOI 10.1016/0896-6273(92)90188-J; ROBERTS HC, 1999, NIPPOSTRONGYLUS BRAS, V118, P117; SAMBROOK J, 1989, MOL CLONING LAB MANA; Sands SA, 1997, PEPTIDES, V18, P1045, DOI 10.1016/S0196-9781(97)00045-4; SCHEERBOOM JEM, 1978, P K NED AKAD C BIOL, V81, P173; Schwartz MW, 1997, J AM DIET ASSOC, V97, P54, DOI 10.1016/S0002-8223(97)00018-7; Sheikh SP, 1998, NEUROSCIENCE, V82, P107; SMELIK WFE, 1995, THESIS U AMSTERDAM N; SMINIA T, 1972, Z ZELLFORSCH MIK ANA, V130, P497, DOI 10.1007/BF00307004; SMIT AB, 1988, NATURE, V331, P535, DOI 10.1038/331535a0; Sonti G, 1996, PEPTIDES, V17, P517, DOI 10.1016/0196-9781(96)00016-2; STEEN WJ, 1969, NETH J ZOOL, V19, P131; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Tensen CP, 1998, EUR J NEUROSCI, V10, P3409, DOI 10.1046/j.1460-9568.1998.00350.x; ter Maat A., 1987, P255; TERMAAT A, 1992, PROG BRAIN RES, V92, P345, DOI 10.1016/S0079-6123(08)61188-7; VANHEUMEN WRA, 1990, NEUROSCIENCE, V39, P493, DOI 10.1016/0306-4522(90)90285-C; VANMINNEN J, 1988, CELL TISSUE RES, V251, P477, DOI 10.1007/BF00215857; Vuagnat BAM, 1998, NEUROENDOCRINOLOGY, V67, P291, DOI 10.1159/000054326; White BD, 1997, P SOC EXP BIOL MED, V214, P222, DOI 10.3181/00379727-214-44090; WIJSMAN TCM, 1987, INT J INVER REP DEV, V12, P199, DOI 10.1080/01688170.1987.10510317; Xu B, 1998, ENDOCRINOLOGY, V139, P466, DOI 10.1210/en.139.2.466; ZONNEVELD C, 1989, FUNCT ECOL, V3, P269, DOI 10.2307/2389365	60	32	33	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1972	1984		10.1096/fasebj.13.14.1972	http://dx.doi.org/10.1096/fasebj.13.14.1972			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544180				2022-12-28	WOS:000083660700009
J	Costa, C; Zhao, L; Burton, WV; Bondioli, KR; Williams, BL; Hoagland, TA; Ditullio, PA; Ebert, KM; Fodor, WL				Costa, C; Zhao, L; Burton, WV; Bondioli, KR; Williams, BL; Hoagland, TA; Ditullio, PA; Ebert, KM; Fodor, WL			Expression of the human alpha 1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype and confers resistance to human serum-mediated cytolysis	FASEB JOURNAL			English	Article						alpha 1; 2; H-transferase; hyperacute rejection; delayed xenograft rejection; xenotransplantation	PRIMATE CARDIAC XENOGRAFTS; COMPLEMENT REGULATORY PROTEINS; DECAY-ACCELERATING FACTOR; HUMAN CD59; HYPERACUTE REJECTION; XENOGENEIC TRANSPLANTATION; NATURAL ANTIBODIES; VASCULAR REJECTION; IN-VIVO; SURVIVAL	Hyperacute rejection (HAR) is the first critical immunological hurdle that must be addressed in order to develop xenogeneic organs for human transplantation. In the area of cell-based xenotransplant therapies, natural antibodies (XNA) and complement have also been considered barriers to successful engraftment. Transgenic expression of human complement inhibitors in donor cells and organs has significantly prolonged the survival of xenografts. However, expression of complement inhibitors without eliminating xenogeneic natural antibody (XNA) reactivity may provide insufficient protection for clinical application. An approach designed to prevent XNA reactivity during HAR is the expression of human alpha 1,2-fucosyltransferase (H-transferase, HT). H-transferase expression modifies the cell surface carbohydrate phenotype of the xenogeneic cell, resulting in the expression of the universal donor O antigen and a concomitant reduction in the expression of the antigenic Gal alpha 1,3-Gal epitope. We have engineered various transgenic pig lines that express HI in different cells and tissues, including the vascular endothelium. We demonstrate that in two different HT transgenic lines containing two different HT promoter constructs, expression can be differentially regulated in a constitutive and cytokine-inducible manner. The transgenic expression of HT results in a significant reduction in the expression of the Gal alpha 1,3-Gal epitope, reduced XNA reactivity, and an increased resistance to human serum-mediated cytolysis. Transgenic pigs that express H-transferase promise to become key components for the development of xenogeneic cells and organs for human traosplantation.-Costa, C., Zhao, L., Burton, W. V., Bondioli, K. R., Williams, B. L., Hoagland, T. A, DiTullio, P. A., Ebert, K. M., Fodor, W. L. Expression of the human alpha 1,2-fucosyltransferase in transgenic pigs modifies the cell surface carbohydrate phenotype human serum-mediated cytolysis.	Alex Pharmaceut Inc, Dept Mol Sci, New Haven, CT 06511 USA; US Surg Corp, N Haven, CT 06473 USA; Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA; TranXenoGen, Shrewsbury, MA 01545 USA	University of Connecticut	Fodor, WL (corresponding author), Alex Pharmaceut Inc, Dept Mol Sci, 25 Sci Pk, New Haven, CT 06511 USA.	fodorw@alxn.com	Costa, Cristina/AAP-4005-2020	Costa, Cristina/0000-0002-1837-4268	NICHD NIH HHS [R44 HD095784] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUCHINCLOSS H, 1988, TRANSPLANTATION, V46, P1, DOI 10.1097/00007890-198807000-00001; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; BACH FH, 1991, TRANSPL P, V23, P205; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; Chen CG, 1998, TRANSPLANTATION, V65, P832, DOI 10.1097/00007890-199803270-00011; Chen CG, 1996, XENOTRANSPLANTATION, V3, P69, DOI 10.1111/j.1399-3089.1996.tb00121.x; Chen SC, 1997, ANN NY ACAD SCI, V831, P350; Cohney S, 1997, TRANSPLANTATION, V64, P495, DOI 10.1097/00007890-199708150-00020; Costa C, 1999, XENOTRANSPLANTATION, V6, P6, DOI 10.1034/j.1399-3089.1999.00004.x; Cowan PJ, 1998, TRANSPLANTATION, V65, P1599, DOI 10.1097/00007890-199806270-00010; Cozzi E., 1997, XENOTRANSPLANTATION, P665; Cramer Donald V., 1996, P473; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DALMASSO AP, 1991, TRANSPLANTATION, V52, P530, DOI 10.1097/00007890-199109000-00029; Davis EA, 1996, TRANSPLANTATION, V62, P1018, DOI 10.1097/00007890-199610150-00022; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Diamond LE, 1996, TRANSPLANTATION, V61, P1241, DOI 10.1097/00007890-199604270-00021; Edge ASB, 1998, CELL TRANSPLANT, V7, P525, DOI 10.1016/S0963-6897(98)00043-8; FLEISCHMAN RA, 1991, AM J MED SCI, V301, P353, DOI 10.1097/00000441-199105000-00011; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; GALLILI U, 1997, XENOTRANSPLANTATION, P95; GOODMAN DJ, 1997, XENOTRANSPLANTATION, P95; HAYES CE, 1974, J BIOL CHEM, V249, P1904; Honmou O, 1996, J NEUROSCI, V16, P3199; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; KENNEDY SP, 1994, TRANSPLANTATION, V57, P1494; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; Kroshus TJ, 1996, TRANSPLANTATION, V61, P1513, DOI 10.1097/00007890-199605270-00018; KRUEGER GG, 1994, J INVEST DERMATOL, V103, pS76, DOI 10.1111/1523-1747.ep12399100; Kwiatkowski P, 1999, TRANSPLANTATION, V67, P219, DOI 10.1097/00007890-199901270-00006; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LEVENTHAL JR, 1994, TRANSPLANTATION, V57, P974; LEVENTHAL JR, 1995, TRANSPLANTATION, V59, P294, DOI 10.1097/00007890-199501270-00024; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; Lin SS, 1998, J CLIN INVEST, V101, P1745, DOI 10.1172/JCI2134; LU CY, 1994, FASEB J, V8, P1122, DOI 10.1096/fasebj.8.14.7958617; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; OHAIR DP, 1994, ANN THORAC SURG, V58, P1311, DOI 10.1016/0003-4975(94)91902-X; Pascher A, 1998, TRANSPLANTATION, V65, P737, DOI 10.1097/00007890-199803150-00023; PLATT JL, 1991, CURR OPIN IMMUNOL, V3, P735, DOI 10.1016/0952-7915(91)90105-A; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; SAADI S, 1995, J EXP MED, V181, P21, DOI 10.1084/jem.181.1.21; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SCHAAPHERDER AFM, 1994, TRANSPLANTATION, V57, P1376, DOI 10.1097/00007890-199405150-00016; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; SOMERVILLE CA, 1993, KIDNEY INT, V44, pS112; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Taniguchi S, 1996, TRANSPLANTATION, V62, P1379, DOI 10.1097/00007890-199611270-00001; Vanhove Bernard, 1994, Xenotransplantation, V1, P17, DOI 10.1111/j.1399-3089.1994.tb00046.x; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6	57	68	81	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1762	1773		10.1096/fasebj.13.13.1762	http://dx.doi.org/10.1096/fasebj.13.13.1762			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506579				2022-12-28	WOS:000083063400011
J	Ho, E; Chen, GM; Bray, TM				Ho, E; Chen, GM; Bray, TM			Supplementation of N-acetylcysteine inhibits NF kappa B activation and protects against alloxan-induced diabetes in CD-1 mice	FASEB JOURNAL			English	Article						free radicals; antioxidants; GSH; transcription factor; IDDM	NITRIC-OXIDE SYNTHASE; ENZYME GENE-EXPRESSION; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; FREE-RADICALS; REDOX REGULATION; BETA-CELLS; RAT ISLETS; ANTIOXIDANT; DESTRUCTION	Reactive oxygen species (ROS) are involved in the destruction of pancreatic beta cells and the development of insulin-dependent diabetes mellitus (IDDM), However, the cellular mechanism responsible for beta cell death is still unclear. We hypothesize that activation of NF kappa B by ROS is the key cellular signal in initiating a cascade of events leading to beta cell death. Thus, enhancement of pancreatic GSH, a known antioxidant and key regulator of NF-KB, should protect against IDDM, Weanling CD1 mice (n=5) were injected with alloxan (50 mg/kg i.v.) to induce IDDM, Using EPR spin trapping techniques, we demonstrated that alloxan generated ROS in the pancreas 15 min after administration. Activation of NF kappa B in pancreatic nuclear extracts was observed 30 min after alloxan injection, as assessed by an electrophoretic mobility shift assay. Fasting blood glucose levels were monitored for 14 days. Supplementation with N-acetylcysteine (NAC, 500 mg/kg), a GSH precursor, inhibited alloxan-induced NF kappa B activation and reduced hyperglycemia, Thus, NF kappa B activation by ROS may initiate a sequence of events leading to IDDM, Inhibition of NF-kappa B activation by NAC attenuated the severity of IDDM, This research will contribute to the understanding of the etiology of IDDM and may lead to the development of better strategies for disease prevention.	Ohio State Univ, Dept Human Nutr, Columbus, OH 43210 USA; Univ Guelph, Dept Clin Studies, Guelph, ON N1G 2W1, Canada	University System of Ohio; Ohio State University; University of Guelph	Bray, TM (corresponding author), Ohio State Univ, Dept Human Nutr, 347 Campbell Hall,1787 Neil Ave, Columbus, OH 43210 USA.							ADAMS DD, 1984, LANCET, V1, P420; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BOITARD C, 1994, DIABETOLOGIA, V37, pS90, DOI 10.1007/BF00400831; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Fehsel K, 1995, RES IMMUNOL, V146, P711, DOI 10.1016/0923-2494(96)84924-8; Fox ES, 1997, J IMMUNOL, V158, P5418; Gilston Vanessa, 1997, Biochemical Society Transactions, V25, p518S; GORUS FK, 1982, BIOCHEM J, V208, P513, DOI 10.1042/bj2080513; HEIKKILA RE, 1976, BIOCHEM PHARMACOL, V25, P1085, DOI 10.1016/0006-2952(76)90502-5; Heller B, 1997, Adv Pharmacol, V38, P629; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; Holstad M, 1997, GEN PHARMACOL-VASC S, V29, P697, DOI 10.1016/S0306-3623(97)00012-8; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Kwon G, 1998, DIABETES, V47, P583, DOI 10.2337/diabetes.47.4.583; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; McDaniel ML, 1997, ADV EXP MED BIOL, V426, P313; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MORISZE ZJ, 1997, J CLIN GASTROENTE S1, V25, pS61; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; RABINOVITCH A, 1992, DIABETOLOGIA, V35, P409, DOI 10.1007/BF02342435; Rabinovitch A, 1996, J CLIN ENDOCR METAB, V81, P3197, DOI 10.1210/jc.81.9.3197; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCOTT FW, 1991, CAN J PHYSIOL PHARM, V69, P311, DOI 10.1139/y91-048; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Stoian I, 1996, BIOCHEM MOL MED, V59, P93, DOI 10.1006/bmme.1996.0072; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WU GY, 1995, DIABETES, V44, P360, DOI 10.2337/diabetes.44.3.360; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZONANA J, 1976, NEW ENGL J MED, V295, P603, DOI 10.1056/NEJM197609092951106	52	121	126	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1845	1854		10.1096/fasebj.13.13.1845	http://dx.doi.org/10.1096/fasebj.13.13.1845			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506589				2022-12-28	WOS:000083063400021
J	Hogaboam, CM; Bone-Larson, CL; Steinhauser, ML; Lukacs, NW; Colletti, LM; Simpson, KJ; Strieter, RM; Kunkel, SL				Hogaboam, CM; Bone-Larson, CL; Steinhauser, ML; Lukacs, NW; Colletti, LM; Simpson, KJ; Strieter, RM; Kunkel, SL			Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines	FASEB JOURNAL			English	Article						acetaminophen; acute liver injury; hepatic regeneration	IL-8 RECEPTOR; ACETAMINOPHEN; NEUTROPHIL; MICE; FAILURE; TRANSPLANTATION; CHEMOATTRACTANT; HEPATOTOXICITY; INTERLEUKIN-8; ANGIOGENESIS	Severe acute liver injury due to accidental or intentional acetaminophen overdose presents a major clinical dilemma often requiring liver transplantation. In the present study, liver regeneration after profound liver injury in mice challenged with acetaminophen was facilitated by the exogenous addition of ELR-containing CXC chemokines such as macrophage inflammatory protein-a (MIP-2), epithelial neutrophil-actavating protein-78 (ENA-78), or interleukin 8, Intravenous administration of ELR-CXC chemokines or N-acetyl-cysteine (NAC) immediately after acetaminophen challenge in mice significantly reduced histological and biochemical markers of hepatic injury. However, when the intervention was delayed until 10 h after acetaminophen challenge, only ELR-CXC chemokines significantly reduced liver injury and mouse mortality. The delayed addition of ELR-CXC chemokines to cultured hepatocytes maintained the proliferation of these cells in a CXCR2-dependent fashion after acetaminophen challenge whereas delayed NAC treatment did not. These observations demonstrate that ELR-CXC chemokines represent novel hepatic regenerative factors that exhibit prolonged therapeutic effects after acetaminophen-induced hepatotoxicity.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Edinburgh, Dept Med, Edinburgh, Midlothian, Scotland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Edinburgh	Hogaboam, CM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 E Catherine, Ann Arbor, MI 48109 USA.		Hogaboam, Cory M./AAI-1433-2021; Steinhauser, Matthew L./GVT-6393-2022; Lukacs, Nicholas W/ABH-5583-2020	Hogaboam, Cory M./0000-0003-3366-4850; Steinhauser, Matthew L./0000-0001-5287-9246; 	NCI NIH HHS [CA66180] Funding Source: Medline; NHLBI NIH HHS [1P50HL60289, 1P50HL56402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066180] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056402, P50HL060289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATILLASOY E, 1995, ANNU REV MED, V46, P181; Bernal W, 1998, HEPATOLOGY, V27, P1050, DOI 10.1002/hep.510270421; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Casey PB, 1997, IRISH MED J, V90, P38; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; Colletti LM, 1996, SHOCK, V6, P397, DOI 10.1097/00024382-199612000-00002; Colletti LM, 1998, SHOCK, V10, P248, DOI 10.1097/00024382-199810000-00004; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DEGROOTE J, 1995, ACTA GASTRO-ENT BELG, V58, P326; Delanty N, 1996, IRISH MED J, V89, P156; DRISCOLL KE, 1995, J LEUKOCYTE BIOL, V58, P359, DOI 10.1002/jlb.58.3.359; EVANOFF HL, 1992, IMMUNOL INVEST, V21, P39, DOI 10.3109/08820139209069361; Farrell GC, 1997, J GASTROEN HEPATOL, V12, pS242, DOI 10.1111/j.1440-1746.1997.tb00507.x; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Heubi JE, 1998, J PEDIATR-US, V132, P22, DOI 10.1016/S0022-3476(98)70479-2; Kay MA, 1997, MOL MED TODAY, V3, P108, DOI 10.1016/S1357-4310(96)10062-9; LEE J, 1995, J IMMUNOL, V155, P2158; Lentsch AB, 1998, HEPATOLOGY, V27, P1172; Lentsch AB, 1998, HEPATOLOGY, V27, P507, DOI 10.1002/hep.510270226; Makin AJ, 1997, ADV INTERNAL MED, V42, P453; Manautou JE, 1996, TOXICOL APPL PHARM, V140, P30, DOI 10.1006/taap.1996.0194; MICHALEK SM, 1992, VACCINE RES, V1, P241; Riordan SM, 1999, LIVER TRANSPLANT SUR, V5, P86, DOI 10.1002/lt.500050107; Rosen HR, 1996, MED CLIN N AM, V80, P1069, DOI 10.1016/S0025-7125(05)70480-6; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; Sprenger H, 1997, GASTROENTEROLOGY, V113, P277, DOI 10.1016/S0016-5085(97)70105-7; Strieter RM, 1996, J IMMUNOL, V156, P3583; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; TAKADA H, 1995, DIGEST DIS SCI, V40, P1831, DOI 10.1007/BF02212709; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	32	94	103	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1565	1574		10.1096/fasebj.13.12.1565	http://dx.doi.org/10.1096/fasebj.13.12.1565			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463948	Green Submitted			2022-12-28	WOS:000082347600012
J	Gurrola, GB; Rosati, B; Rocchetti, M; Pimienta, G; Zaza, A; Arcangeli, A; Olivotto, M; Possani, LD; Wanke, E				Gurrola, GB; Rosati, B; Rocchetti, M; Pimienta, G; Zaza, A; Arcangeli, A; Olivotto, M; Possani, LD; Wanke, E			A toxin to nervous, cardiac, and endocrine ERG K+ channels isolated from Centruroides noxius scorpion venom	FASEB JOURNAL			English	Article						eag gene family; erg gene; ergtoxin; scorpion toxin; action potential	III ANTIARRHYTHMIC AGENT; POTASSIUM-CHANNEL; CELL-LINE; NEUROBLASTOMA-CELLS; I-KR; FUNCTIONAL EXPRESSION; INWARD RECTIFIER; XENOPUS OOCYTES; HERG ENCODES; BLOCK	Toxins isolated from a variety of venoms are tools for probing the physiological function and structure of ion channels. The ether-a-go-go-related genes (erg) codify for the K+ channels (ERG), which are crucial in neurons and are impaired in human long-QT syndrome and Drosophila 'seizure' mutants. We have isolated a peptide from the scorpion Centruroides noxius Hoffmann that has no sequence homologies with other toxins, and demonstrate that it specifically inhibits (IC50=16+/-1 nM) only ERG channels of different species and distinct histogenesis. These results open up the possibility of investigating ERG channel structure-function relationships and novel pharmacological tools with potential therapeutic efficacy.	Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; Univ Milan, Dept Gen Physiol & Biochem, Lab Electrophysiol, I-20133 Milan, Italy; Natl Autonomous Univ Mexico, Inst Biotechnol, Dept Mol Recognit & Struct Biol, Cuernavaca 62271, Morelos, Mexico; Univ Florence, Inst Gen Pathol, I-50134 Florence, Italy	University of Milan; University of Milano-Bicocca; University of Milan; Universidad Nacional Autonoma de Mexico; University of Florence	Wanke, E (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Via Celoria 26, I-20133 Milan, Italy.		Zaza, Antonio/N-2646-2019; Possani, Lourival D/J-2397-2013; Pimienta, Genaro/A-2714-2011	Zaza, Antonio/0000-0001-9355-4958; 	Telethon [1046] Funding Source: Medline	Telethon(Fondazione Telethon)		Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bianchi L, 1998, CANCER RES, V58, P815; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P1094, DOI 10.1007/s004240050240; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CURRAN ME, 1995, CELL, V80, P95; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; GARCIA ML, 1997, ADV PHARMACOL, V39, P426; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; JUDD AM, 1988, ENDOCRINOLOGY, V123, P2341, DOI 10.1210/endo-123-5-2341; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MAGISTRETTI J, 1996, TRENDS NEUROSCI, V19, P531; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Meyer R, 1998, J PHYSIOL-LONDON, V508, P49, DOI 10.1111/j.1469-7793.1998.049br.x; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PLATIKA D, 1985, P NATL ACAD SCI USA, V82, P3499, DOI 10.1073/pnas.82.10.3499; POLLO A, 1993, PFLUG ARCH EUR J PHY, V423, P462, DOI 10.1007/BF00374942; Possani L. D., 1984, HDB NATURAL TOXINS, V2, P513; RORSMAN P, 1986, AM J PHYSIOL, V251, P912; ROSATI B, 1998, SFN ANN M, V792, P2; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1996, NATURE, V384, P78; SCHAFER R, 1998, SFN ANN M, V330, P17; SCHAFER R, 1997, SOC NEUROSCI, V23, pA856; SCHWEITZ H, 1995, J BIOL CHEM, V270, P25121, DOI 10.1074/jbc.270.42.25121; Selisko B, 1998, EUR J BIOCHEM, V254, P468, DOI 10.1046/j.1432-1327.1998.2540468.x; Shi WM, 1997, J NEUROSCI, V17, P9423; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; Shin KS, 1997, J BIOL CHEM, V272, P21227, DOI 10.1074/jbc.272.34.21227; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; SPINELLI W, 1993, CARDIOVASC RES, V27, P1580, DOI 10.1093/cvr/27.9.1580; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Suessbrich H, 1997, BRIT J PHARMACOL, V120, P968, DOI 10.1038/sj.bjp.0700989; Suessbrich H, 1996, FEBS LETT, V385, P77, DOI 10.1016/0014-5793(96)00355-9; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Titus SA, 1997, J NEUROSCI, V17, P875; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TYGAT J, 1998, BIOPHYS J, V74, pA229; Wang XJ, 1997, J NEUROSCI, V17, P882; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Weinsberg F, 1997, PFLUG ARCH EUR J PHY, V434, P1, DOI 10.1007/s004240050356; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Zaza A, 1998, CIRC RES, V82, P947, DOI 10.1161/01.RES.82.9.947	53	94	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					953	962		10.1096/fasebj.13.8.953	http://dx.doi.org/10.1096/fasebj.13.8.953			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224238				2022-12-28	WOS:000080372500018
J	De Haan, G; Van Zant, G				De Haan, G; Van Zant, G			Genetic analysis of hemopoietic cell cycling in mice suggests its involvement in organismal life span	FASEB JOURNAL			English	Article						stem cells; longevity; cell proliferation; aging; quantitative trait locus	HEMATOPOIETIC STEM-CELLS; MALIGNANT MYELOID DISEASES; QUANTITATIVE TRAIT LOCUS; COMMONLY DELETED REGION; IN-VIVO; REPLICATIVE SENESCENCE; MOLECULAR DELINEATION; REPOPULATING ABILITY; ALLOPHENIC MICE; GROWTH-FACTORS	Normal somatic cells undergo replicative senescence in vitro but the significance of this process in organismic aging remains controversial. We have shown previously that hemopoietic stem cells of common inbred strains of mice vary widely in cycling activity and that this parameter is inversely correlated with strain-dependent mean life span, To assess whether cell cycling and life span are causally related, we searched for quantitative trait loci (QTLs) that contributed to variation of these traits in BXH and BXD recombinant inbred mice. Two QTLs, mapping to exactly the same intervals on chromosomes 7 and 11, were identified that were associated with variation of both cell cycling and life span. The locus on chromosome II mapped to the cytokine cluster, a segment that shows synteny with human chromosome 5q, in which deletions are strongly associated with myelodysplastic syndrome. These data indicate that steady-state cell turn-over, here measured in hemopoietic progenitor cells, may have a significant effect on the mean life span of mammals.	Univ Kentucky, Albert B Chandler Med Ctr, Div Hematol Oncol, Blood & Marrow Transplant Program, Lexington, KY 40536 USA; Univ Groningen, Dept Physiol Chem, Groningen, Netherlands	University of Kentucky; University of Groningen	Van Zant, G (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Div Hematol Oncol, Blood & Marrow Transplant Program, 800 Rose St, Lexington, KY 40536 USA.		de Haan, Gerald/AAF-8963-2019; de Haan, Gerald/D-2081-2015	de Haan, Gerald/0000-0001-9706-0138; de Haan, Gerald/0000-0001-9706-0138				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; BOULTWOOD J, 1994, BLOOD, V84, P3253; Boultwood J, 1997, GENOMICS, V45, P88, DOI 10.1006/geno.1997.4899; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHURCHILL GA, 1994, GENETICS, V138, P963; de Haan G, 1998, NAT GENET, V19, P114, DOI 10.1038/465; deHaan G, 1997, BLOOD, V89, P1543, DOI 10.1182/blood.V89.5.1543.1543_1543_1550; deHaan G, 1997, J EXP MED, V186, P529, DOI 10.1084/jem.186.4.529; deHaan G, 1996, BLOOD, V87, P4581, DOI 10.1182/blood.V87.11.4581.bloodjournal87114581; DEHAAN G, 1999, IN PRESS BLOOD; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; DOWN JD, 1993, EXP HEMATOL, V21, P913; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; GELMAN R, 1988, GENETICS, V118, P693; HARRISON DE, 1972, NATURE-NEW BIOL, V237, P220, DOI 10.1038/newbio237220a0; HARRISON DE, 1983, J EXP MED, V157, P1496, DOI 10.1084/jem.157.5.1496; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kennedy BK, 1996, TRENDS GENET, V12, P355, DOI 10.1016/0168-9525(96)10039-1; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; McClearn GE, 1997, EXP GERONTOL, V32, P49, DOI 10.1016/S0531-5565(96)00066-6; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MullerSieburg CE, 1996, J EXP MED, V183, P1141, DOI 10.1084/jem.183.3.1141; NEBEN S, 1994, EXP HEMATOL, V22, P353; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; PLOEMACHER RE, 1993, LEUKEMIA, V7, P120; PLOEMACHER RE, 1991, BLOOD, V78, P2527; PLOMIN R, 1991, BEHAV GENET, V21, P97, DOI 10.1007/BF01066329; ROHME D, 1981, P NATL ACAD SCI-BIOL, V78, P5009, DOI 10.1073/pnas.78.8.5009; ROSENDAAL M, 1979, CELL TISSUE KINET, V12, P17, DOI 10.1111/j.1365-2184.1979.tb00110.x; Rubin H, 1997, MECH AGEING DEV, V98, P1, DOI 10.1016/S0047-6374(97)00067-5; RUSSELL ELIZABETH S., 1966, P511; Smeal T, 1997, CURR OPIN GENET DEV, V7, P281, DOI 10.1016/S0959-437X(97)80139-6; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; VANZANT G, 1983, CELL, V35, P639, DOI 10.1016/0092-8674(83)90096-X; VANZANT G, 1990, J EXP MED, V171, P1547, DOI 10.1084/jem.171.5.1547; VanZant G, 1997, EXP HEMATOL, V25, P187; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Williams RW, 1998, J NEUROSCI, V18, P138; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Wynn RF, 1998, LANCET, V351, P178, DOI 10.1016/S0140-6736(97)08256-1; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	49	68	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					707	713		10.1096/fasebj.13.6.707	http://dx.doi.org/10.1096/fasebj.13.6.707			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094931				2022-12-28	WOS:000079527200012
J	Macko, SA; Lubec, G; Teschler-Nicola, M; Andrusevich, V; Engel, MH				Macko, SA; Lubec, G; Teschler-Nicola, M; Andrusevich, V; Engel, MH			The Ice Man's diet as reflected by the stable nitrogen and carbon isotopic composition of his hair	FASEB JOURNAL			English	Article						stable isotopes; amino acids; paleodiet; neolithic	ANIMALS; FOSSIL	Establishing the diets of ancient human populations is an integral component of most archaeological studies. Stable isotope analysis of well-preserved bone collagen is the most direct approach for a general assessment of paleodiet, However, this method has been limited by the scarcity of well-preserved skeletal materials for this type of destructive analysis. Hair is preserved in many burials, but is often overlooked as an alternative material for isotopic analysis. Here we report that the stable carbon and nitrogen isotope values for the hair of the 5200 year-old Ice Man indicates a primarily vegetarian diet, in agreement with his dental wear pattern. Whereas previous investigations have focused on bone collagen, the stable isotope composition of hair may prove to be a more reliable proxy for paleodiet reconstruction, particularly when skeletal remains are not well preserved and additional archaeological artifacts are unavailable.	Univ Vienna, Dept Pediat, A-1090 Vienna, Austria; Univ Virginia, Dept Environm Sci, Charlottesville, VA 22903 USA; Dept Anthropol, Vienna, Austria; Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73019 USA	University of Vienna; University of Virginia; University of Oklahoma System; University of Oklahoma - Norman	Lubec, G (corresponding author), Univ Vienna, Dept Pediat, Waehringer Guertel 18, A-1090 Vienna, Austria.		Macko, Stephen/K-4588-2015	Lubec, Gert/0000-0002-6333-9461; Teschler-Nicola, Maria Eva/0000-0003-3080-3085				Ambrose S. H., 1993, PREHISTORIC HUMAN BO, P1; Ambrose S.H., 1993, INVESTIGATIONS ANCIE, P59; BOCKLE B, 1995, APPL ENVIRON MICROB, V61, P3705; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; DENIRO MJ, 1981, GEOCHIM COSMOCHIM AC, V45, P341, DOI 10.1016/0016-7037(81)90244-1; Friedrich AB, 1996, APPL ENVIRON MICROB, V62, P2875, DOI 10.1128/AEM.62.8.2875-2882.1996; HARE PE, 1985, CHEM BIOCH AMINO ACI, P415; Hoepfel F., 1992, MANN EIS; Koch P.L., 1994, P63; LEHNINGER AL, 1994, PRINCIPLES BIOCH; LUBEC G, 1994, FASEB J, V8, P1166, DOI 10.1096/fasebj.8.14.7958623; LUBEC G, 1987, J ARCHAEOL SCI, V14, P113, DOI 10.1016/0305-4403(87)90001-X; Macko SA, 1997, ANAL CHEM, V69, P926, DOI 10.1021/ac960956l; MACKO SA, 1991, PHILOS T ROY SOC B, V333, P367, DOI 10.1098/rstb.1991.0086; MINAGAWA M, 1992, APPL GEOCHEM, V7, P145, DOI 10.1016/0883-2927(92)90033-Y; OCONNELL TC, 1996, THESIS U OXFORD UK; OSTROM PH, 1993, GEOLOGY, V21, P491, DOI 10.1130/0091-7613(1993)021<0491:AOTSOC>2.3.CO;2; SCHOENINGER MJ, 1983, SCIENCE, V220, P1381, DOI 10.1126/science.6344217; SERBAN A, 1988, ORG GEOCHEM, V13, P1123, DOI 10.1016/0146-6380(88)90298-7; SILLEN A, 1989, AM ANTIQUITY, V54, P504, DOI 10.2307/280778; SPIELMANN KA, 1990, AM ANTIQUITY, V55, P745, DOI 10.2307/281248; TIESZEN LL, 1991, J ARCHAEOL SCI, V18, P227, DOI 10.1016/0305-4403(91)90063-U; WEBB Y, 1980, SEARCH, V11, P200; WHITTLE A, 1985, NEOLITHIC EUROPE SUR	24	66	70	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					559	562		10.1096/fasebj.13.3.559	http://dx.doi.org/10.1096/fasebj.13.3.559			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064623				2022-12-28	WOS:000079016000016
J	Botchkarev, VA; Botchkareva, NV; Welker, P; Metz, M; Lewin, GR; Subramaniam, A; Bulfone-Paus, S; Hagen, E; Braun, A; Lommatzsch, M; Renz, H; Paus, R				Botchkarev, VA; Botchkareva, NV; Welker, P; Metz, M; Lewin, GR; Subramaniam, A; Bulfone-Paus, S; Hagen, E; Braun, A; Lommatzsch, M; Renz, H; Paus, R			A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control	FASEB JOURNAL			English	Article						BDNF; NT-4; TrkB; p75NTR; catagen	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; FOLLICLE REGRESSION CATAGEN; MURINE SKIN; MESSENGER-RNA; SIGNAL-TRANSDUCTION; HUMAN KERATINOCYTES; DEPENDENT CHANGES; TRANSGENIC MICE; GENE-EXPRESSION	Neurotrophins exert many biological effects not directly targeted at neurons, including modulation of keratinocyte proliferation and apoptosis in vitro. Here we exploit the cyclic growth and regression activity of the murine hair follicle to explore potential nonneuronal functions of neurotrophins in the skin, and analyze the follicular expression and hair growth-modulatory function of BDNF, NT-4, and their high-affinity receptor, TrkB. The cutaneous expression of BDNF and NT-4 mRNA was strikingly hair cycle dependent and peaked during the spontaneous, apoptosis-driven hair follicle regression (catagen). During catagen, BDNF mRNA and immunoreactivity, as well as NT-4-immunoreactivity, were expressed in the regressing hair follicle compartments, whereas TrkB mRNA and immunoreactivity were seen in dermal papilla fibroblasts, epithelial strand, and hair perm. BDNF or NT-4 knockout mice showed significant catagen retardation, whereas BDNF-overexpressing: mice dis played acceleration of catagen and significant shortening of hair length. Finally, BDNF and NT-4 accelerated catagen development in murine skin organ culture. Together, our data suggest that BDNF and NT-4 play a previously unrecognized role in skin physiology as agents of hair growth control. Thus, TrkB agonists and antagonists deserve exploration as novel hair growth-modulatory drugs for the management of common hair growth disorders.	Humboldt Univ, Charite, Dept Dermatol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Inst Lab Med, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, Growth Factor & Regenerat Grp, D-13122 Berlin, Germany; Free Univ Berlin, Inst Immunol, D-12203 Berlin, Germany; Hoechst Marion Roussel Inc, Bridgewater, NJ 08807 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin	Paus, R (corresponding author), Humboldt Univ, Charite, Dept Dermatol, Campus Virchow Clin,Schumannstr 20-21, D-10117 Berlin, Germany.	ralf.paus@charite.de	Metz, Martin/M-5237-2013; Lewin, Gary R/B-8028-2011; Metz, Martin/B-8799-2009; Braun, Armin/B-8750-2009	Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Braun, Armin/0000-0002-1142-1463; Lewin, Gary/0000-0002-2890-6352; Botchkarev, Vladimir/0000-0002-5212-5353				ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; ALBERS KM, 1994, J NEUROSCI, V14, P1422, DOI 10.1523/JNEUROSCI.14-03-01422.1994; Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 1997, ARCH DERMATOL RES, V289, P292, DOI 10.1007/s004030050195; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; Botchkarev VA, 1998, EUR J NEUROSCI, V10, P3276, DOI 10.1046/j.1460-9568.1998.00365.x; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Bothwell M, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P27, DOI 10.1038/jidsymp.1997.7; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BREDMAN JJ, 1992, J ANAT, V180, P263; BRONZETTI E, 1996, ITAL J ANAT EMBRY S1, V100, P565; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Chou TT, 1997, J NEUROSCI RES, V49, P522, DOI 10.1002/(SICI)1097-4547(19970901)49:5<522::AID-JNR2>3.3.CO;2-M; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Davies AM, 1997, CURR BIOL, V7, pR38, DOI 10.1016/S0960-9822(06)00016-9; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; Donohoe TJ, 1996, CONTEMP ORG SYNTH, V3, P1, DOI 10.1039/co9960300001; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; Frade JM, 1996, NATURE, V383, P166; Fundin BT, 1997, DEV BIOL, V190, P94, DOI 10.1006/dbio.1997.8658; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HECKERS S, 1994, J NEUROSCI, V14, P1271, DOI 10.1523/JNEUROSCI.14-03-01271.1994; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Huber LJ, 1996, DEV BIOL, V179, P369, DOI 10.1006/dbio.1996.0268; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; Ibanez CF, 1996, NEUROCHEM RES, V21, P787, DOI 10.1007/BF02532301; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lewin GR, 1996, PHILOS T ROY SOC B, V351, P405, DOI 10.1098/rstb.1996.0035; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; LIU YJ, 1995, IMMUNITY, V2, P239, DOI 10.1016/1074-7613(95)90048-9; Luukko K, 1997, DEV DYNAM, V210, P117, DOI 10.1002/(SICI)1097-0177(199710)210:2<117::AID-AJA5>3.0.CO;2-J; Luukko K, 1996, DEV DYNAM, V206, P87, DOI 10.1002/(SICI)1097-0177(199605)206:1<87::AID-AJA8>3.0.CO;2-X; Ma YT, 1998, J NEUROSCI, V18, P2097; Maurer M, 1997, AM J PATHOL, V150, P1433; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; Muragaki Y, 1997, J NEUROSCI, V17, P530; NAKANISHI T, 1994, BIOCHEM BIOPH RES CO, V198, P891, DOI 10.1006/bbrc.1994.1127; Nosrat CA, 1997, CELL TISSUE RES, V290, P569, DOI 10.1007/s004410050962; Panteleyev AA, 1997, J INVEST DERMATOL, V108, P324, DOI 10.1111/1523-1747.ep12286476; Paus R, 1996, CANCER RES, V56, P4438; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; PAUS R, 1999, IN PRESS J DERMATOL; PERSSON H, 1993, NEUROMETHODS, V25, P57; PethoSchramm A, 1996, ARCH DERMATOL RES, V288, P264, DOI 10.1007/BF02530098; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; PINCELLI C, 1997, J INVEST DERMATOL S, V2, P61; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Rice FL, 1998, DEV BIOL, V198, P57, DOI 10.1006/dbio.1998.8861; Roloff B, 1998, FASEB J, V12, P287, DOI 10.1096/fasebj.12.3.287; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; Schilli MB, 1997, J INVEST DERMATOL, V108, P928, DOI 10.1111/1523-1747.ep12294690; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; Shibayama E, 1996, AM J PATHOL, V148, P1807; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; Stucky CL, 1998, J NEUROSCI, V18, P7040; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SuterCrazzolara C, 1996, MOL BRAIN RES, V43, P351, DOI 10.1016/S0169-328X(96)00243-4; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VICKLAND H, 1995, NEURAL NOTES, V1, P8; Welker P, 1997, ARCH DERMATOL RES, V289, P554, DOI 10.1007/s004030050239	98	88	92	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					395	410		10.1096/fasebj.13.2.395	http://dx.doi.org/10.1096/fasebj.13.2.395			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973328	Bronze			2022-12-28	WOS:000078615200020
J	Iljin, K; Dube, A; Kontusaari, S; Korhonen, J; Lahtinen, I; Oettgen, P; Alitalo, K				Iljin, K; Dube, A; Kontusaari, S; Korhonen, J; Lahtinen, I; Oettgen, P; Alitalo, K			Role of Ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter	FASEB JOURNAL			English	Article						gene therapy; receptor tyrosine kinase; vascular endothelium	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; ENHANCED EXPRESSION; TRANSGENIC MICE; IN-VIVO; ANGIOGENESIS; BINDING; PROTOONCOGENE; KDR/FLK-1; LINE	The Tie gene encodes an endothelial cell receptor tyrosine kinase necessary for normal vascular development, The Tie gene promoter targets expression of heterologous genes specifically to endothelial cells in transgenic mice. Here we have characterized the promoter sequences critical for endothelial cell-specific activity in cultured cells and transgenic mice. Progressive deletions and site-directed mutations of the promoter showed that the critical endothelial cell-specific elements are an octamer transcription factor binding site and several Ets binding sites located in two clusters within 300 bp upstream of the major transcription initiation site, Among members of the Ets transcription factor family tested, NERF-2 (a novel transcription factor related to the ets factor ELF-1), which is expressed in endothelial cells, and ETS2 showed the strongest transactivation of the Tie promoter; ETS1 gave lower levels of stimulation and the other Ets factors gave little or no transactivation, Furthermore, the Tie promoter directed the production of high amounts of human growth hormone into the circulation of transgenic mice, The secreted amounts correlated with transgene copy number, being relatively insensitive to the effects of the transgene integration site, These properties suggest that Tie promoter activity is controlled by endothelial cell Ets factors and that it has potential for use in vectors for endothelial cell-specific gene expression.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland; Univ Helsinki, Dept Biomed, SF-00014 Helsinki, Finland; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, NEB Bone & Joint Inst, Boston, MA 02115 USA; Bioctr Oulu, Oulu 90570, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland	University of Helsinki; University of Helsinki; Harvard University; Beth Israel Deaconess Medical Center; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, SF-00014 Helsinki, Finland.		Oettgen, Peter/AAF-5026-2021; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Iljin, Kristiina/0000-0002-5161-0584	NCI NIH HHS [CA71429-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA071429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almendro N, 1996, J IMMUNOL, V157, P5411; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; HATVA E, 1995, AM J PATHOL, V146, P368; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; KAIPAINEN A, 1994, CANCER RES, V54, P6571; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KORHONEN J, 1994, ONCOGENE, V9, P395; KORHONEN J, 1992, BLOOD, V80, P2548; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; TAKAHASHI K, 1991, IN VITRO CELL DEV B, V27, P766; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WERNERT N, 1992, AM J PATHOL, V140, P119	34	75	78	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					377	386		10.1096/fasebj.13.2.377	http://dx.doi.org/10.1096/fasebj.13.2.377			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973326				2022-12-28	WOS:000078615200018
J	Lucas, T; Krugluger, W; Samorapoompichit, P; Gamperl, R; Beug, H; Forster, O; Boltz-Nitulescu, G				Lucas, T; Krugluger, W; Samorapoompichit, P; Gamperl, R; Beug, H; Forster, O; Boltz-Nitulescu, G			Self-renewal, maturation, and differentiation of the rat myelomonocytic hematopoietic stem cell	FASEB JOURNAL			English	Article						lectins; stem cell factor; cell proliferation; cell differentiation; dexamethasone; calcitriol	COLONY-STIMULATING FACTORS; BONE-MARROW-CELLS; MACROPHAGE PROGENITOR CELLS; TYROSINE KINASE RECEPTOR; PROTOONCOGENE C-KIT; GROWTH-FACTOR; PERIPHERAL-BLOOD; SI-LOCUS; W-LOCUS; LIGAND	Hematopoiesis is viewed as a differentiating system emanating from a pluripotent hematopoietic stem cell capable of both self-renewal and differentiation. By identifying and characterizing a novel and highly specific in vitro mitogenic response to the N-acetyl glucosamyl/sialic acid specific, stem ceh-binding lectin wheat perm agglutinin (WGA), we demonstrate the existance of a rare (0.1%), plastic adherent precursor in rat bone marrow capable of proliferation (two to seven divisions) in response to WGA. Stimulated cells possess a lineage (lin)(low/-) immunophenotype and immature blastoid morphology (WGA blasts). A subsequent proliferative response-to stem cell factor (SCF), the ligand for the proto-oncogene receptor tyrosine kinase c-kit, is characterized by an initial maturation in immunophenotype and subsequent self-renewal of cells (SCF blasts) without differentiation for at least 50 generations. Although granulocyte colony-stimulating factor (G-CSF), interleukin (IL) -6, IL-7, and IL-11 synergize with SCF to increase blast colony formation, cytokines such as granulocyte-macrophage CSF or IL-3 are without significant effect. At all time points in culture, however, cells rapidly differentiate to mature neutrophils with dexamethasone or to mainly monocytes/macrophages in the presence of 1 alpha,25-dihydroxyvitamin D-3, characterized by cell morphology and cytochemistry. Removal of SCF during blast maturation, self-renewal, or induction of differentiation phases results in apoptotic cell. death. Data indicate a pivotal role for SCF/c-kit interaction during antigenic maturation, self-renewal, and apoptotic protection of these lineage-restricted progenitors during non-CSF-mediated induction of differentiation. This approach provides a source of many normal, proliferating myelomonocytic precursor cells, and introduces possible clinical applications of ex vivo expanded myeloid stem cells.	Univ Vienna, Inst Gen & Expt Pathol, AKH 3Q, A-1090 Vienna, Austria; Univ Vienna, Inst Histol & Embryol, A-1090 Vienna, Austria; Inst Med Biol & Human Genet, A-8010 Graz, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Boltz-Nitulescu, G (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, AKH 3Q, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	georg.boltz@akh-wien.ac.at		Lucas, Trevor/0000-0002-5114-8035				AIZAWA S, 1987, P NATL ACAD SCI USA, V84, P4485, DOI 10.1073/pnas.84.13.4485; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BASCH RS, 1977, NATURE, V270, P520, DOI 10.1038/270520a0; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1995, ONCOGENE, V11, P59; BEVERLEY PCL, 1980, NATURE, V287, P332, DOI 10.1038/287332a0; BOL S, 1981, EXP HEMATOL, V9, P431; BOLTZNITULESCU G, 1987, J LEUKOCYTE BIOL, V41, P83, DOI 10.1002/jlb.41.1.83; BRADLEY TR, 1966, AUST J EXP BIOL MED, V44, P287, DOI 10.1038/icb.1966.28; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DEXTER TM, 1984, LONG TERM BONE MARRO, P57; FALKENBURG JHF, 1984, BLOOD, V63, P1125; FERRERO D, 1983, P NATL ACAD SCI-BIOL, V80, P4114, DOI 10.1073/pnas.80.13.4114; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GOLDSCHNEIDER I, 1980, J EXP MED, V152, P419, DOI 10.1084/jem.152.2.419; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KELLER G, 1992, CURR OPIN IMMUNOL, V4, P133, DOI 10.1016/0952-7915(92)90002-V; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KOEFFLER HP, 1984, CANCER RES, V44, P5624; KREUTZ M, 1990, BLOOD, V76, P2449; Krugluger W, 1996, IMMUNOL LETT, V52, P53, DOI 10.1016/0165-2478(96)02581-3; LOWRY PA, 1991, EXP HEMATOL, V19, P994; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MCCARTHY KF, 1987, CYTOMETRY, V8, P296, DOI 10.1002/cyto.990080310; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1995, BIOL CLINB APPL; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; MULDER AH, 1984, CELL IMMUNOL, V88, P401, DOI 10.1016/0008-8749(84)90173-4; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NAKAHATA T, 1982, J CELL PHYSIOL, V111, P239, DOI 10.1002/jcp.1041110304; NELSON DA, 1990, HEMATOLOGY, P1751; OKADA S, 1991, BLOOD, V78, P1706; PAQUETTE RL, 1992, HEMATOL ONCOL CLIN N, V6, P687, DOI 10.1016/S0889-8588(18)30336-8; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHEZEN E, 1985, J CELL PHYSIOL, V124, P545, DOI 10.1002/jcp.1041240326; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Spittler A, 1997, IMMUNOLOGY, V90, P286, DOI 10.1046/j.1365-2567.1997.00148.x; SPOONCER E, 1985, NATURE, V316, P62, DOI 10.1038/316062a0; SZILVASSY SJ, 1989, BLOOD, V74, P930; TSUJI K, 1992, BLOOD, V79, P2855; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; ULICH TR, 1991, EXP HEMATOL, V19, P639; VISSER JWM, 1984, J EXP MED, V159, P1576, DOI 10.1084/jem.159.6.1576; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YU H, 1993, BLOOD, V81, P373; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	10	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					263	272		10.1096/fasebj.13.2.263	http://dx.doi.org/10.1096/fasebj.13.2.263			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973314				2022-12-28	WOS:000078615200006
J	Minotti, G; Cairo, G; Monti, E				Minotti, G; Cairo, G; Monti, E			Role of iron in anthracycline cardiotoxicity: new tunes for an old song?	FASEB JOURNAL			English	Review						mechanisms; cardioprotection; metallothionein; DOX	CARDIOPROTECTIVE AGENT DEXRAZOXANE; DOXORUBICIN-INDUCED CARDIOMYOPATHY; REGULATORY PROTEIN-ACTIVITY; INDUCED CARDIAC TOXICITY; CALCIUM RELEASE CHANNEL; MUSCLE GENE-EXPRESSION; ADVANCED BREAST-CANCER; SPIN-TRAPPING AGENTS; LIPID-PEROXIDATION; SARCOPLASMIC-RETICULUM	The clinical use of anticancer anthracyclines is limited by the development of a distinctive and life-threatening form of cardiomyopathy upon chronic treatment. Commonly accepted mechanistic hypotheses have assigned a pivotal role to iron, which would act as a catalyst for free radical reactions and oxidative stress. Although perhaps involved in acute aspects of anthracycline cardiotoxicity, the role of free radical-based mechanisms in long-term effects has been challenged on both experimental and clinical grounds, and alternative hypotheses independent of iron and free radicals have flourished, More recently, studies of the role of C-13 hydroxy metabolites of anthracyclines have provided new perspectives on the role of iron in the cardiotoxicity of these drugs, showing that such metabolites can impair intracellular iron handling and homeostasis. The present review applies a multisided approach to the critical evaluation of various hypotheses proposed over the last decade for the role of iron in anthracycline-induced cardiotoxicity, The main goal of the authors is to build a unifying pattern that would both account for hitherto unexplained experimental observations and help design novel and more rational strategies toward a much-needed improvement in the therapeutic index of anthracyclines.	Univ G dAnnunzio, Sch Pharm, Inst Drug Sci, Dept Pharmacol & Pharmacognosy, I-66013 Chieti, Italy; Univ Milan, Sch Med, Dept Gen Pathol, Milan, Italy; Univ Insubria, Sch Sci, Dept Struct & Funct Biol, Varese, Italy	G d'Annunzio University of Chieti-Pescara; University of Milan; University of Insubria	Minotti, G (corresponding author), Univ G dAnnunzio, Sch Pharm, Inst Drug Sci, Dept Pharmacol & Pharmacognosy, Via Vestini, I-66013 Chieti, Italy.	gminotti@unich.it	Cairo, Gaetano/M-5104-2016	Cairo, Gaetano/0000-0002-8147-4720; Minotti, Giorgio/0000-0002-5678-6175				AKIMOTO H, 1993, CANCER RES, V53, P4658; Arai M, 1998, J MOL CELL CARDIOL, V30, P243, DOI 10.1006/jmcc.1997.0588; BALDWIN JR, 1992, CANCER CHEMOTH PHARM, V30, P433, DOI 10.1007/BF00685593; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BOUCEK RJ, 1987, J BIOL CHEM, V262, P15851; Bouton C, 1997, J BIOL CHEM, V272, P19969, DOI 10.1074/jbc.272.32.19969; BRATTIN W J, 1985, Journal of Free Radicals in Biology and Medicine, V1, P27, DOI 10.1016/0748-5514(85)90026-1; BUCHER JR, 1983, BIOCHEM BIOPH RES CO, V111, P777, DOI 10.1016/0006-291X(83)91366-9; BUSS JL, 1995, ARCH BIOCHEM BIOPHYS, V317, P121, DOI 10.1006/abbi.1995.1143; BUSS JL, 1993, AGENTS ACTIONS, V40, P86, DOI 10.1007/BF01976756; Cairo G, 1997, BLOOD, V89, P2546, DOI 10.1182/blood.V89.7.2546; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; CAPIZZI RL, 1994, SEMIN ONCOL, V21, P8; COVA D, 1992, FREE RADICAL RES COM, V15, P353, DOI 10.3109/10715769209049151; DEGRAFF W, 1994, BIOCHEM PHARMACOL, V48, P1427, DOI 10.1016/0006-2952(94)90567-3; DERUSSO PA, 1995, J BIOL CHEM, V270, P15451, DOI 10.1074/jbc.270.26.15451; DODD DA, 1993, J CLIN INVEST, V91, P1697, DOI 10.1172/JCI116379; DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210; Dorr RT, 1996, SEMIN ONCOL, V23, P23; FORREST GL, 1991, MOL PHARMACOL, V40, P502; Gariboldi MB, 1998, FREE RADICAL BIO MED, V24, P913, DOI 10.1016/S0891-5849(97)00372-9; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; GREEN MD, 1990, PHARMACOL THERAPEUT, V48, P61, DOI 10.1016/0163-7258(90)90018-W; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAHN SM, 1992, CANCER RES, V52, P1750; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hasinoff BB, 1997, MOL PHARMACOL, V52, P839, DOI 10.1124/mol.52.5.839; Hasinoff BB, 1998, ANTI-CANCER DRUG, V9, P465, DOI 10.1097/00001813-199806000-00014; Hasinoff BB, 1996, ANTI-CANCER DRUG, V7, P558, DOI 10.1097/00001813-199607000-00011; Henderson BR, 1996, BIOESSAYS, V18, P739, DOI 10.1002/bies.950180909; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HERMAN E, 1979, CANCER TREAT REP, V63, P89; HERMAN EH, 1985, CANCER RES, V45, P276; HERSHKO C, 1993, J LAB CLIN MED, V122, P245; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Jeyaseelan R, 1997, J BIOL CHEM, V272, P22800, DOI 10.1074/jbc.272.36.22800; Jeyaseelan R, 1997, J BIOL CHEM, V272, P5828, DOI 10.1074/jbc.272.9.5828; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J; KIM E, 1995, TOXICOL APPL PHARM, V130, P57, DOI 10.1006/taap.1995.1008; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P580; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; KUFFEL MJ, 1992, CANCER CHEMOTH PHARM, V30, P51, DOI 10.1007/BF00686485; Kuppusamy P, 1996, BIOCHEMISTRY-US, V35, P7051, DOI 10.1021/bi952857s; LEGHA SS, 1982, ANN NY ACAD SCI, V393, P411, DOI 10.1111/j.1749-6632.1982.tb31279.x; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MASCOTTI DP, 1995, ANNU REV NUTR, V15, P239, DOI 10.1146/annurev.nu.15.070195.001323; MINOTTI G, 1990, ARCH BIOCHEM BIOPHYS, V277, P268, DOI 10.1016/0003-9861(90)90578-M; Minotti G, 1996, J CLIN INVEST, V98, P650, DOI 10.1172/JCI118836; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MINOTTI G, 1989, ARCH BIOCHEM BIOPHYS, V268, P398, DOI 10.1016/0003-9861(89)90601-2; MINOTTI G, 1993, CHEM RES TOXICOL, V6, P134, DOI 10.1021/tx00032a001; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; MONTI E, 1991, FREE RADICAL RES COM, V14, P41, DOI 10.3109/10715769109088940; Monti E, 1996, FREE RADICAL BIO MED, V21, P463, DOI 10.1016/0891-5849(96)00124-4; MONTI E, 1986, CANCER CHEMOTH PHARM, V18, P289; MONTI E, 1995, ANTICANCER RES, V15, P193; MYERS C, 1986, FASEB J, V45, P2792; MYERS C, 1983, SEMIN ONCOL, V10, P53; OHNISHI S T, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P419; OLSON RD, 1988, P NATL ACAD SCI USA, V85, P3585, DOI 10.1073/pnas.85.10.3585; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; PESSAH IN, 1992, TOXICOLOGY, V72, P189, DOI 10.1016/0300-483X(92)90112-R; PETERS JH, 1984, CANCER RES, V44, P1453; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; PRAET M, 1993, BIOCHIM BIOPHYS ACTA, V1149, P79, DOI 10.1016/0005-2736(93)90027-W; Purpura P, 1996, CANCER RES, V56, P2336; Recalcati S, 1998, BLOOD, V91, P2565, DOI 10.1182/blood.V91.7.2565.2565_2565_2572; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; Shaw LM, 1996, SEMIN ONCOL, V23, P18; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SISTO T, 1995, ANN THORAC SURG, V59, P1519, DOI 10.1016/0003-4975(95)00197-S; SIVESKIILISKOVIC N, 1995, CIRCULATION, V91, P10, DOI 10.1161/01.CIR.91.1.10; SIVESKIILISKOVIC N, 1994, CIRCULATION, V89, P2829, DOI 10.1161/01.CIR.89.6.2829; SOLEM LE, 1994, TOXICOL APPL PHARM, V129, P214, DOI 10.1006/taap.1994.1246; SPERANZA MJ, 1993, J BIOL CHEM, V268, P19039; SPEYER JL, 1988, NEW ENGL J MED, V319, P745, DOI 10.1056/NEJM198809223191203; SPEYER JL, 1992, J CLIN ONCOL, V10, P117, DOI 10.1200/JCO.1992.10.1.117; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STEWART DJ, 1993, ANTICANCER RES, V13, P1945; Swain SM, 1997, J CLIN ONCOL, V15, P1318, DOI 10.1200/JCO.1997.15.4.1318; Tacchini L, 1997, GASTROENTEROLOGY, V113, P946, DOI 10.1016/S0016-5085(97)70191-4; TALCOTT RE, 1985, ARCH BIOCHEM BIOPHYS, V241, P88, DOI 10.1016/0003-9861(85)90365-0; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; THEIL EC, 1983, IRON BINDING PROTEIN, P1; THOMAS CE, 1986, ARCH BIOCHEM BIOPHYS, V248, P684, DOI 10.1016/0003-9861(86)90523-0; TIEN M, 1982, ARCH BIOCHEM BIOPHYS, V216, P142, DOI 10.1016/0003-9861(82)90198-9; Torti SV, 1998, J MOL CELL CARDIOL, V30, P1173, DOI 10.1006/jmcc.1998.0681; VANVLEET JF, 1980, AM J PATHOL, V99, P13; Virtamo J, 1998, ARCH INTERN MED, V158, P668, DOI 10.1001/archinte.158.6.668; WASSERMAN TH, 1994, SEMIN ONCOL, V21, P21; WEISS RB, 1992, SEMIN ONCOL, V19, P670; WORWOOD M, 1989, J INTERN MED, V226, P381, DOI 10.1111/j.1365-2796.1989.tb01412.x; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; YUHAS JM, 1980, CANCER RES, V40, P1519; Zhang J, 1996, J MOL CELL CARDIOL, V28, P1931, DOI 10.1006/jmcc.1996.0186; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P66, DOI 10.1016/S0891-5849(97)00165-2	106	177	185	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					199	212		10.1096/fasebj.13.2.199	http://dx.doi.org/10.1096/fasebj.13.2.199			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973309	Bronze			2022-12-28	WOS:000078615200001
J	Burger, EH; Klein-Nulend, J				Burger, EH; Klein-Nulend, J			Mechanotransduction in bone - role of the lacuno-canalicular network	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular Biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agcy, NASA	BELGIUM NATL ACAD SCI	osteocyte; fluid shear stress; microgravity	MESSENGER-RNA EXPRESSION; STRAIN-RELATED CHANGES; RAT LONG BONES; FLUID-FLOW; IN-VIVO; MECHANICAL STRAIN; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; SHEAR-STRESS; ELECTROMECHANICAL POTENTIALS	The capacity of bone tissue to alter its mass and structure in response to mechanical demands has long been recognized but the cellular mechanisms involved remained poorly understood. Over the last several years significant progress has been made in this field, which we will try to summarize. These studies emphasize the role of osteocytes as the professional mechanosensory cells of bone, and the lacuno-canalicular porosity as the structure that mediates mechanosensing. Strain-derived flow of interstitial fluid through this porosity seems to mechanically activate the osteocytes, as well as ensuring transport of cell signaling molecules and nutrients and waste products. This concept allows an explanation of local bone gain and loss, as well as remodeling in response to fatigue damage, as processes supervised by mechanosensitive osteocytes.	Free Univ Amsterdam, Dept Oral Cell Biol, ACTA, NL-1081 BT Amsterdam, Netherlands	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam	Burger, EH (corresponding author), Free Univ Amsterdam, Dept Oral Cell Biol, ACTA, Van Der Boechorstr 7, NL-1081 BT Amsterdam, Netherlands.	EH.Burger.OCB.ACTA@med.vu.nl						Aarden EM, 1996, HISTOCHEM CELL BIOL, V106, P495, DOI 10.1007/s004180050069; Aarden EM, 1996, BONE, V18, P305, DOI 10.1016/8756-3282(96)00010-5; Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; BACKUP P, 1994, AM J PHYSIOL, V266, pE567, DOI 10.1152/ajpendo.1994.266.4.E567; Bentolila V, 1998, BONE, V23, P275, DOI 10.1016/S8756-3282(98)00104-5; Bronckers ALJJ, 1996, J BONE MINER RES, V11, P1281; BURGER EH, 1993, BONE, V0007, P00037; BURGER EWH, 1998, ADV ORGAN BIOL A, V5, P108; BURR DB, 1993, J BIOMECH, V26, P613, DOI 10.1016/0021-9290(93)90023-8; Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6; Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756-3282(96)00028-2; BURR DB, 1985, J BIOMECH, V18, P189, DOI 10.1016/0021-9290(85)90204-0; BURR DB, 1993, CALCIF TISSUE INT S1, V53, P75; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; Carmeliet G, 1997, J BONE MINER RES, V12, P786, DOI 10.1359/jbmr.1997.12.5.786; CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623-197759070-00021; CARVALHO RS, 1994, J BONE MINER RES, V9, P999; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chow J.W., 1994, AM J PHYSIOL, V267, pE278; Conover Cheryl A., 1996, P607; COWIN SC, 1995, J BIOMECH, V28, P1281, DOI 10.1016/0021-9290(95)00058-P; COWIN SC, 1991, J BIOMECH ENG-T ASME, V113, P191, DOI 10.1115/1.2891234; Cowin SC, 1998, BONE, V22, p119S, DOI 10.1016/S8756-3282(98)00011-8; DALLAS SL, 1993, J BONE MINER RES, V8, P251; Davies PF, 1997, ANNU REV PHYSIOL, V59, P527, DOI 10.1146/annurev.physiol.59.1.527; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; FERMOR B, 1995, J BONE MINER RES, V10, P1935; FEYEN JHM, 1985, PROSTAGLANDINS, V30, P827, DOI 10.1016/0090-6980(85)90011-5; Fiala P, 1993, Funct Dev Morphol, V3, P91; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Forwood MR, 1996, AM J PHYSIOL-ENDOC M, V270, pE419, DOI 10.1152/ajpendo.1996.270.3.E419; GOHEL AR, 1995, J HISTOCHEM CYTOCHEM, V43, P1085, DOI 10.1177/43.11.7560891; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; HERT J, 1994, J BIOMECH, V27, P239, DOI 10.1016/0021-9290(94)90214-3; HILLAM RA, 1995, J BONE MINER RES, V10, P683; Hillsley MV, 1997, CALCIFIED TISSUE INT, V60, P48, DOI 10.1007/s002239900185; Hinghofer-Szalkay HC., 1996, BIOLOGICAL MEDICAL R, P107; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; HUNG CT, 1995, CLIN ORTHOP RELAT R, P256; Hung CT, 1996, J BIOMECH, V29, P1403, DOI 10.1016/0021-9290(96)84535-0; Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021-9290(96)84536-2; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V217, P264, DOI 10.1006/bbrc.1995.2773; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Jagger CJ, 1996, J CLIN INVEST, V98, P2351, DOI 10.1172/JCI119047; Jee W., 1988, CELL TISSUE BIOL TXB, P213; KIRSCH KA, 1993, CLIN INVESTIGATOR, V71, P687; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; KleinNulend J, 1997, J CELL PHYSIOL, V170, P174, DOI 10.1002/(SICI)1097-4652(199702)170:2<174::AID-JCP9>3.0.CO;2-L; KNOTHETATE M, 1997, J BONE MINER, V12, pS341; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; LeBlanc A, 1998, BONE, V22, p113S, DOI 10.1016/S8756-3282(98)00013-1; LeBlanc A, 1996, J BONE MINER RES  S1, V11, pS323; Lozupone E, 1996, CLIN RHEUMATOL, V15, P563, DOI 10.1007/BF02238545; MACK PB, 1967, AMER J ROENTGENOL RA, V100, P503, DOI 10.2214/ajr.100.3.503; MaejimaIkeda A, 1997, BIOCHEM J, V322, P245, DOI 10.1042/bj3220245; Mak AFT, 1997, J BIOMECH, V30, P11, DOI 10.1016/S0021-9290(96)00121-2; Marks Sandy C. Jr., 1996, P3; Mason DJ, 1996, J BONE MINER RES, V11, P350; MIKUNITAKAGAKI Y, 1995, J BONE MINER RES, V10, P231, DOI 10.1002/jbmr.5650100209; MikuniTakagaki Y, 1996, ENDOCRINOLOGY, V137, P2028, DOI 10.1210/en.137.5.2028; Miles RR, 1998, J CELL BIOCHEM, V68, P355, DOI 10.1002/(SICI)1097-4644(19980301)68:3<355::AID-JCB6>3.0.CO;2-T; MOREY ER, 1978, SCIENCE, V201, P1138, DOI 10.1126/science.150643; MULLENDER MG, 1995, J ORTHOPAED RES, V13, P503, DOI 10.1002/jor.1100130405; Mullender MG, 1997, BONE, V20, P527, DOI 10.1016/S8756-3282(97)00036-7; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; Nefussi J R, 1991, J Biol Buccale, V19, P75; NeidlingerWilke C, 1995, J BIOMECH, V28, P1411, DOI 10.1016/0021-9290(95)00089-5; NIJWEIDE PJ, 1990, BONE, V1, P303; NIJWEIDE PJ, 1986, HISTOCHEMISTRY, V84, P343; Norrdin RW, 1998, BONE, V22, P133, DOI 10.1016/S8756-3282(97)00253-6; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; PALUMBO C, 1990, BONE, V11, P401, DOI 10.1016/8756-3282(90)90134-K; PARFITT AM, 1977, CLIN ORTHOP RELAT R, P236; Petrtyl M, 1996, J BIOMECH, V29, P161, DOI 10.1016/0021-9290(94)00035-2; PIEKARSKI K, 1977, NATURE, V269, P80, DOI 10.1038/269080a0; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Prendergast PJ, 1996, J BIOMECH ENG-T ASME, V118, P240, DOI 10.1115/1.2795966; Rawlinson SCF, 1996, BONE, V19, P609, DOI 10.1016/S8756-3282(96)00260-8; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; ROUX W, 1881, KAMPF TEILE ORGANISM; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; RUBIN CT, 1987, J ORTHOPAED RES, V5, P300, DOI 10.1002/jor.1100050217; Salter DM, 1997, J BONE MINER RES, V12, P1133, DOI 10.1359/jbmr.1997.12.7.1133; SALZSTEIN RA, 1987, J BIOMECH, V20, P271, DOI 10.1016/0021-9290(87)90294-6; SALZSTEIN RA, 1987, J BIOMECH, V20, P261, DOI 10.1016/0021-9290(87)90293-4; SCHAFFLER MB, 1994, BONE, V15, P483, DOI 10.1016/8756-3282(94)90271-2; Shapiro F, 1997, CALCIFIED TISSUE INT, V61, P285, DOI 10.1007/s002239900337; SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Smith TS, 1997, J ORTHOP RES, V15, P593, DOI 10.1002/jor.1100150416; SUN YQ, 1995, CALCIFIED TISSUE INT, V57, P456, DOI 10.1007/BF00301950; Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051; TABONY J, 1990, NATURE, V346, P448, DOI 10.1038/346448a0; TABONY J, 1992, P NATL ACAD SCI USA, V89, P6948, DOI 10.1073/pnas.89.15.6948; TANAKA K, 1995, MINER ELECTROL METAB, V21, P189; Tate MLK, 1998, BONE, V22, P107; THORNTON WE, 1992, AVIAT SPACE ENVIR MD, V63, P789; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; Turner C. H., 1996, AM J PHYSIOL, V270, pE639; TURNER CH, 1994, FASEB J, V8, P875, DOI 10.1096/fasebj.8.11.8070637; TURNER CH, 1995, J BIOMECH, V28, P39, DOI 10.1016/0021-9290(95)80005-0; TURNER CH, 1995, AM J PHYSIOL-ENDOC M, V269, pE438, DOI 10.1152/ajpendo.1995.269.3.E438; TURNER RT, 1985, PHYSIOLOGIST, V28, P567; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; van Loon JJWA, 1996, BIOL MED RES SPACE, P259; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANDERPLAS A, 1994, J BONE MINER RES, V9, P1697; VANKOOTEN TG, 1992, J BIOMED MATER RES, V26, P725, DOI 10.1002/jbm.820260604; VANLOON JJWA, 1995, J BONE MINER RES, V10, P550; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; WESTERLIND KC, 1995, J BONE MINER RES, V10, P843; Wolff J, 1892, GESETZ TRANSFORMATIO; Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769; Zhang DJ, 1997, ANN BIOMED ENG, V25, P357, DOI 10.1007/BF02648049; [No title captured]	119	658	694	0	75	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S101	S112		10.1096/fasebj.13.9001.s101	http://dx.doi.org/10.1096/fasebj.13.9001.s101			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352151	Green Submitted			2022-12-28	WOS:000080403800013
J	Camenisch, G; Tini, M; Chilov, D; Kvietikova, I; Srinivas, V; Caro, J; Spielmann, P; Wenger, RH; Gassmann, M				Camenisch, G; Tini, M; Chilov, D; Kvietikova, I; Srinivas, V; Caro, J; Spielmann, P; Wenger, RH; Gassmann, M			General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia-inducible factor 1 alpha	FASEB JOURNAL			English	Article						monoclonal antibody; affinity purification; Western blotting; EMSA; immunoprecipitation; immunofluorescence	FACTOR-I; IMMUNIZED HENS; PROTEIN; PURIFICATION; EXPRESSION; RECEPTOR; ARNT; MICE	Avian embryos and neonates acquire passive immunity by transferring maternal immunoglobulins from serum to egg yolk. Despite being a convenient source of antibodies, egg yolk immunoglobulins (IgY) from immunized hens have so far received scant attention in research. Here we report the generation and rapid isolation of IgY from the egg yolk of hens immunized against the a subunit of the human hypoxia-inducible factor 1 (HIF-1 alpha). Anti-HIF-1 alpha IgY antibodies were affinity purified and tested for their performance in various applications. Abundant HIF-1 alpha protein was detected by Western blot analysis in nuclear extracts derived from hypoxic cells of human, mouse, monkey, swine, and dog origin whereas in hypoxic quail and frog cells, the HIF-1 alpha signal was weak or absent, respectively. In electrophoretic mobility shift assays, affinity-purified IgY antibody was shown to recognize the native :HIF-1 (but not the related HIF-2) complex that specifically binds an oligonucleotide containing the HIF-1 DNA binding site. Furthermore, IgY antibody immunoprecipitated HIF-1 alpha from hypoxic cell extracts. Immunofluorescence experiments using IgY antibody allowed the detection of HIF-1 alpha in the nucleus of hypoxic COS-7 cells. For comparison, the application of a mouse monoclonal antibody raised against the identical HIF-1 alpha fragment was more restricted. Because chicken housing is inexpensive, egg collection is noninvasive, isolation and affinity purification of IgY antibodies are fast and simple, and the applicability of IgY is widespread, immunization of hens represents an excellent alternative for the generation of polyclonal antibodies.	Univ Zurich Irchel, Inst Physiol, CH-8057 Zurich, Switzerland; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA	University of Zurich; Jefferson University	Gassmann, M (corresponding author), Univ Zurich Irchel, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	labbauer@physiol.unizh.ch	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; chilov, dmitri/0000-0002-2279-0854; Spielmann, Patrick/0000-0001-7056-0351				AKITA EM, 1993, J IMMUNOL METHODS, V160, P207, DOI 10.1016/0022-1759(93)90179-B; Doellgast GJ, 1997, J CLIN MICROBIOL, V35, P578, DOI 10.1128/JCM.35.3.578-583.1997; Ebina T, 1996, ARCH VIROL, P217; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fischer M, 1996, Tierarztl Prax, V24, P411; Fortgens PH, 1997, IMMUNOPHARMACOLOGY, V36, P305, DOI 10.1016/S0162-3109(97)00035-0; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GouinThibault I, 1996, BRIT J HAEMATOL, V95, P738, DOI 10.1046/j.1365-2141.1996.d01-1963.x; GROSSMANN A, 1995, J IMMUNOL METHODS, V179, P243, DOI 10.1016/0022-1759(94)00291-4; GUTMANN DH, 1995, DEV DYNAM, V202, P302, DOI 10.1002/aja.1002020309; HASSL A, 1987, ZBL BAKT-INT J MED M, V267, P247; Hatta H, 1997, CARIES RES, V31, P268, DOI 10.1159/000262410; HATTA H, 1993, BIOSCI BIOTECH BIOCH, V57, P450, DOI 10.1271/bbb.57.450; HIGGINS DA, 1995, VET IMMUNOL IMMUNOP, V44, P169, DOI 10.1016/0165-2427(93)05300-4; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; Klemperer F., 1893, ARCH EXPT PATHOL PHA, V31, P356, DOI [10.1007/BF01832882, DOI 10.1007/BF01832882]; Kozak KR, 1997, DEV BIOL, V191, P297, DOI 10.1006/dbio.1997.8758; KUNZ US, 1991, J VET MED B, V38, P292, DOI 10.1111/j.1439-0450.1991.tb00873.x; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LARSSON A, 1990, COMP IMMUNOL MICROB, V13, P199, DOI 10.1016/0147-9571(90)90088-B; Lee SC, 1997, PREP BIOCHEM BIOTECH, V27, P227, DOI 10.1080/10826069708001281; LESLIE GA, 1969, J EXP MED, V130, P1337, DOI 10.1084/jem.130.6.1337; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Murata T, 1996, P SOC EXP BIOL MED, V211, P100; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; POLSON A, 1990, IMMUNOL INVEST, V19, P253; ROSOL TJ, 1993, VET IMMUNOL IMMUNOP, V35, P321, DOI 10.1016/0165-2427(93)90042-3; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SCHADE R, 1997, ANIMAL ALTERNATIVES, P93; SCHMIDT P, 1989, J VET MED B, V36, P619, DOI 10.1111/j.1439-0450.1989.tb00653.x; Schwarzkopf C, 1997, DEV AN VET, V27, P983; SHIMIZU M, 1992, BIOSCI BIOTECH BIOCH, V56, P270, DOI 10.1271/bbb.56.270; SHIMIZU M, 1995, BIOSCI BIOTECH BIOCH, V59, P138, DOI 10.1271/bbb.59.138; SONG CS, 1985, J IMMUNOL, V135, P3354; THALLEY BS, 1990, BIO-TECHNOL, V8, P934, DOI 10.1038/nbt1090-934; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wenger RH, 1997, BIOL CHEM, V378, P609	42	103	107	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					81	88		10.1096/fasebj.13.1.81	http://dx.doi.org/10.1096/fasebj.13.1.81			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872932	Green Accepted, Bronze			2022-12-28	WOS:000078029500009
J	Allen, S; Khan, S; Tam, SP; Koschinsky, M; Taylor, P; Yacoub, M				Allen, S; Khan, S; Tam, SP; Koschinsky, M; Taylor, P; Yacoub, M			Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity	FASEB JOURNAL			English	Article						calcium signaling; VCAM-1; E-selectin; endothelial cells	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; ALPHA-2-MACROGLOBULIN RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-E; CELL LINE; BINDING; PLASMINOGEN; ATHEROSCLEROSIS	Lp(a) is a major inherited risk factor for premature atherosclerosis. The mechanism of Lp(a) atherogenicity has not been elucidated, but likely involves both its ability to interfere with plasminogen activation and its atherogenic potential as a lipoprotein particle after receptor-mediated uptake. We demonstrate that Lp(a) stimulates production of vascular cell. adhesion molecule 1 (VCAM-1) and E-selectin in cultured human coronary artery endothelial cells (HCAEC). This effect resulted from a rise in intracellular free calcium induced by Lp(a) and could be inhibited by the intracellular calcium chelator, BAPTA/AM. The involvement of the LDL and VLDL receptors in Lp(a) activation of HCAEC were ruled out since Lp(a) induction of adhesion molecules was not prevented by an antibody (IgGC7) to the LDL receptor or by receptor-activating protein, an antagonist of ligand binding to the VLDL receptor. Addition of alpha(2)-macroglobulin as well as treatment with heparinase, chondroitinase,ABC, and sodium chlorate did not decrease levels of VCAM-1 and E-selectin stimulated by Lp(a), suggesting that neither the low density lipoprotein receptor-related protein nor cell-surface proteoglycans are involved in Lp(a)-induced adhesion molecule production. Neither does the binding site on HCAEC responsible for adhesion molecule production by Lp(a) appear to involve plasminogen receptors, as levels of VCAM-1 and E-selectin were not significantly decreased by the addition of glu-plasminogen, the lysine analog E-aminocaproic acid, or by trans-4-(aminomethyl)-cyclohexanecarboxymethylic acid (tranexamic acid), which acts by binding to the lysine binding sites carried on the kringle structures in plasminogen. In contrast, recombinant apolipoprotein (a) [r-apo(a)] competed with Lp(a) and attenuated the expression of VCAM-1 and E-selectin. In summary, we have identified a calcium-dependent interaction of Lp(a) with HCAEC capable of inducing potent surface expression of VCAM-1 and E-selectin that does not appear to involve any of the known potential Lp(a) binding sites. Because leukocyte recruitment to the vessel wall appears to represent one of the important early events in atherogenesis, this newly described endothelial cell-activating effect of Lp(a) places it at a crucial juncture in the initiation of atherogenic disease and may lead to a better understanding of the role of Lp(a) in the vascular biology of atherosclerosis.	Univ London Imperial Coll Sci Technol & Med, Dept Cardiothorac Surg, Harefield Hosp,Heart Sci Ctr, FRCS,Royal Brompton & Harefield NHS, Harefield UB9 6JH, Middx, England; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Queens University - Canada	Yacoub, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cardiothorac Surg, Harefield Hosp,Heart Sci Ctr, FRCS,Royal Brompton & Harefield NHS, Hill End Rd, Harefield UB9 6JH, Middx, England.			Koschinsky, Marlys/0000-0002-2643-2288				ALLEN SP, 1998, IN PRESS J CLIN INVE; BARBIR M, 1992, LANCET, V340, P1500, DOI 10.1016/0140-6736(92)92756-6; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BUDDE T, 1994, ARTERIOSCLER THROMB, V14, P1730, DOI 10.1161/01.ATV.14.11.1730; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; Hackman A, 1996, CIRCULATION, V93, P1334, DOI 10.1161/01.CIR.93.7.1334; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; JI ZS, 1993, J BIOL CHEM, V268, P10160; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOSTNER GM, 1993, ARTERIOSCLER THROMB, V13, P1101, DOI 10.1161/01.ATV.13.7.1101; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MARZ W, 1993, FEBS LETT, V325, P271, DOI 10.1016/0014-5793(93)81087-G; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCTIGUE K, 1997, J CLIN INVEST, V100, P2170; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PRITCHARD KA, 1991, ARTERIOSCLER THROMB, V11, P1175, DOI 10.1161/01.ATV.11.5.1175; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; Scanu A M, 1991, Adv Intern Med, V36, P249; SCHAEFER HIMB, 1993, CELL CALCIUM, V14, P507, DOI 10.1016/0143-4160(93)90009-U; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smalley DM, 1996, ARTERIOSCL THROM VAS, V16, P585, DOI 10.1161/01.ATV.16.4.585; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; TAM SP, 1991, J BIOL CHEM, V266, P16764; Tam SP, 1996, J LIPID RES, V37, P518; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	39	72	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1765	1776		10.1096/fasebj.12.15.1765	http://dx.doi.org/10.1096/fasebj.12.15.1765			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837867				2022-12-28	WOS:000077574500019
J	Dougherty, C; Barucha, J; Schofield, PR; Jacobson, KA; Liang, BT				Dougherty, C; Barucha, J; Schofield, PR; Jacobson, KA; Liang, BT			Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A(1) or A(3) receptor	FASEB JOURNAL			English	Article						heart; purinergic; ventricular myocyte; gene transfer	INTRACORONARY ADENOSINE; REPERFUSION; INJURY; CLONING; GENE	Adenosine is an important mediator of the endogenous defense against ischemia-induced injury in the heart. Adenosine can achieve cardioprotection by mediating the effect of ischemic preconditioning and by protecting against myocyte injury when it is present during the infarct-producing ischemia. A novel adenosine A(3) receptor can mediate this protective function. One approach to achieve cardioprotection is to enhance myocardial sensitivity to the endogenous adenosine by increasing the number of adenosine receptors instead of administering an adenosine receptor agonist. The objective of the present study was to investigate whether genetic manipulation of the cardiac myocyte, achieved by gene transfer and overexpression of the human A(3) receptor cDNA, renders the myocytes resistant to the deleterious effect of ischemia. Prolonged hypoxia with glucose deprivation, causing myocyte injury and adenosine release, was used to simulate ischemia in cultured chick embryo ventricular myocytes. During simulated ischemia, cultured myocytes with enhanced expression of the human A(3) receptor and showed significantly higher ATP content, fewer cells killed, and less creatine kinase released into the medium than either control or mock-transfected myocytes. Also, increased expression of the A(3) receptor caused an enhanced cardioprotective effect by the preconditioning ischemia. Overexpressing the adenosine A(1) receptor also led to increased protection against ischemia-induced myocyte injury as well as an enhanced preconditioning effect. Thus, increasing the receptor level improves the myocyte sensitivity to the endogenous adenosine, which in turn causes all of the cardioprotective effects found for exogenously administered adenosine agonists. The study provides the first proof for the new concept that an increased expression of the human A(3) receptor in the cardiac myocyte can be an important cardioprotective therapeutic approach.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Garvan Inst Med Res, Sydney, NSW, Australia; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; Garvan Institute of Medical Research; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, 3610 Hamilton Walk, Philadelphia, PA 19104 USA.		Jacobson, Kenneth Alan/A-1530-2009; Schofield, Peter/C-9669-2011	Jacobson, Kenneth Alan/0000-0001-8104-1493; Trivedi, Julie/0000-0002-2784-0662; Schofield, Peter/0000-0003-2967-9662	Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [R01 HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031117] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkinson MR, 1997, NEUROSCI RES, V29, P73, DOI 10.1016/S0168-0102(97)00073-4; BABBITT DG, 1989, CIRCULATION, V80, P1388, DOI 10.1161/01.CIR.80.5.1388; DOOREY AJ, 1983, CIRC RES, V53, P192, DOI 10.1161/01.RES.53.2.192; ELY SW, 1985, J THORAC CARDIOV SUR, V90, P549; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; HOLMSEN H, 1966, ANAL BIOCHEM, V17, P456, DOI 10.1016/0003-2697(66)90181-3; Jiang JL, 1996, J MED CHEM, V39, P4667, DOI 10.1021/jm960457c; KIM HO, 1994, J MED CHEM, V37, P3614, DOI 10.1021/jm00047a018; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, NUCLEIC ACIDS RES, V24, P1382, DOI 10.1093/nar/24.7.1382; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Matherne GP, 1997, P NATL ACAD SCI USA, V94, P6541, DOI 10.1073/pnas.94.12.6541; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; OLAFSSON B, 1987, CIRCULATION, V76, P1135, DOI 10.1161/01.CIR.76.5.1135; REIBEL DK, 1978, AM J PHYSIOL, V234, pH620; RINIVAS M, 1997, MOL PHARMACOL, V52, P683; Song YJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1233; STAMBAUGH K, 1997, AM J PHYSIOL, V273, pH5010; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	22	58	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1785	1792		10.1096/fasebj.12.15.1785	http://dx.doi.org/10.1096/fasebj.12.15.1785			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837869	Green Accepted			2022-12-28	WOS:000077574500021
J	Lizard, G; Gueldry, S; Sordet, O; Monier, S; Athias, A; Miguet, C; Bessede, G; Lemaire, S; Solary, E; Gambert, P				Lizard, G; Gueldry, S; Sordet, O; Monier, S; Athias, A; Miguet, C; Bessede, G; Lemaire, S; Solary, E; Gambert, P			Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production	FASEB JOURNAL			English	Article						N-acetylcysteine; oxidation; oxysterol; low density lipoproteins; TUNEL	PROGRAMMED CELL-DEATH; SMOOTH-MUSCLE CELLS; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE; CYTOCHROME-C; ELECTROCHEMICAL DETECTOR; CHOLESTEROL DERIVATIVES; PERMEABILITY TRANSITION; ANTIOXIDANT DEFENSE; THYMOCYTE APOPTOSIS	In a number of experimental systems, inhibition of apoptosis by antioxidants has led to the production of radical oxygen species (ROS) in certain apoptotic forms of cell death. Since antioxidant therapies can reduce vascular dysfunctions in hypercholesterolemic patients who frequently have increased plasma levels of oxysterols constituting potent inducers of apoptosis, we speculate that oxysterol-induced apoptosis could involve oxidative stress. Here, we tested the protective effects of the aminothiols glutathione (GSH) and N-acetylcysteine (NAC), which are two potent antioxidants, on apoptosis induced by 7-ketocholesterol in U937 cells, and we present evidence indicating that oxidative processes are involved in 7-ketocholesterol-induced cell death. Thus, GSH and NAC prevented phenomenona linked to apoptosis such as reduction of cell growth, increase cellular permeability to propidium iodide, and occurrence of nuclear condensation and/or fragmentation, and they delayed internucleosomal DNA fragmentation. In addition, cell treatment with GSH impaired cytochrome c release into the cytosol and degradation of caspase-8 occurring during cell death. During 7-ketocholesterol-induced apoptosis, we also observed a rapid decrease in cellular GSH content, oxidation of polyunsaturated fatty acids, and a production of ROS by flow cytometry with the use of the dye 2',7'-dichlorofluorescin-diacetate; both phenomena were inhibited by GSH. Prevention of cell death by GSH and NAC does not seem to be a general rule since these antioxidants impaired etoposide (but not cycloheximide) -induced apoptosis. Taken together, our data demonstrate that GSH is implied in the control of 7-ketocholesterol-induced apoptosis associated with the production of ROS.	CHU, Hop Bocage, INSERM U 498, Lab Biochim Med, F-21034 Dijon, France; INSERM CJF 9408, Fac Med, F-21033 Dijon, France	CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Lizard, G (corresponding author), CHU, Hop Bocage, INSERM U 498, Lab Biochim Med, BP 1542,2 Bd Marechal de Lattre de Tassigny, F-21034 Dijon, France.	Gerard.Lizard@u.bourgogne.fr	Lizard, Gerard/B-2439-2012; Sordet, Olivier/M-3271-2014	Sordet, Olivier/0000-0001-6027-4925; Solary, Eric/0000-0002-8629-1341; Carole, MIGUET-ALFONSI/0000-0002-3317-6454				ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; AUPEIX K, 1995, IMMUNOBIOLOGY, V194, P415, DOI 10.1016/S0171-2985(11)80108-7; BASS DA, 1983, J IMMUNOL, V130, P1910; BERLINER JA, 1992, FREE RADICAL BIO MED, V13, P341; BOISSONNEAULT GA, 1991, P SOC EXP BIOL MED, V196, P338; Breuer O, 1996, BBA-LIPID LIPID MET, V1302, P145, DOI 10.1016/0005-2760(96)00052-5; Briehl M M, 1995, Cell Death Differ, V2, P41; Briehl MM, 1996, CELL DEATH DIFFER, V3, P63; Brown AJ, 1997, J LIPID RES, V38, P1730; BROWN MS, 1974, J BIOL CHEM, V249, P7306; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; CARROCIAMPI G, 1988, J PHARMACOL METHOD, V19, P75, DOI 10.1016/0160-5402(88)90047-2; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; CHRIST M, 1993, IMMUNOLOGY, V78, P455; Colles SM, 1996, J LIPID RES, V37, P2018; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Deckert V, 1997, CIRCULATION, V95, P723, DOI 10.1161/01.CIR.95.3.723; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Esterbauer H, 1996, REV PHYSIOL BIOCH P, V127, P31, DOI 10.1007/BFb0048264; FOLCH J, 1957, J BIOL CHEM, V226, P497; Freyschuss A, 1997, ARTERIOSCL THROM VAS, V17, P1178, DOI 10.1161/01.ATV.17.6.1178; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HARVEY PRC, 1989, CLIN CHIM ACTA, V180, P203, DOI 10.1016/0009-8981(89)90001-6; HEDLEY DW, 1994, CYTOMETRY, V15, P349, DOI 10.1002/cyto.990150411; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LIZARD G, 1995, CYTOMETRY, V21, P275, DOI 10.1002/cyto.990210308; Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7; Lizard G, 1996, AM J PATHOL, V148, P1625; Lizard G, 1997, J PATHOL, V183, P330; Lizard G, 1997, PATHOL BIOL, V45, P281; LOTEM J, 1992, BLOOD, V80, P1750; Macho A, 1997, J IMMUNOL, V158, P4612; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishio E, 1996, BIOCHEM BIOPH RES CO, V226, P928, DOI 10.1006/bbrc.1996.1452; Nishio E, 1996, BIOCHEM BIOPH RES CO, V223, P413, DOI 10.1006/bbrc.1996.0907; PARK SW, 1985, ANAL BIOCHEM, V149, P275, DOI 10.1016/0003-2697(85)90505-6; RAMAKRISHNAN N, 1992, J IMMUNOL, V148, P1817; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHRIEVE DC, 1988, J BIOL CHEM, V263, P14107; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Szabo C, 1997, AM J RESP CELL MOL, V16, P105, DOI 10.1165/ajrcmb.16.2.9032115; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YEH CJG, 1981, J IMMUNOL METHODS, V43, P269, DOI 10.1016/0022-1759(81)90174-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhao ZH, 1997, BBA-MOL CELL RES, V1359, P143, DOI 10.1016/S0167-4889(97)00093-1; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHOU Q, 1993, P SOC EXP BIOL MED, V202, P75	84	190	196	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1651	1663		10.1096/fasebj.12.15.1651	http://dx.doi.org/10.1096/fasebj.12.15.1651			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837855				2022-12-28	WOS:000077574500007
J	Pratico, D; Lee, VMY; Trojanowski, JQ; Rokach, J; Fitzgerald, GA				Pratico, D; Lee, VMY; Trojanowski, JQ; Rokach, J; Fitzgerald, GA			Increased F-2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo	FASEB JOURNAL			English	Article						oxidative stress; schizophrenia; temporal lobes; neurofibrillary tangles	BETA-AMYLOID PEPTIDES; STRESS IN-VIVO; OXIDATIVE DAMAGE; OXIDANT STRESS; BRAIN; PATHOGENESIS; GENERATION; PROTEINS; NEURONS; CORTEX	Alzheimer's disease (AD) includes a group of dementing neurodegenerative disorders that have diverse etiologies but the same hallmark brain lesions. Since oxidative stress may play a role in the pathogenesis of AD and isoprostanes are chemically stable peroxidation products of arachidonic acid, we measured both iPF(2 alpha)-III and iPF(2 alpha)-VI using gas chromatography-mass spectrometry in AD and control brains. The levels of both isoprostanes, but not of 6-keto PGF(1 alpha), an index of prostaglandin production, were markedly elevated in both frontal and temporal poles of AD brains compared to the corresponding cerebella. Levels were also elevated compared to corresponding areas of brains from patients who had died with schizophrenia or Parkinson's disease or from nonneuropsychiatric disorders, iPF(2 alpha) - IV, but not iPF(2 alpha)-III, levels were higher in ventricular CSF of AD brains relative to the non-AD brains. These data suggest that specific isoprostane analysis may reflect increased oxidative stress in AD.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res Pathol & Lab Med, Philadelphia, PA 19104 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Florida Institute of Technology; Florida Institute of Technology	Fitzgerald, GA (corresponding author), 153 Johnson Pavil,3600 Hamilton Walk, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Rokach, Joshu/0000-0003-1814-7505	NHLBI NIH HHS [HL 5400] Funding Source: Medline; NIA NIH HHS [AG 09215, AG-10124] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009215, P30AG010124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARNOLD SE, 1995, AM J PSYCHIAT, V152, P731; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BALAZS L, 1994, NEUROCHEM RES, V19, P1131, DOI 10.1007/BF00965146; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; Delanty N, 1997, CIRCULATION, V95, P2492, DOI 10.1161/01.CIR.95.11.2492; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; Goedert M., 1997, MOL GENETIC BASIS NE, P613; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Hayn M, 1996, LIFE SCI, V59, P537, DOI 10.1016/0024-3205(96)00334-7; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Lovell MA, 1997, NEUROBIOL AGING, V18, P457, DOI 10.1016/S0197-4580(97)00108-5; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Lyras L, 1997, J NEUROCHEM, V68, P2061; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Montine KS, 1997, J NEUROPATH EXP NEUR, V56, P866, DOI 10.1097/00005072-199708000-00004; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; OGOROCHI T, 1984, J NEUROCHEM, V43, P71, DOI 10.1111/j.1471-4159.1984.tb06680.x; PALMER AM, 1994, BRAIN RES, V645, P338, DOI 10.1016/0006-8993(94)91670-5; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; REILLY M, 1998, IN PRESS CIRCULATION; Reilly MP, 1997, CIRCULATION, V96, P3314; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMIDT ML, 1991, LAB INVEST, V64, P352; Schmidt ML, 1996, ACTA NEUROPATHOL, V91, P475, DOI 10.1007/s004010050454; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478	51	352	364	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1777	1783		10.1096/fasebj.12.15.1777	http://dx.doi.org/10.1096/fasebj.12.15.1777			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837868				2022-12-28	WOS:000077574500020
J	Palomino, T; Sanchez-Pacheco, A; Pena, P; Aranda, A				Palomino, T; Sanchez-Pacheco, A; Pena, P; Aranda, A			A direct protein-protein interaction is involved in the cooperation between thyroid hormone and retinoic acid receptors and the transcription factor GHF-1	FASEB JOURNAL			English	Article						growth hormone gene; transcriptional regulation; nuclear receptors	RAT GROWTH-HORMONE; GENE-EXPRESSION; NUCLEAR RECEPTOR; FACTOR GHF-1/PIT-1; FACTOR TFIIB; ACTIVATION; PIT-1; PROMOTER; ELEMENTS; TRANSACTIVATION	The nuclear receptors for thyroid hormone (TRs) and retinoic acid (RARs and RXRs) cooperate with the pituitary-specific transcription factor GHF-1 to activate the rat growth hormone (GH) gene, The GH promoter contains a hormone response element (HRE), which binds TR/RXR and RAR/RXR heterodimers, located close to two binding sites for GHF-1, GHF-1 inhibits binding of TR/RXR and RAR/RXR heterodimers to an isolated HRE, Similarly, the receptors inhibit binding of GHF-1 to its cognate site. These results suggest the existence of direct protein to protein interactions between the receptors and the pituitary transcription factor. This was confirmed by in vitro binding studies with GST fusion proteins, which demonstrated a strong association of GHF-1 with RXR and a weaker interaction with RAR and TR, GHF-1 and the receptor heterodimers form a ternary complex with a fragment of the rat GH promoter, which contains binding sites for both, and GHF-1 increases receptor binding to the promoter when present in limiting conditions. These results suggest that the synergistic activation of the rat GH gene involves protein-DNA interactions as well as a physical association between the nuclear receptors and the pituitary-specific transcription factor GHF-1.-Palomino, T., Sanchez-Pacheco, A. Pena, P., Aranda, A. A direct protein-to-protein interaction is involved in the cooperation between thyroid hormone and retinoic acid receptors and the transcription factor GHF-1.	CSIC, Inst Invest Biomed, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Aranda, A (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.		Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589; Sanchez Pacheco, Aurora/0000-0002-7776-2594				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHAMBON P, 1996, FASEB J, V10, P950; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DESAIYAJNIK V, 1995, J VIROL, V69, P5103, DOI 10.1128/JVI.69.8.5103-5112.1995; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GARCIAVILLALBA P, 1993, BIOCHEM BIOPH RES CO, V19, P580; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; LIRA SA, 1993, MOL ENDOCRINOL, V7, P694, DOI 10.1210/me.7.5.694; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Sanchez-Pacheco A, 1998, FEBS LETT, V422, P103, DOI 10.1016/S0014-5793(97)01609-8; SANCHEZPACHECO A, 1995, ENDOCRINOLOGY, V136, P5391, DOI 10.1210/en.136.12.5391; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; YE ZS, 1988, J BIOL CHEM, V263, P7821; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	31	29	30	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1201	1209		10.1096/fasebj.12.12.1201	http://dx.doi.org/10.1096/fasebj.12.12.1201			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737723				2022-12-28	WOS:000075738500015
J	Schmid, E; El Benna, J; Galter, D; Klein, G; Droge, W				Schmid, E; El Benna, J; Galter, D; Klein, G; Droge, W			Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation	FASEB JOURNAL			English	Article						redox regulation; signal transduction; glutathione; CHO-HIR; BCNU	CELL HEXOSE TRANSPORT; RAT ADIPOCYTES; GLUTATHIONE-REDUCTASE; HYDROGEN-PEROXIDE; INTACT-CELLS; PHOSPHORYLATION; VANADATE; AGENTS; THIOL; INVOLVEMENT	Induction of tyrosine kinase activity of the insulin receptor (IR) beta-chain is believed to require its autophosphorylation at Tyr(1162), Tyr(1163), and Tyr(1158). However, the mechanism of the initial phosphorylation is poorly understood. We show that treatment of IR-transfected Chinese hamster ovary cells with antioxidants inhibits insulin responsiveness. Conversely, partial inhibition of glutathione biosynthesis by buthionine sulfoximine (BSO) and glutathione reductase by 1,3-bis- (2-chloroethyl)-l-nitrosourea (BCNU), i.e., procedures that intracellularly induce mildly oxidative conditions, caused a decrease in IR beta-chain sulfhydryl groups and enhanced synergistically the induction of IR tyrosine phosphorylation by insulin. The IR beta-chain from cells treated with BSO/BCNU in the absence of insulin was not detectably tyrosine phosphorylated, but nevertheless was functionally altered, as demonstrated in vitro by a moderate kinase activity at low ATP concentrations (5 nM) and a strong kinase activity at 25 mu M ATP. This activity was found to be specific for tyrosine (not for serine or threonine), and tryptic peptide maps indicated that it is more selective than that induced by insulin. Moreover, the kinase activity from BSO/BCNU-treated cells showed a spontaneous decay that was not prevented by the phosphatase inhibitor vanadate. Together, these results suggest that optimal insulin responsiveness may require a process of 'redox priming' of the IR beta-chain that involves structural and functional changes in the absence of detectable tyrosine phosphorylation of the beta-chain.-Schmid, E., El Benna, J., Gaiter, D., Klein, G., Droge, W. Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation.	Deutsch Krebsforschungszentrum, Div Immunochem, D-69120 Heidelberg, Germany; INSERM, U294, F-75018 Paris, France; Lab Immunohemato, F-75018 Paris, France	Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm)	Droge, W (corresponding author), Deutsch Krebsforschungszentrum, Div Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Galter, Dagmar/C-4826-2011	Galter, Dagmar/0000-0001-6485-6244				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERNIER M, 1995, BIOCHEMISTRY-US, V34, P8357, DOI 10.1021/bi00026a017; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; CZECH MP, 1976, J BIOL CHEM, V251, P1164; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Gross A, 1996, AIDS RES HUM RETROV, V12, P1639, DOI 10.1089/aid.1996.12.1639; HAYES GR, 1987, P NATL ACAD SCI USA, V84, P8115, DOI 10.1073/pnas.84.22.8115; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HOMMES MJT, 1991, METABOLISM, V40, P651, DOI 10.1016/0026-0495(91)90059-6; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KOSHIO O, 1988, BIOCHEM J, V250, P95, DOI 10.1042/bj2500095; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LUDVIGSEN C, 1982, METABOLISM, V31, P284, DOI 10.1016/0026-0495(82)90066-X; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Seres T, 1996, J IMMUNOL, V156, P1973; TAMURA S, 1984, J BIOL CHEM, V259, P6650; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v	35	64	64	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					863	870		10.1096/fasebj.12.10.863	http://dx.doi.org/10.1096/fasebj.12.10.863			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657526				2022-12-28	WOS:000074580100011
J	Skaper, SD; Ancona, B; Facci, L; Franceschini, D; Giusti, P				Skaper, SD; Ancona, B; Facci, L; Franceschini, D; Giusti, P			Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway	FASEB JOURNAL			English	Article						synaptic transmission; hippocampus; excitotoxicity; NO center dot; ROS; neuroprotection; GSH; astrocytes	NITRIC-OXIDE SYNTHASE; GLUTAMATE NEUROTOXICITY; PYRAMIDAL NEURONS; NERVOUS-SYSTEM; CELL-CULTURE; BRAIN-DAMAGE; GLUTATHIONE; NEURODEGENERATION; EXCITOTOXICITY; DEGENERATION	The mechanisms by which neurons die after stroke and status epilepticus and related neuropathological conditions are unclear, but may involve voltage-dependent Na+ channels, glutamate receptors, and nitric oxide (NO.). These questions were investigated using an in vitro primary cell culture model in which hippocampal pyramidal neurons undergo a gradual and delayed neurodegeneration induced by enhanced excitatory neurotransmission. When cells were treated with Mg2+-free, glycine-supplemented medium for a brief period (15 nain) and examined 24 h later, similar to 30-40% of the neurons had died. Cell death could be inhibited by blockers of voltage-sensitive Na+ channels and by N-methyl-D-aspartate receptor antagonists. Application of either the endogenous antioxidant melatonin (EC50: 19.2+/-2.8 mu M) or the NO. synthase inhibitor N-omega-nitro-L-arginine after, but not during, Mg2+-free exposure protected against delayed neuronal death; significant neuroprotection was observed when the addition was delayed for up to 4 h, This operational time window suggests that an enduring production of NO. and reactive oxygen species from neuronal sources is responsible for delayed cell death. A role fbr reactive oxygen species in this injury process was strengthened by the finding that, whereas neurons cocultured with astroglia were more resistant to killing, agents capable of lowering intracellular glutathione negated this protection. Because secretion levels of melatonin are decreased with aging, reductions in this pineal hormone may place neurons at a heightened risk for damage by excitatory synaptic transmission.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy; Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; CNR, Biopolymer Res Ctr, I-35131 Padua, Italy	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.	stephenskaper-1@sbphrd.com; giusti@dfem.unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				ABELE AE, 1990, NEURON, V4, P413, DOI 10.1016/0896-6273(90)90053-I; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bolanos JP, 1996, FREE RADICAL BIO MED, V21, P995, DOI 10.1016/S0891-5849(96)00240-7; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLIFFORD DB, 1989, EXP NEUROL, V105, P272, DOI 10.1016/0014-4886(89)90130-1; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROUCHER MJ, 1982, SCIENCE, V216, P899, DOI 10.1126/science.7079744; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Desagher S, 1996, J NEUROSCI, V16, P2553; DUBOCOVICH ML, 1988, J PHARMACOL EXP THER, V246, P902; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hou JGG, 1997, J NEUROCHEM, V69, P76; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; IGUCHI H, 1982, J CLIN ENDOCR METAB, V55, P27, DOI 10.1210/jcem-55-1-27; KLATT P, 1994, J BIOL CHEM, V269, P1674; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; Leist M, 1997, EUR J NEUROSCI, V9, P1488, DOI 10.1111/j.1460-9568.1997.tb01503.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Meister A., 1995, BIOTHIOLS HLTH DIS, P165; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MODY I, 1987, J NEUROPHYSIOL, V57, P869, DOI 10.1152/jn.1987.57.3.869; MURPHY SN, 1989, MOL PHARMACOL, V35, P671; Olney J W, 1986, Adv Neurol, V44, P857; OLNEY JW, 1969, SCIENCE, V166, P383; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; SKAPER SD, 1991, NEUROSCI LETT, V126, P98, DOI 10.1016/0304-3940(91)90381-3; Skaper SD, 1996, J NEUROCHEM, V66, P1157; SKAPER SD, 1998, IN PRESS J NEUROCHEM; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SOUETRE E, 1989, AM J PSYCHIAT, V146, P1037; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Tan DX, 1993, ENDOCR J, V1, P57; VIBULSRETH S, 1987, BRAIN RES, V422, P303, DOI 10.1016/0006-8993(87)90937-1; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	56	74	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1998	12	9					725	731		10.1096/fasebj.12.9.725	http://dx.doi.org/10.1096/fasebj.12.9.725			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619451				2022-12-28	WOS:000074011000011
J	Oehler, R; Zellner, M; Hefel, B; Weingartmann, G; Spittler, A; Struse, HM; Roth, E				Oehler, R; Zellner, M; Hefel, B; Weingartmann, G; Spittler, A; Struse, HM; Roth, E			Influence of heat shock on cell volume regulation: protection from hypertonic challenge in a human monocyte cell line	FASEB JOURNAL			English	Article						DIDS; DMA; ion transport; Na+/H+ exchange; intracellular water space; heat treatment	INTRACELLULAR PH; A-431 CELLS; TUMOR-CELLS; HYPERTHERMIA; PROTEIN; MECHANISMS; INCREASES; EXCHANGE; CHLORIDE; DISEASE	Heat shock response provides cells with higher tolerance against a variety of insults such as heavy metals, reperfusion injury, and endotoxin. In addition, heat treatment is known to affect ion transport mechanisms associated with vital cellular processes, including cell volume regulation. However, there has been no reports to date of a heat shock effect on cellular volume regulation itself. The aim of our study was to investigate whether the heat shock response influences volume regulation of cells. Human promonocytic U937 cells display an increase in volume in response to osmotic shrinkage. This regulatory volume increase (RVI) is mediated mainly by ion antiporters. U937 cells exposed to a temperature of 45 degrees C for 10 min (heat shock) show an enhancement of RVI after hypertonic challenge compared with untreated cells. Also, heat-treated cells display a lower intracellular pH (pH(i)) than untreated cells; similar control mechanisms are believed to be involved in regulating both pH(i) and RVI. In agreement with this, heat-shocked cells demonstrated increased activity of an HCO3--independent/DIDS-sensitive pH(i) down-regulator, postulated to be a Cl-/HCO3- exchange. We suggest that heat shock-mediated RVI enhancement is at least partially mediated by an increased Cl-/HCO3- exchange. Our results indicate that heat shock of U937 cells activates a hitherto unknown cytoprotective effect that may help cells to overcome hypertonic challenge.	Univ Vienna, Dept Surg, Surg Res Labs, A-1090 Vienna, Austria; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Vienna; University of Texas System; University of Texas Medical Branch Galveston	Oehler, R (corresponding author), Allgemeines Krankenhaus 8G905, Surg Res Labs, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.oehler@akh-wien.ac.at	Oehler, Rudolf/ABC-7836-2020; Zellner, Maria/AAC-6634-2019	Oehler, Rudolf/0000-0003-2891-7155; Zellner, Maria/0000-0003-2245-2158; Spittler, Andreas/0000-0003-2657-6836				Amorino GP, 1996, J MEMBRANE BIOL, V152, P217, DOI 10.1007/s002329900099; Ding XZ, 1996, J INVEST MED, V44, P144; EISNER DA, 1989, J PHYSIOL-LONDON, V411, P393, DOI 10.1113/jphysiol.1989.sp017580; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAUSSINGER D, 1995, J HEPATOL, V22, P94, DOI 10.1016/0168-8278(95)80266-5; HAUSSINGER D, 1993, LANCET, V341, P1330, DOI 10.1016/0140-6736(93)90828-5; HAUSSINGER D, 1991, BIOCHEM CELL BIOL, V69, P1; HOLDEN HT, 1973, TISSUE CULTURE METHO, P408; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; KALTENBACH JP, 1958, EXP CELL RES, V15, P112, DOI 10.1016/0014-4827(58)90067-3; KIANG JG, 1990, AM J PHYSIOL, V259, pC727, DOI 10.1152/ajpcell.1990.259.5.C727; LADOUX A, 1988, FEBS LETT, V234, P353, DOI 10.1016/0014-5793(88)80115-7; LADOUX A, 1987, EUR J BIOCHEM, V170, P43, DOI 10.1111/j.1432-1033.1987.tb13665.x; LUDT J, 1993, J MEMBRANE BIOL, V134, P143; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MIYAHARA M, 1993, BIOCHIM BIOPHYS ACTA, V1177, P61, DOI 10.1016/0167-4889(93)90158-L; Oehler R, 1996, ANAL BIOCHEM, V241, P269, DOI 10.1006/abio.1996.0412; RESTREPO D, 1988, J GEN PHYSIOL, V92, P489, DOI 10.1085/jgp.92.4.489; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VILLAR J, 1994, CRIT CARE MED, V22, P914; YI PN, 1983, RADIAT RES, V93, P534, DOI 10.2307/3576032	22	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1998	12	7					553	560		10.1096/fasebj.12.7.553	http://dx.doi.org/10.1096/fasebj.12.7.553			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576482				2022-12-28	WOS:000073523100005
J	Fabbrini, MS; Carpani, D; Soria, MR; Ceriotti, A				Fabbrini, MS; Carpani, D; Soria, MR; Ceriotti, A			Cytosolic immunization allows the expression of preATF-saporin chimeric toxin in eukaryotic cells	FASEB JOURNAL			English	Article						ribosome-inactivating proteins; urokinase receptor; urokinase amino-terminal fragment; intracellular immunization; anti-cancer therapy	RIBOSOME-INACTIVATING PROTEINS; UROKINASE-PLASMINOGEN-ACTIVATOR; XENOPUS OOCYTES; SAPONARIA-OFFICINALIS; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; MESSENGER-RNAS; KILLER-CELLS; WILD-TYPE; RECEPTOR	In this work, we have devised an intracellular immunization strategy for the expression in high amounts of ATF-saporin, a targeted chimeric toxin constituted by the ATF receptor binding domain of human urokinase and the plant ribosome-inactivating protein saporin, which has been shown to be highly cytotoxic to target cells. This strategy may allow the production of highly toxic secretory proteins in eukaryotic cells, avoiding cell suicide caused by autointoxication. The procedure consists of equipping host cells with cytosolic neutralizing antibodies directed toward the toxic domain of the heterologous polypeptide, We show that this intracellular immunization is essential for the synthesis of correctly folded, biologically active ATF-SAP in the high amounts needed to investigate its in vivo antimetastatic potential. Such a strategy should be generally useful for the production of toxic molecules of therapeutic value whose folding and maturation require transit through the eukaryotic secretory pathway.	Ist Sci San Raffaele, Dibit Dept Biol & Technol Res, I-20132 Milan, Italy; CNR, Ist Biointesi Vegetali, I-20133 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR)	Fabbrini, MS (corresponding author), Ist Sci San Raffaele, Dibit Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.	fabbrini.serena@hsr.it	Ceriotti, Aldo/A-1448-2016	Ceriotti, Aldo/0000-0002-8230-8863				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BENATTI L, 1989, EUR J BIOCHEM, V183, P465, DOI 10.1111/j.1432-1033.1989.tb14951.x; BIOCCA S, 1994, BIO-TECHNOL, V12, P396, DOI 10.1038/nbt0494-396; BLASI F, 1998, BIOCHIM BIOPHYS ACTA, V1423, pR35; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDAZZA A, 1991, J BIOTECHNOL, V20, P201, DOI 10.1016/0168-1656(91)90228-N; CARZANIGA R, 1994, PLANTA, V194, P461, DOI 10.1007/BF00714457; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, EUR J BIOCHEM, V232, P165, DOI 10.1111/j.1432-1033.1995.tb20795.x; Ceriotti A, 1995, Methods Mol Biol, V37, P151; CERIOTTI A, 1991, EUR J BIOCHEM, V202, P959, DOI 10.1111/j.1432-1033.1991.tb16456.x; Ceriotti A, 1995, METHOD CELL BIOL, V50, P295, DOI 10.1016/S0091-679X(08)61038-9; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; CORTI A, 1989, THROMB HAEMOSTASIS, V62, P934; ENDO Y, 1988, BIOCHEM BIOPH RES CO, V150, P1032, DOI 10.1016/0006-291X(88)90733-4; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; FABBRINI MS, 1993, P NATL ACAD SCI USA, V90, P3923, DOI 10.1073/pnas.90.9.3923; Fitzgerald D, 1996, SEMIN CANCER BIOL, V7, P87, DOI 10.1006/scbi.1996.0013; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; Frigerio L, 1998, J BIOL CHEM, V273, P14194, DOI 10.1074/jbc.273.23.14194; Galili G, 1995, METHOD CELL BIOL, V50, P497, DOI 10.1016/S0091-679X(08)61053-5; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; LEITZGEN K, 1998, CHEMTRACTS BIOCH MOL, V11, P423; Lord JM, 1998, J CELL BIOL, V140, P733; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; OLSON D, 1992, J BIOL CHEM, V267, P9129; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Pastan I, 1997, BBA-REV CANCER, V1333, pC1, DOI 10.1016/S0304-419X(97)00021-8; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; RICHTER JD, 1981, CELL, V27, P183, DOI 10.1016/0092-8674(81)90372-X; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sambrook T, 1989, MOL CLONING LAB MANU; SANTORO C, 1986, NUCLEIC ACIDS RES, V14, P2863, DOI 10.1093/nar/14.7.2863; SAXENA SK, 1989, J BIOL CHEM, V264, P596; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; Williams MD, 1998, PROTEIN EXPRES PURIF, V13, P210, DOI 10.1006/prep.1998.0900; Yang AG, 1997, NAT BIOTECHNOL, V15, P46, DOI 10.1038/nbt0197-46	47	22	24	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					391	398		10.1096/fasebj.14.2.391	http://dx.doi.org/10.1096/fasebj.14.2.391			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657995				2022-12-28	WOS:000085184800018
J	Kay, BK; Williamson, MP; Sudol, P				Kay, BK; Williamson, MP; Sudol, P			The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains	FASEB JOURNAL			English	Review							EPITHELIAL SODIUM-CHANNEL; SRC SH3 DOMAIN; ALDRICH-SYNDROME PROTEIN; METABOTROPIC GLUTAMATE RECEPTORS; AFFINITY-BASED SELECTION; YES-ASSOCIATED PROTEIN; SPLIT-POOL SYNTHESIS; TYROSINE KINASE HCK; WW DOMAIN; C-ABL	A common focus among molecular and cellular biologists is the identification of proteins that interact with each other. Yeast two-hybrid, cDNA expression library screening, and coimmunoprecipitation experiments are powerful methods for identifying novel proteins that bind to one's favorite protein for the purpose of learning more regarding its cellular function, These same techniques, coupled with truncation and mutagenesis experiments, have been used to define the region of interaction between pairs of proteins. One conclusion from this work is that many interactions occur over short regions, often less than 10 amino acids in length within one protein. For example, mapping studies and 3-dimensional analyses of antigen-antibody interactions have revealed that epitopes are typically 4-7 residues long (1), Other examples include protein-interaction modules, such as Src homology (SH) 2 and 3 domains, phosphotyrosine binding domains (PTB), postsynaptic density/disc-large/ZO1 (PDZ) domains, WW domains, Eps15 homology (EH) domains, and 14-3-3 proteins that typically recognize linear regions of 3-9 amino acids. Each of these domains has been the subject of recent reviews published elsewhere (2-7), Among the primary structures of many ligands for protein-protein interactions, the amino acid proline is critical. In particular, SH3, WW, and several new protein-interaction domains prefer ligand sequences that are proline-rich, In addition, even though ligands for EH domains and 14-3-3 domains are not proline-rich, they do include a single proline residue, This review highlights the analysis of those protein-protein interactions that involve proline residues, the biochemistry of proline, and current drug discovery efforts based on proline peptidomimetics.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	University of Wisconsin System; University of Wisconsin Madison; University of Sheffield; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Kay, BK (corresponding author), Univ Wisconsin, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	bkkay@facstaff.wisc.edu		Williamson, Mike/0000-0001-5572-1903				ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chan YR, 1998, J BIOL CHEM, V273, P28978, DOI 10.1074/jbc.273.44.28978; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Combs AP, 1996, J AM CHEM SOC, V118, P287, DOI 10.1021/ja953750v; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; Creamer TP, 1998, PROTEINS, V33, P218, DOI 10.1002/(SICI)1097-0134(19981101)33:2<218::AID-PROT6>3.0.CO;2-E; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1996, CHEM BIOL, V3, P661, DOI 10.1016/S1074-5521(96)90134-9; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; Ibragimova GT, 1998, BIOPHYS J, V74, P2906, DOI 10.1016/S0006-3495(98)77997-4; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; Kapoor TM, 1998, J AM CHEM SOC, V120, P23, DOI 10.1021/ja972728u; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kurakin A, 1998, J PEPT RES, V52, P331; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Linn H, 1997, BIOL CHEM, V378, P531, DOI 10.1515/bchm.1997.378.6.531; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Morken JP, 1998, J AM CHEM SOC, V120, P30, DOI 10.1021/ja972729m; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; Ostrander DB, 1999, EUR J BIOCHEM, V262, P26, DOI 10.1046/j.1432-1327.1999.00354.x; Parrini MC, 1999, CHEM BIOL, V6, P679, DOI 10.1016/S1074-5521(00)80015-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Petrella EC, 1996, BIOCHEMISTRY-US, V35, P16535, DOI 10.1021/bi961498d; Ponting CP, 1997, J MOL MED-JMM, V75, P769, DOI 10.1007/s001090050166; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Raj PA, 1996, BIOCHEMISTRY-US, V35, P4314, DOI 10.1021/bi951681r; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sanchez C, 1996, EUR J BIOCHEM, V241, P765, DOI 10.1111/j.1432-1033.1996.00765.x; SARASTE M, 1994, NAT STRUCT BIOL, V1, P835, DOI 10.1038/nsb1294-835; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Shi JS, 1996, P NATL ACAD SCI USA, V93, P6014, DOI 10.1073/pnas.93.12.6014; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stapley BJ, 1999, PROTEIN SCI, V8, P587; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Stauffer TP, 1997, BIOCHEMISTRY-US, V36, P9388, DOI 10.1021/bi970781p; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Wu WJ, 1998, BIOPOLYMERS, V45, P381, DOI 10.1002/(SICI)1097-0282(19980415)45:5<381::AID-BIP6>3.0.CO;2-H; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; YAO J, 1994, J MOL BIOL, V243, P754, DOI 10.1016/0022-2836(94)90045-0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhang R, 1998, J AM CHEM SOC, V120, P3894, DOI 10.1021/ja972494e; Zhang R, 1999, J ORG CHEM, V64, P330, DOI 10.1021/jo981814p; Zhao H, 1998, J BIOL CHEM, V273, P12061, DOI 10.1074/jbc.273.20.12061	138	1024	1040	5	119	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					231	241		10.1096/fasebj.14.2.231	http://dx.doi.org/10.1096/fasebj.14.2.231			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657980				2022-12-28	WOS:000085184800002
J	Yoon, SS; Nakamura, H; Carroll, NM; Bode, BP; Chiocca, EA; Tanabe, KK				Yoon, SS; Nakamura, H; Carroll, NM; Bode, BP; Chiocca, EA; Tanabe, KK			An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma	FASEB JOURNAL			English	Article						HSV1; gene therapy; ribonucleotide reductase	EXPERIMENTAL BRAIN-TUMORS; THYMIDINE KINASE GENE; RIBONUCLEOTIDE REDUCTASE; ANTITUMOR-ACTIVITY; MALIGNANT GLIOMAS; VIRAL MUTANT; HEPATITIS-B; P53 STATUS; REPLICATION; THERAPY	Viruses used for gene therapy are usually genetically modified to deliver therapeutic transgenes and prevent viral replication. in contrast, replication-competent viruses may be used for cancer therapy because replication of some viruses within cancer cells can result in their destruction (oncolysis). Viral ribonucleotide reductase expression is defective in the HSV1 mutant hrR3, Cellular ribonucleotide reductase, which is scarce in normal liver and abundant in liver metastases, can substitute for its viral counterpart to allow hrR3 replication in infected cells. Two or three log orders more of hrR3 virions are produced from infection of colon carcinoma cells than from infection of normal hepatocytes in viral replication assays. This viral replication is oncolytic, A single intravascular administration of hrR3 into immune-competent mice bearing diffuse Liver metastases dramatically reduces tumor burden. hrR3-mediated tumor inhibition is equivalent in immune-competent and immune-incompetent mice, suggesting that viral oncolysis and not the host immune response is the primary mechanism of tumor destruction. HSV1-mediated oncolysis of diffuse liver metastases is effective in mice preimmunized against HSV1, These results indicate that replication-competent HSV1 mutants hold significant promise as cancer therapeutic agents.	Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Tanabe, KK (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, Dept Surg, Cox 626,100 Blossom St, Boston, MA 02114 USA.				NCI NIH HHS [CA71345, CA60011, CA64454] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA071345, R29CA064454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALZARINI J, 1993, J BIOL CHEM, V268, P6332; Becker TM, 1996, SEX TRANSM DIS, V23, P138, DOI 10.1097/00007435-199603000-00009; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; BOVIATSIS EJ, 1994, CANCER RES, V54, P5745; BOVIATSIS EJ, 1994, GENE THER, V1, P323; BREAKEFIELD XO, 1991, NEW BIOL, V3, P203; BREAKEFIELD XO, 1995, INTERNET BOOK GENE T, P41; Carroll NM, 1997, J SURG RES, V69, P413, DOI 10.1006/jsre.1997.5089; Carroll NM, 1996, ANN SURG, V224, P323, DOI 10.1097/00000658-199609000-00008; Chase M, 1998, NAT BIOTECHNOL, V16, P444, DOI 10.1038/nbt0598-444; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DELUCA NA, 1985, J VIROL, V56, P558, DOI 10.1128/JVI.56.2.558-570.1985; Dranoff G, 1998, J CLIN ONCOL, V16, P2548, DOI 10.1200/JCO.1998.16.7.2548; ENZMINGER WD, 1983, SEMIN ONCOL, V10, P176; GIAVAZZI R, 1986, J NATL CANCER I, V77, P1303; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Herrlinger U, 1998, GENE THER, V5, P809, DOI 10.1038/sj.gt.3300643; Higgins GM, 1931, ARCH PATHOL, V12, P186; JOHNSON PA, 1992, MOL BRAIN RES, V12, P95, DOI 10.1016/0169-328X(92)90072-J; JOHNSON PA, 1992, J VIROL, V66, P2952, DOI 10.1128/JVI.66.5.2952-2965.1992; JOLLY D, 1995, INTERNET BOOK GENE T, P3; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; LELIE PN, 1987, J MED VIROL, V23, P297, DOI 10.1002/jmv.1890230313; LI AP, 1992, J TISSUE CULT METHOD, V14, P139; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MINETA T, 1994, CANCER RES, V54, P3963; MORRISON LA, 1994, J VIROL, V68, P689, DOI 10.1128/JVI.68.2.689-696.1994; NIDERHUBER JE, 1993, CANC PRINICIPLES PRA, P2201; PAGANO JS, 1981, MED MICROBIOLOGY INF, P541; READ GS, 1983, J VIROL, V46, P498, DOI 10.1128/JVI.46.2.498-512.1983; RICE SA, 1993, J VIROL, V67, P1778, DOI 10.1128/JVI.67.4.1778-1787.1993; Roizman B, 1996, FIELDS VIROLOGY, P2231; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Toda M, 1998, J IMMUNOL, V160, P4457; WEISS L, 1986, J PATHOL, V150, P195, DOI 10.1002/path.1711500308; Yoon SS, 1998, ANN SURG, V228, P366, DOI 10.1097/00000658-199809000-00009	44	98	108	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					301	311		10.1096/fasebj.14.2.301	http://dx.doi.org/10.1096/fasebj.14.2.301			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657986				2022-12-28	WOS:000085184800009
J	Drexler, HCA; Risau, W; Konerding, MA				Drexler, HCA; Risau, W; Konerding, MA			Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; proteolysis; cell cycle; p27(Kip1)	NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; TUMOR ANGIOGENESIS FACTOR; C-MYC PROTEIN; BREAST-CANCER; GROWTH-FACTOR; THYMOCYTE APOPTOSIS; U937 CELLS; IN-VIVO	Proteolysis mediated by the ubiquitin-proteasome system has been implicated in the regulation of programmed cell death. Here we investigated the differential effects of proteasomal inhibitors on the viability of proliferating and quiescent primary endothelial cells in vitro and in vivo. Subconfluent, proliferating cells underwent carbobenzoxy-L-isoleucyl-gamma-t-butyl-L-glutamyl-L-alanyl-L-leucinal (PSI)-induces apoptosis at low concentrations (EC50 = 24 nM), whereas at least 340-fold higher concentrations of PSI were necessary to obtain the same effect in confluent, contact-inhibited cells. PSI-mediated cell death could be blocked by a caspase-3 inhibitor (Ac-DEVD-H), but not by a caspase-1 inhibitor (Ac-YVAD-H), suggesting that a caspase-3-like enzyme is activated during PSI-induced apoptosis. When applied to the embryonic chick chorioallantoic membrane, a rapidly expanding tissue, PSI induced massive apoptosis also in vivo. PSI treatment of the CAM led to the formation of areas devoid of blood flow due to the induction of apoptosis in endothelial and other cells and to the collapse of capillaries and first order vessels. Our results demonstrate that proteasomal inhibitors inhibitors such as PSI may prove effective as novel anti-angiogenic and anti-neoplastic substances.	Max Planck Inst Physiol & Klin Forsch, Abt Mol Zellbiol, D-61231 Bad Nauheim, Germany; Univ Mainz, Inst Anat, D-55099 Mainz, Germany	Max Planck Society; Johannes Gutenberg University of Mainz	Drexler, HCA (corresponding author), Max Planck Inst Physiol & Klin Forsch, Abt Mol Zellbiol, Parkstr 1, D-61231 Bad Nauheim, Germany.		Drexler, Hannes/AAI-3449-2020					Adams J, 1999, CANCER RES, V59, P2615; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown JP, 1997, BBA-REV CANCER, V1332, pO1, DOI 10.1016/S0304-419X(96)00048-0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; Dimitropoulou C, 1998, Angiogenesis, V2, P255, DOI 10.1023/A:1009210918738; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DREXLER HCA, 1988, APOPTOSIS, V3, P1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1974, CANCER RES, V34, P2109; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lockyer JM, 1998, CIRC RES, V82, P314, DOI 10.1161/01.RES.82.3.314; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mitchell CA, 1998, DEV DYNAM, V213, P322, DOI 10.1002/(SICI)1097-0177(199811)213:3<322::AID-AJA8>3.0.CO;2-E; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Orlowski RZ, 1998, CANCER RES, V58, P4342; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313, DOI 10.3109/10520296009114754; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SCHWARTZ SM, 1978, IN VITRO CELL DEV B, V14, P966, DOI 10.1007/BF02616210; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tanimoto Y, 1997, J BIOCHEM-TOKYO, V121, P542; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450	61	134	138	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2000	14	1					65	77		10.1096/fasebj.14.1.65	http://dx.doi.org/10.1096/fasebj.14.1.65			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627281				2022-12-28	WOS:000084784700009
J	Singbartl, K; Green, SA; Ley, K				Singbartl, K; Green, SA; Ley, K			Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure	FASEB JOURNAL			English	Article						neutrophils; adhesion molecules; renal function; gene targeting; antibodies	ISCHEMIC-REPERFUSION INJURY; GRANULE MEMBRANE-PROTEIN; RAT-KIDNEY; ENDOTHELIAL-CELLS; IN-VIVO; NEUTROPHIL; ADHESION; ANTIBODY; ICAM-1; MICE		Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Munster, Klin & Poliklin Anasthesiol, Munster, Germany	University of Virginia; University of Virginia; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster	Ley, K (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biomed Engn, Box 377, Charlottesville, VA 22908 USA.	kf13f@virginia.edu			NHLBI NIH HHS [HL-54136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BREZIS M, 1995, NEW ENGL J MED, V332, P647, DOI 10.1056/NEJM199503093321006; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Diacovo TG, 1996, BLOOD, V88, P146; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Goussev AV, 1998, J NEUROL SCI, V161, P16, DOI 10.1016/S0022-510X(98)00262-7; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; Haller H, 1996, KIDNEY INT, V50, P473, DOI 10.1038/ki.1996.338; HELLBERG POA, 1989, KIDNEY INT, V36, P555, DOI 10.1038/ki.1989.230; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; JONSON JP, 1995, ACUTE RENAL FAILURE, P28; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KLAUSNER JM, 1989, AM J PHYSIOL, V256, pF794, DOI 10.1152/ajprenal.1989.256.5.F794; Koo DDH, 1998, AM J PATHOL, V153, P557, DOI 10.1016/S0002-9440(10)65598-8; Lefer DJ, 1996, AM J PHYSIOL-HEART C, V270, pH88, DOI 10.1152/ajpheart.1996.270.1.H88; Linas S, 1997, AM J PHYSIOL-RENAL, V272, pF48, DOI 10.1152/ajprenal.1997.272.1.F48; LINAS SL, 1995, KIDNEY INT, V48, P1584, DOI 10.1038/ki.1995.451; MASON J, 1989, MINER ELECTROL METAB, V15, P114; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MENGER MD, 1994, MICROSURG, V15, P383, DOI 10.1002/micr.1920150605; Muller JM, 1997, J SURG RES, V71, P1, DOI 10.1006/jsre.1997.5132; Ohnishi M, 1999, EUR J PHARMACOL, V366, P271, DOI 10.1016/S0014-2999(98)00923-6; OLOF P, 1990, AM J PHYSIOL, V258, pF1018, DOI 10.1152/ajprenal.1990.258.4.F1018; PALLER MS, 1989, J LAB CLIN MED, V113, P379; RABB H, 1994, AM J PHYSIOL-RENAL, V267, pF1052, DOI 10.1152/ajprenal.1994.267.6.F1052; Rabb H, 1996, AM J PHYSIOL-RENAL, V271, pF408, DOI 10.1152/ajprenal.1996.271.2.F408; RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779; Rabb H, 1998, CLIN EXP PHARMACOL P, V25, P286, DOI 10.1111/j.1440-1681.1998.t01-1-.x; RACUSEN LC, 1995, ACUTE RENAL FAILURE, P1; SANDERS WE, 1992, BLOOD, V80, P795; Singh I, 1998, TRANSPLANT P, V30, P2324, DOI 10.1016/S0041-1345(98)00640-X; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; TETTA C, 1995, ACUTE RENAL FAILURE, P64; THORNTON MA, 1989, AM J PATHOL, V135, P509; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Zizzi HC, 1997, J PEDIATR SURG, V32, P1010, DOI 10.1016/S0022-3468(97)90388-2	45	159	170	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					48	54		10.1096/fasebj.14.1.48	http://dx.doi.org/10.1096/fasebj.14.1.48			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627279				2022-12-28	WOS:000084784700007
J	Fetrow, JS; Siew, N; Skolnick, J				Fetrow, JS; Siew, N; Skolnick, J			Structure-based functional motif identifies a potential disulfide oxidoreductase active site in the serine/threonine protein phosphatase-1 subfamily	FASEB JOURNAL			English	Article						functional genomics; function prediction; structural genomics; structure-based function annotation; fuzzy functional form	INTERLEUKIN-1 SIGNAL-TRANSDUCTION; TUMOR-NECROSIS-FACTOR; TO-FUNCTION PARADIGM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REDOX REGULATION; THIOREDOXIN; INACTIVATION; THIOLTRANSFERASE; RESOLUTION	In previous work, 3-dimensional descriptors of protein function ('fuzzy functional forms') were used to identify disulfide oxidoreductase active sites in high-resolution protein structures. During this analysis, a potential disulfide oxidoreductase active site in the serine/threonine protein phosphatase-1 (PP1) crystal structure was discovered. In PP1, the potential redox active site is located in close proximity to the phosphatase active site. This result is interesting in view of literature suggesting that serine/threonine phosphatases could be subject to redox control mechanisms within the cell; however, the actual source of this control is unknown. Additional analysis presented here shows that the putative oxidoreductase active site is highly conserved in the serine/threonine phosphatase-l subfamily, but not in the serine/threonine phosphatase-2A or -2B subfamilies. These results demonstrate the significant advantages of using structure-based motifs for protein functional site identification. First, a putative disulfide oxidoreductase active site has been identified in serine-threonine phosphatases using a descriptor built from the glutaredoxin/thioredoxin family, proteins that have no apparent evolutionary relationship whatsoever to the PPI proteins. Second, the proximity of the putative disulfide oxidoreductase active site to the phosphatase active site provides evidence toward a regulatory control mechanism. No sequence-based method could provide either piece of information.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Scripps Research Institute	Fetrow, JS (corresponding author), GeneFormat Inc, 5830 Oberlin Dr,Ste 200, San Diego, CA 92121 USA.	jacque@geneformatics.com	Kishore, Gade/C-6943-2011	Kishore, Gade/0000-0003-0911-4381; Fetrow, Jacquelyn/0000-0002-0528-2049				ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; CHAOHONG S, 1997, PROTEIN SCI, V6, P383; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Fetrow JS, 1998, J MOL BIOL, V281, P949, DOI 10.1006/jmbi.1998.1993; Fetrow JS, 1998, J MOL BIOL, V282, P703, DOI 10.1006/jmbi.1998.2061; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; GUY GR, 1993, J BIOL CHEM, V268, P2141; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Jia ZC, 1997, BIOCHEM CELL BIOL, V75, P17, DOI 10.1139/bcb-75-1-17; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEMANI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P24, DOI 10.1006/abbi.1993.1004; REY A, 1993, PROTEINS, V16, P8, DOI 10.1002/prot.340160103; SHENKIN PS, 1991, PROTEINS, V11, P297, DOI 10.1002/prot.340110408; SOULIE JM, 1985, EUR J BIOCHEM, V152, P565, DOI 10.1111/j.1432-1033.1985.tb09232.x; YANG YF, 1991, J BIOL CHEM, V266, P12766; YANG YF, 1991, J BIOL CHEM, V266, P12759; Zhang L, 1998, FOLD DES, V3, P535, DOI 10.1016/S1359-0278(98)00069-8	29	68	70	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1866	1874		10.1096/fasebj.13.13.1866	http://dx.doi.org/10.1096/fasebj.13.13.1866			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506591				2022-12-28	WOS:000083063400023
J	Patel, HJ; Belvisi, MG; Donnelly, LE; Yacoub, MH; Chung, KF; Mitchell, JA				Patel, HJ; Belvisi, MG; Donnelly, LE; Yacoub, MH; Chung, KF; Mitchell, JA			Constitutive expressions of type INOS in human airway smooth muscle cells: evidence for an antiproliferative role	FASEB JOURNAL			English	Article						hyperplasia; human respiratory tract; nitric oxide	NITRIC-OXIDE SYNTHASE; RELAXING FACTOR; HUMAN-NEUTROPHILS; L-ARGININE; RELEASE; RAT; CYCLO-OXYGENASE-2; NEUROTRANSMITTER; INHIBITORS; MESSENGER	In airway diseases, smooth muscle cells can proliferate at exaggerated rates; thus, the identification of endogenous pathways that limit proliferative responses is important. Here we show that human airway smooth muscle express type I nitric oxide synthase (NOS), which results in inhibition of DNA synthesis and cell proliferation. In addition, superoxide dismutase (SOD), a cell-permeable mimetic that increases the biological half-life and therefore enhances the biological activity of endogenously released nitric oxide (NO), or NO-releasing drugs also greatly reduce DNA synthesis and cell proliferation. Observations in this study have important clinical implications: 1) NOS inhibition may exacerbate airway disease and 2) inhaled SOD/mimetics or NO/nitrovasodilators may be therapies for the treatment of asthma or chronic obliterative pulmonary disease.	Royal Brompton & Natl Heart Hosp, Unit Crit Care Med, Imperial Coll, Sch Med, London SW3 6NP, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Thorac Med, London SW3 6LY, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Cardiothorac Surg, London SW3 6LY, England; Rhone Poulenc Rorer, Dept Pharmacol, Dagenham Res Ctr R&D, Dagenham RM10 7XS, Essex, England	Imperial College London; Imperial College London; Imperial College London; Sanofi-Aventis	Mitchell, JA (corresponding author), Royal Brompton & Natl Heart Hosp, Unit Crit Care Med, Imperial Coll, Sch Med, Sydney St, London SW3 6NP, England.		Belvisi, Maria G/A-3055-2009; Mitchell, Jane A/A-1991-2009; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Donnelly, Louise/0000-0002-0753-5425	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNAL JF, 1994, AM J PHYSIOL, V36, pC1381; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; Belvisi MG, 1998, BRIT J PHARMACOL, V125, P1102, DOI 10.1038/sj.bjp.0702104; BELVISI MG, 1995, ARCH INT PHARMACOD T, V329, P97; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; Curzen NP, 1996, INTENS CARE MED, V22, P596, DOI 10.1007/BF01708105; FLOWER MA, 1995, AM J PHYSIOL, V269, P11198; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574, DOI 10.1165/ajrcmb/7.6.574; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kallio EA, 1997, J CLIN INVEST, V100, P2984, DOI 10.1172/JCI119852; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MITCHELL JA, 1993, BRIT J PHARMACOL, V109, P265, DOI 10.1111/j.1476-5381.1993.tb13563.x; MULSCH A, 1990, N-S ARCH PHARMACOL, V341, P143; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Sarkar R, 1998, J VASC RES, V35, P135, DOI 10.1159/000025576; SCHMIDT HHHW, 1989, FEBS LETT, V244, P357, DOI 10.1016/0014-5793(89)80562-9; WARD JK, 1995, J PHYSIOL-LONDON, V483, P525, DOI 10.1113/jphysiol.1995.sp020603; WHITTLE BJR, 1995, HISTOCHEM J, V27, P727; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	32	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1810	1816		10.1096/fasebj.13.13.1810	http://dx.doi.org/10.1096/fasebj.13.13.1810			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506584	Bronze			2022-12-28	WOS:000083063400016
J	Katsumata, M; Burton, KA; Li, J; Dauncey, MJ				Katsumata, M; Burton, KA; Li, J; Dauncey, MJ			Suboptimal energy balance selectively up-regulates muscle GLUT gene expression but reduces insulin-dependent glucose uptake during postnatal development	FASEB JOURNAL			English	Article						glucose transporter; nutrition; food intake; environmental temperature	BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; TRANSPORTER EXPRESSION; THYROID-HORMONE; TRANSGENIC MICE; GROWTH-HORMONE; MESSENGER-RNA; GLYCOGEN; RECEPTOR; CELLS	The major facilitative glucose transporters in muscle, GLUT1 (insulin-independent) and GLUT4 (insulin-dependent), are essential for normal growth and metabolism, but factors controlling their expression during postnatal development are poorly understood. We have therefore determined the role of energy status in regulating muscle GLUT gene expression and function in young, growing pigs on a high (H) or low (L) food intake (H = 2L,) at 35 degrees C or 26 degrees C. RNase protection assays revealed selective up-regulation of GLUT1 and GLUT4 by mild undernutrition 20-24 h after feeding: mRNA levels were elevated in longissimus dorsi (P<0.001) and rhomboideus (P<0.05), but not in diaphragm or cardiac muscles. Assessment of 2-deoxy-glucose uptake in a small isolated muscle, flexor carpi radialis, showed that the 26L group, which had suboptimal energy balance and the greatest GLUT4 expression, had the highest insulin-independent glucose uptake but the lowest insulin-dependent increment: 20% compared with 70% in the other groups. These novel findings are directly relevant to an understanding of mechanisms underlying the development of insulin resistance and demonstrate 1) muscle-specific up-regulation of GLUT gene expression by postnatal undernutrition that is not related simply to myofiber type, but to whole-body function; and 2) that the degree of GLUT up-regulation and the subcellular distribution and function of GLUT proteins are dependent on energy status.	Babraham Inst, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Dauncey, MJ (corresponding author), Babraham Inst, Cambridge CB2 4AT, England.							Barker D J, 1997, Rev Reprod, V2, P105, DOI 10.1530/ror.0.0020105; BECKER BA, 1992, LAB ANIM SCI, V42, P51; BEER SF, 1989, J ENDOCRINOL, V120, P337, DOI 10.1677/joe.0.1200337; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIU PY, 1994, J ANIM SCI, V72, P1196, DOI 10.2527/1994.7251196x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coderre L, 1996, AM J PHYSIOL-ENDOC M, V271, pE643, DOI 10.1152/ajpendo.1996.271.4.E643; DAUNCEY MJ, 1989, J PHYSIOL-LONDON, V418, pP175; Dauncey MJ, 1996, P NUTR SOC, V55, P543, DOI 10.1079/PNS19960047; DAUNCEY MJ, 1994, FASEB J, V8, P81, DOI 10.1096/fasebj.8.1.7507871; Dauncey MJ, 1997, BRIT J NUTR, V78, pS113, DOI 10.1079/BJN19970226; Ebeling P, 1998, FEBS LETT, V436, P301, DOI 10.1016/S0014-5793(98)01149-1; GULVE EA, 1994, J BIOL CHEM, V269, P18366; Harrison AP, 1996, AM J PHYSIOL-REG I, V270, pR667, DOI 10.1152/ajpregu.1996.270.3.R667; Harrison AP, 1997, REPROD FERT DEVELOP, V9, P731, DOI 10.1071/R97026; HARRISON AP, 1994, AM J PHYSIOL, V266, pR102, DOI 10.1152/ajpregu.1994.266.1.R102; Henriksen EJ, 1996, J APPL PHYSIOL, V80, P1540, DOI 10.1152/jappl.1996.80.5.1540; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; James AP, 1998, BIOCHEM J, V329, P341; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KIM YB, 1994, BIOCHEM BIOPH RES CO, V202, P519, DOI 10.1006/bbrc.1994.1959; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; LEWIS DS, 1992, J CLIN ENDOCR METAB, V74, P920, DOI 10.1210/jc.74.4.920; Li J, 1998, J PHYSIOL-LONDON, V507P, p53P; Morovat A, 1998, EUR J ENDOCRINOL, V138, P95, DOI 10.1530/eje.0.1380095; MOROVAT A, 1995, J ENDOCRINOL, V144, P233, DOI 10.1677/joe.0.1440233; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; NIKAMI H, 1992, BIOCHEM BIOPH RES CO, V185, P1078, DOI 10.1016/0006-291X(92)91736-A; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Pethick DW, 1996, AUST J AGR RES, V47, P525, DOI 10.1071/AR9960525; REN JM, 1993, J BIOL CHEM, V268, P16113; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P1013, DOI 10.1210/jcem-68-6-1013; WALKER PS, 1990, J BIOL CHEM, V265, P1516; WEILERGUTTLER H, 1989, BIOL CHEM H-S, V370, P467, DOI 10.1515/bchm3.1989.370.1.467; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; Zorzano A, 1998, GEN PHARMACOL, V31, P705, DOI 10.1016/S0306-3623(98)00095-0	38	25	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1405	1413		10.1096/fasebj.13.11.1405	http://dx.doi.org/10.1096/fasebj.13.11.1405			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428764				2022-12-28	WOS:000082019100012
J	Bernard, C; Berthault, MF; Saulnier, C; Ktorza, A				Bernard, C; Berthault, MF; Saulnier, C; Ktorza, A			Neogenesis vs. apoptosis as main components of pancreatic beta cell mass changes in glucose-infused normal and mildly diabetic adult rats	FASEB JOURNAL			English	Article						pancreas plasticity; streptozotocin; chronic hyperglycemia	ENDOCRINE PANCREAS; NEWBORN RATS; B-CELLS; GROWTH; PROLIFERATION; STREPTOZOTOCIN; REGENERATION; PREGNANCY; INDUCTION; MELLITUS	We have investigated in adult rats made mildly diabetic by a low dose of streptozotocin (35 mg/kg; STZ rats) and in nondiabetic rats (ND rats) the mechanisms leading to adaptive changes in the beta cell mass, during glucose infusion and several days after stopping infusion. As early as 24 h of glucose infusion, the beta cell mass was maximally increased in ND and STZ rats. In both groups, this increase was due mainly to a rapid activation of neogenesis of new endocrine cells rather than to an increase in beta cell proliferation. Seven days after stopping glucose infusion, the beta cell mass returned to basal values in both groups as a result of stimulation of beta cell apoptosis and a decrease in beta cell replication rate. In glucose-infused ND rats, changes in the beta cell mass were correlated to insulin secretion, whereas in STZ rats, insulin secretion in response to glucose was still impaired whatever the beta cell mass. In conclusion, the data stress the impressive plasticity of the endocrine pancreas of adult rats. They also show that changes in beta cell mass in ND and STZ rats resulted from a disruption in the balance between neogenesis and apoptosis.	Univ Paris 07, Lab Physiopathol Nutr, CNRS ESA 7059, F-75251 Paris, France	UDICE-French Research Universities; Universite Paris Cite	Bernard, C (corresponding author), Univ Paris 07, Lab Physiopathol Nutr, CNRS ESA 7059, Tour 23-33 Ler Etage,2 Pl Jussieu, F-75251 Paris, France.							Bernard C, 1998, DIABETES, V47, P1058, DOI 10.2337/diabetes.47.7.1058; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BONNERWEIR S, 1981, METABOLISM, V30, P914, DOI 10.1016/0026-0495(81)90071-8; CANTENYS D, 1981, VIRCHOWS ARCH B, V35, P109; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; COLES HSR, 1993, DEVELOPMENT, V118, P777; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; GU DL, 1993, DEVELOPMENT, V118, P33; Hellerstrom C, 1988, PATHOLOGY ENDOCRINE, P141; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; KRORZA A, 1981, DIABETOLOGIA, V21, P569; Laybutt DR, 1997, AM J PHYSIOL-ENDOC M, V273, pE1, DOI 10.1152/ajpendo.1997.273.1.E1; LIPSETT M, 1998, PANCREATIC DUCTUL S1, V47, pA257; MARYNISSEN G, 1983, J DEV PHYSIOL, V5, P373; MONTANA E, 1993, J CLIN INVEST, V91, P780, DOI 10.1172/JCI116297; Movassat J, 1997, DIABETES, V46, P1445, DOI 10.2337/diabetes.46.9.1445; PARSONS JA, 1992, ENDOCRINOLOGY, V130, P1459, DOI 10.1210/en.130.3.1459; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; ROSENBERG L, 1983, J SURG RES, V35, P63, DOI 10.1016/0022-4804(83)90127-0; ROSENBERG L, 1992, TRANSPLANT P, V24, P1027; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; SWENNE I, 1983, DIABETES, V32, P14, DOI 10.2337/diabetes.32.1.14; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; THIBAULT C, 1993, DIABETOLOGIA, V36, P589, DOI 10.1007/BF00404066; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; WESTERMARK P, 1978, DIABETOLOGIA, V15, P417, DOI 10.1007/BF01219652	31	109	113	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1195	1205		10.1096/fasebj.13.10.1195	http://dx.doi.org/10.1096/fasebj.13.10.1195			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385610				2022-12-28	WOS:000081264800008
J	Everts, V; Korper, W; Jansen, DC; Steinfort, J; Lammerse, I; Heera, S; Docherty, AJP; Beertsen, W				Everts, V; Korper, W; Jansen, DC; Steinfort, J; Lammerse, I; Heera, S; Docherty, AJP; Beertsen, W			Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone	FASEB JOURNAL			English	Article						MMP activity; cathepsin K; proteinase inhibitor; cysteine proteinase	GELATINASE-A MMP-2; CATHEPSIN-K; CYSTEINE-PROTEINASES; RESORBING COMPARTMENT; MOLECULAR-CLONING; COLLAGENASE; INHIBITORS; TISSUE; PYCNODYSOSTOSIS; IDENTIFICATION	Data in the literature suggest that site-specific differences exist in the skeleton with respect to digestion of bone by osteoclasts. Therefore, we investigated whether bone resorption by calvarial osteoclasts (intramembranous bone) differs from resorption by long bone osteoclasts (endochondral bone). The involvement of two major classes of proteolytic enzymes, the cysteine proteinases (CPs) and matrix metalloproteinases (MMPs), was studied by analyzing the effects of selective low molecular weight inhibitors of these enzymes on bone resorption. Mouse tissue explants (calvariae and long bones) as well as rabbit osteoclasts, which had been isolated from both skeletal sites and subsequently seeded on bone slices, were cultured in the presence of inhibitors and resorption was analyzed. The activity of the CP cathepsins B and K and of MMPs was determined biochemically (CPs and MMPs) and enzyme histochemically (CPs) in explants and isolated osteoclasts. We show that osteoclastic resorption of calvarial bone depends on activity of both CPs and MMPs, whereas long bone resorption depends on CPs, but not on the activity of MMPs. Furthermore, significantly higher levels of cathepsin B and cathepsin K activities were expressed by long bone osteoclasts than by calvarial osteoclasts. Resorption of slices of bovine skull or cortical bone by osteoclasts isolated from long bones was not affected by MMP inhibitors, whereas resorption by calvarial osteoclasts was inhibited. Inhibition of CP activity affected the resorption by the two populations of osteoclasts in a similar way. We conclude that this is the first report to show that significant differences exist between osteoclasts of calvariae and long bones with respect to their bone resorbing activities. Resorption by calvarial osteoclasts depends on the activity of CPs and MMPs, whereas resorption by long bone osteoclasts depends primarily on the activity of CPs. We hypothesize that functionally different subpopulations of osteoclasts, such as those described here, originate from different sets of progenitors.	Univ Amsterdam, Dept Cell Biol & Histol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Periodontol, Acad Ctr Dent, NL-1100 DE Amsterdam, Netherlands; Celltech, Slough, Berks, England	University of Amsterdam; Academic Medical Center Amsterdam; Academic Center for Dentistry Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Celltech Group Ltd	Everts, V (corresponding author), Univ Amsterdam, Dept Cell Biol & Histol, Acad Med Ctr, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Beertsen, Wouter/B-5308-2013	Beertsen, Wouter/0000-0001-5698-5986				Aibe K, 1996, BIOL PHARM BULL, V19, P1026; Amling M, 1996, J BONE MINER RES, V11, P36, DOI 10.1002/jbmr.5650110107; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; Beekman B, 1996, FEBS LETT, V390, P221, DOI 10.1016/0014-5793(96)00665-5; BLAVIER L, 1995, J CELL SCI, V108, P3649; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671; Creemers LB, 1998, MATRIX BIOL, V17, P35, DOI 10.1016/S0945-053X(98)90072-5; DEBARI K, 1995, CALCIFIED TISSUE INT, V56, P566, DOI 10.1007/BF00298591; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1993, J CELL SCI, V106, P1071; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; Everts V, 1998, J BONE MINER RES, V13, P1420, DOI 10.1359/jbmr.1998.13.9.1420; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; FULLER K, 1995, J CELL SCI, V108, P2221; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GREENSPAN A, 1991, SKELETAL RADIOL, V20, P561, DOI 10.1007/BF01106087; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; HILL PA, 1995, BIOCHEM J, V308, P167, DOI 10.1042/bj3080167; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; HORTON MA, 1985, CANCER RES, V45, P5663; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JANAKIDEVI K, 1988, ANAL BIOCHEM, V172, P78, DOI 10.1016/0003-2697(88)90413-7; Johnson MR, 1996, GENOME RES, V6, P1050, DOI 10.1101/gr.6.11.1050; Kamiya T, 1998, J BIOCHEM-TOKYO, V123, P752; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Matayoshi A, 1996, P NATL ACAD SCI USA, V93, P10785, DOI 10.1073/pnas.93.20.10785; Mizoguchi I, 1997, ANAT EMBRYOL, V196, P291, DOI 10.1007/s004290050098; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59; Sato T, 1997, J CELL SCI, V110, P589; SCOTT CK, 1991, CALCIFIED TISSUE INT, V49, P349, DOI 10.1007/BF02556258; SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; van Noorden C.J.F., 1992, MICROSCOPY HDB, V26; VANNOORDEN CJF, 1991, BIOCHEM BIOPH RES CO, V178, P178, DOI 10.1016/0006-291X(91)91796-F	45	137	139	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1219	1230		10.1096/fasebj.13.10.1219	http://dx.doi.org/10.1096/fasebj.13.10.1219			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385612	Bronze			2022-12-28	WOS:000081264800010
J	Goodwin, DC; Landino, LM; Marnett, LJ				Goodwin, DC; Landino, LM; Marnett, LJ			Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis	FASEB JOURNAL			English	Review						PGHS; NOS; NO-; interferon; peroxynitrite	SOLUBLE GUANYLATE-CYCLASE; HIGHER OXIDATION-STATES; RESONANCE RAMAN-SPECTROSCOPY; MANGANESE PROTOPORPHYRIN-IX; VESICULAR GLAND MICROSOMES; H SYNTHASE; TYROSYL RADICALS; RIBONUCLEOTIDE REDUCTASE; HORSERADISH-PEROXIDASE; MAMMALIAN LIPOXYGENASE	Prostaglandins and NO. are important mediators of inflammation and other physiological and pathophysiological processes. Continuous production of these molecules in chronic inflammatory conditions has been linked to development of autoimmune disorders, coronary artery disease, and cancer. There is mounting evidence for a biological relationship between prostanoid biosynthesis and NO biosynthesis, Upon stimulation, many cells express high levels of nitric oxide synthase (NOS) and prostaglandin endoperoxide synthase (PGHS), There are reports of stimulation of prostaglandin biosynthesis in these cells by direct interaction between NO. and PGHS, but this is not universally observed. Clarification of the role of NO. in PGHS catalysis has been attempted by examining NO. interactions with purified PGHS, including binding to its heme prosthetic group, cysteines, and tyrosyl radicals, However, a clear picture of the mechanism of PGHS stimulation by NO. has not yet emerged. Available studies suggest that NO. may only be a precursor to the molecule that interacts with PGHS, Peroxynitrite (from O-2(.-)+NO.) reacts directly with PGHS to activate prostaglandin synthesis. Furthermore, removal of O-2(.-) from RAW 267.4 cells that produce NO. and PGHS inhibits prostaglandin biosynthesis to the same extent as NOS inhibitors. This interaction between reactive nitrogen species and PGHS may provide new approaches to the control of inflammation in acute and chronic settings.	Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, AB Hancock Jr Mem Lab Canc Res, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, 221 Kirkland Hall, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu		Goodwin, Douglas/0000-0002-7869-7704	NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [T32ES07028, ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ambs S, 1998, CANCER RES, V58, P334; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Briviba K, 1998, CHEM RES TOXICOL, V11, P1398, DOI 10.1021/tx980086y; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; Curtis JF, 1996, ARCH BIOCHEM BIOPHYS, V335, P369, DOI 10.1006/abbi.1996.0518; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; FRANCHI AM, 1994, P NATL ACAD SCI USA, V91, P539, DOI 10.1073/pnas.91.2.539; Gaspard S, 1996, EUR J BIOCHEM, V238, P529, DOI 10.1111/j.1432-1033.1996.0529z.x; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Habib A, 1997, J IMMUNOL, V158, P3845; HAJJAR DP, 1995, J AM CHEM SOC, V117, P3340, DOI 10.1021/ja00117a004; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1978, BIOCHEM BIOPH RES CO, V85, P1325, DOI 10.1016/0006-291X(78)91148-8; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Holzhutter HG, 1997, EUR J BIOCHEM, V245, P608, DOI 10.1111/j.1432-1033.1997.00608.x; HSI LC, 1995, BIOCHEM BIOPH RES CO, V207, P652, DOI 10.1006/bbrc.1995.1237; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; Hughes FJ, 1999, J BIOL CHEM, V274, P1776, DOI 10.1074/jbc.274.3.1776; IGNARRO LJ, 1984, ADV CYCLIC NUCL PROT, V17, P267; Jang D, 1998, FREE RADICAL BIO MED, V24, P1511, DOI 10.1016/S0891-5849(97)00459-0; JANZEN EG, 1993, J ORG CHEM, V58, P3597, DOI 10.1021/jo00066a001; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KENNEDY TA, 1994, J BIOL CHEM, V269, P27357; KENNEDY TA, 1993, EICOSANOIDS OTHER BI, P161; Kim SY, 1996, J AM CHEM SOC, V118, P8769, DOI 10.1021/ja961411b; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Kosonen O, 1998, BRIT J PHARMACOL, V125, P247, DOI 10.1038/sj.bjp.0702042; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; Lee JB, 1998, J AM CHEM SOC, V120, P6053, DOI 10.1021/ja9801036; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Lianos EA, 1998, KIDNEY INT, V53, P645, DOI 10.1046/j.1523-1755.1998.00791.x; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Maccarrone M, 1996, BIOCHEM BIOPH RES CO, V219, P128, DOI 10.1006/bbrc.1996.0193; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARNETT LJ, 1992, CANCER RES, V52, P5575; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; OGINO N, 1978, J BIOL CHEM, V253, P5061; OHKI S, 1979, J BIOL CHEM, V254, P829; Okamoto H, 1998, STROKE, V29, P1209, DOI 10.1161/01.STR.29.6.1209; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RETTORI V, 1992, P NATL ACAD SCI USA, V89, P11543, DOI 10.1073/pnas.89.23.11543; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SALVEMINI D, 1995, BRIT J PHARMACOL, V114, P1171, DOI 10.1111/j.1476-5381.1995.tb13330.x; Sanakis Y, 1997, BIOCHEMISTRY-US, V36, P1411, DOI 10.1021/bi9622074; SAUTEBIN L, 1995, BRIT J PHARMACOL, V114, P323, DOI 10.1111/j.1476-5381.1995.tb13230.x; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STADLER J, 1993, J LEUKOCYTE BIOL, V53, P165, DOI 10.1002/jlb.53.2.165; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1995, BIOCHEMISTRY-US, V34, P16397, DOI 10.1021/bi00050a021; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; SWIERKOSZ TA, 1995, BRIT J PHARMACOL, V114, P1335, DOI 10.1111/j.1476-5381.1995.tb13353.x; Szalai VA, 1996, BIOCHEMISTRY-US, V35, P15080, DOI 10.1021/bi961117w; Tamir S, 1996, BBA-REV CANCER, V1288, pF31, DOI 10.1016/0304-419X(96)00021-2; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; TSAI AL, 1994, J BIOL CHEM, V269, P5085; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; TSAI AL, 1994, FEBS LETT, V341, P141, DOI 10.1016/0014-5793(94)80445-1; TSAI AL, 1994, BIOPHYS, V313, P3697; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wade ML, 1997, ARCH BIOCHEM BIOPHYS, V347, P174, DOI 10.1006/abbi.1997.0348; Watkins DN, 1997, BRIT J PHARMACOL, V121, P1482; Wiesner R, 1996, FEBS LETT, V389, P229, DOI 10.1016/0014-5793(96)00591-1; WILCOX AL, 1993, J CHEM SOC CHEM COMM, P1377, DOI 10.1039/c39930001377; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao YD, 1998, BIOCHEMISTRY-US, V37, P12458, DOI 10.1021/bi9811563; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	104	147	151	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1121	1136		10.1096/fasebj.13.10.1121	http://dx.doi.org/10.1096/fasebj.13.10.1121			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385604				2022-12-28	WOS:000081264800002
J	Song, DK; Im, YB; Jung, JS; Suh, HW; Huh, SO; Song, JH; Kim, YH				Song, DK; Im, YB; Jung, JS; Suh, HW; Huh, SO; Song, JH; Kim, YH			Central injection of nicotine increases hepatic and splenic interleukin 6 (IL-6) mRNA expression and plasma IL-6 levels in mice: involvement of the peripheral sympathetic nervous system	FASEB JOURNAL			English	Article						norepinephrine; sympathetic nervous system; liver; spleen	C-REACTIVE PROTEIN; ACUTE-PHASE RESPONSE; CARDIOVASCULAR RISK-FACTORS; INTRACEREBROVENTRICULAR INJECTION; IMMOBILIZATION STRESS; IMMUNE-RESPONSES; UNSTABLE ANGINA; DISEASE; RAT; MODULATION	Accumulating evidence suggests that plasma levels of interleukin 6 (IL-6), a major cytokine stimulating the synthesis of acute-phase proteins, are intimately regulated by the central nervous system. Nicotine, one of the major drugs abused by humans, has been shown to affect immunological functions. In the present study, effects of intracerebroventricular (i.c.v.) injection of nicotine on plasma IL-6 levels were investigated in mice. Nicotine administered i.c.v. dose-dependently increased plasma IL-6 levels; the lowest effective dose was 0.3 ng/mouse and the maximal effect was attained with the dose of 105 ng/mouse. The nicotine (105 ng/mouse, i.c.v.)-induced plasma IL-6 levels peaked at 3 h and approached basal levels 6 h after injection. Mecamylamine, a nicotinic receptor antagonist, blocked nicotine-induced plasma IL-6 levels. Depletion of peripheral norepinephrine with 6-hydroxydopamine [100 mg/kg, intraperitoneal (i.p.)] inhibited the nicotine-induced plasma IL 6 levels by 57%, whereas central norepinephrine depletion with 6-hydroxydopamine (50 mu g/mouse, i.c.v.) had no effect. Pretreatment with prazosin (alpha(1)-adrenergic antagonist; 1 mg/kg, i.p.), yohimbine (alpha(2)-adrenergic antagonist; 1 mg/kg, i.p.), and ICI-118,551 (beta(2)-adrenergic antagonist; 2 mg/kg, i.p.), but not with betaxolol (beta(1)-adrenergic antagonist; 2 mg/kg, i.p.), inhibited nicotine-induced plasma IL-6 levels. Among the peripheral organs, including the pituitary, adrenals, heart, lung, liver, spleen, and lymph nodes, nicotine (105 ng/mouse, i.c.v.) increased IL-6 mRNA expression only in the liver and spleen, which was inhibited by peripheral norepinephrine depletion. These results suggest that stimulation of central nicotinic receptors induces plasma IL-6 levels and IL-6 mRNA expression in the liver and spleen via the peripheral sympathetic nervous system, alpha(1)-, alpha(2)-, and beta(2)-adrenoreceptors being involved.	Hallym Univ, Coll Med, Dept Pharmacol, Inst Nat Med, Kangwon Do 200702, South Korea	Hallym University	Song, DK (corresponding author), Hallym Univ, Coll Med, Dept Pharmacol, Inst Nat Med, Kangwon Do 200702, South Korea.	dksong@sun.hallym.ac.kr						BILLIAR TR, 1992, ARCH SURG-CHICAGO, V127, P31; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS I, 1985, CLIN CHIM ACTA, V153, P9, DOI 10.1016/0009-8981(85)90133-0; deMaat MPM, 1996, ATHEROSCLEROSIS, V121, P185, DOI 10.1016/0021-9150(95)05716-1; DERIGGI D, 1994, STAT PROBABIL LETT, V19, P1, DOI 10.1016/0167-7152(94)90061-2; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739, DOI 10.1152/ajpregu.1993.265.4.R739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; FAULKNER CB, 1995, INFECT IMMUN, V63, P4084, DOI 10.1128/IAI.63.10.4084-4090.1995; Felten S Y, 1998, Adv Pharmacol, V42, P583; Finck BN, 1997, AM J PHYSIOL-REG I, V272, pR1880, DOI 10.1152/ajpregu.1997.272.6.R1880; Fu YT, 1997, ENDOCRINOLOGY, V138, P1935, DOI 10.1210/en.138.5.1935; Fu YT, 1998, J PHARMACOL EXP THER, V284, P1188; Geng YM, 1996, J IMMUNOL, V156, P2384; Geng YM, 1995, TOXICOL APPL PHARM, V135, P268, DOI 10.1006/taap.1995.1233; GOTTSCHALL PE, 1992, NEUROENDOCRINOLOGY, V56, P935, DOI 10.1159/000126328; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hirano Toshio, 1998, P197; Huang QH, 1997, AM J PHYSIOL-REG I, V273, pR731, DOI 10.1152/ajpregu.1997.273.2.R731; Kitamura H, 1997, BIOCHEM BIOPH RES CO, V238, P707, DOI 10.1006/bbrc.1997.7368; Komaki Gen, 1994, Neuroimmunomodulation, V1, P127, DOI 10.1159/000097146; LAURSEN SE, 1986, J PHARMACOL METHOD, V16, P355, DOI 10.1016/0160-5402(86)90038-0; LEMAY LG, 1990, PHYSIOL BEHAV, V47, P957, DOI 10.1016/0031-9384(90)90024-X; Li XY, 1998, J NEUROSCI, V18, P1904; Limbird, 1996, GOODMAN GILMANS PHAR, P557; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MADDEN KS, 1995, ANNU REV PHARMACOL, V35, P417, DOI 10.1146/annurev.pharmtox.35.1.417; MATTA SG, 1987, J PHARMACOL EXP THER, V243, P217; MATTA SG, 1992, J PHARMACOL EXP THER, V260, P1285; MATTA SG, 1990, ENDOCRINOLOGY, V127, P1646, DOI 10.1210/endo-127-4-1646; McAllister-Sistilli CG, 1998, PSYCHONEUROENDOCRINO, V23, P175, DOI 10.1016/S0306-4530(97)00080-2; Mendall MA, 1997, HEART, V78, P273, DOI 10.1136/hrt.78.3.273; Mendall MA, 1996, BRIT MED J, V312, P1061; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; NAITOH Y, 1988, BIOCHEM BIOPH RES CO, V155, P1459, DOI 10.1016/S0006-291X(88)81305-6; Papanicolaou DA, 1996, AM J PHYSIOL-ENDOC M, V271, pE601; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rosecrans JA, 1998, PSYCHONEUROENDOCRINO, V23, P95, DOI 10.1016/S0306-4530(97)00073-5; Sato S, 1996, INT J EPIDEMIOL, V25, P521, DOI 10.1093/ije/25.3.521; Song DK, 1999, J NEUROCHEM, V72, P1625, DOI 10.1046/j.1471-4159.1999.721625.x; Song DK, 1996, EUR J PHARMACOL, V316, P165, DOI 10.1016/S0014-2999(96)00666-8; Song DK, 1998, J PHARMACOL EXP THER, V287, P144; Sopori ML, 1998, PSYCHONEUROENDOCRINO, V23, P189, DOI 10.1016/S0306-4530(97)00076-0; Soszynski D, 1996, NEUROENDOCRINOLOGY, V63, P459, DOI 10.1159/000127072; SUAUDEAU C, 1995, NEUROPHARMACOLOGY, V34, P101, DOI 10.1016/0028-3908(94)00109-6; Takaki Atsushi, 1994, Neuroimmunomodulation, V1, P335, DOI 10.1159/000097185; TAPPIA PS, 1995, CLIN SCI, V88, P485, DOI 10.1042/cs0880485; TEREBUH PD, 1992, AM J PATHOL, V140, P649; VANGOOL J, 1990, CLIN IMMUNOL IMMUNOP, V57, P200, DOI 10.1016/0090-1229(90)90034-N; VANLOON GR, 1989, PROG BRAIN RES, V79, P217; YOKOTANI K, 1987, JPN J PHARMACOL, V45, P288, DOI 10.1254/jjp.45.288; ZHOU DH, 1993, ENDOCRINOLOGY, V133, P2523, DOI 10.1210/en.133.6.2523	54	28	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1259	1267		10.1096/fasebj.13.10.1259	http://dx.doi.org/10.1096/fasebj.13.10.1259			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385616				2022-12-28	WOS:000081264800014
J	Canitrot, Y; Frechet, M; Servant, L; Cazaux, C; Hoffmann, JB				Canitrot, Y; Frechet, M; Servant, L; Cazaux, C; Hoffmann, JB			Overexpression of DNA polymerase beta: a genomic instability enhancer process	FASEB JOURNAL			English	Article						DNA replication; Pol beta; mismatch repair; nucleotide excision repair	BASE-EXCISION-REPAIR; MISMATCH REPAIR; MUTATOR PHENOTYPE; MAMMALIAN-CELLS; CANCER-CELLS; IN-VITRO; REPLICATION; GENE; RECOMBINATION; HETERODIMER	DNA polymerase beta (Pol beta) is the most inaccurate of the six DNA polymerases found in mammalian cells. In a normal situation, it is expressed at a constant low level and its role is believed to be restricted to repair synthesis in the base excision repair pathway participating to the genome stability. However, excess of Pol beta, found in some human tumors, could confer an increase in spontaneous mutagenesis and result in a highly mutagenic tolerance phenotype toward bifunctional DNA crosslinking anticancer drugs, Here, we present a hypothesis on the mechanisms used by Pol beta to be a genetic instability enhancer through its overexpression, We hypothesize that an excess of pol beta perturbs the well-defined specific functions of DNA polymerases developed by the cell and propose Pol beta-mediated gap fillings during DNA transactions like repair, replication, or recombination pathways as key processes to introduce illegitimate deoxyribonucleotides or mutagenic base analogs like those produced by intracellular oxidative processes. These mechanisms may predominate during cellular nonproliferative phases in the absence of DNA replication.	IPBS, CNRS, UPR 9062, Grp Instabil Genet & Canc, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS)	Hoffmann, JB (corresponding author), IPBS, CNRS, UPR 9062, Grp Instabil Genet & Canc, 205 Route Narbonne, F-31077 Toulouse, France.		Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X				BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Bouayadi K, 1997, CANCER RES, V57, P110; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; CANITROT Y, 1999, IN PRESS ONCOGENE, V18; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Efrati E, 1997, J BIOL CHEM, V272, P2559; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; HERENDEEN D, 1996, EUKARYOTIC DNA REPLI, P29; HOFFMANN J, 1997, INT J ONCOL, V12, P377; Hoffmann JS, 1996, J BIOL CHEM, V271, P15386, DOI 10.1074/jbc.271.26.15831; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Lawrence CW, 1996, CANCER SURV, V28, P21; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; SHIJVI MKK, 1992, CELL, V69, P367; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	39	73	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1107	1111		10.1096/fasebj.13.9.1107	http://dx.doi.org/10.1096/fasebj.13.9.1107			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336894				2022-12-28	WOS:000080547700016
J	Lombardi, MS; Kavelaars, A; Schedlowski, M; Bijlsma, JWJ; Okihara, KL; Van de Pol, M; Ochsmann, S; Pawlak, C; Schmidt, RE; Heijnen, CJ				Lombardi, MS; Kavelaars, A; Schedlowski, M; Bijlsma, JWJ; Okihara, KL; Van de Pol, M; Ochsmann, S; Pawlak, C; Schmidt, RE; Heijnen, CJ			Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis	FASEB JOURNAL			English	Article						immune system; lymphocytes; cytokines; autoimmunity	MONOCYTE CHEMOATTRACTANT PROTEIN-1; BETA-ADRENERGIC RECEPTORS; FAILING HUMAN HEART; NERVOUS-SYSTEM; SUBSTANCE-P; DESENSITIZATION; GRK6; INTERNALIZATION; PHOSPHORYLATION; IDENTIFICATION	beta(2)-Adrenergic and chemokine receptor antagonists delay the onset and reduce the severity of joint injury in rheumatoid arthritis. beta(2)-adrenergic and chemokine receptors belong to the G-protein-coupled receptor family whose responsiveness is turned off by the G-protein-coupled receptor kinase family (GRK-1 to 6). GRKs phosphorylate receptors in an agonist-dependent manner resulting in receptor/G-protein uncoupling via subsequent binding of arrestin proteins. We assessed the activity of GRKs in lymphocytes of rheumatoid arthritis (RA) patients by rhodopsin phosphorylation. We found a significant decrease in GRK activity in RA subjects that is mirrored by a decrease in GRK-2 protein expression. Moreover, GRK-6 protein expression is reduced in RA patients whereas GRK-5 protein levels were unchanged. In search of an underlying mechanism, we demonstrated that proinflammatory cytokines induce a decrease in GRK-2 protein levels in leukocytes from healthy donors. Since proinflammatory cytokines are abundantly expressed in RA, it may provide an explanation for the decrease in GRK-2 expression and activity in patients. No changes in beta(2)-adrenergic receptor number and K-d were detected. However, RA patients showed a sig nificantly increased cAMP production and inhibition of TNF-alpha production by beta(2)-adrenergic stimulation, suggesting that reduced GRK activity is associated with increased sensitivity to beta(2)-adrenergic activation.	Univ Hosp Children & Youth, Het Wilhemina Kinderziekenhuis, Dept Immunol, NL-3584 CA Utrecht, Netherlands; Univ Essen Gesamthsch, Inst Med Psychol, D-45122 Essen, Germany; Univ Utrecht Hosp, Dept Rheumatol & Clin Immunol, NL-3584 CX Utrecht, Netherlands; Hannover Med Sch, Dept Clin Immunol, D-36025 Hannover, Germany; Hannover Med Sch, Dept Psychol Med, D-36025 Hannover, Germany	Wilhelmina Kinderziekenhuis; University of Duisburg Essen; Utrecht University; Utrecht University Medical Center; Hannover Medical School; Hannover Medical School	Lombardi, MS (corresponding author), Univ Hosp Children & Youth, Het Wilhemina Kinderziekenhuis, Dept Immunol, Lundlaan 6, NL-3584 CA Utrecht, Netherlands.	s.lombardi@wkz.azu.nl						Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BAKER GHB, 1982, PSYCHOTHER PSYCHOSOM, V38, P173, DOI 10.1159/000287625; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; DEBLASI A, 1985, J CLIN ENDOCR METAB, V61, P1081, DOI 10.1210/jcem-61-6-1081; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Felten S Y, 1998, Adv Pharmacol, V42, P583; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIRSOV D, 1997, AM J PHYSIOL, V273, P953; Franci C, 1996, J IMMUNOL, V157, P5606; Gagnon AW, 1997, GENE, V184, P13, DOI 10.1016/S0378-1119(96)00567-7; GARCIAHIGUERA I, 1994, J CLIN INVEST, V93, P937, DOI 10.1172/JCI117099; GARCIAHIGUERA I, 1992, FEBS LETT, V302, P61, DOI 10.1016/0014-5793(92)80285-O; Geenen R, 1996, J RHEUMATOL, V23, P258; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE JD, 1988, P NATL ACAD SCI USA, V85, P4553, DOI 10.1073/pnas.85.12.4553; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; MARSHALL KW, 1990, ARTHRITIS RHEUM, V33, P87; MITCHELL DM, 1982, ARTHRITIS RHEUM, V25, P481, DOI 10.1002/art.1780250501; Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222; PARRUTI G, 1993, J RECEPTOR RES, V13, P95, DOI 10.3109/10799899309073648; PENN RB, 1994, J BIOL CHEM, V269, P14924; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; SCHULZEKOOPS H, 1995, J IMMUNOL, V155, P5029; THOMPSON M, 1962, ANN RHEUM DIS, V21, P370, DOI 10.1136/ard.21.4.370; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	49	183	188	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					715	725		10.1096/fasebj.13.6.715	http://dx.doi.org/10.1096/fasebj.13.6.715			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094932				2022-12-28	WOS:000079527200013
J	Bourdon, E; Loreau, N; Blache, D				Bourdon, E; Loreau, N; Blache, D			Glucose and free radicals impair the antioxidant properties of serum albumin	FASEB JOURNAL			English	Article						oxidation; LDL oxidation; red blood cell hemolysis; atherosclerosis; diabetes	LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; NEPHROTIC SYNDROME; PROTEIN GLYCATION; DIABETES-MELLITUS; BLOOD-PLASMA; ATHEROSCLEROSIS; DISEASE; GLYCOSYLATION; CHOLESTEROL	Epidemiological data consistently show that reduced levels of serum albumin, which is the most abundant protein in plasma, are associated with an increased mortality risk. Various biological properties evidenced by direct effects of the albumin molecule may explain its beneficial effects. The present work aimed to investigate in vitro whether glycation or free radicals or both factors would affect the antioxidant properties of bovine serum albumin (BSA), Glycation was performed by long-term incubations (60 days) of BSA with increasing concentrations of glucose (up to 500 mmol/l) at 37 degrees C, Minimally oxidized BSA was obtained after controlled incubations of dialyzed BSA samples with a water-soluble free radical generator [2,2' azo-bis(2-amidinopropane) HCl], The glycation-mediated modifications and the free radical-induced conformational changes of BSA were monitored using intrinsic fluorescence measurements of the tryptophan residues and acrylamide as a quenching agent. Thiol groups, Amadori glycophore contents, and boronate binding were also measured. We found that the changes observed in the conformation of the BSA molecule were associated with modifications of its antioxidant properties. The latter were studied by the copper-mediated oxidation of human low density lipoproteins and the free radical-induced blood hemolysis test. Our data support the concept that oxidative-induced BSA modifications are important determinants in the antioxidant properties of BSA, Glycated BSA still behaved as an antioxidant but became pro-oxidant in the presence of copper, probably by generating oxygenated species. These data confirm the key role of metals ions in this process. Although these results warrant further in vivo investigations, we propose that, considering the poor glucose control found in diabetics as well as the key role of oxidative stress in vascular complications, glycation-mediated and free radical-induced impairment of the antioxidant properties of albumin might be important parameters in vascular complications encountered in diabetes.	Univ Bourgogne, INSERM, U498, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Blache, D (corresponding author), Univ Bourgogne, INSERM, U498, 7 Bd Jeanne Arc, F-21033 Dijon, France.	dblache@u-bourgogne.fr	Bourdon, Emmanuel/P-8455-2019	Bourdon, Emmanuel/0000-0003-3731-150X				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; Blache D, 1998, J AM OIL CHEM SOC, V75, P107, DOI 10.1007/s11746-998-0019-6; BLACHE D, 1995, FEBS LETT, V357, P135, DOI 10.1016/0014-5793(94)01348-5; BLACHE D, 1995, AM J PHYSIOL-HEART C, V268, pH679, DOI 10.1152/ajpheart.1995.268.2.H679; BLACHE D, 1992, P 9 COLL PARK C CHEM, P82; BROWNLEE M, 1995, CLIN INVEST MED, V18, P275; Cha MK, 1996, BIOCHEM BIOPH RES CO, V222, P619, DOI 10.1006/bbrc.1996.0793; Coussons PJ, 1997, FREE RADICAL BIO MED, V22, P1217, DOI 10.1016/S0891-5849(96)00557-6; DAMMACCO F, 1980, VOX SANG, V39, P153, DOI 10.1111/j.1423-0410.1980.tb01851.x; DAVIES MJ, 1993, FREE RADICAL RES COM, V18, P353, DOI 10.3109/10715769309147502; Dean RT, 1997, BIOCHEM J, V324, P1; DEAN RT, 1991, FREE RADICAL BIO MED, V11, P161, DOI 10.1016/0891-5849(91)90167-2; Durand P, 1997, ARTERIOSCL THROM VAS, V17, P1939, DOI 10.1161/01.ATV.17.10.1939; Durand P, 1997, FASEB J, V11, P1157, DOI 10.1096/fasebj.11.13.9367351; Durand P, 1996, ATHEROSCLEROSIS, V121, P205, DOI 10.1016/0021-9150(95)05720-X; EFTINK MR, 1977, BIOCHEMISTRY-US, V16, P5546, DOI 10.1021/bi00644a024; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FAURE P, 1994, BBA-PROTEIN STRUCT M, V1209, P260, DOI 10.1016/0167-4838(94)90194-5; Girodon F, 1997, J AM COLL NUTR, V16, P357, DOI 10.1080/07315724.1997.10718698; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2; GRANT AJ, 1992, BIOCHIM BIOPHYS ACTA, V1134, P203, DOI 10.1016/0167-4889(92)90177-D; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Halliwell B, 1996, FREE RADICAL RES, V25, P57, DOI 10.3109/10715769609145656; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HARRIS RC, 1994, AM J KIDNEY DIS, V23, P477, DOI 10.1016/S0272-6386(12)80369-6; HUNT JV, 1994, BIOCHEM J, V300, P243, DOI 10.1042/bj3000243; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; LUOMA PV, 1995, J INTERN MED, V237, P49, DOI 10.1111/j.1365-2796.1995.tb01139.x; MONTGOMERY DA, 1962, CLIN SCI, V22, P141; Mooradian AD, 1996, FREE RADICAL BIO MED, V21, P699, DOI 10.1016/0891-5849(96)00127-X; Moriyama Y, 1996, J PROTEIN CHEM, V15, P265, DOI 10.1007/BF01887115; NAGANO Y, 1992, ATHEROSCLEROSIS, V92, P131, DOI 10.1016/0021-9150(92)90272-I; Ogino T, 1995, BBA-GEN SUBJECTS, V1245, P359, DOI 10.1016/0304-4165(95)00101-8; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PHILLIPS A, 1989, LANCET, V2, P1434; PROST M, 1992, Patent No. 5135850; QUINTANILHA AT, 1982, ANN NY ACAD SCI, V393, P32, DOI 10.1111/j.1749-6632.1982.tb31230.x; REAVEN PD, 1992, ARTERIOSCLER THROMB, V12, P318, DOI 10.1161/01.ATV.12.3.318; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schnitzer E, 1997, BBA-LIPID LIPID MET, V1344, P300, DOI 10.1016/S0005-2760(96)00154-3; SHAKLAI N, 1984, J BIOL CHEM, V259, P3812; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORIANI M, 1994, ARCH BIOCHEM BIOPHYS, V312, P180, DOI 10.1006/abbi.1994.1297; STAMPFER MJ, 1995, AM J CLIN NUTR, V62, P1365, DOI 10.1093/ajcn/62.6.1365S; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4; WHEELER DC, 1994, AM J KIDNEY DIS, V23, P331, DOI 10.1016/S0272-6386(12)80994-2; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Woodside JV, 1998, AM J CLIN NUTR, V67, P858, DOI 10.1093/ajcn/67.5.858; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZAWADZKI Z, 1991, J LIPID RES, V32, P243	60	240	246	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	1999	13	2					233	244		10.1096/fasebj.13.2.233	http://dx.doi.org/10.1096/fasebj.13.2.233			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973311				2022-12-28	WOS:000078615200003
J	Benten, WPM; Lieberherr, M; Giese, G; Wrehlke, C; Stamm, O; Sekeris, CE; Mossmann, H; Wunderlich, F				Benten, WPM; Lieberherr, M; Giese, G; Wrehlke, C; Stamm, O; Sekeris, CE; Mossmann, H; Wunderlich, F			Functional testosterone receptors in plasma membranes of T cells	FASEB JOURNAL			English	Article						membrane receptor; androgen receptor; Ca2+ influx; sex steroids	PLASMODIUM-CHABAUDI MALARIA; S-49 LYMPHOMA-CELLS; ANDROGEN-RECEPTOR; IMMUNE-RESPONSE; GLUCOCORTICOID RECEPTORS; PARASITIC INFECTION; PROSTATE-CANCER; SEX STEROIDS; BINDING; HORMONES	T cells are considered to be unresponsive to testosterone due to the absence of androgen receptors (AR). Here, we demonstrate the testosterone responsiveness of murine splenic T cells in vitro as well as the presence of unconventional cell, surface receptors for testosterone and classical intracellular AR. Binding sites for testosterone on the surface of both CD4(+) and CD8(+) subsets of T cells are directly revealed with the impeded ligand testosterone-BSA-FITC by confocal laser scanning microscopy (CLSM) and flow cytometry, respectively. Binding of the plasma membrane impermeable testosterone,BSA conjugate induces a rapid rise (<5 s) in [Ca2+](i) of Fura-2-loaded T cells. This rise reflects influx of extracellular Ca2+ through non-voltage-gated and Ni(2+-)blockable Ca2+ channels of the plasma membrane. The testosterone-BSA-induced Ca2+ import is not affected by cyproterone, a blocker of the AR. In addition, AR are not detectable on the surface of intact T cells when using anti-AR antibodies directed against the amino and carboxy terminus of the AR, although T cells contain AR, as revealed by reverse transcription-polymerase chain reactions and Western blotting. AR can be visualized with the anti-AR antibodies in the cytoplasm of permeabilized T cells by using CLSM, though AR are not detectable in cytosol :fractions when using the charcoal binding assay with H-3-R1881 as ligand. Cytoplasmic AR do not translocate to the nucleus of T cells in the presence of testosterone, in contrast to cytoplasmic AR in human cancer LNCaP cells. These findings suggest that the classical AR press ent in splenic T cells are not active in the genomic pathway. By contrast, the cell surface receptors for testosterone are in a functionally active state, enabling T cells a nongenomic response to testosterone.	Univ Dusseldorf, Div Mol Parasitol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Ctr Biol Med Res, D-40225 Dusseldorf, Germany; INRA, CNRS, UPR 1524, F-78352 Jouy En Josas, France; Max Planck Inst Cell Biol, D-68526 Ladenburg, Germany; Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece; Max Planck Inst Immunbiol, D-78112 Freiburg, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Max Planck Society; National Hellenic Research Foundation; Max Planck Society	Wunderlich, F (corresponding author), Univ Dusseldorf, Div Mol Parasitol, Univ Str 1, D-40225 Dusseldorf, Germany.							ALEXANDER J, 1988, PARASITOL TODAY, V4, P189, DOI 10.1016/0169-4758(88)90077-4; ARANEO BA, 1991, BLOOD, V78, P688, DOI 10.1182/blood.V78.3.688.688; Benten WPM, 1997, FEBS LETT, V407, P211, DOI 10.1016/S0014-5793(97)00346-3; BENTEN WPM, 1991, INFECT IMMUN, V59, P4486, DOI 10.1128/IAI.59.12.4486-4490.1991; Benten WPM, 1998, FEBS LETT, V422, P349, DOI 10.1016/S0014-5793(98)00039-8; Ding VDH, 1998, ENDOCRINOLOGY, V139, P213, DOI 10.1210/en.139.1.213; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FARNSWORTH WE, 1990, MEMBRANE BIOCHEM, V9, P141, DOI 10.3109/09687689009025836; GAMETCHU B, 1991, STEROIDS, V56, P411, DOI 10.1016/0039-128X(91)90029-U; GAMETCHU B, 1991, STEROIDS, V56, P402, DOI 10.1016/0039-128X(91)90028-T; Giese G, 1997, BIOL CELL, V89, P99, DOI 10.1016/S0248-4900(99)80069-0; GROSSMAN C, 1989, J STEROID BIOCHEM, V34, P241, DOI 10.1016/0022-4731(89)90088-5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KONOPLYA EF, 1992, INT J BIOCHEM, V24, P1979, DOI 10.1016/0020-711X(92)90294-B; KOVACS WJ, 1987, J IMMUNOL, V139, P490; KUHNLE U, 1994, J STEROID BIOCHEM, V48, P403, DOI 10.1016/0960-0760(94)90081-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMALLEY V, 1997, J BIOL CHEM, V272, P11902; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MCCRUDEN AB, 1991, PSYCHONEUROIMMUNOLOG, P475; McGuire W L, 1975, Methods Enzymol, V36, P248; MEIKLE AW, 1992, J STEROID BIOCHEM, V42, P293, DOI 10.1016/0960-0760(92)90132-3; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Nakhla AM, 1996, ENDOCRINOLOGY, V137, P4126, DOI 10.1210/en.137.10.4126; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Olsen NJ, 1996, ENDOCR REV, V17, P369, DOI 10.1210/edrv-17-4-369; PAAVONEN T, 1994, ANN MED, V26, P255, DOI 10.3109/07853899409147900; PAPAMICHAIL M, 1980, EXP CELL RES, V125, P490, DOI 10.1016/0014-4827(80)90144-5; PAPAMICHAIL M, 1981, EXP CELL RES, V133, P461, DOI 10.1016/0014-4827(81)90342-6; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RIFE SU, 1990, IMMUNOL INVEST, V19, P259, DOI 10.3109/08820139009041841; Roberts CW, 1996, PARASITOL TODAY, V12, P382, DOI 10.1016/0169-4758(96)10060-0; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCHUURS AHWM, 1990, J STEROID BIOCHEM, V35, P157, DOI 10.1016/0022-4731(90)90270-3; Shapiro H. M., 1988, PRACTICAL FLOW CYTOM; SHERIDAN PJ, 1991, MOL CELL ENDOCRINOL, V76, pC39, DOI 10.1016/0303-7207(91)90279-2; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STEINSAPIR J, 1990, J STEROID BIOCHEM, V37, P697, DOI 10.1016/0960-0760(90)90354-N; Stimson WH, 1987, HORMONES IMMUNITY, P43; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VISELLI SM, 1995, MOL CELL ENDOCRINOL, V109, P19, DOI 10.1016/0303-7207(95)03479-Q; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; WUNDERLICH F, 1991, PARASITE IMMUNOL, V13, P357, DOI 10.1111/j.1365-3024.1991.tb00289.x; WUNDERLICH F, 1988, INFECT IMMUN, V56, P2400, DOI 10.1128/IAI.56.9.2400-2406.1988; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249	48	243	253	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					123	133		10.1096/fasebj.13.1.123	http://dx.doi.org/10.1096/fasebj.13.1.123			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872937				2022-12-28	WOS:000078029500014
J	Hahn, A; Hock, B				Hahn, A; Hock, B			Chromosome mechanics of fungi under spaceflight conditions - tetrad analysis of two-factor crosses between spore color mutants of Sordaria macrospora	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	fungal genetics; sexual recombination; radiation effects	SPACE	Spore color mutants of the Sordaria macrospora Auersw, were crossed under spaceflight conditions on the space shuttle to MIR mission S/MM 05 (STS-81), The arrangement of spores of different colors in the asci allowed conclusions on the influence of spaceflight conditions on sexual recombination in fungi. Experiments on a 1-g centrifuge in space and in parallel on the ground were used for controls. The samples were analyzed microscopically on their return to earth. Each fruiting body was assessed separately. Statistical analysis of the data showed a significant increase in gene recombination frequencies caused by the heavy ion particle stream in space radiation. The lack of gravity did not influence crossing-over frequencies. Hyphae of the flown samples were assessed for DNA strand breaks. No increase in damage was found compared with the ground samples. It was shown that S. macrospora is able to repair radiation-induced DNA strand breaks within hours.	Tech Univ Munchen Weihenstephan, Dept Bot, D-85350 Freising, Germany	Technical University of Munich	Hahn, A (corresponding author), Tech Univ Munchen Weihenstephan, Dept Bot, Alte Akad 12, D-85350 Freising, Germany.							BARBIER M, 1978, LIFE SCI SPACE RES, V6, P207; Beadle GW, 1941, P NATL ACAD SCI USA, V27, P499, DOI 10.1073/pnas.27.11.499; BRUSCHI CV, 1994, BIORACK SPACELAB IML, P83; ESSER K, 1958, Z VEREBUNGSL, V89, P729, DOI 10.1007/BF00888561; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Horneck G, 1974, Life Sci Space Res, V12, P75; HORNECK G, 1992, NUCL TRACKS RAD MEAS, V20, P185; HORNECK G, 1998, BIOSENSORS ENV DIAGN, P215; KIEFER J, 1996, BIOL MED RES SPACE, P300; KOPPEN G, 1997, COMET NEWS, V6, P2; KRANZ AR, 1987, EUROPEAN SPACE AGENC; LINDEGREN CC, 1932, B TORREY BOT CLUB, V59, P119; Manieri P, 1996, J BIOTECHNOL, V47, P71, DOI 10.1016/0168-1656(96)01365-X; MOLOWITZ R, 1976, PLANTA, V128, P143, DOI 10.1007/BF00390315; NELSON GA, 1994, ADV SPACE RES-SERIES, V14, P209, DOI 10.1016/0273-1177(94)90405-7; Nevzgodina L V, 1989, Adv Space Res, V9, P53, DOI 10.1016/0273-1177(89)90054-9; ONEILL KL, 1993, MUTAT RES, V319, P129, DOI 10.1016/0165-1218(93)90071-K; Palagyi Z, 1996, BIOTECHNOL TECH, V10, P565, DOI 10.1007/BF00157362; Peterson D D, 1977, Life Sci Space Res, V15, P151; REITZ G, 1995, ACTA ASTRONAUT, V35, P313, DOI 10.1016/0094-5765(95)98735-R; REITZ G, 1993, CLIN INVESTIGATOR, V71, P710; REITZ G, 1998, RESULTS SPACE SHUTTL; YANG CH, 1994, ADV SPACE RES, V14, P373, DOI 10.1016/0273-1177(94)90490-1; ZHAO HY, 1995, GENETICS, V139, P1045; ZIMMERMANN MW, 1994, ADV SPACE RES, V14, P47, DOI 10.1016/0273-1177(94)90449-9	25	3	5	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S149	S156						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352157				2022-12-28	WOS:000080403800019
J	Himpens, B; Stalmans, P; Gomez, P; Malfait, M; Vereecke, J				Himpens, B; Stalmans, P; Gomez, P; Malfait, M; Vereecke, J			Intra- and intercellular Ca2+ signaling in retinal pigment epithelial cells during mechanical stimulation	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	RCS rats; gap junctions; intercellular communication; protein phosphorylation; calcium wave; confocal imaging; nucleus; cytoplasm; nucleo-cytoplasmic gradient; cytoskeleton	PROTEIN-KINASE-C; SIMULATED MICROGRAVITY; SMOOTH-MUSCLE; CALCIUM; ACTIVATION; PHOSPHORYLATION; LYMPHOCYTES; PROPAGATION	The intercellular communication (IC) was investigated between cultured rat retinal pig ment epithelial (RPE) cells isolated from Long-Evans (LE) or dystrophic Royal College of Surgeons (RCS) rats and gown in solutions containing normal and high glucose concentrations, or after modulation of protein kinase C (PKC), This was performed by studying the conduction of the free Ca2+-concentration ([Ca2+](i)) wave elicited by mechanical stimulation and by analyzing the fluorescence recovery after photobleaching (FRAP), Mechanical stimulation of LE-RPE cells triggers Ca2+ influx, mediated by stretch-sensitive cation channels followed by intracellular Ca2+ release. A regenerative [Ca2+](i) wave was found with a lower propagation rate in RCS-RPE cells, This rate could be increased by PKC downregulation, Mechanical stimulation caused a [Ca2+](i) increase in the mechanically stimulated (MS) cell followed after a delay by a [Ca2+](i) rise in the adjacent cell layers. The intercellular [Ca2+](i) wave propagation could be blocked by gap junction blockers such as halothane or PKC activation. An inhibition of die [Ca2+](i)-wave propagation similar to that induced by halothane could be observed in cells gown in solutions containing 14 mM or higher concentrations of glucose, PKC down-regulated cells gown in glucose-rich medium did not develop this inhibitory effect on gap junction communication (GJC), FRAP experiments confirmed that the observed changes were consistent with a PKC-mediated inhibitory effect of high glucose concentrations on GJC.	Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium	Universite Catholique Louvain	Himpens, B (corresponding author), Catholic Univ Louvain, Physiol Lab, Herestr 49, B-3000 Louvain, Belgium.							BENNETT MVL, 1994, SOC GEN PHY, V49, P223; Cooper D, 1998, J LEUKOCYTE BIOL, V63, P550, DOI 10.1002/jlb.63.5.550; DeSmedt H, 1997, BIOCHEM J, V322, P575; Felix JA, 1998, AM J RESP CELL MOL, V18, P602, DOI 10.1165/ajrcmb.18.5.3105; GALLEMORE RP, 1994, VISUAL NEUROSCI, V11, P753, DOI 10.1017/S0952523800003059; HIMPENS B, 1994, FASEB J, V8, P879, DOI 10.1096/fasebj.8.11.8070638; HIMPENS B, 1995, J VASC RES, V32, P207, DOI 10.1159/000159095; HIMPENS B, 1995, CELL CALCIUM, V18, P111, DOI 10.1016/0143-4160(95)90002-0; HIMPENS B, 1994, CELL CALCIUM, V16, P239, DOI 10.1016/0143-4160(94)90087-6; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; ROOF D, 1994, PRINCIPLES PRACTICE, P309; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; SNEYD J, 1995, AM J PHYSIOL-CELL PH, V268, pC1537, DOI 10.1152/ajpcell.1995.268.6.C1537; Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P176; Stalmans P, 1998, INVEST OPHTH VIS SCI, V39, P1493; Stalmans P, 1997, INVEST OPHTH VIS SCI, V38, P1598; Wang SSH, 1995, BIOPHYS J, V69, P1683, DOI 10.1016/S0006-3495(95)80086-X	23	34	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S63	S68						6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352146				2022-12-28	WOS:000080403800008
J	Schmitt, D				Schmitt, D			Workshop purpose and structure	FASEB JOURNAL			English	Editorial Material									European Space Agcy, Estec, Dept Space Sci, NL-2200 AG Noordwijk, Netherlands	European Space Agency	Schmitt, D (corresponding author), European Space Agcy, Estec, Dept Space Sci, Keplerlaan 1, NL-2200 AG Noordwijk, Netherlands.								0	1	1	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S1	S1						1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352139				2022-12-28	WOS:000080403800001
J	Navarro, F; Navas, P; Burgess, JR; Bello, RI; De Cabo, R; Arroyo, A; Villalba, JM				Navarro, F; Navas, P; Burgess, JR; Bello, RI; De Cabo, R; Arroyo, A; Villalba, JM			Vitamin E and selenium deficiency induces expression of the ubiquinone-dependent antioxidant system at the plasma membrane	FASEB JOURNAL			English	Article						lipid peroxidation; oxidative stress; plasma membrane; ubiquinone; vitamin E and selenium deficiency	HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; PHOSPHOLIPASE A(2) ACTIVITY; COENZYME-Q REDUCTASE; RAT-LIVER CYTOSOL; LIPID-PEROXIDATION; OXIDATIVE STRESS; DT-DIAPHORASE; SUBMITOCHONDRIAL PARTICLES; ELECTRON-TRANSPORT; ALPHA-TOCOPHEROL	We have used a model of dietary deficiency that leads to a chronic oxidative stress to evaluate responses that are adaptations invoked to boost cellular defense systems. Long-Evans hooded rats were fed with a diet lacking vitamin E (E) and selenium (Se) for 7 wk from weaning leading to animals deficient in both nutrients (-E -Se). In the absence of an electron donor, liver plasma membranes from these rats were more sensitive to lipid peroxidation, although they contained 40% greater amounts of ubiquinone than the plasma membranes from rats consuming diets with sufficient vitamin E and Se (+E +Se). The incubation of plasma membranes with NAD(P)H resulted in protection against peroxidation, and this effect was more pronounced in -E -Se membranes. Deficiency was accompanied by a twofold increase in redox activities associated with trans plasma membrane electron transport such as ubiquinone reductase and ascorbate free radical reductase. Staining with a polyclonal antibody against pig liver cytochrome b(5) reductase, which acts as one ubiquinone reductase in the plasma membrane, showed an increased expression of the enzyme in membranes from -E -Se rats. Little DT-diaphorase activity was measured in +E +Se plasma membranes, but this activity was dramatically increased in -E -Se plasma membranes. No such increase was found in liver cytosols, which contained elevated activity of calcium-independent phospholipase A(2). Thus, ubiquinone-dependent antioxidant protection in +E +Se plasma membranes is based primarily on NADH-cytochrome bg reductase, whereas additional protection needed in -E -Se plasma membranes is supported by the increase of ubiquinone levels, increased expression of the cytochrome br,reductase, and translocation of soluble DT-diaphorase to the plasma membrane. Our results indicate that, in the absence of vitamin E and Se, enhancement of ubiquinone-dependent reductase systems can fulfill the membrane antioxidant protection.	Univ Cordoba, Fac Ciencias, Dept Cellular Biol, E-14004 Cordoba, Spain; Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA	Universidad de Cordoba; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Villalba, JM (corresponding author), Univ Cordoba, Fac Ciencias, Dept Cellular Biol, Avd S Alberto Magno S-N, E-14004 Cordoba, Spain.	bclvimoj@lucano.uco.es	de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/E-7996-2010; NAVAS, PLACIDO/R-5943-2019; Navarro Roldán, Francisco/H-8611-2015; de Cabo, Rafael/J-5230-2016	de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0003-2830-5693; NAVAS, PLACIDO/0000-0002-4115-7966; Navarro Roldán, Francisco/0000-0002-6384-5575; de Cabo, Rafael/0000-0002-3354-2442				ABERG F, 1994, CHEM-BIOL INTERACT, V91, P1, DOI 10.1016/0009-2797(94)90002-7; Barroso MP, 1997, J BIOENERG BIOMEMBR, V29, P259, DOI 10.1023/A:1022462111175; BENES SE, 1995, PHYSIOL PLANTARUM, V94, P124, DOI 10.1111/j.1399-3054.1995.tb00793.x; BEYER RE, 1994, J BIOENERG BIOMEMBR, V26, P349, DOI 10.1007/BF00762775; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burgess JR, 1996, J NUTR BIOCHEM, V7, P366, DOI 10.1016/S0955-2863(96)00057-5; CONSTANTINESCU A, 1994, MOL ASPECTS MED, V15, P57, DOI 10.1016/0098-2997(94)90013-2; CONSTANTINESCU A, 1993, J BIOL CHEM, V268, P10906; CRAWFORD DR, 1994, METHODS ENZYMOL, V234, P175; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; ERNSTER L, 1992, BIOFACTORS, V3, P241; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FORSMARKANDREE P, 1995, FREE RADICAL BIO MED, V19, P749, DOI 10.1016/0891-5849(95)00076-A; GOLDMAN R, 1993, FREE RADICAL BIO MED, V15, P542, DOI 10.1016/0891-5849(93)90453-2; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P1; KAGAN VE, 1992, BIOCHEM BIOPH RES CO, V186, P74, DOI 10.1016/S0006-291X(05)80777-6; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; KIM C, 1995, PROTOPLASMA, V184, P111, DOI 10.1007/BF01276907; KUO CF, 1995, J NUTR, V125, P1419; Landi L, 1997, FREE RADICAL BIO MED, V22, P329, DOI 10.1016/S0891-5849(96)00294-8; LEI XG, 1995, J NUTR, V125, P1438; LI Y, 1992, J BIOL CHEM, V267, P15097; LIEBLER DC, 1993, CRIT REV TOXICOL, V23, P147, DOI 10.3109/10408449309117115; LIND C, 1990, METHOD ENZYMOL, V186, P287; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; May JM, 1996, J BIOL CHEM, V271, P10577, DOI 10.1074/jbc.271.18.10577; Mazur A, 1996, BRIT J NUTR, V76, P899, DOI 10.1079/BJN19960096; NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947; NAVAS P, 1989, CANCER RES, V49, P2147; PASCOE GA, 1987, J CHROMATOGR-BIOMED, V414, P440, DOI 10.1016/0378-4347(87)80071-3; REDDY CC, 1982, BIOCHEM BIOPH RES CO, V107, P75, DOI 10.1016/0006-291X(82)91671-0; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schultz JR, 1996, BIOCHEMISTRY-US, V35, P6595, DOI 10.1021/bi960245h; Slater AFG, 1996, CELL DEATH DIFFER, V3, P57; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; Takahashi T, 1996, J BIOCHEM-TOKYO, V119, P256; TAKAHASHI T, 1995, BIOCHEM J, V309, P883, DOI 10.1042/bj3090883; Takahashi T, 1996, BIOL PHARM BULL, V19, P1005; TAKAHASHI T, 1992, FEBS LETT, V314, P331, DOI 10.1016/0014-5793(92)81499-C; Tokumaru S, 1997, FREE RADICAL RES, V26, P169, DOI 10.3109/10715769709097795; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; VILLALBA JM, 1996, TREND COMPAR BIOCHEM, V2, P65; Yang MX, 1996, ARCH BIOCHEM BIOPHYS, V331, P69, DOI 10.1006/abbi.1996.0284	51	102	102	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1665	1673		10.1096/fasebj.12.15.1665	http://dx.doi.org/10.1096/fasebj.12.15.1665			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837856				2022-12-28	WOS:000077574500008
J	Koudinov, AR; Berezov, TT; Koudinova, NV				Koudinov, AR; Berezov, TT; Koudinova, NV			Alzheimer's amyloid beta and lipid metabolism: a missing link?	FASEB JOURNAL			English	Editorial Material							APOLIPOPROTEIN-E; CHOLESTEROL ESTERIFICATION; CEREBROSPINAL-FLUID; TYPE-4 ALLELE; DISEASE BRAIN; SOLUBLE FORM; PLASMA; PROTEIN; A-BETA-1-40; PEPTIDE		Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Russian Acad Med Sci, Inst Biomed Chem, Moscow 117198, Russia; Patrice Lumumba Peoples Friendship Univ, Sch Med, Dept Biochem, Moscow 117198, Russia	Weizmann Institute of Science; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; Peoples Friendship University of Russia	Koudinov, AR (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	koudin@imb.imb.ac.ru			NIA NIH HHS [AG10953, AG08051] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008051, R35AG010953] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baggio G, 1998, FASEB J, V12, P433, DOI 10.1096/fasebj.12.6.433; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CZECH C, 1994, EUR ARCH PSY CLIN N, V243, P291, DOI 10.1007/BF02191587; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GINSBERG L, 1993, BRAIN RES, V615, P355, DOI 10.1016/0006-8993(93)90050-W; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Jacobs C, 1997, SCIENCE, V278, P1731, DOI 10.1126/science.278.5344.1731b; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; KNEBL J, 1994, MECH AGEING DEV, V73, P69, DOI 10.1016/0047-6374(94)90039-6; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; KOUDINOV A, 1997, CELL BIOL INT, V25, P265; Koudinov AR, 1996, BIOCHEM MOL BIOL INT, V38, P747; Koudinov AR, 1996, BIOCHEM BIOPH RES CO, V223, P592, DOI 10.1006/bbrc.1996.0940; Koudinov AR, 1998, CLIN CHIM ACTA, V270, P75, DOI 10.1016/S0009-8981(97)00207-6; Koudinova NV, 1996, FEBS LETT, V395, P204, DOI 10.1016/0014-5793(96)01042-3; LACKO AG, 1983, CLIN CHIM ACTA, V132, P133, DOI 10.1016/0009-8981(83)90241-3; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MURDOCH JC, 1977, BRIT MED J, V2, P226, DOI 10.1136/bmj.2.6081.226; PETTEGREW J, 1988, ALZHEIMERS DIS NEW T, P200; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977	25	33	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1998	12	12					1097	1099		10.1096/fasebj.12.12.1097	http://dx.doi.org/10.1096/fasebj.12.12.1097			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737712				2022-12-28	WOS:000075738500004
J	Massoud, TF; Hademenos, GJ; Young, WL; Gao, EZ; Pile-Spellman, J; Vinuela, F				Massoud, TF; Hademenos, GJ; Young, WL; Gao, EZ; Pile-Spellman, J; Vinuela, F			Principles and philosophy of modeling in biomedical research	FASEB JOURNAL			English	Article						models; biological; experimental design; philosophy; medical		Despite widespread applications in biomedical research, the role of models and modeling is often controversial and ill understood, It is usual to find that fundamental definitions, axioms, and postulates used in the modeling process have become tacit assumptions, What is essential, however, is a clear vision of the fundamental principles of modeling, This is even more compelling for new and emerging interdisciplinary fields that use techniques from previously separate scientific disciplines, This article outlines and reviews the central nature and philosophy of modeling, the rules that govern it, and its underlying key integral relationship to the 'scientific method', A comprehensive understanding of these issues is indispensable to successful research and meaningful progress in all facets of biomedicine.	Univ Calif Los Angeles, Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA; Columbia Univ Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA; Univ Dallas, Dept Phys, Dallas, TX 75062 USA; Columbia Univ Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Elect Engn, New York, NY 10027 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Columbia University; Columbia University; Columbia University; Columbia University	Massoud, TF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Vasc Surg, Sch Med, Fulham Palace Rd, London W6 8RF, England.				NHLBI NIH HHS [1 RO1 HL/NS52352-01A1] Funding Source: Medline; NINDS NIH HHS [R01 NS34949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERMAN M, 1963, J THEOR BIOL, V4, P229, DOI 10.1016/0022-5193(63)90001-8; Beveridge W. I. B., 1961, ART SCI INVESTIGATIO; Cape EG, 1996, J THORAC CARDIOV SUR, V111, P499, DOI 10.1016/S0022-5223(96)90005-7; DAINTY J, 1960, Symp Soc Exp Biol, V14, P140; EDWARDS A W, 1960, Symp Soc Exp Biol, V14, P6; FOGEL LJ, 1963, BIOTECHNOLOGY CONCEP; HARMON L. D., 1968, ADVAN BIOMED ENG MED PHYS, V1, P119; HARRIS JE, 1960, S SOC EXPT BIOL, V14, P250; HOFFMAN H, 1987, ACTA NEUROCHIR S, V40, P117; KACSER H, 1960, Symp Soc Exp Biol, V14, P13; Popper K. R., 1973, OBJECTIVE KNOWLEDGE; PRINGLE J W, 1960, Symp Soc Exp Biol, V14, P41; ROOK A, 1964, ORIGINS GROWTH BIOLO; ROSEN R, 1991, LIFE ITSELF COMPREHE, P152; ROSEN R, 1991, LIFE ITSELF COMPREHE, P49; ROSEN R, 1983, AM J PHYSIOL, V224, pR591; Rosenbluth R., 1945, PHILOS SCI, V12, P316, DOI [10.1086/286874, DOI 10.1086/286874]; Suppes, 1969, STUDIES METHODOLOGY, P10; VERVEEN A A, 1971, Mathematical Biosciences, V11, P5, DOI 10.1016/0025-5564(71)90004-6; WESTCOTT J H, 1960, Symp Soc Exp Biol, V14, P102; WHITE RJ, 1983, ADV CARDIOVASCULAR 1, V5, P162; YATES FE, 1978, AM J PHYSIOL, V234, pR159, DOI 10.1152/ajpregu.1978.234.5.R159; YATES FE, 1977, ENDOCRINOLOGY, V1, P240	23	37	38	3	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1998	12	3					275	285		10.1096/fasebj.12.3.275	http://dx.doi.org/10.1096/fasebj.12.3.275			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YZ898	9580086				2022-12-28	WOS:000072305500016
J	Foster, LC; Wiesel, P; Huggins, GS; Panares, R; Chin, MT; Pellacani, A; Perrella, MA				Foster, LC; Wiesel, P; Huggins, GS; Panares, R; Chin, MT; Pellacani, A; Perrella, MA			Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1 beta in vascular smooth muscle cells	FASEB JOURNAL			English	Article						inflammation; gene transcription; adhesion molecule; arteriosclerosis	INTERCELLULAR-ADHESION MOLECULE-1; EPIDERMAL GROWTH-FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTORS; CHROMOSOMAL-PROTEINS; METASTATIC BEHAVIOR; HYALURONAN-BINDING; ENDOTHELIAL-CELLS; GLYCOPROTEIN CD44; DNA-BINDING	CD44 is a multifunctional cell adhesion molecule that participates in pathological states such as inflammation and tumorigenesis. CD44 is induced on vascular smooth muscle cells after arterial wall injury and may mediate their proliferation and migration into the neointima during arteriosclerosis. We have demonstrated elsewhere that the proinflammatory cytokine interleukin (IL)-1 beta upregulates CD44 mRNA and protein expression in cultured rat aortic smooth muscle cells (RASMC) by increasing gene transcription. By transient transfection of 5'-deletion constructs into RASMC, we show in the present study that a conserved AP-1 site 110 base pairs from the transcription start site of the mouse CD44 promoter is important for basal activity, Mutation of the AP-1 site significantly reduced induction of promoter activity by IL-1 beta, and electrophoretic mobility shift assays demonstrated that Fos and c-Jun were present in the CD44 AP-1 binding complex after IL-1 beta stimulation, in addition, cotransfection of the architectural transcription factor high mobility group (HMG)-I(Y) protein with c-Fos and c-Jun markedly increased trans-activation of the CD44 promoter, Taken together, our studies demonstrate that AP-1 proteins are a central regulatory component used by IL-1 beta to modulate expression of CD44 during an inflammatory response in vascular smooth muscle cells and that transcription of CD44 by AP-1 proteins is enhanced by HMG-1(Y).	Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Perrella, MA (corresponding author), Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	perrella@cvlab.harvard.edu			NHLBI NIH HHS [HL03745, HL60788, HL03194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLINTON SK, 1991, AM J PATHOL, V138, P1005; CLINTON SK, 1992, ARCH PATHOL LAB MED, V116, P1292; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COUFFINHAL T, 1994, CIRC RES, V74, P225, DOI 10.1161/01.RES.74.2.225; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 1996, CANCER RES, V56, P1896; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Fitzgerald K, 1997, BIOCHEM SOC T, V25, pS185, DOI 10.1042/bst025185s; Foster LC, 1998, J BIOL CHEM, V273, P20341, DOI 10.1074/jbc.273.32.20341; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HERRLICH P, 1993, PEZ FDN SYM, V4, P265; HOFMANN M, 1993, CANCER RES, V53, P1516; Holth LT, 1997, DNA CELL BIOL, V16, P1299, DOI 10.1089/dna.1997.16.1299; IKEDA U, 1993, ATHEROSCLEROSIS, V104, P61, DOI 10.1016/0021-9150(93)90176-U; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Levesque MC, 1996, J IMMUNOL, V156, P1557; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; MIANO JM, 1993, AM J PATHOL, V142, P715; MOYER CF, 1991, AM J PATHOL, V138, P951; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NOMOTO A, 1988, ATHEROSCLEROSIS, V72, P213, DOI 10.1016/0021-9150(88)90083-4; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; REEVES R, 1990, J BIOL CHEM, V265, P8573; Riessen R, 1996, CIRCULATION, V93, P1141, DOI 10.1161/01.CIR.93.6.1141; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; ROSS R, 1995, MOL CARDIOVASCULAR M, P11; RUDY W, 1993, CANCER RES, V53, P1262; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; WANG XK, 1994, CARDIOVASC RES, V28, P1808, DOI 10.1093/cvr/28.12.1808; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEGNER M, 1990, BIOCHEM BIOPH RES CO, V166, P1110, DOI 10.1016/0006-291X(90)90981-R; Weiss JM, 1998, J INVEST DERMATOL, V111, P227, DOI 10.1046/j.1523-1747.1998.00286.x; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; YANG-YEN H-F, 1990, New Biologist, V2, P351; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530; Zhang M, 1996, CLIN EXP METASTAS, V14, P268; Zhang M, 1997, J BIOL CHEM, V272, P14139, DOI 10.1074/jbc.272.22.14139	66	47	53	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					368	378		10.1096/fasebj.14.2.368	http://dx.doi.org/10.1096/fasebj.14.2.368			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657993				2022-12-28	WOS:000085184800016
J	Torres, L; Avila, MA; Carretero, MV; Latasa, MU; Caballeria, J; Lopez-Rodas, G; Boukaba, A; Lu, SC; Franco, L; Mato, JM				Torres, L; Avila, MA; Carretero, MV; Latasa, MU; Caballeria, J; Lopez-Rodas, G; Boukaba, A; Lu, SC; Franco, L; Mato, JM			Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation	FASEB JOURNAL			English	Article						S-adenosylmethionine synthesis; DNA methylation; tissue-specific expression; liver cirrhosis; hepatocarcinoma	S-ADENOSYLMETHIONINE SYNTHETASE; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; MESSENGER-RNA; HEPATOCYTES; DEACETYLASE; INHIBITION; GROWTH; INJURY; MECP2	Methionine adenoyltransferase (MAT) is the enzyme that catalyses the synthesis of S-adenosylmethionine (AdoMet), the main donor of methyl groups in the cell. In mammals MAT is the product of two genes, MAT1A and MAT2A. MAT1A is expressed only in the mature liver whereas fetal hepatocytes, extrahepatic tissues and liver cancer cells express MAT2A. The mechanisms behind the tissue and differentiation state specific MAT1A expression are no known. In present work we examined MAT1A promoter methylation status by means of methylation sensitive restriction enzyme analysis. Our data indicate that MAT1A promoter is hypomethylated in liver and hypomethylated in kidney and fetal rat hepatocytes indicating that this modification is tissue specific and developmentally regulated. Immunoprecipitation of mononucleosomes from liver and kidney tissues with antibodies mainly specific to acetylated histone H4 and subsequent Southern blot analysis with MAT1A promoter probe demonstrated that MAT1A expression is linked to elevated levels of chromatin acetylation. Early changes in MAT1A methylation are already observed in the precancerous cirrhotic livers from rats, which slow reduced MAT1A expression. Human hepatoma cell lines which MAT1A is not expressed were also hypermethylated at this locus. Finally we demonstrate that MAT1A expression is reactivated in the human hepatoma cell line hepG2 treated with 5-aza-2'-deoxycytidine or the histone deacetylase inhibitor trichostatin, suggesting a role for DNA hypermethylation and histone deaceytylation in MAT1A silencing.-Torres, L., Avila, M. A, Carretero, M. V., Latasa, M. U., Caballeria, J., Lopez-Rodas, G., Boukaba, A., Lu, S. C., Franco, I., Mato J.M. Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation; im plications for MAT1A silencing during transformation.	Univ Navarra, Fac Med, Dept Med Interna, Div Hepatol & Terapia Gen, Navarra 31008, Spain; Hosp Clin Barcelona, Serv Hepatol, Barcelona 08036, Spain; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Univ So Calif, Sch Med, Dept Med, Ctr Liver Dis Res, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal Liver Dis, Los Angeles, CA 90033 USA	University of Navarra; University of Barcelona; Hospital Clinic de Barcelona; University of Valencia; University of Southern California; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Fac Med, Dept Med Interna, Div Hepatol & Terapia Gen, Navarra 31008, Spain.	jmmato@unav.es	MATO, JOSE/A-5187-2011; Torres, Luis/AAB-2403-2019; Avila, Matias A/Y-6342-2019; LOPEZ-RODAS, GERARDO/I-1349-2015	MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Franco, Luis/0000-0001-9610-6448; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X; Latasa, Maria Ujue/0000-0002-0878-1337	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051719] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51719] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez L, 1997, J BIOL CHEM, V272, P22875, DOI 10.1074/jbc.272.36.22875; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Bender CM, 1998, CANCER RES, V58, P95; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; Carretero MV, 1998, FEBS LETT, V439, P55, DOI 10.1016/S0014-5793(98)01335-0; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; Counts JL, 1997, MOL CARCINOGEN, V18, P97, DOI 10.1002/(SICI)1098-2744(199702)18:2<97::AID-MC5>3.0.CO;2-N; CraneRobinson C, 1997, METHODS, V12, P48, DOI 10.1006/meth.1997.0446; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gil B, 1996, HEPATOLOGY, V24, P876; HOFFMAN RM, 1983, BIOCHIM BIOPHYS ACTA, V738, P49, DOI 10.1016/0304-419X(84)90019-2; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MUDD SH, 1958, J BIOL CHEM, V231, P481; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Sun L, 1997, JPN J CANCER RES, V88, P1165, DOI 10.1111/j.1349-7006.1997.tb00345.x; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; TSAO JL, 1991, ANAL BIOCHEM, V197, P137, DOI 10.1016/0003-2697(91)90369-5; TSUDA H, 1988, GASTROENTEROLOGY, V95, P1664, DOI 10.1016/S0016-5085(88)80093-3; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; VARELAMOREIRAS G, 1995, HEPATOLOGY, V22, P1310, DOI 10.1016/0270-9139(95)90644-4; VELASCO JA, 1994, ONCOGENE, V9, P2065; YASUI H, 1992, CANCER RES, V52, P6810; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	35	69	70	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					95	102		10.1096/fasebj.14.1.95	http://dx.doi.org/10.1096/fasebj.14.1.95			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627284				2022-12-28	WOS:000084784700012
J	Sakiyama, SE; Schense, JC; Hubbell, JA				Sakiyama, SE; Schense, JC; Hubbell, JA			Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering	FASEB JOURNAL			English	Article						antithrombin III; neural cell adhesion molecule; platelet factor 4; regeneration	MOLECULE HB-GAM; CELL SUBSTRATUM ADHESION; AMINO-ACID SEQUENCE; OUTGROWTH IN-VITRO; NERVE REGENERATION; ANTITHROMBIN-III; SILICONE CHAMBER; A-CHAIN; LAMININ; GROWTH	The goal of this work was to improve the potential of fibrin to promote nerve regeneration by enzymatically incorporating exogenous neurite-promoting heparin-binding peptides. The effects on neurite extension of four different heparin-binding peptides, derived from the heparin-binding domains of antithrombin III, neural cell adhesion molecule and platelet factor 4, were determined. These exogenous peptides were synthesized as bi-domain peptide chimeras, with the second domain being a substrate for factor XIIIa. This coagulation transglutaminase covalently bound the peptides within the fibrin gel during coagulation. The heparin-binding peptides enhanced the degree of neurite extension from embryonic chick dorsal root ganglia through 3-dimensional fibrin gels, and the extent of enhancement was found to correlate positively with the heparin-binding affinity of the individual domains. The enhancement could be inhibited by competition with soluble heparin, by degradation of cell-surface proteoglycans, and by inhibition of the covalent immobilization of the peptide. These results demonstrate an important potential role for proteoglycan-binding components of the extracellular matrix in neurite extension and suggest that fibrin gels modified with covalently bound heparin-binding peptides could serve as a therapeutic agent to enhance peripheral nerve regeneration through nerve guide tubes. More generally, the results demonstrate that the biological responses to fibrin, the body's natural wound healing matrix, can be dramatically improved by the addition of exogenous bioactive peptides in a manner such that they become immobilized during coagulation.	ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; ETH Zurich, Dept Mat, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8006 Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology	Hubbell, JA (corresponding author), ETH Zurich, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Sakiyama-Elbert, Shelly/A-6753-2008; Hubbell, Jeffrey A/A-9266-2008	Sakiyama-Elbert, Shelly/0000-0003-4832-5851; Hubbell, Jeffrey A/0000-0003-0276-5456				AEBISCHER P, 1990, BRAIN RES, V531, P211, DOI 10.1016/0006-8993(90)90776-8; AUMAILLEY M, 1990, FEBS LETT, V262, P82, DOI 10.1016/0014-5793(90)80159-G; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Borkenhagen M, 1998, J BIOMED MATER RES, V40, P392, DOI 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.3.CO;2-4; Borrajo AMP, 1997, BIOORG MED CHEM LETT, V7, P1185, DOI 10.1016/S0960-894X(97)00180-7; CARRI NG, 1988, J NEUROSCI RES, V19, P428, DOI 10.1002/jnr.490190407; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1985, J CELL BIOL, V100, P1192, DOI 10.1083/jcb.100.4.1192; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Herbert CB, 1996, J COMP NEUROL, V365, P380, DOI 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0; ICHINOSE A, 1983, FEBS LETT, V153, P369, DOI 10.1016/0014-5793(83)80645-0; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KALLAPUR SG, 1992, J NEUROSCI RES, V33, P538, DOI 10.1002/jnr.490330406; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; LIESI P, 1989, FEBS LETT, V244, P141, DOI 10.1016/0014-5793(89)81180-9; Lundborg G, 1990, Restor Neurol Neurosci, V1, P297, DOI 10.3233/RNN-1990-13418; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; Mooney DJ, 1997, J BIOMED MATER RES, V37, P413, DOI 10.1002/(SICI)1097-4636(19971205)37:3<413::AID-JBM12>3.0.CO;2-C; Nolo R, 1996, EUR J NEUROSCI, V8, P1658, DOI 10.1111/j.1460-9568.1996.tb01309.x; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; RAOLO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; ROGERS SL, 1985, J NEUROSCI, V5, P369; Schense JC, 1999, BIOCONJUGATE CHEM, V10, P75, DOI 10.1021/bc9800769; SEPHEL GC, 1989, DEV NEUROSCI-BASEL, V11, P313, DOI 10.1159/000111909; Sims CD, 1998, PLAST RECONSTR SURG, V101, P1580, DOI 10.1097/00006534-199805000-00022; SMITH JW, 1987, J BIOL CHEM, V262, P11964; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; TYLERCROSS R, 1994, PROTEIN SCI, V3, P620; VARON S, 1972, METHODS TECHNIQUES N, P203; WILLIAMS LR, 1987, NEUROCHEM RES, V12, P851, DOI 10.1007/BF00966306; WILLIAMS LR, 1987, J COMP NEUROL, V264, P284, DOI 10.1002/cne.902640211; ZUCKER MB, 1991, P SOC EXP BIOL MED, V198, P93	48	149	168	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2214	2224		10.1096/fasebj.13.15.2214	http://dx.doi.org/10.1096/fasebj.13.15.2214			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593869				2022-12-28	WOS:000084310800013
J	Kapusta, J; Modelska, A; Figlerowicz, M; Pniewski, T; Letellier, M; Lisowa, O; Yusibov, V; Koprowski, H; Plucienniczak, A; Legocki, AB				Kapusta, J; Modelska, A; Figlerowicz, M; Pniewski, T; Letellier, M; Lisowa, O; Yusibov, V; Koprowski, H; Plucienniczak, A; Legocki, AB			A plant-derived edible vaccine against hepatitis B virus	FASEB JOURNAL			English	Article						oral vaccines; surface antigen (HBsAg); transgenic lupin; lettuce and engineered plants	TRANSGENIC PLANTS; SURFACE-ANTIGEN; IMMUNOGENICITY; EXPRESSION; POTATO; MICE	The infectious hepatitis B virus represents 42 nm spherical double-shelled particles. However, analysis of blood from hepatitis B virus carriers revealed the presence of smaller 22 nm particles consisting of a viral envelope surface protein. These particles are highly immunogenic and have been used in the design of hepatitis B virus vaccine produced in yeast. Upon expression in yeast, these proteins form virus-like particles that are used for parenteral immunization. Therefore, the DNA fragment encoding hepatitis B virus surface antigen was introduced into Agrobacterium tumerifacience LBA4404 and used to obtain transgenic lupin (Lupinus luteus L.) and lettuce (Lactuca sativa L.) cv. Burpee Bibb expressing envelope surface protein. Mice that were fed the transgenic lupin tissue developed significant levels of hepatitis B virus-specific antibodies. Human volunteers, fed with transgenic lettuce plants expressing hepatitis B virus surface antigen, developed specific serum-IgG response to plant produced protein.	Thomas Jefferson Univ, Biotechnol Fdn Labs, Philadelphia, PA 19107 USA; Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland; Marcinkovski Acad Med Sci, Dept Endocrinol, Poznan, Poland; Marcinkovski Acad Med Sci, Dept Pediat, Poznan, Poland; Inst Biotechnol & Antibiot, Warsaw, Poland	Jefferson University; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Institute of Biotechnology & Antibiotics (IBA)	Koprowski, H (corresponding author), Thomas Jefferson Univ, Biotechnol Fdn Labs, Room M85 JAH,1020 Locust St, Philadelphia, PA 19107 USA.		Figlerowicz, Marek/B-9550-2015; Yusibov, Vidadi/AAA-7408-2019					Arakawa T, 1998, NAT BIOTECHNOL, V16, P292, DOI 10.1038/4381; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MICHELMORE R, 1987, PLANT CELL REP 6, V439, P442; MOZO T, 1991, PLANT MOL BIOL, V16, P917, DOI 10.1007/BF00015085; Sambrook S, 1989, MOL CLONING LAB MANU; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; Yusibov V, 1997, P NATL ACAD SCI USA, V94, P5784, DOI 10.1073/pnas.94.11.5784	12	265	329	0	39	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1999	13	13					1796	1799		10.1096/fasebj.13.13.1796	http://dx.doi.org/10.1096/fasebj.13.13.1796			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506582				2022-12-28	WOS:000083063400014
J	Zhang, W; Mannan, I; Schulz, S; Parkinson, SJ; Alekseev, AE; Gomez, LA; Terzic, A; Waldman, SA				Zhang, W; Mannan, I; Schulz, S; Parkinson, SJ; Alekseev, AE; Gomez, LA; Terzic, A; Waldman, SA			Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea	FASEB JOURNAL			English	Article						E-coli heat-stable enterotoxin; intestinal cell water secretion; cyclic GMP; 2-substituted adenine nucleotides; CFTR-mediated chloride current	HEAT-STABLE ENTEROTOXIN; GUANYLYL CYCLASE-C; DEPENDENT PROTEIN-KINASE; CELL-LINE CACO-2; ESCHERICHIA-COLI; RAT INTESTINE; CYCLIC-GMP; RECEPTOR; SECRETION; CHANNELS	Bacteria that produce heat-stable enterotoxins (STs), a leading cause of secretory diarrhea, are a major cause of morbidity and mortality worldwide. ST stimulates guanylyl cyclase C (GCC) and accumulation of intracellular cyclic GMP ([cGMP](i)), which opens the cystic fibrosis transmembrane conductance regulator (CFTR)-related chloride channel, triggering intestinal secretion. Although the signaling cascade mediating ST-induced diarrhea is well characterized, antisecretory therapy targeting this pathway has not been developed. 2-ChloroATP (2ClATP) and its cell-permeant precursor, 2-chloroadenosine (2ClAdo), disrupt ST-dependent signaling in intestinal cells. However, whether the ability to disrupt guanylyl cyclase signaling translates into effective antisecretory therapy remains untested. In this study, the efficacy of 2ClAdo to prevent ST-induced water secretion by human intestinal cells was examined. In Caco-2 human intestinal cells, ST increased [cGMP](i), induced a chloride current, and stimulated net basolateral-to-apical water secretion. This effect on chloride current and water secretion was mimicked by the cell-permeant analog of cGMP, 8-bromo-cGMP. Treatment of Caco-2 cells with 2C1Ado prevented ST-induced increases in [cGMP](i), chloride current and water secretion. Inhibition of the downstream consequences of ST-GCC interaction reflects proximal disruption of cGMP production because 8-bromo-cGMP stimulated chloride current and water secretion in 2ClAdo-treated cells. Thus, this study demonstrates that disruption of guanylyl cyclase signaling is an effective strategy for antisecretory therapy and provides the basis for developing mechanism-based treatments for enterotoxigenic diarrhea.	Thomas Jefferson Univ, Div Clin Pharmacol, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Div Clin Pharmacol, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA	Jefferson University; Jefferson University; Mayo Clinic; Mayo Clinic	Waldman, SA (corresponding author), Thomas Jefferson Univ, Div Clin Pharmacol, Dept Med, MOB 813,1100 Walnut St, Philadelphia, PA 19107 USA.	waldmans@jeflin.tju.edu	Alekseev, Alexey/I-5346-2013	Waldman, Scott/0000-0001-6619-175X	NATIONAL CANCER INSTITUTE [R01CA075123] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059214] Funding Source: NIH RePORTER; NCI NIH HHS [CA75123] Funding Source: Medline; NHLBI NIH HHS [HL59214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alekseev AE, 1996, BIOPHYS J, V70, P786, DOI 10.1016/S0006-3495(96)79618-2; Alekseev AE, 1996, J MOL CELL CARDIOL, V28, P1193, DOI 10.1006/jmcc.1996.0110; Alekseev AE, 1997, J MEMBRANE BIOL, V157, P203, DOI 10.1007/s002329900229; BLACK RE, 1982, AM J EPIDEMIOL, V115, P315, DOI 10.1093/oxfordjournals.aje.a113308; Carrithers SL, 1996, P NATL ACAD SCI USA, V93, P14827, DOI 10.1073/pnas.93.25.14827; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CRAVIOTO A, 1988, EPIDEMIOL INFECT, V101, P123, DOI 10.1017/S0950268800029289; Dorr RA, 1997, COMPUT METH PROG BIO, V53, P9, DOI 10.1016/S0169-2607(96)01801-9; DREYFUS LA, 1984, INFECT IMMUN, V46, P537, DOI 10.1128/IAI.46.2.537-543.1984; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; GRASSET E, 1985, AM J PHYSIOL, V248, pC410, DOI 10.1152/ajpcell.1985.248.5.C410; GUERRANT RL, 1990, REV INFECT DIS, V12, pS41; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; Mann EA, 1996, BBA-GENE STRUCT EXPR, V1305, P7, DOI 10.1016/0167-4781(95)00190-5; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; NATH SK, 1990, J DIARRHOEAL DIS RES, V8, P133; PARISI M, 1995, J MEMBRANE BIOL, V143, P237; PARISI M, 1993, PFLUG ARCH EUR J PHY, V423, P1, DOI 10.1007/BF00374953; Parkinson SJ, 1997, J BIOL CHEM, V272, P754, DOI 10.1074/jbc.272.2.754; PARKINSON SJ, 1994, J BIOL CHEM, V269, P22683; Parkinson SJ, 1996, BIOCHEMISTRY-US, V35, P3213, DOI 10.1021/bi9524326; PINTO M, 1983, BIOL CELL, V47, P323; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RUBAS W, 1993, PHARMACEUT RES, V10, P113, DOI 10.1023/A:1018937416447; SAVARINO SJ, 1991, J CLIN INVEST, V87, P1450, DOI 10.1172/JCI115151; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Schulz S, 1997, J CLIN INVEST, V100, P1590, DOI 10.1172/JCI119683; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Waldman SA, 1998, CANCER EPIDEM BIOMAR, V7, P505; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359; 1985, TRAVELERS DIARRHEA, V5, P1	35	21	22	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					913	922		10.1096/fasebj.13.8.913	http://dx.doi.org/10.1096/fasebj.13.8.913			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224234				2022-12-28	WOS:000080372500014
J	Larocca, D; Kassner, PD; Witte, A; Ladner, RC; Pierce, GF; Baird, A				Larocca, D; Kassner, PD; Witte, A; Ladner, RC; Pierce, GF; Baird, A			Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage	FASEB JOURNAL			English	Article						phage display; transfection; receptor-mediated; ligand	FIBROBLAST GROWTH-FACTOR; PHAGE DISPLAY; BINDING; DELIVERY; SURFACE; INTERLEUKIN-2; SELECTION; RECEPTOR; PEPTIDE; LAMBDA	We have genetically modified filamentous bacteriophage to deliver genes to mammalian cells. In previous studies we showed that noncovalently attached fibroblast growth factor (FGF2) can target bacteriophage to COS-1 cells, resulting in receptor-mediated transduction with a reporter gene, Thus, bacteriophage, which normally lack tropism for mammalian cells, can be adapted for mammalian cell gene transfer. To determine the potential of using phage-mediated gene transfer as a novel display phage screening strategy, we transfected COS-1 cells with phage that were engineered to display FGF2 on their surface coat as a fusion to the minor coat protein, pIII, Immunoblot and ELISA analysis confirmed the presence of FGF2 on the phage coat. Significant transduction was obtained in COS-1 cells with the targeted FGF2-phage compared with the nontargeted parent phage, Specificity was demonstrated by successful inhibition of transduction in the presence of excess free FGF2, Having demonstrated mammalian cell transduction by phage displaying a known gene targeting ligand, it is now feasible to apply phage-mediated transduction as a screen for discovering novel ligands.	Select Genet Inc, San Diego, CA 92121 USA; Dyax Corp, Boston, MA 02115 USA		Larocca, D (corresponding author), Select Genet Inc, 11035 Roselle St, San Diego, CA 92121 USA.			Kassner, Paul/0000-0002-1471-1191; Baird, Andrew/0000-0003-0027-9905; Larocca, Dana/0000-0001-5863-9833				Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; Buchli PJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P79, DOI 10.1006/abbi.1996.9853; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dunn IS, 1996, BIOCHIMIE, V78, P856, DOI 10.1016/S0300-9084(97)84338-6; FOX GM, 1988, J BIOL CHEM, V263, P18452; Goldman CK, 1997, CANCER RES, V57, P1447; GRAM H, 1993, J IMMUNOL METHODS, V161, P169, DOI 10.1016/0022-1759(93)90292-F; HART SL, 1994, J BIOL CHEM, V269, P12468; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HODGSON CP, 1995, BIO-TECHNOL, V13, P222, DOI 10.1038/nbt0395-222; HORST J, 1975, P NATL ACAD SCI USA, V72, P3531, DOI 10.1073/pnas.72.9.3531; ISHIURA M, 1982, MOL CELL BIOL, V2, P607, DOI 10.1128/MCB.2.6.607; KAY BK, 1998, PHAGE DISPLAY PEPTID, P55; LAPPI DA, 1993, ANAL BIOCHEM, V212, P446, DOI 10.1006/abio.1993.1353; Larocca D, 1998, HUM GENE THER, V9, P2393, DOI 10.1089/hum.1998.9.16-2393; Merlin S, 1997, APPL BIOCHEM BIOTECH, V67, P199, DOI 10.1007/BF02788798; MICHAEL SI, 1994, GENE THER, V1, P223; OKAYAMA H, 1985, MOL CELL BIOL, V5, P1136, DOI 10.1128/MCB.5.5.1136; PASQUALINI R, 1995, NAT BIOTECHNOL, V13, P222; ROGERS BE, 1998, TUMOR TARGET, V3, P25; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; Souriau C, 1997, NUCLEIC ACIDS RES, V25, P1585, DOI 10.1093/nar/25.8.1585; Vallejo Abbe N., 1995, P603; Vispo NS, 1997, IMMUNOTECHNOLOGY, V3, P185, DOI 10.1016/S1380-2933(97)00012-2; YOKOYAMAKOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V192, P935, DOI 10.1006/bbrc.1993.1505; YOKOYAMAKOBAYASHI M, 1994, ANAL BIOCHEM, V223, P130, DOI 10.1006/abio.1994.1557	28	110	134	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					727	734		10.1096/fasebj.13.6.727	http://dx.doi.org/10.1096/fasebj.13.6.727			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094933				2022-12-28	WOS:000079527200014
J	Huang, STJ; Cidlowski, JA				Huang, STJ; Cidlowski, JA			Glucocorticoids inhibit serum depletion-induced apoptosis in T lymphocytes expressing Bcl-2	FASEB JOURNAL			English	Article						programmed cell death; protection; growth factors	CELL-DEATH; CYTOCHROME-C; DNA FRAGMENTATION; S49 CELLS; ACTIVATION; THYMOCYTES; PREVENTS; CED-9; BAX; MITOCHONDRIA	Depletion of growth factors and glucocorticoids are known to induce apoptosis and inhibit growth in T lymphocytes. We have examined the effect of Bcl-2 expression on the cellular response to growth factor depletion in the presence or absence of glucocorticoids, Cell growth was determined by cell counting and viability was quantitated by dye exclusion. Apoptosis was evaluated by flow cytometry, analysis of DNA integrity, and enzymatic determination of caspase3-like activity. Serum depletion and glucocorticoid administration inhibited cell growth and stimulated apoptosis in Bcl-2 negative cells. Cotreatment with both stimuli had additive effects on apoptosis but not on inhibition of cell growth. Bcl-2 expression abrogated the repressive effect of glucocorticoids on apoptosis but not on cell growth. In contrast, neither apoptosis nor growth inhibition induced by serum depletion of cells was blocked by Bcl-2 expression. However, glucocorticoid treatment of Bcl-2-overexpressing cells protected them from apoptosis induced by serum depletion. Glucocorticoid protection of Bcl-2-overexpressing cells from serum depletion-induced apoptosis was mimicked by other inducers of apoptosis, which act to inhibit protein synthesis. These data suggest that Bcl-2 expression can switch the effect of glucocorticoids from proapoptotic to antiapoptotic when lymphocytes expressing Bcl-2 are exposed to other apoptotic stimuli.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,MD E2-02, Res Triangle Pk, NC 27709 USA.		Cidlowski, John A/G-2548-2019; Huang, Se-Te/F-6881-2013	Cidlowski, John A/0000-0003-1420-0516; 				Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; CARONLESLIE LAM, 1994, ENDOCRINE, V2, P47; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; FUKUHARA S, 1979, CANCER RES, V39, P3119; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENNET T, 1993, CANCER RES, V53, P1456; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; ITOH N, 1993, J IMMUNOL, V151, P621; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Robertson NM, 1997, CANCER RES, V57, P43; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shimizu S, 1996, ONCOGENE, V12, P2251; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	35	28	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					467	476		10.1096/fasebj.13.3.467	http://dx.doi.org/10.1096/fasebj.13.3.467			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064613				2022-12-28	WOS:000079016000006
J	Nadal, A; Rovira, JM; Laribi, O; Leon-Quinto, T; Andreu, E; Ripoll, C; Soria, B				Nadal, A; Rovira, JM; Laribi, O; Leon-Quinto, T; Andreu, E; Ripoll, C; Soria, B			Rapid insulinotropic effect of 17 beta-estradiol via a plasma membrane receptor	FASEB JOURNAL			English	Article						intracellular calcium; K-ATP channels; insulin secretion; confocal microscopy; membrane estrogen receptor	PANCREATIC BETA-CELL; BURSTING ELECTRICAL-ACTIVITY; VASCULAR SMOOTH-MUSCLE; REPLACEMENT THERAPY; GLUCOSE; ISLETS; ESTROGEN; CALCIUM; OSCILLATIONS; SECRETION	Impaired insulin secretion is a hallmark in both type I and type II diabetic individuals. Whereas type I (insulin-dependent diabetes mellitus) implies p-cen destruction, type II (non-insulin dependent diabetes mellitus), responsible for 75% of diabetic syndromes, involves diminished glucose-dependent secretion of insulin from pancreatic beta-cells. Although a clear demonstration of a direct effect of 17 beta-estradiol on the pancreatic P-cen is lacking, an in vivo insulinotropic effect has been suggested. In this report we describe the effects of 17 beta-estradiol in mouse pancreatic p-cells. 17 beta-Estradiol, at physiological concentrations, closes K-ATP channels, which are also targets for antidiabetic sulfonylureas, in a rapid and reversible manner. Furthermore, in synergy with glucose, 17 beta-estradiol depolarizes the plasma membrane, eliciting electrical activity and intracellular calcium signals, which in turn enhance insulin secretion. These effects occur through a receptor located at the plasma membrane, distinct from the classic cytosolic estrogen receptor. Specific competitive binding and localization of 17 beta-estradiol receptors at the plasma membrane was demonstrated using confocal reflective microscopy and immunocytochemistry. Gaining deeper knowledge of the effect induced by 17 beta-estradiol may be important in order to better understand the hormonal regulation of insulin secretion and for the treatment of NIDDM.	Miguel Hernandez Univ, Sch Med, Inst Bioengn, Alicante 03550, Spain; Miguel Hernandez Univ, Dept Physiol, Alicante 03550, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche	Nadal, A (corresponding author), Miguel Hernandez Univ, Sch Med, Inst Bioengn, San Juan Campus,Carretera Alicante Valencia Km 87, Alicante 03550, Spain.	nadal@umh.es	Andreu, Etelvina/M-1623-2014; , Bernat/AAL-6470-2021; Ripoll, Cristina/F-3324-2016; Nadal, Angel/G-6721-2014	Andreu, Etelvina/0000-0003-0156-8944; Ripoll, Cristina/0000-0003-0935-8722; Nadal, Angel/0000-0003-4178-2152; Soria, Bernat/0000-0002-2356-0380				Alonso R, 1998, NEUROCHEM RES, V23, P675, DOI 10.1023/A:1022442922931; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Barbosa RM, 1996, BIOCHEM BIOPH RES CO, V228, P100, DOI 10.1006/bbrc.1996.1622; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; Brussaard HE, 1997, DIABETOLOGIA, V40, P843, DOI 10.1007/s001250050758; EFRAT S, 1991, ENDOCRINOLOGY, V128, P897, DOI 10.1210/endo-128-2-897; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; HOLTZ GG, 1993, NATURE, V361, P362; JENSEN SL, 1978, AM J PHYSIOL, V235, pE387, DOI 10.1152/ajpendo.1978.235.4.E387; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; KUZNETSOVA VA, 1990, PEDIATRIA, V10, P12; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; MARTIN F, 1995, DIABETES, V44, P300, DOI 10.2337/diabetes.44.3.300; Mermelstein PG, 1996, J NEUROSCI, V16, P595; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; NADAL A, 1994, AM J PHYSIOL-ENDOC M, V267, pE769, DOI 10.1152/ajpendo.1994.267.5.E769; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ramirez VD, 1996, CELL MOL NEUROBIOL, V16, P175, DOI 10.1007/BF02088175; RAMIREZ VD, 1992, NEUROPROTOCOLS, V1, P35; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; SANCHEZANDRES JV, 1991, EUR J PHARMACOL, V205, P89, DOI 10.1016/0014-2999(91)90775-L; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VALDEOLMILLOS M, 1992, J PHYSIOL-LONDON, V455, P173, DOI 10.1113/jphysiol.1992.sp019295; WAHL MA, 1991, ENDOCRINOLOGY, V128, P3247, DOI 10.1210/endo-128-6-3247; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	31	189	201	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1341	1348		10.1096/fasebj.12.13.1341	http://dx.doi.org/10.1096/fasebj.12.13.1341			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761777				2022-12-28	WOS:000076402000009
J	Klotz, IM				Klotz, IM			A bill of responsibilities for whistleblowers in science	FASEB JOURNAL			English	Editorial Material									Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Klotz, IM (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.								0	2	2	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					759	760		10.1096/fasebj.12.10.759	http://dx.doi.org/10.1096/fasebj.12.10.759			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657516				2022-12-28	WOS:000074580100001
J	Gollasch, M; Haase, H; Ried, C; Lindschau, C; Morano, I; Luft, FC; Haller, H				Gollasch, M; Haase, H; Ried, C; Lindschau, C; Morano, I; Luft, FC; Haller, H			L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells	FASEB JOURNAL			English	Article						voltage-dependent Ca2+ channels; dihydropyridines; arterial smooth muscle; differentiation; retinoic acid; A7r5 cells; atherosclerosis	NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; BETA-SUBUNIT; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; RAT PHEOCHROMOCYTOMA; CARDIAC-MUSCLE; CURRENTS; HEART; LINE	Despite intensive interest in understanding the differentiation of vascular smooth muscle cells (VSMC), no information is available about differential regulation of ion channels in these cells. Since expression of the L-type Ca2+ channel can be influenced by differentiation in other cell types, we tested the hypothesis that the L-ype (C class) channel is a specific differentiation marker of VSMC and that expression of these channels depends on the state of cell differentiation. We used rat aortic (A7r5) VSMC, which express functional L-type Ca2+ channels, and induced dedifferentiation by cell culture in different media. Treatment with retinoic acid was used to redifferentiate the VSMC. We characterized the differentiated state of the cells by using immunohistochemistry and Western blot analysis for smooth muscle (SM) alpha-actin and SM-myosin heavy chain (MHC). The number of functional Ca2+ channels was significantly decreased in dedifferentiated VSMC and increased upon differentiation with retinoic acid. Ca2+ channel function was assessed by whole-cell voltage clamp techniques. Using Western blot and dihydropyridine binding analysis, we found that the expression of the Ca2+ channel alpha(1) subunit, and to a lesser extent the beta(2) subunit, was directly correlated with the expression of SM alpha-actin and SM-MHC. We conclude that expression of L-type Ca2+ channel alpha(1) subunits, and thus a functional Ca2+ channel, is highly coordinated with expression of the SM-specific proteins required for specialized smooth muscle cell functions. Furthermore, our results demonstrate that the L-type Ca2+ channel is a novel marker for differentiation of VSMC. The data suggest that regulation of ion channel expression during differentiation may have physiological importance for normal smooth muscle function and may influence VSMC behavior under pathophysiological conditions.	Humboldt Univ, Max Delbruck Ctr Mol Med, Franz Vollard Clin, D-13122 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Haller, H (corresponding author), Humboldt Univ, Max Delbruck Ctr Mol Med, Franz Vollard Clin, Wiltberg Str 50, D-13122 Berlin, Germany.	haller@mdc-berlin.de	Lindschau, Carsten/AAE-6721-2020; Lindschau, Carsten/G-1798-2011	Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				BIEL M, 1991, EUR J BIOCHEM, V200, P81, DOI 10.1111/j.1432-1033.1991.tb21051.x; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CALOVINI T, 1995, J CELL BIOCHEM, V59, P69, DOI 10.1002/jcb.240590109; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CAVALIE A, 1994, J PHYSIOL-LONDON, V479, P11, DOI 10.1113/jphysiol.1994.sp020274; CAVIEDES P, 1993, J MOL CELL CARDIOL, V25, P829, DOI 10.1006/jmcc.1993.1093; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DAUT J, 1994, J CARDIOVASC ELECTR, V5, P154, DOI 10.1111/j.1540-8167.1994.tb01156.x; FURUKAWA K, 1993, NEUROSCI LETT, V161, P13, DOI 10.1016/0304-3940(93)90128-8; GIANNATTASIO B, 1991, J GEN PHYSIOL, V98, P987, DOI 10.1085/jgp.98.5.987; Gollasch M, 1996, AM J PHYSIOL-CELL PH, V271, pC842, DOI 10.1152/ajpcell.1996.271.3.C842; Gollasch M, 1996, CIRC RES, V78, P676, DOI 10.1161/01.RES.78.4.676; GOLLASCH M, 1993, P NATL ACAD SCI USA, V90, P6265, DOI 10.1073/pnas.90.13.6265; GOLLASCH M, 1991, P NATL ACAD SCI USA, V88, P10262, DOI 10.1073/pnas.88.22.10262; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1996, J MOL MED-JMM, V74, P99; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; Haller H, 1996, ARTERIOSCL THROM VAS, V16, P678, DOI 10.1161/01.ATV.16.5.678; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KAMP TJ, 1995, CELL MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02089942; KAZAZOGLOU T, 1983, FEBS LETT, V164, P75, DOI 10.1016/0014-5793(83)80022-2; LEWIS DL, 1993, J PHYSIOL-LONDON, V465, P325, DOI 10.1113/jphysiol.1993.sp019679; LUO ZG, 1994, J BIOL CHEM, V269, P27216; MACVICAR BA, 1987, BRAIN RES, V420, P175, DOI 10.1016/0006-8993(87)90256-3; Maki T, 1996, J CLIN INVEST, V97, P656, DOI 10.1172/JCI118462; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MULLIKINKILPATRICK D, 1994, NEUROSCI LETT, V176, P101, DOI 10.1016/0304-3940(94)90881-8; NAVARRO J, 1986, J NEUROCHEM, V146, P1166; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; OWEN NE, 1985, J CELL BIOL, V101, P454, DOI 10.1083/jcb.101.2.454; OWENS GK, 1995, PHYSIOL REV, V75, P487; PEREZREYES E, 1994, DRUG DEVELOP RES, V33, P295, DOI 10.1002/ddr.430330311; REBER BF, 1991, J PHYSIOL-LONDON, V43, P145; REUTER H, 1994, RENAL PHYSL BIOCH, V17, P3; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SPITZER NC, 1993, J COMP NEUROL, V337, P168, DOI 10.1002/cne.903370111; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; VARADI G, 1989, FEBS LETT, V250, P515, DOI 10.1016/0014-5793(89)80787-2; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106	46	119	127	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1998	12	7					593	601		10.1096/fasebj.12.7.593	http://dx.doi.org/10.1096/fasebj.12.7.593			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576486				2022-12-28	WOS:000073523100009
J	Araga, S; Xu, LK; Nakashima, K; Villain, M; Blalock, JE				Araga, S; Xu, LK; Nakashima, K; Villain, M; Blalock, JE			A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help	FASEB JOURNAL			English	Article						complementary peptide; T cell receptor; anticlonotypic antibody; autoimmunity; acetylcholine receptor	MYELIN BASIC-PROTEIN; ANTI-IDIOTYPIC ANTIBODIES; MAIN IMMUNOGENIC REGION; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MONOCLONAL ANTIIDIOTYPIC ANTIBODIES; CALIFORNICA ACETYLCHOLINE-RECEPTOR; COMPLEMENTARY PEPTIDES; ALPHA-SUBUNIT; MESSENGER-RNA; AMINO-ACIDS	Myasthenia gravis (MG) and its animal model, experimental autoimmune (EA) MG, are caused by T cell-dependent autoantibodies that react with the nicotinic acetylcholine receptor (AChR) on muscle and interfere with neuromuscular transmission. Thus, selective inactivation of CD4(+) AChR-specific T helper cells should lower AChR Ab levels and ameliorate disease. In the Lewis rat model of EAMG, alpha chain residues 100-116 of the AChR represent the dominant T cell epitope, which is important in helping Ab responses to this autoantigen, In the present report, we have applied a new design technique that requires no knowledge of Ag receptor sequences on errant T cells in order to develop a synthetic peptide vaccine against T cells reactive with the aforementioned T cell epitope, Immunization with the peptide 1) induced polyclonal and monoclonal Ab, which inhibited AChR 100-116 stimulation of AChR-sensitized lymphocytes and recognized V beta 15 containing T cell receptors on AChR 100-116-specific T cell lines and clones; 2) lowered AChR Ab levels; 3) reduced the loss of muscle AChR; and 4) lessened the incidence and severity of EAMG, These findings suggest a new strategy for the functional abrogation of epitope-specific T cells that could have potential application to human autoimmune diseases.	Univ Alabama Birmingham, Dept Phys & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Neuroimmunol, Birmingham, AL 35294 USA; Tottori Univ, Fac Med, Inst Neurol Sci, Div Neurol, Yonago, Tottori 683, Japan	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Tottori University	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Phys & Biophys, 1918 Univ Blvd,MCLM 896, Birmingham, AL 35294 USA.	Blalock@uab.edu		Blalock, J. Edwin/0000-0001-5303-8123	NIAID NIH HHS [AI37670] Funding Source: Medline; NIMH NIH HHS [MH52527] Funding Source: Medline; NINDS NIH HHS [NS29719] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037670, R21AI037670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araga S, 1999, J IMMUNOL, V163, P476; ARAGA S, 1993, P NATL ACAD SCI USA, V90, P8747, DOI 10.1073/pnas.90.18.8747; Araga S, 1994, Immunomethods, V5, P130, DOI 10.1006/immu.1994.1047; Araga S, 1996, J IMMUNOL, V157, P386; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; BARKAS T, 1988, J BIOL CHEM, V263, P5916; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; BLALOCK JE, 1989, METHOD ENZYMOL, V178, P63; BLALOCK JE, 1986, BIOCHEM J, V234, P679, DOI 10.1042/bj2340679; Blalock JE, 1999, CELL MOL LIFE SCI, V55, P513, DOI 10.1007/s000180050309; BOQUET D, 1995, MOL IMMUNOL, V32, P303, DOI 10.1016/0161-5890(95)00012-4; BOROVSKY D, 1994, FASEB J, V8, P350, DOI 10.1096/fasebj.8.3.7908271; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; CHRISTADOSS P, 1986, J IMMUNOL, V136, P2437; CLARKE BL, 1990, P NATL ACAD SCI USA, V87, P9708, DOI 10.1073/pnas.87.24.9708; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DAVIES AA, 1987, LYMPHOCYTES PRACTICA, P229; Dery O, 1997, J NEUROIMMUNOL, V76, P1, DOI 10.1016/S0165-5728(97)00026-X; DILL KA, 1995, PROTEIN SCI, V4, P561; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; DRACHMAN DB, 1982, NEW ENGL J MED, V307, P769, DOI 10.1056/NEJM198209233071301; ENGEL AG, 1981, ANN NY ACAD SCI, V377, P158, DOI 10.1111/j.1749-6632.1981.tb33730.x; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FROEHNER SC, 1979, BIOCHEMISTRY-US, V18, P301, DOI 10.1021/bi00569a011; FUJII Y, 1988, J IMMUNOL, V140, P1830; GHISO J, 1990, P NATL ACAD SCI USA, V87, P1288, DOI 10.1073/pnas.87.4.1288; HOHLFELD R, 1983, MUSCLE NERVE, V6, P160, DOI 10.1002/mus.880060213; JARPE MA, 1994, PEPTIDES DESIGN SYNT, P165; Johnson H M, 1994, Immunomethods, V5, P167, DOI 10.1006/immu.1994.1051; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KINEBUCHI M, 1995, TRANSPLANT P, V27, P1511; Kinebuchi M, 1997, J IMMUNOL, V159, P748; LENNON VA, 1975, J EXP MED, V141, P1365, DOI 10.1084/jem.141.6.1365; LINDDELL JE, 1991, PRACTICAL GUIDE MONO, P85; LINDSTROM J, 1985, ANNU REV IMMUNOL, V3, P109; LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054; Maier C C, 1994, Immunomethods, V5, P107, DOI 10.1006/immu.1994.1044; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; McGuigan J E, 1994, Immunomethods, V5, P158, DOI 10.1006/immu.1994.1050; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; OMICHINSKI JG, 1988, DESIGN ANTISENSE PEP, V58, pS321; PALLA E, 1993, J BIOL CHEM, V268, P13486; PASCUAL D W, 1989, Peptide Research, V2, P207; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Ruiz-Opazo N, 1998, MOL MED, V4, P96, DOI 10.1007/BF03401733; RUIZOPAZO N, 1995, NAT MED, V1, P1074, DOI 10.1038/nm1095-1074; Saoudi A, 1999, J IMMUNOL, V162, P7189; SMITH LR, 1991, J IMMUNOL, V147, P375; SMITH LR, 1994, J IMMUNOL, V152, P2596; SMITH LR, 1987, J IMMUNOL, V138, P7; TAYLOR PM, 1987, LYMPHOCYTES PRACTICA, P133; TORRES BA, 1990, J NEUROIMMUNOL, V27, P191, DOI 10.1016/0165-5728(90)90069-Y; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; WALDOR MK, 1983, P NATL ACAD SCI-BIOL, V80, P2713, DOI 10.1073/pnas.80.9.2713; Weigent D A, 1994, Immunomethods, V5, P91, DOI 10.1006/immu.1994.1042; WHITAKER JN, 1989, J NEUROIMMUNOL, V22, P157, DOI 10.1016/0165-5728(89)90047-7; WOFSY L, 1969, J IMMUNOL, V103, P380; YEH TM, 1990, J IMMUNOL, V144, P1654; Zhou S R, 1994, Immunomethods, V5, P136, DOI 10.1006/immu.1994.1048; ZHOU SR, 1994, J IMMUNOL, V153, P2340; ZHOU SR, 1990, J IMMUNOL, V145, P2554; ZHOU SR, 1993, J IMMUNOL, V150, P1629; Zhou SR, 1996, J NEUROSCI RES, V45, P439, DOI 10.1002/(SICI)1097-4547(19960815)45:4<439::AID-JNR13>3.0.CO;2-W; ZHOU SR, 1992, CLIN IMMUNOL IMMUNOP, V63, P74, DOI 10.1016/0090-1229(92)90096-7; ZHOU SR, 1994, CLIN IMMUNOL IMMUNOP, V70, P251, DOI 10.1006/clin.1994.1037	68	27	31	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					185	196		10.1096/fasebj.14.1.185	http://dx.doi.org/10.1096/fasebj.14.1.185			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627293				2022-12-28	WOS:000084784700021
J	Mockett, RJ; Sohal, RS; Orr, WC				Mockett, RJ; Sohal, RS; Orr, WC			Overexpression of glutathione reductase extends survival in transgenic Drosophila melanogaster under hyperoxia but not normoxia	FASEB JOURNAL			English	Article						aging; oxidative stress; reduced glutathione; free radicals; antioxidant defenses	SUPEROXIDE-DISMUTASE; LIFE-SPAN; OXIDATIVE STRESS; OXYGEN-TOXICITY; RESISTANCE; INCREASES; CATALASE; EXTENSION; DAMAGE; GENE	The purpose of this study was to test the hypothesis that overexpression of glutathione reductase in transgenic Drosophila melanogaster increases resistance to oxidative stress and retards the aging process. Transgenic flies were generated by microinjection and subsequent mobilization of a P element construct containing the genomic glutathione reductase gene of Drosophila, with 4 kb upstream and 1.5 kb downstream of the coding region. Transgenic animals stably overexpressed glutathione reductase by up to 100% throughout adult life and under continuous exposure to 100% oxygen or air. Under hyperoxic conditions, overexpressors had increased longevity, decreased accrual of protein carbonyls, and dramatically increased survival rates after recovery from a semi-lethal dose of 100% oxygen, Under normoxic conditions, overexpression of glutathione reductase had no effect on longevity, protein carbonyl content, reduced glutathione, or glutathione disulfide content, although the total consumption of oxygen was slightly decreased, Glutathione reductase activity does not appear to be a rate-limiting factor in anti-aging defenses under normoxic conditions, but it may become a limiting factor when the level of oxidative stress is elevated. -Mockett, R. J., Sohal, R. S., Orr, W. C. Overexpression of glutathione reductase extends survival in transgenic Drosophila melanogaster under hyperoxia but not normoxia.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, 220 Fondren Sci Bldg, Dallas, TX 75275 USA.	borr@mail.smu.edu			NATIONAL INSTITUTE ON AGING [R01AG007657, R01AG015122] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG15122, R01 AG7657] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akerboom T P, 1981, Methods Enzymol, V77, P373; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brack C, 1997, CELL MOL LIFE SCI, V53, P960, DOI 10.1007/PL00013199; Candas M, 1997, ARCH BIOCHEM BIOPHYS, V339, P323, DOI 10.1006/abbi.1996.9872; HOFFMAN DW, 1995, BIOCHEM PHARMACOL, V49, P411, DOI 10.1016/0006-2952(94)00474-Z; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KEHRER JP, 1984, FUND APPL TOXICOL, V4, P760, DOI 10.1016/0272-0590(84)90097-6; Lakritz J, 1997, ANAL BIOCHEM, V247, P63, DOI 10.1006/abio.1997.2032; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; MAKINO N, 1995, BBA-GEN SUBJECTS, V1243, P503, DOI 10.1016/0304-4165(94)00177-Y; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOORE WR, 1989, P NATL ACAD SCI USA, V86, P1461, DOI 10.1073/pnas.86.5.1461; MUNDAY R, 1989, BIOCHEM PHARMACOL, V38, P4349, DOI 10.1016/0006-2952(89)90641-2; ORR WC, 1992, ARCH BIOCHEM BIOPHYS, V297, P35, DOI 10.1016/0003-9861(92)90637-C; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; RALL TW, 1952, J BIOL CHEM, V194, P119; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; RICHIE JP, 1987, P SOC EXP BIOL MED, V184, P113; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SMITH IK, 1988, ANAL BIOCHEM, V175, P408, DOI 10.1016/0003-2697(88)90564-7; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Sun JT, 1999, MOL CELL BIOL, V19, P216; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; WEBER CA, 1990, AM J PHYSIOL, V258, pL308, DOI 10.1152/ajplung.1990.258.6.L308; Wigglesworth VB, 1972, PRINCIPLES INSECT PH	35	89	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1733	1742		10.1096/fasebj.13.13.1733	http://dx.doi.org/10.1096/fasebj.13.13.1733			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506576				2022-12-28	WOS:000083063400008
J	Boczkowski, J; Lisdero, CL; Lanone, S; Samb, A; Carreras, MC; Boveris, A; Aubier, M; Poderoso, JJ				Boczkowski, J; Lisdero, CL; Lanone, S; Samb, A; Carreras, MC; Boveris, A; Aubier, M; Poderoso, JJ			Endogenous peroxynitrite mediates mitochondrial dysfunction in rat diaphragm during endotoxemia	FASEB JOURNAL			English	Article						sepsis; respiratory insufficiency; respiratory muscles; mitochondria; nitric oxide; oxidative stress; nitrotyrosine	NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; SKELETAL-MUSCLE; SUPEROXIDE-DISMUTASE; RADICAL PRODUCTION; ESCHERICHIA-COLI; OXIDATIVE STRESS; METABOLISM; INHIBITION; GENERATION	It has been shown that nitric oxide (NO), synthesized by the inducible NO synthase (iNOS) expressed in the diaphragm during endotoxemia, participates in the development of muscular contractile failure. The aim of the present study was to investigate whether this deleterious action of NO was related to its effects on cellular oxidative pathways. Rats were inoculated with E. coli lipopolysaccharide (LPS) or sterile saline solution (controls) and studied at 3 and 6 h after inoculation. iNOS protein and activity could be detected in the rat diaphragm as early as 3 h after LPS, with a sustained steady-state concentration of 0.5 mu M NO in the muscle associated with increased detection of hydrogen peroxide (H2O2). In vitro, the same NO concentration produced a marked increase in H2O2 production by isolated control diaphragm mitochondria, thus reflecting a higher intramitochondrial concentration of nondiffusible superoxide anion (O-2(-.)). In a similar way, whole diaphragmatic muscle and diaphragm mitochondria from endotoxemic rats showed a progressive increase in H2O2 production associated with uncoupling and decreased phosphorylating capacity. Simultaneous with the maximal impairment in respiration (6 h after LPS), nitration of mitochondrial proteins (a peroxynitrite footprint) was detected and diaphragmatic force was reduced. Functional mitochondrial abnormalities, nitration of mitochondrial proteins, and the decrease in force were significantly attenuated by administration of the NOS inhibitor L-NMMA. These results show that increased and sustained NO levels lead to a consecutive formation of O-2(-.) that reacts with NO to form peroxynitrite, which in turn impairs mitochondrial function, which probably contributes to the impairment of muscle contractility.	Fac Xavier Bichat, INSERM U408, F-75870 Paris 18, France; Fac Xavier Bichat, IFR 02, F-75870 Paris 18, France; Univ Hosp Buenos Aires, Lab Oxygen Metab, Buenos Aires, DF, Argentina; Univ Buenos Aires, Sch Pharm & Biochem, Lab Free Radical Biol, RA-1053 Buenos Aires, DF, Argentina	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Buenos Aires; University of Buenos Aires	Boczkowski, J (corresponding author), Fac Xavier Bichat, INSERM U408, BP416, F-75870 Paris 18, France.	jbb2@bichat.inserm.fr	Lanone, Sophie/I-4042-2016; Boczkowski, Jorge/S-7474-2018	Lanone, Sophie/0000-0003-2509-8799; Boczkowski, Jorge/0000-0001-6619-5785				Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Boczkowski J, 1996, J CLIN INVEST, V98, P1550, DOI 10.1172/JCI118948; BOCZKOWSKI J, 1988, AM REV RESPIR DIS, V138, P260, DOI 10.1164/ajrccm/138.2.260; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; BYRNE E, 1989, J NEUROL SCI, V92, P215, DOI 10.1016/0022-510X(89)90138-X; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2; Costa LE, 1997, AM J PHYSIOL-CELL PH, V273, pC852, DOI 10.1152/ajpcell.1997.273.3.C852; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; El-Dwairi Q, 1998, AM J PHYSIOL-CELL PH, V274, pC770, DOI 10.1152/ajpcell.1998.274.3.C770; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; HANTLER PD, 1975, EUR J BIOCHEM, V60, P67; HAYES DJ, 1985, BIOCHEM J, V229, P109, DOI 10.1042/bj2290109; HUSSAIN SNA, 1985, J APPL PHYSIOL, V58, P2033, DOI 10.1152/jappl.1985.58.6.2033; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LLESUY S, 1994, FREE RADICAL BIO MED, V16, P445, DOI 10.1016/0891-5849(94)90121-X; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1998, AM J PHYSIOL-CELL PH, V274, pC112, DOI 10.1152/ajpcell.1998.274.1.C112; Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9; PUNTARULO S, 1991, BIOCHIM BIOPHYS ACTA, V1074, P277, DOI 10.1016/0304-4165(91)90164-C; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; ROCHESTER DF, 1991, AM REV RESPIR DIS, V143, P901, DOI 10.1164/ajrccm/143.5_Pt_1.901; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHINDOH C, 1992, AM REV RESPIR DIS, V145, P1350, DOI 10.1164/ajrccm/145.6.1350; Supinski G, 1996, J APPL PHYSIOL, V81, P1370, DOI 10.1152/jappl.1996.81.3.1370; Szabo C, 1997, FEBS LETT, V409, P147, DOI 10.1016/S0014-5793(97)00466-3; VANSURELL C, 1992, AM REV RESPIR DIS, V146, P730, DOI 10.1164/ajrccm/146.3.730; VIIRES N, 1988, J APPL PHYSIOL, V64, P26, DOI 10.1152/jappl.1988.64.1.26; Viner RI, 1996, FREE RADICAL RES, V24, P243, DOI 10.3109/10715769609088022; Voisin L, 1996, J CLIN INVEST, V97, P1610, DOI 10.1172/JCI118586; Xie YW, 1998, CIRC RES, V82, P891; Zhang HY, 1997, J IMMUNOL, V158, P1392	52	137	145	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1637	1646		10.1096/fasebj.13.12.1637	http://dx.doi.org/10.1096/fasebj.13.12.1637			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463956				2022-12-28	WOS:000082347600020
J	Rosenquist, TH; Schneider, AM; Monaghan, DT				Rosenquist, TH; Schneider, AM; Monaghan, DT			N-methyl-D-aspartate receptor agonists modulate homocysteine-induced developmental abnormalities	FASEB JOURNAL			English	Article						neural tube defects; neural crest defects; orofacial defects; prevention	NEURAL-TUBE DEFECTS; CONOTRUNCAL HEART-DEFECTS; CEREBELLAR GRANULE CELLS; CENTRAL-NERVOUS-SYSTEM; RISK FACTOR; FOLIC-ACID; NMDA RECEPTORS; HYPERHOMOCYSTEINEMIA; EMBRYOS; NEURONS	We showed previously that the induction of neural crest (NC) and neural tube (NT) defects is a general property of N-methyl-D-aspartate receptor (NMDAR) antagonists. Since homocysteine induces NC and NT defects and can also act as an NMDAR antagonist, we hypothesized that the mechanism of homocysteine-induced developmental defects is mediated by competitive inhibition of the NMDAR by homocysteine. If this hypothesis is correct, homocysteine-induced defects will be reduced by NMDAR agonists, To test the hypothesis, we treated chicken embryos during the process of neural tube closure with sufficient homocysteine thiolactone to induce NC and NT defects in similar to 40% of survivors or with homocysteine thiolactone in combination with each of a selected set of NMDAR agonists in 0.05-5000 nmol doses. Glutamate site agonists selected were L-glutamate and N-methyl-D-aspartate. Glycine site agonists were glycine, D-cycloserine, and aminocyclopropane-carboxylic acid. Glycine was the most effective overall, reducing defects significantly at two different doses (each P>0.001), These results support the hypothesis that homocysteine may affect NC and NT development by its ability to inhibit the NMDAR, One potentially important consequence of this putative mechanism is that homocysteine may interact synergistically with other NMDAR antagonists to enhance its effect on development.	Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rosenquist, TH (corresponding author), Univ Nebraska, Med Ctr, Dept Cell Biol & Anat, 600 S 42nd St, Omaha, NE 68198 USA.	throsenq@unmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055940] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-55940] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andaloro VJ, 1998, PEDIATR RES, V43, P1, DOI 10.1203/00006450-199801000-00001; BALAZS R, 1989, NEUROSCI LETT, V101, P241, DOI 10.1016/0304-3940(89)90539-9; BOSTOM AG, 1995, POST METHIONINE LOAD; Botto LD, 1996, PEDIATRICS, V98, P911; BULLER AL, 1994, J NEUROSCI, V14, P5471; CHRISTENSEN B, 1995, BAILLIERE CLIN HAEM, V8, P617, DOI 10.1016/S0950-3536(05)80223-9; CORNELLBELL AH, 1990, GLIA, V3, P322, DOI 10.1002/glia.440030503; Crews FT, 1996, INT REV NEUROBIOL, V39, P283, DOI 10.1016/S0074-7742(08)60670-4; Czeizel AE, 1996, TERATOLOGY, V53, P345, DOI 10.1002/(SICI)1096-9926(199606)53:6&lt;345::AID-TERA5&gt;3.0.CO;2-Z; ELMAZAR MMA, 1995, REPROD TOXICOL, V9, P427, DOI 10.1016/0890-6238(95)00023-4; ESKES TKAB, 1994, EUR J OBSTET GYN R B, V53, P147, DOI 10.1016/0028-2243(94)90225-9; FINEMAN RM, 1986, AM J MED GENET, V25, P489, DOI 10.1002/ajmg.1320250311; FOHR KJ, 1995, NEUROSCI LETT, V183, P87, DOI 10.1016/0304-3940(94)11121-X; GoddijnWessel TAW, 1996, EUR J OBSTET GYN R B, V66, P23, DOI 10.1016/0301-2115(96)02383-4; Gofflot F, 1996, DEV BRAIN RES, V93, P62, DOI 10.1016/0165-3806(96)00031-4; Graham A, 1996, MOL CELL NEUROSCI, V8, P76, DOI 10.1006/mcne.1996.0046; Graham A, 1996, BIOCHEM SOC SYMP, P77; Hladovec J, 1997, THROMB RES, V88, P361, DOI 10.1016/S0049-3848(97)00266-1; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; ISHII T, 1993, J BIOL CHEM, V268, P2836; Johnson VP, 1996, AM J MED GENET, V61, P329, DOI 10.1002/(SICI)1096-8628(19960202)61:4<329::AID-AJMG6>3.0.CO;2-P; Kim W.-K., 1995, Society for Neuroscience Abstracts, V21, P521; Kim WK, 1996, NEUROSCI LETT, V216, P117; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LAEGREID L, 1993, NEUROPEDIATRICS, V24, P88, DOI 10.1055/s-2008-1071520; Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923; Maden M, 1998, J NUTR, V128, p471S, DOI 10.1093/jn/128.2.471S; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Munger RG, 1996, TERATOLOGY, V54, P27, DOI 10.1002/(SICI)1096-9926(199607)54:1<27::AID-TERA4>3.0.CO;2-0; NODEN DM, 1990, ANN NY ACAD SCI, V588, P236, DOI 10.1111/j.1749-6632.1990.tb13214.x; RASHID NA, 1992, DEV BRAIN RES, V67, P301, DOI 10.1016/0165-3806(92)90231-K; REFSUM H, 1989, CLIN CHEM, V35, P1921; ROBINSON LK, 1987, J PEDIATR-US, V111, P236, DOI 10.1016/S0022-3476(87)80074-4; Romanoff A.L., 1960, AVIAN EMBRYO STRUCTU; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SHAW GM, 1995, AM J MED GENET, V59, P536, DOI 10.1002/ajmg.1320590428; SNEDECOR GW, 1962, STAT METHODS, P90; STEEGERSTHEUNISSEN RP, 1995, AM J OBSTET GYNECOL, V172, P1436, DOI 10.1016/0002-9378(95)90474-3; STEEGERSTHEUNISSEN RPM, 1994, METABOLISM, V43, P1475, DOI 10.1016/0026-0495(94)90004-3; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Tyagi SC, 1998, AM J PHYSIOL-CELL PH, V274, pC396, DOI 10.1152/ajpcell.1998.274.2.C396; Uberti D, 1998, EUR J NEUROSCI, V10, P246, DOI 10.1046/j.1460-9568.1998.00042.x; VanStraaten HWM, 1996, DEV DYNAM, V207, P309, DOI 10.1002/(SICI)1097-0177(199611)207:3<309::AID-AJA8>3.0.CO;2-L; Wang C, 1996, J CELL BIOL, V135, P1565, DOI 10.1083/jcb.135.6.1565; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380; Weil M, 1997, CURR BIOL, V7, P281, DOI 10.1016/S0960-9822(06)00125-4; WITT G, 1999, THESIS U NEBRASKA ME; Wood AM, 1998, J NEUROCHEM, V70, P677; WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820	53	48	49	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1999	13	12					1523	1531		10.1096/fasebj.13.12.1523	http://dx.doi.org/10.1096/fasebj.13.12.1523			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463943				2022-12-28	WOS:000082347600007
J	Sainz, RM; Mayo, JC; Reiter, RJ; Antolin, I; Esteban, MM; Rodriguez, C				Sainz, RM; Mayo, JC; Reiter, RJ; Antolin, I; Esteban, MM; Rodriguez, C			Melatonin regulates glucocorticoid receptor: an answer to its antiapoptotic action in thymus	FASEB JOURNAL			English	Article						antioxidant enzymes; glucocorticoids; apoptosis; DNA fragmentation	PROGRAMMED CELL-DEATH; MESSENGER-RNA; NUCLEAR RECEPTOR; GENE-EXPRESSION; NEUROHORMONE MELATONIN; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; ANTIOXIDANT ENZYMES; HORMONE MELATONIN; RAT THYMUS	We have previously reported that low doses of melatonin inhibit apoptosis in both dexamethasone-treated cultured thymocytes (standard model for the study of apoptosis) and the intact thymus. Here we elucidate the mechanism by which this agent protects thymocytes from cell death induced by glucocorticoids. Our results demonstrate an effect of melatonin on the mRNA for antioxidant enzymes in thymocytes, also showing an unexpected regulation by dexamethasone of these mRNA Both an effect of melatonin on the general machinery of apoptosis and a possible regulation of the expression of the cell death related genes bcl-2 and p53 are shown not to be involved, We found melatonin to down-regulate the mRNA for the glucocorticoid receptor in thymocytes (glucocorticoids up-regulate their own receptor). The decrease by melatonin of mRNA levels for this receptor in IM-9 cells (where glucocorticoids down-regulate it) demonstrates that melatonin actually down-regulates glucocorticoid receptor. These findings allow us to propose the effects of melatonin on this receptor as the likely mediator of its thymocyte protection against dexamethasone-induced cell death. This effect of melatonin, given the oxidant properties of glucocorticoids, adds another mechanism to explain its antioxidant effects.	Fac Med, Dept Morfol & Biol Celular, Oviedo 33006, Spain; Fac Med, Dept Biol Func, Oviedo 33006, Spain; Univ Texas, Ctr Hlth Sci, Dept Cell & Struct Biol, San Antonio, TX 78285 USA	University of Texas System; University of Texas Health San Antonio	Rodriguez, C (corresponding author), Fac Med, Dept Morfol & Biol Celular, Julian Claveria, Oviedo 33006, Spain.		Rodríguez, Carmen/R-9541-2019; Sainz, Rosa M./N-5885-2014; Mayo, Juan Carlos/H-3435-2011; Antolin, Isaac/L-6210-2014	Rodríguez, Carmen/0000-0002-3203-4753; Sainz, Rosa M./0000-0003-3048-5582; Mayo, Juan Carlos/0000-0002-0882-2047; Antolin, Isaac/0000-0002-4232-9248; Martinez-Esteban, Manuel/0000-0001-8904-6010				Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARCENA A, 1990, J EXP MED, V172, P439, DOI 10.1084/jem.172.2.439; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BENITEZKING G, 1991, BRAIN RES, V557, P289, DOI 10.1016/0006-8993(91)90146-M; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CAGNOLI CM, 1995, J PINEAL RES, V20, P187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1996, CELL, V47, P19; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DENTON RR, 1993, ENDOCRINOLOGY, V133, P248, DOI 10.1210/en.133.1.248; ENOCH T, 1995, TRENDS BIOL SCI, V20, P427; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARDELAND R, 1993, NEUROSCI BIOBEHAV R, V17, P347, DOI 10.1016/S0149-7634(05)80016-8; HILL SM, 1988, CANCER RES, V48, P6121; HO YS, 1987, NUCLEIC ACIDS RES, V15, P6746, DOI 10.1093/nar/15.16.6746; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; MAHMOUD I, 1994, J ANAT, V185, P143; Mayo JC, 1998, J PINEAL RES, V25, P12, DOI 10.1111/j.1600-079X.1998.tb00380.x; Mayo JC, 1998, J PINEAL RES, V24, P179, DOI 10.1111/j.1600-079X.1998.tb00531.x; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MOCCHEGIANI E, 1994, J NEUROIMMUNOL, V53, P189, DOI 10.1016/0165-5728(94)90029-9; MolinaCarballo A, 1997, J PINEAL RES, V23, P97, DOI 10.1111/j.1600-079X.1997.tb00341.x; Mor F, 1996, J IMMUNOL, V156, P515; Pappolla MA, 1997, J NEUROSCI, V17, P1683; PELEDKAMAR M, 1995, EMBO J, V14, P4985, DOI 10.1002/j.1460-2075.1995.tb00181.x; Pozo D, 1997, FASEB J, V11, P466, DOI 10.1096/fasebj.11.6.9194527; POZO D, 1994, LIFE SCI, V55, P455; Provinciali M, 1996, MECH AGEING DEV, V90, P1, DOI 10.1016/0047-6374(96)01746-0; Rafii-El-Idrissi M, 1998, J NEUROIMMUNOL, V86, P190, DOI 10.1016/S0165-5728(98)00048-4; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter R J, 1997, Adv Pharmacol, V38, P103; Reiter RJ, 1997, ANN NY ACAD SCI, V825, P70, DOI 10.1111/j.1749-6632.1997.tb48415.x; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RODRIGUEZ C, 1994, ENDOCRINE, V2, P863; Sainz RM, 1998, LIFE SCI, V63, P1109; Sainz RM, 1995, J PINEAL RES, V19, P178, DOI 10.1111/j.1600-079X.1995.tb00187.x; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Tan DX, 1993, ENDOCR J, V1, P57; TILLY JL, 1992, ENDOCRINOLOGY, V131, P1670, DOI 10.1210/en.131.4.1670; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WALKER PR, 1991, CANCER RES, V51, P1078; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YOSHIMURA S, 1988, BIOCHEM BIOPH RES CO, V154, P1024, DOI 10.1016/0006-291X(88)90242-2	58	78	88	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1547	1556		10.1096/fasebj.13.12.1547	http://dx.doi.org/10.1096/fasebj.13.12.1547			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463946				2022-12-28	WOS:000082347600010
J	Fatatis, A; Miller, RJ				Fatatis, A; Miller, RJ			Cell cycle control of PDGF-induced Ca2+ signaling through modulation of sphingolipid metabolism	FASEB JOURNAL			English	Article						DMS; DHS; epidermal growth factor; PDGF	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; SPHINGOSINE 1-PHOSPHATE; TRANSFORMED OLIGODENDROCYTES; INOSITOL TRISPHOSPHATE; RESTRICTION POINT; REGULATORY EVENTS; 2ND MESSENGER; 3T3 CELLS; PROLIFERATION	The effects of growth factors have been shown to depend on the position of a cell in the cell cycle. However, the physiological basis for this phenomenon remains unclear. Here we show that the majority of both CEINGE clone3 (c13) and human embryonic kidney 293 cells, when arrested in a quiescent phase (G(0)), responded to platelet-derived growth factor BE (PDGF-BB) with non-oscillatory Ca2+ signals. Furthermore, the same type of Ca response was also observed in CEINGE c13 cells (and to a lesser extent in HEK 293 cells) blocked at the G(1)/S boundary. In contrast, CEINGE c13 cells synchronized in early G(1) or released from G(1)/S arrest responded in an oscillatory fashion. This cell cycle-dependent modulation of Ca2+ signaling was not observed on epidermal growth factor and G-protein-coupled receptor stimulation and was not due to differences in the expression of PDGF receptors (PDGFRs) during; the cell cycle. We demonstrate that inhibition of sphingosine-kinase, which converts sphingosine to sphingosine-1-phosphate, caused G(0) as well as G(1)/S synchronized cells to restore the oscillatory Ca2+ response to PDGF-BB, In addition, we show that the synthesis of sphingosine and sphingosine-1-phosphate is regulated by the cell cycle and may underlie the differences in Ca2+ signaling after PDGFR stimulation.	Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA	University of Chicago	Miller, RJ (corresponding author), Univ Chicago, Dept Pharmacol & Physiol Sci, 947 E 58th St,MC-0926, Chicago, IL 60637 USA.				NIDA NIH HHS [DA02121, DA02575] Funding Source: Medline; NIMH NIH HHS [MH40165] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040165, R37MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121, R01DA002575] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; CASSACIABONNEFI.P, 1996, SCIENCE, V272, P542; CHEN ZT, 1995, J BIOL CHEM, V270, P27525, DOI 10.1074/jbc.270.46.27525; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Fatatis A, 1997, J BIOL CHEM, V272, P4351, DOI 10.1074/jbc.272.7.4351; Fatatis A, 1996, J BIOL CHEM, V271, P295, DOI 10.1074/jbc.271.1.295; Frade JM, 1996, NATURE, V383, P166; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KIM HRC, 1995, P NATL ACAD SCI USA, V92, P9500, DOI 10.1073/pnas.92.21.9500; KISS Z, 1995, BBA-MOL CELL RES, V1265, P93, DOI 10.1016/0167-4889(94)00242-7; KREK W, 1995, METHOD ENZYMOL, V254, P114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON O, 1989, J CELL PHYSIOL, V139, P477, DOI 10.1002/jcp.1041390305; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PARDEE A B, 1992, Current Opinion in Cell Biology, V4, P186, DOI 10.1016/0955-0674(92)90031-7; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pines J, 1998, Results Probl Cell Differ, V22, P57; Rani CSS, 1997, J BIOL CHEM, V272, P10777; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; RUSSO T, 1993, NEUROSCI LETT, V159, P159, DOI 10.1016/0304-3940(93)90823-4; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; Sheaff R J, 1998, Results Probl Cell Differ, V22, P1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; TAKUWA N, 1995, CELL SIGNAL, V7, P93, DOI 10.1016/0898-6568(94)00074-L; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; URBANI L, 1995, EXP CELL RES, V219, P159, DOI 10.1006/excr.1995.1216; Vaziri C, 1996, J BIOL CHEM, V271, P13642, DOI 10.1074/jbc.271.23.13642; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Whitfield J.F., 1982, P61; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; ZETTERBERG A, 1991, COLD SH Q B, V56, P137; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	54	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1291	1301		10.1096/fasebj.13.11.1291	http://dx.doi.org/10.1096/fasebj.13.11.1291			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428754				2022-12-28	WOS:000082019100002
J	Pazirandeh, A; Xue, YT; Rafter, I; Sjovall, J; Jondal, M; Okret, S				Pazirandeh, A; Xue, YT; Rafter, I; Sjovall, J; Jondal, M; Okret, S			Paracrine glucocorticoid activity produced by mouse thymic epithelial cells	FASEB JOURNAL			English	Article						steroid biosynthesis; thymocyte development; cytochrome P450; reporter cells; paracrine signaling	NEGATIVE SELECTION; POSITIVE SELECTION; TRANSGENIC MICE; RECEPTOR; APOPTOSIS; THYMOCYTES; NEUROSTEROIDS; ANTAGONIST; EXPRESSION; SYSTEM	Previous data have suggested that glucocorticoids (GCs) are involved in the differentiation of thymocytes into mature T cells, In this report we demonstrate that the mouse thymic epithelial cells (TEC) express the cytochrome P450 hydroxylases Cyp11A1, Cyp21, and Cyp11B1, These enzymes, in combination with 3 beta-hydroxysteroid dehydrogenase (3 beta HSD), convert cholesterol into corticosterone, the major GC in rodents. In addition, when TEC were cocultured with 'reporter cells' containing the glucocorticoid receptor (GR) and a GR-dependent reporter gene, a specific induction of reporter gene activity was observed, Induction of reporter gene activity was blocked when the TEC and reporter cells were incubated in the presence of the Cyp11B1 inhibitor metyrapone or the 3 beta HSD inhibitor trilostane, as well as by the GR antagonist RU486, Coculturing of TEC with thymocytes induced apoptosis in the latter, which was partially blocked by the enzyme inhibitors and RU486, We conclude that TEC secrete a GC hormone activity and suggest a paracrine role for this in thymocyte development.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum F60, S-14186 Huddinge, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, MBB, SE-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Okret, S (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Nutr, Novum F60, S-14186 Huddinge, Sweden.							AIRD F, 1993, P NATL ACAD SCI USA, V90, P7104, DOI 10.1073/pnas.90.15.7104; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BATANERO E, 1992, BRAIN BEHAV IMMUN, V6, P249, DOI 10.1016/0889-1591(92)90047-R; Baulieu E E, 1997, Aging (Milano), V9, P12; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELL DA, 1991, NUCLEIC ACIDS RES, V19, P5079, DOI 10.1093/nar/19.18.5079; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; BLALOCK JE, 1994, IMMUNOLOGIST, V2, P8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cascio C, 1998, P NATL ACAD SCI USA, V95, P2862, DOI 10.1073/pnas.95.6.2862; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; ERNST B, 1995, J EXP MED, V182, P961, DOI 10.1084/jem.182.4.961; Ernst BB, 1996, J EXP MED, V183, P1235, DOI 10.1084/jem.183.3.1235; FELTEN SY, 1992, NEUROIMMUNOENDOCRINO, V52, P25; FERLINI C, 1995, CYTOMETRY, V21, P282; GUENNOUN R, 1995, MOL BRAIN RES, V30, P287, DOI 10.1016/0169-328X(95)00016-L; HAAPARANTA T, 1982, BIOCHIM BIOPHYS ACTA, V716, P79, DOI 10.1016/0304-4165(82)90205-7; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY C, 1992, Current Biology, V2, P26, DOI 10.1016/0960-9822(92)90419-B; JONDAL M, 1993, EUR J IMMUNOL, V23, P1246, DOI 10.1002/eji.1830230608; Jondal M, 1995, Curr Top Microbiol Immunol, V200, P67; JONDAL M, 1993, EUR J IMMUNOL, V23, P2734; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Lewis JC, 1998, ANAL CHEM, V70, p579A, DOI 10.1021/ac9819638; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Miller WL., 1995, ENDOCRINOL METAB, P555; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; Sambrook J., 2002, MOL CLONING LAB MANU; Schreiber L, 1996, SCAND J IMMUNOL, V44, P314, DOI 10.1046/j.1365-3083.1996.d01-312.x; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; SCHWARTZMAN RA, 1994, INT ARCH ALLERGY IMM, V105, P347, DOI 10.1159/000236781; SKINNER MA, 1992, INT J DEV BIOL, V36, P573; STROMSTEDT M, 1995, MOL BRAIN RES, V34, P75, DOI 10.1016/0169-328X(95)00140-N; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Vacchio M S, 1996, Behring Inst Mitt, P24; Vacchio MS, 1997, J EXP MED, V185, P2033, DOI 10.1084/jem.185.11.2033; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; VONBOEHMER H, 1997, IMMUNOLOGIST, V5, P185; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; Xue YT, 1996, EUR J IMMUNOL, V26, P428, DOI 10.1002/eji.1830260224; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175; Zilberman Y, 1996, CELL IMMUNOL, V170, P78, DOI 10.1006/cimm.1996.0136	50	102	105	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					893	901		10.1096/fasebj.13.8.893	http://dx.doi.org/10.1096/fasebj.13.8.893			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224232	Bronze			2022-12-28	WOS:000080372500012
J	Etkin, LD; Lipshitz, HD				Etkin, LD; Lipshitz, HD			RNA localization	FASEB JOURNAL			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Etkin, LD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Ide@mdacc.tme.edu; lipshitz@sickkids.on.ca		Lipshitz, Howard/0000-0002-7372-4419				Bassell GJ, 1999, FASEB J, V13, P447, DOI 10.1096/fasebj.13.3.447; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Lasko P, 1999, FASEB J, V13, P421, DOI 10.1096/fasebj.13.3.421; Mowry KL, 1999, FASEB J, V13, P435, DOI 10.1096/fasebj.13.3.435	4	11	11	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1999	13	3					419	420		10.1096/fasebj.13.3.419	http://dx.doi.org/10.1096/fasebj.13.3.419			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064608				2022-12-28	WOS:000079016000001
J	Iacovelli, L; Sallese, M; Mariggio, S; De Blasi, A				Iacovelli, L; Sallese, M; Mariggio, S; De Blasi, A			Regulation of G-protein-coupled receptor kinase subtypes by calcium sensor proteins	FASEB JOURNAL			English	Review						calmodulin; calcium sensor protein; rhodopsin kinase; GRK	BETA-GAMMA-SUBUNITS; RHODOPSIN PHOSPHORYLATION; BINDING-SITE; ACTIVATION; CALMODULIN; RECOVERIN; DESENSITIZATION; PHOSPHATASE; INHIBITION; PHOSPHODIESTERASE	The process of G-protein-coupled receptor (GPCR) homologous desensitization is intrinsically related to the function of a class of S/T kinases named G-protein-coupled receptor kinases (GRK). GRK family is so far composed of six cloned members, named GRK1 to 6, which are classified into three subfamilies: GRK1 is alone in the first (rhodopsin kinase subfamily), GRK2 and 3 form the second [P-adrenergic receptor kinase (PARK) subfamily], and GRK4, 5, and 6 constitute the third (GRK4 subfamily). Recent studies from different laboratories have demonstrated that different calcium sensor proteins (CSP) can selectively regulate the activity of GRK subtypes. In the presence of calcium, rhodopsin kinase (GRK1) is inhibited by the photoreceptor-specific CSP recoverin through direct binding. Several other recoverin homologues (including NGS 1,VILIP 1, and hippocalcin) are also able to inhibit GRK1 in a calcium-dependent manner. The ubiquitous calcium binding protein calmodulin (CaM) can inhibit GRK5 with a high affinity (IC50=40-50 nM). a direct interaction between GRK5 and Ca2+/CaM was documented and this binding did not influence the catalytic activity of the kinase, but rather reduced GRK5 binding to the membrane. These studies suggest that CSP act as functional analog in mediating the regulation of different GRK subtypes by Ca2+. This mechanism, however, is highly selective with respect to the GRK subtypes: GRK1, but not GRK2 and GRK5, is regulated by recoverin and other NCS, but GRK4,, 5, and 6, which belong to the GRK4 subfamily are potently inhibited by CaM, which has little or no effect on members of other GRK subfamilies. Calcium-dependent inhibition of rhodopsin kinase by recoverin represents one of the mechanisms that control adaptation to light. For the other GPCR, CSP-GRK interaction provides a feedback mechanism that can modulate homologous desensitization of these receptors.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	De Blasi, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazl, I-66030 Santa Maria Imbaro, Italy.		Sallese, Michele/J-5347-2016; Mariggio', Stefania/H-5467-2015	Sallese, Michele/0000-0002-2555-3571; Mariggio', Stefania/0000-0002-6397-3016				Boekhoff I, 1997, EUR J CELL BIOL, V72, P151; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Firsov D, 1997, AM J PHYSIOL-CELL PH, V273, pC953, DOI 10.1152/ajpcell.1997.273.3.C953; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1997, LIFE SCI, V96, P1184; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; NIKONOV SS, 1993, FEBS LETT, V316, P34, DOI 10.1016/0014-5793(93)81731-E; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sallese M, 1997, J BIOL CHEM, V272, P10188; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Senin II, 1997, FEBS LETT, V408, P251, DOI 10.1016/S0014-5793(97)00434-1; Senin II, 1997, BIOCHEM J, V321, P551, DOI 10.1042/bj3210551; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	43	64	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1999	13	1					1	8						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872924				2022-12-28	WOS:000078029500001
J	Hjeltnes, N; Galuska, D; Bjornholm, M; Aksnes, AK; Lannem, A; Zierath, JR; Wallberg-Henriksson, H				Hjeltnes, N; Galuska, D; Bjornholm, M; Aksnes, AK; Lannem, A; Zierath, JR; Wallberg-Henriksson, H			Exercise-induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis	FASEB JOURNAL			English	Article						GLUT4; glycogen synthase; hexokinase; phosphofructokinase; skeletal muscle fiber type; glucose transport; insulin resistance	RAT SKELETAL-MUSCLE; DEPENDENT DIABETES-MELLITUS; MIDDLE-AGED MEN; ELECTRICAL-STIMULATION; TRANSGENIC MICE; HEXOKINASE-II; CONTRACTILE ACTIVITY; INSULIN-RESISTANCE; GLYCOGEN-SYNTHASE; PARAPLEGIC PATIENTS	Complete spinal cord lesion leads to profound metabolic abnormalities and striking changes in muscle morphology. Here we assess the effects of electrically stimulated leg cyclic; (ESLC) on whole body insulin sensitivity, skeletal muscle glucose metabolism, and muscle fiber morphology in five tetraplegic subjects with complete C-5-C-7 lesions. Physical training (seven ESLC sessions/wk for 8 wk) increased whole body insulin-stimulated glucose uptake by 33+/-13%, concomitant with a 2.1-fold increase in insulin-stimulated (100 mu U/ml) 3-O-methylglucose transport in isolated vastus lateralis muscle. Physical training led to a marked increase in protein expression of GLUT4 (378+/-85%), glycogen synthase (526+/-146%), and hexokinase II (204+/-47%) in vastus lateralis muscle, whereas phosphofructokinase expression (282+/-97%) was not significantly changed. Hexokinase II activity was significantly increased, whereas activity of phosphofructokinase, glycogen synthase, and citrate synthase was not changed after training. Muscle fiber type distribution and fiber area were markedly altered compared to able-bodied subjects before ESLC training, with no change noted in either parameter after ECSL training. In conclusion, muscle contraction improves insulin action on whole body and cellular glucose uptake in cervical cord-injured persons through a major increase in protein expression of key genes involved in the regulation of glucose metabolism. Furthermore, improvements in insulin action on glucose metabolism are independent of changes in muscle fiber type distribution.	Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden; Sunnaas Hosp, N-1450 Nesoddtangen, Norway	Karolinska Institutet; Karolinska University Hospital	Wallberg-Henriksson, H (corresponding author), Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden.	hwh@klinfys.ks.se		Zierath, Juleen/0000-0001-6891-7497				Aksnes AK, 1996, AM J PHYSIOL-ENDOC M, V271, pE593, DOI 10.1152/ajpendo.1996.271.3.E593; ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; ANDERSEN PH, 1993, ACTA PHYSIOL SCAND, V149, P393, DOI 10.1111/j.1748-1716.1993.tb09635.x; Anderson SL, 1997, ADV GENET, V35, P1, DOI 10.1016/S0065-2660(08)60446-0; BAK JF, 1990, AM J PHYSIOL, V258, pE957, DOI 10.1152/ajpendo.1990.258.6.E957; BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BAUMAN WA, 1994, METABOLISM, V43, P749, DOI 10.1016/0026-0495(94)90126-0; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; CORTEZ MY, 1991, AM J PHYSIOL, V261, pE613; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; DELA F, 1993, J PHYSIOL-LONDON, V469, P615, DOI 10.1113/jphysiol.1993.sp019833; DELA F, 1992, AM J PHYSIOL, V263, pE1134; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; DUCKWORTH WC, 1980, DIABETES, V29, P906, DOI 10.2337/diabetes.29.11.906; ETGEN GJ, 1993, AM J PHYSIOL, V264, pR816, DOI 10.1152/ajpregu.1993.264.4.R816; Figoni S F, 1990, J Am Paraplegia Soc, V13, P33; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GREVE JMD, 1993, PARAPLEGIA, V31, P764, DOI 10.1038/sc.1993.119; GRIMBY G, 1976, SCAND J REHABIL MED, V8, P37; GROSSBARD L, 1966, J BIOL CHEM, V241, P3446; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSSON J, 1986, AM J PHYSIOL, V251, pC614, DOI 10.1152/ajpcell.1986.251.4.C614; Hjeltnes N, 1997, AM J PHYSIOL-REG I, V273, pR1072, DOI 10.1152/ajpregu.1997.273.3.R1072; HOOKER SP, 1992, J REHABIL RES DEV, V29, P1, DOI 10.1682/JRRD.1992.07.0001; Host HH, 1998, J APPL PHYSIOL, V84, P798, DOI 10.1152/jappl.1998.84.3.798; HOUMARD JA, 1993, AM J PHYSIOL, V264, pE896, DOI 10.1152/ajpendo.1993.264.6.E896; HOUMARD JA, 1991, AM J PHYSIOL, V261, pE437, DOI 10.1152/ajpendo.1991.261.4.E437; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; Koval JA, 1998, AM J PHYSIOL-ENDOC M, V274, pE304, DOI 10.1152/ajpendo.1998.274.2.E304; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LOTTA S, 1991, PARAPLEGIA, V29, P247, DOI 10.1038/sc.1991.35; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; MARTIN TP, 1992, J APPL PHYSIOL, V72, P1401, DOI 10.1152/jappl.1992.72.4.1401; ODOHERTY R, 1996, J APPL PHYSIOL, V81, P798; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; OPIE LH, 1967, BIOCHEM J, V103, P391, DOI 10.1042/bj1030391; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PETROFSKY J S, 1984, Journal of Clinical Engineering, V9, P13; PETTE D, 1973, PFLUG ARCH EUR J PHY, V338, P257, DOI 10.1007/BF00587391; PLOUG T, 1990, AM J PHYSIOL, V259, P778; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1994, J BIOL CHEM, V269, P14396; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; RICHTER EA, 1982, J CLIN INVEST, V69, P785, DOI 10.1172/JCI110517; Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615; RODGERS MA, 1988, DIABETES CARE, V11, P613; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; SCELSI R, 1986, PARAPLEGIA, V24, P250, DOI 10.1038/sc.1986.35; SCELSI R, 1982, ACTA NEUROPATHOL, V57, P243, DOI 10.1007/BF00692178; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Vestergaard H, 1995, J CLIN INVEST, V96, P2639, DOI 10.1172/JCI118329; VESTERGAARD H, 1993, J CLIN INVEST, V91, P2342, DOI 10.1172/JCI116466; VESTERGAARD H, 1994, AM J PHYSIOL, V266, pE92, DOI 10.1152/ajpendo.1994.266.1.E92; WALLBERGHENRIKSSON H, 1987, ACTA PHYSIOL SCAND, V131, P1; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; WEBER FE, 1990, FEBS LETT, V261, P291, DOI 10.1016/0014-5793(90)80574-3; YEKUTIEL M, 1989, PARAPLEGIA, V27, P58, DOI 10.1038/sc.1989.9; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; ZAMMIT VA, 1976, BIOCHEM J, V160, P447, DOI 10.1042/bj1600447; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885; Zierath Juleen R., 1995, Acta Physiologica Scandinavica, V155, P1	70	93	94	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1701	1712		10.1096/fasebj.12.15.1701	http://dx.doi.org/10.1096/fasebj.12.15.1701			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837860				2022-12-28	WOS:000077574500012
J	Avalle, B; Thomas, D; Friboulet, A				Avalle, B; Thomas, D; Friboulet, A			Functional mimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolizing beta-lactams	FASEB JOURNAL			English	Article						mimicry; catalytic antibody; abzyme; anti-idiotype; beta-lactamase	CATALYTIC ANTIBODIES; ANTIIDIOTYPIC ANTIBODIES; HYDROLYSIS; AUTOANTIBODY; PEPTIDE	Antigen mimicry by anti-idiotypic antibodies is investigated as a reliable strategy to achieve molecular imprinting of an enzymatic activity. A monoclonal anti-idiotypic antibody (Ab2-9G4H9) was elicited by using a monoclonal antibody (Ab1-7AF9) specific for the beta-lactamase active site. Catalytic features of Ab2 were characterized with beta-lactamase substrates, The antibody combining site appeared to have retained a part of the catalytic specificity. The relevance of the idiotypic mimicry concept for the generation of catalytic antibodies was further demonstrated by eliciting a third generation antibody (Ab3), which was shown to recognize p-lactamase: the complete internal image properties of Ab2 9G4H9, including binding and catalytic properties, were thus checked.	Univ Technol Compiegne, CNRS, UPRES A 6022, Technol Enzymat Lab, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Friboulet, A (corresponding author), Univ Technol Compiegne, CNRS, UPRES A 6022, Technol Enzymat Lab, BP 20529, F-60205 Compiegne, France.							Ban N, 1996, J MOL BIOL, V255, P617, DOI 10.1006/jmbi.1996.0051; Benkovic SJ, 1996, NATURE, V383, P23, DOI 10.1038/383023a0; BRANNIGAN J, 1991, BIOCHEM J, V278, P673, DOI 10.1042/bj2780673; BRONSHTEIN IB, 1992, FEBS LETT, V314, P259, DOI 10.1016/0014-5793(92)81484-4; Bronstein IB, 1996, ONCOL RES, V8, P17; COURAUD PO, 1986, J IMMUNOL, V136, P3365; DANISHEFSKY S, 1993, SCIENCE, V259, P469, DOI 10.1126/science.8424168; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GALLACHER G, 1992, BIOCHEM J, V284, P675, DOI 10.1042/bj2840675; Goldbaum FA, 1997, P NATL ACAD SCI USA, V94, P8697, DOI 10.1073/pnas.94.16.8697; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; Jacobsen JR, 1995, CURR OPIN STRUC BIOL, V5, P818, DOI 10.1016/0959-440X(95)80016-6; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANJIC N, 1989, J AM CHEM SOC, V111, P9109, DOI 10.1021/ja00207a022; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; PAN Y, 1995, FASEB J, V9, P43, DOI 10.1096/fasebj.9.1.7821758; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Resmini M, 1997, BIOCHEM J, V326, P279, DOI 10.1042/bj3260279; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SORENSEN K, 1987, BIOCHIM BIOPHYS ACTA, V912, P56, DOI 10.1016/0167-4838(87)90247-0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797	32	52	54	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1055	1060		10.1096/fasebj.12.11.1055	http://dx.doi.org/10.1096/fasebj.12.11.1055			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707178				2022-12-28	WOS:000075372600016
J	Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z				Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z			Inhibition of adenylyl cyclase isoforms V and VI by various G(beta gamma) subunits	FASEB JOURNAL			English	Article						G(beta gamma); signal transduction; inhibition; plasmid	BETA-GAMMA-SUBUNITS; EXPRESSION; CLONING; ACTIVATION; CELLS; SPECIFICITY; MODULATION; RECEPTORS; CHANNELS; PROTEINS	An intriguing development in the G-protein signaling field has been the finding that not only the G(alpha) subunit, but also G(beta gamma) subunits, affect a number of downstream target molecules. One of the downstream targets of G(beta gamma) is adenylyl cyclase, and it has been demonstrated that a number of isoforms of adenylyl cyclase can be either inhibited or stimulated by G(beta gamma) subunits. Until now, adenylyl cyclase type I has been the only isoform reported to be inhibited by free G(beta gamma). Here we show by transient cotransfection into COS-7 cells of either adenylyl cyclase V or VI, together with G gamma(gamma 2) and various G(beta) subunits, that these two adenylyl cyclase isozymes are markedly inhibited by G(beta gamma). In addition, we show that G(beta 1) and G(beta 5) subunits differ in their activity. G(beta 1) transfected alone markedly inhibited adenylyl cylcase V and VI (probably by recruiting endogenous G(gamma) subunits). On the other hand, G(beta 5) produced less inhibition of these isozymes, and its activity was enhanced by the addition of G(gamma 2). These results demonstrate that adenylyl cyclase types V and VI are inhibited by G(beta gamma) dimers and that G(beta 1) and G(beta 5) Subunits differ in their capacity to regulate these adenylyl cyclase isozymes.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Dusseldorf, Dept Physiol Chem 2, D-40225 Dusseldorf, Germany; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Weizmann Institute of Science; Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Vogel, Z (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnvogel@weizmann.weizmann.ac.il	Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NIDA NIH HHS [DA-06265] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM K, 1989, BIOTECHNIQUES, V7, P576; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MOLLNER S, 1991, EUR J BIOCHEM, V195, P281, DOI 10.1111/j.1432-1033.1991.tb15704.x; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; PFEUFFER E, 1991, METHOD ENZYMOL, P83; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS W, 1991, J BIOL CHEM, V266, P7706; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	41	71	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1019	1025		10.1096/fasebj.12.11.1019	http://dx.doi.org/10.1096/fasebj.12.11.1019			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707174				2022-12-28	WOS:000075372600012
J	Saleh, D; Ernst, P; Lim, S; Barnes, PJ; Giaid, A				Saleh, D; Ernst, P; Lim, S; Barnes, PJ; Giaid, A			Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid	FASEB JOURNAL			English	Article						nitrotyrosine; asthma; steroids; human	ACUTE LUNG INJURY; IN-VIVO; PULMONARY-HYPERTENSION; SUPEROXIDE-DISMUTASE; ALVEOLAR MACROPHAGES; ENHANCED PRODUCTION; ENDOTHELIAL-CELLS; OXYGEN RADICALS; L-ARGININE; INFLAMMATION	Peroxynitrite is a potent oxidant formed by the rapid reaction of the free radicals nitric oxide (NO) and superoxide. It causes airway hyperresponsiveness and airway epithelial damage, enhances inflammatory cell recruitment, and inhibits pulmonary surfactant. Asthma is characterized by increased airway hyperresponsiveness, airway epithelial shedding, and inflammation. We examined the production of peroxynitrite and the expression of inducible nitric oxide synthase (iNOS) in airways of asthmatic patients compared to normal control subjects. We also performed a double-blind, crossover randomized-order, placebo-controlled study on 10 asthmatic patients to study the effects of inhaled glucocorticoid treatment (Budesonide) on the formation of peroxynitrite and NO. Fiberoptic bronchial biopsies were examined by immunohistochemistry with antiserum to nitrotyrosine, a marker of protein nitration by peroxynitrite. We also examined the ex pression of iNOS by immunohistochemistry and in situ hybridization, and measured exhaled NO by chemiluminescence. We correlated the airway production of peroxynitrite with pulmonary functions and airway responsiveness. In airway passages of control subjects, there was weak or no nitrotyrosine immunoreactivity. In contrast, there was strong immunoreactivity for nitrotyrosine in the airway epithelium and inflammatory cells in the airways of persons with asthma. Budesonide treatment resulted in a significant reduction in nitrotyrosine immunoreactivity. Expression of iNOS was evident in the airway pithelium of controls and asthmatic patients, but was significantly more abundant in asthmatic patients. The presence of nitrotyrosine in the airway epithelium (r = -0.841, P < 0.0001; r = -0.771, P = 0.0004) and inflammatory cells (r = -0.727, P = 0014; r = -0.681, P = 0.004) correlated inversely with methacholine PC20 and forced expiratory volume in 1 s, respectively. Asthma is associated with increased peroxynitrite formation in the airways, which is reduced after Budesonide treatment. The potent oxidant peroxynitrite may contribute to airway obstruction and hyperresponsiveness and epithelial damage in asthma.	McGill Univ, Montreal Gen Hosp, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Montreal Gen Hosp, Dept Pathol, Montreal, PQ H3G 1A4, Canada; GenPath Labs, Montreal, PQ, Canada; Natl Heart & Lung Inst, London, England	McGill University; McGill University; Imperial College London	Giaid, A (corresponding author), McGill Univ, Montreal Gen Hosp, Dept Med, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Barnes, Peter/0000-0002-5122-4018				BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLEECKER ER, 1992, CHEST, V101, P297, DOI 10.1378/chest.101.2.297; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; Dugas B, 1995, RES IMMUNOL, V146, P664, DOI 10.1016/0923-2494(96)84914-5; FURUKAWA K, 1996, AM J RESP CRIT CARE, V328, P1732; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HADDAD IY, 1993, AM J PHYSIOL, V265, pL555, DOI 10.1152/ajplung.1993.265.6.L555; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; Halliwell B, 1997, FEBS LETT, V411, P157, DOI 10.1016/S0014-5793(97)00469-9; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hulsmann AR, 1996, AM J RESP CRIT CARE, V153, P841, DOI 10.1164/ajrccm.153.2.8564141; Imaizumi S, 1996, NEUROCHEM INT, V29, P205, DOI 10.1016/0197-0186(95)00120-4; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; JONES OTG, 1993, MOL CHEM NEUROPATHOL, V19, P177, DOI 10.1007/BF03160177; JOSEPH BZ, 1993, INFLAMMATION, V17, P361, DOI 10.1007/BF00918997; JUNIPER EF, 1978, THORAX, V33, P710; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; LEVEY AI, 1986, J HISTOCHEM CYTOCHEM, V34, P1449, DOI 10.1177/34.11.2430010; LI Y, 1995, IMMUNOPHARMACOLOGY, V30, P177, DOI 10.1016/0162-3109(95)00018-O; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510, DOI 10.1164/ajrccm.153.5.8630594; MATALON S, 1994, CHEST, V105, pS74, DOI 10.1378/chest.105.3_Supplement.74S; OSWALD IP, 1994, P NATL ACAD SCI USA, V91, P999, DOI 10.1073/pnas.91.3.999; PENDINO KJ, 1993, J IMMUNOL, V151, P7196; RADI R, 1991, J BIOL CHEM, V266, P4244; SadeghiHashjin G, 1996, AM J RESP CRIT CARE, V153, P1697, DOI 10.1164/ajrccm.153.5.8630623; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; TAKAHASHI T, 1993, AM REV RESPIR DIS, V148, P103, DOI 10.1164/ajrccm/148.1.103; Teramoto S, 1996, J ASTHMA, V33, P149, DOI 10.3109/02770909609054546; Torres A, 1996, CHEST, V109, pS8, DOI 10.1378/chest.109.3_Supplement.8S; Wileman SM, 1995, BRIT J PHARMACOL, V116, P3243, DOI 10.1111/j.1476-5381.1995.tb15131.x; WRIGHT DT, 1994, ENVIRON HEALTH PERSP, V102, P85, DOI 10.2307/3432221; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801	44	352	358	2	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					929	937		10.1096/fasebj.12.11.929	http://dx.doi.org/10.1096/fasebj.12.11.929			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707165				2022-12-28	WOS:000075372600003
J	Bailly, K; Soulet, F; Leroy, D; Amalric, F; Bouche, G				Bailly, K; Soulet, F; Leroy, D; Amalric, F; Bouche, G			Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor	FASEB JOURNAL			English	Article						FGF-2; mitogenicity; signaling pathway; activation; CK2	CASEIN KINASE-II; NIH 3T3 CELLS; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING; FGF RECEPTOR-1; FACTOR MUTANT; ENDOTHELIAL-CELLS; PROTEIN-KINASES; TYROSINE KINASE	FGF-2 exerts its pleiotropic effects on cell growth and differentiation by interacting with specific cell surface receptors. In addition, exogenously added FGF-2 is translocated from outside the cell to the nucleus during G1-S transition. In this study, we show that a single point mutation in FGF-2 (substitution of residue serine 117 by alanine) is sufficient to drastically reduce its mitogenic activity without affecting its differentiation properties. The FGF-2(S117A) mutant binds to and activates tyrosine kinase receptors and induces MAPK and p70S6K activation as strongly as the wild-type FGF-2. We demonstrate that this mutant enters NIH3T3 cells, is translocated to the nucleus, and is phosphorylated similar to the wild-type growth factor. This suggests that FGF-2 mitogenic activity may require, in addition to signaling through cell surface receptors and nuclear translocation, activation of nuclear targets. We have previously shown that, in vitro, FGF-2 directly stimulates the activity of the casein kinase 2 (CK2), a ubiquitous serine/threonine kinase involved in the control of cell proliferation. We report that, in vivo, FGF-2(WT) transiently interacts with CK2 and stimulates its activity in the nucleus during G1-S transition in NIH3T3 cells. In contrast, the FGF-2(S117A) mutant fails to interact with CK2. Thus, our results show that FGF-2 mitogenic and differentiation activities can be dissociated by a single point mutation and that CK2 may be a new nuclear effector involved in FGF-2 mitogenic activity.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France; INSERM, Commiss Energie Atom Biochim Regulat Cellulairs E, U244 CEN, F-38054 Grenoble, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bouche, G (corresponding author), CNRS, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse 4, France.							ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; Ginisty H, 1999, J CELL SCI, V112, P761; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klingenberg O, 1998, J BIOL CHEM, V273, P11164, DOI 10.1074/jbc.273.18.11164; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; Lam K, 1998, J BIOMOL STRUCT DYN, V15, P1009, DOI 10.1080/07391102.1998.10508997; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LORENZ P, 1994, CELL MOL BIOL RES, V40, P519; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mehta VB, 1998, J BIOL CHEM, V273, P4197, DOI 10.1074/jbc.273.7.4197; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOY FJ, 1995, J BIOMOL NMR, V6, P245; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P520; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1996, MOL BIOL CELL, V7, P1290; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TISCHLER AS, 1975, NATURE, V258, P341, DOI 10.1038/258341a0; VILGRAIN I, 1993, FEBS LETT, V331, P228, DOI 10.1016/0014-5793(93)80342-R; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	67	67	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					333	344		10.1096/fasebj.14.2.333	http://dx.doi.org/10.1096/fasebj.14.2.333			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657989				2022-12-28	WOS:000085184800012
J	Fujiyoshi, Y				Fujiyoshi, Y			Molecular structure of proton primp revealed with electron crystallography	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MASSACHUSETTS	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		PURPLE MEMBRANE; HALOBACTERIUM-HALOBIUM; BACTERIORHODOPSIN; RESOLUTION; MICROSCOPY; MODEL		Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Fujiyoshi, Y (corresponding author), Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.		Fujiyoshi, Yoshinori/E-5989-2012	Fujiyoshi, Yoshinori/0000-0002-8070-1493				BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; Fujiyoshi Y, 1998, ADV BIOPHYS, V35, P25, DOI 10.1016/S0065-227X(98)90004-1; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; KRIVANEK OL, 1993, ULTRAMICROSCOPY, V49, P95, DOI 10.1016/0304-3991(93)90216-K; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0	11	3	3	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13			2			S191	S194		10.1096/fasebj.13.9002.S191	http://dx.doi.org/10.1096/fasebj.13.9002.S191			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619126				2022-12-28	WOS:000084390200004
J	Hirschberg, K; Lippincott-Schwartz, J				Hirschberg, K; Lippincott-Schwartz, J			Secretory pathway kinetics and in vivo analysis of protein traffic from the Golgi complex to the cell surface	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		GREEN FLUORESCENT PROTEIN; PLASMA-MEMBRANE PROTEINS; ENDOPLASMIC-RETICULUM; LIVING CELLS; TRANSPORT VESICLES; VISUALIZATION; EXPRESSION; MICROSCOPY; APPARATUS; DYNAMICS		NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hirschberg, K (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Room 101,18 Lib Dr, Bethesda, MD 20892 USA.	jlippin@helix.nih.gov	Hirschberg, Koret/AAF-4566-2019					Alberts B., 1994, MOL BIOL CELL; ARNHEITER H, 1984, CELL, V39, P99, DOI 10.1016/0092-8674(84)90195-8; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Bergmann JE, 1989, METHOD CELL BIOL, V32, P85; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; Lafont F, 1995, COLD SPRING HARB SYM, V60, P753, DOI 10.1101/SQB.1995.060.01.081; LIPPINCOTTSCHWA.J, 1998, METHODS CELL BIOL GF; LippincottSchwartz J, 1997, CURR OPIN NEUROBIOL, V7, P631, DOI 10.1016/S0959-4388(97)80082-7; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PISTON D, 1998, METHODS CELL BIOL GF; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHEELE G, 1985, J BIOL CHEM, V260, P926; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Wacker I, 1997, J CELL SCI, V110, P1453; WEHLAND J, 1982, CELL, V28, P831, DOI 10.1016/0092-8674(82)90062-9	33	34	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S251	S256		10.1096/fasebj.13.9002.S251	http://dx.doi.org/10.1096/fasebj.13.9002.S251			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619138				2022-12-28	WOS:000084390200016
J	Jones, MK; Sasaki, E; Halter, F; Pai, R; Nakamura, T; Arakawa, T; Kuroki, T; Tarnawski, AS				Jones, MK; Sasaki, E; Halter, F; Pai, R; Nakamura, T; Arakawa, T; Kuroki, T; Tarnawski, AS			HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway	FASEB JOURNAL			English	Article						RGM1 cells; receptor phosphorylation; c-Met/HGF receptor	HEPATOCYTE GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; MESSENGER-RNA; ARACHIDONIC-ACID; MUCOSAL LESIONS; STOMACH; CYCLOOXYGENASE-2; EXPRESSION; PROSTAGLANDIN	Although it is established that growth factors and prostaglandins function in the maintenance of gastric mucosal integrity and in the healing of gastric mucosal injury and ulceration, the regulatory relationship between growth factors and prostaglandins in the gastric mucosa is not well characterized. Therefore, we investigated whether hepatocyte growth factor (HGF) affects expression of COX-2 (the inducible form of the prostaglandin synthesizing enzyme, cyclooxygenase) in gastric epithelial cells and whether this action is mediated through the MAP (ERK) kinase signaling pathway. In RGM1 cells (an epithelial cell line derived from normal rat gastric mucosa), HGF caused an increase in COX-2 mRNA and protein by 236% and 175%, respectively (both P<0.05). This induction of COX-2 expression was abolished by pretreatment with the MAPK kinase (MEK) inhibitor PD98059. HGF also triggered a 13-fold increase in c-Met/HGF receptor phosphorylation (P<0.005) and increased ERK2 activity by 684% (P<0.01). Pretreatment with PD98059 abolished the HGF-induced increase in ERK2 activity, but not c-Met/HGF receptor phosphorylation. The specific inhibitor of p38 MAP kinase, SB203580, had no effect on HGF-induced COX-2 expression. Thus, HGF triggers activation of the COX-2 gene in gastric epithelial cells through phosphorylation of c-Met/HGF receptor and activation of the ERK2 signaling pathway.	Vet Affairs Med Ctr, Long Beach, CA 90822 USA; Univ Calif Irvine, Irvine, CA 92717 USA; Osaka City Univ, Sch Med, Dept Internal Med 3, Osaka 545, Japan; Osaka City Univ, Sch Med, Biomed Res Ctr, Div Biochem, Osaka 545, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; Osaka Metropolitan University; Osaka Metropolitan University	Tarnawski, AS (corresponding author), Vet Affairs Med Ctr, 5901 E 7th St, Long Beach, CA 90822 USA.	atarnawski@yahoo.com						ADACHI T, 1995, HEPATOLOGY, V21, P1668; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; BOYCE S, 1994, NEUROPHARMACOLOGY, V33, P1609, DOI 10.1016/0028-3908(94)90137-6; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davies NM, 1997, ALIMENT PHARM THERAP, V11, P1101, DOI 10.1046/j.1365-2036.1997.00247.x; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Donnelly MT, 1997, GASTROENTEROLOGY, V112, pA105; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EHRLICH K, 1998, AM J PHYSIOL, V247, pG955; Ferraz JGP, 1997, GASTROENTEROLOGY, V113, P195, DOI 10.1016/S0016-5085(97)70095-7; Giardiello FM, 1998, DIGEST DIS SCI, V43, P311; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; Gretzer B, 1998, BRIT J PHARMACOL, V123, P927, DOI 10.1038/sj.bjp.0701673; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; HORI T, 1993, FEBS LETT, V334, P331, DOI 10.1016/0014-5793(93)80705-Y; Horie-Sakata K, 1998, J CLIN GASTROENTEROL, V27, pS40, DOI 10.1097/00004836-199800001-00008; INAUEN W, 1988, GASTROENTEROLOGY, V95, P636, DOI 10.1016/S0016-5085(88)80009-X; ISEKI S, 1995, HISTOCHEM J, V27, P323, DOI 10.1007/BF00398975; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; KINOSHITA Y, 1995, GASTROENTEROLOGY, V109, P1068, DOI 10.1016/0016-5085(95)90564-2; Kishimoto Y, 1998, ARCH BIOCHEM BIOPHYS, V352, P153, DOI 10.1006/abbi.1997.0572; KRAMER MF, 1995, CURRENT PROTOCOLS MO, V2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; Majumdar APN, 1996, J LAB CLIN MED, V128, P173, DOI 10.1016/S0022-2143(96)90009-8; MATSUMOTO K, 1995, J BIOCHEM-TOKYO, V117, P458, DOI 10.1093/jb/117.2.458; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; MORHAM SG, 1995, CELL, V83, P437; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Ohta M, 1997, GASTROENTEROLOGY, V112, P1920, DOI 10.1053/gast.1997.v112.pm9178684; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Rainsford K. D., 1995, Inflammopharmacology, V3, P299, DOI 10.1007/BF02668024; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; Ridley SH, 1997, J IMMUNOL, V158, P3165; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sasaki E, 1998, J CLIN GASTROENTEROL, V27, pS21, DOI 10.1097/00004836-199800001-00005; Sawaoka H, 1997, J CLIN GASTROENTEROL, V25, pS105, DOI 10.1097/00004836-199700001-00018; Schmassmann A, 1997, GASTROENTEROLOGY, V113, P1858, DOI 10.1016/S0016-5085(97)70005-2; SCHMASSMANN A, 1995, AM J PHYSIOL-GASTR L, V268, pG276, DOI 10.1152/ajpgi.1995.268.2.G276; Schmassmann A, 1998, BRIT J PHARMACOL, V123, P795, DOI 10.1038/sj.bjp.0701672; Schmassmann A, 1997, FALK SYMP, V94, P180; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; Takahashi M, 1996, J CLIN INVEST, V98, P2604, DOI 10.1172/JCI119080; Tanoue K, 1996, GASTROENTEROLOGY, V110, P549, DOI 10.1053/gast.1996.v110.pm8566603; TARNAWSKI A, 1988, J CLIN INVEST, V81, P1081, DOI 10.1172/JCI113420; Tarnawski A, 1997, GASTROENTEROLOGY, V112, pA309; Tarnawski A, 1995, J CLIN GASTROENTEROL, V21, pS93; Tarnawski A, 1996, GASTROENTEROLOGY, V110, pA275; TSUJI S, 1995, DIGEST DIS SCI, V40, P1132, DOI 10.1007/BF02064211; TYTGAT GNJ, 1986, GASTROENTEROLOGY, V90, P1111, DOI 10.1016/0016-5085(86)90375-6; Ukawa H, 1998, DIGEST DIS SCI, V43, P2003, DOI 10.1023/A:1018846912032; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; Vane J. R., 1998, AM J MED, V104, p2S, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]; WATANABE S, 1993, BIOCHEM BIOPH RES CO, V19, P1452; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yeomans ND, 1998, GASTROENTEROLOGY, V115, P227, DOI 10.1016/S0016-5085(98)70388-9	63	87	89	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13	15					2186	2194		10.1096/fasebj.13.15.2186	http://dx.doi.org/10.1096/fasebj.13.15.2186			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593866				2022-12-28	WOS:000084310800010
J	Silver, RB				Silver, RB			Imaging structured space-time patterns of Ca2+ signals: essential information for decisions in cell division	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium on a Half-Century of Advances in Microscopy	JUL 24-25, 1998	MARINE BIOL LAB, WOODS HOLE, MA	Carl Zeiss Inc, Microscope Div, Federat Amer Soc Exptl Biol, Hamamatsu Photon Inc, JEOL/Japan Electron Opt Lab, Leica Inc, Microscopy & Sci Instruments Div, Marine Biol Lab, NASA, Natl Inst Gen Med Sci, NINCDS, Nikon Inc, Instrument Grp, Olympus Amer Inc, Porter Fdn, Universial Imaging Corp	MARINE BIOL LAB		DOLLAR ECHINARACNIUS-PARMA; STAMEN HAIR-CELLS; CALCIUM-CONCENTRATION MICRODOMAINS; NUCLEAR-ENVELOPE BREAKDOWN; MITOTIC APPARATUS; LEUKOTRIENE B-4; TRADESCANTIA; ANAPHASE; EMBRYOS; RELEASE		Marine Biol Lab, Woods Hole, MA 02543 USA	Marine Biological Laboratory - Woods Hole	Silver, RB (corresponding author), Marine Biol Lab, Woods Hole, MA 02543 USA.	rsilver@mbl.edu						ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BAKER PF, 1971, J PHYSIOL-LONDON, V218, P709, DOI 10.1113/jphysiol.1971.sp009641; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BROWN JE, 1974, J GEN PHYSIOL, V64, P643, DOI 10.1085/jgp.64.6.643; BROWN JE, 1984, NATURE, V312, P315; CHENG H, 1993, SCIENCE, V262, P741; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HEILBRUNN LV, 1956, DYNAMICS LIVING CYTO; HEPLER PK, 1987, J CELL BIOL, V105, P2137, DOI 10.1083/jcb.105.5.2137; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; KANE RE, 1962, J CELL BIOL, V12, P47, DOI 10.1083/jcb.12.1.47; KEITH CH, 1985, NATURE, V316, P848, DOI 10.1038/316848a0; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1991, BIOL BULL, V181, P316, DOI 10.1086/BBLv181n2p316; LLINAS R, 1995, J PHYSIOL-PARIS, V89, P77, DOI 10.1016/0928-4257(96)80554-7; MAZIA D, 1952, P NATL ACAD SCI USA, V38, P826, DOI 10.1073/pnas.38.9.826; MAZIA D, 1961, CELL, V3, P77; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1967, FED PROC, V26, P1370; MITCHISON JM, 1971, BIOL CELL CYCLE; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; RASMUSSEN H, 1985, CALCIUM BIOL SYSTEMS, P13; REBHUN LI, 1972, INT REV CYTOL, V32, P93, DOI 10.1016/S0074-7696(08)60339-3; REBHUN LI, 1967, J GEN PHYSIOL, V50, P233; Shannon C.E., 1964, MATH THEORY COMMUNIC; SILVER RB, 1980, CELL, V19, P505, DOI 10.1016/0092-8674(80)90525-5; SILVER RB, 1994, BIOL BULL-US, V187, P235, DOI 10.1086/BBLv187n2p235; Silver RB, 1996, CELL CALCIUM, V20, P161, DOI 10.1016/S0143-4160(96)90105-0; SILVER RB, 1983, J BIOL CHEM, V258, P3287; Silver RB, 1996, BIOL BULL-US, V191, P278, DOI 10.1086/BBLv191n2p278; SILVER RB, 1995, BIOL BULL-US, V189, P203, DOI 10.1086/BBLv189n2p203; Silver RB, 1998, BIOL BULL-US, V195, P209, DOI 10.2307/1542843; SILVER RB, 1994, BIOL BULL, V187, P293, DOI 10.2307/1542285; SILVER RB, 1986, P NATL ACAD SCI USA, V83, P4302, DOI 10.1073/pnas.83.12.4302; SILVER RB, 1990, ANN NY ACAD SCI, V582, P207; SILVER RB, 1995, BIOL BULL, V187, P237; SILVER RB, 1999, UNPUB LEUKOTRIENE B4; Silvester P. P., 1989, International Journal of Numerical Modelling: Electronic Networks, Devices and Fields, V2, P131, DOI 10.1002/jnm.1660020304; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; SJOSTRAND FS, 1968, J ULTRA MOL STRUCT R, V25, P121, DOI 10.1016/S0022-5320(68)80065-6; SJOSTRAND FS, 1970, J ULTRA MOL STRUCT R, V32, P293, DOI 10.1016/S0022-5320(70)80010-7; SJOSTRAND FS, 1963, J ULTRA MOL STRUCT R, V9, P340, DOI 10.1016/S0022-5320(63)80011-8; SJOSTRAND FS, 1978, J ULTRA MOL STRUCT R, V64, P217, DOI 10.1016/S0022-5320(78)90033-3; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; SUGIMORI M, 1994, BIOL BULL-US, V187, P300, DOI 10.2307/1542286; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; WOLNIAK SM, 1983, J CELL BIOL, V96, P598, DOI 10.1083/jcb.96.3.598; WOLNIAK SM, 1986, EUR J CELL BIOL, V39, P273; WOLNIAK SM, 1985, EUR J CELL BIOL, V39, P33; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; YOSHIMOTO Y, 1986, DEV GROWTH DIFFER, V28, P583	57	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1999	13			2			S209	S215		10.1096/fasebj.13.9002.S209	http://dx.doi.org/10.1096/fasebj.13.9002.S209			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	267ZY	10619129				2022-12-28	WOS:000084390200007
J	Cuzzocrea, S; Tan, DX; Costantino, G; Mazzon, E; Caputi, AP; Reiter, RJ				Cuzzocrea, S; Tan, DX; Costantino, G; Mazzon, E; Caputi, AP; Reiter, RJ			The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat	FASEB JOURNAL			English	Article						inflammation; nitric oxide; peroxynitrite; superoxide; hydroxyl radical	NITRIC-OXIDE SYNTHASE; ADP-RIBOSE SYNTHETASE; ISCHEMIA-REPERFUSION INJURY; CELLULAR-ENERGY DEPLETION; INDUCED OXIDATIVE DAMAGE; ENDOTOXIC-SHOCK; INDUCED MODELS; IN-VIVO; PEROXYNITRITE; INHIBITOR	Peroxynitrite, a potent cytotoxic oxidant formed by the reaction of nitric oxide (NO) with the superoxide anion, was recently proposed to play a major pathogenic role in the inflammatory process. Here we have investigated the effects of endogenous melatonin, a known scavenger of peroxynitrite, in rats subjected to carrageenan-induced pleurisy. Endogenous melatonin was depleted in rats maintained on 24 h light cycle for 1 wk. lit vivo depletion of endogenous melatonin enhanced the carrageenan-induced degree of pleural exudation and polymorphonuclear leukocyte migration in rats subjected to carrageenan-induced pleurisy. Lung myeloperoxidase activity and lipid peroxidation were significantly increased in melatonin-deprived rats. However, the inducible NO synthase in lung samples was unaffected by melatonin depletion. Immunohistochemical analysis for nitrotyrosine revealed a positive staining in lungs from carrageenan-treated rats that was markedly enhanced in melatonin-deprived rats. Furthermore, melatonin depletion significantly increased peroxynitrite formation as measured by the oxidation of the fluorescent dye dihydrorhodamine 123, enhanced DNA damage and the decrease in mitochondrial respiration and reduced the cellular levels of NAD+ in macrophages harvested from the pleural cavity of rats subjected to carrageenan-induced pleurisy. In vivo treatment with exogenous melatonin (15 mg/kg intraperitoneal) significantly reversed the effects of melatonin depletion. Thus, endogenous melatonin plays an important protective role against carrageenan-induced local inflammation.-Cuzzocrea, S., Tan, D.-X., Costantino, G., Mazzon, E., Caputi, A. P., Reiter, R. J. The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat.	Univ Messina, Sch Med, Inst Pharmacol, Policlin, I-98100 Messina, Italy; Univ Texas, Ctr Hlth, Dept Cellular & Struct Biol, San Antonio, TX 78285 USA; Univ Messina, Biomorphol Sch Med, I-98100 Messina, Italy	University of Messina; University of Texas System; University of Messina	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Policlin, Via C Valeria, I-98100 Messina, Italy.		tan, dun-xian/E-3610-2010; Tan, David/HIR-2214-2022; Mazzon, Emanuela/AAL-4334-2020	mazzon, emanuela/0000-0002-5073-717X				ALVAREZ B, 1995, CHEM RES TOXICOL, V8, P859, DOI 10.1021/tx00048a006; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bertuglia S, 1996, CARDIOVASC RES, V31, P947; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Cuzzocrea S, 1998, BRIT J PHARMACOL, V123, P525, DOI 10.1038/sj.bjp.0701612; Cuzzocrea S, 1999, FREE RADICAL BIO MED, V26, P25, DOI 10.1016/S0891-5849(98)00142-7; Cuzzocrea S, 1998, J PINEAL RES, V25, P78, DOI 10.1111/j.1600-079X.1998.tb00543.x; Cuzzocrea S, 1998, J PINEAL RES, V25, P24, DOI 10.1111/j.1600-079X.1998.tb00382.x; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DAMOTTA JIB, 1994, BRIT J PHARMACOL, V112, P111; DANIELS WMU, 1996, J PINEAL RES, V19, P1; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FRASER S, 1983, CLIN CHEM, V29, P396; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; LEE KJ, 1995, P SOC EXP BIOL MED, V209, P178; Marshall KA, 1996, FREE RADICAL BIO MED, V21, P307, DOI 10.1016/0891-5849(96)00046-9; McCord J M, 1993, New Horiz, V1, P70; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nava F, 1997, EUR J PHARMACOL, V331, P267, DOI 10.1016/S0014-2999(97)01049-2; NEMETH L, 1989, BIOMED BIOCHIM ACTA, V48, pS53; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PENTNEY PT, 1995, J PINEAL RES, V19, P31, DOI 10.1111/j.1600-079X.1995.tb00168.x; Petit JF, 1996, BIOCHEM PHARMACOL, V52, P205, DOI 10.1016/0006-2952(96)00177-3; PIERPAOLI W, 1994, P NATL ACAD SCI USA, V91, P787, DOI 10.1073/pnas.91.2.787; Pierre C., 1994, LIFE SCI, V55, P271; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; REITER RJ, 1995, NEUROCHEM INT, V27, P453, DOI 10.1016/0197-0186(95)80002-3; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; SEWERYNEK E, 1995, J CELL BIOCHEM, V58, P436, DOI 10.1002/jcb.240580406; Sewerynek E, 1996, HEPATO-GASTROENTEROL, V43, P898; SINGH A, 1989, CIRCULATION, V80, P1795, DOI 10.1161/01.CIR.80.6.1795; Stasica P, 1998, J PINEAL RES, V25, P65, DOI 10.1111/j.1600-079X.1998.tb00387.x; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; SZABO C, 1994, P NATL ACAD SCI USA, V91, P271, DOI 10.1073/pnas.91.1.271; Tan DX, 1993, ENDOCR J, V1, P57; TRACEY WR, 1995, J PHARMACOL EXP THER, V273, P1295; WALKER MW, 1995, PEDIATR RES, V37, P41, DOI 10.1203/00006450-199501000-00010; WEBB SM, 1985, NEUROENDOCRINOLOGY, V40, P205, DOI 10.1159/000124076; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; YOUN YK, 1991, CIRC SHOCK, V35, P245; [No title captured]	52	62	67	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1930	1938		10.1096/fasebj.13.14.1930	http://dx.doi.org/10.1096/fasebj.13.14.1930			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544176				2022-12-28	WOS:000083660700005
J	Fadeel, B; Zhivotovsky, B; Orrenius, S				Fadeel, B; Zhivotovsky, B; Orrenius, S			All along the watchtower: on the regulation of apoptosis regulators	FASEB JOURNAL			English	Review						Bcl-2 family; BH3-only; caspases; mitochondria	PROGRAMMED CELL-DEATH; BCL-X-L; CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR P53; ENDOPLASMIC-RETICULUM; SUBCELLULAR-DISTRIBUTION; MITOCHONDRIAL-MEMBRANE; INTERACTING PROTEIN; CYCLE PROGRESSION; CALPAIN INHIBITOR	Members of the expanding family of Bcl-2-like proteins have emerged as important regulators of programmed cell death, and recent studies have unearthed numerous mechanisms for regulating the function of these death agonists and antagonists, In addition to the transcriptional control of gene expression, these mechanisms include post-translational events such as phosphorylation, proteolysis, and the induction of conformational changes, which may either activate or inactivate these molecules, Interaction with homologous and nonhomologous proteins and specific subcellular targeting of Bcl-2-like proteins are other means of fine-tuning the cellular response to noxious stimuli. Recently, considerable attention has turned to the regulation of so-called BH3-only molecules, which appear to act as stress sensors that relay signals to other pro- or antiapoptotic family members, We discuss how the regulation of these apoptosis regulators may control the ultimate fate of the cell.-Fadeel, B., Zhivotovsky, B., Orrenius, S. All along the watchtower: on the regulation of apoptosis regulators.	Karolinska Inst, Inst Environm Med, Div Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet	Fadeel, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Doktorsringen 16C, S-17177 Stockholm, Sweden.	bengt.fadeeI@imm.ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Blagosklonny MV, 1997, CANCER RES, V57, P130; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; delPeso L, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Evtodienko YV, 1996, FEBS LETT, V393, P86, DOI 10.1016/0014-5793(96)00875-7; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadeel B, 1999, BRIT J HAEMATOL, V106, P406, DOI 10.1046/j.1365-2141.1999.01538.x; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hu ZB, 1998, BLOOD, V92, P1768, DOI 10.1182/blood.V92.5.1768.417k19_1768_1775; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Inohara N, 1998, J BIOL CHEM, V273, P32479, DOI 10.1074/jbc.273.49.32479; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LILES WC, 1995, BLOOD, V86, P3181; LINDEN M, 1989, J BIOENERG BIOMEMBR, V21, P507, DOI 10.1007/BF00762522; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Maravei DV, 1997, CELL DEATH DIFFER, V4, P707, DOI 10.1038/sj.cdd.4400311; Marin MC, 1996, ONCOGENE, V12, P2259; Martins LM, 1998, BLOOD, V92, P3042, DOI 10.1182/blood.V92.9.3042.421k55_3042_3049; MAY WS, 1994, J BIOL CHEM, V269, P26865; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Motoyama S, 1998, BIOCHEM BIOPH RES CO, V249, P628, DOI 10.1006/bbrc.1998.9205; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OHTA K, 1995, INT IMMUNOL, V7, P1817, DOI 10.1093/intimm/7.11.1817; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTANI H, 1993, J BIOL CHEM, V268, P22733; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yamamoto AM, 1998, LEUKEMIA, V12, P1467, DOI 10.1038/sj.leu.2401132; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	135	121	125	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1999	13	13					1647	1657		10.1096/fasebj.13.13.1647	http://dx.doi.org/10.1096/fasebj.13.13.1647			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	244QZ	10506569				2022-12-28	WOS:000083063400001
J	Wanner, GA; Mica, L; Wanner-Schmid, E; Kolb, SA; Hentze, H; Trentz, O; Ertel, T				Wanner, GA; Mica, L; Wanner-Schmid, E; Kolb, SA; Hentze, H; Trentz, O; Ertel, T			Inhibition of caspase activity prevents CD95-mediated hepatic microvascular perfusion failure and restores Kupffer cell clearance capacity	FASEB JOURNAL			English	Article						liver failure; apoptosis; hepatic microcirculation; cysteine protease	MULTIPLE ORGAN FAILURE; FAS-MEDIATED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; INDUCED LIVER-INJURY; TNF-ALPHA; HEPATOCYTE APOPTOSIS; MOUSE HEPATOCYTES; SIGNALING COMPLEX; CD95 FAS/APO-1; SOLUBLE FORM	Using a murine model, we studied the effect of agonistic anti-CD95 antibodies (aCD95) on sinusoidal lining cells and a potential protection by caspase inhibition. C3H/HeN mice were intravenously administered aCD95 (10 mu g/mouse) or unspecific IgG (control) in the presence or absence of the caspase inhibitor z-VAD-fmk, Analysis of hepatic microcirculation using intravital fluorescence microscopy revealed severe (P<0.01) sinusoidal perfusion failure and reduced (P<0.05) phagocytic activity of Kupffer cells (KC) within 2 h. Transmission electron micrographs demonstrated loss of integrity of sinusoidal endothelial cells as early as 1 h after aCD95 application, whereas histological manifestation of hepatocellular apoptosis and hemorrhagic necrosis was most pronounced at 6 h, Blocking of caspase activity attenuated (P<0.01) both hepatic microvascular perfusion failure and KC dysfunction, Accordingly, full protection of the liver from apoptotic damage and intact microarchitecture was observed in histological sections after z-VAD-fmk treatment. Mortality rate was 40% 6 h after aCD95 administration, whereas all animals survived in the z-VAD-fmk group (P<0.05), The activation of caspases through CD95 may primarily lead to damage of sinusoidal endothelial cells and hepatic microvascular perfusion failure. Moreover, reduced phagocytic capacity of KC may contribute to accumulation of toxic metabolites released by dying cells at the local site of inflammation, further aggravating liver injury.	Univ Zurich Hosp, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Konstanz	Ertel, T (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Raemistr 100, CH-8091 Zurich, Switzerland.	guido.wanner@chi.usz.ch						Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAUE AE, 1994, SHOCK, V2, P385, DOI 10.1097/00024382-199412000-00001; BAUER I, 1995, SHOCK, V4, P324, DOI 10.1097/00024382-199511000-00003; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; Feldmann G, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80491-6; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Gao WS, 1998, HEPATOLOGY, V27, P1652, DOI 10.1002/hep.510270626; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Ksontini R, 1998, J IMMUNOL, V160, P4082; Ksontini Riadh, 1997, Surgical Forum, V48, P58; Lawson JA, 1998, HEPATOLOGY, V28, P761, DOI 10.1002/hep.510280324; Leist M, 1998, Rev Physiol Biochem Pharmacol, V133, P109; LEIST M, 1995, AM J PATHOL, V146, P1220; LIVINGSTON DH, 1995, ANN MED, V27, P13, DOI 10.3109/07853899509031931; MACPHEE PJ, 1993, PROGR APPL MICR, V19, P52; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MENGER MD, 1993, PROGR APPL MICR, V19, P106; Muschen M, 1998, HEPATOLOGY, V27, P200, DOI 10.1002/hep.510270131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; POST S, 1992, HEPATOLOGY, V16, P803, DOI 10.1002/hep.1840160329; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; RUFF MC, 1992, NATURE, V356, P397; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shakil AO, 1997, J VIRAL HEPATITIS, V4, P107, DOI 10.1111/j.1365-2893.1997.tb00170.x; Strand S, 1998, MOL MED TODAY, V4, P63, DOI 10.1016/S1357-4310(97)01191-X; Suzuki A, 1998, P SOC EXP BIOL MED, V217, P450; Takehara T, 1998, HEPATOLOGY, V27, P1643, DOI 10.1002/hep.510270625; TAKEI Y, 1995, J GASTROEN HEPATOL, V10, pS65, DOI 10.1111/j.1440-1746.1995.tb01802.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Vollmar B, 1997, J LEUKOCYTE BIOL, V62, P710, DOI 10.1002/jlb.62.6.710; Vollmar B, 1996, SHOCK, V6, P434, DOI 10.1097/00024382-199612000-00008; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Williams R, 1996, SEMIN LIVER DIS, V16, P343, DOI 10.1055/s-2007-1007247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	53	51	51	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1999	13	10					1239	1248		10.1096/fasebj.13.10.1239	http://dx.doi.org/10.1096/fasebj.13.10.1239			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385614				2022-12-28	WOS:000081264800012
J	Westermarck, J; Kahari, VM				Westermarck, J; Kahari, VM			Regulation of matrix metalloproteinase expression in turner invasion	FASEB JOURNAL			English	Review						extracellular matrix; MMPs; interleukin; tissue inhibitors; SCC	ACTIVATED PROTEIN-KINASE; COLLAGENASE GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; MAP KINASE; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; IN-VITRO; C-FOS; DIFFERENTIAL REGULATION; EXTRACELLULAR-MATRIX	Degradation of basement membranes and stromal extracellular matrix (ECM) is crucial for invasion and metastasis of malignant cells. Degradation of ECM is initiated by proteinases secreted by different cell types participating in tumor cell, invasion, and increased expression or activity of every known class of proteinases (metallo-, serine-, aspartic-, and cysteine) has been linked to malignancy and invasion of tumor cells. Studies performed over the last decade have revealed that matrix metalloproteinases (MMPs) play a crucial role in tumor invasion. Expression of MMP genes is transcriptionally regulated by a variety of extracellular factors including cytokines, growth factors, and cell. contact to ECM. This review will summarize the current view on the role of MMPs in tumor growth, invasion, and survival, and focus on the role of mitogen-activated protein kinases and AP-1 and ETS transcription factors in the regulation of MMP gene expression during invasion process.	Univ Turku, Medicity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Biochem Med, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku	Westermarck, J (corresponding author), Univ Turku, Medicity Res Lab, Tykistokatu 6, FIN-20520 Turku, Finland.	jukwes@utu.fi	Kahari, Veli-Matti/T-4925-2019; Westermarck, Jukka/AAL-6464-2020; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Westermarck, Jukka/0000-0001-7478-3018; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 1998, CANCER RES, V58, P2310; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Atula S, 1997, EXP CELL RES, V235, P180, DOI 10.1006/excr.1997.3676; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805; Bolon I, 1996, LAB INVEST, V75, P1; BOLON I, 1995, AM J PATHOL, V147, P1298; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown PD, 1998, BIOL EXTRAC, P243; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cossins J, 1996, BIOCHEM BIOPH RES CO, V228, P494, DOI 10.1006/bbrc.1996.1688; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Fife RS, 1997, J LAB CLIN MED, V130, P530, DOI 10.1016/S0022-2143(97)90130-X; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GACK S, 1994, J BIOL CHEM, V269, P10363; Gilles C, 1997, LAB INVEST, V76, P651; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Guo HM, 1997, J BIOL CHEM, V272, P24; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Heppner KJ, 1996, AM J PATHOL, V149, P273; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Hua J, 1996, CANCER RES, V56, P5279; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; IOZZO RV, 1995, LAB INVEST, V73, P157; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Itoh T, 1998, CANCER RES, V58, P1048; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, AM J PATHOL, V151, P499; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kauppila S, 1996, AM J PATHOL, V148, P539; Kaya M, 1996, ONCOGENE, V12, P221; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; KOOP S, 1994, CANCER RES, V54, P4791; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Kruger A, 1998, ONCOGENE, V16, P2419, DOI 10.1038/sj.onc.1201774; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; OHagan RC, 1996, ONCOGENE, V13, P1323; OKA H, 1995, CANCER RES, V55, P4182; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Pender SLF, 1998, J IMMUNOL, V160, P4098; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Polette M, 1996, VIRCHOWS ARCH, V428, P29; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; ReifelMiller AE, 1996, J BIOL CHEM, V271, P21666, DOI 10.1074/jbc.271.35.21666; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Ridley SH, 1997, J IMMUNOL, V158, P3165; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Shiozawa S, 1997, J CLIN INVEST, V99, P1210, DOI 10.1172/JCI119277; Simon C, 1998, CANCER RES, V58, P1135; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050; StahleBackdahl M, 1997, LAB INVEST, V76, P717; STAHLEBACKDAHL M, 1993, AM J PATHOL, V142, P995; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WESTERMARCK J, 1995, J INVEST DERMATOL, V105, P197, DOI 10.1111/1523-1747.ep12317114; Westermarck J, 1998, MATRIX BIOL, V17, P547, DOI 10.1016/S0945-053X(98)90107-X; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Woessner JF, 1998, BIOL EXTRAC, P1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	115	1326	1401	0	54	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					781	792		10.1096/fasebj.13.8.781	http://dx.doi.org/10.1096/fasebj.13.8.781			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224222				2022-12-28	WOS:000080372500002
J	Howie, SEM; Fernandes, ML; Heslop, I; Hewson, TJ; Cotton, GJ; Moore, MJ; Innes, D; Ramage, R; Harrison, DJ				Howie, SEM; Fernandes, ML; Heslop, I; Hewson, TJ; Cotton, GJ; Moore, MJ; Innes, D; Ramage, R; Harrison, DJ			A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1 alpha chemokine binding	FASEB JOURNAL			English	Article						antibody; macrophage; PBMC; monoclonal antibody; CDR2 region	IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; CELL-FUSION; AMINO-ACIDS; RECEPTOR; CORECEPTOR; ANTIBODIES; ENTRY; CCR-5; EXPRESSION	This paper describes a branched synthetic peptide [3.7] that incorporates sequence discontinuous residues of HIV-1 gp120 constant regions. The approach was to bring together residues of gp120 known to interact with human cell membranes such that the peptide could fold to mimic the native molecule. The peptide incorporates elements of both the conserved CD4 and CCR5 binding sites. The 3.7 peptide, which cannot be produced by conventional genetic engineering methods, is recognized by antiserum raised to native gp120. The peptide also binds to CD4 and competitively inhibits binding of QS4120 an antibody directed against the CDR2 region of CD4. When preincubated with the CD4+ve MM6 macrophage cell line, which expresses mRNA for the CCR3 and CCR5 chemokine receptors, both 3.7 and gp120 inhibit binding of the chemokine MIP-1 alpha. The peptide also inhibits infection of primary macrophages by M-tropic HIV-1. Thus, 3.7 is a prototype candidate peptide for a vaccine against HIV-1 and represents a novel approach to the rational design of peptides that can mimic complex sequence discontinuous ligand binding sites of clinically relevant proteins.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr Prot Technol, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr HIV Res, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; University of Edinburgh	Howie, SEM (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.e.m.howie@ed.ac.uk						Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Carrillo A, 1996, J VIROL, V70, P1301, DOI 10.1128/JVI.70.2.1301-1309.1996; ChengMayer C, 1997, J VIROL, V71, P1657, DOI 10.1128/JVI.71.2.1657-1661.1997; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CORDONNIER A, 1989, NATURE, V340, P574; Cotton GJ, 1996, MOL IMMUNOL, V33, P171, DOI 10.1016/0161-5890(95)00110-7; CROWL R, 1985, CELL, V41, P979, DOI 10.1016/S0092-8674(85)80078-7; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dittmar MT, 1997, J VIROL, V71, P5140, DOI 10.1128/JVI.71.7.5140-5147.1997; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Howie SEM, 1998, FASEB J, V12, P991, DOI 10.1096/fasebj.12.11.991; James W, 1996, CURR TOP MICROBIOL, V205, P137; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Verrier FC, 1997, P NATL ACAD SCI USA, V94, P9326, DOI 10.1073/pnas.94.17.9326; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514	29	10	10	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	1999	13	3					503	511		10.1096/fasebj.13.3.503	http://dx.doi.org/10.1096/fasebj.13.3.503			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	174CF	10064617				2022-12-28	WOS:000079016000010
J	Davidson, JM; Aquino, AM; Woodward, SC; Wilfinger, WW				Davidson, JM; Aquino, AM; Woodward, SC; Wilfinger, WW			Sustained microgravity reduces intrinsic wound healing and growth factor responses in the rat	FASEB JOURNAL			English	Article						space medicine; granulation tissue; PDGF; bFGF	PERIPHERAL-BLOOD LEUKOCYTES; SPACEFLIGHT; REPAIR; SPACE; BONE	Spaceflight is known to diminish bone mass and reduce immune function, suggesting that repair of connective tissue might be impaired in a microgravity environment. Fisher 344 rats were used to test wound healing responses in the orbiting Space Shuttle Endeavour by preflight implantation of polyvinyl acetal sponge disks in which pellets were placed to release either platelet-derived growth factor (PDGF-EB), basic fibroblast growth factor (bFGF), or placebo. Control groups on the ground included a matched environment group in similar housing modules and temperature control groups in cages at 22 degrees C and 28 degrees C, After 12 days of implantation and 10 days in orbit, the removed sponges were analyzed for histological and biochemical responses. Growth factor responses were histologically evident after release of PDGF-BB and bFGF in ground controls, whereas only immediate-release bFGF and delayed-release PDGF-BB showed significant responses in microgravity, Biochemical data confirmed that cellularity was increased by both factors in ground sponges; however, this response was significantly blunted in flight sponges (P<0.005, ANOVA), irrespective timing of factor release, Collagen content was 62% lower in sponges from animals with 10 days of microgravity exposure (P<0.01, ANOVA) and further reduced by bFGF, These data suggest that orbital exposure retards the capacity of wounds to heal and respond to exogenous stimuli.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; Penn State Univ, Ctr Cell Res, University Pk, PA 16802 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Davidson, JM (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, MCN C-3321,21st & Garland St, Nashville, TN 37232 USA.			Wilfinger, William/0000-0002-7891-2232				Abraham JA, 1996, MOL CELLULAR BIOL WO, P195; ALLEBBAN Z, 1994, J LEUKOCYTE BIOL, V55, P209, DOI 10.1002/jlb.55.2.209; Bolton L, 1997, WOUNDS, V9, P127; BORKOWSKI GL, 1995, AWIC NEWSLETTER, V6, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROADLEY KN, 1989, LAB INVEST, V61, P571; BROADLEY KN, 1989, LAB INVEST, V61, P511; BUCKLEY A, 1985, P NATL ACAD SCI USA, V82, P7340, DOI 10.1073/pnas.82.21.7340; CLARK RAF, 1996, MOL CELLULAR BIOL WO, P611; COHEN IK, 1991, WOUND REPAIR BIOMEDI; DAVIDSON JM, 1996, CELLULAR MOL PATHOGE, P79; DAVIDSON JM, 1998, ANIMAL MODELS WOUND; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; GROTENDORST GR, 1985, J CLIN INVEST, V76, P2323, DOI 10.1172/JCI112243; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; Ichiki AT, 1996, J LEUKOCYTE BIOL, V60, P37, DOI 10.1002/jlb.60.1.37; Ilyina-Kakueva E I, 1991, Physiologist, V34, pS141; Kaplansky A S, 1991, Physiologist, V34, pS196; MCGEE GS, 1988, J SURG RES, V45, P145, DOI 10.1016/0022-4804(88)90034-0; Meehan R, 1987, Adv Exp Med Biol, V225, P273; POSPISILOVA I, 1989, KOSM BIOL AVIAK MED+, V23, P44; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; SONNENFELD G, 1992, J APPL PHYSIOL, V73, pS191, DOI 10.1152/jappl.1992.73.2.S191; TAYLOR GR, 1986, AVIAT SPACE ENVIR MD, V57, P213; VAILAS AC, 1990, FASEB J, V4, P47, DOI 10.1096/fasebj.4.1.2295378; WOODWARD SC, 1968, ARCH SURG-CHICAGO, V96, P189	26	66	68	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					325	329		10.1096/fasebj.13.2.325	http://dx.doi.org/10.1096/fasebj.13.2.325			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973320	Bronze			2022-12-28	WOS:000078615200012
J	Hassan, AHS; Patchev, VK; von Rosenstiel, P; Holsboer, F; Almeida, OFX				Hassan, AHS; Patchev, VK; von Rosenstiel, P; Holsboer, F; Almeida, OFX			Plasticity of hippocampal corticosteroid receptors during aging in the rat	FASEB JOURNAL			English	Article						H-3-dexamethasone uptake; H-3-aldosterone uptake; hippocampus; mineralocorticoid and glucocorticoid receptors; aging	PROLONGED GLUCOCORTICOID EXPOSURE; ADRENAL-STEROID RECEPTORS; AGED RATS; MINERALOCORTICOID RECEPTOR; GENE-EXPRESSION; NEURON NUMBERS; DENTATE GYRUS; BRAIN; PITUITARY; DEXAMETHASONE	Aging is commonly associated with dysregulation of the hypothalamo-pituitary-adrenal axis and cognitive impairment. On the basis of suggestions that these disruptions ensue from changes in the hippocampal complement of corticosteroid (mineralocorticoid and glucocorticoid) receptors (MR and CR), we examined the availability of hippocampal MR and GR by measuring the in vivo uptake of H-3-aldosterone and H-3-dexamethasone (selective MR and GR agonists, respectively); MR and GR mRNA levels were also measured. We observed age-related declines in both the synthesis of MR and GR and the uptake of their respective ligands. Whereas MR mRNA levels and ligand uptake declined in parallel, GR binding declined more steeply than GR mRNA. This latter result, together with our finding that aged rats show impaired corticosteroid receptor mRNA and protein up-regulation after corticosteroid withdrawal, indicates decreased transcription of MR and GR genes and posttranslational modification of GR mRNA during aging. Given that corticosteroids can influence MR and GR synthesis and binding, and based on the finding that aged subjects show reduced basal secretion of corticosterone, we propose that this relative hypocorticalism may be responsible for the changes observed in MR and GR activity, which then leads to disturbances in neuroendocrine regulation and cognitive function in aged subjects.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Almeida, OFX (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.	osa@mpipsyk1.mpg.de	Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928; von Rosenstiel, Philipp/0000-0003-1709-1271				AHIMA R, 1991, J COMP NEUROL, V313, P522, DOI 10.1002/cne.903130312; ALMEIDA OFX, 1997, 27 ANN M SOC NEUR NE, V23; [Anonymous], [No title captured]; ARBEL I, 1994, BRAIN RES, V657, P227, DOI 10.1016/0006-8993(94)90972-5; BIRMINGHAM MK, 1979, EXPERIENTIA, V35, P1240, DOI 10.1007/BF01963313; CIZZA G, 1994, ENDOCRINOLOGY, V134, P1611, DOI 10.1210/en.134.4.1611; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P521, DOI 10.1016/0197-4580(87)90127-8; COLEMAN PD, 1980, J NEUROCHEM, V34, P335; DALLMAN MF, 1992, J NEUROENDOCRINOL, V4, P517, DOI 10.1111/j.1365-2826.1992.tb00200.x; DEKLOET ER, 1995, FRONT NEUROENDOCRIN, V16, P416, DOI 10.1006/frne.1995.1015; deKloet ER, 1996, CELL MOL NEUROBIOL, V16, P345; Dhabhar FS, 1997, NEUROENDOCRINOLOGY, V65, P360, DOI 10.1159/000127196; ELDRIDGE JC, 1989, BRAIN RES, V478, P248; ERMISCH A, 1978, BRAIN RES, V147, P154, DOI 10.1016/0006-8993(78)90780-1; Finch CE, 1997, EXP NEUROL, V143, P82, DOI 10.1006/exnr.1996.6339; FINCH CE, 1990, ANNU REV NEUROSCI, V13, P75, DOI 10.1146/annurev.ne.13.030190.000451; FLOOD DG, 1988, NEUROBIOL AGING, V9, P453, DOI 10.1016/S0197-4580(88)80098-8; Gallagher M, 1996, SCIENCE, V274, P484, DOI 10.1126/science.274.5287.484; Gomez F, 1996, NEUROENDOCRINOLOGY, V63, P327, DOI 10.1159/000126973; Gould E, 1996, DEV NEUROSCI-BASEL, V18, P22, DOI 10.1159/000111392; Hassan AHS, 1996, EXP NEUROL, V140, P43, DOI 10.1006/exnr.1996.0113; HERMAN JP, 1989, MOL ENDOCRINOL, V3, P1886, DOI 10.1210/mend-3-11-1886; HEUSER IJ, 1994, NEUROBIOL AGING, V15, P227, DOI 10.1016/0197-4580(94)90117-1; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; Holsboer Florian, 1995, P957; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P47, DOI 10.1210/jc.83.1.47; HYLKA VW, 1984, P SOC EXP BIOL MED, V175, P1; Igwe OJ, 1997, MOL BRAIN RES, V46, P39, DOI 10.1016/S0169-328X(96)00269-0; ISSA AM, 1990, J NEUROSCI, V10, P3247; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419; Landfield PW, 1987, PROG BRAIN RES <D>, V72, P279; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; LANDFIELD PW, 1981, SCIENCE, V214, P581, DOI 10.1126/science.6270791; LAPING NJ, 1994, J NEUROSCI RES, V39, P710, DOI 10.1002/jnr.490390612; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; MCEWEN BS, 1986, PHYSIOL REV, V66, P1121, DOI 10.1152/physrev.1986.66.4.1121; MOGUILEWSKY M, 1980, J STEROID BIOCHEM, V12, P309, DOI 10.1016/0022-4731(80)90285-X; MORANO MI, 1994, MOL CELL NEUROSCI, V5, P400, DOI 10.1006/mcne.1994.1050; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; OTTENWELLER JE, 1990, ENDOCRINOLOGY, V126, P102, DOI 10.1210/endo-126-1-102; Patchev VK, 1996, J NEUROSCI, V16, P7077; PAVLIDES C, 1995, NEUROSCIENCE, V68, P387, DOI 10.1016/0306-4522(95)00151-8; Rasmussen T, 1996, NEUROBIOL AGING, V17, P143, DOI 10.1016/0197-4580(95)02032-2; RATKA A, 1989, NEUROENDOCRINOLOGY, V50, P117, DOI 10.1159/000125210; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; REUL JMHM, 1988, NEUROBIOL AGING, V9, P253, DOI 10.1016/S0197-4580(88)80062-9; REUL JMHM, 1989, MOL ENDOCRINOL, V3, P1674, DOI 10.1210/mend-3-10-1674; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; SECKL JR, 1995, J ENDOCRINOL, V145, P201, DOI 10.1677/joe.0.1450201; SEEMAN TE, 1994, ENDOCR REV, V15, P233, DOI 10.1210/er.15.2.233; SPENCER RL, 1990, BRAIN RES, V514, P37, DOI 10.1016/0006-8993(90)90433-C; Starr M. P., 1981, PROKARYOTES, V1, P3; STUMPF WE, 1989, HISTOCHEMISTRY, V92, P201, DOI 10.1007/BF00500919; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VANEEKELEN JAM, 1991, J STEROID BIOCHEM, V40, P679, DOI 10.1016/0960-0760(91)90290-L	59	46	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					115	122		10.1096/fasebj.13.1.115	http://dx.doi.org/10.1096/fasebj.13.1.115			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872936	Bronze			2022-12-28	WOS:000078029500013
J	Conti, P; Reale, M; Barbacane, RC; Letourneau, R; Theoharides, TC				Conti, P; Reale, M; Barbacane, RC; Letourneau, R; Theoharides, TC			Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell deficient W/W-V mice	FASEB JOURNAL			English	Article						chemokines; HDC; histamine; polysaccharide	MESSENGER-RNA; CHEMOTACTIC CYTOKINES; ATOPIC SUBJECTS; CC-CHEMOKINES; RANTES; MONOCYTE; HISTAMINE; PROTEIN; RELEASE; MCP-1	RANTES (regulated upon activation, normal T cell expressed and presumably secreted) and other chemoattractant proteins are members of the intercrine or chemokine family of proinflammatory basic polypeptides. RANTES is a prototype of the C-C chemokine subfamily that acts as a selective chemoattractant for human monocytes and CD4-positive lymphocytes and increases the adherence of monocytes to endothelial cells. However, the role of RANTES in white cells is still unclear. We report here that hrRANTES at 20 ng/50 mu l in mice causes mast cell recruitment 4 h after intramuscular injection, an effect inhibited by anti-RANTES, as evidenced by 0.1% Toluidine blue, a specific dye for coloring mast cells. Injections of PBS (50 mu l) vehicle (negative control) did not produce any appreciable inflammatory response, whereas injection of lipopolysaccharide 20 ng/50 mu l (positive control) generated a marked inflammatory state. When RANTES was injected intramuscularly in genetically mast cell-deficient W/W-v mice, the inflammatory effect was not present. The RANTES injection sites were then excised and studied under an optical and electron microscope. A Northern blot analysis was performed using a probe that was prepared to detect mRNA encoding the histidine decarboxylase (HDC) gene on excised muscle tissue. We found that hrRANTES provoked generation of HDC mRNA from muscle tissue after 4 h. These effects were inhibited by an anti-RANTES antibody and were absent in genetically mast cell-deficient mice. The increasing number of mast cells in the RANTES injection sites led to an augmentation of histamine content compared to controls (PBS). The injection of hrRANTES 20 ng/20 mu l into the sole of a rat paw confirmed the inflammatory and the mast cell recruitment potential of this chemokine. In these studies, hrRANTES injections in muscle tissue provided direct in vivo evidence that RANTES has a significant effect on mast cell, recruitment and HDC mRNA generation.	Univ Chieti, Sch Med, Div Immunol, I-66013 Chieti, Italy; Tufts Univ, Sch Med, Dept Pharmacol, Boston, MA 02111 USA	G d'Annunzio University of Chieti-Pescara; Tufts University	Conti, P (corresponding author), Univ Chieti, Sch Med, Div Immunol, Via Dei Vestini, I-66013 Chieti, Italy.		Reale, Marcella/G-4299-2013; Theoharides, Theoharis C/E-5596-2010	Reale, Marcella/0000-0002-4164-8781; 				Armstead VE, 1997, FASEB J, V11, P1271, DOI 10.1096/fasebj.11.14.9409546; AUSTEN KF, 1982, HOSP PRACT, V17, P98; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BRUNEAU G, 1992, HUM GENET, V90, P235, DOI 10.1007/BF00220068; CHOCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Conti P, 1997, J PATHOL, V183, P352, DOI 10.1002/(SICI)1096-9896(199711)183:3<352::AID-PATH938>3.0.CO;2-L; CONTI P, 1995, IMMUNOLOGY, V86, P434; Conti P, 1997, IMMUNOL LETT, V58, P101, DOI 10.1016/S0165-2478(97)00034-5; Conti P, 1997, BLOOD, V89, P4120, DOI 10.1182/blood.V89.11.4120; CONTI P, 1992, IMMUNOL LETT, V32, P117, DOI 10.1016/0165-2478(92)90103-U; CONTI P, 1995, MOL CELL BIOCHEM, V155, P61; DIMITRIADOU V, 1991, NEUROSCIENCE, V44, P97; GALLI SJ, 1987, AM J PATHOL, V127, P191; GO S, 1980, J HERED, V71, P41, DOI 10.1093/oxfordjournals.jhered.a109308; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KITAMURA Y, 1978, BLOOD, V52, P447; KUNA P, 1992, J IMMUNOL, V149, P636; MATSUURA N, 1989, J EXP MED, V170, P1421, DOI 10.1084/jem.170.4.1421; MEININGER CJ, 1992, BLOOD, V79, P958; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; NAKANO T, 1987, FASEB J, V46, P1920; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; TAUB D, 1995, J IMMUNOL, V154, P2393; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; THEOHARIDES TC, 1982, NATURE, V297, P229, DOI 10.1038/297229a0; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153	34	74	74	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1693	1700		10.1096/fasebj.12.15.1693	http://dx.doi.org/10.1096/fasebj.12.15.1693			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837859				2022-12-28	WOS:000077574500011
J	Noel, F; Gumin, GJ; Raju, U; Tofilon, PJ				Noel, F; Gumin, GJ; Raju, U; Tofilon, PJ			Increased expression of prohormone convertase-2 in the irradiated rat brain	FASEB JOURNAL			English	Article							GROWTH-FACTOR EXPRESSION; GENE-EXPRESSION; NEUROPSYCHOLOGIC IMPAIRMENT; PROPROTEIN CONVERTASES; RADIATION INDUCTION; ASTROCYTE CULTURES; IONIZING-RADIATION; FIBROBLAST; CNS; PITUITARY	Changes in gene expression have been suggested to play a role in radiotherapy-induced central nervous system (CNS) injury. To begin to identify radiation-inducible genes in the CNS, we have applied the differential display of reverse transcription-polymerase chain reaction products to RNA extracted from the brain of adult rats. RNA was isolated from a rat brain 6 h after whole-body exposure to 10 Gy and compared with RNA from unirradiated brain. A cDNA band was consistently observed at about 600 bp in samples from the irradiated rat but not from unirradiated (control) rat. Amplification and sequencing of the cDNA revealed that it corresponded to the prohormone convertase-2 (PC2) gene, which is involved in the processing of inert prohormones and neuropeptides to their bioactive forms. Enhanced PC2 expression was detected after irradiation of neuronal cultures but not in cultures of astrocytes, suggesting that the cell type in the CNS responsible for the PC2 induction after in vivo irradiation is the neuron. These results indicate that radiation induces the expression of a neuronal enzyme that is critical to the activation of a number of prohormones and neuropeptides, which may influence the radioresponse of the CNS.	Univ Texas, Md Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tofilon, PJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 66,1515 Holcombe Blvd, Houston, TX 77030 USA.	ptofilon@notes.mdacc.tmc.edu			NCI NIH HHS [CA72156, CA50207, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072156, P30CA016672, R01CA050207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG C, 1993, NEUROLOGY, V43, P1961, DOI 10.1212/WNL.43.10.1961; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Gobbel GT, 1998, J NEUROSCI, V18, P147; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; ISHIHARA H, 1993, RADIAT RES, V133, P321, DOI 10.2307/3578216; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOTAN M, 1992, J NEUROCHEM, V58, P1637, DOI 10.1111/j.1471-4159.1992.tb10035.x; MAIRE JP, 1987, AM J CLIN ONCOL-CANC, V10, P156, DOI 10.1097/00000421-198704000-00052; Marcinkiewicz M, 1996, ACTA NEUROBIOL EXP, V56, P287; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; Noel F, 1997, RADIAT RES, V147, P484, DOI 10.2307/3579506; Noel F, 1998, NEUROREPORT, V9, P1133, DOI 10.1097/00001756-199804200-00032; Oyarce AM, 1996, J NEUROCHEM, V67, P229; RUBIN P, 1992, INT J RADIAT ONCOL, V24, P93, DOI 10.1016/0360-3016(92)91027-K; SAKUMA S, 1995, RADIAT RES, V143, P1, DOI 10.2307/3578919; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHULTHEISS TE, 1992, BRIT J RADIOL, V65, P737, DOI 10.1259/0007-1285-65-777-737; SCHULTHEISS TE, 1995, INT J RADIAT ONCOL, V31, P1093, DOI 10.1016/0360-3016(94)00655-5; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; VRDOLJAK E, 1994, INT J RADIAT BIOL, V66, P739; WITTE L, 1989, CANCER RES, V49, P5066; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	36	14	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1725	1730		10.1096/fasebj.12.15.1725	http://dx.doi.org/10.1096/fasebj.12.15.1725			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837862				2022-12-28	WOS:000077574500014
J	Neve, R; Chang, CH; Scott, GK; Wong, A; Friis, RR; Hynes, NE; Benz, CC				Neve, R; Chang, CH; Scott, GK; Wong, A; Friis, RR; Hynes, NE; Benz, CC			The epithelium-specific Ets transcription factor ESX is associated with mammary gland development and involution	FASEB JOURNAL			English	Article						Ets family; ESX promoter; ESX expression and mammary gland differentiation	EPIDERMAL GROWTH-FACTOR; CELL-DEATH; GENE-EXPRESSION; BREAST-CANCER; DIFFERENTIATION; PROLIFERATION; APOPTOSIS; PROTEIN; FAMILY	To study mammary gland expression of the epithelium-restricted Ets factor, ESX, mouse cDNA and genomic sequences were cloned and a similar to 350 bp proximal promoter region with >80% mouse-human homology was identified that mediates ESX induction by serum, heregulin (HRG)I or epidermal growth factor (EGF). ESX mRNA expression progressively increases during embryonic mouse development from day 7 and is detectable in virgin mammary glands; it shows little if any change during pregnancy, then declines to barely detectable levels after 3 days of lactation. Similarly, cultured HC11 cells from midpregnant mouse mammary epithelium show an increase in ESX expression upon reaching lactogenic competency (in the presence of EGF or HRG), with a decline to barely detectable levels upon exposure to lactogenic hormones that induce milk protein (beta-casein) expression. In contrast, involuting mouse and rat mammary glands show maximal ESX expression. High ESX levels are also seen in the involuting ventral prostate gland of rats. These findings, including the persistence of up-regulated ESX in fully regressed mammary glands, suggest that ESX expression can be induced by soluble growth factors and is maximally up-regulated in those partially com mitted epithelial cells destined to survive both the apoptotic and remodeling phases of glandular involution.	Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94143 USA; Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Bern, Dept Clin Res, CH-3004 Bern, Switzerland	University of California System; University of California San Francisco; Friedrich Miescher Institute for Biomedical Research; University of Bern	Benz, CC (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, Dept Med, Box 1270,3rd & Parnassus, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [P01CA044768, R01CA036773] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA44768, R01-CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; CHAMMAS R, 1994, J CELL SCI, V107, P1031; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chepko G, 1997, TISSUE CELL, V29, P239, DOI 10.1016/S0040-8166(97)80024-9; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Daly JM, 1997, CANCER RES, V57, P3804; Davies JA, 1997, BIOESSAYS, V19, P699, DOI 10.1002/bies.950190810; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HROMAS R, 1994, INT J HEMATOL, V59, P257; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Lochter A., 1997, Biological signalling and the mammary gland, 2nd Hannah Symposium, Ayr, UK, 4-6 September 1996., P77; Lund LR, 1996, DEVELOPMENT, V122, P181; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTI A, 1995, CELL DEATH DIFFER, V2, P277; Nishi N, 1996, PROSTATE, V28, P139; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Russo J, 1997, ENDOCR-RELAT CANCER, V4, P7, DOI 10.1677/erc.0.0040007; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; STRANGE R, 1992, DEVELOPMENT, V115, P49; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; VONDERHAAR BK, 1987, J CELL PHYSIOL, V132, P581, DOI 10.1002/jcp.1041320324; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; Wilde C. J., 1997, Biological signalling and the mammary gland, 2nd Hannah Symposium, Ayr, UK, 4-6 September 1996., P103; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766	29	46	52	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1541	1550		10.1096/fasebj.12.14.1541	http://dx.doi.org/10.1096/fasebj.12.14.1541			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806763				2022-12-28	WOS:000076749500013
J	Oldstone, MBA				Oldstone, MBA			Molecular mimicry and immune-mediated diseases	FASEB JOURNAL			English	Review						autoimmune disease; microbial agent; insulin-independent diabetes mellitus; sequence sharing	DEPENDENT DIABETES-MELLITUS; MYELIN BASIC-PROTEIN; HERPES-SIMPLEX VIRUS; T-CELL CLONES; MULTIPLE-SCLEROSIS; AUTOIMMUNE-DISEASE; ANKYLOSING-SPONDYLITIS; BETA-CELLS; GLUTAMATE-DECARBOXYLASE; TRYPANOSOMA-CRUZI	Molecular mimicry has been proposed as a pathogenetic mechanism for autoimmune disease, as well as a probe useful in uncovering its etiologic agents. The hypothesis is based in part on the abundant epidemiological, clinical, and experimental evidence of an association of infectious agents with autoimmune disease and observed cross-reactivity of immune reagents with host 'self' antigens and microbial determinants. For our purpose, molecular mimicry is defined as similar structures shared by molecules from dissimilar genes or by their protein products. Either the molecules' linear amino acid sequences or their conformational fits may be shared, even though their origins are as separate as, for example, a virus and a normal host-self determinant, An immune response against the determinant shared by the host and virus can evoke a tissue-specific immune response that is presumably capable of eliciting cell and tissue destruction. The probable mechanism is generation of cytotoxic cross-reactive effector lymphocytes or antibodies that recognize specific determinants on target cells. The induction of cross-reactivity does not require a replicating agent, and immune-mediated injury can occur after the immunogen has been removed-a hit-and-run event. Hence, the viral or microbial infection that initiates the autoimmune phenomenon may not be present by the time overt disease develops. By a complementary mechanism, the microbe can induce cellular injury and release self antigens, which generate immune responses that cross-react with additional but genetically distinct self antigens, In both scenarios, analysis of the T cells or antibodies specifically engaged in the autoimmune response and disease provides a fingerprint for uncovering the initiating infectious agent.	Scripps Res Inst, Viral Immunobiol Lab, Div Virol, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Oldstone, MBA (corresponding author), Scripps Res Inst, Viral Immunobiol Lab, Div Virol, Dept Neuropharmacol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mbaobo@scripps.edu			NIAID NIH HHS [AI09484] Funding Source: Medline; NIA NIH HHS [AG04342] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERER E, 1989, ANN NEUROL, V26, P732, DOI 10.1002/ana.410260608; Appelmelk BJ, 1996, INFECT IMMUN, V64, P2031, DOI 10.1128/IAI.64.6.2031-2040.1996; ATKINSON MA, 1994, J CLIN INVEST, V94, P2125, DOI 10.1172/JCI117567; BAHMANYAR S, 1987, J INFECT DIS, V156, P526, DOI 10.1093/infdis/156.3.526; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; Baughn RE, 1996, J IMMUNOL, V157, P720; Baum H, 1997, IMMUNOL TODAY, V18, P252, DOI 10.1016/S0167-5699(97)81665-9; BAUM H, 1995, BBA-MOL BASIS DIS, V1271, P111, DOI 10.1016/0925-4439(95)00017-X; BISSET LR, 1994, MED HYPOTHESES, V43, P388, DOI 10.1016/0306-9877(94)90014-0; BREWERTON DA, 1973, LANCET, V1, P904; BUTLER P, 1995, BIOCHEM MOL BIOL INT, V35, P473; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; CunhaNeto E, 1996, J CLIN INVEST, V98, P1709, DOI 10.1172/JCI118969; DALGLEISH AG, 1995, BRIT J HAEMATOL, V91, P525, DOI 10.1111/j.1365-2141.1995.tb05343.x; EASTMOND CJ, 1977, ANN RHEUM DIS, V36, P360, DOI 10.1136/ard.36.4.360; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; Ebringer A, 1997, ENVIRON HEALTH PERSP, V105, P1172, DOI 10.2307/3433888; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; FROUDE J, 1989, CURR TOP MICROBIOL, V145, P5; FUJINAMI RS, 1988, J VIROL, V62, P100, DOI 10.1128/JVI.62.1.100-105.1988; FUJINAMI RS, 1983, P NATL ACAD SCI-BIOL, V80, P2346, DOI 10.1073/pnas.80.8.2346; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GAIRIN JE, 1992, J VIROL, V66, P6755, DOI 10.1128/JVI.66.11.6755-6762.1992; Gamble D R, 1980, Epidemiol Rev, V2, P49; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gauntt CJ, 1995, EUR HEART J, V16, P56, DOI 10.1093/eurheartj/16.suppl_O.56; GAUTAM AM, 1994, P NATL ACAD SCI USA, V91, P767, DOI 10.1073/pnas.91.2.767; GECZY AF, 1979, LANCET, V1, P719; Gilbert D, 1997, EUR J IMMUNOL, V27, P1055, DOI 10.1002/eji.1830270503; GILLILAND B, 1986, HARRISONS PRINCIPLES, P1977; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GREEN A, 1990, CURR TOP MICROBIOL, V164, P3; HaferMacko C, 1996, ANN NEUROL, V40, P635, DOI 10.1002/ana.410400414; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Honeyman MC, 1998, MOL MED, V4, P231, DOI 10.1007/BF03401920; HUBER SA, 1994, P NATL ACAD SCI USA, V91, P5543, DOI 10.1073/pnas.91.12.5543; Hudrisier D, 1996, J BIOL CHEM, V271, P17829, DOI 10.1074/jbc.271.30.17829; Jury KM, 1996, J AUTOIMMUN, V9, P371, DOI 10.1006/jaut.1996.0050; KAGNOFF MF, 1989, CURR TOP MICROBIOL, V145, P67; KARGES WJP, 1995, MOL ASPECTS MED, V16, P79, DOI 10.1016/0098-2997(95)00001-W; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; Khare SD, 1996, CURR TOP MICROBIOL, V206, P85; KRISHER K, 1985, SCIENCE, V227, P413, DOI 10.1126/science.2578225; KURTZKE JF, 1993, CLIN MICROBIOL REV, V6, P382, DOI 10.1128/CMR.6.4.382-427.1993; LEE MS, 1995, J CLIN INVEST, V95, P486, DOI 10.1172/JCI117689; Maclaren NK, 1997, MOL MED TODAY, V3, P76, DOI 10.1016/S1357-4310(96)10056-3; Marchalonis JJ, 1995, ADV EXP MED BIOL, V383, P211; Marx A, 1997, VIRCHOWS ARCH, V430, P355, DOI 10.1007/s004280050044; MCKEN M, 1992, NATURE, V359, P79; McNamara JO, 1996, COLD SPRING HARB SYM, V61, P327; Merriman TR, 1995, CURR OPIN IMMUNOL, V7, P786, DOI 10.1016/0952-7915(95)80049-2; Miller SD, 1997, NAT MED, V3, P1133, DOI 10.1038/nm1097-1133; Naucler CS, 1996, IMMUNOL REV, V152, P175, DOI 10.1111/j.1600-065X.1996.tb00916.x; NEU N, 1987, J IMMUNOL, V139, P3630; NOTKINS AL, 1984, CONCEPTS VIRAL PATHO, P241; OLDSTONE MBA, 1989, CURR TOP MICROBIOL, V145, P127; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1995, J VIROL, V69, P7423, DOI 10.1128/JVI.69.12.7423-7429.1995; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PANITCH HS, 1994, ANN NEUROL, V36, pS25, DOI 10.1002/ana.410360709; PETRY K, 1987, J NEUROIMMUNOL, V16, P237, DOI 10.1016/0165-5728(87)90078-6; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; RICHMAN DP, 1994, NEUROL CLIN, V12, P273, DOI 10.1016/S0733-8619(18)30097-5; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; RUDY G, 1995, MOL MED, V1, P625, DOI 10.1007/BF03401603; Schulze K, 1995, EUR HEART J, V16, P64, DOI 10.1093/eurheartj/16.suppl_O.64; SCHWIMMBECK PL, 1989, CURR TOP MICROBIOL, V145, P45; SCHWIMMBECK PL, 1989, J CLIN INVEST, V84, P1174, DOI 10.1172/JCI114282; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; SCOTT BB, 1994, SCAND J IMMUNOL, V40, P16, DOI 10.1111/j.1365-3083.1994.tb03427.x; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SIBLEY WA, 1995, LANCET, V346, P1313; SILVESTRIS F, 1995, CLIN IMMUNOL IMMUNOP, V75, P197, DOI 10.1006/clin.1995.1072; SINGH VK, 1990, J IMMUNOL, V144, P1282; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; SOLIMENA M, 1995, NAT MED, V1, P25, DOI 10.1038/nm0195-25; Soos JM, 1997, MED HYPOTHESES, V48, P253, DOI 10.1016/S0306-9877(97)90315-7; SRINIVASAPPA J, 1986, J VIROL, V57, P397, DOI 10.1128/JVI.57.1.397-401.1986; Steinman L, 1997, NAT MED, V3, P1321, DOI 10.1038/nm1297-1321; Talbot PJ, 1996, ANN NEUROL, V39, P233, DOI 10.1002/ana.410390213; TALBOT PJ, 1997, ADV CLIN NEUROSCI, V7, P215; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P150, DOI 10.1016/0167-5699(95)80133-2; Thurau SR, 1997, IMMUNOL LETT, V57, P193, DOI 10.1016/S0165-2478(97)00058-8; TIAN J, 1994, J EXP MED, V180, P1979, DOI 10.1084/jem.180.5.1979; TONIETTI G, 1970, J EXP MED, V132, P89, DOI 10.1084/jem.132.1.89; TUCKOVA L, 1995, CLIN IMMUNOL IMMUNOP, V74, P170, DOI 10.1006/clin.1995.1025; van der Meche F.G.A., 1995, ANN NEUROL, V37, P14; VANVOORHIS WC, 1991, P NATL ACAD SCI USA, V88, P5993, DOI 10.1073/pnas.88.14.5993; VONHERRATH MG, 1994, J EXP MED, V180, P1901, DOI 10.1084/jem.180.5.1901; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; VonHerrath MG, 1997, P NATL ACAD SCI USA, V94, P9808, DOI 10.1073/pnas.94.18.9808; vonHerrath MG, 1996, J CLIN INVEST, V98, P1324, DOI 10.1172/JCI118919; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YAMADA M, 1991, J VIROL, V65, P1370, DOI 10.1128/JVI.65.3.1370-1376.1991; YOON JW, 1979, NEW ENGL J MED, V300, P1173, DOI 10.1056/NEJM197905243002102; Yuki N, 1996, J NEUROIMMUNOL, V70, P1, DOI 10.1016/S0165-5728(96)00042-2; Zaller DM, 1996, CURR TOP MICROBIOL, V206, P15; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	105	440	452	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	1998	12	13					1255	1265		10.1096/fasebj.12.13.1255	http://dx.doi.org/10.1096/fasebj.12.13.1255			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761770	Green Published			2022-12-28	WOS:000076402000002
J	Echeverria, D; Aposhian, HV; Woods, JS; Heyer, NJ; Aposhian, MM; Bittner, AC; Mahurin, RK; Cianciola, M				Echeverria, D; Aposhian, HV; Woods, JS; Heyer, NJ; Aposhian, MM; Bittner, AC; Mahurin, RK; Cianciola, M			Neurobehavioral effects from exposure to dental amalgam Hg degrees: new distinctions between recent exposure and Hg body burden	FASEB JOURNAL			English	Article						behavior; elemental mercury; dentists; DMPS	ELEMENTAL MERCURY; PSYCHOLOGICAL PERFORMANCE; INORGANIC MERCURY; WORKERS; DENTISTS; VAPOR; VALIDATION; CHLORINE; SYSTEM; ACID	Potential toxicity from exposure to mercury vapor (Hg degrees) from dental amalgam fillings is the subject of current public health debate in many countries. We evaluated potential central nervous system (CNS) toxicity associated with handling Hg-containing amalgam materials among dental personnel with very low levels of Hg degrees exposure (i.e., urinary Hg <4 mu g/l), applying a neurobehavioral test battery to evaluate CNS functions in relation to both recent exposure and Hg body burden. New distinctions between subtle preclinical effects on symptoms, mood, motor function, and cognition were found associated with Hg body burden as compared with those associated with recent exposure. The pattern of results, comparable to findings previously reported among subjects with urinary Hg >50 mu g/l, presents convincing new evidence of adverse behavioral effects associated with low Hg degrees exposures within the range of that received by the general population.	Battelle Ctr Publ Hlth Res & Evaluat, Seattle, WA 98105 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Washington, Dept Psychiat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Arizona; University of Washington; University of Washington Seattle	Echeverria, D (corresponding author), Battelle Ctr Publ Hlth Res & Evaluat, 4000 NE 41st St, Seattle, WA 98105 USA.				NIDCR NIH HHS [DE11712] Funding Source: Medline; NIEHS NIH HHS [ES04696, ES04940] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004940, P42ES004696] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AASETH J, 1995, ANALYST, V120, P853, DOI 10.1039/an9952000853; ALBERS JW, 1988, ANN NEUROL, V24, P651, DOI 10.1002/ana.410240510; Anderson T. W., 1958, INTRO MULTIVARIATE S; APOSHIAN HV, 1995, TOXICOLOGY, V97, P23, DOI 10.1016/0300-483X(95)02965-B; *ATSDR, 1995, AD ENV NEUR TEST BAT, P698; BAKER EL, 1985, NEUROBEH TOXICOL TER, V7, P369; BITTNER AC, 1998, IN PRESS NEUROTOXICO; BUELLER K, 1994, THESIS U WASHINGTON; CAMERINO D, 1981, CLIN TOXICOL, V18, P1299, DOI 10.3109/00099308109035070; CLARKSON TW, 1989, J AM COLL TOXICOL, V8, P1291, DOI 10.3109/10915818909009120; *DAN PROD DEV SYST, 1995, TREM AN TEST SYST; DERUEN T, HLTH EFFECTS DENT AM; Droppelman L.F., 1971, EDITS MANUAL PROFILE; ECHEVERRIA D, 1995, NEUROTOXICOL TERATOL, V17, P161, DOI 10.1016/0892-0362(94)00049-J; ECHEVERRIA D, 1989, BRIT J IND MED, V46, P483; FAWER RF, 1983, ADV BIOSCI, V45, P137; GERSTNER HB, 1977, CLIN TOXICOL, V11, P131, DOI 10.3109/15563657708989829; GONZALEZRAMIREZ D, 1995, J PHARMACOL EXP THER, V272, P264; HALBACH S, 1978, BIOCHIM BIOPHYS ACTA, V523, P522, DOI 10.1016/0005-2744(78)90055-4; HENDERSON R, 1974, AM IND HYG ASSOC J, V38, P576; HURSH JB, 1976, ARCH ENVIRON HEALTH, V31, P302, DOI 10.1080/00039896.1976.10667240; KINGMAN A, 1994, J DENT RES; *LAF INSTR CO, HAND MOT STEAD BATT; LANGOLF GD, 1978, AM IND HYG ASSOC J, V39, P976, DOI 10.1080/0002889778507898; LANGWORTH S, 1992, BRIT J IND MED, V49, P545; LETZ R, 1985, NEUROBEHAVIORAL EVAL; MAGOS L, 1989, BIOCHIM BIOPHYS ACTA, V99, P85; MARTIN MD, 1995, J AM DENT ASSOC, V126, P1502, DOI 10.14219/jada.archive.1995.0079; NGIM CH, 1992, BRIT J IND MED, V49, P782; PIIKIVI L, 1989, SCAND J WORK ENV HEA, V15, P69, DOI 10.5271/sjweh.1880; PIIKIVI L, 1984, SCAND J WORK ENV HEA, V10, P35, DOI 10.5271/sjweh.2365; PIIKIVI L, 1981, P 2 FINN EST S EARL, P165; REITAN RM, 1986, NEUROPSYCHOLOGICAL A; ROELS H, 1982, INT ARCH OCC ENV HEA, V50, P77, DOI 10.1007/BF00432495; ROELS H, 1985, AM J IND MED, V7, P45, DOI 10.1002/ajim.4700070106; Salvendy G., 1975, INT J PROD RES, V13, P303; SCHUCKMANN F, 1979, INT ARCH OCC ENV HEA, V44, P193, DOI 10.1007/BF00381134; SHAPIRO IM, 1982, LANCET, V1, P1147; SMITH RG, 1970, AM IND HYG ASSOC J, V31, P687, DOI 10.1080/0002889708506315; SOLEO L, 1990, BRIT J IND MED, V47, P105; *SPSS INC, 1993, SPSS X; TOUTONGHI G, 1991, ADV IND ERGONOMICS S, V3, P629; *US DEP HHS, 1993, DENT AM SCI REV REC; UZZELL BP, 1986, J CLIN EXP NEUROPSYC, V8, P581, DOI 10.1080/01688638608405177; WARRINGTON EK, RECOGNITION MEMORY T; *WHO, 1986, 255 WHO OFF OCC HLTH; WILLIAMSON AM, 1982, INT ARCH OCC ENV HEA, V50, P273, DOI 10.1007/BF00378089; ZALUPS RK, 1993, J PHARMACOL EXP THER, V267, P791; 1989, FED REG, V54, P2415	49	97	102	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					971	980		10.1096/fasebj.12.11.971	http://dx.doi.org/10.1096/fasebj.12.11.971			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707169	Bronze			2022-12-28	WOS:000075372600007
J	Kondo, S; Tanaka, Y; Kondo, Y; Hitomi, M; Barnett, GH; Ishizaka, Y; Liu, J; Haqqi, T; Nishiyama, A; Villeponteau, B; Cowell, JK; Barna, BP				Kondo, S; Tanaka, Y; Kondo, Y; Hitomi, M; Barnett, GH; Ishizaka, Y; Liu, J; Haqqi, T; Nishiyama, A; Villeponteau, B; Cowell, JK; Barna, BP			Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation	FASEB JOURNAL			English	Article						ICE; p27; CDKI; tumor cells; tumorigenicity; oligonucleotide	CISPLATIN-INDUCED APOPTOSIS; DEPENDENT KINASE INHIBITOR; PROTEIN COMPLEMENTARY-DNA; AORTIC ENDOTHELIAL-CELLS; HUMAN GLIOBLASTOMA CELLS; HUMAN ASTROCYTOMA-CELLS; DEATH GENE CED-3; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IMMORTAL CELLS; POTENTIAL MEDIATOR	Telomerase, the enzyme that elongates telomeric DNA (TTAGGG)(n), may be involved in cellular immortality and oncogenesis. To investigate the effect of inhibition of telomerase on tumor cells, we transfected the antisense vector against the human telomerase RNA into human malignant glioma cells exhibiting telomerase activity. After 30 doublings, some subpopulations of transfectants expressed a high level of interleukin-lp-converting enzyme (ICE) protein and underwent apoptosis. In contrast, other subpopulations also showed enhanced ICE protein but escaped from apoptotic crisis and continued to grow, although their DNA synthesis, invasive ability, and tumorigenicity in nude mice were significantly reduced. Surviving cells demonstrated increased expression of glial fibrillary acidic protein and decreased motility, consistent with a more differentiated state. These cells also contained enhanced expression of the cyclin-dependent kinase inhibitors (CDKIs) p21 and p27. Treatment of surviving nonapoptotic cells with antisense oligonucleotides against p27, but not p21, induced apoptotic cell death, suggesting that p27 may have protected differentiating glioma cells from apoptosis. These data show that treatment with antisense telomerase inhibits telomerase activity and subsequently induces either apoptosis or differentiation. Regulation of these two distinct pathways may be dependent on the expression of ICE or CDKIs.-Kondo, S., Tanaka, Y., Kondo, Y., Hitomi, M., Barnett, G. H., Ishizaka, Y., Liu, J., Haqqi, T., Nishiyama, A., Villeponteau, B., Cowell, J. K., Barna, B. P. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation.	Cleveland Clin Fdn, Dept Neurosurg, Brain Tumor Neurooncol Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Tokyo 113, Japan; Int Med Ctr Japan, Dept Hematol, Res Inst, Tokyo 162, Japan; Geron Corp, Menlo Park, CA USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Tokyo Metropolitan Institute of Medical Science; National Center for Global Health & Medicine - Japan; Geron Corporation	Kondo, S (corresponding author), Cleveland Clin Fdn, Dept Neurosurg S80, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kondo@cesmtp.ccf.org		Cowell, John/0000-0002-2079-5950	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033932] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS-33932] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNA BP, 1995, J NEUROIMMUNOL, V60, P75, DOI 10.1016/0165-5728(95)00055-7; BEDNAREK A, 1995, CANCER RES, V55, P4566; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FOX PL, 1994, ONCOGENE, V9, P3519; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1994, EXP CELL RES, V213, P428, DOI 10.1006/excr.1994.1219; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; Kondo S, 1996, FASEB J, V10, P1192, DOI 10.1096/fasebj.10.10.8751721; KONDO S, 1998, IN PRESS ONCOGENE; KONDO Y, 1998, IN PRESS ONCOGENE; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mehle C, 1996, ONCOGENE, V13, P161; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Okada H, 1996, INT J CANCER, V66, P255, DOI 10.1002/(SICI)1097-0215(19960410)66:2<255::AID-IJC20>3.0.CO;2-A; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; SCHOENBERG BS, 1983, ONCOLOGY NERVOUS SYS, P1; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Strahl C, 1996, MOL CELL BIOL, V16, P53; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	68	158	184	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					801	811		10.1096/fasebj.12.10.801	http://dx.doi.org/10.1096/fasebj.12.10.801			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657520				2022-12-28	WOS:000074580100005
J	Fischman, DA				Fischman, DA			What role will chairs of discipline-based subjects play in the evolving medical school of the future?	FASEB JOURNAL			English	Article									Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA	Cornell University	Fischman, DA (corresponding author), Cornell Univ, Coll Med, Dept Cell Biol & Anat, 1300 York Ave, New York, NY 10021 USA.								0	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					621	624		10.1096/fasebj.12.9.621	http://dx.doi.org/10.1096/fasebj.12.9.621			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619441	Bronze			2022-12-28	WOS:000074011000001
J	Kroncke, KD; Carlberg, C				Kroncke, KD; Carlberg, C			Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide	FASEB JOURNAL			English	Article						protein-DNA interaction; transcriptional regulation/1 alpha; 25(OH)(2)D-3 receptor 1 alpha,25(OH)(2)D-3 signaling	NUCLEAR RECEPTOR SUPERFAMILY; RETINOID-X-RECEPTOR; NF-KAPPA-B; FUNCTIONAL-CHARACTERIZATION; D-3 RECEPTOR; DNA-BINDING; VITAMIN-D; IN-VITRO; SYNTHASE; INHIBITION	Nitric oxide (NO) is known to induce Zn2+ release from the zinc-storing protein metallothionein and to induce Zn2+ release within the nuclei and cytoplasm of cells. This suggests that zinc finger proteins may be primary targets of NO-induced stress. Zn this study, the specific interaction of the heterodimeric complex of two zinc finger transcription factors, 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) receptor (VDR) and retinoid X receptor (RXR) with 1 alpha,25(OH)(2)D-3 response elements (VDREs), was used as a model system, NO was applied to this system via the NO donors SNOC and MAMA/NO and caused a dose-dependent inhibition of VDR-RXR-VDRE complex formation (IC50 values 0.5-0.8 mM), Ligand-bound or preformed complexes displayed less sensitivity to NO-induced stress. These in vitro effects of NO were found to be reversible, Functional assays in transiently transfected cells indicated that NO can also act in vivo as a repressor of 1 alpha,25(OH)(2)D-3 signaling (IC50 value of the slow NO donor DETA/NO, 0.5 mM), These findings suggest that NO has a modulatory role on transcription factors depending on their sensitivity to NO-induced stress, thus providing a mechanism for a gene regulatory function of NO.-Kroncke, K. D., Carlberg, C. Inactivation of zinc finger transcription factors provides a mechanism for a gene regulatory role of nitric oxide.	Univ Dusseldorf, Forschungsgruppe Immunbiol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Kroncke, KD (corresponding author), Univ Dusseldorf, Forschungsgruppe Immunbiol, 14-80,Posfach 10 10 07, D-40001 Dusseldorf, Germany.	kroencke@uni-duesseldorf.de	Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P10; Forstermann U, 1998, FASEB J, V12, P773; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; Kahlen JP, 1997, NUCLEIC ACIDS RES, V25, P4307, DOI 10.1093/nar/25.21.4307; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kroncke KD, 1996, METHOD ENZYMOL, V269, P279; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Laurent M, 1996, BIOCHEM J, V314, P109, DOI 10.1042/bj3140109; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Moormann AM, 1996, REDOX REP, V2, P249, DOI 10.1080/13510002.1996.11747057; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Powis G, 1997, Adv Pharmacol, V38, P329; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; Schrader M, 1997, BIOCHEM BIOPH RES CO, V230, P646, DOI 10.1006/bbrc.1996.6025; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6	29	99	100	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2000	14	1					166	173						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	274VA	10627291				2022-12-28	WOS:000084784700019
J	Cao, RH; Farnebo, J; Kurimoto, M; Cao, YH				Cao, RH; Farnebo, J; Kurimoto, M; Cao, YH			Interleukin-18 acts as an angiogenesis and tumor suppressor	FASEB JOURNAL			English	Article						neovascularization; antitumor; interferon-gamma	GAMMA-INDUCING FACTOR; ENDOTHELIAL GROWTH-FACTOR; LEWIS-LUNG-CARCINOMA; X-C CHEMOKINE; IN-VIVO; IFN-GAMMA; INTERFERON-GAMMA; CONVERTING-ENZYME; BLOOD-VESSELS; INHIBITION	Interleukin-18 (IL-18), also called interferon-gamma (IFN-gamma)-inducing factor, has recently been characterized as a potent IFN-gamma-inducing cytokine, We now report that IL-18 is a novel antiangiogenic and antitumor cytokine. In vitro, IL-18 specifically inhibits fibroblast growth factor-2-stimulated proliferation of capillary endothelial cells. In vivo, IL-18 is sufficiently potent to suppress the fibroblast growth factor-induced corneal neovascularization by systemic administration in mice. This cytokine also inhibits embryonic angiogenesis in the chick chorioallantoic membrane assay, Systemic and intralesional administrations of IL-18 produce a significant suppression of the growth of murine T241 fibrosarcoma in syngeneic C57B16/J and immunodeficient SCID mice, The antitumor effect appears to be potent because an average of >75% inhibition of primary tumor growth was observed at a dose of 50 mu g/kg/day, In cell culture, murine T241 fibrosarcoma cells are insensitive to recombinant IL-18 at concentrations that significantly inhibit endothelial cell, proliferation. Immunohistochemical studies of tumor tissues reveal hypovascularization of the IL-18-treated tumors. These results suggest that IL-18 may participate in the regulation of a switch of tumor angiogenesis.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden; Hayashibara Biochem Labs Inc, Fujisaki Inst, Okayama 702, Japan	Karolinska Institutet; Hayashibara Biochemical Laboratories, Inc.	Cao, YH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Angiogenesis Res, S-17177 Stockholm, Sweden.							Ahn HJ, 1997, J IMMUNOL, V159, P2125; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cao Y, 1998, Prog Mol Subcell Biol, V20, P161; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Cao YH, 1998, J CLIN INVEST, V101, P1055, DOI 10.1172/JCI1558; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHEN C, 1995, CANCER RES, V55, P4230; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555; Dao T, 1996, CELL IMMUNOL, V173, P230, DOI 10.1006/cimm.1996.0272; EZEKOWITZ A, 1995, NEW ENGL J MED, V333, P595, DOI 10.1056/NEJM199508313330913; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FOLKMAN J, 1995, NAT MED, V1, P2; Fukushi J, 1998, BIOCHEM BIOPH RES CO, V250, P444, DOI 10.1006/bbrc.1998.9334; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCK AE, 1992, SCIENCE, V258, P1798; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MAIONE TE, 1991, CANCER RES, V51, P1798; MILLAUER B, 1994, NATURE, V367, P578; MUTHUKKARUPPAN VR, 1979, SCIENCE, V205, P1461; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OREILLY MS, 1997, CELL, V88, P1; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sarvetnick N, 1997, J CLIN INVEST, V99, P371, DOI 10.1172/JCI119167; STRIETER RM, 1995, SHOCK, V4, P155, DOI 10.1097/00024382-199509000-00001; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Ushio S, 1996, J IMMUNOL, V156, P4274; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039	51	179	208	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1999	13	15					2195	2202		10.1096/fasebj.13.15.2195	http://dx.doi.org/10.1096/fasebj.13.15.2195			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	266QN	10593867				2022-12-28	WOS:000084310800011
J	Retondaro, FC; Costa, PCD; Pedrosa, RC; Kurtenbach, E				Retondaro, FC; Costa, PCD; Pedrosa, RC; Kurtenbach, E			Presence of antibodies against the third intracellular loop of the m2 muscarinic receptor in the sera of chronic chagasic patients	FASEB JOURNAL			English	Article						Trypanosoma cruzi; autoimmune disease; chagasic cardiomyopathy; G-protein-coupled receptors	IDIOPATHIC DILATED CARDIOMYOPATHY; FUNCTIONAL AUTOIMMUNE EPITOPE; PROTEIN-COUPLED RECEPTORS; TRYPANOSOMA-CRUZI; PATHOLOGICAL IMPLICATIONS; DISEASE; IGG	Patients in the chronic phase of Chagas' disease suffer from a slowly evolving inflammatory cardiomyopathy that can lead to severe cardiac dilatation, congestive heart failure, and death. This process appears to be caused by autoimmune recognition of heart tissue by a mononuclear cell infiltrate decades after infection with the parasite Trypanosoma cruzi, Recent evidence suggests that there are circulating antibodies in chronic chagasic patients that alter the physiological behavior of the heart on binding to G-protein-coupled cardiovascular receptors, including beta 1-adrenergic and m2 muscarinic receptors, A 42 kDa fusion protein was constructed that contains the central part of the third intracellular loop (i3; Arg(267)-Arg(381)) of the human m2 muscarinic receptor, linked to glutathione S-transferase, This fusion protein was overexpressed in Escherichia coli and subsequently purified by affinity chromatography, Based on Western blots, the i3 loop is specifically recognized by the sera of chronic chagasic patients who have reached advanced stages of cardiac failure (according to the Los Andes classification). Analysis of the prevalence and distribution of these antibodies shows a strong association between seropositive patients and moderate (group II) to severe (group III) heart dysfunction.-Retondaro, F. C., dos Santos Costa, P. C., Pedrosa, R. C., Kurtenbach, E. Presence of antibodies against the third intracellular loop of the m2 muscarinic receptor in the sera of chronic chagasic patients.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Ctr Ciencias Saude, BR-21941900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Hosp Clementino Fraga Filho, Ctr Ciencias Saude, BR-21941900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Kurtenbach, E (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Ctr Ciencias Saude, Cidade Univ, BR-21941900 Rio De Janeiro, Brazil.	kurten@bioqmed.ufrj.br	Costa, Patrícia C dos S/AAL-9975-2020; Kurtenbach, Eleonora/L-4148-2016	Kurtenbach, Eleonora/0000-0002-2141-518X; dos Santos Costa, Patricia Cristina/0000-0003-0111-6980				Bohm SK, 1997, BIOCHEM J, V322, P1; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; CARRASCO HA, 1983, TEXTOS U LOS ANDES C; CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541; deOliveira SF, 1997, CIRCULATION, V96, P2031, DOI 10.1161/01.CIR.96.6.2031; DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU MLX, 1994, CLIN IMMUNOL IMMUNOP, V72, P15, DOI 10.1006/clin.1994.1101; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244; Goin JC, 1997, FASEB J, V11, P77, DOI 10.1096/fasebj.11.1.9034169; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; Goin Juan Carlos, 1994, Molecular Neuropharmacology, V3, P189; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; PETRY K, 1989, PARASITOL TODAY, V5, P111, DOI 10.1016/0169-4758(89)90052-5; RASSI A, 1982, DOENCAS INFECCIOSAS, V7; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4	19	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2015	2020		10.1096/fasebj.13.14.2015	http://dx.doi.org/10.1096/fasebj.13.14.2015			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544184				2022-12-28	WOS:000083660700013
J	Westberg, JA; Zhang, KZ; Andersson, LC				Westberg, JA; Zhang, KZ; Andersson, LC			Regulation of neural differentiation by normal and mutant (G654A, amyloidogenic) gelsolin	FASEB JOURNAL			English	Article						PMA; neural sprouting; familial amyloidosis of the Finnish type (FAF); brain	FINNISH HEREDITARY AMYLOIDOSIS; FAMILIAL AMYLOIDOSIS; PLASMA GELSOLIN; ACTIN-FILAMENTS; GENE; IDENTIFICATION; LOCALIZATION; ACTIVATION; MODULATION; MOTILITY	Gelsolin belongs to a family of proteins that modulate the structural dynamics of cytoskeletal actin, Gelsolin activity is required for the redistribution of actin occurring during membrane ruffling, cell crawling, and platelet activation. A point mutation (G654A) in the gelsolin gene causes a dominantly inherited systemic amyloidosis called familial amyloidosis of the Finnish type (FAF), This disease is characterized by a cranial neuropathy that cannot be explained solely by amyloid deposits. To address the question of whether gelsolin has a specific role in neural cell development, we transfected cDNA for wild type and G654A point-mutated gelsolin into a neural cell line, Paju, which can be induced to differentiate by treatment with phorbol 12-myristate Ig-acetate. Overexpressed wild type gelsolin inhibited neural differentiation whereas mutated gelsolin did not, indicating that appropriate gelsolin activity is essential for neural sprouting. The G654A mutant gelsolin induced stabilization of F-actin and reduced the plasticity of neural development. This provides a novel etiopathogenetic mechanism for the neuronal dysfunction in FAF.	Univ Helsinki, Dept Pathol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, Dept Pathol, Helsinki, Finland; Karolinska Hosp & Inst, Stockholm, Sweden	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital	Andersson, LC (corresponding author), Univ Helsinki, Dept Pathol, Haartman Inst, Haartmaninkatu 3,POB 21, FIN-00014 Helsinki, Finland.							Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KIURU S, 1994, MUSCLE NERVE, V17, P299, DOI 10.1002/mus.880170307; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Lu M, 1997, J CELL BIOL, V138, P1279, DOI 10.1083/jcb.138.6.1279; MAURY CPJ, 1992, GENOMICS, V13, P902, DOI 10.1016/0888-7543(92)90183-S; MAURY CPJ, 1990, FEBS LETT, V276, P75, DOI 10.1016/0014-5793(90)80510-P; Maury CPJ, 1997, LAB INVEST, V77, P299; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; Paunio T, 1997, FEBS LETT, V406, P49, DOI 10.1016/S0014-5793(97)00237-8; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; TANAKA J, 1994, J NEUROSCI, V14, P1038, DOI 10.1523/JNEUROSCI.14-03-01038.1994; WANG E, 1984, J CELL BIOL, V98, P761, DOI 10.1083/jcb.98.2.761; WEEDS AG, 1993, FEBS LETT, V335, P119, DOI 10.1016/0014-5793(93)80452-Z; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0	23	21	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	1999	13	12					1621	1626		10.1096/fasebj.13.12.1621	http://dx.doi.org/10.1096/fasebj.13.12.1621			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	232CF	10463954				2022-12-28	WOS:000082347600018
J	Doukas, J; Hoganson, DK; Ong, M; Ying, WB; Lacey, DL; Baird, A; Pierce, GF; Sosnowski, BA				Doukas, J; Hoganson, DK; Ong, M; Ying, WB; Lacey, DL; Baird, A; Pierce, GF; Sosnowski, BA			Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways	FASEB JOURNAL			English	Article						gene therapy; cancer; integrin; affinity	TARGETED GENE DELIVERY; HIGH-AFFINITY RECEPTOR; SMOOTH-MUSCLE CELLS; SELF-ASSOCIATION; FACTOR-II; HEPARIN; INTERNALIZATION; PROLIFERATION; PROTEOGLYCANS; ANGIOGENESIS	A major goal of gene therapy is to improve target specificity by delivering vectors through alternative cellular receptors. We previously reported that adenoviral vector delivery through basic fibroblast growth factor (FGF2) receptors enhances both cellular transduction and in vivo efficacy. We now present studies addressing the cellular pathways and mechanisms underlying these events. Cellular receptors for adenoviruses are not required for transduction by FGF2-retargeted vectors. Moreover, alpha(v) integrins can antagonize FGF2 retargeting, in contrast to their obligatory role in non-retargeted vector delivery. By contrast, high-affinity FGF receptors, which are overexpressed on potential tumor targets, are required for FGF2-retargeted transduction. Low-affinity heparan sulfate proteoglycan interactions, however, are not a prerequisite, in marked contrast to their obligatory role in FGF2 mitogenic signaling. By comparing receptor expression and Ligand binding with transgene expression, we also demonstrate that FGF2 retargeting enhances transduction by mechanisms other than increasing the number of targeted cells. Rather, the use of alternative targeting Ligands supports the conclusion that specific receptor interactions and intracellular events serve to enhance transgene expression. Together, these studies highlight the unique delivery and transduction pathways used by FGF2-retargeted adenoviruses, and help define the basis for their enhanced in vivo efficacy.	Select Genet Inc, San Diego, CA 92121 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Doukas, J (corresponding author), Select Genet Inc, 11035 Roselle St, San Diego, CA 92121 USA.			Baird, Andrew/0000-0003-0027-9905	NCI NIH HHS [R34CA79294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA079294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Doukas J, 1996, DIABETES, V45, P1209, DOI 10.2337/diabetes.45.9.1209; Freimuth P, 1996, J VIROL, V70, P4081, DOI 10.1128/JVI.70.6.4081-4085.1996; GEPPERT TD, 1987, J IMMUNOL, V138, P1660; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLEIZES PE, 1995, EUR J CELL BIOL, V66, P47; Goldman CK, 1997, CANCER RES, V57, P1447; GONZALEZ AM, 1994, BRAIN RES, V665, P285, DOI 10.1016/0006-8993(94)91349-8; GONZALEZ AM, 1994, ENDOCRINOLOGY, V134, P2289, DOI 10.1210/en.134.5.2289; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Gu D., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P512; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; Larocca D, 1998, HUM GENE THER, V9, P2393, DOI 10.1089/hum.1998.9.16-2393; Li YM, 1999, CANCER RES, V59, P325; LINDNER V, 1993, CIRC RES, V73, P589, DOI 10.1161/01.RES.73.3.589; Nemerow Glen R., 1994, Trends in Cell Biology, V4, P52, DOI 10.1016/0962-8924(94)90010-8; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Rancourt C, 1998, CLIN CANCER RES, V4, P2455; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; REYNOLDS PN, 1998, TUMOR TARGET, V3, P156; ROGERS BE, 1998, TUMOR TARGET, V3, P25; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; Stevenson SC, 1997, J VIROL, V71, P4782, DOI 10.1128/JVI.71.6.4782-4790.1997; Takanami I, 1997, NEOPLASMA, V44, P295; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Watkins SJ, 1997, GENE THER, V4, P1004, DOI 10.1038/sj.gt.3300511; Whalen GF, 1989, GROWTH FACTORS, V1, P157, DOI 10.3109/08977198909029125; Wickham TJ, 1997, CANCER IMMUNOL IMMUN, V45, P149, DOI 10.1007/s002620050419; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wickham TJ, 1997, J VIROL, V71, P7663, DOI 10.1128/JVI.71.10.7663-7669.1997; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; Wickham TJ, 1995, GENE THER, V2, P750; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ying W., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P480; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	46	37	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1999	13	11					1459	1466		10.1096/fasebj.13.11.1459	http://dx.doi.org/10.1096/fasebj.13.11.1459			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	226KL	10428769	Bronze			2022-12-28	WOS:000082019100017
J	Heinecke, JW				Heinecke, JW			Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall	FASEB JOURNAL			English	Review						low density lipoprotein; oxidized LDL; reactive oxygen species; myeloperoxidase; 3-chlorotyrosine; atherosclerosis	LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; HUMAN ATHEROSCLEROTIC LESIONS; HERITABLE HYPERLIPIDEMIC RABBITS; HUMAN-BLOOD-PLASMA; NITRIC-OXIDE; LIPID-PEROXIDATION; CATALYZED OXIDATION; ENDOTHELIAL INJURY; HUMAN NEUTROPHILS	Oxidatively damaged low density lipoprotein (LDL) may play an important role in atherogenesis, but the physiologically relevant pathways have proved difficult to identify. Mass spectrometric quantification of stable compounds that result from specific oxidation reactions represents a powerful approach for investigating such mechanisms, Analysis of protein oxidation products isolated from atherosclerotic lesions implicates tyrosyl radical, reactive nitrogen species, and hypochlorous acid in LDL oxidation in the human artery wall. These observations provide chemical evidence for the reaction pathways that promote LDL oxidation and lesion formation in vivo.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Div Atherosclerosis, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.							AASA R, 1963, BIOCHIM BIOPHYS ACTA, V75, P203, DOI 10.1016/0006-3002(63)90599-7; Aji W, 1997, CIRCULATION, V95, P430; ARAUJO JA, 1995, ARTERIOSCL THROM VAS, V15, P1172, DOI 10.1161/01.ATV.15.8.1172; ASCHERIO A, 1994, NEW ENGL J MED, V330, P1152, DOI 10.1056/NEJM199404213301611; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bothwell T.H., 1979, IRON METABOLISM MAN; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROWN MS, 1992, CELL, V71, P187, DOI 10.1016/0092-8674(92)90346-E; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; Dabbagh AJ, 1997, ARTERIOSCL THROM VAS, V17, P2638, DOI 10.1161/01.ATV.17.11.2638; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Garner B, 1997, J BIOL CHEM, V272, P6927, DOI 10.1074/jbc.272.11.6927; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAYASHI K, 1995, FEBS LETT, V370, P37, DOI 10.1016/0014-5793(95)00786-9; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HODIS HN, 1994, J LIPID RES, V35, P669; HOGG N, 1993, FEBS LETT, V334, P170, DOI 10.1016/0014-5793(93)81706-6; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; LAMB DJ, 1995, FEBS LETT, V374, P12, DOI 10.1016/0014-5793(95)01068-P; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; March J., 1992, ADV ORG CHEM, V4th; MCCLOSKEY JA, 1990, METHODS ENZYMOL, V193; McCormick ML, 1998, J BIOL CHEM, V273, P32030, DOI 10.1074/jbc.273.48.32030; MILLER M, 1994, JAMA-J AM MED ASSOC, V272, P231, DOI 10.1001/jama.272.3.231; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; Patrono C, 1997, ARTERIOSCL THROM VAS, V17, P2309, DOI 10.1161/01.ATV.17.11.2309; PETERS T, 1967, J BIOL CHEM, V242, P1574; PORTER NA, 1984, METHOD ENZYMOL, V105, P273; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; STEINBERG D, 1995, LANCET, V346, P36, DOI 10.1016/S0140-6736(95)92657-7; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; THOMAS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P244, DOI 10.1006/abbi.1994.1496; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YATES MT, 1992, FEBS LETT, V309, P135, DOI 10.1016/0014-5793(92)81081-V; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	79	112	121	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1999	13	10					1113	1120		10.1096/fasebj.13.10.1113	http://dx.doi.org/10.1096/fasebj.13.10.1113			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	213GR	10385603				2022-12-28	WOS:000081264800001
J	Lezza, AMS; Mecocci, P; Cormio, A; Beal, MF; Cherubini, A; Cantatore, P; Senin, U; Gadaleta, MN				Lezza, AMS; Mecocci, P; Cormio, A; Beal, MF; Cherubini, A; Cantatore, P; Senin, U; Gadaleta, MN			Mitochondrial DNA 4977 bp deletion and OH(8)dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients	FASEB JOURNAL			English	Article						aging; mtDNA; deletions; mtDNA oxidative damage; neurodegenerative disease	OXIDATIVE DAMAGE; NUCLEAR-DNA; STRESS; REGIONS; DECAY; SITES	The levels of mitochondrial DNA 4977 bp deletion (mtDNA(4977)) and mitochondrial DNA 8'-hydroxy-2'-deoxyguanosine (OH(8)dG) were determined in the same samples from two brain areas of healthy subjects and Alzheimer's disease (AD) patients, A positive correlation between the age-related increases of mtDNA(4977) and of OH(8)dG levels was found in the brain of healthy individuals. On the contrary, in both brain areas of AD patients, mtDNA(4977) levels were very low in the presence of high OH(8)dG amounts. These results might be explained assuming that the increase of OH(8)dG above a threshold level, as in AD patients, implies consequences for mtDNA replication and neuronal cell survival.	Univ Bari, Dept Biochem & Mol Biol, I-70125 Bari, Italy; Univ Perugia, Dept Gerontol & Geriatr, I-06122 Perugia, Italy; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	Universita degli Studi di Bari Aldo Moro; University of Perugia; Harvard University; Harvard Medical School; Massachusetts General Hospital	Gadaleta, MN (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Via Orabona 4, I-70125 Bari, Italy.	m.n.gadaleta@biologia.uniba.it	Mecocci, Patrizia/W-2116-2019; Cherubini, Antonio/AAL-4632-2020	Mecocci, Patrizia/0000-0003-0729-5246; Cherubini, Antonio/0000-0003-0261-9897; Cormio, Antonella/0000-0002-6029-1722				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BENZI G, 1995, FREE RADICAL BIO MED, V19, P77, DOI 10.1016/0891-5849(94)00244-E; Cadet J, 1997, ENVIRON HEALTH PERSP, V105, P1034, DOI 10.2307/3433836; Cahill A, 1997, BIOCHEM BIOPH RES CO, V235, P286, DOI 10.1006/bbrc.1997.6774; CANTATORE P, 1995, J BIOL CHEM, V270, P25020, DOI 10.1074/jbc.270.42.25020; CAVELIER L, 1995, GENOMICS, V29, P217, DOI 10.1006/geno.1995.1234; CHEN X, 1995, BBA-MOL BASIS DIS, V1271, P229, DOI 10.1016/0925-4439(95)00032-Y; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; GADALETA MN, 1999, METHODS AGING RES, P475; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732; Lyras L, 1997, J NEUROCHEM, V68, P2061; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; OZAWA T, 1994, HERZ, V19, P105; PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SACCONE C, IN PRESS FRONTIERS C; Schapira AHV, 1996, CURR OPIN NEUROL, V9, P260, DOI 10.1097/00019052-199608000-00003; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; SOONG NW, 1992, NAT GENET, V2, P318; Wallace DC, 1995, LIFE SCI R, V56, P199; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	34	66	69	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1999	13	9					1083	1088		10.1096/fasebj.13.9.1083	http://dx.doi.org/10.1096/fasebj.13.9.1083			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336891				2022-12-28	WOS:000080547700013
J	Upston, JM; Terentis, AC; Stocker, R				Upston, JM; Terentis, AC; Stocker, R			Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement	FASEB JOURNAL			English	Article; Proceedings Paper	FASEB Summer Research Conference on Molecular and Biological Mechanisms of Antioxidant Action	AUG, 1998	COPPER MOUNTAIN, CO			atherosclerosis; lipid peroxidation; antioxidants; LDL	LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; CORONARY HEART-DISEASE; HUMAN-BLOOD-PLASMA; HERITABLE HYPERLIPIDEMIC RABBITS; RADICAL-INITIATED OXIDATION; CHOLESTEROL-FED RABBITS; D-ALPHA-TOCOPHEROL; LIPID-PEROXIDATION; HYPERCHOLESTEROLEMIC RABBITS	The 'oxidation theory' of atherosclerosis proposes that oxidation of low density lipoprotein (LDL) contributes to atherogenesis. Although little direct evidence for a causative role of 'oxidized LDL' in atherogenesis exists, several studies show that, in vitro, oxidized LDL exhibits potentially proatherogenic activities and Lipoproteins isolated from atherosclerotic lesions are oxidized. As a consequence, the molecular mechanisms of LDL oxidation and the actions of alpha-tocopherol (alpha-TOH, vitamin E), the major lipid-soluble lipoprotein antioxidant, have been studied in detail. Based on the known antioxidant action of alpha-TOH and epidemiological evidence, vitamin E is generally considered to be beneficial in coronary artery disease. However, intervention studies overall show a null effect of vitamin E on atherosclerosis, This confounding outcome can be rationalized by the recently discovered diverse role for alpha-TOH in Lipoprotein oxidation; that is, alpha-TOH displays neutral, anti-, or, indeed, prooxidant activity under various conditions. This review describes the latter, novel action of alpha-TOH, termed tocopherol-mediated peroxidation, and discusses the benefits of vitamin E supplementation alone or together with other antioxidants that work in concert with alpha-TOH in ameliorating lipoprotein lipid peroxidation in the artery wall and, hence, atherosclerosis.	Inst Heart, Biochem Grp, Sydney, NSW 2050, Australia		Stocker, R (corresponding author), Inst Heart, Biochem Grp, 145 Missenden Rd, Sydney, NSW 2050, Australia.	r.stocker@hri.org.au	Stocker, Roland/AAV-4489-2021; Terentis, Andrew/N-9188-2019	Terentis, Andrew/0000-0001-6137-8275				Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; BARCLAY LRC, 1985, CAN J CHEM, V63, P366, DOI 10.1139/v85-062; BARCLAY LRC, 1987, CAN J CHEM, V65, P2541, DOI 10.1139/v87-423; BARCLAY LRC, 1990, BIOCHIM BIOPHYS ACTA, V1047, P255, DOI 10.1016/0005-2760(90)90524-2; BEDWELL S, 1989, BIOCHEM J, V262, P707, DOI 10.1042/bj2620707; BEELER DA, 1962, J NUTR, V78, P184, DOI 10.1093/jn/78.2.184; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; Boger RH, 1998, ATHEROSCLEROSIS, V141, P31, DOI 10.1016/S0021-9150(98)00145-2; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; BROOKS CJW, 1970, BIOCHIM BIOPHYS ACTA, V202, P563, DOI 10.1016/0005-2760(70)90131-1; BRUGER M, 1945, P SOC EXP BIOL MED, V59, P56, DOI 10.3181/00379727-59-14980; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; CAMEJO G, 1990, EUR HEART J, V11, P164, DOI 10.1093/eurheartj/11.suppl_E.164; CAMEJO G, 1991, J LIPID RES, V32, P1983; Carpels M, 1995, BIOREMED SER, V3, P141; CARPENTER KLH, 1995, FREE RADICAL RES, V23, P549, DOI 10.3109/10715769509065276; Cleary J, 1997, FREE RADICAL RES, V26, P175, DOI 10.3109/10715769709097796; CRAIG WY, 1995, J AUTOIMMUN, V8, P713, DOI 10.1006/jaut.1995.0053; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; Dam H, 1944, J NUTR, V28, P289; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; DOBA T, 1985, BIOCHIM BIOPHYS ACTA, V835, P298, DOI 10.1016/0005-2760(85)90285-1; DONALDSON WE, 1982, POULTRY SCI, V61, P2097, DOI 10.3382/ps.0612097; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FRUEBIS J, 1995, ATHEROSCLEROSIS, V117, P217, DOI 10.1016/0021-9150(95)05574-G; Fu S, 1998, BIOCHEM J, V333, P519, DOI 10.1042/bj3330519; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; GILLILAN RE, 1977, AM HEART J, V93, P444, DOI 10.1016/S0002-8703(77)80406-7; GODFRIED SL, 1989, BRIT J NUTR, V61, P607, DOI 10.1079/BJN19890148; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1997, FEBS LETT, V414, P541, DOI 10.1016/S0014-5793(97)01066-1; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HOFF HF, 1995, CURR OPIN LIPIDOL, V6, P317, DOI 10.1097/00041433-199510000-00012; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P153, DOI 10.1006/abbi.1994.1423; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; INGOLD KU, 1962, NATURE, V195, P280, DOI 10.1038/195280b0; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; Iribarren C, 1997, ARTERIOSCL THROM VAS, V17, P1171, DOI 10.1161/01.ATV.17.6.1171; ITABE H, 1994, J BIOL CHEM, V269, P15274; IWATSUKI M, 1995, FEBS LETT, V360, P271, DOI 10.1016/0014-5793(95)00122-P; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; JIALAL I, 1992, J LIPID RES, V33, P899; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KAGAN VE, 1992, J LIPID RES, V33, P385; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEANEY JF, 1994, J CLIN INVEST, V93, P844, DOI 10.1172/JCI117039; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; Kenar JA, 1996, CHEM RES TOXICOL, V9, P737, DOI 10.1021/tx9600098; Killion SL, 1996, ATHEROSCLEROSIS, V126, P289, DOI 10.1016/0021-9150(96)05918-7; KLEINVELD HA, 1994, ARTERIOSCLER THROMB, V14, P1386, DOI 10.1161/01.ATV.14.8.1386; KLEINVELD HA, 1995, ARTERIOSCL THROM VAS, V15, P290, DOI 10.1161/01.ATV.15.2.290; Kontush A, 1996, J LIPID RES, V37, P1436; KONTUSH A, 1994, FEBS LETT, V341, P69, DOI 10.1016/0014-5793(94)80242-4; Kontush A, 1996, J BIOL CHEM, V271, P11106, DOI 10.1074/jbc.271.19.11106; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Lagendijk J, 1997, RES COMMUN MOL PATH, V95, P11; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; LIEBLER DC, 1990, J AM CHEM SOC, V112, P6995, DOI 10.1021/ja00175a037; LIEBLER DC, 1992, BIOCHEMISTRY-US, V31, P8278, DOI 10.1021/bi00150a022; LIEBLER DC, 1993, CRIT REV TOXICOL, V23, P147, DOI 10.3109/10408449309117115; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; MOHR D, 1994, ARTERIOSCLER THROMB, V14, P1186, DOI 10.1161/01.ATV.14.7.1186; MOSES CAMPBELL, 1952, ANGIOLOGY, V3, P397, DOI 10.1177/000331975200300507; Munday JS, 1998, ARTERIOSCL THROM VAS, V18, P114, DOI 10.1161/01.ATV.18.1.114; NAGAOKA S, 1990, J AM CHEM SOC, V112, P8921, DOI 10.1021/ja00180a042; Neuzil J, 1997, P NATL ACAD SCI USA, V94, P7885, DOI 10.1073/pnas.94.15.7885; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; NEUZIL J, 1994, J BIOL CHEM, V269, P16712; NIKI E, 1985, J BIOL CHEM, V260, P2191; NIU X, 1999, ARTERIOSCLE THROMB V; Ozer NK, 1998, FREE RADICAL BIO MED, V24, P226, DOI 10.1016/S0891-5849(97)00136-6; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PARKER RA, 1995, ARTERIOSCL THROM VAS, V15, P349, DOI 10.1161/01.ATV.15.3.349; PEPIN JM, 1991, J LIPID RES, V32, P317; PHAIR RD, 1975, FED PROC, V34, P2263; PORTER NA, 1980, J AM CHEM SOC, V102, P5597, DOI 10.1021/ja00537a032; PORTER NA, 1981, J AM CHEM SOC, V103, P6447, DOI 10.1021/ja00411a032; PRASAD K, 1993, AM HEART J, V125, P958, DOI 10.1016/0002-8703(93)90102-F; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; QIAO Y, 1993, ARTERIOSCLER THROMB, V13, P1885, DOI 10.1161/01.ATV.13.12.1885; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Schwenke DC, 1998, CIRC RES, V83, P366, DOI 10.1161/01.RES.83.4.366; SHARMA MK, 1993, FREE RADICAL BIO MED, V14, P649, DOI 10.1016/0891-5849(93)90146-L; SMITH EB, 1967, J ATHEROSCLER RES, V7, P171, DOI 10.1016/S0368-1319(67)80079-6; SMITH TL, 1989, ATHEROSCLEROSIS, V75, P105, DOI 10.1016/0021-9150(89)90166-4; STAMLER J, 1954, CIRCULATION, V8, P455; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stein O, 1996, BBA-LIPID LIPID MET, V1299, P216, DOI 10.1016/0005-2760(95)00210-3; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STOCKER R, 1993, BIOCHIM BIOPHYS ACTA, V1158, P15, DOI 10.1016/0304-4165(93)90090-U; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Stocker R, 1991, OXIDATIVE STRESS OXI, P213; Stocker Roland, 1994, Current Opinion in Lipidology, V5, P422, DOI 10.1097/00041433-199412000-00005; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Suarna C, 1997, FREE RADICAL RES, V27, P397, DOI 10.3109/10715769709065779; SULKIN NM, 1960, P SOC EXP BIOL MED, V103, P111, DOI 10.3181/00379727-103-25429; Sun JD, 1997, INT J VITAM NUTR RES, V67, P155; TAKAHASHI T, 1995, BIOCHEM J, V309, P883, DOI 10.1042/bj3090883; THOMAS NW, 1971, HORM METAB RES, V3, P21, DOI 10.1055/s-0028-1095041; THOMAS SR, 1995, AM J CLIN NUTR, V62, P1357, DOI 10.1093/ajcn/62.6.1357S; Thomas SR, 1996, ARTERIOSCL THROM VAS, V16, P687, DOI 10.1161/01.ATV.16.5.687; TRABER MG, 1990, J CLIN INVEST, V85, P397, DOI 10.1172/JCI114452; Upston JM, 1996, J LIPID RES, V37, P2650; Upston JM, 1997, J BIOL CHEM, V272, P30067, DOI 10.1074/jbc.272.48.30067; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WAGNER JR, 1993, J BIOL CHEM, V268, P18502; Waldeck AR, 1996, CHEM RES TOXICOL, V9, P954, DOI 10.1021/tx960057s; WEITZEL G, 1955, KLIN WOCHENSCHR, V33, P772, DOI 10.1007/BF01473522; WEITZEL G, 1956, Z PHYSL CHEM, V304; WESTROPE KL, 1982, NUTR REP INT, V25, P83; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H; WILLINGHAM AK, 1993, J NUTR BIOCHEM, V4, P651, DOI 10.1016/0955-2863(93)90038-X; WILSON RB, 1978, J NUTR, V108, P1858, DOI 10.1093/jn/108.11.1858; WITTING PK, 1995, FEBS LETT, V375, P45, DOI 10.1016/0014-5793(95)01172-B; Witting PK, 1999, FASEB J, V13, P667, DOI 10.1096/fasebj.13.6.667; Witting PK, 1996, J LIPID RES, V37, P853; Witting PK, 1997, BIOCHEMISTRY-US, V36, P1251, DOI 10.1021/bi962493j; Witting PK, 1998, SUB CELL BIOCHEM, V30, P345; WOJCICKI J, 1991, ATHEROSCLEROSIS, V87, P9, DOI 10.1016/0021-9150(91)90227-T; Xu RP, 1998, ATHEROSCLEROSIS, V137, P29, DOI 10.1016/S0021-9150(97)00248-7; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535; Ziouzenkova O, 1998, FREE RADICAL BIO MED, V24, P607, DOI 10.1016/S0891-5849(97)00324-9	151	239	246	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	1999	13	9					977	994		10.1096/fasebj.13.9.977	http://dx.doi.org/10.1096/fasebj.13.9.977			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	200NZ	10336881				2022-12-28	WOS:000080547700003
J	Bras, A; Ruiz-Vela, A; De Buitrago, GG; Martinez, C				Bras, A; Ruiz-Vela, A; De Buitrago, GG; Martinez, C			Caspase activation by BCR cross-linking in immature B cells: differential effects on growth arrest and apoptosis	FASEB JOURNAL			English	Article						caspases; cell cycle; PARP	LYMPHOMA-CELLS; CYTOCHROME-C; NEGATIVE SELECTION; CLONAL DELETION; GENE-PRODUCT; BONE-MARROW; DEATH; BCL-2; RECEPTOR; WEHI-231	The B cell lymphoma WEHI-231 has been used as a model to study immature B cell tolerance, based on its capacity to undergo growth arrest and programmed cell death on B cell receptor (BCR) cross-linking. Using this model to identify the molecular mechanisms underlying these processes, we found that BCR cross-linking results in the selective activation of caspase 7/Mch3, but not of the other two members of the CPP32 family, caspase 2/Nedd2 and caspase 3/CPP32. This was evidenced by the induction of proteolytic activity against the substrate for the CPP32 subfamily of caspases (z-DVED-AMC) in vitro, as well as PARP proteolysis in vivo and by the processing of the 35 kDa Mch3 into a 32 kDa species, which was later further proteolyzed. The general caspase inhibitor z-VAD-fmk, but not the CPP32 family inhibitor Ac-DEVD-CHO, blocked anti-lu-induced apoptosis, indicating that a caspase not belonging to the CPP32-like family is also implicated in anti-mu-triggered apoptosis. In contrast, z-VAD-fmk was not able to counteract growth arrest induced by anti-En. treatment, suggesting that caspase activation is not necessary for induction of growth arrest. Neither of the inhibitors prevented Mch3 processing; however, z-VAD-fmk prevented proteolysis of the p32 subunit, suggesting that further processing of this subunit is associated with apoptosis. Bcl-2 overexpression prevented anti-mu induction of CPP32-like activity and apoptosis, and blocked further processing of the Mch3 p32 subunit. In contrast, CD40 stimulation completely blocked the appearance of the p32 subunit in addition to blocking CPP32-like activity and apoptosis induced by BCR cross-linking. Moreover, only CD40 stimulation was able to prevent anti-mu-induced growth arrest, which was correlated with inhibition of retinoblastoma and of cyclin A down-regulation. In splenic B cells, Mch3 is also specifically proteolyzed ex vivo after induction of apoptosis by BCR cross-linking, demonstrating the specific involvement of caspase-7/Mch3 in apoptosis induced in B cell tolerance.	Univ Autonoma Madrid, Dept Immunol & Oncol, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bras, A (corresponding author), Univ Autonoma Madrid, Dept Immunol & Oncol, Ctr Nacl Biotecnol, CSIC, Campus de Cantoblanco, E-28049 Madrid, Spain.	abras@cnb.uam.es		Ruiz-Vela, Antonio/0000-0002-4410-6208				BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOYD AW, 1981, J IMMUNOL, V126, P2466; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLAVERIA C, 1998, IN PRESS EMBO J, V17; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HARTLEY SB, 1993, CELL, V3, P3265; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Hertz M, 1998, CURR OPIN IMMUNOL, V10, P208, DOI 10.1016/S0952-7915(98)80250-1; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LeBein TW, 1998, CURR OPIN IMMUNOL, V10, P188, DOI 10.1016/S0952-7915(98)80248-3; MacLennan ICM, 1998, CURR OPIN IMMUNOL, V10, P220, DOI 10.1016/S0952-7915(98)80252-5; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MERINO R, 1995, J IMMUNOL, V155, P3830; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NISITANI S, 1993, J EXP MED, V178, P1247, DOI 10.1084/jem.178.4.1247; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ONEL KB, 1995, EUR J IMMUNOL, V25, P2940, DOI 10.1002/eji.1830251034; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RUSSELL DM, 1991, NATURE, V6351, P308; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	45	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1999	13	8					931	944		10.1096/fasebj.13.8.931	http://dx.doi.org/10.1096/fasebj.13.8.931			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	10224236				2022-12-28	WOS:000080372500016
J	Hagen, TM; Ingersoll, RT; Lykkesfeldt, J; Liu, JK; Wehr, CM; Vinarsky, V; Bartholomew, JC; Ames, BN				Hagen, TM; Ingersoll, RT; Lykkesfeldt, J; Liu, JK; Wehr, CM; Vinarsky, V; Bartholomew, JC; Ames, BN			(R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate	FASEB JOURNAL			English	Article						aging; ambulatory activity; MDA; antioxidants; liver	ACETYL-L-CARNITINE; ALPHA-LIPOIC ACID; CHROMATOGRAPHY MASS-SPECTROMETRY; THIOCTIC ACID; LIQUID-CHROMATOGRAPHY; DEHYDROASCORBIC ACID; LIPID-PEROXIDATION; HEART MITOCHONDRIA; DIHYDROLIPOIC ACID; ASCORBIC-ACID	A diet supplemented with (R)-lipoic acid, a mitochondrial coenzyme, was fed to old rats to determine its efficacy in reversing the decline in metabolism seen with age. Young (3 to 5 months) and old (24 to 26 months) rats were fed an AlN-93M diet with or without (R)-lipoic acid (0.5% w/w) for 2 wk, killed and their liver parenchymal cells were isolated. Hepatocytes from untreated old rats vs. young controls had significantly lower oxygen consumption (P<0.03) and mitochondrial membrane potential. (R)-Lipoic acid supplementation reversed the age-related decline in O-2 consumption and increased (P<0.03) mitochondrial membrane potential. Ambulatory activity, a measure of general metabolic activity, was almost threefold lower in untreated old rats vs. controls, but this decline was reversed (P<0.005) in old rats fed (R)-lipoic acid. The increase of oxidants with age, as measured by the fluorescence produced on oxidizing 2',7'-dichlorofluorescin, was significantly lowered in (R)-lipoic acid supplemented old rats (P<0.01). Malondialdehyde (MDA) levels, an indicator of lipid peroxidation, were increased fivefold with age in cells from unsupplemented rats. Feeding rats, the (R)-lipoic acid diet reduced MDA levels markedly (P<0.01). Both glutathione and ascorbic acid levels declined in hepatocytes with age, but their loss was completely reversed with (R)-lipoic acid supplementation. Thus, (R)-lipoic acid supplementation improves indices of metabolic activity as well. as lowers oxidative stress and damage evident in aging.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Ames, BN (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.	bnames@uclink4.berkeley.edu	Lykkesfeldt, Jens/A-1072-2011; Liu, Jiankang/A-1610-2011	Lykkesfeldt, Jens/0000-0002-6514-8407; 	NCI NIH HHS [CA39910] Funding Source: Medline; NIEHS NIH HHS [ESO1896] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bustamante J, 1998, FREE RADICAL BIO MED, V24, P1023, DOI 10.1016/S0891-5849(97)00371-7; CARTA A, 1993, ANN NY ACAD SCI, V695, P324, DOI 10.1111/j.1749-6632.1993.tb23077.x; Erdincler DS, 1997, CLIN CHIM ACTA, V265, P77, DOI 10.1016/S0009-8981(97)00106-X; Estrada DE, 1996, DIABETES, V45, P1798, DOI 10.2337/diabetes.45.12.1798; GREGUS Z, 1992, TOXICOL APPL PHARM, V114, P88, DOI 10.1016/0041-008X(92)90100-7; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; HARRISON EH, 1974, ARCH BIOCHEM BIOPHYS, V160, P514, DOI 10.1016/0003-9861(74)90428-7; Jacob S, 1996, EXP CLIN ENDOCR DIAB, V104, P284, DOI 10.1055/s-0029-1211455; JACOB S, 1995, LIPOIC ACID HLT DIS, P373; KAGEN VE, 1992, J LIPID RES, V33, P385; Korkina Ludmila G., 1993, Biochemical Society Transactions, V21, p314S; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Liu JK, 1997, ANAL BIOCHEM, V245, P161, DOI 10.1006/abio.1996.9990; Lykkesfeldt J, 1998, FASEB J, V12, P1183, DOI 10.1096/fasebj.12.12.1183; LYKKESFELDT J, 1995, ANAL BIOCHEM, V229, P329, DOI 10.1006/abio.1995.1421; Maitra I, 1996, BIOCHEM BIOPH RES CO, V221, P422, DOI 10.1006/bbrc.1996.0611; Moldeus P, 1978, Methods Enzymol, V52, P60; OU PM, 1995, BIOCHEM PHARMACOL, V50, P123, DOI 10.1016/0006-2952(95)00116-H; PARADIES G, 1990, BIOCHIM BIOPHYS ACTA, V1016, P207, DOI 10.1016/0005-2728(90)90060-H; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; Paradies G, 1995, MECH AGEING DEV, V84, P103, DOI 10.1016/0047-6374(95)01636-8; PEINADO J, 1989, ARCH BIOCHEM BIOPHYS, V273, P389, DOI 10.1016/0003-9861(89)90497-9; PETER G, 1995, ARZNEIMITTELFORSCH, V45-1, P293; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Sachse G, 1980, Horm Metab Res Suppl, V9, P105; SANZ N, 1997, J HEPATOL, V27, P524; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; SCOTT BC, 1994, FREE RADICAL RES, V20, P119, DOI 10.3109/10715769409147509; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEINKAMP JA, 1973, REV SCI INSTRUM, V44, P1301, DOI [10.1063/1.1686375, 10.1063/1.1686082]; Steyn D G, 1966, S Afr Med J, V40, P405; Streeper RS, 1997, AM J PHYSIOL-ENDOC M, V273, pE185, DOI 10.1152/ajpendo.1997.273.1.E185; SUZUKI YJ, 1991, FREE RADICAL RES COM, V15, P255, DOI 10.3109/10715769109105221; TEICHERT J, 1995, J CHROMATOGR B, V672, P277, DOI 10.1016/0378-4347(95)00225-8; VILLA RF, 1998, NEUROCHEM RES, V10, P909; Xu DP, 1996, J BIOENERG BIOMEMBR, V28, P77; YEO HC, 1994, ANAL BIOCHEM, V220, P391, DOI 10.1006/abio.1994.1355; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603; ZIMMER G, 1991, ARCH BIOCHEM BIOPHYS, V288, P609, DOI 10.1016/0003-9861(91)90243-C; ZIMMER G, 1995, J MOL CELL CARDIOL, V27, P1895, DOI 10.1016/0022-2828(95)90012-8	43	233	258	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					411	418		10.1096/fasebj.13.2.411	http://dx.doi.org/10.1096/fasebj.13.2.411			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973329				2022-12-28	WOS:000078615200021
J	Hamilton, LC; Mitchell, JA; Tomlinson, AM; Warner, TD				Hamilton, LC; Mitchell, JA; Tomlinson, AM; Warner, TD			Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy	FASEB JOURNAL			English	Article						antiinflammatory agents; cyclooxygenase inhibitors; disease models; prostaglandins; prostaglandin endoperoxide synthase	PROSTAGLANDIN-H SYNTHASE-2; NITRIC-OXIDE SYNTHASE; PHOSPHOLIPASE A(2); MESSENGER-RNA; G-PROTEIN; IN-VIVO; EXPRESSION; LIPOPOLYSACCHARIDE; CYCLOOXYGENASE-2; CELLS	Prostanoids produced via the action of cyclo-oxygenase-2 (COX-2) appear central to many inflammatory conditions. Here we show in LPS treated rats, however, that COX-2 induction alone does not greatly increase prostanoid production in vivo. For this, a second, arachidonic acid liberating stimulus is also required. Thus, only after intravenous injection of bradykinin or exogenous arachidonic acid was a marked increase in prostanoid formation seen. There is, therefore, synergy between proinflammatory mediators: both induction of COX-2 protein and an increase in the supply of arachidonic acid are required to greatly enhance prostanoid production, Second, we show that supplying arachidonic acid to increase prostanoid production reduces the effectiveness of both currently used nonsteroidal antiinflammatory drugs (NSAIDs) (diclofenac) and novel COX-2-selective inhibitors (NS-398, celecoxib) as inhibitors of COX-2 activity. Our data lead to two important conclusions. First, increased prostanoid production in inflammation is a two-component response: increased COX-2 expression and increased arachidonic acid supply, Second, the supply of arachidonic acid to COX-2 determines the effectiveness of NSAIDs, NSAIDs and selective COX-2 inhibitors, therefore, will generally be less effective at more inflamed sites, providing a rationale for the very high doses of NSAIDs required in human conditions such as rheumatoid arthritis.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; Royal Brompton Hosp, Unit Crit Care Med, London SW3 6NP, England	University of London; Queen Mary University London; Royal Brompton Hospital	Warner, TD (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	t.d.warner@mds.qmw.ac.uk	Mitchell, Jane A/A-1991-2009; Warner, Timothy D/A-1980-2009	Warner, Timothy D/0000-0003-3988-4408	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; Chinn KS, 1997, LIPIDS, V32, P979, DOI 10.1007/s11745-997-0128-7; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hulkower KI, 1997, EUR J PHARMACOL, V331, P79, DOI 10.1016/S0014-2999(97)01029-7; LEE SH, 1992, J BIOL CHEM, V267, P25934; Liu SF, 1996, CLIN SCI, V90, P301, DOI 10.1042/cs0900301; Mitchell JA, 1997, MOL PHARMACOL, V51, P907, DOI 10.1124/mol.51.6.907; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; Nakatsugi S, 1996, PROSTAG LEUKOTR ESS, V55, P451, DOI 10.1016/S0952-3278(96)90130-1; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RICUPERO D, 1993, AGENTS ACTIONS, V40, P110, DOI 10.1007/BF01976759; SALVEMINI D, 1995, BRIT J PHARMACOL, V114, P1171, DOI 10.1111/j.1476-5381.1995.tb13330.x; Seibert K, 1996, BRIT J PHARMACOL, V117, P1016, DOI 10.1111/j.1476-5381.1996.tb16691.x; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SWIERKOSZ TA, 1995, BRIT J PHARMACOL, V114, P1335, DOI 10.1111/j.1476-5381.1995.tb13353.x; Takahashi S, 1995, ARCH INT PHARMACOD T, V330, P102; Vadas P, 1996, EUR J BIOCHEM, V235, P557, DOI 10.1111/j.1432-1033.1996.t01-1-00557.x; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; VANE JR, 1976, ADV PROSTAG THROMB R, V2, P791; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	27	45	45	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	1999	13	2					245	251		10.1096/fasebj.13.2.245	http://dx.doi.org/10.1096/fasebj.13.2.245			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	167CN	9973312				2022-12-28	WOS:000078615200004
J	Braun, M; Buchen, B; Sievers, A				Braun, M; Buchen, B; Sievers, A			Electron microscopic analysis of gravisensing Chara rhizoids developed under microgravity conditions	FASEB JOURNAL			English	Article; Proceedings Paper	Symposium of the European-Space-Agency/National-Aeronautics-and-Space-Administration Workshop on Cell and Molecular biology Research in Space	JUN, 1998	BELGIUM NATL ACAD SCI, LEUVEN, BELGIUM	European Space Agency, NASA	BELGIUM NATL ACAD SCI	gravitropism; statolith; tip growth	TIP-GROWING CELLS; STATOLITHS; GRAVITY; MICROFILAMENTS; CYTOSKELETON; GRAVITROPISM; TRANSPORT	Tip-growing, unicellular Chara rhizoids that react gravitropically on Earth developed in microgravity, In microgravity, they grew out from the nodes of the green thallus in random orientation. Development and morphogenesis followed an endogenous program that is not affected by the gravitational field. The cell shape, the polar cytoplasmic organization, and the polar distribution of cell organelles, except for the statoliths, were not different from controls that had grown on earth (ground controls), The ultrastructure of the organelles and the microtubules were well preserved. Microtubules were excluded from the apical zone in both ground controls as well as microgravity-grown rhizoids. The statoliths (vesicles containing BaSO4 crystals in a matrix) in microgravity-grown rhizoids were spread over a larger area (up to 50 mu m basal to the tip) than the statoliths of ground controls (10-30 mu m), Some statoliths were even located in the subapical zone close to microtubules, which was not observed in ground controls. The crystals in statoliths from microgravity-gown rhizoids appeared more loosely arranged in the vesicle matrix compared with ground controls. The chemical composition of the crystals was identified as BaSO4 by X-ray microanalysis, There is evidence that the amount of BaSO4 in statoliths of rhizoids developed in microgravity is lower than in ground controls, indicating that the gravisensitivity of microgravity-developed rhizoids might be reduced compared with ground controls. Lack of gravity, however, does not affect the process of tip growth and does not inhibit the development of the structures needed for the gravity-sensing machinery.	Univ Bonn, Inst Bot, D-53115 Bonn, Germany	University of Bonn	Braun, M (corresponding author), Univ Bonn, Inst Bot, Venusbergweg 22, D-53115 Bonn, Germany.							Braun M, 1996, PROTOPLASMA, V191, P1, DOI 10.1007/BF01280820; Braun M, 1998, PLANTA, V205, P39, DOI 10.1007/s004250050294; BRAUN M, 1993, PROTOPLASMA, V174, P50, DOI 10.1007/BF01404042; Braun M, 1997, PLANTA, V203, pS11, DOI 10.1007/PL00008098; BRAUN M, 1994, EUR J CELL BIOL, V63, P289; Braun M, 1996, J BIOTECHNOL, V47, P245, DOI 10.1016/0168-1656(96)01529-5; BUCHEN B, 1993, PROTOPLASMA, V172, P38, DOI 10.1007/BF01403719; BUDER J, 1961, BER DTSCH OT GES, V74, pS14; HEJNOWICZ Z, 1981, PROTOPLASMA, V108, P117, DOI 10.1007/BF01276887; HEMMERSBACH R, 1998, ESA; KISS JZ, 1994, PLANT PHYSIOL, V105, P937, DOI 10.1104/pp.105.3.937; Laurinavicius R, 1996, Adv Space Res, V17, P91, DOI 10.1016/0273-1177(95)00617-N; LEITZ G, 1995, PLANTA, V197, P278; Miller DD, 1996, PROTOPLASMA, V195, P123, DOI 10.1007/BF01279191; SCHROTER K, 1975, PLANTA, V122, P213, DOI 10.1007/BF00385269; SIEVERS A, 1991, BOT ACTA, V104, P103, DOI 10.1111/j.1438-8677.1991.tb00204.x; Sievers A, 1996, TRENDS PLANT SCI, V1, P273; Sievers A., 1991, CYTOSKELETAL BASIS P, P169; VOLKMANN D, 1991, PLANTA, V185, P153, DOI 10.1007/BF00194056; Volkmann D, 1996, PLANT CELL ENVIRON, V19, P1195, DOI 10.1111/j.1365-3040.1996.tb00435.x; VOLKMANN D, 1990, ESA SP307, P497	21	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.		1999	13			S			S113	S120						8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	198CF	10352152				2022-12-28	WOS:000080403800014
J	Cussac, D; Vidal, M; Leprince, C; Liu, WQ; Tiraboschi, G; Roques, BP; Garbay, C				Cussac, D; Vidal, M; Leprince, C; Liu, WQ; Tiraboschi, G; Roques, BP; Garbay, C			A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity	FASEB JOURNAL			English	Article						proline-rich peptidimers; Grb2 SH3 domains inhibition; Sos inhibition	NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; PC12 CELLS; MAP KINASE; ANTENNAPEDIA HOMEODOMAIN; SH3-LIGAND INTERACTIONS; GENERAL-MODEL; HIGH-AFFINITY; DNA-BINDING	With the aim of interrupting the growth factor-stimulated Ras signaling pathway at the level of the Grb2-Sos interaction, a peptidimer, made of two identical proline-rich sequences from Sos linked by a lysine spacer, was designed using structural data from Grb2 and a proline-rich peptide complexed with its SH3 domains. The peptidimer affinity for Grb2 is 40 nM whereas that of the monomer is 16 mu M, supporting the dual recognition of both Grb2 SH3 domains by the dimer. At 50 nM, the peptidimer blocks selectively Grb2-Sos complexation in ER 22 (CCL 39 fibroblasts overexpressing epidermal growth factor receptor) cellular extracts. The peptidimer specifically recognizes Grb2 and does not interact with PI3K or Nck, two SH3 domain-containing adaptors. The peptidimer was modified to enter cells by coupling to a fragment of Antennapedia homeodomain. At 10 mu M, the conjugate inhibits the Grb2-Sos interaction (100%) and MAP kinase (ERK1 and ERK2) phosphorylation (60%) without modifying cellular growth of ER 22 cells. At the same concentration, the conjugate also inhibits both MAP kinase activation induced by nerve growth factor or epidermal growth factor in PC12 cells, and differentiation triggered by nerve growth factor. Finally,when tested for its antiproliferative activity, the conjugate was an efficient inhibitor of the colony formation of transformed NIH3T3/HER2 cells grown in soft agar, with an IC50 of around 1 yM. Thus, the designed peptidimers appear to be interesting leads to investigate signaling and intracellular processes and for designing selective inhibitors of tumorigenic Ras-dependent processes.	UFR Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, INSERM,U266,UMR 8600, F-75270 Paris 06, France; Inst Curie, INSERM, U248, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Roques, BP (corresponding author), UFR Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, INSERM,U266,UMR 8600, 4 Ave Observ, F-75270 Paris 06, France.	Roques@pharmacie.univ-paris5.fr	Vidal, Michel/ABA-3396-2020; Leprince, Corinne/M-7109-2018; LIU, Wang-Qing/V-5422-2017	Leprince, Corinne/0000-0002-4462-5737; Vidal, Michel/0000-0002-4858-1591; LIU, Wang-Qing/0000-0003-0511-3058				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1996, CHEM BIOL, V3, P661, DOI 10.1016/S1074-5521(96)90134-9; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Furet P, 1997, J MED CHEM, V40, P3551, DOI 10.1021/jm9702185; GARELLI N, 1992, BIOCHIM BIOPHYS ACTA, V1127, P41, DOI 10.1016/0005-2760(92)90199-6; GAUGAIN B, 1984, FEBS LETT, V169, P123, DOI 10.1016/0014-5793(84)80302-6; Gay B, 1997, BIOCHEMISTRY-US, V36, P5712, DOI 10.1021/bi962642y; Gishizky ML, 1995, ANNU REP MED CHEM, V30, P247; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; Hermanson G., 1992, IMMOBILIZED AFFINITY, P53; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kapoor TM, 1998, J AM CHEM SOC, V120, P23, DOI 10.1021/ja972728u; KLEIN DJ, 1990, J BIOL CHEM, V265, P9533; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; LEE RJ, 1994, J BIOL CHEM, V269, P3198; LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007; LEPECQ JB, 1975, P NATL ACAD SCI USA, V72, P2915; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; Morken JP, 1998, J AM CHEM SOC, V120, P30, DOI 10.1021/ja972729m; PANDEY P, 1995, CANCER RES, V55, P4000; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; SINGLETON DH, 1996, 24 S EUR PEPT SOC; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	63	86	96	1	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1999	13	1					31	39		10.1096/fasebj.13.1.31	http://dx.doi.org/10.1096/fasebj.13.1.31			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156YB	9872927				2022-12-28	WOS:000078029500004
J	Martin, F; Pintor, J; Rovira, JM; Ripoll, C; Miras-Portugal, MT; Soria, B				Martin, F; Pintor, J; Rovira, JM; Ripoll, C; Miras-Portugal, MT; Soria, B			Intracellular diadenosine polyphosphates: a novel second messenger in stimulus-secretion coupling	FASEB JOURNAL			English	Article						K-ATP channel; pancreatic beta-cell; stimulus-secretion coupling; diabetes	MOUSE PANCREATIC-ISLETS; BETA-CELLS; CHROMAFFIN CELLS; INSULIN RELEASE; GLUCOSE; MECHANISM; ATP; OSCILLATIONS; INHIBITION; CHANNELS	In pancreatic beta-cells, stimulatory glucose concentrations increase cytosolic diadenosine polyphosphates ([Ap(n)A](i)) to concentrations sufficient to block ATP-sensitive K+ (K-ATP) channels, High-performance liquid chromatography and patch clamp techniques were used to study the metabolic pathways by which pancreatic beta-cells synthesize Ap(n)A and the mechanism through which Ap(n)A inhibit K-ATP channels, Ap(n)A show a glucose- and time-dependent cytosolic concentration increase parallel, though 30-to 50-fold higher, to changes observed in adenine nucleotides, Other fuel secretagogues, leucine and 2-ketoisocaproate, waise [Ap(n)A](i) as efficiently as 22 mM glucose, Blockade of glycolysis or Krebs cycle decreases glucose-induced [Ap(n)A](i). No significant increase in cytosolic Ap(n)A concentrations is induced by nonnutrient secretagogues or nonmetabolizable nutrient secretagogues. Inorganic pyrophosphatase inhibition with sodium fluoride blocks 22 mM glucose-induced [Ap(n)A](i) increase. Ap(n)A inhibition of K-ATP channel resembles that of ATP in efficacy, but shows clear functional differences, Unlike ATP, Ap(4)A does not restore channel activity after rundown. Furthermore, these compounds do not compete with each other for the same site, These features suggest a prominent role for Ap(4)A in beta-cell function, comparable to ATP, We conclude that nutrient metabolism through pyrophosphatase activation is necessary to induce Ap(n)A synthesis, which in turn constitutes a new, ATP-independent, metabolic regulator of K-ATP channel activity.	Miguel Hernandez Univ, Dept Physiol, Alicante 03550, Spain; Miguel Hernandez Univ, Inst Bioengn, Alicante 03550, Spain; Miguel Hernandez Univ, Dept Sci & Technol, Alicante 03550, Spain; Univ Complutense Madrid, Fac Vet, Dept Biochem, Madrid, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Complutense University of Madrid	Soria, B (corresponding author), Miguel Hernandez Univ, Dept Physiol, Campus San Juan,Apdo 18, Alicante 03550, Spain.	bernat.soria@umh.es	, Bernat/AAL-6470-2021; Ripoll, Cristina/F-3324-2016; Miras-Portugal, Maria Teresa/L-7137-2014; Martin, Franz/K-4197-2014	Ripoll, Cristina/0000-0003-0935-8722; Martin, Franz/0000-0002-5745-8704; Pintor, Jesus/0000-0002-9191-7679; Soria, Bernat/0000-0002-2356-0380				AAS M, 1968, BIOCHIM BIOPHYS ACTA, V164, P157, DOI 10.1016/0005-2760(68)90142-2; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BAYKOV AA, 1992, ARCH BIOCHEM BIOPHYS, V294, P238, DOI 10.1016/0003-9861(92)90163-Q; CLARKE DD, 1991, NEUROCHEM RES, V16, P1055, DOI 10.1007/BF00965850; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; GHOSH A, 1991, J BIOL CHEM, V266, P22887; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; GRUMMT F, 1978, P NATL ACAD SCI USA, V75, P371, DOI 10.1073/pnas.75.1.371; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HUTTON JC, 1980, ENDOCRINOLOGY, V106, P203, DOI 10.1210/endo-106-1-203; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Jovanovic A, 1996, BRIT J PHARMACOL, V117, P233, DOI 10.1111/j.1476-5381.1996.tb15180.x; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MARTIN F, 1995, DIABETES, V44, P300, DOI 10.2337/diabetes.44.3.300; MCLENNAN AG, 1992, AP A OTHE DINUCLEOTI; OGILVIE A, 1981, ANAL BIOCHEM, V115, P302, DOI 10.1016/0003-2697(81)90009-9; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1991, LIFE SCI, V48, P2317, DOI 10.1016/0024-3205(91)90268-G; RAMOS A, 1995, BBA-PROTEIN STRUCT M, V1253, P103, DOI 10.1016/0167-4838(95)00154-M; Ripoll C, 1996, DIABETES, V45, P1431, DOI 10.2337/diabetes.45.10.1431; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; TRENTHAM DR, 1968, BIOCHEM J, V109, P603, DOI 10.1042/bj1090603; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; Yakovenko I. N., 1993, Biokhimiya, V58, P3; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	31	33	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1998	12	14					1499	1506		10.1096/fasebj.12.14.1499	http://dx.doi.org/10.1096/fasebj.12.14.1499			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	134NM	9806759				2022-12-28	WOS:000076749500009
J	Thomas, SC; Ryan, MA; Shanley, TP; Wong, HR				Thomas, SC; Ryan, MA; Shanley, TP; Wong, HR			Induction of the stress response with prostaglandin A(1) increases I-kappa B alpha gene expression	FASEB JOURNAL			English	Article						PGA(1); NF-kappa B; interleukin 8; inflammation	HEAT-SHOCK RESPONSE; TRANSCRIPTION FACTOR; NUCLEAR TRANSLOCATION; ENDOTHELIAL-CELLS; MORTALITY-RATE; ACTIVATION; INHIBITION; PROMOTER; APOPTOSIS; PROTEINS	I-kappa B alpha is an intracellular protein that functions as a primary inhibitor of the proinflammatory transcription factor NF-KB. Induction of the stress response with heat shock was previously demonstrated to induce I-kappa B alpha gene expression. Because the stress response can also be induced by nonthermal stimuli, we determined whether induction of the stress response with prostaglandin A(1) (PGA(1)) would induce I-kappa B alpha gene expression. Treatment of human bronchial epithelium (BEAS-2B cells) with PGA(1) induced nuclear translocation of heat shock factor 1, thus confirming that PGA(1) induces the stress response in BEAS-2B cells. Induction of the stress response with PGA(1) increased I-kappa B alpha mRNA expression in a time-dependent manner and increased I-kappa B alpha peptide expression. Transient transfection assays involving a human I-kappa B alpha promoter-luciferase reporter construct demonstrated that induction of the stress response with PGA1 activated the I-kappa B alpha promoter. Induction of the stress response with PGA1 and concomitant induction of I-kappa B alpha were associated with inhibition of TNF-alpha-mediated secretion of interleukin 8 and with inhibition of TNF-alpha-mediated nuclear translocation and activation of NF-kappa B. These data demonstrate that induction of the stress response, by a nonthermal stimulus, increases I-kappa B alpha gene expression by a mechanism involving activation of the I-kappa B alpha promoter. Coupled with previous data demonstrating heat shock-mediated induction of I-kappa B alpha gene expression, these data suggest that I-kappa B alpha may be considered to be one of the stress proteins. The functional consequences of stress response-mediated I-kappa B alpha gene expression may involve attenuation of cellular proinflammatory responses.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Wong, HR (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care Med, OSB5,3333 Burnet Ave, Cincinnati, OH 45229 USA.	wonghr@chmcc.org		Wong, Hector/0000-0001-7989-1173; Shanley, Thomas/0000-0001-8936-377X	NICHD NIH HHS [HD-28827-05] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; BOND U, 1985, MOL CELL BIOL, V5, P949, DOI 10.1128/MCB.5.5.949; Chen CG, 1996, MOL IMMUNOL, V33, P57, DOI 10.1016/0161-5890(95)00128-X; CONWAY EM, 1994, J BIOL CHEM, V269, P22804; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; deVera ME, 1996, HEPATOLOGY, V24, P1238; Feinstein D.L., 1996, J BIOL CHEM, V271, P17224; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; Hauser GJ, 1996, AM J PHYSIOL-HEART C, V271, pH2529, DOI 10.1152/ajpheart.1996.271.6.H2529; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Klosterhalfen B, 1997, SHOCK, V7, P254, DOI 10.1097/00024382-199704000-00003; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KWON OJ, 1994, AM J PHYSIOL, V267, P6398; LANKS KW, 1986, EXP CELL RES, V165, P1, DOI 10.1016/0014-4827(86)90528-8; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SCHMIDT JA, 1988, J IMMUNOL, V141, P2027; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SNYDER YM, 1992, J LEUKOCYTE BIOL, V51, P181, DOI 10.1002/jlb.51.2.181; VILLAR J, 1994, CRIT CARE MED, V22, P914; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Wong HR, 1996, AM J RESP CELL MOL, V15, P745, DOI 10.1165/ajrcmb.15.6.8969269; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wong HR, 1997, AM J PHYSIOL-LUNG C, V272, pL132, DOI 10.1152/ajplung.1997.272.1.L132; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; Wong HR, 1997, AM J PHYSIOL-LUNG C, V273, pL1, DOI 10.1152/ajplung.1997.273.1.L1; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	37	41	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	1998	12	13					1371	1378		10.1096/fasebj.12.13.1371	http://dx.doi.org/10.1096/fasebj.12.13.1371			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	128JE	9761780				2022-12-28	WOS:000076402000012
J	Dubois, RN; Abramson, SB; Crofford, L; Gupta, RA; Simon, LS; Van De Putte, LBA; Lipsky, PE				Dubois, RN; Abramson, SB; Crofford, L; Gupta, RA; Simon, LS; Van De Putte, LBA; Lipsky, PE			Cyclooxygenase in biology and disease	FASEB JOURNAL			English	Review						prostaglandins; inflammation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN-G/H SYNTHASE; HUMAN COLON-CANCER; PERIIMPLANTATION MOUSE UTERUS; MESSENGER-RNA EXPRESSION; ALZHEIMERS-DISEASE; COLORECTAL-CANCER; SELECTIVE-INHIBITION; GENE-EXPRESSION; ASPIRIN USE	Cyclooxygenase (COX), the key enzyme required for the conversion of arachidonic acid to prostaglandins was first identified over 20 years ago. Drugs, like aspirin, that inhibit cyclooxygenase activity have been available to the public for about 100 years. In the past decade, however, more progress has been made in understanding the role of cyclooxygenase enzymes in biology and disease than at any other time in history. Two cyclooxygenase isoforms have been identified and are referred to as COX-1 and COX-2, Under many circumstances the COX-1 enzyme is produced constitutively (i.e,, gastric mucosa) whereas COX-2 is inducible (i,e,, sites of inflammation). Here, we summarize the current understanding of the role of cyclooxygenase-l and -2 in different physiological situations and disease processes ranging from inflammation to cancer. We have attempted to include all of the most relevant material in the field, but due to the rapid progress in this area of research we apologize that certain recent findings may have been left out.	Vanderbilt Univ, Med Ctr, Dept Med GI, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; NYU, Sch Med, Dept Rheumatol, Hosp Joint Dis, New York, NY 10003 USA; Univ Michigan, Med Ctr, Div Rheumatol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Beth Israel Deaconness Med Ctr, Div Rheumatol, Boston, MA 02215 USA; Univ Nijmegen Hosp, Div Rheumatol, NL-6500 HB Nijmegen, Netherlands; Univ Texas, SW Med Ctr, Harold C Simmons Arthritis Res Ctr, Div Rheumat Dis, Dallas, TX 75235 USA	Vanderbilt University; Vanderbilt University; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; University of Michigan System; University of Michigan; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Radboud University Nijmegen; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Dubois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, 221 Kirkland Hall,MCN C-2104, Nashville, TN 37232 USA.	duboisrn@ctrvax.vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020; Crofford, Leslie J/J-8010-2013	Crofford, Leslie J/0000-0002-6347-5738; Abramson, Steven/0000-0002-0668-6344				Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; ANDERSEN K, 1995, NEUROLOGY, V45, P1441, DOI 10.1212/WNL.45.8.1441; Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Bauer MKA, 1997, EUR J BIOCHEM, V243, P726, DOI 10.1111/j.1432-1033.1997.00726.x; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; Breitner JCS, 1996, NEUROBIOL AGING, V17, P789; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Breyer MD, 1996, J AM SOC NEPHROL, V7, P8; Cao CY, 1997, ANN NY ACAD SCI, V813, P307, DOI 10.1111/j.1749-6632.1997.tb51710.x; Cao CY, 1997, AM J PHYSIOL-REG I, V272, pR1712, DOI 10.1152/ajpregu.1997.272.6.R1712; CASHMAN J, 1995, DRUGS, V49, P51, DOI 10.2165/00003495-199549010-00005; Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495-199600525-00004; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; Cherng C H, 1996, Acta Anaesthesiol Sin, V34, P81; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Crofford LJ, 1997, J RHEUMATOL, V24, P15; DAVIES NM, 1995, DIS COLON RECTUM, V38, P1311, DOI 10.1007/BF02049158; delaTorre JC, 1997, GERONTOLOGY, V43, P26; DeWitt DL, 1993, AM J MED S2A, V95, P40, DOI DOI 10.1016/0002-9343(93)90396-7; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dray A, 1996, ANNU REV PHARMACOL, V36, P253; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; EUGUI EM, 1993, ANN NY ACAD SCI, V685, P309, DOI 10.1111/j.1749-6632.1993.tb35881.x; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; GIANNELLA RA, 1973, J CLIN INVEST, V52, P441, DOI 10.1172/JCI107201; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; HAMMERMAN C, 1995, CLIN PERINATOL, V22, P457; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harris RC, 1996, J HYPERTENS, V14, P815, DOI 10.1097/00004872-199607000-00003; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; JEFFCOAT MK, 1993, ANN NY ACAD SCI, V696, P292; Kang RY, 1996, BRIT J RHEUMATOL, V35, P711; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kaufmann WE, 1997, BRAIN DEV-JPN, V19, P25, DOI 10.1016/S0387-7604(96)00047-2; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36; Kawamori T, 1998, CANCER RES, V58, P409; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Laird JMA, 1997, INFLAMM RES, V46, P203, DOI 10.1007/s000110050174; LANDS WEM, 1979, ANNU REV PHYSIOL, V41, P633, DOI 10.1146/annurev.ph.41.030179.003221; Lane NE, 1997, J RHEUMATOL, V24, P20; Li JL, 1996, ENDOCRINOLOGY, V137, P2522, DOI 10.1210/en.137.6.2522; Lim H, 1997, ENDOCRINOLOGY, V138, P4599, DOI 10.1210/en.138.11.4599; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lipsky PE, 1997, J RHEUMATOL, V24, P9; Manfield L, 1996, INFLAMM RES, V45, P254, DOI 10.1007/BF02259612; Matsumura K, 1997, ANN NY ACAD SCI, V813, P302, DOI 10.1111/j.1749-6632.1997.tb51709.x; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MEAD JF, 1986, LIPIDS CHEM BIOCH NU, P149; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; Murray M D, 1993, Annu Rev Pharmacol Toxicol, V33, P435; Narko K, 1997, ENDOCRINOLOGY, V138, P3638, DOI 10.1210/en.138.9.3638; Needleman P, 1997, J RHEUMATOL, V24, P6; OBrien WF, 1995, CLIN PERINATOL, V22, P973, DOI 10.1016/S0095-5108(18)30265-3; Onoe Y, 1996, J IMMUNOL, V156, P758; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PALMER BF, 1995, SEMIN NEPHROL, V15, P214; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; PIAZZA GA, 1995, CANCER RES, V55, P3110; Pilbeam Carol C., 1996, P715; Pilbeam CC, 1997, J BONE MINER RES, V12, P1198, DOI 10.1359/jbmr.1997.12.8.1198; RAZ A, 1988, J BIOL CHEM, V263, P3022; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reed DW, 1996, PROSTAGLANDINS, V52, P269, DOI 10.1016/S0090-6980(96)00089-5; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Roth SH, 1996, ARCH INTERN MED, V156, P1623, DOI 10.1001/archinte.156.15.1623; SANO H, 1995, CANCER RES, V55, P3785; SATO T, 1995, ADV PROSTAG THROMB L, V23, P445; SCHAFER AI, 1995, J CLIN PHARMACOL, V35, P209, DOI 10.1002/j.1552-4604.1995.tb04050.x; Scheiman JM, 1996, GASTROENTEROL CLIN N, V25, P279, DOI 10.1016/S0889-8553(05)70247-8; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Simon L S, 1997, Curr Opin Rheumatol, V9, P178, DOI 10.1097/00002281-199705000-00002; Simon Lee S., 1996, Current Opinion in Rheumatology, V8, P169, DOI 10.1097/00002281-199605000-00001; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spangler RS, 1996, SEMIN ARTHRITIS RHEU, V26, P435, DOI 10.1016/S0049-0172(96)80024-2; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; STOKES JB, 1979, J CLIN INVEST, V64, P495, DOI 10.1172/JCI109487; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372; Taniguchi Y, 1997, EUR J PHARMACOL, V330, P221, DOI 10.1016/S0014-2999(97)00183-0; Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594; Thompson HJ, 1997, CANCER RES, V57, P267; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; Tjandrawinata RR, 1997, FASEB J, V11, P493, DOI 10.1096/fasebj.11.6.9194530; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Trevethick MA, 1995, GEN PHARMACOL, V26, P1455, DOI 10.1016/0306-3623(95)00037-2; TSAFRIRI A, 1995, ADV EXP MED BIOL, V377, P121; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Woodiel FN, 1996, J BONE MINER RES, V11, P1249; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yamamoto T, 1996, BRAIN RES, V739, P104, DOI 10.1016/S0006-8993(96)00817-7; Yang ZM, 1997, BIOL REPROD, V56, P368, DOI 10.1095/biolreprod56.2.368; ZAMBRASKI EJ, 1995, SEMIN NEPHROL, V15, P205; ZUCKERMAN H, 1974, OBSTET GYNECOL, V44, P787	117	2049	2157	3	176	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	1998	12	12					1063	1073		10.1096/fasebj.12.12.1063	http://dx.doi.org/10.1096/fasebj.12.12.1063			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	116RN	9737710	Green Submitted			2022-12-28	WOS:000075738500002
J	Lewis, ML; Reynolds, JL; Cubano, LA; Hatton, JP; Lawless, BD; Piepmeier, EH				Lewis, ML; Reynolds, JL; Cubano, LA; Hatton, JP; Lawless, BD; Piepmeier, EH			Spaceflight alters microtubules and increases apoptosis in human lymphocytes (Jurkat)	FASEB JOURNAL			English	Article						cytoskeleton; Fas/APO-1; glucose metabolism; MTOC	PROTEIN-KINASE-C; CELLS; ACTIVATION; MICROGRAVITY; MEMBRANE; ISOZYME	Alteration in cytoskeletal organization appears to underlie mechanisms of gravity sensitivity in space-flown cells. Human T lymphoblastoid cells (Jurkat) were flown on the Space Shuttle to test the hypothesis that growth responsiveness is associated with microtubule anomalies and mediated by apoptosis. Cell growth was stimulated in microgravity by increasing serum concentration. After 4 and 48 h, cells filtered from medium were fixed with formalin, Postflight, confocal microscopy revealed diffuse, shortened microtubules extending from poorly defined microtubule organizing centers (MTOCs), In comparable ground controls, discrete microtubule filaments radiated from organized MTOCs and branched toward the cell membrane. At 4 h, 30% of flown, compared to 17% of ground, cells showed DNA condensation characteristic of apoptosis. Time-dependent increase of the apoptosis-associated Fas/ APO-l protein in static flown, but not the in-flight 1 g centrifuged or ground controls, confirmed microgravity-associated apoptosis, By 48 h, ground cultures had increased by 40%, Flown populations did not increase, though some cells were cycling and actively metabolizing glucose. We conclude that cytoskeletal alteration, growth retardation, and metabolic changes in space-flown lymphocytes are concomitant with increased apoptosis and time-dependent elevation of Fas/APO-1 protein. We suggest that reduced growth response in lymphocytes during spaceflight is linked to apoptosis.	Univ Alabama, Micrograv Biotechnol Lab, Huntsville, AL 35899 USA; Estab Transfus Sanguine Strasbourg, INSERM, U311, F-67065 Strasbourg, France; Rockefeller Univ, Steinman Cohn Lab New York, New York, NY 10021 USA; Univ Texas, Dept Pharmaceut, Austin, TX 78235 USA	University of Alabama System; University of Alabama Huntsville; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Rockefeller University; University of Texas System; University of Texas Austin	Lewis, ML (corresponding author), Univ Alabama, Wilson Hall,Rm 360, Huntsville, AL 35899 USA.			Reynolds, Julie/0000-0002-6749-4514				Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Cogoli A, 1996, J Gravit Physiol, V3, P1; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; GENZEL P, 1988, ESA, P21; GRINDELAND R, 1990, FINAL REPORTS US EXP; GRUENER R, 1993, ASGSB B, V7, P65; HOEGER G, 1990, ASGSB B, V4, P42; HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116; HUGHESFULFORD M, 1924, ASGSB B, V731, P93; Hymer W C, 1985, Physiologist, V28, pS197; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; KAPLAN J, 1982, J CELL BIOL, V94, P12, DOI 10.1083/jcb.94.1.12; KILEY SC, 1995, J CELL SCI, V108, P1003; Klaus D, 1997, MICROBIOL-SGM, V143, P449, DOI 10.1099/00221287-143-2-449; KOLBER MA, 1990, FASEB J, V4, P3021, DOI 10.1096/fasebj.4.12.2394319; LEWIS ML, 1996, FUNDAMENTALS SPACE L, P21; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; MATYLEVICH N P, 1991, Radiobiologiya, V31, P27; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; Moos P. J., 1988, ASGSB B, V2, P55; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OSBORN M, 1976, P NATL ACAD SCI USA, V73, P867, DOI 10.1073/pnas.73.3.867; Piepmeier EH, 1997, EXP CELL RES, V237, P410, DOI 10.1006/excr.1997.3813; RIJKENP J, 1989, ELGRA NEWS, V11, P3; Schmitt DA, 1996, FASEB J, V10, P1627, DOI 10.1096/fasebj.10.14.9002555; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Todd P, 1989, ASGSB Bull, V2, P95; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173	33	211	232	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					1007	1018		10.1096/fasebj.12.11.1007	http://dx.doi.org/10.1096/fasebj.12.11.1007			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707173				2022-12-28	WOS:000075372600011
J	Maghazachi, AA; Al-Aoukaty, A				Maghazachi, AA; Al-Aoukaty, A			Chemokines activate natural killer cells through heterotrimeric G-proteins: implications for the treatment of AIDS and cancer	FASEB JOURNAL			English	Review						signaling pathway; HIV-1	LARGE GRANULAR LYMPHOCYTES; MACROPHAGE INFLAMMATORY PROTEIN-1; HUMAN INTERLEUKIN-8 RECEPTOR; FUNCTIONAL EXPRESSION; HIV-1 ENTRY; NK CELLS; T-CELLS; TISSUE LOCALIZATION; KINASE ACTIVATION; TYROSINE KINASES	Natural killer (NK) cells are anti-tumor and anti-viral effector cells. These cells show increased cytolytic activity upon stimulation with interleukin 2 or chemokines. In addition, members of the C, CC, CXC, or CX3C chemokines induce the in vitro chemotaxis of NK cells and contribute to their in vivo tissue accumulation. Chemokines induce various intracellular signaling pathways in NK cells by activating members of the heterotrimeric G-proteins. Understanding these pathways should provide an insight into NK cell activation, in vivo distribution, and tissue localization. Based on evidence showing the high lytic activity of these effector cells against transformed or virally infected cells, it is suggested that NK cells can be used to maximize the immunotherapeutic protocols for AIDS and cancer patients.	Univ Oslo, Dept Anat, Inst Basic Med Sci, N-0317 Oslo, Norway	University of Oslo	Maghazachi, AA (corresponding author), Univ Oslo, Dept Anat, Inst Basic Med Sci, Postboks 1105, N-0317 Oslo, Norway.	azzam.maghazachi@basalmed.uio.no		Maghazachi, Azzam/0000-0002-3310-678X				Ahmad A, 1996, AIDS, V10, P143, DOI 10.1097/00002030-199602000-00003; AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; AlAoukaty A, 1997, J BIOL CHEM, V272, P31604, DOI 10.1074/jbc.272.50.31604; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; Barritt GJ, 1997, CELL SIGNAL, V9, P207, DOI 10.1016/S0898-6568(96)00131-3; BIANCHI G, 1996, EUR J IMMUNOL, V26, P3238; Biron CA, 1997, CURR OPIN IMMUNOL, V9, P24, DOI 10.1016/S0952-7915(97)80155-0; BITTI R, 1997, NAT MED, V3, P252; Black PL, 1996, INT J IMMUNOPHARMACO, V18, P633, DOI 10.1016/S0192-0561(96)00064-1; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bluman EM, 1996, J CLIN INVEST, V97, P2722, DOI 10.1172/JCI118726; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brumbaugh KM, 1996, J IMMUNOL, V157, P2804; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FELGAR RE, 1990, CELL IMMUNOL, V129, P288, DOI 10.1016/0008-8749(90)90205-6; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Frederick M, 1997, J INTERF CYTOK RES, V17, P435, DOI 10.1089/jir.1997.17.435; Furci L, 1997, J EXP MED, V186, P455, DOI 10.1084/jem.186.3.455; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Guimond MJ, 1998, J EXP MED, V187, P217, DOI 10.1084/jem.187.2.217; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Knudsen E, 1997, INT IMMUNOL, V9, P1043, DOI 10.1093/intimm/9.7.1043; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Loetscher P, 1996, J IMMUNOL, V156, P322; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MAGHAZACHI AA, 1990, CANCER IMMUNOL IMMUN, V31, P139, DOI 10.1007/BF01744727; Maghazachi AA, 1997, BIOCHEM BIOPH RES CO, V236, P270, DOI 10.1006/bbrc.1997.6937; Maghazachi AA, 1996, EUR J IMMUNOL, V26, P315, DOI 10.1002/eji.1830260207; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MAGHAZACHI AA, 1988, J IMMUNOL, V141, P4039; MAGHAZACHI AA, 1991, J LEUKOCYTE BIOL, V49, P302, DOI 10.1002/jlb.49.3.302; MAGHAZACHI AA, 1993, INT IMMUNOL, V5, P825, DOI 10.1093/intimm/5.8.825; MAGHAZACHI AA, 1989, INTERLEUKIN 2 KILLER, P259; MAGHAZACHI AA, 1994, J BIOL CHEM, V269, P3440; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PHILLIPS JH, 1989, J EXP MED, V170, P291, DOI 10.1084/jem.170.1.291; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLSTAD B, 1986, J IMMUNOL, V136, P2800; Salazar-Mather TP, 1998, J EXP MED, V187, P1, DOI 10.1084/jem.187.1.1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SAYERS TJ, 1990, CELL IMMUNOL, V127, P311, DOI 10.1016/0008-8749(90)90135-E; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SEBOK K, 1993, J IMMUNOL, V150, P1524; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SMYTH MJ, 1991, J IMMUNOL, V146, P3815; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Strieter RM, 1996, J IMMUNOL, V156, P3583; Tanabe S, 1997, J IMMUNOL, V159, P905; TAUB DD, 1995, J IMMUNOL, V155, P3877; Tay CH, 1997, J VIROL, V71, P267, DOI 10.1128/JVI.71.1.267-275.1997; Theodorou I, 1997, LANCET, V349, P1219; THORNTON AJ, 1990, J IMMUNOL, V144, P2609; Timonen T, 1997, J LEUKOCYTE BIOL, V62, P693, DOI 10.1002/jlb.62.6.693; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TURNER L, 1995, J IMMUNOL, V155, P2437; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VUJANOVIC NL, 1988, J EXP MED, V167, P15, DOI 10.1084/jem.167.1.15; VUJANOVIC NL, 1995, J IMMUNOL, V154, P281; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wilkinson PC, 1997, AUTOIMMUNITY, V26, P55, DOI 10.3109/08916939709009550; WILTROUT RH, 1984, J EXP MED, V160, P1431, DOI 10.1084/jem.160.5.1431; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; WONG YH, 1995, ONCOGENE, V10, P1927; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Yang AG, 1997, P NATL ACAD SCI USA, V94, P11567, DOI 10.1073/pnas.94.21.11567; YASUMURA S, 1994, CANCER RES, V54, P3808	116	56	58	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	1998	12	11					913	924		10.1096/fasebj.12.11.913	http://dx.doi.org/10.1096/fasebj.12.11.913			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	110GR	9707163				2022-12-28	WOS:000075372600001
J	Ahmed, A; Dearn, S; Shams, M; Li, XF; Sangha, RK; Rola-Pleszczynski, M; Jiang, JQ				Ahmed, A; Dearn, S; Shams, M; Li, XF; Sangha, RK; Rola-Pleszczynski, M; Jiang, JQ			Localization, quantification, and activation of platelet-activating factor receptor in human endometrium during the menstrual cycle: PAF stimulates NO, VEGF, and FAK(pp125)	FASEB JOURNAL			English	Article						PAF receptor; uterus; nitric oxide; menstruation; implantation	ENDOTHELIAL GROWTH-FACTOR; IN-VIVO ANGIOGENESIS; MESSENGER-RNAS; NITRIC-OXIDE; CELLS; IDENTIFICATION; EXPRESSION; HYDROLYSIS; ESTROGEN; VITRO	Implantation is characterized by an inflammatory-like response with expansion of extracellular fluid volume, increased vascular permeability, and vasodilatation. These effects are believed to be mediated at the paracrine level by prostaglandin EP and platelet-activating factor (PAF), but the cellular mechanism (or mechanisms) remains largely unknown. We demonstrate that PAF receptor (PAF-R) immunoreactivity and mRNA are detected in proliferative and secretory endometrial glands, however, the responsiveness of endometrium to physiological concentrations of PAF is confined predominantly to the secretory endometrium. Semiquantitative reverse transcription-polymerase chain reaction revealed that PAF-R transcript levels were highest in the mid-late proliferative and late secretory phases of the cycle. Interaction of PAF with its receptor resulted in the rapid release of nitric oxide (NO), increased expression of vascular endothelial growth factor (VEGF), and activation of FAK(pp125), a focal adhesion kinase, demonstrating that the PAF-R is functionally active. Inhibition of NO synthesis by N-G-monomethyl-L-arginine produced dose-dependent attenuation of PAF-evoked NO release, indicating NOS activation; the dependency of PAF-evoked NO release on PKC and extracellular Ca2+ was confirmed by PRO inhibitor Ro 31-8220 and by the removal of extracellular Ca2+ PAF up-regulated VEGF gene expression in a concentration- and time-dependent fashion in human endometrial epithelial cell lysates. Transcription of VEGF was rapidly followed by secretion of the protein. These data support our premise that this auto-coid acts as an angiogenic mediator in the regeneration of the endometrium after menses and as a vasodilator to promote blastocyst attachment during the implantation process.-Ahmed, A., Dearn, S., Shams, M., Li, X. F., Sangha, R. K., Rola-Pleszczynski, M., Jiang, J. Localization, quantification, and activation of platelet-activating factor receptor in human endometriun during the menstrual cycle: PAF stimulates NO, VEGF, and FAK(pp125).	Univ Birmingham, Womens Hosp, Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England	Birmingham Women's Hospital; University of Birmingham	Ahmed, A (corresponding author), Univ Birmingham, Womens Hosp, Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England.	A.S.Ahmed@bham.ac.uk	Ahmed, Asif/ABE-9544-2020; Ahmed, Asif/A-7268-2010	Ahmed, Asif/0000-0002-8755-8546; Goswami, Kaushal/0000-0002-7052-4358				AHMED A, 1995, J CLIN INVEST, V96, P848, DOI 10.1172/JCI118131; AHMED A, 1994, J REPROD FERTIL, V101, P459; Ahmed A, 1997, LAB INVEST, V76, P779; AHMED A, 1992, J CELL PHYSIOL, V152, P207, DOI 10.1002/jcp.1041520126; AHMED A, 1992, BIOL REPROD, V47, P59, DOI 10.1095/biolreprod47.1.59; AHMED A, 1997, ADV EXP MED BIOL, V416, P277; AHMED A, 1995, CELL SIGNAL, V7, P1; ALECOZAY AA, 1991, J REPROD FERTIL, V91, P301; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CAMUSSI G, 1991, INT ARCH ALLER A IMM, V96, P84, DOI 10.1159/000235539; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; CHAUDHURI G, 1992, STEROID HORMONES AND UTERINE BLEEDING, P241; DEARN S, 1998, IN PRESS LAB INVEST; FOX H, 1983, ATLAS GYNAECOLOGICAL, P61; GUYTON AC, 1981, TXB MED PHYSL, P1005; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; JUNCOS LA, 1993, J CLIN INVEST, V91, P1374, DOI 10.1172/JCI116339; KAMATA K, 1989, BRIT J PHARMACOL, V98, P360; KUDOLO GB, 1991, CELL TISSUE RES, V265, P231, DOI 10.1007/BF00398071; LI XF, 1994, GROWTH FACTORS, V11, P277, DOI 10.3109/08977199409011000; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MCRAE AC, 1988, J REPROD FERTIL, V82, P617, DOI 10.1530/jrf.0.0820617; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; MULLER E, 1993, P NATL ACAD SCI USA, V90, P5818, DOI 10.1073/pnas.90.12.5818; MUTOH H, 1993, FEBS LETT, V322, P129, DOI 10.1016/0014-5793(93)81552-B; MUTOH H, 1994, BIOCHEM BIOPH RES CO, V205, P1130, DOI 10.1006/bbrc.1994.2783; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Sangha RK, 1997, LAB INVEST, V77, P389; Sato S, 1996, ADV EXP MED BIOL, V416, P95; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; Shams M, 1996, MOL HUM REPROD, V2, P35, DOI 10.1093/molehr/2.1.35; SHAMS M, 1994, GROWTH FACTORS, V11, P105, DOI 10.3109/08977199409001052; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH SK, 1988, J REPROD FERTIL, V82, P271; SPINKS NR, 1990, J REPROD FERTIL, V88, P241, DOI 10.1530/jrf.0.0880241; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	38	39	39	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					831	843		10.1096/fasebj.12.10.831	http://dx.doi.org/10.1096/fasebj.12.10.831			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657523				2022-12-28	WOS:000074580100008
J	Chow, SE; Lee, RS; Shih, SH; Chen, JK				Chow, SE; Lee, RS; Shih, SH; Chen, JK			Oxidized LDL promotes vascular endothelial cell pinocytosis via a prooxidation mechanism	FASEB JOURNAL			English	Article						membrane ruffling; EC; antioxidant; ROI; pinocytotic activity; low density lipoprotein	LOW-DENSITY-LIPOPROTEIN; FLUID-PHASE PINOCYTOSIS; SMOOTH-MUSCLE CELLS; ATHEROGENIC LEVELS; HYDROGEN-PEROXIDE; GROWTH-FACTOR; ATHEROSCLEROSIS; EXPRESSION; INCREASE; TRANSCRIPTION	Human low density lipoprotein (LDL) is prepared in the presence of antioxidants and is oxidized to different levels (measured by thiobarbituric acid reactive substance) with copper ion. The effects of unoxidized LDL and oxidized LDL (ox-LDL) on stress fiber formation, cell. membrane ruffling, and pinocytosis (measured by [C-14]sucrose uptake) in cultured human umbilical cord vein endothelial cells (EC) are compared. We show that at a concentration range of 100 to 200 mu g cholesterol/ml, both unoxidized LDL and ox-LDL promote EC elongation and stress fiber formation, but the effect by the latter is more prominent when compared at the same dose range. In addition, ox-LDL also induces EC membrane ruffling and promotes pinocytosis, These effects are positively correlated with the extent of LDL oxidation and depend on the dose of ox-LDL, Ox-LDL-promoted membrane ruffling and pinocytosis are effectively blocked by brief preexposure of the cells to antioxidants, In contrast, stress fiber formation is not affected by antioxidant pretreatment. Although unoxidized LDL also promotes [C-14]sucrose uptake, it is less potent than ox-LDL and significantly higher concentrations are required to produce a detectable effect. Unlike ox-LDL, unoxidized LDL-enhanced pinocytosis is not accompanied by the appearance of membrane ruffling; therefore, they may act via different mechanisms. Elevated pinocytosis may increase transcytotic activity of the endothelium, leading to an increased influx of plasma components such as LDL into the subendothelial space.-Chow, S.-E., Lee, R.-S., Shih, S. H., Chen, J.-K. Oxidized LDL promotes vascular endothelial cell pinocytosis via a prooxidation mechanism.	Chang Gung Univ, Coll Med, Dept Physiol, Taoyuan 333, Taiwan; Natl Taiwan Normal Univ, Dept Biol, Taipei, Taiwan; Chang Gung Univ, Ctr Gen Studies, Taoyuan, Taiwan	Chang Gung University; National Taiwan Normal University; Chang Gung University	Chen, JK (corresponding author), Chang Gung Univ, Coll Med, Dept Physiol, Taoyuan 333, Taiwan.							BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BORSUM T, 1985, ATHEROSCLEROSIS, V58, P81, DOI 10.1016/0021-9150(85)90057-7; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1990, NATURE, V343, P508, DOI 10.1038/343508a0; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; CHEN JK, 1986, J CELL PHYSIOL, V129, P207, DOI 10.1002/jcp.1041290212; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DAVIES PF, 1980, J CELL PHYSIOL, V102, P119, DOI 10.1002/jcp.1041020204; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Holland JA, 1996, J CELL PHYSIOL, V166, P144, DOI 10.1002/(SICI)1097-4652(199601)166:1<144::AID-JCP17>3.0.CO;2-F; HOLLAND JA, 1992, AM J PATHOL, V140, P551; HOLVOET P, 1994, FASEB J, V8, P1279, DOI 10.1096/fasebj.8.15.8001740; Ishii H, 1996, J BIOL CHEM, V271, P8458, DOI 10.1074/jbc.271.14.8458; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PHILLIPS PG, 1988, J APPL PHYSIOL, V64, P1196, DOI 10.1152/jappl.1988.64.3.1196; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Rangaswamy S, 1997, CIRC RES, V80, P37, DOI 10.1161/01.RES.80.1.37; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Salonen JT, 1997, CIRCULATION, V95, P840; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stiko A, 1996, ARTERIOSCL THROM VAS, V16, P194, DOI 10.1161/01.ATV.16.2.194; THAKKAR K, 1993, J MED CHEM, V36, P2950, DOI 10.1021/jm00072a015; THORIN E, 1994, ARTERIOSCLER THROMB, V14, P453, DOI 10.1161/01.ATV.14.3.453; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Zhu WM, 1996, ARTERIOSCL THROM VAS, V16, P1104, DOI 10.1161/01.ATV.16.9.1104	41	21	22	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	1998	12	10					823	830		10.1096/fasebj.12.10.823	http://dx.doi.org/10.1096/fasebj.12.10.823			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657522				2022-12-28	WOS:000074580100007
J	Li, YP; Schwartz, RJ; Waddell, ID; Holloway, BR; Reid, MB				Li, YP; Schwartz, RJ; Waddell, ID; Holloway, BR; Reid, MB			Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappa B activation in response to tumor necrosis factor alpha	FASEB JOURNAL			English	Article						cachexia; myosin; cytokines; inflammatory disease; tumor necrosis factor; ubiquitin; free radicals	UBIQUITIN-PROTEASOME PATHWAY; OXIDATIVE STRESS; GENE-EXPRESSION; TNF-ALPHA; PROSTAGLANDIN-E2 PRODUCTION; TRANSCRIPTION FACTOR; CANCER CACHEXIA; NITRIC-OXIDE; BEARING RATS; CACHECTIN	Skeletal muscle atrophy and weakness are thought to be stimulated by tumor necrosis factor a (TNF-alpha) in a variety of chronic diseases. However, little is known about the direct effects of TNF-alpha on differentiated skeletal muscle cells or the signaling mechanisms involved, We have tested the effects of TNF-alpha on the mouse-derived C2C12 muscle cell line and on primary cultures from rat skeletal muscle. TNF-alpha treatment of differentiated myotubes stimulated time- and concentration-dependent reductions in total protein content and loss of adult myosin heavy chain (MHCf) content; these changes were evident at low TNF-alpha concentrations (1-3 ng/ml) that did not alter muscle DNA content and were not associated with a decrease in MHCf synthesis. TNF-alpha activated binding of nuclear factor KB (NF-kappa B) to its targeted DNA sequence and stimulated degradation of I-kappa B alpha, an NF-kappa B inhibitory protein. TNF-alpha stimulated total ubiquitin conjugation whereas a 26S proteasome inhibitor (MG132 10-40 mu M) blocked TNF-alpha activation of NF-kappa B, Catalase 1 kU/ml inhibited NF-kappa B activation by TNF-alpha; exogenous hydrogen peroxide 200 mu M activated NF-kappa B and stimulated I-kappa B alpha degradation. These data demonstrate that TNF-alpha directly induces skeletal muscle protein loss, that NF-kappa B is rapidly activated by TNF-alpha in differentiated skeletal muscle cells, and that TNF-alpha/NF-kappa B signaling in skeletal muscle is regulated by endogenous reactive oxygen species.-Li, Y.-P., Schwartz, R. J., Waddell, I. D., Holloway, B. R., Reid, M. B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappa B activation in response to tumor necrosis factor alpha.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	Baylor College of Medicine; Baylor College of Medicine	Reid, MB (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	reid@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1994, LIFE SCI, V55, P1383, DOI 10.1016/0024-3205(94)00752-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beckman J.S., 1986, PHYSL OXYGEN RADICAL, P39; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GARCIAMARTINEZ C, 1994, BIOCHEM BIOPH RES CO, V201, P682, DOI 10.1006/bbrc.1994.1754; GELIN J, 1991, CANCER RES, V51, P415; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; GOODMAN MN, 1991, AM J PHYSIOL, V260, pE727, DOI 10.1152/ajpendo.1991.260.5.E727; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; LI YP, 1995, MOL BRAIN RES, V30, P106, DOI 10.1016/0169-328X(94)00285-M; Liotta AL, 1989, INFLUENCE TUMOR DEV, P176; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Llovera M, 1996, BIOCHEM BIOPH RES CO, V221, P653, DOI 10.1006/bbrc.1996.0651; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makropoulos V, 1996, ARCH TOXICOL, V70, P277, DOI 10.1007/s002040050274; MEALY K, 1990, ARCH SURG-CHICAGO, V125, P42; MEYER M, 1994, MCBU, P217; MICHIE HR, 1989, ANN SURG, V209, P19, DOI 10.1097/00000658-198901000-00002; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NAKASHIMA J, 1995, CANCER RES, V55, P4881; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROFE AM, 1987, BIOCHEM J, V247, P789, DOI 10.1042/bj2470789; SAPPEY C, 1994, AIDS RES HUM RETROV, V10, P1451, DOI 10.1089/aid.1994.10.1451; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHINDOH C, 1995, AM J RESP CRIT CARE, V152, P1690, DOI 10.1164/ajrccm.152.5.7582314; SHINDOH C, 1992, AM REV RESPIR DIS, V145, P1350, DOI 10.1164/ajrccm/145.6.1350; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; SUPINSKI G, 1993, AM REV RESPIR DIS, V148, P1318, DOI 10.1164/ajrccm/148.5.1318; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; TESSITORE L, 1993, BRIT J CANCER, V67, P15, DOI 10.1038/bjc.1993.4; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Zar JH, 1974, BIOSTATISTICAL ANAL	64	399	412	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	1998	12	10					871	880		10.1096/fasebj.12.10.871	http://dx.doi.org/10.1096/fasebj.12.10.871			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZY035	9657527				2022-12-28	WOS:000074580100012
J	Gilad, E; Wong, HR; Zingarelli, B; Virag, L; O'Connor, M; Salzman, AL; Szabo, C				Gilad, E; Wong, HR; Zingarelli, B; Virag, L; O'Connor, M; Salzman, AL; Szabo, C			Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NF kappa B activation	FASEB JOURNAL			English	Article						inflammation; antioxidants; scavengers; gene expression; LPS; mesangial cells	INDUCED LIPID-PEROXIDATION; NEUROHORMONE MELATONIN; PINEAL-GLAND; ANTIBODY-RESPONSE; INDUCTION; CANCER; CELLS; SHOCK; NEUROIMMUNOTHERAPY; LIPOPOLYSACCHARIDE	The role of melatonin as an immunomodulator is well established. Recent reports showed that melatonin exerts protective effects iu septic and hemorrhagic shock and in inflammation. The expression of the inducible isoform of nitric oxide synthase (iNOS) makes an important contribution to the pathophysiology of shock and inflammation, We studied, in cultured murine macrophages, the role of melatonin in the regulation of the expression of iNOS and defined the mode of melatonin's action. Our results show that melatonin, at 1 mu M-1 mM, decreased the production of nitrite/nitrate (the breakdown products of NO) as well as the production of 6-ketoprostaglandin F-1 alpha (the major stable breakdown product of prostacyclin) in macrophages stimulated with bacterial lipopolysaccharide (10 mu g/ml), We observed that melatonin reduces iNOS steady-state mRNA levels and iNOS protein expression in the same concentration range (1 mu M-1 mM) Melatonin, up to 10 mM, exerted only a slight direct inhibitory effect on iNOS activity. Using iNOS promoter-luciferase constructs, we found that melatonin inhibits iNOS promoter activation, Inhibition of iNOS expression was associated with inhibition of activation of the transcription factor nuclear factor kappa B (NF kappa B), We conclude that melatonin inhibits NO production in immunostimulated macrophages mainly by inhibiting the expression of iNOS, This is due to inhibition of iNOS transcription, in part through inhibition of NF kappa B activation, Inhibition of iNOS-derived NO production by melatonin may contribute to the anti-inflammatory effects of this pineal secretory product.	Childrens Hosp, Med Ctr, Div Crit Care, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Szabo, C (corresponding author), Childrens Hosp, Med Ctr, Div Crit Care, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Szabo, Csaba/ABG-2644-2021; Virag, Laszlo/E-6124-2010; , Basilia/AAV-7582-2021	Wong, Hector/0000-0001-7989-1173; Virag, Laszlo/0000-0002-7099-6718				AKARASEREENONT P, 1994, BRIT J PHARMACOL, V113, P1522, DOI 10.1111/j.1476-5381.1994.tb17169.x; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Cazevieille C, 1997, BRAIN RES, V755, P91, DOI 10.1016/S0006-8993(97)00090-5; Chuang JI, 1996, CELL BIOL INT, V20, P687, DOI 10.1006/cbir.1996.0091; Conti A, 1995, J PINEAL RES, V19, P103, DOI 10.1111/j.1600-079X.1995.tb00177.x; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; Hasko G, 1996, J IMMUNOL, V157, P4634; HAZELRIGG DG, 1996, ENDOCRINOLOGY, V137, P210; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Invernizzi P, 1997, AM J PHYSIOL-GASTR L, V273, pG131, DOI 10.1152/ajpgi.1997.273.1.G131; Kilbourn RG, 1997, SHOCK, V7, P235, DOI 10.1097/00024382-199704000-00001; KILBOURN RG, 1995, CRIT CARE MED, V23, P1018, DOI 10.1097/00003246-199506000-00005; Lissoni P, 1995, J BIOL REG HOMEOS AG, V9, P155; LISSONI P, 1993, ONCOLOGY-BASEL, V50, P399; LISSONI P, 1994, J BIOL REG HOMEOS AG, V8, P126; LISSONI P, 1990, ANTICANCER RES, V10, P1759; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Maestroni GJM, 1996, J PINEAL RES, V20, P84, DOI 10.1111/j.1600-079X.1996.tb00244.x; MAESTRONI GJM, 1995, J PINEAL RES, V18, P84, DOI 10.1111/j.1600-079X.1995.tb00144.x; MAESTRONI GJM, 1987, CLIN EXP IMMUNOL, V68, P384; MAESTRONI GJM, 1990, J NEUROIMMUNOL, V28, P167, DOI 10.1016/0165-5728(90)90031-H; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; MAESTRONI GJM, 1994, CANCER RES, V54, P4740; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pierpaoli W, 1993, Int J Neurosci, V68, P123; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; POZO D, 1994, LIFE SCI, V55, P455; REITER RJ, 1995, FRONT NEUROENDOCRIN, V16, P383, DOI 10.1006/frne.1995.1014; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; SEWERYNEK E, 1995, FREE RADICAL BIO MED, V19, P903, DOI 10.1016/0891-5849(95)00101-3; Shaikh AY, 1997, NEUROSCI LETT, V229, P193, DOI 10.1016/S0304-3940(97)00307-8; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Sullivan DJ, 1996, J SURG RES, V64, P13, DOI 10.1006/jsre.1996.0299; SWIERKOSZ TA, 1995, BRIT J PHARMACOL, V114, P1335, DOI 10.1111/j.1476-5381.1995.tb13353.x; Szabo C, 1995, New Horiz, V3, P2; SZABO C, 1994, BRIT J PHARMACOL, V113, P757, DOI 10.1111/j.1476-5381.1994.tb17058.x; Szabo C, 1997, INT J ONCOL, V10, P1093; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Wichmann MW, 1996, J SURG RES, V65, P109, DOI 10.1006/jsre.1996.0351; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; ZINGARELLI B, 1997, BRIT J PHARMACOL, V119, P1; [No title captured]	50	230	249	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	1998	12	9					685	693		10.1096/fasebj.12.9.685	http://dx.doi.org/10.1096/fasebj.12.9.685			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZR760	9619447				2022-12-28	WOS:000074011000007
J	Ruehlmann, DO; Steinert, JR; Valverde, MA; Jacob, R; Mann, GE				Ruehlmann, DO; Steinert, JR; Valverde, MA; Jacob, R; Mann, GE			Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells	FASEB JOURNAL			English	Article						environmental pollutants; DDT; nonylphenol; octylphenol; estrogen; antiestrogen; ICI 182,870; Ca2+ and K+ channels; vascular smooth muscle cells; coronary vascular tone; heart	PLASMA-MEMBRANE; BINDING; RABBIT; CONDUCTANCE; RECEPTOR; CURRENTS; ARTERY; INFLUX; WOMEN; DDT	There is an ongoing scientific debate concerning the potential threat of environmental estrogenic pollutants to animal and human health (1-5). Pollutants including the detergents 4-octylphenol and p-nonylphenol and chlorinated insecticides have recently been reported to modulate sexual differentiation by interacting with nuclear steroid receptors (6-8). So far, the focus has been on reproductive organs, but sex steroids have far more widespread actions. The lower incidence of cardiovascular disease in women has been attributed to estrogens (9-14), yet no information is available on the vascular actions of environmental estrogenic pollutants. Zn the present study we have investigated the effects of acute exposure to 17 beta-estradiol, the antiestrogen ICI 182,780, and estrogenic pollutants on coronary vascular tone as well as on intracellular Ca2+ levels ([Ca2+](i)) and Ca2+ and K+ channel activity in vascular smooth muscle cells. We report here that 4-octylphenol, p-nonylphenol, o.p'-DDT, and the antiestrogen ICI 182,780 inhibit L-type Ca2+ channels in vascular smooth muscle cells and evoke a rapid and endothelium-independent relaxation of the coronary vasculature similar to that induced by 17 beta-estradiol. Thus, inhibition of Ca2+ influx via L-type Ca2+ channels in vascular smooth muscle cells may explain the acute, nongenomic vasodilator actions of environmental estrogenic pollutants.	Kings Coll London, Vasc Biol Res Ctr, Biomed Sci Div, London W8 7AH, England; Kings Coll London, Neurosci Res Ctr, Div Biomed Sci, London WC2R 2LS, England	University of London; King's College London; University of London; King's College London	Mann, GE (corresponding author), Kings Coll London, Vasc Biol Res Ctr, Biomed Sci Div, Campden Hill Rd, London W8 7AH, England.	g.mann@kcl.ac.uk	Steinert, Joern/ABB-4561-2020; Steinert, Joern/A-6678-2008; Steinert, Joern R/AAI-2742-2020	Steinert, Joern/0000-0003-1640-0845; Steinert, Joern R/0000-0003-1640-0845; Valverde, Miguel A./0000-0002-6961-3361	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMEZCUA JL, 1989, BRIT J PHARMACOL, V97, P1119, DOI 10.1111/j.1476-5381.1989.tb12569.x; BAYDOUN AR, 1993, BRIT J PHARMACOL, V109, P987, DOI 10.1111/j.1476-5381.1993.tb13718.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; DEFRIEND DJ, 1994, CANCER RES, V54, P408; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GODFRAIND T, 1994, PHARMACOL THERAPEUT, V64, P37, DOI 10.1016/0163-7258(94)90033-7; GUILLETTE LJ, 1994, ENVIRON HEALTH PERSP, V102, P680, DOI 10.2307/3432198; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; Hunter DJ, 1997, NEW ENGL J MED, V337, P1253, DOI 10.1056/NEJM199710303371801; JIANG CW, 1991, BRIT J PHARMACOL, V104, P1033, DOI 10.1111/j.1476-5381.1991.tb12545.x; Kauser K, 1997, J VASC RES, V34, P229, DOI 10.1159/000159227; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; Morgan AJ, 1996, BIOCHEM J, V320, P505; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.2307/3433065; Nakajima T, 1995, EUR J PHARMACOL, V294, P625, DOI 10.1016/0014-2999(95)00602-8; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Ogata R, 1996, BRIT J PHARMACOL, V117, P351, DOI 10.1111/j.1476-5381.1996.tb15198.x; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; RiveroRodriguez L, 1997, ENVIRON HEALTH PERSP, V105, P98, DOI 10.2307/3433069; Ruehlmann DO, 1997, BIOCHEM SOC T, V25, P40, DOI 10.1042/bst0250040; Safe SH, 1997, NEW ENGL J MED, V337, P1303, DOI 10.1056/NEJM199710303371809; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHARPE RM, 1995, ENV HLTH PERSPECT, V12, P1137; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; VALVERDE MA, 1992, NEUROSCIENCE, V51, P621, DOI 10.1016/0306-4522(92)90301-H; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WHITE MM, 1995, ENDOCR REV, V16, P739, DOI 10.1210/er.16.6.739; WHITE R, 1994, ENDOCRINOLOGY, V135, P175, DOI 10.1210/en.135.1.175; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	41	134	140	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1998	12	7					613	619		10.1096/fasebj.12.7.613	http://dx.doi.org/10.1096/fasebj.12.7.613			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	ZM284	9576488	Bronze			2022-12-28	WOS:000073523100011
